PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Takasawa, S; Akiyama, T; Nata, K; Kuroki, M; Tohgo, A; Noguchi, N; Kobayashi, S; Kato, I; Katada, T; Okamoto, H				Takasawa, S; Akiyama, T; Nata, K; Kuroki, M; Tohgo, A; Noguchi, N; Kobayashi, S; Kato, I; Katada, T; Okamoto, H			Cyclic ADP-ribose and inositol 1,4,5-trisphosphate as alternate second messengers for intracellular Ca2+ mobilization in normal and diabetic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INSULIN-SECRETION; PANCREATIC-ISLETS; PROINSULIN SYNTHESIS; RYANODINE RECEPTOR; MOLECULAR-CLONING; SURFACE-MOLECULE; CYCLASE ACTIVITY; CD38; RELEASE	Intracellular Ca2+ mobilization occurs in a variety of cellular processes and is mediated by two major systems, the inositol 1,4,5-trisphosphate (IP3) and cyclic ADP-ribose (cADPR) systems, cADPR has been proposed to be a second messenger for insulin secretion induced by glucose in pancreatic beta-cells (Takasawa, S., Nata, K., Yonekura, H., and Okamoto, H. (1993) Science 259, 370-373). Here we show that the cADPR signal system for insulin secretion is replaced by the IP3 system in diabetic beta-cells such as ob/ob mouse islets and RINm5F cells. We measured the cADPR content in these beta-cells by radioimmunoassay and found that the increase of the cADPR content by glucose did not occur in ob/ob mouse islets and RINm5F cells, whereas the increased cADPR level by glucose was observed in normal rat and mouse islets, Microsomes of these diabetic beta-cells released Ca2+ in response to IP3 but not to cADPR. In the diabetic beta-cells, CD38 (ADP-ribosyl cyclase/cADPR hydrolase) and type 2 ryanodine receptor mRNAs were scarcely detected and, in contrast, an increased expression of IP3 receptor mRNAs was observed, The diabetic beta-cells secreted insulin rather by carbamylcholine than by glucose.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Physiol Chem, Tokyo 113, Japan	Tohoku University; University of Tokyo	Okamoto, H (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Sieryo Machi, Sendai, Miyagi 98077, Japan.							ASHCROFT FM, 1992, INSULIN MOL BIOL PAT, P97; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1993, NATURE, V365, P388, DOI 10.1038/365388a0; BLONDEL O, 1993, J BIOL CHEM, V268, P11356; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; DONG C, 1994, INT IMMUNOL, V6, P1353, DOI 10.1093/intimm/6.9.1353; Ebihara S, 1997, J BIOL CHEM, V272, P16023, DOI 10.1074/jbc.272.25.16023; FURUICHI T, 1989, NUCLEIC ACIDS RES, V17, P5385, DOI 10.1093/nar/17.13.5385; FURUYA Y, 1995, GENE, V165, P329, DOI 10.1016/0378-1119(95)00540-M; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GOTO Y, 1975, P JPN ACAD, V51, P80, DOI 10.2183/pjab1945.51.80; HARADA N, 1993, J IMMUNOL, V151, P3111; HEDESKOV CJ, 1980, PHYSIOL REV, V60, P442, DOI 10.1152/physrev.1980.60.2.442; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; ISLAM MS, 1993, SCIENCE, V262, P584, DOI 10.1126/science.8211188; ITOH M, 1994, BIOCHEM BIOPH RES CO, V203, P1309, DOI 10.1006/bbrc.1994.2325; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; Kajimoto Y, 1996, BIOCHEM BIOPH RES CO, V219, P941, DOI 10.1006/bbrc.1996.0327; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; KOGUMA T, 1994, BBA-MOL CELL RES, V1223, P160, DOI 10.1016/0167-4889(94)90087-6; KUEMMERLE JF, 1995, J BIOL CHEM, V270, P25488, DOI 10.1074/jbc.270.43.25488; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; Malaisse WJ, 1997, BIOCHEM BIOPH RES CO, V231, P546, DOI 10.1006/bbrc.1996.5715; MATSUOKA TA, 1995, BIOCHEM BIOPH RES CO, V214, P239, DOI 10.1006/bbrc.1995.2280; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; Okamoto H, 1997, METHOD ENZYMOL, V280, P306; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; PRAZ GA, 1983, BIOCHEM J, V210, P345, DOI 10.1042/bj2100345; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; RUTTER GA, 1994, CELL CALCIUM, V16, P71, DOI 10.1016/0143-4160(94)90002-7; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TAKESHIMA H, 1995, EMBO J, V14, P2999, DOI 10.1002/j.1460-2075.1995.tb07302.x; TAKESUE S, 1970, J BIOCHEM-TOKYO, V67, P259, DOI 10.1093/oxfordjournals.jbchem.a129249; Tohgo A, 1997, J BIOL CHEM, V272, P3879, DOI 10.1074/jbc.272.7.3879; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074	42	107	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2497	2500		10.1074/jbc.273.5.2497	http://dx.doi.org/10.1074/jbc.273.5.2497			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446548	hybrid			2022-12-25	WOS:000071736600003
J	Wu, HJ; MacLeod, AR; Lima, WF; Crooke, ST				Wu, HJ; MacLeod, AR; Lima, WF; Crooke, ST			Identification and partial purification of human double strand RNase activity - A novel terminating mechanism for oligoribonucleotide antisense drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; ESCHERICHIA-COLI; GENE-EXPRESSION; III CLEAVAGE; OLIGONUCLEOTIDES; REPLICATION; TRANSLATION; INHIBITION; INVITRO; INVIVO	We have identified a double strand RNase (dsRNase) activity that can serve as a novel mechanism for chimeric antisense oligonucleotides comprised of 2'-methoxy 5' and 3' "wings" on either side of an oligoribonucleotide gap. Antisense molecules targeted to the point mutation in codon 12 of Harvey Ras (Ha-Ras) mRNA resulted in a dose-dependent reduction in Ha-Ras RNA, Reduction in Ha-Ras RNA was dependent on the oligoribonucleotide gap size with the minimum gap size being four nucleotides, An antisense oligonucleotide of the same composition, but containing four mismatches, was inactive. When chimeric antisense oligonucleotides were prehybridized with 17-mer oligoribonucleotides, extracts prepared from T24 cells, cytosol, and nuclei resulted in cleavage in the oligoribonucleotide gap, Both strands were cleaved. Neither mammalian nor Escherichia coli RNase HI cleaved the duplex, nor did single strand nucleases. The dsRNase activity resulted in cleavage products with 5'-phosphate and 8'-hydroxyl termini. Partial purification of dsRNase from rat liver cytosolic and nuclear fractions was effected, The cytosolic enzyme was purified approximately 165-fold. It has an approximate molecular weight of 50,000-65,000, a pH optimum of approximately 7.0, requires divalent cations, and is inactivated by approximately 300 mM NaCl. It is inactivated by heat, proteinase K, and also by a number of detergents and several organic solvents.	ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA	Isis Pharmaceuticals Inc	Crooke, ST (corresponding author), ISIS Pharmaceut, Dept Mol Pharmacol, 2292 Faraday Ave, Carlsbad, CA 92008 USA.							AbouElela S, 1996, CELL, V85, P115, DOI 10.1016/S0092-8674(00)81087-9; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BLOMBERG P, 1990, EMBO J, V9, P2331, DOI 10.1002/j.1460-2075.1990.tb07405.x; CESARENI G, 1991, TRENDS GENET, V7, P230, DOI 10.1016/0168-9525(91)90370-6; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; Crooke ST, 1996, J PHARMACOL EXP THER, V277, P923; CROOKE ST, 1995, THERAPEUTICS APPL OL, P1; CROUCH RJ, 1982, RIBONUCLEASE H NUCL, P211; CROUCH RJ, 1982, NUCLEASES, P21; CRUM C, 1988, NUCLEIC ACIDS RES, V16, P4569, DOI 10.1093/nar/16.10.4569; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DUNN JJ, 1975, J MOL BIOL, V99, P487, DOI 10.1016/S0022-2836(75)80140-9; GERDES K, 1992, J MOL BIOL, V226, P637, DOI 10.1016/0022-2836(92)90621-P; KRINKE L, 1990, GENE DEV, V4, P2223, DOI 10.1101/gad.4.12a.2223; MEEGAN JM, 1989, SCIENCE, V244, P1089, DOI 10.1126/science.2471268; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; NECKERS L, 1992, Critical Reviews in Oncogenesis, V3, P175; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NELLEN W, 1992, BIOCHEM SOC T, V20, P750, DOI 10.1042/bst0200750; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; SANKAR S, 1989, EUR J BIOCHEM, V184, P39, DOI 10.1111/j.1432-1033.1989.tb14987.x; SIEGEL V, 1988, P NATL ACAD SCI USA, V85, P1801, DOI 10.1073/pnas.85.6.1801; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277; STOLT P, 1993, MOL MICROBIOL, V7, P875, DOI 10.1111/j.1365-2958.1993.tb01178.x; SZYF M, 1991, J BIOL CHEM, V266, P10027; WANG M, 1994, P NATL ACAD SCI USA, V91, P10591, DOI 10.1073/pnas.91.22.10591; WEINBERG RA, 1988, CANCER-AM CANCER SOC, V61, P1963, DOI 10.1002/1097-0142(19880515)61:10<1963::AID-CNCR2820611005>3.0.CO;2-8	33	50	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2532	2542		10.1074/jbc.273.5.2532	http://dx.doi.org/10.1074/jbc.273.5.2532			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446554	hybrid			2022-12-25	WOS:000071736600009
J	Abu-Abed, SS; Beckett, BR; Chiba, H; Chithalen, JV; Jones, G; Metzger, D; Chambon, P; Petkovich, M				Abu-Abed, SS; Beckett, BR; Chiba, H; Chithalen, JV; Jones, G; Metzger, D; Chambon, P; Petkovich, M			Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor gamma and retinoid X receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERATOCARCINOMA STEM-CELLS; EMBRYONAL CARCINOMA-CELLS; INVITRO METABOLISM; DIFFERENTIATION; INDUCTION; KERATINOCYTES; 4-HYDROXYLASE; BIOSYNTHESIS; KETOCONAZOLE; DISRUPTION	We have cloned a mouse cDNA homolog of P450RAI, a cytochrome P450 belonging to a new family (CYP26), which has previously been isolated from zebrafish and human cDNAs and found to encode a retinoic acid-inducible retinoic acid hydroxylase activity. The cross-species conservation of the amino acid sequence is high, particularly between the mouse and the human enzymes, in which it is over 90%. Like its human and zibrafish counterparts, the mouse P450RAI cDNA catalyzes metabolism of retinoic acid into 4-OH-retinoic acid, 4-oxo-retinoic acid, 18-OH-retinoic acid, and unidentified water-soluble metabolites when transfected into COS-1 cells. Retinoic acid-inducible retinoic acid metabolism has previously been observed in F9 murine embryonal carcinoma cells and some derivatives lacking retinoid receptors. We were interested in determining whether P450RAI could be responsible for retinoic acid metabolism in F9 cells and in studying the effect of retinoid receptor ablation on P450RAI expression. In wild-type F9 cells and derivatives lacking RAR gamma, RAR alpha, and/or RXR alpha, we observed a direct relationship between the level of retinoic acid metabolic activity and retinoic acid-induced P450RAI mRNA. These experiments, as well as others using synthetic receptor subtype-specific retinoids, suggest that the RAR gamma and RXR alpha receptors mediate the effects of retinoic acid on the expression of the P450RAI gene.	Queens Univ, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Univ Strasbourg 1, Coll France, INSERM, CNRS,Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Queens University - Canada; Queens University - Canada; Queens University - Canada; Queens University - Canada; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Petkovich, M (corresponding author), Queens Univ, Canc Res Labs, Rm 355,Botterell Hall, Kingston, ON K7L 3N6, Canada.	petkovic@post.queensu.ca		Metzger, Daniel/0000-0002-5555-046X				Achkar CC, 1996, P NATL ACAD SCI USA, V93, P4879, DOI 10.1073/pnas.93.10.4879; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Clifford J, 1996, EMBO J, V15, P4142, DOI 10.1002/j.1460-2075.1996.tb00789.x; DeCoster R, 1996, J STEROID BIOCHEM, V56, P133, DOI 10.1016/0960-0760(95)00230-8; Duell EA, 1996, J INVEST DERMATOL, V106, P316, DOI 10.1111/1523-1747.ep12342972; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FISHER C, 1995, CRIT REV ORAL BIOL M, V6, P284, DOI 10.1177/10454411950060040201; Fisher GJ, 1996, FASEB J, V10, P1002, DOI 10.1096/fasebj.10.9.8801161; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; GUDAS LJ, 1994, RETINOIDS BIOL CHEM, V2, P443; Han IS, 1996, J CLIN ENDOCR METAB, V81, P2069, DOI 10.1210/jc.81.6.2069; Hofmann Clementine, 1994, P387; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kurlandsky SB, 1996, J BIOL CHEM, V271, P15346, DOI 10.1074/jbc.271.26.15346; LAMPRON C, 1995, DEVELOPMENT, V121, P539; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; Li CY, 1996, J BIOL CHEM, V271, P6810, DOI 10.1074/jbc.271.12.6810; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEANS AL, 1995, ANNU REV BIOCHEM, V64, P201, DOI 10.1146/annurev.bi.64.070195.001221; MEYSKENS FL, 1995, AM J CLIN NUTR, V62, P1417, DOI 10.1093/ajcn/62.6.1417S; Napoli JL, 1996, FASEB J, V10, P993, DOI 10.1096/fasebj.10.9.8801182; PIJNAPPEL WWM, 1993, NATURE, V366, P340, DOI 10.1038/366340a0; Ray WJ, 1997, J BIOL CHEM, V272, P18702, DOI 10.1074/jbc.272.30.18702; RIGAS JR, 1993, J NATL CANCER I, V85, P1921, DOI 10.1093/jnci/85.23.1921; ROBERTS AB, 1979, J BIOL CHEM, V254, P6303; ROBERTS AB, 1979, J BIOL CHEM, V254, P6296; Ross SA, 1996, NUTR REV, V54, P355; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Saari John C., 1994, P351; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; Taimi M, 1997, BIOCHEM BIOPH RES CO, V232, P432, DOI 10.1006/bbrc.1997.6309; Takatsuka J, 1996, CANCER RES, V56, P675; Taneja R, 1996, P NATL ACAD SCI USA, V93, P6197, DOI 10.1073/pnas.93.12.6197; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; Warrell RP, 1996, ANNU REV MED, V47, P555, DOI 10.1146/annurev.med.47.1.555; WHITE JA, 1994, DEVELOPMENT, V120, P1861; White JA, 1997, J BIOL CHEM, V272, P18538, DOI 10.1074/jbc.272.30.18538; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658	52	159	161	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2409	2415		10.1074/jbc.273.4.2409	http://dx.doi.org/10.1074/jbc.273.4.2409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442090	hybrid			2022-12-25	WOS:000071595200079
J	Boffa, MB; Wang, W; Bajzar, L; Nesheim, ME				Boffa, MB; Wang, W; Bajzar, L; Nesheim, ME			Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; HAMSTER-KIDNEY CELLS; PROTEIN-C; MAMMALIAN-CELLS; PROCARBOXYPEPTIDASE-B; CARBOXYPEPTIDASE-B; FACTOR-VIII; CLOT LYSIS; THROMBOMODULIN; PURIFICATION	Thrombin-activable fibrinolysis inhibitor (TAFI) is a human plasma zymogen similar to pancreatic pro-carboxypeptidase B, Cleavage of the zymogen by thrombin/thrombomodulin generates the enzyme, activated TAFI (TAFIa), which retards fibrin clot lysis in vitro and likely modulates fibrinolysis in vivo, In the present work we stably expressed recombinant TAFI in baby hamster kidney cells, purified it to homogeneity from conditioned serum-free medium, and compared it to plasma TAFI (pTAFI) with respect to glycosylation and kinetics of activation by thrombin/thrombomodulin. Although rTAFI is glycosylated somewhat differently than pTAFI, cleavage products with thrombin/thrombomodulin are indistinguishable, and parameters of activation kinetics are very similar with k(cat) = 0.55 s(-1), K-m = 0.54 mu M, and K-d = 6.0 nM for rTAFI and k(cat) = 0.61 s(-1), K-m = 0.55 mu M, and K-d = 6.6 nM for pTAFI, The respective TAFIa species also were prepared and compared with respect to thermal stability and enzymatic properties, including inhibition of fibrinolysis, The half-life of both enzymes at 37 degrees C is about 10 min, and the decay of enzymatic activity is associated with a quenching (to similar to 62% of the initial value at 60 min) of the intrinsic fluorescence of the enzyme, Stability was highly temperature-dependent, which, according to transition state theory, indicates both high enthalpy and entropy changes associated with inactivation (Delta H-o double dagger congruent to 45 kcal/mol and Delta S-o double dagger congruent to 80 cal/mol/K), Both species of TAFIa are stabilized by the competitive inhibitors 2-guanidinoethylmercaptosuccinic acid and epsilon-aminocaproic acid, rTAFIa and pTAFIa are very similar with respect to kinetics of cleavage of small substrates, susceptibility to inhibitors, and ability to retard both tPA-induced and plasmin-mediated fibrinolysis, These studies provide new insights into the thermal instability of TAFIa, a property which could be a significant regulator of its activity in vivo; in addition, they show that rTAFI and rTAFIa are excellent surrogates for the natural plasma-derived species, a necessary prerequisite for future studies of structure and function by site-specific mutagenesis.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Nesheim, ME (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064	NHLBI NIH HHS [P01-HL46703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BURDICK MD, 1987, THROMB RES, V45, P413, DOI 10.1016/0049-3848(87)90230-1; BUSBY SJ, 1991, J BIOL CHEM, V266, P15286; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COTE HCF, 1994, J BIOL CHEM, V269, P11374; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; EATON DL, 1991, J BIOL CHEM, V266, P21833; EATON DL, 1987, J BIOL CHEM, V262, P3285; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FAN BQ, 1993, J BIOL CHEM, V268, P17588; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HIRONAKA T, 1992, J BIOL CHEM, V267, P8012; MARSHALL AG, 1978, BIOPHYSICAL CHEM, P102; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7670, DOI 10.1021/bi00445a023; PARKINSON JF, 1990, J BIOL CHEM, V265, P12602; PEDERSEN AH, 1989, BIOCHEMISTRY-US, V28, P9331, DOI 10.1021/bi00450a013; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; Redlitz A, 1996, CIRCULATION, V93, P1328, DOI 10.1161/01.CIR.93.7.1328; RUDD PM, 1995, BBA-PROTEIN STRUCT M, V1248, P1, DOI 10.1016/0167-4838(94)00230-E; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; Valnickova Z, 1996, J BIOL CHEM, V271, P12937, DOI 10.1074/jbc.271.22.12937; Wang DI, 1996, FASEB J, V10, P82; WANG W, 1994, J BIOL CHEM, V269, P15937	31	154	165	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2127	2135		10.1074/jbc.273.4.2127	http://dx.doi.org/10.1074/jbc.273.4.2127			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442053	hybrid			2022-12-25	WOS:000071595200042
J	Huang, CH				Huang, CH			The human Rh50 glycoprotein gene - Structural organization and associated splicing defect resulting in Rh-null disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY SYNDROME; MOLECULAR-CLONING; DUFFY GENE; EXPRESSION; PROTEIN; ANTIGENS; PHENOTYPE; MEMBRANE; DELETION; LOCUS	The Rh (Rhesus) protein family comprises Rh50 glycoprotein and Rh30 polypeptides, which form a complex essential for Rh antigen expression and erythrocyte membrane integrity, This article describes the structural organization of Rh50 gene and identification of its associated splicing defect causing Rh-null disease, The Rh50 gene, which maps at chromosome 6p11-21.1, has an exon/intron structure nearly identical to Rh30 genes, which map at 1p34-36, Of the 10 exons assigned, conservation of size and sequence is confined mainly to the region from exons 2 to 9, suggesting that RH50 and RH30 were formed as two separate genetic loci from a common ancestor via a transchromosomal insertion event, The available information on the structure of RH50 facilitated search for candidate mutations underlying the Rh deficiency syndrome, an autosomal recessive disorder characterized by mild to moderate chronic hemolytic anemia and spherostomatocytosis. In one patient with the Rh-null disease of regulator type, a shortened Rh50 transcript lacking the sequence of exon 7 was detected, while no abnormality was found in transcripts encoding Rh30 polypeptides and Rh-related CD47 glycoprotein, Amplification and sequencing of the genomic region spanning exon 7 revealed a G --> A transition in the invariant GT motif of the donor splice site in both Rh50 alleles, This splicing mutation caused not only a total skipping of exon 7 but also a frameshift and premature chain termination, Thus, the deduced translation product contained 351 instead of 409 amino acids, with an entirely different C-terminal sequence following Thr(315), These results identify the donor splicing defect, for the first time, as a loss-of-function mutation at the RH50 locus and pinpoint the importance of the C-terminal region of Rh50 in Rh complex formation via protein-protein interactions.	New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, New York, NY 10021 USA	New York Blood Center	Huang, CH (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Biochem & Mol Genet, 310 E 67th St, New York, NY 10021 USA.				NHLBI NIH HHS [HL54459] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054459] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANSTEE DJ, 1993, BAILLIERE CLIN HAEM, V6, P401, DOI 10.1016/S0950-3536(05)80152-0; AVENT N, 1988, BIOCHEM J, V251, P499, DOI 10.1042/bj2510499; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; Avent ND, 1996, J BIOL CHEM, V271, P14233, DOI 10.1074/jbc.271.24.14233; CAMPBELL IG, 1992, CANCER RES, V52, P5416; CARRITT B, 1993, ANN HUM GENET, V57, P273, DOI 10.1111/j.1469-1809.1993.tb00900.x; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CARTRON JP, 1995, BLOOD CEL B, V6, P189; CHERIFZAHAR B, 1994, GENOMICS, V19, P68, DOI 10.1006/geno.1994.1014; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; CHERIFZAHAR B, 1993, BLOOD, V82, P656, DOI 10.1182/blood.V82.2.656.bloodjournal822656; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; Goossens M, 1981, Methods Enzymol, V76, P805; Hermand P, 1996, BLOOD, V87, P2962, DOI 10.1182/blood.V87.7.2962.bloodjournal8772962; Huang C H, 1997, Curr Opin Hematol, V4, P94; Huang CH, 1996, AM J HUM GENET, V58, P133; HUANG CH, 1987, BLOOD, V70, P1830; HUANG CH, 1991, BLOOD, V77, P381; Huang CH, 1996, BLOOD, V88, P2326, DOI 10.1182/blood.V88.6.2326.bloodjournal8862326; Huang CH, 1996, AM J HUM GENET, V59, P825; KRAWCZAK M, 1992, HUM GENET, V90, P41; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LINDBERG FP, 1994, J BIOL CHEM, V269, P1567; MALLINSON G, 1995, BRIT J HAEMATOL, V90, P823, DOI 10.1111/j.1365-2141.1995.tb05202.x; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; NASH R, 1987, AM J HEMATOL, V24, P267, DOI 10.1002/ajh.2830240306; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RACE RR, 1975, BLOOD GROUPS MAN, P78; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7156; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224	34	53	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2207	2213		10.1074/jbc.273.4.2207	http://dx.doi.org/10.1074/jbc.273.4.2207			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442063	hybrid			2022-12-25	WOS:000071595200052
J	Kawahara, T; Yanagi, H; Yura, T; Mori, K				Kawahara, T; Yanagi, H; Yura, T; Mori, K			Unconventional splicing of HAC1/ERN4 mRNA required for the unfolded protein response - Sequence-specific and non-sequential cleavage of the splice sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEIN; CELL-LINE; INDUCTION; KINASE; GENES; YEAST; GLUCOSE; NUCLEUS; GRP78	Accumulation of unfolded proteins in the endoplasmic reticulum (ER) activates an intracellullar signaling pathway from the ER to the nucleus, termed the unfolded protein response, We and others recently identified transcription factor Hac1p/Ern4p responsible for the response in Saccharomyces cerevisiae and found that Hac1p expression is controlled by the regulated splicing of HAC1 mRNA. Walter and co-workers (Sidrauski, C., Cox, J. S., and Walter, P. (1996) Cell, 87, 405-413) further showed that the splicing requires tRNA ligase but not spliceosome. In this report, we carried out mutational analysis of HAC1 mRNA and revealed several unique features of the splicing, First, a mutation or deletion of the branchpoint-like sequence present in HAC1 intron did not affect the splicing, Second, cleavage of the splice sites was sequence-specific and thus completely blocked by some point mutations introduced at the 5' or 3' splice site. Third, cleavage of the 5' and 3' splice sites could occur independently as judged by the nature of splicing intermediates accumulated, Fourth, swapping the nucleotide sequences of the 5' and 3' splice sites inhibited the ligation but not the cleavage step, We conclude that signaling from the ER activates putative endonucleases that can carry out sequence-specific cleavage of the splice sites in a random order.	HSP Res Inst, Shimogyo Ku, Kyoto 6008813, Japan		Mori, K (corresponding author), HSP Res Inst, Shimogyo Ku, Kyoto Res Pk, Kyoto 6008813, Japan.		Mori, Kazutoshi/K-6106-2015					Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; ELBEIN AD, 1981, TRENDS BIOCHEM SCI, V6, P219, DOI 10.1016/0968-0004(81)90080-3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kawahara T, 1997, MOL BIOL CELL, V8, P1845, DOI 10.1091/mbc.8.10.1845; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kreivi JP, 1996, CURR BIOL, V6, P802, DOI 10.1016/S0960-9822(02)00599-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; LI X, 1991, MOL CELL BIOL, V11, P3446, DOI 10.1128/MCB.11.7.3446; LITTLE E, 1995, J BIOL CHEM, V270, P9526, DOI 10.1074/jbc.270.16.9526; McMillan D. Randy, 1994, Current Opinion in Biotechnology, V5, P540, DOI 10.1016/0958-1669(94)90071-X; MORI K, 1993, CELL, V74, P743; Mori K, 1996, GENES CELLS, V1, P803, DOI 10.1046/j.1365-2443.1996.d01-274.x; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nikawa J, 1996, NUCLEIC ACIDS RES, V24, P4222, DOI 10.1093/nar/24.21.4222; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; Sambrook J., 2002, MOL CLONING LAB MANU; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Sherman F., 1986, METHODS YEAST GENETI; Sidrauski C, 1997, CELL, V90, P1031, DOI 10.1016/S0092-8674(00)80369-4; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Tarn WY, 1997, TRENDS BIOCHEM SCI, V22, P132, DOI 10.1016/S0968-0004(97)01018-9; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; Will CL, 1997, CURR OPIN CELL BIOL, V9, P320, DOI 10.1016/S0955-0674(97)80003-8	29	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1802	1807		10.1074/jbc.273.3.1802	http://dx.doi.org/10.1074/jbc.273.3.1802			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430730	hybrid			2022-12-25	WOS:000071411500077
J	Leber, R; Wise, TW; Mizuta, R; Meek, K				Leber, R; Wise, TW; Mizuta, R; Meek, K			The XRCC4 gene product is a target for and interacts with the DNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; V(D)J RECOMBINATION; SCID MUTATION; PHOSPHATIDYLINOSITOL 3-KINASE; JUNCTIONAL SEQUENCES; RECEPTOR GENES; CELL MUTANTS; KU ANTIGEN	The gene product of XRCC4 has been implicated in both V(D)J recombination and the more general process of double strand break repair (DSBR). To date its role in these processes is unknown, Here, we describe biochemical characteristics of the murine XRCC4 protein. XRCC4 expressed in insect cells exists primarily as a disulfide-linked homodimer, although it can also form large multimers. Recombinant XRCC4 is phosphorylated during expression in insect cells, XRCC4 phosphorylation in Sf9 cells occurs on serine, threonine, and tyrosine residues. We also investigated whether XRCC4 interacts with the other factor known to be requisite for both V(D)J recombination and DSBR, the DNA-dependent protein kinase. We report that XRCC4 is an efficient in vitro substrate of DNA-PR and another unidentified serine/ threonine protein kinase(s). Both DNA-PK dependent and independent phosphorylation of XRCC4 in vitro occurs only on serine and threonine residues within the COOH-terminal 130 amino acids, a region of the molecule that is not absolutely required for XRCC4's DSBR function, Finally, recombinant XRCC4 facilitates Ku binding to DNA, promoting assembly of DNA-PK and complexing with DNA-PK bound to DNA, These data are consistent with the hypothesis that XRCC4 functions as an alignment factor in the DNA-PK complex.	Univ Texas, SW Med Ctr, Dept Internal Med, Harold C Simmons Arthrit Res Ctr, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Program Immunol, Dallas, TX 75235 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School	Meek, K (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, Harold C Simmons Arthrit Res Ctr, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIAID NIH HHS [R01 AI048758, AI31229, AI32600] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI031229, R01AI048758, R01AI032600] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FEENEY AJ, 1991, J EXP MED, V174, P115, DOI 10.1084/jem.174.1.115; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; Hart Gerald W., 1992, Current Opinion in Cell Biology, V4, P1017, DOI 10.1016/0955-0674(92)90134-X; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LANDOLFI NF, 1986, NATURE, V323, P548, DOI 10.1038/323548a0; LEE SE, 1995, MUTAT RES-DNA REPAIR, V336, P279, DOI 10.1016/0921-8777(95)00002-2; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEU TMJ, 1995, MOL CELL BIOL, V15, P5657; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; OKADA T, 1994, J BIOL CHEM, V269, P3563; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1989, CELL, V59; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; WILER R, 1995, P NATL ACAD SCI USA, V92, P11485, DOI 10.1073/pnas.92.25.11485; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	47	153	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1794	1801		10.1074/jbc.273.3.1794	http://dx.doi.org/10.1074/jbc.273.3.1794			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430729	hybrid			2022-12-25	WOS:000071411500076
J	Terada, K; Nakako, T; Yang, XL; Iida, M; Aiba, N; Minamiya, Y; Nakai, M; Sakaki, T; Miura, N; Sugiyama, T				Terada, K; Nakako, T; Yang, XL; Iida, M; Aiba, N; Minamiya, Y; Nakai, M; Sakaki, T; Miura, N; Sugiyama, T			Restoration of holoceruloplasmin synthesis in LEC rat after infusion of recombinant adenovirus bearing WND cDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; COPPER TRANSPORTING ATPASE; P-TYPE ATPASES; HUMAN HEPATOCYTES; CYSTIC-FIBROSIS; CERULOPLASMIN; EXPRESSION; DEFICIENCY; PROTEIN; THERAPY	Wilson's disease, an autosomal recessive disorder, is characterized by the excessive accumulation of copper in the liver. WND (ATP7B) gene, which encodes a putative copper transporting P-type ATPase, is defective in the patients. To investigate the in vivo function of WND protein as well as its intracellular localization, WND cDNA was introduced to the Long-Evans Cinnamon rat, known as a rodent model for Wilson's disease, by recombinant adenovirus-mediated gene delivery. An immunofluorescent study and a subcellular fractionation study revealed the transgene expression in liver and its localization to the Golgi apparatus. Moreover, since the synthesis of holoceruloplasmin is disturbed in the Long-Evans Cinnamon rat, the plasma level of holoceruloplasmin, oxidase-active and copper-bound form, was examined to evaluate the function of WND protein with respect to the copper transport. Consequently, the appearance of holoceruloplasmin in plasma was confirmed by Western blot analysis and plasma measurements for the oxidase activity and the copper content. These findings indicate that introduced WND protein may function in the copper transport coupled with the synthesis of ceruloplasmin and that the Golgi apparatus is the likely site for WND protein to manifest its function.	Akita Univ, Sch Med, Dept Biochem, Akita 010, Japan; Akita Univ, Sch Med, Dept Surg, Akita 010, Japan; Sumitomo Pharmaceut Co Ltd, Res Ctr, Discovery Res Labs 3, Osaka 554, Japan	Akita University; Akita University	Sugiyama, T (corresponding author), Akita Univ, Sch Med, Dept Biochem, Hondo 1-1-1, Akita 010, Japan.	sugiyama@med.akita-u.ac.jp						BUIL PC, 1993, NAT GENET, V5, P327; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; ENGELHARDT JF, 1994, P NATL ACAD SCI USA, V91, P6196, DOI 10.1073/pnas.91.13.6196; FRIEDEN E, 1981, MET IONS BIOL SYST, V13, P117; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KAY MA, 1994, TRENDS GENET, V10, P253, DOI 10.1016/0168-9525(94)90173-2; Kiwaki K, 1996, HUM GENE THER, V7, P821, DOI 10.1089/hum.1996.7.7-821; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MCKEE DJ, 1971, BIOCHEMISTRY-US, V10, P3880, DOI 10.1021/bi00797a013; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORI M, 1991, LEC RAT NEW MODEL HE, P122; MORREL AG, 1969, J BIOL CHEM, V244, P3494; MORSY MA, 1993, J CLIN INVEST, V92, P1580, DOI 10.1172/JCI116739; Muzzin P, 1996, P NATL ACAD SCI USA, V93, P14804, DOI 10.1073/pnas.93.25.14804; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1994, HUM MOL GENET, V3, P1647, DOI 10.1093/hmg/3.9.1647; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; SAITO I, 1985, J VIROL, V54, P711, DOI 10.1128/JVI.54.3.711-719.1985; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHEINBERG IH, 1984, WILSONS DIS SERIES M, V23; SCHILSKY ML, 1994, AM J PHYSIOL, V266, pG907, DOI 10.1152/ajpgi.1994.266.5.G907; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SUZUKI M, 1994, PEDIATR RES, V35, P598, DOI 10.1203/00006450-199405000-00012; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TERADA K, 1995, J BIOL CHEM, V270, P20410, DOI 10.1074/jbc.270.35.20410; TERADA K, 1995, BBA-MOL BASIS DIS, V1270, P58, DOI 10.1016/0925-4439(94)00072-X; THOMAS GR, 1995, NAT GENET, V9, P210, DOI 10.1038/ng0295-210; TRIPATHY SK, 1996, NAT MED, V2, P546; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WU JS, 1994, NAT GENET, V7, P541, DOI 10.1038/ng0894-541; YAMADA T, 1993, J BIOL CHEM, V268, P8965; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1994, BIOCHEM J, V301, P1; Yang XL, 1997, BIOCHEM J, V326, P897, DOI 10.1042/bj3260897; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Ye XH, 1996, J BIOL CHEM, V271, P3639; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	46	133	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1815	1820		10.1074/jbc.273.3.1815	http://dx.doi.org/10.1074/jbc.273.3.1815			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430732	hybrid			2022-12-25	WOS:000071411500079
J	Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S				Komurasaki, T; Toyoda, H; Uchida, D; Morimoto, S			Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4	ONCOGENE			English	Article						epiregulin; EGF family; ErbB receptors; tyrosine phosphorylation	NEU DIFFERENTIATION FACTOR; HUMAN-BREAST CANCER; TUMOR-CELL-LINES; EGF RECEPTOR; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; NERVOUS-SYSTEM; GENE-PRODUCT; FACTOR-ALPHA; PROTEIN	Epiregulin is a member of the epidermal growth factor (EGF) family, and has certain characteristics that are different from that of EGF, including mitogenic responses and binding to EGF receptor (EGFR). Epiregulin may also have another cell surface receptor and/or induces different receptor heterodimerizations for intracellular signaling. We investigated the binding ability of epiregulin to four ErbB family receptors using four human breast carcinoma cell lines that expressed different subsets of receptors. Chemical cross-linking experiments showed that [I-125]epiregulin directly bound to each of EGFR and ErbB-4 but not to ErbB-2 and ErbB-3. Furthermore, although epiregulin stimulated tyrosine phosphorylation of all four ErbB receptors, the main intracellular signal was mediated by ErbB-4 and/or EGFR. The pattern of activation of ErbB family receptors was different from that of other EGF-related ligands. Our findings indicate that ErbB-4 and EGFR are receptors for epiregulin, and suggest that EGF-related ligands transduce signals for different biological responses by the hierarchical mechanism.			Komurasaki, T (corresponding author), TAISHO PHARMACEUT CO LTD, MED RES LABS, MOL BIOL LAB, 1-403 YOSHINO CHO, OHMIYASHI, SAITAMA 330, JAPAN.							ALIMANDI M, 1995, ONCOGENE, V10, P1813; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; HANCOCK MC, 1991, CANCER RES, V51, P4575; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOMES WE, 1992, SCIENCE, V256, P1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEE DC, 1995, PHARMACOL REV, V47, P51; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; PinkasKramarski R, 1996, J BIOL CHEM, V271, P19029, DOI 10.1074/jbc.271.32.19029; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIGENT SA, 1992, ONCOGENE, V7, P1273; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SAVAGE CR, 1972, J BIOL CHEM, V247, P7612; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; Toyoda H, 1995, FEBS LETT, V377, P403, DOI 10.1016/0014-5793(95)01403-9; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	49	117	122	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	1997	15	23					2841	2848		10.1038/sj.onc.1201458	http://dx.doi.org/10.1038/sj.onc.1201458			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419975				2022-12-25	WOS:A1997YJ80300010
J	Kinscherf, R; Deigner, HP; Usinger, C; Pill, J; Wagner, M; Kamencic, H; Hou, DM; Chen, M; Schmiedt, W; Schrader, M; Kovacs, G; Kato, K; Metz, J				Kinscherf, R; Deigner, HP; Usinger, C; Pill, J; Wagner, M; Kamencic, H; Hou, DM; Chen, M; Schmiedt, W; Schrader, M; Kovacs, G; Kato, K; Metz, J			Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits	FASEB JOURNAL			English	Article						antioxidants; apoptosis; glutathione; p53	LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; LIPID-PROTEIN ADDUCTS; ANTIOXIDANT ENZYMES; OXIDATIVE STRESS; INTRACELLULAR GLUTATHIONE; PROTECTIVE ROLE; HUMAN-MONOCYTES; FREE-RADICALS; VITAMIN-E	The objective of the study was to analyze the intracellular antioxidative response of macrophages (M Phi) exposed to increased levels of low density lipoprotein (LDL). We studied manganese superoxide dismutase (MnSOD) and, in part, GSH in cultured human and rabbit M Phi, and in atheromatous arterial tissue of humans and heritable hyperlipidemic (HHL) rabbits. Incubation of human M Phi with oxidized-LDL (ox-LDL) resulted in an induction of MnSOD mRNA production as shown by RT-PCR. MnSOD immunoreactivity (IR) was found to be located in the mitochondria of M Phi. In HHL rabbits, MnSOD activity and GSH concentration were significantly increased in atherosclerotic intima compared to the media of the aorta, but significantly decreased (P < 0.01) in larger plaques compared with smaller ones, resulting in a significant inverse correlation of MnSOD activity (r = -0.67, P < 0.001) and GSH concentration (r = -0.57, P < 0.01) with plaque size. Immunohistology of the atherosclerotic intima revealed MnSOD-IR in Mac-1 (CD 11b/CD 18)-immunoreactive (ir) M Phi of human arteries and, similarly, in RAM-11-ir M Phi, of rabbit ones. The relation of MnSOD-ir M Phi decreased with plaque advancement, which is consistent with biochemical finding. Most MnSOD-ir M Phi in atherosclerotic plaques revealed TUNEL-positive nuclei, indicating DNA strand breaks, and p53-1R. We conclude that mitochondrial antioxidants such as MnSOD are induced in M Phi in vitro and in atherosclerotic arteries as a reply to increased mitochondrial oxidation. As normal consequences of an increased oxidative stress due to the exposure to ox-LDL nuclear DNA strand breaks occur, which are suggested to be a signal to increase p53 protein levels. Reactive oxygen species-mediated mitochondrial-dependent pathways are suggested as major contributing pathomechanisms to nuclear damage, which eventually may result in apoptosis. A common response to increased oxidative stress due to modified LDL is presumed in rabbit and human atherosclerotic plaques.	Univ Heidelberg, Dept Anat & Cell Biol 3, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Anat & Cell Biol 2, D-69120 Heidelberg, Germany; Univ Heidelberg, Inst Pharmaceut Chem, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Urol, D-69120 Heidelberg, Germany; Dept Cardiothorac & Vasc Surg, D-55101 Mainz, Germany; Boehringer Mannheim GmbH, Dept Preclin Res, D-68298 Mannheim, Germany; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 48003, Japan	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kinscherf, R (corresponding author), Univ Heidelberg, Dept Anat & Cell Biol 3, INF 307, D-69120 Heidelberg, Germany.		Kinscherf, Ralf/AAV-7164-2021					ASAYAMA K, 1985, AM J PHYSIOL, V249, pC393, DOI 10.1152/ajpcell.1985.249.5.C393; Bjorkerud S, 1996, AM J PATHOL, V149, P367; BOCCIO GD, 1990, ATHEROSCLEROSIS, V81, P127; COHN ZA, 1965, J EXP MED, V121, P153, DOI 10.1084/jem.121.1.153; DARLEYUSMAR VM, 1991, BIOCHEM J, V278, P429, DOI 10.1042/bj2780429; DAUGHERTY A, 1995, CARDIOVASC RES, V29, P297, DOI 10.1016/0008-6363(96)88585-3; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DHAUNSI GS, 1994, CARCINOGENESIS, V15, P1923, DOI 10.1093/carcin/15.9.1923; ESTERBAUER H, 1989, FETT WISS TECHNOL, V91, P316, DOI 10.1002/lipi.19890910805; Gomez EO, 1996, BIOCHEM BIOPH RES CO, V228, P505, DOI 10.1006/bbrc.1996.1690; GOTOH N, 1993, BIOCHEM J, V296, P151, DOI 10.1042/bj2960151; GOTZ C, 1995, REV PHYSL BIOCH PHAR, V127, P64; GRECO AV, 1990, EXP PATHOL-JENA, V40, P19, DOI 10.1016/S0232-1513(11)80281-1; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HAN DKM, 1995, AM J PATHOL, V147, P267; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HARRIS ED, 1992, FASEB J, V6, P2675, DOI 10.1096/fasebj.6.9.1612291; Henkart PA, 1996, J EXP MED, V183, P1293, DOI 10.1084/jem.183.4.1293; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOFFMAN R, 1992, ATHEROSCLEROSIS, V93, P105, DOI 10.1016/0021-9150(92)90204-T; HOSHIDA S, 1993, AM J PHYSIOL, V264, pH33, DOI 10.1152/ajpheart.1993.264.1.H33; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KAESBERG B, 1993, ARTERIOSCLER THROMB, V13, P133, DOI 10.1161/01.ATV.13.1.133; KIKKAWA Y, 1984, LAB INVEST, V50, P62; KINSCHERF R, 1994, FASEB J, V8, P448, DOI 10.1096/fasebj.8.6.7909525; KINSCHERF R, 1995, HISTOCHEM CELL BIOL, V104, P295, DOI 10.1007/BF01464325; Kinscherf R, 1997, FEBS LETT, V405, P55, DOI 10.1016/S0014-5793(97)00157-9; KUZUYA M, 1989, BIOCHEM BIOPH RES CO, V163, P1466, DOI 10.1016/0006-291X(89)91144-3; MACHLIN LJ, 1987, FASEB J, V1, P441, DOI 10.1096/fasebj.1.6.3315807; MANTHA SV, 1993, ATHEROSCLEROSIS, V101, P135, DOI 10.1016/0021-9150(93)90110-G; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; MASUDA A, 1988, FASEB J, V2, P3087, DOI 10.1096/fasebj.2.15.3263930; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; METZ J, 1990, Z GERONTOL, V23, P140; Nakano T, 1996, CANCER RES, V56, P2771; Napoli C, 1994, Cardiologia, V39, P345; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; PARATHASARATHY S, 1986, J CLIN INVEST, V77, P641; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; POLIMENI PI, 1987, COMPUT BIOMED RES, V20, P113, DOI 10.1016/0010-4809(87)90039-5; Polla BS, 1996, FREE RADICAL RES, V25, P125, DOI 10.3109/10715769609149917; PORRECA E, 1993, ATHEROSCLEROSIS, V100, P141, DOI 10.1016/0021-9150(93)90200-E; REID VC, 1993, J PATHOL, V171, P321, DOI 10.1002/path.1711710413; Roma P, 1996, ATHEROSCLEROSIS, V127, P147, DOI 10.1016/S0021-9150(96)05952-7; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSENFELD ME, 1991, J CLIN INVEST, V87, P90, DOI 10.1172/JCI115006; SARAFIAN TA, 1994, FREE RADICAL RES, V21, P1, DOI 10.3109/10715769409056549; SCACCINI C, 1994, FREE RADICAL BIO MED, V16, P49, DOI 10.1016/0891-5849(94)90242-9; SCHRADER M, 1994, EUR J CELL BIOL, V64, P281; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SCHWARTZ SM, 1995, AM J PATHOL, V147, P229; SLOT JW, 1986, LAB INVEST, V55, P363; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUKADA T, 1986, ARTERIOSCLEROSIS, V6, P601, DOI 10.1161/01.ATV.6.6.601; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	67	88	91	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1317	1328		10.1096/fasebj.11.14.9409551	http://dx.doi.org/10.1096/fasebj.11.14.9409551			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409551				2022-12-25	WOS:000071144100013
J	Vitale, N; Moss, J; Vaughan, M				Vitale, N; Moss, J; Vaughan, M			Molecular characterization of the GTPase-activating domain of ADP-ribosylation factor domain protein 1 (ARD1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEIN; BINDING-PROTEIN; CHOLERA-TOXIN; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-D; ACID PHOSPHOLIPIDS; CHROMAFFIN CELLS; GOLGI MEMBRANES; ALPHA-SUBUNIT; FACTOR-I	ADP-ribosylation factors (ARFs) are similar to 20-kDa guanine nucleotide-binding proteins recognized as critical components in intracellular vesicular transport and phospholipase D activation, Both guanine nucleotide-exchange proteins and GTPase-activating proteins (GAPs) for ARFs have been cloned recently. A zinc finger motif near the amino terminus of the ARF1 GAP was required for stimulation of GTP hydrolysis. ARD1 is an ARF family member that differs from other ARFs by the presence of a 46-kDa amino-terminal extension, We had reported that the ARF domain of ARD1 binds specifically GDP and GTP and that the amino-terminal extension acts as a GAP for the ARF domain of ARD1 but not for ARF proteins, The GAP domain of ARD1, synthesized in Escherichia coli, stimulated hydrolysis of GTP bound to the ARF domain of ARD1, Using ARD1 truncations, it appears that amino acids 101-190 are critical for GAP activity, whereas residues 190-333 are involved in physical interaction between the two domains of ARD1 and are required for GTP hydrolysis. The GAP function of the amino-terminal extension of ARD1 required two arginines, an intact zinc finger motif, and a group of residues which resembles a sequence present in Rho/Pac GAPs, Interaction between the two domains of ARD1 required two negatively charged residues (Asp(427) and Glu(428)) located in the effector region of the ARF domain and two basic amino acids (Arg(249) and Lys(250)) found in the amino-terminal extension, The GAP domain of ARD1 thus is similar to ARF GAPs but differs from other GAPs in its covalent association with the GTP-binding domain.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vitale, N (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Room 5N-307,Bldg 10,10 Ctr Dr,MSC 1434, Bethesda, MD 20892 USA.	vitalen@fido.nhlbi.nih.gov	Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907				Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; Barrett T, 1997, NATURE, V385, P458, DOI 10.1038/385458a0; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Burton JL, 1997, J BIOL CHEM, V272, P3663, DOI 10.1074/jbc.272.6.3663; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CUKIERMAN E, 1995, SCIENCE, V270, P1999, DOI 10.1126/science.270.5244.1999; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ding M, 1996, J BIOL CHEM, V271, P24005, DOI 10.1074/jbc.271.39.24005; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; HONG JX, 1995, P NATL ACAD SCI USA, V92, P3056, DOI 10.1073/pnas.92.7.3056; HONG JX, 1994, J BIOL CHEM, V269, P9743; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; MAKLER V, 1995, J BIOL CHEM, V270, P5232, DOI 10.1074/jbc.270.10.5232; MARKBY DW, 1993, SCIENCE, V262, P1895, DOI 10.1126/science.8266082; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MISHIMA K, 1993, J BIOL CHEM, V268, P8801; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Poon PP, 1996, P NATL ACAD SCI USA, V93, P10074, DOI 10.1073/pnas.93.19.10074; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TERUI T, 1994, J BIOL CHEM, V269, P28130; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TSAI SC, 1988, J BIOL CHEM, V263, P1768; Tsai SC, 1996, P NATL ACAD SCI USA, V93, P305, DOI 10.1073/pnas.93.1.305; TSAI SC, 1993, J BIOL CHEM, V268, P10820; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; Vitale N, 1997, J BIOL CHEM, V272, P3897, DOI 10.1074/jbc.272.7.3897; Vitale N, 1997, J BIOL CHEM, V272, P25077, DOI 10.1074/jbc.272.40.25077; Vitale N, 1996, P NATL ACAD SCI USA, V93, P1941, DOI 10.1073/pnas.93.5.1941; VITALE N, 1993, J BIOL CHEM, V268, P14715; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; ZHANG GF, 1995, J BIOL CHEM, V270, P21, DOI 10.1074/jbc.270.1.21	55	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2553	2560		10.1074/jbc.273.5.2553	http://dx.doi.org/10.1074/jbc.273.5.2553			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446556	hybrid			2022-12-25	WOS:000071736600011
J	Hallstrom, TC; Moye-Rowley, WS				Hallstrom, TC; Moye-Rowley, WS			Divergent transcriptional control of multidrug resistance genes in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING CASSETTE TRANSPORTER; DRUG-RESISTANCE; ENCODING GENE; METAL RESISTANCE; PLEIOTROPIC DRUG; YEAST; EXPRESSION; PROTEIN; PDR1; OVEREXPRESSION	Improper control of expression of ATP binding cassette transporter encoding genes is an important contributor to acquisition of multidrug resistance in human tumor cells, La this study, we have analyzed the function of the promoter region of the Saccharomyces cerevisiae YOR1 gene, which encodes an ATP binding cassette transporter protein that is required for multidrug tolerance in S. cerevisiae, Deletion analysis of a YOR1-lacZ fusion gene defines three important transcriptional regulatory elements, Two of these elements serve to positively regulate expression of YOR1, and the third element is a negative regulatory site, One positive element corresponds to a Pdr1p/Pdr3p response element, a site required for transcriptional control by the homologous zinc finger transcription factors Pdr1p and Pdr3p in other promoters, The second positive element is located between nucleotides -535 and -299 and is referred to as UAS(YOR1) (where UAS is upstream activation sequence), Interestingly, function of UA(YOR1) is inhibited by the downstream negative regulatory site, Promoter fusions constructed between UAS(YOR1) and the PDR5 promoter, another gene under Pdr1p/Pdr3p control, are active, whereas analogous promoter fusions constructed with the CYC1 promoter are not. This suggests the possibility that UAS(YOR1) has promoter-specific sequence requirements that are satisfied by another Pdr1p/Pdr3p-regulated gene but not by a heterologous promoter.	Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Moye-Rowley, WS (corresponding author), Univ Iowa, Program Mol Biol, Iowa City, IA 52242 USA.		Moye-Rowley, Scott/AFL-7135-2022	Moye-Rowley, Scott/0000-0002-7163-1120	NIGMS NIH HHS [GM49825] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049825] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Cui ZF, 1996, J BIOL CHEM, V271, P14712, DOI 10.1074/jbc.271.25.14712; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARSHMAN KD, 1988, CELL, V53, P321, DOI 10.1016/0092-8674(88)90393-5; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; IYER V, 1995, MOL CELL BIOL, V15, P7059; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KOVARI L, 1990, MOL CELL BIOL, V10, P5087, DOI 10.1128/MCB.10.10.5087; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; PELLMAN D, 1990, NATURE, V348, P82, DOI 10.1038/348082a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SHATZMAN AR, 1987, METHOD ENZYMOL, V152, P661; Sherman F, 1979, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; SUMRADA RA, 1987, P NATL ACAD SCI USA, V84, P3997, DOI 10.1073/pnas.84.12.3997; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; WU AL, 1993, J BIOL CHEM, V268, P18850	35	37	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2098	2104		10.1074/jbc.273.4.2098	http://dx.doi.org/10.1074/jbc.273.4.2098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442049	hybrid			2022-12-25	WOS:000071595200038
J	Henriksen, A; Welinder, KG; Gajhede, M				Henriksen, A; Welinder, KG; Gajhede, M			Structure of barley grain peroxidase refined at 1.9-angstrom resolution - A plant peroxidase reversibly inactivated at neutral pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COPRINUS-CINEREUS PEROXIDASE; CRYSTAL-STRUCTURE; HORSERADISH-PEROXIDASE; PHANEROCHAETE-CHRYSOSPORIUM; ANGSTROM RESOLUTION; ASP245->ASN MUTANT; FUNGAL PEROXIDASE; LIGNIN PEROXIDASE; RESONANCE RAMAN	The crystal structure of the major peroxidase of barley grain (BP 1) has been solved by molecular replacement and phase combination and refined to an R-factor of 19.2% for all data between 38 and 1.9 Angstrom, The refined model includes amino acid residues 1-309, one calcium ion, one sodium ion, iron-protoporphyrin IX, and 146 solvent molecules, BP 1 has the apparently unique property of being unable to catalyze the reaction with the primary substrate hydrogen peroxide to form compound I at pH values > 5, a feature investigated by obtaining crystal structure data at pH 5.5, 7.5, and 8.5, Structural comparison shows that the overall fold of inactive barley grain peroxidase at these pH values resembles that of both horseradish peroxidase C and peanut peroxidase, The key differences between the structures of active horseradish peroxidase C and inactive BP 1 include the orientation of the catalytic distal histidine, disruption of a hydrogen bond between this histidine and a conserved asparagine, and apparent substitution of calcium at the distal cation binding site with sodium at pH 7.5. These profound changes are a result of a dramatic structural rearrangement to the loop region between helices B and C, This is the first time that structural rearrangements linked to active site chemistry have been observed by crystallography in the peroxidase domain distal to heme.	Univ Copenhagen, Inst Chem, Dept Phys Chem, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Dept Prot Chem, DK-1353 Copenhagen K, Denmark	University of Copenhagen; University of Copenhagen	Henriksen, A (corresponding author), Univ Copenhagen, Inst Chem, Dept Phys Chem, Univ Pk 5, DK-2100 Copenhagen O, Denmark.	anette@jerne.ki.ku.dk		Welinder, Karen Gjesing/0000-0002-5409-0131; Henriksen, Anette/0000-0003-4051-5079; Gajhede, Michael/0000-0001-9864-2287				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Greppin H., 1993, PLANT PEROXIDASES BI, P35; HASCHKE RH, 1978, BIOCHEM BIOPH RES CO, V80, P1039, DOI 10.1016/0006-291X(78)91350-5; HENRIKSEN A, 1992, J MOL BIOL, V228, P690, DOI 10.1016/0022-2836(92)90851-A; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MORISHIMA I, 1986, J BIOL CHEM, V261, P9391; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; PETERSEN JFW, 1994, FEBS LETT, V339, P291, DOI 10.1016/0014-5793(94)80433-8; PIONTEK K, 1993, FEBS LETT, V315, P119, DOI 10.1016/0014-5793(93)81146-Q; POULOS TL, 1980, J BIOL CHEM, V255, P575; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RASMUSSEN CB, 1993, FEBS LETT, V321, P102, DOI 10.1016/0014-5793(93)80630-D; Rasmussen CB, 1997, PHYSIOL PLANTARUM, V100, P102, DOI 10.1034/j.1399-3054.1997.1000110.x; Rasmussen CB, 1998, J BIOL CHEM, V273, P2232, DOI 10.1074/jbc.273.4.2232; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SMULEVICH G, 1991, BIOCHEMISTRY-US, V30, P9546, DOI 10.1021/bi00103a023; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; VEITCH NC, 1995, EUR J BIOCHEM, V233, P650, DOI 10.1111/j.1432-1033.1995.650_2.x; Veitch NC, 1996, BIOCHEMISTRY-US, V35, P14370, DOI 10.1021/bi961582t; Welinder K.G, 1992, PLANT PEROXIDASES, P1; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]	36	80	83	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2241	2248		10.1074/jbc.273.4.2241	http://dx.doi.org/10.1074/jbc.273.4.2241			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442067	hybrid			2022-12-25	WOS:000071595200056
J	Klarlund, JK; Rameh, LE; Cantley, LC; Buxton, JM; Holik, JJ; Sakelis, C; Patki, V; Corvera, S; Czech, MP				Klarlund, JK; Rameh, LE; Cantley, LC; Buxton, JM; Holik, JJ; Sakelis, C; Patki, V; Corvera, S; Czech, MP			Regulation of GRP1-catalyzed ADP ribosylation factor guanine nucleotide exchange by phosphatidylinositol 3,4,5-trisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GOLGI-APPARATUS; PROTEIN; 3-KINASE; KINASES; DOMAINS	Cellular levels of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3) are rapidly elevated in response to activation of growth factor receptor tyrosine kinases. This polyphosphoinositide binds the pleckstrin homology (PH) domain of GRP1, a protein that also contains 200 residues with high sequence similarity to a segment of the yeast Sec7 protein that functions as an ADP ribosylation exchange factor (ARF) (Klarlund, J., Guilherme, A., Holik, J. J., Virbasius, J. V., Chawla, A. and Czech, M. P. (1997) Science 275, 1927-1930). Here we show that dioctanoyl PtdIns(3,4,5)P, binds the PH domain of GRP1 with a K-d = 0.5 mu M, an affinity 2 orders of magnitude greater than dioctanoyl-PtdIns(4,5)P-2. Further, the Sec7 domain of GRP1 is found to catalyze guanine nucleotide exchange of ARF1 and -5 but not ARF6. Importantly, PtdIns(3,4,5)P-3, but not PtdIns(4,5)P-2, markedly enhances the ARF exchange activity of GRP1 in a reaction mixture containing dimyristoylphosphatidylcholine micelles, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid, and a low concentration of sodium cholate. PtdIns(3,4,5)P-3-mediated ARF nucleotide exchange through GRP1 is selectively blocked by 100 mu M inositol 1,3,4,5-tetrakisphosphate, which also binds the PH domain of GRP1. Taken together, these data are consistent with the hypothesis that selective recruitment of GRP1 to PtdIns(3,4,5)P-3 in membranes activates ARF1 and -5, known regulators of intracellular membrane trafficking.	Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01605 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Signal Transduct, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Czech, MP (corresponding author), Univ Massachusetts, Med Ctr, Program Mol Med, Worcester, MA 01605 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648, R01DK030898, R37DK030898, R01DK040330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30898, DK40330, DK30648] Funding Source: Medline; NIGMS NIH HHS [R01 GM041890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RT, 1996, CURR OPIN IMMUNOL, V8, P412, DOI 10.1016/S0952-7915(96)80132-4; ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; Kasuga M, 1996, DIABETIC MED, V13, pS87; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; MACCI E, 1997, P NATL ACAD SCI USA, V94, P1745; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Ptasznik A, 1996, J BIOL CHEM, V271, P25204, DOI 10.1074/jbc.271.41.25204; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; Shepherd PR, 1996, TRENDS CELL BIOL, V6, P92, DOI 10.1016/0962-8924(96)80998-6; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3063, DOI 10.1073/pnas.91.8.3063; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; Zvelebil MJ, 1996, PHILOS T R SOC B, V351, P217, DOI 10.1098/rstb.1996.0019	29	138	140	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1859	1862		10.1074/jbc.273.4.1859	http://dx.doi.org/10.1074/jbc.273.4.1859			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442017	hybrid			2022-12-25	WOS:000071595200006
J	Tramonti, A; De Biase, D; Giartosio, A; Bossa, F; John, RA				Tramonti, A; De Biase, D; Giartosio, A; Bossa, F; John, RA			The roles of His-167 and His-275 in the reaction catalyzed by glutamate decarboxylase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-METHIONINE DECARBOXYLASE; SUBSTRATE DECARBOXYLATION; ABORTIVE TRANSAMINATION; STEREOCHEMICAL COURSE; ACID DECARBOXYLASE; AMINOTRANSFERASE; PURIFICATION; 4-AMINOBUTYRATE; SPECIFICITY; MECHANISM	Two histidine residues in glutamate decarboxylase from Escherichia coli, potential participants in catalysis because they are conserved among amino acid decarboxylases and because they are at the active site in the homologous enzyme ornithine decarboxylase, were mutated, His-275 is shown to bind the cofactor pyridoxal 5'-phosphate but not to contribute directly to catalysis, The H275N enzyme was unable to bind the cofactor whereas the H275Q mutant contained 50% of the normal complement of cofactor and its specific activity (expressed per mole of cofactor) was 70% of that of the wild-type enzyme, The H167N mutant bound the cofactor tightly, its specific activity was approximately half that of the wild-type enzyme and experiments in D2O showed that it catalyzed replacement of the carboxyl group with retention of configuration as does the wildtype enzyme, Comparison of reaction profiles by observing changes in the absorbance of the cofactor after stopped-flow mixing, revealed that a slow reaction, in which approximately one-third of the wild-type enzyme is converted to an unreactive complex during catalysis, does not occur with the H167N mutant enzyme, This reaction is attributed to a substrate-induced conformational change, a proposal that is supported by differential scanning calorimetry.	Univ Wales, Sch Mol & Med Biosci, Cardiff CF1 1XL, S Glam, Wales; Univ La Sapienza, Consiglio Nazl Ric, Dipartimento Sci Biochim A Rossi Fanelli, Rome, Italy; Univ La Sapienza, Consiglio Nazl Ric, Ctr Biol Mol, Rome, Italy	Cardiff University; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	John, RA (corresponding author), Univ Wales, MOMED, POB 911, Cardiff CF1 3US, S Glam, Wales.		De Biase, Daniela/H-3678-2019; Tramonti, Angela/K-5325-2019; Messier, Claude/A-2322-2008	De Biase, Daniela/0000-0003-3536-9927; Tramonti, Angela/0000-0002-5625-1170; Messier, Claude/0000-0002-4791-1763				AKHTAR M, 1990, BIOCHEMISTRY-US, V29, P7648, DOI 10.1021/bi00485a014; ALMAZOV VP, 1985, J MOL BIOL USSR, V2, P359; BOUCLIER M, 1979, EUR J BIOCHEM, V98, P363, DOI 10.1111/j.1432-1033.1979.tb13195.x; DEBIASE D, 1991, J BIOL CHEM, V266, P20056; DeBiase D, 1996, PROTEIN EXPRES PURIF, V8, P430; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; ECCLESTON JF, 1980, ANAL BIOCHEM, V106, P73, DOI 10.1016/0003-2697(80)90120-7; GRANT PL, 1987, BIOCHEM J, V241, P699, DOI 10.1042/bj2410699; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JULIN DA, 1989, BIOCHEMISTRY-US, V28, P3825, DOI 10.1021/bi00435a031; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; MARTIN DL, 1993, PROG BIOPHYS MOL BIO, V60, P17, DOI 10.1016/0079-6107(93)90010-H; MILES EW, 1989, J BIOL CHEM, V264, P6280; MINELLI A, 1979, BIOCHEM J, V183, P361, DOI 10.1042/bj1830361; MOMANY C, 1995, J MOL BIOL, V252, P643, DOI 10.1006/jmbi.1995.0526; MOMANY C, 1995, PROTEIN SCI, V4, P849; NO ZS, 1988, BIOORG CHEM, V16, P184, DOI 10.1016/0045-2068(88)90007-7; OLEARY MH, 1974, J BIOL CHEM, V249, P3737; OLEARY MH, 1977, J BIOL CHEM, V252, P7168; OLEARY MH, 1981, BIOCHEMISTRY-US, V20, P1476, DOI 10.1021/bi00509a011; RELIMPIO A, 1981, J BIOL CHEM, V256, P4478; SANDMEIER E, 1994, EUR J BIOCHEM, V221, P997, DOI 10.1111/j.1432-1033.1994.tb18816.x; SHUKUYA R, 1960, J BIOL CHEM, V235, P1653; STEVENSON DE, 1990, BIOCHEMISTRY-US, V29, P7631, DOI 10.1021/bi00485a013; STEVENSON DE, 1990, BIOCHEMISTRY-US, V29, P7660, DOI 10.1021/bi00485a015; STOVER P, 1992, J BIOL CHEM, V267, P17679; SUKHAREVA V S, 1971, Molecular Biology (English Translation of Molekulyarnaya Biologiya (Moscow)), V5, P241; TILLEY K, 1994, J CHEM SOC PERK T 1, P3079, DOI 10.1039/p19940003079; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; YAMADA H, 1978, BIOCHEMISTRY-US, V17, P669, DOI 10.1021/bi00597a017	31	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1939	1945		10.1074/jbc.273.4.1939	http://dx.doi.org/10.1074/jbc.273.4.1939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442028	hybrid, Green Published			2022-12-25	WOS:000071595200017
J	DeStefano, J; Ghosh, J; Prasad, B; Raja, A				DeStefano, J; Ghosh, J; Prasad, B; Raja, A			High fidelity of internal strand transfer catalyzed by human immunodeficiency virus reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-I; RETROVIRAL RECOMBINATION; NUCLEOCAPSID PROTEIN; HIV-1; RNA; MECHANISM; TYPE-1; REPLICATION; TEMPLATES; GENOMES	A system to study the fidelity of internal strand transfer events was constructed, A donor RNA, on which reverse transcriptase (RT)-directed DNA synthesis was initiated, shared homology with an acceptor RNA, to which DNAs initiated on the donor could transfer, The homology occurred over a 119-base internal region of the donor which coded for the N-terminal portion of the alpha-lac gene. Polymerase chain reaction (PCR) was used to amplify DNA synthesis products, The PCR products were then digested with PvuII and EcoRI and ligated into a vector which had this same region excised. Transformed Escherichia coli were screened for the ability to produce a functional beta-galactosidase protein by blue-white phenotype analysis with white colonies scored as those with errors in alpha-lac, Products synthesized on the donor were used to assess the error rate of human immunodeficiency virus-RT while products transferring to and subsequently extended on the acceptor (transfer products) were used to monitor transfer fidelity. Human immunodeficiency virus-RT made approximately 1 error per 7500 bases copied in the assay, Nucleocapsid protein (NCp), although stimulating strand transfer 3-fold, had no effect on RT fidelity. Transfer products in the absence of NCp had essentially the same amount of errors as donor-directed products while those produced with NCp showed a slight increase in error frequency. Overall, strand transfer events on this template were highly accurate, Since experiments with other templates have suggested that transfer is error prone, the fidelity of strand transfer may be highly sequence dependent.	Univ Maryland, Dept Microbiol, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park	DeStefano, J (corresponding author), Univ Maryland, Dept Microbiol, Bldg 231, College Pk, MD 20742 USA.				NIGMS NIH HHS [GM51140-01, R29 GM051140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051140, R29GM051140] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DeStefano JJ, 1996, J BIOL CHEM, V271, P16350; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HHBNER A, 1992, J MOL BIOL, V223, P595; HU WS, 1992, J VIROL, V66, P4457, DOI 10.1128/JVI.66.7.4457-4463.1992; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HU WS, 1993, REVERSE TRANSCRIPTAS, P251; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; JUNGHANS RP, 1982, J VIROL, V43, P544, DOI 10.1128/JVI.43.2.544-554.1982; LOEB LA, 1973, NATURE-NEW BIOL, V242, P66, DOI 10.1038/newbio242066a0; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sambrook J., 2002, MOL CLONING LAB MANU; SKALKA AM, 1983, J CELL BIOL, V294, P75; SWAIN A, 1992, SCIENCE, V255, P841, DOI 10.1126/science.1371365; TAKEUCHI Y, 1988, J VIROL, V62, P3900, DOI 10.1128/JVI.62.10.3900-3902.1988; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VOGT PK, 1973, POSSIBLE EPISOMES EU, P35; WAINHOBSON S, 1989, AIDS, V3, pS13, DOI 10.1097/00002030-198901001-00003; WEBER J, 1989, NUCLEIC ACIDS RES, V17, P1379, DOI 10.1093/nar/17.4.1379; WU W, 1996, NUCLEIC ACIDS RES, V9, P1710; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; XU H, 1987, P NATL ACAD SCI USA, V76, P3751; Yin PD, 1997, J VIROL, V71, P6237, DOI 10.1128/JVI.71.8.6237-6242.1997; ZHANG JY, 1994, J VIROL, V68, P2409, DOI 10.1128/JVI.68.4.2409-2414.1994; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784	40	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1483	1489		10.1074/jbc.273.3.1483	http://dx.doi.org/10.1074/jbc.273.3.1483			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430686	hybrid			2022-12-25	WOS:000071411500033
J	Lecointe, F; Simos, G; Sauer, A; Hurt, EC; Motorin, Y; Grosjean, H				Lecointe, F; Simos, G; Sauer, A; Hurt, EC; Motorin, Y; Grosjean, H			Characterization of yeast protein Deg1 as pseudouridine synthase (Pus3) catalyzing the formation of Psi(38) and Psi(39) in tRNA anticodon loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RNAS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MODIFIED NUCLEOSIDES; MODIFIED NUCLEOTIDES; RIBOSOMAL-RNA; PURIFICATION; MITOCHONDRIAL; CONFORMATION; SPECIFICITY	The enzymatic activity of yeast gene product Deg1 was identified using both disrupted yeast strain and cloned recombinant protein expressed in yeast and in Escherichia coli, The results show that the DEG1-disrupted yeast strain lacks synthase activity for the formation of pseudouridines Psi(38),,,, and Psi(39) in tRNA whereas the other activities, specific for Psi formation at positions 13, 27, 28, 32, 34, 35, 36, and 55 in tRNA, remain unaffected, Also, the His(6)-tagged recombinant yeast Deg1p expressed in E., coli as well as a protein fusion with protein A in yeast display the enzymatic activity only toward Psi(38) and Psi(39) formation in different tRNA substrates, Therefore, Deg1p is the third tRNA:pseudouridine synthase (Pus3p) characterized so far in yeast, Disruption of the DEG1 gene is not lethal but reduces considerably the yeast growth rate, especially at an elevated temperature (37 degrees C), Deg1p localizes both in the nucleus and in the cytoplasm, as shown by immunofluorescence microscopy. Identification of the pseudouridine residues present (or absent) in selected naturally occurring cytoplasmic and mitochondrial tRNAs from DEG1-disrupted strain points out a common origin of Psi(38),, and Psi(39)-synthesizing activity in both of these two cellular compartments, The sensitivity of Pus3p (Deg1p) activity to overall three-dimensional tRNA architecture and to a few individual mutations in tRNA was also studied, The results indicate the existence of subtle differences in the tRNA recognition by yeast Pus3p and by its homologous tRNA:pseudouridine synthase truA from E., coli (initially called hisT or PSU-I gene product).	CNRS, Lab Enzymol & Biochim Struct, Gif Sur Yvette, France; Univ Heidelberg, Inst Biochem, D-69120 Heidelberg, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Ruprecht Karls University Heidelberg	Motorin, Y (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Ave Terrasse,Bat 34, Gif Sur Yvette, France.	Yuri.Motorin@lebs.cnrs-gif.fr	MOTORIN, Yuri/E-2499-2011; Simos, George/AAH-2596-2021; MOTORIN, Yuri/AAQ-9527-2020; Ed Hurt, Dr./AAE-8874-2019	MOTORIN, Yuri/0000-0002-8018-334X; Ed Hurt, Dr./0000-0002-4535-8255; Simos, George/0000-0001-5453-3185; Lecointe, Francois/0000-0002-9596-2514; Motorin, Alexandr/0000-0001-9622-4591				ARENA F, 1978, NUCLEIC ACIDS RES, V5, P4523, DOI 10.1093/nar/5.12.4523; ARPS PJ, 1985, NUCLEIC ACIDS RES, V13, P5297, DOI 10.1093/nar/13.14.5297; Auxilien S, 1996, J MOL BIOL, V262, P437, DOI 10.1006/jmbi.1996.0527; BAKIN A, 1995, NUCLEIC ACIDS RES, V23, P3290, DOI 10.1093/nar/23.16.3290; BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BARNES WM, 1978, P NATL ACAD SCI USA, V75, P4281, DOI 10.1073/pnas.75.9.4281; Bjork Glenn R., 1995, P165; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONE MLA, 1991, CURR GENET, V19, P1; FOSTER PG, 1997, FASEB J, V11, P862; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; GREEN CJ, 1982, J BIOL CHEM, V257, P3045; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Grosjean H, 1997, BIOCHIMIE, V79, P293, DOI 10.1016/S0300-9084(97)83517-1; GROSJEAN H, 1995, BIOCHIMIE, V77, P139, DOI 10.1016/0300-9084(96)88117-X; Gu J, 1996, RNA, V2, P909; Huang LX, 1997, FASEB J, V11, pA1320; Jiang HQ, 1997, NUCLEIC ACIDS RES, V25, P2694, DOI 10.1093/nar/25.14.2694; KAHANA J, 1996, CURR PROT MOL BIOL, V9, P722; KAMMEN HO, 1988, J BIOL CHEM, V263, P2255; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; LIMBACH PA, 1994, NUCLEIC ACIDS RES, V22, P2183, DOI 10.1093/nar/22.12.2183; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; Motorin Y, 1997, RNA, V3, P721; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; NURSE K, 1995, RNA, V1, P102; Ofengand J, 1997, J MOL BIOL, V266, P246, DOI 10.1006/jmbi.1996.0737; PATTON JR, 1994, BIOCHIMIE, V76, P1129, DOI 10.1016/0300-9084(94)90041-8; PERRET V, 1990, BIOCHIMIE, V72, P735, DOI 10.1016/0300-9084(90)90158-D; ROSE AM, 1995, BIOCHIMIE, V77, P45, DOI 10.1016/0300-9084(96)88103-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SAMUELSSON T, 1990, J BIOL CHEM, V265, P8782; SHERMAN F, 1990, METHOD ENZYMOL, V194, P3; Sherman F., 1986, METHODS YEAST GENETI; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; SINGER CE, 1972, NATURE-NEW BIOL, V238, P72, DOI 10.1038/newbio238072a0; Smith CM, 1997, CELL, V89, P669, DOI 10.1016/S0092-8674(00)80247-0; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; SWERDLOW H, 1984, J BIOL CHEM, V259, P5197; SZWEYKOWSKAKULINSKA Z, 1994, EMBO J, V13, P4636, DOI 10.1002/j.1460-2075.1994.tb06786.x; WALLACE DC, 1993, TRENDS GENET, V9, P128, DOI 10.1016/0168-9525(93)90207-X; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x; WISE JA, 1983, CELL, V35, P743, DOI 10.1016/0092-8674(83)90107-1; WRZESINSKI J, 1995, BIOCHEMISTRY-US, V34, P8904, DOI 10.1021/bi00027a043; WRZESINSKI J, 1995, RNA, V1, P437; Zhao XM, 1997, J BIOL CHEM, V272, P1950, DOI 10.1074/jbc.272.3.1950	52	112	116	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1316	1323		10.1074/jbc.273.3.1316	http://dx.doi.org/10.1074/jbc.273.3.1316			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430663	hybrid, Green Published			2022-12-25	WOS:000071411500010
J	Perisic, O; Fong, S; Lynch, DE; Bycroft, M; Williams, RL				Perisic, O; Fong, S; Lynch, DE; Bycroft, M; Williams, RL			Crystal structure of a calcium-phospholipid binding domain from cytosolic phospholipase A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PRODUCT-CONTAINING VESICLES; MOBILIZING PHOSPHOLIPASE-A2; CATALYTIC ACTIVITY; NUCLEAR-ENVELOPE; RAT-KIDNEY; C2A DOMAIN; SYNAPTOTAGMIN; TRANSLOCATION	Cytosolic phospholipase A2 (cPLA2) is a calcium-sensitive 85-kDa enzyme that hydrolyzes arachidonic acid-containing membrane phospholipids to initiate the bio synthesis of eicosanoids and platelet-activating factor, potent inflammatory mediators, The calcium-dependent activation of the enzyme is mediated by an N-terminal C2 domain, which is responsible for calcium-dependent translocation of the enzyme to membranes and that enables the intact enzyme to hydrolyze membrane-resident substrates. The 2.4-Angstrom x-ray crystal structure of this C2 domain was solved by multiple isomorphous replacement and reveals a beta-sandwich with the same topology as the C2 domain from phosphoinositide-specific phospholipase C delta 1, Two clusters of exposed hydrophobic residues surround two adjacent calcium binding sites, This region, along with an adjoining strip of basic residues, appear to constitute the membrane binding motif. The structure provides a striking insight into the relative importance of hydrophobic and electrostatic components of membrane binding for cPLA2, Although hydrophobic interactions predominate for cPLA2, for other C2 domains such as in "conventional" protein kinase C and synaptotagmins, electrostatic forces prevail.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; MRC Ctr, Ctr Prot Engn, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology; MRC Laboratory Molecular Biology; University of Cambridge	Williams, RL (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk	Bycroft, Mark/D-9446-2017	Williams, Roger/0000-0001-7754-4207; Perisic, Olga/0000-0002-3842-2896; Bycroft, Mark/0000-0002-0673-2216	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DAVLETOV BA, 1994, J BIOL CHEM, V269, P28547; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; FUKUDA M, 1995, J BIOL CHEM, V270, P26523, DOI 10.1074/jbc.270.44.26523; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HAYAKAWA M, 1993, J BIOL CHEM, V268, P11290; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Irvine R, 1996, CURR BIOL, V6, P537, DOI 10.1016/S0960-9822(02)00536-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kojima T, 1996, J BIOCHEM-TOKYO, V120, P671; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1994, SIGNAL ACTIVATED PHO; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; Lindqvist Y, 1997, CURR OPIN STRUC BIOL, V7, P422, DOI 10.1016/S0959-440X(97)80061-9; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Mosior M, 1997, MOL MEMBR BIOL, V14, P65, DOI 10.3109/09687689709068436; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Nicholls A., 1992, GRASP GRAPHICAL REPR; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Ponting CP, 1996, PROTEIN SCI, V5, P162; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Scarlata S, 1996, BIOCHEMISTRY-US, V35, P14882, DOI 10.1021/bi961072z; Schiavo G, 1996, P NATL ACAD SCI USA, V93, P13327, DOI 10.1073/pnas.93.23.13327; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; Williams RL, 1996, STRUCTURE, V4, P1387, DOI 10.1016/S0969-2126(96)00146-3; YOSHIHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P484, DOI 10.1016/0006-291X(90)92117-I; ZUPAN LA, 1991, FEBS LETT, V284, P27, DOI 10.1016/0014-5793(91)80753-P	73	233	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1596	1604		10.1074/jbc.273.3.1596	http://dx.doi.org/10.1074/jbc.273.3.1596			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430701	hybrid			2022-12-25	WOS:000071411500048
J	Davis, CR; Richman, TJ; Deliduka, SB; Blaisdell, JO; Collins, CC; Johnson, DI				Davis, CR; Richman, TJ; Deliduka, SB; Blaisdell, JO; Collins, CC; Johnson, DI			Analysis of the mechanisms of action of the Saccharomyces cerevisiae dominant lethal cdc42(G12V) and dominant negative cdc42(D118A) mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; CELL POLARITY; MOLECULAR-CLONING; BUDDING YEAST; BUD FORMATION; RAS PROTEINS; SCHIZOSACCHAROMYCES-POMBE; CAENORHABDITIS-ELEGANS; SIGNAL TRANSDUCTION	The Saccharomyces cerevisiae Cdc42p GTPase is localized to the plasma membrane and involved in signal transduction mechanisms controlling cell polarity. The mechanisms of action of the dominant negative cdc42(D118A) mutant and the lethal, gain of function cdc42(G12V) mutant were examined. Cdc42(D118A,C188S)p and its guanine-nucleotide exchange factor Cdc24p displayed a temperature-dependent interaction in the two-hybrid system, which correlated with the temperature dependence of the cdc42(D118A) phenotype and supported a Cdc24p sequestration model for the mechanism of cdc42(D118A) action. Five cdc42 mutations were isolated that led to decreased interactions with Cdc24p. The isolation of one mutation (V44A) correlated with the observations that the T35A effector domain mutation could interfere with Cdc42(D118,C188S)p-Cdc24p interactions and could suppress the cdc42(D118A) mutations, suggesting that Cdc24p may interact with Cdc42p through its effector domain. The cdc42(G12V) mutant phenotypes were suppressed by the intragenic T35A and K183-187Q mutations and in skm1 Delta and cla4 Delta cells but not ste20 Delta cells, suggesting that the mechanism of cdc42(G12V) action is through the Skm1p and Cla4p protein kinases at the plasma membrane. Two intragenic suppressors of cdc42(G12V) were also identified that displayed a dominant negative phenotype at 16 degrees C, which was not suppressed by overexpression of Cdc24p, suggesting an alternate mechanism of action for these dominant negative mutations.	Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA; Univ Vermont, Markey Ctr Mol Genet, Burlington, VT 05405 USA	University of Vermont; University of Vermont	Johnson, DI (corresponding author), Univ Vermont, Dept Microbiol & Mol Genet, 202A Stafford Hall, Burlington, VT 05405 USA.	dijohnso@zoo.uvm.edu						BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANT J, 1994, TRENDS GENET, V10, P328, DOI 10.1016/0168-9525(94)90036-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; CHEN WN, 1993, J BIOL CHEM, V268, P13280; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Herskowitz I, 1995, COLD SPRING HARB SYM, V60, P717, DOI 10.1101/SQB.1995.060.01.078; Imai J, 1996, GENETICS, V142, P359; Inoue SB, 1996, CELL STRUCT FUNCT, V21, P395, DOI 10.1247/csf.21.395; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSON DI, 1993, RAS SUPERFAMILY GTPA, P297; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; Madden K, 1992, Trends Cell Biol, V2, P22, DOI 10.1016/0962-8924(92)90140-I; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Martin H, 1997, MOL MICROBIOL, V23, P431, DOI 10.1046/j.1365-2958.1997.d01-1870.x; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Miller PJ, 1997, YEAST, V13, P561; MILLER PJ, 1994, MOL CELL BIOL, V14, P1075, DOI 10.1128/MCB.14.2.1075; MUNEMITSU S, 1990, MOL CELL BIOL, V10, P5977, DOI 10.1128/MCB.10.11.5977; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Parrini MC, 1996, EMBO J, V15, P1107, DOI 10.1002/j.1460-2075.1996.tb00448.x; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; REYNOLDS A, 1989, CURRENT PROTOCOLS MO, V2; ROKEACH LA, 1988, P NATL ACAD SCI USA, V85, P4832, DOI 10.1073/pnas.85.13.4832; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SIKORSKI RS, 1989, GENETICS, V122, P19; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WOOD DR, 1994, J BIOL CHEM, V269, P5322; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052; ZIMAN M, 1994, YEAST, V10, P463, DOI 10.1002/yea.320100405; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	72	41	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					849	858		10.1074/jbc.273.2.849	http://dx.doi.org/10.1074/jbc.273.2.849			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422741	hybrid			2022-12-25	WOS:000071411400030
J	Kosaki, A; Yamada, K; Suga, J; Otaka, A; Kuzuya, H				Kosaki, A; Yamada, K; Suga, J; Otaka, A; Kuzuya, H			14-3-3 beta protein associates with insulin receptor substrate 1 and decreases insulin-stimulated phosphatidylinositol 3 '-kinase activity in 3T3L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3-PROTEINS ASSOCIATE; IN-VIVO; KINASE; RAF; ACTIVATION; IDENTIFICATION; INHIBITION; BINDING; COMPLEX; MANNER	The 14-3-3 protein family has been implicated in growth factor signaling. We investigated whether 14-3-3 protein is involved in insulin signaling in 3T3L1 adipocytes. A significant amount of insulin receptor substrate 1 (IRS-1) was immunodetected in the immunoprecipitate with anti-14-3-3 beta antibody at the basal condition. 100 nM insulin increased the amount of IRS-1 in the immunoprecipitate 2.5-fold. The effect of insulin was abolished by 100 nM wortmannin. An in vitro binding study revealed that glutathione S-transferase-14-3-3 beta fusion protein directly associates with recombinant IRS-1. Pretreatment of recombinant IRS-1 with alkaline phosphatase clearly decreased this association. Because the recombinant IRS-1 was not phosphorylated on its tyrosine residues, the results suggest that serine/threonine phosphorylation of IRS-1 is responsible for the association, When the cells are treated with insulin, phosphatidylinositol 3'-kinase (PI3K) is supposed to complex either 14-3-3 beta-IRS-1 or IRS-1. The 14-3-3 beta-IRS-1-PI3K and IRS-1-PI3K complexes were separately prepared by a sequential immunoprecipitation, first with anti-14-3-3 beta and then with anti-IRS-1 antibodies. The specific activity of the PI3K in the former was approximately half of that in the latter, suggesting that 14-3-3 beta protein bound to IRS-1 inhibits insulin-stimulated lipid kinase activity of PI3K in 3T3L1 adipocytes.	S Kyoto Natl Hosp, Ctr Diabet, Clin Res Unit, Fushimi Ku, Kyoto 612, Japan; Kyoto Univ, Grad Sch Med, Dept Med & Clin Sci, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Pharmaceut Sci, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University	Kosaki, A (corresponding author), S Kyoto Natl Hosp, Ctr Diabet, Clin Res Unit, Fushimi Ku, 1-1 Fukakusa Mukaihata, Kyoto 612, Japan.	akosaki@osk2.3web.ne.jp						AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BURKE TR, 1993, TETRAHEDRON LETT, V34, P4125, DOI 10.1016/S0040-4039(00)60508-7; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DU XP, 1994, J BIOL CHEM, V269, P18287; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HARBST JJ, 1995, J BIOL CHEM, V270, P26000; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kosaki A, 1996, DIABETES, V45, P1744, DOI 10.2337/diabetes.45.12.1744; LAM K, 1994, J BIOL CHEM, V269, P20648; LAMPHERE L, 1994, AM J PHYSIOL, V266, pE486, DOI 10.1152/ajpendo.1994.266.3.E486; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; MYERS MG, 1995, TRENDS ENDOCRIN MET, V6, P209, DOI 10.1016/1043-2760(95)00092-V; OTAKA A, 1995, J ORG CHEM, V60, P3967, DOI 10.1021/jo00118a011; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	32	57	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					940	944		10.1074/jbc.273.2.940	http://dx.doi.org/10.1074/jbc.273.2.940			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422753	hybrid			2022-12-25	WOS:000071411400042
J	Wells, GB; Anand, R; Wang, F; Lindstrom, J				Wells, GB; Anand, R; Wang, F; Lindstrom, J			Water-soluble nicotinic acetylcholine receptor formed by alpha 7 subunit extracellular domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; AGONIST BINDING-SITE; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; BOVINE ENTEROKINASE; EPSILON SUBUNIT; XENOPUS OOCYTES; INFLUENZA-VIRUS; GROWTH-HORMONE; DELTA-SUBUNIT	Water-soluble models of ligand gated ion channels would be advantageous for structural studies. We investigated the suitability of three versions of the N-terminal extracellular domain (ECD) of the alpha 7 subunit of the nicotinic acetylcholine receptor (AChR) family for this purpose by examining their ligand-binding and assembly properties. Two versions included the first transmembrane domain and were solubilized with detergent after expression in Xenopus oocytes. The third was truncated before the first transmembrane domain and was soluble without detergent. For all three, their equilibrium binding affinities for alpha-bungarotoxin, nicotine, and acetylcholine, combined with their velocity sedimentation profiles, were consistent with the formation of native-like AChRs. These characteristics imply that the alpha 7 ECD can form a water-soluble AChR that is a model of the ECD of the full-length alpha 7 AChR.	Univ Penn, Dept Neurosci, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA	University of Pennsylvania; University of Pennsylvania; Louisiana State University System; Louisiana State University System	Wells, GB (corresponding author), Univ Penn, Dept Neurosci, Sch Med, 235 Stemmler Hall,36th & Hamilton Walk, Philadelphia, PA 19104 USA.		Wells, Gregg/AAU-7798-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033625] Funding Source: NIH RePORTER; NCRR NIH HHS [RR06009] Funding Source: Medline; NINDS NIH HHS [NS33625, NS01903] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; ANAND R, 1993, FEBS LETT, V327, P241, DOI 10.1016/0014-5793(93)80177-V; ANDERSON LE, 1977, BIOCHEMISTRY-US, V16, P3354, DOI 10.1021/bi00634a011; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BEROUKHIM R, 1995, NEURON, V15, P323, DOI 10.1016/0896-6273(95)90037-3; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CANTOR C, 1980, BIOPHYSICAL CHEM, V2, P607; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CHAVEZ RA, 1992, J BIOL CHEM, V267, P23023; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; CONROY WG, 1990, J BIOL CHEM, V265, P21642; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1994, CURR OPIN STRUC BIOL, V4, P554, DOI 10.1016/S0959-440X(94)90218-6; GARCIAGUZMAN M, 1994, BIOCHEMISTRY-US, V33, P15198, DOI 10.1021/bi00254a031; GELMAN MS, 1995, J BIOL CHEM, V270, P15085, DOI 10.1074/jbc.270.25.15085; GERZANICH V, 1994, MOL PHARMACOL, V45, P212; GU Y, 1991, NEURON, V6, P879, DOI 10.1016/0896-6273(91)90228-R; Hackam AS, 1997, J BIOL CHEM, V272, P13750, DOI 10.1074/jbc.272.21.13750; Hall Z W, 1992, Trends Cell Biol, V2, P66, DOI 10.1016/0962-8924(92)90058-U; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KARLSSON E, 1971, EUR J BIOCHEM, V21, P1, DOI 10.1111/j.1432-1033.1971.tb01433.x; Keller SH, 1996, J BIOL CHEM, V271, P22871, DOI 10.1074/jbc.271.37.22871; Koke J A, 1991, Protein Expr Purif, V2, P51, DOI 10.1016/1046-5928(91)90009-8; KREIENKAMP HJ, 1995, NEURON, V14, P1; KUHSE J, 1993, NEURON, V11, P1049, DOI 10.1016/0896-6273(93)90218-G; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LAVALLIE ER, 1993, J BIOL CHEM, V268, P23311; LAZARENO S, 1993, BRIT J PHARMACOL, V109, P1110, DOI 10.1111/j.1476-5381.1993.tb13737.x; LENTZ TL, 1995, BIOCHEMISTRY-US, V34, P1316, DOI 10.1021/bi00004a026; Lindstrom J, 1996, Ion Channels, V4, P377; Medof ME, 1996, FASEB J, V10, P574, DOI 10.1096/fasebj.10.5.8621057; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBURN MV, 1991, SCIENCE, V254, P142; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P10864, DOI 10.1021/bi00202a003; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; Palma E, 1996, J PHYSIOL-LONDON, V491, P151, DOI 10.1113/jphysiol.1996.sp021203; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SCHOEPFER R, 1990, NEURON, V5, P35, DOI 10.1016/0896-6273(90)90031-A; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SUMIKAWA K, 1994, MOL BRAIN RES, V25, P257, DOI 10.1016/0169-328X(94)90161-9; SUMIKAWA K, 1992, MOL BRAIN RES, V13, P349, DOI 10.1016/0169-328X(92)90218-Z; TANFORD C, 1961, PHYSICAL CHEM MACROM, P379; TOBIMATSU T, 1987, FEBS LETT, V222, P56, DOI 10.1016/0014-5793(87)80191-6; Tsigelny I, 1997, BIOPHYS J, V73, P52, DOI 10.1016/S0006-3495(97)78047-0; Unwin N, 1996, J MOL BIOL, V257, P586, DOI 10.1006/jmbi.1996.0187; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VicenteAgullo F, 1996, FEBS LETT, V399, P83, DOI 10.1016/S0014-5793(96)01291-4; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; Wang ZZ, 1996, COLD SPRING HARB SYM, V61, P363; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WILCHEK M, 1984, METHOD ENZYMOL, V104, P3; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YU XM, 1991, NATURE, V352, P64, DOI 10.1038/352064a0; YU XM, 1994, NEURON, V13, P247, DOI 10.1016/0896-6273(94)90473-1	70	35	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					964	973		10.1074/jbc.273.2.964	http://dx.doi.org/10.1074/jbc.273.2.964			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422757	hybrid			2022-12-25	WOS:000071411400046
J	Cawley, NX; Olsen, V; Zhang, CF; Chen, HC; Tan, M; Loh, YP				Cawley, NX; Olsen, V; Zhang, CF; Chen, HC; Tan, M; Loh, YP			Activation and processing of non-anchored yapsin 1 (Yap3p)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST ASPARTIC PROTEASE-3; SACCHAROMYCES-CEREVISIAE; PROTEINASE-A; SUBSTRATE-SPECIFICITY; PROCATHEPSIN-D; ALPHA-FACTOR; IN-VIVO; GENE; MATURATION; SECRETION	A C-terminally truncated form of yapsin 1 (yeast aspartic protease 3), the first member of the novel subclass of aspartic proteases with specificity for basic residues (designated the Yapsins), was overexpressed and purified to apparent homogeneity, yielding similar to 1 mu g of yapsin 1/g of wet yeast, N-terminal amino acid analysis of the purified protein confirmed that the propeptide was absent and that the mature enzyme began at Ala(68). The mature enzyme was shown to be composed of approximately equimolar amounts of two subunits, designated alpha and beta, that were associated to each other by a disulfide bond. C-terminally truncated proyapsin 1 was also expressed in the baculovirus/Sf9 insect cell expression system and secreted as a zymogen that could be activated upon incubation at an acidic pH with an optimum at similar to 4.0, When expressed without its pro-region, it was localized intracellularly and lacked activity, indicating that the pro-region was required for the correct folding of the enzyme, The activation of proyapsin 1 in vitro exhibited linear kinetics and generated an intermediate form of yapsin 1 or pseudo-yapsin 1.	NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Cawley, NX (corresponding author), NICHD, Cellular Neurobiol Sect, Dev Neurobiol Lab, NIH, Bldg 49,Rm 5A38, Bethesda, MD 20892 USA.							AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ASH J, 1995, J BIOL CHEM, V270, P20847, DOI 10.1074/jbc.270.35.20847; AZARYAN AV, 1993, J BIOL CHEM, V268, P11968; Beyer BM, 1996, J BIOL CHEM, V271, P15590, DOI 10.1074/jbc.271.26.15590; BOURBONNAIS Y, 1991, ENZYME, V45, P244, DOI 10.1159/000468899; BUSSEY H, 1988, YEAST, V4, P17, DOI 10.1002/yea.320040103; Cawley N.X., 1995, THESIS UNIFORMED SER; CAWLEY NX, 1993, FEBS LETT, V332, P273, DOI 10.1016/0014-5793(93)80648-E; Cawley NX, 1996, J BIOL CHEM, V271, P4168; CAWLEY NX, 1995, BIOCHEMISTRY-US, V34, P7430, DOI 10.1021/bi00022a016; Cawley NX, 1996, ENDOCRINOLOGY, V137, P5135, DOI 10.1210/en.137.11.5135; CAWLEY NX, 1996, HDB PROTEOLYTIC ENZY; Cool DR, 1996, ENDOCRINOLOGY, V137, P5441, DOI 10.1210/en.137.12.5441; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DUNN BM, 1986, BIOCHEM J, V237, P899, DOI 10.1042/bj2370899; EGELMITANI M, 1990, YEAST, V6, P127, DOI 10.1002/yea.320060206; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INAGAKI T, 1983, J BIOL CHEM, V258, P7476; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAY J, 1992, SCAND J CLIN LAB INV, V52, P23, DOI 10.3109/00365519209104651; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P10752, DOI 10.1073/pnas.92.23.10752; Ledgerwood EC, 1996, FEBS LETT, V383, P67, DOI 10.1016/0014-5793(96)00219-0; LOH YP, 1984, J BIOL CHEM, V259, P8238; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7095; Olsen V., 1994, THESIS U COPENHAGEN; PANTHIER JJ, 1982, NATURE, V298, P90, DOI 10.1038/298090a0; PEDERSEN VB, 1979, EUR J BIOCHEM, V94, P573, DOI 10.1111/j.1432-1033.1979.tb12927.x; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; REUDELHUBER TL, 1994, KIDNEY INT, V46, P1522, DOI 10.1038/ki.1994.435; RICHO GR, 1994, J BIOL CHEM, V269, P14806; SARKKINEN P, 1992, PLANTA, V186, P317, DOI 10.1007/BF00195311; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; TAKAHASHI K, 1991, J BIOL CHEM, V266, P19480; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; VALVERDE V, 1995, J BIOL CHEM, V270, P15821, DOI 10.1074/jbc.270.26.15821; VANDENHAZEL HB, 1993, J BIOL CHEM, V268, P18002; VANDENHAZEL HB, 1995, J BIOL CHEM, V270, P8602, DOI 10.1074/jbc.270.15.8602	43	27	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					584	591		10.1074/jbc.273.1.584	http://dx.doi.org/10.1074/jbc.273.1.584			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417119	hybrid			2022-12-25	WOS:000071295600085
J	Horuk, R; Hesselgesser, J; Zhou, YQ; Faulds, D; Halks-Miller, M; Harvey, S; Taub, D; Samson, M; Parmentier, M; Rucker, J; Doranz, BJ; Doms, RW				Horuk, R; Hesselgesser, J; Zhou, YQ; Faulds, D; Halks-Miller, M; Harvey, S; Taub, D; Samson, M; Parmentier, M; Rucker, J; Doranz, BJ; Doms, RW			The CC chemokine I-309 inhibits CCR8-dependent infection by diverse HIV-1 strains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; T-LYMPHOCYTES; RECEPTOR; GENE; CELLS; INDIVIDUALS; PROGRESSION; EXPRESSION; CORECEPTOR; RESISTANCE	Using a chemokine receptor model based on known receptor sequences, we identified several members of the seven transmembrane domain G-protein superfamily as potential chemokine receptors, The orphan receptor ChemR1, which has recently been shown to be a receptor for the CC chemokine I-309, scored very high in our model, We have confirmed that I-309, but not a number of other chemokines, can induce a transient Ca2+ flux in cells expressing CCR8, In addition, the human erythroleukemic cell line K562 responded chemotactically in a dose-responsive manner to this chemokine, Since several chemokine receptors have been shown to be required as coreceptors for HIV-1 infection, we asked whether human immunodeficiency virus type 1 (HIV-1) could efficiently utilize CCR8, Here we show that the CCR8 receptor can serve as a coreceptor for diverse T-cell tropic, dual-tropic, and macrophage-tropic HIV-1 strains and that I-309 was a potent inhibitor of HIV-1 envelope-mediated cell-cell fusion and virus infection, Furthermore, we show by flow cytometry and immunohistochemistry that antibodies generated against the CCR8 receptor amino-terminal peptide cross-reacted with U-87 MG cells stably expressing CCR8, THP-1 cells, HL-60 cells, and human monocytes, a target cell for HIV-1 infectivity in vivo.	Berlex Biosci, Dept Immunol, Richmond, CA 94804 USA; Berlex Biosci, Dept Pharmacol, Richmond, CA 94804 USA; Berlex Biosci, Dept Cell Biol, Richmond, CA 94804 USA; NIA, Immunol Lab, NIH, Baltimore, MD 21224 USA; Free Univ Brussels, IRIBHN, B-1070 Brussels, Belgium; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Pennsylvania	Horuk, R (corresponding author), Berlex Biosci, Dept Immunol, 15049 San Pablo Ave, Richmond, CA 94804 USA.		Samson, Michel/F-8356-2013; Miller, Meredith/K-5963-2019	Parmentier, Marc/0000-0001-8081-4685	NIAID NIH HHS [AI-38225, AI-40880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038225, R01AI040880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAGGIOLINI M, 1994, ADV EXP MED BIOL, V351, P1; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GUO HG, 1997, VIROLOGY, V228, P871; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Liao F, 1997, J EXP MED, V185, P2015, DOI 10.1084/jem.185.11.2015; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; LUO Y, 1994, J IMMUNOL, V153, P4616; MILLER MD, 1992, P NATL ACAD SCI USA, V89, P2950, DOI 10.1073/pnas.89.7.2950; MILLER MD, 1989, J IMMUNOL, V143, P2907; Napolitano M, 1996, J IMMUNOL, V157, P2759; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; Rana S, 1997, J VIROL, V71, P3219, DOI 10.1128/JVI.71.4.3219-3227.1997; Reeves JD, 1997, VIROLOGY, V231, P130, DOI 10.1006/viro.1997.8508; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; SCHALL TJ, 1994, CYTOKINE HDB, P419; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; TAUB DD, 1995, J IMMUNOL METHODS, V184, P187, DOI 10.1016/0022-1759(95)00087-Q; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; VanSnick J, 1996, J IMMUNOL, V157, P2570; Watson S., 1994, G PROTEIN LINKED REC; Zaballos A, 1996, BIOCHEM BIOPH RES CO, V227, P846, DOI 10.1006/bbrc.1996.1595	38	141	148	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					386	391		10.1074/jbc.273.1.386	http://dx.doi.org/10.1074/jbc.273.1.386			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417093	hybrid			2022-12-25	WOS:000071295600059
J	Passantino, R; Antona, V; Barbieri, G; Rubino, P; Melchionna, R; Cossu, G; Feo, S; Giallongo, A				Passantino, R; Antona, V; Barbieri, G; Rubino, P; Melchionna, R; Cossu, G; Feo, S; Giallongo, A			Negative regulation of beta enolase gene transcription in embryonic muscle is dependent upon a zinc finger factor that binds to the G-rich box within the muscle-specific enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC PROMOTERS; ACTIVE REPRESSION; FACTORS H4TF-1; EXPRESSION; PROTEIN; ACTIVATION; RNA; DNA; DIFFERENTIATION; SEQUENCES	We have previously identified a muscle-specific enhancer within the first intron of the human beta enolase gene, Present in this enhancer are an APT-rich box that binds MEF-2 protein(s) and a G-rich box (AGTGGGG-GAGGGGGCTGCG) that interacts with ubiquitously expressed factors, Both elements are required for tissue-specific expression of the gene in skeletal muscle cells, Here, we report the identification and characterization of a Kruppel-like zinc finger protein, termed beta enolase repressor factor 1, that binds in a sequence-specific manner to the G-rich box and functions as a repressor of the beta enolase gene transcription in transient transfection assays, Using fusion polypeptides of beta enolase repressor factor 1 and the yeast GAL4 DNA-binding do main, we have identified an amino-terminal region responsible for the transcriptional repression activity, whereas a carboxyl-terminal region was shown to contain a potential transcriptional activation domain, The expression of this protein decreases in developing skeletal muscles, correlating with lack of binding activity in nuclear extract from adult skeletal tissue, in which novel binding activities have been detected, These results suggest that in addition to the identified factor, which functionally acts as a negative regulator and is enriched in embryonic muscle, the G-rich box binds other factors, presumably exerting a positive control on transcription. The interplay between factors that repress or activate transcription may constitute a developmentally regulated mechanism that modulates beta enolase gene expression in skeletal muscle.	CNR, Ist Biol Sviluppo, I-90146 Palermo, Italy; Univ Palermo, Dipartimento Biol Cellulare & Sviluppo, I-90128 Palermo, Italy; Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Palermo; Sapienza University Rome	Giallongo, A (corresponding author), CNR, Ist Biol Sviluppo, Via Ugo La Malfa 153, I-90146 Palermo, Italy.		Giallongo, Agata/ABD-1103-2020; passantino, rosa/C-3993-2015; Barbieri, Giovanna/AAH-3645-2019; melchionna, Roberta/G-2479-2011; Feo, Salvatore/C-1333-2012; Melchionna, Roberta/AAZ-4111-2021	Giallongo, Agata/0000-0001-9998-4481; passantino, rosa/0000-0001-6598-2664; Feo, Salvatore/0000-0003-3877-2906; Melchionna, Roberta/0000-0002-8410-9681; BARBIERI, GIOVANNA/0000-0002-5895-1795; ANTONA, VINCENZO/0000-0001-7643-9560	Telethon [943] Funding Source: Medline	Telethon(Fondazione Telethon)		AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BARBIERI G, 1990, DIFFERENTIATION, V45, P179, DOI 10.1111/j.1432-0436.1990.tb00471.x; BASSELDUBY R, 1994, MOL CELL BIOL, V14, P4596, DOI 10.1128/MCB.14.7.4596; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSSU G, 1988, DEVELOPMENT, V102, P65; COSSU G, 1992, NEUROMUSCULAR DEV DI, P183; COWELL IG, 1994, NUCLEIC ACIDS RES, V22, P59, DOI 10.1093/nar/22.1.59; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1987, MOL CELL BIOL, V7, P4582, DOI 10.1128/MCB.7.12.4582; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEO S, 1995, MOL CELL BIOL, V15, P5991; FEO S, 1990, GENOMICS, V6, P192, DOI 10.1016/0888-7543(90)90467-9; Ferrari S, 1997, CELL GROWTH DIFFER, V8, P23; FLETCHER L, 1978, DEV BIOL, V65, P462, DOI 10.1016/0012-1606(78)90041-6; GIALLONGO A, 1993, EUR J BIOCHEM, V214, P367, DOI 10.1111/j.1432-1033.1993.tb17932.x; GIALLONGO A, 1990, EUR J BIOCHEM, V190, P567, DOI 10.1111/j.1432-1033.1990.tb15611.x; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HARRIS AJ, 1989, DEVELOPMENT, V107, P771; Hasegawa T, 1997, J BIOL CHEM, V272, P4915, DOI 10.1074/jbc.272.8.4915; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; KELLER A, 1992, MECH DEVELOP, V38, P41, DOI 10.1016/0925-4773(92)90037-K; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LAMANDE N, 1989, P NATL ACAD SCI USA, V86, P4445, DOI 10.1073/pnas.86.12.4445; LETVOSKY J, 1993, NUCLEIC ACIDS RES, V17, P2639; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LI ZL, 1993, J BIOL CHEM, V268, P10403; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADDEN SL, 1993, ONCOGENE, V8, P1713; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MouraNeto V, 1996, GENE, V168, P261, DOI 10.1016/0378-1119(95)00789-X; OLIVA D, 1991, GENOMICS, V10, P157, DOI 10.1016/0888-7543(91)90496-2; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; PETERSON CA, 1992, DEV BIOL, V151, P626, DOI 10.1016/0012-1606(92)90201-Q; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAETE RR, 1985, J VIROL, V56, P135, DOI 10.1128/JVI.56.1.135-143.1985; Taniuchi T, 1997, BIOCHEM BIOPH RES CO, V233, P154, DOI 10.1006/bbrc.1997.6310; TAYLOR JM, 1995, J BIOL CHEM, V270, P2535, DOI 10.1074/jbc.270.6.2535; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WANG YK, 1993, MOL CELL BIOL, V13, P5691, DOI 10.1128/MCB.13.9.5691; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZAHRADKA P, 1989, EXP CELL RES, V185, P8, DOI 10.1016/0014-4827(89)90032-3; ZOU YM, 1995, MOL CELL BIOL, V15, P2972	60	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					484	494		10.1074/jbc.273.1.484	http://dx.doi.org/10.1074/jbc.273.1.484			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417107	hybrid			2022-12-25	WOS:000071295600073
J	Spitz, F; Demignon, J; Demeurie, J; Sabourin, JC; Kahn, A; Daegelen, D; Maire, P				Spitz, F; Demignon, J; Demeurie, J; Sabourin, JC; Kahn, A; Daegelen, D; Maire, P			A binding site for nuclear receptors is required for the differential expression of the aldolase A fast-twitch muscle promoter in body and head muscles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; SKELETAL-MUSCLE; REGULATORY ELEMENTS; HORMONE-RECEPTOR; GENE-EXPRESSION; CHAIN ISOFORMS; IN-VIVO; A GENE; SEQUENCES; ORPHAN	In hind limb muscles, the aldolase A muscle-specific promoter is specifically expressed in glycolytic fast-twitch fibers. Here, we show that in addition, it is expressed at higher levels in trunk and limb muscles than in neck and head muscles independent of their fiber-type content. Ne have identified by analysis of trans genic mice a DNA element that is required for this differential expression and, to a lesser extent, for fiber-type specificity. We show that members of the nuclear receptor superfamily bind this element in skeletal muscle nuclear extracts. Interestingly, in gel mobility shift assays, different complexes were formed with this sequence in tongue nuclear extracts compared with limb or trunk muscle nuclear extracts. Therefore, binding of distinct nuclear receptors to a single regulatory sequence appears to be associated with the location-dependent expression of the aldolase A muscle-specific promoter.	CHU St Antoine, URA CNRS 1283, F-75012 Paris, France; Univ Paris 05, INSERM U129, ICGM, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Maire, P (corresponding author), CHU St Antoine, URA CNRS 1283, 27 Rue Chaligny, F-75012 Paris, France.	maire@icgm.cochin.inserm.fr	Maire, Pascal/E-6339-2016	Maire, Pascal/0000-0001-7795-0029				ASAKURA A, 1995, DEV BIOL, V171, P386, DOI 10.1006/dbio.1995.1290; AUSONI S, 1990, J NEUROSCI, V10, P153; BANERJEEBASU S, 1993, MOL CELL BIOL, V13, P7019, DOI 10.1128/MCB.13.11.7019; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; COLBERT MC, 1992, DEV BIOL, V149, P66, DOI 10.1016/0012-1606(92)90264-H; CONCORDET JP, 1993, MOL CELL BIOL, V13, P9, DOI 10.1128/MCB.13.1.9; Conti A, 1996, BIOCHEM J, V316, P19, DOI 10.1042/bj3160019; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; CORIN SJ, 1995, P NATL ACAD SCI USA, V92, P6185, DOI 10.1073/pnas.92.13.6185; COULY GF, 1993, DEVELOPMENT, V117, P409; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; DONOGHUE MJ, 1994, TRENDS GENET, V10, P396, DOI 10.1016/0168-9525(94)90056-6; GAUDET F, 1995, J BIOL CHEM, V270, P29916; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; HALLAUER PL, 1993, DEVELOPMENT, V119, P691; HATTA K, 1990, SCIENCE, V250, P802, DOI 10.1126/science.1978412; KADOWAKI Y, 1995, P NATL ACAD SCI USA, V92, P4432, DOI 10.1073/pnas.92.10.4432; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Leng X, 1996, MOL CELL BIOL, V16, P2332; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Marcus SL, 1996, J BIOL CHEM, V271, P27197, DOI 10.1074/jbc.271.44.27197; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUSCAT GEO, 1995, NUCLEIC ACIDS RES, V23, P1311, DOI 10.1093/nar/23.8.1311; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; PATAPOUTIAN A, 1993, DEVELOPMENT, V118, P61; Pette D, 1990, Rev Physiol Biochem Pharmacol, V116, P1; POWER RF, 1991, SCIENCE, V252, P1546, DOI 10.1126/science.2047861; Rao MV, 1996, MOL CELL BIOL, V16, P3909; RINDT H, 1993, J BIOL CHEM, V268, P5332; SALMINEN M, 1995, J MOL BIOL, V253, P17, DOI 10.1006/jmbi.1995.0532; Salminen M, 1996, MOL CELL BIOL, V16, P76; SALMINEN M, 1994, MOL CELL BIOL, V14, P6797, DOI 10.1128/MCB.14.10.6797; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Shield MA, 1996, MOL CELL BIOL, V16, P5058; Spitz F, 1997, MOL CELL BIOL, V17, P656, DOI 10.1128/MCB.17.2.656; STAUFFER JK, 1990, J BIOL CHEM, V265, P11773; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; ZARDINI DM, 1994, MUSCLE NERVE, V17, P1308, DOI 10.1002/mus.880171110	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					561	567		10.1074/jbc.273.1.561	http://dx.doi.org/10.1074/jbc.273.1.561			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417116	hybrid			2022-12-25	WOS:000071295600082
J	De Vries, HE; Ronken, E; Reinders, JH; Buchner, B; Van Berkel, TJC; Kuiper, J				De Vries, HE; Ronken, E; Reinders, JH; Buchner, B; Van Berkel, TJC; Kuiper, J			Acute effects of oxidized low density lipoprotein on metabolic responses in macrophages	FASEB JOURNAL			English	Article						microphysiometer; oxLDL; scavenger receptor; atheroclerosis	SCAVENGER RECEPTOR; POTENTIAL ROLE; LYSOPHOSPHATIDYLCHOLINE; ATHEROGENESIS; DEGRADATION; EXPRESSION; ACTIVATION; CELLS; LDL	The immediate effects of oxidized low density lipoprotein (OxLDL) on the metabolic activity of cultured macrophages (RAW 264.7) were studied using a microphysiometer. Administration of OxLDL acutely induced a concentration-dependent increase in metabolic activity, with an EC50 of 16 +/- 3 mu g/ml OxLDL and a maximal effect of 35% +/- 4% (mean +/- SEM; n=5). A biphasic response was measured after administration of 75 or 100 mu g/ml OxLDL consisting of an initial sharp increase, followed by the induction of a long-lasting hypoactivity of 80% of the control value. Incubation of cells with polyinosinic acid (polyI; 100 mu g/ml) for 30 min prior to OxLDL administration could completely block the effect of 25 mu g/ml OxLDL. In addition, polyI acted as a full antagonist on the decrease of the biphasic response of cells generated by 75 and 100 mu g/ml OxLDL. Macrophages used in this study possessed a specific binding site for OxLDL, with a dissociation constant (K-D) of 9 +/- 2 mu g/ml and a maximal binding of 610 +/- 32 ng I-125-OxLDL/mg cell protein. Binding of I-125-OxLDL to macrophages could be completely competed for by unlabeled OxLDL, by polyI for 58%, and by AcLDL for 46%. Tn conclusion, OxLDL can acutely activate the metabolic state of macrophages by a receptor-mediated process in a concentration-dependent fashion, which could be antagonized by polyI. Metabolic responses to OxLDL may underlie the changes observed in macrophages in the early atherosclerotic plaque.	Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Solway Duphar, CNS Pharmacol, Weesp, Netherlands	Leiden University; Leiden University - Excl LUMC	De Vries, HE (corresponding author), Leiden Univ, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, POB 9503, NL-2300 RA Leiden, Netherlands.		Büchner, Bernd/E-2437-2016; Van Berkel, Theo/ABD-7677-2021	Büchner, Bernd/0000-0002-3886-2680; 				ACTON SL, 1994, J BIOL CHEM, V269, P21003; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; CHEN Y, 1995, ATHEROSCLEROSIS, V112, P69, DOI 10.1016/0021-9150(94)05400-D; DERIJKE YB, 1994, J BIOL CHEM, V269, P1; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; ESTERBAUER H, 1990, CHEM RES TOXICOL, V3, P77, DOI 10.1021/tx00014a001; Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573; KODAMA T, 1990, NATURE, V343, P1313; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; PARHAMI F, 1995, ARTERIOSCL THROM VAS, V15, P2019, DOI 10.1161/01.ATV.15.11.2019; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Sakai M, 1996, J BIOL CHEM, V271, P27346, DOI 10.1074/jbc.271.44.27346; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; vanderKooij MA, 1996, ARTERIOSCL THROM VAS, V16, P106, DOI 10.1161/01.ATV.16.1.106; WEIS JR, 1991, FASEB J, V5, P2459, DOI 10.1096/fasebj.5.10.2065893; Yuan YP, 1996, J BIOL CHEM, V271, P27090, DOI 10.1074/jbc.271.43.27090	24	25	26	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					111	118		10.1096/fasebj.12.1.111	http://dx.doi.org/10.1096/fasebj.12.1.111			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438416				2022-12-25	WOS:000071523800012
J	Loffreda, S; Yang, SQ; Lin, HZ; Karp, CL; Brengman, ML; Wang, DJ; Klein, AS; Bulkley, GB; Bao, C; Noble, PW; Lane, MD; Diehl, AM				Loffreda, S; Yang, SQ; Lin, HZ; Karp, CL; Brengman, ML; Wang, DJ; Klein, AS; Bulkley, GB; Bao, C; Noble, PW; Lane, MD; Diehl, AM			Leptin regulates proinflammatory immune responses	FASEB JOURNAL			English	Article						obesity; macrophage; cytokine; phagocytic function; TNF; lipopolysaccharide	TUMOR-NECROSIS-FACTOR; INSULIN-RESISTANCE; DIABETIC MICE; FACTOR-ALPHA; ZUCKER RAT; RECEPTOR; IDENTIFICATION; EXPRESSION; MUTATION; OBESITY	Obesity is associated with an increased incidence of infection, diabetes, and cardiovascular disease, which together account for most obesity-related morbidity and mortality. Decreased expression of leptin or of functional leptin receptors results in hyperphagia, decreased energy expenditure, and obesity. It is unclear, however, whether defective leptin-dependent signal transduction directly promotes any of the conditions that frequently complicate obesity. Abnormalities in tumor necrosis factor cc expression have been noted in each of the above comorbid conditions, so leptin deficiency could promote these complications if leptin had immunoregulatory activity. Studies of rodents with genetic abnormalities in leptin or leptin receptors revealed obesity-related deficits in macrophage phagocytosis and the expression of proinflammatory cytokines both in vivo and in vitro. Exogenous leptin up-regulated both phagocytosis and the production of proinflammatory cytokines. These results identify an important and novel function for leptin: up-regulation of inflammatory immune responses, which may provide a common pathogenetic mechanism that contributes to several of the major complications of obesity.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.			Karp, Christopher/0000-0002-0832-2659				Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gorsky RD, 1996, AM J PREV MED, V12, P388, DOI 10.1016/S0749-3797(18)30296-4; HALAAS JL, 1995, SCIENCE, V269, P544; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; JOUISLAHTI P, 1996, CIRCULATION, V93, P1372; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KLEIN A, 1994, J LEUKOCYTE BIOL, V55, P248, DOI 10.1002/jlb.55.2.248; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Plotkin BJ, 1996, J MED MICROBIOL, V44, P277, DOI 10.1099/00222615-44-4-277; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; Seidell JC, 1996, ARCH INTERN MED, V156, P958, DOI 10.1001/archinte.156.9.958; SOLBACH W, 1991, IMMUNOL TODAY, V12, P4, DOI 10.1016/0167-5699(91)90103-Z; Takao S, 1996, AM J PHYSIOL-CELL PH, V271, pC1278, DOI 10.1152/ajpcell.1996.271.4.C1278; TANAKA S, 1993, INT J OBESITY, V17, P631; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRIENCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; YAMAKAWA T, 1995, CLIN IMMUNOL IMMUNOP, V75, P51, DOI 10.1006/clin.1995.1052; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	37	1021	1074	0	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					57	65		10.1096/fasebj.12.1.57	http://dx.doi.org/10.1096/fasebj.12.1.57			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438411				2022-12-25	WOS:000071523800007
J	Kaul, M; Loos, M				Kaul, M; Loos, M			Dissection of C1q capability of interacting with IgG - Time-dependent formation of a tight and only partly reversible association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST COMPONENT; MONOCLONAL-ANTIBODIES; COMPLEMENT COMPONENT; IMMUNOGLOBULIN-G; ELECTRON-MICROSCOPY; SUBCOMPONENT C1Q; MEMBRANE-PROTEIN; BINDING-SITE; HUMAN CLQ; MACROPHAGES	C1q-bearing immune complexes have been observed in diseases such as rheumatoid arthritis and human immunodeficiency virus infection-associated neuropathy. For the purpose of understanding better the phenomenon of C1q-bearing immune complexes, we investigated the constancy of the C1q-IgG interaction. An enzyme-linked immunosorbent assay was developed in which wells were coated with IgG to mimic antigen-complexed IgG. Serial dilutions of C1q were applied for distinct time intervals, and bound C1q was detected either directly or after exposure to one of several elution buffers. Our results show that a part of C1q attached to IgG forms a tight association that is not reversible under treatment with buffers containing usually protein-protein interaction-dissociating reagents such as 3 M NaCl, 5 M urea, sodium dodecyl sulfate, or beta-mercaptoethanol. The formation of the highly stable C1q-IgG complex was found to be time-, temperature-, and pH-dependent and to proceed with bound C1q even in the absence of free C1q in the supernatant. In ligand blotting experiments we demonstrate for the first time directly that all three chains of C1q can individually bind IgG. Altogether, our results provide a suitable explanation for the formation and persistence of C1q-bearing immune complexes.	Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Loos, M (corresponding author), Univ Mainz, Inst Med Microbiol & Hyg, Hochhaus Augustuspl, D-55101 Mainz, Germany.		Kaul, Marcus/AAS-8955-2020					ANTES U, 1988, ARTHRITIS RHEUM, V31, P457, DOI 10.1002/art.1780310401; ANTES U, 1984, J IMMUNOL METHODS, V74, P299, DOI 10.1016/0022-1759(84)90297-7; ATKINSON JP, 1980, J IMMUNOL METHODS, V33, P351, DOI 10.1016/0022-1759(80)90005-8; BINDON CI, 1988, J EXP MED, V168, P127, DOI 10.1084/jem.168.1.127; BURTON DR, 1980, NATURE, V288, P338, DOI 10.1038/288338a0; DUNCAN AR, 1988, NATURE, V332, P738, DOI 10.1038/332738a0; EASTERBROOKSMITH SB, 1983, BIOSCIENCE REP, V3, P135, DOI 10.1007/BF01121944; Fukushima Y, 1991, Rinsho Ketsueki, V32, P1540; GOLAN MD, 1982, J IMMUNOL, V129, P445; GOLAN MD, 1981, FEBS LETT, V128, P281, DOI 10.1016/0014-5793(81)80099-3; HEUSSER CH, 1975, IMMUNOCHEMISTRY, V12, P213, DOI 10.1016/0019-2791(75)90234-7; HUGHESJONES NC, 1979, MOL IMMUNOL, V16, P697, DOI 10.1016/0161-5890(79)90010-5; ISENMAN DE, 1975, J IMMUNOL, V114, P1726; JENSEN EV, 1959, SCIENCE, V130, P1319, DOI 10.1126/science.130.3385.1319; JIANG H, 1992, J EXP MED, V175, P1373, DOI 10.1084/jem.175.5.1373; JOKIRANTA TS, 1993, J IMMUNOL, V151, P2124; KAUL M, 1995, J IMMUNOL, V155, P5795; KAUL M, 1993, EUR J IMMUNOL, V23, P2166, DOI 10.1002/eji.1830230918; KISHORE U, 1996, MOL IMMUNOL, V33, P88; KNOBEL HR, 1975, EUR J IMMUNOL, V5, P78, DOI 10.1002/eji.1830050119; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LOOS M, 1983, CURR TOP MICROBIOL, V102, P1; MARQUES G, 1993, J BIOL CHEM, V268, P10393; MARTIN H, 1987, J IMMUNOL, V138, P3863; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; PAINTER RH, 1993, BEHRING I MITT, V93, P131; POON PH, 1985, J BIOL CHEM, V260, P9357; REID KBM, 1979, BIOCHEM J, V179, P367, DOI 10.1042/bj1790367; REID KBM, 1976, BIOCHEM J, V155, P19, DOI 10.1042/bj1550019; SMITH KF, 1994, BIOCHEM J, V301, P249, DOI 10.1042/bj3010249; Storm D, 1996, J IMMUNOL METHODS, V199, P87, DOI 10.1016/S0022-1759(96)00172-X; TAKADA A, 1984, IMMUNOPHARMACOLOGY, V8, P27, DOI 10.1016/0162-3109(84)90054-7; TAKADA A, 1982, IMMUNOLOGY, V47, P679; TENNER AJ, 1981, J IMMUNOL, V127, P648; TSCHOPP J, 1980, EUR J IMMUNOL, V10, P529, DOI 10.1002/eji.1830100709; WEBSTER S, 1994, J NEUROSCI RES, V39, P448, DOI 10.1002/jnr.490390412; WINES BD, 1990, MOL IMMUNOL, V27, P221, DOI 10.1016/0161-5890(90)90133-K; XU Y, 1994, J BIOL CHEM, V269, P3469	39	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33234	33244		10.1074/jbc.272.52.33234	http://dx.doi.org/10.1074/jbc.272.52.33234			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407113	hybrid			2022-12-25	WOS:000071182900074
J	Demaurex, N; Furuya, W; D'Souza, S; Bonifacino, JS; Grinstein, S				Demaurex, N; Furuya, W; D'Souza, S; Bonifacino, JS; Grinstein, S			Mechanism of acidification of the trans-Golgi network (TGN) - In situ measurements of pH using retrieval of TGN38 and furin from the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; CYTOPLASMIC DOMAIN; INTRACELLULAR PH; CA2+/H+ EXCHANGE; CYSTIC-FIBROSIS; LIVING CELLS; BREFELDIN-A; LOCALIZATION; MEMBRANE; SEQUENCE	Sorting of secretory cargo and retrieval of components of the biosynthetic pathway occur at the trans-Golgi network (TGN), The pH within the TGN is thought to be an important determinant of these functions, However, studies of the magnitude and regulation of the pH of the TGN have been hampered by the lack of appropriate detection methods, This report describes a noninvasive strategy to measure the luminal pH of the TGN in intact cells, We took advantage of endogenous cellular mechanisms for the specific retrieval of TGN resident proteins, such as TGN38 and furin, that transit briefly to the plasma membrane, Cells were transfected with chimeric constructs that contained the internalization and retrieval signals of TGN resident proteins, and a luminal (extracellular) epitope (CD25), Like TGN38 and furin, the chimeras were shown by fluorescence microscopy to accumulate within the TGN, During their transient exposure at the cell surface, the chimeras were labeled with extracellular anti-CD25 antibodies conjugated with a pH-sensitive fluorophore. Subsequent endocytosis and retrograde transport resulted in preferential labeling of the TGN with the pH-sensitive probe, Continuous, quantitative measurements of the pH of the TGN were obtained by ratio fluorescence imaging, The resting pH, calibrated using either ionophores or the "null point" technique, averaged 5.95 in Chinese hamster ovary cells and 5.91 in HeLa cells, The acidification was dissipated upon addition of concanamycin, a selective blocker of vacuolar-type ATPases, The counterion conductance was found to be much greater than the rate of H+ pumping at the steady state, suggesting that the acidification is not limited by an electrogenic potential, Both Cl- and K+ were found to contribute to the overall counterion permeability of the TGN, No evidence was found for the presence of active Na+/H+ or Ca2+/H+ exchangers on the TGN membrane, In conclusion, selective retrieval of recombinant proteins can be exploited to target ion-sensitive fluorescent probes to specific organelles, The technique provides real-time, noninvasive, and quantitative determinations of the pH, allowing the study of pH regulation within the TGN in intact cells, The acidic pH of the TGN reflects active H+ pumping into an organelle with a low intrinsic H+ permeability and a high conductance to monovalent ions.	Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Geneva, Med Ctr, Dept Physiol, CH-1211 Geneva, Switzerland; NICHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Geneva; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Grinstein, S (corresponding author), Hosp Sick Children, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.on.ca		Bonifacino, Juan S./0000-0002-5673-6370; Demaurex, Nicolas/0000-0002-9933-6772				ALAWQATI Q, 1992, J EXP BIOL, V172, P245; ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Boyarsky G, 1996, FASEB J, V10, P1205, DOI 10.1096/fasebj.10.10.8751723; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; DEMAUREX N, 1993, J PHYSIOL-LONDON, V466, P329; DEMAUREX N, 1996, J CELL BIOL, V133, P1; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; Kim JH, 1996, J CELL BIOL, V134, P1387, DOI 10.1083/jcb.134.6.1387; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LUKACS GL, 1993, AM J PHYSIOL, V265, pC3, DOI 10.1152/ajpcell.1993.265.1.C3; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Maxfield FR, 1991, INTRACELLULAR TRAFFI, P157; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; ORCI L, 1987, NATURE, V326, P77, DOI 10.1038/326077a0; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; VERCESI AE, 1994, BIOCHEM J, V304, P227, DOI 10.1042/bj3040227; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; WONG SH, 1993, J BIOL CHEM, V268, P22853; WOO JT, 1992, EUR J BIOCHEM, V207, P383, DOI 10.1111/j.1432-1033.1992.tb17061.x; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5	37	161	166	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2044	2051		10.1074/jbc.273.4.2044	http://dx.doi.org/10.1074/jbc.273.4.2044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442042	hybrid			2022-12-25	WOS:000071595200031
J	Nabirochkin, S; Ossokina, M; Heidmann, T				Nabirochkin, S; Ossokina, M; Heidmann, T			A nuclear matrix/scaffold attachment region co-localizes with the gypsy retrotransposon insulator sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAIRY-WING PROTEIN; DNA-BINDING PROTEIN; METAPHASE CHROMOSOME STRUCTURE; SCAFFOLD-ASSOCIATED REGIONS; ZINC FINGER PROTEIN; TOPOISOMERASE-II; DROSOPHILA-MELANOGASTER; TRANSPOSABLE ELEMENT; CHROMATIN INSULATOR; MOLECULAR ANALYSIS	The 5'-untranslated region of the Drosophila gypsy retrotransposon contains an "insulator," which disrupts the interactions between enhancer and promoter elements located apart, The insulator effect is dependent on the suppressor of Hairy-wing (su(Hw)) protein, which binds to reiterated sites within the 350 base pairs of the gypsy insulator, whereby it additionally acts as a transcriptional activator of gypsy, Here, we show that the 350 base pair su(Hw) binding site containing gypsy insulator behaves in addition as a matrix/scaffold attachment region (MAR/SAR), involved in interactions with the nuclear matrix. In vitro experiments using nuclear matrices from Drosophila, murine, and human cells demonstrate specific binding of the gypsy insulator, not observed with any other sequence within the retrotransposon, Moreover, we show that the gypsy insulator, like previously characterized MAR/SARs, specifically interacts with topoisomerase II and histone H1, i.e. with two essential components of the nuclear matrix, Finally, experiments within cells in culture demonstrate differential effects of the gypsy MAR sequence on reporter genes, namely no effect under conditions of transient transfection and a repressing effect in stable transformants, as expected for a sequence involved in chromatin structure and organization, A model for the gypsy insulator, which combines within a short "compacted" retroviral sequence three functional domains (insulator, enhancer, and the presently unraveled MAR/SAR) dispersed within more extended regions in other "boundary" domains, is discussed in relation to previously proposed models for insulation.	Inst Gustave Roussy, Unite Physicochim & Pharmacol Macromol Biol, CNRS URA147, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Heidmann, T (corresponding author), Inst Gustave Roussy, Unite Physicochim & Pharmacol Macromol Biol, CNRS URA147, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.							ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; BAYEV AA, 1984, NUCLEIC ACIDS RES, V12, P3707, DOI 10.1093/nar/12.8.3707; BEREZNEY R, 1975, SCIENCE, V189, P291, DOI 10.1126/science.1145202; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; Coffin JM, 1996, FIELDS VIROLOGY, P1767; CORCES VG, 1995, NATURE, V376, P462, DOI 10.1038/376462a0; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1986, EMBO J, V5, P2657, DOI 10.1002/j.1460-2075.1986.tb04548.x; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HANCOCK R, 1982, BIOL CELL, V44, P201; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; Herrscher RF, 1995, GENE DEV, V9, P3067, DOI 10.1101/gad.9.24.3067; Iarovaia O, 1996, MOL CELL BIOL, V16, P302; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Kim J, 1996, MOL CELL BIOL, V16, P3381; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; Maniatis T., 1989, MOL CLONING LAB MANU; MARLOR RL, 1986, MOL CELL BIOL, V6, P1129, DOI 10.1128/MCB.6.4.1129; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MODOLELL J, 1983, P NATL ACAD SCI-BIOL, V80, P1678, DOI 10.1073/pnas.80.6.1678; NAKAGOMI K, 1994, MOL CELL BIOL, V14, P1852, DOI 10.1128/MCB.14.3.1852; Neznanov N, 1996, MOL BIOL CELL, V7, P541, DOI 10.1091/mbc.7.4.541; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; PARKHURST SM, 1986, MOL CELL BIOL, V6, P47, DOI 10.1128/MCB.6.1.47; PAULSON JR, 1977, CELL, V12, P815; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PhiVan L, 1996, BIOCHEMISTRY-US, V35, P10735, DOI 10.1021/bi9603783; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x; SAITOH Y, 1994, CELL, V76, P609, DOI 10.1016/0092-8674(94)90502-9; SANDER M, 1985, NUCLEIC ACIDS RES, V13, P1057, DOI 10.1093/nar/13.4.1057; SCHEDL P, 1995, CHROMATIN STRUCTURE, P172; Schubeler D, 1996, BIOCHEMISTRY-US, V35, P11160, DOI 10.1021/bi960930o; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; SMITH PA, 1995, GENETICS, V139, P215; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; SPANA C, 1990, GENE DEV, V4, P1505, DOI 10.1101/gad.4.9.1505; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; Strick R, 1995, CELL, V83, P1137, DOI 10.1016/0092-8674(95)90140-X; VAZQUEZ J, 1994, EMBO J, V13, P5984, DOI 10.1002/j.1460-2075.1994.tb06944.x; VAZQUEZ J, 1993, COLD SPRING HARB SYM, V58, P45, DOI 10.1101/SQB.1993.058.01.008; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	67	71	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2473	2479		10.1074/jbc.273.4.2473	http://dx.doi.org/10.1074/jbc.273.4.2473			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442099	hybrid			2022-12-25	WOS:000071595200088
J	Ogawa, H; Harada, S; Sassa, T; Yamamoto, H; Hosono, R				Ogawa, H; Harada, S; Sassa, T; Yamamoto, H; Hosono, R			Functional properties of the unc-64 gene encoding a Caenorhabditis elegans syntaxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; C-ELEGANS; ACETYLCHOLINE LEVELS; VESICULAR TRANSPORT; MUTATIONS; NEMATODE; BINDING; SPECIFICITY; EXPRESSION; RECEPTORS	Phenotypes of Caenorhabditis elegans unc-18 and unc-64 gene mutations are similar. While unc-18 is known to be essential for normal synaptic transmission (Hosono, R., Hekimi, S., Kamiya, Y., Sassa, T., Murakami, S., Nishiwaki, S., Miwa, J., Taketo, A, and Kodaira, K.-I. (1992) J. Neurochem. 58, 1517-1525), the function of unc-64 remains unclear. Here we describe the cloning, and the molecular and genetic characterization of the unc-64 gene, especially in relation to unc-18. unc-64 encodes a protein (C. elegans syntaxin) showing sequence and structural similarities to mammalian syntaxin 1A. From unc-64, at least three types of poly(A)(+) RNA are transcribed, which encode two types of syntaxin that differ in the deduced transmembrane domain. In gene expression, unc-64 closely resembles unc-18, that is, both are expressed in neural cells, especially in motor neurons and neurons constituting head ganglions. C. elegans syntaxin binds to UNC-18 with high affinity. The unc-64 (e246) mutation producing a mild phenotype causes an Ala --> Val conversion in the conserved COOH-terminal region in mammalian syntaxin 1A or Drosophila syntaxin-1A whose site is included in three types of transcripts. The binding of the mutant C. elegans syntaxin tb UNC-18 is greatly reduced, indicating the mutation Site contributes to the binding.	Kanazawa Univ, Fac Med, Dept Phys Informat, Kanazawa, Ishikawa 920, Japan; Kanazawa Univ, Fac Med, Dept Biochem, Kanazawa, Ishikawa 920, Japan; Univ Tokushima, Sch Med, Dept Nutr, Tokushima 770, Japan; Fujita Hlth Univ, Dept Biol, Aichi 47011, Japan	Kanazawa University; Kanazawa University; Tokushima University; Fujita Health University	Hosono, R (corresponding author), Kanazawa Univ, Fac Med, Dept Phys Informat, 13-1 Takara Machi, Kanazawa, Ishikawa 920, Japan.							AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BRENNER S, 1974, GENETICS, V77, P71; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; COULSON A, 1991, BIOESSAYS, V13, P413, DOI 10.1002/bies.950130809; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; GENGYOANDO K, 1993, NEURON, V11, P703, DOI 10.1016/0896-6273(93)90080-B; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HOSONO R, 1989, ZOOL SCI, V6, P697; HOSONO R, 1987, J NEUROCHEM, V49, P1820, DOI 10.1111/j.1471-4159.1987.tb02442.x; HOSONO R, 1992, J NEUROCHEM, V58, P1517, DOI 10.1111/j.1471-4159.1992.tb11373.x; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller KG, 1996, P NATL ACAD SCI USA, V93, P12593, DOI 10.1073/pnas.93.22.12593; MITANI S, 1993, DEVELOPMENT, V119, P773; Ogawa H, 1996, NEUROCHEM INT, V29, P553, DOI 10.1016/0197-0186(95)00012-7; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; RIDDLE DL, 1997, CELEGANS, V2; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J., 2002, MOL CLONING LAB MANU; Sassa T, 1996, NEUROCHEM INT, V29, P543, DOI 10.1016/0197-0186(96)00009-5; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SCHULZE K, 1995, CELL, V80, P331; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0	29	69	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2192	2198		10.1074/jbc.273.4.2192	http://dx.doi.org/10.1074/jbc.273.4.2192			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442061	hybrid			2022-12-25	WOS:000071595200050
J	Sagami, I; Shimizu, T				Sagami, I; Shimizu, T			The crucial roles of Asp-314 and Thr-315 in the catalytic activation of molecular oxygen by neuronal nitric-oxide synthase - A site-directed mutagenesis study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NO SYNTHASE; DISTAL SITE; AMINO-ACID; CYTOCHROME-P-450; HEME; TETRAHYDROBIOPTERIN; REDUCTASE; STABILITY; GLU(318); COMPLEX	Nitric-oxide synthase (NOS) is a flavohemoprotein that has a cytochrome P450 (P450)-type heme active site and catalyzes the monooxygenation of L-Arg to N-G-hydroxy-L-Arg (NHA) according to the normal P450 type reaction in the first step of NO synthesis, However, there is some controversy as to how the second step of the reaction, from NHA to NO and L-citrulline, occurs within the P450 domain of NOS, By referring to the heme active site of P450, it is conjectured that polar amino acid(s) such as Asp/Glu and Thr must be responsible for the activation of molecular oxygen in NOS, In this study, we have created Asp-314 --> Ala and Thr-315 --> Ala mutants of neuronal NOS, both of which had absorption maxima at 450 nm in the spectra of the GO-reduced complexes and studied NO formation rates and other kinetic parameters as well as the substrate binding affinity, The Asp-314 --> Ala mutant totally abolished NO formation activity and markedly increased the rate of H2O2 formation by 20-fold compared with the wild type when L-Arg was used as the substrate, The NADPH oxidation and O-2, consumption rates for the Asp-314 --> Ala mutant were 60-65% smaller than for the wild type, The Thr-315 --> Ala mutant, on the other hand, retained NO formation activity that was 23% higher than the wild type, but like the Asp-314 --> Ala mutation, markedly increased the H,O, formation rate, The NADPH oxidation and O-2, consumption rates for the Thr-315 --> Ala mutant were, respectively, 56 and 27% higher than for the wild type, When NHA was used as the substrate, similar values were obtained, Thus, we propose that Asp-314 is crucial for catalysis, perhaps through involvement in the stabilization of an oxygen-bound intermediate, An important role for Thr-315 in the catalysis is also suggested.	Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan	Tohoku University	Sagami, I (corresponding author), Tohoku Univ, Inst Chem React Sci, Sendai, Miyagi 9808577, Japan.	ikuko@icrs.tohoku.ac.jp						BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CRANE BR, 1997, SCIENCE, V257, P424; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Feelisch M., 1996, METHODS NITRIC OXIDE; FELDMAN PL, 1993, CHEM ENG NEWS, V71, P26; GERBER NC, 1994, J BIOL CHEM, V269, P4260; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Gorren ACF, 1997, BIOCHEMISTRY-US, V36, P4360, DOI 10.1021/bi962381s; IGNARRO L, 1996, NITRIC OXIDE BIOCH M; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; Klatt P, 1996, METHOD ENZYMOL, V268, P358; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MASTERS BSS, 1994, ANNU REV NUTR, V14, P131, DOI 10.1146/annurev.nu.14.070194.001023; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3683; Mueller Ernest J., 1995, P83; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; NELSON DR, 1988, J BIOL CHEM, V263, P6038; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; RAAG R, 1991, BIOCHEMISTRY-US, V26, P8165; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; RICHARDS MK, 1994, BIOCHEMISTRY-US, V33, P14723, DOI 10.1021/bi00253a010; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHETA EA, 1994, J BIOL CHEM, V269, P15147; SHIMADA H, 1990, INT S OXYGENASES OXY, P133; SHIMIZU T, 1994, J BIOL CHEM, V269, P13296; Stuehr DJ, 1996, METHOD ENZYMOL, V268, P324; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014	37	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2105	2108		10.1074/jbc.273.4.2105	http://dx.doi.org/10.1074/jbc.273.4.2105			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442050	hybrid			2022-12-25	WOS:000071595200039
J	Arnold, I; Folsch, H; Neupert, W; Stuart, RA				Arnold, I; Folsch, H; Neupert, W; Stuart, RA			Two distinct and independent mitochondrial targeting signals function in the sorting of an inner membrane protein, cytochrome c(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMEMBRANE SPACE; MATRIX ATP; IMPORT; YEAST; COMPLEX; FAMILY; MEMBER; IDENTIFICATION; TRANSLOCATION; TOPOGENESIS	Proteins of the mitochondrial inner membrane display a wide variety of orientations, many spanning the membrane more than once, Some of these proteins are synthesized with NH2-terminal cleavable targeting sequences (presequences) whereas others are targeted to mitochondria via internal signals, Here we report that two distinct mitochondrial targeting signals can be present in precursors of inner membrane proteins, an NH2-terminal one and a second, internal one, Using cytochrome c(1) as a model protein, we demonstrate that these two mitochondrial targeting signals operate independently of each other, The internal targeting signal, consisting of a transmembrane segment and a stretch of positively charged amino acid residues directly following it, initially directs the translocation of the preprotein into the intermembrane space, It then inserts into the inner membrane from the intermembrane space side in a Delta psi-dependent manner and thereby determines the orientation the protein attains in the inner membrane, Analysis of a number of other presequence-containing protein of the inner membrane suggest that they too contain such internal targeting signals.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Arnold, I (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.			Folsch, Heike/0000-0003-0897-0311				BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOM J, 1995, EUR J BIOCHEM, V232, P309, DOI 10.1111/j.1432-1033.1995.tb20813.x; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; Gruhler A, 1997, J BIOL CHEM, V272, P17410, DOI 10.1074/jbc.272.28.17410; GUELIN E, 1994, YEAST, V10, P1389, DOI 10.1002/yea.320101016; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; HERRMANN JM, 1995, J BIOL CHEM, V270, P27079, DOI 10.1074/jbc.270.45.27079; HORWICH AL, 1985, EMBO J, V4, P1129, DOI 10.1002/j.1460-2075.1985.tb03750.x; HURT EC, 1984, FEBS LETT, V178, P306, DOI 10.1016/0014-5793(84)80622-5; KUBRICH M, 1994, FEBS LETT, V349, P222, DOI 10.1016/0014-5793(94)00670-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mashkevich G, 1997, J BIOL CHEM, V272, P14356, DOI 10.1074/jbc.272.22.14356; NUNNARI J, 1993, SCIENCE, V262, P1997, DOI 10.1126/science.8266095; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PRIEST JW, 1993, BIOCHIM BIOPHYS ACTA, V1144, P229, DOI 10.1016/0005-2728(93)90178-I; ROJO EE, 1995, EMBO J, V14, P3445, DOI 10.1002/j.1460-2075.1995.tb07350.x; ROMISCH J, 1987, EUR J BIOCHEM, V164, P111, DOI 10.1111/j.1432-1033.1987.tb11000.x; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Stuart RA, 1996, TRENDS BIOCHEM SCI, V21, P261, DOI 10.1016/S0968-0004(96)10035-9; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; STUART RA, 1990, J BIOL CHEM, V265, P20210; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; Teichmann U, 1996, J BIOL CHEM, V271, P10137, DOI 10.1074/jbc.271.17.10137; Towbin H., 1979, P NATL ACAD SCI USA, V79, P267; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	39	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1469	1476		10.1074/jbc.273.3.1469	http://dx.doi.org/10.1074/jbc.273.3.1469			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430684	hybrid			2022-12-25	WOS:000071411500031
J	Kimura, M; Kaneko, I; Komiyama, M; Takatsuki, A; Koshino, H; Yoneyama, K; Yamaguchi, I				Kimura, M; Kaneko, I; Komiyama, M; Takatsuki, A; Koshino, H; Yoneyama, K; Yamaguchi, I			Trichothecene 3-O-acetyltransferase protects both the producing organism and transformed yeast from related mycotoxins - Cloning and characterization of Tri101	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSARIUM-SPOROTRICHIOIDES NRRL-3299; S DEAMINASE GENE; SCHIZOSACCHAROMYCES-POMBE; TRICHODIENE SYNTHASE; GIBBERELLA-PULICARIS; ASPERGILLUS-TERREUS; REDUCED VIRULENCE; MAMMALIAN-CELLS; T-2 TOXIN; BIOSYNTHESIS	Trichothecene mycotoxins such as deoxynivalenol, 4,15-diacetoxyscirpenol, and T-2 toxin, are potent protein synthesis inhibitors for eukaryotic organisms, The 3-O-acetyl derivatives of these toxins were shown to reduce their in vitro activity significantly as assessed by assays using a rabbit reticulocyte translation system, The results suggested that the introduction of an O-acetyl group at the C-3 position in the biosynthetic pathway works as a resistance mechanism for Fusarium species that produce t-type trichothecenes (trichothecenes synthesized via the precursor trichotriol). A gene responsible for the 3-O-acetylation reaction, Tri101, has been successfully cloned from a Fusarium graminearum cDNA library that was designed to be expressed in Schizosaccharomyces pombe. Fission yeast transformants were selected for their ability to grow in the presence of T-2 toxin, and this strategy allowed isolation of 25 resistant clones, all of which contained a cDNA for Tri101, This is the first drug-inactivating O-acetyltransferase gene derived from antibiotic-producing organisms, The open reading frame of Tri101 codes for a polypeptide of 451 amino acid residues, which shows no similarity to any other proteins reported so far, TRI101 from recombinant Escherichia coli catalyzes O-acetylation of the trichothecene ring specifically at the C-3 position in an acetyl-CoA-dependent manner. By using the Tri101 cDNA as a probe, two least overlapping cosmid clones that cover a region of 70 kilobase pairs have been isolated from the genome off. graminearum. Other trichothecene biosynthetic genes, Tri4, Tri5, and Tri6, were not clustered in the region covered by these cosmid clones, These new cosmid clones are considered to be located in other parts of the large biosynthetic gene cluster and might be useful for the study of tricho thecene biosynthesis.	Inst Phys & Chem Res, Microbial Toxicol Lab, Wako, Saitama 35101, Japan; Inst Phys & Chem Res, Anim & Cellular Syst Lab, Wako, Saitama 35101, Japan; Inst Phys & Chem Res, Div Mol Characterizat, Wako, Saitama 35101, Japan	RIKEN; RIKEN; RIKEN	Kimura, M (corresponding author), Inst Phys & Chem Res, Microbial Toxicol Lab, 2-1 Hirosawa, Wako, Saitama 35101, Japan.		Koshino, Hiroyuki/N-7948-2015; Koshino, Hiroyuki/ABF-4899-2021; Kimura, Makoto/I-6906-2014	Koshino, Hiroyuki/0000-0002-0954-9839; Koshino, Hiroyuki/0000-0002-0954-9839; Kimura, Makoto/0000-0001-5310-2893				ANDERSON DW, 1989, J MED CHEM, V32, P555, DOI 10.1021/jm00123a008; BALLANCE DJ, 1986, YEAST, V2, P229, DOI 10.1002/yea.320020404; BEAN GA, 1984, J NAT PROD, V47, P727, DOI 10.1021/np50034a031; BLACKWELL BA, 1985, J BIOL CHEM, V260, P4243; CORLEY DG, 1987, J ORG CHEM, V52, P4405, DOI 10.1021/jo00228a053; CUNDLIFFE E, 1989, ANNU REV MICROBIOL, V43, P207, DOI 10.1146/annurev.micro.43.1.207; Desjardins AE, 1996, MOL PLANT MICROBE IN, V9, P775, DOI 10.1094/MPMI-9-0775; DESJARDINS AE, 1989, PHYTOPATHOLOGY, V79, P170, DOI 10.1094/Phyto-79-170; DESJARDINS AE, 1993, MICROBIOL REV, V57, P595, DOI 10.1128/MMBR.57.3.595-604.1993; DESJARDINS AE, 1992, MOL PLANT MICROBE IN, V5, P214, DOI 10.1094/MPMI-5-214; EHRLICH KC, 1987, BIOCHIM BIOPHYS ACTA, V923, P206, DOI 10.1016/0304-4165(87)90005-5; FRIED HM, 1981, P NATL ACAD SCI-BIOL, V78, P238, DOI 10.1073/pnas.78.1.238; HESKETH AR, 1990, J CHEM SOC CHEM COMM, P1184, DOI 10.1039/c39900001184; HOHN TM, 1989, GENE, V79, P131, DOI 10.1016/0378-1119(89)90098-X; HOHN TM, 1992, MOL PLANT MICROBE IN, V5, P249, DOI 10.1094/MPMI-5-249; HOHN TM, 1993, CURR GENET, V24, P291, DOI 10.1007/BF00336778; HOHN TM, 1995, MOL GEN GENET, V248, P95, DOI 10.1007/BF02456618; HOHN TM, 1986, ARCH BIOCHEM BIOPHYS, V251, P756, DOI 10.1016/0003-9861(86)90386-3; IGLESIAS M, 1994, EUR J BIOCHEM, V223, P447, DOI 10.1111/j.1432-1033.1994.tb19012.x; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; KIMURA M, 1994, MOL GEN GENET, V242, P121, DOI 10.1007/BF00391004; MCCORMICK SP, 1990, APPL ENVIRON MICROB, V56, P702, DOI 10.1128/AEM.56.3.702-706.1990; MCCORMICK SP, 1989, APPL ENVIRON MICROB, V55, P2195, DOI 10.1128/AEM.55.9.2195-2199.1989; McCormick SP, 1996, APPL ENVIRON MICROB, V62, P353, DOI 10.1128/AEM.62.2.353-359.1996; MILLER JD, 1983, CAN J BOT, V61, P3080, DOI 10.1139/b83-345; MILLER JD, 1986, CAN J PLANT PATHOL, V8, P147; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; PLATTNER RD, 1989, APPL ENVIRON MICROB, V55, P2190, DOI 10.1128/AEM.55.9.2190-2194.1989; PROCTOR RH, 1995, APPL ENVIRON MICROB, V61, P1923, DOI 10.1128/AEM.61.5.1923-1930.1995; PROCTOR RH, 1995, MOL PLANT MICROBE IN, V8, P593, DOI 10.1094/MPMI-8-0593; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; SHI Z, 1995, PHYTOPATHOLOGY, V85, P329, DOI 10.1094/Phyto-85-329; TAKATSUK.A, 1969, J ANTIBIOT, V22, P241, DOI 10.7164/antibiotics.22.241; TAKITANI S, 1979, J CHROMATOGR, V172, P335, DOI 10.1016/S0021-9673(00)90970-1; UENO Y, 1973, J BIOCHEM-TOKYO, V74, P285; Vesonder R. F., 1989, Fusarium: mycotoxins, taxonomy and pathogenicity., P1; YOSHIZAWA T, 1975, APPL MICROBIOL, V29, P54, DOI 10.1128/AEM.29.1.54-58.1975; Zamir LO, 1996, J BIOL CHEM, V271, P27353, DOI 10.1074/jbc.271.44.27353; ZAMIR LO, 1990, J BIOL CHEM, V265, P6713	40	194	213	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1654	1661		10.1074/jbc.273.3.1654	http://dx.doi.org/10.1074/jbc.273.3.1654			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430709	hybrid			2022-12-25	WOS:000071411500056
J	Langelier, Y; Champoux, L; Hamel, M; Guilbault, C; Lamarche, N; Gaudreau, P; Massie, B				Langelier, Y; Champoux, L; Hamel, M; Guilbault, C; Lamarche, N; Gaudreau, P; Massie, B			The R1 subunit of herpes simplex virus ribonucleotide reductase is a good substrate for host cell protein kinases but is not itself a protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE N-TERMINUS; ESCHERICHIA-COLI; TYPE-2; ICP10; PHOSPHORYLATION; BINDING; DOMAIN; ALPHA; SITES; ATP	The N terminus of the R1 subunit of herpes simplex virus type 2 ribonucleotide reductase is believed to be a protein kinase domain mainly because the R1 protein was phosphorylated in a protein kinase assay on blot. Using Escherichia coli and adenovirus expression vectors to produce R1, we found that, whereas the reductase activity of both recombinant proteins was similar, efficient phosphorylation of R1 and casein in the presence of Mg2+ was obtained only with the R1 purified from eukaryotic cells, Phosphorylation of this R1, in solution or on blot, results mainly from the activity of casein kinase II (CKII), a co-purifying protein kinase. Labeling on blot occurs from CKII Leakage off the membrane and its subsequent high affinity binding to in vivo CKII-phosphorylated R1. CKII target sites were mapped to an acidic serine-rich segment of the R1 N terminus. Improvement in purification of the R1 expressed in eukaryotic cells nearly completely abolished its phosphorylation potential, An extremely low level of phosphorylation observed in the presence of Mn2+ with the R1 produced in E. coli was probably due to an unidentified prokaryotic protein kinase. These results provide evidence that the herpes simplex virus type 2 R1 does not possess an intrinsic protein kinase activity.	Univ Montreal, Ctr Hosp, Ctr Rech, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Universite de Montreal; Universite de Montreal; National Research Council Canada	Langelier, Y (corresponding author), Univ Montreal, Ctr Hosp, Ctr Rech, Pavillon Notre Dame,1560 Est, Montreal, PQ H2L 4M1, Canada.	langeliy@ere.umontreal.ca						Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; ALI MA, 1992, VIROLOGY, V187, P360, DOI 10.1016/0042-6822(92)90328-M; ALI MA, 1995, VIROLOGY, V207, P409, DOI 10.1006/viro.1995.1100; CARDENAS ME, 1993, J CELL SCI, V104, P533; CHARLTON LA, 1992, J BIOL CHEM, V267, P8840; CHUNG TD, 1990, VIROLOGY, V179, P168, DOI 10.1016/0042-6822(90)90286-Z; CHUNG TD, 1989, J VIROL, V63, P3389, DOI 10.1128/JVI.63.8.3389-3398.1989; CONNER J, 1992, J VIROL, V66, P7511, DOI 10.1128/JVI.66.12.7511-7516.1992; CONNER J, 1994, J GEN VIROL, V75, P3327, DOI 10.1099/0022-1317-75-12-3327; CONNER J, 1992, J GEN VIROL, V73, P103, DOI 10.1099/0022-1317-73-1-103; COOPER J, 1995, J VIROL, V69, P4979, DOI 10.1128/JVI.69.8.4979-4985.1995; COZZONE AJ, 1993, J CELL BIOCHEM, V51, P7, DOI 10.1002/jcb.240510103; DeFrutos T, 1997, BIOL CHEM, V378, P31, DOI 10.1515/bchm.1997.378.1.31; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; FURLONG J, 1991, VIROLOGY, V182, P846, DOI 10.1016/0042-6822(91)90627-N; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; HERRMANN CPE, 1991, ONCOGENE, V6, P877; INGEMARSON R, 1987, VIROLOGY, V156, P417, DOI 10.1016/0042-6822(87)90422-3; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; JOLICOEUR N, 1994, THESIS U MONTREAL MO; Joyal JL, 1996, BIOCHEMISTRY-US, V35, P6267, DOI 10.1021/bi9600198; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Lamarche N, 1996, BIOCHEM J, V320, P129, DOI 10.1042/bj3200129; LANKINEN H, 1993, J GEN VIROL, V74, P1871, DOI 10.1099/0022-1317-74-9-1871; LITCHFIELD DW, 1990, J BIOL CHEM, V265, P7638; LUO JH, 1991, J BIOL CHEM, V266, P20976; LUO JH, 1992, J BIOL CHEM, V267, P9645; MALEK SN, 1994, J BIOL CHEM, V269, P33009; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MASSIE B, 1995, BIO-TECHNOL, V13, P602, DOI 10.1038/nbt0695-602; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MURTHY LR, 1991, ANAL BIOCHEM, V193, P299, DOI 10.1016/0003-2697(91)90025-O; Nelson JW, 1996, J BIOL CHEM, V271, P17021, DOI 10.1074/jbc.271.29.17021; NIKAS I, 1986, Proteins Structure Function and Genetics, V1, P376, DOI 10.1002/prot.340010411; ORMO M, 1990, ANAL BIOCHEM, V189, P138, DOI 10.1016/0003-2697(90)90059-I; OU WJ, 1992, J BIOL CHEM, V267, P23789; PARADIS H, 1991, J BIOL CHEM, V266, P9647; Peng T, 1996, VIROLOGY, V216, P184, DOI 10.1006/viro.1996.0045; Postel EH, 1996, CURR TOP MICROBIOL, V213, P233; Sacks DB, 1996, EUR J BIOCHEM, V239, P98, DOI 10.1111/j.1432-1033.1996.0098u.x; SMITH CC, 1994, VIROLOGY, V200, P598, DOI 10.1006/viro.1994.1223; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SWAIN MA, 1986, J VIROL, V57, P802, DOI 10.1128/JVI.57.3.802-808.1986; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; VANCUROVA I, 1995, J CELL SCI, V108, P779; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Wearsch PA, 1997, J BIOL CHEM, V272, P5152, DOI 10.1074/jbc.272.8.5152	50	26	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1435	1443		10.1074/jbc.273.3.1435	http://dx.doi.org/10.1074/jbc.273.3.1435			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430680	hybrid			2022-12-25	WOS:000071411500027
J	McPhee, JC; Ragsdale, DS; Scheuer, T; Catterall, WA				McPhee, JC; Ragsdale, DS; Scheuer, T; Catterall, WA			A critical role for the S4-S5 intracellular loop in domain IV of the sodium channel alpha-subunit in fast inactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHAKER-K+ CHANNEL; NA+-CHANNEL; RAT-BRAIN; PROTEIN-STRUCTURE; N-BROMOACETAMIDE; MEMBRANE PATCHES; EXPRESSION; CURRENTS; GATE; ACTIVATION	Na+ channel fast inactivation is thought to involve the closure of an intracellular inactivation gate over the channel pore, Previous studies have implicated the intracellular loop connecting domains III and IV and a critical IFM motif within it as the inactivation gate, but amino acid residues at the intracellular mouth of the pore required for gate closure and binding have not been positively identified, The short intracellular loops connecting the S4 and S5 segments in each domain of the Na+ channel alpha-subunit are good candidates for this role in the Na+ channel inactivation process, In this study, we used scanning mutagenesis to examine the role of the IVS4-S5 region in fast inactivation, Mutations F1651A, near the middle of the loop, and L1660A and N1662A, near the COOP-terminal end, substantially disrupted Na+ channel fast inactivation, The mutant F1651A conducted Na+ currents that decayed very slowly, while L1660A and N1662A had large sustained Na+ currents at the end of 30-ms depolarizing pulses. Inactivation of macroscopic Na+ currents was nearly abolished by the N1662A mutation and the combination of the F1651A/L1660A mutations, Single channel analysis revealed frequent reopenings for all three mutant during 40-ms depolarizing pulses, indicating a substantial impairment of the stability of the inactivated state compared with wild type (WT), The F1651A and N1662A mutants also had increased mean open times relative to WT, indicating a slowed rate of entry into the inactivated state, In addition to these effects on inactivation of open Na+ channels, mutants F1651A, L1660A, and N1662A also impaired fast inactivation of closed Na+ channels, as assessed from measurements of the maximum open probability of single channels, The peptide KIFMK mimics the IFM motif of the inactivation gate and provides a test of the effect of mutations on the hydrophobic interaction of this motif with the inactivation gate receptor, KIFMX restores fast inactivation of open channels to the F1651A/1660A mutant but does not restore fast inactivation of closed F1651A/L1660A channels, suggesting that these residues interact with the IFM motif during inactivation of closed channels, Our results implicate F1651, L1660, and N1662 of the IVS4-S5 loop in inactivation of both closed and open Na+ channels and suggest that the IFM motif of the inactivation gate interacts with F1651 and/or L1660 in the IVS4-S5 loop during inactivation of closed channels.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	McPhee, JC (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15751] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALDRICH RW, 1987, J NEUROSCI, V7, P418; ALDRICH RW, 1983, NATURE, V306, P436, DOI 10.1038/306436a0; ARMSTRONG CM, 1981, PHYSIOL REV, V61, P644, DOI 10.1152/physrev.1981.61.3.644; ARMSTRONG CM, 1973, J GEN PHYSIOL, V62, P375, DOI 10.1085/jgp.62.4.375; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Colquhoun David, 1995, P483; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; EAHOLTZ G, 1997, IN PRESS J GEN PHYSL; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; Filatov G. Nh., 1997, Biophysical Journal, V72, pA260; GOLDIN AL, 1986, P NATL ACAD SCI USA, V83, P7503, DOI 10.1073/pnas.83.19.7503; Hille B., 1992, IONIC CHANNELS EXCIT; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; HORN R, 1984, BIOPHYS J, V45, P323, DOI 10.1016/S0006-3495(84)84158-2; HOSHI T, 1994, J GEN PHYSIOL, V103, P249, DOI 10.1085/jgp.103.2.249; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; Kellenberger S, 1996, J BIOL CHEM, V271, P30971, DOI 10.1074/jbc.271.48.30971; Kellenberger S, 1997, J GEN PHYSIOL, V109, P589, DOI 10.1085/jgp.109.5.589; KUO CC, 1994, NEURON, V12, P819, DOI 10.1016/0896-6273(94)90335-2; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; McPhee J. C., 1996, Biophysical Journal, V70, pA318; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Mitrovic N, 1996, NEUROSCI LETT, V214, P9; NILIUS B, 1988, BIOPHYS J, V53, P857, DOI 10.1016/S0006-3495(88)83166-7; NODA M, 1986, NATURE, V322, P826, DOI 10.1038/322826a0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PATLAK J, 1982, J GEN PHYSIOL, V79, P333, DOI 10.1085/jgp.79.3.333; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SCANLEY BE, 1990, J GEN PHYSIOL, V95, P411, DOI 10.1085/jgp.95.3.411; STIMERS JR, 1985, J GEN PHYSIOL, V85, P65, DOI 10.1085/jgp.85.1.65; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; Tang LH, 1996, J GEN PHYSIOL, V108, P89, DOI 10.1085/jgp.108.2.89; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; ZHANG XJ, 1992, PROTEIN SCI, V1, P761, DOI 10.1002/pro.5560010608; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	49	148	149	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1121	1129		10.1074/jbc.273.2.1121	http://dx.doi.org/10.1074/jbc.273.2.1121			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422778	hybrid			2022-12-25	WOS:000071411400067
J	Wong, SH; Xu, Y; Zhang, T; Hong, WJ				Wong, SH; Xu, Y; Zhang, T; Hong, WJ			Syntaxin 7, a novel syntaxin member associated with the early endosomal compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANINE KIDNEY-CELLS; TRANS-GOLGI NETWORK; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; BREFELDIN-A; ASIALOGLYCOPROTEIN RECEPTOR; ORGANELLE STRUCTURE; COAT PROTEINS; LOCALIZATION; FUSION	Members of the syntaxin family are key molecules involved in diverse vesicle docking/fusion events. We report here the molecular, biochemical, and cell biological characterizations of a novel member (syntaxin 7) of the syntaxin family. Syntaxin 7 is structurally related to all known syntaxins. Within a 79-residue region preceding the C-terminal hydrophobic tail, syntaxin 7 is 35, 34, 34, 34, 25, and 19% identical to syntaxins 1, 2, 3, 4, 5, and 6, respectively. Northern blot analysis showed that syntaxin 7 is widely expressed, Indirect immunofluorescence microscopy revealed that syntaxin 7 is primarily associated with the early endosome, In vitro binding assays established that syntaxin 7 in membrane extracts interacts with immobilized recombinant at-soluble N-ethylmaleimide-sensitive factor attachment proteins fused to glutathione S-transferase. Our results highlight the general importance of members of the syntaxin family in protein trafficking and provide new avenues for future functional and mechanistic studies of this first endosomal syntaxin as well as the endocytotic pathway.	Natl Univ Singapore, Inst Mol & Cell Biol, Membrane Biol Lab, Singapore 119076, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Hong, WJ (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Membrane Biol Lab, 15 Lower Kent Ridge Rd, Singapore 119076, Singapore.		HONG, Wanjin/E-9927-2010					BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CLAGUE MJ, 1995, FEBS LETT, V367, P272, DOI 10.1016/0014-5793(95)00576-U; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; DASCHER C, 1994, J BIOL CHEM, V269, P29363; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Gaisano HY, 1996, MOL BIOL CELL, V7, P2019, DOI 10.1091/mbc.7.12.2019; GRAEVE L, 1990, J BIOL CHEM, V265, P1216; HANSEN SH, 1995, J BIOL CHEM, V270, P28425; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; JONES AT, 1995, BIOCHEM J, V311, P31, DOI 10.1042/bj3110031; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LODISH HF, 1991, TRENDS BIOCHEM SCI, V16, P374, DOI 10.1016/0968-0004(91)90154-N; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; Lowe SL, 1996, J CELL SCI, V109, P209; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1993, J CELL PHYSIOL, V155, P579, DOI 10.1002/jcp.1041550316; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Reaves BJ, 1996, J CELL SCI, V109, P749; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAKAI T, 1991, J BIOCHEM-TOKYO, V100, P828; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHELLER RH, 1995, NEURON, V14, P893; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPIES M, 1990, BIOCHEMISTRY-US, V29, P10018; SUBRAMANIAM VN, 1992, J BIOL CHEM, V267, P12016; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; WHITNEY JA, 1995, CELL, V83, P703; WONG SH, 1993, J BIOL CHEM, V268, P22853; WONG SH, 1992, J CELL BIOL, V117, P245, DOI 10.1083/jcb.117.2.245; WOOD SA, 1991, CELL, V67, P591, DOI 10.1016/0092-8674(91)90533-5; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273	46	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					375	380		10.1074/jbc.273.1.375	http://dx.doi.org/10.1074/jbc.273.1.375			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417091	hybrid			2022-12-25	WOS:000071295600057
J	Kozlovsky, N; Rudich, A; Potashnik, R; Ebina, Y; Murakami, T; Bashan, N				Kozlovsky, N; Rudich, A; Potashnik, R; Ebina, Y; Murakami, T; Bashan, N			Transcriptional activation of the Glut1 gene in response to oxidative stress in L6 myotubes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULINOMIMETIC AGENTS H2O2; GLUCOSE-TRANSPORTER; TYROSINE PHOSPHORYLATION; 3T3-L1 ADIPOCYTES; THYROID-HORMONE; MUSCLE-CELLS; INSULIN; EXPRESSION; STIMULATION; PROTEIN	Exposure of L6 myotubes to prolonged low grade oxidative stress results in increased Glut1 expression at both the protein and mRNA levels, leading to elevated glucose transport activity, To further understand the cellular mechanisms responsible for this adaptive response, the Glut1 transcription rate and mRNA stability were assessed. Nuclear run on assays revealed 2.0- and 2.4 fold increases in Glut1 transcription rates in glucose oxidase- and xanthine/xanthine oxidase-pretreated cells, respectively, Glut1 mRNA stability was increased with both treatments compared with the control (t(1/2) = 7.8 +/- 1.3, 6.0 +/- 2.0, and 2.4 +/- 0.5 h, respectively), The serum-responsive element and AP-1 (but not the cAMP-responsive element) showed increased binding capacity following oxidative stress. Both activation of AP-1 binding and elevation of Glut1 mRNA were prevented by cycloheximide. The involvement of enhancer 1 of the Glut1 gene was demonstrated using transfected 293 cells, Induction of Glut1 mRNA in response to oxidative stress differed from its activation by chronic insulin exposure as demonstrated by the ability of rapamycin to inhibit the latter without an effect on the former, In conclusion, oxidative stress increases the Glut1 transcription rate by mechanisms that may involve activation of AP-1 binding to enhancer 1 of the Glut1 gene.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Univ Tokushima, Inst Enzyme Res, Dept Enzyme Genet, Tokushima 770, Japan	Ben Gurion University; Tokushima University	Bashan, N (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Clin Biochem, IL-84105 Beer Sheva, Israel.			Rudich, Assaf/0000-0002-1366-1444				BASHAN N, 1992, AM J PHYSIOL, V262, pC682, DOI 10.1152/ajpcell.1992.262.3.C682; BASHAN N, 1993, AM J PHYSIOL, V264, pC430, DOI 10.1152/ajpcell.1993.264.2.C430; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; BOLLI R, 1995, J CLIN INVEST, V96, P1066, DOI 10.1172/JCI118093; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURELLO S, 1995, CARDIOVASC RES, V29, P118, DOI 10.1016/S0008-6363(96)88556-7; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FURLER SM, 1991, AM J PHYSIOL, V261, pE337, DOI 10.1152/ajpendo.1991.261.3.E337; Giugliano D, 1996, DIABETES CARE, V19, P257, DOI 10.2337/diacare.19.3.257; GIUGLIANO D, 1995, METABOLISM, V44, P363, DOI 10.1016/0026-0495(95)90167-1; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; KINGSTON RE, 1993, CURRENT PROTOCOLS MO; Kozlovsky N, 1997, FREE RADICAL BIO MED, V23, P859, DOI 10.1016/S0891-5849(97)00069-5; MAHAJAN PB, 1987, J BIOL CHEM, V262, P16150; MCMAHON RJ, 1995, J BIOL CHEM, V270, P12094, DOI 10.1074/jbc.270.20.12094; MUECKLER M, 1990, DIABETES, V39, P6, DOI 10.2337/diabetes.39.1.6; MURAKAMI T, 1992, J BIOL CHEM, V267, P9300; NOUROOZZADEH J, 1995, DIABETES, V44, P1054, DOI 10.2337/diabetes.44.9.1054; NouroozZadeh J, 1997, DIABETOLOGIA, V40, P647, DOI 10.1007/s001250050729; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; PAOLISSO G, 1994, METABOLISM, V43, P1426, DOI 10.1016/0026-0495(94)90039-6; Pinkus R, 1996, J BIOL CHEM, V271, P13422, DOI 10.1074/jbc.271.23.13422; Potashnik R, 1995, AM J PHYSIOL-ENDOC M, V269, pE1052, DOI 10.1152/ajpendo.1995.269.6.E1052; Rudich A, 1997, AM J PHYSIOL-ENDOC M, V272, pE935, DOI 10.1152/ajpendo.1997.272.5.E935; Sambrook J., 2002, MOL CLONING LAB MANU; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TAHA C, 1995, J BIOL CHEM, V270, P24678, DOI 10.1074/jbc.270.42.24678; TODAKA M, 1994, J BIOL CHEM, V269, P29265; TORDJMAN KM, 1989, P NATL ACAD SCI USA, V86, P7761, DOI 10.1073/pnas.86.20.7761; WEINSTEIN SP, 1990, ENDOCRINOLOGY, V126, P1421, DOI 10.1210/endo-126-3-1421; WEINSTEIN SP, 1993, THYROID, V3, P135, DOI 10.1089/thy.1993.3.135; WILDEN PA, 1995, J CELL BIOCHEM, V58, P279, DOI 10.1002/jcb.240580303	34	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33367	33372		10.1074/jbc.272.52.33367	http://dx.doi.org/10.1074/jbc.272.52.33367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407130	hybrid			2022-12-25	WOS:000071182900091
J	Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M				Bartunek, P; Karafiat, V; Dvorakova, M; Zahorova, V; Mandikova, S; Zenke, M; Dvorak, M			The Myb leucine zipper is essential for leukemogenicity of the v-Myb protein	ONCOGENE			English	Article						v-myb; leukemia; leucine zipper; protein-protein interaction	MYELOMONOCYTIC GROWTH-FACTOR; C-MYB; TRANSCRIPTIONAL ACTIVATION; MYELOID CELLS; CELLULAR PROGENITOR; MAMMALIAN-CELLS; DNA-BINDING; NF-M; TRANSFORMATION; ONCOGENE	The AMV v-Myb oncoprotein causes oncogenic transformation of myelomonocytic cells in vivo and in vitro, Its transforming capacity is strictly dependent upon the N-terminal DNA binding domain, the central transactivation region, and on the C-terminal domain containing a putative leucine zipper motif, Here we show that the v-Myb(L3.4A) mutant, in which Leu(325) and Leu(332) of the leucine zipper have been replaced by alanines, failed to induce leukemia in virus infected chicken, This demonstrates that the leucine zipper domain is indispensable for v-myb induced leukemogenesis in vivo, v-Myb(L3,3A) was, however, still able to transform myelomonocytic cells from chicken bone marrow in vitro. Yet, while v-myb(L3,4) transformed cells were impaired in growth at 37 degrees C, they failed to grow at 42 degrees C, the physiological body temperature of avian species, This might explain the loss of v-Myb(L3,4A) leukemogenic potential in vivo, We also demonstrate that the v-Myb leucine zipper domain interacts in vitro with two host cell proteins, p26 and p28, This interaction is compromised in v-Myb(L3,4A) indicating that binding of v-Myb to p26 and p28 might be important for the leukemogenic potential of v-Myb.	ACAD SCI CZECH REPUBL,INST MOL GENET,CR-16637 PRAGUE 6,CZECH REPUBLIC; MAX DELBRUCK CTR MOL MED,D-13125 BERLIN,GERMANY	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Helmholtz Association; Max Delbruck Center for Molecular Medicine			Bartunek, Petr/J-3897-2014; Dvorak, Michal/G-5861-2014; Škopová, Václava/F-4992-2017; Dvořák, Michal/I-9939-2014	Bartunek, Petr/0000-0002-6202-7650; Škopová, Václava/0000-0002-6560-4177; 				Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; BEUG H, 1995, METHOD ENZYMOL, V254, P41; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CORBEL C, 1992, EXP CELL RES, V203, P91, DOI 10.1016/0014-4827(92)90043-8; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; EBNETH A, 1994, FEBS LETT, V337, P265, DOI 10.1016/0014-5793(94)80205-X; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FAVIER D, 1994, ONCOGENE, V9, P305; FEY EG, 1986, J CELL BIOL, V102, P1654, DOI 10.1083/jcb.102.5.1654; FOOS G, 1993, ONCOGENE, V8, P1775; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HLOZANEK I, 1968, Veterinarni Medicina (Prague), V13, P489; HURST HC, 1995, PROTEIN PROFILE, V2, P105; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1994, J BIOL CHEM, V269, P15768; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KASPERS B, 1993, VET IMMUNOL IMMUNOP, V36, P333, DOI 10.1016/0165-2427(93)90029-4; KAUFMAN J, 1990, J IMMUNOL, V144, P2258; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1996, ONCOGENE, V13, P223; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OLSON WC, 1994, CELL IMMUNOL, V154, P328, DOI 10.1006/cimm.1994.1081; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; STERNECK E, 1992, MOL CELL BIOL, V12, P1728, DOI 10.1128/MCB.12.4.1728; STERNECK E, 1992, EMBO J, V11, P115, DOI 10.1002/j.1460-2075.1992.tb05034.x; Vainio O, 1996, J CELL BIOL, V135, P1655, DOI 10.1083/jcb.135.6.1655; VRANOVSKY K, 1992, GENE, V117, P233; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	45	26	26	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2939	2949		10.1038/sj.onc.1201457	http://dx.doi.org/10.1038/sj.onc.1201457			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416837				2022-12-25	WOS:A1997YK37700006
J	Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC				Hu, JF; Cheng, ZQ; Chisari, FV; Vu, TH; Hoffman, AR; Campbell, TC			Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet	ONCOGENE			English	Article						hepatitis B virus; dietary protein; IGF2; IGF1; HGF; gene expression	GROWTH-FACTOR-II; PRIMARY HEPATOCELLULAR-CARCINOMA; LARGE ENVELOPE POLYPEPTIDE; INSITU HYBRIDIZATION; PARTIAL-HEPATECTOMY; INTEGRATION SITE; CARRIER STATE; RISK-FACTORS; EXPRESSION; MICE	Persistent infection with hepatitis B virus (HBV) is one of the primary risk factors for human hepatocellular carcinoma (HCC). In a human ecological study, we have shown that, in addition to HBV, animal food consumption also significantly contributes to the variance of HCC. To test the interacting effect of HBV and animal food consumption on the development of HCC, we investigated HBV expression in HBV transgenic mice fed three levels of casein diet. HBV expression in transgenic animals was substantially inhibited when dietary casein was reduced from the traditional level of 22% to the level of 6%. Northern analysis revealed that suppression of HBV was derived from both the; upstream albumin promoter and the internal HBV promoter. Immunochemical staining of liver sections indicated that only a few hepatocytes around the central vein expressed viral surface antigen (HBsAg) in the 6% casein animals, whereas virtually all hepatocytes stained positively for HBsAg in the 22% dietary casein animals. Serum HBsAg concentrations at 4 months were increased by 1.6-, 2.1-, and 5.1-fold over baseline for animals fed the 6%, 14%, and 22% casein diets, respectively. Correspondingly, liver injury was much less severe in animals fed 6% casein diet than in those fed 14% and 22% casein diets. These results demonstrate that a low casein diet is a potent suppresser of HBV transgene and HBV-induced liver injury, suggesting that diet management may be a practical means to aid in the control HBV infection.	VET ADM MED CTR, GRECC, PALO ALTO, CA 94304 USA; STANFORD UNIV, DEPT MED, DIV ENDOCRINOL, PALO ALTO, CA 94304 USA; Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA; CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Stanford University; Scripps Research Institute; Cornell University	Hu, JF (corresponding author), VET ADM MED CTR, MED SERV, PALO ALTO, CA 94304 USA.		Chisari, Francis V/A-3086-2008; Hu, Jifan/Q-3003-2019	Chisari, Francis/0000-0002-4832-1044; HU, Jifan/0000-0002-2174-0361	NCI NIH HHS [R01-CA34205] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARTEAGA CL, 1989, J CLIN INVEST, V84, P1418, DOI 10.1172/JCI114315; BALSANO C, 1991, BIOCHEM BIOPH RES CO, V176, P985, DOI 10.1016/0006-291X(91)90379-L; BEASLEY RP, 1981, LANCET, V2, P1129; BOSCH FX, 1988, IARC SCI PUBLICATION, V89; CAMPBELL TC, 1990, CANCER RES, V50, P6882; CHANG MH, 1991, HEPATOLOGY, V13, P316, DOI 10.1016/0270-9139(91)92446-F; CHISARI FV, 1985, SCIENCE, V230, P1157, DOI 10.1126/science.3865369; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; CLEMMONS DR, 1991, ANNU REV NUTR, V11, P393, DOI 10.1146/annurev.nu.11.070191.002141; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DIBISCEGLIE AM, 1988, ANN INTERN MED, V108, P390, DOI 10.7326/0003-4819-108-3-390; DIBISCEGLIE AM, 1987, PRINCIPLES PRACT ONC, V1, P1; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253; *INT AG RES CANC, 1988, IARC MON EV CARC RIS, P416; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, P83; Kew MC, 1996, CLIN LAB MED, V16, P395, DOI 10.1016/S0272-2712(18)30276-2; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; LONDON WT, 1981, HUM PATHOL, V12, P1085, DOI 10.1016/S0046-8177(81)80329-2; LUTWICK LI, 1979, LANCET, V1, P755; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MAITER D, 1988, J ENDOCRINOL, V118, P113, DOI 10.1677/joe.0.1180113; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PASQUINELLI C, 1994, TRANSGENICS, V1, P451; POPPER H, 1987, HEPATOLOGY, V7, P764, DOI 10.1002/hep.1840070425; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROGLER CE, 1985, SCIENCE, V230, P319, DOI 10.1126/science.2996131; SALLIE R, 1994, GASTROENTEROL CLIN N, V23, P567; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; STRAUS DS, 1990, ENDOCRINOLOGY, V127, P1849, DOI 10.1210/endo-127-4-1849; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; Szmuness W, 1978, Prog Med Virol, V24, P40; TANAKA K, 1995, CANCER CAUSE CONTROL, V6, P91, DOI 10.1007/BF00052768; TANAKA T, 1986, HUM PATHOL, V17, P202; VATANASAPT V, 1995, CANCER EPIDEM BIOMAR, V4, P475; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; YAGINUMA K, 1987, J VIROL, V61, P1808, DOI 10.1128/JVI.61.6.1808-1813.1987; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; YOUNGMAN LD, 1992, CARCINOGENESIS, V13, P1607, DOI 10.1093/carcin/13.9.1607; YOUNGMAN LD, 1992, CANCER LETT, V66, P165, DOI 10.1016/0304-3835(92)90229-O; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; ZARNEGAR R, 1991, BIOCHEM BIOPH RES CO, V177, P559, DOI 10.1016/0006-291X(91)92020-K	47	19	19	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2795	2801		10.1038/sj.onc.1201444	http://dx.doi.org/10.1038/sj.onc.1201444			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419970				2022-12-25	WOS:A1997YJ80300005
J	Chien, YT; Cheung, AL				Chien, YT; Cheung, AL			Molecular interactions between two global regulators, sar and agr, in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRULENCE; LOCUS; EXPRESSION; SEQUENCES; RNA	The expression of many virulence determinants in Staphylococcus aureus is controlled by regulatory loci such as agr and sar, We have previously shown that the SarA protein is required for optimal transcription of RNAII and RNAIII in the agr locus, To define the specific molecular interaction, we overexpressed SarA as a glutathione S-transferase (GST) fusion protein by cloning the 372-base pair (bp) sarA gene into the vector, The purified GST-SarA as well as cleaved SarA were able to bind specifically to the P2, P3, and the combined P2-P3 promoter fragments of agr in gel shift assays, Using monoclonal antibodies to SarA, we found that SarA is a part of the retarded protein-DNA complex as evidenced by the formation of a supershifted band, The SarA binding site on the agr promoter, mapped by DNase I footprinting assay, covered a 29-bp region between the P2 and P3 promoters devoid of any direct repeats, A synthetic 45-bp fragment encompassing the 29-bp sequence also bound the SarA protein in band shift assays, Serial in-frame deletion analysis of sarA revealed that, with the exception of 15 residues in the N terminus, almost all of SarA (residues 16-124) is essential for agr binding activity. Northern analysis confirmed that only the sar mutant clone containing a truncated sarA gene with a 15-residue deletion in the N terminus (SarA(16-124)) could activate agr transcription to a level approaching that of the full-length counterpart (SarA(1-124)), Taken together, these data indicated that SarA is a DNA-binding protein with binding specificity to the P2 and P3 interpromoter region of agr, thereby activating RNAII and RNAIII transcription.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA	Rockefeller University	Cheung, AL (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA.	cheunga@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030061, R01AI037142] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37142, AI30061] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bayer MG, 1996, J BACTERIOL, V178, P4563, DOI 10.1128/jb.178.15.4563-4570.1996; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; CHEUNG AL, 1992, P NATL ACAD SCI USA, V89, P6462, DOI 10.1073/pnas.89.14.6462; Cheung AL, 1997, J BACTERIOL, V179, P3963, DOI 10.1128/jb.179.12.3963-3971.1997; Cheung AL, 1997, INFECT IMMUN, V65, P2243, DOI 10.1128/IAI.65.6.2243-2249.1997; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; CHEUNG AL, 1994, J CLIN INVEST, V94, P1815, DOI 10.1172/JCI117530; CHEUNG AL, 1994, ANAL BIOCHEM, V222, P511, DOI 10.1006/abio.1994.1528; CHEUNG AL, 1997, 37 ICAAC TOR CAN; CROSSLEY KB, 1997, STAPHYLOCOCCI HUMAN; FLUCIGER U, 1997, ANN M AM SOC MICR MI; Giraudo AT, 1997, ARCH MICROBIOL, V168, P53, DOI 10.1007/s002030050469; Heinrichs JH, 1996, J BACTERIOL, V178, P418, DOI 10.1128/jb.178.2.418-423.1996; JONES KF, 1986, J EXP MED, V164, P1226, DOI 10.1084/jem.164.4.1226; Kornblum J., 1990, MOL BIOL STAPHYLOCOC, P373; Maniatis T., 1989, MOL CLONING LAB MANU; MORFELDT E, 1995, EMBO J, V14, P4569, DOI 10.1002/j.1460-2075.1995.tb00136.x; Morfeldt E, 1996, MOL MICROBIOL, V21, P1227, DOI 10.1046/j.1365-2958.1996.751447.x; NOVICK RP, 1993, EMBO J, V12, P3967, DOI 10.1002/j.1460-2075.1993.tb06074.x; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDENESCH F, 1991, J BACTERIOL, V173, P6313, DOI 10.1128/jb.173.20.6313-6320.1991; VANDENESCH F, 1993, FEMS MICROBIOL LETT, V111, P115, DOI 10.1016/0378-1097(93)90191-4; VANWAMEL W, 1996, ANN M AM SOC MICR NE; [No title captured]	25	120	130	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2645	2652		10.1074/jbc.273.5.2645	http://dx.doi.org/10.1074/jbc.273.5.2645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446568	hybrid			2022-12-25	WOS:000071736600023
J	Katoh, Y; Molkentin, JD; Dave, V; Olson, EN; Periasamy, M				Katoh, Y; Molkentin, JD; Dave, V; Olson, EN; Periasamy, M			MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; TRANSCRIPTION FACTORS; REGULATORY ELEMENTS; PROMOTER ELEMENTS; MYOGENIC LINEAGES; ENHANCER; CELLS; FAMILY; IDENTIFICATION; PROTEINS	To understand smooth muscle-specific gene expression, we have focused our studies on the smooth muscle myosin heavy chain (SMHC) gene, a smooth muscle-specific marker, In this study, we demonstrate that the SMHC promoter region (-1594 to -1462 base pairs) containing the A/T-rich element can activate the heterologous thymidine kinase promoter in smooth muscle cells, but not in fibroblasts, Mutations of this APT-rich element decreased SMHC promoter activity significantly, Both gel mobility shift assays and DNase I footprinting revealed that this region binds to specific protein complexes from smooth muscle nuclear extracts, whereas nuclear extracts from skeletal muscle and fibroblasts produced a different binding pattern, We also demonstrate that the protein complex obtained from smooth muscle nuclear extract reacts with MEF2B-specific antibody, but not with antibodies specific to MEF2A, MEF2C, or MEF2D, suggesting that only MEF2B protein binds to the A/T-rich element, Furthermore, MEF2B overexpression in smooth muscle cells up-regulated the SMHC promoter, suggesting that MEF2B is important for SMHC gene regulation, This is the first report demonstrating a role for MEF2 factors in smooth muscle-specific gene expression.	Univ Cincinnati, Sect Mol Cardiol, Div Cardiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Cardiovasc Res Ctr, Cincinnati, OH 45267 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Periasamy, M (corresponding author), Univ Cincinnati, Sect Mol Cardiol, Div Cardiol, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Dave, Vrushank/K-5262-2012	Dave, Vrushank/0000-0003-4044-2658; Molkentin, Jeffery/0000-0002-3558-6529; Periasamy, Muthu/0000-0001-8834-5975	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038355] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38355] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLANK RS, 1992, J BIOL CHEM, V267, P984; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN T, 1989, MOL CELL BIOL, V9, P2513, DOI 10.1128/MCB.9.6.2513; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CARROLL SL, 1988, MOL CELL BIOL, V8, P241, DOI 10.1128/MCB.8.1.241; CHAMBERS AE, 1992, EMBO J, V11, P4981, DOI 10.1002/j.1460-2075.1992.tb05605.x; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DIGMAN JD, 1983, NUCLEIC ACIDS RES, V11, P1475; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Groisman R, 1996, J BIOL CHEM, V271, P5258; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kallmeier RC, 1995, J BIOL CHEM, V270, P30949, DOI 10.1074/jbc.270.52.30949; KATOH Y, 1994, J BIOL CHEM, V269, P30538; Katoh Y, 1996, TRENDS CARDIOVAS MED, V6, P100, DOI 10.1016/1050-1738(96)00014-X; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Mao ZX, 1996, J BIOL CHEM, V271, P14371, DOI 10.1074/jbc.271.24.14371; MARTIN JF, 1994, MOL CELL BIOL, V14, P1647, DOI 10.1128/MCB.14.3.1647; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Maxam A M, 1980, Methods Enzymol, V65, P499; Miano JM, 1996, J BIOL CHEM, V271, P7095, DOI 10.1074/jbc.271.12.7095; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OWENS GK, 1986, J CELL BIOL, V102, P343, DOI 10.1083/jcb.102.2.343; PARMACEK MS, 1990, J BIOL CHEM, V265, P15970; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; QUIN J, 1996, DEV DYNAM, V207, P135; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Samaha FF, 1996, J BIOL CHEM, V271, P395, DOI 10.1074/jbc.271.1.395; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SIMONS M, 1993, NEW ENGL J MED, V328, P608, DOI 10.1056/NEJM199303043280903; SOLWAY J, 1995, J BIOL CHEM, V270, P13460, DOI 10.1074/jbc.270.22.13460; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; White SL, 1996, J BIOL CHEM, V271, P15008, DOI 10.1074/jbc.271.25.15008; YU YT, 1992, GENE DEV, V6, P1763; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	46	33	34	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1511	1518		10.1074/jbc.273.3.1511	http://dx.doi.org/10.1074/jbc.273.3.1511			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430690	hybrid			2022-12-25	WOS:000071411500037
J	Doering, AE; Nicoll, DA; Lu, YJ; Lu, LY; Weiss, JN; Philipson, KD				Doering, AE; Nicoll, DA; Lu, YJ; Lu, LY; Weiss, JN; Philipson, KD			Topology of a functionally important region of the cardiac Na+/Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOLEMMAL NA+-CA2+ EXCHANGER; CA2+-BINDING DOMAIN; CALCIUM; IDENTIFICATION; INACTIVATION; RECEPTOR	The cardiac Na+/Ca2+ exchanger, NCX1, has been modeled to consist of 11 transmembrane segments and a large cytoplasmic loop (loop f), Cysteine mutagenesis and sulfhydryl modification experiments demonstrate that the loop connecting transmembrane segments 1 and 2 (loop b) is located on the cytoplasmic side of the membrane, as previously modeled. A mutation in loop b, asparagine 101 to cysteine (N101C), renders the exchanger insensitive to regulation by cytoplasmic Na+ and Ca2+. Nearby mutations at residue threonine 103 (T103C or T103V) increase the apparent affinity of the exchanger for cytoplasmic Na+ and also produce a significant Li+ transport capacity, The evidence suggests that the region at the interface of cytoplasmic loop b and transmembrane segment 2 is important in Na+ transport and also in secondary regulation, Thus, this region may form part of the link between the ion translocation pathway formed by the transmembrane segments and regulatory sites that have previously been localized to loop f.	Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Philipson, KD (corresponding author), Univ Calif Los Angeles, Sch Med, Cardiovasc Res Lab, MRL 3645, Los Angeles, CA 90095 USA.				NHLBI NIH HHS [HL49101] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; IWATA T, 1995, CELL CALCIUM, V17, P263, DOI 10.1016/0143-4160(95)90072-1; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; KURZ LL, 1995, BIOPHYS J, V68, P900, DOI 10.1016/S0006-3495(95)80266-3; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1991, J BIOL CHEM, V266, P1014; MATSUOKA S, 1994, J PHYSIOL-LONDON, V476, P443, DOI 10.1113/jphysiol.1994.sp020146; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Nicoll DA, 1996, J BIOL CHEM, V271, P13385, DOI 10.1074/jbc.271.23.13385; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; SAHINTOTH M, 1995, BIOCHEM BIOPH RES CO, V212, P968, DOI 10.1006/bbrc.1995.2064; SKOU J C, 1992, News in Physiological Sciences, V7, P95; TERZIC A, 1996, MOL PHYSL PHARM CARD, P555	20	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					778	783		10.1074/jbc.273.2.778	http://dx.doi.org/10.1074/jbc.273.2.778			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422731	hybrid			2022-12-25	WOS:000071411400020
J	Danilov, V; Blum, M; Schweickert, A; Campione, M; Steinbeisser, H				Danilov, V; Blum, M; Schweickert, A; Campione, M; Steinbeisser, H			Negative autoregulation of the organizer-specific homeobox gene goosecoid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMEODOMAIN PROTEINS; EARLY EMBRYOGENESIS; SPEMANNS ORGANIZER; XENOPUS EMBRYOS; MOUSE EMBRYO; EXPRESSION; DROSOPHILA; CLONING; ZEBRAFISH; HOMOLOG	The homeobox gene goosecoid has been implicated to play a central role in the Spemann organizer tissue of the vertebrate embryo. Misexpression of goosecoid on the ventral side of a Xenopus laevis gastrula embryo was shown to result in a partial duplication of the primary body axis, reminiscent of the Spemann organizer graft, Normal embryonic development thus requires tight temporal and spatial control of genes instrumental for organizer function. In the present study we investigated the transcriptional control of goosecoid gene expression, Sequence analysis of the mouse and human promoter region revealed the presence of two palindromic binding elements for homeobox genes of the prd type to which goosecoid belongs. We show that Goosecoid protein can bind to these sites in vitro. By using reporter gene constructs of the human and mouse promoter, we demonstrate that Goosecoid can act as a repressor of its own promoter activity in transient co-transfection experiments in mouse P19 cells and in Xenopus embryos. Autorepression depends on the presence of the homeodomain and is mediated through the prd element more proximal to the transcriptional start site, Our results suggest a role for goosecoid in restricting organizer activity in the vertebrate gastrula embryo.	Forschungszentrum Karlsruhe, Genet Inst, D-76021 Karlsruhe, Germany; Max Planck Inst Dev Biol, Dept Cell Biol, D-72011 Tubingen, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Max Planck Society	Blum, M (corresponding author), Forschungszentrum Karlsruhe, Genet Inst, POB 3640, D-76021 Karlsruhe, Germany.		Campione, Marina/G-9001-2013; Campione, Marina/P-3369-2019	Campione, Marina/0000-0003-0582-5303				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASTIAN H, 1992, MAMM GENOME, V3, P241, DOI 10.1007/BF00355726; BASTIAN H, 1990, EMBO J, V9, P1839, DOI 10.1002/j.1460-2075.1990.tb08309.x; BLUM M, 1994, GENOMICS, V21, P388, DOI 10.1006/geno.1994.1281; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; DEROBERTIS EM, 1994, DEVELOPMENT, P117; DIEFFENBACH CW, 1995, PCR PRIMER LAB MANUA, P388; DIEFFENBACH CW, 1995, PCR PRIMER, P604; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; GAUNT SJ, 1993, DEVELOPMENT, V117, P769; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERNHARDT JC, 1980, BIOL REGUL DEV, V2, P133; Goriely A, 1996, DEVELOPMENT, V122, P1641; Hahn M, 1996, EMBO J, V15, P3077, DOI 10.1002/j.1460-2075.1996.tb00670.x; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; Hermesz E, 1996, DEVELOPMENT, V122, P41; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; KERN MJ, 1992, NUCLEIC ACIDS RES, V20, P5189, DOI 10.1093/nar/20.19.5189; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; Lemaire L, 1997, DEVELOPMENT, V124, P1443; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Moos M, 1995, DEVELOPMENT, V121, P4293; NIEHRS C, 1994, SCIENCE, V263, P817, DOI 10.1126/science.7905664; NIEHRS C, 1993, CELL, V72, P491, DOI 10.1016/0092-8674(93)90069-3; Nieuwkoop P. D., 1956, NORMAL TABLES XENOPU; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; Pinsonneault J, 1997, EMBO J, V16, P2032, DOI 10.1093/emboj/16.8.2032; Psychoyos D, 1996, DEVELOPMENT, V122, P3263; RIVERAPEREZ JA, 1995, DEVELOPMENT, V121, P3005; ROSA FM, 1989, CELL, V57, P965, DOI 10.1016/0092-8674(89)90335-8; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J., 1989, MOL CLONING; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Shih J, 1996, DEVELOPMENT, V122, P1313; SIMEONE A, 1994, NEURON, V13, P83, DOI 10.1016/0896-6273(94)90461-8; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; Smith ST, 1996, DEVELOPMENT, V122, P3141; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; Stuart ET, 1996, CELL GROWTH DIFFER, V7, P405; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; TREISMAN J, 1989, CELL, V59, P553; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; YAMADA G, 1995, DEVELOPMENT, V121, P2917	58	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					627	635		10.1074/jbc.273.1.627	http://dx.doi.org/10.1074/jbc.273.1.627			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417125	hybrid			2022-12-25	WOS:000071295600091
J	Gesemann, M; Brancaccio, A; Schumacher, B; Ruegg, MA				Gesemann, M; Brancaccio, A; Schumacher, B; Ruegg, MA			Agrin is a high-affinity binding protein of dystroglycan in non-muscle tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEIN; CONGENITAL MUSCULAR-DYSTROPHY; EXTRACELLULAR-MATRIX; ALPHA-DYSTROGLYCAN; ORGANIZING PROTEIN; SKELETAL-MUSCLE; NERVOUS-SYSTEM; CHICK AGRIN; LAMININ; RECEPTOR	Agrin is a basement membrane-associated proteoglycan that induces the formation of postsynaptic specializations at the neuromuscular junction, This activity is modulated by alternative splicing and is thought to be mediated by receptors expressed in muscle fibers, An isoform of agrin that does not induce postsynaptic specializations binds with high affinity to dystroglycan, a component of the dystrophin-glycoprotein complex. Transcripts encoding this agrin isoform are expressed in a variety of non-muscle tissues, Here, we analyzed the tissue distribution of agrin and dystroglycan on the protein level and determined their binding affinities, We found that agrin is most abundant in lung, kidney, and brain, Only a little agrin was detected in skeletal muscle, and no agrin was found in liver, Dystroglycan was highly expressed in all tissues examined except in liver, In a solid-phase radioligand binding assay, agrin bound to dystroglycan from lung, kidney, and skeletal muscle with a dissociation constant between 1.8 and 2.2 nar, while the affinity to brain-derived dystroglycan was 4.6 nM. In adult kidney and lung, agrin co-purified and co-immunoprecipitated with dystroglycan, and both molecules were co-localized in embryonic tissue, These data show that the agrin isoform expressed in non-muscle tissue is a high-affinity binding partner of dystroglycan and they suggest that this interaction, like that between laminin and dystroglycan, may be important for the mechanical integrity of the tissue.	Univ Basel, Dept Pharmacol, Biozentrum, CH-4056 Basel, Switzerland; Univ Basel, Dept Biophys Chem, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; University of Basel	Ruegg, MA (corresponding author), Univ Basel, Dept Pharmacol, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Ruegg, Markus/X-7256-2019; Brancaccio, Andrea/C-5876-2009	Ruegg, Markus/0000-0002-4974-9384; Brancaccio, Andrea/0000-0003-4690-8826				Barber AJ, 1997, DEV DYNAM, V208, P62, DOI 10.1002/(SICI)1097-0177(199701)208:1<62::AID-AJA6>3.0.CO;2-#; BEWICK GS, 1993, NEUROMUSCULAR DISORD, V3, P503, DOI 10.1016/0960-8966(93)90105-S; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; BRANCACCIO A, 1995, FEBS LETT, V368, P139, DOI 10.1016/0014-5793(95)00628-M; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Chiba A, 1997, J BIOL CHEM, V272, P2156; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gesemann M, 1996, NEURON, V16, P755, DOI 10.1016/S0896-6273(00)80096-3; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; GODFREY EW, 1991, EXP CELL RES, V195, P99, DOI 10.1016/0014-4827(91)90504-N; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; Hopf C, 1996, J BIOL CHEM, V271, P5231; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KHURANA TS, 1992, J CELL BIOL, V119, P357, DOI 10.1083/jcb.119.2.357; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; LIDOV HGW, 1990, NATURE, V348, P725, DOI 10.1038/348725a0; MA E, 1994, J NEUROSCI, V14, P2943; Mann S, 1996, MOL CELL NEUROSCI, V8, P1, DOI 10.1006/mcne.1996.0039; McMahan Uel J., 1992, Current Opinion in Cell Biology, V4, P869, DOI 10.1016/0955-0674(92)90113-Q; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MONTANARO F, 1995, J NEUROSCI RES, V42, P528, DOI 10.1002/jnr.490420411; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; Pall EA, 1996, J BIOL CHEM, V271, P3817; REIST NE, 1987, J CELL BIOL, V105, P2457, DOI 10.1083/jcb.105.6.2457; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SMALHEISER NR, 1995, J BIOL CHEM, V270, P15425, DOI 10.1074/jbc.270.25.15425; SMALHEISER NR, 1993, J NEUROSCI RES, V36, P528, DOI 10.1002/jnr.490360505; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; STONE DM, 1995, J NEUROSCI, V15, P6767; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; THOMAS WS, 1993, DEV BIOL, V158, P523, DOI 10.1006/dbio.1993.1210; Tian M, 1996, EUR J NEUROSCI, V8, P2739, DOI 10.1111/j.1460-9568.1996.tb01568.x; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE BG, 1989, J NEUROSCI, V9, P1294; Williamson RA, 1997, HUM MOL GENET, V6, P831, DOI 10.1093/hmg/6.6.831; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755; Yamada H, 1996, J NEUROCHEM, V66, P1518	50	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					600	605		10.1074/jbc.273.1.600	http://dx.doi.org/10.1074/jbc.273.1.600			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417121	Green Published, hybrid			2022-12-25	WOS:000071295600087
J	Hennet, T; Dinter, A; Kuhnert, P; Mattu, TS; Rudd, PM; Berger, EG				Hennet, T; Dinter, A; Kuhnert, P; Mattu, TS; Rudd, PM; Berger, EG			Genomic cloning and expression of three murine UDP-galactose: beta-N-acetylglucosamine beta 1,3-galactosyltransferase genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOLECULAR-CLONING; GALNAC ALPHA-2,6-SIALYLTRANSFERASE; HOMOLOGOUS SEQUENCES; LOCUS; BIOSYNTHESIS; ENZYME; LIPOOLIGOSACCHARIDE; IDENTIFICATION; PURIFICATION	Based on the detection of expressed sequence tags that are similar to known galactosyltransferase sequences, we have isolated three novel UDP-galactose:beta-N-acetylglucosamine beta 1,3-galactosyltransferase (beta 3GalT) genes from a mouse genomic library, The three genes, named beta 3GalT-I, -II, and -III, encode type II transmembrane proteins of 326, 422, and 331 amino acids, respectively, The three proteins constitute a distinct subfamily as they do not share any sequence identity with other eucaryotic galactosyltransferases. Also, the entire protein-coding region of the three beta 3GalT genes was contained in a single exon, which contrasts with the genomic organization of the beta 1,4 and alpha 1,3-galactosyltransferase genes, The three beta 3GalT genes were mainly expressed in brain tissue, The expression of the full-length murine genes as recombinant baculoviruses in insect cells revealed that the beta 3GalT enzymes share the same acceptor specificity for beta-linked GlcNAc, although they differ in their K-m for this acceptor and the donor UDP-Gal. The identification of beta 3GalT genes emphasizes the structural diversity present in the galactosyltransferase gene family.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Bern, Inst Vet Bacteriol, CH-3012 Bern, Switzerland; Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England	University of Zurich; University of Bern; University of Oxford	Hennet, T (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Kuhnert, Peter/O-1651-2014	Kuhnert, Peter/0000-0002-1575-5225				ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; COPE LD, 1991, MOL MICROBIOL, V5, P1113, DOI 10.1111/j.1365-2958.1991.tb01884.x; DRICKAMER K, 1993, GLYCOBIOLOGY, V1, P2; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; GOODE S, 1992, DEVELOPMENT, V116, P177; GOTSCHLICH EC, 1994, J EXP MED, V180, P2181, DOI 10.1084/jem.180.6.2181; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1997, LAB GUIDE GLYCOCONJU, V11, P199; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HILL HD, 1977, J BIOL CHEM, V252, P3791; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; Jennings MP, 1995, MOL MICROBIOL, V18, P729, DOI 10.1111/j.1365-2958.1995.mmi_18040729.x; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Koyama N, 1996, EUR J BIOCHEM, V238, P853, DOI 10.1111/j.1432-1033.1996.0853w.x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Malissard M, 1996, EUR J BIOCHEM, V239, P340, DOI 10.1111/j.1432-1033.1996.0340u.x; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; Sjoberg ER, 1996, J BIOL CHEM, V271, P7450, DOI 10.1074/jbc.271.13.7450; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TUO XH, 1992, CANCER RES, V52, P5744; Varki Ajit, 1995, Seminars in Developmental Biology, V6, P127, DOI 10.1016/S1044-5781(06)80022-8; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; Yuan YP, 1997, CELL, V88, P9, DOI 10.1016/S0092-8674(00)81852-8	36	62	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					58	65		10.1074/jbc.273.1.58	http://dx.doi.org/10.1074/jbc.273.1.58			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417047	hybrid			2022-12-25	WOS:000071295600013
J	Kobayashi, K; Kuroda, S; Fukata, M; Nakamura, T; Nagase, T; Nomura, N; Matsuura, Y; Yoshida-Kubomura, N; Iwamatsu, A; Kaibuchi, K				Kobayashi, K; Kuroda, S; Fukata, M; Nakamura, T; Nagase, T; Nomura, N; Matsuura, Y; Yoshida-Kubomura, N; Iwamatsu, A; Kaibuchi, K			p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH SYNDROME; RHO-FAMILY GTPASES; BINDING PROTEIN; CDC42HS; ACTIN; KINASE; EFFECTOR; IDENTIFICATION; ACTIVATION; CALMODULIN	Rac1 small GTPase plays pivotal roles in various cell functions such as cell morphology, cell polarity, and cell proliferation, We have previously identified IQGAP1 from bovine brain cytosol as a target for Rad by an affinity purification method, By using the same method, we purified a specifically Rac1-associated protein with a molecular mass of about 140 kDa (p140) from bovine brain cytosol, This protein interacted with guanosine 5'-(3-O-thio)triphosphate (GTP gamma S).glutathione S-transferase (GST)-Rac1 but not with the GDP.GST-Rac1, GTP gamma S.GST-Cdc42, or GTP gamma S.GST-RhoA. The amino acid sequences of this protein revealed that p140 is identified as a product of KIAA0068 gene, We denoted this protein as Sra-1 (Specifically Rad-associated protein), Recombinant Sra-1 interacted with GTP gamma S.GST-Rac1 and weakly with GDP.Rac1 but not with GST-Cdc42 or GST-RhoA, The N-terminal domain of Sra-1 (1-407 amino acids) was responsible for the interaction with Rad. Myc-tagged Sra-1 and the deletion mutant capable of interacting with Rad, but not the mutants unable to bind Rad, were colocalized with dominant active Rac1(Val-12) and cortical actin filament at the Rac1(Val-12)-induced membrane ruffling area in KB cells, Sra-1 was cosedimented with filamentous actin (F-actin), indicating that Sra-1 directly interacts with F-actin, These results suggest that Sra-1 is a novel and specific target for Rac1.	Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 63001, Japan; Japan Sci & Technol, Precursory res Embryon Sci & Technol, Inheritance & Variat Grp, Kyoto 61902, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Hiroshima 734, Japan; Kazusa DNA Res Inst, Kisarazu 292, Japan; Natl Inst Infect Dis, Dept Virol 2, Tokyo 162, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 236, Japan	Nara Institute of Science & Technology; Japan Science & Technology Agency (JST); Hiroshima University; Kazusa DNA Research Institute; National Institute of Infectious Diseases (NIID); Kirin Brewery Company Limited	Kaibuchi, K (corresponding author), Nara Inst Sci & Technol, Div Signal Transduct, Ikoma 63001, Japan.		KURODA, SHINYA/G-4961-2014; Fukata, Masaki/AAZ-2476-2021	Fukata, Masaki/0000-0001-5200-9806				AELST LV, 1996, EMBO J, V15, P3778; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAUMGARTNER S, 1995, J MOL BIOL, V251, P41, DOI 10.1006/jmbi.1995.0414; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brill S, 1996, MOL CELL BIOL, V16, P4869; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MACKAY DJG, 1995, TRENDS NEUROSCI, V18, P496, DOI 10.1016/0166-2236(95)92773-J; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8	32	171	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					291	295		10.1074/jbc.273.1.291	http://dx.doi.org/10.1074/jbc.273.1.291			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417078	hybrid			2022-12-25	WOS:000071295600044
J	Tetzloff, SU; Bizzozero, OA				Tetzloff, SU; Bizzozero, OA			Palmitoylation of proteolipid protein from rat brain myelin using endogenously generated O-18-fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-MODULATED PALMITOYLATION; PLASMA-MEMBRANE; FATTY-ACIDS; ALPHA-SUBUNIT; ACYLATION; RECEPTOR; PALMITOYLTRANSFERASE; ACYLTRANSFERASE; IDENTIFICATION; PHOSPHOLIPIDS	Proteolipid protein (PLP), the major protein of central nervous system myelin, contains covalently bound fatty acids, predominantly palmitic acid, This study adapts a stable isotope technique (Kuwae, T., Schmid, P. C., Johnson, S. B., and Schmid, H. O. (1990) J. Biol. Chem. 265, 5002-5007) to quantitatively determine the minimal proportion of PLP molecules which undergo palmitoylation, In these experiments, brain white matter slices from 20-day-old rats were incubated for up to 6 h in a physiological buffer containing 50% (H2O)-O-18. The uptake of O-18 into the carbonyl groups of fatty acids derived hom PLP, phospholipids, and the free fatty acid pool was measured by gas-liquid chromatography/mass spectrometry of the respective methyl esters, Palmitic acid derived from PLP acquired increasing amounts of O-18, ending with 2.9% O-18 enrichment after 6 h of incubation, O-18 incorporation into myelin free palmitic acid also increased over the course of the incubation (67.2% O-18 enrichment). After correcting for the specific activity of the O-18-enriched free palmitic acid pool, 7.6% of the PLP molecules were found to acquire palmitic acid in 6 h, This value is not only too large to be the result of the palmitoylation of newly synthesized PLP molecules, it was also unchanged upon the inhibition of protein synthesis with cycloheximide. O-18 enrichment in less actively myelinating 60-day-old rats was significantly reduced, In conclusion our experiments suggest that a substantial proportion of PLP molecules acquire palmitic acid via an acylation/deacylation cycle and that this profile changes during development.	Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Albuquerque, NM 87131 USA	University of New Mexico	Bizzozero, OA (corresponding author), Univ New Mexico, Sch Med, Dept Cell Biol & Physiol, Basic Med Sci Bldg,914 Camino Salud, Albuquerque, NM 87131 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008139] Funding Source: NIH RePORTER; NIGMS NIH HHS [SO6-GM 08139] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGRAWAL HC, 1976, BIOCHEM J, V154, P265, DOI 10.1042/bj1540265; ARIENTI G, 1981, NEUROCHEM RES, V6, P729, DOI 10.1007/BF00965471; BERGER M, 1985, FEBS LETT, V187, P289, DOI 10.1016/0014-5793(85)81261-8; BERTHIAUME L, 1995, J BIOL CHEM, V270, P22399, DOI 10.1074/jbc.270.38.22399; BIZZOZERO O, 1982, J CHROMATOGR, V227, P33, DOI 10.1016/S0378-4347(00)80353-9; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BIZZOZERO OA, 1992, J BIOL CHEM, V267, P7886; BIZZOZERO OA, 1990, J NEUROCHEM, V55, P1986, DOI 10.1111/j.1471-4159.1990.tb05786.x; BIZZOZERO OA, 1990, BIOCHEM BIOPH RES CO, V170, P375, DOI 10.1016/0006-291X(90)91284-Y; BIZZOZERO OA, 1983, NEUROCHEM INT, V5, P729, DOI 10.1016/0197-0186(83)90098-0; BIZZOZERO OA, 1994, NEUROCHEM RES, V19, P923, DOI 10.1007/BF00968702; BIZZOZERO OA, 1986, J NEUROCHEM, V46, P630, DOI 10.1111/j.1471-4159.1986.tb13013.x; BIZZOZERO OA, 1991, J BIOL CHEM, V266, P17092; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DOLCI ED, 1985, J BIOL CHEM, V260, P728; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; FALES HM, 1973, ANAL CHEM, V45, P2302, DOI 10.1021/ac60335a020; FOLCH J, 1951, J BIOL CHEM, V191, P807; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GRANGE E, 1995, J NEUROCHEM, V65, P2290; HUANG EM, 1989, BIOCHIM BIOPHYS ACTA, V1011, P134, DOI 10.1016/0167-4889(89)90200-0; Hudson Lynn D., 1992, P677; JAMES G, 1989, J BIOL CHEM, V264, P20998; JOCHEN A, 1991, BIOCHEM BIOPH RES CO, V177, P797, DOI 10.1016/0006-291X(91)91859-B; KENNEDY ME, 1994, J BIOL CHEM, V269, P31915; KINET JP, 1985, BIOCHEMISTRY-US, V24, P7342, DOI 10.1021/bi00346a048; KISHIMOTO Y, 1972, METHODS NEUROCHEMIST, V3, P75; KUWAE T, 1987, BIOCHEM BIOPH RES CO, V142, P86, DOI 10.1016/0006-291X(87)90454-2; KUWAE T, 1990, J BIOL CHEM, V265, P5002; LEES MB, 1989, J NEUROCHEM S, V52, P195; LEES MB, 1988, NEURONAL GLIAL PROTE, P267; Liu L, 1996, J BIOL CHEM, V271, P23269, DOI 10.1074/jbc.271.38.23269; MCCLOSKEY J. A., 1970, Topics in Lipid Chemistry, V1, P369; MCLAFFERTY FW, 1959, ANAL CHEM, V31, P82, DOI 10.1021/ac60145a015; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; SCHMID PC, 1988, CHEM PHYS LIPIDS, V46, P165, DOI 10.1016/0009-3084(88)90018-7; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT MFG, 1980, J BIOL CHEM, V255, P3334; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; Schroeder H, 1996, J CELL BIOL, V134, P647, DOI 10.1083/jcb.134.3.647; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; STOFFYN P, 1971, BIOCHEM BIOPH RES CO, V44, P157, DOI 10.1016/S0006-291X(71)80172-9; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWNSEND LE, 1982, J BIOL CHEM, V257, P9745; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WEIMBS T, 1992, BIOCHEMISTRY-US, V31, P12289, DOI 10.1021/bi00164a002	51	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					279	285		10.1074/jbc.273.1.279	http://dx.doi.org/10.1074/jbc.273.1.279			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417076	hybrid			2022-12-25	WOS:000071295600042
J	McNees, AG; O'Donnell, M; Horton, PH; Kim, HY; Kim, SJ; Harris, CM; Harris, TM; Lloyd, RS				McNees, AG; O'Donnell, M; Horton, PH; Kim, HY; Kim, SJ; Harris, CM; Harris, TM; Lloyd, RS			Lack of correlation between in vitro and in vivo replication of precisely defined benz[a]anthracene adducted DNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; COVALENT NUCLEOSIDE ADDUCTS; DIOL-EPOXIDES; DEOXYADENOSINE ADDUCTS; ESCHERICHIA-COLI; IN-VIVO; ADENINE; MUTAGENICITY; ACTIVATION; INDUCTION	Like other polycyclic aromatic hydrocarbons, certain metabolites of benz[a]anthracene have been implicated as potent carcinogens. These effects are thought to be caused by the covalent binding of these species to nucleophilic groups on the bases of DNA. To address the molecular mechanisms by which these molecules induce mutations, this study employed oligonucleotides containing four site-specific N-6 adenine-benz[a]anthracene diol epoxide adducts. Using a prokaryotic in vivo replication system, we have shown that both non-bay region anti-trans-benz[a]anthracene adducts are essentially nonmutagenic. In contrast, the bay region anti-trans-benz[a]anthracene lesions do induce point mutations at the adduct site. The mutagenic frequency of these bay region lesions is dependent on the stereochemistry about the adduct-forming bond, as well as the strain of Escherichia coli in which they are replicated. The ability of the bacterial replication machinery to bypass the lesions does not correlate with the differences observed in their mutagenesis. While both non-bay region adducts are readily bypassed in vivo, the bay region adducts are both blocking to approximately the same degree. In vitro studies of the interactions of E. coli DNA polymerase III with these adducts have also been undertaken to further dissect the relationship between adduct structure and biological activity.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Cornell Univ, Coll Med, Hearst Res Fdn, Dept Microbiol, New York, NY 10021 USA; Cornell Univ, Coll Med, Howard Hughes Med Inst, New York, NY 10021 USA; Vanderbilt Univ, Sch Med, Ctr Mol Toxicol, Nashville, TN 37235 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Cornell University; Cornell University; Howard Hughes Medical Institute; Vanderbilt University	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.			Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES05355, ES06766, ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267, R01ES006766, P01ES005355] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783; BASU AK, 1990, MUTAT RES, V233, P189, DOI 10.1016/0027-5107(90)90162-W; BONNER CA, 1992, J BIOL CHEM, V267, P11431; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOYLAND E, 1974, FEBS LETT, V47, P30; CARBERRY SE, 1989, CARCINOGENESIS, V10, P97, DOI 10.1093/carcin/10.1.97; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; CHEH AM, 1993, J ORG CHEM, V58, P4013, DOI 10.1021/jo00067a039; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; CONNEY AH, 1982, CANCER RES, V42, P4875; DIPPLE A, 1983, CANCER RES, V43, P4132; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P409; Geacintov NE, 1997, CHEM RES TOXICOL, V10, P111, DOI 10.1021/tx9601418; Harvey R. G., 1991, POLYCYCLIC AROMATIC; HARVEY RG, 1981, ACCOUNTS CHEM RES, V14, P218, DOI 10.1021/ar00067a004; HIGASHITANI N, 1992, J BACTERIOL, V174, P1612, DOI 10.1128/jb.174.5.1612-1618.1992; *ICF CLEM, 1990, TOX PROF BENZ; JEFFREY AM, 1979, SCIENCE, V206, P1309, DOI 10.1126/science.316186; KARGA H, 1991, J CLIN ENDOCR METAB, V73, P832, DOI 10.1210/jcem-73-4-832; KIM SJ, 1992, J AM CHEM SOC, V114, P5480, DOI 10.1021/ja00039a101; KIM SJ, 1995, BIOORGAN MED CHEM, V3, P811, DOI 10.1016/0968-0896(95)00065-O; KIM SK, 1989, CARCINOGENESIS, V10, P1333, DOI 10.1093/carcin/10.7.1333; Kornberg A., 1992, DNA REPLICATION, P165; KUZMINOV A, 1995, J THEOR BIOL, V177, P29, DOI 10.1006/jtbi.1995.0222; LATHAM GJ, 1993, J BIOL CHEM, V268, P23427; LAVERY PE, 1992, J BIOL CHEM, V267, P20648; LEHR RE, 1977, TETRAHEDRON LETT, V18, P539; LEHR RE, 1985, POLYCYCLIC HYDROCARB; MACNICOLL AD, 1981, CANCER LETT, V11, P243, DOI 10.1016/0304-3835(81)90115-4; MAKI H, 1988, J BACTERIOL, V171, P3139; Ogawa H, 1990, Adv Biophys, V26, P33, DOI 10.1016/0065-227X(90)90006-F; Ralston SL, 1995, CARCINOGENESIS, V16, P2899, DOI 10.1093/carcin/16.12.2899; Rangarajan S, 1997, P NATL ACAD SCI USA, V94, P946, DOI 10.1073/pnas.94.3.946; Sambrook J, 1995, MOL CLONING LAB MANU; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SLAGA TJ, 1978, CANCER RES, V38, P1699; THAKKER DR, 1982, J BIOL CHEM, V257, P5103; THAKKER DR, 1978, MOL PHARMACOL, V15, P138; VOUSDEN KH, 1986, P NATL ACAD SCI USA, V83, P1222, DOI 10.1073/pnas.83.5.1222; WOOD AW, 1977, P NATL ACAD SCI USA, V74, P2746, DOI 10.1073/pnas.74.7.2746; WOOD AW, 1976, BIOCHEM BIOPH RES CO, V72, P680, DOI 10.1016/S0006-291X(76)80093-9; WOODGATE R, 1991, MOL GEN GENET, V229, P10, DOI 10.1007/BF00264207	43	28	28	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33211	33219		10.1074/jbc.272.52.33211	http://dx.doi.org/10.1074/jbc.272.52.33211			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407110	hybrid			2022-12-25	WOS:000071182900071
J	Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N				Matsuda, T; Sasaki, M; Kato, H; Yamada, H; Cohen, M; Barrett, JC; Oshimura, M; Wake, N			Human chromosome 7 carries a putative tumor suppressor gene(s) involved in choriocarcinoma	ONCOGENE			English	Article						tumor suppressor gene; choriocarcinoma; chromosome 7; homozygous deletion	HUMAN ENDOGENOUS RETROVIRUS; PRIMARY BREAST-CANCER; CARCINOMA CELL-LINE; HYDATIDIFORM MOLE; SQUAMOUS-CELL; MESSENGER-RNAS; TUMORIGENIC EXPRESSION; PANCREATIC-CARCINOMA; HOMOZYGOUS DELETIONS; FREQUENT LOSS	Choriocarcinoma developed from a complete hydatidiform mole has an unique genetic feature that involves monoallelic contribution from the paternal genome, To the chromosome carrying putative tumor gene(s), microcell-hybrids were isolated following fusion of choriocarcinoma cells with microcells from mouse A9 cells containing a single human chromosome (1, 2, 6, 7, 9 or 11), Microcell-hybrids with the introduction of chromosome 7 were suppressed or modulated for tumorigenicity and exhibited altered in vitro growth properties, Introduction of chromosomes 1, 2, 6, 9 or 11 had no effect, Tumorigenic revertants isolated from microcell-hybrids with the introduced chromosome 7 contains reduced numbers of chromosome 7, These findings suggest that chromosome 7 contains a putative tumor suppressor gene(s) for choriocarcinoma, Alterations in tumorigenic phenotypes seen in microcell-hybrids were not associated with the presence of either ERV3 or H-plk locus located on the introduced chromosome 7, indicating the putative tumor suppressor gene(s) is outside of ERV3 and H-plk gene loci, Furthermore, we obtained evidence to define a critical region on chromosome 7 (7p12-7q11.23) that was frequently lost in surgically removed choriocarcinoma tissues and cell lines, Using a panel of microsatellite markers, biallelic deletions were observed, which strongly suggests the presence of a tumor suppressor gene(s) within this critical region.	KYUSHU UNIV,MED INST BIOREGULAT,DEPT REPROD PHYSIOL & ENDOCRINOL,BEPPU,OITA 874,JAPAN; TOTTORI UNIV,FAC MED,SCH LIFE SCI,DEPT MOL & CELL GENET,YONAGO,TOTTORI 683,JAPAN; ABBOTT LABS,DEPT CORP MOL BIOL,ABBOTT PK,IL 60064; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Kyushu University; Tottori University; Abbott Laboratories; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								Achille A, 1996, CANCER RES, V56, P3808; [Anonymous], 1982, MOL CLONING LAB MANU; ARCARI P, 1984, NUCLEIC ACIDS RES, V12, P9179, DOI 10.1093/nar/12.23.9179; ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; BELLEFROID EJ, 1989, DNA-J MOLEC CELL BIO, V8, P377, DOI 10.1089/dna.1.1989.8.377; BELLEFROID EJ, 1992, GENOMICS, V14, P780, DOI 10.1016/S0888-7543(05)80185-5; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOYD MT, 1993, VIROLOGY, V196, P905, DOI 10.1006/viro.1993.1556; CAVANEE WK, 1983, NATURE, V305, P779; CHERIF D, 1989, HUM GENET, V81, P358, DOI 10.1007/BF00283691; COHEN M, 1988, J CELL BIOCHEM, V36, P121, DOI 10.1002/jcb.240360203; CONWAY K, 1992, CANCER RES, V52, P6487; Decker HJH, 1996, HUM GENET, V97, P770; JACOBS PA, 1980, NATURE, V286, P714, DOI 10.1038/286714a0; KAJII T, 1977, NATURE, V268, P633, DOI 10.1038/268633a0; Kastury K, 1996, CANCER RES, V56, P978; KATO N, 1990, MOL CELL BIOL, V10, P4401, DOI 10.1128/MCB.10.8.4401; KATO N, 1987, J VIROL, V61, P2182, DOI 10.1128/JVI.61.7.2182-2191.1987; KATO N, 1988, INT J CANCER, V41, P380, DOI 10.1002/ijc.2910410310; KOHLER PO, 1971, J CLIN ENDOCR METAB, V32, P683, DOI 10.1210/jcem-32-5-683; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; MARTIN MA, 1981, P NATL ACAD SCI USA, V78, P4896; NOZAWA S, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P889; OCONNELL C, 1984, VIROLOGY, V138, P225, DOI 10.1016/0042-6822(84)90347-7; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; OHAMA K, 1981, NATURE, V292, P551, DOI 10.1038/292551a0; Ohnishi H, 1996, LEUKEMIA, V10, P1104; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PARK WW, 1971, CHORIOCARCINOMA STUD, P55; PATTILLO RA, 1971, IN VITRO CELL DEV B, V6, P398; PATTILLO RA, 1968, CANCER RES, V28, P1231; PATTILLO RA, 1981, AM J OBSTET GYNECOL, V141, P104; PORTEOUS DJ, 1989, GENOMICS, V5, P680, DOI 10.1016/0888-7543(89)90108-0; Roche J, 1996, ONCOGENE, V12, P1289; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCABLE H, 1989, P NATL ACAD SCI USA, V86, P7480; SCHUTTE M, 1995, P NATL ACAD SCI USA, V92, P5950, DOI 10.1073/pnas.92.13.5950; SPEICHER MR, 1995, CANCER RES, V55, P1010; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; STANBRIDGE EJ, 1988, CANC SURVEYS, V29, P317; SUGIURA M, 1988, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V40, P1447; SURTI U, 1979, HUM GENET, V51, P153, DOI 10.1007/BF00287169; Suzumori K, 1983, Asia Oceania J Obstet Gynaecol, V9, P309; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TSUI LC, 1995, CYTOGENET CELL GENET, V71, P1, DOI 10.1159/000134055; VENABLES PJW, 1995, VIROLOGY, V211, P589, DOI 10.1006/viro.1995.1442; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; WAKE N, 1978, J NATL CANCER I, V60, P51, DOI 10.1093/jnci/60.1.51; WAKE N, 1978, P JPN ACAD B-PHYS, V54, P533, DOI 10.2183/pjab.54.533; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMADA H, 1990, ONCOGENE, V5, P1141; YAMASHITA K, 1979, AM J OBSTET GYNECOL, V135, P597, DOI 10.1016/S0002-9378(16)32983-0; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	59	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2773	2781		10.1038/sj.onc.1201461	http://dx.doi.org/10.1038/sj.onc.1201461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419968				2022-12-25	WOS:A1997YJ80300003
J	Roy, SK; Yoko-o, T; Ikenaga, H; Jigami, Y				Roy, SK; Yoko-o, T; Ikenaga, H; Jigami, Y			Functional evidence for UDP-galactose transporter in Saccharomyces cerevisiae through the in vivo galactosylation and in vitro transport assay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; SCHIZOSACCHAROMYCES-POMBE; GUANOSINE DIPHOSPHATASE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; OUTER CHAIN; YEAST; PURIFICATION; VESICLES; GALACTOSYLTRANSFERASE	The oligosaccharide profiles in glycoproteins are determined by a series of processing reactions catalyzed by Golgi glycosyltransferases and glycosidases. Recently in vivo galactose incorporation in Saccharomyces cerevisiae has been demonstrated through the expression of human beta-1,4-galactosyltransferase in an alg1 mutant, suggesting the presence of a UDP-galactose transporter in S. cerevisiae (Schwientek, T., Narimatsu, H., and Ernst, J. F. (1996) J. Biol. Chem. 271, 3398-3405). However, this is quite unexpected, because S. cerevisiae does not have galactose residues in its glycoproteins. To address this question we have constructed S. cerevisiae mnn1 mutant strains expressing Schizosaccharomyces pombe alpha-1,2-galactosyltransferase. The mnn1 mutant of S. cerevisiae provides endogenous accepters for galactose transfer by the expressed alpha-1,2-galactosyltransferase. We present here three lines of evidences for the existence of UDP-galactose transporter in S. cerevisiae. (i) About 15-20% of the total transformed mnn1 cells grown in a galactose medium were stained with fluorescein isothiocyanate-conjugated alpha-galactose-specific lectin, indicating the presence of Lu-galactose residues on the cell surface. (ii) Galactomannan proteins can be precipitated with agarose-immobilized cu-galactose-specific lectin from a whole cell lysate prepared from transformed mnn1 cells grown in a galactose medium. (iii) The presence of UDP-galactose transporter was demonstrated by direct transport assay. This transport in S. cerevisiae is dependent on time, temperature, and protein concentration and is inhibited by nucleotide monophosphate and Triton X-100. The overall UDP-galactose transport in S. cerevisiae is comparable with that in S. pombe, indicating a more or less similar reaction velocity, while the rate of GDP-mannose transport is higher in S. pombe than in S. cerevisiae.	Natl Inst Biosci & Human Technol, Tsukuba, Ibaraki 305, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanagawa 236, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Kirin Brewery Company Limited	Jigami, Y (corresponding author), Natl Inst Biosci & Human Technol, 1-1 Higashi, Tsukuba, Ibaraki 305, Japan.	jigami@nibh.go.jp	Yoko-o, Takehiko/L-7093-2018	Yoko-o, Takehiko/0000-0003-0291-8299				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BALLOU CE, 1994, P NATL ACAD SCI USA, V91, P9327, DOI 10.1073/pnas.91.20.9327; BERNINSONE P, 1994, J BIOL CHEM, V269, P207; Berninsone P, 1997, J BIOL CHEM, V272, P12616, DOI 10.1074/jbc.272.19.12616; BOSSUYT X, 1994, EUR J BIOCHEM, V223, P981, DOI 10.1111/j.1432-1033.1994.tb19076.x; BUSSEY H, 1991, MOL MICROBIOL, V5, P2339, DOI 10.1111/j.1365-2958.1991.tb02079.x; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; Eckart MR, 1996, CURR OPIN BIOTECH, V7, P525, DOI 10.1016/S0958-1669(96)80056-5; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; Hirschberg CB, 1996, SOC GEN PHY, V51, P105; ICHIKAWA Y, 1992, ANAL BIOCHEM, V202, P215, DOI 10.1016/0003-2697(92)90099-S; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLEENE R, 1994, BIOCHEM BIOPH RES CO, V201, P160, DOI 10.1006/bbrc.1994.1683; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREZDORN CH, 1993, EUR J BIOCHEM, V212, P113, DOI 10.1111/j.1432-1033.1993.tb17640.x; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHLE L, 1995, GLYCOPROTEINS, P475; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MASON TL, 1973, J BIOL CHEM, V248, P1346; MUDGAPALLI A, 1994, J BIOL CHEM, V269, P11327; NAKANISHISHINDO Y, 1993, J BIOL CHEM, V268, P26338; NAKAYAMA K, 1992, EMBO J, V11, P2511, DOI 10.1002/j.1460-2075.1992.tb05316.x; Odani T, 1996, GLYCOBIOLOGY, V6, P805, DOI 10.1093/glycob/6.8.805; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PEAT S, 1961, J CHEM SOC, P29, DOI 10.1039/jr9610000029; RASCHKE WC, 1973, J BIOL CHEM, V248, P4660; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROY SK, 1989, ENZYME MICROB TECH, V11, P431, DOI 10.1016/0141-0229(89)90138-5; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 2002, MOL CLONING LAB MANU; Schwientek T, 1996, J BIOL CHEM, V271, P3398; SHERMAN F, 1986, LAB COURSE MANNUAL M; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TRIMBLE RB, 1995, TRENDS GLYCOSCI GLYC, V7, P1, DOI 10.4052/tigg.7.1; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wang XH, 1997, J BIOL CHEM, V272, P18117, DOI 10.1074/jbc.272.29.18117; YANAGISAWA K, 1990, J BIOL CHEM, V265, P19351; ZIEGLER FD, 1994, J BIOL CHEM, V269, P12527	43	27	27	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2583	2590		10.1074/jbc.273.5.2583	http://dx.doi.org/10.1074/jbc.273.5.2583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446560	hybrid			2022-12-25	WOS:000071736600015
J	Song, Y; Withers, DA; Hakomori, S				Song, Y; Withers, DA; Hakomori, S			Globoside-dependent adhesion of human embryonal carcinoma cells, based on carbohydrate-carbohydrate interaction, initiates signal transduction and induces enhanced activity of transcription factors AP1 and CREB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-INDUCED DIFFERENTIATION; HUMAN TERATOCARCINOMA CELLS; NF-KAPPA-B; MONOCLONAL-ANTIBODY; PREIMPLANTATION EMBRYOS; MOUSE EMBRYOS; GLYCOSPHINGOLIPIDS; EXPRESSION; ANTIGEN; PROTEIN	Undifferentiated human embryonal carcinoma cells are characterized by high expression of lactoneotetraosylceramide (nLc(4)), globoside (Gb4), and extended globe-series glycosphingolipids (GSLs) termed "stage-specific embryonic antigens 3 and 4" (SSEA-3 and -4), Expression of these GSLs declines in association with a decline of homotypic adhesion during the differentiation process, Therefore, these GSLs may play an essential role in adhesion among these cells, As an example, human embryonal carcinoma 2102 cells display strong adhesion to plates coated with Gb4 ("Gb4-dependent cell adhesion"), This adhesion, which simulates homotypic 2102 cell aggregation, is based on interaction between Gb4 and nLc(4), or between Gb4 and GalGb4 (IV(3)GalGb4; the major SSEA-3 epitope), as indicated by the following observations: (i) adhesion of 2102 cells or GSL-liposomes to GSL-coated plates in various combinations; (ii) inhibition of Gb4-dependent 2102 cell adhesion by preincubation of cells with anti-SSEA-3 or anti-nLc(4) antibodies, or by pretreatment of Gb4-coated plates with aqueous micellar solution of nLc(4) or GalGb4; (iii) decline of the cell adhesion in association with retinoic acid-induced differentiation, whereby SSEA-3 and nLc(4) levels are reduced, Since cell adhesion is an essential prerequisite for induction of differentiation, as observed at each step of embryogenesis, expression of seven transcription fac tors following adhesion of 2102 cells to Gb4-coated plates, and to detergent-insoluble substrate adhesion matrix prepared from 2102 cells, were studied, In both types of adhesion, a strong enhancement of AP1 and CREB site binding activity was observed during the early stage (15-60 min following initial adhesion), Although 2102 cells showed strong adhesion to Gg3-coated plates, based on interaction between Gg3 and Gb4, adhesion of the cells to Gg3 did not cause changes of AP1 and CREB activity, No other transcription factors showed changes induced by Gg3- or Gb4-dependent adhesion.	Pacific NW Res Fdn, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Song, Y (corresponding author), NIDDK, Lab Cell Biochem, NIH, MSC 0850,Bldg 8,Rm 402, Bethesda, MD 20892 USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1982, INT J CANCER, V29, P523, DOI 10.1002/ijc.2910290507; ANDREWS PW, 1987, INT J ANDROL, V10, P95, DOI 10.1111/j.1365-2605.1987.tb00170.x; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BOMSZTYK K, 1990, J BIOL CHEM, V265, P9413; Boubelik M, 1996, BIOCHEM BIOPH RES CO, V224, P283, DOI 10.1006/bbrc.1996.1022; Bovin N. V., 1997, GLYCOSCIENCES STATUS, P277; Buck C A, 1992, Semin Cell Biol, V3, P179; CARTER WG, 1981, J BIOL CHEM, V256, P6953; CHEN C, 1989, BIOCHEMISTRY-US, V28, P2229, DOI 10.1021/bi00431a039; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CROCKER PR, 1995, J CLIN INVEST, V95, P635, DOI 10.1172/JCI117708; CROCKER PR, 1994, EMBO J, V13, P4490, DOI 10.1002/j.1460-2075.1994.tb06771.x; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Grobstein C., 1975, EXTRACELLULAR MATRIX, P9; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAKOMORI S, 1992, TOHOKU J EXP MED, V168, P211, DOI 10.1620/tjem.168.211; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HANDA K, 1995, INT J ONCOL, V6, P773; HERRLICH P, 1995, EUR J CANCER, V31A, P1110, DOI 10.1016/0959-8049(95)00252-E; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO K, 1994, GLYCOCONJUGATE J, V11, P232, DOI 10.1007/BF00731223; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANNAGI R, 1983, J BIOL CHEM, V258, P8934; KANNAGI R, 1983, EMBO J, V2, P2355, DOI 10.1002/j.1460-2075.1983.tb01746.x; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KOJIMA N, 1991, Glycobiology, V1, P623, DOI 10.1093/glycob/1.6.623; KOJIMA N, 1994, GLYCOCONJUGATE J, V11, P238, DOI 10.1007/BF00731224; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; KOSCIELAK J, 1968, IMMUNOCHEMISTRY, V5, P441, DOI 10.1016/0019-2791(68)90181-X; Koshy KM, 1996, J BIOL CHEM, V271, P3496; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SHEVINSKY LH, 1982, CELL, V30, P697, DOI 10.1016/0092-8674(82)90274-4; SMYTH SS, 1993, BLOOD, V81, P2827; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STROUD MR, 1991, J BIOL CHEM, V266, P8439; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VESTWEBER D, 1987, DEV BIOL, V124, P451, DOI 10.1016/0012-1606(87)90498-2; VONDEMBORNE AEG, 1986, BR J HAEMATOL, V63; WILLISON KR, 1982, J IMMUNOL, V129, P603; YAMAKAWA T, 1952, J BIOCHEM-TOKYO, V39, P393, DOI 10.1093/oxfordjournals.jbchem.a126309; Yamamura S, 1997, BIOCHEM BIOPH RES CO, V236, P218, DOI 10.1006/bbrc.1997.6933; YOUNG WW, 1979, J EXP MED, V150, P1008, DOI 10.1084/jem.150.4.1008; YOUNG WW, 1981, J BIOL CHEM, V256, P967	56	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2517	2525		10.1074/jbc.273.5.2517	http://dx.doi.org/10.1074/jbc.273.5.2517			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446552	hybrid			2022-12-25	WOS:000071736600007
J	Warwicker, J				Warwicker, J			Modeling charge interactions and redox properties in DsbA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; FORMATION IN-VIVO; ACTIVE-SITE; IONIZABLE GROUPS; PROTEIN; THIOREDOXIN; ELECTROSTATICS; ISOMERASE; RESIDUES	Accurate prediction of charge interactions in macromolecules presents a significant challenge for computational biology, A model for the low Cys(30) pK(a), and oxidizing power of DsbA (Gane, P.J., Freedman, R. B., and Warwicker, J. (1995) J. Mol. Biol. 249, 376-387) has been investigated experimentally (Hennecke, J., Spleiss, C., and Glockshuber, R. (1997) J. Biol. Chem. 272, 189-195), with substitutions for Glu(37) and Glu(38) and with residues 38-40 removed, Measured changes in Cys(30) pK(a) and redox potential were relatively small and reported to be in contrast to model predictions, It is now shown, particularly with calculations of wild-type:mutant differences for a range of salt concentrations, that the data are consistent with the model and support the key finding that a number of different factors contribute to the oxidizing power of DsbA, so that any particular one need not necessarily be large, A feature of the model is a low protein dielectric, and higher values (which are becoming popular in predictions of pH dependence) are inconsistent with both the difference data and the wild-type Cys(30) pK(a).	Inst Food Res, Reading Lab, Reading RG6 6BZ, Berks, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute	Warwicker, J (corresponding author), Inst Food Res, Reading Lab, Earley Gate,Whiteknights Rd, Reading RG6 6BZ, Berks, England.			Warwicker, Jim/0000-0002-1302-0815				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARDWELL JCA, 1993, CELL, V74, P769, DOI 10.1016/0092-8674(93)90455-Y; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BASHFORD D, 1990, BIOCHEMISTRY-US, V29, P10219, DOI 10.1021/bi00496a010; BEROZA P, 1991, P NATL ACAD SCI USA, V88, P5804, DOI 10.1073/pnas.88.13.5804; Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; Demchuk E, 1996, J PHYS CHEM-US, V100, P17373, DOI 10.1021/jp960111d; GANE PJ, 1995, J MOL BIOL, V249, P376, DOI 10.1006/jmbi.1995.0303; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Hennecke J, 1997, J BIOL CHEM, V272, P189; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Hu SH, 1997, J MOL BIOL, V268, P137, DOI 10.1006/jmbi.1997.0940; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; LUNDSTROM J, 1992, J BIOL CHEM, V267, P9047; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; Ruddock LW, 1996, BIOCHEM J, V315, P1001, DOI 10.1042/bj3151001; VANGUNSTEREN WF, 1987, GROMOS MANUAL; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WARWICKER J, 1986, J THEOR BIOL, V121, P199, DOI 10.1016/S0022-5193(86)80093-5; WARWICKER J, 1987, PROTEINS, V2, P283, DOI 10.1002/prot.340020404; Warwicker J, 1996, FEBS LETT, V385, P105, DOI 10.1016/0014-5793(96)00358-4; Warwicker J, 1997, PROTEIN ENG, V10, P809, DOI 10.1093/protein/10.7.809	24	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2501	2504		10.1074/jbc.273.5.2501	http://dx.doi.org/10.1074/jbc.273.5.2501			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446549	hybrid			2022-12-25	WOS:000071736600004
J	Allan, BW; Beechem, JM; Lindstrom, WM; Reich, NO				Allan, BW; Beechem, JM; Lindstrom, WM; Reich, NO			Direct real time observation of base flipping by the EcoRI DNA methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC RECOGNITION; S-ADENOSYLMETHIONINE; CRYSTAL-STRUCTURE; TARGET BASE; MECHANISM; METHYLASE; BINDING; NMR; ADENINE; 2-AMINOPURINE	DNA methyltransferases are excellent prototypes for investigating DNA distortion and enzyme specificity because catalysis requires the extrahelical stabilization of the target base within the enzyme active site, The energetics and kinetics of base flipping by the EcoRI DNA methyltransferase were investigated by two methods, First, equilibrium dissociation constants (K-D(DNA)) were determined for the binding of the methyltransferase to DNA containing abasic sites or base analogs incorporated at the target base. Consistent with a base flipping mechanism, tighter binding-to oligonucleotides containing destabilized target base pairs was observed, Second, total intensity stopped flow fluorescence measurements of DNA containing a-aminopurine allowed presteady-state real time observation of the base flipping transition, Following the rapid formation of an enzyme-DNA collision complex, a biphasic increase in total intensity was observed, The fast phase dominated the total intensity increase with a rate nearly identical to k(methylation) determined by rapid chemical quench-flow techniques (Reich, N. O., and Mashoon, N. (1993) J. Biol. Chem. 268, 9191-9193). The restacking of the extrahelical base also revealed biphasic kinetics with the recovered amplitudes from these off-rate experiments matching very closely to those observed during the base unstacking process, These results provide the first direct and continuous observation of base flipping and show that at least two distinct conformational transitions occurred at the flipped base subsequent to complex formation, Furthermore, our results suggest that the commitment to catalysis during the methylation of the target site is not determined at the level of the chemistry step but rather is mediated by prior intramolecular isomerization within the enzyme-DNA complex.	Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Program Biochem & Mol Biol, Santa Barbara, CA 93106 USA; Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; Vanderbilt University	Reich, NO (corresponding author), Univ Calif Santa Barbara, Dept Chem, Santa Barbara, CA 93106 USA.	reich@sbmm1.ucsb.edu						Adams GM, 1997, BIOCHEMISTRY-US, V36, P8284, DOI 10.1021/bi961885n; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; Bjornson KP, 1996, J MOL BIOL, V263, P411, DOI 10.1006/jmbi.1996.0585; BLOOM LB, 1994, BIOCHEMISTRY-US, V33, P7576, DOI 10.1021/bi00190a010; BLOOM LB, 1993, BIOCHEMISTRY-US, V32, P11247, DOI 10.1021/bi00092a039; BRENNAN CA, 1986, J BIOL CHEM, V261, P7270; BRENNAN CA, 1985, NUCLEIC ACIDS RES, V13, P8665, DOI 10.1093/nar/13.24.8665; Cal S, 1996, J BIOL CHEM, V271, P1008, DOI 10.1074/jbc.271.2.1008; CHAZIN WJ, 1991, NUCLEIC ACIDS RES, V19, P5507, DOI 10.1093/nar/19.20.5507; Cheng XD, 1996, STRUCTURE, V4, P639, DOI 10.1016/S0969-2126(96)00068-8; COLL M, 1986, J BIOMOL STRUCT DYN, V4, P157, DOI 10.1080/07391102.1986.10506337; Dunkak KS, 1996, ANAL BIOCHEM, V243, P234, DOI 10.1006/abio.1996.0511; Fasman GD., 1975, HDB BIOCH MOL BIOL N, V1, P589; FAZAKERLEY GV, 1985, BIOCHEMISTRY-US, V24, P4540, DOI 10.1021/bi00338a009; Garcia RA, 1996, P NATL ACAD SCI USA, V93, P7618, DOI 10.1073/pnas.93.15.7618; Gong WM, 1997, NUCLEIC ACIDS RES, V25, P2702, DOI 10.1093/nar/25.14.2702; GREENE PJ, 1978, NUCLEIC ACIDS RES, V5, P2373, DOI 10.1093/nar/5.7.2373; HO DK, 1991, ARCH BIOCHEM BIOPHYS, V284, P264, DOI 10.1016/0003-9861(91)90294-S; KLIMASAUSKAS S, 1995, NUCLEIC ACIDS RES, V23, P1388, DOI 10.1093/nar/23.8.1388; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LYCKSELL PO, 1987, NUCLEIC ACIDS RES, V15, P9011, DOI 10.1093/nar/15.21.9011; MALONE T, 1995, J MOL BIOL, V253, P618, DOI 10.1006/jmbi.1995.0577; Menger M, 1996, BIOCHEMISTRY-US, V35, P14710, DOI 10.1021/bi960440w; MOE JG, 1992, BIOCHEMISTRY-US, V31, P8421, DOI 10.1021/bi00151a005; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Parkhurst KM, 1996, BIOCHEMISTRY-US, V35, P7459, DOI 10.1021/bi9530301; POGOLOTTI AL, 1988, J BIOL CHEM, V263, P7461; QUIGNARD E, 1985, EUR J BIOCHEM, V152, P99, DOI 10.1111/j.1432-1033.1985.tb09168.x; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V91, P10957; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; REICH NO, 1990, J BIOL CHEM, V265, P8966; REICH NO, 1992, J BIOL CHEM, V267, P15802; REICH NO, 1993, J BIOL CHEM, V268, P9191; REICH NO, 1991, BIOCHEMISTRY-US, V30, P2933, DOI 10.1021/bi00225a029; REICH NO, 1992, BIOCHEMISTRY-US, V31, P1937, DOI 10.1021/bi00122a006; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; RUBIN RA, 1977, J BIOL CHEM, V252, P7265; Sastry SS, 1996, BIOCHEMISTRY-US, V35, P15715, DOI 10.1021/bi960729d; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SibghatUllah, 1996, BIOCHEMISTRY-US, V35, P12926, DOI 10.1021/bi961022u; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; Surby MA, 1996, BIOCHEMISTRY-US, V35, P2209, DOI 10.1021/bi951884f; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; WARD DC, 1969, J BIOL CHEM, V244, P1228; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	51	88	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2368	2373		10.1074/jbc.273.4.2368	http://dx.doi.org/10.1074/jbc.273.4.2368			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442083	hybrid			2022-12-25	WOS:000071595200072
J	Bloemers, SM; Verheule, S; Peppelenbosch, MP; Smit, MJ; Tertoolen, LGJ; de Laat, S				Bloemers, SM; Verheule, S; Peppelenbosch, MP; Smit, MJ; Tertoolen, LGJ; de Laat, S			Sensitization of the histamine H-1 receptor by increased ligand affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; INHALED LEUKOTRIENE-D4; PROTEIN; CELLS; EXOCYTOSIS; INTERNALIZATION; RESPONSIVENESS; EXPRESSION; PATHWAYS; MEMBRANE	Histamine regulates a variety of physiological processes including inflammation, gastric acid secretion, and neurotransmission. The cellular response to histamine is subject to dynamic control, and exaggerated histamine reactivity in response to cysteinyl leukotrienes and other stimuli is important in a variety of different pathological conditions, The molecular mechanisms controlling histamine responsiveness are still unresolved, In investigating histamine responses in embryonic stem (ES5) and F9 embryonic carcinoma cells, we encountered a novel mechanism controlling the cellular reaction to histamine, Unstimulated cells displayed neither [H-3]pyrilamine binding nor histamine-induced increases in cytosolic Ca2+ levels, Pretreatment of these cells, however, with leukotriene D-4, leukotriene E-4, serotonin, or fetal calf serum induced an immediate and transient ability of these cells to respond to histamine with an increase in cytosolic Ca2+ levels, This effect could be inhibited by pertussis toxin and was mimicked by GTP analogues, Importantly, the latter compounds also provoked immediate high affinity [H-3]pyrilamine binding, We conclude that in these cells histamine responsiveness is directly controlled by pertussis toxin-sensitive G protein-coupled receptors, whose activation enables the H-1 receptor to bind its ligand, These findings define a novel mechanism for regulating histamine H-1 receptor activity and provide for the first time molecular insight into the mechanism by which cysteinyl leukotrienes and other external stimuli can increase histamine responsiveness.	Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands; Vrije Univ Amsterdam, Fac Chem, Dept Pharmacochem, NL-1081 HV Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam	Peppelenbosch, MP (corresponding author), Netherlands Inst Dev Biol, Hubrecht Lab, Uppsalalaan 8, NL-3584 CT Utrecht, Netherlands.			Peppelenbosch, Maikel/0000-0001-9112-6028; Smit, Martine/0000-0003-2713-0238; Verheule, Sander/0000-0001-5196-5425				ARM JP, 1988, J ALLERGY CLIN IMMUN, V82, P654, DOI 10.1016/0091-6749(88)90979-7; BLOEMERS SM, 1992, BIOCHEM BIOPH RES CO, V191, P118; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1506, DOI 10.1164/ajrccm/146.6.1506; CIVITELLI R, 1987, J CELL PHYSIOL, V131, P434, DOI 10.1002/jcp.1041310316; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gerthoffer WT, 1996, J PHARMACOL EXP THER, V278, P800; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HILL SJ, 1990, PHARMACOL REV, V42, P45; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAYE MG, 1990, AM REV RESPIR DIS, V141, P993, DOI 10.1164/ajrccm/141.4_Pt_1.993; KERN R, 1986, AM REV RESPIR DIS, V133, P1127; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Krueger KM, 1997, J BIOL CHEM, V272, P5; LANG JC, 1993, EMBO J, V12, P2671, DOI 10.1002/j.1460-2075.1993.tb05928.x; LAW GJ, 1993, FEBS LETT, V333, P56, DOI 10.1016/0014-5793(93)80374-4; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053, DOI 10.1164/ajrccm/144.5.1053; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEPPELENBOSCH MP, 1995, J NEUROSCI METH, V58, P49, DOI 10.1016/0165-0270(94)00158-D; SAKURAI T, 1994, PROSTAG LEUKOTR ESS, V51, P95, DOI 10.1016/0952-3278(94)90084-1; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; Smit MJ, 1996, J BIOL CHEM, V271, P7574, DOI 10.1074/jbc.271.13.7574; Smit MJ, 1996, P NATL ACAD SCI USA, V93, P6802, DOI 10.1073/pnas.93.13.6802; THIEN FCK, 1995, PROSTAG LEUKOTR ESS, V52, P271, DOI 10.1016/0952-3278(95)90027-6; TILLY BC, 1990, BIOCHEM J, V266, P235, DOI 10.1042/bj2660235; VITALE N, 1994, BIOCHEM J, V300, P217, DOI 10.1042/bj3000217; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Werle E, 1936, BIOCHEM Z, V288, P292; YAMASHITA M, 1991, P NATL ACAD SCI USA, V88, P11515, DOI 10.1073/pnas.88.24.11515	30	10	10	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2249	2255		10.1074/jbc.273.4.2249	http://dx.doi.org/10.1074/jbc.273.4.2249			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442068	Green Published, hybrid			2022-12-25	WOS:000071595200057
J	Cram, EJ; Ramos, RA; Wang, EC; Cha, HH; Nishio, Y; Firestone, GL				Cram, EJ; Ramos, RA; Wang, EC; Cha, HH; Nishio, Y; Firestone, GL			Role of the CCAAT/enhancer binding protein-alpha transcription factor in the glucocorticoid stimulation of p21(waf1/cip1) gene promoter activity in growth-arrested rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; STEROID-HORMONE RECEPTORS; CYCLE PROGRESSION; NUCLEAR RECEPTORS; LIVER DEVELOPMENT; EXPRESSION; ACTIVATION; PROLIFERATION; INDUCTION; C/EBP	The preceding paper (Cha, H. H., Cram, E. J., Wang, E. C., Huang, A. J., Kasler, R. G., and Firestone, G. L. (1998) J. Biol. Chem. 273, 0000-0000(478563) defined a glucocorticoid responsive region within the promoter of the p21 CDK inhibitor gene that contains a putative DNA-binding site for the transcription factor CCAAT/enhancer binding protein-alpha (C/EBP alpha). Wild type rat BDS1 hepatoma cells as well as as4 hepatoma cells, which: express antisense sequences to C/EBP alpha and ablate its protein production, were utilized to investigate the role of this transcription factor in the glucocorticoid regulation of p21 gene expression, The stimulation of p21 protein levels and promoter activity, as well as inhibition of CDR2-mediated retinoblastoma protein phosphorylation, by the synthetic glucocorticoid, dexamethasone, required the expression of C/EBP alpha. Overexpression of C/EBP alpha in as4 cells rescued the dexamethasone responsiveness of the p21 promoter, Site-directed mutagenesis of the p21 promoter revealed that dexamethasone stimulation of p21 promoter activity required the C/EBP consensus DNA-binding site, Furthermore, in glucocorticoid receptor-defective EDR1 hepatoma cells, dexamethasone failed to stimulate C/EBP alpha and p21 protein expression and promoter activities, Our results have established a functional link between the glucocorticoid receptor signaling pathway that mediates a G(1) cell cycle arrest of rat hepatoma cells and the transcriptional control of p21 by a cascade that requires the steroid induction of C/EBP alpha gene expression.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.							Altucci L, 1996, ONCOGENE, V12, P2315; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BAUMANN H, 1991, J BIOL CHEM, V266, P20390; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; CASTELLANO TJ, 1978, ENDOCRINOLOGY, V102, P1107, DOI 10.1210/endo-102-4-1107; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COOK PW, 1988, J BIOL CHEM, V263, P19296; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DIEHL AM, 1994, GASTROENTEROLOGY, V106, P1625, DOI 10.1016/0016-5085(94)90420-0; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDIERY WS, 1995, CANCER RES, V55, P2910; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FULLER PJ, 1991, FASEB J, V5, P3092, DOI 10.1096/fasebj.5.15.1743440; GOYA L, 1993, MOL ENDOCRINOL, V7, P1121, DOI 10.1210/me.7.9.1121; GOYA L, 1991, CANCER LETT, V58, P211, DOI 10.1016/0304-3835(91)90103-O; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HABER BA, 1993, J CLIN INVEST, V91, P1319, DOI 10.1172/JCI116332; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HENDERSON IC, 1974, ENDOCRINOLOGY, V94, P1637, DOI 10.1210/endo-94-6-1637; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUANG DP, 1984, CANCER RES, V44, P2976; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; LEGRAVEREND C, 1993, NUCLEIC ACIDS RES, V21, P1735, DOI 10.1093/nar/21.8.1735; Li XS, 1996, CANCER RES, V56, P5055; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LOEB JN, 1979, ENDOCRINOLOGY, V104, P1003, DOI 10.1210/endo-104-4-1003; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; Osada S, 1996, J BIOL CHEM, V271, P3891; PETERSEN JA, 1972, P NATL ACAD SCI USA, V69, P571, DOI 10.1073/pnas.69.3.571; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245	56	108	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2008	2014		10.1074/jbc.273.4.2008	http://dx.doi.org/10.1074/jbc.273.4.2008			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442037	hybrid			2022-12-25	WOS:000071595200026
J	Dichek, HL; Brecht, W; Fan, JL; Ji, ZS; McCormick, SPA; Akeefe, H; Conzo, L; Sanan, DA; Weisgraber, KH; Young, SG; Taylor, JM; Mahley, RW				Dichek, HL; Brecht, W; Fan, JL; Ji, ZS; McCormick, SPA; Akeefe, H; Conzo, L; Sanan, DA; Weisgraber, KH; Young, SG; Taylor, JM; Mahley, RW			Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; TRIGLYCERIDE LIPASE; LIVER LIPASE; RAT-LIVER; POLYACRYLAMIDE GELS; ENDOTHELIAL LIPASE; ADRENAL-GLAND; CDNA SEQUENCE; SR-BI; PLASMA	To determine the mechanisms by which human hepatic lipase (HL) contributes to the metabolism of apolipoprotein (ape) B-containing lipoproteins and high density Lipoproteins (HDL) in, vivo, we developed and characterized HL transgenic mice, HL was localized by immunohistochemistry to the liver and to the adrenal cortex, In hemizygous (hHLTg(+/0)) and homozygous (hHLTg(+/+)) mice, postheparin plasma HL activity increased by 25- and 60-fold and plasma cholesterol levels decreased by 80% and 85%, respectively. In mice fed a high fat, high cholesterol diet to increase endogenous apoB-containing lipoproteins, plasma cholesterol decreased 33% (hHLTg(+/0)) and 75% (hHLTg+/+). Both apoB- containing remnant lipoproteins and HDL were reduced, To extend this observation, the HL transgene was expressed in human apoB transgenic (huBTg) and apoE-deficient (apoE(-/-)) mice, both of which have high plasma levels of apoB-containing lipoproteins. (Note that the huBTg mice that were used in these studies were all hemizygous for the human apoB gene.) In both the huBTg,hHLTg(+/0) mice and the apoE(-/-),hHLTg(+/0) mice, plasma cholesterol decreased by 50%. This decrease was reflected in both the apoB-containing and the HDL fractions. To determine if HL catalytic activity is required for these decreases, we expressed catalytically inactive HL (HL-CAT) in QpoE(-/-) mice, The postheparin:plasma HL activities were similar in the apoE(-/-) and the apoE(-/-), HL-CAT(+/0) mice, reflecting the activity of the endogenous mouse HL and confirming that the HL CAT was catalytically inactive, However, the postheparin plasma HL activity was 20-fold higher in the apoE(-/-),hHLTg(+/0) mice, indicating expression of the active human HL, Immunoblotting demonstrated high levels of human HL in postheparin plasma of both apoE(-/-),hHLTg(+/0) and apoE(-/-), HL-CAT(+/0) mice, Plasma cholesterol and apoB-containing lipoprotein levels were similar to 60% lower in apoE(-/-), HL-CAT+/0 mice than in apoE(-/-) mice, However, the HDL were only minimally reduced. Thus,the catalytic activity of HL is critical for its effects on HDL but not for its effects on apoB-containing lipoproteins. These results provide evidence that HL can act as a ligand to remove apoB-containing lipoproteins from plasma.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mahley, RW (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Young, Stephen/0000-0001-7270-3176; Fan, Jianglin/0000-0002-1737-6130; McCormick, Sally/0000-0001-9857-0703	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633, R01HL051588, P01HL047660] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47660, HL41633, HL51588] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ApplebaumBowden D, 1996, J CLIN INVEST, V97, P799, DOI 10.1172/JCI118479; AUWERX JH, 1989, ARTERIOSCLEROSIS, V9, P319, DOI 10.1161/01.ATV.9.3.319; BAMBERGER M, 1983, J LIPID RES, V24, P869; Brand K, 1996, J LIPID RES, V37, P1213; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P161, DOI 10.1016/0021-9150(82)90136-8; Breedveld B, 1997, BIOCHEM J, V321, P425, DOI 10.1042/bj3210425; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BUSCH SJ, 1994, J BIOL CHEM, V269, P16376; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI SSY, 1994, J LIPID RES, V35, P848; COLLET X, 1990, BIOCHIM BIOPHYS ACTA, V1043, P301, DOI 10.1016/0005-2760(90)90031-R; CONNELLY PW, 1990, ARTERIOSCLEROSIS, V10, P40, DOI 10.1161/01.ATV.10.1.40; DAGGY BP, 1986, BIOCHIM BIOPHYS ACTA, V877, P252, DOI 10.1016/0005-2760(86)90302-4; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEMANT T, 1988, J LIPID RES, V29, P1603; DIARD P, 1994, BIOCHEM J, V299, P889, DOI 10.1042/bj2990889; DOOLITTLE MH, 1987, J LIPID RES, V28, P1326; FAN JL, 1994, P NATL ACAD SCI USA, V91, P8724, DOI 10.1073/pnas.91.18.8724; FAZIO S, 1992, J BIOL CHEM, V267, P6941; GAFNEY E, 1992, LAB METHODS HISTOTEC, P157; GOLDBERG IJ, 1982, J CLIN INVEST, V70, P1184, DOI 10.1172/JCI110717; GROOT PHE, 1983, BIOCHIM BIOPHYS ACTA, V751, P393, DOI 10.1016/0005-2760(83)90298-9; GROSSER J, 1981, J LIPID RES, V22, P437; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hayden M.R., 1991, CURRENT OPINION LIPI, V2, P104; HEGELE RA, 1993, ARTERIOSCLER THROMB, V13, P720, DOI 10.1161/01.ATV.13.5.720; HEGELE RA, 1991, BIOCHEM BIOPH RES CO, V179, P78, DOI 10.1016/0006-291X(91)91336-B; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOMANICS GE, 1995, J BIOL CHEM, V270, P2974, DOI 10.1074/jbc.270.7.2974; HORIE Y, 1992, J BIOL CHEM, V267, P1962; IVERIUS PH, 1985, AM J PHYSIOL, V249, pE107, DOI 10.1152/ajpendo.1985.249.1.E107; JACKSON RL, 1983, ENZYMES, V16, P141; JANSEN H, 1981, BIOCHEM J, V196, P739, DOI 10.1042/bj1960739; JANSEN H, 1978, BIOCHEM BIOPH RES CO, V85, P148, DOI 10.1016/S0006-291X(78)80022-9; JANSEN H, 1981, METABOLISM, V30, P428, DOI 10.1016/0026-0495(81)90175-X; JANSEN H, 1980, BIOCHEM BIOPH RES CO, V92, P53, DOI 10.1016/0006-291X(80)91518-1; JENSEN GL, 1982, BIOCHIM BIOPHYS ACTA, V710, P464, DOI 10.1016/0005-2760(82)90130-8; JI ZS, 1994, J BIOL CHEM, V269, P13429; Ji ZS, 1997, J BIOL CHEM, V272, P31285, DOI 10.1074/jbc.272.50.31285; Komaromy M, 1996, J BIOL CHEM, V271, P16906, DOI 10.1074/jbc.271.28.16906; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; Krapp A, 1996, J LIPID RES, V37, P926; KRUL ES, 1988, J LIPID RES, V29, P937; KUUSI T, 1979, BIOCHEM J, V181, P245, DOI 10.1042/bj1810245; KUUSI T, 1980, ATHEROSCLEROSIS, V36, P589, DOI 10.1016/0021-9150(80)90251-8; KUUSI T, 1979, FEBS LETT, V104, P384, DOI 10.1016/0014-5793(79)80858-3; LALOUEL JM, 1992, CURR OPIN LIPIDOL, V3, P86; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MORTIMER BC, 1993, CLIN EXP PHARMACOL P, V20, P51, DOI 10.1111/j.1440-1681.1993.tb01502.x; MURASE T, 1981, ATHEROSCLEROSIS, V39, P293, DOI 10.1016/0021-9150(81)90015-0; Nielsen LB, 1997, J BIOL CHEM, V272, P29752, DOI 10.1074/jbc.272.47.29752; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; PETERSON J, 1986, BIOCHIM BIOPHYS ACTA, V878, P65, DOI 10.1016/0005-2760(86)90344-9; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Sanan DA, 1997, J LIPID RES, V38, P1002; Schoonderwoerd K, 1996, BIOCHEM J, V318, P463, DOI 10.1042/bj3180463; SHIRAI K, 1981, BIOCHEM BIOPH RES CO, V100, P591, DOI 10.1016/S0006-291X(81)80217-3; STAHNKE G, 1987, DIFFERENTIATION, V35, P45, DOI 10.1111/j.1432-0436.1987.tb00150.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; Wang N, 1996, J BIOL CHEM, V271, P21001, DOI 10.1074/jbc.271.35.21001; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	70	97	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1896	1903		10.1074/jbc.273.4.1896	http://dx.doi.org/10.1074/jbc.273.4.1896			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442022	hybrid			2022-12-25	WOS:000071595200011
J	Johnston, DS; Wright, WW; Shaper, JH; Hokke, CH; Van den Eijnden, DH; Joziasse, DH				Johnston, DS; Wright, WW; Shaper, JH; Hokke, CH; Van den Eijnden, DH; Joziasse, DH			Murine sperm-zona binding, a fucosyl residue is required for a high affinity sperm-binding ligand - A second site on sperm binds a nonfucosylated, beta-galactosyl-capped oligosaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PELLUCIDA GLYCOPROTEIN ZP3; O-LINKED OLIGOSACCHARIDES; MOUSE SPERM; RECEPTOR ACTIVITY; ENZYMATIC-SYNTHESIS; IN-VITRO; IDENTIFICATION; FERTILIZATION; ADHESION; PROTEIN	An essential initial step in murine fertilization is the binding of acrosome-intact sperm to specific O-linked oligosaccharides on zona pellucida glycoprotein 3. While there is agreement on the primary role of O-linked glycans in this process, there is a lack of consensus on both the terminal monosaccharide(s) required for a functional sperm binding site and the corresponding protein on the sperm cell surface that recognizes this ligand. Much current debate centers on an essential role for either a terminal N-acetylglucosaminyl or, alternatively,: a terminal alpha-galactosyl residue, To gain insight into the terminal saccharides required to form a functional,sperm-binding ligand, dose-response curves were generated for a series of related tri-and tetrasaccharides to evaluate their relative effectiveness to competitively inhibit the in vitro binding of murine sperm to zona pellucida-enclosed eggs, A GlcNAc-capped trisaccharide, GlcNAc beta 1,4GlcNAc beta 1,4GlcNAc,was inactive (1-72 mu M range), In contrast, a beta 4-galactosyl-capped trisaccharide (Gal beta 1,BGIcNA alpha 1, 4GlcNAc) and an alpha 3-galactosyl-capped trisaccharide (Gal alpha 1,3Gal beta 1,4 GlcNAc) inhibited sperm-zona binding with low or moderate affinity (ED50 = 42 mu M and 5.5 mu M, respectively), The addition of an alpha 3-fucosyl residue to each of these two competitive inhibitors, forming Gal beta 1,4[Fuc alpha 1,3] GlcNAc beta 1,4GlcNAc or Gal alpha 1,3Gal beta 1, B[Fuc alpha 1,3]Glc NAc, resulted in ligands with 85- and 12-fold higher affinities for sperm, respectively (ED50 = 500 and 430 nM), Thus, the presence of a fucosyl residue appears to be obligatory for an oligosaccharide to bind sperm with high affinity, Last, mixing experiments with pairs of competitive inhibitors suggest that murine sperm-zona binding is mediated by two independent oligosaccharide-binding sites on sperm, The first (apparently high affinity) site binds both the alpha 3-galactosyl-capped trisaccharide and the two fucosylated tetrasaccharides. The second (apparently low affinity) site binds a nonfucosylated beta-galactosyl-capped trisaccharide.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Cell Struct & Funct Lab, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Div Reprod Biol, Baltimore, MD 21205 USA; Free Univ Amsterdam, Dept Med Chem, NL-1081 BT Amsterdam, Netherlands	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Vrije Universiteit Amsterdam	Shaper, JH (corresponding author), Johns Hopkins Univ, Sch Med, Ctr Oncol, Cell Struct & Funct Lab, Room 1-127,600 N Wolfe St, Baltimore, MD 21287 USA.	jshaper@welchlink.welch.jhu.edu	Hokke, Cornelis Hendrik/AAQ-4712-2021	Hokke, Cornelis Hendrik/0000-0003-3545-7804	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017989, R01HD006308, R23HD017989] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NICHD NIH HHS [P30-HD06308, HD17989] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABDULLAH M, 1989, J CELL BIOL, V108, P367, DOI 10.1083/jcb.108.2.367; ABDULLAH M, 1991, MOL CELL BIOCHEM, V103, P155; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BLEIL JD, 1980, DEV BIOL, V76, P185, DOI 10.1016/0012-1606(80)90371-1; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BLEIL JD, 1988, P NATL ACAD SCI USA, V85, P6778, DOI 10.1073/pnas.85.18.6778; BLEIL JD, 1980, CELL, V20, P873, DOI 10.1016/0092-8674(80)90334-7; BOOKBINDER LH, 1995, SCIENCE, V269, P86, DOI 10.1126/science.7604284; BROOKS SA, 1995, HISTOCHEM J, V27, P689; CARDULLO RA, 1989, BIOCHEMISTRY-US, V28, P1611, DOI 10.1021/bi00430a028; CHENG A, 1994, J CELL BIOL, V125, P867, DOI 10.1083/jcb.125.4.867; COZENSROBERTS C, 1990, BIOPHYS J, V58, P841, DOI 10.1016/S0006-3495(90)82430-9; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FLORMAN HM, 1985, CELL, V41, P313, DOI 10.1016/0092-8674(85)90084-4; FLORMAN HM, 1982, DEV BIOL, V91, P121, DOI 10.1016/0012-1606(82)90015-X; Foster JA, 1997, J BIOL CHEM, V272, P12714, DOI 10.1074/jbc.272.19.12714; GOLUBOFF ET, 1995, MOL REPROD DEV, V40, P460, DOI 10.1002/mrd.1080400410; HAKOMORI SI, 1992, HISTOCHEM J, V24, P771, DOI 10.1007/BF01046348; Hokke CH, 1996, GLYCOCONJUGATE J, V13, P687, DOI 10.1007/BF00731458; JOHNSTON DS, 1995, DEV BIOL, V171, P224, DOI 10.1006/dbio.1995.1273; JOZIASSE DH, 1993, BIOCHEM BIOPH RES CO, V194, P358, DOI 10.1006/bbrc.1993.1828; JOZIASSE DH, 1990, EUR J BIOCHEM, V191, P75, DOI 10.1111/j.1432-1033.1990.tb19095.x; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; LIE JT, 1993, GLYCOCONJUGATE J, V10, P257, DOI 10.1007/BF01209920; Litscher ES, 1996, BIOCHEMISTRY-US, V35, P3980, DOI 10.1021/bi952722m; LITSCHER ES, 1995, BIOCHEMISTRY-US, V34, P4662, DOI 10.1021/bi00014a020; LOPEZ LC, 1985, J CELL BIOL, V101, P1501, DOI 10.1083/jcb.101.4.1501; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; Sears P, 1996, P NATL ACAD SCI USA, V93, P12086, DOI 10.1073/pnas.93.22.12086; Streit A, 1996, J NEUROCHEM, V66, P834; Thaler CD, 1996, J BIOL CHEM, V271, P23289, DOI 10.1074/jbc.271.38.23289; Thaler CD, 1996, MOL REPROD DEV, V45, P535, DOI 10.1002/(SICI)1098-2795(199612)45:4&lt;535::AID-MRD16&gt;3.0.CO;2-V; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Whitten WK, 1971, ADV BIOSCI, V6, P129, DOI DOI 10.1016/B978-0-08-017571-3.50013-9	36	110	114	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1888	1895		10.1074/jbc.273.4.1888	http://dx.doi.org/10.1074/jbc.273.4.1888			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442021	hybrid			2022-12-25	WOS:000071595200010
J	Kim, SO; Jiang, J; Yi, WS; Feng, GS; Frank, SJ				Kim, SO; Jiang, J; Yi, WS; Feng, GS; Frank, SJ			Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; GH RECEPTOR; IM-9 CELLS; IN-VIVO; PHOSPHORYLATION; JAK2	Growth hormone (GH) signaling requires activation of the GH receptor (GHR)-associated tyrosine kinase, JAK2. JAK2 activation by GH is believed to facilitate initiation of various pathways including the Ras, mitogen-activated protein kinase, STAT, insulin receptor substrate (IRS), and phosphatidylinositol 3-kinase systems. In the present study, we explore the biochemical and functional involvement of the Src homology 2 (SH2)-containing protein-tyrosine phosphatase, SHP-2, in GH signaling. GH stimulation of murine NIH 3T3-F442A fibroblasts, cells that homologously express GHRs, resulted in tyrosine phosphorylation of SHP-2. As assessed specifically by anti-SHP-2 coimmunoprecipitation and by affinity precipitation with a glutathione S-transferase fusion protein incorporating the SH2 domains of SHP-2, GI-I induced formation of a complex of tyrosine phosphoproteins including SHP-2, GHR, JAK2, and a glycoprotein with properties consistent with being a SIRP-alpha-like molecule. A reciprocal binding assay using IM-9 cells as a source of SHP-1 and SHP-2 revealed specific association of SHP-2 (but not SHP-1) with a glutathione S-transferase fusion incorporating GHR cytoplasmic domain residues 485-620, but only if the fusion was first rendered tyrosine-phosphorylated. GH-dependent tyrosine phosphorylation of SHP-2 was also observed in murine 32D cells (which lack IRS-1 and -2) stably transfected with the GHR. Further, GH-dependent anti-SHP-2 coimmunoprecipitation of the Grb2 adapter protein was detected in both 3T3-F442A and 32D-rGHR cells, indicating that biochemical involvement of SHP-2 in GH signaling may not require IRS-1 or -2. Finally, GH-induced transactivation of a c-Fos enhancer-driven luciferase reporter in GHR-and JAK2-transfected COS-7 cells was significantly reduced when a catalytically inactive SHP-2 mutant (but not wild-type SHP-2) was coexpressed; in contrast, expression of a catalytically inactive SHP-1 mutant allowed modestly enhanced GH-induced transactivation of the reporter in comparison with that found with expression of wildtype SHP-1, Collectively, these biochemical and functional data imply a positive role for SHP-2 in GH signaling.	Univ Alabama, DREB, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Adm Med Ctr, Birmingham, AL 35294 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Frank, SJ (corresponding author), Univ Alabama, DREB, Dept Med, Div Endocrinol & Metab, Room 756,UAB Stn, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu			NIDDK NIH HHS [DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R01DK046395, R29DK046395] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, J BIOL CHEM, V271, P29415, DOI 10.1074/jbc.271.46.29415; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COLOSI P, 1993, J BIOL CHEM, V268, P12617; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P2228, DOI 10.1210/en.135.5.2228; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FUHRER DK, 1995, J BIOL CHEM, V270, P24826, DOI 10.1074/jbc.270.42.24826; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; Gu HH, 1997, J BIOL CHEM, V272, P16421, DOI 10.1074/jbc.272.26.16421; Hackett RH, 1997, J BIOL CHEM, V272, P11128; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KHARITONENKOV A, 1995, J BIOL CHEM, V270, P29189, DOI 10.1074/jbc.270.49.29189; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LESNIAK MA, 1974, J BIOL CHEM, V249, P1661; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Plas DR, 1996, SCIENCE, V272, P1173, DOI 10.1126/science.272.5265.1173; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; Silva CM, 1996, MOL ENDOCRINOL, V10, P508, DOI 10.1210/me.10.5.508; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUCHI T, 1995, J BIOL CHEM, V270, P5631, DOI 10.1074/jbc.270.10.5631; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, J BIOL CHEM, V270, P14871, DOI 10.1074/jbc.270.25.14871; YAMAUCHI K, 1995, J BIOL CHEM, V270, P17716, DOI 10.1074/jbc.270.30.17716; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; Yi WS, 1996, MOL ENDOCRINOL, V10, P1425, DOI 10.1210/me.10.11.1425; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; Yu ZB, 1997, J BIOL CHEM, V272, P7519, DOI 10.1074/jbc.272.11.7519; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	69	131	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2344	2354		10.1074/jbc.273.4.2344	http://dx.doi.org/10.1074/jbc.273.4.2344			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442080	hybrid			2022-12-25	WOS:000071595200069
J	Rasmussen, CB; Hiner, ANP; Smith, AT; Welinder, KG				Rasmussen, CB; Hiner, ANP; Smith, AT; Welinder, KG			Effect of calcium, other ions, and pH on the reactions of barley peroxidase with hydrogen peroxide and fluoride - Control of activity through conformational change	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I FORMATION; HORSERADISH-PEROXIDASE; ARTHROMYCES-RAMOSUS; ANGSTROM RESOLUTION; PEANUT PEROXIDASE; SUBSTRATE-BINDING; FUNGAL PEROXIDASE; CRYSTAL-STRUCTURE; HEME CAVITY	Transient-state kinetic analysis of compound I formation for barley grain peroxidase (BP 1) has revealed properties that are highly unusual for a heme peroxidase but which may be relevant to its biological function. The enzyme shows very little reaction with H2O2 at pH > 5 and exhibited saturation kinetics at higher H2O2 concentrations (k(cat)(app) increases from 1.1 s(-1) at pH 4.5 to 4.5 s(-1) at pH 3.1 with an enzyme-linked pK(a) < 3.7 (Rasmussen, C. B., Bakovic, M., Welinder, K. G., and Dunford, H. B. (1993) FEES Lett. 321, 102-105)). In the present paper, it is shown that the presence of Ca2+ gives rise to biphasic kinetics for compound I formation, with a slow phase as described above and a fast phase that exhibits a second order rate constant more typical of a classical peroxidase (k(1)(app) = 1.5 x 10(7) M-1 s(-1), which is pH-independent between 3.3 and 5.0). The amount of enzyme reacting in the fast phase increases with Ca2+ concentration (K-d = 4 +/- 1 mM at pH 4.0), although it is also moderately inhibited by Cl-. The absorption spectrum of BP-1, which appears to be a five-coordinate high spin ferric in the resting state changes insignificantly in the presence of Ca2+. In the presence of Cl-, it becomes six-coordinate high spin (K-d approximately 60 mM at pH 4.0) but only if Ca2+ is also present. Fluoride binds to BP 1 with monophasic kinetics in the presence of 0-5 mM Ca2+. The activating effect of Ca2+ can be mimicked only by replacing it with Sr2+ and Ba2+ ions. Comparing these data with the crystal structure of the inactive neutral form of BP 1 (Henriksen, k, Welinder, K. G., and Gajhede, M. (1997) J. Biol. Chem. 273, 2241-2248) and similar data for wild-type and mutant peroxidases of plant and fungal origin suggests (i) a proton-induced conformational change from an inactive BP 1 at neutral pH to a low activity BP 1 form with a functional distal histidine and (ii) a Ca2+-induced slow conformational change (at least compared with compound I formation) of this low activity form to a high activity BP 1 with a typical peroxidase reactivity. BP 1 is the first example of a plant peroxidase whose activity can be reversibly controlled at the enzyme level by pH-and Ca2+-induced conformational changes.	Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, DK-1353 Copenhagen K, Denmark	University of Copenhagen	Welinder, KG (corresponding author), Univ Copenhagen, Inst Mol Biol, Dept Prot Chem, Oster Farimagsgade 2A, DK-1353 Copenhagen K, Denmark.	welinder@biobase.dk		Welinder, Karen Gjesing/0000-0002-5409-0131; Smith, Andrew/0000-0002-0926-1878				ANDERSEN MB, 1991, BIOCH MOL PHYSL ASPE, P169; BARBER KR, 1995, EUR J BIOCHEM, V232, P825, DOI 10.1111/j.1432-1033.1995.tb20879.x; Dalton DA., 1991, PEROXIDASES CHEM BIO, V2, P139; EDWARDS SL, 1990, J BIOL CHEM, V265, P2588; ERMAN JE, 1993, BIOCHEMISTRY-US, V32, P9798, DOI 10.1021/bi00088a035; FARHANGRAZI ZS, 1995, BIOCHEMISTRY-US, V34, P14970, DOI 10.1021/bi00046a003; FULOP V, 1994, STRUCTURE, V2, P201, DOI 10.1016/S0969-2126(00)00021-6; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Henriksen A, 1998, J BIOL CHEM, V273, P2241, DOI 10.1074/jbc.273.4.2241; HU CF, 1987, PHYSIOL PLANTARUM, V70, P99, DOI 10.1111/j.1399-3054.1987.tb08703.x; Jespersen HM, 1997, BIOCHEM J, V326, P305, DOI 10.1042/bj3260305; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; Kunishima N, 1996, FEBS LETT, V378, P291, DOI 10.1016/0014-5793(95)01458-6; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; MAKINO R, 1973, ARCH BIOCHEM BIOPHYS, V157, P3576; MILLER MA, 1994, NAT STRUCT BIOL, V1, P524, DOI 10.1038/nsb0894-524; MIYAKE C, 1991, PLANT CELL PHYSIOL, V32, P33; Neri F, 1997, BIOCHEMISTRY-US, V36, P8947, DOI 10.1021/bi970248+; NERI F, 1998, IN PRESS BIOCHEMISTR; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; RASMUSSEN CB, 1993, FEBS LETT, V321, P102, DOI 10.1016/0014-5793(93)80630-D; Rasmussen CB, 1997, PHYSIOL PLANTARUM, V100, P102, DOI 10.1034/j.1399-3054.1997.1000110.x; RASMUSSEN CB, 1995, BIOCHEMISTRY-US, V34, P4022, DOI 10.1021/bi00012a021; RASMUSSEN SK, 1991, PLANT MOL BIOL, V16, P317, DOI 10.1007/BF00020562; RodriguezLopez JN, 1996, J BIOL INORG CHEM, V1, P136, DOI 10.1007/s007750050032; RodriguezLopez JN, 1996, J BIOL CHEM, V271, P4023; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SHIRO Y, 1986, J BIOL CHEM, V261, P9382; SMITH AT, 1992, EUR J BIOCHEM, V207, P507, DOI 10.1111/j.1432-1033.1992.tb17077.x; Smulevich G, 1996, BIOCHEMISTRY-US, V35, P10576, DOI 10.1021/bi9605898; Sutherland GRJ, 1997, BIOCHEMISTRY-US, V36, P3654, DOI 10.1021/bi962195m; VITELLO LB, 1993, BIOCHEMISTRY-US, V32, P9807, DOI 10.1021/bi00088a036; Welinder K. G., 1996, PLANT PEROXIDASES BI, P173; WELINDER KG, PLANT PEROXIDASES BI, P35; Welinder KG, 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [DOI 10.1016/0959-440X(92)90230-5, 10.1016/0959-440x(92)90230-5]; WINK M, 1993, J EXP BOT, V44, P231; YONETANI T, 1987, J BIOL CHEM, V262, P9547	39	31	31	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2232	2240		10.1074/jbc.273.4.2232	http://dx.doi.org/10.1074/jbc.273.4.2232			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442066	hybrid			2022-12-25	WOS:000071595200055
J	Wen, Y; Edelman, JL; Kang, T; Zeng, NX; Sachs, G				Wen, Y; Edelman, JL; Kang, T; Zeng, NX; Sachs, G			Two functional forms of vascular endothelial growth factor receptor-2 Flk-1 mRNA are expressed in normal rat retina	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; PERMEABILITY FACTOR; CELL GROWTH; EPITHELIAL-CELLS; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; HYPOXIC INDUCTION; FACTOR FAMILY; FACTOR VEGF; ANGIOGENESIS	Vascular endothelial growth factor (VEGF) is an important mediator of ocular neovascularization by exerting its endothelial specific mitogenic effects through high affinity tyrosine kinase receptors. By screening a rat retina cDNA library, we have isolated a clone encoding the full-length prototypic form of the rat VEGF receptor-2/FLk-1, as well as a short form of the mRNA that encodes the complete seven N-terminal immunoglobulin-like extracellular ligand-binding domains, transmembrane region, NH2-terminal half of the intracellular kinase domain, and kinase insert domain but does not encode the COOH-terminal half of the intracellular kinase domain and carboxyl-terminal region. Both forms of mRNA are detected in rat retina, although the short form is expressed at a lower level. VEGF induced a biphasic increase of cytoplasmic calcium with both forms in RR 293 transfected cells, indicating that both forms of the VEGF receptor-2/Flk-1 are functional and that the COOH-terminal half of the intracellular kinase domain and carboxyl region of VEGF receptor-2/Flk-1 are not strictly necessary for either Ligand binding or this biological activity.	W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Los Angeles, CA 90073 USA; Allergan, Irvine, CA 92713 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; AbbVie; Allergan	Sachs, G (corresponding author), W Los Angeles Vet Affairs Med Ctr, Membrane Biol Lab, Dept Med, 11301 Wilshire Blvd,Bldg 113,Room 324, Los Angeles, CA 90073 USA.							ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BREIER G, 1992, DEVELOPMENT, V114, P521; BROCK TA, 1991, AM J PATHOL, V138, P213; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAVAGNA C, 1995, J BIOL CHEM, V270, P3165, DOI 10.1074/jbc.270.7.3165; LEE BS, 1991, J BIOL CHEM, V266, P11448; LEE CC, 1994, J BIOL CHEM, V269, P19457; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; McCoon PE, 1996, J BIOL CHEM, V271, P20119, DOI 10.1074/jbc.271.33.20119; MEAKIN SO, 1992, P NATL ACAD SCI USA, V89, P2374, DOI 10.1073/pnas.89.6.2374; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLER JW, 1994, AM J PATHOL, V145, P574; Mukhopadhyay D, 1996, BIOCHEM BIOPH RES CO, V229, P733, DOI 10.1006/bbrc.1996.1873; OELRICHS RB, 1993, ONCOGENE, V8, P11; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; PRINZ C, 1993, GASTROENTEROLOGY, V105, P449, DOI 10.1016/0016-5085(93)90719-S; REUBEN M, 1994, BBA-GENE STRUCT EXPR, V1219, P321, DOI 10.1016/0167-4781(94)90055-8; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shima DT, 1996, INVEST OPHTH VIS SCI, V37, P1334; SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; Soans C, 1996, J CELL BIOL, V135, P781, DOI 10.1083/jcb.135.3.781; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; TAKESHITA S, 1994, J CLIN INVEST, V93, P662, DOI 10.1172/JCI117018; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; THIEME H, 1995, DIABETES, V44, P98, DOI 10.2337/diabetes.44.1.98; WEN Y, 1995, GENE, V158, P269, DOI 10.1016/0378-1119(95)00168-6; YANG K, 1996, J NEUROSCI, V16, P6089	45	54	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2090	2097		10.1074/jbc.273.4.2090	http://dx.doi.org/10.1074/jbc.273.4.2090			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442048	hybrid			2022-12-25	WOS:000071595200037
J	Yamada, S; Yamane, Y; Tsuda, H; Yoshida, K; Sugahara, K				Yamada, S; Yamane, Y; Tsuda, H; Yoshida, K; Sugahara, K			A major common trisulfated hexasaccharide core sequence, hexuronic acid(2-sulfate)-glucosamine(N-sulfate)-iduronic acid-N-acetylglucosamine-glucuronic acid-glucosamine(N-sulfate), isolated from the low sulfated irregular region of porcine intestinal heparin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III-BINDING SITE; HUMAN-ENDOTHELIAL CELLS; PROTEIN LINKAGE REGION; GROWTH-FACTOR; FLAVOBACTERIUM-HEPARINUM; LIPOPROTEIN-LIPASE; MASS-SPECTROMETRY; MOUSE MASTOCYTOMA; OLIGOSACCHARIDES; TETRASACCHARIDES	The major structure of the low sulfated irregular region of porcine intestinal heparin was investigated by characterizing the hexasaccharide fraction prepared by extensive digestion of the highly sulfated region with Flavobacterium heparinase and subsequent size fractionation by gel chromatography, Structures of a tetrasaccharide, a pentasaccharide, and eight hexasaccharide components in this fraction, which accounted for approximately 19% (w/w) of the starting heparin representing the major oligosaccharide fraction derived from the irregular region, were determined by chemical and enzymatic analyses as well as H-1 NMR spectroscopy, Five compounds including one penta-and four hexasaccharides had hitherto unreported structures, The structure of the pentasaccharide with a glucuronic acid at the reducing terminus was assumed to be derived from the reducing terminus of a heparin glycosaminoglycan chain and may represent the reducing terminus exposed by a tissue endo-a-glucuronidase involved in the intracellular post-synthetic fragmentation of macromolecular heparin, Eight out of the 10 isolated oligosaccharides shared the trisaccharide sequence, -4IdceA alpha 1-4Glc-NAc alpha 1-4GlcAp beta 1-, and its reverse sequence, 4GlcA beta 1-4GlcNAc alpha 1-4IdceA alpha 1-, was not found, The latter has not been reported to date for heparin/heparan sulfate, indicating the substrate specificity of the D-glucuronyl C-5 epimerase, Furthermore, seven hexasaccharides shared the common trisulfated hexasaccharide core sequence Delta HexA(2-sulfate) alpha 1-4GlcN(N-sulfate) alpha 1-4IdceA alpha 1-4G1cNA alpha 1-4GlcA beta 1-4GlcN(N-sulfate) which contained the above trisaccharide sequence (Delta HexA, IdceA, GlcN, and GlcA represent 4-deoxy-alpha-L-threo-hex-4-enepyranosyluronic acid, L-iduronic acid, D-glucosamine, and D-glucuronic acid, respectively) and additional sulfate groups, The specificity of the heparinase used for preparation of the oligosaccharides indicates the occurrence of the common pentasulfated octasaccharide core sequence, -4GlcN(N-sulfate)alpha 1-4HexA(B-sulfate)1-4GlcN(N-sulfate) alpha 1-4IdceA alpha 1-4GlcNAc alpha 1-4GlcA beta 1-4 GlcN(N-sulfate)alpha 1-4HexA(2-sulfate)1-, where the central hexasaccharide is flanked by GlcN(N-sulfate) and HexA(2-sulfate) on the nonreducing and reducing sides, respectively, The revealed common sequence constituted a low sulfated trisaccharide representing the irregular region sandwiched by highly sulfated regions and should reflect the control mechanism of heparin biosynthesis.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan; Seikagaku Corp, Tokyo Res Inst, Tokyo 207, Japan	Kobe Pharmaceutical University; Seikagaku Corporation	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 658, Japan.	k-sugar@kobepharma-u.ac.jp						ALHAKIM A, 1990, ELECTROPHORESIS, V11, P23, DOI 10.1002/elps.1150110106; ATHA DH, 1984, P NATL ACAD SCI-BIOL, V81, P1030, DOI 10.1073/pnas.81.4.1030; Bame KJ, 1997, J BIOL CHEM, V272, P2245; BARZU T, 1989, J CELL PHYSIOL, V140, P538, DOI 10.1002/jcp.1041400320; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BOURIN MC, 1993, BIOCHEM J, V289, P313, DOI 10.1042/bj2890313; CHAI WG, 1995, CARBOHYD RES, V269, P139, DOI 10.1016/0008-6215(94)00349-K; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; FOLKMAN J, 1989, HEPARIN, P317; FREEMAN C, 1992, BIOCHEM J, V282, P899, DOI 10.1042/bj2820899; GALLAGHER JT, 1989, HEPARIN, P135; Hopwood J. J., 1989, HEPARIN CHEM BIOL PR, P191; HORNE A, 1992, CARBOHYD RES, V225, P43, DOI 10.1016/0008-6215(92)80038-3; JUHASZ P, 1995, CARBOHYD RES, V270, P131, DOI 10.1016/0008-6215(94)00012-5; KLAGSBRUN M, 1985, P NATL ACAD SCI USA, V82, P805, DOI 10.1073/pnas.82.3.805; LARNKJAER A, 1995, BIOCHEM J, V307, P205, DOI 10.1042/bj3070205; LARNKJAER A, 1995, CARBOHYD RES, V266, P37, DOI 10.1016/0008-6215(94)00247-D; LINDAHL U, 1983, J BIOL CHEM, V258, P9826; Lindahl U., 1989, HEPARIN, P159; LINHARDT RJ, 1992, J BIOL CHEM, V267, P2380; LINKER A, 1960, J BIOL CHEM, V235, P3061; LINKER A, 1984, CARBOHYD RES, V127, P75, DOI 10.1016/0008-6215(84)85107-1; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MACIAG T, 1984, SCIENCE, V225, P932, DOI 10.1126/science.6382607; MALLIS LM, 1989, ANAL CHEM, V61, P1453, DOI 10.1021/ac00188a030; MARCUM JA, 1989, HEPARIN, P275; MCLEAN MW, 1984, EUR J BIOCHEM, V145, P607, DOI 10.1111/j.1432-1033.1984.tb08600.x; MERCHANT ZM, 1985, BIOCHEM J, V229, P369, DOI 10.1042/bj2290369; NADER HB, 1990, J BIOL CHEM, V265, P16807; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; OGREN S, 1975, J BIOL CHEM, V250, P2690; OLDBERG A, 1980, BIOCHEMISTRY-US, V19, P5755, DOI 10.1021/bi00566a014; PARTHASARATHY N, 1994, J BIOL CHEM, V269, P22391; PERLIN AS, 1971, CARBOHYD RES, V18, P185, DOI 10.1016/S0008-6215(00)80341-9; PERVIN A, 1995, GLYCOBIOLOGY, V5, P83, DOI 10.1093/glycob/5.1.83; ROBINSON HC, 1978, J BIOL CHEM, V253, P6687; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; SUGAHARA K, 1995, J BIOL CHEM, V270, P22914, DOI 10.1074/jbc.270.39.22914; SUGAHARA K, 1992, J BIOL CHEM, V267, P1528; SUGAHARA K, 1987, ARCH BIOCHEM BIOPHYS, V258, P391, DOI 10.1016/0003-9861(87)90360-2; SUGAHARA K, 1994, CARBOHYD RES, V255, P165, DOI 10.1016/S0008-6215(00)90977-7; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; THUNBERG L, 1982, J BIOL CHEM, V257, P278; Toida T, 1996, J BIOL CHEM, V271, P32040, DOI 10.1074/jbc.271.50.32040; Tsuda H, 1996, J BIOL CHEM, V271, P10495, DOI 10.1074/jbc.271.18.10495; TSUKADA T, 1987, COMP BIOCHEM PHYS B, V86, P565, DOI 10.1016/0305-0491(87)90449-4; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAMADA SH, 1993, J BIOL CHEM, V268, P4780; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, P 10 INT S GLYC JER, P330	56	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1863	1871		10.1074/jbc.273.4.1863	http://dx.doi.org/10.1074/jbc.273.4.1863			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442018	hybrid			2022-12-25	WOS:000071595200007
J	Feng, L; Wang, B; Jong, A				Feng, L; Wang, B; Jong, A			Saccharomyces cerevisiae Cdc6 stimulates Abf1 DNA binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST-CELL CYCLE; BUDDING YEAST; FACTOR-I; S-PHASE; REPLICATION; PROTEIN; INITIATION; GENE; SEQUENCE	In budding yeast Saccharomyces cerevisiae, an ARS binding factor 1 (Abf1) binds to the sequence-specific DNA element involved in DNA replication and transcription, We describe in this study how yeast Cdc6 protein stimulates Abf1 protein DNA binding activities, The Abf1 binding activity was reduced approximately 20-fold in a cdc6-1 mutant than in the wild-type strain, Introducing a copy of the wild-type CDC6 gene into the cdc6-1 mutant strain restored the Abf1 DNA binding activity, We demonstrated that recombinant Abf1 binds to ARSI in vitro, and its DNA binding activity can be highly stimulated by the addition of a fusion glutathione S-transferase (GST)-Cdc6 protein, Deletion analysis revealed that the stimulating region is located at the amino terminus of the Cdc6 protein, However, we could not find the direct physical interaction between Cdc6 and Abf1., Instead, we found that the GST-Cdc6 can compete with distamycin A for binding to the DNA molecule, As distamycin A is a specific reagent that binds noncovalently to DNA at (A + T)-rich tracks, the stimulation of Abf1 DNA binding activity may be mediated by the Cdc6/DNA interaction, Our results favor a hypothesis that Cdc6 may function as an architectural factor in the as sembly of a functional initiation replication complex.	Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California	Jong, A (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Hematol Oncol, 4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NIGMS NIH HHS [GM 48492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Detweiler CS, 1997, J CELL SCI, V110, P753; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DORN A, 1992, EMBO J, V11, P279, DOI 10.1002/j.1460-2075.1992.tb05050.x; EISENBERG S, 1988, P NATL ACAD SCI USA, V85, P743, DOI 10.1073/pnas.85.3.743; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; Jong A, 1996, DNA CELL BIOL, V15, P883, DOI 10.1089/dna.1996.15.883; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KORNBERG A, 1992, DNA REPLICATION, P451; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; RHODE PR, 1989, GENE DEV, V3, P1926, DOI 10.1101/gad.3.12a.1926; RHODE PR, 1992, MOL CELL BIOL, V12, P1064, DOI 10.1128/MCB.12.3.1064; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; VENDITTI P, 1994, BBA-GENE STRUCT EXPR, V1219, P677, DOI 10.1016/0167-4781(94)90227-5; ZHOU C, 1989, J BIOL CHEM, V264, P9022; ZHOU C, 1990, J BIOL CHEM, V265, P19904	32	6	7	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1298	1302		10.1074/jbc.273.3.1298	http://dx.doi.org/10.1074/jbc.273.3.1298			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430660	hybrid			2022-12-25	WOS:000071411500007
J	Gong, JG; Ko, TC; Brattain, MG				Gong, JG; Ko, TC; Brattain, MG			Disruption of fibronectin binding to the alpha(5)beta(1) integrin stimulates the expression of cyclin-dependent kinases and DNA synthesis through activation of extracellular signal-regulated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANCHORAGE-INDEPENDENT GROWTH; COLLAGENASE GENE-EXPRESSION; CELL-CYCLE; TRANSFORMED PHENOTYPE; POTENTIAL MEDIATOR; PROTEIN; RECEPTOR; INHIBITOR; MATRIX; FIBROBLASTS	The alpha(5) alpha(1) integrin, a fibronectin receptor, has been implicated in the control of cell growth and the regulation of gene expression. We report that disruption of ligation between alpha(5) alpha(1) and fibronectin by integrin alpha(5) subunit or fibronectin monoclonal antibodies stimulated DNA synthesis in growth-arrested FET human colon carcinoma cells. This stimulation only occurred when monoclonal antibody was added in the early G(1) phase of the cell cycle after release from quiescence by fresh medium. Stimulation of DNA synthesis by alpha(5) or fibronectin antibody was concentration- and time-dependent. FET cells expressed alpha(4) beta(1) integrin (another fibronectin receptor); however, addition of anti-human integrin alpha(4) monoclonal antibody had no effect on DNA synthesis. Treatment with alpha(5) monoclonal antibody led to a marked increase in the expression of CDK4 in G(1) phase of the cell cycle and consequently increased the phosphorylation of retinoblastoma protein, alpha(5) monoclonal antibody treatment increased both cyclin A- and cyclin E-associated kinase activity which was accompanied by increased protein levels of CDK2 and cyclin A. Western blotting of immunoprecipitates demonstrated increased CDK2-cyclin E and CDK2-cyclin A complexes in cells treated with alpha(5) monoclonal antibody. Furthermore, disruption of alpha(5) alpha(1)/fibronectin ligation activated mitogen-activated protein kinase p44 and p42 (extracellular signal-regulated kinase 1 and 2). Pretreatment of the cells with a specific inhibitor of MEK-1, PD98059, blocked the alpha(5) monoclonal antibody-induced mitogen-activated protein kinase activity. In addition PD98059 prevented alpha(5) monoclonal antibody-induced DNA synthesis. Since alpha(5) alpha(1) ligation to fibronectin is associated with decreased growth parameters, our results indicate that ligation of alpha(5) alpha(1) integrin to fibronectin results in suppressed mitogen-activated protein kinase activity which in turn inhibits cyclin-dependent kinase activity in growth-arrested cells.	Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Brattain, MG (corresponding author), Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA.				NCI NIH HHS [CA64191, CA 38173, CA50457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050457, R01CA038173, R37CA038173, K08CA064191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BURRIDGE K, 1989, BIOESSAYS, V10, P104, DOI 10.1002/bies.950100403; BURRIDGE K, 1984, NATURE, V308, P744, DOI 10.1038/308744a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Day ML, 1997, J BIOL CHEM, V272, P8125, DOI 10.1074/jbc.272.13.8125; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Gong JG, 1997, CELL GROWTH DIFFER, V8, P83; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUADAGNO TM, 1991, J CELL BIOL, V115, P1419, DOI 10.1083/jcb.115.5.1419; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HAN EKH, 1993, J CELL BIOL, V122, P461, DOI 10.1083/jcb.122.2.461; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KATO J, 1993, GENE DEV, V7, P331; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUHISA T, 1981, EXP CELL RES, V135, P393, DOI 10.1016/0014-4827(81)90176-2; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MULDER KM, 1989, J CELL PHYSIOL, V138, P450, DOI 10.1002/jcp.1041380303; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTSUKA H, 1976, J CELL PHYSIOL, V87, P213, DOI 10.1002/jcp.1040870209; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; SCHREINER C, 1991, CANCER RES, V51, P1738; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SYMINGTON BE, 1995, BIOCHEM BIOPH RES CO, V208, P126, DOI 10.1006/bbrc.1995.1314; SYMINGTON BE, 1992, J BIOL CHEM, V267, P25744; SYMINGTON BE, 1990, CELL REGUL, V1, P637, DOI 10.1091/mbc.1.9.637; TREMBLE P, 1994, MOL BIOL CELL, V5, P439, DOI 10.1091/mbc.5.4.439; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; VARRER JA, 1995, MOL BIOL CELL, V6, P725; VUORI K, 1993, J BIOL CHEM, V268, P21459; WANG DH, 1995, J CELL PHYSIOL, V164, P499, DOI 10.1002/jcp.1041640308; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	57	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1662	1669		10.1074/jbc.273.3.1662	http://dx.doi.org/10.1074/jbc.273.3.1662			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430710	hybrid			2022-12-25	WOS:000071411500057
J	Kim, E; DeMarco, SJ; Marfatia, SM; Chishti, AH; Sheng, M; Strehler, EE				Kim, E; DeMarco, SJ; Marfatia, SM; Chishti, AH; Sheng, M; Strehler, EE			Plasma membrane Ca2+ ATPase isoform 4b binds to membrane-associated guanylate kinase (MAGUK) proteins via their PDZ (PSD-95/Dlg/ZO-1) domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; NMDA RECEPTOR SUBUNITS; CALCIUM-PUMP; MONOCLONAL-ANTIBODIES; MESSENGER-RNAS; PSD-95 FAMILY; HUMAN HOMOLOG; RAT-BRAIN; JUNCTIONS; CELLS	Plasma membrane Ca2+ ATPases are P-type pumps important for intracellular Ca2+ homeostasis. The extreme C termini of alternatively spliced "b"-type Ca2+ pump isoforms resemble those of K+ channels and N-methyl-D-aspartate receptor subunits that interact with channel-clustering proteins of the membrane-associated guanylate kinase (MAGUK) family via PDZ domains, Yeast two-hybrid assays demonstrated strong interaction of Ca2+ pump 4b with the PDZ1+2 domains of several mammalian MAGUKs. Pump 4b and PSD-95 could be co-immunoprecipitated from COS-7 cells overexpressing these proteins. Surface plasmon resonance revealed that a C-terminal pump 4b peptide interacted with the PDZ1+2 domains of hDlg with nanomolar affinity (K-D = 1.6 nm), whereas binding to PDZ3 was in the micromolar range (K-D = 1.2 mu M). In contrast, the corresponding C-terminal peptide of Ca2+ pump 2b interacted weakly with PDZ1+2 and not at all with PDZ3 of hDlg. Ca2+ pump 4b bound strongly to PDZ1+2+3 of hDlg on filter assays, whereas isoform 2b bound weakly, and the splice variants 2a and 4a failed to bind. Together, these data demonstrate a direct physical binding of Ca2+ pump isoform 4b to MAGUKs via their PDZ domains and reveal a novel role of alternative splicing within the family of plasma membrane Ca2+ pumps. Alternative splicing may dictate their specific interaction with PDZ domain-containing proteins, potentially influencing their localization and incorporation into functional multiprotein complexes at the plasma membrane.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Mol Neurosci, Rochester, MN 55905 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurobiol, Boston, MA 02114 USA; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Tumor Cell Biol Lab, Boston, MA 02135 USA	Mayo Clinic; Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; St. Elizabeth's Medical Center; Tufts University	Strehler, EE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Program Mol Neurosci, Rochester, MN 55905 USA.		Kim, Eunjoon/C-1566-2011		NATIONAL CANCER INSTITUTE [P01CA066263] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BORKE JL, 1987, J CLIN INVEST, V80, P1225, DOI 10.1172/JCI113196; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BRANDT P, 1992, J BIOL CHEM, V267, P4376; Brandt PC, 1996, GLYCOBIOLOGY, V6, P665, DOI 10.1093/glycob/6.7.665; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; ENYEDI A, 1991, J BIOL CHEM, V266, P8952; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; Fischer R, 1996, BIOTECHNIQUES, V21, P292; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; Hillman DE, 1996, NEUROSCIENCE, V72, P315, DOI 10.1016/0306-4522(95)00518-8; HOWARD A, 1993, AM J PHYSIOL, V265, pG917, DOI 10.1152/ajpgi.1993.265.5.G917; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lue RA, 1996, J CELL BIOL, V135, P1125, DOI 10.1083/jcb.135.4.1125; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; MONTEITH GR, 1995, CELL CALCIUM, V18, P459, DOI 10.1016/0143-4160(95)90009-8; Niethammer M, 1996, J NEUROSCI, V16, P2157; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1994, J BIOL CHEM, V269, P32022; Stauffer TP, 1997, BRAIN RES, V748, P21, DOI 10.1016/S0006-8993(96)01282-6; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; STREHLER EE, 1991, J MEMBRANE BIOL, V120, P1, DOI 10.1007/BF01868586; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Verma AK, 1996, J BIOL CHEM, V271, P3714; ZACHARIAS DA, 1995, MOL BRAIN RES, V28, P263, DOI 10.1016/0169-328X(94)00215-Z	49	140	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1591	1595		10.1074/jbc.273.3.1591	http://dx.doi.org/10.1074/jbc.273.3.1591			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430700	hybrid			2022-12-25	WOS:000071411500047
J	Nishimura, N; Harada-Shiba, M; Tajima, S; Sugano, R; Yamamura, T; Qiang, QZ; Yamamoto, A				Nishimura, N; Harada-Shiba, M; Tajima, S; Sugano, R; Yamamura, T; Qiang, QZ; Yamamoto, A			Acquisition of secretion of transforming growth factor-beta 1 leads to autonomous suppression of scavenger receptor activity in a monocyte-macrophage cell line, THP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TUMOR-NECROSIS-FACTOR; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MOLECULAR-WEIGHT COMPLEX; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-E; INTERFERON-GAMMA; FACTOR-BETA; FOAM CELLS; ATHEROSCLEROTIC LESIONS	Macrophage cells derived from the human monocytic leukemia cell line, THP-1, accumulate esterified cholesterol when cultivated in the presence of acetylated low density lipoprotein (Ac-LDL) through scavenger receptors (ScR). In the present study, we isolated a subtype of THP-1 cells that failed to accumulate esterified cholesterol when cultivated in the presence of Ac-LDL. The cells had negligible amounts of cell association and degradation of Ac-LDL compared with the parent THP-1 cells. The subtype THP-1 cells did not express ScR mRNA as well as that of lipoprotein lipase. In contrast, the expression of apolipoprotein E mRNA was greater than that found in parent THP-1 cells. The culture medium of subtype THP-1 cells treated with 12-O-tetradecanoylphorbol-13-acetate inhibited the uptake of Ac-LDL and the expression of ScR in parent THP-1 cells. After a 48-h incubation in the culture medium containing 12-O-tetradecanoylphorbol-13-acetate, the culture medium of differentiated subtype THP-1 cells contained 6.9 ng/ml transforming growth factor (TGF)-beta 1, while that of parent THP-1 cells secreted below detection level, which was less than 3 ng/ml. This inhibitory effect of the conditioned medium on the expression of ScR in parent THP-1 cells was abolished by pretreatment of the culture medium with anti-TGF-beta 1 antibodies. Parent THP-1 cells expressed as much TGF-beta 1 mRNA as sTHP-1 cells after stimulation of differentiation. Although the precursor forms of TGF-beta 1 that were synthesized in both parent and subtype THP-1 cells were of similar size and were expressed at similar levels, latent TGF-beta 1-binding protein, which is necessary for the secretion of TGF-beta 1, could only be co-immunoprecipitated with antiTGF-beta 1 antibody from subtype THP-1 cells. This suggests that subtype THP-1 cells secrete TGF-beta 1 into the medium by forming a functional complex with the latent TGF-beta 1-binding protein. We conclude that subtype THP-1 cells could not take up Ac-LDL because ScR was inhibited (leading to a loss of function) caused by the secreted TGF-beta 1.	Natl Cardiovasc Ctr, Res Inst, Dept Etiol & Pathophysiol, Osaka 565, Japan; Natl Cardiovasc Ctr, Inst Prot Res, Osaka 565, Japan	National Cerebral & Cardiovascular Center - Japan; National Cerebral & Cardiovascular Center - Japan	Harada-Shiba, M (corresponding author), Case Western Reserve Univ, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.							AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BANKA CL, 1991, J LIPID RES, V32, P35; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BEKSAC M, 1993, LEUKEMIA, V7, P1773; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BOTTALICO LA, 1991, J BIOL CHEM, V266, P22866; BRESLOW JL, 1982, J BIOL CHEM, V257, P4639; BROWN MS, 1980, J BIOL CHEM, V255, P9344; CAVAILLON JM, 1994, BIOMED PHARMACOTHER, V48, P445, DOI 10.1016/0753-3322(94)90005-1; CHAIT A, 1982, J CLIN INVEST, V69, P490, DOI 10.1172/JCI110473; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINGOLD KR, 1994, ARTERIOSCLER THROMB, V14, P1866, DOI 10.1161/01.ATV.14.11.1866; FOGELMAN AM, 1981, J LIPID RES, V22, P1131; FONG LG, 1990, J BIOL CHEM, V265, P11751; FREEMAN M, 1991, P NATL ACAD SCI USA, V88, P4931, DOI 10.1073/pnas.88.11.4931; FURUYA M, 1991, BIOCHEM BIOPH RES CO, V177, P927, DOI 10.1016/0006-291X(91)90627-J; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDBERG DI, 1987, BIOCHEM BIOPH RES CO, V142, P1, DOI 10.1016/0006-291X(87)90443-8; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; HARA H, 1987, BIOCHEM BIOPH RES CO, V146, P802, DOI 10.1016/0006-291X(87)90601-2; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOLVOET P, 1994, J CLIN INVEST, V93, P89, DOI 10.1172/JCI116988; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; Hulten LM, 1996, J CLIN INVEST, V97, P461, DOI 10.1172/JCI118436; JONASSON L, 1990, BIOCHIM BIOPHYS ACTA, V1053, P43, DOI 10.1016/0167-4889(90)90024-8; KAFONEK SD, 1993, ATHEROSCLEROSIS, V102, P23, DOI 10.1016/0021-9150(93)90081-5; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAS C, 1990, J IMMUNOL, V145, P1415; LUOMA J, 1994, J CLIN INVEST, V93, P2014, DOI 10.1172/JCI117195; MACKAY AG, 1990, BIOCHEM J, V269, P123, DOI 10.1042/bj2690123; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MENJU M, 1989, J BIOCHEM-TOKYO, V106, P505, DOI 10.1093/oxfordjournals.jbchem.a122882; MIYAZONO K, 1991, EMBO J, V10, P1091, DOI 10.1002/j.1460-2075.1991.tb08049.x; MIYAZONO K, 1993, GASTROENTEROL JPN, V28, P81; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; OKADA F, 1989, J BIOCHEM-TOKYO, V106, P304, DOI 10.1093/oxfordjournals.jbchem.a122849; REYNOLDS GD, 1985, AM J PATHOL, V121, P200; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SPARKS RL, 1992, J CELL PHYSIOL, V150, P568, DOI 10.1002/jcp.1041500318; STEPHAN ZF, 1993, J LIPID RES, V34, P325; SUGA S, 1992, J CLIN INVEST, V90, P1145, DOI 10.1172/JCI115933; TAJIMA S, 1985, BIOCHEM BIOPH RES CO, V126, P526, DOI 10.1016/0006-291X(85)90637-0; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; TSUCHIYA S, 1982, CANCER RES, V42, P1530; VANDERMEIDE PH, 1991, J IMMUNOASSAY, V12, P65, DOI 10.1080/01971529108055057; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; VIA DP, 1989, J LIPID RES, V30, P1515; WAKEFIELD LM, 1988, J BIOL CHEM, V263, P7646; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; YAMAMOTO A, 1986, ATHEROSCLEROSIS, V106, P505; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028; ZUCKERMAN SH, 1992, ATHEROSCLEROSIS, V96, P203, DOI 10.1016/0021-9150(92)90066-P	60	29	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1562	1567		10.1074/jbc.273.3.1562	http://dx.doi.org/10.1074/jbc.273.3.1562			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430696	hybrid			2022-12-25	WOS:000071411500043
J	Park, MH; Joe, YA; Kang, KR				Park, MH; Joe, YA; Kang, KR			Deoxyhypusine synthase activity is essential for cell viability in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-5A; PROTEIN-SYNTHESIS; HYPUSINE MODIFICATION; SHUTTLE VECTORS; AEROBIC GROWTH; FACTOR EIF-5A; RAT TESTIS; HELA-CELLS; PURIFICATION; GENE	Deoxyhypusine synthase catalyzes the first step in the posttranslational synthesis of an unusual amino acid, hypusine (N-epsilon-(4-amino-2-hydroxybutyl)lysine), in the eukaryotic translation initiation factor 5A (eIF 5A) precursor protein, The null mutation in the single copy gene, gamma DHS, encoding deoxyhypusine synthase results in the loss of viability in the yeast Saccharomyces cerevisiae. Upon depletion of deoxyhypusine synthase, and consequently of eIF-5A, cessation of growth was accompanied by a marked enlargement of cells, suggesting a defect in cell cycle progression or in cell division. Two residues of the yeast enzyme, Lys(308) and Lys(350), corresponding to Lys(287) and Lys(329), respectively, known to be critical for the activity of the human enzyme, were targeted for site-directed mutagenesis, The chromosomal gamma dhs null mutation was complemented by the plasmid-borne gamma DHS wild-type gene, but not by mutated genes encoding inactive proteins, including that with Lys(350) --> Arg substitution or with substitutions at both Lys(308) and Lys(350). The mutated gene gamma dhs(K308R) encoding a protein with diminished activities (<1% of wild type) could support growth but only to a very limited extent, These findings provide strong evidence that the hypusine modification is indeed essential for the survival of S. cerevisiae and imply a vital function for eIF-5A in all eukaryotes.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Park, MH (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, Bldg 30,Rm 211, Bethesda, MD 20892 USA.	mpark@yoda.nidr.nih.gov						ABBRUZZESE A, 1986, J BIOL CHEM, V261, P3085; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, V2; BALASUNDARAM D, 1993, P NATL ACAD SCI USA, V90, P4693, DOI 10.1073/pnas.90.10.4693; Balasundaram D, 1996, J BACTERIOL, V178, P2721, DOI 10.1128/jb.178.9.2721-2724.1996; BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; BALASUNDARAM D, 1994, P NATL ACAD SCI USA, V91, P172, DOI 10.1073/pnas.91.1.172; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BYERS TL, 1992, BIOCHEM J, V287, P717, DOI 10.1042/bj2870717; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; CABIB E, 1975, J BACTERIOL, V124, P1586, DOI 10.1128/JB.124.3.1586-1593.1975; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; HANAUSKEABEL HM, 1994, BBA-MOL CELL RES, V1221, P115, DOI 10.1016/0167-4889(94)90003-5; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; JOE YA, 1995, J BIOL CHEM, V270, P22386, DOI 10.1074/jbc.270.38.22386; Joe YA, 1997, J BIOL CHEM, V272, P32679, DOI 10.1074/jbc.272.51.32679; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; KANG HA, 1994, J BIOL CHEM, V269, P3934; KANG KR, 1995, J BIOL CHEM, V270, P18408, DOI 10.1074/jbc.270.31.18408; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KLIER H, 1995, FEBS LETT, V364, P207, DOI 10.1016/0014-5793(95)00394-O; PARK MH, 1982, J BIOL CHEM, V257, P7217; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PARK MH, 1993, BIOFACTORS, V4, P95; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; SCHWELBERGER HG, 1993, J BIOL CHEM, V268, P14018; SIKORSKI RS, 1989, GENETICS, V122, P19; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAO Y, 1995, J BIOL CHEM, V270, P383, DOI 10.1074/jbc.270.1.383; TAO Y, 1995, J BIOL CHEM, V270, P23984, DOI 10.1074/jbc.270.41.23984; TAO Y, 1996, BIOCHEM J, V315, P429; WOHL T, 1995, ELECTROPHORESIS, V16, P876, DOI 10.1002/elps.11501601145; WOHL T, 1993, MOL GEN GENET, V241, P305; WOLFF EC, 1990, J BIOL CHEM, V265, P4793; WOLFF EC, 1995, J BIOL CHEM, V270, P8660, DOI 10.1074/jbc.270.15.8660; Wolff EC, 1997, J BIOL CHEM, V272, P15865, DOI 10.1074/jbc.272.25.15865	43	99	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1677	1683		10.1074/jbc.273.3.1677	http://dx.doi.org/10.1074/jbc.273.3.1677			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430712	hybrid			2022-12-25	WOS:000071411500059
J	Fryer, CJ; Nordeen, SK; Archer, TK				Fryer, CJ; Nordeen, SK; Archer, TK			Antiprogestins mediate differential effects on glucocorticoid receptor remodeling of chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; TUMOR VIRUS PROMOTER; TRANSCRIPTION FACTOR ACCESS; HORMONE REGULATORY ELEMENT; MMTV PROMOTER; IN-VIVO; ESTROGEN-RECEPTOR; RESPONSE ELEMENT; GENE-EXPRESSION; DEPENDENT TRANSCRIPTION	We examined the mechanism(s) by which the progesterone receptor (PR) is able to inhibit glucocorticoid receptor (GR) activation from the mouse mammary tumor virus (MMTV) promoter in vivo. Using specific hormone antagonists, we demonstrate that the PR complexed with an type II antiprogestin blocks glucocorticold-induced activation of the MMTV promoter, However, when complexed with a type I antiprogestin the PR is unable to block glucocorticoid-induced activation. PR repression of GrR activity results from the inhibition of the ability of the GR to remodel chromatin such that the antiprogestin-occupied/PR prevents the glucocorticold induced assembly of a preinitiation complex at MMTV promoter. These experiments suggest that the specific chromatin organization of the MMTV promoter provides a mechanism for regulating cross-talk between the GR and PR in vivo.	Univ Western Ontario, London Reg Canc Ctr, Dept Obstet Gynecol, London, ON N6A 4L6, Canada; Univ Western Ontario, London Reg Canc Ctr, Dept Biochem & Oncol, London, ON N6A 4L6, Canada; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Archer, TK (corresponding author), Univ Western Ontario, London Reg Canc Ctr, Dept Obstet Gynecol, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.		Archer, Trevor K/E-5191-2019	Archer, Trevor K/0000-0001-7651-3644				Allan GF, 1996, MOL ENDOCRINOL, V10, P1206, DOI 10.1210/me.10.10.1206; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P568, DOI 10.1210/me.8.5.568; ARCHER TK, 1994, MOL ENDOCRINOL, V8, P1154, DOI 10.1210/me.8.9.1154; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1995, NUCLEOSOME, P123; ARCHER TK, 1989, STEROID THYROID HORM, P221; BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BEATO M, 1995, ONCOGENESIS, V2, P1991; Beck CA, 1996, J BIOL CHEM, V271, P1209, DOI 10.1074/jbc.271.2.1209; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1993, J STEROID BIOCHEM, V45, P205, DOI 10.1016/0960-0760(93)90334-S; CAPONY F, 1989, CANCER RES, V49, P3904; CATO ACB, 1987, EMBO J, V6, P363, DOI 10.1002/j.1460-2075.1987.tb04763.x; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHALBOS D, 1994, J BIOL CHEM, V269, P23007; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHARRON J, 1989, MOL CELL BIOL, V9, P3127, DOI 10.1128/MCB.9.7.3127; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Eggert M, 1995, J BIOL CHEM, V270, P30755, DOI 10.1074/jbc.270.51.30755; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOWLAND PL, 1989, MOL CELL BIOL, V9, P3999, DOI 10.1128/MCB.9.9.3999; HAGER GL, 1993, COLD SPRING HARB SYM, V58, P63, DOI 10.1101/SQB.1993.058.01.010; HAGER GL, 1991, NUCLEAR HORMONE RECE, P217; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE HL, 1994, MOL CELL BIOL, V14, P32, DOI 10.1128/MCB.14.1.32; LIEBERMAN BA, 1993, MOL ENDOCRINOL, V7, P515, DOI 10.1210/me.7.4.515; Liu WH, 1995, P NATL ACAD SCI USA, V92, P12480, DOI 10.1073/pnas.92.26.12480; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MITTAL R, 1993, J VIROL, V67, P5656, DOI 10.1128/JVI.67.9.5656-5659.1993; MIZUTANI T, 1992, J STEROID BIOCHEM, V42, P695, DOI 10.1016/0960-0760(92)90110-5; MOYER ML, 1993, J BIOL CHEM, V268, P22933; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MYMRYK JS, 1995, MOL ENDOCRINOL, V9, P1825, DOI 10.1210/me.9.12.1825; NATH R, 1992, ARCH BIOCHEM BIOPHYS, V292, P303, DOI 10.1016/0003-9861(92)90083-9; NEEF G, 1984, STEROIDS, V44, P349, DOI 10.1016/S0039-128X(84)80027-6; NOONAN KE, 1990, P NATL ACAD SCI USA, V87, P7160, DOI 10.1073/pnas.87.18.7160; NORDEEN SK, 1990, MOL ENDOCRINOL, V4, P1866, DOI 10.1210/mend-4-12-1866; NORDEEN SK, 1989, MOL ENDOCRINOL, V3, P1270, DOI 10.1210/mend-3-8-1270; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ONATE SA, 1995, SCIENCE, V270, P1354; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PERLMANN T, 1988, EMBO J, V7, P3073, DOI 10.1002/j.1460-2075.1988.tb03172.x; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Smith CL, 1997, J BIOL CHEM, V272, P14227, DOI 10.1074/jbc.272.22.14227; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P11202, DOI 10.1073/pnas.90.23.11202; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WOLFFE AP, 1994, CURR BIOL, V4, P525, DOI 10.1016/S0960-9822(00)00114-7; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; ZARET KS, 1984, CELL, V38, P29, DOI 10.1016/0092-8674(84)90523-3; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	68	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1175	1183		10.1074/jbc.273.2.1175	http://dx.doi.org/10.1074/jbc.273.2.1175			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422784	hybrid			2022-12-25	WOS:000071411400073
J	Ottinger, EA; Botfield, MC; Shoelson, SE				Ottinger, EA; Botfield, MC; Shoelson, SE			Tandem SH2 domains confer high specificity in tyrosine kinase signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-CONTAINING PEPTIDES; SRC HOMOLOGY-2 DOMAIN; T-CELL RECEPTOR; HIGH-AFFINITY BINDING; FACTOR BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATED PEPTIDES; PHOSPHATASE SH-PTP2	SH2 domain proteins transmit intracellular signals initiated by activated tyrosine kinase-linked receptors. Recent three-dimensional structures suggest mechanisms by which tandem SH2 domains might confer higher specificity than individual SH2 domains, To test this, binding studies were conducted with tandem domains from the five signaling enzymes: phosphatidylinositol 3-kinase p85, ZAP-70, Syk, SHP-2, and phospho; lipase C-gamma 1. Bisphosphorylated TAMs (tyrosine-based activation motifs) were derived from biologically relevant sites in platelet-derived growth factor, T cell, B cell, and high affinity IgE receptors and the receptor substrates IRS-1 (insulin receptor substrate-1) and SHPS-1/SIRP. Each tandem SH2 domain binds a distinct TAM corresponding to its appropriate biological partner with highest affinity (0.5-3.0 nM). Alternative TAMs bind the tandem SH2 domains with 1,000- to >10,000- fold lower affinity than biologically relevant TAMs. This level of specificity is significantly greater than the similar to 20-50-fold typically seen for individual SH2 domains, We conclude that high biological specificity is conferred by the simultaneous interaction of two SH2 domains in a signaling enzyme with bisphosphorylated TAMs in activated receptors and substrates.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Takeda Oncology	Shoelson, SE (corresponding author), 130 Waverly St, Cambridge, MA 02139 USA.	Shoelson@Joslab.Harvard.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK043123, R01DK045943] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43123, DK45943, DK36836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CASE RD, 1994, J BIOL CHEM, V269, P10467; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KONG GH, 1995, IMMUNITY, V2, P485, DOI 10.1016/1074-7613(95)90029-2; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NARULA SS, 1995, STRUCTURE, V3, P1061, DOI 10.1016/S0969-2126(01)00242-8; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nolte RT, 1996, NAT STRUCT BIOL, V3, P364, DOI 10.1038/nsb0496-364; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; OTTINGER EA, 1993, BIOCHEMISTRY-US, V32, P4354, DOI 10.1021/bi00067a027; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PONS S, 1995, MOL CELL BIOL, V15, P4453; Rahuel J, 1996, NAT STRUCT BIOL, V3, P586, DOI 10.1038/nsb0796-586; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON BS, 1995, J BIOL CHEM, V270, P4013, DOI 10.1074/jbc.270.8.4013; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	53	170	171	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					729	735		10.1074/jbc.273.2.729	http://dx.doi.org/10.1074/jbc.273.2.729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422724	hybrid			2022-12-25	WOS:000071411400013
J	Stomski, FC; Woodcock, JM; Zacharakis, B; Bagley, CJ; Sun, QY; Lopez, AF				Stomski, FC; Woodcock, JM; Zacharakis, B; Bagley, CJ; Sun, QY; Lopez, AF			Identification of a Cys motif in the common beta chain of the interleukin 3, granulocyte-macrophage colony-stimulating factor, and interleukin 5 receptors essential for disulfide-linked receptor heterodimerization and activation of all three receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; GROWTH SIGNAL-TRANSDUCTION; HUMAN GM-CSF; CYTOPLASMIC DOMAINS; ALPHA-CHAIN; TYROSINE PHOSPHORYLATION; IL-5 RECEPTORS; SUBUNIT; CELLS; DIMERIZATION	The human interleukin 3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors undergo covalent dimerization of the respective specific alpha chains with the common beta subunit (beta(c)) in the presence of the cognate ligand, We have now performed alanine substitutions of individual Cys residues in beta(c) to identify the Cys residues involved and their contribution to activation of the IL-3, GM-CSF, and IL-5 receptors, We found that substitution of Cys-86, Cys-91, and Cys-96 in beta(c) but not of Cys-100 or Cys-234 abrogated disulfide-linked IL-3 receptor dimerization, However, although Cys-86 and Cys-91 beta(c) mutants retained their ability to form non-disulfide-linked dimers with IL-3R alpha, substitution of Cys-96 eliminated this interaction, Binding studies demonstrated that all beta(c) mutants with the exception of C96A supported high affinity binding of IL-3 and GMCSF, In receptor activation experiments, we found that beta(c) mutants C86A, C91A, and C96A but not C100A or C234A abolished phosphorylation of beta(c) in response to IL-3, GM-CSF, or IL-5, These data show that although Cys-96 is important for the structural integrity of beta(c), Cys-86 and Cys-91 participate in disulfide-linked receptor heterodimerization and that this linkage is essential for tyrosine phosphorylation of beta(c). Sequence alignment of beta(c) with other cytokine receptor signaling subunits in light of these data shows that Cys-86 and Cys-91 represent a motif restricted to human and mouse beta chains, suggesting a unique mechanism of activation utilized by the IL-3, GM-CSF, and IL-5 receptors.	Inst Med & Vet Sci, Hanson Ctr Canc Res, Cytokine Receptor Lab, Adelaide, SA 5000, Australia	Institute Medical & Veterinary Science Australia	Lopez, AF (corresponding author), Inst Med & Vet Sci, Hanson Ctr Canc Res, Cytokine Receptor Lab, POB 14,Rundle Mall, Adelaide, SA 5000, Australia.		Lopez, Angel F/E-2260-2011	Woodcock, Joanna/0000-0001-5127-9687; Lopez, Angel F/0000-0001-7430-0135				Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482; BARRY SC, 1994, J BIOL CHEM, V269, P8488; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CONTRERAS MA, 1983, METHOD ENZYMOL, V92, P277; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DEVOS R, 1994, EUR J BIOCHEM, V225, P635, DOI 10.1111/j.1432-1033.1994.00635.x; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIRAOKA O, 1994, FEBS LETT, V356, P255, DOI 10.1016/0014-5793(94)01278-4; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Lia F, 1996, J BIOL CHEM, V271, P28287, DOI 10.1074/jbc.271.45.28287; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUTO A, 1995, BIOCHEM BIOPH RES CO, V208, P368, DOI 10.1006/bbrc.1995.1347; Nakamura N, 1996, J BIOL CHEM, V271, P19483, DOI 10.1074/jbc.271.32.19483; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NELSON BH, 1994, NATURE, V369, P333, DOI 10.1038/369333a0; PAONESSA G, 1995, EMBO J, V14, P1942, DOI 10.1002/j.1460-2075.1995.tb07186.x; Patel N, 1996, J BIOL CHEM, V271, P30386, DOI 10.1074/jbc.271.48.30386; Rapoport AP, 1996, BLOOD, V87, P112; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Shikama Y, 1996, BLOOD, V88, P455, DOI 10.1182/blood.V88.2.455.bloodjournal882455; SPIELHOLZ C, 1995, BLOOD, V85, P973, DOI 10.1182/blood.V85.4.973.bloodjournal854973; Stomski FC, 1996, MOL CELL BIOL, V16, P3035; Sun QY, 1996, BLOOD, V87, P83; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; WALSH FS, 1977, NATURE, V269, P307, DOI 10.1038/269307a0; WEISS M, 1993, BLOOD, V82, P3298; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	38	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1192	1199		10.1074/jbc.273.2.1192	http://dx.doi.org/10.1074/jbc.273.2.1192			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422786	hybrid			2022-12-25	WOS:000071411400075
J	Taniura, H; Taniguchi, N; Hara, M; Yoshikawa, K				Taniura, H; Taniguchi, N; Hara, M; Yoshikawa, K			Necdin, a postmitotic neuron-specific growth suppressor, interacts with viral transforming proteins and cellular transcription factor E2F1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA GENE-PRODUCT; EMBRYONAL CARCINOMA-CELLS; LARGE TUMOR-ANTIGEN; NUCLEAR-PROTEIN; BINDING PROTEIN; EXPRESSION; MOUSE; BRAIN; RB; IDENTIFICATION	Necdin is a nuclear protein expressed in virtually all postmitotic neurons, and ectopic expression of this protein strongly suppresses the proliferation of NIH3T3 cells, Simian virus 40 large T antigen targets both p53 and the retinoblastoma protein (Rb) for cellular transformation, By analogy with the interactions of the large T antigen with these nuclear growth suppressors, we examined the ability of necdin to bind to the large T antigen, Necdin was co-immunoprecipitated with the large T antigen from the nuclear extract of necdin cDNA-transfected COS-1 cells, Yeast two-hybrid and in vitro binding analyses revealed that necdin bound to an amino-terminal region of the large T antigen, which encompasses the Rb-binding domain, Moreover, necdin bound to adenovirus E1A, another viral oncoprotein that forms a specific complex with Rb, We then examined the ability of necdin to bind to the transcription factor E2F1, a cellular Rb-binding factor involved in cell-cycle progression, Intriguingly, necdin, like Rb, bound to a carboxyl-terminal domain of E2F1, and repressed E2F-dependent transactivation in vivo, In addition, necdin suppressed the colony formation of Rb-deficient SAOS-2 osteosarcoma cells. These results suggest that necdin is a postmitotic neuron-specific growth suppressor that is functionally similar to Rb.	Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Suita, Osaka 565, Japan	Osaka University	Yoshikawa, K (corresponding author), Osaka Univ, Inst Prot Res, Div Regulat Macromol Funct, Yamadaoka 3-2, Suita, Osaka 565, Japan.		Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; AIZAWA T, 1992, DEV BRAIN RES, V68, P265, DOI 10.1016/0165-3806(92)90069-9; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; OKANO HJ, 1993, J NEUROSCI, V13, P2930; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SLACK RS, 1993, ONCOGENE, V8, P1585; Uetsuki T, 1996, J BIOL CHEM, V271, P918, DOI 10.1074/jbc.271.2.918; UETSUKI T, 1990, MOL CELL BIOL, P2562; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1995, CANCER BIOL, V6, P83; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	28	143	156	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					720	728		10.1074/jbc.273.2.720	http://dx.doi.org/10.1074/jbc.273.2.720			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422723	hybrid			2022-12-25	WOS:000071411400012
J	Vincent, MJ; Martin, AS; Compans, RW				Vincent, MJ; Martin, AS; Compans, RW			Function of the KKXX motif in endoplasmic reticulum retrieval of a transmembrane protein depends on the length and structure of the cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS ENVELOPE GLYCOPROTEIN; INTRACELLULAR-TRANSPORT; GOLGI-COMPLEX; ENDOPROTEOLYTIC CLEAVAGE; SECRETORY PATHWAY; MEMBRANE-PROTEIN; RETENTION MOTIF; FUSION ACTIVITY; ER RETRIEVAL; DELTA-COP	Transmembrane glycoproteins with type 1 topology can be retrieved to the endoplasmic reticulum (ER) by a retrieval signal containing a di-lysine (KK) motif near the C terminus, To investigate the structural requirements for ER retrieval, we have constructed mutants of the simian immunodeficiency virus (SIV) envelope (Env) protein with cytoplasmic tails of different lengths and containing a KK motif at the -3 and -4 positions, Such proteins were found to be retained intracellularly when the signal was located 18 amino acids or more away from the membrane spanning domain, The retrieval signal was found to be functional even when placed at the distal end of the wild-type SIV Env protein with 164 amino acids in the cytoplasmic tail, as shown by the lack of proteolytic processing and lack of cell surface expression of the mutant proteins, However, proteins with a cytoplasmic tail length of 13 amino acids or less having the di-lysine motif at the -3 and -4 positions were not retrieved to the ER since they were found to be processed and transported to the cell surface. The surface-expressed proteins were found to be functional in inducing cell fusion, whereas the proteins retained intracellularly were defective in fusion activity, We also found that the KK motif introduced near an amphipathic helical region in the cytoplasmic tail was not functional. These results demonstrate that the ability of the KK motif to cause protein retrieval and retention in the endoplasmic reticulum depends on the length and structure of the cytoplasmic domain. The ER retrieval of the mutant proteins was found to correlate with increased intracellular binding to beta COP proteins.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Rollins Res Ctr 3001, Atlanta, GA 30322 USA	Emory University	Compans, RW (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Rollins Res Ctr 3001, Atlanta, GA 30322 USA.		Compans, Richard W/I-4087-2013	Compans, Richard W/0000-0003-2360-335X	NIAID NIH HHS [AI 34242, AI 38501] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038501, R01AI034242] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; Cosson P, 1996, EMBO J, V15, P5783, DOI 10.1002/j.1460-2075.1996.tb00964.x; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; Faulstich D, 1996, J CELL BIOL, V135, P53, DOI 10.1083/jcb.135.1.53; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GOEPFERT PA, 1995, CELL, V82, P543, DOI 10.1016/0092-8674(95)90026-8; HAFFAR OK, 1988, J CELL BIOL, V107, P1677, DOI 10.1083/jcb.107.5.1677; HAFFAR OK, 1991, VIROLOGY, V180, P439, DOI 10.1016/0042-6822(91)90054-F; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HOFFMAN R, 1979, Journal of the Biological Photographic Association, V47, P111; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSTON PB, 1993, J VIROL, V67, P3077, DOI 10.1128/JVI.67.6.3077-3086.1993; KINOSAKI M, 1993, CELL STRUCT FUNCT, V18, P41, DOI 10.1247/csf.18.41; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Martire G, 1996, J BIOL CHEM, V271, P3541; MILLER MA, 1991, AIDS RES HUM RETROV, V7, P511, DOI 10.1089/aid.1991.7.511; MULLIGAN MJ, 1992, J VIROL, V66, P3971, DOI 10.1128/JVI.66.6.3971-3975.1992; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PARKS GD, 1990, J VIROL, V64, P3605, DOI 10.1128/JVI.64.8.3605-3616.1990; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; RAJA NU, 1993, J GEN VIROL, V74, P2085, DOI 10.1099/0022-1317-74-10-2085; Rasenick Mark M., 1993, Methods (Orlando), V5, P252, DOI 10.1006/meth.1993.1031; RITTER GD, 1993, VIROLOGY, V197, P255, DOI 10.1006/viro.1993.1586; ROSE JK, 1983, CELL, V34, P513, DOI 10.1016/0092-8674(83)90384-7; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROWELL JF, 1995, J IMMUNOL, V155, P473; SCHINDLER R, 1993, EUR J CELL BIOL, V61, P1; SPIES CP, 1994, J VIROL, V68, P585, DOI 10.1128/JVI.68.2.585-591.1994; SPIES CP, 1994, VIROLOGY, V203, P8, DOI 10.1006/viro.1994.1449; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; STEIN BS, 1990, J BIOL CHEM, V265, P2640; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; VINCENT MJ, 1993, J VIROL, V67, P5538, DOI 10.1128/JVI.67.9.5538-5549.1993; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871; YAO QH, 1995, J VIROL, V69, P7045, DOI 10.1128/JVI.69.11.7045-7053.1995; ZINGLER K, 1993, J VIROL, V67, P2824, DOI 10.1128/JVI.67.5.2824-2831.1993	45	49	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					950	956		10.1074/jbc.273.2.950	http://dx.doi.org/10.1074/jbc.273.2.950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422755	hybrid			2022-12-25	WOS:000071411400044
J	Wu, SL; Staudinger, J; Olson, EN; Rubin, CS				Wu, SL; Staudinger, J; Olson, EN; Rubin, CS			Structure, expression, and properties of an atypical protein kinase C (PKC3) from Caenorhabditis elegans - PKC3 is required for the normal progression of embryogenesis and viability of the organism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; REGULATORY SUBUNIT; ZETA-ISOFORM; SELECTIVE INHIBITOR; GENE-EXPRESSION; BINDING-PROTEIN; RAT-BRAIN; IN-VITRO; II-BETA; CELLS	Little is known about differential expression, functions, regulation, and targeting of "atypical" protein kinase C (aPKC) isoenzymes in vivo, We have cloned and characterized a novel cDNA that encodes a Caenorhabditis elegans aPKC (PKC3) composed of 597 amino acids, In post-embryonic animals, a 647 base pair segment of promoter/enhancer DNA directs transcription of the 3.6-kilobase pair pkc-3 gene and coordinates accumulation of PKC3 protein in similar to 85 muscle, epithelial, and hypodermal cells, These cells are incorporated into tissues involved in feeding, digestion, excretion, and reproduction, Mammalian aPKCs promote mitogenesis and survival of cultured cells, In contrast, C. elegans PKC3 accumulates in non-dividing, terminally differentiated cells that will not undergo apoptosis. Thus, aPKCs may control cell functions that are independent of cell cycle progression and programmed cell death. PKC3 is also expressed during embryogenesis, Ablation of PKC3 function by microinjection of antisense RNA into oocytes yields disorganized, developmentally arrested embryos. Thus, PKC3 is essential for viability, PKC3 is enriched in particulate fractions of disrupted embryos and larvae, Immunofluorescence microscopy revealed that PKC3 accumulates near cortical actin cytoskeleton/plasma membrane at the apical surface of intestinal cells and in embryonic cells, A candidate anchoring/targeting protein, which binds PKC3 in vitro, has been identified.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, Bronx, NY 10461 USA; Glaxo Wellcome Inc, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA	Yeshiva University; Albert Einstein College of Medicine; GlaxoSmithKline; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rubin, CS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Atran Labs, 1300 Morris Pk Ave,F-229, Bronx, NY 10461 USA.	rubin@aecom.yu.edu			NIDDK NIH HHS [DK44597] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK044597] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARBEE JL, 1993, GENE, V132, P305, DOI 10.1016/0378-1119(93)90213-M; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BERG DT, 1993, BIOTECHNIQUES, V14, P972; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Bjorkoy G, 1997, J BIOL CHEM, V272, P11557; BLUMENTHAL T, 1997, C ELEGANS, V2, P117; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FIRE A, 1991, DEVELOPMENT, V113, P503; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FREEDMAN JH, 1993, J BIOL CHEM, V268, P2554; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HU ED, 1990, J BIOL CHEM, V265, P5072; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; HUBBARD SR, 1991, SCIENCE, V254, P1776; IslasTrejo A, 1997, J BIOL CHEM, V272, P6629, DOI 10.1074/jbc.272.10.6629; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KENYON C, 1988, SCIENCE, V240, P1448, DOI 10.1126/science.3287621; KILEY SC, 1995, J CELL SCI, V108, P1003; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KRAMER IM, 1989, J BIOL CHEM, V264, P5876; LAND M, 1994, J BIOL CHEM, V269, P9234; LI Y, 1995, J BIOL CHEM, V270, P1935, DOI 10.1074/jbc.270.4.1935; Li Y, 1996, J BIOL CHEM, V271, P16862, DOI 10.1074/jbc.271.28.16862; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIZUNO K, 1995, FEBS LETT, V359, P259, DOI 10.1016/0014-5793(95)00042-8; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; ORR JW, 1994, J BIOL CHEM, V269, P27715; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SULSTON J, 1988, NEMATODE CAENORHABDI, P123; Sulston J., 1988, NEMATODE CAENORHABDI, P603; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAYS DK, 1992, J BIOL CHEM, V267, P4799; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WHITE JG, 1987, J CELL BIOL, V105, P41, DOI 10.1083/jcb.105.1.41; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; WOOTEN MW, 1994, CELL GROWTH DIFFER, V5, P395; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; [No title captured]	68	32	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1130	1143		10.1074/jbc.273.2.1130	http://dx.doi.org/10.1074/jbc.273.2.1130			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422779	hybrid			2022-12-25	WOS:000071411400068
J	Dumler, I; Weis, A; Mayboroda, OA; Maasch, C; Jerke, U; Haller, H; Gulba, DC				Dumler, I; Weis, A; Mayboroda, OA; Maasch, C; Jerke, U; Haller, H; Gulba, DC			The Jak/Stat pathway and urokinase receptor signaling inhuman aortic vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; PLASMINOGEN-ACTIVATOR; ENDOTHELIAL-CELLS; CELLULAR RECEPTOR; IN-VITRO; TRANSDUCTION; EXPRESSION; MIGRATION; SURFACE; PHOSPHORYLATION	The binding of urokinase plasminogen activator (uPA) to its specific receptor (uPAR) facilitates migration of vascular smooth muscle cells (VSMC). However, the signaling cascade utilized by the urokinase receptor is only incompletely understood, We investigated intracellular uPA/uPAR signaling in human aortic VSMC from the cell membrane to the nucleus. uPA binding to VSMC induced a rapid and pronounced increase in tyrosine phosphorylation of several proteins with molecular masses of 53-60, 85-90, and 130-140 kDa, By using co-immunoprecipitation techniques and in vitro kinase assays, the uPAR-associated proteins were identified as Janus (Jab) and Src non-receptor protein-tyrosine kinases (PTK) Jak1, Tyk2, and p59(fyn), p53/56(lyn), p53/59(hck), and p55(fgr). Furthermore, uPA induced a time-dependent reversible translocation of the Stat1 (signal transducer and activator of transcription) protein to the VSMC nuclei, as shown by confocal microscopy studies, Using an electrophoretic mobility shift assay, we then demonstrated that Stat1 is rapidly activated in response to stimulation with uPA and specifically binds to the DNA regulatory elements GAS (interferon-gamma activation site) and ISRE (interferon-stimulated response element), Mobility supershift experiments confirmed DNA-protein complexes containing Stat1 protein, Migration experiments with double immunofluorescence staining revealed polarization of uPAR, and colocalization with Jak1 and Tyk2 to the leading edge of the migrating cells, Under the same conditions, Jak2, Jak3, and the Src-PTKs remained randomly distributed over the entire body of the cells, Our studies therefore suggest that, in VSMC, the uPAR-signaling complex utilizes at least two different mechanisms, a direct signaling pathway utilizing the Jak/Stat cascade and a second signal transduction mechanism via Src-like protein-tyrosine kinases, uPA-induced signaling via Jak/Stat is most Likely involved in the regulation of cell migration, while the functional purpose of the uPA associated Src-PTR activation remains to be elucidated.	Franz Volhard Clin, D-13125 Berlin, Germany; Humboldt Univ, Virchow Klinikum, Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Otto Von Guericke Univ, Inst Med Neurobiol, D-39116 Magdeburg, Germany	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin; Otto von Guericke University	Dumler, I (corresponding author), Franz Volhard Clin, Wiltbergstr 50, D-13125 Berlin, Germany.		Mayboroda, Oleg/N-4850-2019; Mayboroda, Oleg/B-5634-2008	Mayboroda, Oleg/0000-0001-8739-9875; Mayboroda, Oleg/0000-0001-8739-9875				BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; Briscoe J, 1996, TRENDS CELL BIOL, V6, P336, DOI 10.1016/0962-8924(96)10028-3; BRISCOE J, 1994, CURR BIOL, V4, P1033, DOI 10.1016/S0960-9822(00)00236-0; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; Conway G, 1997, P NATL ACAD SCI USA, V94, P3082, DOI 10.1073/pnas.94.7.3082; Crabtree GR, 1996, TRENDS BIOCHEM SCI, V21, P418, DOI 10.1016/S0968-0004(96)20027-1; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DELROSSO M, 1993, BIOCHEM BIOPH RES CO, V190, P347, DOI 10.1006/bbrc.1993.1054; DUMLER I, 1994, FEBS LETT, V343, P103, DOI 10.1016/0014-5793(94)80298-X; DUMLER I, 1993, FEBS LETT, V322, P37, DOI 10.1016/0014-5793(93)81106-A; Dumler I, 1997, FIBRINOLYSIS PROTEOL, V11, P165, DOI 10.1016/S0268-9499(97)80092-6; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HALLER H, 1995, KIDNEY INT, V47, P1057, DOI 10.1038/ki.1995.152; HALLER H, 1995, CIRC RES, V76, P21, DOI 10.1161/01.RES.76.1.21; Marrero MB, 1996, CELL SIGNAL, V8, P21, DOI 10.1016/0898-6568(95)02016-0; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; STAHL A, 1994, CANCER RES, V54, P3006; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanLeeuwen RTJ, 1996, FIBRINOLYSIS, V10, P59, DOI 10.1016/S0268-9499(96)80081-6; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	34	156	165	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					315	321		10.1074/jbc.273.1.315	http://dx.doi.org/10.1074/jbc.273.1.315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417082	hybrid			2022-12-25	WOS:000071295600048
J	Hilliard, JJ; Maurizi, MR; Simon, LD				Hilliard, JJ; Maurizi, MR; Simon, LD			Isolation and characterization of the phage T4 PinA protein inhibitor of the ATP-dependent Lon protease of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLP PROTEASE; BACTERIOPHAGE-T4 GENE; LAMBDA-N; ION GENE; LA; DEGRADATION; PROTEOLYSIS; COMPONENT; SEQUENCE; QUANTITATION	The bacteriophage T4 PinA protein, expression of which leads to inhibition of protein degradation in Escherichia coli cells, has been purified from cells carrying multiple copies of the pinA gene. PinA is a heat-stable protein with a subunit M-r of 18,800 and an isoelectric point of 4.6, Under nondenaturing conditions on a gel filtration column, PinA migrated in two peaks corresponding to a dimer and a tetramer, Purified Pink inhibited ATP-dependent protein degradation by Lon protease in vitro; it did not inhibit the activity of other E. coli ATP-dependent proteases, ClpAP or ClpYQ, Furthermore, PinA did not inhibit ATP-independent proteolysis in E. coli cell extracts, PinA binds with high affinity to Lon protease (K-d similar to 10 nM for dimer binding), and a complex with similar to 1 dimer of PinA per tetramer of Lon protease could be isolated by gel filtration, Lon activity was partially restored upon dilution of the PinA-Lon complex to subnanomolar concentrations, indicating that inhibition was reversible and that PinA did not covalently modify Lon protease, PinA was not cleaved by Lon protease, and heating the Lon-PinA complex at 65 degrees C denatured Lon protease and released active Pink The properties of PinA in vitro suggest that PinA inhibits protein degradation in vivo by forming a tight, reversible complex with Lon protease.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08855 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Simon, LD (corresponding author), Rutgers State Univ, Waksman Inst, Piscataway, NJ 08855 USA.							BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARETTE MF, 1981, P NATL ACAD SCI-BIOL, V78, P4728, DOI 10.1073/pnas.78.8.4728; CHIN DT, 1988, J BIOL CHEM, V263, P11718; CHUNG CH, 1981, P NATL ACAD SCI-BIOL, V78, P4931, DOI 10.1073/pnas.78.8.4931; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DRISCOLL J, 1992, P NATL ACAD SCI USA, V89, P4986, DOI 10.1073/pnas.89.11.4986; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1989, ANNU REV GENET, V23, P163, DOI 10.1146/annurev.ge.23.120189.001115; GOTTESMAN S, 1981, CELL, V24, P225, DOI 10.1016/0092-8674(81)90518-3; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Hilliard JJ, 1998, J BIOL CHEM, V273, P524, DOI 10.1074/jbc.273.1.524; Hirs CHW, 1967, METHOD ENZYMOL, P59, DOI [10.1016/S0076-6879(67)11008-2, DOI 10.1016/S0076-6879(67)11008-2]; HUNKAPILLER M, 1984, NATURE, V310, P105, DOI 10.1038/310105a0; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KROH HE, 1990, J BACTERIOL, V172, P6026, DOI 10.1128/jb.172.10.6026-6034.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RL, 1982, BIOCHEMISTRY-US, V21, P2600, DOI 10.1021/bi00540a004; LI XC, 1991, BIOCHEMISTRY-US, V30, P9709, DOI 10.1021/bi00104a020; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MAURIZI MR, 1994, METHOD ENZYMOL, V244, P314; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MAURIZI MR, 1985, J BACTERIOL, V164, P1124, DOI 10.1128/JB.164.3.1124-1135.1985; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MENON AS, 1987, J BIOL CHEM, V262, P722; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MIZUSAWA S, 1983, P NATL ACAD SCI-BIOL, V80, P358, DOI 10.1073/pnas.80.2.358; POLGAR L, 1989, MECH PROTEASE ACTION; SIMON LD, 1978, NATURE, V275, P424, DOI 10.1038/275424a0; SIMON LD, 1983, P NATL ACAD SCI-BIOL, V80, P2059, DOI 10.1073/pnas.80.7.2059; SIMON LD, 1985, MICROBIOLOGY 1985, P350; SKORUPSKI K, 1988, J BACTERIOL, V170, P3016, DOI 10.1128/jb.170.7.3016-3024.1988; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; TORRESCABASSA AS, 1987, J BACTERIOL, V169, P981, DOI 10.1128/jb.169.3.981-989.1987; VANMELDEREN L, 1994, MOL MICROBIOL, V11, P1151; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257	41	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					518	523		10.1074/jbc.273.1.518	http://dx.doi.org/10.1074/jbc.273.1.518			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417110	hybrid			2022-12-25	WOS:000071295600076
J	Jayson, GC; Lyon, M; Paraskeva, C; Turnbull, JE; Deakin, JA; Gallagher, JT				Jayson, GC; Lyon, M; Paraskeva, C; Turnbull, JE; Deakin, JA; Gallagher, JT			Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; CELL-SURFACE; FLAVOBACTERIUM-HEPARINUM; SUBSTRATE-SPECIFICITY; HIGH-AFFINITY; BINDING; TETRASACCHARIDES; LYASES; PROTEOGLYCANS; BIOSYNTHESIS	We report a detailed analysis of heparan sulfate (HS) structure using a model of human colon carcinogenesis, Metabolically radiolabeled HS was isolated from adenoma and carcinoma cells, The chain length of HS was the same in both cell populations (M-r 20,000; 45-50 disaccharides), and the chains contained on average of two sulfated domains (S domains), identified by heparinase I scission, This enzyme produced fragments of approximate size 7 kDa, suggesting that the S domains were evenly spaced in the intact HS chain, The degree of polymer sulfation and the patterns of sulfation were strikingly different between the two HS species, When compared with adenoma HS, the iduronic acid 2-O-sulfate content of the carcinoma-derived material was reduced by 33%, and the overall level of N-sulfation was reduced by 20%. However, the level of 6-O-sulfation was increased by 24%, and this was almost entirely attributable to an enhanced level of N-sulfated glucosamine 6-O-sulfate, a species whose data implied was mainly located in the mixed sequences of alternating N-sulfated and N-acetylated disaccharides. The results indicate that in the transition to malignancy in human colon adenoma cells, the overall molecular organization of HS is preserved, but there are distinct modifications in both the S domains and their flanking mixed domains that may contribute to the aberrant behavior of the cancer cell.	Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Manchester M20 4BX, Lancs, England; Univ Manchester, Canc Res Campaign Dept, Manchester M20 4BX, Lancs, England; Univ Bristol, Canc Res Campaign Dept, Bristol, Avon, England	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Bristol	Jayson, GC (corresponding author), Christie Hosp NHS Trust, Dept Med Oncol, Canc Res Campaign, Wilmslow Rd, Manchester M20 4BX, Lancs, England.		Jayson, Gordon C/O-8224-2015	Jayson, Gordon C/0000-0002-8515-8944; Lyon, Malcolm/0000-0001-9575-6879				Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; CASU B, 1988, TRENDS BIOCHEM SCI, V13, P221, DOI 10.1016/0968-0004(88)90088-6; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GALLAGHER JT, 1992, INT J BIOCHEM, V24, P553, DOI 10.1016/0020-711X(92)90326-V; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; KATO M, 1994, J BIOL CHEM, V269, P18881; KELLER KL, 1980, BIOCHEMISTRY-US, V19, P2529, DOI 10.1021/bi00552a035; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; LIDHOLT K, 1989, BIOCHEM J, V261, P999, DOI 10.1042/bj2610999; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; NAKAMURA N, 1981, CANCER RES, V41, P278; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; PEJLER G, 1987, BIOCHEM J, V248, P69, DOI 10.1042/bj2480069; SANDERSON PN, 1984, BIOCHEM J, V223, P495, DOI 10.1042/bj2230495; SANDERSON RD, 1992, J INVEST DERMATOL, V99, P390, DOI 10.1111/1523-1747.ep12616103; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; TURNBULL JE, 1991, BIOCHEM J, V273, P553, DOI 10.1042/bj2730553; WALKER A, 1994, J BIOL CHEM, V269, P931; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WILLIAMS AC, 1990, CANCER RES, V50, P4727; WINTERBOURNE DJ, 1978, J BIOL CHEM, V253, P5109; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; YAMADA S, 1995, J BIOL CHEM, V270, P8696; YAMADA S, 1994, GLYCOBIOLOGY, V4, P69, DOI 10.1093/glycob/4.1.69; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	35	121	123	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					51	57		10.1074/jbc.273.1.51	http://dx.doi.org/10.1074/jbc.273.1.51			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417046	hybrid			2022-12-25	WOS:000071295600012
J	Kieboom, J; Dennis, JJ; de Bont, JAM; Zylstra, GJ				Kieboom, J; Dennis, JJ; de Bont, JAM; Zylstra, GJ			Identification and molecular characterization of an efflux pump involved in Pseudomonas putida S12 solvent tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SEQUENCE-ANALYSIS; ORGANIC-SOLVENTS; CLONING; RESISTANCE; AERUGINOSA; TOLUENE; GENE	Bacteria able to grow in aqueous:organic two-phase systems have evolved resistance mechanisms to the toxic effects of solvents. One such mechanism is the active efflux of solvents from the cell, preserving the integrity of the cell interior, Pseudomonas putida S12 is resistant to a wide variety of normally detrimental solvents due to the action of such an efflux pump. The genes for this solvent efflux pump were cloned from P. putida S12 and their nucleotide sequence determined. The deduced amino acid sequences encoded by the three genes involved show a striking resemblance to proteins known to be involved in proton-dependent multidrug efflux systems. Transfer of the genes for the solvent efflux pump to solvent-sensitive P. putida strains results in the acquisition of solvent resistance. This opens up the possibilities of using the solvent efflux system to construct bacterial strains capable of performing biocatalytic transformations of insoluble substrates in two-phase aqueous:organic medium.	Rutgers State Univ, Cook Coll, Ctr Agr Mol Biol, New Brunswick, NJ 08903 USA; Agr Univ Wageningen, Dept Food Sci, Div Ind Microbiol, NL-6700 EV Wageningen, Netherlands	Rutgers State University New Brunswick; Wageningen University & Research	Zylstra, GJ (corresponding author), Rutgers State Univ, Cook Coll, Ctr Agr Mol Biol, Foran Hall,Dudley Rd, New Brunswick, NJ 08903 USA.		Dennis, Jonathan/E-8515-2014	Dennis, Jonathan/0000-0001-9288-6555; Zylstra, Gerben/0000-0003-0419-1353				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AONO R, 1992, BIOSCI BIOTECH BIOCH, V56, P145, DOI 10.1271/bbb.56.145; AONO R, 1991, AGR BIOL CHEM TOKYO, V55, P1935, DOI 10.1080/00021369.1991.10870883; AONO R, 1995, BIOSCI BIOTECH BIOCH, V59, P213, DOI 10.1271/bbb.59.213; AONO R, 1994, APPL ENVIRON MICROB, V60, P4624, DOI 10.1128/AEM.60.12.4624-4626.1994; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CRUDEN DL, 1992, APPL ENVIRON MICROB, V58, P2723, DOI 10.1128/AEM.58.9.2723-2729.1992; Dennis J J, 1995, Methods Mol Biol, V47, P125; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; FERRANTE AA, 1995, P NATL ACAD SCI USA, V92, P7617, DOI 10.1073/pnas.92.17.7617; GOTOH N, 1995, ANTIMICROB AGENTS CH, V39, P2567, DOI 10.1128/AAC.39.11.2567; HARTMANS S, 1990, APPL ENVIRON MICROB, V56, P1347, DOI 10.1128/AEM.56.5.1347-1351.1990; HEIPIEPER HJ, 1994, TRENDS BIOTECHNOL, V12, P409, DOI 10.1016/0167-7799(94)90029-9; HEIPIEPER HJ, 1994, APPL ENVIRON MICROB, V60, P4440, DOI 10.1128/AEM.60.12.4440-4444.1994; HEIPIEPER HJ, 1995, CHEMOSPHERE, V30, P1041, DOI 10.1016/0045-6535(95)00015-Z; Heipieper HJ, 1996, APPL ENVIRON MICROB, V62, P2773, DOI 10.1128/AEM.62.8.2773-2777.1996; INOUE A, 1989, NATURE, V338, P264, DOI 10.1038/338264a0; Isken S, 1996, J BACTERIOL, V178, P6056, DOI 10.1128/jb.178.20.6056-6058.1996; Keweloh H, 1996, LIPIDS, V31, P129, DOI 10.1007/BF02522611; KIM E, 1995, J BACTERIOL, V177, P3095, DOI 10.1128/jb.177.11.3095-3103.1995; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; Li L, 1995, BIOSCI BIOTECH BIOCH, V59, P2358, DOI 10.1271/bbb.59.2358; NAKAJIMA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1323, DOI 10.1271/bbb.59.1323; NAKAJIMA H, 1995, APPL ENVIRON MICROB, V61, P2302, DOI 10.1128/AEM.61.6.2302-2307.1995; Nikaido H, 1996, J BACTERIOL, V178, P5853, DOI 10.1128/jb.178.20.5853-5859.1996; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Pinkart HC, 1996, APPL ENVIRON MICROB, V62, P1129, DOI 10.1128/AEM.62.3.1129-1132.1996; POOLE K, 1993, MOL MICROBIOL, V10, P529, DOI 10.1111/j.1365-2958.1993.tb00925.x; RAMOS JL, 1995, J BACTERIOL, V177, P3911, DOI 10.1128/jb.177.14.3911-3916.1995; Ramos JL, 1997, J BIOL CHEM, V272, P3887, DOI 10.1074/jbc.272.7.3887; REKKER RF, 1979, EUR J MED CHEM, V14, P479; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SIKKEMA J, 1994, J BIOL CHEM, V269, P8022; STANIER RY, 1966, J GEN MICROBIOL, V43, P159, DOI 10.1099/00221287-43-2-159; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X; WEBER FJ, 1994, MICROBIOL-UK, V140, P2013, DOI 10.1099/13500872-140-8-2013; WEBER FJ, 1993, APPL ENVIRON MICROB, V59, P3502, DOI 10.1128/AEM.59.10.3502-3504.1993; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZYLSTRA GJ, 1989, J BACTERIOL, V171, P5907, DOI 10.1128/jb.171.11.5907-5914.1989; ZYLSTRA GJ, 1995, MOL ENV BIOL, P83	44	199	220	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					85	91		10.1074/jbc.273.1.85	http://dx.doi.org/10.1074/jbc.273.1.85			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417051	hybrid			2022-12-25	WOS:000071295600017
J	Lochnit, G; Dennis, RD; Ulmer, AJ; Geyer, R				Lochnit, G; Dennis, RD; Ulmer, AJ; Geyer, R			Structural elucidation and monokine-inducing activity of two biologically active zwitterionic glycosphingolipids derived from the porcine parasitic nematode Ascaris suum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXCRETORY-SECRETORY PRODUCT; TUMOR-NECROSIS-FACTOR; CALLIPHORA-VICINA INSECTA; ACANTHOCHEILONEMA-VITEAE; POLAR GLYCOSPHINGOLIPIDS; PHERETIMA-HILGENDORFI; CHEMICAL STRUCTURES; CELL PROLIFERATION; IMMUNE-RESPONSES; APLYSIA-KURODAI	The isolated neutral glycosphingolipid fraction from the pig parasitic nematode, Ascaris suum, was fractionated by silica gel chromatography to yield a neutral and a zwitterionic glycosphingolipid fraction, the latter of which mainly contained two zwitterionic glycosphingolipids termed components A and C, Preliminary chemical characterization with hydrofluoric acid treatment and immunochemical characterization with a phosphocholine-specific monoclonal antibody indicated that both components contained phosphodiester substitutions: phosphocholine for component A, and phosphocholine and phosphoethanolamine for component C, Both components were biologically active in inducing human peripheral blood mononuclear cells to release the inflammatory monokines tumor necrosis factor alpha, interleukin 1, and interleukin 6, Component A was the more bioactive molecule, and its biological activity was abolished on removal of the phosphocholine substituent by hydrofluoric acid, The glycosphingolipid components were structurally analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, liquid secondary ion mass spectrometry, methylation analysis, H-1 NMR spectroscopy, exoglycosidase cleavage, and ceramide analysis, Their chemical structures were elucidated to be (see Structure I below), [GRAPHICS] The carbohydrate moiety oligosaccharide core was characterized as belonging to the arthro series of protostomial glycosphingolipids. The ceramide moiety was distinguished;by (R)-2-hydroxytetracosanoic acid as the dominant fatty acid species and by the C17 iso-branched sphingosine and sphinganine bases, 15-methylhexadecasphing-4-enine and 15-methylhexadecasphinganine, respectively.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Res Ctr Borstel, Dept Immunol & Cell Biol, D-23845 Borstel, Germany	Justus Liebig University Giessen; Forschungszentrum Borstel	Geyer, R (corresponding author), Univ Giessen Klinikum, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.							Allen JE, 1996, INT IMMUNOL, V8, P143, DOI 10.1093/intimm/8.1.143; ARAKI S, 1987, J BIOL CHEM, V262, P14141; ARAKI S, 1987, J BIOCHEM-TOKYO, V101, P145, DOI 10.1093/oxfordjournals.jbchem.a121885; BAUMEISTER S, 1994, PARASITE IMMUNOL, V16, P629, DOI 10.1111/j.1365-3024.1994.tb00319.x; BROWN AR, 1976, J IMMUNOL, V116, P1105; CHU JWK, 1995, IMMUNOLOGY, V84, P396; CRANDALL CA, 1971, EXP PARASITOL, V30, P426, DOI 10.1016/0014-4894(71)90107-X; DABROWSKI U, 1990, J BIOL CHEM, V265, P9737; DELL A, 1990, METHOD ENZYMOL, V193, P647, DOI 10.1016/0076-6879(90)93443-O; DENNIS RD, 1995, PARASITOLOGY, V110, P611, DOI 10.1017/S0031182000065331; DYATLOVITSKAYA EV, 1987, BIOCHIM BIOPHYS ACTA, V907, P125, DOI 10.1016/0304-419X(87)90002-3; FEIST W, 1989, IMMUNOBIOLOGY, V179, P293, DOI 10.1016/S0171-2985(89)80036-1; FEIST W, 1992, FEMS MICROBIOL IMMUN, V89, P73, DOI 10.1016/0378-1097(92)90264-O; FLETCHER TC, 1980, PARASITE IMMUNOL, V2, P237, DOI 10.1111/j.1365-3024.1980.tb00056.x; GAVER RC, 1965, J AM OIL CHEM SOC, V42, P294, DOI 10.1007/BF02540132; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GEYER R, 1994, METHOD ENZYMOL, V230, P86; Gomes NA, 1996, J IMMUNOL, V156, P628; GUALZATA M, 1986, EXP PARASITOL, V61, P95, DOI 10.1016/0014-4894(86)90139-6; GUTMAN GA, 1977, EXP PARASITOL, V43, P161, DOI 10.1016/0014-4894(77)90019-4; HARNETT W, 1993, EXP PARASITOL, V77, P498, DOI 10.1006/expr.1993.1113; HARNETT W, 1993, J IMMUNOL, V151, P4829; Heitger A, 1996, BBA-LIPID LIPID MET, V1303, P161, DOI 10.1016/0005-2760(96)00091-4; HELLING F, 1991, EUR J BIOCHEM, V200, P409, DOI 10.1111/j.1432-1033.1991.tb16199.x; HENSEL J, 1995, EUR J BIOCHEM, V232, P373, DOI 10.1111/j.1432-1033.1995.373zz.x; HOLTJE JV, 1975, P NATL ACAD SCI USA, V72, P1690, DOI 10.1073/pnas.72.5.1690; HOLTJE JV, 1975, J BIOL CHEM, V250, P6072; Houston KM, 1996, J PARASITOL, V82, P320, DOI 10.2307/3284169; ITASAKA O, 1979, J BIOCHEM-TOKYO, V85, P1469, DOI 10.1093/oxfordjournals.jbchem.a132475; ITONORI S, 1991, BIOCHIM BIOPHYS ACTA, V1081, P321, DOI 10.1016/0005-2760(91)90289-T; ITONORI S, 1991, J BIOCHEM-TOKYO, V110, P479, DOI 10.1093/oxfordjournals.jbchem.a123607; JOSEPH CK, 1994, J BIOL CHEM, V269, P17606; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P368; KRZIWON C, 1995, INFECT IMMUN, V63, P2899, DOI 10.1128/IAI.63.8.2899-2905.1995; Kuby J., 1992, IMMUNOLOGY, P245; LAL RB, 1990, AM J TROP MED HYG, V42, P56, DOI 10.4269/ajtmh.1990.42.56; LAL RB, 1987, J IMMUNOL, V138, P3454; LOCHNIT G, 1995, EUR J BIOCHEM, V228, P805, DOI 10.1111/j.1432-1033.1995.tb20326.x; Lochnit G, 1997, GLYCOCONJUGATE J, V14, P389, DOI 10.1023/A:1018530914067; LOPPNOW H, 1989, IMMUNOBIOLOGY, V179, P283, DOI 10.1016/S0171-2985(89)80023-3; Maizels R. M., 1988, The biology of parasitism. A molecular and immunological approach., P285; MITCHELL GF, 1976, INT ARCH ALLER A IMM, V52, P235, DOI 10.1159/000231687; MITCHELL GF, 1976, INT ARCH ALLER A IMM, V52, P64, DOI 10.1159/000231669; NODA N, 1993, BIOCHIM BIOPHYS ACTA, V1169, P30; NODA N, 1993, CHEM PHARM BULL, V41, P1733; NODA N, 1992, TETRAHEDRON LETT, V33, P7527, DOI 10.1016/S0040-4039(00)60815-8; NORES GA, 1994, J CHROMATOGR A, V686, P155, DOI 10.1016/S0021-9673(94)89015-3; PAZPARENTE J, 1985, CARBOHYD RES, V141, P41; Persat F, 1996, INFECT IMMUN, V64, P3682, DOI 10.1128/IAI.64.9.3682-3687.1996; PERY P, 1979, ANN INST PASTEUR IMM, VC130, P889; PERY P, 1974, EUR J IMMUNOL, V4, P637, DOI 10.1002/eji.1830040914; RIETSCHEL ET, 1996, CURR TOP MICROBIOL I, V216, P40; Sugita M, 1995, BBA-LIPID LIPID MET, V1259, P220, DOI 10.1016/0005-2760(95)00168-9; SUGITA M, 1992, J BIOL CHEM, V267, P22595; WESKE B, 1990, EUR J BIOCHEM, V191, P379, DOI 10.1111/j.1432-1033.1990.tb19133.x; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; WINTER G, 1994, J CELL SCI, V107, P2741; WRIGHT SD, 1995, IMMUNOL TODAY, V16, P297, DOI 10.1016/0167-5699(95)80185-5; ZIEGLERHEITBROCK HWL, 1992, J IMMUNOL, V148, P1753	59	82	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					466	474		10.1074/jbc.273.1.466	http://dx.doi.org/10.1074/jbc.273.1.466			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417105	hybrid			2022-12-25	WOS:000071295600071
J	Lyon, M; Deakin, JA; Rahmoune, H; Fernig, DG; Nakamura, T; Gallagher, JT				Lyon, M; Deakin, JA; Rahmoune, H; Fernig, DG; Nakamura, T; Gallagher, JT			Hepatocyte growth factor scatter factor binds with high affinity to dermatan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; MET HGF RECEPTOR; MITOGENIC ACTIVITY; OLIGOSACCHARIDES; EXPRESSION; CELLS; GLYCOSAMINOGLYCANS; TUMORIGENICITY; IDENTIFICATION; MOTILITY	We have demonstrated by affinity chromatography that hepatocyte growth factor/scatter factor (HGF/SF) binds strongly to dermatan sulfate (DS), with a similar ionic strength dependence to that previously seen with heparan sulfate (HS). Analysis of binding kinetics on a biosensor yields an equilibrium dissociation constant, K-D, of 19.7 nM. This corresponds to a 10-100-fold weaker interaction than that with HS, primarily due to a faster dissociation rate of the complex. The smallest DS oligosaccharide with significant affinity for HGF/SF by affinity chromatography appears to be an octasaccharide. A sequence comprising unsulfated iduronate residues in combination with 4-O-sulfated N-acetylgalactosamine is sufficient for high affinity binding. The presence of 2-O-sulfation on the iduronate residues does not appear to be inhibitory. These observations concur with our previous suggestions, from analyses of HS binding (Lyon, NL, Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J.T. (1994) J. Biol. Chem. 269, 11216-11223), that N-sulfation of hexosamines and 2-O-sulfation of iduronates are not absolute requirements for glycosaminoglycan binding to HGF/SF. This is the first described example of a high affinity interaction between a growth factor and DS, and is likely to have significant implications for the biological activity of this paracrine-acting factor.	Christie Hosp NHS Trust, Univ Manchester, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Christie Hosp NHS Trust, Canc Res Campaign, Dept Med Oncol, Manchester M20 4BX, Lancs, England; Univ Liverpool, Sch Biol Sci, Liverpool L69 7ZB, Merseyside, England; Osaka Univ, Sch Med, Biomed Res Ctr, Div Biochem, Osaka 565, Japan	Christie NHS Foundation Trust; Christie Hospital; University of Manchester; Christie NHS Foundation Trust; Christie Hospital; University of Liverpool; Osaka University	Lyon, M (corresponding author), Christie Hosp NHS Trust, Christie CRC Res Ctr, Dept Med Oncol, Wilmslow Rd, Manchester M20 4BX, Lancs, England.		Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Lyon, Malcolm/0000-0001-9575-6879				ASHIKARI S, 1995, J BIOL CHEM, V270, P29586, DOI 10.1074/jbc.270.49.29586; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CELLA G, 1992, ANGIOLOGY, V43, P59, DOI 10.1177/000331979204300107; CLARKE D, 1995, CYTOKINE, V7, P325, DOI 10.1006/cyto.1995.0041; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; FERRO DR, 1986, J AM CHEM SOC, V108, P6773, DOI 10.1021/ja00281a052; GIGLI M, 1993, BIOCHIM BIOPHYS ACTA, V1167, P211, DOI 10.1016/0005-2760(93)90164-5; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, BIOCHEM SOC T, V22, P365, DOI 10.1042/bst0220365; Maaroufi RM, 1997, BIOMATERIALS, V18, P359, DOI 10.1016/0142-9612(95)00355-X; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MASCELLANI G, 1993, BIOCHEM J, V296, P639, DOI 10.1042/bj2960639; Matsumoto K, 1996, J BIOCHEM-TOKYO, V119, P591; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; PEARSON CH, 1983, J BIOL CHEM, V258, P5101; PRIGLINGER U, 1994, J BIOL CHEM, V269, P14705; RONG S, 1993, CANCER RES, V53, P5355; Sakata H, 1997, J BIOL CHEM, V272, P9457; SAMBANDAM T, 1991, ARTERIOSCLER THROMB, V11, P561, DOI 10.1161/01.ATV.11.3.561; SCHOR SL, 1985, J CELL SCI, V73, P221; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SCOTT JE, 1995, BIOCHEMISTRY-US, V34, P15467, DOI 10.1021/bi00047a011; SCOTT JE, 1993, DERMATAN SULFATE PRO; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SVENNEVIG K, 1995, BIOCHEM J, V311, P881, DOI 10.1042/bj3110881; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VANBOECKEL CAA, 1987, RECL TRAV CHIM PAY B, V106, P19; VENKATARAMAN G, 1994, P NATL ACAD SCI USA, V91, P6171, DOI 10.1073/pnas.91.13.6171; Walker A, 1996, BIOCHEM J, V317, P871, DOI 10.1042/bj3170871; Yoshida K., 1993, DERMATAN SULFATE PRO, P55; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	38	133	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					271	278		10.1074/jbc.273.1.271	http://dx.doi.org/10.1074/jbc.273.1.271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417075	hybrid			2022-12-25	WOS:000071295600041
J	Shon, KJ; Stocker, M; Terlau, H; Stuhmer, W; Jacobsen, R; Walker, C; Grilley, M; Watkins, M; Hillyard, DR; Gray, WR; Olivera, BM				Shon, KJ; Stocker, M; Terlau, H; Stuhmer, W; Jacobsen, R; Walker, C; Grilley, M; Watkins, M; Hillyard, DR; Gray, WR; Olivera, BM			kappa-conotoxin PVIIA is a peptide inhibiting the Shaker K+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHARYBDOTOXIN; RECEPTOR; DIVERSITY; STRATEGY; FAMILY; VENOM	kappa-Conotoxin PVIIA (kappa-PVIIA), a 27-amino acid toxin from Conus purpurascens venom that inhibits the Shaker potassium channel, was chemically synthesized in a biologically active form, The disulfide connectivity of the peptide was determined, kappa-Conotoxin PVIIA has the following structure. [GRAPHICS] This is the first Conus peptide known to target K+ channels, Although the Shaker K+ channel is sensitive to kappa-PVIIA, the rat brain Kv1.1 subtype is resistant, Chimeras between Shaker and the Kv1.1 K+ channels were constructed and expressed in Xenopus oocytes, Only channels containing the putative pore-forming region between the fifth and sixth transmembrane domains of Shaker retained toxin sensitivity, indicating that the toxin target site is in this region of the channel, Evidence is presented that kappa-PVIIA interacts with the external tetraethyl-ammonium binding site on the Shaker channel. Although both kappa-PVIIA and charybdotoxin inhibit the Shaker channel, they must interact differently, The F425G Shaker mutation increases charybdotoxin affinity by 3 orders of magnitude but abolishes kappa-PVIIA sensitivity, The precursor sequence of kappa-PVIIA was deduced from a cDNA clone, revealing a prepropeptide comprising 72 amino acids, The N-terminal region of the kappa-PVIIA prepropeptide exhibits striking homology to the omega-, mu O-, and delta-conotoxins. Thus, at least four pharmacologically distinct superfamilies of Conus peptides belong to the same "O" superfamily, with the omega- and kappa-conotoxins forming one branch, and the delta- and mu O-conotoxins forming a second major branch.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Max Planck Inst Expt Med, D-37075 Gottingen, Germany	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Case Western Reserve University; Max Planck Society	Olivera, BM (corresponding author), Univ Utah, Dept Biol, 201 S Biol, Salt Lake City, UT 84112 USA.		Stocker, Martin/C-1844-2008; Stuehmer, Walter/A-2176-2009	Stuehmer, Walter/0000-0002-0642-7764	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048677] Funding Source: NIH RePORTER; NIGMS NIH HHS [P01 GM48677] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; GOLDSTEIN SAN, 1997, BIOPHYS J, V62, P5; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HOPKINS C, 1995, J BIOL CHEM, V270, P22361, DOI 10.1074/jbc.270.38.22361; KAMB A, 1988, NEURON, V1, P421, DOI 10.1016/0896-6273(88)90192-4; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; MONJE VD, 1993, NEUROPHARMACOLOGY, V32, P1141, DOI 10.1016/0028-3908(93)90008-Q; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; OLIVERA BM, 1991, J BIOL CHEM, V266, P22067; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Terlau H, 1996, NATURE, V381, P148, DOI 10.1038/381148a0	16	121	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					33	38		10.1074/jbc.273.1.33	http://dx.doi.org/10.1074/jbc.273.1.33			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417043	hybrid			2022-12-25	WOS:000071295600009
J	Titievsky, A; Titievskaya, I; Pasternack, M; Kaila, K; Tornquist, K				Titievsky, A; Titievskaya, I; Pasternack, M; Kaila, K; Tornquist, K			Sphingosine inhibits voltage-operated calcium channels in GH(4)C(1) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROTROPIN-RELEASING-HORMONE; PROTEIN-KINASE-C; FREE CA-2+ CONCENTRATIONS; GH3 PITUITARY-CELLS; INTRACELLULAR CALCIUM; SIGNALING PATHWAYS; COUPLED RECEPTORS; MEMBRANE-RECEPTOR; HUMAN NEUTROPHILS; PHORBOL ESTERS	In the present study we investigated the mechanism of inhibitory action of sphingosine (SP) on voltage-activated calcium channels (VOCCs) in pituitary GH(4)C(1) cells. Using the patch-clamp technique in the whole-cell mode, we show that SP inhibits Ba2+ currents (I-Ba) when 0.1 mM BAPTA is included in the patch pipette. However, when the BAPTA concentration was raised to 1-10 mm, SP was without a significant effect. The effect of SP was apparently not mediated via a kinase, as it was not inhibited by staurosporine. By using the double-pulse protocol (to release possible functional inhibition of the VOCCs by G proteins), we observed that G proteins apparently evoked very little functional inhibition of the VOCCs. Furthermore, including GDP beta S (guanyl-5'-yl thiophosphate) in the patch pipette did not alter the inhibitory effect of SP on the Ba2+ current, suggesting that SP did not modulate the VOCCs via a G protein-dependent pathway. Single-channel experiments with SP in the pipette, and experiments with excised outside-out patches, suggested that SP directly inhibited VOCCs. The main mechanism of action was a dose-dependent prolongation of the closed time of the channels. The results thus show that SP is a potent inhibitor of VOCCs in GH(4)C(1) cells, and that calcium may be a cofactor in this inhibition.	Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Univ Helsinki, Div Anim Physiol, Dept Biosci, Helsinki, Finland; Minerva Fdn, Inst Med Res, Helsinki, Finland	Abo Akademi University; University of Helsinki	Tornquist, K (corresponding author), Abo Akad Univ, Dept Biol, Artillerigatan 6, FIN-20520 Turku, Finland.		Kaila, Kai K/R-8528-2016	Kaila, Kai K/0000-0003-0668-5955				ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; ARMSTRONG CM, 1985, SCIENCE, V227, P65, DOI 10.1126/science.2578071; BREITTMAYER JP, 1994, J BIOL CHEM, V269, P5054; Bunemann M, 1996, EMBO J, V15, P5527, DOI 10.1002/j.1460-2075.1996.tb00937.x; Choi OH, 1996, NATURE, V380, P634; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; DAY RN, 1990, MOL ENDOCRINOL, V4, P736, DOI 10.1210/mend-4-5-736; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DETTBARN CA, 1994, J MOL CELL CARDIOL, V26, P229, DOI 10.1006/jmcc.1994.1026; DIETER P, 1993, BIOL CHEM H-S, V374, P171, DOI 10.1515/bchm3.1993.374.1-6.171; DUFY B, 1987, ENDOCRINOLOGY, V121, P793, DOI 10.1210/endo-121-2-793; ENYEART JJ, 1987, J BIOL CHEM, V262, P3154; ENYEART JJ, 1985, AM J PHYSIOL, V248, pC510, DOI 10.1152/ajpcell.1985.248.5.C510; GERSHENGORN MC, 1985, ENDOCRINOLOGY, V116, P591, DOI 10.1210/endo-116-2-591; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GLOSSMANN H, 1988, VITAM HORM, V44, P155; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; LI PZ, 1992, MOL ENDOCRINOL, V6, P1393, DOI 10.1210/me.6.9.1393; MANTEGAZZA M, 1995, EMBO J, V14, P1075, DOI 10.1002/j.1460-2075.1995.tb07090.x; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MCDONOUGH PM, 1994, CIRC RES, V75, P981, DOI 10.1161/01.RES.75.6.981; MOLLARD P, 1994, J BIOL CHEM, V269, P25158; OKAJIMA F, 1995, J BIOL CHEM, V270, P26332, DOI 10.1074/jbc.270.44.26332; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PETROU S, 1994, J GEN PHYSIOL, V103, P471, DOI 10.1085/jgp.103.3.471; RAMSDELL JS, 1986, J BIOL CHEM, V261, P5301; REBECCHI MJ, 1983, BIOCHEM J, V216, P287, DOI 10.1042/bj2160287; SABBADINI RA, 1992, J BIOL CHEM, V267, P15475; SITGES M, 1993, J NEUROCHEM, V61, P443; SUZUKI N, 1990, J CELL PHYSIOL, V144, P62, DOI 10.1002/jcp.1041440109; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TASHJIAN AH, 1968, ENDOCRINOLOGY, V82, P342, DOI 10.1210/endo-82-2-342; TORNQUIST K, 1994, BIOCHEM J, V299, P213, DOI 10.1042/bj2990213; TORNQUIST K, 1995, ENDOCRINOLOGY, V136, P4894, DOI 10.1210/en.136.11.4894; vanKoppen CJ, 1996, MOL PHARMACOL, V49, P956; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; WHITE BA, 1981, J BIOL CHEM, V256, P5942; WONG K, 1993, CELL CALCIUM, V14, P493, DOI 10.1016/0143-4160(93)90008-T; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yasui KJ, 1996, AM J PHYSIOL-CELL PH, V270, pC645, DOI 10.1152/ajpcell.1996.270.2.C645; YULE DI, 1993, J BIOL CHEM, V268, P12353; ZHANG H, 1990, J BIOL CHEM, V265, P76	51	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					242	247		10.1074/jbc.273.1.242	http://dx.doi.org/10.1074/jbc.273.1.242			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417071	hybrid			2022-12-25	WOS:000071295600037
J	Sarcevic, B; Lilischkis, R; Sutherland, RL				Sarcevic, B; Lilischkis, R; Sutherland, RL			Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M-PHASE PHOSPHOPROTEINS; DEPENDENT KINASES; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; CLONING; IDENTIFICATION; TRANSITION; EXPRESSION; GENES; SPECIFICITY	The cyclin-dependent kinases (CDKs) promote cell cycle transitions in mammalian cells by phosphorylation of key substrates, To characterize substrates of the G(1) and S phase cyclin-CDK complexes, including cyclin D1-CDK4, cyclin D3-CDK4, cyclin D3-CDK6, cyclin E-CDK2, and cyclin A-CDK2, which are largely undefined, we phosphorylated T-47D breast cancer cell nuclear lysates partially purified by ion-exchange chromatography with purified baculovirus expressed cyclin-CDK complexes, A comparison of the substrates that were phosphorylated by the different cyclin D-CDKs revealed some common as well as specific substrates, Hence, cyclin D1-CDK4 specifically phosphorylated a 38-kDa protein while cyclin D3-CDK4 specifically phosphorylated proteins of 105, 102, and 42 kDa, A 24-kDa protein was phosphorylated by both complexes, Cyclin D3-CDK6 exhibited similar substrate preferences to cyclin D3-CDK4, phosphorylating the 105- and 102-kDa proteins but not the 24-kDa protein, Hence, both the cyclin D1 and D3 as well as CDK4 and CDK6 subunits can confer substrate specificity on the overall cyclin D-CDK complex, Cyclin E-CDK2 and cyclin A-CDK2 phosphorylated a greater number of substrates than the cyclin D-CDKs, ranging in size from 10 kDa to over 200 kDa, Twenty-two substrates were common to both complexes, while six were specific for cyclin A-CDK2 and only one protein of 34 kDa was specific for cyclin E-CDK2, These studies indicate that cyclins E and A modulate the specificity of CDK2 and have demonstrated substrates that may be important for the specific roles of these cyclin-CDKs during G(1) and S phase progression, Protein sequencing of one of the cyclin-CDK substrates characterized in this study identified this protein as nucleolin, a previously characterized CDC2 (CDK1) substrate, thus indicating the utility of this approach in identifying cycln-CDK targets, These results show that both the cyclin and CDK subunits can regulate the substrate specificity of the overall cyclin-CDK complex and have demonstrated numerous substrates of D-, E-, and A-type cyclin-CDK complexes potentially involved in regulating transit through the G(1) and S phases of the cell cycle.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Sarcevic, B (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia.	b.sarcevic@garvam.unsw.edu.au	Sutherland, Robert L/A-8378-2008	Sarcevic, Boris/0000-0002-8063-1050				AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; Hara E, 1997, EMBO J, V16, P332, DOI 10.1093/emboj/16.2.332; Higashi H, 1996, EUR J BIOCHEM, V237, P460, DOI 10.1111/j.1432-1033.1996.0460k.x; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Horton LE, 1997, ONCOGENE, V14, P491, DOI 10.1038/sj.onc.1200851; KATO J, 1993, GENE DEV, V7, P331; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KWON TK, 1995, ONCOGENE, V11, P2077; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MatsumotoTaniura N, 1996, MOL BIOL CELL, V7, P1455, DOI 10.1091/mbc.7.9.1455; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOTOKURA T, 1992, J BIOL CHEM, V267, P20412; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1994, TRENDS BIOCHEM SCI, V19, P143, DOI 10.1016/0968-0004(94)90272-0; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Sweeney KJ, 1997, ONCOGENE, V14, P1329, DOI 10.1038/sj.onc.1200951; VALLANCE SJ, 1994, HYBRIDOMA, V13, P37, DOI 10.1089/hyb.1994.13.37; WANG X, 1995, J NEUROCHEM, V65, P595; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	52	60	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33327	33337		10.1074/jbc.272.52.33327	http://dx.doi.org/10.1074/jbc.272.52.33327			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407125	hybrid			2022-12-25	WOS:000071182900086
J	Yan, YX; Nakagawa, H; Lee, MH; Rustgi, AK				Yan, YX; Nakagawa, H; Lee, MH; Rustgi, AK			Transforming growth factor-alpha enhances cyclin D1 transcription through the binding of early growth response protein to a cis-regulatory element in the cyclin D1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUAMOUS-CELL CARCINOMA; RETINOBLASTOMA PROTEIN; ESOPHAGEAL CANCER; MESSENGER-RNA; EXPRESSION; GENE; PROGRESSION; FIBROBLASTS; G(1); SP1	Cyclin D1 is a critical oncogene involved in the regulation of progression through the G(1) phase of the cell cycle, thereby contributing to cell proliferation. This is mediated through interaction of cyclin D1 with its catalytic partners, the cyclin dependent kinases, and the subsequent phosphorylation of the retinoblastoma protein. Cyclin D1, in turn, is regulated by mitogenic stimuli. We demonstrate that transforming growth factor-alpha (TGF alpha) induces cyclin D1 mRNA in esophageal squamous epithelial cells, and this appears to correlate with increased cyclin D1 protein expression and cyclin-dependent kinase 6 activity. The induction of cyclin D1 transcription by TGF alpha is mediated in part through the induction of the early growth response protein (Egr-1) and its subsequent binding of Egr-1 to a cis-regulatory region spanning nucleotides -144 to -104 of the cyclin D1 promoter. The Egr-1 binding activity to the cyclin D1 promoter appears to require de novo protein synthesis and is not influenced by Sp1 binding to overlapping Sp1 motifs. Taken together, these data provide evidence that TGF alpha enhances cyclin D1 transcription through the induction of Egr-1 binding to a cis-regulatory region in the cyclin D1 promoter. This has important mechanistic implications into the transcriptional regulation of cyclin D1 by an essential proproliferative growth factor and cell cycle progression.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gastrointestinal Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Hematol Oncol Unit, Boston, MA 02114 USA; Boston Univ, Sch Med, Dept Med, Div Pulm, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Boston University	Rustgi, AK (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Gastrointestinal Unit, Jackson 904, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK043351, P30DK040561, R01DK053377] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40561, DK53377, DK43351] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Arber N, 1997, CANCER RES, V57, P1569; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARNARD JA, 1995, GASTROENTEROLOGY, V108, P564, DOI 10.1016/0016-5085(95)90087-X; BARTKOVA J, 1995, CANCER RES, V55, P949; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO X, 1995, MOL CELL BIOL, V10, P1931; CARTLIDGE SA, 1989, BRIT J CANCER, V60, P657, DOI 10.1038/bjc.1989.334; DASKIS JL, 1994, ONCOGENE, V9, P3635; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FURLANETTO RW, 1994, MOL ENDOCRINOL, V8, P510, DOI 10.1210/me.8.4.510; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, ONCOGENE, V9, P323; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Nakagawa H, 1997, ONCOGENE, V14, P1185, DOI 10.1038/sj.onc.1200937; Nakagawa H, 1997, J BIOL CHEM, V272, P16688, DOI 10.1074/jbc.272.26.16688; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAO SS, 1995, J BIOL CHEM, V270, P4093, DOI 10.1074/jbc.270.8.4093; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIODA T, 1994, P NATL ACAD SCI USA, V91, P11919, DOI 10.1073/pnas.91.25.11919; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SURMACZ E, 1992, CANCER RES, V52, P4522; TIMMERMANN S, 1997, CELL GROWTH DIFFER, V8, P861; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; YOSHIDA K, 1990, INT J CANCER, V45, P131, DOI 10.1002/ijc.2910450124; ZANDOMENI R, 1982, P NATL ACAD SCI-BIOL, V79, P3167, DOI 10.1073/pnas.79.10.3167; ZHANG SY, 1994, CANCER RES, V54, P5050	51	83	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33181	33190		10.1074/jbc.272.52.33181	http://dx.doi.org/10.1074/jbc.272.52.33181			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407106	hybrid			2022-12-25	WOS:000071182900067
J	Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D				Schwachtgen, JL; Janel, N; Barek, L; Duterque-Coquillaud, M; Ghysdael, J; Meyer, D; Kerbiriou-Nabias, D			Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene	ONCOGENE			English	Article						Ets family of proteins; gene regulation; von Willebrand factor; endothelial cells	HUMAN-ENDOTHELIAL-CELLS; HUMAN VONWILLEBRAND-FACTOR; DNA-BINDING; ACTIVATION PROPERTIES; VASCULAR ENDOTHELIUM; 5'-FLANKING REGION; INITIATION SITE; IIB GENE; EXPRESSION; PROTEIN	von Willebrand factor (VWF) gene expression is restricted to endothelial cells and megakaryocytes. Previous results demonstrated that basal transcription of the human vWF gene is mediated through a promoter located between base pairs -89 and +19 (cap site: +1) which is functional in endothelial and non endothelial cells, Two DNA repeats TTTCCTTT correlating,vith inverted consensus binding sites for the Ets family of transcription factors are present in the -56/-36 sequence, In order to analyse whether these DNA elements are involved in transcription, human umbilical vein endothelial cells (HUVEC), bovine calf pulmonary endothelial cell line (CPAE), HeLa and COS cells mere transfected with constructs containing deletions of the -89/+19 fragment, linked to the chloramphenicol acetyl transferase (CAT) reporter gene, The -60/+19 region exhibits significant promoter activity in HUVEC and CPAE cells only, The -42/+19 fragment is not active, Mutations of the -60/+19 promoter fragment in the 5' (-56/-49) Ets binding site abolish transcription in endothelial cells whereas mutations in the 3' (-43/ -36) site does not, The -60/-33 fragment forms three complexes with proteins from HUVEC nuclear extracts in electrophoretic mobility shift assay which are dependent on the presence of the 5' Ets binding site, Binding of recombinant Ets-1 protein to the -60/-33 fragment gives a complex which also depends on the 5' site, The -60/+19 VWF gene core promoter is transactivated in HeLa cells by cotransfecting with Ets-1 or Erg (Ets-related gene) expression plasmids, In contrast to the wild type construct, transcription of the 5' site mutants is not increased by these expressed proteins, The results indicate that the promoter activity of the -60/+19 region of the vWF gene depends on transcription factors of the Ets family of which several members like Ets-1, Ets-2 and Erg are expressed in endothelium. Cotransfection of Ets-1 and Erg expression plasmids is sufficient to induce the -60/+19 vWF promoter activity in HeLa cells.	Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France; Inst Biol Lille, CNRS, UMR 319, F-59021 Lille, France; Inst Curie, Ctr Univ, CNRS, UMR 146, F-91405 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Kerbiriou-Nabias, D (corresponding author), Hop Bicetre, Unite Rech Hemostase & Thrombose, INSERM U 143, F-94275 Le Kremlin Bicetre, France.		GHYSDAEL, Jacques/F-3377-2013	Janel, Nathalie/0000-0002-4746-8941; Duterque-Coquillaud, Martine/0000-0003-3943-5629				AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; ASSOULINE Z, 1988, BIOCHEM BIOPH RES CO, V153, P1159, DOI 10.1016/S0006-291X(88)81349-4; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BONTHRON D, 1988, EUR J BIOCHEM, V171, P51, DOI 10.1111/j.1432-1033.1988.tb13757.x; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; Buttice G, 1996, ONCOGENE, V13, P2297; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLLINS CJ, 1987, P NATL ACAD SCI USA, V84, P4393, DOI 10.1073/pnas.84.13.4393; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; DEGROOT PG, 1987, ARTERIOSCLEROSIS, V7, P605, DOI 10.1161/01.ATV.7.6.605; DEGUINE V, 1995, BLOOD COAGUL FIBRIN, V6, P42, DOI 10.1097/00001721-199502000-00007; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUTERQUECOQUILLAUD M, 1993, ONCOGENE, V8, P1865; FERREIRA V, 1993, BIOCHEM J, V293, P641, DOI 10.1042/bj2930641; FISHER RJ, 1992, J BIOL CHEM, V269, P17957; FREBOURG T, 1988, GENE, V65, P315, DOI 10.1016/0378-1119(88)90468-4; GEBRANEYOUNES J, 1991, AM J PATHOL, V139, P1471; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEGONNE A, 1992, NEW BIOL, V4, P512; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; HASHIMOTO Y, 1995, J BIOL CHEM, V270, P24532, DOI 10.1074/jbc.270.41.24532; HOSHI H, 1984, P NATL ACAD SCI-BIOL, V81, P6413, DOI 10.1073/pnas.81.20.6413; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; JAFFE EA, 1974, P NATL ACAD SCI USA, V71, P1906, DOI 10.1073/pnas.71.5.1906; Jahroudi N, 1996, J BIOL CHEM, V271, P21413, DOI 10.1074/jbc.271.35.21413; JAHROUDI N, 1994, MOL CELL BIOL, V14, P999, DOI 10.1128/MCB.14.2.999; Janel N, 1995, GENE, V167, P291, DOI 10.1016/0378-1119(95)00696-6; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; LEMARCHANDEL V, 1993, MOL CELL BIOL, P668; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTIN F, 1993, J BIOL CHEM, V268, P21606; NACHMAN RL, 1975, J EXP MED, V141, P101; PAGE C, 1992, AM J PATHOL, V141, P673; PRASAD DDK, 1994, ONCOGENE, V9, P669; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REDDY ESP, 1991, ONCOGENE, V6, P2285; ROSEN GD, 1994, J BIOL CHEM, V269, P15652; ROUET P, 1992, BIOTECHNIQUES, V13, P700; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SCHWACHTGEN JL, 1994, BIOTECHNIQUES, V17, P882; SCHWACHTGEN JL, 1996, J VASC RES S1, V33, P90; Shore P, 1996, MOL CELL BIOL, V16, P3338; SPORN LA, 1985, J CLIN INVEST, V76, P1102, DOI 10.1172/JCI112064; TYMMS MJ, 1994, MOL REPROD DEV, V39, P208, DOI 10.1002/mrd.1080390214; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VONDERAHE D, 1993, NUCLEIC ACIDS RES, V21, P5636, DOI 10.1093/nar/21.24.5636; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNERT N, 1992, AM J PATHOL, V140, P119; WERNERT N, 1994, CANCER RES, P5683	63	75	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3091	3102		10.1038/sj.onc.1201502	http://dx.doi.org/10.1038/sj.onc.1201502			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444957				2022-12-25	WOS:000070968000009
J	Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B				Gloushankova, N; Ossovskaya, V; Vasiliev, J; Chumakov, P; Kopnin, B			Changes in p53 expression can modify cell shape of ras-transformed fibroblasts and epitheliocytes	ONCOGENE			English	Article						p53; ras; morphological transformation	P-GLYCOPROTEIN FUNCTION; TATA-BINDING PROTEIN; MAP KINASE KINASE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; FUNCTION MUTATIONS; TUMOR-ANTIGEN; DOMAINS; GENE	p53 plays an important role in restriction of abnormal cell proliferation, Loss of this safeguard function induced by p53 mutations seems to be a key mechanism in oncogenesis, It cannot be excluded however, that in addition to elimination of p53-dependent checkpoints and/or apoptosis p53 mutations may cause additional effects that contribute to oncogenic transformation. In order to analyse the effects of 7 wild-type (wt) and mutant p53 on expression of res-induced morphological transformation we used the method of computer-assisted morphometry, The following parameters were determined: a) the area covered by the spread cells; b) dispersion and c) elongation of cell contours, The last two indices characterise cell shape, Elongation indicates the degree of bipolarity of cell contour and dispersion the degree of its multipolarity. Transformation of Rat1 and mouse 10(3) fibroblasts by N-rasasp12 oncocgene, was accompanied by dramatic decrease of cell area and increase of dispersion and elongation. IAR-2 discoid epitheliocytes expressing exogenous res oncogene transformed into polarised cells with decreased cell area, Fluorescent microscopic examination of actin cytoskeleton stained with rhodamine-phalloidin had shown that res-induced transformation of IAR-2 cells is characterised by disappearance of circumferential actin bundle and straight fibers, Neither did we reveal actin stress-fibers in the ras-transformed Rat1 cells, Transduction of p53 cDNAs caused no significant changes in morphometric parameters of non-transformed parental Rat1, IAR-2 and 10(3) cells, but some of the p53 mutants modified cell shape of ras-transformed cells, p53-His273, unlike other tested p53 mutants (Tyr141, His194, Trp248), induced partial reversion of morphological transformation in both Rat1 fibroblasts and IAR-2 epitheliocytes. Its expression led to increase of average cell area, decrease of dispersion and elongation indices, and re-appearance of actin bundles, Exogenous wild-type p53 also caused some reversion of transformed phenotype of Rat/ras cells, but its effect was weaker than that of the p53-His273. In contrast, another p53 mutant p53-His175 was able to enhance ras-induced morphological transformation in p53-deficient murine 10(3) fibroblasts that is consistent with possible involvement of some gain of function activity of mutant p53 in modulation of cell shape, Possible pathways that might be responsible for p53-induced changes of cell morphology are discussed.	RUSSIAN ACAD SCI,ENGELHARDT INST MOL BIOL,MOSCOW,RUSSIA; RUSSIAN ACAD SCI,CANC RES CTR,INST CANCEROGENESIS,MOSCOW,RUSSIA	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Russian Academy of Sciences			Chumakov, Peter M/E-7731-2014; Kopnin, Boris/R-8240-2019; Gloushankova, Natalya/S-2577-2019	Kopnin, Boris/0000-0003-3100-2212; Gloushankova, Natalya/0000-0002-2044-2063; Chumakov, Peter/0000-0002-8078-2908				AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BROWN AF, 1989, CELL BIOL INT REP, V13, P357, DOI 10.1016/0309-1651(89)90162-8; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dunn G. A., 1986, J CELL SCI, V108, P1659; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FUKASAWA K, 1995, ONCOGENE, V11, P1447; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSIAO M, 1994, AM J PATHOL, V145, P702; JENKINS JR, 1984, NATURE, V312, P851; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KOPNIN BP, 1995, ONCOL RES, V7, P299; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MACHESKY LM, 1996, TRENDS CELL BIOL, V6, P394; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTESANO R, 1975, INT J CANCER, V16, P550, DOI 10.1002/ijc.2910160405; NIEWOLIK D, 1995, ONCOGENE, V10, P881; OKAZAKI K, 1995, ONCOGENE, V10, P1149; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PERREM K, 1995, ONCOGENE, V11, P1299; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ransone Lynn J., 1993, Gene Expression, V3, P37; SCHENENBERGER CA, 1991, J CELL BIOL, V112, P873; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULSKY G, 1991, CANCER RES, V51, P5232; STROMSKAYA TP, 1995, FEBS LETT, V368, P373, DOI 10.1016/0014-5793(95)00662-S; Thomas M, 1996, ONCOGENE, V13, P265; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAICHUK TA, 1993, P RUSSIAN ACAD SCI, V330, P386; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	52	28	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2985	2989		10.1038/sj.onc.1201483	http://dx.doi.org/10.1038/sj.onc.1201483			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416842				2022-12-25	WOS:A1997YK37700011
J	McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG				McCracken, S; Kim, CS; Xu, Y; Minden, M; Miyamoto, NG			An alternative pathway for expression of p56(lck) from type I promoter transcripts in colon carcinoma	ONCOGENE			English	Article						lck; colon cancer; transcription	T-CELL DEVELOPMENT; PP60C-SRC PROTEIN-KINASE; THYMOCYTE DEVELOPMENT; LCK TRANSCRIPTS; GENE-EXPRESSION; HMG DOMAIN; BINDING; ACTIVATION; RECEPTOR; P56LCK	The lymphoid-specific protein tyrosine kinase, p56(lck) which is essential for both T cell development and function, is aberrantly expressed in colon and small lung carcinoma lines, In this paper, we demonstrate p56(lck) is also expressed in colon tumour biopsies due predominantly or exclusively to the use of the lck type I promoter, In T leukaemia lines, the lck type I promoter requires binding sites for both Ets- and Myb-related transcription factors, In contrast, in colon tumour lines the activation of the lck type I promoter requires the Ets but not the Myb binding site, In these lines, a consensus binding site for HMG-related transcription factors, AACAAAG, is required for efficient lck type I promoter activity, Sox-4 is a candidate transcription factor for binding and activating the lck type I promoter in colon carcinoma cells. Go-expression of Ets-1 and Sox-4, but neither protein alone, was sufficient to activate the lck type I promoter in HeLa cells which do not normally express lck transcripts, These results suggest that aberrant expression of p56(lck) from the lck type I promoter in colon carcinoma arises from transcriptional activation mediated by Ets-and HMG-related transcription factors.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DIV CELLULAR & MOL BIOL,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; PRINCESS MARGARET HOSP,AMGEN RES INST,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre								ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GROETTRUP M, 1993, IMMUNOL TODAY, V14, P610, DOI 10.1016/0167-5699(93)90201-U; GRONOSTAJSKI RM, 1986, NUCLEIC ACIDS RES, V14, P9117, DOI 10.1093/nar/14.22.9117; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEUNG S, 1993, ONCOGENE, V8, P989; LEUNG S, 1991, J CELL PHYSIOL, V148, P344, DOI 10.1002/jcp.1041480304; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; PARK JS, 1993, ONCOGENE, V8, P2627; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; SARTOR O, 1989, MOL CELL BIOL, V9, P2983, DOI 10.1128/MCB.9.7.2983; SIYANOVA EY, 1994, ONCOGENE, V9, P2053; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAKADERA T, 1989, MOL CELL BIOL, V9, P2173, DOI 10.1128/MCB.9.5.2173; TOMITA N, 1992, CANCER RES, V52, P6840; TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; WILDIN RS, 1991, J EXP MED, V173, P383, DOI 10.1084/jem.173.2.383; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840	34	40	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2929	2937		10.1038/sj.onc.1201474	http://dx.doi.org/10.1038/sj.onc.1201474			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416836				2022-12-25	WOS:A1997YK37700005
J	Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A				Barboule, N; Chadebech, P; Baldin, V; Vidal, S; Valette, A			Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line	ONCOGENE			English	Article						p21; paclitaxel; p34(cdc2) activity; mitotic exit	CYCLIN-DEPENDENT KINASES; HUMAN OVARIAN-CARCINOMA; TAXOL-INDUCED APOPTOSIS; LEUKEMIA-CELLS; GROWTH ARREST; DNA-DAMAGE; EXPRESSION; ACTIVATION; P53; DIFFERENTIATION	It has been shown recently that expression of p21 is enhanced by paclitaxel, This cytotoxic compound induces mitotic spindle damage resulting in blockade of the mitotic cell cycle associated or not with apoptotic cell death, In the present study, we showed that, in MCF-7 cells, paclitaxel induced accumulation of p21 in cells with a G2/M DNA content, corresponding to cells either in abnormal mitosis or in an interphase-like state (decondensed chromatin) with multiple nuclei, In MCF-7 cells, the increase in p21 was subsequent to the mitotic arrest and was associated with the exit from abnormal mitosis leading to formation of cells with micronuclei. In this cell line, we noted a relationship between the elevation of p21 expression and the inhibition of p34(cdc2) activity, High levels of p21 protein were also found to be associated with inactive p34(cdc2)/cyclin B protein complex after treatment with paclitaxel, Treatment with p21 antisense oligonucleotide partially blocked induction of p21 expression by paclitaxel and significantly reduced survival of MCF-7 cells exposed to this agent, In NIH-OVCAR-3 cells, which are deficient in basal and paclitaxel-induced p21 expression, paclitaxel led to a prolonged activation of p34(cdc2) and a delayed mitotic exit associated with apoptotic cell death, These observations suggest that p21 is not required for the mitotic arrest in response to paclitaxel, but argue in favor of a role for this inhibitor in facilitating the exit from abnormal mitosis, This effectively enhances cell survival after paclitaxel-induced spindle-damage.	IPBS,CNRS,F-31077 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			BALDIN, Véronique/Y-8397-2019; CHADEBECH, Philippe/ABB-4423-2020	BALDIN, Véronique/0000-0001-8523-0494; CHADEBECH, Philippe/0000-0003-0757-4309				ANDREASSEN PR, 1994, J CELL BIOL, V127, P789, DOI 10.1083/jcb.127.3.789; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BHALLA K, 1993, LEUKEMIA, V7, P563; BLAGOSKLONNY MV, 1995, CANCER RES, V55, P4623; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P421; Debernardis D, 1997, CANCER RES, V57, P870; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONALDSON KL, 1994, CELL GROWTH DIFFER, V5, P1041; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; JIANG HP, 1994, ONCOGENE, V9, P3397; Jordan MA, 1996, CANCER RES, V56, P816; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; Lafon C, 1996, CELL GROWTH DIFFER, V7, P1095; LEVEDAKOU EN, 1995, CANCER RES, V55, P2500; LI Y, 1994, ONCOGENE, V9, P2261; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; LONG BH, 1994, CANCER RES, V54, P4355; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAZARS P, 1995, FEBS LETT, V362, P295, DOI 10.1016/0014-5793(95)00247-7; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; ROWINSKY EK, 1988, CANCER RES, V48, P4093; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU T, 1995, CANCER RES, V55, P228; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANG C, 1994, LEUKEMIA, V8, P1960; TISHLER RB, 1995, CANCER RES, V55, P6021; TRIELLI MO, 1996, J CELL BIOL, V3, P689; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359	45	86	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2867	2875		10.1038/sj.onc.1201469	http://dx.doi.org/10.1038/sj.onc.1201469			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419978				2022-12-25	WOS:A1997YJ80300013
J	Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A				Guha, A; Feldkamp, MM; Lau, N; Boss, G; Pawson, A			Proliferation of human malignant astrocytomas is dependent on Ras activation	ONCOGENE			English	Article						astrocytomas; ras; receptor tyrosine kinases; farnesyl transferase inhibitors	EPIDERMAL GROWTH-FACTOR; PROTEIN-KINASE-C; NUCLEOTIDE EXCHANGE FACTOR; RECEPTOR TYROSINE KINASES; HUMAN GLIOBLASTOMA CELLS; FARNESYLTRANSFERASE INHIBITORS BLOCK; MITOGENIC SIGNAL TRANSDUCTION; GRB2 ADAPTER PROTEIN; FACTOR BETA-RECEPTOR; HUMAN-BRAIN TUMORS	Overexpression and activation of receptor tyrosine kinases, such as platelet derived growth factor receptors (PDGFRs) and epidermal growth factor receptor (EGFR), leads to proliferation of human malignant astrocytoma cells. Although oncogenic mutations affecting Pas are not prevalent in human malignant astrocytomas, we have investigated whether levels of activated Ras.GTP might be elevated in these tumors secondary to the mitogenic signals originating from activated receptor tyrosine kinases. In support of this hypothesis high levels of Ras.GTP, similar to those found in oncogenic Pas transformed fibroblasts, were present in four established human malignant astrocytoma cell lines which express PDGFRs and EGFR, and 20 operative malignant astrocytoma specimens. Stimulation of PDGFR's and EGFR's induced tyrosine phosphorylation of the Shc adaptor protein and its association with Grb2, suggesting a mechanism by which Pas may be activated in human malignant astrocytoma cells. Furthermore, blocking Pas activation by expression of the Ha-Ras-Asn17 dominant-negative mutant, or by farnesyl transferase inhibitors, decreased in vitro proliferation of the human astrocytoma cell lines. These results support the hypothesis that proliferative signals from receptor tyrosine kinases expressed by human malignant astrocytoma cells utilize the Pas mitogenic pathway. Pharmacological inhibitors of the Ras pathway may therefore be of therapeutic value in these presently terminal tumors.	UNIV TORONTO,TORONTO HOSP,DIV NEUROSURG & SURG ONCOL,TORONTO,ON,CANADA; UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California San Diego	Guha, A (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOL BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013	Boss, Gerry/0000-0002-9758-8714				AHMAD S, 1994, NEUROSURGERY, V35, P904, DOI 10.1227/00006123-199411000-00015; ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BASU T, 1994, ONCOGENE, V9, P3483; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BENZIL DL, 1992, CANCER RES, V52, P2951; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GLICK RP, 1992, J NEUROSURG, V77, P445, DOI 10.3171/jns.1992.77.3.0445; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERMANSON M, 1992, CANCER RES, V52, P3213; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JOHN J, 1993, J BIOL CHEM, V268, P923; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOVALENKO M, 1994, CANCER RES, V54, P6106; Li BQ, 1996, P NATL ACAD SCI USA, V93, P1001, DOI 10.1073/pnas.93.3.1001; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIBERMANN TA, 1987, EMBO J, V6, P1627, DOI 10.1002/j.1460-2075.1987.tb02410.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAHALEY MS, 1989, J NEUROSURG, V71, P826, DOI 10.3171/jns.1989.71.6.0826; MANNE V, 1995, ONCOGENE, V10, P1763; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MISRAPRESS A, 1992, GLIA, V6, P188, DOI 10.1002/glia.440060306; MORRISON RS, 1991, J BIOL CHEM, V266, P728; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUROYA K, 1992, ONCOGENE, V7, P277; NAGASU T, 1995, CANCER RES, V55, P5310; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1991, J BIOL CHEM, V266, P16755; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; PAULUS W, 1990, ACTA NEUROPATHOL, V79, P418, DOI 10.1007/BF00308718; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; POLLACK IF, 1990, J NEUROSURG, V73, P98, DOI 10.3171/jns.1990.73.1.0098; PRISELL P, 1987, ACTA NEUROCHIR, V89, P48, DOI 10.1007/BF01406667; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RAK J, 1995, CANCER RES, V55, P4575; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; ROSAKISADCOCK M, 1992, NATURE, V360, P689; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SANDBERGNORDQVIST AC, 1993, CANCER RES, V53, P2475; Satoh T, 1992, Semin Cancer Biol, V3, P169; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; STECK PA, 1988, CANCER RES, V48, P5433; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WINDEL K, 1994, NEUROSURGERY, V35, P439; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; YAN N, 1995, CANCER RES, V55, P3569; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	98	260	267	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2755	2765		10.1038/sj.onc.1201455	http://dx.doi.org/10.1038/sj.onc.1201455			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419966				2022-12-25	WOS:A1997YJ80300001
J	Alhonen, L; Karppinen, A; Uusi-Oukari, M; Vujcic, S; Korhonen, VP; Halmekyto, M; Kramer, DL; Hines, R; Janne, J; Porter, CW				Alhonen, L; Karppinen, A; Uusi-Oukari, M; Vujcic, S; Korhonen, VP; Halmekyto, M; Kramer, DL; Hines, R; Janne, J; Porter, CW			Correlation of polyamine and growth responses to N-1,N-11-diethylnorspermine in primary fetal fibroblasts derived from transgenic mice overexpressing spermidine/spermine N-1-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA CELL-LINES; ORNITHINE DECARBOXYLASE; SPERMINE N-1-ACETYLTRANSFERASE; ALPHA-DIFLUOROMETHYLORNITHINE; IRREVERSIBLE INHIBITOR; ESCHERICHIA-COLI; LUNG-CANCER; MOUSE SKIN; N1-ACETYLTRANSFERASE; TRANSFORMATION	A recently generated transgenic mouse line having activated polyamine catabolism due to systemic overexpression of spermidine/spermine N-1-acetyltransferase (SSAT) was used to isolate primary fetal fibroblasts as a means to further elucidate the cellular consequences of activated polyamine catabolism, Basal levels of SSAT activity and steady-state mRNA in the transgenic fibroblasts were about similar to 20- and similar to 40-fold higher than in nontransgenic fibroblasts, Consistent with activated polyamine catabolism, there was an overaccumulation of putrescine and N-1-acetylspermidine and a decrease in spermidine and spermine pools. Treatment with the polyamine analogue N-1,N-11-diethylnorspermine (DENSPM) increased SSAT activity in the transgenic fibroblasts similar to 380-fold, whereas mRNA increased only similar to 3-fold, indicating post-mRNA regulation, SSAT activity in the nontransgenic fibroblasts increased similar to 200-fold, By Western blot, enzyme protein was found to increase similar to 46 times higher in the treated transgenic fibroblasts than non-transgenic fibroblasts: a value comparable to 36-fold differential in enzyme activity, With DENSPM treatment, spermidine pools were more rapidly depleted in the transgenic fibroblasts than in nontransgenic fibroblasts, Similarly, transgenic fibroblasts were much more sensitive to DENSPM-induced growth inhibition, This was not diminished by co-treatment with an inhibitor of polyamine oxidase, suggesting that growth inhibition was due to polyamine depletion per se as opposed to oxidative stress, Since the two fibroblasts were genetically identical except for the transgene, the various metabolic and growth response differences are directly attributable to overexpression of SSAT.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA; Univ Kuopio, AI Virtanen Inst, FIN-70211 Kuopio, Finland	Roswell Park Cancer Institute; University of Eastern Finland	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	porter@sc3101.med.buffalo.edu	Uusi-Oukari, Mikko/AAI-7382-2020; Uusi-Oukari, Mikko/AAC-3762-2020	Uusi-Oukari, Mikko/0000-0003-1756-4577	NCI NIH HHS [CA-22153, CA-65942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065942, R01CA022153] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; Bernacki RJ, 1995, CLIN CANCER RES, V1, P847; BEY P, 1985, J MED CHEM, V28, P1, DOI 10.1021/jm00379a001; CASERO RA, 1992, CANCER RES, V52, P5359; CASERO RA, 1990, BIOCHEM J, V270, P615, DOI 10.1042/bj2700615; CASERO RA, 1989, CANCER RES, V49, P3829; COLEMAN CS, 1995, BIOCHEMISTRY-US, V34, P13423, DOI 10.1021/bi00041a020; FogelPetrovic M, 1996, BIOCHEMISTRY-US, V35, P14436, DOI 10.1021/bi9612273; FOGELPETROVIC M, 1993, BIOCHIM BIOPHYS ACTA, V1216, P255, DOI 10.1016/0167-4781(93)90152-4; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; FOGELPETROVIC M, 1993, J BIOL CHEM, V268, P19118; Ha H. C., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P27; HIBSHOOSH H, 1991, ONCOGENE, V6, P739; Ignatenko NA, 1996, BIOCHEM J, V319, P435, DOI 10.1042/bj3190435; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; LIBBY PR, 1991, ARCH BIOCHEM BIOPHYS, V284, P238, DOI 10.1016/0003-9861(91)90291-P; LIBBY PR, 1989, CANCER RES, V49, P6226; MEGOSH L, 1995, CANCER RES, V55, P4205; MOSHIER JA, 1993, CANCER RES, V53, P2618; OBrien TG, 1997, CANCER RES, V57, P2630; OBRIEN TG, 1975, CANCER RES, V35, P1662; PARRY L, 1995, BIOCHEMISTRY-US, V34, P2701, DOI 10.1021/bi00008a038; PARRY L, 1995, BIOCHEM J, V305, P451, DOI 10.1042/bj3050451; PEGG AE, 1989, J BIOL CHEM, V264, P11744; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Porter C. W., 1992, V62, P301; PORTER CW, 1991, CANCER RES, V51, P3715; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; SEILER N, 1987, CAN J PHYSIOL PHARM, V65, P2024, DOI 10.1139/y87-317; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; TAKIGAWA M, 1982, BIOCHEM BIOPH RES CO, V105, P969, DOI 10.1016/0006-291X(82)91065-8; TAMORI A, 1995, CANCER RES, V55, P3500; VARGIU C, 1994, FEBS LETT, V355, P163, DOI 10.1016/0014-5793(94)01183-4; WEEKS CE, 1982, P NATL ACAD SCI-BIOL, V79, P6028, DOI 10.1073/pnas.79.19.6028; XIAO L, 1991, BIOCHEM BIOPH RES CO, V179, P407, DOI 10.1016/0006-291X(91)91385-P	36	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1964	1969		10.1074/jbc.273.4.1964	http://dx.doi.org/10.1074/jbc.273.4.1964			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442032	hybrid			2022-12-25	WOS:000071595200021
J	Diep, DB; Nelson, KL; Raja, SM; Pleshak, EN; Buckley, JT				Diep, DB; Nelson, KL; Raja, SM; Pleshak, EN; Buckley, JT			Glycosylphosphatidylinositol anchors of membrane glycoproteins are binding determinants for the channel-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; MONOCLONAL-ANTIBODIES; CELL-LINE; PROTEIN; RECEPTOR; ACTIVATION; PURIFICATION; LYMPHOCYTES; EXPRESSION; ENDOTOXIN	Cells that are sensitive to the channel-forming toxin aerolysin contain surface glycoproteins that bind the toxin with high affinity, Here we show that a common feature of aerolysin receptors is the presence of a glycosylphosphatidylinositol anchor, and we present evidence that the anchor itself is an essential part of the toxin binding determinant, The glycosylphosphatidylinositol (GPI)-anchored T-lymphocyte protein Thy-1 is an example of a protein that acts as an aerolysin recep tor, This protein retained its ability to bind aerolysin when it was expressed in Chinese hamster ovary cells, but could not bind the toxin when expressed in Escherichia coli, where the GPI anchor is absent, An unrelated GPI-anchored protein, the variant surface glycoprotein of trypanosomes, was shown to bind aerolysin with similar affinity to Thy-1, and this binding ability was significantly reduced when the anchor was removed chemically, Cathepsin D, a protein with no affinity for aerolysin, was converted to an aerolysin binding form when it was expressed as a GPI-anchored hybrid in COS cells, Not all GPI-anchored proteins bind aerolysin, In some cases this may be due to differences in the structure of the anchor itself. Thus the GPI-anchored proteins procyclin of Trypanosoma congolense and gp63 of Leishmania major did not bind aerolysin, but when gp63 was expressed with a mammalian GPI anchor in Chinese hamster ovary cells, it bound the toxin.	Univ Victoria, Dept Biochem & Microbiol, Victoria, BC V8W 3P6, Canada	University of Victoria	Buckley, JT (corresponding author), Univ Victoria, Dept Biochem & Microbiol, POB 3055, Victoria, BC V8W 3P6, Canada.		Diệp, Dzũng/ABG-9262-2020; Diep, Dzung B./AAK-1419-2021	Diep, Dzung/0000-0001-7661-5501				AMES BN, 1960, J BIOL CHEM, V235, P769; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; CLISSOLD PM, 1992, BIOCHEM J, V281, P129, DOI 10.1042/bj2810129; Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; ENGLUND PT, 1993, ANN REV BIOCH, V62, P12; EVANS GA, 1987, IMMUNOGENETICS, V25, P28, DOI 10.1007/BF00768830; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FUJITA N, 1995, CELL GROWTH DIFFER, V6, P355; GRUBER HJ, 1994, MOL MICROBIOL, V14, P1093, DOI 10.1111/j.1365-2958.1994.tb01341.x; GUNTER KC, 1984, J EXP MED, V159, P716, DOI 10.1084/jem.159.3.716; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HORST M, 1991, BIOCHEM J, V273, P355, DOI 10.1042/bj2730355; HOWARD SP, 1982, BIOCHEMISTRY-US, V21, P1662, DOI 10.1021/bi00536a029; HUEBER AO, 1994, J EXP MED, V179, P785, DOI 10.1084/jem.179.3.785; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; KROCZEK RA, 1986, J IMMUNOL, V136, P4379; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LETARTEMUIRHEAD M, 1975, BIOCHEM J, V151, P685, DOI 10.1042/bj1510685; LOW MG, 1987, BIOCHEM J, V241, P615, DOI 10.1042/bj2410615; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; LUNDJOHANSEN F, 1993, EUR J IMMUNOL, V23, P2782, DOI 10.1002/eji.1830231110; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MISUMI Y, 1990, EUR J BIOCHEM, V191, P563, DOI 10.1111/j.1432-1033.1990.tb19158.x; Morrison CJ, 1997, BIOTECHNOL BIOENG, V53, P594, DOI 10.1002/(SICI)1097-0290(19970320)53:6<594::AID-BIT7>3.3.CO;2-M; MUKASA R, 1995, ARCH BIOCHEM BIOPHYS, V318, P182, DOI 10.1006/abbi.1995.1219; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OGIERDENIS E, 1995, BIOCHEM BIOPH RES CO, V221, P935; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PaturiauxHanocq F, 1997, BIOCHEM J, V324, P885, DOI 10.1042/bj3240885; PELES E, 1995, CELL, V82, P251, DOI 10.1016/0092-8674(95)90312-7; PU MY, 1995, FEBS LETT, V361, P295, DOI 10.1016/0014-5793(95)00193-D; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; Rossjohn J, 1997, EMBO J, V16, P3426, DOI 10.1093/emboj/16.12.3426; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Solomon KR, 1996, P NATL ACAD SCI USA, V93, P6053, DOI 10.1073/pnas.93.12.6053; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOBIAS PS, 1993, IMMUNOBIOLOGY, V187, P227, DOI 10.1016/S0171-2985(11)80341-4; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wang X, 1996, BIOCHEMISTRY-US, V35, P16305, DOI 10.1021/bi961098q; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZANG F, 1992, P NATL ACAD SCI USA, V89, P5231	48	158	164	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2355	2360		10.1074/jbc.273.4.2355	http://dx.doi.org/10.1074/jbc.273.4.2355			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442081	hybrid			2022-12-25	WOS:000071595200070
J	Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B				Tanaka, K; Chazenbalk, GD; McLachlan, SM; Rapoport, B			Thyrotropin receptor cleavage at site 1 does not involve a specific amino acid motif but instead depends on the presence of the unique, 50 amino acid insertion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSH RECEPTOR; EXTRACELLULAR DOMAIN; CELLS; BINDING; CHAIN	Thyrotropin (TSH) receptor (TSHR) A and B subunits are formed by intramolecular cleavage of the single chain receptor at two separate sites, The region in volved in cleavage at Site 2 has been identified, but previous mutagenesis studies failed to identify Site 1. We now report fortuitous observations on the effect of trypsin on the TSHR that localizes a small region harboring Site 1. Thus, as detected by immunoblotting and by I-125-TSH cross-linking to TSHR expressed on the surface of intact CHO cells, trypsin clipped a small polypeptide fragment bearing a glycan moiety from the C terminus of the A subunit. Based on the TSHR primary structure, this small fragment (1-2 kDa) contains Asn-302. This information, together with estimation of the size of the deglycosylated A subunit relative to a series of C-terminal truncated TSHR ectodomain variants, places cleavage Site 1 in the vicinity of, or closely upstream to, residue 317. Remarkably, mutagenesis of every amino acid residue between residues 298-316 (present study) and 317-362 (previous data) did not prevent cleavage at Site 1. However, cleavage at this site was abrogated by deletion of a 50-amino acid segment (residues 317-366) unique to the TSHR in the glycoprotein hormone receptor family. In summary, these data provide novel insight into TSHR intramolecular cleavage, Cleavage at Site 1 does not depend on a specific amino acid motif and differs from cleavage at Site 2 by involvement of a mechanism requiring the presence of the enigmatic TSHR 50-amino acid "insertion."	Vet Affairs Med Ctr, Thyroid Mol Biol Unit 111T, San Francisco, CA 94121 USA; Vet Adm Med Ctr, San Francisco, CA 94121 USA; Nagasaki Univ, Sch Med, Nagasaki 852, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Nagasaki University	Rapoport, B (corresponding author), Vet Affairs Med Ctr, Thyroid Mol Biol Unit 111T, 4150 Clement St, San Francisco, CA 94121 USA.				NIDDK NIH HHS [DK19289, DK48216] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048216, R01DK019289] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams D., 1956, P U OTAGO MED SCH, V34, P11; Black RA, 1996, BIOCHEM BIOPH RES CO, V225, P400, DOI 10.1006/bbrc.1996.1186; CHAZENBALK GD, 1994, J BIOL CHEM, V269, P32209; Chazenbalk GD, 1997, ENDOCRINOLOGY, V138, P2893, DOI 10.1210/en.138.7.2893; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; Chazenbalk GD, 1997, J BIOL CHEM, V272, P18959, DOI 10.1074/jbc.272.30.18959; Couet J, 1996, J BIOL CHEM, V271, P4545; FURMANIAK J, 1987, FEBS LETT, V215, P316, DOI 10.1016/0014-5793(87)80169-2; Kakinuma A, 1997, J BIOL CHEM, V272, P28296, DOI 10.1074/jbc.272.45.28296; KRISS JP, 1964, J CLIN ENDOCR METAB, V24, P1005, DOI 10.1210/jcem-24-10-1005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MISRAHI M, 1994, EUR J BIOCHEM, V222, P711, DOI 10.1111/j.1432-1033.1994.tb18916.x; NAGAYAMA Y, 1991, P NATL ACAD SCI USA, V88, P902, DOI 10.1073/pnas.88.3.902; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; NAGAYAMA Y, 1992, ENDOCRINOLOGY, V131, P548, DOI 10.1210/en.131.2.548; Nicholson LB, 1996, J MOL ENDOCRINOL, V16, P159, DOI 10.1677/jme.0.0160159; Rapoport B, 1996, J CLIN ENDOCR METAB, V81, P2525, DOI 10.1210/jc.81.7.2525; RUSSO D, 1991, MOL ENDOCRINOL, V5, P1607, DOI 10.1210/mend-5-11-1607; RUSSO D, 1992, ENDOCRINOLOGY, V130, P2135, DOI 10.1210/en.130.4.2135; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VanSande J, 1996, MOL CELL ENDOCRINOL, V119, P161, DOI 10.1016/0303-7207(96)03804-X; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649	23	49	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1959	1963		10.1074/jbc.273.4.1959	http://dx.doi.org/10.1074/jbc.273.4.1959			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442031	hybrid			2022-12-25	WOS:000071595200020
J	Zhang, JW; Lesort, M; Guttmann, RP; Johnson, GVW				Zhang, JW; Lesort, M; Guttmann, RP; Johnson, GVW			Modulation of the in situ activity of tissue transglutaminase by calcium and GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; PIG LIVER TRANSGLUTAMINASE; RETINOIC ACID; CROSS-LINKING; SH-SY5Y NEUROBLASTOMA; PROMYELOCYTIC LEUKEMIA; II TRANSGLUTAMINASE; BINDING PROTEIN; EXPRESSION; APOPTOSIS	Tissue transglutaminase (tTG) is a calcium-dependent enzyme that catalyzes the posttranslational modification of proteins by transamidation of specific polypeptide-bound glutamine residues. Previous in vitro studies have demonstrated that the transamidating activity of tTG requires calcium and is inhibited by GTP, To investigate the endogenous regulation of tTG, a quantitative in situ transglutaminase (TG) activity assay was developed, Treatment of human neuroblastoma SH-SY5Y cells with retinoic acid (RA) resulted in a significant increase in tTG levels and in vitro TG activity. In contrast, basal in situ TG activity did not increase concurrently with RA-induced increased tTG levels. However, stimulation of cells with the calcium-mobilizing drug maitotoxin (MTX) resulted in increases in in situ TG activity that correlated (r(2) = 0.76) with increased tTG levels. To examine the effects of GTP on in situ TG; activity, tiazofurin, a drug that selectively decreases GTP levels, was used. Depletion of GTP resulted in a significant increase in in situ TG activity; however, treatment of SH-SY5Y cells with a combination of MTX and tiazofurin resulted in significantly less in situ TG activity compared with treatment with MTX alone, This raised the possibility of calcium-dependent proteolysis due to the effects of tiazofurin, because in vitro GTP protects tTG against proteolysis by trypsin. Studies with a selective membrane permeable calpain inhibitor indicated that tTG is likely to be an endogenous substrate of calpain, and that depletion of GTP increases tTG degradation after elevation of intracellular calcium levels. TG activity was also increased in response to activation of muscarinic cholinergic receptors, which increases intracellular calcium through inositol 1,4,5-trisphosphate generation. The results of these experiments demonstrate that selective changes in calcium and GTP regulate the activity and levels of tTG in situ.	Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, 1720 7th Ave S,SC1061, Birmingham, AL 35294 USA.	gvwj@uab.edu	Johnson, Gail V.W./K-4723-2012; guttmann, rodney/AAN-8880-2021	Johnson, Gail V.W./0000-0003-3464-0404; guttmann, rodney/0000-0001-5553-3099	NIA NIH HHS [AG12396] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1993, J CELL BIOL, V120, P1461, DOI 10.1083/jcb.120.6.1461; Amendola A, 1996, P NATL ACAD SCI USA, V93, P11057, DOI 10.1073/pnas.93.20.11057; Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; Ballestar E, 1996, J BIOL CHEM, V271, P18817, DOI 10.1074/jbc.271.31.18817; Benedetti L, 1996, BLOOD, V87, P1939; Beninati S, 1988, Adv Exp Med Biol, V250, P411; BIEDLER JL, 1973, CANCER RES, V33, P2643; Borge L, 1996, BBA-MOL CELL RES, V1312, P117, DOI 10.1016/0167-4889(96)00028-6; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CORDELLAMIELE E, 1993, J BIOCHEM-TOKYO, V113, P164, DOI 10.1093/oxfordjournals.jbchem.a124021; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DECKER T, 1988, J IMMUNOL METHODS, V115, P61, DOI 10.1016/0022-1759(88)90310-9; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; EITAN S, 1993, SCIENCE, V261, P106, DOI 10.1126/science.8100369; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FINCH RA, 1993, J BIOL CHEM, V268, P5823; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1972, ANN NY ACAD SCI, V202, P59, DOI 10.1111/j.1749-6632.1972.tb16322.x; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; HAND D, 1993, J NEUROCHEM, V61, P1064, DOI 10.1111/j.1471-4159.1993.tb03621.x; Hettasch JM, 1996, LAB INVEST, V75, P637; HOHENADL C, 1995, J BIOL CHEM, V270, P23415, DOI 10.1074/jbc.270.40.23415; Hwang KC, 1996, CIRCULATION, V94, P718, DOI 10.1161/01.CIR.94.4.718; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; Kojima S, 1997, J BIOL CHEM, V272, P9410; KOSA K, 1995, CANCER RES, V55, P4850; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Li XH, 1996, J NEUROSCI, V16, P5914; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MEUCCI O, 1992, J NEUROCHEM, V59, P679, DOI 10.1111/j.1471-4159.1992.tb09422.x; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MILLER ML, 1995, J NEUROCHEM, V65, P1760; Mitrovic DM, 1995, J CHEMOTHERAPY, V7, P543, DOI 10.1179/joc.1995.7.6.543; MORTON AJ, 1992, MOL BRAIN RES, V13, P53, DOI 10.1016/0169-328X(92)90044-C; Nagy L, 1996, J BIOL CHEM, V271, P4355; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Nunes I, 1997, J CELL BIOL, V136, P1151, DOI 10.1083/jcb.136.5.1151; PAYNE SM, 1982, ANAL BIOCHEM, V123, P151, DOI 10.1016/0003-2697(82)90636-4; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PIACENTINI M, 1988, J BIOL CHEM, V263, P3790; Raghunath M, 1996, J CLIN INVEST, V98, P1174, DOI 10.1172/JCI118901; ROSS RA, 1983, J NATL CANCER I, V71, P741; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; SUTO N, 1993, J BIOL CHEM, V268, P7469; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Weber G, 1996, ANTICANCER RES, V16, P3313; WEBER G, 1992, ADV ENZYME REGUL, V32, P57; Xie HQ, 1997, J NEUROCHEM, V69, P1020	63	180	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2288	2295		10.1074/jbc.273.4.2288	http://dx.doi.org/10.1074/jbc.273.4.2288			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442073	hybrid			2022-12-25	WOS:000071595200062
J	Brinson, AE; Harding, T; Diliberto, PA; He, YQ; Li, X; Hunter, D; Herman, B; Earp, HS; Graves, LM				Brinson, AE; Harding, T; Diliberto, PA; He, YQ; Li, X; Hunter, D; Herman, B; Earp, HS; Graves, LM			Regulation of a calcium-dependent tyrosine kinase in vascular smooth muscle cells by angiotensin II and platelet-derived growth factor - Dependence on calcium and the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; PROTEIN-KINASE; FACTOR-BB; ACTIVATION; PHOSPHORYLATION; PAXILLIN; MIGRATION; PYK2; IDENTIFICATION; MEGAKARYOCYTES	A novel, p125(FAK) homologue, CADTK, has been detected in neural, epithelial, or hematopoietic cells but not in fibroblasts. We now demonstrate CADTK expression in a mesenchymal cell, rat aortic smooth muscle cells (RSMC). Angiotensin II (Ang II) or platelet-derived growth factor (PDGF-BB and PDGF-AA) markedly stimulated CADTK tyrosine phosphorylation in RSMC: but did not affect p125(FAK) phosphorylation. The PDGF-dependent CADTK tyrosine phosphorylation was slower and more prolonged than that of Ang II, correlating well with the differential effects of these agonists on cytosolic calcium ([Ca2+](i)) signaling. An intracellular calcium chelator inhibited both the rapid and sustained activation of CADTK by Ang II and PDGF. Extracellular calcium chelation inhibited the PDGF-stimulated increase in CADTK tyrosine phosphorylation as well as the sustained (but not the early) activation by Ang II, In contrast, p125(FAK) tyrosine phosphorylation was maximal in quiescent, adherent RSMC and was not affected by incubation with EGTA. Depletion of protein kinase C activity partially inhibited both the Ang II- and PDGF-induced CADTK tyrosine phosphorylation. Additional results confirm a relation between CADTK and the cytoskeleton, First, the tyrosine phosphorylation of paxillin correlated with activation of CADTK; this increase was inhibited by EGTA, Second, cytochalasin D blocked the PDGF- or Ang II stimulated tyrosine phosphorylation of CADTK, suggesting a role for the cytoskeleton in agonist-dependent CADTK activation. Third, immunofluorescence analysis of CADTK localization demonstrated actin-like cytoskeleton staining extending into focal contacts, These results suggest that in mesenchymal cells, CADTK is localized to and activated by an actin cytoskeleton-dependent mechanism; a mechanism that is regulated in a calcium and protein kinase C-dependent manner independently of p125(FAK).	Univ N Carolina, Dept Med & Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Graves, LM (corresponding author), Univ N Carolina, Dept Med & Pharmacol, Chapel Hill, NC 27599 USA.		Graves, Lee/AAG-5470-2021		NIGMS NIH HHS [GM54010, GM49304] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054010, R29GM049304] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEDI H, 1995, J BIOL CHEM, V270, P11367, DOI 10.1074/jbc.270.19.11367; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; BUTCHER RD, 1993, BIOCHEM BIOPH RES CO, V196, P1280, DOI 10.1006/bbrc.1993.2391; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; DILIBERTO PA, 1992, J BIOL CHEM, V267, P11888; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EARP HS, 1995, J BIOL CHEM, V270, P28440; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; GIASSON E, 1995, J BIOL CHEM, V270, P5225, DOI 10.1074/jbc.270.10.5225; Graves LM, 1997, J BIOL CHEM, V272, P1920, DOI 10.1074/jbc.272.3.1920; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; HIMPENS B, 1995, J VASC RES, V32, P207, DOI 10.1159/000159095; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Huckle William R., 1994, Progress in Growth Factor Research, V5, P177, DOI 10.1016/0955-2235(94)90004-3; ISHIDA M, 1995, CIRC RES, V77, P1053, DOI 10.1161/01.RES.77.6.1053; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEE RMKW, 1995, CAN J PHYSIOL PHARM, V73, P574, DOI 10.1139/y95-073; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; MARRERO MB, 1995, CARDIOVASC RES, V30, P530, DOI 10.1016/0008-6363(95)00094-1; Naftilan A J, 1994, Curr Opin Nephrol Hypertens, V3, P218, DOI 10.1097/00041552-199403000-00014; PARSONS JT, 1994, J CELL SCI, P109; POLTE TR, 1994, J CELL BIOCHEM, V55, P106, DOI 10.1002/jcb.240550113; Raja S, 1997, J BIOL CHEM, V272, P10941; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; ROSS R, 1980, MORPHOGENESIS VASCUL, P69; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1995, J CELL SCI, V108, P333; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	40	106	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1711	1718		10.1074/jbc.273.3.1711	http://dx.doi.org/10.1074/jbc.273.3.1711			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430717	hybrid			2022-12-25	WOS:000071411500064
J	Dalby, KN; Morrice, N; Caudwell, FB; Avruch, J; Cohen, P				Dalby, KN; Morrice, N; Caudwell, FB; Avruch, J; Cohen, P			Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90(rsk) that are inducible by MAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; RABBIT SKELETAL-MUSCLE; P70 S6 KINASE; IN-VITRO; INSULIN; INHIBITION; SUBSTRATE; DOMAINS; VIVO; RAF	Mitogen activated protein kinase-activated protein kinase-1 (MAPKAP-K1; also known as p90(rsk)) contains two protein kinase domains in a single polypeptide, The N-terminal kinase domain is necessary for the phosphorylation of peptide substrates, whereas the C-terminal kinase domain is required for full activation of the N-terminal domain, Here we identify six sites in MAPKAP-K1a that become phosphorylated in transfected COS-1 cells, The inactive form of MAPKAP-K1a in unstimulated cells is partially phosphorylated at Ser(222) and Ser(733). Stimulation with phorbol 12-myristate 13-acetate induces the phosphorylation of Thr(360), Ser(364), Thr(574), and Ser(381) and increases the phosphorylation of Ser(222) and Ser(733). Our data indicate that mitogen-activated protein kinase activates the C-terminal kinase domain by phosphorylating Thr(574) and contributes to the activation of the N-terminal kinase domain by phosphorylating Ser(364). The activated C-terminal domain phosphorylates Ser(381), which, together with phosphorylation of Ser(364), activates the N-terminal kinase domain, The phosphorylation of Ser(222) and Ser(733), which can be catalyzed by the N-terminal domain, does not activate MAPKAP-K1a per se, but Ser(222) phosphorylation appears to be required for activation, Ser(222), Ser(364), and Ser(381) are situated in analogous positions to phosphorylation sites in protein kinase B, protein kinase C, and p70(S6K), suggesting a common mechanism of activation for these growth factor-stimulated protein kinases.	Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA	University of Dundee; Harvard University; Massachusetts General Hospital	Cohen, P (corresponding author), Univ Dundee, Dept Biochem, MRC, Prot Phosphorylat Unit, Dundee DD1 4HN, Scotland.	pcohen@BAD.dundee.ac.uk	Dalby, Kevin N/A-1905-2013	Dalby, Kevin N/0000-0001-9272-5129				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Carew TJ, 1996, NEURON, V16, P5, DOI 10.1016/S0896-6273(00)80016-1; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DONELLADEANA A, 1993, BIOCHIM BIOPHYS ACTA, V1178, P189, DOI 10.1016/0167-4889(93)90008-D; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; GROVE JR, 1993, BIOCHEMISTRY-US, V32, P7727, DOI 10.1021/bi00081a018; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; LAVOINNE A, 1991, EUR J BIOCHEM, V199, P723, DOI 10.1111/j.1432-1033.1991.tb16176.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; TRAVERSE S, 1993, ONCOGENE, V8, P3175; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vik TA, 1997, BIOCHEM BIOPH RES CO, V235, P398, DOI 10.1006/bbrc.1997.6794; WASSARMAN DA, 1994, GENE, V144, P309, DOI 10.1016/0378-1119(94)90396-4; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	36	313	326	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1496	1505		10.1074/jbc.273.3.1496	http://dx.doi.org/10.1074/jbc.273.3.1496			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430688	hybrid			2022-12-25	WOS:000071411500035
J	Imokawa, G; Higuchi, K; Yada, Y				Imokawa, G; Higuchi, K; Yada, Y			Purification and characterization of an allergy-induced melanogenic stimulating factor in brownish guinea pig skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MELANOCYTES; SIGNAL-TRANSDUCTION; CONTACT-DERMATITIS; GROWTH-FACTOR; HUMAN KERATINOCYTES; IN-VIVO; EXPRESSION; EPIDERMIS; PROTEIN; GENE	We have demonstrated recently that phenylazonaphthol (PAN) allergy-induced hyperpigmentation in brownish guinea pig skin is associated with the concomitant appearance of a melanogenic soluble factor(s) that activates the intracellular signal transduction system, including phosphatidylinositol turnover subsequent to ligand-receptor binding in cultured guinea pig melanocytes. In this study we have purified and characterized the PAN-induced melanogenic stimulating factor (PIMSF) that occurs in allergy-associated hyperpigmented skin. By successive column chromatography on TSH 2000SW, Mono Q, and octadecyl-NPR, the PIMSF was purified to homogeneity with a single band of apparent molecular mass of 7.9 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, The specific bioactivity of PIMSF increased by 5,195-fold over the original skin homogenate. In cultured guinea pig melanocytes, this purified PIMSF had the potential of activating an intracellular signal transduction system such as inositol 1,4,5-trisphosphate formation and intracellular calcium levels through a pertussis toxin-sensitive G protein-coupled receptor. PIMSF consistently caused a rapid translocation of cytosolic protein kinase C (PRC) to membrane-bound PKC within 5 min of treatment with a return to the basal level after 120 min, The stimulating effects of PIMSF on proliferation and melanization of cultured guinea pig melanocytes were abolished completely by a PKC down-regulating agent (phorbol 12,13-dibutyrate), PIMSF was similar in molecular mass to rat growth-related oncogene alpha (GRO-alpha; molecular mass of 7.9 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and had immunocross-reactivity with GRO-alpha upon Western immune blotting analysis, Further, the stimulatory effect of purified PIMSF on DNA synthesis of cultured guinea pig melanocytes was suppressed markedly by the addition of anti-rat GRO-alpha antibody, implying that the PIMSF is apparently identical to GRO-alpha. These findings suggest that PAN allergy provides a new mechanism of hyperpigmentation in which biological factors such as the GRO-alpha superfamily generated within allergy-induced skin stimulate melanocytes through activation of the PKC-related signal transduction pathway.	Kao Corp, Biol Sci Lab, Ichikai, Tochigi 32134, Japan; Kao Corp, Tokyo Res Labs, Ichikai, Tochigi 32134, Japan	KAO Corporation; KAO Corporation	Imokawa, G (corresponding author), Kao Corp, Biol Sci Lab, Ichikaimachi 2606, Ichikai, Tochigi 32134, Japan.	073733@kastanet.Kao.co.jp						ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; CASTOR CW, 1983, P NATL ACAD SCI-BIOL, V80, P765, DOI 10.1073/pnas.80.3.765; DERYNCK R, 1990, BIOCHEMISTRY-US, V29, P10225, DOI 10.1021/bi00496a011; Groves RW, 1996, J CLIN INVEST, V98, P336, DOI 10.1172/JCI118797; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; Halaban R, 1988, PIGM CELL RES, V1, P18; IMOKAWA G, 1986, ARCH DERMATOL RES, V278, P352, DOI 10.1007/BF00418162; Imokawa G, 1996, BIOCHEM J, V314, P305, DOI 10.1042/bj3140305; IMOKAWA G, 1995, J INVEST DERMATOL, V105, P32, DOI 10.1111/1523-1747.ep12312500; IMOKAWA G, 1992, J BIOL CHEM, V267, P24675; Imokawa G, 1996, BIOCHEM J, V313, P625, DOI 10.1042/bj3130625; IMOKAWA G, 1987, J INVEST DERMATOL, V89, P540, DOI 10.1111/1523-1747.ep12461181; Imokawa G, 1996, INT CONGR SER, V1096, P35; IMOKAWA G, 1992, J INVEST DERMATOL, V99, P482, DOI 10.1111/1523-1747.ep12616165; IMOKAWA G, 1993, J INVEST DERMATOL, V100, P47, DOI 10.1111/1523-1747.ep12354117; IMOKAWA G, 1988, J INVEST DERMATOL, V92, P296; KOJIMA T, 1993, J INVEST DERMATOL, V101, P767, DOI 10.1111/1523-1747.ep12371692; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; MOSER B, 1991, J BIOL CHEM, V266, P10666; NORDLUND JJ, 1986, J INVEST DERMATOL, V86, P433, DOI 10.1111/1523-1747.ep12285717; RICHMOND A, 1983, CANCER RES, V43, P2106; SEISHIMA M, 1988, BIOCHEM BIOPH RES CO, V156, P1077, DOI 10.1016/S0006-291X(88)80742-3; Venner T J, 1995, Exp Dermatol, V4, P138, DOI 10.1111/j.1600-0625.1995.tb00237.x; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; YADA Y, 1989, BIOCHEM BIOPH RES CO, V163, P1517, DOI 10.1016/0006-291X(89)91152-2; YADA Y, 1991, J BIOL CHEM, V266, P18352	27	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1605	1612		10.1074/jbc.273.3.1605	http://dx.doi.org/10.1074/jbc.273.3.1605			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430702	hybrid			2022-12-25	WOS:000071411500049
J	Martin, PEM; George, CH; Castro, C; Kendall, JM; Capel, J; Campbell, AK; Revilla, A; Barrio, LC; Evans, WE				Martin, PEM; George, CH; Castro, C; Kendall, JM; Capel, J; Campbell, AK; Revilla, A; Barrio, LC; Evans, WE			Assembly of chimeric connexin-aequorin proteins into functional gap junction channels - Reporting intracellular and plasma membrane calcium environments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR COMMUNICATION; ENDOPLASMIC-RETICULUM; RECOMBINANT AEQUORIN; ADENOVIRUS VECTOR; CELL CHANNELS; HELA-CELLS; EXPRESSION; PERMEABILITY; VOLTAGE; LIVER	Chimeric proteins comprising connexins 26, 32, and 43 and aequorin, a chemiluminescent calcium indicator, were made by fusing the amino terminus of aequorin to the carboxyl terminus of connexins, The retention of function by the chimeric partners was investigated, Connexin 32-aequorin and connexin 43-aequorin retained chemiluminescent activity whereas that of connexin 26-aequorin was negligible, Immunofluorescent staining of COS-7 cells expressing the chimerae showed they were targeted to the plasma membrane, Gap junction intercellular channel formation by the chimerae alone and in combination with wild-type connexins was investigated, Stable HeLa cells expressing connexin 43-aequorin were functional, as demonstrated by Lucifer yellow transfer, Pairs of Xenopus oocytes expressing connexin 43-aequorin were electrophysiologically coupled, but those expressing chimeric connexin 26 or 32 showed no detectable levels of coupling, The formation of heteromeric channels constructed of chimeric connexin 32 or connexin 43 and the respective wild-type connexins was inferred from the novel voltage gating properties of the junctional conductance. The results show that the preservation of function by each partner of the chimeric protein is dictated mainly by the nature of the connexin, especially the length of the cytoplasmic carboxyl-terminal domain, The aequorin partner of the connexin 43 chimera reported calcium levels in COS-7 cells in at least two different calcium environments.	Univ Wales Coll Med, Dept Med Biochem, Cardiff CF4 4XN, S Glam, Wales; Hosp Ramon y Cajal, Dept Invest, Serv Neurol Expt, E-28034 Madrid, Spain	Cardiff University; Hospital Universitario Ramon y Cajal	Evans, WE (corresponding author), Univ Wales Coll Med, Dept Med Biochem, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.	wmbwhe@cardiff.ac.uk	Capel, Juan/M-3772-2018; Carmen, Castro/C-7813-2009; Campbell, Anthony K/N-5855-2014	Capel, Juan/0000-0002-4327-0604; Carmen, Castro/0000-0002-6802-0572; Campbell, Anthony K/0000-0002-2506-5500; George, Christopher/0000-0001-9852-1135				Badminton MN, 1996, J BIOL CHEM, V271, P31210, DOI 10.1074/jbc.271.49.31210; BADMINTON MN, 1995, EXP CELL RES, V216, P236, DOI 10.1006/excr.1995.1030; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BECKER DL, 1995, J CELL SCI, V108, P1455; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; Button D, 1996, MOL BIOL CELL, V7, P419, DOI 10.1091/mbc.7.3.419; Campbell AK, 1996, CELL CALCIUM, V19, P211, DOI 10.1016/S0143-4160(96)90022-6; CAMPBELL AK, 1988, J BIOLUM CHEMILUM, V2, P188; Carter TD, 1996, J CELL SCI, V109, P1765; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Christ GJ, 1996, CIRC RES, V79, P631, DOI 10.1161/01.RES.79.4.631; Cobbold PH, 1991, CELLULAR CALCIUM PRA, P55; DAHL G, 1987, SCIENCE, V236, P1290, DOI 10.1126/science.3035715; DRUMHELLER PD, 1991, ARTERIOSCLER THROMB, V11, P1258, DOI 10.1161/01.ATV.11.5.1258; DUNHAM B, 1992, CIRC RES, V70, P1233, DOI 10.1161/01.RES.70.6.1233; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Falk MM, 1997, EMBO J, V16, P2703, DOI 10.1093/emboj/16.10.2703; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GROVES JD, 1992, J BIOL CHEM, V267, P22163; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Kendall JM, 1996, CELL CALCIUM, V19, P133, DOI 10.1016/S0143-4160(96)90082-2; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; MUNARISILEM Y, 1995, J CLIN INVEST, V95, P1429, DOI 10.1172/JCI117813; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; PAUL DL, 1995, DEVELOPMENT, V121, P371; REAVES B, 1992, J CELL BIOL, V116, P85, DOI 10.1083/jcb.116.1.85; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; SALANEWBY GB, 1991, BIOCHEM J, V279, P727, DOI 10.1042/bj2790727; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAKI Y, 1982, BIOCHEM BIOPH RES CO, V104, P451, DOI 10.1016/0006-291X(82)90658-1; SHIMOMURA O, 1988, BIOCHEM J, V251, P405, DOI 10.1042/bj2510405; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SULLIVAN R, 1995, J CELL BIOL, V130, P419, DOI 10.1083/jcb.130.2.419; Torok K, 1997, BIOCHEM J, V326, P479; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; VERSELIS VK, 1994, NATURE, V368, P348, DOI 10.1038/368348a0; Wang XG, 1996, PFLUG ARCH EUR J PHY, V431, P844; WARNER A, 1995, J PHYSIOL-LONDON, V488, P721, DOI 10.1113/jphysiol.1995.sp021003; WHITE TW, 1995, KIDNEY INT, V48, P1148, DOI 10.1038/ki.1995.398; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Willecke K, 1996, J BIOENERG BIOMEMBR, V28, P319, DOI 10.1007/BF02110108; ZHANG JT, 1989, J CELL BIOL, V109, P3391, DOI 10.1083/jcb.109.6.3391	55	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1719	1726		10.1074/jbc.273.3.1719	http://dx.doi.org/10.1074/jbc.273.3.1719			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430718	Green Accepted, hybrid			2022-12-25	WOS:000071411500065
J	Srinivasa, SP; Watson, N; Overton, MC; Blumer, KJ				Srinivasa, SP; Watson, N; Overton, MC; Blumer, KJ			Mechanism of RGS4, a GTPase-activating protein for G protein alpha subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR PHEROMONES; TRANSITION-STATE; A-FACTOR; RAS; HYDROLYSIS; DOMAIN; ARREST; FAMILY; GENE	GTP hydrolysis by guanine nucleotide-binding proteins, an essential step in many biological processes, is stimulated by GTPase-activating proteins (GAPs), The mechanisms whereby GAPs stimulate GTP hydrolysis are unknown. We have used mutational, biochemical, and structural data to investigate how RGS4, a GAP for heterotrimeric G protein alpha subunits, stimulates GTP hydrolysis, Many of the residues of RGS4 that interact with G(i alpha 1) are important for GAP activity, Furthermore, optimal GAP activity appears to require the additive effects of interactions along the RGS4-G(alpha) interface, GAP-defective RGS4 mutants invariably were defective in binding G(alpha) subunits in their transition state; furthermore, the apparent strengths of GAP and binding defects were correlated. Thus, none of these residues of RGS4, including asparagine 128, the only residue positioned at the active site of G(i alpha 1), is required exclusively for catalyzing GTP hydrolysis. These results and structural data (Tesmer, J. G. G., Berman, D. M., Gilman, K.G., and Sprang, S. R. (1997) Cell 89, 251-261) indicate that RGS4 stimulates GTP hydroly- sis primarily by stabilizing the transition state conformation of the switch regions of the G protein, favoring the transition state of the reactants. Therefore, although monomeric and heterotrimeric G proteins are related, their GAPs have evolved distinct mechanisms of action.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Blumer, Kendall J/C-5268-2012		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07279-18] Funding Source: Medline; NIGMS NIH HHS [GM44592] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LINDER ME, 1991, J BIOL CHEM, V266, P4654; Miao WY, 1996, J BIOL CHEM, V271, P15322, DOI 10.1074/jbc.271.26.15322; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yu JH, 1996, EMBO J, V15, P5184, DOI 10.1002/j.1460-2075.1996.tb00903.x	25	105	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1529	1533		10.1074/jbc.273.3.1529	http://dx.doi.org/10.1074/jbc.273.3.1529			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430692	hybrid			2022-12-25	WOS:000071411500039
J	Butler, GS; Butler, MJ; Atkinson, SJ; Will, H; Tamura, T; van Westrum, SS; Crabbe, T; Clements, J; d'Ortho, MP; Murphy, G				Butler, GS; Butler, MJ; Atkinson, SJ; Will, H; Tamura, T; van Westrum, SS; Crabbe, T; Clements, J; d'Ortho, MP; Murphy, G			The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A - A kinetic study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; HUMAN 72-KDA GELATINASE; 72 KDA PROGELATINASE; CELL-SURFACE BINDING; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; IV COLLAGENASE; HUMAN FIBROBLASTS; CATALYTIC DOMAIN; IDENTIFICATION	We have used C-terminal domain mutants to further define the role of interactions of progelatinase A and membrane type 1 matrix metalloproteinase (MT1 MMP) in the binding of TIMP2 and in the cell-associated activation of progelatinase A. Soluble constructs of MT1 MMP were used to demonstrate that binding with TIMP2 occurs primarily through N-terminal domain interactions, leaving the C-terminal domain free for interactions with progelatinase A. The rate of autolytic activation of progelatinase A initiated by MT1 MMP cleavage could be potentiated by concentration of the proenzyme by binding to heparin, Residues 568-631 of the progelatinase A C-terminal domain are important in formation of the heparin binding site, since replacement of this region with the corresponding stromelysin-1 sequence abolished binding to heparin and the potentiation of activation. The same region of gelatinase A was required for binding of latent and active enzyme to TIMP2, but residues 418-474 were not important. A similar pattern was seen using cell membrane-associated MT1 MMP; residues 568-631 were required for binding and activation of progelatinase A, whereas residues 418-474 were not. Neither region was required for activation in solution. The addition of TIMP2 to HT1080 membrane preparations expressing MT1 MMP, but depleted of endogenous TIMP2, resulted in potentiation of progelatinase A activation, This effect was dependent upon TIMP2 binding to MT1 MMP rather than at an independent membrane site. Together, the data suggest that TIMP2 forms a receptor with MT1 MMP that regulates the concentration and efficient generation of functionally active gelatinase A.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Strangeways Res Lab, Cambridge CB1 4RN, England; InVitek GmbH, D-13125 Berlin, Germany; Chugai Pharmaceut Co Ltd, Gotemba, Shizuoka 412, Japan; Celltech Ltd, Slough SL1 4EN, Berks, England; British Biotech Pharmaceut Ltd, Oxford OX4 5LY, England; Fac Med, INSERM, U296, F-94010 Creteil, France	University of East Anglia; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Celltech Group Ltd; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Murphy, G (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	g.murphy@uea.ac.uk	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Butler GS, 1997, EUR J BIOCHEM, V244, P653, DOI 10.1111/j.1432-1033.1997.t01-1-00653.x; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P6684, DOI 10.1021/bi00187a039; CRABBE T, 1994, BIOCHEMISTRY-US, V33, P14419, DOI 10.1021/bi00252a007; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; GREEN DR, 1994, ENDOTHELIUM, V2, P191; HIPPS DS, 1991, BIOL CHEM H-S, V372, P287, DOI 10.1515/bchm3.1991.372.1.287; HOWARD EW, 1991, J BIOL CHEM, V266, P17972; Imai K, 1996, CANCER RES, V56, P2707; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kolkenbrock H, 1997, BIOL CHEM, V378, P71, DOI 10.1515/bchm.1997.378.2.71; KOLKENBROCK H, 1994, BIOL CHEM H-S, V375, P589; LIBSON AM, 1995, NAT STRUCT BIOL, V2, P938, DOI 10.1038/nsb1195-938; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; MURPHY G, 1981, BIOCHEM J, V199, P807, DOI 10.1042/bj1990807; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Puente XS, 1996, CANCER RES, V56, P944; Sang QXA, 1996, J PROTEIN CHEM, V15, P243, DOI 10.1007/BF01887112; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STETLERSTEVENSON WG, 1994, INVAS METAST, V14, P259; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; WARD RV, 1991, BIOCHEM J, V278, P179, DOI 10.1042/bj2780179; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; WILL H, 1995, EUR J BIOCHEM, V231, P602, DOI 10.1111/j.1432-1033.1995.0602d.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLENBROCK F, 1993, BIOCHEMISTRY-US, V32, P4330, DOI 10.1021/bi00067a023; WILLON UM, 1997, J BIOL CHEM, V272, P7473	42	517	531	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					871	880		10.1074/jbc.273.2.871	http://dx.doi.org/10.1074/jbc.273.2.871			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422744	hybrid			2022-12-25	WOS:000071411400033
J	Kamimoto, T; Nagai, Y; Onogi, H; Muro, Y; Wakabayashi, T; Hagiwara, M				Kamimoto, T; Nagai, Y; Onogi, H; Muro, Y; Wakabayashi, T; Hagiwara, M			Dymple, a novel dynamin-like high molecular weight GTPase lacking a proline-rich carboxyl-terminal domain in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE MX1 PROTEIN; NERVE-TERMINALS; MECHANOCHEMICAL ENZYME; BINDING PROTEINS; INFLUENZA-VIRUS; GOLGI-APPARATUS; YEAST; MICROTUBULES; EXPRESSION; GENE	We have cloned human dymple, a novel dynamin family member. The full-length cDNA sequence encodes a protein composed of 736 amino acids with a molecular mass of 80 kDa. This amino acid sequence most resembles yeast DNM1P and VPS1P. Dymple lacks a proline-rich carboxyl-terminal domain through which dynamin binds to SH3 domains to be activated. Northern blot analysis revealed two transcript sizes of 2.5 and 4.2 kilobases with alternative polyadenylation at the highest levels in brain, skeletal muscle, and testis. It was further established that there are three patterns of alternative splicing producing in-frame deletions in the coding sequence of dymple in a tissue specific manner. When overexpressed, wild-type dymple exhibited a punctate perinuclear cytoplasmic pattern, whereas an amino-terminal deletion mutant formed large aggregates bounded by a trans-Golgi network marker, Since dynamin participates in clathrin-mediated endocytosis through a well-characterized mechanism, the existence of a dynamin-like molecule in each specific vesicle transport pathway has been predicted. Our findings suggest that dymple may be the first example of such a subfamily in mammalian cells other than dynamin itself, although its precise role and membrane localization remain to be resolved.	Tokyo Med & Dent Univ, Dept Endocrinol, Inst Med Res, Bunkyo Ku, Tokyo 113, Japan; Nagoya Univ, Sch Med, Dept Anat, Showa Ku, Nagoya, Aichi 466, Japan; Nagoya Univ, Sch Med, Dept Dermatol, Showa Ku, Nagoya, Aichi 466, Japan	Tokyo Medical & Dental University (TMDU); Nagoya University; Nagoya University	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Dept Endocrinol, Inst Med Res, Bunkyo Ku, 1-5-45 Yushima, Tokyo 113, Japan.	m.hagiwara.end@mri.tmd.ac.jp	MURO, Yoshinao/M-8883-2014	Muro, Yoshinao/0000-0003-2329-8375				AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; CLUETT EB, 1993, J CELL BIOL, V120, P15, DOI 10.1083/jcb.120.1.15; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; GAMMIE AE, 1995, J CELL BIOL, V130, P553, DOI 10.1083/jcb.130.3.553; Gu XJ, 1996, EMBO J, V15, P695, DOI 10.1002/j.1460-2075.1996.tb00405.x; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JONES BA, 1992, GENE DEV, V6, P380, DOI 10.1101/gad.6.3.380; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MEIER E, 1988, J VIROL, V62, P2386, DOI 10.1128/JVI.62.7.2386-2393.1988; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; NAKATA T, 1991, NEURON, V7, P461, DOI 10.1016/0896-6273(91)90298-E; NAKATA T, 1993, J CELL SCI, V105, P1; NAKAYAMA M, 1991, J BIOL CHEM, V266, P21404; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; NOTHWEHR SF, 1995, J CELL BIOL, V129, P35, DOI 10.1083/jcb.129.1.35; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON PJ, 1994, TRENDS NEUROSCI, V17, P348, DOI 10.1016/0166-2236(94)90179-1; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; ROTHMAN JH, 1990, CELL, V61, P1063, DOI 10.1016/0092-8674(90)90070-U; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Shpetner HS, 1996, J BIOL CHEM, V271, P13, DOI 10.1074/jbc.271.1.13; Shupliakov O, 1997, SCIENCE, V276, P259, DOI 10.1126/science.276.5310.259; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; STAEHELI P, 1986, CELL, V44, P147, DOI 10.1016/0092-8674(86)90493-9; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Yasunami M, 1996, BIOCHEM BIOPH RES CO, V220, P754, DOI 10.1006/bbrc.1996.0476; YEH E, 1991, NATURE, V349, P713, DOI 10.1038/349713a0	43	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1044	1051		10.1074/jbc.273.2.1044	http://dx.doi.org/10.1074/jbc.273.2.1044			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422767	hybrid			2022-12-25	WOS:000071411400056
J	Levinger, L; Bourne, R; Kolla, S; Cylin, E; Russell, K; Wang, XD; Mohan, A				Levinger, L; Bourne, R; Kolla, S; Cylin, E; Russell, K; Wang, XD; Mohan, A			Matrices of paired substitutions show the effects of tRNA D/T loop sequence on Drosophila RNase P and 3 '-tRNase processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS RIBONUCLEASE-P; PRECURSOR TRANSFER-RNAS; RIBOSOMAL-RNA; BASE-PAIR; 3' END; AMINOACYLATION; SUBSTRATE; CLEAVAGE; ENZYME; IDENTIFICATION	Drosophila RNase P and 3'-tRNase endonucleolytically process the 5' and 3' ends of tRNA precursors, We examined the processing kinetics of normal substrates and the inhibitory effect of the tRNA product on both processing reactions. The product is not a good RNase P inhibitor, with a K-I, approximately 7 times greater than the substrate K-M Of similar to 200 nM and is a better inhibitor of 3'-tRNase, with a K-I, approximately two times the K-M, of similar to 80 nM. We generated matrices of substitutions at positions G(18)/U-55 and G(19)/C-56 (two contiguous universally conserved D/T loop base pairs) in Drosophila tRNA precursors, More than half the variants display a significant reduction in their ability to be processed by RNase P and 3'-tRNase, Minimal substrates with deleted D and anticodon stems could be processed by RNase P and 3'-tRNase much like full-length substrates, indicating that D/T loop contacts and D arm/enzyme contacts are not required by either enzyme. Selected tRNAs that were poor substrates for one or both enzymes were further analyzed using Michaelis-Menten kinetics and by structure probing, Processing reductions arise principally due to an increase in K-M, with relatively little change in V-max,,, consistent with the remote location of the sequence and structure changes from the processing site for both enzymes. Local changes in variant tRNA susceptibility to RNase T1 and RNase A did not coincide with processing disabilities.	CUNY, Grad Sch, Jamaica, NY 11451 USA; CUNY York Coll, Jamaica, NY 11451 USA	City University of New York (CUNY) System; City University of New York (CUNY) System; York College NY (CUNY)	Levinger, L (corresponding author), CUNY, Grad Sch, Jamaica, NY 11451 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008153, R15GM052654, T34GM008498] Funding Source: NIH RePORTER; NIGMS NIH HHS [SO6GM08153, T34GM08498, R15GM52654] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beebe JA, 1996, BIOCHEMISTRY-US, V35, P10493, DOI 10.1021/bi960870m; BEEBE JA, 1994, BIOCHEMISTRY-US, V33, P10294, DOI 10.1021/bi00200a009; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; CARRARA G, 1995, P NATL ACAD SCI USA, V92, P2627, DOI 10.1073/pnas.92.7.2627; CASTANO JG, 1985, J BIOL CHEM, V260, P9002; COOLEY L, 1982, P NATL ACAD SCI-BIOL, V79, P6475, DOI 10.1073/pnas.79.21.6475; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; GUTTELL RR, 1993, NUCLEIC ACIDS RES, V20, P5785; HARDT WD, 1993, BIOCHEMISTRY-US, V32, P13046, DOI 10.1021/bi00211a014; HARDT WD, 1995, J MOL BIOL, V247, P161, DOI 10.1006/jmbi.1994.0130; HOLLEY RW, 1965, SCIENCE, V147, P1462, DOI 10.1126/science.147.3664.1462; HOU YM, 1995, RNA, V1, P707; KIRSEBOM LA, 1994, EMBO J, V13, P4870, DOI 10.1002/j.1460-2075.1994.tb06814.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee Y, 1997, RNA, V3, P175; LEVINGER L, 1995, J BIOL CHEM, V270, P18903, DOI 10.1074/jbc.270.32.18903; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; Nashimoto M, 1996, RNA, V2, P523; Nashimoto M, 1997, NUCLEIC ACIDS RES, V25, P1148, DOI 10.1093/nar/25.6.1148; NICHOLS M, 1988, P NATL ACAD SCI USA, V85, P1379, DOI 10.1073/pnas.85.5.1379; Pan T, 1995, P NATL ACAD SCI USA, V92, P12510, DOI 10.1073/pnas.92.26.12510; PREISER PR, 1991, J BIOL CHEM, V266, P7509; PUGLISI JD, 1993, NUCLEIC ACIDS RES, V21, P41, DOI 10.1093/nar/21.1.41; QUIGLEY GJ, 1976, SCIENCE, V194, P706; REICH C, 1988, SCIENCE, V239, P178, DOI 10.1126/science.3122322; Saenger W, 1985, PRINCIPLES NUCL ACID; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; STERNER T, 1995, RNA, V1, P841; Su┬ll D., 1995, TRNA STRUCTURE BIOSY; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; True HL, 1996, J BIOL CHEM, V271, P16559, DOI 10.1074/jbc.271.28.16559; YAP LP, 1995, RNA, V1, P418; YUAN Y, 1995, EMBO J, V14, P159, DOI 10.1002/j.1460-2075.1995.tb06986.x; ZENNARO E, 1989, NUCLEIC ACIDS RES, V17, P5741	39	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1015	1025		10.1074/jbc.273.2.1015	http://dx.doi.org/10.1074/jbc.273.2.1015			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422763	hybrid			2022-12-25	WOS:000071411400052
J	Snyder, PM; Cheng, C; Prince, LS; Rogers, JC; Welsh, MJ				Snyder, PM; Cheng, C; Prince, LS; Rogers, JC; Welsh, MJ			Electrophysiological and biochemical evidence that DEG/ENaC cation channels are composed of nine subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL SODIUM-CHANNEL; SENSITIVE NA+ CHANNEL; CAENORHABDITIS-ELEGANS; LIDDLES SYNDROME; EXPRESSION; MUTATIONS; CLONING; NEURODEGENERATION; STOICHIOMETRY	Members of the DEG/ENaC protein family form ion channels with diverse functions, DEG/ENaC subunits associate as hetero-and homomultimers to generate channels; however the stoichiometry of these complexes is unknown, To determine the subunit stoichiometry of the human epithelial Na+ channel (hENaC), we expressed the three wild-type hENaC subunits (alpha, beta, and gamma) with subunits containing mutations that alter channel inhibition by methanethiosulfonates. The data indicate that hENaC contains three alpha, three beta, and three gamma subunits, Sucrose gradient sedimentation of alpha hENaC translated in vitro, as well as alpha-, beta-, and gamma hENaC coexpressed in cells, was consistent with complexes containing nine subunits. FaNaCh and BNC1, two related DEG/ENaC channels, produced complexes of similar mass. Our results suggest a novel nine-subunit stoichiometry for the DEG/ENaC family of ion channels.	Univ Iowa, Coll Med, Dept Internal Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Howard Hughes Med Inst, Iowa City, IA 52242 USA	Howard Hughes Medical Institute; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Snyder, PM (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Howard Hughes Med Inst, 200K EMRB, Iowa City, IA 52242 USA.			Welsh, Michael/0000-0002-1646-6206				Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Guy H. Robert, 1995, Biophysical Journal, V68, pA243; Hille B., 1992, IONIC CHANNELS EXCIT, P236; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1992, BIOPHYS J, V63, P1406, DOI 10.1016/S0006-3495(92)81703-4; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Schild L, 1997, J GEN PHYSIOL, V109, P15, DOI 10.1085/jgp.109.1.15; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0	29	184	191	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					681	684		10.1074/jbc.273.2.681	http://dx.doi.org/10.1074/jbc.273.2.681			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422716	hybrid			2022-12-25	WOS:000071411400005
J	Iglesias, T; Rozengurt, E				Iglesias, T; Rozengurt, E			Protein kinase D activation by mutations within its pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED AGAMMAGLOBULINEMIA; BRUTONS TYROSINE KINASE; EXCHANGE FACTOR SON; PH DOMAIN; PHORBOL ESTERS; SIGNAL-TRANSDUCTION; MITOGENIC RESPONSE; MOLECULAR-CLONING; D PKD; DIACYLGLYCEROL	Protein kinase D (PKD) is a serine/threonine protein kinase that contains a cysteine-rich repeat sequence homologous to that seen in the regulatory domain of protein kinase C (PKC) and a catalytic domain with only a low degree of sequence similarity to PKCs, PKD also contains a pleckstrin homology (PH) domain inserted between the cysteine-rich motifs and the catalytic domain that is not present in any of the PKCs, To investigate the function of the PH domain in the regulation of PKD activity, we determined the kinase activity of several PKD PH domain mutants immunoprecipitated from lysates of transiently transfected COS-7 cells. Deletion of the entire PH domain (amino acids 429-557) markedly increased the basal activity of the enzyme as assessed by autophosphorylation (similar to 16-fold) and exogenous syntide-2 peptide substrate phosphorylation assays (similar to 12-fold), Mutant PKD proteins with partial deletions or single amino acid substitutions within the PH domain (e.g, R447C and W538A) also exhibited increased basal kinase activity, These constitutive active mutants of PKD were only slightly further stimulated by phorbol-12,13-dibutyrate treatment of intact cells, Our results demonstrate, for the first time, that the PKD PH domain plays a negative role in the regulation of enzyme activity.	Imperial Canc Res Fund, Growth Regulat Lab, London WC2A 3PX, England	Cancer Research UK	Rozengurt, E (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, 900 Vet Ave,Warren Hall Rm 11-124, Los Angeles, CA 90095 USA.		Vacas, Teresa Iglesias/ABF-8663-2020	Vacas, Teresa Iglesias/0000-0002-4326-9005				Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; COLLINS MKL, 1982, J CELL PHYSIOL, V112, P42, DOI 10.1002/jcp.1041120108; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DebBurman SK, 1996, J BIOL CHEM, V271, P22552, DOI 10.1074/jbc.271.37.22552; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; Dieterich S, 1996, FEBS LETT, V381, P183, DOI 10.1016/0014-5793(96)00116-0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; GATLIN J, 1995, BIOTECHNIQUES, V19, P559; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KIKKAWA U, 1986, ANNU REV CELL BIOL, V2, P149, DOI 10.1146/annurev.cb.02.110186.001053; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MARAIS RM, 1989, EUR J BIOCHEM, V182, P129, DOI 10.1111/j.1432-1033.1989.tb14809.x; Matthews SA, 1997, J BIOL CHEM, V272, P20245, DOI 10.1074/jbc.272.32.20245; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MOCHIZUKI H, 1993, J BIOL CHEM, V268, P9143; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; Rozengurt E, 1995, MUTAT RES-FUND MOL M, V333, P153, DOI 10.1016/0027-5107(95)00141-7; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SMITH MK, 1990, J BIOL CHEM, V265, P1837; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TYERS M, 1988, NATURE, V333, P470, DOI 10.1038/333470a0; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; VIHINEN M, 1995, BIOCHEMISTRY-US, V34, P1475, DOI 10.1021/bi00005a002; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	46	128	130	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					410	416		10.1074/jbc.273.1.410	http://dx.doi.org/10.1074/jbc.273.1.410			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417097	hybrid			2022-12-25	WOS:000071295600063
J	Vaughan, PS; van der Meijden, CMJ; Aziz, F; Harada, H; Taniguchi, T; van Wijnen, AJ; Stein, JL; Stein, GS				Vaughan, PS; van der Meijden, CMJ; Aziz, F; Harada, H; Taniguchi, T; van Wijnen, AJ; Stein, JL; Stein, GS			Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR HINF-D; FACTOR-II; NUCLEOTIDE-SEQUENCE; MESSENGER-RNAS; FACTOR E2F; EXPRESSION; PROMOTER; PROTEIN; ELEMENTS; IFN	Histone genes display a peak in transcription in early S phase and are ideal models for cell cycle regulated gene expression, We have previously shown that the transcription factor interferon regulatory factor 2 (IRF-2) can activate histone H4 gene expression. In this report we establish that a mouse histone H4 gene and its human homolog lose stringent cell cycle control in synchronized embryonic fibroblasts in which IRF-2 has been ablated, We also show that there are reduced mRNA levels of this endogenous mouse histone H4 gene in the IRF-2(-/-) cells. Strikingly, the overall mRNA level and cell cycle regulation of histone H4 transcription are restored when IRF-2 is reintroduced to these cells. IRF-2 is a negative regulator of the interferon response and has oncogenic potential, but little is known of the mechanism of these activities. Our results suggest that IRF-2 is an active player in E2F-independent cell cycle-regulated gene expression at the G(1)/S phase transition, IRF-2 was previously considered a passive antagonist to the tumor suppressor IRF-1 but can now join other oncogenic factors such as c-Myb and E2F1 that are predicted to mediate their transforming capabilities by actively regulating genes necessary for cell cycle progression.	Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA; Univ Massachusetts, Med Ctr, Ctr Canc, Worcester, MA 01655 USA; Washington Univ, Sch Med, Dept Med, Div Mol Oncol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, Div Mol Oncol, St Louis, MO 63110 USA; Univ Tokyo, Fac Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL); Washington University (WUSTL); University of Tokyo	Stein, GS (corresponding author), Univ Massachusetts, Med Ctr, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.		van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NIGMS NIH HHS [GM 32010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTISHEVSKY A, 1984, MOL CELL BIOL, V4, P2364, DOI 10.1128/MCB.4.11.2364; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; BAUMBACH LL, 1987, BIOCHEMISTRY-US, V26, P6178, DOI 10.1021/bi00393a034; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; Birnbaum MJ, 1997, J CELL BIOCHEM, V66, P175, DOI 10.1002/(SICI)1097-4644(19970801)66:2<175::AID-JCB5>3.0.CO;2-N; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DELISLE AJ, 1983, MOL CELL BIOL, V3, P1920, DOI 10.1128/MCB.3.11.1920; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; JIANG SW, 1995, NUCLEIC ACIDS RES, V23, P3607, DOI 10.1093/nar/23.17.3607; KIM YK, 1991, MOL CELL BIOL, V11, P2296, DOI 10.1128/MCB.11.4.2296; Luo W, 1996, J BIOL CHEM, V271, P23445, DOI 10.1074/jbc.271.38.23445; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PLUMB M, 1983, NUCLEIC ACIDS RES, V11, P2391, DOI 10.1093/nar/11.8.2391; RAMSEYEWING A, 1994, P NATL ACAD SCI USA, V91, P4475, DOI 10.1073/pnas.91.10.4475; SEILERTUYNS A, 1987, MOL CELL BIOL, V7, P1048, DOI 10.1128/MCB.7.3.1048; Sharf R, 1997, J BIOL CHEM, V272, P9785; STEIN GS, 1994, CELL BIOL LAB HDB, P282; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; VANWIJNEN AJ, 1992, MOL CELL BIOL, V12, P3273, DOI 10.1128/MCB.12.7.3273; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; VANWIJNEN AJ, 1994, P NATL ACAD SCI USA, V91, P12882, DOI 10.1073/pnas.91.26.12882; VANWIJNEN AJ, 1991, J CELL BIOCHEM, V46, P174, DOI 10.1002/jcb.240460211; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0	33	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					194	199		10.1074/jbc.273.1.194	http://dx.doi.org/10.1074/jbc.273.1.194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417064	hybrid			2022-12-25	WOS:000071295600030
J	Wang, Z; Templeton, DM				Wang, Z; Templeton, DM			Induction of c-fos proto-oncogene in mesangial cells by cadmium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; KINASE-C; METALLOTHIONEIN GENE; INDUCED GENOTOXICITY; INDUCED APOPTOSIS; IN-VIVO; ACTIVATION; EXPRESSION; CALMODULIN; RAT	Cadmium is mitogenic under some circumstances and has been shown to cause accumulation of transcripts for several proto-oncogenes in a variety of cells, but the mechanism(s) remain to be delineated, Here we show that CdCl2 causes an increase in c-fos mRNA within 30 min of exposure of mesangial cells, At 10 mu M Cd2+, this increase persists for at least 8 h in both rat and human cells, The half-Life of c-fos mRNA is the same whether it accumulates following 4 h of treatment with Cd2+ or is induced transiently by phorbol ester, Cycloheximide, which stabilizes the transcript, causes a synergistic increase when administered with CdCl2. Nuclear run-on analysis confirms that Cd2+ causes transcriptional activation of the c-fos gene, Calmodulin and Ca2+/calmodulin-dependent kinase, and classical protein kinase C (PKC) isoforms represent two Ca2+-dependent signaling pathways that can lead to induction of c-fos, and Cd2+ h, been shown to activate both calmodulin and PRC in vitro, possibly by virtue of the similar ionic radii of Cd2+ and Ca2+, Therefore, we investigated the effect of Cd2+ on these pathways in vivo, 10 mu M CdCl2 did not increase total PRC activity or Ca2+/calmodulin-dependent kinase II activity and inhibited the latter at higher concentrations, ruling out either pathway in the Cd2+-dependent induction of c-fos. However, Cd2+ did lead to a sustained activation of the Erk family mitogen-activated protein kinases (MAPK) that correlated with induction of c-fos. A specific inhibitor of the MAPK kinases, PD98059, partially inhibited the induction of c-fos by Cd2+, We conclude that Cd2+ induces c-fos at least in part by causing a sustained activation of MAPK independent of its ability to activate PKC and calmodulin in vitro.	Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5G 1L5, Canada	University of Toronto	Templeton, DM (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 100 Coll St, Toronto, ON M5G 1L5, Canada.	doug.templeton@utoronto.ca		Templeton, Douglas/0000-0003-0693-662X				Abshire MK, 1996, CARCINOGENESIS, V17, P1349, DOI 10.1093/carcin/17.6.1349; BLOCK C, 1992, J BIOL CHEM, V267, P19824; CELANO P, 1989, J BIOL CHEM, V264, P8922; CHAO SH, 1984, MOL PHARMACOL, V26, P75; CHEUNG WY, 1988, ANN NY ACAD SCI, V522, P74; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; COOGAN TP, 1995, TOXICOL APPL PHARM, V132, P164, DOI 10.1006/taap.1995.1097; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELAZZOUZI B, 1994, TOXICOLOGY, V88, P127; EPNER DE, 1991, J CELL PHYSIOL, V148, P68, DOI 10.1002/jcp.1041480109; FLIK G, 1987, ARCH TOXICOL, V59, P353, DOI 10.1007/BF00295089; Fowler B A, 1987, Experientia Suppl, V52, P661; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GNEGY ME, 1993, ANNU REV PHARMACOL, V33, P45, DOI 10.1146/annurev.pa.33.040193.000401; GONG Z, 1992, BIOTECHNIQUES, V12, P74; HAMADA T, 1994, NEPHRON, V68, P104, DOI 10.1159/000188227; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HARTWIG A, 1994, ENVIRON HEALTH PERSP, V102, P45, DOI 10.2307/3431762; International Agency for Research on Cancer & International Agency for Research on Cancer, 1993, BER CADM MERC EXP GL, V58; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Long GJ, 1997, TOXICOL APPL PHARM, V143, P189, DOI 10.1006/taap.1996.8060; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MATSUOKA M, 1995, KIDNEY INT, V48, P383, DOI 10.1038/ki.1995.306; MAZZEI GJ, 1984, FEBS LETT, V173, P124, DOI 10.1016/0014-5793(84)81030-3; Miralem T, 1996, J BIOL CHEM, V271, P17100, DOI 10.1074/jbc.271.29.17100; MISRA RP, 1994, J BIOL CHEM, V269, P25483; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NIEWENHUIS RJ, 1987, BIOL REPROD, V37, P127, DOI 10.1095/biolreprod37.1.127; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEI J, 1990, J BIOL CHEM, V265, P14061; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; QUAMME GA, 1992, KIDNEY INT, V41, P1237, DOI 10.1038/ki.1992.185; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHIRAISHI N, 1995, TOXICOL APPL PHARM, V130, P229, DOI 10.1006/taap.1995.1028; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUZUKI Y, 1985, ARCH TOXICOL, V57, P205, DOI 10.1007/BF00290889; TAMAOKI T, 1991, BIOCH BIOOPHYS RES C, V135, P397; TANG N, 1993, TOXICOLOGY, V81, P155, DOI 10.1016/0300-483X(93)90007-F; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; TEMPLETON DM, 1990, J BIOL CHEM, V265, P21764; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Waalkes, 1990, BIOL EFFECTS HEAVY M, V2, P129; Wang AM, 1996, KIDNEY INT, V49, P437, DOI 10.1038/ki.1996.63; WANG AM, 1994, J CELL PHYSIOL, V159, P295, DOI 10.1002/jcp.1041590213; Wang Z, 1996, CELL MOTIL CYTOSKEL, V33, P208, DOI 10.1002/(SICI)1097-0169(1996)33:3<208::AID-CM5>3.0.CO;2-6; WEAST RC, 1982, HDB CHEM PHYSICS; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; Xu CY, 1996, TOXICOLOGY, V107, P1, DOI 10.1016/0300-483X(95)03195-L; YANAGIHARA N, 1991, J NEUROCHEM, V56, P294, DOI 10.1111/j.1471-4159.1991.tb02595.x	64	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					73	79		10.1074/jbc.273.1.73	http://dx.doi.org/10.1074/jbc.273.1.73			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417049	hybrid			2022-12-25	WOS:000071295600015
J	Sheu, GT; Traugh, JA				Sheu, GT; Traugh, JA			Recombinant subunits of mammalian elongation factor 1 expressed in Escherichia coli - Subunit interactions, elongation activity, and phosphorylation by protein kinase CKII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; NUCLEOTIDE-EXCHANGE PROTEIN; MATURATION-PROMOTING FACTOR; FACTOR-I; MOLECULAR-CLONING; FACTOR-1-BETA; ARTEMIA; BINDING; COMPLEX; RABBIT	The first step in elongation requires two different activities; elongation factor (EF)-1 alpha transfers aminoacyl-tRNA to the ribosome and is released upon hydrolysis of GTP, EF-1 beta gamma delta catalyzes exchange of GDP on EF-1 alpha with GTP, To analyze the role of the individual subunits of EF-1 in elongation, the cDNAs for the beta, gamma, and delta subunits of EF-1 from rabbit were cloned, and proteins of 225, 437, and 280 amino acids, respectively, were expressed in Escherichia coli. The purified recombinant beta subunit migrates as a dimer and the gamma subunit as a trimer upon gel filtration, whereas the delta subunit forms a large aggregate. Complexes of beta gamma, gamma delta and beta gamma delta were formed by self-association and eluted with a molecular mass of approximately 160, 530, and 670 kDa, respectively; no interaction was observed between beta and delta. The activity of the recombinant subunits was determined with native EF-1 alpha by measuring stimulation of the rate of elongation by poly(U)-directed polyphenylalanine synthesis. Recombinant beta and delta alone stimulated the rate of elongation by 10-fold, with a ratio of 5 alpha:2 beta or delta. The beta gamma delta complex stimulated EF-1 alpha activity up to 10-fold with a ratio of 20 alpha to 1 beta gamma delta. Phosphorylation of the beta and delta subunits alone or in beta gamma delta by protein kinase CKII had no effect on the rate of elongation.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Calif Riverside, Genet Grad Grp, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Traugh, JA (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.		Sheu, Gwo-Tarng/H-8855-2019	Sheu, Gwo-Tarng/0000-0002-1299-3375				[Anonymous], 1982, MOL CLONING LAB MANU; BEC G, 1994, J BIOL CHEM, V269, P2086; BEC G, 1989, J BIOL CHEM, V264, P21138; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDS JHGM, 1986, EUR J BIOCHEM, V155, P167, DOI 10.1111/j.1432-1033.1986.tb09472.x; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Chang YWE, 1997, J BIOL CHEM, V272, P28252, DOI 10.1074/jbc.272.45.28252; Chen CJ, 1995, BBA-GENE STRUCT EXPR, V1264, P303, DOI 10.1016/0167-4781(95)00166-2; CORMIER P, 1993, NUCLEIC ACIDS RES, V21, P743, DOI 10.1093/nar/21.3.743; CORMIER P, 1991, NUCLEIC ACIDS RES, V19, P6644, DOI 10.1093/nar/19.23.6644; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; HATHAWAY GM, 1982, CURRENT TOPICS CELLU, P101; IWASAKI K, 1976, J BIOL CHEM, V251, P1843; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JANSSEN GMC, 1991, J BIOL CHEM, V266, P14885; JANSSEN GMC, 1988, EUR J BIOCHEM, V171, P119, DOI 10.1111/j.1432-1033.1988.tb13766.x; JANSSEN GMC, 1994, J BIOL CHEM, V269, P31410; KOONIN EV, 1994, PROTEIN SCI, V3, P2045, DOI 10.1002/pro.5560031117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAESSEN GDF, 1986, FEBS LETT, V208, P77, DOI 10.1016/0014-5793(86)81536-8; MAESSEN GDF, 1987, FEBS LETT, V223, P181, DOI 10.1016/0014-5793(87)80532-X; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MORALES J, 1992, NUCLEIC ACIDS RES, V20, P4091, DOI 10.1093/nar/20.15.4091; MOTORIN YA, 1988, FEBS LETT, V238, P262, DOI 10.1016/0014-5793(88)80492-7; MOTOYOSHI K, 1977, Journal of Biochemistry (Tokyo), V82, P703; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULNERLORILLON O, 1994, J BIOL CHEM, V269, P20201; PALEN E, 1990, FEBS LETT, V274, P12, DOI 10.1016/0014-5793(90)81317-H; PALEN E, 1994, BIOCHEMISTRY-US, V33, P8515, DOI 10.1021/bi00194a016; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; Sambrook J., MOL CLONING LAB MANU; SANDERS J, 1992, NUCLEIC ACIDS RES, V20, P5907, DOI 10.1093/nar/20.22.5907; SANDERS J, 1991, NUCLEIC ACIDS RES, V19, P4551, DOI 10.1093/nar/19.16.4551; SANDERS J, 1993, BIOCHIM BIOPHYS ACTA, V1174, P87, DOI 10.1016/0167-4781(93)90097-W; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEU GT, 1993, NUCLEIC ACIDS RES, V20, P5849; SHEU GT, 1996, THESIS U CALIFORNIA; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; TAL M, 1985, J BIOL CHEM, V260, P9976; VANDAMME HTF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P241, DOI 10.1016/0167-4781(90)90174-Z; VANDAMME HTF, 1992, EUR J BIOCHEM, V207, P1025; VENEMA RC, 1991, J BIOL CHEM, V266, P12574; VENEMA RC, 1991, J BIOL CHEM, V266, P11993; VONDERKAMMER H, 1991, BIOCHEM BIOPH RES CO, V177, P312, DOI 10.1016/0006-291X(91)91984-K	45	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33290	33297		10.1074/jbc.272.52.33290	http://dx.doi.org/10.1074/jbc.272.52.33290			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407120	hybrid			2022-12-25	WOS:000071182900081
J	Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K				Thompson, DA; Belinsky, G; Chang, THT; Jones, DL; Schlegel, R; Munger, K			The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints	ONCOGENE			English	Article						viral oncoproteins; mitosis; checkpoint; human papillomavirus; cyclin-dependent kinases; p53 tumor suppressor	INDUCED PREMATURE MITOSIS; CELL-CYCLE CHECKPOINTS; LARGE T-ANTIGEN; GROWTH ARREST; GENE-EXPRESSION; DNA-DAMAGE; MUTATIONAL ANALYSIS; IONIZING-RADIATION; HUMAN FIBROBLASTS; EPITHELIAL-CELLS	The E6 and E7 proteins of the high risk human papillomaviruses (HPVs) are consistently expressed in HPV-positive cervical carcinomas, We investigated the ability of HPV-16 E6 and E7 to disrupt mitotic checkpoints in normal diploid human cells, Acute expression of HPV-16 E6, but not HPV-16 E7, decreased the fidelity of multiple checkpoints controlling entry into and exit from mitosis, After irradiation, nearly 50% of cells containing HPV-16 E6 readily entered mitosis as opposed to less than 10% of control cells, Consistent with this, asynchronous populations of cells expressing HPV-16 E6 had increased cdc2-associated histone Hi kinase activity relative to control populations, In addition, HPV-16 E6 increased sensitivity to chemically-induced S-phase premature mitosis and decreased mitotic spindle assembly checkpoint function relative to control populations, HPV-16 E6 mutants with a reduced ability to target p53 for degradation were unable to abrogate mitotic checkpoints, suggesting a possible mechanism by which HPV-16 E6 disrupts mitotic checkpoints, Expression of a mutant p53 gene yielded an intermediate phenotype relative to HPV-16 E6, generating moderate increases in sensitivity to chemically-induced S-phase PCC and mitotic spindle disruption and a heightened propensity to enter mitosis after irradiation.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Mol & Cellular Toxicol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Munger, K (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Thompson, David/0000-0003-2372-7766; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA066980] Funding Source: NIH RePORTER; NCI NIH HHS [CA 66980] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; CLARKE PR, 1995, J CELL SCI, V108, P1217; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dalal S, 1996, J VIROL, V70, P683, DOI 10.1128/JVI.70.2.683-688.1996; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; Di Leonardo A, 1997, CANCER RES, V57, P1013; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; Heselmeyer K, 1996, P NATL ACAD SCI USA, V93, P479, DOI 10.1073/pnas.93.1.479; HICKMAN ES, 1994, ONCOGENE, V9, P2177; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jones DL, 1997, J VIROL, V71, P2905, DOI 10.1128/JVI.71.4.2905-2912.1997; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KAUFMANN WK, 1995, CANCER RES, V55, P7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1993, BIOCHIM BIOPHYS ACTA, V1155, P111, DOI 10.1016/0304-419X(93)90025-8; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAULES RS, 1995, CANCER RES, V55, P1763; Pines J, 1996, BIOCHEM SOC T, V24, P15, DOI 10.1042/bst0240015; POWELL SN, 1995, CANCER RES, V55, P1643; Russell KJ, 1996, INT J RADIAT ONCOL, V36, P1099, DOI 10.1016/S0360-3016(96)00432-4; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STEINBECK RG, 1995, ACTA ONCOL, V34, P171, DOI 10.3109/02841869509093952; STEINMANN KE, 1991, P NATL ACAD SCI USA, V88, P6843, DOI 10.1073/pnas.88.15.6843; STEINMANN KE, 1994, ONCOGENE, V9, P387; STEWART N, 1995, ONCOGENE, V10, P109; Stoppler MC, 1996, J VIROL, V70, P6987; TAM SW, 1995, J CELL BIOCHEM, V59, P339, DOI 10.1002/jcb.240590306; TSANG NM, 1995, ONCOGENE, V10, P2403; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Xiong Y, 1996, J VIROL, V70, P999, DOI 10.1128/JVI.70.2.999-1008.1996; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	56	94	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3025	3035		10.1038/sj.onc.1201495	http://dx.doi.org/10.1038/sj.onc.1201495			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444951				2022-12-25	WOS:000070968000003
J	Qi, XM; Simonson, M; Distelhorst, CW				Qi, XM; Simonson, M; Distelhorst, CW			Bcl-2 inhibits c-fos induction by calcium	ONCOGENE			English	Article						Bcl-2; calcium; c-fos; thapsigargin	PROGRAMMED CELL-DEATH; GENE-EXPRESSION; APOPTOSIS; THAPSIGARGIN; PROTEIN; FAMILY; CA2+; BCL-X(L); PATHWAY; NUCLEAR	Transient elevation of cytosolic Ca2+ induces the expression of a variety of genes involved in cell growth and transformation, including the early response gene c-fos. Previously, we reported that Bcl-2 inhibits the transient elevation of cytosolic Ca2+ induced by thapsigargin (TG), a selective inhibitor of the endoplasmic reticulum-associated Ca2+-ATPase. Therefore, to determine if the effect of Bcl-2 on cytosolic Ca2+ elevation modulates Ca2+ signaling, we investigated the induction of c-fos by TG in WEHI7.2 mouse lymphoma cells, control transfectants (WEHI7.2-neo), and transfectants that stably express a high level of Bcl-2 (W.Hb12 and W.Hb15). TG induced 20-fold elevation of c-fos mRNA in WEHI7.2 and WEHI7.2-neo cells, but c-fos mRNA induction by TG was only fivefold in W.Hb12 and W.Hb15 cells, In contrast, phorbol 12-myristate acetate induced marked c-fos mRNA elevation in both WEHI7.2 and W.Hb12 cells, indicating that the inhibitory effect of Bcl-2 is selective for induction of c-fos by Ca2+. To measure c-fos promoter activity, WEHI7.2 and W.Hb12 cells were transiently transfected with a c-fos promoter-luciferase reporter plasmid, TG induced c-fos promoter activity in WEHI7.2 cells, but not in W.Hb12 cells. In WEHI7.2 cells, the signal for c-fos induction by TG was cytosolic Ca2+ elevation, as the increase in both c-fos mRNA level and promoter activity were prevented by lowering extracellular Ca2+ concentration, a condition that inhibits cytosolic Ca2+ elevation by reducing the TG-mobilizable Ca2+ pool, In summary, the findings indicate that Bcl-2 regulates Ca2+ signaling.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NCI NIH HHS [R01 CA42755-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CURRAN T, 1987, ONCOGENE, V2, P79; FLOMERFELT FA, 1994, J CELL BIOL, V127, P1729, DOI 10.1083/jcb.127.6.1729; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Marin MC, 1996, ONCOGENE, V12, P2259; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Preston GA, 1996, MOL CELL BIOL, V16, P211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WERLEN G, 1993, J BIOL CHEM, V268, P16596; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2849	2853		10.1038/sj.onc.1201463	http://dx.doi.org/10.1038/sj.onc.1201463			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419976				2022-12-25	WOS:A1997YJ80300011
J	Jin, JG; Daniel, JL; Kunapuli, SP				Jin, JG; Daniel, JL; Kunapuli, SP			Molecular basis for ADP-induced platelet activation II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; ADENYLATE-CYCLASE; BLOOD-PLATELETS; MESSENGER-RNA; PURINOCEPTOR; IDENTIFICATION; ANTAGONISTS; CLONING; CELLS; AGGREGATION	ADP is an important platelet agonist causing shape change from smooth discoid shape to spiculated spheres and platelet aggregation. However, the molecular mechanisms involved in ADP-induced platelet activation have not been elucidated. We demonstrated earlier the existence of two distinct ADP receptors on platelets, one coupled to phospholipase C, P2T(PLC), and the other to inhibition of adenylyl cyclase, P2T(AC) (Daniel, J. L., Dangelmaier, C., Jin, J., Ashby, B., Smith, J. B,, and Kunapuli, S. P. (1998) J. Biol. Chem. 273, 2024-2029), in addition to the previously described P2X1 receptor. Here we report the cloning of a cDNA clone encoding the P2Y1 receptor from a human platelet cDNA Library by homology screening with radiolabeled P2Y1-P2Y6 receptor cDNAs. ADP or 2-methyl(thio)-ADP-induced intracellular calcium increases were inhibited by the P2Y1 receptor-specific antagonists, adenosine 3'-phosphate 5'-phosphosulfate (A3P5PS), adenosine 3'-phosphate 5'-phosphate (A3P5P), and adenosine 2'-phosphate 5'-phosphate (A2P5P), in a concentration-dependent manner, but not by ARL 66096 or alpha,beta-MeATP. A3P5PS, A3P5P, and A2P5P also inhibited the shape change of aspirinated platelets induced by 10 mu M ADP or 3 mu M 2-methyl(thio)-ADP in a concentration-dependent manner, with complete inhibition occurring at 300 mu M. On the other hand ARL 66096 (100 nM), a potent P2T(AC) antagonist and alpha,beta-methylene-ATP (40 mu M), a P2X1 receptor agonist, had no effect on ADP-induced platelet shape change. On the contrary, ADP-induced inhibition of adenylyl cyclase was blocked by ARL 66096, but not by alpha,beta-MeATP or the P2Y1 receptor-specific antagonists, A3P5PS, A3P5P, or A2P5P. These results demonstrate the role of the P2Y1 receptor in ADP-induced platelet shape change and calcium mobilization and support the idea that several P2 receptors are involved in the regulation of different aspects of platelet stimulus-response coupling.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, 3420 N Broad St, Philadelphia, PA 19140 USA.	kunapuli@sgi1.fels.temple.edu						Akbar GK, 1996, J RECEPT SIGNAL TR R, V16, P209, DOI 10.3109/10799899609039949; Akbar GKM, 1996, J BIOL CHEM, V271, P18363, DOI 10.1074/jbc.271.31.18363; Akbar GKM, 1997, BIOCHEM BIOPH RES CO, V233, P71, DOI 10.1006/bbrc.1997.6396; Ayyanathan K, 1996, BIOCHEM BIOPH RES CO, V218, P783, DOI 10.1006/bbrc.1996.0139; Ayyanathan K, 1996, SOMAT CELL MOLEC GEN, V22, P419, DOI 10.1007/BF02369897; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; BOYER JL, 1994, BRIT J PHARMACOL, V113, P614, DOI 10.1111/j.1476-5381.1994.tb17034.x; Boyer JL, 1996, MOL PHARMACOL, V50, P1323; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; COLMAN RW, 1992, NEWS PHYSIOL SCI, V7, P274; DANIEL JL, 1984, J BIOL CHEM, V259, P9826; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Fredholm BB, 1997, TRENDS PHARMACOL SCI, V18, P79, DOI 10.1016/S0165-6147(96)01038-3; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; GAARDER A., 1961, NATURE, V192, P531, DOI 10.1038/192531a0; Gachet C, 1996, PLATELETS, V7, P261, DOI 10.3109/09537109609023587; GACHET C, 1995, BRIT J HAEMATOL, V91, P434, DOI 10.1111/j.1365-2141.1995.tb05319.x; GRECO NJ, 1995, BBA-BIOMEMBRANES, V1236, P142, DOI 10.1016/0005-2736(95)00038-5; HALL DA, 1993, BRIT J PHARMACOL, V108, P728, DOI 10.1111/j.1476-5381.1993.tb12869.x; HUMPHRIES RG, 1995, TRENDS PHARMACOL SCI, V16, P179, DOI 10.1016/S0165-6147(00)89018-5; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MACFARLANE DE, 1975, BLOOD, V46, P309; MACKENZIE AB, 1996, J BIOL CHEM, V271, P2789; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; Nguyen T, 1995, J BIOL CHEM, V270, P30845, DOI 10.1074/jbc.270.52.30845; PIDLAOAN LV, 1997, IN PERSS SOM CELL MO; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SINTO M, 1994, NUCLEIC ACIDS RES, V22, P427; VITTET D, 1992, EXP HEMATOL, V20, P1129; Webb TE, 1996, BIOCHEM BIOPH RES CO, V219, P105, DOI 10.1006/bbrc.1996.0189; Webb TE, 1996, BRIT J PHARMACOL, V119, P1385, DOI 10.1111/j.1476-5381.1996.tb16050.x; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	37	382	393	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2030	2034		10.1074/jbc.273.4.2030	http://dx.doi.org/10.1074/jbc.273.4.2030			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442040	hybrid			2022-12-25	WOS:000071595200029
J	Kaouass, M; Gamache, I; Ramotar, D; Audette, M; Poulin, R				Kaouass, M; Gamache, I; Ramotar, D; Audette, M; Poulin, R			The spermidine transport system is regulated by ligand inactivation, endocytosis, and by the Npr1p Ser/Thr protein kinase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; YEAST URACIL PERMEASE; AMINO-ACID PERMEASES; BREAST-CANCER CELLS; POLYAMINE TRANSPORT; ORNITHINE DECARBOXYLASE; MAMMALIAN-CELLS; PLASMA-MEMBRANE; APURINIC ENDONUCLEASE; FEEDBACK REPRESSION	We have characterized the regulation of spermidine transport in yeast and identified some of the genes involved in its control, Disruption of the SPE2 gene encoding S-adenosylmethionine decarboxylase, which catalyzes an essential step in polyamine biosynthesis, up-regulated the initial velocity of spermidine uptake in wild-type cells as well as in the polyamine transport-deficient pcp1 mutants, Exogenous spermidine rapidly inactivated spermidine transport with a half-life of approximate to 10-15 min via a process that did not require de nova protein synthesis but was accelerated by cycloheximide addition, Conversely, reactivation of spermidine influx upon polyamine deprivation required active protein synthesis, The stability of polyamine carrier activity was increased a-fold in polyamine-depleted spe2 deletion mutants, indicating that endogenous polyamines also contribute to the down-regulation of spermidine transport, Ligand-mediated repression of spermidine transport was delayed in end3 and end4 mutants that are deficient in the initial steps of the endocytic pathway, and spermidine uptake activity was increased 4- to 5-fold in end3 mutants relative to parental cells, although the stability of the transport system was similar in both strains, Disruption of the NPR1 gene, which encodes a putative Ser/Thr protein kinase essential for the reactivation of several nitrogen permeases, resulted in a 3-fold decrease in spermidine transport in NH4+-rich media but did not prevent its down-regulation by spermidine, The defect in spermidine transport was more pronounced in NH4+- than proline-grown npr1 cells, suggesting that NPR1 protects against nitrogen catabolite repression of polyamine uptake activity, These results suggest that (a) the polyamine carrier is an unstable protein subject to down-regulation by spermidine via a process involving Ligand inactivation followed by endocytosis and that (b) NPR1 expression fully prevents nitrogen catabolite repression of polyamine transport, unlike the role predicted for that gene by the inactivation/reactivation model proposed for other nitrogen permeases.	CHU Laval, Res Ctr, Dept Physiol & Anat, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Res Ctr, Dept Med Biol, Mol Endocrinol Lab, Quebec City, PQ G1V 4G2, Canada; Hop Maison Neuve Rosemont, Res Ctr, Quebec City, PQ H1T 2M4, Canada	Laval University; Laval University; Universite de Montreal	Poulin, R (corresponding author), CHU Laval, Res Ctr, Dept Physiol & Anat, Mol Endocrinol Lab, 2705 Blvd Laurie, Quebec City, PQ G1V 4G2, Canada.	Richard.Poulin@crchul.ulaval.ca						BALASUNDARAM D, 1991, P NATL ACAD SCI USA, V88, P5872, DOI 10.1073/pnas.88.13.5872; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TL, 1987, AM J PHYSIOL, V252, pC663, DOI 10.1152/ajpcell.1987.252.6.C663; BYERS TL, 1989, AM J PHYSIOL, V257, pC545, DOI 10.1152/ajpcell.1989.257.3.C545; BYERS TL, 1990, J CELL PHYSIOL, V143, P460, DOI 10.1002/jcp.1041430309; CRAMER CL, 1984, J BIOL CHEM, V259, P5152; DAVIS RH, 1991, ARCH BIOCHEM BIOPHYS, V285, P297, DOI 10.1016/0003-9861(91)90363-N; DEBENEDETTE M, 1993, J IMMUNOL, V150, P4218; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; EGNER R, 1995, MOL CELL BIOL, V15, P5879; FONZI WA, 1989, J BIOL CHEM, V264, P18110; FURUCHI T, 1991, J BIOL CHEM, V266, P20928; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; GAWELTHOMPSON KJ, 1989, J CELL PHYSIOL, V140, P359, DOI 10.1002/jcp.1041400222; GRENSON M, 1983, EUR J BIOCHEM, V133, P141, DOI 10.1111/j.1432-1033.1983.tb07439.x; GRENSON M, 1983, EUR J BIOCHEM, V133, P135, DOI 10.1111/j.1432-1033.1983.tb07438.x; GRENSON M, 1982, EUR J BIOCHEM, V121, P643, DOI 10.1111/j.1432-1033.1982.tb05834.x; HE Y, 1994, BIOCHEM BIOPH RES CO, V203, P608, DOI 10.1006/bbrc.1994.2226; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; Hein C, 1997, MOL MICROBIOL, V24, P607, DOI 10.1046/j.1365-2958.1997.3771735.x; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Huber M, 1996, J CLIN ENDOCR METAB, V81, P113, DOI 10.1210/jc.81.1.113; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Igarashi K, 1996, AMINO ACIDS, V10, P83, DOI 10.1007/BF00806095; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JAUNIAUX JC, 1987, EUR J BIOCHEM, V164, P601, DOI 10.1111/j.1432-1033.1987.tb11169.x; KAKINUMA Y, 1995, BIOCHEM BIOPH RES CO, V216, P985, DOI 10.1006/bbrc.1995.2717; KAKINUMA Y, 1988, EUR J BIOCHEM, V176, P409, DOI 10.1111/j.1432-1033.1988.tb14297.x; KAKINUMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P126, DOI 10.1016/0005-2736(92)90337-L; KANO K, 1976, J BIOL CHEM, V251, P2795; Kaouass M, 1997, MOL CELL BIOL, V17, P2994, DOI 10.1128/MCB.17.6.2994; KASHIWAGI K, 1991, J BIOL CHEM, V266, P20922; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KUMAGAI J, 1989, AM J PHYSIOL, V256, pG905, DOI 10.1152/ajpgi.1989.256.5.G905; LAI K, 1995, J BIOL CHEM, V270, P2525, DOI 10.1074/jbc.270.6.2525; LESSARD M, 1995, J BIOL CHEM, V270, P1685, DOI 10.1074/jbc.270.4.1685; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; MARTIN RL, 1991, HEPATOLOGY, V14, P1243, DOI 10.1002/hep.1840140646; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MARUYAMA T, 1994, BBA-BIOMEMBRANES, V1194, P289, DOI 10.1016/0005-2736(94)90311-5; Matsufuji S, 1996, EMBO J, V15, P1360, DOI 10.1002/j.1460-2075.1996.tb00478.x; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MITCHELL JLA, 1992, BIOCHEM BIOPH RES CO, V186, P81, DOI 10.1016/S0006-291X(05)80778-8; MITCHELL JLA, 1994, BIOCHEM J, V299, P19, DOI 10.1042/bj2990019; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; Nozaki T, 1996, BIOCHEM BIOPH RES CO, V228, P452, DOI 10.1006/bbrc.1996.1681; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; PARK MH, 1993, TRENDS BIOCHEM SCI, V18, P475, DOI 10.1016/0968-0004(93)90010-K; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PISTOCCHI R, 1993, J BIOL CHEM, V268, P146; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; POULIN R, 1995, J BIOL CHEM, V270, P1695, DOI 10.1074/jbc.270.4.1695; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RINEHART CA, 1984, J BIOL CHEM, V259, P4750; Seiler N, 1996, INT J BIOCHEM CELL B, V28, P843, DOI 10.1016/1357-2725(96)00021-0; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; STANBROUGH M, 1995, J BACTERIOL, V177, P94, DOI 10.1128/jb.177.1.94-102.1995; SUZUKI T, 1994, P NATL ACAD SCI USA, V91, P8930, DOI 10.1073/pnas.91.19.8930; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TYAGI AK, 1981, J BIOL CHEM, V256, P2156; VANDENBOL M, 1990, MOL GEN GENET, V222, P393, DOI 10.1007/BF00633845; VANDENBOL M, 1987, EUR J BIOCHEM, V164, P607, DOI 10.1111/j.1432-1033.1987.tb11170.x; VOLLAND C, 1994, J BIOL CHEM, V269, P9833; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WIAME JM, 1985, ADV MICROB PHYSIOL, V26, P1, DOI 10.1016/S0065-2911(08)60394-X; Williams K, 1997, BIOCHEM J, V325, P289, DOI 10.1042/bj3250289	70	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2109	2117		10.1074/jbc.273.4.2109	http://dx.doi.org/10.1074/jbc.273.4.2109			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442051	hybrid			2022-12-25	WOS:000071595200040
J	Merino, G; Shuman, HA				Merino, G; Shuman, HA			Truncation of MalF results in lactose transport via the maltose transport system of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; MEMBRANE-PROTEIN; P-GLYCOPROTEIN; CYTOPLASMIC MEMBRANE; ACTIVE-TRANSPORT; NUCLEOTIDE-BINDING; SITE; RECOGNITION; MUTAGENESIS; EXPRESSION	The active accumulation of maltose and maltodextrins by Escherichia coli is dependent on the maltose transport system. Several lines of evidence suggest that the substrate specificity of the system is not only determined by the periplasmic maltose-binding protein but that a further level of substrate specificity is contributed by the inner membrane integral membrane components of the system, MalF and MalG. We have isolated and characterized an altered substrate specificity mutant that transports lactose. The mutation responsible for the altered substrate specificity results in an amber stop codon at position 99 of MalF. The mutant requires functional MalK-ATPase activity and hydrolyzes ATP constitutively. It also requires MalG. The data suggest that in this mutant the MalG protein is capable of forming a low affinity transport path for substrate.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA	Columbia University	Shuman, HA (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St, New York, NY 10032 USA.							BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BIBI E, 1992, P NATL ACAD SCI USA, V89, P3180, DOI 10.1073/pnas.89.8.3180; BOOS W, 1996, ESCHERICHIA COLI SAL, V1, P1175; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; COVITZ KMY, 1994, EMBO J, V13, P1752, DOI 10.1002/j.1460-2075.1994.tb06439.x; DASSA E, 1993, MOL MICROBIOL, V7, P29, DOI 10.1111/j.1365-2958.1993.tb01094.x; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; DENGEN DA, 1974, J BACTERIOL, V117, P477; Ehrle R, 1996, J BACTERIOL, V178, P2255, DOI 10.1128/jb.178.8.2255-2262.1996; EHRMANN M, 1991, J BIOL CHEM, V266, P16530; FERENCI T, 1980, EUR J BIOCHEM, V108, P631, DOI 10.1111/j.1432-1033.1980.tb04758.x; FERENCI T, 1986, BIOCHIM BIOPHYS ACTA, V860, P44, DOI 10.1016/0005-2736(86)90496-7; FROSHAUER S, 1988, J MOL BIOL, V200, P501, DOI 10.1016/0022-2836(88)90539-6; GEISSELSODER J, 1987, BIOTECHNIQUES, V5, P786; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hanna M, 1996, BIOCHEMISTRY-US, V35, P3625, DOI 10.1021/bi951333p; HEKSTRA D, 1993, J BACTERIOL, V175, P6546, DOI 10.1128/jb.175.20.6546-6552.1993; HIGGINS CF, 1986, NATURE, V323, P448, DOI 10.1038/323448a0; HOR LI, 1991, THESIS COLUMBIA U; KABACK HR, 1994, J EXP BIOL, V196, P183; KELLERMANN O, 1974, EUR J BIOCHEM, V47, P139, DOI 10.1111/j.1432-1033.1974.tb03677.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; Miller J.H., 1972, EXPT MOL GENETICS; MORRIS DI, 1994, MOL PHARMACOL, V46, P329; PANAGIOTIDIS CH, 1993, J BIOL CHEM, V268, P23685; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; REYES M, 1986, J BACTERIOL, V165, P918, DOI 10.1128/jb.165.3.918-922.1986; SADOSKY B, 1994, J BACTERIOL, V176, P3790, DOI 10.1128/JB.176.12.3790-3799.1994; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHUMAN HA, 1982, J BIOL CHEM, V257, P5455; SHUMAN HA, 1981, J BIOL CHEM, V256, P560; SILHAVY TJ, 1979, MOL GEN GENET, V174, P249, DOI 10.1007/BF00267797; SPURLINO JC, 1991, J BIOL CHEM, V266, P5202; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985; TREPTOW NA, 1988, J MOL BIOL, V202, P809, DOI 10.1016/0022-2836(88)90560-8; WALTER C, 1992, J BIOL CHEM, V267, P8863; ZHANG F, 1993, J BIOL CHEM, V268, P19889; ZHANG XP, 1995, J BIOL CHEM, V270, P5441, DOI 10.1074/jbc.270.10.5441	49	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2435	2444		10.1074/jbc.273.4.2435	http://dx.doi.org/10.1074/jbc.273.4.2435			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442094	hybrid			2022-12-25	WOS:000071595200083
J	Nakanishi, A; Oshida, T; Matsushita, T; Imajoh-Ohmi, S; Ohnuki, T				Nakanishi, A; Oshida, T; Matsushita, T; Imajoh-Ohmi, S; Ohnuki, T			Identification of DNA gyrase inhibitor (GyrI) in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							42.84-43.6 F-SEGMENT; SEX FACTOR-F; CELL-DIVISION; COUMARIN DRUGS; MICROCIN B17; B-PROTEIN; PURIFICATION; GENES; REPLICATION; NOVOBIOCIN	DNA gyrase is an essential enzyme in DNA replication in Escherichia coli. It mediates the introduction of negative supercolis near oriC, removal of positive supercolis ahead of the growing DNA fork, and separation of the two daughter duplexes, In the course of purifying DNA gyrase from E. coli KL16, we found an 18-kDa protein that inhibited the supercoliing activity of DNA gyrase, and we coined it DNA gyrase inhibitory protein (GyrI). Its NH2-terminal amino acid sequence of 16 residues was determined to be identical to that of a putative gene product (a polypeptide of 157 amino acids) encoded by yeeB (EMBL accession no. U00009) and sbmC (Baquero, M. R., Bouzon, M., Varea, J., and Moreno, F. (1995) Mol. Microbiol. 18, 301-311) of E. coli. Assuming the identity of the gene (gyrI) encoding GyrI with the previously reported genes yeeB and sbmC, we cloned the gene after amplification by polymerase chain reaction and purified the 18-kDa protein from an E. coli strain overexpressing it. The purified 18-kDa protein was confirmed to inhibit the supercoliing activity of DNA gyrase in vitro. In vivo, both overexpression and antisense expression of the gyrI gene induced filamentous growth of cells and suppressed cell proliferation, GyrI protein is the first identified chromosomally nucleoid-encoded regulatory factor of DNA gyrase in E. coli.	Tanabe Seiyaku Co Ltd, Lead Generat Res Lab, Toda, Saitama 335, Japan; Tanabe Seiyaku Co Ltd, Pharmaceut Dev Res Lab, Toda, Saitama 335, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 108, Japan	Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation; University of Tokyo	Nakanishi, A (corresponding author), Tanabe Seiyaku Co Ltd, Lead Generat Res Lab, 2-50 Kawagishi 2 Chome, Toda, Saitama 335, Japan.	anaka@tanabe.co.jp						ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Andronova TM, 1991, SOV MED REV D, V4, P1; AOYAMA H, 1988, ANTIMICROB AGENTS CH, V32, P104, DOI 10.1128/AAC.32.1.104; ASHBY J, 1987, J ANTIMICROB CHEMOTH, V20, P15, DOI 10.1093/jac/20.1.15; BAQUERO MR, 1995, MOL MICROBIOL, V18, P301, DOI 10.1111/j.1365-2958.1995.mmi_18020301.x; DAVAGNINO J, 1986, Proteins Structure Function and Genetics, V1, P230, DOI 10.1002/prot.340010305; DRLICA K, 1989, PHARMACOL THERAPEUT, V44, P107, DOI 10.1016/0163-7258(89)90093-4; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P4474, DOI 10.1073/pnas.73.12.4474; GomezGomez JM, 1996, J BACTERIOL, V178, P3331, DOI 10.1128/jb.178.11.3331-3334.1996; HALLETT P, 1990, GENE, V93, P139, DOI 10.1016/0378-1119(90)90148-K; HIGGINS NP, 1978, P NATL ACAD SCI USA, V75, P1773, DOI 10.1073/pnas.75.4.1773; Kaneko T, 1996, MOL GEN GENET, V250, P593; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; KRUEGER S, 1990, J MOL BIOL, V211, P211, DOI 10.1016/0022-2836(90)90021-D; KUROIWA T, 1981, EXPERIENTIA, V37, P969, DOI 10.1007/BF01971784; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERC C, 1986, Critical Reviews in Therapeutic Drug Carrier Systems, V2, P353; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P71; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MAKI S, 1992, J BIOL CHEM, V267, P12244; MAXWELL A, 1992, J ANTIMICROB CHEMOTH, V30, P409, DOI 10.1093/jac/30.4.409; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; Menzel R, 1994, Adv Pharmacol, V29A, P39; MIKI T, 1984, J MOL BIOL, V174, P627, DOI 10.1016/0022-2836(84)90087-1; MIKI T, 1984, J MOL BIOL, V174, P605, DOI 10.1016/0022-2836(84)90086-X; Miller JH., 1972, EXPT MOL GENETICS; Mizushima T, 1996, MOL GEN GENET, V253, P297, DOI 10.1007/PL00008596; MIZUUCHI K, 1978, P NATL ACAD SCI USA, V75, P5960, DOI 10.1073/pnas.75.12.5960; OGURA T, 1983, P NATL ACAD SCI-BIOL, V80, P4784, DOI 10.1073/pnas.80.15.4784; OMORI K, 1994, PLASMID, V32, P233, DOI 10.1006/plas.1994.1061; PHILLIPS GJ, 1988, J BACTERIOL, V170, P2089, DOI 10.1128/jb.170.5.2089-2094.1988; PHILLIPS GJ, 1987, J BIOL CHEM, V262, P455; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SATO K, 1986, ANTIMICROB AGENTS CH, V30, P777, DOI 10.1128/AAC.30.5.777; STAUDENBAUER WL, 1981, NUCLEIC ACIDS RES, V9, P3589, DOI 10.1093/nar/9.15.3589; SUGINO A, 1980, J BIOL CHEM, V255, P6299; TAKAHATA M, 1988, ANTIMICROB AGENTS CH, V32, P1192, DOI 10.1128/AAC.32.8.1192; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; VIZAN JL, 1991, EMBO J, V10, P467, DOI 10.1002/j.1460-2075.1991.tb07969.x; WANG JC, 1987, BIOCHIM BIOPHYS ACTA, V909, P1, DOI 10.1016/0167-4781(87)90040-6; WARREN HS, 1988, IMMUNOLOGY, V8, P1	42	43	46	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1933	1938		10.1074/jbc.273.4.1933	http://dx.doi.org/10.1074/jbc.273.4.1933			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442027	hybrid			2022-12-25	WOS:000071595200016
J	Reginato, MJ; Krakow, SL; Bailey, ST; Lazar, MK				Reginato, MJ; Krakow, SL; Bailey, ST; Lazar, MK			Prostaglandins promote and block adipogenesis through opposing effects on peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE FATTY-ACID; ADIPOCYTE DIFFERENTIATION; ARACHIDONIC-ACID; PREADIPOCYTE DIFFERENTIATION; ADIPOSE DIFFERENTIATION; 3T3-L1 ADIPOCYTES; GENE-EXPRESSION; PLASMA-GLUCOSE; MESSENGER-RNAS; INSULIN	Fat cell differentiation is a critical aspect of obesity and diabetes, Dietary fatty acids are converted to arachidonic acid, which serves as precursor of prostaglandins (PGs). PGJ2 derivatives function as activating ligands for peroxisome proliferator-activated receptor gamma (FPAB gamma), a nuclear hormone receptor that is central to adipogenic determination. We report here that PGF2 alpha blocks adipogenesis through activation of mitogen-activated protein kinase, resulting in inhibitory phosphorylation of PPAR gamma. Both mitogen-activated protein kinase activation and PPAR gamma phosphorylation are required for the anti-adipogenic effects of PGF2 alpha. Thus, PG signals generated at a cell surface receptor regulate the program of gene expression required for adipogenesis by modulating the activity of a nuclear hormone receptor that is directly activated by other PG signals. The balance between PGF2 alpha and PGJ2 signaling may thus be central to the development of obesity and diabetes.	Univ Penn, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MK (corresponding author), Univ Penn, Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, 611 CRB,415 Curie Blvd, Philadelphia, PA 19104 USA.	lazar@mail.med.upenn.edu	Reginato, Mauricio/I-6155-2013; Bailey, Shannon/B-8045-2014	Reginato, Mauricio/0000-0002-7541-4094; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049780] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK49780] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAMOVITZ M, 1994, J BIOL CHEM, V269, P2632; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ARISAKA M, 1986, J PEDIATR GASTR NUTR, V5, P878, DOI 10.1097/00005176-198611000-00009; BARNETT AH, 1981, CLIN ENDOCRINOL, V15, P499, DOI 10.1111/j.1365-2265.1981.tb00694.x; Berk PD, 1997, J BIOL CHEM, V272, P8830, DOI 10.1074/jbc.272.13.8830; BERNLOHR DA, 1984, P NATL ACAD SCI-BIOL, V81, P5468, DOI 10.1073/pnas.81.17.5468; Camp HS, 1997, J BIOL CHEM, V272, P10811; Casimir DA, 1996, DIFFERENTIATION, V60, P203, DOI 10.1046/j.1432-0436.1996.6040203.x; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; COOK KS, 1987, SCIENCE, V237, P402, DOI 10.1126/science.3299705; COOK KS, 1985, J CELL BIOL, V100, P514, DOI 10.1083/jcb.100.2.514; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIMARZO V, 1995, PROSTAG LEUKOTR ESS, V53, P239, DOI 10.1016/0952-3278(95)90123-X; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GOLAY A, 1986, J CLIN ENDOCR METAB, V63, P481, DOI 10.1210/jcem-63-2-481; Greene M. E., 1995, Gene Expression, V4, P281; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Kallen CB, 1996, P NATL ACAD SCI USA, V93, P5793, DOI 10.1073/pnas.93.12.5793; KLETZIEN RF, 1992, MOL PHARMACOL, V41, P393; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Long SD, 1996, J BIOL CHEM, V271, P1138, DOI 10.1074/jbc.271.2.1138; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Micheal LF, 1997, ENDOCRINOLOGY, V138, P3695, DOI 10.1210/en.138.9.3695; Miller CW, 1996, ENDOCRINOLOGY, V137, P5641, DOI 10.1210/en.137.12.5641; NOLAN JJ, 1994, NEW ENGL J MED, V331, P1188, DOI 10.1056/NEJM199411033311803; PELIKANOVA T, 1991, METABOLISM, V40, P175, DOI 10.1016/0026-0495(91)90170-2; RANDLE PJ, 1994, DIABETOLOGIA, V37, pS155, DOI 10.1007/BF00400839; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; SAKAMOTO K, 1994, J BIOL CHEM, V269, P3881; Schwarz EJ, 1997, MOL CELL BIOL, V17, P1552, DOI 10.1128/MCB.17.3.1552; SERRERO G, 1992, ENDOCRINOLOGY, V131, P2545, DOI 10.1210/en.131.6.2545; Shao DL, 1997, J BIOL CHEM, V272, P21473, DOI 10.1074/jbc.272.34.21473; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; TEBBEY PW, 1994, J BIOL CHEM, V269, P639; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	47	245	257	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1855	1858		10.1074/jbc.273.4.1855	http://dx.doi.org/10.1074/jbc.273.4.1855			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442016	hybrid			2022-12-25	WOS:000071595200005
J	Creutz, CE; Tomsig, JL; Snyder, SL; Gautier, MC; Skouri, F; Beisson, J; Cohen, J				Creutz, CE; Tomsig, JL; Snyder, SL; Gautier, MC; Skouri, F; Beisson, J; Cohen, J			The copines, a novel class of C2 domain-containing, calcium-dependent, phospholipid-binding proteins conserved from Paramecium to humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; C-2-DOMAIN PROTEINS; CHROMAFFIN GRANULES; CRYSTAL-STRUCTURE; FUSION PROTEINS; ANNEXIN-II; FAMILY; IDENTIFICATION; SYNAPTOTAGMIN; PURIFICATION	In an attempt to identify proteins that might underlie membrane trafficking processes in ciliates, calcium-dependent, phospholipid-binding proteins were isolated from extracts of Paramecium tetraurelia, The major protein obtained, named copine, had a mass of 55 kDa, bound phosphatidylserine but not phosphatidylcholine at micromolar levels of calcium but not magnesium, and promoted lipid vesicle aggregation, The sequence of a 920-base pair partial cDNA revealed that copine is a novel protein that contains a Ca domain likely to be responsible for its membrane active properties, Paramecium was found to have two closely related copine genes, CPN1 and CPN2., Current sequence data bases indicate the presence of multiple copine homologs in green plants, nematodes, and humans, The full-length sequences reveal that copines consist of two C2 domains at the N terminus followed by a domain similar to the A domain that mediates interactions between integrins and extracellular ligands, A human homolog, copine I, was expressed in bacteria as a fusion protein with glutathione S-transferase. This recombinant protein exhibited calcium-dependent phospholipid binding properties similar to those of Paramecium copine, An antiserum raised against a fragment of human copine I was used to identify chromobindin 17, a secretory vesicle-binding protein, as a copine, This association with secretory vesicles, as well the general ability of copines to bind phospholipid bilayers in a calcium-dependent manner, suggests that these proteins may function in membrane trafficking.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	University of Virginia; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Creutz, CE (corresponding author), Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA.	Creutz@virginia.edu		Skouri-Panet, Feriel/0000-0002-2623-9058	FOGARTY INTERNATIONAL CENTER [F06TW002133] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031618] Funding Source: NIH RePORTER; FIC NIH HHS [FO6 TWO2133] Funding Source: Medline; NIGMS NIH HHS [GM53266] Funding Source: Medline; NINDS NIH HHS [NS31618] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; BURGOYNE RD, 1986, NATURE, V319, P68, DOI 10.1038/319068a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COLOMBATTI A, 1991, BLOOD, V77, P2305; CREUTZ CE, 1985, J BIOL CHEM, V260, P7171; CREUTZ CE, 1981, J CELL BIOL, V91, P247, DOI 10.1083/jcb.91.1.247; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CREUTZ CE, 1983, J BIOL CHEM, V258, P4664; CREUTZ CE, 1992, J CELL SCI, V103, P1177; Creutz CE, 1996, J CELL BIOL, V132, P1079, DOI 10.1083/jcb.132.6.1079; DAMER CK, 1994, J BIOL CHEM, V269, P31115; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; EMANS N, 1993, J CELL BIOL, V120, P1357, DOI 10.1083/jcb.120.6.1357; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; GERKE V, 1991, J BIOL CHEM, V266, P1697; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Knochel M, 1996, HISTOCHEM CELL BIOL, V105, P269, DOI 10.1007/BF01463930; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MADEDDU L, 1995, MOL BIOL CELL, V6, P649, DOI 10.1091/mbc.6.6.649; MARTINDALE DW, 1989, J PROTOZOOL, V36, P29; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P39; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; Skouri F, 1997, MOL BIOL CELL, V8, P1063; SMALLWOOD M, 1990, BIOCHEM J, V270, P157, DOI 10.1042/bj2700157; Sonneborn T. M., 1970, Methods Cell Physiol., V4, P241, DOI 10.1016/S0091-679X(08)61758-6; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; WALLNER BP, 1986, NATURE, V320, P77, DOI 10.1038/320077a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	44	167	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1393	1402		10.1074/jbc.273.3.1393	http://dx.doi.org/10.1074/jbc.273.3.1393			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430674	hybrid			2022-12-25	WOS:000071411500021
J	Gallagher, PG; Forget, BG				Gallagher, PG; Forget, BG			An alternate promoter directs expression of a truncated, muscle-specific isoform of the human ankyrin 1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ERYTHROCYTE ANKYRIN; LINKED DILATED CARDIOMYOPATHY; POLYMERASE-II TRANSCRIPTION; MYOSIN LIGHT CHAIN-1; SKELETAL-MUSCLE; DYSTROPHIN GENE; CARDIAC-MUSCLE; RAT-BRAIN; HEREDITARY SPHEROCYTOSIS; BINDING PROTEINS	Ankyrin I, an erythrocyte membrane protein that links the underlying cytoskeleton to the plasma membrane, is also expressed in brain and muscle. We cloned a truncated, muscle-specific ankyrin 1 cDNA composed of novel 5' sequences and 3' sequences previously identified in the last 3 exons of the human ankyrin 1 erythroid gene. Northern blot analysis revealed expression restricted to cardiac and skeletal muscle tissues. Deduced amino acid sequence of this muscle cDNA predicted a peptide of 155 amino acids in length with a hydrophobic NH, terminus. Cloning of the corresponding chromosomal gene revealed that the ankyrin 1 muscle transcript is composed of four exons spread over similar to 10 kilobase pairs of DNA. Reverse transcriptase-polymerase chain reaction of skeletal muscle cDNA identified multiple cDNA isoforms created by alternative splicing. The ankyrin 1 muscle promoter was identified as a (G + C)-rich promoter located >200 kilobase pairs from the ankyrin 1 erythroid promoter. An ankyrin 1 muscle promoter fragment directed high level expression of a reporter gene in cultured C2C12 muscle cells, but not in HeLa or K562 (erythroid) cells. DNA-protein interactions were identified in vitro at a single Spl and two E box consensus binding sites contained within the promoter. A MyoD cDNA expression plasmid transactivated an ankyrin 1 muscle promoter fragment/reporter gene plasmid in a dose-dependent fashion in both HeLa and K562 cells. A polyclonal antibody raised to human ankyrin 1 muscle-specific sequences reacted with peptides of 28 and 30 kDa on immunoblots of human skeletal muscle.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Gallagher, PG (corresponding author), Yale Univ, Sch Med, Dept Pediat, 333 Cedar St,POB 208064, New Haven, CT 06520 USA.	Patrick_Gallagher@QM.Yale.edu						AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BIRKENMEIER CS, 1993, BLOOD, V82, pA5; BUCKINGHAM ME, 1985, ESSAYS BIOCHEM, V20, P77; BUSHBY KMD, 1991, HUM GENET, V88, P195; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIG SW, 1983, CELL MOTIL CYTOSKEL, V3, P449, DOI 10.1002/cm.970030513; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DAVIS LH, 1992, J BIOL CHEM, V267, P18966; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; DAVIS LH, 1990, J BIOL CHEM, V265, P10589; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DONOGHUE MJ, 1991, J CELL BIOL, V115, P423, DOI 10.1083/jcb.115.2.423; Eber SW, 1996, NAT GENET, V13, P214, DOI 10.1038/ng0696-214; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FLUCHER BE, 1990, NEURON, V5, P339, DOI 10.1016/0896-6273(90)90170-K; FLUCHER BE, 1989, NEURON, V3, P163, DOI 10.1016/0896-6273(89)90029-9; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GALLAGHER PG, 1994, BLOOD, V84, pA361; Gallagher PG, 1997, J BIOL CHEM, V272, P19220, DOI 10.1074/jbc.272.31.19220; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; HALL TG, 1987, J BIOL CHEM, V262, P10537; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; Hoock TC, 1997, J CELL BIOL, V136, P1059, DOI 10.1083/jcb.136.5.1059; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAROLIM P, 1992, BLOOD S, V80, pA144; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KORDELI E, 1990, J CELL BIOL, V110, P1341, DOI 10.1083/jcb.110.4.1341; KORDELI E, 1991, J CELL BIOL, V114, P1243, DOI 10.1083/jcb.114.6.1243; KORDELI E, 1995, J BIOL CHEM, V270, P2352, DOI 10.1074/jbc.270.5.2352; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNIMOTO M, 1991, J CELL BIOL, V115, P1319, DOI 10.1083/jcb.115.5.1319; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAMBERT S, 1993, J NEUROSCI, V13, P3725; LAMBERT S, 1993, EUR J BIOCHEM, V211, P1, DOI 10.1111/j.1432-1033.1993.tb19863.x; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; LUX SE, 1909, BLOOD PRINCIPLES PRA, P1701; MASON P, 1993, GENE TRANSCRIPTION P, P47; McGrew MJ, 1996, MOL CELL BIOL, V16, P4524; MOISEYEV VS, 1987, LANCET, V2, P853; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; MOON RT, 1985, J CELL BIOL, V100, P152, DOI 10.1083/jcb.100.1.152; MORROW JS, 1996, HDB PHYSL, P485; MUNTONI F, 1995, AM J HUM GENET, V56, P151; MUNTONI F, 1995, J CLIN INVEST, V96, P693, DOI 10.1172/JCI118112; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; NELSON WJ, 1985, J CELL BIOL, V100, P1726, DOI 10.1083/jcb.100.5.1726; NELSON WJ, 1984, P NATL ACAD SCI-BIOL, V81, P3292, DOI 10.1073/pnas.81.11.3292; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; OTTO E, 1991, J CELL BIOL, V114, P241, DOI 10.1083/jcb.114.2.241; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PERIASAMY M, 1984, J BIOL CHEM, V259, P3595; PETERS LL, 1993, BLOOD, V81, P2144; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; PLATT OS, 1993, J BIOL CHEM, V268, P24421; Porter GA, 1997, CELL MOTIL CYTOSKEL, V37, P7, DOI 10.1002/(SICI)1097-0169(1997)37:1<7::AID-CM2>3.0.CO;2-7; ROBERT B, 1984, CELL, V39, P129, DOI 10.1016/0092-8674(84)90198-3; RUBENSTEIN PA, 1990, BIOESSAYS, V12, P309, DOI 10.1002/bies.950120702; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SPENCER SE, 1987, NEUROLOGY, V37, P645, DOI 10.1212/WNL.37.4.645; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STREHLER EE, 1985, MOL CELL BIOL, V5, P3168, DOI 10.1128/MCB.5.11.3168; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; WINKELMANN JC, 1993, BLOOD, V81, P3173; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; YAMAGATA T, 1995, MOL CELL BIOL, V15, P3830; Zhou DX, 1997, J CELL BIOL, V136, P621, DOI 10.1083/jcb.136.3.621	82	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1339	1348		10.1074/jbc.273.3.1339	http://dx.doi.org/10.1074/jbc.273.3.1339			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430667	hybrid			2022-12-25	WOS:000071411500014
J	Glogauer, M; Arora, P; Chou, D; Janmey, PA; Downey, GP; McCulloch, CAG				Glogauer, M; Arora, P; Chou, D; Janmey, PA; Downey, GP; McCulloch, CAG			The role of actin-binding protein 280 in integrin-dependent mechanoprotection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN PHAGOCYTOSIS; CHANNEL ACTIVATION; FILAMIN; FIBROBLASTS; CYTOSKELETON; MYOSIN; STRESS; IDENTIFICATION; TRANSDUCTION; LOCOMOTION	To survive in a mechanically active environment, cells must adapt to variations of applied membrane tension, A collagen-coated magnetic bead model was used to apply forces directly to the actin cytoskeleton through integrin receptors, We demonstrate here that by a calcium-dependent mechanism, human fibroblasts reinforce locally their connection with extracellular adhesion sites by inducing actin assembly and by recruiting actin-binding protein 280 (ABP-280) into cortical adhesion complexes, ABP-280 was phosphorylated on serine residues as a result of force application, This phosphorylation and the force-induced actin reorganization were largely abrogated by inhibitors of protein kinase C. In a human melanoma cell line that does not express ABP-280, actin accumulation could not be induced by force, whereas in stable transfectants expressing ABP-280, force-induced actin accumulation was similar to human fibroblasts, Cortical actin assembly played a role in regulating the activity of stretch-activated, calcium permeable channels (SAG) since sustained force application desensitized SAC to subsequent force applications, and the decrease in stretch sensitivity was reversed after treatment with cytochalasin D. ABP-280-deficient cells showed a >90% increase in cell death compared with ABP-280+ve cells after force application. We conclude that ABP-280 plays an important role in mechanoprotection by reinforcing the membrane cortex and desensitizing SACs.	Univ Toronto, Fac Dent, MRC, Periodontal Physiol Grp, Toronto, ON M5S 1A8, Canada; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Toronto, Fac Med, Dept Med, Toronto, ON M5S 1A8, Canada	University of Toronto; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto	Glogauer, M (corresponding author), Univ Toronto, Fac Dent, MRC, Periodontal Physiol Grp, 124 Edward St,Rm 4384,Med Sci Bldg, Toronto, ON M5S 1A8, Canada.		Glogauer, Michael/D-2504-2011	Glogauer, Michael/0000-0002-6248-5977; Downey, Gregory P/0000-0003-3253-5862				ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; ARORA PD, 1994, J CELL PHYSIOL, V161, P187, DOI 10.1002/jcp.1041610202; AUSIELLO DA, 1984, AM J PHYSIOL, V246, pF101, DOI 10.1152/ajprenal.1984.246.1.F101; BROTSCHI EA, 1978, J BIOL CHEM, V253, P8988; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; BYERS TJ, 1995, FEBS LETT, V368, P500, DOI 10.1016/0014-5793(95)00722-L; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; CANTIELLO HF, 1993, J BIOL CHEM, V268, P4596; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; Chou DHI, 1996, J IMMUNOL, V156, P4354; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, PFLUG ARCH EUR J PHY, V435, P320; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; GOTLIEB AI, 1979, J CELL PHYSIOL, V100, P563, DOI 10.1002/jcp.1041000318; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; JANSON LW, 1992, CELL MOTIL CYTOSKEL, V22, P274, DOI 10.1002/cm.970220407; JANSON LW, 1991, J CELL BIOL, V114, P1005, DOI 10.1083/jcb.114.5.1005; KNOWLES GC, 1991, J CELL SCI, V98, P551; Kovacsovics TJ, 1996, BLOOD, V87, P618, DOI 10.1182/blood.V87.2.618.bloodjournal872618; Lee W, 1996, J CELL PHYSIOL, V168, P695, DOI 10.1002/(SICI)1097-4652(199609)168:3<695::AID-JCP22>3.0.CO;2-X; MAIEK AM, 1996, J CELL SCI, V109, P713; MCCULLOCH CAG, 1993, J CELL PHYSIOL, V155, P461, DOI 10.1002/jcp.1041550305; McNeil Paul L., 1993, Trends in Cell Biology, V3, P302, DOI 10.1016/0962-8924(93)90012-P; McNeil PL, 1997, J CELL BIOL, V137, P1, DOI 10.1083/jcb.137.1.1; NAKAJO S, 1987, BIOCHEM INT, V15, P321; NUNNALLY MH, 1981, J BIOL CHEM, V256, P2083; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PAVALKO FM, 1989, J CELL SCI, V94, P109; PENDER N, 1991, J CELL SCI, V100, P187; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; SACHS F, 1988, CRIT REV BIOMED ENG, V16, P141; SCHINDL M, 1995, BIOPHYS J, V68, P1177, DOI 10.1016/S0006-3495(95)80294-8; SENGER R, 1995, BIOCHEM SOC T, V23, pS57, DOI 10.1042/bst023057s; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHIZUTA Y, 1976, J BIOL CHEM, V251, P6562; SOKABE M, 1991, BIOPHYS J, V59, P722, DOI 10.1016/S0006-3495(91)82285-8; STOSSEL TP, 1976, J CELL BIOL, V68, P602, DOI 10.1083/jcb.68.3.602; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WU MP, 1994, CELL MOL BIOL RES, V40, P351; Xu JH, 1997, J CELL BIOL, V136, P473, DOI 10.1083/jcb.136.2.473; YASUTAKA O, 1995, BIOCHEMISTRY-US, V34, P6745, DOI 10.1021/bi00020a020	46	203	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1689	1698		10.1074/jbc.273.3.1689	http://dx.doi.org/10.1074/jbc.273.3.1689			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430714	hybrid			2022-12-25	WOS:000071411500061
J	Nalefski, EA; McDonagh, T; Somers, W; Seehra, J; Falke, JJ; Clark, JD				Nalefski, EA; McDonagh, T; Somers, W; Seehra, J; Falke, JJ; Clark, JD			Independent folding and ligand specificity of the C2 calcium-dependent lipid binding domain of cytosolic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PRODUCT-CONTAINING VESICLES; PROTEIN-KINASE-C; MOBILIZING PHOSPHOLIPASE-A2; INTERFACIAL CATALYSIS; NUCLEAR-ENVELOPE; MEMBRANE-BINDING; MAP KINASE; RAT-KIDNEY; METAL-ION	The Ca2+-dependent lipid binding domain of the 85-kDa cytosolic phospholipase A(2), (cPLA(2)) is a homolog of C2 domains present in protein kinase C, synaptotagmin, and numerous other proteins involved in signal transduction, NH2-terminal fragments of cPLA(2), spanning the C2 domain were expressed as inclusion bodies in Escherichia coli, extracted with solvent to remove phospholipids, and refolded to yield a domain capable of binding phospholipid vesicles in a Ca2+-dependent manner. Unlike other C2 domains characterized to date, the cPLA(2), C2 domain bound preferentially to vesicles comprised of phosphatidylcholine in response to physiological concentrations of Ca2+. Binding of the cPLA(2), C2 domain to vesicles in the presence of excess Ca2+ chelator was induced by high concentrations of salts that promote hydrophobic interactions. Despite the selective hydrolysis of arachidonyl-containing phospholipid vesicles by cPLA(2), the cPLA(2), C2 domain did not discriminate among phospholipid vesicles containing saturated or unsaturated sn-2 fatty acyl chains. Moreover, the cPLA(2), C2 domain bound to phospholipid vesicles containing sn-l and -2 ether linkages and sphingomyelin at Ca2+ concentrations that caused binding to vesicles containing ester linkages, demonstrating that the carbonyl oxygens of the sn-l and-a ester linkage are not critical for binding, These results suggest that the cPLA(2), C2 domain interacts primarily with the headgroup of the phospholipid, The cPLA(2) C2 domain displayed selectivity among group IIA cations, preferring Ca2+ approximately 50-fold over Sr2+ and nearly 10,000-fold over Ba2+ for vesicle binding, No binding to vesicles was observed in the presence of greater than 10 mM Mg2+. Such strong selectivity for Ca2+ over Mg2+ reinforces the view that C2 domains link second messenger Ca2+ to signal transduction events at the membrane.	Genet Inst Inc, Small Mol Drug Discovery Grp, Cambridge, MA 02140 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80493 USA	University of Colorado System; University of Colorado Boulder	Clark, JD (corresponding author), Genet Inst Inc, Small Mol Drug Discovery Grp, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.			Clark, James D./0000-0002-4801-0123	NIGMS NIH HHS [GM 18303] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018303] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Creighton T. E., 1993, PROTEINS STRUCTURES, P156; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIEZ E, 1992, J BIOL CHEM, V267, P18342; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1986, PRINCIPLES FLUORESCE, P345; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LI C, 1995, J BIOL CHEM, V270, P24898, DOI 10.1074/jbc.270.42.24898; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; PETERSGOLDEN M, 1993, BIOCHEM BIOPH RES CO, V196, P147, DOI 10.1006/bbrc.1993.2227; Ponting CP, 1996, PROTEIN SCI, V5, P162; QUI ZH, 1994, J BIOL CHEM, V269, P19480; RAAFLAUB J, 1956, Methods Biochem Anal, V3, P301; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SierraHonigmann R, 1996, LAB INVEST, V74, P684; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x; WIJKANDER J, 1992, BIOCHEM BIOPH RES CO, V184, P118, DOI 10.1016/0006-291X(92)91166-N; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	47	112	112	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1365	1372		10.1074/jbc.273.3.1365	http://dx.doi.org/10.1074/jbc.273.3.1365			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430670	hybrid			2022-12-25	WOS:000071411500017
J	Zhang, Y; Wang, ZY; Liu, DX; Pagano, M; Ravid, K				Zhang, Y; Wang, ZY; Liu, DX; Pagano, M; Ravid, K			Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; REQUIRES BINDING; S-PHASE; MITOSIS; DESTRUCTION; P34(CDC2); PATHWAY; INHIBITOR	During the endomitotic cell cycle of megakaryocytic cell lines, the levels of cyclin B1 and the activity of cyclin B1-dependent Cdc2 kinase, although detectable, are reduced as compared with megakaryocytes undergoing a mitotic cell cycle, The levels of cyclin A, however, are comparable during both cell cycles, The expression of cyclin B1 mRNA is also equivalent in proliferating and polyploidizing cells, In the current study, we found that the rate of cyclin B1 protein degradation is enhanced in polyploidizing megakaryocytes, This finding has led us to further investigate whether the ubiquitin-proteosome pathway responsible for cyclin B degradation is accelerated in these cells, Our data indicate that polyploidizing megakaryocytic cell lines and primary bone marrow cells treated with the megakaryocyte proliferation-and ploidy-promoting factor, the c-Mpl ligand, display increased activities of the ubiquitin-proteosome pathway, which degrades cyclin B, as compared with proliferating megakaryocytic cell lines or diploid bone marrow cells, respectively. This degradation has all the hallmarks of a ubiquitin pathway, including the dependence on ATP, the appearance of high molecular weight conjugated forms of cyclin B, and inhibition of the proteolytic process by a mutated form of the ubiquitin-conjugating enzyme Ubc4., Our studies also indicate that the ability to degrade cyclin A is equivalent in both the mitotic and endomitotic cell cycles, The increased potential of polyploid megakaryocytes to degrade cyclin B may be part of the cellular programming that leads to aborted mitosis.	Boston Univ, Sch Med, Dept Biochem, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; NYU, Med Ctr, New York, NY 10016 USA; NYU, Kaplan Canc Ctr, New York, NY 10016 USA	Boston University; New York University; New York University	Ravid, K (corresponding author), Boston Univ, Sch Med, Dept Biochem, Whitaker Cardiovasc Inst, K225,80 E Concord St, Boston, MA 02118 USA.			pagano, michele/0000-0003-3210-2442; Ravid, Katya/0000-0002-9918-3024	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053080, R01HL058547] Funding Source: NIH RePORTER; NCI NIH HHS [CA66229-02] Funding Source: Medline; NHLBI NIH HHS [HL58547-01, HL53080-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURSTEIN SA, 1992, EXP HEMATOL, V20, P1170; CARROW CE, 1996, BLOOD, V88, P287; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CORREABORDES J, 1995, CELL, V83, P1001, DOI 10.1016/0092-8674(95)90215-5; Datta NS, 1996, MOL BIOL CELL, V7, P209, DOI 10.1091/mbc.7.2.209; DATTA NS, 1993, BLOOD, V82, pA209; DOI T, 1987, MOL CELL BIOL, V7, P898, DOI 10.1128/MCB.7.2.898; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; ISHIDA Y, 1993, EXP HEMATOL, V21, P289; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KAUSHANSKY K, 1995, THROMB HAEMOSTASIS, V74, P521; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; KUBIAK JZ, 1993, EMBO J, V12, P3773, DOI 10.1002/j.1460-2075.1993.tb06055.x; KUTER DJ, 1989, BLOOD, V74, P1952; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LU KP, 1993, J BIOL CHEM, V268, P8769; MORENO S, 1994, J CELL SCI, P63; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; ODELL TT, 1968, BLOOD, V32, P102, DOI 10.1182/blood.V32.1.102.102; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; RAVID K, 1991, P NATL ACAD SCI USA, V88, P1521, DOI 10.1073/pnas.88.4.1521; RAVID K, 1993, J CELL BIOL, V123, P1545, DOI 10.1083/jcb.123.6.1545; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Stern B, 1997, EMBO J, V16, P534, DOI 10.1093/emboj/16.3.534; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VANDERVELDEN HMW, 1994, MOL BIOL CELL, V5, P713, DOI 10.1091/mbc.5.7.713; Vitrat N, 1996, BLOOD, V88, P1135; WANG ZY, 1995, BLOOD, V86, P3783, DOI 10.1182/blood.V86.10.3783.bloodjournal86103783; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zhang Y, 1996, J BIOL CHEM, V271, P4266	42	69	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1387	1392		10.1074/jbc.273.3.1387	http://dx.doi.org/10.1074/jbc.273.3.1387			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430673	hybrid			2022-12-25	WOS:000071411500020
J	Lo, B; Silverman, M				Lo, B; Silverman, M			Replacement of Ala-166 with cysteine in the high affinity rabbit sodium/glucose transporter alters transport kinetics and allows methanethiosulfonate ethylamine to inhibit transporter function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; NA+ GLUCOSE COTRANSPORTER; BINDING-SITE CREVICE; EXPRESSION; RESIDUES; MEMBRANE; TRAFFICKING; CLONING; PROTEIN; SEGMENT	An alanine to cysteine mutation at position 166 has been introduced by site-directed mutagenesis into the rabbit sodium/glucose transporter (rSGLT1). When expressed in Xenopus laevis oocytes, this mutant transporter (A166C rSGLT1) demonstrates a significantly lower apparent affinity for alpha-methyl glucoside (alpha MG) compared with the wild-type transporter (apparent K-m = 0.8 versus 0.15 mM). Using the two-electrode voltage clamp technique, transient currents have also been measured, and for the mutant transporter, the transients induced by large depolarizations exhibit longer time constants than those for wild type, Moreover, the substitution of Ala-166 with a cysteine allows the sulfydryl specific reagent, methanethiosulfonate ethylamine (MTSEA), to react with and alter the function of the transporter, Whereas the wild-type transporter is unaffected by reaction with MTSEA, A166C rSGLT1 has its steady-state currents induced by 1 mM alpha MG inhibited 83% within a minute of exposure to MTSEA. Furthermore, the pre steady-state transients of the A166C mutant after MTSEA exposure demonstrate much shorter time constants than before while the total amount of charge transferred is only slightly diminished. These results together provide evidence that position 166 is situated in a region critical to the functioning of rSGLT1.	Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada	University of Toronto	Silverman, M (corresponding author), Med Sci Bldg,Rm 7207, Toronto, ON M5S 1A8, Canada.							AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; Javitch JA, 1995, BIOCHEMISTRY-US, V34, P16433, DOI 10.1021/bi00050a026; Javitch JA, 1996, MOL PHARMACOL, V49, P692; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; Lostao MP, 1995, FEBS LETT, V377, P181, DOI 10.1016/0014-5793(95)01339-3; Lund AH, 1996, NUCLEIC ACIDS RES, V24, P800, DOI 10.1093/nar/24.4.800; Martin MG, 1996, NAT GENET, V12, P216, DOI 10.1038/ng0296-216; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PanayotovaHeiermann M, 1996, J BIOL CHEM, V271, P10029, DOI 10.1074/jbc.271.17.10029; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; TATE SS, 1990, FASEB J, V4, P227, DOI 10.1096/fasebj.4.2.2298343; Turk E, 1996, J BIOL CHEM, V271, P1925, DOI 10.1074/jbc.271.4.1925; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	21	13	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					903	909		10.1074/jbc.273.2.903	http://dx.doi.org/10.1074/jbc.273.2.903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422748	hybrid			2022-12-25	WOS:000071411400037
J	Zhu, XR; Muller, L; Mains, RE; Lindberg, I				Zhu, XR; Muller, L; Mains, RE; Lindberg, I			Structural elements of PC2 required for interaction with its helper protein 7B2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROHORMONE CONVERTASE PC2; NEUROENDOCRINE POLYPEPTIDE 7B2; SITE-DIRECTED MUTAGENESIS; PROPROTEIN CONVERTASES; NH2-TERMINAL SEQUENCE; PROCESSING ACTIVITY; PITUITARY PROTEIN; SUBTILISIN; BIOSYNTHESIS; CELLS	The structures of the eukaryotic subtilisin protease family members can be divided into four distinct domains as follows: the proreson, the catalytic domain, the P domain, and the carboxyl-terminal region, Although these enzymes are evolutionarily related, only prohormone convertase 2 (PC2) requires 7B2 for activation, To examine the potential contribution of each domain of PC2 to PC2-7B2 interactions, we performed sequential deletions, site-directed mutagenesis, and domain swapping to replace individual domains or particular amino acids of pro-PC2 with the corresponding segments/amino acids of pro-PC1. These chimeras and mutant enzyme molecules were then expressed in AtT-20 cells and analyzed for 7B2 binding, maturation ability, and enzymatic activity, The results revealed that 1) the PC2 proregion is required but is not sufficient to confer 7B2 binding; 2) the P domain is required for the stabilization of PC2 structure and is not exchangeable with the P domain of PC1; and 3) the carboxyl-terminal domain is not involved in 7B2 binding, Site-directed mutagenesis of pro-PC2 further showed that a single residue replacement in the catalytic domain, Tyr-194 --> Asp, prevented pro-PCS from binding 7B2 and blocked activation, This residue is present within a loop rich in aromatic amino acids which appears to be on the surface of the molecule as extrapolated from the crystal structure of subtilisin, This loop may represent the pri mary recognition site for 7B2 within the catalytic domain.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Louisiana State University System; Johns Hopkins University; Johns Hopkins University	Lindberg, I (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	ilindb@lsumc.edu	muller, laurent/S-1990-2016; Lindberg, Iris/Q-3825-2019	muller, laurent/0000-0001-9634-4323; 	NIDA NIH HHS [DA 05084, R56 DA005084, DA 00266] Funding Source: Medline; NIDDK NIH HHS [R01 DK049703, DK 49703] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266, R56DA005084, R01DA005084] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; BENJANNET S, 1995, FEBS LETT, V362, P151, DOI 10.1016/0014-5793(95)00228-2; BENJANNET S, 1995, J NEUROCHEM, V64, P2303; BRAKS JAM, 1994, CELL, V78, P263, DOI 10.1016/0092-8674(94)90296-8; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRYAN P N, 1986, Proteins Structure Function and Genetics, V1, P326; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; Creemers JWM, 1996, J BIOL CHEM, V271, P25284, DOI 10.1074/jbc.271.41.25284; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; HSI KL, 1982, FEBS LETT, V147, P261, DOI 10.1016/0014-5793(82)81055-7; Hutton JC, 1990, CURR OPIN CELL BIOL, V2, P1131, DOI 10.1016/0955-0674(90)90167-D; IGUCHI H, 1984, NEUROENDOCRINOLOGY, V39, P453, DOI 10.1159/000124020; Johanning K, 1996, J BIOL CHEM, V271, P27871, DOI 10.1074/jbc.271.44.27871; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; LI YY, 1994, J BIOL CHEM, V269, P4169; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; MARTENS GJM, 1994, P NATL ACAD SCI USA, V91, P5784, DOI 10.1073/pnas.91.13.5784; MATTHEWS G, 1994, J BIOL CHEM, V269, P588; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Muller L, 1997, J CELL BIOL, V139, P625, DOI 10.1083/jcb.139.3.625; REHEMTULLA A, 1992, P NATL ACAD SCI USA, V89, P8235, DOI 10.1073/pnas.89.17.8235; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SEIDAH NG, 1983, ARCH BIOCHEM BIOPHYS, V225, P525, DOI 10.1016/0003-9861(83)90063-2; SEIDAH NG, 1994, METHOD ENZYMOL, V244, P171; SHEN FS, 1993, J BIOL CHEM, V268, P24910; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; STEINER DF, 1992, J BIOL CHEM, V267, P23435; VANHORSSEN AM, 1995, J BIOL CHEM, V270, P14292; VINDROLA O, 1992, MOL ENDOCRINOL, V6, P1088, DOI 10.1210/me.6.7.1088; YI Z, 1993, J BIOL CHEM, V268, P5615; ZHOU A, 1993, J BIOL CHEM, V268, P1763; ZHOU A, 1995, J BIOL CHEM, V270, P21509, DOI 10.1074/jbc.270.37.21509; ZHOU Y, 1994, J BIOL CHEM, V269, P18408; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641; Zhu XR, 1996, J BIOL CHEM, V271, P23582, DOI 10.1074/jbc.271.38.23582	39	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1158	1164		10.1074/jbc.273.2.1158	http://dx.doi.org/10.1074/jbc.273.2.1158			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422782	hybrid			2022-12-25	WOS:000071411400071
J	Chalaux, E; Lopez-Rovira, T; Rosa, JL; Bartrons, R; Ventura, F				Chalaux, E; Lopez-Rovira, T; Rosa, JL; Bartrons, R; Ventura, F			JunB is involved in the inhibition of myogenic differentiation by bone morphogenetic protein-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; I RECEPTORS; DNA-BINDING; OSTEOGENIC PROTEIN-1; SIGNALING PATHWAYS; NEGATIVE REGULATOR; GENE-EXPRESSION; C-JUN; ACTIVIN; MYOBLASTS	Bone morphogenetic proteins (BMPs) constitute a family of multifunctional growth and differentiation factors structurally related to transforming growth factor-beta. BMPs were first identified by their osteoinductive effects, inducing ectopic bone formation when implanted in skeletal muscle, and have an important role as regulators of skeletal development in vivo, In vitro, BMP-S is able to transdifferentiate myogenic C2C12 cells into the osteoblastic phenotype, In this report, we show that the osteoinductive effects of BMP-S in C2C12 cells are mediated by bone morphogenetic protein receptor type-LA in combination with both activin receptor type II and bone morphogenetic protein receptor type II, We also analyzed the expression levels of nuclear protooncogenes to understand early transcriptional events induced by BMP-2. We show that junB is an immediate early gene induced by BMP-2 and transforming growth factor-beta. BMP-2 induces transcriptional activation of JunB expression as early as 30 min after Ligand addition, reaching maximal levels after 90 min, Increase of JunB mRNA correlates with a higher AP-1 binding activity. Furthermore, ectopic overexpression of JunB is sufficient to inhibit expression of myoblast differentiation markers in C2C12 cells, These data, taken together, show the involvement of JunB in the early steps of inhibition of myogenic differentiation induced by transforming growth factor-beta family members.	Univ Barcelona, Unitat Bioquim, E-08907 Hospitalet De Llobregat, Spain	University of Barcelona	Ventura, F (corresponding author), Univ Barcelona, Unitat Bioquim, Campus Bellvitge,Feixa Llarga S-N, E-08907 Hospitalet De Llobregat, Spain.		Ventura, Francesc/K-9700-2014; Rosa, Jose Luis/K-6685-2014; Ventura, Francesc/ABG-2285-2020	Ventura, Francesc/0000-0001-9673-9405; Rosa, Jose Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405; Bartrons, Ramon/0000-0001-9349-5847				Ausubel FM, 1992, CURRENT PROTOCOLS MO; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; Brun RP, 1996, CURR OPIN CELL BIOL, V8, P826, DOI 10.1016/S0955-0674(96)80084-6; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; DUDLEY AT, 1995, GENE DEV, V9, P2795, DOI 10.1101/gad.9.22.2795; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KONG YF, 1995, MOL CELL BIOL, V15, P5205; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIU F, 1995, MOL CELL BIOL, V15, P3479; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; OGATA T, 1993, P NATL ACAD SCI USA, V90, P9219, DOI 10.1073/pnas.90.19.9219; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; Rawls A, 1997, CELL, V89, P5, DOI 10.1016/S0092-8674(00)80175-0; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; Rodan GA, 1997, CELL, V89, P677, DOI 10.1016/S0092-8674(00)80249-4; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1995, J CELL BIOL, V130, P217, DOI 10.1083/jcb.130.1.217; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	53	89	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					537	543		10.1074/jbc.273.1.537	http://dx.doi.org/10.1074/jbc.273.1.537			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417113	hybrid, Green Published			2022-12-25	WOS:000071295600079
J	Ferreira, V; Tarantino, N; Korner, M				Ferreira, V; Tarantino, N; Korner, M			Discrimination between RelA and RelB transcriptional regulation by a dominant negative mutant of I kappa B alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-EXPRESSION; C-REL; DNA-BINDING; NUCLEAR-LOCALIZATION; ACTIVATION; PROTEINS; PROMOTER; CELLS; PROTEOLYSIS	RelA and RelB belong to the nuclear factor-kappa B (NF-kappa B-Rel) transcription factor family. Both proteins are structurally and functionally related, but their intracellular and tissue distributions are different. In resting cells, RelB is found mostly in the nucleus, whereas RelA is sequestered in the cytosol by protein inhibitors, among which I kappa B alpha is the dominant form in lymphocytes. Upon cellular activation I kappa B alpha is proteolyzed, allowing RelA dimers to enter the nucleus and activate target genes. To study the selectivity of gene regulation by RelA and RelB, we generated T cell lines stably expressing a dominant negative mutant of I kappa B alpha. We show that selective inhibition of RelA-NF-kappa B decreased induction of NPKB1, interleukin-2, and interleukin-2R alpha genes but not c-myc. Transcription driven by the I kappa B alpha promoter was blocked by the transgenic I kappa B alpha; however, wild type I kappa B alpha was expressed in the transgenic cell clones but with much slower kinetics than that in control cells. Wild type I kappa B alpha expression was concomitant with RelB up-regulation, suggesting that RelB could be involved in transcription of I kappa B alpha through binding to an alternative site. These results indicate that RelB and RelA have both distinct and overlapping effects on gene expression.	Hop La Pitie Salpetriere, CNRS URA 625, Lab Immunol Cellulaire, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Korner, M (corresponding author), Hop La Pitie Salpetriere, CNRS URA 625, Lab Immunol Cellulaire, Bat CERVI,83 Bd Hop, F-75013 Paris, France.							ALCAMI J, 1995, EMBO J, V13, P4608; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOHNLEIN E, 1989, J BIOL CHEM, V264, P8475; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN AM, 1994, MOL CELL BIOL, V14, P2926, DOI 10.1128/MCB.14.5.2926; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Cai ZZ, 1997, J BIOL CHEM, V272, P96; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRESSMAN DE, 1993, ONCOGENE, V8, P2567; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; Feuillard J, 1996, EUR J IMMUNOL, V26, P2547, DOI 10.1002/eji.1830261102; Feuillard J, 1997, J IMMUNOL, V158, P2585; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; JI L, 1994, MOL CELL BIOL, V14, P7967, DOI 10.1128/MCB.14.12.7967; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Krappmann D, 1996, EMBO J, V15, P6716, DOI 10.1002/j.1460-2075.1996.tb01061.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEDERER JA, 1994, J IMMUNOL, V152, P77; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PETRAK D, 1994, J IMMUNOL, V153, P2046; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROSS EK, 1991, J VIROL, V65, P4350, DOI 10.1128/JVI.65.8.4350-4358.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; Shapiro VS, 1996, J EXP MED, V184, P1663, DOI 10.1084/jem.184.5.1663; SICA A, 1992, P NATL ACAD SCI USA, V89, P1740, DOI 10.1073/pnas.89.5.1740; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	62	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					592	599		10.1074/jbc.273.1.592	http://dx.doi.org/10.1074/jbc.273.1.592			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417120	hybrid			2022-12-25	WOS:000071295600086
J	Wang, SC; Ohata, M; Schrum, L; Rippe, RA; Tsukamoto, H				Wang, SC; Ohata, M; Schrum, L; Rippe, RA; Tsukamoto, H			Expression of interleukin-10 by in vitro and in vivo activated hepatic stellate cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAT-STORING CELLS; GROWTH-FACTOR-BETA; LIVER FIBROGENESIS; TRANSFORMING GROWTH-FACTOR-BETA-1; PROLIFERATION; COLLAGEN; MATRIX; LIPOCYTES; IL-10; METALLOPROTEINASE	Activated hepatic stellate cells (HSC) participate in matrix remodeling and deposition in liver fibrosis. The present study demonstrates that interleukin (IL)-10 is expressed by HSC upon activation in vitro or in vivo and that autocrine effects of this cytokine include inhibition of collagen production. Culture activation of HSC caused a distinct increase in IL-10 mRNA level compared with freshly isolated quiescent HSC. Treatment of cultured HSC with tumor necrosis factor-alpha, transforming growth factor-beta, or lipopolysaccharide further increased IL-10 mRNA by a-fold and resulted in the release of IL-10 protein into the medium. HSC isolated from rats after bile duct ligation (BDL) showed prominent increases in IL-10 mRNA(x 100) and protein (x 30) levels at 7 days after BDL, but such induction disappeared in advanced liver fibrosis (19 days after BDL). IL-10 expression correlated positively with mRNA expression of interstitial collagenase and inversely with that of alpha 1(I) collagen. Addition of anti-IL-10 IgG to cultured HSC caused enhanced collagen production under a basal or stimulated condition with TGF-beta, tumor necrosis factor-alpha, Or lipopolysaccharide. These effects were associated with increased alpha 1(I) collagen mRNA and reciprocally reduced collagenase mRNA levels. Co-transfection of HSC with an IL-10 expression vector and collagen reporter genes showed a 40% inhibition of alpha 1(I) collagen promoter activity. These results demonstrate that activation of HSC causes enhanced autocrine expression of IL-10 which possesses a negative autoregulatory effect on HSC collagen production mediated at least in part by alpha 1(I) collagen transcriptional inhibition and stimulation of collagenase expression. These findings, along with the demonstrated early induction of HSC IL-10 expression and its late disappearance during biliary liver fibrosis, suggest its in vivo role in matrix remodeling and a possibility that failure for HSC to sustain IL-10 expression underlies pathologic progression to liver cirrhosis.	Univ So Calif, Sch Med, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA; Dept Vet Affairs Outpatient Clin, Los Angeles, CA 90033 USA; Univ N Carolina, Gastrointestinal Res Lab, Chapel Hill, NC 27599 USA	University of Southern California; University of North Carolina; University of North Carolina Chapel Hill	Tsukamoto, H (corresponding author), Univ So Calif, Sch Med, Div Gastrointestinal & Liver Dis, 2011 Zonal Ave,HMR-101, Los Angeles, CA 90033 USA.				NIAAA NIH HHS [AA06603, AA10459] Funding Source: Medline; NIDDK NIH HHS [P30-DK-48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA006603, R37AA006603, R29AA010459, R01AA010459] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BACHEM MG, 1989, J CLIN CHEM CLIN BIO, V27, P555; BACHEM MG, 1993, VIRCHOWS ARCH B, V63, P123, DOI 10.1007/BF02899251; BACHEM MG, 1992, J CLIN INVEST, V89, P19, DOI 10.1172/JCI115561; DAVIS BH, 1988, J CELL PHYSIOL, V136, P547, DOI 10.1002/jcp.1041360323; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DEUEL TF, 1984, J CLIN INVEST, V74, P669, DOI 10.1172/JCI111482; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Friedman S L, 1996, Prog Liver Dis, V14, P101; FRIEDMAN SL, 1989, J CLIN INVEST, V84, P1780, DOI 10.1172/JCI114362; GRESSNER AM, 1992, HEPATOLOGY, V16, P1250; Hellerbrand C, 1996, HEPATOLOGY, V24, P670; KAMIMURA S, 1995, HEPATOLOGY, V21, P1304; LACRAZ S, 1995, J CLIN INVEST, V96, P2304, DOI 10.1172/JCI118286; Maher J. J., 1996, Hepatology, V24, p353A; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; MATSUOKA M, 1989, LIVER, V9, P71; MATSUOKA M, 1990, HEPATOLOGY, V11, P599, DOI 10.1002/hep.1840110412; Ohata M, 1997, AM J PHYSIOL-GASTR L, V272, pG589, DOI 10.1152/ajpgi.1997.272.3.G589; OVERALL CM, 1995, J CELL PHYSIOL, V164, P17, DOI 10.1002/jcp.1041640104; PIERCE GF, 1989, J CELL BIOL, V109, P429, DOI 10.1083/jcb.109.1.429; PINZANI M, 1989, J CLIN INVEST, V84, P1786, DOI 10.1172/JCI114363; PINZANI M, 1994, GASTROENTEROLOGY, V106, P1301, DOI 10.1016/0016-5085(94)90023-X; PINZANI M, 1992, AM J PHYSIOL, V262, pC876, DOI 10.1152/ajpcell.1992.262.4.C876; REITAMO S, 1994, J CLIN INVEST, V94, P2489, DOI 10.1172/JCI117618; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; TRAMS EG, 1957, AM J PATHOL, V33, P13; Tsukamoto H, 1996, AM J PHYSIOL-GASTR L, V270, pG581, DOI 10.1152/ajpgi.1996.270.4.G581; VIDALVANACLOCHA F, 1996, J NATL CANCER I, V88, P3; Yokozeki M, 1997, EXP CELL RES, V231, P328, DOI 10.1006/excr.1997.3473	32	123	145	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					302	308		10.1074/jbc.273.1.302	http://dx.doi.org/10.1074/jbc.273.1.302			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417080	Green Published, hybrid			2022-12-25	WOS:000071295600046
J	Eckhardt, AE; Timpte, CS; DeLuca, AW; Hill, RL				Eckhardt, AE; Timpte, CS; DeLuca, AW; Hill, RL			The complete cDNA sequence and structural polymorphism of the polypeptide chain of porcine submaxillary mucin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; MOLECULAR-CLONING; GEL-ELECTROPHORESIS; GLAND APOMUCIN; GENE; IDENTIFICATION; DOMAINS; MULTIMERIZATION; DIMERIZATION; EXPRESSION	The complete structure of the DNA encoding the polypeptide chain of porcine submaxillary mucin has been determined. The polypeptide is composed of distinct domains. A large central domain containing tandem repeats of 81 residues each is flanked by much shorter domains with sequences similar to the tandem repeats. Four disulfide-rich domains, three at the amino terminus and one at the carboxyl terminus, complete the chain. The disulfide-rich domains have significant sequence identity to those of other mucins and preprovon Willebrand factor. The coding region of the mucin gene is highly polymorphic, and three alleles were identified in a single animal that encoded different numbers of the 81-residue tandem repeats. A single large exon devoid of introns encodes the tandem repeat domains. The largest allele with 135 tandem repeats encoded 13,288 amino acids to give a polypeptide with M-r = 1,184,106. The other two alleles contained 99 and 125 tandem repeats, respectively. Each allele also showed different restriction fragment length polymorphisms, which is consistent with the different patterns seen in individual animals. Fragment length polymorphism was also seen within two different families of animals, indicating that the polymorphism observed occurs in a single generation.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.				PHS HHS [25766] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAAS F, 1984, HUM GENET, V67, P301, DOI 10.1007/BF00291357; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; ECKHARDT AE, 1987, J BIOL CHEM, V262, P11339; Gerken TA, 1997, J BIOL CHEM, V272, P9709; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1994, J BIOL CHEM, V269, P2440; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; JOHANSSON M, 1993, J HERED, V84, P259, DOI 10.1093/oxfordjournals.jhered.a111336; KOZAK M, 1989, J CELL BIOL, V98, P503; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MAYADAS TN, 1989, J BIOL CHEM, V264, P13497; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; RACKWITZ HR, 1984, GENE, V30, P195, DOI 10.1016/0378-1119(84)90120-3; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Sambrook J., 2002, MOL CLONING LAB MANU; SHOGREN RL, 1984, J BIOL CHEM, V259, P4657; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THORNTON DJ, 1991, BIOCHEM J, V276, P266; TIMPTE CS, 1988, J BIOL CHEM, V263, P1081; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; VERMA M, 1993, P NATL ACAD SCI USA, V90, P7144, DOI 10.1073/pnas.90.15.7144; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195	32	47	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33204	33210		10.1074/jbc.272.52.33204	http://dx.doi.org/10.1074/jbc.272.52.33204			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407109	hybrid			2022-12-25	WOS:000071182900070
J	Perez-Vilar, J; Hill, RL				Perez-Vilar, J; Hill, RL			Norrie disease protein (norrin) forms disulfide-linked oligomers associated with the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; MISSENSE MUTATIONS; CANDIDATE GENE; ND GENE; MUCIN; DIMERIZATION; IDENTIFICATION; DOMAINS; CELLS; RICH	COS-7 cells transfected with a DNA construct encoding the 133 amino acids in norrin plus six histidine residues at its carboxyl terminus were pulse-labeled with [S-35]cysteine, and the labeled norrin was examined in cell lysates, the medium, and the extracellular matrix. SDS-gel electrophoresis under reducing conditions showed that the norrin expressed had an apparent M-r = 14,000 and was present only in cell lysates and the extracellular matrix. Under nonreducing conditions, most of the norrin in the extracellular matrix was oligomers that contained up to similar to 20 monomers. One of the major extracellular species of norrin under reducing conditions after cross-linking of norrin oligomers with bis(sulfosuccinimidyl)suberate had an apparent M-r = 28,000, consistent with covalent cross-linked dimers. Thus the covalently cross-linked dimers are key structural components of norrin oligomers. By site-directed mutagenesis, the codon for half-cystine 95 in norrin was changed to one encoding alanine. The norrin C95A found in the extracellular matrix of cells transfected with this mutant was the size of dimers, indicating that half-cystine 95 is involved in oligomer formation. The corresponding half-cystine residue in human preprovon Willebrand factor is also involved in interchain disulfide bond formation, which is consistent with the sequence identity of the half-cystine residues in norrin and part of the half-cystine residues in a disulfide-rich domain of von Willebrand factor. Replacement of valine at residue 60 in norrin by glutamic acid, a mutation found in humans with a severe type of Norrie disease, results in a considerable reduction (50%) in the amount of norrin in the extracellular matrix of transfected COS-7 cells. Replacement of arginine at residue 121 by glutamine, which is associated with a less severe type of Norrie disease, results in a reduction in the amount of norrin R121Q in the extracellular matrix (26%). These studies suggest that norrin is a secreted protein that forms disulfide-bonded oligomers that are associated with the extracellular matrix upon secretion from cells. Moreover, the disulfide-rich motif of norrin and preprovon Willebrand factor promotes interchain disulfide bond formation among polypeptides in which it is found.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hill, RL (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	hill@biochem.duke.edu			PHS HHS [25766] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Berger W, 1996, HUM MOL GENET, V5, P51, DOI 10.1093/hmg/5.1.51; BERGER W, 1992, NAT GENET, V1, P199, DOI 10.1038/ng0692-199; BLENIS J, 1983, P NATL ACAD SCI-BIOL, V80, P770, DOI 10.1073/pnas.80.3.770; CHEN ZY, 1992, NAT GENET, V1, P204, DOI 10.1038/ng0692-204; CHEN ZY, 1993, GENOMICS, V16, P533, DOI 10.1006/geno.1993.1224; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FUCHS S, 1995, HUM MUTAT, V6, P257, DOI 10.1002/humu.1380060312; FUENTES JJ, 1993, HUM MOL GENET, V2, P1953, DOI 10.1093/hmg/2.11.1953; GUM JR, 1992, J BIOL CHEM, V267, P21375; ISASHIKI Y, 1995, BRIT J OPHTHALMOL, V79, P703, DOI 10.1136/bjo.79.7.703; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P2493; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MEINDL A, 1992, NAT GENET, V2, P139, DOI 10.1038/ng1092-139; MEINDL A, 1995, HUM MOL GENET, V4, P489, DOI 10.1093/hmg/4.3.489; MEITINGER T, 1993, NAT GENET, V5, P376, DOI 10.1038/ng1293-376; NORRIE GORDON, 1927, ACTA OPHTHALMOLOGICA, V5, P357; PerezVilar J, 1996, J BIOL CHEM, V271, P9845, DOI 10.1074/jbc.271.16.9845; PROBST JC, 1990, BIOCHEMISTRY-US, V29, P6240, DOI 10.1021/bi00478a018; SADLER JE, 1991, J BIOL CHEM, V266, P22777; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; SCHUBACK DE, 1995, HUM MUTAT, V5, P285, DOI 10.1002/humu.1380050403; Shastry BS, 1997, HUM MUTAT, V9, P396, DOI 10.1002/(SICI)1098-1004(1997)9:5<396::AID-HUMU3>3.3.CO;2-8; Shastry BS, 1997, ARCH OPHTHALMOL-CHIC, V115, P651, DOI 10.1001/archopht.1997.01100150653015; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Toribara NW, 1997, J BIOL CHEM, V272, P16398, DOI 10.1074/jbc.272.26.16398; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; Walker JL, 1997, HUM MUTAT, V9, P53, DOI 10.1002/(SICI)1098-1004(1997)9:1<53::AID-HUMU9>3.3.CO;2-L; Warburg M., 1966, ACTA OPHTHALMOL SCAN, V89, P1	36	46	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33410	33415		10.1074/jbc.272.52.33410	http://dx.doi.org/10.1074/jbc.272.52.33410			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407136	hybrid			2022-12-25	WOS:000071182900097
J	Srivastava, RAK; Srivastava, N; Averna, M; Lin, RC; Korach, KS; Lubahn, DB; Schonfeld, G				Srivastava, RAK; Srivastava, N; Averna, M; Lin, RC; Korach, KS; Lubahn, DB; Schonfeld, G			Estrogen up-regulates apolipoprotein E (ApoE) gene expression by increasing ApoE mRNA in the translating pool via the estrogen receptor alpha-mediated pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; B MESSENGER-RNA; A-I; INBRED STRAINS; PLASMA-LIPOPROTEINS; LDL-RECEPTOR; RAT-LIVER; INVIVO REGULATION; MICE; PROTEIN	The antiatherogenic property of estrogens is mediated via at least two mechanisms: first by affecting plasma lipoprotein profiles, and second by affecting the components of the vessel wall. Raising plasma apolipoprotein E (apoE) in mice protects them against diet-induced atherosclerosis (Shimano, H., Yamada, N., Katsuki, M., Gotoda, T., Harada, K., Murase, T., Fukuzawa, C., Takaku, F., and Yazaka, Y. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 1750-1754). It is possible that estrogen may be antiatherogenic at least in part by increasing plasma apoE levels. Therefore, we studied the regulation of apoE by estrogen. A survey of 15 inbred strains of mice showed that some mouse strains responded to injections or subcutaneously implanted pellets of estradiol by raising their apoB and apoE levels and some did not. We performed detailed studies in two "responder" strains, C57L and C57BL, and two "non-responder" strains, C3H and BALBc. Responders increased their plasma apoE levels 2.5-fold. Non-responders' levels were altered +/-10%. In the responders the distribution of apoE among the plasma lipoproteins shifted from high density lipoprotein toward the apoB-containing lipoprotein fractions. In nonresponders the shift was toward high density lipoprotein. Hepatic apoE mRNA levels and relative rates of apoE mRNA transcription were unchanged in all strains, suggesting that apoE regulation occurred at posttranscriptional loci. Therefore, we measured apoE synthesis in fresh liver slices and on isolated hepatic polysomes. Two-fold increases were noted but only in responders accompanied by selective 1.5-fold increases in polysomal apoE mRNA levels. Similar increases in apoE synthesis were also observed in castrated C57BL mice given either physiological or pharmacological replacement doses of estradiol, but not testosterone, suggesting that the effect of estradiol was specific on the distribution of apoE mRNA in the translationally active polysomal pool. Next, we examined whether the effects of estrogen on apoE translation were mediated by estrogen receptors (ER). ER-alpha knock-out mice and their wild-type littermates were administered estradiol. As expected, apoE levels and hepatic apoE synthesis increased more than 2-fold in the wildtype littermates, but only 20% increases in the plasma apoE and hepatic synthesis were observed in the ER knock-out mice. Hepatic apoE mRNA levels did not change in either the wild-type or the ER knock-out mice. Thus, estradiol up-regulates apoE gene expression by increasing levels of apoE mRNA in the polysomal translating pool. Furthermore, the increased polysomal recruitment of apoE mRNA is largely mediated by estrogen receptors.	Washington Univ, Sch Med, Dept Internal Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA; Dept Vet Affairs, Vet Affairs Med Ctr, Indianapolis, IN 46202 USA; Univ Palermo, Palermo, Italy; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; Univ Missouri, Dept Child Hlth, Columbia, MO 65211 USA	Washington University (WUSTL); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Palermo; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Srivastava, RAK (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Atherosclerosis Nutr & Lipid Res, 660 S Euclid Ave,Box 8046, St Louis, MO 63110 USA.		Averna, Maurizio/U-9527-2017	Korach, Kenneth/0000-0002-7765-418X; Averna, Maurizio/0000-0003-3558-9209	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020579] Funding Source: NIH RePORTER; NHLBI NIH HHS [2RO1HL42460] Funding Source: Medline; NIDDK NIH HHS [P60 DK20579] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AJIT R, 1993, EUR J BIOCHEM, V216, P527, DOI 10.1111/j.1432-1033.1993.tb18171.x; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; Bourassa PAK, 1996, P NATL ACAD SCI USA, V93, P10022, DOI 10.1073/pnas.93.19.10022; Byers M, 1997, MOL ENDOCRINOL, V11, P172, DOI 10.1210/me.11.2.172; CAMPOS H, 1993, METABOLISM, V42, P1153, DOI 10.1016/0026-0495(93)90273-Q; CHEN XL, 1993, J BIOL CHEM, V268, P21007; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FAGAN RJ, 1993, MOL CELL ENDOCRINOL, V90, P171, DOI 10.1016/0303-7207(93)90149-E; GRANFONE A, 1992, METABOLISM, V41, P1193, DOI 10.1016/0026-0495(92)90008-X; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; IFRATI MD, 1997, NAT MED, V3, P545; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; KUSHWAHA RS, 1991, ARTERIOSCLER THROMB, V11, P23, DOI 10.1161/01.ATV.11.1.23; LIN RC, 1986, ANAL BIOCHEM, V154, P316, DOI 10.1016/0003-2697(86)90531-2; LINLEE YC, 1981, BIOCHEMISTRY-US, V20, P6474, DOI 10.1021/bi00525a028; LINLEE YC, 1985, BIOCHEMISTRY-US, V24, P3751, DOI 10.1021/bi00335a050; LINTON MF, 1996, CIRCULATION S, V94, P398; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MADER S, 1994, BIOCHIMIE PARIS, V77, P40; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MEINSTEIN I, 1978, BIOCHIM BIOPHYS ACTA, V530, P394; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; OGBONNA G, 1993, INT J BIOCHEM, V25, P635, DOI 10.1016/0020-711X(93)90347-H; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; RAJAVASHISTH TB, 1985, P NATL ACAD SCI USA, V82, P8085, DOI 10.1073/pnas.82.23.8085; Rubanyi GM, 1997, J CLIN INVEST, V99, P2429, DOI 10.1172/JCI119426; Ruehlmann DO, 1997, BIOCHEM SOC T, V25, P40, DOI 10.1042/bst0250040; SCHAEFER EJ, 1983, J CLIN ENDOCR METAB, V57, P262, DOI 10.1210/jcem-57-2-262; SEISHIMA M, 1991, J LIPID RES, V32, P941; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SRIVASTAVA RAK, 1992, BIOCHEM INT, V27, P85; SRIVASTAVA RAK, 1991, BIOTECHNIQUES, V11, P584; Srivastava RAK, 1996, BIOCHEM MOL BIOL INT, V38, P91; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; Srivastava RAK, 1996, MOL CELL BIOCHEM, V155, P153, DOI 10.1007/BF00229312; SRIVASTAVA RAK, 1995, BIOCHEM BIOPH RES CO, V212, P381, DOI 10.1006/bbrc.1995.1981; SRIVASTAVA RAK, 1992, BIOCHEM BIOPH RES CO, V188, P135, DOI 10.1016/0006-291X(92)92360-A; SRIVASTAVA RAK, 1991, BIOCHIM BIOPHYS ACTA, V1090, P95, DOI 10.1016/0167-4781(91)90042-K; Srivastava RAK, 1997, MOL CELL BIOCHEM, V173, P161, DOI 10.1023/A:1006896131186; STAELS B, 1989, J LIPID RES, V30, P1137; STROBL W, 1989, J BIOL CHEM, V264, P1190; TANG JJ, 1991, J LIPID RES, V32, P1571; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; WEISGRABER KH, 1982, J BIOL CHEM, V257, P2518; Wiseman H, 1997, BIOCHEM SOC T, V25, P54, DOI 10.1042/bst0250054; Zhang WY, 1996, J BIOL CHEM, V271, P28641, DOI 10.1074/jbc.271.45.28641	51	129	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33360	33366		10.1074/jbc.272.52.33360	http://dx.doi.org/10.1074/jbc.272.52.33360			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407129	hybrid			2022-12-25	WOS:000071182900090
J	Pahan, K; Sheikh, FG; Khan, M; Namboodiri, AMS; Singh, I				Pahan, K; Sheikh, FG; Khan, M; Namboodiri, AMS; Singh, I			Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; PROGRAMMED CELL-DEATH; C6 GLIOMA-CELLS; PROTEIN-KINASE; ACTIVATION; APOPTOSIS; INDUCTION; PATHWAY; ALPHA	The sphingomyelin signal transduction pathway is known to play a role in mediating the action of various cytokines, Here we examined the possible role of the sphingomyelin signaling pathway on lipopolysaccharide (LPS)- and cytokine-mediated production of NO and the expression of inducible nitric-oxide synthase (iNOS). Sphingomyelinase (SMase) treatment of astrocytes increased the cellular levels of ceramide without the induction of NO production, However, incubation of LPS or cytokine-stimulated astrocytes with SMase or by increasing intracellular ceramide by cell-permeable ceramide analogs (C-2- or C-6-ceramide) or inhibitor of ceramidase (N-oleoyl ethanolamine) led to a time-and dose-dependent increase in the production of NO, This increase in NO production was accompanied by an increase in iNOS activity, MOS protein, and iNOS mRNA, Similar to astrocytes, SMase or ceramide analogs also stimulated the LPS-and cytokine-mediated expression of iNOS in the C-6 glial cell line, Since activation of NF-kappa B is necessary for the induction of MOS, we examined the effect of SMase and C-2-ceramide on the activation of NF-kappa B. Although SMase or C-2-ceramide alone was ineffective in activating NF-kappa B, both stimulated the LPS-mediated activation of NF-kappa B in LPS-activated astrocytes, Inhibition of ceramide and LPS-mediated induction of iNOS by antioxidant inhibitors of NF-kappa B (N-acetylcysteine and pyrrolidine dithiocarbamate) suggest that the stimulatory effect of ceramide on the induction of iNOS is due to the stimulation of NF-kappa B activation and that cellular redox plays a role in the activation of NF-kappa B and induction of iNOS, Inhibition of LPS-mediated as well as LPS and ceramide-mediated induction of iNOS and activation of NF-kappa B by PD98059, a specific inhibitor of activation of mitogen activated protein (MAP) kinase kinase (MEK), and FPT inhibitor II, a selective inhibitor of Ras farnesyl protein transferase, indicate that the Ras-MAP kinase pathway is involved in LPS-ceramide induced activation of NF-kappa B and induction of iNOS, and that ceramide-mediated signaling events probably converge into the LPS-modulated MAP kinase signaling pathway resulting in greater activation of NF-KB and iNOS induction, This study illustrates a novel role of the sphingomyelin-ceramide signaling pathway in stimulating the expression of iNOS via LPS-or cytokine-mediated activation of NF-KB in astrocytes.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA	Medical University of South Carolina	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS022576, R01NS034741, R01NS022576] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-34741, NS-22576] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brugg B, 1996, J NEUROCHEM, V66, P733; CAIRA F, 1995, BIOCHEM PHARMACOL, V49, P611, DOI 10.1016/0006-2952(94)00480-A; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dobashi K, 1997, J NEUROCHEM, V68, P1896; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KANTEY H, 1995, J BIOL CHEM, V270, P23780; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790; Linardic CM, 1996, CELL GROWTH DIFFER, V7, P765; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NISHIYA T, 1995, FEBS LETT, V371, P333, DOI 10.1016/0014-5793(95)00933-Z; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PRIESS J, 1986, J BIOL CHEM, V261, P8597; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Wiesner DA, 1996, GLYCOCONJUGATE J, V13, P327, DOI 10.1007/BF00731508; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; ZHANG YH, 1995, ENDOCRINOLOGY, V136, P4157, DOI 10.1210/en.136.10.4157	37	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2591	2600		10.1074/jbc.273.5.2591	http://dx.doi.org/10.1074/jbc.273.5.2591			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446561	hybrid			2022-12-25	WOS:000071736600016
J	Fu, HY; Sadis, S; Rubin, DM; Glickman, M; van Nocker, S; Finley, D; Vierstra, RD				Fu, HY; Sadis, S; Rubin, DM; Glickman, M; van Nocker, S; Finley, D; Vierstra, RD			Multiubiquitin chain binding and protein degradation are mediated by distinct domains within the 26 S proteasome subunit Mcb1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEOLYTIC PATHWAY; MOLECULAR-CLONING; SHUTTLE VECTORS; UBIQUITIN; EXPRESSION; COMPONENT; COMPLEX; SYSTEM; GENE	The 26 S proteasome is a multisubunit proteolytic complex responsible for degrading eukaryotic proteins targeted by ubiquitin modification. Substrate recognition by the complex is presumed to be mediated by one or more common receptor(s) with affinity for multiubiquitin chains, especially those internally linked through lysine 48. We have identified previously a candidate for one such receptor from diverse species, designated here as Mcb1 for Multiubiquitin chain-binding protein, based on its ability to bind Lys(48)-linked multiubiquitin chains and its location within the 26 S proteasome complex. Even though Mcb1 is likely not the only receptor in yeast, it is necessary for conferring resistance to amino acid analogs and for degrading a subset of ubiquitin pathway substrates such as ubiquitin-Pro-beta-galactosidase (Ub-Pro-beta-gal) (van Necker, S., Sadis, S., Rubin, D. M., Glickman, M., Fu, H., Coux, O., Wefes, I., Finley, D., and Vierstra, R. D. (1996) Mol. Cell. Biol. 16, 6020-28). To further define the role of Meb1 in substrate recognition by the 26 S proteasome, a structure/function analysis of various deletion and site-directed mutants of yeast and Arabidopsis Mcb1 was performed. From these studies, we identified a single stretch of conserved hydrophobic amino acids (LAM/LALRL/V (ScMcb1 228-234 and At-Mcb1 226-232)) within the C-terminal half of each polypeptide that is necessary for interaction with Lys(48)-linked multiubiquitin chains. Unexpectedly, this domain was not essential for either Ub-Pro-beta-gal degradation or conferring resistance to amino acid analogs. The domain responsible for these two activities was mapped to a conserved region near the N terminus. Yeast and Arabidopsis Mcb1 derivatives containing an intact multiubiquitin-binding site but missing the N-terminal region failed to promote Ub-Pro-beta-gal degradation and even accentuated the sensitivity of the yeast Delta mcb1 strain to amino acid analogs. This hypersensitivity was not caused by a gross defect in 26 S proteasome assembly as mutants missing either the N-terminal domain or the multiubiquitin chain-binding site could still associate with 26 S proteasome and generate a complex indistinguishable in size from that present in wild-type yeast. Together, these data indicate that residues near the N terminus, and not the multiubiquitin chain-binding site, are most critical for Mcb1 function in vivo.	Univ Wisconsin, Dept Hort, Program Mol & Cellular Biol, Madison, WI 53706 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Harvard Medical School	Vierstra, RD (corresponding author), Univ Wisconsin, Dept Hort, Program Mol & Cellular Biol, 1575 Linden Dr, Madison, WI 53706 USA.		Fu, Hongyong/A-7575-2011	Fu, Hongyong/0000-0001-5143-3269; Glickman, Michael/0000-0002-1222-8104	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043601, R37GM043601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand G, 1997, J BIOL CHEM, V272, P19140, DOI 10.1074/jbc.272.31.19140; ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; EYTAN E, 1993, J BIOL CHEM, V268, P4668; Ferrell K, 1996, FEBS LETT, V381, P143, DOI 10.1016/0014-5793(96)00101-9; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HARACSKA L, 1995, EUR J BIOCHEM, V231, P720, DOI 10.1111/j.1432-1033.1995.0720d.x; HARACSKA L, 1997, EUR J BIOCHEM, V412, P331; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHANSSON E, 1995, J BIOL CHEM, V270, P20615, DOI 10.1074/jbc.270.35.20615; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; Kominami K, 1997, MOL BIOL CELL, V8, P171, DOI 10.1091/mbc.8.1.171; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIKORSKI RS, 1989, GENETICS, V122, P19; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; vanNocker S, 1996, P NATL ACAD SCI USA, V93, P856, DOI 10.1073/pnas.93.2.856; Vierstra RD, 1996, PLANT MOL BIOL, V32, P275, DOI 10.1007/BF00039386	43	155	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1970	1981		10.1074/jbc.273.4.1970	http://dx.doi.org/10.1074/jbc.273.4.1970			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442033	Green Published, hybrid			2022-12-25	WOS:000071595200022
J	Louis, JM; Martin, RG; Clore, GM; Gronenborn, AM				Louis, JM; Martin, RG; Clore, GM; Gronenborn, AM			Preparation of uniformly isotope-labeled DNA oligonucleotides for NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-DIMENSIONAL HETERONUCLEAR NMR; PROTEIN NMR; RNA; C-13; ENHANCEMENT; OLIGOMERS; DODECAMER; LARGER	Two methods for the large scale preparation of uniformly isotope-labeled DNA for NMR studies have been developed, The first method comprises the growth of a suitable plasmid harboring multiple copies of the desired oligonucleotide in a medium based on N-15 and C-13 nutrients. The second method uses a polymerase chain reaction (PCR)-based approach with N-15-and/or C-13-labeled deoxynucleoside triphosphates. The novelty of our PCR strategy over existing ones is that the primer and template are the identical molecule, resulting in an exponential growth in the length of the double strand that contains tandem repeats of the target DNA sequence. This novel PCR approach, which we have termed ESRA for endonuclease-sensitive repeat amplification, is easy to use, results in high fields, and can be accomplished at low costs, The utility of both methods is demonstrated for the preparation of a double-stranded 21-mer uniformly labeled with N-15 and a double-stranded 17-mer DNA uniformly labeled with N-15 and C-13.	NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDKD, Chem Phys Lab, NIH, Bldg 5, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Gronenborn, Angela M/0000-0001-9072-3525				ASHCROFT J, 1991, BIOPOLYMERS, V31, P45, DOI 10.1002/bip.360310105; Batey RT, 1995, METHOD ENZYMOL, V261, P300; BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; Chen W, 1997, J IND MICROBIOL BIOT, V18, P43, DOI 10.1038/sj.jim.2900355; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; FOLDESI A, 1992, TETRAHEDRON, V48, P9033, DOI 10.1016/S0040-4020(01)82001-9; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; MESELSON M, 1958, P NATL ACAD SCI USA, V44, P671, DOI 10.1073/pnas.44.7.671; Michalczyk R, 1996, MAGN RESON CHEM, V34, pS97; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NIKONOWICZ EP, 1992, NATURE, V355, P184, DOI 10.1038/355184a0; NIKONOWICZ EP, 1992, J AM CHEM SOC, V114, P1082, DOI 10.1021/ja00029a043; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; ONO A, 1994, J BIOMOL NMR, V4, P581, DOI 10.1007/BF00156622; Pardi A, 1995, METHOD ENZYMOL, V261, P350; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; QUANT S, 1994, TETRAHEDRON LETT, V35, P6649, DOI 10.1016/S0040-4039(00)73458-7; Radha PK, 1996, MAGN RESON CHEM, V34, pS18, DOI 10.1002/(SICI)1097-458X(199612)34:13<S18::AID-OMR48>3.0.CO;2-K; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIEDER P, 1992, NUCLEIC ACIDS RES, V20, P4747, DOI 10.1093/nar/20.18.4747; Smith DE, 1997, J BIOMOL NMR, V10, P245, DOI 10.1023/A:1018358602001; TATE S, 1994, J AM CHEM SOC, V116, P5977, DOI 10.1021/ja00092a062; Varani G, 1996, PROG NUCL MAG RES SP, V29, P51, DOI 10.1016/0079-6565(96)01028-X; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Zimmer DP, 1996, MAGN RESON CHEM, V34, pS177, DOI 10.1002/(SICI)1097-458X(199612)34:13<S177::AID-OMR76>3.0.CO;2-S; ZIMMER DP, 1995, P NATL ACAD SCI USA, V92, P3091, DOI 10.1073/pnas.92.8.3091	32	54	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2374	2378		10.1074/jbc.273.4.2374	http://dx.doi.org/10.1074/jbc.273.4.2374			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442084	hybrid			2022-12-25	WOS:000071595200073
J	Zhu, ZW; Labbe, S; Pena, MMO; Thiele, DJ				Zhu, ZW; Labbe, S; Pena, MMO; Thiele, DJ			Copper differentially regulates the activity and degradation of yeast Mac1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHARACTERIZATION; BINDING PROTEIN; EXPRESSION; GENE; TRANSPORT; ACE1	Copper is an essential metal ion that is toxic when accumulated to high intracellular concentrations. The yeast Mad protein is a copper-sensing transcription factor that is essential for both the activation and inactivation of genes required for high affinity copper ion transport. Here we demonstrate that in response to low copper ion concentrations Mac1 protein is rendered inactive for copper transporter gene transcription. Under high copper ion concentrations Mac1 is degraded in a rapid, copper-specific manner. This degradation is critical to prevent copper toxicity that would otherwise result from sustained expression of the copper transport genes. These results demonstrate that nutritional and toxic copper concentrations elicit distinct fates for the Mad copper-sensing transcription factor and establish a new mechanism by which trace metals regulate gene expression.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Thiele, DJ (corresponding author), Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA.	dthiele@umich.edu		Labbe, Simon/0000-0002-4947-523X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017067, F32GM018089, R01GM041840] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18089, R01 GM41840, GM17067] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CULOTTA VC, 1994, J BIOL CHEM, V269, P25295; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; GRALLA EB, 1991, P NATL ACAD SCI USA, V88, P8558, DOI 10.1073/pnas.88.19.8558; GUO B, 1994, J BIOL CHEM, V269, P24252; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Koch KA, 1996, MOL CELL BIOL, V16, P724; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Linder MC, 1996, AM J CLIN NUTR, V63, P797; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; PANTOPOULOS K, 1995, RNA, V1, P155; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; Willett WS, 1996, BIOCHEMISTRY-US, V35, P5992, DOI 10.1021/bi9530191; YamaguchiIwai Y, 1997, J BIOL CHEM, V272, P17711, DOI 10.1074/jbc.272.28.17711	25	75	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1277	1280		10.1074/jbc.273.3.1277	http://dx.doi.org/10.1074/jbc.273.3.1277			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430656	hybrid			2022-12-25	WOS:000071411500003
J	Gorka, C; Brocard, MP; Curtet, S; Khochbin, S				Gorka, C; Brocard, MP; Curtet, S; Khochbin, S			Differential recognition of histone H1(0) by monoclonal antibodies during cell differentiation and the arrest of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; LINKER HISTONES; GLOBULAR DOMAIN; MESSENGER-RNA; JUNCTION DNA; CHROMATIN; H1; BINDING; H5; ACCUMULATION	Individual anti-H1(0) monoclonal antibodies were screened in an immunolocalization assay to isolate clones able to recognize H1(0) in a differentiation-dependent manner using a murine erythroleukemia cell line, Two clones were selected, one recognizing H1(0) only in differentiating cells (clone 27 antibody), and the other recognizing the protein constitutively (clone 34 antibody), Both antibodies recognized a restricted region of the protein located at the N-terminal part of the globular domain, Amino acids 24-30, essential for the recognition of the protein by the clone 27 antibody, are extremely conserved in all known H1(0)-like proteins from sea urchin to human, Within these residues, proline 26, responsible for a bend in this region, plays a particularly important role in the epitope recognition, The region involved in the protein recognition by clone 34 antibody is larger and encompasses amino acids 20-30, However, proline 26 does not play an essential role in the structure of this epitope, Detailed analysis of the differential recognition of H1(0) in chromatin during cell differentiation and proliferation suggests that the modification of chromatin structure as well as that of H1(0) conformation can account for this effect, Indeed, in vitro study of H1(0)-four-way junction DNA interaction showed that the N-terminal tail domain of the protein can influence the recognition of H1(0) by these antibodies when the protein interacts with DNA, The two monoclonal antibodies described here therefore seem to be valuable tools for investigating fine modulations in chromatin structure and the concomitant changes occurring in the conformation of the protein.	Fac Med, Inst Albert Bonniot, Lab Biol Mol Cycle Cellulaire, INSERM,U309, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Khochbin, S (corresponding author), Fac Med, Inst Albert Bonniot, Lab Biol Mol Cycle Cellulaire, INSERM,U309, Domaine Merci, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013; CURTET, Sandrine/N-3517-2013; CURTET, Sandrine/E-8217-2019	Khochbin, Saadi/0000-0002-0455-0857; CURTET, Sandrine/0000-0002-9419-8868				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALONSO A, 1988, EMBO J, V7, P3003, DOI 10.1002/j.1460-2075.1988.tb03163.x; BANCHEV T, 1988, EXP CELL RES, V177, P1, DOI 10.1016/0014-4827(88)90019-5; Baxevanis AD, 1996, NUCLEIC ACIDS RES, V24, P245, DOI 10.1093/nar/24.1.245; Brocard MP, 1997, GENE, V189, P127, DOI 10.1016/S0378-1119(96)00845-1; DOENECKE D, 1986, J MOL BIOL, V187, P461, DOI 10.1016/0022-2836(86)90446-8; DOUSSON S, 1989, EUR J IMMUNOL, V19, P1123, DOI 10.1002/eji.1830190624; GORKA C, 1993, EXP CELL RES, V205, P152, DOI 10.1006/excr.1993.1069; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; GRUNWALD D, 1995, EXP CELL RES, V218, P586, DOI 10.1006/excr.1995.1196; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KHOCHBIN S, 1988, J MOL BIOL, V200, P55, DOI 10.1016/0022-2836(88)90333-6; KHOCHBIN S, 1989, CYTOMETRY, V10, P484, DOI 10.1002/cyto.990100418; KHOCHBIN S, 1994, EUR J BIOCHEM, V225, P501, DOI 10.1111/j.1432-1033.1994.00501.x; KRYLOV D, 1993, P NATL ACAD SCI USA, V90, P5052, DOI 10.1073/pnas.90.11.5052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUBA SH, 1993, J MOL BIOL, V229, P917, DOI 10.1006/jmbi.1993.1096; LIEBER T, 1988, P NATL ACAD SCI USA, V85, P4123, DOI 10.1073/pnas.85.12.4123; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; Martinez P, 1995, GENE, V166, P313, DOI 10.1016/0378-1119(95)00594-3; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROUSSEAU D, 1991, J MOL BIOL, V217, P85, DOI 10.1016/0022-2836(91)90613-B; SCHULZE E, 1994, J CELL BIOL, V127, P1789, DOI 10.1083/jcb.127.6.1789; Schulze E, 1995, J MOL EVOL, V41, P833; SHEN XT, 1995, CELL, V82, P47, DOI 10.1016/0092-8674(95)90051-9; TEO SH, 1995, EMBO J, V14, P3844, DOI 10.1002/j.1460-2075.1995.tb00054.x; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; VARGAWEISZ P, 1993, J BIOL CHEM, V268, P20699; Wolffe AP, 1997, BIOESSAYS, V19, P249, DOI 10.1002/bies.950190311; ZLATANOVA J, 1994, FASEB J, V8, P1260, DOI 10.1096/fasebj.8.15.8001738; ZLATANOVA JS, 1990, MOL CELL BIOCHEM, V92, P1	36	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1208	1215		10.1074/jbc.273.2.1208	http://dx.doi.org/10.1074/jbc.273.2.1208			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422788	hybrid			2022-12-25	WOS:000071411400077
J	Kuroiwa, A; Yamashita, Y; Inui, M; Yuasa, T; Ono, M; Nagabukuro, A; Matsuda, Y; Takai, T				Kuroiwa, A; Yamashita, Y; Inui, M; Yuasa, T; Ono, M; Nagabukuro, A; Matsuda, Y; Takai, T			Association of tyrosine phosphatases SHP-1 and SHP-2, inositol 5-phosphatase SHIP with gp49B1, and chromosomal assignment of the gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RIIB; NATURAL-KILLER-CELLS; IMMUNOGLOBULIN-SUPERFAMILY; INHIBITORY RECEPTOR; NEGATIVE REGULATION; CYTOPLASMIC DOMAIN; MOLECULAR-CLONING; ANTIGEN RECEPTOR; MOUSE; ACTIVATION	We have analyzed the molecules participating in the inhibitory function of gp49B1, a murine type I transmembrane glycoprotein expressed on mast cells and natural killer cells, as well as the chromosomal location of its gene. As assessed by SDS-polyacrylamide gel electrophoresis and immunoblot analysis, tyrosine-phosphorylated, but not nonphosphorylated, synthetic peptides matching each of the two immunoreceptor tyrosine-based inhibitory motif (ITIM)-like sequences found in the cytoplasmic portion of gp49B1 associated with the similar to 65-kDa tyrosine phosphatase SHP-1 and similar to 70-kDa SHP-2 derived from RBL-2H3 cells, In addition, the phosphotyrosyl peptide matching the second ITIM-like sequence also bound the similar to 145-kDa inositol polyphosphate 5-phosphatase SHIP. Thus, it has been strongly suggested that the inhibitory nature of gp49B involves the recruitment of SHP-1, SHP-2, and SHIP for the delivery of inhibitory signal to the cell interior upon phosphorylation of tyrosine residues in their ITIMs. The gp49B gene has been found to be in the juxtaposition of its cognate gene, gp49A. The gene pair was shown to locate in the B4 band of mouse chromosome 10. In this region, no conserved linkage homology to human chromosome 19, where the genes for killer cell inhibitory receptors are found, has been identified.	Nagoya Univ, Sch Agr Sci, Anim Genet Lab, Chikusa Ku, Nagoya, Aichi 46401, Japan; Okayama Univ, Fac Engn, Dept Biotechnol, Okayama 700, Japan	Nagoya University; Okayama University	Takai, T (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Mol Embryol Lab, Seiryo 4-1, Sendai, Miyagi 98077, Japan.			Kuroiwa, Asato/0000-0002-3942-3372				AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; ARM JP, 1991, J BIOL CHEM, V266, P15966; BAKER E, 1995, CHROMOSOME RES, V3, P511; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; Campbell KS, 1996, J EXP MED, V184, P93, DOI 10.1084/jem.184.1.93; CASTELLS MC, 1994, J BIOL CHEM, V269, P8393; Cella M, 1997, J EXP MED, V185, P1743, DOI 10.1084/jem.185.10.1743; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; DANDREA A, 1995, J IMMUNOL, V155, P2306; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; EVANS EP, 1996, GENETIC VARIANTS STR, P1446; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Katz HR, 1997, J IMMUNOL, V158, P5065; Katz HR, 1996, P NATL ACAD SCI USA, V93, P10809, DOI 10.1073/pnas.93.20.10809; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; Lanier LL, 1996, IMMUNOL TODAY, V17, P86, DOI 10.1016/0167-5699(96)80585-8; Leibson PJ, 1997, IMMUNITY, V6, P655, DOI 10.1016/S1074-7613(00)80441-0; Long EO, 1997, IMMUNOL REV, V155, P135, DOI 10.1111/j.1600-065X.1997.tb00946.x; MATSUDA Y, 1995, ELECTROPHORESIS, V16, P261, DOI 10.1002/elps.1150160142; MATSUDA Y, 1992, CYTOGENET CELL GENET, V61, P282, DOI 10.1159/000133423; Matsuda Y, 1996, GENOMICS, V34, P347, DOI 10.1006/geno.1996.0297; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; Rojo S, 1997, J IMMUNOL, V158, P9; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; THOMAS ML, 1995, J EXP MED, V181, P1953, DOI 10.1084/jem.181.6.1953; WAGTMANN N, 1995, IMMUNITY, V2, P439, DOI 10.1016/1074-7613(95)90025-X; Wang LL, 1997, J IMMUNOL, V158, P13; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1070	1074		10.1074/jbc.273.2.1070	http://dx.doi.org/10.1074/jbc.273.2.1070			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422771	hybrid			2022-12-25	WOS:000071411400060
J	Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T				Tamada, M; Hu, CD; Kariya, K; Okada, T; Kataoka, T			Membrane recruitment of Raf-1 is not the only function of Ras in Raf-1 activation	ONCOGENE			English	Article						Ras; Raf-1; membrane translocation	PLASMA-MEMBRANE; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; HA-RAS; P21; PHOSPHORYLATION; EXPRESSION; MECHANISM; P21(RAS); DOMAINS	Pas interacts with Raf-1 and stimulates its kinase activity, which results in activation of the mitogen-activated protein (MAP) kinase cascade. It has been proposed that the main function of Ras in Raf-1 activation is to recruit Raf-1 to the plasma membrane, where a separate activation event such as phosphorylation takes place, Here, we examined the activities of various mutants of human Ha-Pas to induce membrane translocation of Raf-1 and to activate Raf-1 in vivo. Overexpression of an activator region mutant Ha-Ras(V45E) in COS7 cells induced membrane translocation of Raf-1 as effectively as wild-type Ha-Ras. However, the activity of this mutant to activate Raf-1 and extracellular signal-regulated kinase-2 (ERK2) was attenuated by approximately 70% compared to that of wild-type Ha-Pas. The decrease in the specific activity was further demonstrated by measuring the activity of the Ha-Ras(V45E)-associated Raf-1 purified from the membrane fraction. These results imply that the association of Pas with Raf-1 has another important consequence, presumably dependent on the interaction between its activator region and Raf-1, than the simple recruitment of Raf-1 to the plasma membrane.	KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE,HYOGO 650,JAPAN	Kobe University								Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Ferrier AF, 1997, J BIOL CHEM, V272, P2136; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mineo C, 1997, J BIOL CHEM, V272, P10345; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; Shinkai M, 1996, BIOCHEM BIOPH RES CO, V223, P729, DOI 10.1006/bbrc.1996.0964; SHIROUZU M, 1994, ONCOGENE, V9, P2153; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X	36	32	32	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2959	2964		10.1038/sj.onc.1201582	http://dx.doi.org/10.1038/sj.onc.1201582			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416839				2022-12-25	WOS:A1997YK37700008
J	Soltoff, SP; Avraham, H; Avraham, S; Cantley, LC				Soltoff, SP; Avraham, H; Avraham, S; Cantley, LC			Activation of P-2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PC12 CELLS; EXTRACELLULAR ATP; GROWTH-FACTOR; EPITHELIAL-CELLS; PHOSPHOLIPASE-C; SIGNAL-TRANSDUCTION; CALCIUM INFLUX; SUBSTANCE-P; MAP KINASE; DELTA	We examined downstream signaling events that followed the exposure of PC12 cells to extracellular ATP and UTP, and we compared the effects of these P-2 receptor agonists with those of growth factors and other stimuli, Based on early findings, we focused particular attention on the mitogen-activated protein (MAP) kinase pathway, ATP and/or UTP produced increases in tyrosine phosphorylation of multiple proteins, including p42 MAP (ERK2) kinase, related adhesion focal tyrosine kinase (RAFTK) (PYK2, CAK beta), focal adhesion kinase (FAK), Shc, and protein kinase C delta (PKC delta). MAP (ERK2) kinase activity (quantified by substrate phosphorylation) was increased by UTP, ATP, phorbol la-myristate 13-acetate, ionomycin, and growth factors, UTP and ATP were equipotent (EC50 similar to 25 mu M) in stimulating MAP kinase activity, suggesting that these effects were mediated via the G(i)-linked P-2Y2 (P-2U) receptor. Consistent with this, the UTP-and ATP-promoted activation of MAP kinase was diminished in pertussis toxin-treated cells, Treatment of cells with pertussis toxin also reduced both the UTP-dependent increases in intracellular calcium ion concentration ([Ca2+](i)) and the tyrosine phosphorylation of RAFTK, Similarly, when [Ca2+](i) elevation was prevented using BAPTA and EGTA, the activation of MAP kinase by UTP and ionomycin was blocked, and the tyrosine phosphorylation of RAFTK was reduced, The UTP-promoted increase in MAP kinase activity was partially reduced in cells in which PKC was down-regulated, suggesting that both PKC-dependent and PKC independent pathways were involved, PKC delta, which increases MAP kinase activity in some systems, became tyrosine-phosphorylated within 15 s of exposure of cells to ATP or UTP; but epidermal growth factor, nerve growth factor, and insulin had little effect, UTP also promoted the association of Shc with Grb2. These results suggest that the P,,, receptor-initiated activation of MAP kinase was dependent on the elevation of [Ca2+](i), involved the recruitment of Shc and Grb2, and was mediated by RAFTK and PKC.	Harvard Univ, Beth Israel Med Ctr, Div Signal Transduct, Harvard Inst Med,Dept Med,Sch Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Med Ctr, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School	Soltoff, SP (corresponding author), Harvard Univ, Beth Israel Med Ctr, Div Signal Transduct, Harvard Inst Med,Dept Med,Sch Med, 330 Brookline Ave, Boston, MA 02215 USA.	ssoltoff@bidmc.harvard.edu	Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Avraham, Hava/0000-0002-7545-3640	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055445] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010877] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL55445] Funding Source: Medline; NIDCR NIH HHS [DE10877] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BANBIESEN T, 1995, NATURE, V270, P781; BARRY VA, 1994, J CELL SCI, V107, P451; Borgatti P, 1996, EXP CELL RES, V224, P72, DOI 10.1006/excr.1996.0112; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; COWEN DS, 1990, BIOCHIM BIOPHYS ACTA, V1053, P195, DOI 10.1016/0167-4889(90)90014-5; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FASOLATO C, 1990, J BIOL CHEM, V265, P20351; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HUANG NN, 1989, P NATL ACAD SCI USA, V86, P7904, DOI 10.1073/pnas.86.20.7904; Hwang TH, 1996, AM J PHYSIOL-CELL PH, V270, pC1611, DOI 10.1152/ajpcell.1996.270.6.C1611; INOUE K, 1989, NEUROSCI LETT, V106, P294, DOI 10.1016/0304-3940(89)90179-1; Kadotani M, 1997, J BIOCHEM-TOKYO, V121, P1047; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; KIM WK, 1994, J BIOL CHEM, V269, P6471; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LUSTIG KD, 1993, P NATL ACAD SCI USA, V90, P5113, DOI 10.1073/pnas.90.11.5113; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MAJID MA, 1993, BIOCHEM BIOPH RES CO, V195, P415, DOI 10.1006/bbrc.1993.2059; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; MURRIN RJA, 1992, MOL PHARMACOL, V41, P561; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; Palmer RK, 1996, AM J PHYSIOL-CELL PH, V271, pC43, DOI 10.1152/ajpcell.1996.271.1.C43; RAPAPORT E, 1983, CANCER RES, V43, P4402; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHULZELOHOFF E, 1992, AM J PHYSIOL, V263, pF374, DOI 10.1152/ajprenal.1992.263.3.F374; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SELA D, 1991, J BIOL CHEM, V266, P17990; SIPMA H, 1994, EUR J PHARM-MOLEC PH, V268, P431, DOI 10.1016/0922-4106(94)90069-8; SOLTOFF SP, 1989, J GEN PHYSIOL, V93, P285, DOI 10.1085/jgp.93.2.285; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WOLKOFF LI, 1995, CELL CALCIUM, V17, P375, DOI 10.1016/0143-4160(95)90111-6	46	155	157	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2653	2660		10.1074/jbc.273.5.2653	http://dx.doi.org/10.1074/jbc.273.5.2653			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446569	hybrid			2022-12-25	WOS:000071736600024
J	Ji, S; John, SA; Lu, YJ; Weiss, JN				Ji, S; John, SA; Lu, YJ; Weiss, JN			Mechanosensitivity of the cardiac muscarinic potassium channel - A novel property conferred by Kir3.4 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+-CHANNEL; XENOPUS-OOCYTES; ION CHANNELS; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; I-KACH; CELLS; HEART; ACTIVATION; PROTEINS	Muscarinic potassium channels are heterotetramers of Kir3.1 and other Kir3 channel subunits and play major roles in regulating membrane excitability in cardiac atrial, neuronal, and neuroendocrine tissues, We report here that rabbit atrial muscarinic potassium channels are rapidly and reversibly inhibited by membrane stretch, possibly serving as a mechanoelectrical feedback pathway. To probe the molecular basis for this phenomenon, we heterologously expressed heteromeric Kir3.1/Kir3.4 channels in Xenopus oocytes and found that they possess similar mechanosensitivity in response to hypo-osmolar stress. This could be attributed in part, if not exclusively, to the Kir3.4 subunit, which reproduced the mechanosensitivity of the heteromeric channel when expressed as a homomeric channel in oocytes. Kir3.4 is the first stretch-inactivated potassium channel to be identified molecularly. Physiologically, this feature may be important in atrial volume-sensing and other responses to stretch.	Univ Calif Los Angeles, Div Cardiol, Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cardiovasc Res Lab, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weiss, JN (corresponding author), Univ Calif Los Angeles, Div Cardiol, Sch Med, 3645 MRL Bldg, Los Angeles, CA 90095 USA.	jweiss@ephys.ucla.edu		John, Scott/0000-0002-1232-9140	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036729, P50HL052319] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50 HL52319, R01 HL36729] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; Berdiev BK, 1996, J BIOL CHEM, V271, P17704, DOI 10.1074/jbc.271.30.17704; BERNTSSON KE, 1964, J CELL COMP PHYSL, V65, P101; BROPHY CM, 1993, BIOCHEM BIOPH RES CO, V190, P576, DOI 10.1006/bbrc.1993.1087; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; DIFRANCESCO D, 1989, SCIENCE, V243, P669, DOI 10.1126/science.2916119; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamill OP, 1996, PHARMACOL REV, V48, P231; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; KIM DH, 1993, CIRC RES, V72, P225, DOI 10.1161/01.RES.72.1.225; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KURACHI Y, 1995, AM J PHYSIOL-CELL PH, V269, pC821, DOI 10.1152/ajpcell.1995.269.4.C821; Lab MJ, 1996, CARDIOVASC RES, V32, P3, DOI 10.1016/S0008-6363(96)00088-0; MITRA R, 1985, AM J PHYSIOL, V249, P1056, DOI 10.1152/ajpheart.1985.249.5.H1056; SACHS F, 1996, SOC GEN PHYSL SER, V52, P209; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shieh RC, 1996, J PHYSIOL-LONDON, V494, P363, DOI 10.1113/jphysiol.1996.sp021498; SIGURDSON WJ, 1987, J EXP BIOL, V127, P191; SOROTA S, 1992, CIRC RES, V70, P679, DOI 10.1161/01.RES.70.4.679; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659; TSENG GN, 1992, AM J PHYSIOL, V262, pC1056, DOI 10.1152/ajpcell.1992.262.4.C1056; VANWAGONER DR, 1993, CIRC RES, V72, P973, DOI 10.1161/01.RES.72.5.973; VANWAGONER DR, 1991, BIOPHYS J, V59, P546; WICKMAN KD, 1995, CURR OPIN NEUROBIOL, V5, P278, DOI 10.1016/0959-4388(95)80039-5; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333	35	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1324	1328		10.1074/jbc.273.3.1324	http://dx.doi.org/10.1074/jbc.273.3.1324			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430664	hybrid			2022-12-25	WOS:000071411500011
J	MacDiarmid, CW; Gardner, RC				MacDiarmid, CW; Gardner, RC			Overexpression of the Saccharomyces cerevisiae magnesium transport system confers resistance to aluminum ion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVALENT-CATION TRANSPORT; ACID-SOIL STRESS; SALMONELLA-TYPHIMURIUM; CELL-CYCLE; ESCHERICHIA-COLI; PLASMA-MEMBRANE; YEAST-CELLS; PROTEIN; GENE; MANGANESE	Ionic aluminum (Al3+) is toxic to plants, microbes, fish, and animals, but the mechanism of its toxicity is unknown. We describe the isolation of two yeast genes (ALR1 and ALR2) which confer increased tolerance to Al3+ and Ga3+ ions when overexpressed while increasing strain sensitivity to Zn2+, Mn2+, Ni2+, Cu2+, Ca2+, and La3+ ions, The Air proteins are homologous to the Salmonella typhimurium CorA protein, a bacterial Mg2+ and Co2+ transport system located in the periplasmic membrane. Yeast strains lacking ALR gene activity required additional Mg2+ for growth, and expression of either ALR1 or ALR2 corrected the Mg2+-requiring phenotype. The results suggest that the ALR genes encode the yeast uptake system for Mg2+ and other divalent cations, This hypothesis was supported by evidence that Co-57(2+) accumulation was elevated in ALR-overexpressing strains and reduced in strains lacking ALR expression. ALR overexpression also overcame the inhibition of Co2+ uptake by Al3+ ions. The results indicate that aluminum toxicity to yeast occurs as a consequence of reduced Mg2+ influx via the Air proteins. The molecular identification of the yeast Mg2+ transport system should lead to a better understanding of the regulation of Mg2+ homeostasis in eukaryote cells.	Univ Auckland, Sch Biol Sci, Ctr Gene Technol, Auckland 1, New Zealand	University of Auckland	Gardner, RC (corresponding author), Univ Auckland, Sch Biol Sci, Ctr Gene Technol, Private Bag 92019, Auckland 1, New Zealand.	r.gardner@auckland.ac.nz	Gardner, Richard C/C-9002-2009	MacDiarmid, Colin/0000-0001-8578-5756				ANIOL A, 1991, DEV PLANT SOIL SCI, V45, P1007; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHIEN MM, 1990, J BIOL CHEM, V265, P9201; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CONKLIN DS, 1993, MOL CELL BIOL, V13, P2041, DOI 10.1128/MCB.13.4.2041; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; DAI LJ, 1991, J CLIN INVEST, V88, P1255, DOI 10.1172/JCI115429; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; delaFuente JM, 1997, SCIENCE, V276, P1566, DOI 10.1126/science.276.5318.1566; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; DRISCOLL CT, 1980, NATURE, V284, P161, DOI 10.1038/284161a0; EXLEY C, 1992, J THEOR BIOL, V159, P83, DOI 10.1016/S0022-5193(05)80769-6; FLATMAN PW, 1991, ANNU REV PHYSIOL, V53, P259, DOI 10.1146/annurev.ph.53.030191.001355; FROMMER WB, 1995, ANNU REV PLANT PHYS, V46, P419, DOI 10.1146/annurev.pp.46.060195.002223; FUHRMANN GF, 1968, BIOCHIM BIOPHYS ACTA, V163, P325, DOI 10.1016/0005-2736(68)90117-X; GABER RF, 1988, MOL CELL BIOL, V8, P2848, DOI 10.1128/MCB.8.7.2848; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; KAISER C, 1994, METHODS YEAST GENETI, P141; KASMUSSEN SW, 1994, YEAST, V10, pS63; KINRAIDE TB, 1987, PLANT PHYSIOL, V83, P546, DOI 10.1104/pp.83.3.546; KOCHIAN LV, 1995, ANNU REV PLANT PHYS, V46, P237, DOI 10.1146/annurev.pp.46.060195.001321; LOUKIN S, 1995, J CELL BIOL, V131, P1025, DOI 10.1083/jcb.131.4.1025; MacDiarmid CW, 1996, PLANT PHYSIOL, V112, P1101, DOI 10.1104/pp.112.3.1101; MAGUIRE ME, 1988, ANN NY ACAD SCI, V551, P201, DOI 10.1111/j.1749-6632.1988.tb22338.x; MAGUIRE ME, 1992, ANN NY ACAD SCI, V671, P244, DOI 10.1111/j.1749-6632.1992.tb43800.x; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; MOELLER T, 1984, CHEM INORGANIC QUALI, P929; NORRIS PR, 1977, J GEN MICROBIOL, V99, P317, DOI 10.1099/00221287-99-2-317; OKOROKOV LA, 1977, EUR J BIOCHEM, V75, P373, DOI 10.1111/j.1432-1033.1977.tb11538.x; Pina RG, 1996, BIOMETALS, V9, P311, DOI 10.1007/BF00817932; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; PRESTON RR, 1990, SCIENCE, V250, P285, DOI 10.1126/science.2218533; RENGEL Z, 1989, PLANT PHYSIOL, V91, P1407, DOI 10.1104/pp.91.4.1407; Robinson D. L., 1991, Current Topics in Plant Biochemistry and Physiology, V10, P107; ROST B, 1995, PROTEIN SCI, V4, P521; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIMANSKY C, 1991, Z PFLANZ BODENKUNDE, V154, P195, DOI 10.1002/jpln.19911540308; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; Schott EJ, 1997, MOL GEN GENET, V254, P63, DOI 10.1007/s004380050391; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHIRAHIGE K, 1993, MOL CELL BIOL, V13, P5043, DOI 10.1128/MCB.13.8.5043; SMITH FW, 1995, MOL GEN GENET, V247, P709, DOI 10.1007/BF00290402; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; TAN KZ, 1991, PLANT SOIL, V136, P65, DOI 10.1007/BF02465221; TAN KZ, 1995, PLANT SOIL, V171, P147, DOI 10.1007/BF00009578; Triolo T, 1996, NATURE, V381, P251, DOI 10.1038/381251a0; WALKER GM, 1986, MAGNESIUM, V5, P9; WALKER GM, 1980, J CELL SCI, V42, P329; WALKER GM, 1984, J GEN MICROBIOL, V130, P1941; WHEELER DM, 1992, J PLANT NUTR, V15, P387, DOI 10.1080/01904169209364328; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; WISNIEWSKI HM, 1990, ENVIRON GEOCHEM HLTH, V12, P115, DOI 10.1007/BF01734060; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	58	169	186	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1727	1732		10.1074/jbc.273.3.1727	http://dx.doi.org/10.1074/jbc.273.3.1727			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430719	hybrid			2022-12-25	WOS:000071411500066
J	Reinscheid, RK; Higelin, J; Henningsen, RA; Monsma, FJ; Civelli, O				Reinscheid, RK; Higelin, J; Henningsen, RA; Monsma, FJ; Civelli, O			Structures that delineate orphanin FQ and dynorphin A pharmacological selectivities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPIOID RECEPTOR; NEUROPEPTIDE; PEPTIDE	Strict pharmacological selectivity in families of structurally related ligands and receptors may result from a key process in evolution aiming at increasing diversity in neurotransmission. An intriguing example of such exclusive specificity can be found in the newly discovered orphanin FQ (OFQ) system when it is compared with the opioid system, Both OFQ and its receptor share a high degree of sequence similarity to the opioid peptides and their corresponding receptors, respectively, However, OFQ does not activate opioid receptors, nor do the opioid peptides elicit biological activity at the OFQ receptor, We have therefore investigated the basis for the inherent selectivity of the primary structures of OFQ and dynorphin A, its closest counterpart, A series of truncated and/or chimeric peptides led to the conclusion that both peptides contain domains which establish their pharmacological selectivity, In the OFQ molecule we could delineate a domain that prevents its ability to activate the kappa-opioid receptor by apparently repelling its binding. In both peptides the selectivity-generating domains are composed of single residues in key positions together with short stretches of amino acids which do not overlap. To prove this concept, we designed a universal agonist and found it active at both the OFQ receptor and the kappa-opioid receptor, Our observations suggest that a coordinated mechanism of evolution has separated the orphanin FQ system from the opioid system.	Univ Calif Irvine, Coll Med, Dept Pharmacol, Irvine, CA 92717 USA; Hoffmann La Roche Ag, CNS Res, Div Pharma, CH-4070 Basel, Switzerland	University of California System; University of California Irvine; Roche Holding	Civelli, O (corresponding author), Univ Calif Irvine, Coll Med, Dept Pharmacol, 354 Med Surge 2, Irvine, CA 92717 USA.	ocivelli@uci.edu	Civelli, Olivier/A-8392-2012					Ardati A, 1997, MOL PHARMACOL, V51, P816, DOI 10.1124/mol.51.5.816; Berthold M, 1997, NEUROCHEM RES, V22, P1023, DOI 10.1023/A:1022483027858; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; HRUBY VJ, 1989, MED RES REV, V9, P343, DOI 10.1002/med.2610090306; LAZARENO S, 1995, MOL PHARMACOL, V48, P362; Meng F, 1996, J BIOL CHEM, V271, P32016, DOI 10.1074/jbc.271.50.32016; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NISHI M, 1994, BIOCHEM BIOPH RES CO, V205, P1353, DOI 10.1006/bbrc.1994.2814; Nothacker HP, 1996, P NATL ACAD SCI USA, V93, P8677, DOI 10.1073/pnas.93.16.8677; PATERSON SJ, 1984, NEUROPEPTIDES, V5, P177, DOI 10.1016/0143-4179(84)90056-8; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Schulz S, 1996, NEUROREPORT, V7, P3021, DOI 10.1097/00001756-199611250-00045	16	102	105	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1490	1495		10.1074/jbc.273.3.1490	http://dx.doi.org/10.1074/jbc.273.3.1490			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430687	hybrid			2022-12-25	WOS:000071411500034
J	Toyofuku, T; Yabuki, M; Otsu, K; Kuzuya, T; Hori, M; Tada, M				Toyofuku, T; Yabuki, M; Otsu, K; Kuzuya, T; Hori, M; Tada, M			Intercellular calcium signaling via gap junction in connexin-43-transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; MECHANICAL STIMULATION; SARCOPLASMIC-RETICULUM; FUNCTIONAL EXPRESSION; MEMBRANE CHANNEL; PHOSPHOLIPASE-C; GLIOMA-CELLS; CA2+ RELEASE; LONG-RANGE; HELA-CELLS	In excitable cells, intracellular Ca2+ is released via the ryanodine receptor from the intracellular Ca2+ storing structure, the sarcoplasmic reticulum, To determine whether this released Ca2+ propagates through gap junctions to neighboring cells and thereby constitutes a long range signaling network, we developed a cell system in which cells expressing both connexin-43 and ryanodine receptor are surrounded by cells expressing only connexin-43, When the ryanodine receptor in cells was activated by caffeine, propagation of Ca2+ from these caffeine-responsive cells to neighboring cells was observed with a Ca2+ imaging system using fura-2/AM, Inhibitors of gap junctional communication rapidly and reversibly abolished this propagation of Ca2+, Together with the electrophysiological analysis of transfected cells, the observed intercellular Ca2+ wave was revealed to be due to the reconstituted gap junction of transfected cells. We next evaluated the functional roles of cysteine residues in the extracellular loops of connexin-43 in gap junctional communication. Mutations of Cys(54), Cys(187), Cys(192), and Cys(198) to Ser showed the failure of Ca2+ propagation to neighboring cells in accordance with the electrical uncoupling between transfected cells, whereas mutations of Cys(61) and Cys(68) to Ser showed the same pattern as the wild type, [C-14]Iodoacetamide labeling of free thiols of cysteine residues in mutant connexin-43s showed that two pairs of intramolecular disulfide bonds are formed between Cys(54) and Cys(192) and between Cys(187) and Cys(198). These results suggest that intercellular Ca2+ signaling takes place in cultured cells expressing connexin-43, leading to their own synchronization and that the extracellular disulfide bonds of connexin-43 are crucial for this process.	Osaka Univ, Sch Med, Dept Med & Pathophysiol, Osaka 565, Japan	Osaka University	Toyofuku, T (corresponding author), Osaka Univ, Sch Med, Dept Pathophysiol, 2-2 Yamada Oka, Osaka 565, Japan.	toyofuku@mr-path.med.osaka-u.ac.jp						BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BURT JM, 1988, AM J PHYSIOL, V254, pH1206, DOI 10.1152/ajpheart.1988.254.6.H1206; BURT JM, 1989, AM J PHYSIOL, V256, pC913, DOI 10.1152/ajpcell.1989.256.4.C913; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DAHL G, 1991, EUR J BIOCHEM, V197, P141, DOI 10.1111/j.1432-1033.1991.tb15892.x; DAHL G, 1987, SCIENCE, V236, P1290, DOI 10.1126/science.3035715; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; DUBYAK GR, 1991, AM J RESP CELL MOL, V4, P295, DOI 10.1165/ajrcmb/4.4.295; EGHBALI B, 1990, P NATL ACAD SCI USA, V87, P1328, DOI 10.1073/pnas.87.4.1328; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; FISHMAN GI, 1990, J CELL BIOL, V111, P589, DOI 10.1083/jcb.111.2.589; FLAGGNEWTON J, 1979, SCIENCE, V205, P404, DOI 10.1126/science.377490; HANSEN M, 1993, J CELL SCI, V106, P995; HOYLE CHV, 1990, BRIT J PHARMACOL, V99, P617, DOI 10.1111/j.1476-5381.1990.tb12979.x; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IMANAGA I, 1987, AM J PHYSIOL, V252, pH223, DOI 10.1152/ajpheart.1987.252.1.H223; ISHIDE N, 1990, AM J PHYSIOL, V259, pH940, DOI 10.1152/ajpheart.1990.259.3.H940; JOHN SA, 1991, BIOCHEM BIOPH RES CO, V178, P1312, DOI 10.1016/0006-291X(91)91037-D; JONGEN WMF, 1991, J CELL BIOL, V114, P545, DOI 10.1083/jcb.114.3.545; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MAKOWSKI L, 1984, J MOL BIOL, V174, P449, DOI 10.1016/0022-2836(84)90331-0; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MILLER TM, 1985, J CELL BIOL, V101, P1741, DOI 10.1083/jcb.101.5.1741; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; RAHMAN S, 1991, J CELL SCI, V100, P567; ROSE B, 1975, NATURE, V254, P250, DOI 10.1038/254250a0; Ruegg U T, 1977, Methods Enzymol, V47, P111; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDBERG K, 1992, J CELL BIOL, V117, P157, DOI 10.1083/jcb.117.1.157; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0; SOSINSKY GE, 1988, BIOPHYS J, V53, P709, DOI 10.1016/S0006-3495(88)83152-7; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; TAKAMATSU T, 1990, FASEB J, V4, P1519, DOI 10.1096/fasebj.4.5.2307330; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; VEENSTRA RD, 1994, BIOPHYS J, V66, P1915, DOI 10.1016/S0006-3495(94)80985-3; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; ZHU D, 1991, P NATL ACAD SCI USA, V88, P1883, DOI 10.1073/pnas.88.5.1883	65	88	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1519	1528		10.1074/jbc.273.3.1519	http://dx.doi.org/10.1074/jbc.273.3.1519			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430691	hybrid			2022-12-25	WOS:000071411500038
J	Cheng, XD; Lee, JC				Cheng, XD; Lee, JC			Interactive and dominant effects of residues 128 and 141 on cyclic nucleotide and DNA bindings in Escherichia coli cAMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-MONOPHOSPHATE RECEPTOR; TRANSCRIPTION ACTIVATOR PROTEIN; NUCLEAR MAGNETIC-RESONANCE; CONFORMATIONAL TRANSITIONS; FUNCTIONAL SUBUNIT; LIGAND-BINDING; AMP; GENE; CRP; INTERSUBUNIT	The molecular events in the cAMP-induced allosteric activation of cAMP receptor protein (CRP) involve interfacial communications between subunits and domains. However, the roles of intersubunit and interdomain interactions in defining the selectivity of cAMP against other cyclic nucleotides and cooperativity in ligand binding are still not known, Natural occurring CRP mutants with different phenotypes were employed to address these issues. Thermodynamic analyses of subunit association, protein stability, and cAMP and DNA binding as well as conformational studies of the mutants and wild-type CRPs lead to an identification of the apparently dominant roles of residues 128 and 141 in the cAMP-modulated DNA binding activity of CRP, Serine 128 and the C-helix were implicated as playing a critical role in modulating negative cooperativity of cyclic nucleotide binding. A correlation was established between a weak affinity for subunit assembly and the relaxation of cyclic nucleotide selectivity in the G141Q and S128A/G141Q mutants, These results imply that intersubunit interaction is important for cyclic nucleotide discrimination in CRP, The double mutant S128A/G141Q, constructed from two single mutations of S128A and G141Q, which exhibit opposite phenotypic characteristics of CRP- and CRP*, respectively, assumes a CRP* phenotype and has biochemical properties similar to those of the G141Q mutant. These observations suggest that mutation G141Q exerts a dominant effect over mutation S128A and that the subunit realignment induced by the G141Q mutation can override the local structural disruption created by mutation S128A.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lee, JC (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.		Lee, James C/A-7849-2009		NIGMS NIH HHS [GM-45579] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045579] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1982, NUCLEIC ACIDS RES, V10, P1345, DOI 10.1093/nar/10.4.1345; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; CERIONE RA, 1983, BIOCHEMISTRY-US, V22, P769, DOI 10.1021/bi00273a010; CHENG X, 1998, IN PRESS BIOCHEMISTR; CHENG X, 1994, THESIS U TEXAS GALVE; CHENG XD, 1993, BIOCHEMISTRY-US, V32, P8130, DOI 10.1021/bi00083a011; CHENG XD, 1995, BIOCHEMISTRY-US, V34, P10816, DOI 10.1021/bi00034a014; CHENG XD, 1994, J BIOL CHEM, V269, P30781; COHN EJ, 1943, PROTEINS AMINO ACIDS, P372; COSSART P, 1982, NUCLEIC ACIDS RES, V10, P1363, DOI 10.1093/nar/10.4.1363; DECROMBRUGGHE B, 1984, SCIENCE, V224, P831, DOI 10.1126/science.6372090; EILEN E, 1977, J MOL BIOL, V114, P47, DOI 10.1016/0022-2836(77)90282-0; FRIED MG, 1984, J MOL BIOL, V172, P241, DOI 10.1016/S0022-2836(84)80025-X; GRONENBORN AM, 1982, BIOCHEMISTRY-US, V21, P4040, DOI 10.1021/bi00260a020; HEYDUK E, 1992, BIOCHEMISTRY-US, V31, P3682, DOI 10.1021/bi00129a017; HEYDUK E, 1992, J BIOL CHEM, V267, P3200; HEYDUK T, 1990, P NATL ACAD SCI USA, V87, P1744, DOI 10.1073/pnas.87.5.1744; HEYDUK T, 1992, BIOCHEMISTRY-US, V31, P5165, DOI 10.1021/bi00137a011; HEYDUK T, 1989, BIOCHEMISTRY-US, V28, P6914, DOI 10.1021/bi00443a021; HINDS MG, 1992, BIOCHEM J, V287, P627, DOI 10.1042/bj2870627; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KIM J, 1992, P NATL ACAD SCI USA, V89, P9700, DOI 10.1073/pnas.89.20.9700; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; KRAKOW JS, 1973, P NATL ACAD SCI USA, V70, P2529, DOI 10.1073/pnas.70.9.2529; LEE BJ, 1990, J BIOCHEM-TOKYO, V107, P304, DOI 10.1093/oxfordjournals.jbchem.a123043; Lee J C, 1979, Methods Enzymol, V61, P49; MCKAY DB, 1982, J BIOL CHEM, V257, P9518; *MERCK CO INC, 1976, MERCK IND, P353; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PAMPENO C, 1979, BIOCHEMISTRY-US, V18, P1519, DOI 10.1021/bi00575a020; Pyles EA, 1996, BIOCHEMISTRY-US, V35, P1162, DOI 10.1021/bi952187q; PYLES EA, 1994, BIOPHYS J, V66, pA370; RIGGS AD, 1971, P NATL ACAD SCI USA, V68, P1222, DOI 10.1073/pnas.68.6.1222; SANDERS R, 1973, P NATL ACAD SCI USA, V70, P1017, DOI 10.1073/pnas.70.4.1017; SIPPEL TO, 1981, J HISTOCHEM CYTOCHEM, V29, P1377, DOI 10.1177/29.12.7320496; SIXL F, 1990, BIOCHEM J, V266, P545, DOI 10.1042/bj2660545; TAKAHASHI M, 1980, BIOCHEMISTRY-US, V19, P5124, DOI 10.1021/bi00563a029; TAN GS, 1991, BIOCHEMISTRY-US, V30, P5076, DOI 10.1021/bi00234a034; TSUGITA A, 1982, FEBS LETT, V144, P304, DOI 10.1016/0014-5793(82)80659-5; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WU CW, 1974, BIOCHEMISTRY-US, V13, P2573, DOI 10.1021/bi00709a016; WU FYH, 1974, BIOCHEMISTRY-US, V13, P2567, DOI 10.1021/bi00709a015; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; ZHOU YH, 1994, EMBO J, V13, P4549, DOI 10.1002/j.1460-2075.1994.tb06776.x; ZHOU YH, 1993, CELL, V73, P375, DOI 10.1016/0092-8674(93)90236-J	45	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					705	712		10.1074/jbc.273.2.705	http://dx.doi.org/10.1074/jbc.273.2.705			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422721	hybrid			2022-12-25	WOS:000071411400010
J	Ekena, K; Katzenellenbogen, JA; Katzenellenbogen, BS				Ekena, K; Katzenellenbogen, JA; Katzenellenbogen, BS			Determinants of ligand specificity of estrogen receptor-alpha: Estrogen versus androgen discrimination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; SUPERFAMILY; CELLS; MUTAGENESIS; FLUORESCENT; ANTIESTROGENS; MUTATION; PROTEINS; DNA	We have been interested in understanding how the estrogen receptor (ER) binds estrogens and discriminates between different classes of steroids with closely related structures, Using insights from our prior studies on ER and from sequence comparisons of steroid receptors, we identified three residues in the hormone-binding domain of the human ER, Leu(345), Thr(347), and Glu(353), that we considered were likely to be involved in steroid A-ring recognition and therefore estrogen versus androgen discrimination. We then tested the effect on ER activity of mutating these ER residues to the corresponding androgen receptor residues, Specifically, we examined the ability of the mutant receptors to bind and be activated by 17 beta-estradiol and three different androgens, No change in receptor activity was observed with the T347N mutation, while the L345S mutation greatly reduced ER activity in response to all ligands. Interestingly, the E353Q substitution behaved as expected, causing a 9-fold reduction in the transactivation potency of estradiol and a concomitant 10-140-fold increase in the transactivation potency of different androgens, These reciprocal changes in the transcriptional effectiveness of estrogens and androgens correlated with a decreased affinity of the E353Q ER for estradiol binding and an increased affinity for androgen binding, Therefore, amino acid Glu(353) appears to be playing a significant role in binding the A-ring phenolic group of estradiol and in receptor discrimination between estrogens and the most closely structurally related steroids, androgens. Based on this data and our earlier observations, we propose a model for the orientation of ligand within the binding pocket of ER in which the A-ring 3-phenol of estradiol is hydrogen bonded to Glu(353) in helix-3 and the 17 beta-hydroxyl of estradiol is hydrogen bonded to His(524) in helix-11. Our findings with estrogen and androgen suggest that this orientation of the steroid in the ligand-binding pocket, with the steroid A-ring in contact with helix-3 and the D-ring in contact with helix-11 residues, is likely to be general for all the steroid hormone receptors.	Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Katzenellenbogen, BS (corresponding author), Univ Illinois, Dept Mol & Integrat Physiol, 524 Burrill Hall,407 S Goodwin Ave, Urbana, IL 61801 USA.				NCI NIH HHS [2R37CA18119, 1 F32CA68653] Funding Source: Medline; NIDDK NIH HHS [2R37DK15556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA068653, R37CA018119] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK015556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anstead GM, 1997, STEROIDS, V62, P268, DOI 10.1016/S0039-128X(96)00242-5; Bocchinfuso WP, 1997, MOL ENDOCRINOL, V11, P587, DOI 10.1210/me.11.5.587; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Ekena K, 1997, J BIOL CHEM, V272, P5069, DOI 10.1074/jbc.272.8.5069; Ekena K, 1996, J BIOL CHEM, V271, P20053, DOI 10.1074/jbc.271.33.20053; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GARCIA T, 1992, MOL ENDOCRINOL, V6, P2071, DOI 10.1210/me.6.12.2071; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HWANG KJ, 1992, J ORG CHEM, V57, P1262, DOI 10.1021/jo00030a039; HWANG KJ, 1992, BIOCHEMISTRY-US, V31, P11536, DOI 10.1021/bi00161a035; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KATZENELLENBOGEN JA, 1973, BIOCHEMISTRY-US, V12, P4085, DOI 10.1021/bi00745a010; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MIKSICEK RJ, 1995, MOL ENDOCRINOL, V9, P592, DOI 10.1210/me.9.5.592; Montano MM, 1996, MOL ENDOCRINOL, V10, P230, DOI 10.1210/me.10.3.230; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; OJASOO T, 1978, CANCER RES, V38, P4186; REESE JC, 1992, J BIOL CHEM, V267, P9868; REESE JC, 1991, J BIOL CHEM, V266, P10880; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Vivat V, 1997, J MOL ENDOCRINOL, V18, P147, DOI 10.1677/jme.0.0180147; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WESTPHAL U, 1986, STEROID PROTEIN INTE, V2, P214; WILLIAMS D, 1974, BIOCHEMISTRY-US, V13, P5537, DOI 10.1021/bi00724a013; WRENN CK, 1990, MOL ENDOCRINOL, V4, P1647, DOI 10.1210/mend-4-11-1647; WRENN CK, 1993, J BIOL CHEM, V268, P24089; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87	34	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					693	699		10.1074/jbc.273.2.693	http://dx.doi.org/10.1074/jbc.273.2.693			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422719	hybrid			2022-12-25	WOS:000071411400008
J	Hansen, WK; Deutsch, WA; Yacoub, A; Xu, Y; Williams, DA; Kelley, MR				Hansen, WK; Deutsch, WA; Yacoub, A; Xu, Y; Williams, DA; Kelley, MR			Creation of a fully functional human chimeric DNA repair protein - Combining O-6-methylguanine DNA methyltransferase (MGMT) and AP endonuclease (APE redox effector factor 1 (Ref 1)) DNA repair proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS-MEDIATED EXPRESSION; APURINIC APYRIMIDINIC SITES; HAMSTER OVARY CELLS; ENZYME HAP1; CHROMOSOMAL-ABERRATIONS; DIRECTED MUTAGENESIS; HEMATOPOIETIC-CELLS; ALKYLATING-AGENTS; BINDING ACTIVITY; CROSS-LINKING	A dose-limiting toxicity of certain chemotherapeutic alkylating agents is their toxic effects on nontarget tissues such as the bone marrow, To overcome the myelo-suppression observed by chemotherapeutic alkylating agents, one approach is to increase the level of DNA repair proteins in hematopoietic stem and progenitor cells. Toward this goal, we have constructed a human fusion protein consisting of O-6-methylguanine DNA methyltransferase coupled with an apurinic endonuclease, resulting in a fully functional protein for both O-6-methylguanine and apurinic/apyrimidinic (AP) site repair as determined by biochemical analysis, The chimeric protein protected AP endonuclease-deficient Escherichia coli cells against methyl methanesulfonate and hydrogen peroxide (H2O2) damage. A retroviral construct expressing the chimeric protein also protected HeLa cells against 1,3-bis(2-chloroethyl)-1-nitrosourea and methyl methanesulfonate cytotoxicity either when these agents were used separately or in combination. Moreover, as predicted from previous analysis, truncating the amino 150 amino acids of the apurinic endonuclease portion of the O-6-methylguanine DNA methyltransferase-apurinic endonuclease protein resulted in the retention of O-6-methylguanine DNA methyltransferase activity but loss of all AP endonuclease activity, These results demonstrate that the fusion of O-6-methylguanine DNA methyltransferase and apurinic endonuclease proteins into a combined single repair protein can result in a fully functional protein retaining the repair activities of the individual repair proteins. These and other related constructs may be useful for protection of sensitive tissues and, therefore, are candidate constructs to be tested in preclinical models of chemotherapy toxicity.	Indiana Univ, Sch Med, Wells Ctr, Howard Hughes Med Inst, Indianapolis, IN 46202 USA; Dept Pediat, Baton Rouge, LA 70808 USA; Dept Biochem & Mol Biol, Baton Rouge, LA 70808 USA; Wells Ctr Pediat Res, Baton Rouge, LA 70808 USA; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Howard Hughes Medical Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Kelley, MR (corresponding author), Indiana Univ, Sch Med, Wells Ctr, Howard Hughes Med Inst, Rm 2600,702 Barnhill Dr, Indianapolis, IN 46202 USA.	mkelley@indyvax.iupui.edu		Kelley, Mark/0000-0002-6120-9532	NATIONAL CENTER FOR RESEARCH RESOURCES [F32RR005063, R01RR009884] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007815] Funding Source: NIH RePORTER; NCRR NIH HHS [F32 RR05063, RR09884] Funding Source: Medline; NIEHS NIH HHS [ES07815] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLAY JA, 1995, BLOOD, V85, P3342, DOI 10.1182/blood.V85.11.3342.bloodjournal85113342; BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544; BARZILAY G, 1995, NAT STRUCT BIOL, V2, P561, DOI 10.1038/nsb0795-561; BARZILAY G, 1995, BIOESSAYS, V17, P713, DOI 10.1002/bies.950170808; BRENT TP, 1988, P NATL ACAD SCI USA, V85, P1759, DOI 10.1073/pnas.85.6.1759; Carter S K, 1972, Adv Cancer Res, V16, P273; COQUERELLE T, 1995, MUTAT RES-DNA REPAIR, V336, P9, DOI 10.1016/0921-8777(94)00035-5; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DUGUID JR, 1995, CANCER RES, V55, P6097; ERICKSON LC, 1980, NATURE, V288, P727, DOI 10.1038/288727a0; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P135; GENSLER HL, 1981, Q REV BIOL, V56, P279, DOI 10.1086/412317; GERSON SL, 1986, CARCINOGENESIS, V7, P745, DOI 10.1093/carcin/7.5.745; GONZAGA PE, 1992, CANCER RES, V52, P6052; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IBEANU G, 1992, CARCINOGENESIS, V13, P1989, DOI 10.1093/carcin/13.11.1989; Izumi T, 1996, BIOCHEMISTRY-US, V35, P14679, DOI 10.1021/bi961995u; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Jelinek J, 1996, BLOOD, V87, P1957; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; Maze R, 1996, P NATL ACAD SCI USA, V93, P206, DOI 10.1073/pnas.93.1.206; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MORGAN SE, 1993, J BIOL CHEM, V268, P19802; MORITZ T, 1995, CANCER RES, V55, P2608; ONO Y, 1995, DEV BRAIN RES, V86, P1, DOI 10.1016/0165-3806(94)00212-I; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Qin J, 1996, STRUCTURE, V4, P613, DOI 10.1016/S0969-2126(96)00065-2; Robertson KA, 1997, CELL GROWTH DIFFER, V8, P443; ROBINS P, 1983, NUCLEIC ACIDS RES, V11, P7743, DOI 10.1093/nar/11.22.7743; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SAMSON L, 1986, P NATL ACAD SCI USA, V83, P5607, DOI 10.1073/pnas.83.15.5607; Tomicic M, 1997, MUTAT RES-DNA REPAIR, V383, P155, DOI 10.1016/S0921-8777(96)00055-9; WALKER LJ, 1994, NUCLEIC ACIDS RES, V22, P4884, DOI 10.1093/nar/22.23.4884; WILSON DM, 1994, J BIOL CHEM, V269, P25359; WILSON DM, 1994, ALCOHOL CLIN EXP RES, V18, P1267, DOI 10.1111/j.1530-0277.1994.tb00117.x; WILSON TM, 1995, CANCER RES, V55, P5146; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yacoub A, 1996, EMBO J, V15, P2306, DOI 10.1002/j.1460-2075.1996.tb00584.x; YEN L, 1995, MUTAT RES-DNA REPAIR, V337, P179, DOI 10.1016/0921-8777(95)00022-C	48	30	31	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					756	762		10.1074/jbc.273.2.756	http://dx.doi.org/10.1074/jbc.273.2.756			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422728	hybrid			2022-12-25	WOS:000071411400017
J	Klemm, DJ; Roesler, WJ; Boras, T; Colton, LA; Felder, K; Reusch, JEB				Klemm, DJ; Roesler, WJ; Boras, T; Colton, LA; Felder, K; Reusch, JEB			Insulin stimulates cAMP-response element binding protein activity in HepG2 and 3T3-L1 cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; C-FOS TRANSCRIPTION; NUCLEAR FACTOR CREB; CYCLIC-AMP; KINASE-A; PEPCK GENE; PHOSPHORYLATION; PROMOTER; IDENTIFICATION; EXPRESSION	Earlier studies from our laboratory demonstrated an insulin-mediated increase in cAMP-response element binding protein (CREB) phosphorylation. In this report, we show that insulin stimulates both CREB phosphorylation and transcriptional activation in HepG2 and 3T3-L1 cell lines, models of insulin sensitive tissues. Insulin stimulated the phosphorylation of CREB at serine 133, the protein kinase A site, and mutation of serine 133 to alanine blocked the insulin effect. Many of the signaling pathways known to be activated by insulin have been implicated in CREB phosphorylation and activation, The ability of insulin to induce CREB phosphorylation and activity was efficiently blocked by PD98059, a potent inhibitor of mitogen-activated protein kinase kinase (MEK1), but not significantly by rapamycin or wortmannin. Likewise, expression of dominant negative forms of Raf-1 completely blocked insulin-stimulated CREB transcriptional activity. Finally, we demonstrate an essential role for CREB in insulin activation of fatty-acid synthase and fatty acid binding protein (FABP) indicating the potential tial physiologic relevance of insulin regulation of CREB. In summary, insulin regulates CREB transcriptional activity in insulin-sensitive tissues via the Raf --> MEK pathway and has an impact on physiologically relevant genes in these cells.	Vet Affairs Med Ctr, Sect Endocrinol 111H, Res Serv, Denver, CO 80220 USA; Natl Jewish Ctr Immunol & Resp Med, Dept Allergy & Clin Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80220 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80220 USA; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Saskatchewan	Reusch, JEB (corresponding author), Vet Affairs Med Ctr, Sect Endocrinol 111H, Res Serv, 1055 Clermont St, Denver, CO 80220 USA.			Reusch, Jane/0000-0001-8620-1003	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047117] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02351] Funding Source: Medline; NIGMS NIH HHS [GM47117] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; ARMSTRONG R, 1995, MOL CELL BIOL, V15, P1826; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; CIFUENTES ME, 1991, J BIOL CHEM, V266, P1557; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; ELMAGHRABI MR, 1991, J BIOL CHEM, V266, P2115; ENSLEN H, 1995, BIOCHEM BIOPH RES CO, V207, P1038, DOI 10.1006/bbrc.1995.1289; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRANNER D, 1990, J BIOL CHEM, V265, P10173; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; Houglum K, 1997, J CLIN INVEST, V99, P1322, DOI 10.1172/JCI119291; IYNEDJIAN PB, 1989, J BIOL CHEM, V264, P21824; JERKINS AA, 1995, J BIOL CHEM, V270, P1416, DOI 10.1074/jbc.270.38.22135; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEE CQ, 1990, EMBO J, V9, P4455, DOI 10.1002/j.1460-2075.1990.tb07896.x; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; PARK EA, 1993, J BIOL CHEM, V268, P613; PARK KR, 1991, J BIOL CHEM, V266, P12249; QUINN PG, 1994, J BIOL CHEM, V269, P14375; REUSCH JEB, 1995, ENDOCRINOLOGY, V136, P2464, DOI 10.1210/en.136.6.2464; REUSCH JEB, 1994, ENDOCRINOLOGY, V135, P2418, DOI 10.1210/en.135.6.2418; ROESLER WJ, 1995, J BIOL CHEM, V270, P8225, DOI 10.1074/jbc.270.14.8225; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SHORT MK, 1992, MOL CELL BIOL, V12, P1007, DOI 10.1128/MCB.12.3.1007; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUWANICKUL A, 1993, J BIOL CHEM, V268, P17063; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; XIE HJ, 1995, J IMMUNOL, V154, P1717; XIN J, 1996, SCIENCE, V273, P959; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	42	76	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					917	923		10.1074/jbc.273.2.917	http://dx.doi.org/10.1074/jbc.273.2.917			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422750	hybrid			2022-12-25	WOS:000071411400039
J	Dana, R; Leto, TL; Malech, HL; Levy, R				Dana, R; Leto, TL; Malech, HL; Levy, R			Essential requirement of cytosolic phospholipase A(2) for activation of the phagocyte NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; LEUKEMIA CELL-LINE; HUMAN NEUTROPHILS; ARACHIDONIC-ACID; PROTEIN-KINASE; HL-60 CELLS; CYTOPLASMIC PHOSPHOLIPASE-A(2); SUPEROXIDE GENERATION; RESPIRATORY BURST; EXPRESSION	Arachidonic acid (AA) can trigger activation of the phagocyte NADPH oxidase in a cell-free assay. However, a role for AA in activation of the oxidase in intact cells has not been established, nor has the AA generating enzyme critical to this process been identified, The human myeloid cell line PLB-985 was transfected to express p85 cytosolic phospholipase A(2) (cPLA(2)) antisense mRNA and stable clones were selected that lack detectable cPLA(2). cPLA(2)-deficient PLB-985 cells differentiate similarly to control PLB-985 cells in response to retinoic acid or 1,25-dihydroxyvitamin D-3, indicating that cPLA(2) is not involved in the differentiation process. Neither cPLA(2) nor stimulated [H-3]AA release were detectable in differentiated cPLA(2)-deficient PLB-985 cells, demonstrating that cPLA(2) is the major type of PLA(2) activated in phagocytic-like cells. Despite the normal synthesis of NADPH oxidase subunits during differentiation of cPLA(2)-deficient PLB-985 cells, these cells fail to activate NADPH oxidase in response to a variety of soluble and particulate stimuli, but the addition of exogenous AA fully restores oxidase activity. This establishes an essential requirement of cPLA(2)-generated AA for activation of phagocyte NADPH oxidase.	Ben Gurion Univ Negev, Fac Hlth Sci, Infect Dis Lab, Dept Clin Biochem, IL-84105 Beer Sheva, Israel; Soroka Med Ctr, IL-84105 Beer Sheva, Israel; NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA	Ben Gurion University; Ben Gurion University; Soroka Medical Center; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Levy, R (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Infect Dis Lab, Dept Clin Biochem, IL-84105 Beer Sheva, Israel.			Malech, Harry/0000-0001-5874-5775				ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; BOLOGNESE B, 1995, BBA-LIPID LIPID MET, V1256, P201, DOI 10.1016/0005-2760(95)00023-6; BRAULDY SA, 1996, BIOCHIM BIOPHYS ACTA, V1299, P223; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COCKCROFT S, 1991, BIOCHEM J, V275, P127, DOI 10.1042/bj2750127; DANA R, 1994, BIOCHEM J, V297, P217, DOI 10.1042/bj2970217; DOERFLER ME, 1994, J CLIN INVEST, V93, P1583, DOI 10.1172/JCI117138; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867; HAZAV P, 1989, CANCER RES, V49, P72; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HENDERSON LM, 1989, BIOCHEM J, V264, P249, DOI 10.1042/bj2640249; JACOBSON PB, 1993, J IMMUNOL, V151, P5639; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KWONG CH, 1993, BIOCHEMISTRY-US, V32, P5711, DOI 10.1021/bi00072a029; LEFKOWITH JB, 1992, J IMMUNOL, V149, P1729; LENNARTZ MR, 1991, J IMMUNOL, V147, P621; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LEVY R, 1990, J IMMUNOL, V145, P2595; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Liu Y, 1997, BBA-MOL CELL RES, V1355, P270, DOI 10.1016/S0167-4889(96)00148-6; LOEATI M, 1996, J BIOL CHEM, V271, P6010; LOMAX KJ, 1989, SCIENCE, V245, P409, DOI 10.1126/science.2547247; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; ROSENTHAL MD, 1995, BIOCHEM BIOPH RES CO, V208, P650, DOI 10.1006/bbrc.1995.1388; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; RUBINEK T, 1993, BIOCHIM BIOPHYS ACTA, V1176, P51, DOI 10.1016/0167-4889(93)90176-P; SAKATA A, 1987, J IMMUNOL, V138, P4353; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; TUCKER KA, 1987, BLOOD, V70, P372; VOLPP BD, 1989, P NATL ACAD SCI USA, V86, P7195, DOI 10.1073/pnas.86.18.7195; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318; XING MZ, 1994, J BIOL CHEM, V269, P3117; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832	44	178	185	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					441	445		10.1074/jbc.273.1.441	http://dx.doi.org/10.1074/jbc.273.1.441			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417101	hybrid			2022-12-25	WOS:000071295600067
J	Distel, B; Bauer, U; Le Borgne, R; Hoflack, B				Distel, B; Bauer, U; Le Borgne, R; Hoflack, B			Basolateral sorting of the cation-dependent mannose 6-phosphate receptor in Madin-Darby canine kidney cells - Identification of a basolateral determinant unrelated to clathrin-coated pit localization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; FACTOR-II RECEPTOR; INFLUENZA-VIRUS HEMAGGLUTININ; HIGH-AFFINITY INTERACTION; GOLGI ASSEMBLY PROTEINS; MDCK CELLS; CYTOPLASMIC DOMAIN; EPITHELIAL-CELLS; PLASMA-MEMBRANE; INTRACELLULAR-TRANSPORT	In polarized Madin-Darby canine kidney (MDCK) cells, sorting of membrane proteins in the trans-Golgi network for basolateral delivery depends on the presence of cytoplasmic determinants that are related or unrelated to clathrin-coated pit localization signals, Whether these signals mediate basolateral protein sorting through common or distinct pathways is unknown, The cytoplasmic domain of the cation-dependent mannose B-phosphate receptor (CD-MPR) contains clathrin-coated pit localization signals that are necessary for endocytosis and lysosomal enzyme targeting, In this study, we have addressed the function of these signals in polarized sorting of the CD-MPR. A chimeric protein, made of the luminal domain of the influenza virus hemagglutinin fused to the transmembrane and cytoplasmic mic domains of the CD-MPR was stably expressed in MDCK cells, This chimera (HCD) is able to interact with the AP-1 Golgi specific assembly proteins and is detected on the basolateral plasma membrane of MDCK cells where it is endocytosed, Deletion analysis and site-directed mutagenesis of the cytoplasmic domain of the CD-MPR indicate that HCD chimeras devoid of clathrin-coated pit localization signals are still transported to the basolateral membrane where they accumulate, A HCD chimera containing only the transmembrane domain and the 12 membrane-proximal amino acids of the CD-MPR cytoplasmic tail is also found on the basolateral membrane but is unable to interact with the AP-1 assembly proteins, However, the overexpression of this mutant results in partial apical delivery, It is concluded, therefore, that the basolateral transport of this chimera requires a saturable sorting machinery distinct from AP-1.	European Mol Biol Lab, D-69012 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Hoflack, B (corresponding author), Inst Pasteur Lille, EP CNRS 525, Inst Biol, BP 447,1 Rue Calmette, F-59021 Lille, France.		HOFLACK, Bernard/AAZ-6668-2020	LE BORGNE, Roland/0000-0001-6892-278X				AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BALCAROVASTANDER J, 1984, EMBO J, V3, P2687, DOI 10.1002/j.1460-2075.1984.tb02194.x; Boll W, 1996, EMBO J, V15, P5789, DOI 10.1002/j.1460-2075.1996.tb00965.x; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; EHNO H, 1995, SCIENCE, V269, P1872; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KUMKEL TA, 1985, P NATL ACAD SCI USA, V82, P488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LeBorgne R, 1997, J CELL BIOL, V137, P335; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MATLIN KS, 1981, J CELL BIOL, V91, P601, DOI 10.1083/jcb.91.3.601; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MAUXION F, 1995, EUR J CELL BIOL, V66, P119; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; PELHAM HRB, 1993, CELL, V75, P603, DOI 10.1016/0092-8674(93)90479-A; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; PRYDZ K, 1990, J BIOL CHEM, V265, P12629; RAJASEKARAN AK, 1994, MOL BIOL CELL, V5, P1093, DOI 10.1091/mbc.5.10.1093; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247	52	26	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					186	193		10.1074/jbc.273.1.186	http://dx.doi.org/10.1074/jbc.273.1.186			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417063	hybrid			2022-12-25	WOS:000071295600029
J	Kallal, L; Gagnon, AW; Penn, RB; Benovic, JL				Kallal, L; Gagnon, AW; Penn, RB; Benovic, JL			Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; COUPLED RECEPTOR; ADENYLYL-CYCLASE; CULTURED-CELLS; INTERNALIZATION; SALMETEROL; MEMBRANE; DESENSITIZATION; LOCALIZATION; ENDOCYTOSIS	To date, the visualization of beta(2)-adrenergic receptor (beta(2)AR) trafficking has been largely limited to immunocytochemical analyses of acute internalization events of epitope-tagged receptors in various transfection systems, The development of a beta(2)AR conjugated with green fluorescent protein (beta(2)AR-GFP) provides the opportunity for a more extensive optical analysis of beta(2)AR sequestration, down-regulation, and recycling in cells. Here we demonstrate that stable expression of beta(2)AR-GFP in HeLa cells enables a detailed temporal and spatial analysis of these events, Time dependent colocalization of beta(2)AR-GFP with rhodamine-labeled transferrin and rhodamine-labeled dextran following agonist exposure demonstrates receptor distribution to early endosomes (sequestration) and lysosomes (down-regulation), respectively. The observed temporal distribution of beta(2)AR-GFP was consistent with measures of receptor sequestration and down-regulation generated by radioligand-receptor binding assays. Cells stimulated with different beta-agonists revealed time courses of beta(2)AR-GFP redistribution reflective of the intrinsic activity of each agonist.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, 233 S 10th ST, Philadelphia, PA 19107 USA.				NIGMS NIH HHS [GM47417, GM44944] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047417, R01GM044944, R37GM047417] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; CHUANG DM, 1982, BIOCHEM BIOPH RES CO, V105, P1466, DOI 10.1016/0006-291X(82)90953-6; Clark RB, 1996, MOL PHARMACOL, V49, P182; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FORSAYETH JR, 1994, BIOTECHNIQUES, V17, P354; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Green SA, 1996, J BIOL CHEM, V271, P24029, DOI 10.1074/jbc.271.39.24029; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; Krueger KM, 1997, J BIOL CHEM, V272, P5; KURZ JB, 1992, MOL PHARMACOL, V41, P375; LIAO JF, 1993, MOL PHARMACOL, V44, P364; Linden A, 1996, LUNG, V174, P1; OHKUMA S, 1978, P NATL ACAD SCI USA, V75, P3327, DOI 10.1073/pnas.75.7.3327; PENN RB, 1994, AM J RESP CELL MOL, V11, P496, DOI 10.1165/ajrcmb.11.4.7917318; Petrou C, 1997, J BIOL CHEM, V272, P2326; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; TOEWS ML, 1987, MOL PHARMACOL, V32, P737; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; WAKSHULL E, 1985, J CELL BIOCHEM, V29, P127, DOI 10.1002/jcb.240290208; WALDO GL, 1983, J BIOL CHEM, V258, P3900	27	153	158	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					322	328		10.1074/jbc.273.1.322	http://dx.doi.org/10.1074/jbc.273.1.322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417083	hybrid			2022-12-25	WOS:000071295600049
J	Panayotou, G; Brown, T; Barlow, T; Pearl, LH; Savva, R				Panayotou, G; Brown, T; Barlow, T; Pearl, LH; Savva, R			Direct measurement of the substrate preference of uracil-DNA glycosylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; EXCISION-REPAIR; CRYSTALLIZATION; INHIBITOR; COMPLEX; BASE; RECOGNITION; MIMICRY; ENZYME	Site-directed mutants of the herpes simplex virus type 1 uracil-DNA glycosylase lacking catalytic activity have been used to probe the substrate recognition of this highly conserved and ubiquitous class of DNA repair enzyme utilizing surface plasmon resonance. The residues aspartic acid-88 and histidine-210, implicated in the catalytic mechanism of the enzyme (Savva, R., McAuley-Hecht, K., Brown, T., and Pearl, L. (1995) Nature 373, 487-493; Slupphaug, G., Mol, C. D., Kavli, B., Arvai, A. S., Krokan, H. E. and Tainer, J. A. (1996) Nature 384, 87-92) were separately mutated to asparagine to allow investigations of substrate recognition in the absence of catalysis, The mutants were shown to be correctly folded and to lack catalytic activity. Binding to single-and double-stranded oligonucleotides, with or without uracil, was monitored by real-time biomolecular interaction analysis using surface plasmon resonance. Both mutants exhibited comparable rates of binding and dissociation on the same uracil-containing substrates, Interaction with single-stranded uracil-DNA was found to be stronger than with double-stranded uracil-DNA, and the binding to Gua:Ura mismatches was significantly stronger than that to Ade:Ura base pairs suggesting that the stability of the base pair determines the efficiency of interaction. Also, there was negligible interaction between the mutants and single- or double-stranded DNA lacking uracil, or with DNA containing abasic sites, These results suggest that it is uracil in the DNA, rather than DNA itself, that is recognized by the uracil-DNA glycosylases.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	University of London; University College London; Ludwig Institute for Cancer Research; University of London; University College London; University of Southampton	Pearl, LH (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	pearl@bsm.biochemistry.ucl.ac.uk	Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Brown, Tom/0000-0002-6538-3036; Savva, Renos/0000-0001-7375-2340; Pearl, Laurence/0000-0002-6910-1809				Berg O, 1981, BIOCHEMISTRY-US, V20, P6926; BONDESON K, 1993, ANAL BIOCHEM, V214, P245, DOI 10.1006/abio.1993.1484; CHANG KJ, 1975, BIOCHIM BIOPHYS ACTA, V406, P294, DOI 10.1016/0005-2736(75)90011-5; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; FISHER RJ, 1994, PROTEIN SCI, V3, P257; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; HIGLEY M, 1993, MUTAT RES, V294, P109, DOI 10.1016/0921-8777(93)90019-D; JONSSON U, 1991, BIOTECHNIQUES, V11, P520; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Koulis A, 1996, FEMS MICROBIOL LETT, V143, P267; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1988, REV BIOCHEM TOXICOL, V9, P69; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PURMAL AA, 1994, J BIOL CHEM, V269, P22046; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, PROTEINS, V22, P287, DOI 10.1002/prot.340220310; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SAVVA R, 1993, J MOL BIOL, V234, P910, DOI 10.1006/jmbi.1993.1642; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675	25	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					45	50		10.1074/jbc.273.1.45	http://dx.doi.org/10.1074/jbc.273.1.45			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417045	hybrid, Green Accepted			2022-12-25	WOS:000071295600011
J	Temple, CS; Stewart, AK; Meredith, D; Lister, NA; Morgan, KM; Collier, ID; Vaughan-Jones, RD; Boyd, CAR; Bailey, PD; Bronk, JR				Temple, CS; Stewart, AK; Meredith, D; Lister, NA; Morgan, KM; Collier, ID; Vaughan-Jones, RD; Boyd, CAR; Bailey, PD; Bronk, JR			Peptide mimics as substrates for the intestinal peptide transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; DIPEPTIDE TRANSPORT; MEMBRANE; COTRANSPORT; HYDROLYSIS; CORTEX	4-Aminophenylacetic acid (4-APAA), a peptide mimic lacking a peptide bond, has been shown to interact with a proton-coupled oligopeptide transporter using a number of different experimental approaches, In addition to inhibiting transport of labeled peptides, these studies show that 4-APAA is itself translocated, 4-APAA transport across the rat intact intestine was stimulated 18-fold by luminal acidification (to pH 6.8) as determined by high performance liquid chromatography (HPLC); in enterocytes isolated from mouse small intestine the intracellular pH was reduced on application of 4-APAA, as shown fluorimetrically with the pH indicator carboxy-SNARF; 4-APAA trans-stimulated radiolabeled peptide transport in brush-border membrane vesicles isolated from rat renal cortex; and in Xenopus oocytes expressing PepT1, 4-APAA produced trans-stimulation of radiolabeled peptide efflux, and as determined by HPLC, was a substrate for translocation by this transporter, These results with 4-APAA show for the first time that the presence of a peptide bond is not a requirement for rapid translocation through the proton-linked oligopeptide transporter (PepT1), Further investigation will be needed to determine the minimal structural requirements for a molecule to be a substrate for this transporter.	Univ Oxford, Dept Human Anat, Oxford OX1 3QX, England; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England; Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England; Heriot Watt Univ, Dept Chem, Edinburgh EH14 4AS, Midlothian, Scotland	University of Oxford; University of Oxford; University of York - UK; Heriot Watt University	Boyd, CAR (corresponding author), Univ Oxford, Dept Human Anat, S Parks Rd, Oxford OX1 3QX, England.		Meredith, David/F-3664-2010		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BIBER J, 1981, BIOCHIM BIOPHYS ACTA, V647, P169, DOI 10.1016/0005-2736(81)90243-1; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; DANIEL H, 1994, FASEB J, V8, P753, DOI 10.1096/fasebj.8.10.8050675; FEI YJ, 1994, NATURE, V368, P563, DOI 10.1038/368563a0; Lister N, 1997, BBA-BIOMEMBRANES, V1324, P245, DOI 10.1016/S0005-2736(96)00230-1; LISTER N, 1995, J PHYSIOL-LONDON, V484, P173, DOI 10.1113/jphysiol.1995.sp020656; Loh SH, 1996, BRIT J PHARMACOL, V118, P1905, DOI 10.1111/j.1476-5381.1996.tb15623.x; MATTHEWS DM, 1991, PROTEIN ABSORPTION, P111; Meredith D, 1996, J PHYSIOL-LONDON, V497P, pP89; NICHOLLS TJ, 1983, BIOCHEM J, V212, P183, DOI 10.1042/bj2120183; Stein WD, 1986, TRANSPORT DIFFUSION, P231; TEMPLE CS, 1995, PFLUG ARCH EUR J PHY, V430, P825, DOI 10.1007/BF00386182; Temple CS, 1996, J PHYSIOL-LONDON, V494, P795, DOI 10.1113/jphysiol.1996.sp021533	13	69	69	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					20	22		10.1074/jbc.273.1.20	http://dx.doi.org/10.1074/jbc.273.1.20			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417040	hybrid			2022-12-25	WOS:000071295600006
J	Beers, J; Glerum, DM; Tzagoloff, A				Beers, J; Glerum, DM; Tzagoloff, A			Purification, characterization, and localization of yeast Cox17p, a mitochondrial copper shuttle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE ENCODES; CYTOCHROME B(2); PROTEIN; GENE; MEMBRANE; OXIDASE; SCO1	Cox17p was previously shown to be essential for the expression of cytochrome oxidase in Saccharomyces cerevisiae. In the present study COX17 has been placed under the control of the GAL10 promoter in an autonomously replicating plasmid. A yeast transformant harboring the high copy construct was used to purify Cox17p to homogeneity. Purified Cox17p contains 0.2-0.3 mol of copper per mol of protein. The molar copper content is increased to 1.8 after incubation of Cox17p in the presence of a 6-fold molar excess of cuprous chloride under reduced conditions. An antibody against Cox17p was obtained by immunization of rabbits with a carboxyl-terminal peptide coupled to bovine serum albumin. The antiserum detects Cox17p in both the mitochondrial and soluble protein fractions of wild type yeast and of the transformant overexpressing Cox17p. Exposure of intact mitochondria to hypotonic conditions causes most of Cox17p to be released as a soluble protein indicating that the mitochondrial fraction of Cox17p is localized in the intermembrane space. These results are consistent with the previously proposed function of Cox17p, namely in providing cytoplasmic copper for mitochondrial utilization.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Glerum, Moira/AHD-3271-2022		NIGMS NIH HHS [R01 GM050187, GM50187] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; Amaravadi R, 1997, HUM GENET, V99, P329, DOI 10.1007/s004390050367; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Broach J. R., 1983, EXPT MANIPULATION GE, P83; BUCHWALD P, 1991, MOL GEN GENET, V229, P413, DOI 10.1007/BF00267464; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; FELSENFELD G, 1960, ARCH BIOCHEM BIOPHYS, V87, P247, DOI 10.1016/0003-9861(60)90168-5; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GRUHLER A, 1995, EMBO J, V14, P1349, DOI 10.1002/j.1460-2075.1995.tb07121.x; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Hancock D C, 1992, Methods Mol Biol, V10, P23, DOI 10.1385/0-89603-204-3:23; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING LAB MANU; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144	28	190	194	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33191	33196		10.1074/jbc.272.52.33191	http://dx.doi.org/10.1074/jbc.272.52.33191			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407107	hybrid			2022-12-25	WOS:000071182900068
J	DiDonato, M; Narindrasorasak, S; Forbes, JR; Cox, DW; Sarkar, B				DiDonato, M; Narindrasorasak, S; Forbes, JR; Cox, DW; Sarkar, B			Expression, purification, and metal binding properties of the N-terminal domain from the Wilson disease putative copper-transporting ATPase (ATP7B)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; MENKES DISEASE; CANDIDATE GENE; PROTEIN; ENCODES; ZINC; DNA	The putative copper binding domain from the copper-transporting ATPase implicated in Wilson disease (ATP7B) has been expressed and purified as a fusion to glutathione S-transferase, Immobilized metal ion affinity chromatography revealed that the fusion protein is able to bind to columns charged with different transition metals with varying affinities as follows: Cu(II)much greater than Zn(II)>Ni(II)>Co(II). The fusion protein did not bind to columns charged with Fe(II) or Fe(III), (65)Zinc(II) blotting analysis showed that the domain is able to bind Zn(II) over a range of pH values from 6.5 to 9.0, Competition Zn-65(II) blotting showed that Cd(II)), Hg(II), Au(III), and Fe(III) can successfully compete with Zn(II), at comparable concentrations, for binding to the domain, In contrast, the domain had little or no affinity for Ca(II), Mg(II), Mn(II), and Ni(II) relative to copper. Neutron activation analysis of the copper bound to the domain showed a copper:protein ratio of 6.5-7.3:1, Both Cu(II) and Cu(I) were found to have a higher affinity for the domain relative to Zn(II). In addition, a sharp, reproducible transition was only observed in competition experiments with copper, which may suggest that copper binding has some degree of cooperativity.	Hosp Sick Children, Dept Biochem Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Alberta, Dept Med Genet, Edmonton, AB T6G 2S2, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Alberta	Sarkar, B (corresponding author), Hosp Sick Children, Dept Biochem Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.			DiDonato, Michael/0000-0002-9074-7284				[Anonymous], 1995, METABOLIC BASIS INHE; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Chen P, 1996, BIOCHEM J, V317, P389, DOI 10.1042/bj3170389; Conte D, 1996, J BIOL CHEM, V271, P5125; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; JIN JP, 1994, FEBS LETT, V341, P135, DOI 10.1016/0014-5793(94)80256-4; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; ODERMATT A, 1994, BIOCHEM BIOPH RES CO, V202, P44, DOI 10.1006/bbrc.1994.1891; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PHUNG LT, 1994, P NATL ACAD SCI USA, V91, P9651, DOI 10.1073/pnas.91.20.9651; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; Scopes RK, 1994, PROTEIN PURIFICATION, P317; SILVER S, 1989, TRENDS BIOCHEM SCI, V14, P76, DOI 10.1016/0968-0004(89)90048-0; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TOMBS M P, 1985, Journal of Applied Biochemistry, V7, P3; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030	21	128	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33279	33282		10.1074/jbc.272.52.33279	http://dx.doi.org/10.1074/jbc.272.52.33279			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407118	hybrid			2022-12-25	WOS:000071182900079
J	Dowell, P; Ishmael, JE; Avram, D; Peterson, VJ; Nevrivy, DJ; Leid, M				Dowell, P; Ishmael, JE; Avram, D; Peterson, VJ; Nevrivy, DJ; Leid, M			p300 functions as a coactivator for the peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; LIGAND-BINDING DOMAIN; THYROID-HORMONE RECEPTOR; NUCLEAR RECEPTORS; RESPONSE ELEMENT; FATTY-ACIDS; TRANSCRIPTIONAL COACTIVATOR; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; OXIDASE GENE	The integrator protein, p300, was demonstrated to interact with mouse peroxisome proliferator-activated receptor a in a ligand-enhanced manner. The PPAR alpha-interacting domain of p300 was mapped to amino acids 39-117 which interacted strongly with PPAR alpha but did not interact with retinoic acid receptor-gamma or retinoid X receptor-alpha. Amino acids within the carboxyl terminus of PPAR alpha as well as residues within the hinge region were required for ligand-dependent interaction with p300. p300 enhanced the transcriptional activation properties of PPAR alpha and, therefore, can be considered a bona fide coactivator for this nuclear receptor. These observations extend the group of p300-interacting proteins to include mPPAR alpha and further characterize the molecular mechanisms of PPAR alpha-mediated transcriptional regulation.	Oregon State Univ, Coll Pharm, Program Mol & Cellular Biol, Corvallis, OR 97331 USA; Oregon State Univ, Coll Pharm, Mol Pharmacol Lab, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Leid, M (corresponding author), Oregon State Univ, Coll Pharm, Program Mol & Cellular Biol, Corvallis, OR 97331 USA.	leidm@ccmail.orst.edu			NIEHS NIH HHS [ES00210, ES00040] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES000040, P30ES000210] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P102; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1997, J BIOL CHEM, V272, P2013, DOI 10.1074/jbc.272.3.2013; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Green S, 1995, MUTAT RES-FUND MOL M, V333, P101, DOI 10.1016/0027-5107(95)00136-0; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HSU MH, 1995, MOL PHARMACOL, V48, P559; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; ING NH, 1992, J BIOL CHEM, V267, P17617; ISSEMANN I, 1992, BIOCHEM SOC T, V20, P824, DOI 10.1042/bst0200824; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, BIOCHIMIE, V75, P251, DOI 10.1016/0300-9084(93)90084-6; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KIPPERT F, 1995, FEMS MICROBIOL LETT, V128, P201, DOI 10.1016/0378-1097(95)00113-J; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Lee JS, 1996, J BIOL CHEM, V271, P17666, DOI 10.1074/jbc.271.30.17666; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; Schoonjans K, 1996, BBA-LIPID LIPID MET, V1302, P93, DOI 10.1016/0005-2760(96)00066-5; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; Thenot S, 1997, J BIOL CHEM, V272, P12062, DOI 10.1074/jbc.272.18.12062; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; Varanasi U, 1996, J BIOL CHEM, V271, P2147, DOI 10.1074/jbc.271.4.2147; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	90	140	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33435	33443		10.1074/jbc.272.52.33435	http://dx.doi.org/10.1074/jbc.272.52.33435			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407140	hybrid			2022-12-25	WOS:000071182900101
J	Luo, H; Bellofatto, V				Luo, H; Bellofatto, V			Characterization of two protein activities that interact at the promoter of the trypanosomatid spliced leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-EXON GENE; SMALL NUCLEAR; POLYMERASE-II; LEPTOMONAS-SEYMOURI; TRANSCRIPTION; EXPRESSION; ELEMENTS; BINDING; PURIFICATION; INITIATION	All trypanosome mRNAs have a spliced leader (SL). The SL RNA gene in Leptomonas seymouri is a member of the small nuclear RNA gene family. However, the SL RNA is required in stoichiometric amounts for transsplicing during mRNA formation. Expression of the SL RNA gene requires sequence elements at bp -60 to -70 and bp -30 to -40 upstream from the transcription initiation site. Using conventional and affinity chromatography, we have identified and characterized an -122-kDa protein, promoter-binding protein (PBP) -1, that binds to double-strand DNA. The PBP-1-binding site is within the bp -60 to -70 element determined by DNase I footprinting. Therefore, PBP-1 is the first characterized double-strand DNA binding activity that interacts with a trypanosome gene promoter. A second protein, PBP-2, interacts with the PBP-1:DNA complex and its DNase I footprint extends to include the second promoter element (bp -30 to -40). An alteration of the spacing between the two promoter elements or mutation of the second element decreases PBP-2/PBP-1:DNA stability. Taken together, these data suggest that PBP-1 and PBP-2 are components of a transcription initiation complex that assembles within the SL RNA gene promoter.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bellofatto, V (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.				NIAID NIH HHS [AI 29478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGAMI R, 1994, NUCLEIC ACIDS RES, V22, P1959, DOI 10.1093/nar/22.11.1959; BELLOFATTO V, 1993, J PARASITOL, V79, P637, DOI 10.2307/3283594; BELLOFATTO V, 1991, P NATL ACAD SCI USA, V88, P6711, DOI 10.1073/pnas.88.15.6711; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; CONNELLY S, 1994, MOL CELL BIOL, V14, P5910, DOI 10.1128/MCB.14.9.5910; Dahlberg JE, 1988, STRUCTURE FUNCTION M, P38, DOI [10.1007/978-3-642- 73020-7_2, DOI 10.1007/978-3-642-73020-7_2]; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FANTONI A, 1994, MOL CELL BIOL, V14, P2021, DOI 10.1128/MCB.14.3.2021; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; HARTREE D, 1995, MOL BIOCHEM PARASIT, V71, P27, DOI 10.1016/0166-6851(95)00034-X; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; HENRY RW, 1995, NATURE, V374, P653, DOI 10.1038/374653a0; Hernandez N, 1992, TRANSCRIPTIONAL REGU, P281; HUIE J, 1998, IN PRESS MOL BIOCH P; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Li JM, 1996, MOL CELL BIOL, V16, P1275; LOBO SM, 1994, TRANSCRIPTION MECH R, P127; MELENDY T, 1987, MOL BIOCHEM PARASIT, V24, P215, DOI 10.1016/0166-6851(87)90108-3; NAKAAR V, 1994, MOL CELL BIOL, V14, P6736, DOI 10.1128/MCB.14.10.6736; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; VANHAMME L, 1995, MICROBIOL REV, V59, P223, DOI 10.1128/MMBR.59.2.223-240.1995; VANHAMME L, 1995, MOL CELL BIOL, V15, P5598; Yoon JB, 1996, MOL CELL BIOL, V16, P1	25	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33344	33352		10.1074/jbc.272.52.33344	http://dx.doi.org/10.1074/jbc.272.52.33344			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407127	hybrid			2022-12-25	WOS:000071182900088
J	Tong, X; Salgia, R; Li, JL; Griffin, JD; Howley, PM				Tong, X; Salgia, R; Li, JL; Griffin, JD; Howley, PM			The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; ACTIN; SITE; CRK	The bovine papillomavirus type 1 (BPV-1) E6 oncoprotein can transform fibroblasts and induce anchorage-independent growth and disassembly of the actin stress fibers, We have previously shown that the E6 protein interacts with the focal adhesion protein, paxillin, suggesting a direct role of E6 in the disruption of the actin cytoskeleton. We have now mapped the E6 binding sites on paxillin to the LD motif repeats region, which has been implicated in mediating paxillin binding to two other focal adhesion proteins, vinculin and the focal adhesion kinase. The five LD motif repeats identified in paxillin do not contribute equally to its interaction with E6. The first LD repeat is most critical for paxillin binding to E6 both in vitro and in vivo. Furthermore, the binding of recombinant wild-type E6 protein to paxillin blocked the interaction of several cellular proteins with paxillin, including vinculin and the focal adhesion kinase, A mutant E6 protein (H105) which does not bind to paxillin had no effect on the binding of these cellular proteins to paxillin, These data suggest that E6 disruption of the actin stress fibers occurs through blocking the interaction of paxillin with its cellular effecters such as vinculin and the focal adhesion kinase.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Howley, PM (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.		Li, J L/E-6100-2018; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; Li, Jian-Liang/0000-0002-6487-081X; Howley, Peter/0000-0002-8668-9579	NATIONAL CANCER INSTITUTE [P01CA050661, K12CA001730] Funding Source: NIH RePORTER; NCI NIH HHS [CA01730, P01CA50661-08, CA39147] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1985, SCIENCE, V230, P442, DOI 10.1126/science.2996134; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; McCormack SJ, 1997, ONCOGENE, V15, P265, DOI 10.1038/sj.onc.1201186; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Sastry SK, 1996, DEV BIOL, V180, P455, DOI 10.1006/dbio.1996.0319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOOD CK, 1994, J CELL SCI, V107, P709	20	85	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33373	33376		10.1074/jbc.272.52.33373	http://dx.doi.org/10.1074/jbc.272.52.33373			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407131	hybrid			2022-12-25	WOS:000071182900092
J	Katoh, H; Aoki, J; Ichikawa, A; Negishi, M				Katoh, H; Aoki, J; Ichikawa, A; Negishi, M			p160 RhoA-binding kinase ROK alpha induces neurite retraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE KINASE; SMALL GTPASE-RHO; PROTEIN-RHO; SERINE/THREONINE KINASE; PUTATIVE TARGET; ADP-RIBOSYLTRANSFERASE; ACTIVATION; CELLS; RIBOSYLATION; CYTOSKELETON	We previously reported that the activation of prostaglandin E receptor EP3 subtype caused neurite retraction via small GTPase Rho in the EP3B receptor-expressing PC12 cells (Katoh, H., Negishi, M., and Ichikawa, A. (1996) J. Biol. Chem. 271, 29780-29784). However, a potential downstream effector of Rho that induces neurite retraction was not identified, Here we examined the morphological effect of p160 RhoA-binding kinase ROK alpha, a target for RhoA recently identified, on the nerve growth factor-differentiated PC12 cells. Microinjection of the catalytic domain of ROK alpha rapidly induced neurite retraction similar to that induced by microinjection of a constitutively active Rho, Rho(V14) whereas microinjection of the kinase-deficient catalytic domain of ROK alpha did not induce neurite retraction. This morphological change was observed even though C3 exoenzyme, which was known to inactivate Rho, had been preinjected. On the other hand, microinjection of the Rho-binding domain or the pleckstrin homology domain of ROK alpha inhibited the EP3 receptor-induced neurite retraction, These results demonstrate that ROK alpha induces neurite retraction acting downstream of Rho in neuronal cells.	Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 606, Japan; Kyoto Univ, Fac Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan	Kyoto University; Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Fac Pharmaceut Sci, Dept Mol Neurobiol, Sakyo Ku, Kyoto 606, Japan.							AKTORIES K, 1987, FEBS LETT, V212, P109, DOI 10.1016/0014-5793(87)81566-1; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Hasegawa H, 1997, BIOCHEM BIOPH RES CO, V234, P631, DOI 10.1006/bbrc.1997.6655; HIRATA K, 1992, J BIOL CHEM, V267, P8719; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JALINK K, 1992, J CELL BIOL, V118, P411, DOI 10.1083/jcb.118.2.411; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; Katoh H, 1996, J BIOL CHEM, V271, P29780, DOI 10.1074/jbc.271.47.29780; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; Kosako H, 1997, J BIOL CHEM, V272, P10333; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakagawa O, 1996, FEBS LETT, V392, P189, DOI 10.1016/0014-5793(96)00811-3; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TAKAISHI K, 1994, ONCOGENE, V9, P273; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 1996, J NEUROCHEM, V66, P537; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044	31	161	161	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2489	2492		10.1074/jbc.273.5.2489	http://dx.doi.org/10.1074/jbc.273.5.2489			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446546	hybrid			2022-12-25	WOS:000071736600001
J	Lopez-Ilasaca, M; Gutkind, JS; Wetzker, R				Lopez-Ilasaca, M; Gutkind, JS; Wetzker, R			Phosphoinositide 3-kinase gamma is a mediator of G beta gamma-dependent Jun kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAY; SUBUNITS; CDC42; RAS	Jun kinases (JNK) are involved in the stress response of mammalian cells, Stimulation of JNK can be induced by stress factors and by agonists of tyrosine kinase and G protein coupled receptors, G protein-dependent receptors stimulate JNK via G beta gamma subunits of heterotrimeric G proteins, but the subsequent signaling reaction has been undefined. Here we demonstrate JNK activation in COS-7 cells by G beta gamma-stimulated phosphoinositide S-kinase gamma (PI3K gamma). Signal transduction from PI3K gamma to JNK can be suppressed by dominant negative mutants of Ras, Rac, and the protein kinase PAK. These results identify PI3K gamma as a mediator of G beta gamma-dependent regulation of JNK activity.	Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, D-07747 Jena, Germany; NIH, Mol Signaling Unit, Cellular Dev & Oncol Lab, NIDR, Bethesda, MD 20892 USA	Friedrich Schiller University of Jena; Max Planck Society; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Wetzker, R (corresponding author), Univ Jena, Fac Med, Max Planck Res Unit Mol Cell Biol, Drackendorfer Str 1, D-07747 Jena, Germany.	i5rewe@rz.uni-jena.de	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016; Wetzker, Reinhard/AAD-8713-2019	Gutkind, J. Silvio/0000-0002-5150-4482; 				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731	16	88	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2505	2508		10.1074/jbc.273.5.2505	http://dx.doi.org/10.1074/jbc.273.5.2505			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446550	hybrid			2022-12-25	WOS:000071736600005
J	Baburina, I; Jackowski, S				Baburina, I; Jackowski, S			Apoptosis triggered by 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine is prevented by increased expression of CTP : phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LEUKEMIC-CELLS; PHOSPHOLIPID ANALOG HEXADECYLPHOSPHOCHOLINE; ETHER LIPID ANALOGS; CANINE KIDNEY-CELLS; PROTEIN-KINASE-C; HAMSTER OVARY CELLS; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; ALKYL-LYSOPHOSPHOLIPIDS; HL-60 CELLS; SELECTIVE DESTRUCTION	A HeLa cell line was constructed for the regulation of CTP:phosphocholine cytidylyltransferase (CCT) expression via a tetracycline-responsive promoter to test the role of CCT in apoptosis triggered by exposure of cells to the antineoplastic phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET 18-OCH3). Basal CCT expression in the engineered HeLa cell line was the same as in control HeLa cells lines, and CCT activity and protein were elevated 25-fold following 48 h of induction with doxycycline. Increased CCT expression prevented ET-18-OCH3-induced apoptosis. Acylation of exogenous lysophosphatidylcholine circumvented the requirement for CCT activity by providing an alternate route to phosphatidylcholine, and heightened CCT expression and lysophosphatidylcholine supplementation were equally effective in reversing the cytotoxic effect of ET-18-OCH3. Neither CCT overexpression nor lysophosphatidylcholine supplementation allowed the HeLa cells to proliferate in the presence of ET-18-OCH3, indicating that the cytostatic property of ET-18-OCH3 was independent of its effect on membrane phospholipid synthesis. These data provide compelling genetic evidence to support the conclusion that the interruption of phosphatidylcholine synthesis at the CCT step by ET-18-OCH3 is the primary physiological imbalance that accounts for the cytotoxic action of the drug.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale, Memphis, TN 38105 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045737] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBANI PD, 1993, NEUROCHEM INT, V22, P567; ANDREESEN R, 1978, CANCER RES, V38, P3894; ANDREESEN R, 1979, BLOOD, V54, P519; ARAKI S, 1994, J BIOCHEM-TOKYO, V115, P245, DOI 10.1093/oxfordjournals.jbchem.a124325; BAZILL GW, 1990, CANCER RES, V50, P7505; BERDEL WE, 1980, EUR J CANCER, V16, P1119; BERGGREN MI, 1993, CANCER RES, V53, P4297; Berkovic D, 1995, EUR J CANCER, V31A, P2080, DOI 10.1016/0959-8049(95)00350-9; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; BOGGS KP, 1997, IN PRESS BIOCH BIOPH; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNN G, 1994, CANCER CHEMOTH PHARM, V35, P71, DOI 10.1007/BF00686287; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; DANIEL LW, 1987, LIPIDS, V22, P851, DOI 10.1007/BF02535543; DANIEL LW, 1993, CANCER CHEMOTHERAPY, P146; DETMAR M, 1994, J INVEST DERMATOL, V102, P490, DOI 10.1111/1523-1747.ep12373109; DIOMEDE L, 1993, INT J CANCER, V53, P124, DOI 10.1002/ijc.2910530123; ESKO JD, 1982, P NATL ACAD SCI-BIOL, V79, P1698, DOI 10.1073/pnas.79.6.1698; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FLEER EAM, 1993, LIPIDS, V28, P731, DOI 10.1007/BF02535995; GEILEN CC, 1992, J BIOL CHEM, V267, P6719; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HAASE R, 1991, FEBS LETT, V288, P129, DOI 10.1016/0014-5793(91)81018-4; HEESBEEN EC, 1994, BIOCHEM PHARMACOL, V47, P1481, DOI 10.1016/0006-2952(94)90521-5; HEESBEEN EC, 1993, LEUKEMIA RES, V17, P143, DOI 10.1016/0145-2126(93)90059-T; HERRMANN DBJ, 1986, J BIOL CHEM, V261, P7742; HERRMANN DBJ, 1985, J NATL CANCER I, V75, P423; HOFFMAN DR, 1986, CANCER RES, V46, P5803; HOULIHAN WJ, 1995, MED RES REV, V15, P157, DOI 10.1002/med.2610150302; JACKOWSKI S, 1994, J BIOL CHEM, V269, P3858; KELLEY EE, 1993, BIOCHEM PHARMACOL, V45, P2435, DOI 10.1016/0006-2952(93)90224-K; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; Lohmeyer Matthias, 1994, Drugs of the Future, V19, P1021; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; MODOLELL M, 1979, CANCER RES, V39, P4681; MOLLINEDO F, 1993, BIOCHEM BIOPH RES CO, V192, P603, DOI 10.1006/bbrc.1993.1458; MOLLINEDO F, 1994, BIOCHEM J, V302, P325, DOI 10.1042/bj3020325; PARKER J, 1987, J BIOL CHEM, V262, P5385; PAWELCZYK T, 1993, BIOCHEM PHARMACOL, V45, P493, DOI 10.1016/0006-2952(93)90087-D; POWIS G, 1992, CANCER RES, V52, P2835; PRINCIPE P, 1995, CRIT REV ONCOL HEMAT, V18, P155, DOI 10.1016/1040-8428(94)00118-D; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; RUNGE MH, 1980, J NATL CANCER I, V64, P1301, DOI 10.1093/jnci/64.6.1301; SALARI H, 1992, BIOCHIM BIOPHYS ACTA, V1134, P81, DOI 10.1016/0167-4889(92)90030-F; SEEWALD MJ, 1990, CANCER RES, V50, P4458; Surette ME, 1996, BIOCHEMISTRY-US, V35, P9187, DOI 10.1021/bi9530245; Takahara N, 1996, METABOLISM, V45, P559, DOI 10.1016/S0026-0495(96)90024-4; TRONCHERE H, 1991, BIOCHEM BIOPH RES CO, V176, P157, DOI 10.1016/0006-291X(91)90903-K; VALLARI DS, 1988, BIOCHEM BIOPH RES CO, V156, P1, DOI 10.1016/S0006-291X(88)80797-6; VANCE DE, 1989, PHOSPHATIDYLCHOLINE, P225; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1982, BIOCHEMISTRY-US, V21, P2753, DOI 10.1021/bi00540a027; VOGLER WR, 1991, LIPIDS, V26, P1418, DOI 10.1007/BF02536579; VOGLER WR, 1985, EXP HEMATOL, V13, P629; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WESTPHAL O, 1987, LIPIDS, V22, P787, DOI 10.1007/BF02535532; WIEDER T, 1993, BIOCHEM J, V291, P561, DOI 10.1042/bj2910561; WIEDER T, 1995, LIPIDS, V30, P389, DOI 10.1007/BF02536296; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951; ZHOU X, 1995, EUR J BIOCHEM, V232, P881, DOI 10.1111/j.1432-1033.1995.881zz.x; Zhou X, 1997, BIOCHEM J, V324, P897, DOI 10.1042/bj3240897; ZOELLER RA, 1995, J LIPID RES, V36, P1866	64	102	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2169	2173		10.1074/jbc.273.4.2169	http://dx.doi.org/10.1074/jbc.273.4.2169			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442058	hybrid			2022-12-25	WOS:000071595200047
J	Srivastava, SP; Kumar, KU; Kaufman, RJ				Srivastava, SP; Kumar, KU; Kaufman, RJ			Phosphorylation of eukaryotic translation initiation factor 2 mediates apoptosis in response to activation of the double-stranded RNA-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; MALIGNANT TRANSFORMATION; FACTOR-II; SIGNAL-TRANSDUCTION; MESSENGER-RNAS; P68 KINASE; 3T3 CELLS; INTERFERON; PKR	The interferon-inducible, double-stranded (ds) RNA-dependent serine/threonine protein kinase (PKR) plays a role in viral pathogenesis, cell growth, and differentiation and is implicated as a tumor suppressor gene. Expression of a trans-dominant negative, catalytically inactive mutant PKR protected NIH3T3 cells from apoptosis in response to either treatment with tumor necrosis factor alpha (TNF alpha), serum deprivation. In cells expressing mutant PKR, TNF alpha, but not dsRNA induced transcription from a nuclear factor kappa B-dependent promoter, demonstrating specificity for dsRNA in signaling through the PKR pathway. Serum or platelet-derived growth factor addition to serum-deprived mutant PI(R-expressing cells induced transcription of the early response genes c-fos and c-jun, indicating that the immediate early response signaling was intact. Overexpression of wild-type PKR in a transient DNA transfection system was sufficient to induce apoptosis. TNF alpha-induced apoptosis correlated with increased phosphorylation of the alpha subunit of eukaryotic translation initiation factor 2 (eIF-2 alpha), the primary physiological substrate of the PKR Furthermore, forced expression of a nonphosphorylatable S51A mutant eIF-2 alpha partially protected cells from TNF alpha-induced apoptosis, and expression of a S51D mutant eIF-2 alpha, a mutant that mimics phosphorylated eIF-2 alpha, was sufficient to induce apoptosis. Taken together, these studies identify a novel requirement for PKR in stress-induced apoptosis that is mediated through eIF-2 alpha phosphorylation.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA.							ANTWERP DJV, 1996, SCIENCE, V274, P787; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Brostrom CO, 1996, J BIOL CHEM, V271, P24995, DOI 10.1074/jbc.271.40.24995; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Hinnebusch A.G., 1996, TRANSLATIONAL CONTRO, P199; HOVANESSIAN AG, 1993, SEMIN VIROL, V4, P237, DOI 10.1006/smvy.1993.1020; HUISMANS H, 1976, VIROLOGY, V70, P411, DOI 10.1016/0042-6822(76)90282-8; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; LANGLAND JO, 1994, J VIROL, V68, P3821, DOI 10.1128/JVI.68.6.3821-3829.1994; Lee SB, 1997, VIROLOGY, V231, P81, DOI 10.1006/viro.1997.8494; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEE TG, 1994, MOL CELL BIOL, V14, P2331, DOI 10.1128/MCB.14.4.2331; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; LLOYD RM, 1992, J VIROL, V66, P6878, DOI 10.1128/JVI.66.12.6878-6884.1992; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; Melville MW, 1997, P NATL ACAD SCI USA, V94, P97, DOI 10.1073/pnas.94.1.97; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PERKINS ND, 1992, P NATL ACAD SCI USA, V89, P1529, DOI 10.1073/pnas.89.5.1529; PETRYSHYN R, 1984, J BIOL CHEM, V259, P4736; PETRYSHYN R, 1988, P NATL ACAD SCI USA, V85, P1427, DOI 10.1073/pnas.85.5.1427; PROTSKO CR, 1995, J BIOL CHEM, V270, P6211; RAMAIAH KVA, 1994, MOL CELL BIOL, V14, P4546, DOI 10.1128/MCB.14.7.4546; SAFER B, 1983, CELL, V33, P7, DOI 10.1016/0092-8674(83)90326-4; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SRIVASTAVA SP, 1995, J BIOL CHEM, V270, P16619, DOI 10.1074/jbc.270.28.16619; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Takizawa T, 1996, J VIROL, V70, P8128, DOI 10.1128/JVI.70.11.8128-8132.1996; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WARING P, 1990, J BIOL CHEM, V265, P14476; WILLIAMS BRG, 1995, SEMIN VIROL, V6, P191, DOI 10.1006/smvy.1995.0024; Wong GHW, 1992, TUMOR NECROSIS FACTO, P371; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; ZINN K, 1988, SCIENCE, V240, P210, DOI 10.1126/science.3281258	70	315	325	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2416	2423		10.1074/jbc.273.4.2416	http://dx.doi.org/10.1074/jbc.273.4.2416			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442091	hybrid			2022-12-25	WOS:000071595200080
J	Banuelos, MA; Rodriguez-Navarro, A				Banuelos, MA; Rodriguez-Navarro, A			P-type ATPases mediate sodium and potassium effluxes in Schwanniomyces occidentalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; NA+/H+-ANTIPORTER GENE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL EXPRESSION; HETEROSIGMA-AKASHIWO; YEAST; PURIFICATION; TRANSPORT; TOLERANCE	Two genes isolated from Schwanniomyces occidentalis, ENA1 and ENA2, encode P-type ATPases highly homologous to the Na-ATPases of Saccharomyces cerevisiae and complement the Na+ sensitivity of an S. cerevisiae mutant strain lacking its own Na-ATPases. The expression of both ENA1 and ENA2 was highly dependent on a high external pH, but whereas a high pH was sufficient for the expression of ENA2, the expression of ENA1 required a high pH and the presence of Na+. Disruption of ENA1 rendered the cells less tolerant to Na+ than the wild-type strain and decreased their capacity for Na+ extrusion. Disruption of ENA2 did not affect Na+ tolerance, but decreased both the growth at high pH and K+ efflux. We discuss these results and propose that fungal Na-ATPases should be considered alkali cation ATPases. By sequence comparison, we found that fungal Na-ATPases form a homogeneous group that can be distinguished from other cation-pumping P-type ATPases, except from the cta3 Ca-ATPase of Schizosaccharomyces pombe.	Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain	Universidad Politecnica de Madrid	Rodriguez-Navarro, A (corresponding author), Univ Politecn Madrid, Escuela Tecn Super Ingn Agron, Dept Biotecnol, E-28040 Madrid, Spain.	arodrignavar@bit.etsia.upm.es	Rodriguez-Navarro, Alonso/AAB-4574-2019	Rodriguez-Navarro, Alonso/0000-0003-0462-223X; BANUELOS BERNABE, MARIA ANTONIA/0000-0002-0924-754X				BANUELOS MA, 1995, EMBO J, V14, P3021, DOI 10.1002/j.1460-2075.1995.tb07304.x; BANUELOS MA, 1995, BBA-BIOENERGETICS, V1229, P233, DOI 10.1016/0005-2728(95)00006-5; Benito B, 1997, BBA-BIOMEMBRANES, V1328, P214, DOI 10.1016/S0005-2736(97)00098-9; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRUNELLI JP, 1993, YEAST, V9, P1309, DOI 10.1002/yea.320091204; Camarasa C, 1996, YEAST, V12, P1301, DOI 10.1002/(SICI)1097-0061(199610)12:13<1301::AID-YEA18>3.0.CO;2-A; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CLAROS MG, 1993, CURR GENET, V24, P75, DOI 10.1007/BF00324668; DEIBEL MR, 1988, PREP BIOCHEM, V18, P77, DOI 10.1080/00327488808062514; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Dibrov P, 1997, FEBS LETT, V405, P119, DOI 10.1016/S0014-5793(97)00169-5; FAGAN MJ, 1994, J MOL EVOL, V38, P57; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GARCIADEBLAS B, 1993, MOL GEN GENET, V236, P363, DOI 10.1007/BF00277134; GHISLAIN M, 1990, J BIOL CHEM, V265, P18400; Hahnenberger KM, 1996, P NATL ACAD SCI USA, V93, P5031, DOI 10.1073/pnas.93.10.5031; HARO R, 1991, FEBS LETT, V291, P189, DOI 10.1016/0014-5793(91)81280-L; HARO R, 1993, PHYSIOL PLANTARUM, V89, P868, DOI 10.1111/j.1399-3054.1993.tb05298.x; JIA ZP, 1992, EMBO J, V11, P1631, DOI 10.1002/j.1460-2075.1992.tb05209.x; KLEIN RD, 1988, J BACTERIOL, V170, P5572, DOI 10.1128/jb.170.12.5572-5578.1988; KLEIN RD, 1988, CURR GENET, V13, P29, DOI 10.1007/BF00365753; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MORQUEZ JA, 1996, FEBS LETT, V382, P89; ORTEGA MD, 1985, Z NATURFORSCH C, V40, P721; PHAFF HJ, 1984, YEAST TAXONOMIC STUD, P379; Prior C, 1996, FEBS LETT, V387, P89, DOI 10.1016/0014-5793(96)00470-X; Ramirez J, 1996, BBA-BIOMEMBRANES, V1285, P175, DOI 10.1016/S0005-2736(96)00153-8; RODRIGUEZNAVARRO A, 1981, BIOCHIM BIOPHYS ACTA, V640, P352, DOI 10.1016/0005-2736(81)90558-7; RODRIGUEZNAVARRO A, 1994, BBA-BIOENERGETICS, V1187, P203, DOI 10.1016/0005-2728(94)90111-2; RODRIGUEZNAVARRO A, 1984, J BACTERIOL, V159, P940; ROOMANS GM, 1977, BIOCHIM BIOPHYS ACTA, V467, P65, DOI 10.1016/0005-2736(77)90242-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULDINER S, 1993, ALKALI CATION TRANSP, P25; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; SHONO M, 1995, PLANT PHYSIOL, V108, P1615, DOI 10.1104/pp.108.4.1615; VERSAW WK, 1995, P NATL ACAD SCI USA, V92, P3884, DOI 10.1073/pnas.92.9.3884; WADA M, 1989, PLANT CELL PHYSIOL, V30, P923, DOI 10.1093/oxfordjournals.pcp.a077826; WATANABE Y, 1995, YEAST, V11, P829, DOI 10.1002/yea.320110905; WIELAND J, 1995, EMBO J, V14, P3870, DOI 10.1002/j.1460-2075.1995.tb00059.x; YARROW D, 1984, YEASTS TAXONOMIC STU, P379; Yarrow D, 1984, YEASTS TAXONOMIC STU, P414	44	49	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1640	1646		10.1074/jbc.273.3.1640	http://dx.doi.org/10.1074/jbc.273.3.1640			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430707	hybrid			2022-12-25	WOS:000071411500054
J	Caumont, AS; Galas, MC; Vitale, N; Aunis, D; Bader, MF				Caumont, AS; Galas, MC; Vitale, N; Aunis, D; Bader, MF			Regulated exocytosis in chromaffin cells - Translocation of ARF6 stlmulates a plasma membrane-associated phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PHOSPHATIDIC-ACID; G-PROTEINS; CATECHOLAMINE SECRETION; SYNTHETIC PEPTIDE; BINDING PROTEINS; CHOLERA-TOXIN; BREFELDIN-A; PC12 CELLS; ACTIVATION	The ADP-ribosylation factor (ARF) GTP-binding proteins have been implicated in a wide range of vesicle transport and fusion steps along the secretory pathway. In chromaffin cells, ARF6 is specifically associated with the membrane of secretory chromaffin granules, Since ARF6 is an established regulator of phospholipase D (PLD), we have examined the intracellular distribution of ARF6 and PLD activity in resting and stimulated chromaffin cells. We found that stimulation of intact chromaffin cells or direct elevation of cytosolic calcium in permeabilized cells triggered the rapid translocation of ARF6 from secretory granules to the plasma membrane and the concomitant activation of PLD in the plasma membrane. To probe the existence of an ARF6-dependent PLD in chromaffin cells, we measured the PLD activity in purified plasma membranes. PLD could be activated by a nonhydrolyzable analogue of GTP and by recombinant myristoylated ARF6 and inhibited by specific anti-ARF6 antibodies, Furthermore, a synthetic myristoylated peptide corresponding to the N-terminal domain of ARF6 inhibited both PLD activity and catecholamine secretion in calcium-stimulated chromaffin cells. The possibility that ARF6 participates in the exocytotic reaction by controlling a plasma membrane-bound PLD and thereby generating fusogenic lipids at the exocytotic sites is discussed.	INSERM, U338, F-67084 Strasbourg, France; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20814 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Bader, MF (corresponding author), INSERM, U338, 5 Rue Blaise Pascal, F-67084 Strasbourg, France.	bader@neurochem.u-strasbg.fr	Bader, Marie-France/O-2098-2016; Dominique, Aunis/W-1419-2019; Galas, Marie-Christine/AAL-9812-2020; Vitale, Nicolas/G-5967-2014	Vitale, Nicolas/0000-0002-4752-4907; Galas, Marie-Christine/0000-0002-3766-7103				BADER MF, 1989, J BIOL CHEM, V264, P16426; BARRFA, 1996, FEBS LETT, V384, P6; BLACKWOOD RA, 1990, BIOCHEM J, V266, P195, DOI 10.1042/bj2660195; Blackwood RA, 1997, AM J PHYSIOL-CELL PH, V272, pC1279, DOI 10.1152/ajpcell.1997.272.4.C1279; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Calakos N, 1996, PHYSIOL REV, V76, P1; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; ChasserotGolaz S, 1996, J CELL BIOL, V133, P1217, DOI 10.1083/jcb.133.6.1217; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COLOMBO MI, 1995, J BIOL CHEM, V270, P24564, DOI 10.1074/jbc.270.41.24564; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; EXTON JH, 1990, J BIOL CHEM, V265, P1; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GARCIA MD, 1992, J NEUROCHEM, V59, P2244; Gasman S, 1997, J BIOL CHEM, V272, P20564, DOI 10.1074/jbc.272.33.20564; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HAY JC, 1995, NATURE, V374, P172; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KANOH H, 1992, J NEUROCHEM, V59, P1786, DOI 10.1111/j.1471-4159.1992.tb11011.x; KOBAYASHI M, 1987, J NEUROCHEM, V48, P1597, DOI 10.1111/j.1471-4159.1987.tb05707.x; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; MEERS P, 1993, BIOCHIM BIOPHYS ACTA, V1147, P1177; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MORGAN A, 1993, FEBS LETT, V329, P121, DOI 10.1016/0014-5793(93)80206-A; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; OKAMURA S, 1994, J BIOL CHEM, V269, P31207; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PURKISS J, 1991, J NEUROCHEM, V57, P1084, DOI 10.1111/j.1471-4159.1991.tb08262.x; RUPNIK M, 1995, NEUROREPORT, V6, P853, DOI 10.1097/00001756-199504190-00007; SONTAG JM, 1988, EUR J CELL BIOL, V46, P316; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; Vitale N, 1996, EUR J NEUROSCI, V8, P1275, DOI 10.1111/j.1460-9568.1996.tb01296.x; VITALE N, 1994, J BIOL CHEM, V269, P30293; VITALE N, 1993, J BIOL CHEM, V268, P14715; WELSH CF, 1994, MOL CELL BIOCHEM, V138, P157, DOI 10.1007/BF00928458; Wiedemann C, 1996, EMBO J, V15, P2094, DOI 10.1002/j.1460-2075.1996.tb00563.x	52	144	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1373	1379		10.1074/jbc.273.3.1373	http://dx.doi.org/10.1074/jbc.273.3.1373			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430671	hybrid			2022-12-25	WOS:000071411500018
J	Menotti, E; Henderson, BR; Kuhn, LC				Menotti, E; Henderson, BR; Kuhn, LC			Translational regulation of mRNAs with distinct IRE sequences by iron regulatory proteins 1 and 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING-PROTEIN; FERRITIN MESSENGER-RNA; ERYTHROID 5-AMINOLEVULINATE SYNTHASE; TRANSFERRIN RECEPTOR EXPRESSION; 5' UNTRANSLATED REGION; RESPONSIVE ELEMENT; OXIDATIVE STRESS; NITRIC-OXIDE; CYTOSOLIC PROTEIN; DROSOPHILA-MELANOGASTER	Iron regulatory proteins 1 and 2 (IRP-1, IRP-2) interact with iron-responsive elements (IREs) present in the 5'- or 3'-untranslated regions (UTR) of several mRNAs coding for proteins in iron metabolism, Whereas binding of IRP-1 and -2 to an IRE in the 5'-UTR inhibits mRNA translation in vitro, it has remained unknown whether either endogenous protein is sufficient to control translation in mammalian cells. We analyzed this question by taking advantage of published mutant IREs that are exclusively recognized by either IRP-1 or IRP-2 in vitro. These IREs were inserted into the 5'-UTR of a human growth hormone reporter mRNA, and translational regulation was measured in stably transfected mouse L cells, Cells cultured in iron-rich or -depleted medium were labeled with [S-35]methionine, and secreted growth hormone was immunoprecipitated, IREs with loop sequences specific for IRP-1 (UAGUAC), IRP-2 (CCGAGC), or both proteins (GAGUCG and the wild-type CAGUGC sequence) all mediated translational regulation, in contrast to a control sequence (GCUCCG) that binds neither IRP-1 nor IRP-2, Control experiments excluded IRP-1 binding to the IRP-2-specific sequence in vivo, The present data demonstrate that IRP-1 and IRP-2 can independently function as translational repressors in living cells.,	Swiss Inst Expt Canc Res, Genet Unit, CH-1066 Lausanne, Switzerland	Swiss Institute Experimental Cancer Research	Kuhn, LC (corresponding author), Swiss Inst Expt Canc Res, Genet Unit, 155 Ch Boveresses, CH-1066 Lausanne, Switzerland.	lukas.kuehn@isrec.unil.ch						AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BHASKER CR, 1993, J BIOL CHEM, V268, P12699; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; CAIRO G, 1994, J BIOL CHEM, V269, P6405; CASEY JL, 1988, SCIENCE, V240, P924, DOI 10.1126/science.2452485; CHAN RYY, 1994, EUR J BIOCHEM, V220, P683, DOI 10.1111/j.1432-1033.1994.tb18669.x; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; DERUSSO PA, 1995, J BIOL CHEM, V270, P15451, DOI 10.1074/jbc.270.26.15451; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; GOOSSEN B, 1990, EMBO J, V9, P4127, DOI 10.1002/j.1460-2075.1990.tb07635.x; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gray NK, 1996, P NATL ACAD SCI USA, V93, P4925, DOI 10.1073/pnas.93.10.4925; GUO B, 1995, J BIOL CHEM, V270, P16529, DOI 10.1074/jbc.270.28.16529; GUO B, 1994, J BIOL CHEM, V269, P24252; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENDERSON BR, 1994, J BIOL CHEM, V269, P17481; HENDERSON BR, 1995, J BIOL CHEM, V270, P20509, DOI 10.1074/jbc.270.35.20509; Henderson ER, 1996, J BIOL CHEM, V271, P4900; HENTZE MW, 1987, P NATL ACAD SCI USA, V84, P6730, DOI 10.1073/pnas.84.19.6730; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; KENNEDY MC, 1992, P NATL ACAD SCI USA, V89, P11730, DOI 10.1073/pnas.89.24.11730; KIM HY, 1995, J BIOL CHEM, V270, P4983, DOI 10.1074/jbc.270.10.4983; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOELLER DM, 1989, P NATL ACAD SCI USA, V86, P3574, DOI 10.1073/pnas.86.10.3574; Kohler SA, 1995, J BIOL CHEM, V270, P30781, DOI 10.1074/jbc.270.51.30781; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; KUHN LC, 1989, SCHWEIZ MED WSCHR, V119, P1319; LEIBOLD EA, 1987, J BIOL CHEM, V262, P7335; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LEIBOLD EA, 1992, ANNU REV NUTR, V12, P345, DOI 10.1146/annurev.nu.12.070192.002021; MARTINS EAL, 1995, ARCH BIOCHEM BIOPHYS, V316, P128, DOI 10.1006/abbi.1995.1019; Melefors O, 1996, BIOCHEM BIOPH RES CO, V221, P437, DOI 10.1006/bbrc.1996.0613; MELEFORS O, 1993, J BIOL CHEM, V268, P5974; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1988, CELL, V53, P815, DOI 10.1016/0092-8674(88)90098-0; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1992, BIOMETALS, V5, P131, DOI 10.1007/BF01061319; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; WALDEN WE, 1989, J BIOL CHEM, V264, P13765; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x	55	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1821	1824		10.1074/jbc.273.3.1821	http://dx.doi.org/10.1074/jbc.273.3.1821			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430733	hybrid			2022-12-25	WOS:000071411500080
J	Ramos-Morales, F; Infante, C; Fedriani, C; Bornens, M; Rios, RM				Ramos-Morales, F; Infante, C; Fedriani, C; Bornens, M; Rios, RM			NA14 is a novel nuclear autoantigen with a coiled-coil domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECONDARY-STRUCTURE; MOLECULAR-CLONING; BINDING-PROTEIN; AUTO-ANTIGEN; CDNA; AUTOANTIBODIES; LOCALIZATION	The serum from a patient with Sjogren's syndrome (RM serum) was used to screen a human testis cDNA expression library. A cDNA of 865 base pairs containing the entire coding sequence for a novel protein was isolated. The 14-kDa predicted protein contains an acidic domain (amino acids 6-80) with a high frequency of heptad repeats characteristic of alpha-helices that form dimeric coiled-coil structures and an alkaline carboxyl-terminal domain (amino acids 81-119). It seems to be widely expressed, but its expression level varies depending on tissues. A protein of apparent molecular mass of 14 kDa was immunoprecipitated from cell lysates by the autoimmune serum, and it was recognized by rabbit antibodies raised to a recombinant bacterial fusion pro tein generated from the cDNA clone. Conventional and confocal immunofluorescence microscopy on HeLa and 3T3 cells transiently transfected with a tagged form of the protein showed numerous punctate structures scattered throughout the nucleus. This novel protein has been termed NA14 for Nuclear Autoantigen of 14 kDa.	Univ Sevilla, Fac Biol, Dept Microbiol, E-41080 Seville, Spain; Inst Curie, Sect Rech, CNRS, UMR 144, F-75248 Paris 05, France	University of Sevilla; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Rios, RM (corresponding author), Univ Sevilla, Fac Biol, Dept Microbiol, Apdo 1095, E-41080 Seville, Spain.		rios, rosa m/G-5742-2015; Ramos-Morales, Francisco/C-5734-2008	rios, rosa m/0000-0001-5778-6946; Ramos-Morales, Francisco/0000-0002-1151-4547; Infante, Carlos/0000-0002-6158-9344				ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLASCHEK MA, 1988, SCAND J RHEUMATOL, V17, P291, DOI 10.3109/03009748809098799; BUCKLAND R, 1992, J GEN VIROL, V73, P1703, DOI 10.1099/0022-1317-73-7-1703; CHAMBERS JC, 1985, P NATL ACAD SCI USA, V82, P2115, DOI 10.1073/pnas.82.7.2115; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CUNNINGHAM MW, 1993, CLIN IMMUNOL IMMUNOP, V68, P118, DOI 10.1006/clin.1993.1106; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GE Q, 1992, J CLIN INVEST, V90, P559, DOI 10.1172/JCI115895; Gress TM, 1996, ONCOGENE, V13, P1819; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; ORAND MG, 1992, DEV BIOL, V154, P37, DOI 10.1016/0012-1606(92)90045-I; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; Racevskis J, 1996, CELL GROWTH DIFFER, V7, P271; REEVES WH, 1989, J BIOL CHEM, V264, P5047; RIOS RM, 1994, J CELL BIOL, V125, P997, DOI 10.1083/jcb.125.5.997; RODRIGUEZ JL, 1982, CLIN EXP IMMUNOL, V49, P579; Roe JL, 1997, J BIOL CHEM, V272, P5838, DOI 10.1074/jbc.272.9.5838; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Surette MG, 1996, J BIOL CHEM, V271, P17966, DOI 10.1074/jbc.271.30.17966; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAN EM, 1991, CELL, V67, P841, DOI 10.1016/0092-8674(91)90356-4; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vanVenrooij WJ, 1995, CURR OPIN IMMUNOL, V7, P819, DOI 10.1016/0952-7915(95)80054-9; WICKENS M, 1990, TRENDS BIOCHEM SCI, V15, P277, DOI 10.1016/0968-0004(90)90054-F; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YANEVA M, 1989, J BIOL CHEM, V264, P13407; YANG CH, 1992, J CELL BIOL, V116, P1303, DOI 10.1083/jcb.116.6.1303	37	22	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1634	1639		10.1074/jbc.273.3.1634	http://dx.doi.org/10.1074/jbc.273.3.1634			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430706	hybrid			2022-12-25	WOS:000071411500053
J	Tanaka, S; Hanafusa, H				Tanaka, S; Hanafusa, H			Guanine-nucleotide exchange protein C3G activates JNK1 by a Ras-independent mechanism - JNK1 activation inhibited by kinase negative forms of MLK3 and DLK mixed lineage kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER-BEARING KINASE; C-JUN; SIGNAL-TRANSDUCTION; PATHWAY; IDENTIFICATION; DOMAIN; CDC42; PHOSPHORYLATION; GTPASES; CLONING	Recently we have reported that the adaptor protein Crk transmits signals to c-Jun kinase (JNK) through C3G, a guanine-nucleotide exchange protein for the Ras family of small G proteins. Transient expression of C3G in 293T cells induced JNK1 activation without a significant effect on extracellular signal-related kinase 1 (ERK1), whereas mSos1 activated equally both JNK1 and ERK1. Coexpression of the dominant negative form of Ras-N17 did not suppress C3G-induced JNK1 activation but reduced the activity of JNK1 induced by mSos1, suggesting that Res is not required for JNK activation by C3G. Ras-independent activation of JNK: was supported by the finding that C3G-induced JNK activation was not inhibited by the dominant negative forms of Rac or Pak, which are components of the signaling pathway from Ras leading to JNK activation. In contrast, C3G-induced JNK1 activation was strongly inhibited by coexpression of the kinase negative forms of the mixed lineage kinase (MLK) family of proteins, MLK3 and dual leucine zipper kinase (DLK). In addition, MLK3-induced JNK1 activation was found to be suppressed by the kinase negative form of DLK, which bound to MLK3. These results suggest that C3G activates JNK1 through a pathway involving the MLK family of proteins.	Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA	Rockefeller University	Hanafusa, H (corresponding author), Rockefeller Univ, Mol Oncol Lab, Box 169,1230 York Ave, New York, NY 10021 USA.	saburo@rockvax.rockefeller.edu	Tanaka, Shinya/D-3586-2011		NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3; EZOE K, 1994, ONCOGENE, V9, P935; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATOH M, 1995, ONCOGENE, V10, P1447; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ONG YL, 1994, ONCOGENE, V9, P1745; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; YAN MH, 1994, NATURE, V372, P798	31	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1281	1284		10.1074/jbc.273.3.1281	http://dx.doi.org/10.1074/jbc.273.3.1281			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430657	hybrid			2022-12-25	WOS:000071411500004
J	Bai, G; Norton, DD; Prenger, MS; Kusiak, JW				Bai, G; Norton, DD; Prenger, MS; Kusiak, JW			Single-stranded DNA-binding proteins and neuron-restrictive silencer factor participate in cell-specific transcriptional control of the NMDAR1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; SUBUNIT GENE; RECEPTOR; PROMOTER; IDENTIFICATION; EXPRESSION; ELEMENT; REGION; CLONING; REPRESSOR	Our previous studies revealed that a proximal region of the N-methyl-D-aspartate receptor I (NMDAR1) promoter is important for cell-type-specific expression. We have now explored the contributions of several regulatory elements to this specificity, Deletion of the neuron restrictive silencer element partially relieved the suppression of promoter activity in C6 glioma and HeLa cells. An overlapping G(C/G)G/tandem Sp1-containing region crucial for both basal and nerve growth factor (NGF)-regulated promoter activity specifically bound nuclear proteins on its purine-rich sense strand. A faster migrating complex, single-stranded binding protein complex 1 (SBPC1), was highly enriched in HeLa cells, whereas a slower migrating complex, SBPC2, was enriched in PC12 cells. A high ratio of 2/1 complex correlated with a high level of promoter activity. NGF treatment of PC12 cells reduced SBPC1 but increased SBPC2. Competition experiments showed that the SBPC1 binding required a dG(4) sequence and the SBPC2 needed a core of TG(3)A plus a 5'-flanking sequence. Single-stranded DNA encompassing TG(3)A and/or dG(4) specifically suppressed cotransfected NMDAR1 promoter activity. UV cross-linking studies indicated that a 31.5-kDa protein mainly formed SBPC1, whereas SBPC1 contained several larger proteins, Our results suggest that neuron-restrictive silencer factor and single-stranded DNA-binding proteins may both play a role in cell-type specificity of the NMDAR1 gene, and the latter may also be involved in basal and NGF-regulated activity.	NIA, Mol Neurobiol Unit, Ctr Gerontol Res, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bai, G (corresponding author), Brigham & Womens Hosp, CNS Res Inst, LMRC, Rm LM111,221 Longwood Ave, Boston, MA 02115 USA.	gbai@rics.bhw.harvard.edu						ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; ALTIOK S, 1994, MOL CELL BIOL, V14, P6004, DOI 10.1128/MCB.14.9.6004; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; BILAK SR, 1995, SYNAPSE, V20, P257, DOI 10.1002/syn.890200310; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROSE N, 1993, J BIOL CHEM, V268, P22663; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GROSSMANN ME, 1995, J BIOL CHEM, V270, P10968, DOI 10.1074/jbc.270.18.10968; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MATTERSADZINSKI L, 1992, EMBO J, V11, P4529, DOI 10.1002/j.1460-2075.1992.tb05554.x; MICHELOTTI EF, 1995, J BIOL CHEM, V270, P9494, DOI 10.1074/jbc.270.16.9494; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NEGISHI Y, 1994, ONCOGENE, V9, P1133; PAN WT, 1990, J BIOL CHEM, V265, P7022; PETRALIA RS, 1994, J NEUROSCI, V14, P667; RAJAVASHISTH TB, 1989, SCIENCE, V245, P640, DOI 10.1126/science.2562787; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SCHOENHERR CJ, 1995, CURR OPIN NEUROBIOL, V5, P566, DOI 10.1016/0959-4388(95)80060-3; SOMMER B, 1990, DNA CELL BIOL, V9, P561, DOI 10.1089/dna.1990.9.561; Taira E, 1997, J NEUROCHEM, V68, P2255; Tomonaga T, 1996, P NATL ACAD SCI USA, V93, P5830, DOI 10.1073/pnas.93.12.5830; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; WANG ZY, 1993, J BIOL CHEM, V268, P10681; WILKISON WO, 1990, J BIOL CHEM, V265, P477	42	51	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1086	1091		10.1074/jbc.273.2.1086	http://dx.doi.org/10.1074/jbc.273.2.1086			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422773	hybrid			2022-12-25	WOS:000071411400062
J	Ikeda, M; Ishida, O; Hinoi, T; Kishida, S; Kikuchi, A				Ikeda, M; Ishida, O; Hinoi, T; Kishida, S; Kikuchi, A			Identification and characterization of a novel protein interacting with Ral-binding protein 1, a putative effector protein of Ral	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE DISSOCIATION STIMULATOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE SUBSTRATE; SRC HOMOLOGY-3 DOMAINS; ACTIN CYTOSKELETON; ASSOCIATION; SEQUENCES; P21; TRANSFORMATION; ORGANIZATION	Ral-binding protein 1 (RalBP1) is a putative effector protein of Ral and exhibits a GTPase activating activity for Rac and CDC42. To clarify the function of RalBP1, we isolated a novel protein that interacts with RalBP1 by yeast two-hybrid screening and designated it POB1 (partner of RalBP1), POB1 consists of 521 amino acids, shares a homology with Eps15, which has been identified as an epidermal growth factor (EGF) receptor substrate, and has two proline-rich motifs. The POB1 mRNA was expressed in cerebrum, cerebellum, lung, kidney, and testis, POB1 interacted with BalBP1 in COS cells and the C-terminal region of POB1 was responsible for this interaction, The binding domain of RalBP1 to POB1 was distinct from its binding domain to Ral. Ral and POB1 simultaneously interacted with RalBP1 in COS cells. The binding of POB1 to RalBP1 did not affect the GTPase activating activity of RalBP1, Furthermore, POB1 bound to Grb2 but not to Nck or Crk, POB1 was tyrosine-phosphorylated in COS cells upon stimulation with EGF and made a complex with EGF receptor, These results suggest that RalBP1 makes a complex with POB1 and that this complex may provide a link between tyrosine kinase, Src homology 3 (SH3) containing protein, and Ral.	Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 734, Japan	Hiroshima University	Kikuchi, A (corresponding author), Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 734, Japan.	akikucki@mcai.med.hiroshima-u.ac.jp	Hinoi, Takao/AAI-1443-2020	Hinoi, Takao/0000-0003-0462-6177; kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EMKEY R, 1991, J BIOL CHEM, V266, P9703; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KIKUCHI A, 1992, ONCOGENE, V7, P289; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KISHIDA S, 1997, IN PRESS ONCOGENE, V15; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee T, 1996, DEVELOPMENT, V122, P409; Maniatis T., 1982, MOL CLONING LAB MANU; Mark BL, 1996, BIOCHEM BIOPH RES CO, V225, P40, DOI 10.1006/bbrc.1996.1128; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; MIKI H, 1994, J BIOL CHEM, V269, P5489; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Murai H, 1997, J BIOL CHEM, V272, P10483; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Park SH, 1995, ONCOGENE, V11, P2349; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Shimizu K, 1996, J BIOL CHEM, V271, P27013, DOI 10.1074/jbc.271.43.27013; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VOLKNANDT W, 1993, FEBS LETT, V317, P53, DOI 10.1016/0014-5793(93)81490-Q; WATANABE K, 1995, J BIOL CHEM, V270, P13733, DOI 10.1074/jbc.270.23.13733; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	46	126	132	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					814	821		10.1074/jbc.273.2.814	http://dx.doi.org/10.1074/jbc.273.2.814			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422736	hybrid			2022-12-25	WOS:000071411400025
J	Meiner, VL; Welch, CL; Cases, S; Myers, HM; Lusis, HAJ; Farese, RV				Meiner, VL; Welch, CL; Cases, S; Myers, HM; Lusis, HAJ; Farese, RV			Adrenocortical lipid depletion gene (ald) in AKR mice is associated with an acyl-CoA : cholesterol acyltransferase (ACAT) mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE; METABOLISM; COENZYME; CDNA	ald, a recessive allele in AKR inbred mice, is responsible for complete adrenocortical lipid depletion in postpubertal males, which appears to be androgen dependent, Two recent observations (adrenocortical lipid depletion in acyl-CoA:cholesterol acyltransferase-deficient (Acact-/-) mice and the mapping of Acact to a region of chromosome 1 containing the ald locus) prompted us to ask whether adrenocortical lipid depletion in AKR mice results from an Acact mutation, Refined genetic mapping of Acact and ald was consistent with colocalization of these loci, Crossing Acact-/- with AKR (ald/ald) mice yielded postpubertal male offspring characterized by adrenocortical lipid depletion, indicating that these loci are not complementational and are therefore allelic, Immunoblotting of preputial gland homogenates demonstrated that AKR mice had an ACAT protein with a lower molecular mass than other mouse strains, Analysis of Acact cDNA from AKR mice revealed a deletion of the first coding exon and two missense mutations, Despite these coding sequence differences, the ACAT protein from the ald allele catalyzed cholesterol esterification activity at levels similar to that of wild-type protein, We speculate that the adrenocortical lipid depletion resulting from the ald mutation is caused by an altered susceptibility of the mutant protein to modifying factors, such as androgen production at puberty, in an as yet undetermined manner.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif Los Angeles, Dept Microbiol & Mol Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Farese, RV (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	bob_farese.gicd@quickmail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042488, P01HL030568, R37HL042488] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42488, HL30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARNESEN K, 1955, ACTA ENDOCRINOL-COP, V18, P396, DOI 10.1530/acta.0.0180396; ARNESEN K, 1964, ACTA PATHOL MIC SC, V60, P487, DOI 10.1111/apm.1964.60.4.487; Arnesen K, 1974, Acta Pathol Microbiol Scand Suppl, VSuppl 248, P15; ARNESEN K, 1963, ACTA PATHOL MIC SC, V58, P212; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG TY, 1983, ENZYMES, V16, P523; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COALSON RE, 1981, STAINING PROCEDURES, P228; DIETRICH W, 1992, GENETICS, V131, P423; DOERING CH, 1973, BIOCHEM GENET, V8, P101, DOI 10.1007/BF00485560; ERICKSON SK, 1980, J LIPID RES, V21, P930; GOODMAN DS, 1965, PHYSIOL REV, V45, P747, DOI 10.1152/physrev.1965.45.4.747; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI DOI 10.1083/JCB.108.2.229; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MEINER V, IN PRESS J LIPID RES; Meiner VL, 1996, P NATL ACAD SCI USA, V93, P14041, DOI 10.1073/pnas.93.24.14041; MOLNE K, 1968, ACTA PATHOL MIC SC, V72, P478; Pitas R.E., 1992, LIPOPROTEIN ANAL PRA, P215; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Reue K, 1996, J LIPID RES, V37, P1387; SUCKLING KE, 1985, J LIPID RES, V26, P647; TAYLOR BA, 1975, GENET RES, V26, P307, DOI 10.1017/S0016672300016104; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; WARDEN CH, 1993, GENOMICS, V18, P295, DOI 10.1006/geno.1993.1469; Welch CL, 1996, J LIPID RES, V37, P1406	28	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1064	1069		10.1074/jbc.273.2.1064	http://dx.doi.org/10.1074/jbc.273.2.1064			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422770	hybrid			2022-12-25	WOS:000071411400059
J	Migita, CT; Matera, KM; Ikeda-Saito, M; Olson, JS; Fujii, H; Yoshimura, T; Zhou, H; Yoshida, T				Migita, CT; Matera, KM; Ikeda-Saito, M; Olson, JS; Fujii, H; Yoshimura, T; Zhou, H; Yoshida, T			The oxygen and carbon monoxide reactions of heme oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; CATALYTIC SITE; LIGAND-BINDING; COMPLEX; DEGRADATION; PURIFICATION; HISTIDINE-25; MECHANISMS; MICROSOMES; VERDOHEME	The O(2) and CO reactions with the heme, alpha-hydroxyheme, and verdoheme complexes of heme oxygenase have been studied, The heme complexes of heme oxygenase isoforms-1 and -2 have similar O(2) and CO binding properties. The O(2) affinities are very high, KO(2) = 30-80 mu M(-1), which is 30-90-fold greater than those of mammalian myoglobins, The O(2) association rate constants are similar to those for myoglobins (k(O2)', = 7-20 mu M(-1) s(-1)), whereas the O(2) dissociation rates are remarkably slow (k(O2) = 0.25 s(-1)), implying the presence of very favorable interactions between bound O(2) and protein residues in the heme pocket, The CO affinities estimated for both isoforms are only 1-6-fold higher than the corresponding O(2) affinities. Thus, heme oxygenase discriminates much more strongly against CO binding than either myoglobin or hemoglobin. The CO binding reactions with the ferrous alpha-hydroxyheme complex are similar to those of the protoheme complex, and hydroxylation at the alpha-meso position does not appear to affect the reactivity of the iron atom. In contrast, the CO affinities of the verdoheme complexes are >10,000 times weaker than those of the heme complexes because of a 100-fold slower association rate constant (k(CO)' approximate to 0.004 mu M(-1) s(-1)) and a 300-fold greater dissociation rate constant (k(CO) approximate to 3 s(-1)) compared with the corresponding rate constants of the protoheme and alpha-hydroxyheme complexes, positive charge on the verdoporphyrin ring causes a large decrease in reactivity of the iron.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA; Yamagata Technopolis Fdn, Inst Life Support Technol, Yamagata 990, Japan; Yamagata Univ, Sch Med, Dept Biochem, Yamagata 99023, Japan; Yamaguchi Univ, Sch Allied Hlth Sci, Yamaguchi 755, Japan	Case Western Reserve University; Rice University; Rice University; Yamagata University; Yamaguchi University	Ikeda-Saito, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA.		Ikeda-Saito, Masao/K-2703-2015; Ikeda-Saito, Masao/A-5992-2008	Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051588, R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIGMS NIH HHS [GM51588, GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E, 1971, HEMOGLOBINS MYOGLOBI; BALCH AL, 1993, J AM CHEM SOC, V115, P1422, DOI 10.1021/ja00057a027; CARVER TE, 1990, J BIOL CHEM, V265, P20007; FUJII H, 1990, THESIS KYOTO U KYOTO; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HERNANDEZ G, 1994, BIOCHEMISTRY-US, V33, P6631, DOI 10.1021/bi00187a033; Ikeda-Saito M, 1998, KEIO UNIV SYMP LIFE, V1, P304; ISHIKAWA K, 1995, J BIOL CHEM, V270, P6345, DOI 10.1074/jbc.270.11.6345; ITOMAKI M, 1995, ARCH BIOCHEM BIOPHYS, V317, P253, DOI 10.1006/abbi.1995.1160; KIKUCHI G, 1980, TRENDS BIOCHEM SCI, V5, P323, DOI 10.1016/0968-0004(80)90141-3; LIGHT WR, 1987, J BIOL CHEM, V262, P46; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matera KM, 1996, J BIOL CHEM, V271, P6618, DOI 10.1074/jbc.271.12.6618; Matera KM, 1997, BIOCHEMISTRY-US, V36, P4909, DOI 10.1021/bi962321m; NOGUCHI M, 1981, J BIOCHEM-TOKYO, V90, P1671, DOI 10.1093/oxfordjournals.jbchem.a133642; ROHLFS RJ, 1990, J BIOL CHEM, V265, P3168; SONO M, 1976, J BIOL CHEM, V251, P1418; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SUN J, 1994, BIOCHEMISTRY-US, V33, P13734, DOI 10.1021/bi00250a026; Takahashi S, 1997, BIOCHEMISTRY-US, V36, P1402, DOI 10.1021/bi962361q; TAKAHASHI S, 1994, J BIOL CHEM, V269, P1010; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; YOSHIDA T, 1978, J BIOL CHEM, V253, P4230; YOSHIDA T, 1980, J BIOL CHEM, V255, P4418; YOSHIDA T, 1978, J BIOL CHEM, V253, P4224; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487; YOSHIDA T, 1982, J BIOL CHEM, V257, P9345; YOSHIDA T, 1980, J BIOCHEM-TOKYO, V88, P557, DOI 10.1093/oxfordjournals.jbchem.a133003	30	68	71	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					945	949		10.1074/jbc.273.2.945	http://dx.doi.org/10.1074/jbc.273.2.945			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422754	hybrid			2022-12-25	WOS:000071411400043
J	Zucker, S; Drews, M; Conner, C; Foda, HD; DeClerck, YA; Langley, KE; Bahou, WF; Docherty, AJP; Cao, J				Zucker, S; Drews, M; Conner, C; Foda, HD; DeClerck, YA; Langley, KE; Bahou, WF; Docherty, AJP; Cao, J			Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1 matrix metalloproteinase 1 (MT1-MMP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; C-TERMINAL DOMAIN; PRO-GELATINASE-A; PROGELATINASE-A; AUTOPROTEOLYTIC ACTIVATION; DEPENDENT MECHANISM; 72-KDA GELATINASE; IV COLLAGENASE; MT-MMP; FIBROBLASTS	It has been proposed that tissue inhibitor of metalloproteinase-2 (TIMP-2), in stoichiometric concentrations, serves as an intermediate in progelatinase A activation by binding to activated membrane type 1-matrix metalloproteinase 1 (MT1-MMP) on the plasma membrane, An MT1-MMP-independent cell surface receptor for TIMP-2 has also been postulated. To clarify TIMP-2 binding, we have performed I-125-TIMP-2 binding studies on transfected COS-1 cells and endothelial cells. Specific receptors for TIMP-2 were identified on COS-1 cells transfected with MT1-MMP cDNA, but not on vector-transfected cells, Treatment of MT1-MMP transfected COS-1 cells with a hydroxamic acid inhibitor of MMPs, CT-1746, but not an inactive stereoisomer, CT-1915, produced dose-dependent inhibition of specific TIMP-2 binding comparable with that noted with excess unlabeled TIMP-2. This result suggests that TIMP-2 binds to the zinc catalytic site of MT1-MMP. As demonstrated by the limited competition for binding of C-terminal deleted TIMP-2, the C-terminal domain of TIMP-2 participates in binding to MT1-MMP. Cross-linking studies fol lowed by immunoprecipitation using antibodies to MT1-MMP were employed to identify I-125-TIMP-2.MT1-MMP complexes in MT1-MMP-transfected COS-1 cell membrane extracts, TIMP-2 receptors were also identified on concanavalin A-treated human umbilical vein endothelial cells; inhibition of TIMP-2 binding with CT-1746 was demonstrated.	Dept Vet Affairs Med Ctr, Dept Med, Northport, NY 11768 USA; Dept Vet Affairs Med Ctr, Dept Res, Northport, NY 11768 USA; Childrens Hosp, Dept Pediat, Div Hematol Oncol, Los Angeles, CA 90027 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90027 USA; Amgen Inc, Thousand Oaks, CA 91320 USA; Celltech Ltd, Slough SL1 4EN, Berks, England	Children's Hospital Los Angeles; University of Southern California; Amgen; Celltech Group Ltd	Zucker, S (corresponding author), Dept Vet Affairs Med Ctr, Dept Med, Mail Code 151, Northport, NY 11768 USA.			DeClerck, Yves/0000-0002-3688-0113	NATIONAL CANCER INSTITUTE [R01CA042919] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049141, K08HL002431] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42919] Funding Source: Medline; NHLBI NIH HHS [HL-02431, HL-49141] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson IC, 1996, CANCER RES, V56, P715; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; EMONARD HP, 1992, CANCER RES, V52, P5845; Foda HD, 1996, LAB INVEST, V74, P538; HANEMAAIJER R, 1993, BIOCHEM J, V296, P803, DOI 10.1042/bj2960803; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; Imai K, 1996, CANCER RES, V56, P2707; Kinoh H, 1996, J CELL SCI, V109, P953; Kinoshita T, 1996, CANCER RES, V56, P2535; Ko YC, 1997, BIOCHEM BIOPH RES CO, V236, P100, DOI 10.1006/bbrc.1997.6859; LELIEVRE Y, 1990, MATRIX, V10, P292, DOI 10.1016/S0934-8832(11)80184-8; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Lichte A, 1996, FEBS LETT, V397, P277, DOI 10.1016/S0014-5793(96)01206-9; MURPHY G, 1992, BIOCHEM J, V283, P637, DOI 10.1042/bj2830637; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1996, FEBS LETT, V385, P238, DOI 10.1016/0014-5793(96)00389-4; Sato H, 1996, J BIOCHEM-TOKYO, V119, P209; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; UNEMORI EN, 1990, J BIOL CHEM, V265, P445; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730; ZUCKER S, 1987, CANCER RES, V47, P1608	39	254	263	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1216	1222		10.1074/jbc.273.2.1216	http://dx.doi.org/10.1074/jbc.273.2.1216			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422789	hybrid			2022-12-25	WOS:000071411400078
J	Filppula, SA; Yagi, AI; Kilpelainen, SH; Novikov, D; FitzPatrick, DR; Vihinen, M; Valle, D; Hiltunen, JK				Filppula, SA; Yagi, AI; Kilpelainen, SH; Novikov, D; FitzPatrick, DR; Vihinen, M; Valle, D; Hiltunen, JK			Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase from rat liver - Molecular characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSATURATED FATTY-ACIDS; PROTEIN SECONDARY STRUCTURE; PEROXISOMAL-BETA-OXIDATION; ENOYL-COA HYDRATASE; COENZYME-A; DELTA(3,5),DELTA(2,4)-DIENOYL-COA ISOMERASE; STRUCTURE PREDICTION; DELTA-3,DELTA-2-ENOYL-COA ISOMERASE; 3-HYDROXYACYL-COA DEHYDROGENASE; 2,4-DIENOYL-COA REDUCTASE	rECH1, a recently identified rat cDNA (FitzPatrick, D. R., Germain-Lee, E., and Valle, D. (1995) Genomics 27, 457-466) encodes a polypeptide belonging to the hydratase/isomerase superfamily, We modeled the structure of rECH1 based on rat mitochondrial 2-enoyl-CoA hydratase 1, The model predicts that rECH1p has the hydratase fold in the core domain and two domains for interaction with other subunits. When we incubated 3,5,8,11,14-eicosapentaenoyl-CoA with purified rECH1p, the spectral data suggested a switching of the double bonds from the Delta(3)-Delta(5) to the Delta(2)-Delta(4) positions. This was confirmed by demonstrating that the product was a valid substrate for 2,4-dienoyl-CoA reductase, These results indicate that rECH1p is Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, Subcellular fractionation and immunoelectron microscopy using antibodies to a synthetic polypeptide derived from the C terminus of rECH1p showed that rECH1p is located in the matrix of both mitochondria and peroxisomes in rat liver, Consistent with these observations, the 36,000-Da rECH1p has a potential N-terminal mitochondrial targeting signal as well as a C-terminal peroxisomal targeting signal type 1, Transport of the protein into the mitochondria with cleavage of the targeting signal results in a mature mitochondrial form with a molecular mass of 32,000 Da; transport to peroxisomes yields a protein of 36,000 Da.	Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90570 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90220 Oulu, Finland; Univ Edinburgh, Mol Med Ctr, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Helsinki, Dept Biosci, Div Biochem, FIN-00014 Helsinki, Finland; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; University of Oulu; University of Edinburgh; University of Helsinki; Howard Hughes Medical Institute; Johns Hopkins University	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, FIN-90570 Oulu, Finland.		FitzPatrick, David R/C-7301-2013; FitzPatrick, David R/B-8311-2008; Vihinen, Mauno/A-8452-2012	Vihinen, Mauno/0000-0002-9614-7976; FitzPatrick, David R./0000-0003-4861-969X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD010981] Funding Source: NIH RePORTER; NICHD NIH HHS [HD10981] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P404; Ashmarina LI, 1996, BIOCHEM J, V315, P71, DOI 10.1042/bj3150071; BABBITT PC, 1992, BIOCHEMISTRY-US, V31, P5594, DOI 10.1021/bi00139a024; Benning MM, 1996, BIOCHEMISTRY-US, V35, P8103, DOI 10.1021/bi960768p; BERNSTEIN FC, 1977, J MOL BIOL, V112, P586; CHEN LS, 1994, BIOCHEMISTRY-US, V33, P10527, DOI 10.1021/bi00200a039; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CUEBAS D, 1982, J BIOL CHEM, V257, P4140; Danpure CJ, 1997, BIOESSAYS, V19, P317, DOI 10.1002/bies.950190409; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOMMES V, 1984, J BIOL CHEM, V259, P1781; Engel CK, 1996, EMBO J, V15, P5135, DOI 10.1002/j.1460-2075.1996.tb00897.x; FAHL WE, 1983, BIOCHEM J, V210, P876; FITZPATRICK DR, 1995, GENOMICS, V27, P457, DOI 10.1006/geno.1995.1077; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; HAKKOLA EH, 1993, EUR J BIOCHEM, V215, P1999; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HILTUNEN JK, 1983, BIOCHIM BIOPHYS ACTA, V752, P223, DOI 10.1016/0005-2760(83)90116-9; Hiltunen JK, 1996, ANN NY ACAD SCI, V804, P116, DOI 10.1111/j.1749-6632.1996.tb18612.x; HIROSE A, 1990, BIOCHIM BIOPHYS ACTA, V1049, P346, DOI 10.1016/0167-4781(90)90109-F; HOVIK R, 1987, BIOCHEM J, V247, P531, DOI 10.1042/bj2470531; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUO MJ, 1994, J BIOL CHEM, V269, P2384; LUTHRIA DL, 1995, J BIOL CHEM, V270, P13771, DOI 10.1074/jbc.270.23.13771; MALILA LH, 1993, J BIOL CHEM, V268, P21578; MENDISHANDAGAMA SMLC, 1990, J ANDROL, V11, P270; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; MULLERNEWEN G, 1991, BIOL CHEM H-S, V372, P613, DOI 10.1515/bchm3.1991.372.2.613; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PALOSAARI PM, 1991, J BIOL CHEM, V266, P10750; PALOSAARI PM, 1990, J BIOL CHEM, V265, P3347; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; ROE CR, 1990, J CLIN INVEST, V85, P1703, DOI 10.1172/JCI114624; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; Rost B, 1996, METHOD ENZYMOL, V266, P525; SMELAND TE, 1992, P NATL ACAD SCI USA, V89, P6673, DOI 10.1073/pnas.89.15.6673; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOKUYASU KT, 1976, J CELL BIOL, V71, P894, DOI 10.1083/jcb.71.3.894; Tserng KY, 1996, BIOCHEM J, V313, P581, DOI 10.1042/bj3130581; VANHOVE G, 1991, J BIOL CHEM, V266, P24670; VERHEYDEN K, 1992, BIOCHIM BIOPHYS ACTA, V1109, P48, DOI 10.1016/0005-2736(92)90185-O; YANG SY, 1986, J BIOL CHEM, V261, P2238	49	44	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					349	355		10.1074/jbc.273.1.349	http://dx.doi.org/10.1074/jbc.273.1.349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417087	hybrid			2022-12-25	WOS:000071295600053
J	Frank, S; Upender, S; Hansen, SH; Casanova, JE				Frank, S; Upender, S; Hansen, SH; Casanova, JE			ARNO is a guanine nucleotide exchange factor for ADP-ribosylation factor 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST GOLGI-APPARATUS; BREFELDIN-A; BETA-COP; ARF; MEMBRANE; PROTEIN; CELLS; COMPARTMENTS; CONTAINS; HOMOLOGY	ADP-ribosylation factors (ARFs) constitute a family of small monomeric GTPases, ARFs 1 and 3 function in the recruitment of coat proteins to membranes of the Golgi apparatus, whereas ARF6 is localized to the plasma membrane, where it appears to modulate both the assembly of the actin cytoskeleton and endocytosis, Like other GTPases, ARF activation is facilitated by specific guanine nucleotide exchange factors (GEFs). ARNO (ARF nucleotide-binding site opener) is a member of a growing family of ARF-GEFs that share a common, tripartite structure consisting of an N-terminal coiled-coil domain, a central domain with homology to the yeast protein Sec7p, and a C-terminal pleckstrin homology domain, Recently, ARNO and its close homologue cytohesin-1 were found to catalyze in vitro nucleotide exchange on ARF1 and ARF3, respectively, raising the possibility that these GEFs function in the Golgi. However, the actual function of these proteins may be determined in part by their ability to interact with specific ARFs and in part by their subcellular localization. We report here that in vitro ARNO can stimulate nucleotide exchange on both ARF1 and ARF6, Furthermore, based on subcellular fractionation and immunolocalization experiments, we find that ARNO is localized to the plasma membrane in mammalian cells rather than the Golgi. It is therefore likely that ARNO functions in plasma membrane events by modulating the activity of ARF6 in vivo, These findings are consistent with the previous observation that cytohesin-1 regulates the adhesiveness of alpha L beta(2), integrins at the plasma membrane of lymphocytes.	Massachusetts Gen Hosp E, Combined Program Pediat Gastroenterol & Nutr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Program Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Frank, S (corresponding author), Massachusetts Gen Hosp E, Combined Program Pediat Gastroenterol & Nutr, 149 13th St, Charlestown, MA 02129 USA.			Hansen, Steen/0000-0002-9408-4676	NIAID NIH HHS [AI32991] Funding Source: Medline; NIDDK NIH HHS [DK33506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032991, R29AI032991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK033506] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; Cavenagh MM, 1996, J BIOL CHEM, V271, P21767, DOI 10.1074/jbc.271.36.21767; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Deitz SB, 1996, MOL CELL BIOL, V16, P3275; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FRANZUSOFF A, 1989, EMBO J, V8, P2695, DOI 10.1002/j.1460-2075.1989.tb08410.x; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LIU L, 1992, BIOCHIM BIOPHYS ACTA, V1132, P75, DOI 10.1016/0167-4781(92)90055-5; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1996, P NATL ACAD SCI USA, V93, P12856, DOI 10.1073/pnas.93.23.12856; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P342; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TERUI T, 1994, J BIOL CHEM, V269, P28130; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	29	198	205	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					23	27		10.1074/jbc.273.1.23	http://dx.doi.org/10.1074/jbc.273.1.23			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417041	hybrid			2022-12-25	WOS:000071295600007
J	Jones, JM; Welty, DJ; Nakai, H				Jones, JM; Welty, DJ; Nakai, H			Versatile action of Escherichia coli ClpXP as protease or molecular chaperone for bacteriophage Mu transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATIVE TRANSPOSITION; SPECIFICITY COMPONENT; DNA-REPLICATION; IN-VITRO; SEQUENCE; INITIATION; COMPLEX; TRANSPOSOSOMES; PROTEOLYSIS; POLYMERASE	The molecular chaperone ClpX of Escherichia coli plays two distinct functions for bacteriophage Mu DNA replication by transposition, As specificity component of a chaperone-linked protease, it recognizes the Mu immunity repressor for degradation by the peptidase component ClpP, thus derepressing Mu transposition functions, After strand exchange has been promoted by MuA transposase, ClpX alone can alter the conformation of the transpososome (the complex of MuA with Mu ends), and the remodeled MuA promotes transition to replisome assembly, Although ClpXP can degrade MuA, the presence of both ClpP and ClpX in the reconstituted transposition system did not destroy MuA essential for initiation of DNA replication by specific host replication enzymes, Levels of ClpXP needed to overcome inhibition by the repressor did not prevent MuA from promoting strand transfer, and ClpP stimulated alteration of the transpososome by ClpX Apparently intact MuA was still present in the resulting transpososome, promoting initiation of Mu DNA replication by specific replication enzymes, The results indicate that ClpXP can discriminate repressor and MuA in the transpososome as substrates of the protease or the molecular chaperone alone, degrading repressor while remodeling MuA for its next critical function.	Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Nakai, H (corresponding author), Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.				NIGMS NIH HHS [R01 GM49649] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GOTTESMAN S, 1990, J BIOL CHEM, V265, P7886; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KUO CF, 1991, EMBO J, V10, P1585, DOI 10.1002/j.1460-2075.1991.tb07679.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MAURIZI MR, 1990, J BIOL CHEM, V265, P12546; MAURIZI MR, 1990, J BIOL CHEM, V265, P12536; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAI H, 1993, J BIOL CHEM, V268, P23997; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; RESIBOIS A, 1984, PROTEINS INVOLVED DN, P69; ROSS W, 1986, J BACTERIOL, V167, P905, DOI 10.1128/jb.167.3.905-919.1986; Sambrook J., 2002, MOL CLONING LAB MANU; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; TOUSSAINT A, 1974, MOL GEN GENET, V131, P209, DOI 10.1007/BF00267960; TOUSSAINT A, 1983, MOBILE GENETIC ELEME, P105; Vogel JL, 1996, GENETICS, V142, P661; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1989, J BIOL CHEM, V264, P2088; Wu ZG, 1997, J MOL BIOL, V267, P132, DOI 10.1006/jmbi.1996.0854	46	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					459	465		10.1074/jbc.273.1.459	http://dx.doi.org/10.1074/jbc.273.1.459			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417104	hybrid			2022-12-25	WOS:000071295600070
J	Liou, GI; Matragoon, S; Chen, DM; Gao, CL; Zhang, L; Fei, YJ; Katz, ML; Stark, WS				Liou, GI; Matragoon, S; Chen, DM; Gao, CL; Zhang, L; Fei, YJ; Katz, ML; Stark, WS			Visual sensitivity and interphotoreceptor retinoid binding protein in the mouse: regulation by vitamin A	FASEB JOURNAL			English	Article						vitamin A (retinol) deficiency and repletion; IRBP; photoreceptor; electroretinography	PIGMENT-EPITHELIUM; GENE-EXPRESSION; MESSENGER-RNA; BOVINE RETINA; DEPRIVED RATS; PHOTORECEPTOR; LIGHT; IRBP; RHODOPSIN; DROSOPHILA	Interphotoreceptor retinoid binding protein (IRBP) is a retinoid and fatty acid binding glycoprotein secreted by rod and cone photoreceptors in all vertebrates, IRBP is believed to serve as a carrier for retinoids in the bleaching and regeneration cycle of rhodopsin. IRBP protein has been found to be decreased in vitamin A-deprived rats; it is rapidly recovered after retinol repletion, To understand the mechanism for this recovery, we determined whether vitamin A affects transcription and translation of the IRBP gene, Wild-type and transgenic mice harboring the IRBP promoter-CAT reporter fusion gene were maintained on a retinol-deficient diet supplemented with retinoic acid (-A) or on a control diet (+A) for up to 60 wk postweaning, Some of the -A mice were given retinol repletion for 7 days (-A+A), Electroretinography analysis revealed alterations in waveform and a 2 log unit decrease in b-wave sensitivity in the -A mice over a broad range of stimulus wavelengths, Retinol repletion effected a full recovery, Immunochemistry showed a significant decrease in the immunogold-labeled IRBP between the retinal pigment epithelium and the outer segments of the -A mice compared with +A and -A+A mice, Northern blots showed no differences in the amounts of IRBP or CAT mRNA between these three treatment groups, These results suggest that the regulation of IRBP by retinol is not transcriptional.	St Louis Univ, Dept Biol, St Louis, MO 63103 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA; Univ Missouri, Sch Med, Mason Eye Inst, Columbia, MO 65212 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA	Saint Louis University; University System of Georgia; Augusta University; University of Missouri System; University of Missouri Columbia; University System of Georgia; Augusta University	Stark, WS (corresponding author), St Louis Univ, Dept Biol, St Louis, MO 63103 USA.				NEI NIH HHS [EY07192, EY08813, EY03829] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY007192, R01EY003829, R01EY008813] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER AJ, 1991, EXP EYE RES, V53, P337, DOI 10.1016/0014-4835(91)90239-B; ADLER AJ, 1985, J BIOL CHEM, V260, P4850; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; CARTERDAWSON L, 1986, DEV BIOL, V116, P431, DOI 10.1016/0012-1606(86)90144-2; Cochran W.G., 1957, EXPT DESIGN, V2nd ed.; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DONOSO LA, 1990, CURR EYE RES, V9, P357, DOI 10.3109/02713689008999623; DOWLING JE, 1960, P NATL ACAD SCI USA, V46, P587, DOI 10.1073/pnas.46.5.587; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T; Fei Y., 1997, Investigative Ophthalmology and Visual Science, V38, pS699; Fei Y., 1996, Investigative Ophthalmology and Visual Science, V37, pS336; GONZALEZFERNANDEZ F, 1990, J CELL BIOL, V111, P2775, DOI 10.1083/jcb.111.6.2775; HAUSWIRTH WW, 1992, EXP EYE RES, V54, P661, DOI 10.1016/0014-4835(92)90021-J; HUSMANN M, 1992, BIOCHEM BIOPH RES CO, V187, P1558, DOI 10.1016/0006-291X(92)90480-9; JACOBS GH, 1991, NATURE, V353, P655, DOI 10.1038/353655a0; KATZ ML, 1987, BIOCHIM BIOPHYS ACTA, V924, P432, DOI 10.1016/0304-4165(87)90157-7; KATZ ML, 1991, INVEST OPHTH VIS SCI, V32, P1968; KATZ ML, 1993, EXP EYE RES, V56, P671, DOI 10.1006/exer.1993.1084; KATZ ML, 1993, EXP EYE RES, V57, P393, DOI 10.1006/exer.1993.1140; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; KUTTY G, 1994, EXP EYE RES, V58, P65, DOI 10.1006/exer.1994.1195; LIN ZS, 1989, VISION RES, V29, P1699, DOI 10.1016/0042-6989(89)90152-1; Liou G. I., 1997, Investigative Ophthalmology and Visual Science, V38, pS4; LIOU GI, 1990, J BIOL CHEM, V265, P8373; LIOU GI, 1994, DEV BIOL, V161, P345, DOI 10.1006/dbio.1994.1036; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; LIOU GI, 1992, BIOTECHNIQUES, V13, P719; LIOU GI, 1992, METHODS NEUROSCIENCE, V9, P101; Mangelsdorf David J., 1994, P319; OKAJIMA TIL, 1989, EXP EYE RES, V49, P629, DOI 10.1016/S0014-4835(89)80059-4; OKAJIMA TIL, 1990, P NATL ACAD SCI USA, V87, P6907, DOI 10.1073/pnas.87.17.6907; ORGANISCIAK DT, 1991, EXP EYE RES, V53, P772; PEPPERBERG DR, 1993, MOL NEUROBIOL, V7, P61, DOI 10.1007/BF02780609; Picking WL, 1996, EXP EYE RES, V63, P493, DOI 10.1006/exer.1996.0139; RAJAN N, 1990, J LIPID RES, V31, P821; Saari J.C., 1990, Progress in Retinal Research, V9, P363, DOI 10.1016/0278-4327(90)90011-6; SAARI JC, 1985, J BIOL CHEM, V260, P195; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEMER J, 1992, COLLOQ INSE, V221, P277; SHIM K, 1997, IN PRESS EXP EYE RES; STARK WS, 1977, J COMP PHYSIOL, V121, P289, DOI 10.1007/BF00613010; SUN DX, 1993, EXP EYE RES, V57, P177, DOI 10.1006/exer.1993.1113; TTIMMERS AM, 1996, INVEST OPHTH VIS SCI, V37, pS693; Wagner E, 1997, FASEB J, V11, P271, DOI 10.1096/fasebj.11.4.9068616	46	6	6	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					129	138		10.1096/fasebj.12.1.129	http://dx.doi.org/10.1096/fasebj.12.1.129			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438418				2022-12-25	WOS:000071523800014
J	Ku, NO; Liao, J; Omary, MB				Ku, NO; Liao, J; Omary, MB			Apoptosis generates stable fragments of human type I keratins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC SKIN DISEASES; INTERMEDIATE FILAMENTS; PHOSPHORYLATION; CYTOKERATIN; IDENTIFICATION; EXPRESSION; CELLS; CYTOSKELETON; EPITHELIA; MUTATIONS	Type I and II keratins help maintain the structural integrity of epithelial cells. Since apoptosis involves progressive cell breakdown, we examined its effect on human keratin polypeptides 8, 18, and 19 (K8, K18, K19) that are expressed in simple-type epithelia as noncovalent type I (K18, K19) and type II (K8) heteropolymers. Apoptosis induces rapid hyperphosphorylation of most known K8/18 phosphorylation sites and delayed formation of K18 and K19 stable fragments. In contrast, K8 is resistant to proteolysis and remains associated with the K18 fragments. Transfection of phosphorylation/glycosylation-mutant K8 and K18 does not alter fragment formation. The protein domains of the keratin fragments were determined using epitope-defined antibodies, and microsequencing indicated that K18 cleavage occurs at a conserved caspase-specific aspartic acid. The fragments are found preferentially within the detergent-insoluble pool and can be generated, in a phosphorylation-independent manner, by incubating keratins with caspase-3 or with detergent lysates of apoptotic cells but not with lysates of nonapoptotic cells. Our results indicate that type I keratins are targets of apoptosis-activated caspases, which is likely a general feature of keratins in most if not all epithelial cells undergoing apoptosis. Keratin hyperphosphorylation occurs early but does not render the keratins better substrates of the downstream caspases.	Vet Adm Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Ctr Digest Dis, Palo Alto, CA 94305 USA; Clontech Labs Inc, Palo Alto, CA 94303 USA	Stanford University	Omary, MB (corresponding author), Vet Affairs Med Ctr, 154J,3801 Miranda Ave, Palo Alto, CA 94304 USA.			Omary, Bishr/0000-0002-8624-2347	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707, R01DK047918] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38707, DK47918] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BJORKLUND B, 1980, TUMORDIAGNOSTIK, V1, P9; BOTTGER V, 1995, EUR J BIOCHEM, V231, P475, DOI 10.1111/j.1432-1033.1995.tb20721.x; CALNEK D, 1993, DIFFERENTIATION, V53, P95, DOI 10.1111/j.1432-0436.1993.tb00649.x; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Coulombe PA, 1993, CURR OPIN CELL BIOL, V5, P17, DOI 10.1016/S0955-0674(05)80004-3; ECKERT RL, 1988, P NATL ACAD SCI USA, V85, P1114, DOI 10.1073/pnas.85.4.1114; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FEY SJ, 1983, FEBS LETT, V157, P165, DOI 10.1016/0014-5793(83)81138-7; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Fuchs E, 1996, ANNU REV GENET, V30, P197, DOI 10.1146/annurev.genet.30.1.197; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; HUMPHRIES MM, 1993, HUM MUTAT, V2, P37, DOI 10.1002/humu.1380020107; Inagaki M, 1997, J BIOCHEM, V121, P407; Inagaki M, 1996, BIOESSAYS, V18, P481, DOI 10.1002/bies.950180610; Irvine AD, 1997, NAT GENET, V16, P184, DOI 10.1038/ng0697-184; KLYMKOWSKY MW, 1991, J CELL BIOL, V114, P787, DOI 10.1083/jcb.114.4.787; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Ku NO, 1997, J BIOL CHEM, V272, P7556, DOI 10.1074/jbc.272.11.7556; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZARIDES E, 1980, NATURE, V283, P249, DOI 10.1038/283249a0; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Liao J, 1997, J BIOL CHEM, V272, P17565, DOI 10.1074/jbc.272.28.17565; LIAO J, 1995, J CELL BIOL, V131, P1291, DOI 10.1083/jcb.131.5.1291; MARCHUK D, 1984, CELL, V39, P491, DOI 10.1016/0092-8674(84)90456-2; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MOLL R, 1993, DIFFERENTIATION, V53, P75, DOI 10.1111/j.1432-0436.1993.tb00648.x; MOLL R, 1990, J CELL BIOL, V111, P567, DOI 10.1083/jcb.111.2.567; Omary MB, 1997, HEPATOLOGY, V25, P1043, DOI 10.1002/hep.510250537; OMARY MB, 1998, IN PRESS INTERMEDIAT; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RUGG EL, 1993, NAT GENET, V5, P294, DOI 10.1038/ng1193-294; STASIAK PC, 1989, J INVEST DERMATOL, V92, P707, DOI 10.1111/1523-1747.ep12721500; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1975, BIOCHEM J, V151, P603, DOI 10.1042/bj1510603; STEINERT PM, 1993, TRENDS GENET, V9, P280, DOI 10.1016/0168-9525(93)90014-9; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Toivola DM, 1997, J CELL SCI, V110, P23; vanDalen A, 1996, ANTICANCER RES, V16, P2345; WEBER K, 1984, EMBO J, V3, P2707, DOI 10.1002/j.1460-2075.1984.tb02198.x	49	202	209	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33197	33203		10.1074/jbc.272.52.33197	http://dx.doi.org/10.1074/jbc.272.52.33197			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407108	hybrid			2022-12-25	WOS:000071182900069
J	Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N				Kato, K; Ueoka, Y; Kato, K; Hachiya, T; Nishida, J; Wake, N			Contribution of enhanced transcriptional activation by ER to [(12)Val] K-Ras mediated NIH3T3 cell transformation	ONCOGENE			English	Article						Ras; transformation; ER; PR	STEROID-HORMONE RECEPTORS; HUMAN ESTROGEN-RECEPTOR; PROTEIN; PHOSPHORYLATION; STIMULATION; BINDING; REGION; KINASE; GROWTH	We investigated the biological significance of estrogen receptors (ER) in NM3T3 cell transformation by the [(12)Val] K-Ras mutant, This mutant enhanced the steady state level of ER, Cells expressing mutant K-Ras (K12V cell) were tumorigenic, To determine the role of ER accumulation in Ras-transformed cells, we developed cells (KwtER cells) that overexpressed both wild-type (wt) K-Ras and ER, and found these cells were also tumorigenic. E-2 stimulated the transcriptional activity by ER dominantly in K12V cells, However, only partial activation of ER by E-2 was seen in KwtER cells, In the presence of 10% serum in media, the activation of ER appeared only in transformed KtwER and K12V cells, suggesting that two independently transmitted signals, the E-2-ER binding and the ER-AF1 activation, are necessary for ER activation and that the dominant activation of ER might be involved in Ras-mediated cell transformation, Co-expression of progesterone receptor (PR) with mutant K-Ras led to suppression of tumorigenicity and inhibition of the activation of ER, The antisense oligomers complementary to the ER suppressed proliferation and transformed phenotypes of K12V cells, These observations support the importance of ER in aas-mediated cell transformation.	Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, Beppu, Oita 874, Japan	Kyushu University	Wake, N (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Reprod Physiol & Endocrinol, 4546 Tsurumihara, Beppu, Oita 874, Japan.							ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CICATIELLO L, 1992, J STEROID BIOCHEM, V41, P523, DOI 10.1016/0960-0760(92)90377-U; COEZY E, 1982, CANCER RES, V42, P317; DUBIK D, 1987, CANCER RES, V47, P6517; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; INOUE S, 1993, P NATL ACAD SCI USA, V90, P11117, DOI 10.1073/pnas.90.23.11117; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KRAUS WL, 1995, MOL CELL BIOL, V15, P1847; KUMAR R, 1990, SCIENCE, V248, P1101, DOI 10.1126/science.2188364; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; PETRANGELI E, 1994, J STEROID BIOCHEM, V49, P327, DOI 10.1016/0960-0760(94)90275-5; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOJEK AB, 1993, CELL, V74, P205; WALMER DK, 1995, CANCER RES, V55, P1168; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	20	21	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3037	3046		10.1038/sj.onc.1201497	http://dx.doi.org/10.1038/sj.onc.1201497			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444952				2022-12-25	WOS:000070968000004
J	Liliental, J; Chang, DD				Liliental, J; Chang, DD			Rack1, a receptor for activated protein kinase C, interacts with integrin beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; CYTOPLASMIC DOMAIN; CELL-ADHESION; SIGNAL-TRANSDUCTION; ALPHA-ACTININ; BINDING; CALRETICULIN; POLYPEPTIDE; AFFINITY; ICAM-1	The integrin beta subunit cytoplasmic domains are important for activation-dependent cell adhesion and adhesion-dependent signaling events. We report an interaction between integrin beta subunit cytoplasmic domain and Rack1, a Trp-Asp (WD) repeat protein that has been shown to bind activated protein kinase C, The Rack1-binding site on integrin beta(2) subunit resides within a conserved, membrane proximal region. In the yeast two-hybrid assay, WD repeats five to seven of Rack1 (Rack1-WD5/7) interact with integrin beta(1), beta(2), and beta(5) cytoplasmic domain, In eukaryotic cells, Rack1 co-immunoprecipitates with at least two different beta integrins, beta(1) integrins in 293T cells and beta(1) integrins in JY lymphoblastoid cells, Whereas Rack1-WD5/7 binds integrins constitutively, the association of full length Rack1 to integrins in vivo requires a treatment with phorbol esters, which promotes cell spreading and adhesion, These findings suggest that Rack1 may link protein kinase C directly to integrins and participate in the regulation of integrin functions.	Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chang, DD (corresponding author), Univ Calif Los Angeles, Sch Med, Div Hematol Oncol, Dept Med Microbiol & Immunol, Factor 11-934,10833 Le Conte Ave, Los Angeles, CA 90095 USA.							AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, P911; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chang DD, 1997, J CELL BIOL, V138, P1149, DOI 10.1083/jcb.138.5.1149; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COPPOLINO GG, 1997, NATURE, V386, P843; COPPOLINO M, 1995, J BIOL CHEM, V270, P23132, DOI 10.1074/jbc.270.39.23132; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; HUGHES PE, 1995, J BIOL CHEM, V270, P12411, DOI 10.1074/jbc.270.21.12411; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; LAFLAMME SE, 1994, J CELL BIOL, V126, P1287, DOI 10.1083/jcb.126.5.1287; Lafrenie RM, 1996, J CELL BIOCHEM, V61, P543, DOI 10.1002/(SICI)1097-4644(19960616)61:4<543::AID-JCB7>3.0.CO;2-O; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTOOLE TE, 1995, J BIOL CHEM, V270, P8553, DOI 10.1074/jbc.270.15.8553; PAVALKO FM, 1993, J IMMUNOL, V151, P3795; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHARMA CP, 1995, J IMMUNOL, V154, P3461; SHATTIL SJ, 1995, J CELL BIOL, V131, P807, DOI 10.1083/jcb.131.3.807; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart MP, 1996, J IMMUNOL, V156, P1810; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3	34	296	303	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2379	2383		10.1074/jbc.273.4.2379	http://dx.doi.org/10.1074/jbc.273.4.2379			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442085	hybrid			2022-12-25	WOS:000071595200074
J	Scheel, AA; Pelham, HRB				Scheel, AA; Pelham, HRB			Identification of amino acids in the binding pocket of the human KDEL receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RETENTION; PROTEINS; TOPOLOGY; YEAST; GOLGI; ERD2; LOCALIZATION; SPECIFICITY	Retention of soluble proteins in the endoplasmic reticulum is dependent on their interaction with the KDEL (Lys-Asp-Glu-Leu) receptor in the Golgi apparatus and their subsequent retrieval back to the endoplasmic reticulum. We have studied the three-dimensional organization of the human KDEL receptor using site-directed mutagenesis and sulfhydryl-specific labeling, We have identified four amino acid residues, Arg-5, Asp-50, Tyr-162, and Asn-165, which we suggest participate in the formation of the ligand binding pocket. Arg-5 and Asp-50 are shown to be located on the lumenal side of the membrane and are inaccessible from the cytoplasm, In addition, our results strongly support a topology of the KDEL receptor similar to the family of G-protein-coupled receptors with seven transmembrane domains, Furthermore, Asp-50 plays a crucial role in the binding of His/Lys-Asp-Glu-Leu ligands, but is not required for Asp-Asp-Glu-Leu binding, suggesting that this residue forms an ion pair with the positively charged amino acid residue positioned 4 residues from the carboxyl terminus of the ligand.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Pelham, HRB (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							ELMENDORF HG, 1993, EMBO J, V12, P4763, DOI 10.1002/j.1460-2075.1993.tb06165.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE HI, 1993, P NATL ACAD SCI USA, V90, P11433, DOI 10.1073/pnas.90.23.11433; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Scheel AA, 1996, BIOCHEMISTRY-US, V35, P10203, DOI 10.1021/bi960807x; SEMENZA JC, 1992, J MOL BIOL, V224, P1, DOI 10.1016/0022-2836(92)90571-Z; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SINGH P, 1993, MOL CELL BIOL, V13, P6435, DOI 10.1128/MCB.13.10.6435; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; Sonnichsen B, 1996, J CELL BIOL, V134, P1411, DOI 10.1083/jcb.134.6.1411; Summers MD, 1987, MANUAL METHODS BACUL; TANG BL, 1993, J CELL BIOL, V120, P325, DOI 10.1083/jcb.120.2.325; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; WILSON DW, 1993, J BIOL CHEM, V268, P7465	20	38	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2467	2472		10.1074/jbc.273.4.2467	http://dx.doi.org/10.1074/jbc.273.4.2467			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442098	hybrid			2022-12-25	WOS:000071595200087
J	Dey, D; Bochkariov, DE; Jokhadze, GG; Traut, RR				Dey, D; Bochkariov, DE; Jokhadze, GG; Traut, RR			Cross-linking of selected residues in the N- and C-terminal domains of Escherichia coli protein L7/L12 to other ribosomal proteins and the effect of elongation factor Tu	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE ELECTRON-MICROSCOPY; NUCLEAR MAGNETIC-RESONANCE; MONOCLONAL-ANTIBODIES; GTP HYDROLYSIS; FACTOR-BINDING; HINGE REGION; 50S SUBUNIT; L7-L12; LOCALIZATION; IDENTIFICATION	Five different variants of protein L7/L12, each with a single cystein substitution at a selected site, were produced, modified with I-125-N-[4-(p-azidosalicylamido)-butyl]-3-(2'-pyridyldithio)propionamide, a radiolabeled, sulfhydryl-specific, heterobifunctional, cleavable photocross-linking reagent that transfers radiolabel to the target molecule upon reduction of the disulfide bond, The proteins were reconstituted with core particles depleted of wild type L7/L12 to yield 70 S ribosomes, Cross-linked molecules were identified and quantified by the radiolabel, No cross-linking of RNA was detected. Two sites in the dimeric N-termnal domain, Cys-12 and Cys-33, cross-linked strongly to L10 and in lower yield to L11 but to no other proteins. The three sites in the globular C-terminal domain all cross-linked strongly to L11 and, in lower yield, to L10, Weaker crosslinking to 50 S proteins L2 and L5 occurred from all three C-terminal domain locations, The 30 S ribosomal proteins S2, S3, S7, S14, S18 were also cross-linked from all three of these sites. Binding of the ternary complex [C-14]-Phe-tRNA-elongation elongation factor Tu-guanyl-5'-yl imidodiphosphate but not [C-14]Phe-tRNA-elongation factor Tu-GDP-kirromycin increased labeling of L2, L5, and all of the 30 S proteins, These results imply the flexibility of L7/L12 and the transient proximity of three sin-faces of the C-terminal domain with the base of the stalk, the peptidyl transferase domain, and the head of the 30 S subunit.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Traut, RR (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA.	rrtraut@ucdavis.edu			NIGMS NIH HHS [GM17924] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM017924, R37GM017924] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bayley H, 1983, PHOTOGENERATED REAGE; Bocharov EV, 1996, FEBS LETT, V379, P291, DOI 10.1016/0014-5793(95)01531-0; Bodley J W, 1974, Methods Enzymol, V30, P235; CASIANO C, 1990, J BIOL CHEM, V265, P18757; COWGILL CA, 1984, J BIOL CHEM, V259, P5257; Dey D, 1995, BIOCHIMIE, V77, P925, DOI 10.1016/0300-9084(95)80003-4; EXPERT BA, 1976, J MOL BIOL, V108, P781; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GUDKOV AT, 1989, BIOCHIMIE, V71, P779, DOI 10.1016/0300-9084(89)90040-0; GUDKOV AT, 1978, EUR J BIOCHEM, V90, P309, DOI 10.1111/j.1432-1033.1978.tb12605.x; GUDKOV AT, 1982, FEBS LETT, V138, P229, DOI 10.1016/0014-5793(82)80448-1; HAMEL E, 1972, J BIOL CHEM, V247, P805; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16672, DOI 10.1021/bi9615001; Hamman BD, 1996, BIOCHEMISTRY-US, V35, P16680, DOI 10.1021/bi9624189; Hamman BD, 1996, J BIOL CHEM, V271, P7568, DOI 10.1074/jbc.271.13.7568; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; KNOPF UC, 1975, MOL BIOL REP, V2, P35, DOI 10.1007/BF00357295; KOTELIANSKY VE, 1978, EUR J BIOCHEM, V90, P319, DOI 10.1111/j.1432-1033.1978.tb12607.x; LAMBERT JM, 1981, J MOL BIOL, V149, P451, DOI 10.1016/0022-2836(81)90481-2; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEIJONMARCK M, 1987, J MOL BIOL, V195, P555, DOI 10.1016/0022-2836(87)90183-5; LEIJONMARCK M, 1981, STRUCTURAL ASPECTS R, P761; LILJAS A, 1987, BIOCHIMIE, V69, P1043, DOI 10.1016/0300-9084(87)90004-6; LILJAS A, 1982, PROG BIOPHYS MOL BIO, V40, P161, DOI 10.1016/0079-6107(82)90013-X; MAKAROV EM, 1993, BIOCHIMIE, V75, P963, DOI 10.1016/0300-9084(93)90146-J; Miller D L, 1974, Methods Enzymol, V30, P219; MOLLER W, 1983, J MOL BIOL, V163, P553, DOI 10.1016/0022-2836(83)90112-2; Moller W., 1986, STRUCTURE FUNCTION G, P309; NAG B, 1995, INDIAN J BIOCHEM BIO, V32, P343; OLEINIKOV AV, 1993, J BIOL CHEM, V268, P917; OLEINIKOV AV, 1993, P NATL ACAD SCI USA, V90, P9828, DOI 10.1073/pnas.90.21.9828; OLSON HM, 1986, J BIOL CHEM, V261, P6924; PARMEGGIANI A, 1985, ANNU REV MICROBIOL, V39, P557, DOI 10.1146/annurev.mi.39.100185.003013; SCHEINMAN A, 1992, BIOCHIMIE, V74, P307, DOI 10.1016/0300-9084(92)90108-Q; SOMMER A, 1985, J BIOL CHEM, V260, P6522; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STOFFLERMEILICKE M, 1983, P NATL ACAD SCI-BIOL, V80, P6780, DOI 10.1073/pnas.80.22.6780; STOFFLERMEILICKE M, 1990, RIBOSOME, P123; STRYCHARZ WA, 1978, J MOL BIOL, V126, P123, DOI 10.1016/0022-2836(78)90355-8; TERHORST C, 1973, EUR J BIOCHEM, V34, P138, DOI 10.1111/j.1432-1033.1973.tb02740.x; TOKIMATSU H, 1981, J MOL BIOL, V152, P397, DOI 10.1016/0022-2836(81)90250-3; Traut R. R., 1986, STRUCTURE FUNCTION G, P286; TRAUT RR, 1993, TRANSLATIONAL APPARATUS, P521; TRAUT RR, 1983, J BIOL CHEM, V258, P4592; UCHIUMI T, 1987, P NATL ACAD SCI USA, V84, P5580, DOI 10.1073/pnas.84.16.5580; VANAGTHOVEN AJ, 1975, BIOCHEM BIOPH RES CO, V64, P1184, DOI 10.1016/0006-291X(75)90818-9; VERSCHOOR A, 1985, J ULTRA MOL STRUCT R, V92, P180, DOI 10.1016/0889-1605(85)90045-X; ZECHERLE GN, 1992, J BIOL CHEM, V267, P5889; ZECHERLE GN, 1992, BIOCHEMISTRY-US, V31, P9526, DOI 10.1021/bi00155a003	49	37	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1670	1676		10.1074/jbc.273.3.1670	http://dx.doi.org/10.1074/jbc.273.3.1670			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430711	hybrid			2022-12-25	WOS:000071411500058
J	Sears, C; Olesen, J; Rubin, D; Finley, D; Maniatis, T				Sears, C; Olesen, J; Rubin, D; Finley, D; Maniatis, T			NF-kappa B p105 processing via the ubiquitin-proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							SITE-SPECIFIC PHOSPHORYLATION; MEDIATED SIGNAL-TRANSDUCTION; END RULE PATHWAY; CELL-CYCLE GENE; SACCHAROMYCES-CEREVISIAE; DEPENDENT PROTEOLYSIS; PROTEIN-DEGRADATION; CONJUGATING ENZYMES; 26S PROTEASE; IN-VIVO	The p50 subunit of NF-KB is generated by proteolytic processing of a 105-kDa precursor (p105) in yeast and mammalian cells. Here we show that yeast mutants in the ubiquitin-proteasome pathway inhibit or abolish p105 processing, Specifically, p105 processing is inhibited by a mutation in a 20 S proteasome subunit (pre1-1), by mutations in the ATPases located in the 19 S regulatory complexes of the proteasome (yta1, yta2/sug1, yta5, cim5), and by a mutation in a proteasome-associated isopeptidase (deal). A ubiquitinated intermediate of the p105 processing reaction accumulates in some of these mutants, strongly suggesting that ubiquitination is required for processing. However, none of the ubiquitin conjugating enzyme mutants tested (ubc1, -2, -3, -4/5, -6/7, -8, -9, -10, -11) had an effect on p105 processing, suggesting that more than one of these enzymes is sufficient for p105 processing. Interestingly, a mutant "N-end rule" ligase does not adversely affect p105 processing, showing that the N-end rule pathway is not involved in degrading the C-terminal region of p105. Unexpectedly, we found that a glycine-rich region of p105 that is required for p105 processing in mammalian cells is not required for processing in yeast. Thus, p105 processing in both yeast and mammalian cells requires the ubiquitin-proteasome pathway, but the mechanisms of processing, while similar, are not identical.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02122 USA	Harvard University; Harvard University; Harvard Medical School	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 7 Divin Ave, Cambridge, MA 02138 USA.			Olesen, Jes/0000-0002-6712-2702	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043601, R37GM043601] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20642] Funding Source: Medline; NIGMS NIH HHS [GM43601] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Bauer VW, 1996, GENE, V181, P63, DOI 10.1016/S0378-1119(96)00463-5; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG CC, 1994, ONCOGENE, V9, P923; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DAWSON BA, 1991, J CELL BIOCHEM, V46, P166, DOI 10.1002/jcb.240460210; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DUBIEL W, 1994, BIOL CHEM H-S, V375, P237, DOI 10.1515/bchm3.1994.375.4.237; DUBIEL W, 1995, MOL BIOL REP, V21, P27, DOI 10.1007/BF00990967; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FigueiredoPereira ME, 1996, J BIOL CHEM, V271, P16455, DOI 10.1074/jbc.271.28.16455; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; Fujiwara T, 1996, FEBS LETT, V387, P184, DOI 10.1016/0014-5793(96)00489-9; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRILLI M, 1993, INT REV CYTOL, V143, P1; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; Harhaj EW, 1996, ONCOGENE, V12, P2385; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heron E, 1995, GENOMICS, V30, P493, DOI 10.1006/geno.1995.1270; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOUGH R, 1986, J BIOL CHEM, V261, P2400; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; IKAI A, 1991, FEBS LETT, V292, P21, DOI 10.1016/0014-5793(91)80824-M; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LI CCH, 1994, J BIOL CHEM, V269, P30089; Lin L, 1996, MOL CELL BIOL, V16, P2248; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MAGNANI M, 1994, BBA-PROTEIN STRUCT M, V1206, P180, DOI 10.1016/0167-4838(94)90206-2; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; NEUMANN M, 1994, P AM ASSOC CANC RES, V35, P3561; Newman RH, 1996, BBA-BIOMEMBRANES, V1281, P111, DOI 10.1016/0005-2736(96)00028-4; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; QIN S, 1991, J BIOL CHEM, V266, P15549; REVILLARD JP, 1991, INT C AIDS, V7, P73; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICHTERRUOFF B, 1992, FEBS LETT, V302, P192, DOI 10.1016/0014-5793(92)80438-M; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; RUBIN DM, 1995, CURR BIOL, V5, P854, DOI 10.1016/S0960-9822(95)00172-2; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; SADIS S, 1995, MOL CELL BIOL, V15, P4086; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHNALL R, 1994, YEAST, V10, P1141, DOI 10.1002/yea.320100903; SCHORK SM, 1995, J BIOL CHEM, V270, P26446, DOI 10.1074/jbc.270.44.26446; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Seeger M, 1996, J MOL BIOL, V263, P423, DOI 10.1006/jmbi.1996.0586; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TANAKA K, 1983, J CELL BIOL, V96, P1580, DOI 10.1083/jcb.96.6.1580; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1981, J BIOL CHEM, V256, P9235; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; WILKINSON KD, 1986, BIOCHEMISTRY-US, V25, P4999, DOI 10.1021/bi00366a005; ZHANG N, 1993, DEV BIOL, V157, P214, DOI 10.1006/dbio.1993.1125; ZHANG Y, 1990, MOL CELL BIOL, V10, P3818, DOI 10.1128/MCB.10.7.3818	106	74	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1409	1419		10.1074/jbc.273.3.1409	http://dx.doi.org/10.1074/jbc.273.3.1409			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430676	hybrid			2022-12-25	WOS:000071411500023
J	Yoshida, T; Pan, Y; Hanada, H; Iwata, Y; Shigekawa, M				Yoshida, T; Pan, Y; Hanada, H; Iwata, Y; Shigekawa, M			Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-ASSOCIATED GLYCOPROTEIN; GIRDLE MUSCULAR-DYSTROPHY; CARDIOMYOPATHIC HAMSTER HEART; EXTRACELLULAR-MATRIX; SKELETAL-MUSCLE; DELTA-SARCOGLYCAN; CELL-ADHESION; PROTEIN; EXPRESSION; BINDING	The rat L6 skeletal muscle cell line was used to study expression of the dystrophin-containing glycoprotein complex and its interaction with the integrin system involved in the cell-matrix adhesion reaction. A complex of dystrophin and its associated proteins was fully expressed in L6 myotubes, from which anti-dystrophin or anti-alpha-sarcoglycan co-precipitated integrin alpha(5) beta(1) and other focal adhesion-associated proteins vinculin, talin, paxillin, and focal adhesion kinase. Immunostaining and confocal microscopy revealed that dystrophin, alpha-sarcoglycan, integrin alpha(5) beta(1), and vinculin exhibited overlapping distribution in the sarcolemma, especially at focal adhesion-like, spotty structures. Adhesion of cells to fibronectin-or collagen type I-coated dishes resulted in induction of tyrosine phosphorylation of alpha- and gamma-sarcoglycans but not beta-sarcoglycan. The same proteins were also tyrosine-phosphorylated when L6 cells in suspension were exposed to Arg-Gly-Asp-Ser peptide. All of these tyrosine phosphorylations were inhibited by herbimycin A. On the other hand, treatment of L6 myotubes with alpha- and gamma-sarcoglycan antisense oligodeoxynucleotides resulted in complete disappearance of alpha- and gamma-sarcoglycans and in significant reduction of levels of the associated focal adhesion proteins, which caused about 50% reduction of cell adhesion. These results indicate the existence of bidirectional communication between the dystrophin-containing complex and the integrin adhesion system in cultured L6 myocytes.	Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Osaka 565, Japan	National Cerebral & Cardiovascular Center - Japan	Shigekawa, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Mol Physiol, Fujishiro Dai 5-7, Osaka 565, Japan.							BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BYERS HR, 1982, J CELL BIOL, V93, P804, DOI 10.1083/jcb.93.3.804; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; GEE SH, 1993, J BIOL CHEM, V268, P14972; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hanada H, 1997, BIOL PHARM BULL, V20, P134; Herrmann R, 1996, BIOCHEM SOC T, V24, P501, DOI 10.1042/bst0240501; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; IWATA Y, 1993, FEBS LETT, V329, P227, DOI 10.1016/0014-5793(93)80227-L; Iwata Y, 1996, J MOL CELL CARDIOL, V28, P2501, DOI 10.1006/jmcc.1996.9999; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Jung D, 1996, J BIOL CHEM, V271, P32321, DOI 10.1074/jbc.271.50.32321; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KRAMARCY NR, 1990, FEBS LETT, V274, P171, DOI 10.1016/0014-5793(90)81356-S; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; MCDONALD KA, 1995, J CELL SCI, V108, P2573; McDonald Kevin A., 1995, Seminars in Developmental Biology, V6, P105, DOI 10.1016/S1044-5781(06)80020-4; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MITSUMOTO Y, 1992, J BIOL CHEM, V267, P4957; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Nigro V, 1996, HUM MOL GENET, V5, P1179, DOI 10.1093/hmg/5.8.1179; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; PARDO JV, 1983, P NATL ACAD SCI-BIOL, V80, P1008, DOI 10.1073/pnas.80.4.1008; PIERSCHBACHER MD, 1984, P NATL ACAD SCI USA, V81, P5986; PORTER GA, 1992, J CELL BIOL, V117, P997, DOI 10.1083/jcb.117.5.997; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; ROBERDS SL, 1993, J BIOL CHEM, V268, P23739; Sastry SK, 1996, J CELL BIOL, V133, P169, DOI 10.1083/jcb.133.1.169; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; TAWADAIWATA Y, 1993, AM J PHYSIOL, V264, pH1447; TERRACIO L, 1989, ANAT RECORD, V223, P62, DOI 10.1002/ar.1092230110; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V225, P11, DOI 10.1006/bbrc.1996.1123	43	103	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1583	1590		10.1074/jbc.273.3.1583	http://dx.doi.org/10.1074/jbc.273.3.1583			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430699	hybrid			2022-12-25	WOS:000071411500046
J	Zhu, SH; Wek, RC				Zhu, SH; Wek, RC			Ribosome-binding domain of eukaryotic initiation factor-2 kinase GCN2 facilitates translation control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; TRANSFER-RNA; MALIGNANT TRANSFORMATION; EIF-2-ALPHA KINASE; ESCHERICHIA-COLI; FACTOR-II; YEAST; GENE; PHOSPHORYLATION	A family of protein kinases regulate translation initiation in response to cellular stresses by phosphorylation of eukaryotic initiation factor-2 (eIF-2). One family member from yeast, GCN2, contains a region homologous to histidyl-tRNA synthetases juxtaposed to the kinase catalytic domain, It is thought that uncharged tRNA accumulating during amino acid starvation binds to the synthetase-related sequences and stimulates phosphorylation of the alpha subunit of eIF-2, In this report, we define another domain in GCN2 that functions to target the kinase to ribosomes, A truncated version of GCN2 containing only amino acid residues 1467 to 1590 can independently associate with the translational machinery, Interestingly; this region of GCN2 shares sequence similarities with the core of the double-stranded RNA-binding domain (DRBD), Substitutions of the lysine residues conserved among DRBD sequences block association of GCN2 with ribosomes and impaired the ability of the kinase to stimulate translational central in response to amino acid limitation, Additionally, as found for other DRBD sequences, recombinant protein containing GCN2 residues 1467-1590 can bind double-stranded RNA in vitro, suggesting that interaction with rRNA mediates ribosome targeting, These results indicate that appropriate ribosome localization of the kinase is an obligate step in the mechanism leading to translational control by GCN2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Wek, RC (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164, R29GM049164] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49164] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Cashel M, 1987, ESCHERICHIA COLI SAL, P1410; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; CLEMENS MJ, 1996, TRANSLATIONAL CONTRO; DEALDANA CRV, 1995, EMBO J, V14, P3184, DOI 10.1002/j.1460-2075.1995.tb07321.x; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DRISCOLLPENN M, 1984, MOL CELL BIOL, V4, P520; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; GRAACK HR, 1988, FEBS LETT, V242, P4, DOI 10.1016/0014-5793(88)80975-X; GRAACK HR, 1992, EUR J BIOCHEM, V206, P373, DOI 10.1111/j.1432-1033.1992.tb16937.x; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HADFIELD C, 1986, GENE, V45, P149, DOI 10.1016/0378-1119(86)90249-0; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Kaiser C. S., 1994, METHODS YEAST GENETI, P207; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LUCCHINI G, 1984, MOL CELL BIOL, V4, P1326, DOI 10.1128/MCB.4.7.1326; Marton MJ, 1997, MOL CELL BIOL, V17, P4474, DOI 10.1128/MCB.17.8.4474; MARTON MJ, 1993, MOL CELL BIOL, V13, P3541, DOI 10.1128/MCB.13.6.3541; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; Merrick WC., 1996, TRANSLATION CONTROL, P31; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; NEGRUTSKII BS, 1992, P NATL ACAD SCI USA, V89, P3601, DOI 10.1073/pnas.89.8.3601; NEGRUTSKII BS, 1994, P NATL ACAD SCI USA, V91, P964, DOI 10.1073/pnas.91.3.964; OMALLEY RP, 1986, CELL, V44, P391, DOI 10.1016/0092-8674(86)90460-5; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P217; Qian WJ, 1996, J BIOL CHEM, V271, P13202, DOI 10.1074/jbc.271.22.13202; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SAMUEL CE, 1986, METHOD ENZYMOL, V119, P499; SCHWEMMLE M, 1992, P NATL ACAD SCI USA, V89, P10292, DOI 10.1073/pnas.89.21.10292; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; WEK RC, 1994, TRENDS BIOCHEM SCI, V19, P491, DOI 10.1016/0968-0004(94)90136-8; WEK RC, 1990, MOL CELL BIOL, V10, P2820, DOI 10.1128/MCB.10.6.2820; WEK SA, 1995, MOL CELL BIOL, V15, P4497; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhu SH, 1997, J BIOL CHEM, V272, P14434, DOI 10.1074/jbc.272.22.14434; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	41	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1808	1814		10.1074/jbc.273.3.1808	http://dx.doi.org/10.1074/jbc.273.3.1808			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430731	hybrid			2022-12-25	WOS:000071411500078
J	Corbin, J; Methot, N; Wang, HH; Baenziger, JE; Blanton, MP				Corbin, J; Methot, N; Wang, HH; Baenziger, JE; Blanton, MP			Secondary structure analysis of individual transmembrane segments of the nicotinic acetylcholine receptor by circular dichroism and Fourier transform infrared spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; TORPEDO-CALIFORNICA; 3-DIMENSIONAL STRUCTURE; NONCOMPETITIVE ANTAGONIST; PROTEIN CONFORMATION; GEL-ELECTROPHORESIS; ALPHA-SUBUNIT; ION-CHANNEL; RESOLUTION; LIGAND	Circular dichroism (CD) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy are used to establish the secondary structure of peptides containing one or more transmembrane segments (M1-M4) of the Torpedo californica nicotinic acetylcholine receptor (AChR), Peptides containing the M2-M3 and M1-M2-M3 transmembrane segments of the AChR beta-subunit and the M4 segment of the alpha- and gamma-subunits were isolated from proteolytic digests of receptor subunits, purified, and reconstituted into lipid vesicles, For each peptide, an amide I vibrational frequency centered between 1650 and 1656 cm(-1) and negative CD absorption bands at 208 and 222 nm indicate that the peptide is largely alpha-helical. In addition, the CD spectrum of a tryptic peptide of the alpha-subunit containing the M1 segment is also consistent with a largely alpha-helical structure, However, secondary structure analysis of the alpha-M1 CD spectrum indicates the presence of other structures, suggesting that the M1 segment may represent either a distorted alpha-helix, likely the consequence of several proline residues, or may not be entirely alpha-helical. Overall, these findings are consistent with studies that indicate that the transmembrane region of the AChR comprises predominantly, if not exclusively, membrane-spanning alpha-helices.	Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA; Univ Calif Santa Cruz, Dept Biol, Santa Cruz, CA 95064 USA; Univ Ottawa, Dept Biochem, Ottawa, ON K1H 8M5, Canada	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of California System; University of California Santa Cruz; University of Ottawa	Blanton, MP (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, 3601 4th St, Lubbock, TX 79430 USA.	phrmpb@ttuhsc.edu		Baenziger, John/0000-0002-2888-5328	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER; NINDS NIH HHS [R29 NS35786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Baenziger JE, 1997, BIOCHEMISTRY-US, V36, P3617, DOI 10.1021/bi962845m; BAENZIGER JE, 1995, J BIOL CHEM, V270, P29129, DOI 10.1074/jbc.270.49.29129; BECHINGER B, 1991, Journal of Biomolecular NMR, V1, P167, DOI 10.1007/BF01877228; Blanton M. P., 1995, Biophysical Journal, V68, pA377; Blanton M. P., 1997, Biophysical Journal, V72, pA152; BLANTON MP, 1994, BIOCHEMISTRY-US, V33, P2859, DOI 10.1021/bi00176a016; BLANTON MP, 1992, BIOCHEMISTRY-US, V31, P3738, DOI 10.1021/bi00130a003; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHANGEUX JP, 1992, Q REV BIOPHYS, V25, P395, DOI 10.1017/S0033583500004352; Cheng AC, 1997, NATURE, V387, P627, DOI 10.1038/42517; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CONTITRONCONI BM, 1994, CRIT REV BIOCHEM MOL, V29, P69, DOI 10.3109/10409239409086798; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GALZI JL, 1995, NEUROPHARMACOLOGY, V34, P563, DOI 10.1016/0028-3908(95)00034-4; GORNETSCHELNOKOW U, 1994, EMBO J, V13, P338, DOI 10.1002/j.1460-2075.1994.tb06266.x; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HENRY GD, 1994, METHOD ENZYMOL, V239, P515; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; JACKSON MB, 1995, ANNU REV PHYSIOL, V57, P447; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1992, INT J PEPT PROT RES, V40, P243; Li SC, 1996, P NATL ACAD SCI USA, V93, P6676, DOI 10.1073/pnas.93.13.6676; LI SC, 1994, BIOCHEMISTRY-US, V33, P14333, DOI 10.1021/bi00251a047; LOMIZE AL, 1992, J BIOMOL NMR, V2, P361, DOI 10.1007/BF01874814; METHOT N, 1995, BIOCHEMISTRY-US, V34, P15142, DOI 10.1021/bi00046a021; METHOT N, 1994, BIOCHEMISTRY-US, V33, P7709, DOI 10.1021/bi00190a026; MITRA AK, 1989, J CELL BIOL, V109, P755, DOI 10.1083/jcb.109.2.755; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; NODA M, 1983, NATURE, V301, P251, DOI 10.1038/301251a0; Ozawa S, 1997, BBA-BIOMEMBRANES, V1323, P145, DOI 10.1016/S0005-2736(96)00182-4; PARK K, 1992, PROTEIN SCI, V1, P1032, DOI 10.1002/pro.5560010809; PEDERSEN SE, 1992, J BIOL CHEM, V267, P10489; PEDERSEN SE, 1986, J BIOL CHEM, V261, P3735; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; Reid SE, 1996, SPECTROCHIM ACTA A, V52, P1347, DOI 10.1016/0584-8539(96)01718-7; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH GB, 1995, TRENDS PHARMACOL SCI, V16, P162, DOI 10.1016/S0165-6147(00)89009-4; SOBEL A, 1977, EUR J BIOCHEM, V80, P215, DOI 10.1111/j.1432-1033.1977.tb11874.x; TAMAMIZU S, 1995, CELL MOL NEUROBIOL, V15, P427, DOI 10.1007/BF02071878; TOBIMATSU T, 1987, FEBS LETT, V222, P56, DOI 10.1016/0014-5793(87)80191-6; TOYOSHIMA C, 1990, J CELL BIOL, V111, P2623, DOI 10.1083/jcb.111.6.2623; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Walz T, 1997, NATURE, V387, P624, DOI 10.1038/42512; Wang HL, 1997, J GEN PHYSIOL, V109, P757, DOI 10.1085/jgp.109.6.757; WATERHOUS DV, 1994, BIOCHEMISTRY-US, V33, P2121, DOI 10.1021/bi00174a019; WHITE BH, 1992, J BIOL CHEM, V267, P15770; Yeagle PL, 1997, BIOCHEMISTRY-US, V36, P3864, DOI 10.1021/bi962403a	62	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					771	777		10.1074/jbc.273.2.771	http://dx.doi.org/10.1074/jbc.273.2.771			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422730	hybrid			2022-12-25	WOS:000071411400019
J	Schroeder, RJ; Ahmed, SN; Zhu, YZ; London, E; Brown, DA				Schroeder, RJ; Ahmed, SN; Zhu, YZ; London, E; Brown, DA			Cholesterol and sphingolipid enhance the Triton X-100 insolubility of glycosylphosphatidylinositol-anchored proteins by promoting the formation of detergent-insoluble ordered membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; KIDNEY EPITHELIAL-CELLS; ALKALINE-PHOSPHATASE; TYROSINE KINASES; LIPID BILAYERS; COMPLEXES; SOLUBILIZATION; BIOSYNTHESIS; RESISTANCE; TRANSPORT	Glycosylphosphatidylinositol (GPI)-anchored proteins can be isolated from both cells and sphingolipid and cholesterol-rich liposomes (SCRLs) in association with detergent-insoluble membranes. We found previously that detergent insolubility of lipids was characteristic of phases in which lipid acyl chains are ordered, We presented evidence that GPI-anchored proteins are insoluble because they associate with cholesterol and sphingolipid-rich lipid domains with properties similar to the liquid-ordered phase, Here, this model was tested by a variety of approaches. First, we demonstrated that saponin, which removes cholesterol from cell membranes and allows solubilization of GPI-anchored pro teins by Triton X-100, had the same effect on the GPI-anchored protein alkaline phosphatase (FLAP) in SCRLs of appropriate lipid composition, The similarity of saponin action in cells and simple liposomes suggests that the compound disrupts protein-lipid interactions, However, direct interactions between FLAP and cholesterol were not needed for insolubility, because the protein was also insoluble in cholesterol-free liposomes containing lipid in an ordered phase, Instead, cholesterol acted by greatly enhancing the formation of a detergent-insoluble phase by sphingolipids, which have a tendency to form ordered phases, We propose that saponin solubilizes GPI-anchored proteins because the lipid composition of cell membranes (and the SCRLs used above) supports ordered phase formation in the presence but not the absence of cholesterol. Supporting this model, saponin did not promote Triton X-100 solubilization of FLAP in SCRLs with sphingolipid levels high enough to allow ordered phase formation in the absence of cholesterol, We also showed that two additional GPI-anchored proteins are detergent-insoluble in SCRLs and that detergent does not artifactually create ordered domains or cause components of solubilized membranes to associate with detergent-resistant membranes present in separate bilayers in the same lysate, We conclude that the ordered domain model explains the behavior of detergent-resistant membranes in liposomes and cells.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Brown, DA (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048596, R01GM047897] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 47897, GM 48596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; ALMEIDA PFF, 1992, BIOCHEMISTRY-US, V31, P6739, DOI 10.1021/bi00144a013; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; ARREAZA G, 1995, J BIOL CHEM, V270, P23641, DOI 10.1074/jbc.270.40.23641; BARENHOLZ Y, 1976, BIOCHEMISTRY-US, V15, P2441, DOI 10.1021/bi00656a030; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; DENCHER NA, 1978, FEBS LETT, V96, P322, DOI 10.1016/0014-5793(78)80427-X; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELIAS PM, 1978, J CELL BIOL, V78, P577, DOI 10.1083/jcb.78.2.577; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HARLOW E, 1988, ANTIBODIES LABORATOR, P651; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; IPSEN JH, 1987, BIOCHIM BIOPHYS ACTA, V905, P162; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MATEO CR, 1995, BIOPHYS J, V68, P978, DOI 10.1016/S0006-3495(95)80273-0; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Oesterhelt D, 1974, Methods Enzymol, V31, P667; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; RIBEIRO AA, 1973, BIOCHIM BIOPHYS ACTA, V332, P26; ROBERTS WL, 1987, P NATL ACAD SCI USA, V84, P7817, DOI 10.1073/pnas.84.22.7817; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1988, BIOCHEM BIOPH RES CO, V150, P271, DOI 10.1016/0006-291X(88)90516-5; ROBERTS WL, 1988, J BIOL CHEM, V263, P18776; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Sevinsky JR, 1996, J CELL BIOL, V133, P293, DOI 10.1083/jcb.133.2.293; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; Silvius JR, 1996, BIOCHEMISTRY-US, V35, P15198, DOI 10.1021/bi9615506; URBANEJA MA, 1987, BIOCHIM BIOPHYS ACTA, V904, P337, DOI 10.1016/0005-2736(87)90383-X	39	370	373	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1150	1157		10.1074/jbc.273.2.1150	http://dx.doi.org/10.1074/jbc.273.2.1150			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422781	hybrid			2022-12-25	WOS:000071411400070
J	Yang, ZY; Boffelli, D; Boonmark, N; Schwartz, K; Lawn, R				Yang, ZY; Boffelli, D; Boonmark, N; Schwartz, K; Lawn, R			Apolipoprotein(a) gene enhancer resides within a LINE element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA LIPOPROTEIN(A) CONCENTRATION; APO(A) MESSENGER-RNA; TRANSGENIC MICE; TISSUE-SPECIFICITY; HUMAN PLASMINOGEN; DNA-BINDING; L1 ELEMENT; LIVER; SIZE; SEQUENCE	Apolipoprotein(a), (apo(a)), is the distinguishing protein portion of the lipoprotein(a) particle, elevated plasma levels of which are a major risk factor for cardiovascular disease. A search for enhancer elements that control the transcription of the apo(a) gene led to the identification of an upstream element that contains target binding sites for members of the Ets and Sp1 nuclear protein families. The enhancer element functions in either orientation to confer a greater than 10-fold increase in the activity of the apo(a) minimal promoter in cultured hepatocyte cells. Unexpectedly, the enhancer element is located within a LINE retrotransposon element, suggesting that LINE elements may function as mobile regulatory elements to control the expression of nearby genes.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Stanford, CA 94305 USA	Stanford University	Lawn, R (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, 300 Pasteur Dr, Stanford, CA 94305 USA.	richard.lawn@forsythe.stanford.edu			PHS HHS [48638] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Assmann G, 1996, AM J CARDIOL, V77, P1179, DOI 10.1016/S0002-9149(96)00159-2; AZROLAN N, 1991, J BIOL CHEM, V266, P13866; Block KL, 1996, BLOOD, V88, P2071, DOI 10.1182/blood.V88.6.2071.bloodjournal8862071; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BYRNE CD, 1994, ARTERIOSCLER THROMB, V14, P534, DOI 10.1161/01.ATV.14.4.534; COHEN JC, 1993, J CLIN INVEST, V91, P1630, DOI 10.1172/JCI116370; DEMEESTER CA, 1995, AM J HUM GENET, V56, P287; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; GALLARDA JL, 1989, GENE DEV, V3, P1845, DOI 10.1101/gad.3.12a.1845; GAVISH D, 1989, J CLIN INVEST, V84, P2021, DOI 10.1172/JCI114395; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; HAJJAR KA, 1989, NATURE, V339, P303, DOI 10.1038/339303a0; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Hata K, 1997, GENE, V189, P227, DOI 10.1016/S0378-1119(96)00856-6; HIXSON JE, 1989, J BIOL CHEM, V264, P6013; HOLMES SE, 1994, NAT GENET, V7, P143, DOI 10.1038/ng0694-143; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Kamura T, 1997, J BIOL CHEM, V272, P11361; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KRAFT HG, 1992, HUM GENET, V90, P220; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; Lawn RM, 1996, J BIOL CHEM, V271, P31367, DOI 10.1074/jbc.271.49.31367; MAGNAGHI P, 1994, BIOCHEM BIOPH RES CO, V205, P930, DOI 10.1006/bbrc.1994.2754; MAGNAGHI P, 1994, HUM MOL GENET, V3, P437, DOI 10.1093/hmg/3.3.437; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; MIKI Y, 1992, CANCER RES, V52, P643; MILES LA, 1989, NATURE, V339, P301, DOI 10.1038/339301a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PALABRICA TM, 1995, NAT MED, V1, P256, DOI 10.1038/nm0395-256; PEROMBELON YFN, 1994, J CLIN INVEST, V93, P1481, DOI 10.1172/JCI117126; Puckey LH, 1997, HUM MOL GENET, V6, P1099, DOI 10.1093/hmg/6.7.1099; Sassaman DM, 1997, NAT GENET, V16, P37, DOI 10.1038/ng0597-37; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SCOTT A F, 1987, Genomics, V1, P113, DOI 10.1016/0888-7543(87)90003-6; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SINGER MF, 1993, GENE, V135, P183, DOI 10.1016/0378-1119(93)90064-A; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; SWERGOLD GD, 1990, MOL CELL BIOL, V10, P6718, DOI 10.1128/MCB.10.12.6718; TOMLINSON JE, 1989, J BIOL CHEM, V264, P5957; Umezawa A, 1997, MOL CELL BIOL, V17, P4885, DOI 10.1128/MCB.17.9.4885; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WADE DP, 1994, J BIOL CHEM, V269, P19757; WADE DP, 1991, ATHEROSCLEROSIS, V91, P63, DOI 10.1016/0021-9150(91)90187-8; WALSH A, 1993, J LIPID RES, V34, P617; WHITE AL, 1994, J BIOL CHEM, V269, P9060; YANG ZY, 1994, MOL CELL BIOL, V14, P2201, DOI 10.1128/MCB.14.3.2201	59	91	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					891	897		10.1074/jbc.273.2.891	http://dx.doi.org/10.1074/jbc.273.2.891			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422746	hybrid			2022-12-25	WOS:000071411400035
J	Knutson, KL; Hmama, Z; Herrera-Velit, P; Rochford, R; Reiner, NE				Knutson, KL; Hmama, Z; Herrera-Velit, P; Rochford, R; Reiner, NE			Lipoarabinomannan of Mycobacterium tuberculosis promotes protein tyrosine dephosphorylation and inhibition of mitogen-activated protein kinase in human mononuclear phagocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SRC HOMOLOGY-2 DOMAINS; BACTERIAL LIPOPOLYSACCHARIDE; INTERFERON-GAMMA; HUMAN MONOCYTES; MEDIATED ACTIVATION; MURINE MACROPHAGES; FACTOR-ALPHA; PHOSPHORYLATION; IDENTIFICATION	Lipoarabinomannan (LAM) is a putative virulence factor of Mycobacterium tuberculosis that inhibits monocyte functions, and this may involve antagonism of cell signaling pathways, The effects of LAM on protein tyrosine phosphorylation in cells of the human monocytic cell Line THP-1 were examined. LAM promoted tyrosine dephosphorylation of multiple cell proteins and attenuated phorbol 12-myristate 13 acetate-induced activation of mitogen-activated protein kinase. To examine whether these effects of LAM could be related to activation of a phosphatase, fractions from LAM-treated cells were analyzed for dephosphorylation of para-nitrophenol phosphate, The data show that LAM induced increased phosphatase activity associated with the membrane fraction. The Src homology 2 containing tyrosine phosphatase 1 (SHP-1) is important for signal termination and was examined as a potential target of LAM Exposure of cells to LAM brought about (i) an increase in tyrosine phosphorylation of SHP-1, and (ii) translocation of the phosphatase to the membrane. Phosphatase assay of SHP-1 immunoprecipitated from LAM-treated cells, using phosphorylated mitogen-activated protein kinase as substrate, indicated that LAM promoted increased activity of SHP-1 in vivo. LAM also activated SHP-1 directly in. vitro. Exposure of cells to LAM also attenuated the expression of tumor necrosis factor-alpha, interleukin-12, and major histocompatibility class Il molecules, These results suggest that one mechanism by which LAM deactivates monocytes involves activation of SHP-1.	Univ British Columbia, Dept Med, Div Infect Dis, Fac Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Microbiol & Immunol, Fac Med, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Microbiol & Immunol, Fac Sci, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Med, Fac Sci, Div Infect Dis, Vancouver, BC V5Z 3J5, Canada; Vancouver Hosp & Hlth Sci Ctr, Res Inst, Vancouver, BC V57 3J5, Canada; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia; University of Michigan System; University of Michigan	Reiner, NE (corresponding author), Univ British Columbia, Dept Med, Div Infect Dis, Fac Med, 2733 Heather St,Rm 452D, Vancouver, BC V5Z 3J5, Canada.			Herrera, Patricia/0000-0001-8754-9335				ADAMS LB, 1993, INFECT IMMUN, V61, P4173, DOI 10.1128/IAI.61.10.4173-4181.1993; ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BOUCHARD P, 1994, J BIOL CHEM, V269, P19585; BRADBURY MG, 1993, CLIN EXP IMMUNOL, V94, P57; Brumell JH, 1997, J BIOL CHEM, V272, P875, DOI 10.1074/jbc.272.2.875; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHAN J, 1992, J EXP MED, V175, P111; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1992, INFECT IMMUN, V60, P1249, DOI 10.1128/IAI.60.3.1249-1253.1992; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; CHUJOR CSN, 1992, CLIN EXP IMMUNOL, V87, P398; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Dahl KE, 1996, INFECT IMMUN, V64, P399, DOI 10.1128/IAI.64.2.399-405.1996; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DOUVAS GS, 1985, INFECT IMMUN, V50, P1; GERCKEN J, 1994, INFECT IMMUN, V62, P3472, DOI 10.1128/IAI.62.8.3472-3478.1994; HIRSCH CS, 1994, J INFECT DIS, V170, P1229, DOI 10.1093/infdis/170.5.1229; HOBBS MV, 1993, J IMMUNOL, V150, P3602; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; IGARASHI K, 1994, J BIOL CHEM, V269, P14333; JIAO H, 1997, MOL CELL BIOL, V16, P6985; Kaufmann S H, 1993, Trends Microbiol, V1, P2, DOI 10.1016/0966-842X(93)90015-J; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LIU MK, 1994, J IMMUNOL, V153, P2642; Mazzaccaro RJ, 1996, P NATL ACAD SCI USA, V93, P11786, DOI 10.1073/pnas.93.21.11786; MCDONOUGH KA, 1993, INFECT IMMUN, V61, P2763, DOI 10.1128/IAI.61.7.2763-2773.1993; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; MYRVIK QN, 1984, AM REV RESPIR DIS, V129, P322; NANDAN D, 1995, INFECT IMMUN, V63, P4495, DOI 10.1128/IAI.63.11.4495-4500.1995; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Ono M, 1997, CELL, V90, P293, DOI 10.1016/S0092-8674(00)80337-2; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; REINER NE, 1994, IMMUNOL TODAY, V15, P374, DOI 10.1016/0167-5699(94)90176-7; ROACH TIA, 1995, IMMUNOLOGY, V85, P106; ROACH TIA, 1993, J IMMUNOL, V150, P1886; ROSSOMANDO A, 1992, P NATL ACAD SCI USA, V89, P5221, DOI 10.1073/pnas.89.12.5221; Sanghera JS, 1996, J IMMUNOL, V156, P4457; SEGER R, 1992, J BIOL CHEM, V267, P14373; SIBLEY LD, 1990, CLIN EXP IMMUNOL, V80, P141; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; Zhang C, 1997, J IMMUNOL, V158, P4968; ZHANG YH, 1993, J CLIN INVEST, V91, P2076, DOI 10.1172/JCI116430; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251	57	116	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					645	652		10.1074/jbc.273.1.645	http://dx.doi.org/10.1074/jbc.273.1.645			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417127	hybrid			2022-12-25	WOS:000071295600093
J	Ohnishi, M; Hayashi, T; Terawaki, Y				Ohnishi, M; Hayashi, T; Terawaki, Y			Purification and characterization of procytotoxin of Pseudomonas aeruginosa - Dimer to monomer conversion of protoxin by proteolytic activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEPTICUM ALPHA-TOXIN; CYTO-TOXIN; FORMING TOXIN; CYTOTOXIN; PROTEIN; MECHANISM; AEROLYSIN; CONSTRUCTION; MEMBRANES; PHAGE	Cytotoxin of Pseudomonas aeruginosa is a cytolytic toxin that forms a pore on the target membrane by oligomerizing into a pentamer. This toxin is produced as an inactive precursor (proCTX) and is converted to an active form by proteolytic cleavage at the C terminus. We purified proCTX to apparent homogeneity and characterized it in a comparison with the active toxin. ProCTX bound to the erythrocyte membrane but did not form an oligomer on the membrane, hence the lack of hemolytic activity in proCTX, Circular dichroic experiments showed that active and proCTX have similar beta-sheet dominant structures. Intrinsic fluorescence analysis indicated that a molecule-buried tryptophan residue(s) of proCTX was exposed to the surface of the molecule as a result of conversion to the active form, In analytical gel filtration, chemical cross-linking, and analytical ultracentrifugation experiments, dimer to monomer conversion occurred with proteolytic activation.	Shinshu Univ, Sch Med, Dept Bacteriol, Nagano 390, Japan	Shinshu University	Ohnishi, M (corresponding author), Shinshu Univ, Sch Med, Dept Bacteriol, 3-1-1 Asahi, Nagano 390, Japan.							BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BALLARD J, 1995, INFECT IMMUN, V63, P340, DOI 10.1128/IAI.63.1.340-344.1995; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; BALTCH AL, 1994, TOXICON, V32, P27, DOI 10.1016/0041-0101(94)90018-3; BRAUN V, 1991, CRIT REV MICROBIOL, V18, P115, DOI 10.3109/10408419109113511; EDSALL JT, 1943, PROTEINS AMINO ACIDS, P155; HAYASHI T, 1989, MOL MICROBIOL, V3, P861, DOI 10.1111/j.1365-2958.1989.tb00235.x; HAYASHI T, 1990, MOL MICROBIOL, V4, P1703, DOI 10.1111/j.1365-2958.1990.tb00547.x; HAYASHI T, 1993, MOL MICROBIOL, V7, P657, DOI 10.1111/j.1365-2958.1993.tb01157.x; HAYASHI T, 1989, MICROB PATHOGENESIS, V6, P103, DOI 10.1016/0882-4010(89)90013-2; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORY S, 1985, CURR TOP MICROBIOL, V118, P53; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTZ F, 1982, N-S ARCH PHARMACOL, V320, P78, DOI 10.1007/BF00499077; LUTZ F, 1979, TOXICON, V17, P467, DOI 10.1016/0041-0101(79)90280-0; LUTZ F, 1983, TOXICON S, V3, P257; NAKANISHI T, 1994, BIOL MASS SPECTROM, V23, P230, DOI 10.1002/bms.1200230408; NICAS S, 1986, BACTERIA, V10, P195; OHNISHI M, 1994, FEBS LETT, V356, P357, DOI 10.1016/0014-5793(94)01311-X; Parker MW, 1996, MOL MICROBIOL, V19, P205, DOI 10.1046/j.1365-2958.1996.355887.x; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; SCHARMANN W, 1976, J GEN MICROBIOL, V93, P292, DOI 10.1099/00221287-93-2-292; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; WEINER RN, 1985, BIOCHIM BIOPHYS ACTA, V820, P173, DOI 10.1016/0005-2736(85)90110-5; YANG JT, 1986, METHOD ENZYMOL, V130, P208	27	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					453	458		10.1074/jbc.273.1.453	http://dx.doi.org/10.1074/jbc.273.1.453			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417103	hybrid			2022-12-25	WOS:000071295600069
J	Ohya, T; Sasaki, T; Kato, M; Takai, Y				Ohya, T; Sasaki, T; Kato, M; Takai, Y			Involvement of rabphilin3 in endocytosis through interaction with rabaptin5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLE; BOVINE BRAIN; CA2+-DEPENDENT EXOCYTOSIS; MOLECULAR-WEIGHT; TARGET PROTEIN; SMG P25A; MEMBRANE; RAB3A; PURIFICATION	Rabphilin3 and rabaptin5 are downstream target molecules of the Rab3 and -5 subfamily small G proteins that are implicated in exocytosis and endocytosis, respectively. We examined here the physical and functional relationship between the Rab3-rabphilin3 and Rab5-rabaptin5 systems. Rabphilin3 interacted with rabaptin5 at the N-terminal region (amino acids 1-280), which GTP-Rab3A interacted with. The interaction of rabphilin3 with rabaptin5 was inhibited by guanosine 5'-(3-0-thio)triphosphate-Rab3A. Overexpression of the N-terminal fragment of rabphilin3 (amino acids 1-280) inhibited the receptor-mediated endocytosis of transferrin, and this inhibition was overcome by co-transfection with a dominant active mutant of Rab3A or rabaptin5 in PC12 and HeLa cells. These results suggest that rabphilin3, free of GTP-Rab3A, regulates endocytosis through interaction with rabaptin5 after rabphilin3 complexed with GTP-Rab3A regulates exocytosis.	Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 565, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Sch Med, Dept Biochem & Mol Biol, Suita, Osaka 565, Japan.							BENNETT V, 1989, BIOCHIM BIOPHYS ACTA, V988, P107, DOI 10.1016/0304-4157(89)90006-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Kato M, 1996, J BIOL CHEM, V271, P31775, DOI 10.1074/jbc.271.50.31775; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MIYAZAKI M, 1994, BIOCHEM BIOPH RES CO, V205, P460, DOI 10.1006/bbrc.1994.2688; MIYAZAKI M, 1995, MOL BRAIN RES, V28, P29, DOI 10.1016/0169-328X(94)00180-M; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Orita S, 1997, J BIOL CHEM, V272, P16081, DOI 10.1074/jbc.272.26.16081; Orita S, 1996, J BIOL CHEM, V271, P7257, DOI 10.1074/jbc.271.13.7257; OTTO J, 1996, CURR OPIN CELL BIOL, V6, P105; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHWEIZER FE, 1995, NEURON, V14, P689, DOI 10.1016/0896-6273(95)90213-9; Sherman F., 1986, METHODS YEAST GENETI; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SHIRATAKI H, 1994, J BIOL CHEM, V269, P32717; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SHIRATAKI H, 1995, METHOD ENZYMOL, V257, P291; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; Stahl B, 1996, EMBO J, V15, P1799, DOI 10.1002/j.1460-2075.1996.tb00529.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; TAKAISHI K, 1995, ONCOGENE, V11, P39; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; XIUO GH, 1997, J BIOL CHEM, V272, P6097; YAMAGUCHI T, 1993, J BIOL CHEM, V268, P27164	42	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					613	617		10.1074/jbc.273.1.613	http://dx.doi.org/10.1074/jbc.273.1.613			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417123	hybrid			2022-12-25	WOS:000071295600089
J	Rui, H; Xu, J; Mehta, S; Fang, H; Williams, J; Dong, F; Grimley, PM				Rui, H; Xu, J; Mehta, S; Fang, H; Williams, J; Dong, F; Grimley, PM			Activation of the Jak2-Stat5 signaling pathway in Nb2 lymphoma cells by an anti-apoptotic agent, aurintricarboxylic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AURIN TRICARBOXYLIC-ACID; TYROSINE KINASE JAK2; PROLACTIN RECEPTOR; GROWTH-FACTOR; MAP KINASE; PHOSPHORYLATION; PROLIFERATION; GENE; RAT; INTERLEUKIN-2	Biological effects of many hormones and cytokines are mediated through receptor-associated Jak tyrosine kinases and cytoplasmic Stat transcription factors, including critical physiological processes such as immunity, reproduction, and cell growth and differentiation. Pharmaceuticals that control Jak-Stat pathways are therefore of considerable interest. Here we demonstrate that a single Jak-Stat pathway can be activated by aurintricarboxylic acid (ATA), a negatively charged triphenylmethane derivative (475 Da) with anti-apoptotic properties, In prolactin (PRL)-dependent Nb2 lymphocytes, ATA sustained cell growth in the absence of hormone and mimicked rapid PRL-induced tyrosine phosphorylation of Jak2 and activation of Stat5a and Stat5b with tyrosine phosphorylation, heterodimerization, DNA binding, and induction of the Stat5-regulated pim-1 protooncogene. ATA also mimicked PRL activation of serine kinases ERK1 and ERK2, However, unlike PRL, ATA did not regulate Stat1 or Stat3, ATA also did not affect Jak8, which is activated in these cells by interleukin-a family cytokines, Although the mechanism and specificity by which ATA activates Jak2, Stat5, and ERKs in Nb2 cells are still unclear, the present study demonstrates that certain hormone or cytokine effects on Jak-Stat pathways can be discretely imitated by a low molecular weight, non-peptide pharmaceutical. The results are also consistent with Stat5 involvement in lymphocyte growth and survival.	Uniformed Serv Univ Hlth Sci, Sch Med, Dept Pathol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Rui, H (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Pathol, Bethesda, MD 20814 USA.	hrui@usuhs.mil			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052013] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK52013-O1A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APIRION D, 1975, ANTIBIOTICS, V3, P327; BUCKLEY AR, 1995, ENDOCRINOLOGY, V136, P5252, DOI 10.1210/en.136.12.5252; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; DASILVA L, 1994, J BIOL CHEM, V269, P18267; DaSilva L, 1996, MOL CELL ENDOCRINOL, V117, P131, DOI 10.1016/0303-7207(95)03738-1; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUT PW, 1980, CANCER RES, V40, P2433; GUO ZZ, 1993, THROMB RES, V71, P77, DOI 10.1016/0049-3848(93)90207-5; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081; Kirken RA, 1997, J BIOL CHEM, V272, P14098, DOI 10.1074/jbc.272.22.14098; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LAVOIE HA, 1995, P SOC EXP BIOL MED, V209, P257; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miller S.A., 1989, NUCLEIC ACIDS RES, V16, P1216; MULI AL, 1996, EMBO J, V15, P2425; Okada N, 1997, BIOCHEM BIOPH RES CO, V230, P266, DOI 10.1006/bbrc.1996.5934; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; WALKER A, 1987, ENDOCRINOLOGY, V120, P2389, DOI 10.1210/endo-120-6-2389; WINGETT D, 1992, NUCLEIC ACIDS RES, V20, P3183, DOI 10.1093/nar/20.12.3183; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837	32	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					28	32		10.1074/jbc.273.1.28	http://dx.doi.org/10.1074/jbc.273.1.28			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417042	hybrid			2022-12-25	WOS:000071295600008
J	Lorenzo, PS; Bogi, K; Acs, P; Pettit, GR; Blumberg, PM				Lorenzo, PS; Bogi, K; Acs, P; Pettit, GR; Blumberg, PM			The catalytic domain of protein kinase C delta confers protection from down-regulation induced by bryostatin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER-INDUCED DIFFERENTIATION; PHORBOL-ESTER; TUMOR PROMOTERS; CELLS; ALPHA; DEGRADATION; INHIBITION; RECEPTOR; ISOZYMES; PROTEOLYSIS	Bryostatin 1 (Bryo) has been shown to induce biphasic dose-response curves for down-regulating protein kinase C delta (PKC delta) as well as for protecting PKC delta from down-regulation induced by phorbol 12-myristate 13-acetate (PMA). To identify regions within PKC delta that confer these responses to Bryo, we utilized reciprocal PKC alpha and PKC delta chimeras (PKC alpha/delta and PKC delta/alpha) constructed by exchanging the regulatory and catalytic domains of these PKCs, These chimeras and wild-type PKC alpha/alpha and PKC delta/delta constructed in the same way were stably expressed in NIH 3T3 fibroblasts. Twenty-four h of treatment with Bryo induced a biphasic dose-response curve for down-regulating both wild-type PKC delta/delta and the PKC alpha/delta chimera. In contrast, Bryo led to a nearly complete down-regulation of both PKC alpha/alpha and PKC delta/alpha and also produced a faster mobility form of these species on SDS-polyacrylamide gel electrophoresis, The nature of both the regulatory and, to a lesser extent, the catalytic domains affected the potency of Bryo to down-regulate the chimeric PKC proteins as well as to protect PKC alpha/delta and PKC delta/delta from down-regulation. Bryo at high concentrations also inhibited the down-regulation of PKC delta/delta and PKC alpha/delta induced by 1 mu M PMA when co-applied, The portion of PKC protected by Bryo from down-regulation by either Bryo or PMA was localized in the particulate fraction of the cells. We conclude that the catalytic domain of PKC delta confers protection from down-regulation induced by Bryo or Bryo plus PMA, suggesting that this domain contains the isotype-specific determinants involved in the unique effect of Bryo on PKC delta.	NCI, MMTP, LCCTP, NIH, Bethesda, MD 20892 USA; Arizona State Univ, Canc Res Inst, Tempe, AZ 85287 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Arizona State University; Arizona State University-Tempe	Blumberg, PM (corresponding author), NCI, MMTP, LCCTP, NIH, Bldg 37,Rm 3A01,37 Convent Dr,MSC 4255, Bethesda, MD 20892 USA.	blumberp@dc37a.nci.nih.gov						Acs P, 1997, J BIOL CHEM, V272, P22148, DOI 10.1074/jbc.272.35.22148; ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BLUMBERG PM, 1988, CANCER RES, V48, P1; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; DELLAQUILA ML, 1987, CANCER RES, V47, P6006; Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382; Gysin S, 1996, EUR J BIOCHEM, V240, P747, DOI 10.1111/j.1432-1033.1996.0747h.x; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; HUWILER A, 1994, BIOCHEM PHARMACOL, V48, P689, DOI 10.1016/0006-2952(94)90046-9; ISAKOV N, 1993, J IMMUNOL, V150, P1195; KAZANIETZ MG, 1994, MOL PHARMACOL, V46, P374; KENNEDY MJ, 1992, CANCER RES, V52, P1278; KILEY SC, 1995, J CELL SCI, V108, P1003; KILEY SC, 1995, BIOCHEM SOC T, V23, P601, DOI 10.1042/bst0230601; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; KUBO K, 1987, FEBS LETT, V223, P138, DOI 10.1016/0014-5793(87)80524-0; Lee HW, 1996, AM J PHYSIOL-CELL PH, V271, pC304, DOI 10.1152/ajpcell.1996.271.1.C304; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Lee HW, 1997, MOL PHARMACOL, V51, P439; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; Pettit G R, 1991, Fortschr Chem Org Naturst, V57, P153; PETTIT GR, 1982, J AM CHEM SOC, V104, P6846, DOI 10.1021/ja00388a092; Pluda J M, 1996, Oncology (Williston Park), V10, P740; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SMITH JB, 1985, BIOCHEM BIOPH RES CO, V132, P939, DOI 10.1016/0006-291X(85)91898-4; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Szallasi Z, 1996, CANCER RES, V56, P2105; WALKER SD, 1995, P NATL ACAD SCI USA, V92, P9156, DOI 10.1073/pnas.92.20.9156; Wang WJ, 1997, J BIOL CHEM, V272, P76; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775	41	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33338	33343		10.1074/jbc.272.52.33338	http://dx.doi.org/10.1074/jbc.272.52.33338			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407126	hybrid			2022-12-25	WOS:000071182900087
J	Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA				Carstens, RP; Eaton, JV; Krigman, HR; Walther, PJ; Garcia-Blanco, MA			Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer	ONCOGENE			English	Article						prostate cancer; alternative splicing; androgen sensitivity; fibroblast growth factor receptors; xenograft cell lines	CARCINOMA CELL-LINE; EPITHELIAL-CELLS; EXPRESSION; GENES; ESTABLISHMENT; SPECIFICITY; CLONING; MODEL; KGF	Progression of prostate cancer from sensitive to androgen insensitive tumor been shown to be accompanied by a change in alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in a rat model of prostate cancer, This change results in loss of the FGF-R2(IIIb) isoform and predominant expression of the FGF-R2(IIIc) isoform, We sought to determine whether this change in FGF-R2 splicing is also associated with androgen insensitivity in human prostate tumors, We analysed three web characterized human prostate cancer cell lines and three metastatic prostate tumors which have been maintained as xenografts in nude mice, One of the cell lines, LNCaP, and two of the xenografts, DUKAP-1 and DUKAP-2, have been characterized as androgen sensitive, whereas two of the cell lines, DU-145 and PC-3, and one of the xenografts, DU9479, display androgen independent growth, Using an RT-PCR based assay, me demonstrated that progressive loss of the FGF-R2(111b) isoform correlated with androgen insensitivity in these human prostate cancer models. These findings lend support to the hypothesis that that loss of FGF-R2(IIIb) may be one step in a series of events which lead to progression of human prostate cancer.	Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Nephrol, Durham, NC USA; Duke Univ, Med Ctr, Dept Med, Durham, NC USA; Duke Univ, Med Ctr, Div Urol, Durham, NC USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC USA; Duke Univ, Med Ctr, Duke Comprehens Canc Ctr, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Garcia-Blanco, MA (corresponding author), Duke Univ, Med Ctr, Dept Mol Canc Biol, Durham, NC 27710 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRIGATI DJ, 1988, J HISTOTECHNOL, V11, P165, DOI 10.1179/his.1988.11.3.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; CUNHA GR, 1985, CELL DIFFER DEV, V17, P137, DOI 10.1016/0045-6039(85)90481-6; deMedina SGD, 1997, ONCOGENE, V14, P323, DOI 10.1038/sj.onc.1200830; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; EPSTEIN JI, 1983, HUM PATHOL, V15, P853; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GLEAVE ME, 1992, J UROLOGY, V147, P1151, DOI 10.1016/S0022-5347(17)37506-7; GRAHAM SD, 1985, PROSTATE, V7, P369, DOI 10.1002/pros.2990070405; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; ISAACS JT, 1978, CANCER RES, V38, P4353; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAIGHN ME, 1979, INVEST UROL, V17, P16; LAROCHELLE WJ, 1995, J CELL BIOL, V129, P357, DOI 10.1083/jcb.129.2.357; MANSSON PE, 1989, CANCER RES, V49, P2485; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MCKEEHAN WL, 1991, CANCER SURV, V11, P165; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x	32	128	134	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3059	3065		10.1038/sj.onc.1201498	http://dx.doi.org/10.1038/sj.onc.1201498			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444954				2022-12-25	WOS:000070968000006
J	Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV				Nikiforov, MA; Kwek, SSS; Mehta, R; Artwohl, JE; Lowe, SW; Das Gupta, T; Deichman, GI; Gudkov, AV			Suppression of apoptosis by bcl-2 does not prevent p53-mediated control of experimental metastasis and anchorage dependence	ONCOGENE			English	Article						p53; apoptosis; bcl-2; metastasis; anchorage dependence; circulation	PROGNOSTIC-SIGNIFICANCE; P53 MUTATIONS; BREAST-CANCER; EXPRESSION; CELLS; ASSOCIATION; CARCINOMA; TUMORS; GENE; PROGRESSION	Mutations in the p53 tumor suppressor gene are frequently associated with the metastatic stage of tumor progression, Inactivation of p53 was shown to promote metastasis under experimental conditions, To determine the p53 functions that are involved in the control of tumor metastasis, we compared properties of three types of transformed mouse fibroblasts: with intact p53, with p53-mediated apoptosis suppressed by bcl-2 and with p53 inactivated by dominant negative mutants, Although expression of bcl-2 blocked apoptosis in detached cells and increased tumor cell survival in the blood circulation, it was insufficient to affect the ability of p53 to cause cell cycle arrest in detached cells and suppress experimental metastasis. For the suppression of metastasis complete inactivation of p53 was required, We conclude that the apoptotic function of p53 is dispensable for the p53-dependent suppression of experimental metastasis that is presumably achieved by controlling anchorage dependence, These data provide a possible explanation to dramatic differences in values of bcl-2 and mutant p53 as prognostic markers in human cancer.	Univ Illinois, Dept Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Surg Oncol, Chicago, IL 60607 USA; Univ Illinois, Biol Resources Lab, Chicago, IL 60607 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow 115478, Russia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory; Russian Academy of Medical Sciences	Gudkov, AV (corresponding author), Univ Illinois, Dept Mol Genet MC669, 900 S Ashland Ave, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA60730, R21CA62045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAS AL, 1996, NAT MED, V2, P811; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; DAMERON KM, 1994, SCIENCE, V265, P1502; DONG ZY, 1994, CANCER RES, V54, P789; Fidler I.J., 1997, CANC PRINCIPLES PRAC; FUGMANN RA, 1977, CANCER RES, V37, P496; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAGUE A, 1994, ONCOGENE, V9, P3367; Herod JJO, 1996, CANCER RES, V56, P2178; HSIAO M, 1994, AM J PATHOL, V145, P702; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Nikiforov MA, 1996, ONCOGENE, V13, P1709; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P5463; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSURUO T, 1981, CANCER RES, V41, P3058; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1988, CYTOMETRY, V3, P323	34	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3007	3012		10.1038/sj.onc.1201723	http://dx.doi.org/10.1038/sj.onc.1201723			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444949				2022-12-25	WOS:000070968000001
J	Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ				Hogg, A; Schirm, S; Nakagoshi, H; Bartley, P; Ishii, S; Bishop, JM; Gonda, TJ			Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2	ONCOGENE			English	Article						Myb; differentiation; target genes; bcl-2; apoptosis	RNA INHIBITS PROLIFERATION; MURINE HEMATOPOIETIC-CELLS; MYELOID-LEUKEMIA CELLS; HUMAN LYMPHOCYTES-T; V-MYB; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; ERYTHROID-DIFFERENTIATION; DEPENDENT TRANSFORMATION; CONSTITUTIVE EXPRESSION	Primary murine fetal hemopoietic cells were transformed with a fusion protein consisting of the ligand-binding domain of the estrogen receptor and a carboxyl-terminally truncated c-Myb protein (ERMYB), The ERMYB-transformed hemopoietic cells exhibit an immature myeloid phenotype when grown in the presence of beta-estradiol. Upon removal of beta-estradiol, the ERMYB cells display increased adherence, decreased clonogenicity and differentiate to cells exhibiting granulocyte or macrophage morphology, The expression of the c-myc, c-kit, cdc2 and bcl-2 genes, which are putatively regulated by Myb, was investigated in ERMYB cells grown in the presence or absence of beta-estradiol. Neither c-myc nor cdc2 expression was down-regulated after removal of beta-estradiol demonstrating that differentiation is not a consequence of decreased transactivation of these genes by ERMYB. While bcl-2 expression was reduced by 50% in ERMYB cells grown in the absence of beta-estradiol, there was no increase in DNA laddering, suggesting that Myb was not protecting ERMYB cells from apoptosis, In contrast, a substantial (200-fold) decrease in c-kit mRNA level was observed following differentiation of ERMYB cells, and c-kit mRNA could be partially re-induced by the re-addition of beta-estradiol. Furthermore, a reporter construct containing the c-kit promoter was activated when cotransfected with a Myb expression vector, providing further evidence of a role for Myb in the regulation of c-kit.	INST MED & VET SCI,HANSON CTR CANC RES,ADELAIDE,SA 5000,AUSTRALIA; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143; RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOL GENET LAB,TSUKUBA,IBARAKI 305,JAPAN	Institute Medical & Veterinary Science Australia; University of California System; University of California San Francisco; RIKEN			NAKAGOSHI, Hideki/B-2145-2011; Gonda, Thomas J/A-3620-2012; Ishii, Shunsuke/A-5271-2016	NAKAGOSHI, Hideki/0000-0003-0850-1814; Ishii, Shunsuke/0000-0002-6530-2478				ANDRE C, 1989, ONCOGENE, V4, P1047; ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; CRAIG RW, 1995, SEMIN CANCER BIOL, V6, P35, DOI 10.1006/scbi.1995.0005; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Deng QL, 1996, NUCLEIC ACIDS RES, V24, P766, DOI 10.1093/nar/24.4.766; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; EVAN GI, 1992, CELL, V69, P19; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1993, BLOOD, V82, P2813; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GORMAN CM, 1985, DNA CLONING PRACTICA, P143; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HAYASHI SI, 1995, DNA RES, V2, P21; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KU DH, 1993, J BIOL CHEM, V268, P2255; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; MACMILLAN EM, 1994, BLOOD, V83, P209; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P1710, DOI 10.1073/pnas.89.5.1710; REITH AD, 1991, EMBO J, V10, P2451, DOI 10.1002/j.1460-2075.1991.tb07784.x; ROSL F, 1992, NUCLEIC ACIDS RES, V20, P5243, DOI 10.1093/nar/20.19.5243; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Salomoni P, 1997, P NATL ACAD SCI USA, V94, P3296, DOI 10.1073/pnas.94.7.3296; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEBER F, 1984, CELL, V36, P983, DOI 10.1016/0092-8674(84)90048-5; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; YANAGISAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P380, DOI 10.1016/0167-4781(91)90128-9; YASUDA H, 1993, BIOCHEM BIOPH RES CO, V191, P893, DOI 10.1006/bbrc.1993.1301; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	73	56	58	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2885	2898		10.1038/sj.onc.1201472	http://dx.doi.org/10.1038/sj.onc.1201472			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416832				2022-12-25	WOS:A1997YK37700001
J	Mallozzi, C; Di Stasi, AMM; Minetti, M				Mallozzi, C; Di Stasi, AMM; Minetti, M			Peroxynitrite modulates tyrosine-dependent signal transduction pathway of human erythrocyte band 3	FASEB JOURNAL			English	Article						nitric oxide; peroxynitrite; band 3; tyrosine phosphorylation; tyrosine nitration; GAPDH; glycolysis	RED BLOOD-CELL; NITRIC-OXIDE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PROTEIN MODIFICATIONS; MEMBRANE-PROTEIN; PHOSPHORYLATION; SUPEROXIDE; BINDING; INACTIVATION; DEGRADATION	Peroxynitrite, the product of the reaction between nitric oxide and superoxide anion, is able to nitrate protein tyrosines. If this modification occurs on phosphotyrosine kinase substrates, it can down-regulate cell signaling, We investigated the effects of peroxynitrite on band 3-mediated signal transduction of human erythrocytes, Peroxynitrite treatment induced two different responses, At low concentrations (10-100 mu M) it stimulated a metabolic response, leading to 1) a reversible inhibition of phosphotyrosine phosphatase activity, 2) a rise of tyrosine phosphorylation in the 22K cytoplasmic domain of band 3, 3) the release of glyceraldehyde 3-phosphate dehydrogenase from the membrane, and 4) the enhancement of lactate production, At high concentrations (200-1000 mu M), peroxynitrite induced 1) cross-linking of membrane proteins, 2) inhibition of band 3 tyrosine phosphorylation, 3) nitration of tyrosines in the 22K cytoplasmic domain of band 3, 4) binding of hemoglobin to the membrane, 5) irreversible inhibition of phosphotyrosine kinase activity, 6) massive methemoglobin production, and 7) irreversible inhibition of lactate production, Our results demonstrate that at concentrations that could conceivably be achieved in vivo (10-100 mu M), peroxynitrite behaves like other oxidants, i.e., it stimulates band 3 tyrosine phosphorylation and increases glucose metabolism, Thus, one plausible physiologic effect of peroxynitrite is the up-regulation of signaling through the reversible inhibition of phosphotyrosine phosphatase activity, At high concentrations of peroxynitrite, the tyrosine phosphorylation ceases in parallel with the nitration of band 3 tyrosines, but at these concentrations phosphotyrosine kinase activity and glycolysis are also irreversibly inhibited, Thus, at least in red blood cells, the postulated down-regulation of signaling by peroxynitrite cannot merely be ascribed to the nitration of tyrosine kinase targets.	Ist Super Sanita, Dept Cell Biol, Lab Biol Cellulare, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Minetti, M (corresponding author), Ist Super Sanita, Dept Cell Biol, Lab Biol Cellulare, 299 Viale Regina Elena, I-00161 Rome, Italy.			MALLOZZI, CINZIA/0000-0002-6126-9500				Balagopalakrishna C, 1996, BIOCHEMISTRY-US, V35, P6393, DOI 10.1021/bi952875+; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CARRERAS MC, 1994, FEBS LETT, V341, P65, DOI 10.1016/0014-5793(94)80241-6; CASELLI A, 1994, J BIOL CHEM, V269, P24878; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; Epe B, 1996, NUCLEIC ACIDS RES, V24, P4105, DOI 10.1093/nar/24.21.4105; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FUKUDA M, 1978, J BIOL CHEM, V253, P2419; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HARRISON ML, 1991, J BIOL CHEM, V266, P4106; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; JENKINS JD, 1984, J BIOL CHEM, V259, P9374; KAUL R K, 1983, Journal of Biological Chemistry, V258, P7981; KEY MMB, 1996, CELL MOL BIOL, V42, P919; Kong SK, 1996, P NATL ACAD SCI USA, V93, P3377, DOI 10.1073/pnas.93.8.3377; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LANDER HM, 1993, J IMMUNOL, V150, P1509; LOW PS, 1987, J BIOL CHEM, V262, P4592; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1993, J BIOL CHEM, V268, P14627; LOW PS, 1995, PROTOPLASMA, V184, P196, DOI 10.1007/BF01276920; MALLOZZI C, 1995, ARCH BIOCHEM BIOPHYS, V321, P345, DOI 10.1006/abbi.1995.1404; Minetti M, 1996, BIOCHEM J, V319, P369, DOI 10.1042/bj3190369; MINETTI M, 1986, J CELL BIOCHEM, V30, P361, DOI 10.1002/jcb.240300409; Mohr S, 1996, J BIOL CHEM, V271, P4209; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; Mondoro TH, 1997, FREE RADICAL BIO MED, V22, P1055, DOI 10.1016/S0891-5849(96)00510-2; Monteiro HP, 1996, FREE RADICAL BIO MED, V21, P323, DOI 10.1016/0891-5849(96)00051-2; MORENO JJ, 1992, CHEM RES TOXICOL, V5, P425, DOI 10.1021/tx00027a017; MORO MA, 1995, BRIT J PHARMACOL, V116, P1999, DOI 10.1111/j.1476-5381.1995.tb16404.x; MURTHY SNP, 1981, J BIOL CHEM, V256, P1203; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pietraforte D, 1997, BIOCHEM J, V321, P743, DOI 10.1042/bj3210743; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; ROGALSKI AA, 1989, J BIOL CHEM, V264, P6438; RUBBO H, 1994, J BIOL CHEM, V269, P26066; STECK TL, 1978, BIOCHEMISTRY-US, V17, P1216, DOI 10.1021/bi00600a013; STECK TL, 1973, METHOD ENZYMOL, V31, P178; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; TSAI IH, 1982, J BIOL CHEM, V257, P1438; WAUGH SM, 1985, BIOCHEMISTRY-US, V24, P34, DOI 10.1021/bi00322a006; WINTERBOURN CC, 1990, METHOD ENZYMOL, V186, P265; YANAGI S, 1995, CELL SIGNAL, V7, P185, DOI 10.1016/0898-6568(94)00088-S; Zipser Y, 1996, BIOCHEM J, V314, P881, DOI 10.1042/bj3140881	54	140	142	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1281	1290		10.1096/fasebj.11.14.9409547	http://dx.doi.org/10.1096/fasebj.11.14.9409547			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409547				2022-12-25	WOS:000071144100009
J	Bannwarth, S; Giordanengo, V; Lesimple, J; Lefebvre, JC				Bannwarth, S; Giordanengo, V; Lesimple, J; Lefebvre, JC			Molecular cloning of a new secreted sulfated mucin-like protein with a c-type lectin domain that is expressed in lymphoblastic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERED GLYCOSYLATION; BINDING-PROTEIN; CD43; LYMPHOCYTES; TETRANECTIN; AUTOANTIBODIES; PURIFICATION; LEUKOSIALIN; INDIVIDUALS; RECEPTOR	We have previously demonstrated hyposialylation of the two major CD45 and leukosialin (CD43) molecules at the surface of latently human immunodeficiency virus type 1-infected CEM T cells (CEMLAI/NP), (Lefebvre, J. C., Giordanengo, V., Doglio, A, Cagnon, L., Breittmayer, J. P., Peyron, J. F., and Lesimple, J. (1994) Virology 199, 265-274; Lefebvre, J. C., Giordanengo, V., Limouse, M., Doglio, A., Cucchiarini, M., Monpoux, F., Mariani, R., and Peyron, J. F. (1994) J. Exp. Med. 180, 1609-1617). Searching to clarify mechanism(s) of hyposialylation, we observed two sulfated secreted glycoproteins (molecular mass similar to 47 and similar to 40 kDa) (P47 and P40), which were differentially sulfated and/or differentially secreted in the culture supernatants of CEMLAI/NP cells when compared with parental CEM cells. A hybridoma clone (7H1) resulting from the fusion between CEMLAI/NP and human embryonic fibroblasts MRC5 cells produced very large amounts of P47 that was purified using Jacalin lectin (specific for O-glycans) and microsequenced. Cloning of P47 was achieved using a CEMLAI/NP cDNA library screened with a degenerate oligonucleotide probe based on its NH2-terminal amino acid sequence. A single open reading frame encoding a protein of 323 amino acids was deduced from the longest isolated recombinant (1.4 kilobase). P47 is a secreted sulfated protein. It carries an NH2-terminal RGD (Arg-Gly-Asp) triplet, a striking a-helical leucine zipper composed of six heptads, and a C-terminal C-type lectin domain. The NH2-terminal portion is rich in glutamic acids with a predicted pi of 3.9. In addition, a hinge region with numerous condensed potential sites for O-glycan side chains, which are also the most likely sulfation sites, is located between the RGD and leucine zipper domains. Transcripts were detected in lymphoid tissues (notably bone marrow) and abundantly in T and B lymphoblastoid but very faintly in monocytoid cell lines.	Fac Med Nice, Virol Lab, F-06107 Nice 02, France	UDICE-French Research Universities; Universite Cote d'Azur	Lefebvre, JC (corresponding author), Fac Med Nice, Virol Lab, F-06107 Nice 02, France.	lefebvre@unice.fr		giordanengo, valerie/0000-0002-5114-1124				AFROUN S, 1988, BIOCHIM BIOPHYS ACTA, V971, P137; ARDMAN B, 1990, J EXP MED, V172, P1151, DOI 10.1084/jem.172.4.1151; BARKER RL, 1988, J EXP MED, V168, P1493, DOI 10.1084/jem.168.4.1493; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; COHEN J, 1995, SCIENCE, V269, P1044, DOI 10.1126/science.7652551; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DAVIS LG, 1986, BASIC METHODS MOL BI, P130; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; GIORDANENGO V, 1995, EUR J IMMUNOL, V25, P274, DOI 10.1002/eji.1830250145; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; GIORDANENGO V, 1995, BLOOD, V86, P2302, DOI 10.1182/blood.V86.6.2302.bloodjournal8662302; Hiraoka A, 1997, P NATL ACAD SCI USA, V94, P7577, DOI 10.1073/pnas.94.14.7577; HORTIN G, 1986, BIOCHEM BIOPH RES CO, V141, P326, DOI 10.1016/S0006-291X(86)80372-2; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; KAKU H, 1989, METHOD ENZYMOL, V179, P327; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDOLFI NF, 1986, MOL IMMUNOL, V23, P297, DOI 10.1016/0161-5890(86)90057-X; LEFEBVRE JC, 1994, J EXP MED, V180, P1609, DOI 10.1084/jem.180.5.1609; LEFEBVRE JC, 1994, VIROLOGY, V199, P265, DOI 10.1006/viro.1994.1124; LOTAN R, 1975, J BIOL CHEM, V250, P8518; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; NEAME PJ, 1992, PROTEIN SCI, V1, P161; Nielsen BB, 1997, FEBS LETT, V412, P388, DOI 10.1016/S0014-5793(97)00664-9; Perrin C, 1997, CLIN EXP IMMUNOL, V110, P22; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEWER UM, 1992, LAB INVEST, V67, P253; WILSON AP, 1992, J IMMUNOL, V148, P1777; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884	37	15	18	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1911	1916		10.1074/jbc.273.4.1911	http://dx.doi.org/10.1074/jbc.273.4.1911			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442024	hybrid			2022-12-25	WOS:000071595200013
J	Chestkov, VV; Radko, SP; Cho, MS; Chrambach, A; Vogel, SS				Chestkov, VV; Radko, SP; Cho, MS; Chrambach, A; Vogel, SS			Reconstitution of calcium-triggered membrane fusion using "reserve" granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; MEDIATING CELL-ADHESION; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; BIOLOGICAL-MEMBRANES; REGULATED SECRETION; VESICLE EXOCYTOSIS; YOLK PLATELETS; PROTEINS; ATP	Calcium-gated secretion of proteins involves the transfer of "reserve" granules, exocytotic vesicles that are cytoplasmic and, hence, plasma membrane-naive, from the cell interior to the surface membrane where they dock prior to fusion. Docking and subsequent priming steps are thought to require cytoplasmic factors. These steps are believed to induce fusion competence. We have tested this hypothesis by isolating reserve granules from sea urchin eggs and determining under which conditions these granules will fuse, We find that isolated reserve granules, lacking soluble cofactors, support calcium-dependent membrane fusion in vitro, Preincubation with adenosine 5'-3-O-(thio)triphosphate and guanosine 5'-3-O-(thio)triphosphate did not prevent fusion, Thus, isolated reserve granules have all the necessary components required for calcium-gated fusion prior to docking.	Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA; NINDS, Synapt Mechanisms Sect, NIH, Bethesda, MD 20892 USA; NICHD, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; Russian Acad Med Sci, Ctr Genet Med, Moscow, Russia	University System of Georgia; Augusta University; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Russian Academy of Medical Sciences	Vogel, SS (corresponding author), Med Coll Georgia, Inst Mol Med & Genet, 1120 15th St CB 2803, Augusta, GA 30912 USA.		Vogel, Steven/A-3585-2012; Oka, Yoshitaka/C-9670-2010; Radko, Sergey P/G-1783-2017	Oka, Yoshitaka/0000-0002-3482-3051; Radko, Sergey P/0000-0002-0519-1745; Vogel, Steven/0000-0002-3005-2667				ALLIEGRO MC, 1988, DEV BIOL, V125, P208, DOI 10.1016/0012-1606(88)90074-7; ANDERSON E, 1968, J CELL BIOL, V37, P514, DOI 10.1083/jcb.37.2.514; ARMANT DR, 1986, DEV BIOL, V113, P342, DOI 10.1016/0012-1606(86)90169-7; BAKER PF, 1978, NATURE, V276, P513, DOI 10.1038/276513a0; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; Bauer J, 1996, ELECTROPHORESIS, V17, P526, DOI 10.1002/elps.1150170319; Bi GQ, 1995, J CELL BIOL, V131, P1747, DOI 10.1083/jcb.131.6.1747; BISGROVE BW, 1991, DEV BIOL, V146, P89, DOI 10.1016/0012-1606(91)90449-D; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; Calakos N, 1996, PHYSIOL REV, V76, P1; CAZALIS M, 1987, J PHYSIOL-LONDON, V390, P71, DOI 10.1113/jphysiol.1987.sp016687; CERVELLO M, 1989, CELL DIFFER DEV, V26, P67, DOI 10.1016/0922-3371(89)90784-3; CHERNOMORDIK L, 1995, J MEMBRANE BIOL, V146, P1; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; CRABB JH, 1985, J CELL BIOL, V101, P2263, DOI 10.1083/jcb.101.6.2263; EPEL D, 1977, SCI AM, V237, P128, DOI 10.1038/scientificamerican1177-128; FISHKIND DJ, 1990, DEV BIOL, V142, P439, DOI 10.1016/0012-1606(90)90366-Q; FISHKIND DJ, 1990, DEV BIOL, V142, P453, DOI 10.1016/0012-1606(90)90367-R; Gallant PE, 1995, J NEUROCYTOL, V24, P943, DOI 10.1007/BF01215644; GRATWOHL EKM, 1991, MECH DEVELOP, V33, P127, DOI 10.1016/0925-4773(91)90079-L; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOLZ RW, 1989, J BIOL CHEM, V264, P5412; HOWELL TW, 1989, CELL SIGNAL, V1, P157, DOI 10.1016/0898-6568(89)90005-3; JACKSON RC, 1990, J MEMBRANE BIOL, V115, P83, DOI 10.1007/BF01869108; JAFFE LA, 1986, ANNU REV PHYSIOL, V48, P191, DOI 10.1146/annurev.ph.48.030186.001203; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; KAST C, 1994, J BIOL CHEM, V269, P5179; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE MC, 1993, DEVELOPMENT, V117, P1049; MATESE J, 1997, DEV BIOL, V186, P12; MATRANGA V, 1986, EMBO J, V5, P3125, DOI 10.1002/j.1460-2075.1986.tb04619.x; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Miyake K, 1995, J CELL BIOL, V131, P1737, DOI 10.1083/jcb.131.6.1737; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MORRE DJ, 1994, J CHROMATOGR A, V668, P201, DOI 10.1016/0021-9673(94)80110-X; NOLL H, 1985, P NATL ACAD SCI USA, V82, P8062, DOI 10.1073/pnas.82.23.8062; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PAULIK M, 1988, J BIOL CHEM, V263, P17738; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SASAKI H, 1983, DEV BIOL, V98, P327, DOI 10.1016/0012-1606(83)90363-9; Schmid S L, 1993, Subcell Biochem, V19, P1; SCOTT LB, 1990, DEV BIOL, V137, P368, DOI 10.1016/0012-1606(90)90261-G; Shafi Nadeem I., 1994, Methods (Orlando), V6, P82, DOI 10.1006/meth.1994.1010; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; VACQUIER VD, 1975, DEV BIOL, V43, P62, DOI 10.1016/0012-1606(75)90131-1; VATER CA, 1989, DEV BIOL, V135, P111, DOI 10.1016/0012-1606(89)90162-0; VIDAL M, 1995, J BIOL CHEM, V270, P17823, DOI 10.1074/jbc.270.30.17823; VILMARTSEUWEN J, 1986, J CELL BIOL, V103, P1279, DOI 10.1083/jcb.103.4.1279; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; VOGEL SS, 1993, J BIOL CHEM, V268, P25764; WHALLEY T, 1995, J CELL BIOL, V131, P1183, DOI 10.1083/jcb.131.5.1183; WHALLEY T, 1988, BIOSCIENCE REP, V8, P335, DOI 10.1007/BF01115224; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245; ZIMMERBERG J, 1985, J CELL BIOL, V101, P2398, DOI 10.1083/jcb.101.6.2398	60	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2445	2451		10.1074/jbc.273.4.2445	http://dx.doi.org/10.1074/jbc.273.4.2445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442095	hybrid			2022-12-25	WOS:000071595200084
J	Qi, Z; Tang, DM; Zhu, XD; Fujita, DJ; Wang, JH				Qi, Z; Tang, DM; Zhu, XD; Fujita, DJ; Wang, JH			Association of neurofilament proteins with neuronal Cdk5 activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; PAIRED HELICAL FILAMENTS; TAU-PROTEIN; CDC2-LIKE KINASE; RAT CEREBELLUM; BOVINE BRAIN; INTERMEDIATE FILAMENTS; DEVELOPMENTAL-CHANGES; PHOSPHORYLATES TAU	Cdk5 exists in brain extracts in multiple forms, one of which is a macromolecular protein complex comprising Cdk5, neuron-specific Cdk5 activator p35(nck5a) and other protein components (Lee, K.-Y., Resales, J. L., Tang, D., and Wang, J. H. (1996) J. Biol. Chem. 271, 1538-1543). The yeast two-hybrid system was employed to identify p35(nck5a)-interacting proteins from a human brain cDNA library. One of the isolated clones encodes a fragment of glial fibrillary acidic protein, which is a glial-specific protein. Sequence alignment revealed significant homology between the p35(nck5a)-binding fragment of glial fibrillary acidic protein and corresponding regions in neurofilaments. The association between p35(nck5a) and neurofilament medium molecular weight subunit (NF-M) was confirmed by both the yeast two-hybrid assay and direct binding of the bacteria-expressed proteins. The p35(nck5a) binding site on NF-M was mapped to a carboxyl-terminal region of the rod domain, in close proximity to the putative Cdk5 phosphorylation sites in NF-M, A region immediately amino-terminal to the kinase-activating domain in p35(nck5a) is required for its binding with NF-M. In in vitro binding assays, NF-M binds both monomeric p35(nck5a) and the Cdk5/p35(nck5a) complex. The binding of NF-M has no effect on the kinase activity of Cdk5/p35(nck5a).	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada	Hong Kong University of Science & Technology; University of Calgary	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong.		Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Betts JC, 1997, J BIOL CHEM, V272, P12922, DOI 10.1074/jbc.272.20.12922; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; Guidato S, 1996, J NEUROCHEM, V66, P1698; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; Hirooka K, 1996, J NEUROCHEM, V67, P2478; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazaro JB, 1996, NEUROSCI LETT, V218, P21; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; Lee MH, 1996, P NATL ACAD SCI USA, V93, P3259, DOI 10.1073/pnas.93.8.3259; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; Matsushita M, 1996, BRAIN RES, V734, P319, DOI 10.1016/S0006-8993(96)00702-0; MATSUSHITA M, 1995, NEUROREPORT, V6, P1267, DOI 10.1097/00001756-199506090-00009; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Pant HC, 1995, BIOCHEM CELL BIOL, V73, P575, DOI 10.1139/o95-063; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; Poon RYC, 1997, J BIOL CHEM, V272, P5703, DOI 10.1074/jbc.272.9.5703; QI Z, 1995, MOL CELL BIOCHEM, V149, P35, DOI 10.1007/BF01076561; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPERBER BR, 1995, NEUROSCI LETT, V197, P149, DOI 10.1016/0304-3940(95)11902-9; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Sun DM, 1996, J BIOL CHEM, V271, P14245, DOI 10.1074/jbc.271.24.14245; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1996, BIOCHEM CELL BIOL, V74, P419, DOI 10.1139/o96-046; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VULLIET R, 1992, J BIOL CHEM, V267, P22570	41	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2329	2335		10.1074/jbc.273.4.2329	http://dx.doi.org/10.1074/jbc.273.4.2329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442078	hybrid			2022-12-25	WOS:000071595200067
J	Zhang, F; Subbaramaiah, K; Altorki, N; Dannenberg, AJ				Zhang, F; Subbaramaiah, K; Altorki, N; Dannenberg, AJ			Dihydroxy bile acids activate the transcription of cyclooxygenase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FAMILIAL ADENOMATOUS POLYPOSIS; PROSTAGLANDIN-H SYNTHASE-2; CAMP RESPONSE ELEMENT; HUMAN COLON-CANCER; PHORBOL-ESTER; EPITHELIAL-CELLS; ESOPHAGEAL-CARCINOMA; MESSENGER-RNA; CARCINOGENESIS	Bile acids, endogenous promoters of gastrointestinal cancer, activate protein kinase C (PKC) and the activator protein-1 (AP-1) transcription factor. Because other activators of PKC and AP-1 induce cyclooxygenase-a (COX-2), we determined the effects of bile acids on the expression of COX-2 in human esophageal adenocarcinoma cells. Treatment with the dihydroxy bile acids chenodeoxycholate and deoxycholate resulted in an similar to 10-fold increase in the production of prostaglandin E-2 (PGE(2)). Enhanced synthesis of PGE, was associated with a marked increase in the levels of COX-2 mRNA and protein, with maximal effects at 8-12 and 12-24 h, respectively. In contrast, neither cholic acid nor conjugated bile acids affected the levels of COX-2 or the synthesis of PGE(2). Nuclear run-off assays and transient transfections with a human COX-2 promoter construct showed that induction of COX-2 mRNA by chenodeoxycholate and deoxycholate was due to increased transcription. Bile acid-mediated induction of COX-2 was blocked by inhibitors of PI(C activity, including calphostin C and staurosporine. Treatment with bile acid enhanced the phosphorylation of c-Jun and increased binding of AP-1 to DNA. These data are important because dihydroxy bile acid-mediated induction of COX-2 may explain, at least in part, the tumor-promoting effects of bile acids.	New York Hosp, Cornell Med Ctr, Div Digest Dis, Dept Med, New York, NY 10021 USA; New York Hosp, Cornell Med Ctr, Dept Surg, New York, NY 10021 USA; New York Hosp, Cornell Med Ctr, Dept Cardiothorac Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital; Cornell University; NewYork-Presbyterian Hospital	Dannenberg, AJ (corresponding author), New York Hosp, Cornell Med Ctr, Div Digest Dis, Dept Med, Room F-231,1300 York Ave, New York, NY 10021 USA.							ALTORKI N, 1993, CANCER-AM CANCER SOC, V72, P649, DOI 10.1002/1097-0142(19930801)72:3<649::AID-CNCR2820720305>3.0.CO;2-L; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ATTWOOD SEA, 1992, SURGERY, V111, P503; BENNETT A, 1986, PROG LIPID RES, V25, P539, DOI 10.1016/0163-7827(86)90109-8; BENNETT A, 1987, GUT, V28, P315, DOI 10.1136/gut.28.3.315; Boolbol SK, 1996, CANCER RES, V56, P2556; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; FITZER CJ, 1987, CARCINOGENESIS, V8, P217, DOI 10.1093/carcin/8.2.217; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GILLEN P, 1988, BRIT J SURG, V75, P540, DOI 10.1002/bjs.1800750612; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GUILLEM JG, 1987, ARCH SURG-CHICAGO, V122, P1475; HILL MJ, 1991, EUROPEAN JOURNAL OF CANCER PREVENTION, VOL 1, SUPPLEMENT 2, OCTOBER 1991, P69, DOI 10.1097/00008469-199110002-00012; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; Huang CS, 1997, P NATL ACAD SCI USA, V94, P5826, DOI 10.1073/pnas.94.11.5826; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; JONES DA, 1993, J BIOL CHEM, V268, P9049; KAIBARA N, 1984, CANCER RES, V44, P5482; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATOBA N, 1986, J LIPID RES, V27, P1154; MCJUNKIN B, 1981, GASTROENTEROLOGY, V80, P1454; Mestre JR, 1997, CANCER RES, V57, P1081; Mestre JR, 1997, CANCER RES, V57, P2890; Miller BW, 1997, AM J PHYSIOL-CELL PH, V273, pC130, DOI 10.1152/ajpcell.1997.273.1.C130; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PERA M, 1993, ANN THORAC SURG, V55, P1386, DOI 10.1016/0003-4975(93)91077-Z; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; RAMPTON DS, 1981, CLIN SCI, V61, P641, DOI 10.1042/cs0610641; RAO CV, 1995, CANCER RES, V55, P1464; REDDY BS, 1977, CANCER RES, V37, P3238; REDDY BS, 1973, J NATL CANCER I, V50, P1437, DOI 10.1093/jnci/50.6.1437; Ristimaki A, 1997, CANCER RES, V57, P1276; RUBIO CA, 1984, J NATL CANCER I, V72, P705; RUBIO CA, 1986, CANCER, V58, P1029, DOI 10.1002/1097-0142(19860901)58:5<1029::AID-CNCR2820580508>3.0.CO;2-D; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Subbaramaiah K, 1996, CANCER RES, V56, P4424; TIANO H, 1997, P AM ASSOC CANC RES, V38, P1727; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622	57	187	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2424	2428		10.1074/jbc.273.4.2424	http://dx.doi.org/10.1074/jbc.273.4.2424			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442092	hybrid			2022-12-25	WOS:000071595200081
J	Dooley, KA; Millinder, S; Osborne, TF				Dooley, KA; Millinder, S; Osborne, TF			Sterol regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase gene through a direct interaction between sterol regulatory element binding protein and the trimeric CCAAT-binding factor nuclear factor Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; COENZYME-A SYNTHASE; NF-Y; TRANSCRIPTIONAL REGULATION; DNA COMPLEX; FACTOR CBF; ACTIVATION; PROMOTER; SUBUNIT; DOMAINS	3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, a key regulatory enzyme in the pathway for endogenous cholesterol synthesis, is a target for negative feedback regulation by cholesterol. The promoter for HMG-CoA synthase contains two binding sites for the sterol regulatory element-binding proteins (SREBPs), When cellular sterol levels are low, the SREBPs are released from the endoplasmic reticulum membrane, allowing them to translocate to the nucleus and activate SREBP target genes, In all SREBP-regulated promoters studied to date, additional co-regulatory transcription factors are required, In the HMG-CoA synthase promoter there are several potential co-regulatory transcription factor binding sites, including an inverted CCAAT box, A similar element has been shown to function with SREBP to mediate sterol regulation of another gene involved in cholesterol metabolism, farnesyl diphosphate synthase, Here, we show that CCAAT binding factor/nuclear factor Y (CBF/NF-Y) binding to the CCAAT box is required for sterol-regulated transcription of HMG-CoA synthase, The SREBP sites and the inverted CCAAT box are normally separated by 17 base pairs, and we show that increasing this distance results in a decrease in the level of transcriptional regulation by sterols, Furthermore, we provide evidence that there is a direct interaction between CBF/NF-Y and the basic helix-loop-helix-zipper region of SREBP, Interestingly, this interaction does not occur efficiently with any of the isolated subunits and appears to require all three nonidentical CBF/NF-Y subunits in a preassembled complex, Since CBF/NF-Y only binds to DNA when all three subunits are in a complex, this would prevent SREBP from forming nonproductive associations with the individual subunits.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline; NIGMS NIH HHS [GM07311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI LD, 1993, GENE DEV, V7, P1341, DOI 10.1101/gad.7.7b.1341; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; Ericsson J, 1997, J BIOL CHEM, V272, P7298, DOI 10.1074/jbc.272.11.7298; Ericsson J, 1996, J BIOL CHEM, V271, P24359, DOI 10.1074/jbc.271.40.24359; GIL G, 1986, J BIOL CHEM, V261, P3710; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Groisman R, 1996, J BIOL CHEM, V271, P5258; Guan GM, 1997, J BIOL CHEM, V272, P10295; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LI XY, 1992, J BIOL CHEM, V267, P8984; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MILOS PM, 1992, GENE DEV, V6, P991, DOI 10.1101/gad.6.6.991; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SMITH JR, 1988, J BIOL CHEM, V263, P18480; VALLETT SM, 1994, NUCLEIC ACIDS RES, V22, P5184, DOI 10.1093/nar/22.24.5184; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x; Yokoyama C., 1993, CELL, V75, P185	34	158	158	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1349	1356		10.1074/jbc.273.3.1349	http://dx.doi.org/10.1074/jbc.273.3.1349			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430668	hybrid			2022-12-25	WOS:000071411500015
J	Sahoo, D; Narayanaswami, V; Kay, CM; Ryan, RO				Sahoo, D; Narayanaswami, V; Kay, CM; Ryan, RO			Fluorescence studies of exchangeable apolipoprotein-lipid interactions - Superficial association of apolipophorin III with lipoprotein surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PENETRATION DEPTH; HIGH-DENSITY-LIPOPROTEINS; MANDUCA-SEXTA; A-I; RESIDUES; BINDING; MODEL; HELIX; CONFORMATION; SPECTROSCOPY	Apolipophorin III (apoLp-III) from the Sphinx moth, Manduca sexta, is an 18-kDa exchangeable apolipoprotein that reversibly associates with lipoprotein particles, In the absence of Lipid, apoLp-III exists as an elongated bundle of five amphipathic alpha-helices. Upon lipid association, the protein is postulated to undergo a major conformational change, wherein the bundle opens around hinge loop regions, resulting in exposure of its hydrophobic interior, Fluorescence quenching techniques have been employed to study apoLp-III helix topography and spatial arrangement in phospholipid disc complexes and intact lipoprotein particles, Intrinsic fluorescence of the single tyrosine in apoLp-III was exploited to monitor the location of helix 5 in model disc complexes, To investigate other regions of the protein, site-directed mutagenesis was performed to introduce cysteine residues, replacing Asn-40 (helix 2, N40C) or Leu-90 (helix 3, L90C), thereby providing two mutant apoLp-IIIs, each with a single site for covalent attachment of the extrinsic fluorescent probe, N-(l-pyrene) maleimide, In the lipid-free state, pyrene-N40C- and pyrene-L90C-apoLp-III were highly accessible to the negatively charged aqueous quencher KI, yielding K-sv, values of 27.1 and 19.8 M-1, respectively, Upon binding to the surface of a spherical lipoprotein particle, K-sv, values for hi decreased by about 90% for bath pyrene-labeled apoLp-IIIs, indicating a significant change in the local microenvironment of the fluorophores. A lesser decrease in K-sv,, was observed when the pyrene-labeled apoLp-IIIs were bound to phospholipid disc complexes. When spin-labeled fatty acids 5-doxylstearic acid and 12-doxylstearic acid were used as lipophilic quenchers, tyrosine and pyrene fluorescence were more effectively quenched by 5-doxylstearic acid in both phospholipid bilayer disc complexes and spherical lipoprotein particles., These data provide insight into the spatial topography of apoLp-III alpha-helices in phospholipid disc complexes and support the concept that interaction with spherical lipoprotein particles results in superficial contact of apoLp-III helical segments with the monolayer surface, providing a basis for its reversible binding ability.	Univ Alberta, Dept Biochem, Prot Engn Network Ctr Excellence, Lipid & Lipoprotein Res Grp, Edmonton, AB T6G 2S2, Canada	University of Alberta	Ryan, RO (corresponding author), Univ Alberta, Dept Biochem, Prot Engn Network Ctr Excellence, Lipid & Lipoprotein Res Grp, 328 Heritage Med Res Ctr, Edmonton, AB T6G 2S2, Canada.	Robert.Ryan@Ualberta.ca		Narayanaswami, Vasanthy/0000-0001-7088-4057				ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5312, DOI 10.1021/bi00138a010; Benetollo C, 1996, EUR J BIOCHEM, V242, P657, DOI 10.1111/j.1432-1033.1996.0657r.x; BLACKLOCK BJ, 1994, INSECT BIOCHEM MOLEC, V24, P855, DOI 10.1016/0965-1748(94)90015-9; BLATT E, 1985, BIOCHIM BIOPHYS ACTA, V822, P43, DOI 10.1016/0304-4157(85)90003-6; BRASSEUR R, 1990, BIOCHIM BIOPHYS ACTA, V1043, P245, DOI 10.1016/0005-2760(90)90023-Q; BRIETER DR, 1991, BIOCHEMISTRY-US, V30, P603; CALABRESI L, 1993, BIOCHEMISTRY-US, V32, P6477, DOI 10.1021/bi00076a023; CHATELIER RC, 1985, EUR BIOPHYS J BIOPHY, V11, P179, DOI 10.1007/BF00257396; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; DALTON LA, 1987, BIOCHEMISTRY-US, V26, P2117, DOI 10.1021/bi00382a009; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FIELDING CJ, 1995, J LIPID RES, V36, P211; GREEN JA, 1973, J CHEM PHYS, V58, P2690, DOI 10.1063/1.1679569; GRIESER F, 1980, J AM CHEM SOC, V102, P7258, DOI 10.1021/ja00544a016; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LIANG HQ, 1994, J LIPID RES, V35, P1187; LINS L, 1993, BIOCHIM BIOPHYS ACTA, V1149, P267, DOI 10.1016/0005-2736(93)90210-Q; LIU H, 1993, FEBS LETT, V316, P27, DOI 10.1016/0014-5793(93)81730-N; LIU H, 1991, BIOCHEM BIOPH RES CO, V179, P734, DOI 10.1016/0006-291X(91)91878-G; MITRA B, 1990, BIOCHEMISTRY-US, V29, P9879, DOI 10.1021/bi00494a018; Narayanaswami V, 1996, ARCH BIOCHEM BIOPHYS, V334, P143, DOI 10.1006/abbi.1996.0439; Narayanaswami V, 1996, J BIOL CHEM, V271, P26855, DOI 10.1074/jbc.271.43.26855; Narayanaswami V, 1997, BIOCHEM SOC T, V25, P1113, DOI 10.1042/bst0251113; NARAYANASWAMI V, 1994, BIOCHEMISTRY-US, V33, P13312, DOI 10.1021/bi00249a018; NARAYANASWAMI V, 1993, BIOCHEMISTRY-US, V32, P12413, DOI 10.1021/bi00097a020; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; ROZEK A, 1995, BIOCHEMISTRY-US, V34, P7401, DOI 10.1021/bi00022a013; RYAN RO, 1995, J LIPID RES, V36, P1066; RYAN RO, 1993, J BIOL CHEM, V268, P1525; SANGER F, 1977, P NATL ACAD SCI USA, V74, P563; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; VOGES KP, 1987, BIOCHIM BIOPHYS ACTA, V896, P64, DOI 10.1016/0005-2736(87)90357-9; Wang JJ, 1997, J BIOL CHEM, V272, P17912, DOI 10.1074/jbc.272.29.17912; WANG JJ, 1995, BIOCHEMISTRY-US, V34, P6755, DOI 10.1021/bi00020a021; WANG JJ, 1992, BIOCHEMISTRY-US, V31, P8706, DOI 10.1021/bi00152a004; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	40	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1403	1408		10.1074/jbc.273.3.1403	http://dx.doi.org/10.1074/jbc.273.3.1403			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430675	hybrid			2022-12-25	WOS:000071411500022
J	Kain, R; Angata, K; Kerjaschki, D; Fukuda, M				Kain, R; Angata, K; Kerjaschki, D; Fukuda, M			Molecular cloning and expression of a novel human trans-Golgi network glycoprotein, TGN51, that contains multiple tyrosine-containing motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; DI-LEUCINE MOTIF; LYSOSOMAL MEMBRANE-PROTEIN; CYTOPLASMIC DOMAIN; ENDOCYTIC PATHWAY; MAMMALIAN-CELLS; GLYCOPHORIN-A; TGN38; SEQUENCE; LOCALIZATION	Previously, it has been shown that glycoproteins with similar to 130-kDa molecular mass react with antisera from patients with renal vasculitis (Kain, R., Matsui, K.,, Exner, Wi., Binder, S.,, Schaffner, G.;,, Sommer, E., M., and Kerjaschki, D., (1995) J., Exp, Med, 181, 585-597), To search for a molecule that reacts with the antibodies, we screened a lambda gt11 human placental cDNA library, Two of the isolated clones were found to encode a putative counterpart of the rodent trans-Golgi network (TGN) glycoprotein 38, hTGN46, which has the tyrosine containing motif YQRL shared by mouse and rat TGN38. Moreover, reverse transcription-polymerase chain reaction analysis of hTGN46 transcripts and genomic analysis of a cDNA deposited as an expressed sequence tag in dbEST Data Base revealed that additional cDNAs exist that are produced by alternate usage of 3'-splice sites of intron III, Alternative splicing results in frame shifts and leads to novel larger translation products with one (for hTGN48) or two (for hTGN51) additional tyrosine-containing motifs, hTGN51 expressed in Chinese hamster ovary cells were localized to the trans-Golgi network, overlapping with beta-1,4-galactosyltransferase even after mutating the tyrosine-containing motif common to hTGN46. In contrast, mutated hTGN48 and hTGN46 are no longer retrieved to the TGN, These results strongly suggest that hTGN51 may have a unique function compared with hTGN46 or hTGN48 in shuttling between the cell surface and the TGN.	Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA; Univ Vienna, Inst Clin Pathol, Div Ultrastruct Pathol & Cell Biol, A-1090 Vienna, Austria	Sanford Burnham Prebys Medical Discovery Institute; University of Vienna	Fukuda, M (corresponding author), Burnham Inst, La Jolla Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018; Kain, Renate/ACR-4709-2022	Angata, Kiyohiko/0000-0001-5561-1368; Kain, Renate/0000-0002-2428-543X	NATIONAL CANCER INSTITUTE [R01CA048737] Funding Source: NIH RePORTER; NCI NIH HHS [CA48737] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Angata K, 1997, J BIOL CHEM, V272, P7182, DOI 10.1074/jbc.272.11.7182; AOKI D, 1992, P NATL ACAD SCI USA, V89, P4319, DOI 10.1073/pnas.89.10.4319; BURKE J, 1992, J BIOL CHEM, V267, P24433; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; Fukuda M, 1994, Subcell Biochem, V22, P199; FUKUDA MN, 1995, GENE DEV, V9, P1199, DOI 10.1101/gad.9.10.1199; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gough NR, 1997, J CELL BIOL, V137, P1161, DOI 10.1083/jcb.137.5.1161; GRIFFIN HG, 1994, PCR TECHNOLOGY, P37; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HATEM CL, 1995, J CELL SCI, V108, P2093; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; KAIN R, 1995, J EXP MED, V181, P585, DOI 10.1084/jem.181.2.585; KASAI K, 1995, J BIOL CHEM, V270, P14471, DOI 10.1074/jbc.270.24.14471; KERJASCHKI D, 1989, J IMMUNOL, V143, P546; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; Nakayama J, 1996, J BIOL CHEM, V271, P3684; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; OGATA S, 1994, J BIOL CHEM, V269, P5210; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; ONDA M, 1995, GENE, V159, P225, DOI 10.1016/0378-1119(95)00075-H; PETERS C, 1990, EMBO J, V9, P3497, DOI 10.1002/j.1460-2075.1990.tb07558.x; POND L, 1995, J BIOL CHEM, V270, P19989, DOI 10.1074/jbc.270.34.19989; PONNAMBALAM S, 1994, J CELL BIOL, V125, P253, DOI 10.1083/jcb.125.2.253; Ponnambalam S, 1996, J CELL SCI, V109, P675; REAVES B, 1992, BIOCHEM J, V283, P313, DOI 10.1042/bj2830313; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; SAWADA R, 1993, J BIOL CHEM, V268, P9014; SIEBERT PD, 1987, P NATL ACAD SCI USA, V84, P6735, DOI 10.1073/pnas.84.19.6735; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UEMURA M, 1992, CANCER RES, V52, P6153; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955; WONG SH, 1993, J BIOL CHEM, V268, P22853	46	28	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					981	988		10.1074/jbc.273.2.981	http://dx.doi.org/10.1074/jbc.273.2.981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422759	hybrid			2022-12-25	WOS:000071411400048
J	Porwoll, S; Loch, N; Kannicht, C; Nuck, R; Grunow, D; Reutter, W; Tauber, R				Porwoll, S; Loch, N; Kannicht, C; Nuck, R; Grunow, D; Reutter, W; Tauber, R			Cell surface glycoproteins undergo postbiosynthetic modification of their N-glycans by stepwise demannosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; PLASMA-MEMBRANE GLYCOPROTEINS; BROAD-SPECIFICITY ALPHA-1->2; RAT-LIVER; SUBCELLULAR-DISTRIBUTION; INTRACELLULAR MOVEMENT; GOLGI-APPARATUS; HEPATOMA-CELLS; MANNOSIDASE-I; CORE SUGARS	Primary rat hepatocytes and two hepatoma cell lines have been used to study whether high mannose-type N-glycans of plasma membrane glycoproteins may be modified by the removal of mannose residues even after transport to the cell surface. To examine glycan remodeling of cell surface glycoproteins, high mannose-type glycoforms were generated by adding the reversible mannosidase I inhibitor deoxymannojirimycin during metabolic labeling with [H-3]mannose, thereby preventing further processing of high mannose-type N-glycans to complex structures. Upon transport to the cell surface, glycoproteins were additionally labeled with sulfo-succinimidyl-2-(biotinamido)ethyl-1,3-dithiopropionate. This strategy allowed us to follow selectively the fate of cell surface glycoproteins. Postbiosynthetic demannosylation was monitored by determining the conversion of Man(8-9)GlcNAc(2) to smaller structures during reculture of cells in the absence of deoxymannojirimycin. The results show that high mannose-type N-glycans of selected cell surface glycoproteins are trimmed from Man(8-9)GlcNAc(2) to Man(5)GlcNAc(2) with Man(7)GlcNAc(2) and Man(6)GlcNAc(2) formed as intermediates. It could be clearly shown in MH 7777 as well as in HepG2 cells that demannosylation affects plasma membrane glycoproteins after they are routed to the cell surface, As was determined for total cell surface glycoproteins in HepG2 cells, this process occurs with a half-time of 6.7 h, By analyzing the size of high mannose-type glycans of glycoproteins isolated from the cell surface at the end of the reculture period, i.e, after trimming had occurred, we were able to demonstrate that glycoproteins carrying trimmed high mannose glycans become exposed at the cell surface. From these data we conclude that cell surface glycoproteins can be trimmed by mannosidases at sites peripheral to N-acetylglucosaminyltransferase I without further processing of their glycans to the complex form. This glycan remodeling may occur at the cell surface or during endocytosis and recycling back to the cell surface.	Humboldt Univ, Klinikum Rudolf Virchow, Inst Klin Chem & Biochem, D-13353 Berlin, Germany; Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Tauber, R (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, Hindenburgdamm 30, D-12200 Berlin, Germany.							ANUMULA KR, 1991, EUR J BIOCHEM, V195, P269, DOI 10.1111/j.1432-1033.1991.tb15703.x; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BAUMANN H, 1983, J CELL BIOL, V96, P139, DOI 10.1083/jcb.96.1.139; BAUSE E, 1992, EUR J BIOCHEM, V208, P451, DOI 10.1111/j.1432-1033.1992.tb17207.x; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; BECKER A, 1993, EUR J BIOCHEM, V214, P539, DOI 10.1111/j.1432-1033.1993.tb17952.x; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; BONAY P, 1991, EUR J BIOCHEM, V197, P229, DOI 10.1111/j.1432-1033.1991.tb15903.x; BONAY P, 1992, EUR J BIOCHEM, V205, P399, DOI 10.1111/j.1432-1033.1992.tb16793.x; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRANDLI AW, 1989, EMBO J, V8, P3207, DOI 10.1002/j.1460-2075.1989.tb08479.x; CUMMINGS RD, 1992, GLYCOCONJUGATES COMP, P333; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; GEYER R, 1987, GLYCOCONJUGATE J, V4, P17, DOI 10.1007/BF01048441; GREEN SA, 1990, J BIOL CHEM, V265, P21269; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HUANG KM, 1993, J BIOL CHEM, V268, P9302; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KREISEL W, 1980, P NATL ACAD SCI-BIOL, V77, P1828, DOI 10.1073/pnas.77.4.1828; KREISEL W, 1988, J BIOL CHEM, V263, P11736; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCH N, 1992, EUR J BIOCHEM, V210, P161, DOI 10.1111/j.1432-1033.1992.tb17404.x; LOCH N, 1991, FEBS LETT, V294, P217, DOI 10.1016/0014-5793(91)81433-9; LUCKA L, 1995, EUR J BIOCHEM, V234, P527, DOI 10.1111/j.1432-1033.1995.527_b.x; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; NEUMEIER R, 1984, FEBS LETT, V168, P241, DOI 10.1016/0014-5793(84)80254-9; NUCK R, 1993, EUR J BIOCHEM, V216, P215, DOI 10.1111/j.1432-1033.1993.tb18135.x; OKU H, 1991, J BIOCHEM-TOKYO, V110, P982, DOI 10.1093/oxfordjournals.jbchem.a123700; REICHNER JS, 1988, J BIOL CHEM, V263, P16316; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SNIDER MD, 1991, INTRACELLULAR TRAFFI, P361; TAUBER R, 1989, EUR J BIOCHEM, V186, P55, DOI 10.1111/j.1432-1033.1989.tb15177.x; TAUBER R, 1983, P NATL ACAD SCI-BIOL, V80, P4026, DOI 10.1073/pnas.80.13.4026; TAUBER R, 1992, GLYCOCONJUGATE J, V9, P132, DOI 10.1007/BF00780760; TAUBER R, 1992, ENDOCYTOSIS, P187; TULSIANI DRP, 1989, J CELL BIOL, V109, P1257, DOI 10.1083/jcb.109.3.1257; TULSIANI DRP, 1985, J BIOL CHEM, V260, P3081; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; VOLK BA, 1983, FEBS LETT, V163, P150, DOI 10.1016/0014-5793(83)81183-1; VOLZ B, 1995, J CELL BIOL, V130, P537, DOI 10.1083/jcb.130.3.537	48	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1075	1085		10.1074/jbc.273.2.1075	http://dx.doi.org/10.1074/jbc.273.2.1075			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422772	hybrid			2022-12-25	WOS:000071411400061
J	van Echten-Deckert, G; Giannis, A; Schwarz, A; Futerman, AH; Sandhoff, K				van Echten-Deckert, G; Giannis, A; Schwarz, A; Futerman, AH; Sandhoff, K			L-Methylthiodihydroceramide, a novel analog of dihydroceramide, stimulates sphinganine degradation resulting in decreased de novo sphingolipid biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY CULTURED NEURONS; SPHINGOSINE KINASE; SIGNAL-TRANSDUCTION; DENDRITE GROWTH; 2ND MESSENGER; CERAMIDE; CELLS; INHIBITION; BASES; FUMONISIN-B(1)	1-Methylthiodihydroceramide (10 mu M) decreased de novo ceramide biosynthesis by about 90% in primary cultured cerebellar neurons, Accordingly, de novo formation of sphingomyelin and of glycosphingolipids, all of which contain ceramide in their backbone, was reduced in a time-and concentration-dependent manner by up to 80%. Complex sphingolipid synthesis was restored upon addition of dihydroceramide or ceramide, in micromolar concentrations, to the culture medium, suggesting that none of the glycosyltransferases in volved in glycosphingolipid biosynthesis is inhibited by this analog, Assays of the enzymes catalyzing sphinganine biosynthesis, as well as its N-acylation to form dihydroceramide, revealed that they were also not affected, In contrast, there was a 2.5-fold increase in the activity of sphinganine kinase, Reduction of de novo sphingolipid biosynthesis by 1-methylthiodihydroceramide is therefore due to its ability to deplete cells of newly formed free sphinganine. As a consequence of depletion of sphinganine levels, 1-methylthiodihydroceramide disrupted axonal growth in cultured hippocampal neurons in a manner similar to that reported for direct inhibitors of sphingolipid synthesis; thus, there was essentially no axon growth after incubation with 1-methylthiodihydroceramide between days 2 and 3, and co-incubation with short acyl chain analogs of ceramide (5 mu m) antagonized the inhibition of growth, Interestingly, the D-erythro and the L-threo isomere were equally effective, but the corresponding free base as well as other structurally related compounds did not affect either sphingolipid biosynthesis or neuronal growth.	Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany; Weizmann Inst Sci, Dept Membrane Res & Biophys, IL-76100 Rehovot, Israel	University of Bonn; Weizmann Institute of Science	van Echten-Deckert, G (corresponding author), Univ Bonn, Kekule Inst Organ Chem & Biochem, Gerhard Domagkstr 1, D-53121 Bonn, Germany.	echten@snchemie1.chemie.uni-bonn.de		Futerman, Anthony/0000-0003-0013-0115				BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; Boldin S, 1997, J NEUROCHEM, V68, P882; BRENNERWEISS G, 1992, TETRAHEDRON, V48, P5855, DOI 10.1016/S0040-4020(01)90177-2; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; Buehrer BM, 1996, BBA-LIPID LIPID MET, V1303, P233, DOI 10.1016/0005-2760(96)00092-6; CLASEN K, 1994, THESIS U BONN GERMAN; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; FURUYA S, 1995, J NEUROCHEM, V65, P1551; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; Goslin K., 1991, CULTURING NERVE CELL, P251; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAREL R, 1993, J BIOL CHEM, V268, P14476; Hirschberg K, 1996, J BIOL CHEM, V271, P14876, DOI 10.1074/jbc.271.25.14876; INOKUCHI JI, 1987, J LIPID RES, V28, P565; Kolter T, 1996, CHEM SOC REV, V25, P371, DOI 10.1039/cs9962500371; MANDON EC, 1991, EUR J BIOCHEM, V198, P667, DOI 10.1111/j.1432-1033.1991.tb16065.x; Merrill AH, 1996, TRENDS CELL BIOL, V6, P218, DOI 10.1016/0962-8924(96)10021-0; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; MESSER A, 1977, BRAIN RES, V130, P1, DOI 10.1016/0006-8993(77)90838-1; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; NAGAI Y, 1995, BEHAV BRAIN RES, V66, P99, DOI 10.1016/0166-4328(94)00130-8; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; OLIVERA A, 1994, ANAL BIOCHEM, V223, P306, DOI 10.1006/abio.1994.1589; Radin N S, 1981, Methods Enzymol, V72, P673; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Schwarz A, 1997, J NEUROSCI, V17, P2929; SMITH ER, 1995, J BIOL CHEM, V270, P18749, DOI 10.1074/jbc.270.32.18749; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1994, PROGR BRAIN RES, V101; TRENKNER E, 1977, J CELL BIOL, V75, P915, DOI 10.1083/jcb.75.3.915; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, J BIOL CHEM, V265, P9333; vanEchtenDeckert G, 1997, J BIOL CHEM, V272, P15825, DOI 10.1074/jbc.272.25.15825; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Wang F, 1996, GLYCOCONJUGATE J, V13, P937, DOI 10.1007/BF01053189; Wiesner DA, 1996, J NEUROCHEM, V66, P1418; ZIMMERMANN P, 1988, LIEBIGS ANN CHEM, P663	43	25	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1184	1191		10.1074/jbc.273.2.1184	http://dx.doi.org/10.1074/jbc.273.2.1184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422785	hybrid			2022-12-25	WOS:000071411400074
J	Fulkerson, JF; Garner, RM; Mobley, HLT				Fulkerson, JF; Garner, RM; Mobley, HLT			Conserved residues and motifs in the NixA protein of Helicobacter pylori are critical for the high affinity transport of nickel ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELIC EXCHANGE MUTAGENESIS; ESCHERICHIA-COLI; ALCALIGENES-EUTROPHUS; UREASE; INFECTION; PURIFICATION; EXPRESSION; INHIBITORS; GASTRITIS; STOMACH	NixA, the high affinity nickel transport protein of Helicobacter pylori, imports Ni2+ ions across the cytoplasmic membrane for insertion into the active site of the urease metalloenzyme, which is essential for colonization of the gastric mucosa, Twelve conserved aspartate (aspartates 47, 49, 55, 194, 231, and 234), glutamate (glutamates 106, 198, and 274), and histidine (histidines 44, 50, and 79) residues were identified by alignment of NixA with homologous transporters, Polymerase chain reaction-generated site-directed mutants of these residues mere expressed in E. coli along with the H. pylori urease gene cluster. Mutations in residues within the predicted periplasmic domains of NixA maintained near wild type levels of Ni2+ uptake and urease activity, as did control mutations of conserved positively charged residues (lysines 140 and 268; arginines 162 and 167). Mutations in highly conserved motifs in predicted helices II and III of NixA abolished Ni2+ uptake and urease activity, Mutations in helices V and VI and the cytoplasmic domains decreased Ni2+ transport rates by greater than or equal to 90%. Reduction in rates of Ni2+ transport correlated with reduction in urease activities (r = 0.77), Ni2+ transport was inhibited in the presence of Co2+, Cu2+ and Zn2+ indicating that these ions may also be bound or trans ported by NixA. We conclude that conserved Asp, Glu, and His residues in the transmembrane domains of NixA are critical for the transport of the divalent cations Ni2+, Co2+, Cu2+, and Zn2+ into the cytoplasm of H. pylori.	Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Mobley, HLT (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, 655 W Baltimore St,Room 13-009, Baltimore, MD 21201 USA.		Mobley, Harry L T/A-6901-2009	Mobley, Harry/0000-0001-9195-7665	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bauerfeind P, 1996, INFECT IMMUN, V64, P2877, DOI 10.1128/IAI.64.7.2877-2880.1996; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BLASER MJ, 1990, J INFECT DIS, V161, P626, DOI 10.1093/infdis/161.4.626; BLASER MJ, 1990, REV INFECTIOUS DI S1, V12, P99; Creighton T.E., 1993, PROTEINS STRUCTURES, P186; DEPINA K, 1995, EUR J BIOCHEM, V227, P857; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; Eitinger T, 1997, J BIOL CHEM, V272, P17139, DOI 10.1074/jbc.272.27.17139; Eitinger T, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P235; EITINGER T, 1994, MOL MICROBIOL, V12, P1025, DOI 10.1111/j.1365-2958.1994.tb01090.x; FIGURA N, 1989, J CLIN MICROBIOL, V27, P225, DOI 10.1128/JCM.27.1.225-226.1989; FORMAN D, 1991, BRIT MED J, V302, P1302, DOI 10.1136/bmj.302.6788.1302; FU CL, 1994, P NATL ACAD SCI USA, V91, P5099, DOI 10.1073/pnas.91.11.5099; GE ZM, 1995, MOL MICROBIOL, V15, P97, DOI 10.1111/j.1365-2958.1995.tb02224.x; HAMILTONMILLER JMT, 1979, INVEST UROL, V16, P327; HAWTIN PR, 1991, FEMS MICROBIOL LETT, V77, P51, DOI 10.1016/S0378-1097(99)00303-1; HAZELL SL, 1985, CAMPYLOBACTER, V3, P189; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HU LT, 1990, INFECT IMMUN, V58, P992, DOI 10.1128/IAI.58.4.992-998.1990; HU LT, 1993, INFECT IMMUN, V61, P2563, DOI 10.1128/IAI.61.6.2563-2569.1993; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; LEE A, 1994, HELICOBACTER PYLORI; MAEDA M, 1994, J BACTERIOL, V176, P432, DOI 10.1128/JB.176.2.432-442.1994; MARSHALL BJ, 1985, MED J AUSTRALIA, V142, P439, DOI 10.5694/j.1326-5377.1985.tb113444.x; MARSHALL BJ, 1984, LANCET, V1, P1311; MARSHALL BJ, 1988, CAMPYLOBACTER, V4, P402; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; MOBLEY HLT, 1995, MOL MICROBIOL, V16, P97, DOI 10.1111/j.1365-2958.1995.tb02395.x; MOBLEY HLT, 1986, INFECT IMMUN, V54, P161, DOI 10.1128/IAI.54.1.161-169.1986; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUNDERMAN FW, 1993, SCAND J WORK ENV HEA, V19, P34; TOMB JF, 1997, NATURE, V388, P534; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; WOLFRAM L, 1995, J BACTERIOL, V177, P1840, DOI 10.1128/jb.177.7.1840-1843.1995	37	62	65	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					235	241		10.1074/jbc.273.1.235	http://dx.doi.org/10.1074/jbc.273.1.235			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417070	hybrid			2022-12-25	WOS:000071295600036
J	Ghosh, A; Sarkar, SN; Guo, WD; Bandyopadhyay, S; Sen, GC				Ghosh, A; Sarkar, SN; Guo, WD; Bandyopadhyay, S; Sen, GC			Enzymatic activity of 2 '-5 '-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING DOMAIN; 2',5'-OLIGOADENYLATE SYNTHETASE; 2-5A SYNTHETASE; INTERFERON; KINASE; IDENTIFICATION; EXPRESSION; ENZYMES; 69-KDA	Previous studies from our laboratory have shown that deletion of residues 321 to 344 of the 9-2 isozyme of 2'-5'-oligoadenylate (2-5(A)) synthetase causes a loss of its enzyme activity (Ghosh, S. K., Kusari, J., Bandyopadhyay, S. K., Samanta, H., Kumar, R., and Sen, G. C. (1991) J. Biol. Chem. 266, 15293-15299). Sequence comparison of this region among the different isozymes of 2-5(A) synthetases revealed that the residues at positions 330 to 333 are highly conserved. Alanine-scanning mutagenesis of these residues demonstrated that the residues present at 331, 332, and 333 are important for activity but the proline at position 330 was dispensable. The triple mutant containing Ala residues at 331, 332, and 333 was completely inactive. Different double mutants were slightly active, and the three single mutants were partially active. The triple mutant was further characterized for delineating the nature of its defect. The mutant protein was enzymatically inactive irrespective of whether it was synthesized in rabbit reticulocyte lysate, Escherichia coli or Trichoplusia ni insect cells. It could bind double-stranded RNA and ATP as efficiently as the wild type protein. It was, however, defective in oligomerization. Gel filtration and sedimentation velocity analyses of in vitro synthesized proteins revealed that the wild type protein, but not the triple mutant, formed tetramers. The tetrameric fraction, but not the monomeric fraction of the wild type protein was enzymatically active. The failure of the triple mutant to participate in homomeric protein-protein interaction was confirmed by in vivo assays in insect cells. These results indicate that tetramerization of the protein is required for the enzymatic activity of the small 2-5(A) synthetases.	Cleveland Clin Fdn, Dept Mol Biol, Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sen, GC (corresponding author), Cleveland Clin Fdn, Dept Mol Biol, Res Inst, 9500 Euclid Ave,NC20, Cleveland, OH 44195 USA.		Sarkar, Saumendra N/B-5038-2011	Sarkar, Saumendra N/0000-0002-2850-6121	NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASADAKUBOTA M, 1995, J INTERF CYTOK RES, V15, P863, DOI 10.1089/jir.1995.15.863; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; DESAI SY, 1995, J BIOL CHEM, V270, P3454, DOI 10.1074/jbc.270.7.3454; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; Ghosh A, 1997, J BIOL CHEM, V272, P15452, DOI 10.1074/jbc.272.24.15452; GHOSH SK, 1991, J BIOL CHEM, V266, P15293; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; HOVANESSIAN AG, 1991, J INTERFERON RES, V11, P199, DOI 10.1089/jir.1991.11.199; ICHII Y, 1986, NUCLEIC ACIDS RES, V14, P10117, DOI 10.1093/nar/14.24.10117; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; Kon N, 1996, J BIOL CHEM, V271, P19983, DOI 10.1074/jbc.271.33.19983; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MARIE I, 1990, J BIOL CHEM, V265, P18601; MARIE I, 1992, J BIOL CHEM, V267, P9933; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MORY Y, 1989, J INTERFERON RES, V9, P295, DOI 10.1089/jir.1989.9.295; PATEL RC, 1992, J BIOL CHEM, V267, P7671; PATEL RC, 1995, P NATL ACAD SCI USA, V92, P8283, DOI 10.1073/pnas.92.18.8283; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; VILCEK J, 1996, FIELDS VIROLOGY, P375	21	61	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33220	33226		10.1074/jbc.272.52.33220	http://dx.doi.org/10.1074/jbc.272.52.33220			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407111	hybrid			2022-12-25	WOS:000071182900072
J	Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM				Bardelli, A; Longati, P; Gramaglia, D; Stella, MC; Comoglio, PM			Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential	ONCOGENE			English	Article						HGF/MET-receptor; Gab1; transformation	HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR-RECEPTOR; MET RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; PROTEIN; ONCOGENE; GENE	Activation of the HGF receptor, encoded by the c-MET protooncogene (Met receptor), triggers motility, matrix-invasion and branching morphogenesis in epithelial cells. It has recently been shown that the Met receptor interacts with Gab-1, an IRS-like adaptor protein, via the docking site (Y(1349)VHVNATY(1356)VNV) known to bind Grb2 and multiple SH2-containing signal transducers. Here we show that Gab1 is the major phosphorylation-substrate of the Met receptor and of its oncogenic variant Tpr-Met. A series of point mutations in the docking site established a direct correlation between the ability to recruit and phosphorylate Gab1 and the transforming potential, Interestingly. the mutations of either Y-1356 or N-1358 abolished the binding of both Grb2 and Gab1 in intact cells, Furthermore, peptides designed to block either the SH2 or the SH3 domains of Grb2 interfered,vith the receptor-Gab1 interaction, These data indicate that Gab1 coupling to the Met receptor requires binding of Grb2 and correlates with the transforming potential of Tpr-Met.	Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Bardelli, A (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC, I-10060 Candiolo, Italy.		GRAMAGLIA, DANIELA/A-6354-2012; BARDELLI, Alberto/J-9721-2018	BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328; Gramaglia, Daniela/0000-0001-6259-0059				BARDELLI A, 1997, IN PRESS BIOCH BIOPH; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; FIXMAN ED, 1995, ONCOGENE, V10, P237; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GIORDANO S, 1997, IN PRESS P NATL ACAD; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; NALDINI L, 1991, EMBO J, V10, P2687; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PONZETTO P, 1996, J BIOL CHEM, V271, P14119; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	24	110	120	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3103	3111		10.1038/sj.onc.1201561	http://dx.doi.org/10.1038/sj.onc.1201561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444958				2022-12-25	WOS:000070968000010
J	Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW				Flores, JF; Pollock, PM; Walker, GJ; Glendening, JM; Lin, AHT; Palmer, JM; Walters, MK; Hayward, NK; Fountain, JW			Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds	ONCOGENE			English	Article						CDKN2A; CDKN2B; CDK4; melanoma; familial; mutation	CUTANEOUS MALIGNANT-MELANOMA; KINASE-4 INHIBITOR GENE; FAMMM SYNDROME FAMILIES; CELL-CYCLE ARREST; HOMOZYGOUS DELETIONS; MUTATIONAL ANALYSIS; GERMLINE MUTATIONS; SPORADIC MELANOMA; CHROMOSOME 9P; HUMAN CANCERS	Germline mutations within the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and one of its targets, the cyclin dependent kinase 4 (CDK4) gene, have been identified in a proportion of melanoma kindreds, In the case of CDK4, only one specific mutation, resulting in the substitution of a cysteine for an arginine at codon 24 (R24C), has been found to be associated with melanoma. We have previously reported the identification of germline CDKN2A mutations in 7/18 Australian melanoma kindreds and the absence of the R24C CDK4 mutation in 21 families lacking evidence of a CDKN2A mutation. The current study represents an expansion of these efforts and includes a total of 48 melanoma families from Australia. All of these families have now been screened for mutations within CDKN2A and CDK4, as well as for mutations within the CDKN2A homolog and 9p21 neighbor, the CDKN2B gene, and the alternative exon 1 (E1 beta) of CDKN2A. Families lacking CDKN2A mutations, but positive for a polymorphism(s) within this gene, were further evaluated to determine if their disease was associated with transcriptional silencing of one CDKN2A allele, Overall, CDKN2A mutations were detected in 3/30 (10%) of the new kindreds. Two of these mutations have been observed previously: a 24 bp duplication at the 5' end of the gene and a G to C transversion in exon 2 resulting in an M53I substitution. A novel G to A transition in exon 2, resulting in a D108N substitution was also detected, Combined with our previous findings, we have now detected germline CDKN2A mutations in 10/48 (21%) of our melanoma kindreds, In none of the 'CDKN2A-negative' families was melanoma found to segregate with either an untranscribed CDKN2A allele, an R24C CDK4 mutation, a CDKN2B mutation, or an E1 beta mutation. The last three observations suggest that these other cell cycle control genes (or alternative gene products) are either not involved at all, or to any great extent, in melanoma predisposition.	UNIV SO CALIF,INST MED GENET,DEPT BIOCHEM & MOL BIOL,LOS ANGELES,CA 90033; QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,HERSTON,QLD 4029,AUSTRALIA	University of Southern California; QIMR Berghofer Medical Research Institute			hayward, nicholas k/C-1367-2015; hayward, nick/AAV-8802-2020; Walker, Graeme J/C-2548-2012	hayward, nicholas k/0000-0003-4760-1033; Walker, Graeme J/0000-0002-9392-8769; Pollock, Pamela/0000-0001-8420-1026	NATIONAL CANCER INSTITUTE [R01CA066021] Funding Source: NIH RePORTER; NCI NIH HHS [CA66021] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Borg A, 1996, CANCER RES, V56, P2497; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; Dracopoli NC, 1996, CANCER SURV, V26, P115; FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541; Flores JF, 1996, CANCER RES, V56, P5023; FOUKES WD, 1997, MOL MED, V3, P5; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GLENDENING JM, 1995, CANCER RES, V55, P5531; GOLDSTEIN AM, 1994, AM J HUM GENET, V54, P489; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, MELANOMA RES, V5, P169, DOI 10.1097/00008390-199506000-00005; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HOLLAND EA, 1994, ONCOGENE, V9, P1361; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; ISSHIKI K, 1994, ONCOGENE, V9, P1649; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LIU Q, 1995, ONCOGENE, V10, P1061; LUCA M, 1995, ONCOGENE, V11, P1399; LUI L, 1995, ONCOGENE, V11, P405; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MACLENNAN R, 1992, J NCI, V84, P1437; MAO L, 1995, CANCER RES, V55, P2995; NANCARROW DJ, 1993, AM J HUM GENET, V53, P96; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; Ohta M, 1996, INT J CANCER, V65, P762, DOI 10.1002/(SICI)1097-0215(19960315)65:6<762::AID-IJC9>3.0.CO;2-X; Platz A, 1997, J NATL CANCER I, V89, P697, DOI 10.1093/jnci/89.10.697; Platz A, 1996, BRIT J CANCER, V73, P344, DOI 10.1038/bjc.1996.59; POLLOCK PM, 1995, ONCOGENE, V11, P663; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; WALKER GJ, 1994, MELANOMA RES, V4, P29, DOI 10.1097/00008390-199402000-00005; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	45	67	67	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2999	3005		10.1038/sj.onc.1201470	http://dx.doi.org/10.1038/sj.onc.1201470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416844				2022-12-25	WOS:A1997YK37700013
J	Howard, S; He, SM; Withers, SG				Howard, S; He, SM; Withers, SG			Identification of the active site nucleophile in jack bean alpha-mannosidase using 5-fluoro-beta-L-guloxyl fluoride	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; GLYCOSYL HYDROLASES; PROCESSING ALPHA-1,2-MANNOSIDASE; BETA-GALACTOSIDASE; GLYCOSIDASE; CLASSIFICATION; INHIBITORS; MECHANISMS; PURIFICATION; GLUCOSIDASE	Mannosidases play a key role in the processing of glycoproteins and thus are of considerable pharmaceutical interest and indeed have emerged as targets for the development of anti-cancer therapies, Access to useful quantities of the mammalian enzymes has not yet been achieved; therefore, jack bean mannosidase, a readily available enzyme, has become the model system, However, the relevance of this enzyme has not been demonstrated, nor is anything known about the active site structure of this, or any other, mannosidase. Hydrolysis by this enzyme occurs with net retention of sugar anomeric configuration; thus, a double displacement mechanism involving a mannosyl-enzyme intermediate is presumably involved, Two new mechanism-based inhibitors, 5-fluoro-alpha-D-mannosyl fluoride and 5-fluoro-beta-L-gulosyl fluoride, which function by the steady state trapping of such an intermediate, have been synthesized and tested, Both show high affinity for jack bean alpha-mannosidase (K-i' = 71 and 86 mu M, respectively), and the latter has been used to label the active site nucleophile. The labeled peptide present in a peptic digest of this trapped glycosyl-enzyme intermediate was identified by neutral loss scans on an electrospray ionization triple quadrupole mass spectrometer, Comparative liquid chromatographic/mass spectrometric analysis of peptic digests of labeled and unlabeled enzyme samples confirmed the unique presence of this peptide of mit 1180.5 in the labeled sample, The label was cleaved from the peptide by treatment with ammonia, and the resultant unlabeled peptide was purified and sequenced by Edman degradation, The peptide identified contained only one candidate for the catalytic nucleophile, an aspartic acid, This residue was contained within the sequence Gly-Trp-Gln-Ile-Asp-Pro-Phe-Gly-His-Ser, which showed excellent sequence similarity with regions in mammalian lysosomal and Golgi cu mannosidase sequences, These mammalian alpha-mannosidases belong to family 38 (or class II alpha-mannosidases) in which the Asp in the above sequence is totally conserved, This finding therefore assigns jack bean alpha-mannosidase to family 38, validating it as a model for other pharmaceutically interesting enzymes and thereby identifying the catalytic nucleophile within this family.	Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Prot Engn Network, Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada	University of British Columbia; University of British Columbia	Withers, SG (corresponding author), Univ British Columbia, Dept Chem, 2036 Main Mall, Vancouver, BC V6T 1Z1, Canada.	withers@chem.ubc.ca						BENNET JK, 1995, AM J MED GENET, V55, P21, DOI 10.1002/ajmg.1320550108; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; ELBEIN AD, 1987, BIOCHEMISTRY-US, V26, P2502, DOI 10.1021/bi00383a015; ERMERT P, 1993, CARBOHYD RES, V250, P113, DOI 10.1016/0008-6215(93)84160-8; GEBLER J, 1992, J BIOL CHEM, V267, P12559; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; Goss PE, 1995, CLIN CANCER RES, V1, P935; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Howard S, 1997, BIOCHEM BIOPH RES CO, V238, P896, DOI 10.1006/bbrc.1997.7148; LI YT, 1966, J BIOL CHEM, V241, P1010; Liao YF, 1996, J BIOL CHEM, V271, P28348, DOI 10.1074/jbc.271.45.28348; LIPARI F, 1995, BIOCHEM BIOPH RES CO, V209, P322, DOI 10.1006/bbrc.1995.1506; LIPARI F, 1994, GLYCOBIOLOGY, V4, P697, DOI 10.1093/glycob/4.5.697; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; McCarter JD, 1996, J AM CHEM SOC, V118, P241, DOI 10.1021/ja952732a; McCarter JD, 1996, J BIOL CHEM, V271, P6889, DOI 10.1074/jbc.271.12.6889; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; OGAWA S, 1995, BIOORGAN MED CHEM, V3, P939, DOI 10.1016/0968-0896(95)00079-V; SHARMA SK, 1995, TETRAHEDRON LETT, V36, P5627; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; SNAITH SM, 1975, BIOCHEM J, V147, P83, DOI 10.1042/bj1470083; TULL D, 1995, ANAL BIOCHEM, V224, P509, DOI 10.1006/abio.1995.1080; WENTWORTH DF, 1974, BIOCHEMISTRY-US, V13, P4715, DOI 10.1021/bi00720a006; WITHERS SG, 1990, J AM CHEM SOC, V112, P5887, DOI 10.1021/ja00171a043; WITHERS SG, 1995, PROTEIN SCI, V4, P361	29	79	87	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2067	2072		10.1074/jbc.273.4.2067	http://dx.doi.org/10.1074/jbc.273.4.2067			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442045	hybrid			2022-12-25	WOS:000071595200034
J	Pelle, R; Schramm, VL; Parkin, DW				Pelle, R; Schramm, VL; Parkin, DW			Molecular cloning and expression of a purine-specific N-ribohydrolase from Trypanosoma brucei brucei - Sequence, expression, and molecular analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; AFRICAN TRYPANOSOMES; CRITHIDIA-FASCICULATA; NUCLEOSIDE HYDROLASE; KINETIC MECHANISM; IDENTIFICATION; PURIFICATION; GENE; METABOLISM; CULTURE	N-Ribohydrolases, including the inosine-adenosine-guanosine-preferring (IAG) nucleoside hydrolase, have been proposed to be involved in the nucleoside salvage pathway of protozoan parasites and may constitute rational therapeutic targets for the treatment of these diseases. Reported is the complete sequence of the Trypanosoma brucei brucei iagnh gene, which encodes IAG-nucleoside hydrolase, The 1.4-kilobase iagnh cDNA contains an open reading frame of 981 base pairs, corresponding to 327 amino acids, The iagnh gene is present as one copy/haploid genome and is located on the size-polymorphic pair of chromosome ill or TV in the genome of T, b. brucei, In Southern blot analysis, the iagnh probe hybridized strongly with Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, Trypanosoma evansi, Trypanosoma. congolense, and Trypanosoma vivax and, to a lesser extent, with Trypanosoma cruzi genomic DNA The iagnh gene is expressed in bloodstream forms and procyclic (insect) life-cycle stages of T, b. brucei, There are no close amino acid homologues of IAG-nucleoside hydrolase outside bacterial, yeast, or parasitic organisms, Low amino acid sequence similarity is seen with the inosine-uridine-preferring nucleoside hydrolase isozyme from Crithidia fasciculata. The T, b, brucei iagnh open reading frame was cloned into Escherichia coli BL21(DE3), and a soluble recombinant IAG-nucleoside hydrolase was expressed and purified to > 97% homogeneity, The molecular weights of the recombinant IAG-nucleoside hydrolase, based on the amino acid sequence and observed mass, were 35,735 and 35,737, respectively, The kinetic parameters of the recombinant IAG-nucleoside hydrolase are experimentally identical to the native IAG-nucleoside hydrolase.	Int Livestock Res Inst, Nairobi, Kenya; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	CGIAR; International Livestock Research Institute (ILRI); Yeshiva University; Albert Einstein College of Medicine	Parkin, DW (corresponding author), Int Livestock Res Inst, POB 30709, Nairobi, Kenya.	d.parkin@cgnet.com			NIGMS NIH HHS [GM41916] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM041916, R01GM041916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; ALONSO G, 1992, MEM I OSWALDO CRUZ, V87, P517, DOI 10.1590/S0074-02761992000400009; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; BRUN R, 1979, ACTA TROP, V36, P289; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES MJ, 1983, PARASITOLOGY, V87, P211, DOI 10.1017/S0031182000052574; Degano M, 1996, BIOCHEMISTRY-US, V35, P5971, DOI 10.1021/bi952999m; DEWEY VC, 1973, ARCH BIOCHEM BIOPHYS, V157, P380, DOI 10.1016/0003-9861(73)90653-X; EELLS JT, 1983, NEUROCHEM RES, V8, P1451; ESTUPINAN B, 1994, J BIOL CHEM, V269, P23068; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISH WR, 1985, ANTIMICROB AGENTS CH, V27, P33, DOI 10.1128/AAC.27.1.33; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; Gopaul DN, 1996, BIOCHEMISTRY-US, V35, P5963, DOI 10.1021/bi952998u; HAMMOND DJ, 1996, MOL BIOCHEM PARASIT, V13, P243; HANAHAN G, 1985, DNA CHONING PRACTICA, P109; HARTWICK RA, 1979, J CHROMATOGR, V186, P659, DOI 10.1016/S0021-9673(00)95286-5; HASSAN HF, 1988, FEMS MICROBIOL LETT, V54, P47, DOI 10.1111/j.1574-6968.1988.tb02709.x; Hoare C. A., 1970, P24; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; Innis MA, 1990, PCR PROTOCOLS GUIDE; JAMES DM, 1980, PARASITOLOGY, V81, P383, DOI 10.1017/S0031182000056110; JENNI L, 1986, NATURE, V322, P173, DOI 10.1038/322173a0; KOSZALKA GW, 1979, J BIOL CHEM, V254, P8185; MARCHAND M, 1989, EUR J BIOCHEM, V184, P455, DOI 10.1111/j.1432-1033.1989.tb15038.x; MBAWA ZR, 1991, EUR J BIOCHEM, V195, P183, DOI 10.1111/j.1432-1033.1991.tb15693.x; MICHELS PAM, 1986, EMBO J, V5, P1049, DOI 10.1002/j.1460-2075.1986.tb04321.x; MILLER EN, 1981, PARASITOLOGY, V82, P63, DOI 10.1017/S0031182000041871; MILLER RL, 1984, J BIOL CHEM, V259, P5073; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; OGBUNUDE POJ, 1983, MOL BIOCHEM PARASIT, V9, P279, DOI 10.1016/0166-6851(83)90084-1; OLEMOIYOI OK, 1992, BIOCHEMISTRY-US, V31, P6193, DOI 10.1021/bi00142a004; PAMER EG, 1989, MOL BIOCHEM PARASIT, V33, P27, DOI 10.1016/0166-6851(89)90038-8; Parkin DW, 1997, BIOCHEMISTRY-US, V36, P3528, DOI 10.1021/bi962319v; PARKIN DW, 1991, J BIOL CHEM, V266, P20658; Parkin DW, 1996, J BIOL CHEM, V271, P21713, DOI 10.1074/jbc.271.36.21713; PELLE R, 1993, NUCLEIC ACIDS RES, V21, P2783, DOI 10.1093/nar/21.11.2783; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHMIDT G, 1975, TROPENMED PARASITOL, V26, P19; SIMMONDS RJ, 1981, J CHROMATOGR, V226, P369, DOI 10.1016/S0378-4347(00)86071-5; SLOWIACZEK P, 1982, ANAL BIOCHEM, V125, P6, DOI 10.1016/0003-2697(82)90376-1; THOMASHOW LS, 1983, CELL, V32, P35, DOI 10.1016/0092-8674(83)90494-4; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; Turner CMR, 1997, PARASITOL TODAY, V13, P5, DOI 10.1016/S0169-4758(96)20056-0; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; VANDERPLOEG LHT, 1984, CELL, V37, P77, DOI 10.1016/0092-8674(84)90302-7; Vickerman K., 1993, Immunology and molecular biology of parasitic infections., P170; VICKERMAN K, 1971, ECOLOGY PHYSL PARASI, P58; ZAKARIA M, 1982, ANAL BIOCHEM, V120, P25, DOI 10.1016/0003-2697(82)90313-X	54	51	52	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2118	2126		10.1074/jbc.273.4.2118	http://dx.doi.org/10.1074/jbc.273.4.2118			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442052	hybrid			2022-12-25	WOS:000071595200041
J	Stauffer, DR; Chukwumezie, BN; Wilberding, JA; Rosen, ED; Castellino, FJ				Stauffer, DR; Chukwumezie, BN; Wilberding, JA; Rosen, ED; Castellino, FJ			Characterization of transcriptional regulatory elements in the promoter region of the murine blood coagulation factor VII gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FACTOR-IX; ENHANCER BINDING-PROTEIN; HEMOPHILIA-B LEYDEN; LIVER-SPECIFIC EXPRESSION; NUCLEAR FACTOR-III; HUMAN FACTOR-X; TISSUE FACTOR; NUCLEOTIDE-SEQUENCE; FUNCTIONAL-CHARACTERIZATION; CATALYTIC DOMAIN	To identify the 5' sequences of the murine coagulation factor VII (fVII) gene that resulted in its efficient transcription, a variety of 5'-flanking sequences up to 7 kilobase pairs upstream of the translation ATG initiation codon were fused to the reporter gene, bacterial chloramphenicol acetyltransferase, and relative expression levels of this gene in mouse Hepa 1-6 cells were determined. It was found that the 5' region extending approximately 85 base pairs (bp) upstream of the transcriptional initiation site served as the minimal DNA region that provided full relative promoter activity for chloramphenicol acetyltransferase expression, This region of the gene also contains consensus sequences for liver-enriched transcription factors, C/EBP beta and HNF4, as well as for the ubiquitous protein factors, AP1, H4TF1, NF1, and Spl, In vitro DNase I footprinting of the 200-bp proximal region of the promoter with a murine Hepa 1-6 cell nuclear extract revealed a clear footprint of a region corresponding to -80 to -28 bp of the murine fVII gene, suggesting that liver factors interact with this region of the DNA. Competitive gel shift and supershift assays with different synthetic oligonucleotide probes demonstrate that proteins contained in the nuclear extract, identified as C/EBP beta, H4TF1, and HNF4, bind to a region of the murine fVII DNA from 85 to 32 bp upstream of the transcription start site, Purified Spl also interacts with this region of the DNA at a site that substantially overlaps, but is not identical to, the H4TF1 binding locus, Binding of Spl to the mouse DNA was not observed with the nuclear extract as the source of the transcription factors, suggesting that Spl is likely displaced from its binding site by H4TF1 in the crude extract. In vivo dimethyl sulfate footprint analysis confirmed the existence of these sites and additionally revealed two other binding regions slightly upstream of the CCAAT/enhancer-binding protein (C/EBP) binding locus that are homologous to NF1 binding sequences, The data demonstrate that appropriate transcription factor binding sites exist in the proximal promoter region of the murine fVII gene that are consistent with its strong liver-based expression in a highly regulated manner.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Ctr Transgene Res, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu			NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, BIOCHEMISTRY-US, V31, P1928, DOI 10.1021/bi00122a005; Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; Arenzana N, 1996, J IMMUNOL, V156, P168; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bernardi F, 1996, HUM MUTAT, V8, P108; BERNARDI F, 1994, HUM MOL GENET, V3, P1175, DOI 10.1093/hmg/3.7.1175; Bhardwaj D, 1996, J BIOL CHEM, V271, P30685, DOI 10.1074/jbc.271.48.30685; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BOM VJJ, 1991, THROMB HAEMOSTASIS, V66, P283; BROZE GJ, 1987, P NATL ACAD SCI USA, V84, P1886, DOI 10.1073/pnas.84.7.1886; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAING S, 1994, BLOOD, V83, P3524; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DAILEY L, 1988, GENE DEV, V2, P1700, DOI 10.1101/gad.2.12b.1700; DAILEY L, 1986, P NATL ACAD SCI USA, V83, P7241, DOI 10.1073/pnas.83.19.7241; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; ESCOFFRE M, 1995, BRIT J HAEMATOL, V91, P739, DOI 10.1111/j.1365-2141.1995.tb05378.x; FEO S, 1995, MOL CELL BIOL, V15, P5991; FOSTER DC, 1985, P NATL ACAD SCI USA, V82, P4673, DOI 10.1073/pnas.82.14.4673; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GALAS DJ, 1978, NUCLEIC ACIDS RES, V5, P3157, DOI 10.1093/nar/5.9.3157; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HUANG LH, 1989, BIOCHEM BIOPH RES CO, V160, P133, DOI 10.1016/0006-291X(89)91631-8; HUANG MN, 1992, J BIOL CHEM, V267, P15440; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; Idusogie E, 1996, THROMB HAEMOSTASIS, V76, P957; ISSHIKI H, 1991, NEW BIOL, V3, P63; JACKSON DA, 1993, MOL CELL BIOL, V13, P2401, DOI 10.1128/MCB.13.4.2401; Junker R, 1997, ARTERIOSCL THROM VAS, V17, P1539, DOI 10.1161/01.ATV.17.8.1539; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; KAZAMA Y, 1992, BLOOD COAGUL FIBRIN, V3, P697, DOI 10.1097/00001721-199212000-00001; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LANE A, 1992, ATHEROSCLEROSIS, V94, P43, DOI 10.1016/0021-9150(92)90186-K; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; MADHUSUDHAN KT, 1995, BIOCHEMISTRY-US, V34, P1288, DOI 10.1021/bi00004a023; MARIANI G, 1983, HAEMOSTASIS, V13, P169; MATSUSHITA T, 1994, J BIOL CHEM, V269, P7355; Maxam A M, 1980, Methods Enzymol, V65, P499; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MIAO CH, 1992, J BIOL CHEM, V267, P7395; Miao CH, 1996, J BIOL CHEM, V271, P9587, DOI 10.1074/jbc.271.16.9587; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; Patthy L, 1996, MATRIX BIOL, V15, P301, DOI 10.1016/S0945-053X(96)90131-6; PICKETTS DJ, 1994, BLOOD, V84, P2992; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RADCLIFFE R, 1975, J BIOL CHEM, V250, P388; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REITSMA PH, 1989, BLOOD, V73, P743; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; RUF W, 1991, J BIOL CHEM, V266, P15719; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Singh M, 1996, P NATL ACAD SCI USA, V93, P4392, DOI 10.1073/pnas.93.9.4392; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TANABE S, 1991, J BIOCHEM-TOKYO, V109, P924, DOI 10.1093/oxfordjournals.jbchem.a123481; TOOMEY JR, 1991, J BIOL CHEM, V266, P19198; TRONCHE F, 1991, J MOL BIOL, V222, P31, DOI 10.1016/0022-2836(91)90735-O; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x; YAMAGUCHI Y, 1994, J BIOL CHEM, V269, P19410; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZIMMERMANN R, 1979, BLUT, V38, P119, DOI 10.1007/BF01007952	79	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2277	2287		10.1074/jbc.273.4.2277	http://dx.doi.org/10.1074/jbc.273.4.2277			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442072	hybrid			2022-12-25	WOS:000071595200061
J	Enslen, H; Raingeaud, J; Davis, RJ				Enslen, H; Raingeaud, J; Davis, RJ			Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PHOSPHORYLATION; MEMBER; CASCADE; IDENTIFICATION; INTERLEUKIN-1; TYROSINE; BINDING; FAMILY; MEK	The cellular response to treatment with proinflammatory cytokines or exposure to environmental stress is mediated, in part, by the p38 group of mitogen-activated protein (MAP) kinases. We report the molecular cloning of a novel isoform of p38 MAP kinase, p38 beta 2. This p38 MAP kinase, like p38 alpha, is inhibited by the pyridinyl imidazole drug SB203580. The p38 MAP kinase kinase MKK6 is identified as a common activator of p38 alpha, p38 beta 2, and p38 gamma MAP kinase isoforms, while MKK3 ac- tivates only p38 alpha and p38 gamma MAP kinase isoforms. The MKK3 and MKK6 signal transduction pathways are therefore coupled to distinct, but overlapping, groups of p38 MAP kinases.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St, Worcester, MA 01605 USA.		Enslen, Hervé/M-3400-2017; Enslen, Hervé/AAH-4492-2021	Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293	NCI NIH HHS [CA65861, CA72009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072009, R01CA065861] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GOERDERT M, 1997, EMBO J, V16, P3663; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iordanov M, 1997, EMBO J, V16, P1009, DOI 10.1093/emboj/16.5.1009; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RON D, 1992, BIOTECHNIQUES, V13, P866; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SETH A, 1992, J BIOL CHEM, V267, P24796; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	57	454	487	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1741	1748		10.1074/jbc.273.3.1741	http://dx.doi.org/10.1074/jbc.273.3.1741			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430721	hybrid			2022-12-25	WOS:000071411500068
J	Bafetti, LM; Young, TN; Itoh, Y; Stack, MS				Bafetti, LM; Young, TN; Itoh, Y; Stack, MS			Intact vitronectin induces matrix metalloproteinase-2 and tissue inhibitor of metalloproteinases-2 expression and enhanced cellular invasion by melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; PLASMINOGEN-ACTIVATOR; INTEGRIN ALPHA-V-BETA-3; BASEMENT-MEMBRANE; PROGELATINASE-A; SURFACE BINDING; TUMOR-CELLS; COMPLEX; METASTASIS; RECEPTOR	The initial site of melanoma cell metastasis is frequently the regional lymph nodes, and the appearance of lymph node metastasis correlates with poor prognosis, Lymph node adhesion is mediated by an interaction between the tumor cell integrin alpha v beta 3 and lymph node vitronectin. In this study, we explored the relationship between adhesion and proteolysis by examining the direct effect of vitronectin receptor ligation on matrix metalloproteinase-2 (MMP-2) production by B16F1 and B16F10 melanoma cells. We report a dose-dependent increase in secretion of both MMP-2 and tissue inhibitor of metalloproteinases-2 (TIMP-2) in response to vitronectin. Cellular invasiveness was also enhanced by vitronectin, as shown by the increased ability of vitronectin-treated cells to invade a synthetic basement membrane (Matrigel). Both the vitronectin-induced MMP-2 production and vitronectin-enhanced invasion were blocked by the peptide ligand Arg-Gly-Asp-Ser (RGDS). Furthermore, neither plasmin-degraded vitronectin nor the peptide ligand RGDS stimulated MMP-2 secretion or invasiveness, indicating that a multivalent ligand-receptor interaction rather than simple receptor occupancy was required for MMP-2 induction. MMP-2 and MMP-2/TIMP-2 interaction with the plasma membrane of melanoma cells resulted in enhanced catalytic activity against C-14-labeled gelatin, suggesting that membrane association may function in posttranslational regulation of MMP-2 activity, This is supported by data showing increased cellular invasion by cells containing membrane-bound MMP-2. Binding of proMMP-2 and proMMP-2/TIMP-2 to melanoma cells was not inhibited by RGDS, and melanoma cell adhesion to vitronectin was unaffected by pro-or active MMP-2, indicating that MMP-2 did not interact with the murine vitronectin receptor, Together, these data provide evidence for a functional link between adhesion and proteolysis and suggest a potential mechanism whereby adhesion of an invasive cell to the extracellular matrix regulates subsequent invasive behavior.	Northwestern Univ, Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Washington Univ, Sch Med, St Louis, MO 63110 USA	Northwestern University; Northwestern University; Washington University (WUSTL)	Stack, MS (corresponding author), Northwestern Univ, Sch Med, Dept Obstet & Gynecol, 303 E Chicago Ave,Tarry 4-751, Chicago, IL 60611 USA.	mss130@anima.nums.nwu.edu		Itoh, Yoshifumi/0000-0002-2128-2823	NATIONAL CANCER INSTITUTE [R01CA058900, R55CA058900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALLAN JA, 1995, BIOCHEM J, V309, P299, DOI 10.1042/bj3090299; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; COCKETT MI, 1994, BIOCHEM SOC T, V22, P55, DOI 10.1042/bst0220055; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; EMMERTBUCK MR, 1995, FEBS LETT, V364, P28, DOI 10.1016/0014-5793(95)00345-A; EMONARD HP, 1992, CANCER RES, V52, P5845; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; GONZALEZGRONOW M, 1984, BIOCHEMISTRY-US, V23, P190, DOI 10.1021/bi00297a003; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HARRIS ED, 1972, BIOCHIM BIOPHYS ACTA, V258, P566, DOI 10.1016/0005-2744(72)90249-5; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Nagase H, 1996, ADV EXP MED BIOL, V389, P23; NATHANSON SD, 1986, J SURG ONCOL, V33, P41, DOI 10.1002/jso.2930330112; NIP J, 1995, CANCER METAST REV, V14, P241, DOI 10.1007/BF00690295; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SANDERS LC, 1992, COLD SPRING HARB SYM, V57, P233, DOI 10.1101/SQB.1992.057.01.028; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; STACK MS, 1993, CANCER RES, V53, P1998; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STETLERSTEVENSON WG, 1990, CANCER METAST REV, V9, P289, DOI 10.1007/BF00049520; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Toth M, 1997, CANCER RES, V57, P3159; TURPEENNIEMIHUJANEN T, 1985, J NATL CANCER I, V75, P99; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WARD RV, 1994, BIOCHEM J, V304, P263, DOI 10.1042/bj3040263; YOUNG TN, 1995, J BIOL CHEM, V270, P999, DOI 10.1074/jbc.270.3.999; YOUNG TN, 1994, AM J OBSTET GYNECOL, V170, P1285; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	40	119	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					143	149		10.1074/jbc.273.1.143	http://dx.doi.org/10.1074/jbc.273.1.143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417058	hybrid			2022-12-25	WOS:000071295600024
J	Graeff, RM; Franco, L; De Flora, A; Lee, HC				Graeff, RM; Franco, L; De Flora, A; Lee, HC			Cyclic GMP-dependent and -independent effects on the synthesis of the calcium messengers cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; CA2+ RELEASE; INTRACELLULAR CALCIUM; MOBILIZING METABOLITE; CRYSTAL-STRUCTURE; CYCLASE; CD38; CELLS; FERTILIZATION	Cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP) have been shown to mobilize intracellular Ca2+ stores by totally independent mechanisms, which are pharmacologically distinct from that activated by inositol trisphosphate, Although cADPR and NAADP are structurally and functionally different, they can be synthesized by a single enzyme having ADP-ribosyl cyclase activity, In this study, three different assays were used to measure the metabolism of cADPR in sea urchin egg homogenates including a radioimmunoassay, a Ca2+ release assay, and a thin layer chromatographic assay, Soluble and membrane-bound ADP-ribosyl cyclases were identified and both cyclized NAD to produce cADPR, The soluble cyclase was half-maximally stimulated by 5.3 mu M cGMP, but not by cAMP, while the membrane-bound form was independent of cGMP, The two forms of the cyclase were also different in the pH dependence of utilizing nicotinamide guanine dinucleotide (NGD), a guanine analog of NAD, as substrate, indicating they are two separate enzymes, The stimulatory effect of cGMP required ATP or ATP gamma S (adenosine 5'-O-(3-thiotriphosphate)) and a cGMP-dependent kinase activity was shown to be present in the soluble fraction, The degradation of cADPR to ADP-ribose was catalyzed by cADPR hydrolase, which was found to be predominantly associated with membranes. Similar to the membrane-bound cyclase, the cADPR hydrolase activity was also independent of cGMP. Both the soluble and membrane fractions also catalyzed the synthesis of NAADP through exchanging the nicotinamide group of NADP with nicotinic acid (NA), The base-exchange activity was independent of cGMP and the half-maximal concentrations of NADP and NA needed were about 0.2 mM and 10 mM, respectively. The exchange reaction showed a preference for acidic pH, contrasting with the neutral pH optimum of the cyclase activities. The complex metabolic pathways characterized in this study indicate that there may be a multitude of regulatory mechanisms for controlling the endogenous concentrations of cADPR and NAADP.	Univ Minnesota, Dept Physiol, Lyon Lab 6182, Minneapolis, MN 55455 USA; Univ Genoa, Ist Policattedra Chim Biol, I-16132 Genoa, Italy	University of Minnesota System; University of Minnesota Twin Cities; University of Genoa	Lee, HC (corresponding author), Univ Minnesota, Dept Physiol, Lyon Lab 6182, Minneapolis, MN 55455 USA.		Lee, Hon Cheung/C-4329-2009; Graeff, Richard Milton/B-3425-2011		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040, R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484, HD32040] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarhus R, 1996, J BIOL CHEM, V271, P8513, DOI 10.1074/jbc.271.15.8513; Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; AARHUS R, 1995, J BIOL CHEM, V270, P7745, DOI 10.1074/jbc.270.13.7745; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; Clementi E, 1996, J BIOL CHEM, V271, P17739, DOI 10.1074/jbc.271.30.17739; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1993, NATURE, V365, P456, DOI 10.1038/365456a0; GARBERS DL, 1989, J BIOL CHEM, V264, P9103; Graeff RM, 1996, BIOCHEMISTRY-US, V35, P379, DOI 10.1021/bi952083f; Graeff RM, 1997, METHOD ENZYMOL, V280, P230; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LEE HC, 1995, BIOCHIMIE, V77, P345, DOI 10.1016/0300-9084(96)88145-4; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1996, RECENT PROG HORM RES, V51, P355; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; Lee HC, 1997, J BIOL CHEM, V272, P4172, DOI 10.1074/jbc.272.7.4172; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; LEE HC, 1993, J BIOL CHEM, V268, P293; LEE HC, 1991, J BIOL CHEM, V266, P2276; LEE HC, 1997, CELL BIOCH BIOPHYS, V28, P1; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Munshi CB, 1997, METHOD ENZYMOL, V280, P318; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; Sethi JK, 1996, BIOCHEM J, V319, P613, DOI 10.1042/bj3190613; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; Walseth TF, 1997, METHOD ENZYMOL, V280, P294; Walseth TF, 1997, METHOD ENZYMOL, V280, P287; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; Willmott N, 1996, J BIOL CHEM, V271, P3699	45	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					118	125		10.1074/jbc.273.1.118	http://dx.doi.org/10.1074/jbc.273.1.118			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417055	hybrid			2022-12-25	WOS:000071295600021
J	Oka, N; Yamamoto, M; Schwencke, C; Kawabe, J; Ebina, T; Ohno, S; Couet, J; Lisanti, MP; Ishikawa, Y				Oka, N; Yamamoto, M; Schwencke, C; Kawabe, J; Ebina, T; Ohno, S; Couet, J; Lisanti, MP; Ishikawa, Y			Caveolin interaction with protein kinase C - Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SEQUENCE; FAMILY; CELLS	Caveolar localization of protein kinase C and the regulation of caveolar function by protein kinase C are well known, This study was undertaken to examine whether caveolin subtypes interact with various protein kinase C isoenzymes using the caveolin scaffolding domain peptide. When protein kinase C-alpha, -epsilon, and -zeta were overexpressed in COS cells followed by subcellular fractionation using the sucrose gradient method, all the isoenzymes (alpha, epsilon, and zeta) were detected in the same fraction as caveolin. The scaffolding domain peptide of caveolin-1 and -3, but not -2, inhibited the kinase activity and autophosphorylation of protein kinase C-alpha and -zeta, but not of protein kinase C-epsilon, overexpressed in insect cells. Truncation mutation studies of the caveolin-1 and -3 peptides demonstrated that a minimum of 16 or 14 amino acid residues of the peptide were required for the inhibition or direct binding of protein kinase C, Thus, the caveolin peptide physically interacted with protein kinase C and regulated its function. Further, this regulation occurred in a protein kinase C isoenzyme-dependent manner. Our results may provide a new mechanism regarding the regulation of protein kinase C isoenzyme activity and the molecular interaction of protein kinase C with its putative binding proteins.	Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA; Yokohama City Univ, Dept Biochem, Yokohama, Kanagawa 232, Japan; Albert Einstein Coll Med, Dept Mol Pharmacol, New York, NY 10461 USA	Yokohama City University; Yeshiva University	Ishikawa, Y (corresponding author), Allegheny Univ Hlth Sci, Cardiovasc & Pulm Res Inst, Pittsburgh, PA 15212 USA.	yishikaw@pgh.auhs.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Ohno, Shigeo/B-1768-2010	Lisanti, Michael/0000-0003-2034-1382; Ohno, Shigeo/0000-0002-1294-5269; Couet, Jacques/0000-0001-5409-8689	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59139, HL54895] Funding Source: Medline; NIGMS NIH HHS [GM 50443] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; KAWABE J, 1994, J BIOL CHEM, V269, P16554; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Monier S, 1996, FEBS LETT, V388, P143, DOI 10.1016/0014-5793(96)00519-4; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NSIHIZUKA Y, 1992, SCIENCE, V258, P607; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; STABEL S, 1991, METHOD ENZYMOL, V200, P670; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	24	232	237	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33416	33421		10.1074/jbc.272.52.33416	http://dx.doi.org/10.1074/jbc.272.52.33416			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407137	hybrid			2022-12-25	WOS:000071182900098
J	Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W				Ueffing, M; Lovric, J; Philipp, A; Mischak, H; Kolch, W			Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity	ONCOGENE			English	Article						PKC epsilon; Raf-1 kinase; growth factors; autocrine loops	ACTIVATES RAF-1; PLASMA-MEMBRANE; SIGNAL-TRANSDUCTION; RAT FIBROBLASTS; TYROSINE KINASE; CELLS; PHOSPHORYLATION; ISOZYMES; OVEREXPRESSION; MECHANISMS	Several observations indicate that the Raf-1 kinase is a downstream effector of protein kinase C-epsilon (PKC epsilon). We recently have shown that Raf-1 is constitutively activated in PKC epsilon transformed Rat6 fibroblasts, and transformation can be reverted by expression of a dominant negative Raf-1, but not a dominant negative Ras mutant (Cacace et al., 1996), Cai et al, (1997) demonstrated that PKC epsilon induced proliferation of NIH3T3 cells is independent of Ras or Src, but depends on Raf-1. These authors further suggested that PKC epsilon activates Raf-1 by direct phosphorylation. Here we have investigated the functional interaction between PKC epsilon and Raf-1, PKCE, but not PKC alpha, was found to bind to the Raf-1 kinase domain, The association appeared to be direct, as it could be reconstituted in vitro with purified proteins, Raf-1 and PKC epsilon could be co-precipitated from Sf-9 insect cells and PKC epsilon transformed NIH313 cells (NIH/epsilon). The association was negatively regulated by ATP in vitro and by TPA treatment in NIH/epsilon cells, but not in Sf-9 insect cells, Raf-1 was constitutively activated in NIH/epsilon cells, How ever, using coexpression experiments in Sf-9 cells and transiently transfected A293 cells we did not obtain any evidence for a direct activation of Raf-1 by PKC epsilon. PKCE did not induce translocation of Raf-1 to the membrane, Furthermore, PKCE did not activate Raf-1 nor enhance the kinase activity of Raf-1 that had been pre-activated by coexpression of Ras or the Lck tyrosine kinase, In contrast, conditioned media from PKC epsilon transformed cells induced a robust activation of Raf-1. This activation could be partially reproduced by recombinant TGF beta, a growth factors secreted by PKC epsilon transformed Rat6 cells. In conclusion, our results suggest that PKC epsilon stimulates Raf-1 indirectly by inducing the production of autocrine growth factors.			Ueffing, M (corresponding author), GSF FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT,INST KLIN MOL BIOL & TUMORGENET,MARCHIONINSTR 25,D-81377 MUNICH,GERMANY.		Mischak, Harald/E-8685-2011; Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	Kolch, Walter/0000-0001-5777-5016; Lovric, Josip/0000-0002-0338-6581; Mischak, Harald/0000-0003-0323-0306				ARITA Y, 1992, CANCER RES, V52, P4514; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; BORNER C, 1995, J BIOL CHEM, V270, P78, DOI 10.1074/jbc.270.1.78; CACACE AM, 1993, ONCOGENE, V8, P2095; Cacace AM, 1996, ONCOGENE, V13, P2517; CACACE AM, UNPUB; Cai H, 1997, MOL CELL BIOL, V17, P732, DOI 10.1128/MCB.17.2.732; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GOODNIGHT J, 1994, PROTEIN KINASE C DIF, P160; HA KS, 1993, J BIOL CHEM, V268, P10534; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KIESER A, 1994, ONCOGENE, V9, P963; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI PM, 1993, ONCOGENE, V8, P1731; Malarkey K, 1996, CELL SIGNAL, V8, P123, DOI 10.1016/0898-6568(95)02036-5; Marais R, 1996, CANCER SURV, V27, P101; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MISCHAK H, 1993, J BIOL CHEM, V268, P60090; MORRISON DK, 1995, MOL REPROD DEV, V42, P507, DOI 10.1002/mrd.1080420420; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Perletti GP, 1996, ONCOGENE, V12, P847; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681	37	70	70	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2921	2927		10.1038/sj.onc.1201477	http://dx.doi.org/10.1038/sj.onc.1201477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416835				2022-12-25	WOS:A1997YK37700004
J	Faussner, A; Proud, D; Towns, M; Bathon, JM				Faussner, A; Proud, D; Towns, M; Bathon, JM			Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MEDIATED INTERNALIZATION; BRADYKININ RECEPTOR; HUMAN-FIBROBLASTS; MECHANISMS; CLONING	To determine the role of the cytoplasmic carboxyl termini of human B1 and B2 kinin receptors (B1KR and B2KR, respectively) in the internalization of their respective ligands, des-Arg(10)-kallidin and bradykinin (BK), both wild type receptors, as well as truncated B2KRs, a mutated B2KR, and chimeric receptors were stably expressed in Chinese hamster ovary cells. Incubation of [H-3]BK at 37 degrees C with cells expressing wild type B2KR resulted in pronounced and rapid ligand internalization (similar to 80% after 10 min), By contrast, incubation of H-3-labeled des-Arg(10)-kallidin with cells expressing B1KR resulted in a modest, slow internalization of the Ligand (<20% after 10 min), Replacement, from Cys(324), Of the cytoplasmic carboxyl terminus of the B2KR with that of the B1KR from Cys(330) (both Cys residues are putative palmitoylation sites) greatly reduced ligand internalization (similar to 40% after 10 min) without significantly altering K-d or ligand-induced signal activation, By marked contrast, the corresponding replacement, of the sequence from Cys(330) Of the cytoplasmic carboxyl terminus of the B1KR with the segment of the B2KR, led to a striking increase of ligand internalization (similar to 75% within 10 min) without altering K-d Or ligand-induced signal activation. Truncation of the B2KR to within three amino acids of Cys(324) (truncation at Gly(327)) led to strongly reduced ligand internalization (similar to 40% after 10 min), Truncation of the B2KR up to Lys(315) almost completely abolished internalization of [H-3]BK (10% after 10 min). This additional reduction is apparently not caused by the loss of the potential palmitoylation site at Cys(324), since a B2KR with a point mutation of Cys(324) to Ala internalized [H-3]BK as rapidly as the wild type B2KR, From these results we conclude that the cytoplasmic carboxyl terminus of the human B2KR contains sequences that are necessary and sufficient to permit rapid ligand-induced sequestration of human kinin receptors and internalization of their agonists.	Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University	Faussner, A (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR001856] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32272] Funding Source: Medline; NIAMS NIH HHS [AR01856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Austin CE, 1997, J BIOL CHEM, V272, P11420; BATHON JM, 1991, ANNU REV PHARMACOL, V31, P129; BENYA RV, 1993, J BIOL CHEM, V268, P20285; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; Bohm SK, 1997, J BIOL CHEM, V272, P2363; FARMER GS, 1992, ANN REV PHARM TOXICO, V32, P511; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HUANG ZM, 1995, J BIOL CHEM, V270, P151, DOI 10.1074/jbc.270.1.151; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MENKE JG, 1994, J BIOL CHEM, V269, P21583; MORO O, 1993, J BIOL CHEM, V268, P6862; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Petrou C, 1997, J BIOL CHEM, V272, P2326; Prado GN, 1997, J BIOL CHEM, V272, P14638, DOI 10.1074/jbc.272.23.14638; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49, DOI 10.1146/annurev.iy.06.040188.000405; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; ROSCHER AA, 1990, J CARDIOVASC PHARM, V15, pS39, DOI 10.1097/00005344-199015061-00008; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; Shapiro MJ, 1996, J BIOL CHEM, V271, P32874, DOI 10.1074/jbc.271.51.32874; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THOMAS WG, 1995, J BIOL CHEM, V270, P22153, DOI 10.1074/jbc.270.38.22153; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; YU SS, 1993, J BIOL CHEM, V268, P337	34	76	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2617	2623		10.1074/jbc.273.5.2617	http://dx.doi.org/10.1074/jbc.273.5.2617			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446564	hybrid			2022-12-25	WOS:000071736600019
J	Herrero, I; Miras-Portugal, MT; Sanchez-Prieto, J				Herrero, I; Miras-Portugal, MT; Sanchez-Prieto, J			Functional switch from facilitation to inhibition in the control of glutamate release by metabotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CEREBROCORTICAL NERVE-TERMINALS; RAT HIPPOCAMPUS; SYNAPTIC TRANSMISSION; SIGNAL-TRANSDUCTION; MOLECULAR CHARACTERIZATION; CALCIUM CURRENTS; PHORBOL ESTERS; AMINO-ACIDS; NEURONS	We have,investigated the role of metabotropic glutamate receptors linked to phosphoinositide hydrolysis in the control of glutamate release in cerebrocortical nerve terminals. The activation of these receptors with the agonist 3,5-dihydroxyphenylglycine enhanced intrasynaptosomal diacylglycerol and facilitated both the depolarization-induced increase in the cytosolic free Ca2+ concentration and the release of glutamate. However, 5 min after receptor activation, a second stimulation of the pathway with the agonist failed to produce diacylglycerol and to facilitate glutamate release. Interestingly, during the period in which the diacylglycerol response was desensitized, a strong agonist-induced inhibition of Ca2+ entry and glutamate release was observed. This change in the presynaptic effects of 3,5-dihydroxyphenylglycine is reversible since 30 min after the first stimulation, the agonist-induced inhibition of release disappeared, whereas both the production of diacylglycerol and the facilitation of glutamate release were recovered. The tonic elevation of the extracellular glutamate concentration from basal levels (0.8 mu M) up to 5 mu M also produced the switch from facilitation to inhibition in the receptor response. The existence of this activity-dependent switch in the presynaptic control of glutamate release suggests that release facilitation is limited to conditions under which an appropriate clearance of synaptic glutamate exists, probably to prevent the neurotoxic accumulation of glutamate in the synapse.	Univ Complutense Madrid, Fac Vet, Dept Bioquim, E-28040 Madrid, Spain	Complutense University of Madrid	Sanchez-Prieto, J (corresponding author), Univ Complutense Madrid, Fac Vet, Dept Bioquim, E-28040 Madrid, Spain.	jsprieto@eucmax.sim.ucm.es	Miras-Portugal, Maria Teresa/L-7137-2014	Sanchez-Prieto, Jose/0000-0002-8513-3501				ABE T, 1992, J BIOL CHEM, V267, P13361; ALALUF S, 1995, FEBS LETT, V367, P301, DOI 10.1016/0014-5793(95)00575-T; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CATANIA MV, 1991, J NEUROCHEM, V56, P1329, DOI 10.1111/j.1471-4159.1991.tb11429.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; COFFEY ET, 1994, J NEUROCHEM, V63, P1303; COLQUHOUN D, 1992, J PHYSIOL-LONDON, V458, P261, DOI 10.1113/jphysiol.1992.sp019417; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GEREAU RW, 1995, J NEUROSCI, V15, P6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HERRERO I, 1994, EUR J NEUROSCI, V6, P115, DOI 10.1111/j.1460-9568.1994.tb00253.x; HERRERO I, 1991, NEUROSCI LETT, V126, P41, DOI 10.1016/0304-3940(91)90366-2; Herrero I, 1996, EUR J NEUROSCI, V8, P700, DOI 10.1111/j.1460-9568.1996.tb01255.x; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Herrero I, 1996, J BIOL CHEM, V271, P30554, DOI 10.1074/jbc.271.48.30554; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; KANNER BI, 1983, BIOCHIM BIOPHYS ACTA, V726, P293, DOI 10.1016/0304-4173(83)90013-7; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LOMBARDI G, 1993, BRIT J PHARMACOL, V110, P1407, DOI 10.1111/j.1476-5381.1993.tb13977.x; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; Lujan R, 1996, EUR J NEUROSCI, V8, P1488, DOI 10.1111/j.1460-9568.1996.tb01611.x; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; Manzoni O, 1995, EUR J NEUROSCI, V7, P2518, DOI 10.1111/j.1460-9568.1995.tb01051.x; MANZONI OJJ, 1990, NEUROSCI LETT, V109, P146, DOI 10.1016/0304-3940(90)90553-L; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; PARFITT KD, 1993, J PHYSIOL-LONDON, V471, P245, DOI 10.1113/jphysiol.1993.sp019900; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; RAINNIE DG, 1992, NEUROSCI LETT, V139, P87, DOI 10.1016/0304-3940(92)90864-4; ROMANO C, 1995, J COMP NEUROL, V355, P455, DOI 10.1002/cne.903550310; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SanchezPrieto J, 1996, TRENDS NEUROSCI, V19, P235, DOI 10.1016/0166-2236(96)10031-X; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP DD, 1994, J NEUROCHEM, V63, P769; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANABE Y, 1993, J NEUROSCI, V13, P1372; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; VAZQUEZ E, 1995, NEUROSCIENCE, V68, P117, DOI 10.1016/0306-4522(95)00121-X; VERHAGE M, 1991, NEURON, V6, P517, DOI 10.1016/0896-6273(91)90054-4; Zorumski CF, 1996, J PHYSIOL-LONDON, V494, P465, DOI 10.1113/jphysiol.1996.sp021506	57	81	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1951	1958		10.1074/jbc.273.4.1951	http://dx.doi.org/10.1074/jbc.273.4.1951			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442030	hybrid			2022-12-25	WOS:000071595200019
J	Hughes, BW; King, SA; Allan, PW; Parker, WB; Sorscher, EJ				Hughes, BW; King, SA; Allan, PW; Parker, WB; Sorscher, EJ			Cell to cell contact is not required for bystander cell killing by Escherichia coli purine nucleoside phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUICIDE GENES; CANCER; THERAPY; PROLIFERATION; CARCINOMA; TUMORS	Expression of Escherichia coli purine nucleoside phosphorylase (PNP) activates prodrugs and kills entire populations of mammalian cells, even when as few as 1% of the cells express this gene. This phenomenon of bystander billing has been previously investigated for herpes simplex virus-thymidine kinase (HSV-TR) and has been shown to require cell to cell contact. Using silicon rings to separate E. coli PNP expressing cells from non-expressing cells sharing the same medium, we demonstrate that bystander cell killing by E. coli PNP does not require cell-cell contact. Initially, cells expressing E. coli PNP convert the non-toxic prodrug, 6-methylpurine-2'-deoxyriboside (MeP-dR) to the highly toxic membrane permeable toxin, 6-methylpurine (MeP). As the expressing cells die, E. coli PNP is released into the culture medium, retains activity, and continues precursor conversion extracellularly (as determined by reverse phase high performance liquid chromatography of both prodrug and toxin). Bystander killing can also be observed in the absence of extracellular E. coli PNP by removing the MeP-dR prior to death of the expressing cells. In this case, 100% of cultured cells die when as few as 3% of the cells of a population express E. coli PNP. Blocking nucleoside transport with nitrobenzylthioinosine reduces MeP-dR mediated cell killing but not MeP cell killing. These mechanisms differ fundamentally from those previously reported for the HSV-TK gene.	Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; So Res Inst, Birmingham, AL 35255 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Sorscher, EJ (corresponding author), Univ Alabama, Dept Physiol & Biophys, Basic Hlth Sci Bldg,Rm 796,1918 Univ Blvd, Birmingham, AL 35294 USA.			Sorscher, Eric J./0000-0001-9341-3354	NCI NIH HHS [U19-CA67763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA067763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allan P. W., 1997, Proceedings of the American Association for Cancer Research Annual Meeting, V38, P379; Beck C, 1995, HUM GENE THER, V6, P1525, DOI 10.1089/hum.1995.6.12-1525; Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; BOTH GW, 1997, MOL CELLULAR BIOL GE, P26; Caruso M, 1996, P NATL ACAD SCI USA, V93, P11302, DOI 10.1073/pnas.93.21.11302; CHANG MW, 1995, MOL MED, V1, P172, DOI 10.1007/BF03401565; Connors TA, 1995, GENE THER, V2, P702; DaCosta LT, 1996, P NATL ACAD SCI USA, V93, P4192, DOI 10.1073/pnas.93.9.4192; DENNIG CN, 1997, MOL CELLULAR BIOL GE; Freeman SM, 1996, SEMIN ONCOL, V23, P31; GIVENS KT, 1990, INVEST OPHTH VIS SCI, V31, P1856; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Hall SJ, 1997, INT J CANCER, V70, P183, DOI 10.1002/(SICI)1097-0215(19970117)70:2<183::AID-IJC8>3.0.CO;2-T; HUGHES BW, 1995, CANCER RES, V55, P3339; KEINKELEIN M, 1997, MOL CELLULAR BIOL GE, P32; MESNIL M, 1997, MOL CELLULAR BIOL GE, P67; MONTGOMERY JA, 1968, J MED CHEM, V11, P48, DOI 10.1021/jm00307a010; MOOLTEN FL, 1994, CANCER GENE THER, V1, P279; Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637; RAM Z, 1993, CANCER RES, V53, P83; ROBERTS B, 1997, MOL CELLULAR BIOL GE, P68; Sacco MG, 1996, GENE THER, V3, P1151; Smith SM, 1996, P NATL ACAD SCI USA, V93, P7955, DOI 10.1073/pnas.93.15.7955; SORSCHER EJ, 1994, GENE THER, V1, P233; Wygoda MR, 1997, CANCER RES, V57, P1699	25	55	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2322	2328		10.1074/jbc.273.4.2322	http://dx.doi.org/10.1074/jbc.273.4.2322			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442077	hybrid			2022-12-25	WOS:000071595200066
J	Ludwig, S; Hoffmeyer, A; Goebeler, M; Kilian, K; Hafner, H; Neufeld, B; Han, JH; Rapp, UR				Ludwig, S; Hoffmeyer, A; Goebeler, M; Kilian, K; Hafner, H; Neufeld, B; Han, JH; Rapp, UR			The stress inducer arsenite activates mitogen-activated protein kinases extracellular signal-regulated kinases 1 and 2 via a MAPK kinase 6 p38-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASCADES; PROMOTER; RAF	Cell response to a wide variety of extracellular signals is mediated by either mitogenic activation of the Raf/ MEK/ERK kinase cascade or stress-induced activation of the mitogen-activated protein kinase (MAPK) family members c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) or p38. We have examined communications between these stress and mitogen-induced signaling pathways. We show here that the stress cascade activator arsenite activates extracellular signal-regulated kinase (ERK) in addition to p38 albeit with different kinetics. Whereas p38 is an early response kinase, ERK activation occurs with delayed time kinetics at 2-4 h, We observed activation of ERK upon arsenite treatment in many different cell lines, ERK activation is strongly enhanced by overexpression of p38 and mitogen-activated protein kinase kinase 6 (MKK6) but is blocked by dominant negative kinase versions of p38 and MKK6 or the specific p38 inhibitor SB203580. Arsenite-induced ERK activation is mediated by Ras, Raf, and MEK but appears to be independent of de novo protein synthesis. These data provide the first evidence for a p38 dependent activation of the mitogenic kinase cascade in stress-stimulated cells.	Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, D-97078 Wurzburg, Germany; Univ Klinikums Wurzburg, Hautklin, D-97078 Wurzburg, Germany; Scripps Res Inst, La Jolla, CA 92037 USA	University of Wurzburg; University of Wurzburg; Scripps Research Institute	Rapp, UR (corresponding author), Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, MSZ, Versbacher Str 5, D-97078 Wurzburg, Germany.	rappur@rzbox.uni-wuerzburg.de	Goebeler, Matthias/P-3612-2019; Han, J/G-4671-2010; Goebeler, Matthias/F-7118-2013	Ludwig, Stephan/0000-0003-4490-3052				Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Cavigelli M, 1996, EMBO J, V15, P6269, DOI 10.1002/j.1460-2075.1996.tb01017.x; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; Flory E, 1996, J VIROL, V70, P2260, DOI 10.1128/JVI.70.4.2260-2268.1996; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Furstenau U, 1997, MOL CELL BIOL, V17, P1805; HARTWIG A, 1995, BIOMETALS, V8, P3; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Ludwig S, 1996, MOL CELL BIOL, V16, P6687; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SNOW ET, 1992, PHARMACOL THERAPEUT, V53, P31, DOI 10.1016/0163-7258(92)90043-Y; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	26	192	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1917	1922		10.1074/jbc.273.4.1917	http://dx.doi.org/10.1074/jbc.273.4.1917			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442025	hybrid			2022-12-25	WOS:000071595200014
J	Singh, US; Li, QB; Cerione, R				Singh, US; Li, QB; Cerione, R			Identification of the eukaryotic initiation factor 5A as a retinoic acid-stimulated cellular binding partner for tissue transglutaminase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; GTP-BINDING; CYCLE PROGRESSION; PROTEIN; CELLS; SITE; G(H); TRANSFECTION; HYDROLYSIS; EIF-5A	GTP-binding protein/transglutaminases (tissue transglutaminases or TGases) have been implicated in a variety of cellular processes including retinoic acid (RA)induced apoptosis. Recently, we have shown that RA activates TGases as reflected by stimulated GTP binding, increased membrane association, and stimulated phosphoinositide lipid turnover. This prompted us to search for cellular proteins that bind TGases in a RA-stimulated manner, In this report, we show that the eukaryotic initiation factor (eIF-5A), a protein that is essential for cell viability, perhaps through effects on protein synthesis and/or RNA export, associates with the TGase in vivo, The interaction between eIF-5A and TGase is specific for the GDP-bound form of the TGase and is not detected when the TGase is pre-loaded with GTP gamma S, The TGase-elF-5A interaction also is promoted by Ca2+, Mg2+, and RA treatment of HeLa cells, In the presence of retinoic acid, millimolar levels of Ca2+ are no longer required for the TGase-eIF-5A interaction, Nocodazole treatment, which blocks the cell cycle at mitosis (M. phase), strongly inhibits the interaction between eIF-5A and cytosolic TGase, The interaction between TGase and eIF-5A and its sensitivity to the nucleotide-occupied state of the TGase provides a potentially interesting connection between RA signaling and protein synthesis and/or RNA trafficking activities.	Cornell Univ, Coll Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA	Cornell University	Singh, US (corresponding author), Cornell Univ, Coll Vet Med, Dept Pharmacol, Ithaca, NY 14853 USA.				NEI NIH HHS [EY06429] Funding Source: Medline; NIGMS NIH HHS [GM40654] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY006429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040654] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; ADAMS SL, 1975, J BIOL CHEM, V250, P9083; BENINATI S, 1995, BIOCHEM J, V305, P725, DOI 10.1042/bj3050725; Bevec D, 1996, SCIENCE, V271, P1858, DOI 10.1126/science.271.5257.1858; Brown EJ, 1996, CELL, V86, P517, DOI 10.1016/S0092-8674(00)80125-7; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; CHUNG SI, 1972, ANN NY ACAD SCI, V202, P240, DOI 10.1111/j.1749-6632.1972.tb16338.x; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; FESUS L, 1995, J CELL BIOCHEM, P151; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; Fraij BM, 1996, BIOCHEM BIOPH RES CO, V218, P45, DOI 10.1006/bbrc.1996.0009; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOSWAMI BB, 1991, BIOTECHNIQUES, V10, P626; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; JOHNSON TS, 1994, ONCOGENE, V9, P2935; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; KYUNG NL, 1989, BIOCHEM BIOPH RES CO, V162, P1370; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Park MH, 1996, AMINO ACIDS, V10, P109, DOI 10.1007/BF00806584; Singh US, 1996, J BIOL CHEM, V271, P27292, DOI 10.1074/jbc.271.44.27292; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032	30	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1946	1950		10.1074/jbc.273.4.1946	http://dx.doi.org/10.1074/jbc.273.4.1946			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442029	hybrid			2022-12-25	WOS:000071595200018
J	Lehman, AM; Ellwood, KB; Middleton, BE; Carey, M				Lehman, AM; Ellwood, KB; Middleton, BE; Carey, M			Compensatory energetic relationships between upstream activators and the RNA polymerase II general transcription machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BARR-VIRUS TRANSACTIVATOR; DNA-BINDING SPECIFICITY; IN-VIVO; SACCHAROMYCES-CEREVISIAE; ZTA TRANSACTIVATOR; DROSOPHILA EMBRYO; BICOID PROTEIN; EARLY PROMOTER; BZLF1 PROTEIN; DOMAIN	Activation of RNA polymerase II transcription in vivo and in vitro is synergistic with respect to increasing numbers of activator binding sites or increasing concentrations of activator. The Epstein-Barr virus ZEBRA protein manifests both forms of synergy during activation of genes involved in the viral lytic cycle. The synergy has an underlying mechanistic basis that we and others have proposed is founded largely on the energetic contributions of (i) upstream ZEBRA binding to its sites, (ii) the general pol II machinery binding to the core promoter, and (iii) interactions between ZEBRA and the general machinery. We hypothesize that these interactions form a network for which a minimum stability must be attained to activate transcription. One prediction of this model is that the energetic contributions should be reciprocal, such that a strong core promoter linked to a weak upstream promoter would be functionally analogous to a weak core linked to a strong upstream promoter. We tested this view by measuring the transcriptional response after systematically altering the upstream and core promoters. Our data provide strong qualitative support for this hypothesis and provide a theoretical basis for analyzing Epstein-Barr virus gene regulation.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Carey, M (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, 10833 LeConte Ave, Los Angeles, CA 90095 USA.			Carey, Michael/0000-0003-3899-6280	NIGMS NIH HHS [GM 07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERS GK, 1982, P NATL ACAD SCI-BIOL, V79, P1129, DOI 10.1073/pnas.79.4.1129; ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; BEACHY PA, 1993, MOL CELL BIOL, V13, P6941, DOI 10.1128/MCB.13.11.6941; BLAIR WS, 1994, MOL CELL BIOL, V14, P7226, DOI 10.1128/MCB.14.11.7226; Blau J, 1996, MOL CELL BIOL, V16, P2044; CAREY M, 1992, J VIROL, V66, P4803, DOI 10.1128/JVI.66.8.4803-4813.1992; CHANG YN, 1990, J VIROL, V64, P3358, DOI 10.1128/JVI.64.7.3358-3369.1990; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; CHI TH, 1993, MOL CELL BIOL, V13, P7045, DOI 10.1128/MCB.13.11.7045; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; COUNTRYMAN JK, 1994, J VIROL, V68, P7628, DOI 10.1128/JVI.68.11.7628-7633.1994; COUREY AJ, 1995, BBA-GENE STRUCT EXPR, V1261, P1, DOI 10.1016/0167-4781(94)00234-T; COX MA, 1990, J VIROL, V64, P313, DOI 10.1128/JVI.64.1.313-321.1990; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EMAMI KH, 1992, EMBO J, V11, P5005, DOI 10.1002/j.1460-2075.1992.tb05607.x; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FLEMINGTON E, 1990, J VIROL, V64, P1227, DOI 10.1128/JVI.64.3.1227-1232.1990; FLEMINGTON E, 1990, P NATL ACAD SCI USA, V87, P9459, DOI 10.1073/pnas.87.23.9459; FLEMINGTON EK, 1992, J VIROL, V66, P922, DOI 10.1128/JVI.66.2.922-929.1992; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GINIGER E, 1988, P NATL ACAD SCI USA, V85, P382, DOI 10.1073/pnas.85.2.382; GIOT JF, 1991, NUCLEIC ACIDS RES, V19, P1251, DOI 10.1093/nar/19.6.1251; HAYWARD SD, 1991, HERPESVIRUS TRANSCRI, P363; KOHN MC, 1993, RISK ANAL, V13, P565, DOI 10.1111/j.1539-6924.1993.tb00016.x; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LEE M, 1995, MOL CELL BIOL, V15, P5461; LIEBERMAN PM, 1990, J VIROL, V64, P1143, DOI 10.1128/JVI.64.3.1143-1155.1990; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIEBERMAN PM, 1990, J VIROL, V64, P2560, DOI 10.1128/JVI.64.6.2560-2568.1990; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; MELLINGHOFF I, 1991, VIROLOGY, V185, P922, DOI 10.1016/0042-6822(91)90574-U; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER G, 1993, J VIROL, V67, P7472, DOI 10.1128/JVI.67.12.7472-7481.1993; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PACKHAM G, 1990, J VIROL, V64, P2110, DOI 10.1128/JVI.64.5.2110-2116.1990; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PONTICELLI AS, 1990, MOL CELL BIOL, V10, P2832, DOI 10.1128/MCB.10.6.2832; QUINLIVAN EB, 1993, NUCLEIC ACIDS RES, V21, P1999, DOI 10.1093/nar/21.8.1999; SINCLAIR AJ, 1991, J VIROL, V65, P2237, DOI 10.1128/JVI.65.5.2237-2244.1991; Steger David J., 1996, Bioessays, V18, P875, DOI 10.1002/bies.950181106; SVAREN J, 1994, J BIOL CHEM, V269, P20771; SZYMANSKI P, 1995, EMBO J, V14, P2229, DOI 10.1002/j.1460-2075.1995.tb07217.x; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; TAKADA K, 1986, J VIROL, V57, P1016, DOI 10.1128/JVI.57.3.1016-1022.1986; TAKADA K, 1989, J VIROL, V63, P445, DOI 10.1128/JVI.63.1.445-449.1989; Tanaka M, 1996, P NATL ACAD SCI USA, V93, P4311, DOI 10.1073/pnas.93.9.4311; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; VASHEE S, 1995, P NATL ACAD SCI USA, V92, P10683, DOI 10.1073/pnas.92.23.10683; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; XU HE, 1995, P NATL ACAD SCI USA, V92, P7677, DOI 10.1073/pnas.92.17.7677; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	56	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					932	939		10.1074/jbc.273.2.932	http://dx.doi.org/10.1074/jbc.273.2.932			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422752	hybrid			2022-12-25	WOS:000071411400041
J	Roos, M; Soskic, V; Poznanovic, S; Grodovac-Zimmermann, J				Roos, M; Soskic, V; Poznanovic, S; Grodovac-Zimmermann, J			Post-translational modifications of endothelin receptor B from bovine lungs analyzed by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CROSS-LINKING REAGENTS; SIGNAL-TRANSDUCTION; BETA-2-ADRENERGIC RECEPTOR; HIRSCHSPRUNGS-DISEASE; CYTOPLASMIC DOMAINS; LIGAND-BINDING; CLONING; IDENTIFICATION; EXPRESSION	A new mild experimental approach for isolation of peptide membrane receptors and subsequent analysis of post-translational modifications is described. Endothelin receptors A and B were isolated on oligo(dT)-cellulose using N-(epsilon-maleimidocaproyloxy) succinimide endothelin coupled to a protected (dA)-30-mer. This allowed a one-step isolation of the receptor from oligo(dT)-cellulose via variation solely of salt concentration. The identity of the receptor was confirmed by direct amino acid sequencing of electroblotted samples or by using antibodies against ETA and ETB receptors. The method used here is very fast, requires only very mild elution conditions and, for the first time, gave both ETA and ETB receptors concurrently in very good yield. Following enzymatic in-gel digestion, MALDI, and electrospray ion trap mass spectrometric analysis of the isolated endothelin B receptor showed phosphorylation at Ser-304, -418, -438, -439, -440, and -441. Further phosphorylation at either Ser-434 or -435 was observed. The endothelin B receptor is also palmitoylated at Cys residues 402 and 404. Phosphorylation of Ser(304) may play a role in Hirschsprung's disease.	Inst Mol Biotechnol EV, D-07745 Jena, Germany		Grodovac-Zimmermann, J (corresponding author), Inst Mol Biotechnol EV, Beutenbergstr 11, D-07745 Jena, Germany.	jzimm@imb-jena.de	Zimmermann, Jasminka Godovac/E-6863-2010					Aquilla E, 1996, J BIOL CHEM, V271, P31572, DOI 10.1074/jbc.271.49.31572; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Atherton E., 1990, SOLID PHASE PEPTIDE; Auricchio A, 1996, HUM MOL GENET, V5, P351, DOI 10.1093/hmg/5.3.351; BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; BULLESBACH EE, 1991, J BIOL CHEM, V266, P10754; CHAKRAVARTI A, 1966, HUM MOL GENET, V5, P303; EASON MG, 1994, P NATL ACAD SCI USA, V91, P11178, DOI 10.1073/pnas.91.23.11178; Greenstein-Baynash A., 1994, CELL, V79, P1277; HAGIWARA H, 1993, AM J PHYSIOL, V264, pR777, DOI 10.1152/ajpregu.1993.264.4.R777; HASHIDO K, 1993, CELL MOL BIOL RES, V39, P3; HAWES BE, 1994, J BIOL CHEM, V269, P15776; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HICK S, 1995, J CARDIOVASC PHARM, V26, pS276; HICK S, 1995, EUR J BIOCHEM, V234, P251, DOI 10.1111/j.1432-1033.1995.251_c.x; HillEubanks D, 1996, J BIOL CHEM, V271, P3058, DOI 10.1074/jbc.271.6.3058; Horstmeyer A, 1996, J BIOL CHEM, V271, P20811, DOI 10.1074/jbc.271.34.20811; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; HOSODA K, 1991, FEBS LETT, V287, P23, DOI 10.1016/0014-5793(91)80007-P; KAMBER B, 1980, HELV CHIM ACTA, V63, P899, DOI 10.1002/hlca.19800630418; KARNE S, 1993, J BIOL CHEM, V268, P19126; KHOUJA A, 1992, J DEV PHYSIOL, V18, P263; KITAGAWA T, 1981, CHEM PHARM BULL, V29, P1130; KOZUKA M, 1991, J BIOL CHEM, V266, P16892; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Kusafuka T, 1996, HUM MOL GENET, V5, P347, DOI 10.1093/hmg/5.3.347; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JA, 1994, BIOCHEMISTRY-US, V33, P14543, DOI 10.1021/bi00252a022; LIN HY, 1991, P NATL ACAD SCI USA, V88, P3185, DOI 10.1073/pnas.88.8.3185; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OGAWA Y, 1991, BIOCHEM BIOPH RES CO, V178, P248, DOI 10.1016/0006-291X(91)91806-N; Ohguro H, 1996, J BIOL CHEM, V271, P5215; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; SAKAMOTO A, 1993, J BIOL CHEM, V268, P8547; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Shapiro PS, 1996, J BIOL CHEM, V271, P5750, DOI 10.1074/jbc.271.10.5750; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Stewart JM, 1984, SOLID PHASE PEPTIDE; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; TAKAGI Y, 1995, J BIOL CHEM, V270, P10072, DOI 10.1074/jbc.270.17.10072; Taylor JA, 1996, RAPID COMMUN MASS SP, V10, P679, DOI 10.1002/(SICI)1097-0231(199604)10:6<679::AID-RCM528>3.0.CO;2-Q; THOMPSON P, 1984, BIOCHEM J, V220, P773, DOI 10.1042/bj2200773; Wilkins MR, 1996, BIO-TECHNOL, V14, P61, DOI 10.1038/nbt0196-61; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	50	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					924	931		10.1074/jbc.273.2.924	http://dx.doi.org/10.1074/jbc.273.2.924			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422751	hybrid			2022-12-25	WOS:000071411400040
J	Zhang, YJ; Center, DM; Wu, DMH; Cruikshank, WW; Yuan, JY; Andrews, DW; Kornfeld, H				Zhang, YJ; Center, DM; Wu, DMH; Cruikshank, WW; Yuan, JY; Andrews, DW; Kornfeld, H			Processing and activation of pro-interleukin-16 by caspase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE CHEMOATTRACTANT FACTOR; INTERLEUKIN-16; APOPTOSIS; PROTEASE; SUBSTRATE; FODRIN	Interleukin-16, a proinflammatory cytokine produced in CD8(+) lymphocytes, is synthesized as a precursor protein (pro-IL-16), It is postulated that the C-terminal region of pro-IL-16 is cleaved, releasing bioactive IL-16. To characterize IL-16 cleavage, we transfected COS cells with a cDNA encoding a similar to 50-kDa form of pro-IL-16, Transfected COS cells released a similar to 20-kDa IL-16 cleavage product shown to consist of the 121 C-terminal residues of pro-IL-le by immunoblotting and amino acid sequencing, Cleaved IL-16, but not pro-IL-16, exhibited lymphocyte chemoattractant activity, A C-terminal similar to 20 kDa IL-16 polypeptide was also released when pro-IL-16 was treated with concanavalin A-stimulated CD8(+) lymphocyte lysate, Cleavage occurred after an Asp, suggesting involvement of a caspase (interleukin-1 beta-converting enzyme/CED-3) family protease, Using recombinant caspases and granzyme B, we determined that pro-IL-16 cleavage is mediated only by caspase-3, Relevance to pro-IL-16 processing in primary lymphocytes was supported by identifying the p20 subunit of activated caspase-3 in stimulated CD8(+) lymphocytes and by inhibition of CD8(+) lymphocyte lysate mediated cleavage with Ac-DEVD-CHO. Pro-IL-16 is a substrate for caspase-3, and cleavage by this enzyme releases biologically active IL-16 from its inactive precursor.	Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; ImmuLog Pharmaceut Corp, Waltham, MA 02154 USA	Boston University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Zhang, YJ (corresponding author), Boston Univ, Sch Med, Ctr Pulm, R-3,80 E Concord St, Boston, MA 02118 USA.	yzhang@bupula.bu.edu	Kornfeld, Hardy/AAS-2903-2021	Center, David/0000-0002-5879-7978	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032802] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-32802] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baier M, 1997, P NATL ACAD SCI USA, V94, P5273, DOI 10.1073/pnas.94.10.5273; Bannert N, 1996, NATURE, V381, P30, DOI 10.1038/381030a0; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; Bazan JF, 1996, NATURE, V381, P29, DOI 10.1038/381029a0; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; CENTER DM, 1982, J IMMUNOL, V128, P2562; CRUIKSHANK W, 1982, J IMMUNOL, V128, P2569; Cruikshank W, 1996, NATURE, V382, P501, DOI 10.1038/382501b0; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; Laberge S, 1996, J IMMUNOL, V156, P310; LABERGE S, 1995, J IMMUNOL, V155, P2902; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; PILARO AM, 1990, J IMMUNOL METHODS, V135, P213, DOI 10.1016/0022-1759(90)90275-Z; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; TEWARI M, 1995, CELL, V81, P1; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x	24	202	221	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1144	1149		10.1074/jbc.273.2.1144	http://dx.doi.org/10.1074/jbc.273.2.1144			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422780	hybrid			2022-12-25	WOS:000071411400069
J	Bajorath, J; Greenfield, B; Munro, SB; Day, AJ; Aruffo, A				Bajorath, J; Greenfield, B; Munro, SB; Day, AJ; Aruffo, A			Identification of CD44 residues important for hyaluronan binding and delineation of the binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE HOMING RECEPTOR; EXTRACELLULAR DOMAIN; LIGAND INTERACTION; SPLICED EXONS; PROTEIN; RECOGNITION; ADHESION; GLYCOSYLATION; VARIANTS; MEMBER	CD44 is a widely distributed cell surface protein that plays a role in cell adhesion and migration. As a proteoglycan, CD44 is also implicated in growth factor and chemokine binding and presentation, The extracellular region of CD44 is variably spliced, giving rise to multiple CD44 isoforms. All isoforms contain an amino-terminal domain, which is homologous to cartilage link proteins. The cartilage link protein-like domain of CD44 is important for hyaluronan binding. The structure of the link protein domain of TSG-6 has been determined by MMR. Based on this structure, a molecular model of the link-homologous region of CD44 was constructed, This model was used to select residues for site-specific mutagenesis in an effort to identify residues important for ligand binding and to outline the hyaluronan binding site. Twenty-four point mutants were generated and characterized, and eight residues were identified as critical for binding or to support the interaction. In the model, these residues form a coherent surface the location of which approximately corresponds to the carbohydrate binding sites in two functionally unrelated calcium-dependent lectins, mannose-binding protein and E-selectin (CD62E).	Bristol Myers Squibb Pharmaceut Res Inst, Seattle, WA 98121 USA; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Washington, Dept Biol Struct, Seattle, WA 98194 USA	Bristol-Myers Squibb; University of Oxford; University of Washington; University of Washington Seattle	Bajorath, J (corresponding author), MDS Panlabs, 11804 N Creek Pkwy S, Bothell, WA 98011 USA.		Bajorath, Jürgen/F-7493-2014; Day, Anthony/O-1658-2015; Munro, Sandra B/S-2611-2019	Day, Anthony/0000-0002-1415-3134; Munro, Sandra B/0000-0002-9643-0528				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAJORATH J, 1995, BIOCHEMISTRY-US, V34, P1833, DOI 10.1021/bi00006a003; BAJORATH J, 1992, IMMUNOMETHODS, V1, P137; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BRUCCOLERI RE, 1993, MOL SIMULAT, V10, P151, DOI 10.1080/08927029308022163; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LESLEY J, 1995, J EXP MED, V182, P419; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0	34	139	147	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					338	343		10.1074/jbc.273.1.338	http://dx.doi.org/10.1074/jbc.273.1.338			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417085	hybrid			2022-12-25	WOS:000071295600051
J	Deans, JP; Robbins, SM; Polyak, MJ; Savage, JA				Deans, JP; Robbins, SM; Polyak, MJ; Savage, JA			Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; GPI-ANCHORED PROTEINS; CELL-SURFACE-ANTIGEN; HUMAN LYMPHOCYTES-B; CAVEOLAE MEMBRANE; PLASMA-MEMBRANE; ACTIVATION; BP35; DOMAINS; PHOSPHORYLATION	CD20 is a B cell integral membrane protein capable of initiating growth-modulating signals in human B lymphocytes upon its engagement with monoclonal anti-CD20 antibodies, In this report, we demonstrate that treatment of B cells with CD20 antibodies induces rapid redistribution of CD20 into a detergent-insoluble membrane compartment, Redistribution is detected as early as 15 s, following antibody addition, and involves up to 95% of CD20 molecules, depending on the antibody used. All of the detergent-insoluble CD20 was found in the low density fractions of sucrose density gradients, indicating that CD20 redistributes to glycolipid-rich membrane domains, analogous to caveolae in some cell types, As CD20 has previously been shown to associate with Src family tyrosine kinases, their co-existence in these compartments suggests a link to the role of CD20 in signal transduction. This study provides insight into the mechanism by which CD20 commmunicates signals to the cell interior and indicates that the search for membrane-proximal intracellular signaling partners should be directed to the Triton-insoluble fraction.	Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Immunol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Oncol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary	Deans, JP (corresponding author), Univ Calgary, Hlth Sci Ctr, Dept Med Biochem, Immunol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Robbins, Stephen/0000-0001-7475-1665				ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BUBIEN JK, 1993, J CELL BIOL, V121, P1121, DOI 10.1083/jcb.121.5.1121; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; CINEK T, 1992, J IMMUNOL, V149, P2262; CLARK EA, 1987, J IMMUNOL, V138, P720; CLARK EA, 1985, P NATL ACAD SCI USA, V82, P1766, DOI 10.1073/pnas.82.6.1766; CLARK EA, 1986, P NATL ACAD SCI USA, V83, P4494, DOI 10.1073/pnas.83.12.4494; DEANS JP, 1995, J BIOL CHEM, V270, P22632, DOI 10.1074/jbc.270.38.22632; DEANS JP, 1993, J IMMUNOL, V151, P4494; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GOLAY JT, 1985, J IMMUNOL, V135, P3795; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KUSTER H, 1992, J BIOL CHEM, V267, P12782; LISANTI MP, 1995, MOL MEMBR BIOL, V12, P121, DOI 10.3109/09687689509038506; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu J, 1997, J BIOL CHEM, V272, P7211, DOI 10.1074/jbc.272.11.7211; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Parolini I, 1996, BLOOD, V87, P3783, DOI 10.1182/blood.V87.9.3783.bloodjournal8793783; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; RAPOSO G, 1987, BIOL CELL, V60, P117, DOI 10.1111/j.1768-322X.1987.tb00551.x; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SIMONS K, 1997, NATURE, V387, P589; SMELAND E, 1985, P NATL ACAD SCI USA, V82, P6255, DOI 10.1073/pnas.82.18.6255; STAMENKOVIC I, 1988, J EXP MED, V167, P1975, DOI 10.1084/jem.167.6.1975; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; TEDDER TF, 1986, EUR J IMMUNOL, V16, P881, DOI 10.1002/eji.1830160802; TEDDER TF, 1988, J BIOL CHEM, V263, P10009; TEDDER TF, 1989, LEUKOCYTE TYPING, V4, P48; VALENTINE MA, 1989, J BIOL CHEM, V264, P11282	42	130	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					344	348		10.1074/jbc.273.1.344	http://dx.doi.org/10.1074/jbc.273.1.344			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417086	hybrid			2022-12-25	WOS:000071295600052
J	Draper, LB; Matzuk, MM; Roberts, VJ; Cox, E; Weiss, J; Mather, JP; Woodruff, TK				Draper, LB; Matzuk, MM; Roberts, VJ; Cox, E; Weiss, J; Mather, JP; Woodruff, TK			Identification of an inhibin receptor in gonadal tumors from inhibin alpha-subunit knockout mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; SITU LIGAND-BINDING; GROWTH-FACTOR-BETA; ACTIVIN-A; DEFICIENT MICE; FEMALE RAT; RECOMBINANT INHIBIN; FUNCTIONAL-ANALYSIS; MOLECULAR-CLONING; GENE-EXPRESSION	Inhibins and activins are dimeric proteins that are functional antagonists and are structurally related to the transforming growth factor-beta (TGF beta) family of growth and differentiation factors. Receptors for activin and TGF beta have been identified as dimers of serine threonine kinase subunits that regulate cytoplasmic proteins known as Smads, Despite major advances in our understanding of activin and TGF beta receptors and signaling pathways, little is known about inhibin receptors or the mechanism by which this molecule provides a functionally antagonistic signal to activin. Studies described in this paper indicate that an independent inhibin receptor exists, Numerous tissues were examined for inhibin-specific binding sites, including the developing embryo, in which the spinal ganglion and trigeminal ganglion-bound iodinated inhibin A. Sex cord stromal tumors, derived from male and female inhibin Lu-subunit deficient mice, were also identified as a source of inhibin receptor, Abundant inhibin and few activin binding sites were identified in tumor tissue sections by in situ ligand binding using iodinated recombinant human inhibin A and I-125-labeled recombinant human inhibin A, Tumor cell binding was specific for each ligand (competed by excess unlabeled homologous ligand and not competed by heterologous ligand). Based on these results and the relative abundance and homogeneity of tumor tissues versus the embryonic ganglion, tumor tissues were homogenized, membrane proteins were purified, and putative inhibin receptors were isolated using an inhibin affinity column, Four proteins were eluted from the column that bind iodinated inhibin but not iodinated activin. These data suggest that inhibin-specific membrane-associated proteins (receptors) exist.	Northwestern Univ, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Dept Neurobiol & Physiol, Chicago, IL 60611 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Univ Calif San Diego, Dept Reprod Med, San Diego, CA 92093 USA; Genentech Inc, San Francisco, CA 94080 USA	Northwestern University; Northwestern University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Diego; Roche Holding; Genentech	Woodruff, TK (corresponding author), Northwestern Univ, Dept Med, Tarry Bldg I5-716,303 Chicago Ave, Chicago, IL 60611 USA.	tkw@nwu.edu		Woodruff, Teresa/0000-0002-1197-3399	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R29HD029464] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA060651] Funding Source: NIH RePORTER; NCI NIH HHS [CA60651] Funding Source: Medline; NICHD NIH HHS [HD 29464] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alak BM, 1996, FERTIL STERIL, V66, P646, DOI 10.1016/S0015-0282(16)58583-5; ALBANO RM, 1993, DEVELOPMENT, V117, P711; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BLAUER M, 1992, DEVELOPMENT, V115, P1079; BURGER HG, 1993, HUM REPROD, V8, P129, DOI 10.1093/humrep/8.suppl_2.129; Coerver KA, 1996, MOL ENDOCRINOL, V10, P534, DOI 10.1210/me.10.5.534; Daopin Sun, 1993, Proteins Structure Function and Genetics, V17, P176, DOI 10.1002/prot.340170207; DEPAOLO LV, 1991, P SOC EXP BIOL MED, V198, P500; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; Fang JM, 1996, BIOCHEM BIOPH RES CO, V228, P669, DOI 10.1006/bbrc.1996.1715; GRIEGER DM, 1993, 75TH ANN M END SOC L, P298; Griffith DL, 1996, P NATL ACAD SCI USA, V93, P878, DOI 10.1073/pnas.93.2.878; HILLIER SG, 1991, MOL CELL ENDOCRINOL, V75, pR1, DOI 10.1016/0303-7207(91)90234-J; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KRUMMEN LA, 1994, BIOL REPROD, V50, P734, DOI 10.1095/biolreprod50.4.734; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lebrun JJ, 1997, MOL CELL BIOL, V17, P1682, DOI 10.1128/MCB.17.3.1682; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1992, CANCER SURV, V12, P81; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MATZUK MM, 1995, NATURE, V374, P311; MAYO KE, 1994, TRENDS ENDOCRIN MET, V5, P407, DOI 10.1016/1043-2760(95)92523-L; McCullagh DR, 1932, SCIENCE, V76, P19, DOI 10.1126/science.76.1957.19; Miro F, 1996, ENDOCRINOLOGY, V137, P464, DOI 10.1210/en.137.2.464; ODA S, 1995, BIOCHEM BIOPH RES CO, V210, P581, DOI 10.1006/bbrc.1995.1699; PHOCAS I, 1992, HUM REPROD, V7, P545, DOI 10.1093/oxfordjournals.humrep.a137687; RIVIER C, 1991, ENDOCRINOLOGY, V129, P2463, DOI 10.1210/endo-129-5-2463; RIVIER C, 1991, ENDOCRINOLOGY, V129, P2160, DOI 10.1210/endo-129-4-2160; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; Roberts VJ, 1996, ENDOCRINOLOGY, V137, P4201, DOI 10.1210/en.137.10.4201; Schmitt J, 1996, GENOMICS, V32, P358, DOI 10.1006/geno.1996.0130; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SHAO LE, 1992, BLOOD, V79, P773; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; STERN CD, 1995, DEV BIOL, V172, P192, DOI 10.1006/dbio.1995.0015; Stock AE, 1997, BIOL REPROD, V56, P1559, DOI 10.1095/biolreprod56.6.1559; Teixeira J, 1996, J ANDROL, V17, P336; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; TRUDEAU VL, 1994, BIOCHEM BIOPH RES CO, V203, P105, DOI 10.1006/bbrc.1994.2155; VALE W, 1988, RECENT PROG HORM RES, V44, P1; VANDENEIJNDENVANRAAIJ AJM, 1992, DEV BIOL, V154, P356, DOI 10.1016/0012-1606(92)90074-Q; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WEISS J, 1993, TRENDS ENDOCRIN MET, V4, P265, DOI 10.1016/1043-2760(93)90097-X; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; WOODRUFF TK, 1993, ENDOCRINOLOGY, V132, P2332, DOI 10.1210/en.132.6.2332; Woodruff TK, 1996, ENDOCRINOLOGY, V137, P5463, DOI 10.1210/en.137.12.5463; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196; WOODRUFF TK, 1988, SCIENCE, V239, P1296, DOI 10.1126/science.3125611; WOODRUFF TK, 1993, ENDOCRINOLOGY, V133, P2998, DOI 10.1210/en.133.6.2998; XU JM, 1995, J BIOL CHEM, V270, P6308, DOI 10.1074/jbc.270.11.6308	57	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					398	403		10.1074/jbc.273.1.398	http://dx.doi.org/10.1074/jbc.273.1.398			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417095	hybrid			2022-12-25	WOS:000071295600061
J	Jones, PLS; Korte, T; Blumenthal, R				Jones, PLS; Korte, T; Blumenthal, R			Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUSION; BINDING; ENTRY; GP120; HEMAGGLUTININ; MEMBRANES; COFACTOR; KINETICS; PROTEINS; LINES	We have continuously measured CD4-induced conformational changes of cell surface expressed human immunodeficiency virus type-1 envelope glycoprotein gp120-gp41 irt situ using 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid, a fluorescent probe that binds to hydrophobic groups. CD4-expressing human T cell lines induced significant and rapid conformational changes (<1 min delay) in gp120-gp41 from T cell-tropic strains, and little conformational changes in gp120-gp41 from macrophage-tropic strains, with equivalent levels of envelope expression. Conversely, CD4-expressing human macrophages induced significant and rapid conformational changes in gp120-gp41 from macrophage-tropic strains, and little conformational changes in gp120-gp41 from T cell-tropic strains. Thus, the conformational changes undergone by gp120-gp41, which lead to membrane fusion, are highly cooperative and require both receptor and co-receptor. We used a dye transfer assay to show that neither membrane lipid fusion or fusion pore formation can occur with host cells having different tropism from the envelope.	NCI, Frederick Canc Res & Dev Ctr, Sect Membrane Struct & Funct, Lab Expt & Computat Biol,Div Basic Sci,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Blumenthal, R (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Sect Membrane Struct & Funct, Lab Expt & Computat Biol,Div Basic Sci,NIH, Bldg 469,Rm 213,POB B,Miller Dr, Frederick, MD 21702 USA.	blumen@helix.nih.gov						Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BLUMENTHAL R, 1991, ANN NY ACAD SCI, V635, P285, DOI 10.1111/j.1749-6632.1991.tb36499.x; Blumenthal R, 1996, J CELL BIOL, V135, P63, DOI 10.1083/jcb.135.1.63; BLUMENTHAL R, 1997, HDB PHYSL, P569; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; Broder CC, 1996, PATHOBIOLOGY, V64, P171, DOI 10.1159/000164032; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DIMITROV DS, 1992, AIDS, V6, P249, DOI 10.1097/00002030-199203000-00023; DIMITROV DS, 1992, J VIROL, V66, P132, DOI 10.1128/JVI.66.1.132-138.1992; Dimitrov DS, 1996, NAT MED, V2, P640, DOI 10.1038/nm0696-640; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FU YK, 1993, J VIROL, V67, P3818, DOI 10.1128/JVI.67.7.3818-3825.1993; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; GROENINK M, 1995, J VIROL, V69, P523, DOI 10.1128/JVI.69.1.523-527.1995; Holowka D, 1996, ANNU REV BIOPH BIOM, V25, P79; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; LIFSON JD, 1986, NATURE, V323, P725, DOI 10.1038/323725a0; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MATTHEWS TJ, 1994, IMMUNOL REV, V140, P93, DOI 10.1111/j.1600-065X.1994.tb00866.x; Puri A, 1996, VIROLOGY, V219, P262, DOI 10.1006/viro.1996.0244; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0	31	171	179	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					404	409		10.1074/jbc.273.1.404	http://dx.doi.org/10.1074/jbc.273.1.404			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417096	hybrid			2022-12-25	WOS:000071295600062
J	Holme, PA; Muller, F; Solum, NO; Brosstad, F; Froland, SS; Aukrust, P				Holme, PA; Muller, F; Solum, NO; Brosstad, F; Froland, SS; Aukrust, P			Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection	FASEB JOURNAL			English	Article						HIV; RANTES; platelets; antiretroviral therapy; P-selection	NF-KAPPA-B; PROTEIN-S; T-CELLS; CHEMOKINES; MICROPARTICLES; NEUTROPHILS; CYTOKINES; RECEPTOR; DISEASE; BLOOD	Besides their role in hemostasis, platelets are involved in inflammatory and immunological processes, and we hypothezise that platelet activation may play an immunopathogenetic role in HIV-1 infection. Blood was drawn from 15 controls and 20 HIV-1-infected patients with normal platelet counts, classified into groups of non-AIDS and AIDS. Platelet activation was detected using flow cytometry with mAbs against the release markers P-selectin and CD63, mAb against GPIb, and the probe annexin V detecting surface exposure of aminophospholipids. The amount of microvesicles was measured using mAb against GPIIIa. Compared to controls, blood samples from HIV-1-infected patients showed significantly enhanced levels of microvesicles and activated platelets as detected by their exposure of P-selectin, CD63, and aminophospholipids, as well as reduction in GPIb expression. Increased expression of P-selectin and amounts of microvesicles were most pronounced in advanced clinical and immunological disease. When studying the effect of HIV-1 protease inhibitor therapy (indinavir) on platelet activation, we found that concomitant with a profound decrease in plasma viral load, there was a near normalization of several of the parameters reflecting enhanced platelet activation. Finally, we demonstrated that platelets may be an important source of the chemokine RANTES in HIV-1-infected patients. Although both unstimulated and SFLLRN-stimulated platelets from asymptomatic patients had enhanced release of RANTES, platelets from AIDS patients were characterized by markedly enhanced spontaneous, but decreased SFLLRN-stimulated release of this chemokine. Taken together, these results, which demonstrate for the first time increased platelet activation in HIV-1-infected patients with normal platelet counts, may represent a previously unrecognized immunopathogenic factor in HIV-1 infection.	Univ Oslo, Natl Hosp, Dept Med A, Sect Clin Immunol & Infect Dis, Oslo, Norway; Univ Oslo, Natl Hosp, Internal Med Res Inst, Oslo, Norway	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	Aukrust, P (corresponding author), Rikshosp, Dept Med A, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway.	pal.aukrust@klinmed.uio.no						ABRAMS CS, 1990, BLOOD, V75, P128; AUKRUST P, 1994, J INFECT DIS, V169, P420, DOI 10.1093/infdis/169.2.420; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BIERLING P, 1995, SEMIN THROMB HEMOST, V21, P68, DOI 10.1055/s-2007-1000380; BISSUEL F, 1992, J ACQ IMMUN DEF SYND, V5, P484; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CHIGNARD M, 1994, ANN NY ACAD SCI, V725, P309, DOI 10.1111/j.1749-6632.1994.tb39814.x; Clerici M, 1996, AIDS, V10, P1432, DOI 10.1097/00002030-199610000-00019; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DAMLE NK, 1992, EUR J IMMUNOL, V22, P1789, DOI 10.1002/eji.1830220718; ELBIM C, 1994, BLOOD, V84, P2759, DOI 10.1182/blood.V84.8.2759.bloodjournal8482759; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Gris JC, 1996, THROMB HAEMOSTASIS, V76, P38; HAWRYLOWICZ CM, 1989, J IMMUNOL, V143, P4015; Hedrick JA, 1996, CURR OPIN IMMUNOL, V8, P343, DOI 10.1016/S0952-7915(96)80123-3; HOLME PA, 1994, THROMB HAEMOSTASIS, V72, P666; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; Holme PA, 1995, THROMB HAEMOSTASIS, V74, P1533; JANES SL, 1995, THROMB HAEMOSTASIS, V74, P1059; JY W, 1992, J LAB CLIN MED, V119, P334; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KLINGER MHF, 1995, INT ARCH ALLERGY IMM, V107, P541, DOI 10.1159/000237097; Lundahl TH, 1996, BLOOD COAGUL FIBRIN, V7, P218, DOI 10.1097/00001721-199603000-00027; MERINO J, 1992, J IMMUNOL METHODS, V153, P151, DOI 10.1016/0022-1759(92)90317-M; MICHELSON AD, 1991, BLOOD, V77, P770; Murakami T, 1996, EUR J CLIN INVEST, V26, P996, DOI 10.1046/j.1365-2362.1996.2360585.x; NAGATA K, 1993, J IMMUNOL, V151, P3267; ORYO M, 1996, J LEUKOCYTE BIOL, V60, P77; PAGE CP, 1989, IMMUNOPHARMACOLOGY, V17, P51, DOI 10.1016/0162-3109(89)90008-8; POWER CA, 1994, GENE, V151, P333, DOI 10.1016/0378-1119(94)90682-3; Rubbert A, 1997, AIDS RES HUM RETROV, V13, P63, DOI 10.1089/aid.1997.13.63; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; Stein DS, 1996, AIDS, V10, P485, DOI 10.1097/00002030-199605000-00006; Strieter RM, 1996, J IMMUNOL, V156, P3583; Su SB, 1996, J LEUKOCYTE BIOL, V59, P420, DOI 10.1002/jlb.59.3.420; TAIT JF, 1989, J BIOL CHEM, V264, P7944; TAUB R, 1989, J BIOL CHEM, V264, P259; TODOROKI N, 1991, BIOCHEM BIOPH RES CO, V179, P756, DOI 10.1016/0006-291X(91)91881-C; TOULON P, 1993, THROMB HAEMOSTASIS, V70, P730; TSCHOEPE D, 1991, SEMIN THROMB HEMOST, V17, P433, DOI 10.1055/s-2007-1002650; WEKSLER B. B., 1992, INFLAMMATION BASIC P, P727; Weyrich AS, 1996, J CLIN INVEST, V97, P1525, DOI 10.1172/JCI118575; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005; YAN ZQ, 1994, BLOOD, V84, P2329; Zalavary S, 1996, J LEUKOCYTE BIOL, V60, P58, DOI 10.1002/jlb.60.1.58; ZAULI G, 1992, BLOOD, V79, P2680; ZUCKERFRANKLIN D, 1990, BLOOD, V75, P120	52	137	141	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					79	89		10.1096/fasebj.12.1.79	http://dx.doi.org/10.1096/fasebj.12.1.79			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438413				2022-12-25	WOS:000071523800009
J	Ferrando, AA; Pendas, AM; Llano, E; Velasco, G; Lidereau, R; Lopez-Otin, C				Ferrando, AA; Pendas, AM; Llano, E; Velasco, G; Lidereau, R; Lopez-Otin, C			Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE AMINOPEPTIDASE GENE; FRAXE MENTAL-RETARDATION; FRAGILE-X-SYNDROME; BREAST-CANCER; GENOMIC ORGANIZATION; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; IDENTIFICATION; PROTEINASE; PEPC	The human gene encoding bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance, has been cloned, and its overall organization has been established. The gene is composed of 12 coding exons and 11 introns and spans more than 30 kilobases, The number and distribution of exons and introns differ from those reported for other human cysteine proteinases, indicating that these genes are only distantly related. Nucleotide sequence analysis of about 1.2 kilobases of the 5'-flanking region of the human bleomycin hydrolase gene revealed a high GC content, a ratio of CpG/GpC close to unity, and the absence of consensus transcriptional sequences such as TATA box or CCAAT box. All these features are characteristic of housekeeping genes and provide an explanation for the widespread expression of bleomycin hydrolase in human tissues. The B'-flanking region of the gene also contains a polymorphic CCG trinucleotide repeat that may be a target of genetic instability events and affect its transcriptional activity. Chromosomal localization of the human bleomycin hydrolase gene revealed that it maps to chromosome 17q11.2, very close to the locus of the neurofibromatosis type 1 gene. This location is unique for any cysteine proteinase mapped to date. Finally, Southern blot analysis of DNA from leukocytes and autologous breast tumors has shown that the bleomycin hydrolase gene is not a frequent target of amplification in human breast carcinomas.	Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain; Ctr Rene Huguenin, Lab Oncogenet, F-92211 St Cloud, France	University of Oviedo; Rene Huguenin Hospital	Lopez-Otin, C (corresponding author), Univ Oviedo, Fac Med, Dept Bioquim & Biol Mol, E-33006 Oviedo, Spain.		Pendas, Alberto M/L-1017-2014; Velasco, Gloria/AAS-5842-2021; López-Otín, Carlos/AAB-2106-2020; Llano, Elena/K-1723-2014; Llano, Elena/AAS-5517-2021	Velasco, Gloria/0000-0001-8032-5056; López-Otín, Carlos/0000-0001-6964-1904; Llano, Elena/0000-0002-2626-5723; Llano, Elena/0000-0002-2626-5723; Pendas, Alberto M/0000-0001-9264-3721				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; Bieche I, 1996, CANCER RES, V56, P3886; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bromme D, 1996, BIOCHEMISTRY-US, V35, P6706, DOI 10.1021/bi960092y; Carter S.K., 1985, BLEOMYCIN CHEMOTHERA, P3; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; CHAPOTCHARTIER MP, 1994, EUR J BIOCHEM, V224, P497, DOI 10.1111/j.1432-1033.1994.00497.x; CHAPOTCHARTIER MP, 1993, APPL ENVIRON MICROB, V59, P330, DOI 10.1128/AEM.59.1.330-333.1993; CHAUHAN SS, 1993, J BIOL CHEM, V268, P1039; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENENKEL C, 1993, J BIOL CHEM, V268, P7036; Ferrando AA, 1996, CANCER RES, V56, P1746; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; Gelb BD, 1997, GENOMICS, V41, P258, DOI 10.1006/geno.1997.4631; Gelb BD, 1996, SCIENCE, V273, P1236, DOI 10.1126/science.273.5279.1236; GONG QM, 1993, DNA CELL BIOL, V12, P299, DOI 10.1089/dna.1993.12.299; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; HAMILTON RF, 1995, AM J PHYSIOL-LUNG C, V269, pL318, DOI 10.1152/ajplung.1995.269.3.L318; Haston CK, 1996, CANCER RES, V56, P2596; JOSHUATOR L, 1995, SCIENCE, V269, P945, DOI 10.1126/science.7638617; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KAMBOURIS NG, 1992, J BIOL CHEM, V267, P21570; KLEIN JR, 1994, FEMS MICROBIOL LETT, V124, P291, DOI 10.1111/j.1574-6968.1994.tb07299.x; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; LAZO JS, 1990, PHARMACOL THERAPEUT, V47, P347, DOI 10.1016/0163-7258(90)90061-6; LAZO JS, 1989, ANTICANCER DRUG RESI, P267; LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T; LINNEVERS C, 1997, FEBS LETT, V405, P235; Mir LM, 1996, GEN PHARMACOL-VASC S, V27, P745, DOI 10.1016/0306-3623(95)02101-9; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIMURA C, 1987, BIOCHEMISTRY-US, V26, P1574, DOI 10.1021/bi00380a013; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; Paulson HL, 1996, ANNU REV NEUROSCI, V19, P79; PEI ZD, 1995, MOL PHARMACOL, V48, P676; PENDAS AM, 1994, CYTOGENET CELL GENET, V66, P263, DOI 10.1159/000133708; PENDAS AM, 1994, CYTOGENET CELL GENET, V67, P31, DOI 10.1159/000133792; Rao NV, 1997, J BIOL CHEM, V272, P10260; Rood JA, 1997, GENOMICS, V41, P169, DOI 10.1006/geno.1997.4614; SEBTI SM, 1989, BIOCHEMISTRY-US, V28, P6544, DOI 10.1021/bi00442a003; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SHI GP, 1994, J BIOL CHEM, V269, P11530; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; UMEZAWA H, 1974, Journal of Antibiotics (Tokyo), V27, P419; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VESANTO E, 1994, EUR J BIOCHEM, V224, P991, DOI 10.1111/j.1432-1033.1994.00991.x; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WANG X, 1987, CYTOGENET CELL GENET, V46, P710; XU HE, 1994, J BIOL CHEM, V269, P21177	53	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33298	33304		10.1074/jbc.272.52.33298	http://dx.doi.org/10.1074/jbc.272.52.33298			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407121	hybrid			2022-12-25	WOS:000071182900082
J	Sun, ZJ; Pan, J; Bubley, G; Balk, SP				Sun, ZJ; Pan, J; Bubley, G; Balk, SP			Frequent abnormalities of TSG101 transcripts in human prostate cancer	ONCOGENE			English	Article						prostate cancer; tumor suppressor; aberrant RNA splicing; TSG101	DEPENDENT PROTEIN-KINASE; FHIT GENE; STATHMIN; CELLS; PHOSPHORYLATION; PHOSPHOPROTEIN; EXPRESSION; 3P14.2	TSG101 has been identified as a candidate tumor suppressor gene and abnormal transcripts have been identified in a substantial fraction of breast cancers, To determine whether TSG101 expression is commonly altered in other tumors, a series of 15 primary and metastatic prostate cancers were analysed by reverse transcriptase-PCR amplification, Abnormal transcripts with extensive deletions in the coding region were found in nine of these tumors, while only the normal transcript was found in control and benign prostatic hypertrophy tissues, More than one abnormal transcript was found in four of these nine cases and distinct abnormal TSG101 transcripts were found in separate biopsies taken from one tumor, Importantly, the normal TSG101 transcript was undetectable in two metastatic prostate cancers, indicating the absence of TSG101 protein, Sequence analysis demonstrated that there were at least sh distinct deletions, with four of these deletions found in more than one tumor sample, The most commonly identified deletion, from bp 153 to 1055, was identical to a deletion reported previously in breast cancer, These results demonstrate that TSG101 transcripts are frequently abnormal in prostate cancer and suggest that loss of TSG101 protein contributes to disease development or progression.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Sun, ZJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA065647, R01CA070297, R29CA070297] Funding Source: NIH RePORTER; NCI NIH HHS [R29 CA070297-03, R29 CA070297, R01 CA070297, CA65647, R01 CA070297-12, CA70297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERETTA L, 1993, J BIOL CHEM, V268, P20076; CHNEIWEISS H, 1989, J NEUROCHEM, V53, P856, DOI 10.1111/j.1471-4159.1989.tb11783.x; DURAJ J, 1995, LEUKEMIA RES, V19, P457, DOI 10.1016/0145-2126(94)00154-3; EUSTACE W, 1995, FEBS LETT, V364, P309, DOI 10.1016/0014-5793(95)00416-7; GUSSOW D, 1987, J IMMUNOL, V139, P3132; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; LEFF SE, 1986, ANNU REV BIOCHEM, V55, P1091, DOI 10.1146/annurev.bi.55.070186.005303; LEIGHTON IA, 1993, MOL CELL BIOCHEM, V128, P151, DOI 10.1007/BF01076766; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NAKAMURA K, 1995, ELECTROPHORESIS, V16, P1530, DOI 10.1002/elps.11501601253; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8	16	45	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3121	3125		10.1038/sj.onc.1201521	http://dx.doi.org/10.1038/sj.onc.1201521			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444960				2022-12-25	WOS:000070968000012
J	Thien, CBF; Langdon, WY				Thien, CBF; Langdon, WY			Tyrosine kinase activity of the EGF receptor is enhanced by the expression of oncogenic 70Z-Cbl	ONCOGENE			English	Article						growth factor; oncogene; receptor; signal transduction; tyrosine kinase	EPIDERMAL GROWTH-FACTOR; C-CBL PROTOONCOGENE; CELL ANTIGEN RECEPTOR; PC12 CELLS; ADAPTER PROTEINS; SH3 DOMAIN; V-CBL; PHOSPHOTYROSINE PHOSPHATASE; NEURONAL DIFFERENTIATION; PHOSPHORYLATED CBL	The 120kD product of the c-Cbl oncogene is a prominent substrate of protein tyrosine kinases that lacks a known catalytic activity but possesses an array of binding sites for cytoplasmic signalling proteins, An oncogenic form of Cbl was recently identified in the 70Z/3 pre-B cell lymphoma which has a small deletion at the N-terminus of the Ring finger domain. This form of Cbl, termed 70Z-Cbl, exhibits an enhanced level of tyrosine phosphorylation compared with c-Cbl, Here we demonstrate that the expression of 70Z-Cbl induces a tenfold enhancement in the kinase activity of the EGF receptor in serum-starved and EGF-stimulated cells, In serum-starved cells this results in EGF receptor autophosphorylation and the recruitment of Grb2, Shc and Sos1 but does not induce a corresponding increase in MAP kinase activity, Furthermore the expression of 70Z-Cbl greatly enhances EGF-induced tyrosine phosphorylation of the protein tyrosine phosphatase SHP-2, We also show that the Cbl/EGF receptor complex is predominantly associated with CrkII and is distinct to the Grb2/Shc/Sos1 complex that associates with the EGF receptor. These findings therefore demonstrate a biochemical effect of an oncogenic Cbl protein and support predictions from C, elegans that Cbl functions as regulator of receptor tyrosine kinases.	UNIV WESTERN AUSTRALIA,QUEEN ELIZABETH II MED CTR,DEPT PATHOL,NEDLANDS,WA 6907,AUSTRALIA	University of Western Australia			Thien, Christine/GQP-0424-2022	Thien, Christine/0000-0003-3884-5546				Andoniou CE, 1996, ONCOGENE, V12, P1981; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Buday L, 1996, J BIOL CHEM, V271, P6159, DOI 10.1074/jbc.271.11.6159; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASE RD, 1994, J BIOL CHEM, V269, P10467; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20241; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; Ingham RJ, 1996, J BIOL CHEM, V271, P32306, DOI 10.1074/jbc.271.50.32306; JONGEWARD GD, 1995, GENETICS, V139, P1553; Khwaja A, 1996, ONCOGENE, V12, P2491; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; KizakaKondoh S, 1996, P NATL ACAD SCI USA, V93, P12177, DOI 10.1073/pnas.93.22.12177; Kontani K, 1996, J BIOL CHEM, V271, P1534; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Liu YC, 1997, J BIOL CHEM, V272, P168; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PANCHAMOORTHY G, 1996, J BIOL CHEM, V271, P387; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; Ribon V, 1996, MOL CELL BIOL, V16, P45; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sabe H, 1995, J BIOL CHEM, V270, P31219, DOI 10.1074/jbc.270.52.31219; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Sattler M, 1996, ONCOGENE, V12, P839; Sawasdikosol S, 1996, J IMMUNOL, V157, P110; SCHAEFER E, 1996, PROMEGA NOTES, V59, P2; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Thien CBF, 1997, ONCOGENE, V14, P2239, DOI 10.1038/sj.onc.1201193; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSYGANKOV AY, 1996, J BIOL CHEM, V271; Ueno H, 1997, J BIOL CHEM, V272, P8739, DOI 10.1074/jbc.272.13.8739; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	64	55	56	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2909	2919		10.1038/sj.onc.1201468	http://dx.doi.org/10.1038/sj.onc.1201468			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416834				2022-12-25	WOS:A1997YK37700003
J	Barth, A; Martin, SR; Bayley, PM				Barth, A; Martin, SR; Bayley, PM			Specificity and symmetry in the interaction of calmodulin domains with the skeletal muscle myosin light chain kinase target sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW FLUORESCENCE; TERMINAL TRYPTIC FRAGMENT; OXIDE SYNTHASE ACTIVITIES; CALCIUM-BINDING; CENTRAL HELIX; NUCLEOTIDE PHOSPHODIESTERASE; AMPHIPHILIC PEPTIDES; REGULATORY DOMAIN; SCALLOP MYOSIN; TROPONIN-C	The specificity of interaction of the isolated N- and C-terminal domains of calmodulin with peptide WFFp (Ac-KRRWKKNFIAVSAANRFK-amide) and variants of the target sequence of skeletal muscle myosin light chain kinase was investigated using CD and fluorescence. Titrations show that two molecules of either domain bind to 18-residue target peptides. For WFFp, the C-domain binds with 4-fold higher affinity to the native compared with the non-native site; the N-domain shows similar affinity for either site. The selectivity of the C-domain suggests that it promotes occupancy of the correct binding site for intact calmodulin on the target sequence. Far UV CD spectra show the extra helicity induced in forming the 2:1 C-domain-peptide or the 1:1:1 C-domain-N-domain-peptide complex is similar to that induced by calmodulin itself; binding of the C-domain to the Trp-4 site is essential for developing the full helicity. Calmodulin-MLCK-peptide complexes show an approximate two-fold rotational relationship between the two highly homologous domains, and the 2:1 C (or N)-domain-peptide complexes evidently have a similar rotational symmetry. This implies that a given domain can bind sequences with opposite peptide polarities, significantly increasing the possible range of conformations of calmodulin in its complexes, and extending the versatility and diversity of calmodulin-target interactions.	Natl Inst Med Res, Div Phys Biochem, London NW7 1AA, England	MRC National Institute for Medical Research	Bayley, PM (corresponding author), Natl Inst Med Res, Div Phys Biochem, Mill Hill, London NW7 1AA, England.	p-bayley@nimr.mrc.ac.uk	Barth, Andreas/N-8872-2013	Barth, Andreas/0000-0001-5784-7673	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AFSHAR M, 1994, J MOL BIOL, V244, P554, DOI 10.1006/jmbi.1994.1752; AFSHAR M, 1995, THESIS U MONTPELLIER; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BAYLEY P, 1988, FEBS LETT, V238, P61, DOI 10.1016/0014-5793(88)80225-4; Bayley PM, 1996, PROTEIN SCI, V5, P1215, DOI 10.1002/pro.5560050701; BAYLEY PM, 1992, BIOCHIM BIOPHYS ACTA, V1160, P16, DOI 10.1016/0167-4838(92)90034-B; CHAZIN WJ, 1995, NAT STRUCT BIOL, V2, P707, DOI 10.1038/nsb0995-707; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; DRABIKOWSKI W, 1982, J BIOL CHEM, V257, P1584; DRABIKOWSKI W, 1977, BIOCHIM BIOPHYS ACTA, V485, P124, DOI 10.1016/0005-2744(77)90199-1; FINDLAY WA, 1995, BIOCHEMISTRY-US, V34, P2087, DOI 10.1021/bi00007a001; FINDLAY WA, 1995, PROTEIN SCI, V4, P2375, DOI 10.1002/pro.5560041116; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; ITAKURA M, 1992, J BIOCHEM, V112, P183, DOI 10.1093/oxfordjournals.jbchem.a123875; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEE CB, 1985, CALMODULIN, P35; KLUMPP S, 1987, BIOCHEM BIOPH RES CO, V142, P857, DOI 10.1016/0006-291X(87)91492-6; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; KUZNICKI J, 1981, FEBS LETT, V130, P141, DOI 10.1016/0014-5793(81)80683-7; LINSE S, 1991, J BIOL CHEM, V266, P8050; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTIN SR, 1986, BIOCHEM J, V238, P485, DOI 10.1042/bj2380485; MAUNE JF, 1992, J BIOL CHEM, V267, P5286; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Medvedeva MV, 1996, BIOCHEM J, V315, P1021, DOI 10.1042/bj3151021; MINOWA O, 1984, J BIOCHEM-TOKYO, V96, P1175, DOI 10.1093/oxfordjournals.jbchem.a134935; NEWTON D, 1985, BIOCHIM BIOPHYS ACTA, V845, P533, DOI 10.1016/0167-4889(85)90222-8; NEWTON DL, 1984, J BIOL CHEM, V259, P4419; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; PERSECHINI A, 1991, P NATL ACAD SCI USA, V88, P449, DOI 10.1073/pnas.88.2.449; PERSECHINI A, 1989, J BIOL CHEM, V264, P8052; PERSECHINI A, 1994, J BIOL CHEM, V269, P16148; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; PERSECHINI A, 1988, J CARDIOVASC PHARM, V12, pS1; POTTER JD, 1982, CALCIUM CELL FUNCTIO, V2, P145; SANYAL G, 1988, BIOCHEMISTRY-US, V27, P6229, DOI 10.1021/bi00417a006; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; STEINER RF, 1986, ARCH BIOCHEM BIOPHYS, V246, P286, DOI 10.1016/0003-9861(86)90474-1; SUKO J, 1985, EUR J BIOCHEM, V153, P451, DOI 10.1111/j.1432-1033.1985.tb09323.x; TOROK K, 1992, BIOCHEMISTRY-US, V31, P3452, DOI 10.1021/bi00128a020; VOGEL HJ, 1994, BIOCHEM CELL BIOL, V72, P357, DOI 10.1139/o94-049; WALSH M, 1977, J BIOL CHEM, V252, P7440; WOLFF J, 1986, BIOCHEMISTRY-US, V25, P7950, DOI 10.1021/bi00372a025; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZHANG MJ, 1994, BIOCHEMISTRY-US, V33, P10883, DOI 10.1021/bi00202a006	54	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2174	2183		10.1074/jbc.273.4.2174	http://dx.doi.org/10.1074/jbc.273.4.2174			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442059	hybrid			2022-12-25	WOS:000071595200048
J	Imai, H; Narashima, K; Arai, M; Sakamoto, H; Chiba, N; Nakagawa, Y				Imai, H; Narashima, K; Arai, M; Sakamoto, H; Chiba, N; Nakagawa, Y			Suppression of leukotriene formation in RBL-2H3 cells that overexpressed phospholipid hydroperoxide glutathione peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; BASOPHILIC LEUKEMIA-CELLS; 5-LIPOXYGENASE ACTIVITY; MAST-CELLS; SOYBEAN LIPOXYGENASE-1; CALCIUM IONOPHORE; NUCLEAR-ENVELOPE; OXIDATIVE DAMAGE; TRANSLOCATION; EXPRESSION	The overexpression of phospholipid hydroperoxide glutathione peroxidase (PHGPx) by RBL-2H3 cells was used as the basis for an investigation of the effects of PRGPx on the formation of leukotrienes. The rates of production of leukotriene C-4 (LTC4) and leukotriene B-4 (LTB4) in cells that overexpressed PHGPx were 8 times lower than those in a control line of cells. The reduction in rates of production of leukotrienes apparently resulted from the increase in the PHGPx activity since control rates of formation of leukotrienes could be achieved in PHGPx-overexpressing cells upon inhibition Of PHGPx activity by diethyl malate. The conversion Of radioactively labeled arachidonic acid to intermediates in the lipoxygenase pathway, such as 5-hydroxyeicosatetraenoic acid (B-HETE), LTC4, and LTB4, was strongly inhibited in PHGPx overexpressing cells that had been prelabeled with [C-14]arachidonic acid. PHGPx apparently inactivated the Fi-Lipoxygenase that catalyzed the conversion of arachidonic acid to 5-hydroperoxyeicosatetraenoic acid (5-HPETE) since 5-HPETE is a common precursor of 5-HETE, LTC4, and LTB4. The rates of formation of LTC4 and LTE4 in PHGPx-overexpressing cells returned to control rates upon the addition of a small amount of 12-HPETE. Flow cytometric analysis revealed that the rapid burst of formation of lipid hydroperoxides induced by A23187 was suppressed in PHGPx-overexpressing cells as compared with the control lines of cells, Subcellular fractionation analysis showed that the amount of PHGPx associated with nuclear fractions from PHGPx-overexpressing cells was 3.5 times higher than that from the control line of cells. These results indicate that PHGPx might be involved in inactivation of 5-lipoxygenase via reductions in levels of the fatty acid hydroperoxides that are required for the full activation of 5-lipoxygenase. Thus, in addition to its role as an antioxidant enzyme, PHGPx appears to have a novel function as a modulator of the production of leukotrienes.	Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 108, Japan; Japan Energy Corp, Toda, Saitama 335, Japan	Kitasato University; Japan Energy Corporation	Nakagawa, Y (corresponding author), Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, 5-9-1 Shirokane, Tokyo 108, Japan.	nakagaway@pharm.kitasato-u.ac.jp						AHARONY D, 1987, PROSTAGLANDINS, V33, P85, DOI 10.1016/0090-6980(87)90307-8; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; Arai M, 1997, EUR J BIOCHEM, V244, P513, DOI 10.1111/j.1432-1033.1997.00513.x; BERG P, 1982, MOL APPL GENET, V1, P327; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORGEAT P, 1989, CAN J PHYSIOL PHARM, V67, P936, DOI 10.1139/y89-147; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; Camandola S, 1996, BIOCHEM BIOPH RES CO, V229, P643, DOI 10.1006/bbrc.1996.1857; CHEESBROUGH TM, 1983, BIOCHEMISTRY-US, V22, P3837, DOI 10.1021/bi00285a019; Claiborne A., 1985, CRC HDB METHODS OXYG, P283; DAHINDEN CA, 1985, P NATL ACAD SCI USA, V82, P6632, DOI 10.1073/pnas.82.19.6632; de Duve C, 1995, BIOCHEM J, V60, P604; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; G?nzler W.A., 1985, HDB METHODS OXYGEN R, P285; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Godeas C, 1996, BIOCHEM MOL MED, V59, P118, DOI 10.1006/bmme.1996.0076; GUO LH, 1995, FREE RADICAL BIO MED, V18, P1003, DOI 10.1016/0891-5849(94)00234-B; HATZELMANN A, 1989, EUR J BIOCHEM, V180, P527, DOI 10.1111/j.1432-1033.1989.tb14678.x; HATZELMANN A, 1987, EUR J BIOCHEM, V169, P175, DOI 10.1111/j.1432-1033.1987.tb13595.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; IMAI H, 1994, J IMMUNOL, V153, P2290; IMAI H, 1995, J BIOCHEM-TOKYO, V118, P1061, DOI 10.1093/jb/118.5.1061; Imai H, 1996, BIOCHEM BIOPH RES CO, V222, P432, DOI 10.1006/bbrc.1996.0762; Imanaka T, 1996, J BIOL CHEM, V271, P3706; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; Jakoby W B, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P383; Jones GD, 1996, BIOCHEMISTRY-US, V35, P7197, DOI 10.1021/bi952425h; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JJ, 1976, BIOCHEMISTRY-US, V15, P3301, DOI 10.1021/bi00660a021; LUDWIG P, 1987, EUR J BIOCHEM, V168, P325, DOI 10.1111/j.1432-1033.1987.tb13424.x; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; MURAKAMI M, 1995, J BIOL CHEM, V270, P22653, DOI 10.1074/jbc.270.39.22653; NELSON MJ, 1995, BIOCHEMISTRY-US, V34, P6159, DOI 10.1021/bi00018a019; OHISHI N, 1985, BIOCHEM INT, V10, P205; PORTER N, 1985, J CHEM SOC CHEM COMM, P1472, DOI 10.1039/c39850001472; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; ROVERI A, 1994, METHOD ENZYMOL, V143, P307; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SANDSTROM PA, 1995, FEBS LETT, V365, P66, DOI 10.1016/0014-5793(95)00443-D; SCHILSTRA MJ, 1993, BIOCHEMISTRY-US, V32, P7686, DOI 10.1021/bi00081a012; Schnurr K, 1996, J BIOL CHEM, V271, P4653; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1995, METHOD ENZYMOL, V252, P38; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; VICKERS PJ, 1995, J LIPID MEDIAT CELL, V12, P185, DOI 10.1016/0929-7855(95)00018-L; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; Werz O, 1996, EUR J BIOCHEM, V242, P90, DOI 10.1111/j.1432-1033.1996.0090r.x; WILLIAM R, 1994, ANN INTERN MED, V121, P684; WONG A, 1992, BIOCHEMISTRY-US, V31, P4046, DOI 10.1021/bi00131a021; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOSHIMOTO T, 1985, P NATL ACAD SCI USA, V82, P8399, DOI 10.1073/pnas.82.24.8399; ZHANG YY, 1994, ANAL BIOCHEM, V220, P28, DOI 10.1006/abio.1994.1294	63	145	149	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1990	1997		10.1074/jbc.273.4.1990	http://dx.doi.org/10.1074/jbc.273.4.1990			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442035	hybrid			2022-12-25	WOS:000071595200024
J	Rotenberg, SA; Sun, XG				Rotenberg, SA; Sun, XG			Photoinduced inactivation of protein kinase C by dequalinium identifies the RACK-1-binding domain as a recognition site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR RECEPTORS; BETA-SUBUNIT; INHIBITION; REGION; AGENT	1,1'-Decamethylenebis-4-aminoquinaldinium diiodide (DECA; dequalinium) is an anti-tumor agent and protein kinase C (PKC) inhibitor whose mechanism of action with PKC is unknown, This study reports that with human PKC alpha, DECA exhibited competitive inhibition (K-i = 11.5 +/- 5 mu M) with respect to RACK-1 (receptor for activated C kinase-1), an adaptor protein that has been proposed to bind activated PKC following translocation (Ron, D., Luo, J., and Mochly-Rosen, D. (1995) J. Biol. Chem. 270, 24180-24187), When exposed to UV light, DECA covalently modified and irreversibly inhibited PKC (alpha or beta), with IC50 = 7-18 mu M. UV/DECA treatment of synthetic peptides modeled after the RACK-1-binding site in the C2 region of PKC beta induced modification of Ser(218)-Leu-Asn-Pro-Glu-Trp-Asn-Glu-Thr(226), but not of a control peptide, This modification occurred ata tryptophan residue (Trp(223)) that is conserved in all conventional PKC isoforms. In overlay assays with native RACK-1 that had been immobilized on nitrocellulose, UV-treated control PKC alpha bound well to RACK-1, whereas UV/DECA-inactivated PKC alpha had reduced binding activity, The significance of these findings is shown with adenocarcinoma cells, which, when pretreated with 10 mu M DECA and UV light, exhibited diminished 12-O-tetradecanoylphorbol-13-acetate-induced PKC alpha translocation. Overall, this work identifies DECA as a tool that prevents PKC translocation by inhibiting formation of the PRC RACK-1 complex.	CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	City University of New York (CUNY) System; Queens College NY (CUNY)	Rotenberg, SA (corresponding author), CUNY Queens Coll, Dept Chem & Biochem, 65-30 Kissena Blvd, Flushing, NY 11367 USA.	rotenber@qcvaxa.acc.qc.edu		Rotenberg, Susan/0000-0002-6618-686X	NCI NIH HHS [CA60618] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA060618] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; Faux MC, 1996, TRENDS BIOCHEM SCI, V21, P312, DOI 10.1016/0968-0004(96)10040-2; HELIGE C, 1993, EUR J CANCER, V29A, P124, DOI 10.1016/0959-8049(93)90589-8; LESTER DS, 1992, PROTEIN KINASE C CUR, P80; MANETTA A, 1993, GYNECOL ONCOL, V50, P38, DOI 10.1006/gyno.1993.1161; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOCHLYROSEN D, 1992, BIOCHEMISTRY-US, V31, P8120, DOI 10.1021/bi00150a003; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; ORR JW, 1994, J BIOL CHEM, V269, P8383; Parker P.J., 1992, PROTEIN KINASE C CUR, P3; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; ROSENBERG IM, 1996, PROTEIN ANAL PURIFIC, P38; ROTENBERG SA, 1990, CANCER RES, V50, P677; ROTENBERG SA, 1991, BIOCH MOL ASPECTS SE, V1, P25; SEGEL IH, 1975, ENZYME KINETICS, P110; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SMITH BL, 1992, BIOCHEM BIOPH RES CO, V188, P1235, DOI 10.1016/0006-291X(92)91363-U; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TAYLOR EP, 1951, J CHEM SOC, P1150, DOI 10.1039/jr9510001150; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS MJ, 1987, P NATL ACAD SCI USA, V84, P5444, DOI 10.1073/pnas.84.15.5444; YOUNG P M, 1990, Peptide Research, V3, P287; ZHUO SQ, 1988, BIOCHEM BIOPH RES CO, V152, P968, DOI 10.1016/S0006-291X(88)80378-4; ZHUO SQ, 1993, BIOCHEMISTRY-US, V32, P2219, DOI 10.1021/bi00060a013	29	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2390	2395		10.1074/jbc.273.4.2390	http://dx.doi.org/10.1074/jbc.273.4.2390			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442087	hybrid			2022-12-25	WOS:000071595200076
J	Geppert, M; Khvotchev, M; Krasnoperov, V; Goda, Y; Missler, M; Hammer, RE; Ichtchenko, K; Petrenko, AG; Sudhof, TC				Geppert, M; Khvotchev, M; Krasnoperov, V; Goda, Y; Missler, M; Hammer, RE; Ichtchenko, K; Petrenko, AG; Sudhof, TC			Neurexin I alpha is a major alpha-latratoxin receptor that cooperates in alpha-latrotoxin action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEINS; HIGH-AFFINITY BINDING; CENTRAL SYNAPSE; BETA-NEUREXINS; VESICLES; POOL	alpha-Latrotoxin is a potent neurotoxin from black widow spider venom that binds to presynaptic receptors and causes massive neurotransmitter release. A surprising finding was the biochemical description of two distinct cell surface proteins that bind alpha-latrotoxin with nanomolar affinities; Neurexin I alpha binds alpha-latrotoxin in a Ca2+- dependent manner, and CIRL/latrophilin binds in a Ca2+-independent manner. We have now generated and analyzed mice that lack neurexin I alpha to test its importance in alpha-latrotoxin action, alpha-Latrotoxin binding to brain membranes from mutant mice was decreased by almost 50% compared with wild type membranes; the decrease was almost entirely due to a loss of Ca2+-dependent alpha-latrotoxin binding sites. In cultured hippocampal neurons, alpha-latrotoxin was still capable of activating neurotransmission in the absence of neurexin I alpha. Direct measurements of [H-3]glutamate release from synaptosomes, however, showed a major decrease in the amount of release triggered by alpha-latrotoxin in the presence of Ca2+. Thus neurexin I alpha is not essential for alpha-latrotoxin action but contributes to alpha-latrotoxin action when Ca2+ is present. Viewed as a whole, our results show that mice contain two distinct types of alpha-latrotoxin receptors with similar affinities and abundance but different properties and functions. The action of alpha-latrotoxin may therefore be mediated by independent parallel pathways, of which the CIRL/latrophilin pathway is sufficient for neurotransmitter release, whereas the neurexin I alpha pathway contributes to the Ca2+-dependent action of alpha-latrotoxin.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA; NYU, Dept Pharmacol, New York, NY 10016 USA; NYU, Dept Physiol, New York, NY 10016 USA; NYU, Dept Neurosci, New York, NY 10016 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; New York University; New York University; New York University; University of California System; University of California San Diego	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA.		Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020; Khvotchev, Mikhail/G-5411-2013	Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498; Hammer, Robert E./0000-0001-5487-7551; Khvotchev, Mikhail/0000-0001-9328-8549; Missler, Markus/0000-0001-8008-984X; Petrenko, Alexander/0000-0002-6689-6546	NATIONAL INSTITUTE OF MENTAL HEALTH [S15MH050824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034937, R01NS035098] Funding Source: NIH RePORTER; NIMH NIH HHS [MH50824] Funding Source: Medline; NINDS NIH HHS [NS34937, NS35098] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CECCARELLI B, 1980, J CELL BIOL, V87, P297, DOI 10.1083/jcb.87.1.297; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; MISSLER M, 1998, IN PRESS TRENDS GENE; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; Petrenko AG, 1996, J NEUROSCI, V16, P4360; RASAHL TW, 1995, NATURE, V375, P488; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; Sambrook J., 2002, MOL CLONING LAB MANU; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410	26	79	85	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1705	1710		10.1074/jbc.273.3.1705	http://dx.doi.org/10.1074/jbc.273.3.1705			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430716	hybrid			2022-12-25	WOS:000071411500063
J	Ito, K; Suzuki, H; Hirohashi, T; Kume, K; Shimizu, T; Sugiyama, Y				Ito, K; Suzuki, H; Hirohashi, T; Kume, K; Shimizu, T; Sugiyama, Y			Functional analysis of a canalicular multispecific organic anion transporter cloned from rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; EISAI HYPERBILIRUBINEMIC RATS; CONJUGATE EXPORT PUMP; PRIMARY ACTIVE-TRANSPORT; ATP-DEPENDENT TRANSPORT; DUBIN-JOHNSON SYNDROME; BILIARY-EXCRETION; MUTANT RATS; MEMBRANE-VESICLES; MRP GENE	Transport of many organic anions across the bile canalicular membrane is mediated by the canalicular multispecific organic anion transporter (cMOAT). Previously, we cloned cDNA that may encode cMOAT from Sprague-Dawley rate liver (Ito, K., Suzuki, H., Hirohashi, T., Kume, K., Shimizu, T., and Sugiyama, Y. (1997) Am. J. Physiol. 272, G16-G22). In the present study, the function of this cloned cDNA was investigated by examining the ATP-dependent uptake of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) into membrane vesicles isolated from an NIH/3T3 cell line transfected with an expression vector containing the cloned cDNA. Although the membrane vesicles from the control NIH/3T3 cells exhibited endogenous activity in transporting DNP-SG and leukotriene C-4 in an ATP-dependent manner, the transfection of cMOAT cDNA resulted in a significant increase in the transport activity for these ligands. The uptake of DNP-SG into membrane vesicles was osmotically sensitive and was stimulated to some extent by other nucleotide triphosphates (GTP, UTP, and CTP) but not by AMP or ADP. The K-m and V-max values for the uptake of DNP-SG by the membrane vesicles were 0.175 +/- 0.031 mu M and 11.0 +/- 0.73 pmol/min/mg protein, respectively, for the transfected rat cMOAT and 0.141 +/- 0.036 mu M and 3.51 +/- 0.39 pmol/min/mg protein, respectively, for the endogenous transporter expressed on control NIH/3T3 cells. These results suggest that the product of the previously cloned cDNA has cMOAT activity being able to transport organic anions in an ATP-dependent manner. Alternatively, it is possible that the cDNA product encodes an activator of endogenous transporter since the K-m value for DNP-SG was comparable between the vector- and cMOAT-transfected cells. The transport activity found in the control NIH/3T3 cells may be ascribed to mouse cMOAT since Northern blot analysis indicated the presence of a transcript that hybridyzed to the carboxyl-terminal ATP-binding cassette sequence of the murine protein.	Univ Tokyo, Fac Pharmaceut Sci, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo	Sugiyama, Y (corresponding author), Univ Tokyo, Fac Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 113, Japan.			Kume, Kazuhiko/0000-0003-4232-1657				AKERBOOM TPM, 1991, J BIOL CHEM, V266, P13147; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; Buchler M, 1996, J BIOL CHEM, V271, P15091; Chu XY, 1997, J PHARMACOL EXP THER, V281, P304; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DUBIN IN, 1954, MEDICINE, V33, P155, DOI 10.1097/00005792-195409000-00001; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; Ishikawa T, 1996, J BIOL CHEM, V271, P14981, DOI 10.1074/jbc.271.25.14981; Ishizuka H, 1997, J PHARMACOL EXP THER, V280, P1304; Ito K, 1997, AM J PHYSIOL-GASTR L, V272, pG16, DOI 10.1152/ajpgi.1997.272.1.G16; Ito K, 1996, INT HEPATOL COMMUN, V4, P291, DOI 10.1016/0928-4346(96)00259-9; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; Jedlitschky G, 1996, CANCER RES, V56, P988; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; Keppler D, 1996, Prog Liver Dis, V14, P55; KITAMURA T, 1992, HEPATOLOGY, V15, P1154, DOI 10.1002/hep.1840150629; KOBAYASHI K, 1990, J BIOL CHEM, V265, P7737; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; MIKAMI T, 1986, CONGENIT ANOM, V26, P250; Muller M, 1996, SEMIN LIVER DIS, V16, P211, DOI 10.1055/s-2007-1007233; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; SATHIRAKUL K, 1994, J PHARMACOL EXP THER, V268, P65; SATHIRAKUL K, 1993, J PHARMACOL EXP THER, V265, P1301; SAXENA M, 1995, J BIOL CHEM, V270, P5312, DOI 10.1074/jbc.270.10.5312; SHIMAMURA H, 1994, J PHARMACOL EXP THER, V271, P370; Stride BD, 1996, MOL PHARMACOL, V49, P962; TAKENAKA O, 1995, J PHARMACOL EXP THER, V274, P1362; TAKENAKA O, 1995, PHARMACEUT RES, V12, P1746, DOI 10.1023/A:1016278008658; Taniguchi K, 1996, CANCER RES, V56, P4124; Yamazaki M, 1996, PHARMACEUT RES, V13, P497, DOI 10.1023/A:1016077517241; Yamazaki M, 1996, BIOPHARM DRUG DISPOS, V17, P645, DOI 10.1002/(SICI)1099-081X(199611)17:8<645::AID-BDD986>3.0.CO;2-L	39	99	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1684	1688		10.1074/jbc.273.3.1684	http://dx.doi.org/10.1074/jbc.273.3.1684			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430713	hybrid			2022-12-25	WOS:000071411500060
J	Jones, MK; Jackson, JH				Jones, MK; Jackson, JH			Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras 4B, protein in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTORS; T-CELL ACTIVATION; TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; DISSOCIATION STIMULATOR; FUNCTIONAL INTERACTION; DEPENDENT ACTIVATION; MOLECULAR MECHANISM; RECEPTOR; IDENTIFICATION	Human cells contain four homologous Ras proteins, but it is unknown whether these homologues have different biological functions. As a first step in determining if Ras homologues might participate in distinct signaling cascades, we assessed whether a given Ras guanine nucleotide exchange factor could selectively activate a single Ras homologue in vivo. No found that Ras-GRF/ Cdc25(Mm) activates Ha-Ras, but does not activate N-Ras or K-Ras 4B, protein in vivo. Moreover, our results suggested that residues within the C-terminal hypervariable domains of Ras proteins may dictate, at least in part, the specificity of Ras-GRF/CDC25(Mm) for Ha-Ras protein, Our studies represent the first biochemical evidence that a Ras GEF can selectively activate a single Ras homologue in vivo. Selective activation of a single Ras homologue by Ras-GRF/Cdc25(Mm) or other Ras guanine nucleotide exchange factors could potentially enable each of the Ras homologues to participate in different signal transduction pathways.	Scripps Res Inst, La Jolla, CA 92037 USA	Scripps Research Institute	Jackson, JH (corresponding author), Scripps Res Inst, 10550 N Torrey Pines Rd,Box IMM 12, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA054298] Funding Source: NIH RePORTER; NCI NIH HHS [CA-54298] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1992, NATURE, V258, P282; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GUTZIEREZ L, 1989, EMBO J, V8, P1093; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOWE LR, 1993, ONCOGENE, V8, P2583; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KRAMER SM, 1988, CANCER RES, V48, P920; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; ORITA S, 1993, J BIOL CHEM, V268, P25542; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEGAL M, 1995, EUR J BIOCHEM, V228, P96, DOI 10.1111/j.1432-1033.1995.tb20235.x; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WINITZ S, 1993, J BIOL CHEM, V268, P19196	48	78	79	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1782	1787		10.1074/jbc.273.3.1782	http://dx.doi.org/10.1074/jbc.273.3.1782			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430727	hybrid			2022-12-25	WOS:000071411500074
J	Martin, LB; Shewan, A; Millar, CA; Gould, GW; James, DE				Martin, LB; Shewan, A; Millar, CA; Gould, GW; James, DE			Vesicle-associated membrane protein 2 plays a specific role in the insulin-dependent trafficking of the facilitative glucose transporter GLUT4 in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; CLOSTRIDIAL NEUROTOXINS; TRANSFERRIN RECEPTORS; SENSITIVE CELLS; TERMINAL DOMAIN; FUSION COMPLEX; TRANSLOCATION; LOCALIZATION; CELLUBREVIN; SYNAPTOBREVIN-2	Vesicle-associated membrane protein 2 (VAMP2) has been implicated in the insulin-regulated trafficking of GLUT4 in adipocytes. It has been proposed that VAMP2 co-localizes with GLUT4 in a postendocytic storage compartment (Martin, S., Tellam, J., Livingstone, C., Slot, J. W., Gould, G. W., and James, D. E. (1996) J. Cell Biol. 134, 625-635), suggesting that it may play a role distinct from endosomal v-SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) such as cellubrevin that are also expressed in adipocytes, The present study examines the effects of recombinant glutathione S-transferase (GST) fusion proteins encompassing the entire cytoplasmic tails of VAMP1, VAMP2, and cellubrevin on insulin-stimulated GLUT4 translocation in streptolysin O permeabilized 3T3-L1 adipocytes, GST-VAMPS inhibited insulin-stimulated GLUT4 trans location by similar to 35%, whereas GST-VAMP1 and GST-cellubrevin were without effect, A synthetic peptide corresponding to the unique N terminus of VAMP2 also inhibited insulin-stimulated GLUT4 translocation in a dose-dependent manner, This peptide had no effect on either guanosine 5'-3-O-(thio)triphosphate-stimulated GLUT4 translocation or on insulin-stimulated GLUT1 translocation, These results imply that GLUT4 and GLUT1 may undergo insulin stimulated translocation to the cell surface from separate intracellular compartments, To confirm this, adipocytes were incubated with a transferrin-horseradish peroxidase conjugate to fill the itinerant endocytic system after which cells were incubated with H2O2 and diaminobenzidine. This treat ment completely blocked insulin-stimulated movement of GLUT1, whereas in the case of GLUT4, movement to the surface was delayed but still reached similar levels to that observed in insulin-stimulated control cells after 30 min, These results suggest that the N terminus of VAMP2 plays a unique role in the insulin-dependent recruitment of GLUT4 from its intracellular storage compartment to the cell surface.	Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia; Univ Queensland, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Glasgow, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Queensland; University of Queensland; University of Glasgow	James, DE (corresponding author), Univ Queensland, Ctr Cellular & Mol Biol, St Lucia, Qld 4072, Australia.		Shewan, Annette/B-3251-2011; Martin, Laura/N-1789-2013; Gould, Gwyn/AAF-6721-2019	Shewan, Annette/0000-0003-4936-9207; Martin, Laura/0000-0002-4431-4381; Gould, Gwyn/0000-0001-6571-2875; James, David/0000-0001-5946-5257	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BALDINI G, 1991, J BIOL CHEM, V266, P4037; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; BHAKDI S, 1984, INFECT IMMUN, V46, P394, DOI 10.1128/IAI.46.2.394-400.1984; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; CAIN CC, 1992, J BIOL CHEM, V267, P11681; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; CORNILLE F, 1995, J BIOL CHEM, V270, P16826, DOI 10.1074/jbc.270.28.16826; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FROST SC, 1985, J BIOL CHEM, V260, P2646; GIBBS EM, 1991, BIOCHEM J, V275, P145, DOI 10.1042/bj2750145; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; James David E., 1994, Trends in Cell Biology, V4, P120, DOI 10.1016/0962-8924(94)90066-3; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; KANDROR KV, 1994, P NATL ACAD SCI USA, V91, P8017, DOI 10.1073/pnas.91.17.8017; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; Martin S, 1997, J CELL SCI, V110, P2281; Martin S, 1996, J CELL BIOL, V134, P625, DOI 10.1083/jcb.134.3.625; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SALTIS J, 1991, J BIOL CHEM, V266, P261; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STOORVOGEL W, 1989, J CELL BIOL, V108, P2137, DOI 10.1083/jcb.108.6.2137; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tamori Y, 1996, BIOCHEM BIOPH RES CO, V220, P740, DOI 10.1006/bbrc.1996.0474; TANNER LI, 1989, J CELL BIOL, V108, P1537, DOI 10.1083/jcb.108.4.1537; TANNER LI, 1987, J BIOL CHEM, V262, P8975; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; YAMASAKI S, 1994, BIOCHEM BIOPH RES CO, V200, P829, DOI 10.1006/bbrc.1994.1526; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	49	123	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1444	1452		10.1074/jbc.273.3.1444	http://dx.doi.org/10.1074/jbc.273.3.1444			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430681	hybrid			2022-12-25	WOS:000071411500028
J	Pizard, A; Marchetti, J; Allegrini, J; Alhenc-Gelas, F; Rajerison, RM				Pizard, A; Marchetti, J; Allegrini, J; Alhenc-Gelas, F; Rajerison, RM			Negative cooperativity in the human bradykinin B-2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; SIGNAL-TRANSDUCTION PATHWAYS; ARTERY ENDOTHELIAL-CELLS; B2 KININ RECEPTORS; PHARMACOLOGICAL CHARACTERIZATION; MEDIATED INTERNALIZATION; HUMAN-FIBROBLASTS; MAMMALIAN-CELLS; BINDING-SITES; GROWTH-FACTOR	A human kidney bradykinin (BH) B-2, receptor cDNA was transfected in CHO-KI cells to establish cell lines that express stably and at high density a receptor exhibiting B-2, receptor properties in terms of coupling to cell signaling effecters, desensitization, and internalization. A cell line with a density of 1.3 x 10(6) receptors/cell allowed us to carry out a detailed study of BK-receptor interaction over a wide range of BK concentrations. A model assuming that BK binds to two receptor affinity states (depending on guanine nucleotide-sensitive coupling) was not sufficient to account for the kinetics of EE binding. Equilibrium kinetic analysis and studies of the effects of receptor occupancy by agonists or antagonists on the kinetics of BH-receptor complex dissociation revealed features typical of negative cooperative binding. The negative cooperativity phenomenon was also observed in isolated membranes in both the presence and absence of guanine nucleotide, Thus, following the interaction with Bg, B-2, receptor molecules likely interact with each other, resulting in an acceleration of bound ligand dissociation and a decrease in the apparent affinity of the receptor for BR This phenomenon can participate in the desensitization process.	INSERM, U367, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rajerison, RM (corresponding author), INSERM, U367, 17 Rue Fer Moulin, F-75005 Paris, France.	aprsu367@pratique.fr	Pizard, Anne CM/P-4754-2016; Alhenc-Gelas, Francois/F-9511-2017	Pizard, Anne CM/0000-0003-2705-6365; 				Ardaillou N, 1996, AM J PHYSIOL-RENAL, V271, pF754, DOI 10.1152/ajprenal.1996.271.3.F754; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Blaukat A, 1996, J BIOL CHEM, V271, P32366, DOI 10.1074/jbc.271.50.32366; BOCKMANN S, 1995, EUR J PHARM-MOLEC PH, V291, P159, DOI 10.1016/0922-4106(95)90138-8; CASADO V, 1991, FEBS LETT, V286, P221, DOI 10.1016/0014-5793(91)80978-C; Chazenbalk GD, 1996, ENDOCRINOLOGY, V137, P4586, DOI 10.1210/en.137.11.4586; CHRISTOFFERSEN CT, 1994, ENDOCRINOLOGY, V135, P472, DOI 10.1210/en.135.1.472; COGGAN JS, 1995, AM J PHYSIOL-CELL PH, V269, pC841, DOI 10.1152/ajpcell.1995.269.4.C841; EGGERICKX D, 1992, BIOCHEM BIOPH RES CO, V187, P1306, DOI 10.1016/0006-291X(92)90445-Q; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; Hess J. F., 1993, MOL PHARMACOL, V45, P1; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; ILONDO MM, 1991, ENDOCRINOLOGY, V128, P1597, DOI 10.1210/endo-128-3-1597; LEEBLUNDBERG LMF, 1994, J BIOL CHEM, V269, P25970; LEEBLUNDBERG LMF, 1990, J BIOL CHEM, V265, P9621; LIAO JK, 1993, J CLIN INVEST, V92, P2168, DOI 10.1172/JCI116818; Liebmann C, 1996, BIOCHEM J, V313, P109, DOI 10.1042/bj3130109; LIMBIRD LE, 1976, J BIOL CHEM, V251, P5007; MARASCO WA, 1985, J CELL BIOCHEM, V27, P359, DOI 10.1002/jcb.240270406; MARCHETTI J, 1995, AM J PHYSIOL-RENAL, V268, pF1053, DOI 10.1152/ajprenal.1995.268.6.F1053; Mathis SA, 1996, MOL PHARMACOL, V50, P128; Meneton P, 1996, AM J PHYSIOL-RENAL, V271, pF382, DOI 10.1152/ajprenal.1996.271.2.F382; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; MUNOZ CM, 1993, ARCH BIOCHEM BIOPHYS, V301, P336, DOI 10.1006/abbi.1993.1153; MUNOZ CM, 1992, J BIOL CHEM, V267, P303; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4412, DOI 10.1073/pnas.91.10.4412; PERIYASAMY SM, 1985, EUR J PHARMACOL, V116, P17, DOI 10.1016/0014-2999(85)90180-3; PORTEU F, 1988, J BIOL CHEM, V263, P5091; Praddaude F, 1995, EUR J PHARMACOL, V294, P173, DOI 10.1016/0014-2999(95)00532-3; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; REGOLI D, 1980, PHARMACOL REV, V32, P1; ROBERTS RA, 1990, BIOCHEMISTRY-US, V29, P1975, DOI 10.1021/bi00460a002; ROBERTS RA, 1989, J CELL SCI, V94, P524; ROSCHER AA, 1984, J CLIN INVEST, V74, P552, DOI 10.1172/JCI111452; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1632; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SMITH JAM, 1995, MOL PHARMACOL, V47, P525; TROPEA MM, 1993, J PHARMACOL EXP THER, V264, P930; VOYNOYASENETSKAYA TA, 1989, FASEB J, V3, P44, DOI 10.1096/fasebj.3.1.2535990; WEINTRAUB WH, 1992, AM J PHYSIOL, V263, pC1029; WESS J, 1993, TRENDS PHARMACOL SCI, V14, P308, DOI 10.1016/0165-6147(93)90049-P; WESS J, 1993, LIFE SCI, V53, P1447, DOI 10.1016/0024-3205(93)90618-D; Wiernas TK, 1997, BRIT J PHARMACOL, V121, P649, DOI 10.1038/sj.bjp.0701168; WOLSING DH, 1991, J PHARMACOL EXP THER, V257, P621	47	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1309	1315		10.1074/jbc.273.3.1309	http://dx.doi.org/10.1074/jbc.273.3.1309			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430662	hybrid			2022-12-25	WOS:000071411500009
J	Chalfant, CE; Watson, JE; Bisnauth, LD; Kang, JB; Patel, N; Obeid, LM; Eichler, DC; Cooper, DR				Chalfant, CE; Watson, JE; Bisnauth, LD; Kang, JB; Patel, N; Obeid, LM; Eichler, DC; Cooper, DR			Insulin regulates protein kinase C beta II expression through enhanced exon inclusion in L6 skeletal muscle cells - A novel mechanism of insulin- and insulin-like growth factor-I-induced 5 ' splice site selection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED 2-DEOXYGLUCOSE UPTAKE; GLUCOSE-TRANSPORT; PHORBOL ESTERS; SR PROTEINS; TRANSLOCATION; HYDROLYSIS; ACTIN; GENE	The protein kinase C beta (PKC beta) gene encodes two isoforms, PKC beta I and PKC beta II, as a result of alternative splicing. The unique mechanism that underlies insulin-induced alternative splicing of PKC beta pre-mRNA was examined in L6 myotubes. Mature PKC beta II mRNA and protein rapidly increased >3-fold following acute insulin treatment, while PKC beta I mRNA and protein levels remained unchanged. Mature PKC beta II mRNA resulted from inclusion of the PKC beta II-specific exon rather than from selection of an alternative polyadenylation site. Increased PKC beta II expression was also not likely accounted for by transcriptional activation of the gene or increased stabilization of the PKC beta II mRNA, and suggest that PKC beta II expression is regulated primarily at the level of alternative splicing, Insulin effects on exon inclusion were observed as early as 15 min after insulin treatment; by 20 min, a new 5'-splice site variant of PKC beta II was also observed. After 30 min, the longer 5'-splice site variant became the predominate species through activation of a downstream 5' splice site, Similar lar results were obtained using IGF-I. Although the role of this new PKC beta II mRNA species is presently unknown, inclusion of either PKC beta II-specific exon results in the same PKC beta II protein.	James A Haley Vet Hosp, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Internal Med, Tampa, FL 33612 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); James A. Haley Veterans Hospital; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Duke University	Cooper, DR (corresponding author), James A Haley Vet Hosp, VAR 151,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	dcooper@com1.med.usf.edu	Patel, Niketa/A-1392-2012; Eichler, Duane/A-1906-2012	obeid, lina/0000-0002-0734-0847; Patel, Niketa A./0000-0003-4811-8596				BLOBE GC, 1993, J BIOL CHEM, V268, P10627; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; Chalfant CE, 1996, MOL ENDOCRINOL, V10, P1273, DOI 10.1210/me.10.10.1273; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; CHALFANT CE, 1995, DIABETES, V44, pA243; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; COOPER DR, 1993, ARCH BIOCHEM BIOPHYS, V302, P490, DOI 10.1006/abbi.1993.1244; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HARUTA T, 1995, J BIOL CHEM, V270, P27991; ISHIZUKA T, 1991, DIABETES, V40, P1274, DOI 10.2337/diabetes.40.10.1274; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1992, J BIOL CHEM, V267, P20804; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; ONO Y, 1986, FEBS LETT, V206, P647; Sambrook J., 2002, MOL CLONING LAB MANU; SELL SM, 1994, J BIOL CHEM, V269, P30769; SRINIVASAN M, 1994, J BIOL CHEM, V269, P16662; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STANDAERT ML, 1990, METABOLISM, V39, P1170, DOI 10.1016/0026-0495(90)90090-Y; Standaert ML, 1996, ENDOCRINOLOGY, V137, P3014, DOI 10.1210/en.137.7.3014; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; YU BZ, 1992, ENDOCRINOLOGY, V130, P3345, DOI 10.1210/en.130.6.3345	27	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					910	916		10.1074/jbc.273.2.910	http://dx.doi.org/10.1074/jbc.273.2.910			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422749	hybrid			2022-12-25	WOS:000071411400038
J	Hsu, HY; Hajjar, DP; Khan, KMF; Falcone, DJ				Hsu, HY; Hajjar, DP; Khan, KMF; Falcone, DJ			Ligand binding to macrophage scavenger receptor-A induces urokinase-type plasminogen activator expression by a protein kinase-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FIBROBLAST GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; ACETYL-LDL RECEPTOR; ATHEROSCLEROTIC LESIONS; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; LEUKEMIA-CELLS; CHOLESTEROL DEPOSITION; MURINE MACROPHAGES	Macrophage scavenger receptor-type A (MSR-A) has been implicated in the transmission of cell signals and the regulation of diverse cellular functions (Falcone, D. J., and Ferenc, M. J. (1988) J. Cell. Physiol, 135, 387-396; Falcone, D. J., McCaffrey, T. A., and Verglio, J. A. (1991) J. Biol. Chem. 266, 22726-22732; Palkama, T. (1991) Immunology 74, 432-438; Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637); however, the signaling mechanisms are unknown, In studies reported here, we demonstrate that binding of both lipoprotein and non-lipoprotein ligands to MSR-A induced protein tyrosine phosphorylation and increased protein kinase C (PKC) activity leading to up-regulated urokinase-type plasminogen activator (uPA) expression, Specifically, the binding of acetylated low density lipoprotein and fucoidan to MSR-A in human THP-1 macrophages triggered tyrosine phosphorylation of many proteins including phospholipase C-gamma 1 and phosphatidylinositol-3-OH kinase, Inhibitors of tyrosine kinase dramatically reduced MSR-induced protein tyrosine phosphorylation and PKC activity, Moreover, inhibitors of tyrosine kinase and PKC reduced uPA activity expressed by THP-1 macrophages exposed to MSR-A ligands, The intracellular signaling response for tyrosine phosphorylation following ligand binding was further demonstrated by using the stable MSR-transfected Bowes cells that express surface MSR-A. These findings establish for the first time a signaling pathway induced by ligand binding to MSR-A and suggest a molecular model for the regulation of macrophage uPA expression by specific ligands of the MSR-A.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Cell Biol & Anat, New York, NY 10021 USA	Cornell University; Cornell University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, Rm A678,1300 York Ave, New York, NY 10021 USA.	dfalcone@mail.med.cornell.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003158, R01HL040819, T32HL007423] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL40819, T32 HL07423, K14 HL03158] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMILLI PD, 1996, SCIENCE, V271, P1533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; ELKHOURY J, 1994, J BIOL CHEM, V269, P10197; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FALCONE DJ, 1989, J CELL PHYSIOL, V140, P219, DOI 10.1002/jcp.1041400205; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOPALAKRISHNA R, 1992, FEBS LETT, V314, P149, DOI 10.1016/0014-5793(92)80962-G; GOWN AM, 1986, AM J PATHOL, V125, P191; GREENBERG S, 1995, TRENDS CELL BIOL, V5, P93, DOI 10.1016/S0962-8924(00)88957-6; HABERLAND ME, 1982, P NATL ACAD SCI-BIOL, V79, P1712, DOI 10.1073/pnas.79.6.1712; HAJJAR DP, 1985, J BIOL CHEM, V260, P6124; HAMILTON JA, 1991, BLOOD, V77, P616; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745; Hsu HY, 1996, J BIOL CHEM, V271, P7767, DOI 10.1074/jbc.271.13.7767; HSU HY, 1994, J BIOL CHEM, V269, P9213; JARVIS WD, 1994, CANCER RES, V54, P1707; JOHNSON WJ, 1982, SCIENCE, V218, P574, DOI 10.1126/science.6289443; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LIN TH, 1994, J CELL BIOL, V126, P1585, DOI 10.1083/jcb.126.6.1585; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARSHALL PJ, 1985, ANAL BIOCHEM, V145, P192, DOI 10.1016/0003-2697(85)90347-1; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MUNRO JM, 1988, LAB INVEST, V58, P249; NAITO M, 1992, AM J PATHOL, V141, P591; NICHOLSON AC, 1995, ARTERIOSCL THROM VAS, V15, P269, DOI 10.1161/01.ATV.15.2.269; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OKADA T, 1994, J BIOL CHEM, V269, P3563; OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391; PALKAMA T, 1991, IMMUNOLOGY, V74, P432; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; PEARSON AM, 1993, J BIOL CHEM, V268, P3546; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; RESNICK D, 1993, J BIOL CHEM, V268, P3538; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHECHTER I, 1981, J LIPID RES, V22, P63; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TSUCHIYA S, 1982, CANCER RES, V42, P1530; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vassalli J D, 1992, Curr Top Microbiol Immunol, V181, P65; VASSALLI JD, 1977, CELL, V11, P695, DOI 10.1016/0092-8674(77)90086-1; VIA DP, 1989, J LIPID RES, V30, P1515	64	90	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1240	1246		10.1074/jbc.273.2.1240	http://dx.doi.org/10.1074/jbc.273.2.1240			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422792	hybrid			2022-12-25	WOS:000071411400081
J	Mesri, M; Plescia, J; Altieri, DC				Mesri, M; Plescia, J; Altieri, DC			Dual regulation of ligand binding by CD11b I domain - Inhibition of intercellular adhesion and monocyte procoagulant activity by a factor X-derived peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN MAC-1 CD11B/CD18; CELL-ADHESION; NEUTROPHIL ADHESION; LEUKOCYTE ADHESION; MOLECULES; THROMBIN; ICAM-1; ALPHA(M)BETA(2); RECOGNITION; FIBRINOGEN	The role of coagulation factor X as a ligand for CD11b/CD18 (Mac-1, alpha(M) beta(2)) in leukocyte adhesion was investigated, A factor X peptide, (G)L(238)YQAKRFKV(246) (G), blocked ligand binding to CD11b/CD18 and prevented monocyte procoagulant activity, This peptide also inhibited monocytic THP-1 cell adhesion to tumor necrosis factor alpha-stimulated endothelium and blocked neutrophil migration through tumor necrosis factor alpha-activated endothelial cell monolayers. In contrast, other factor X-derived peptides were ineffective, Radiolabeled peptide (G)LYQAKRFKV(G) bound specifically and saturably to isolated recombinant CD11b I domain. Functionally, the factor X sequence (G)LYQAKRFKV(G) dose-dependently inhibited THP-1 cell attachment to intercellular adhesion molecule 1 (ICAM-1) transfectants (IC50 = similar to 50 mu g/ml), indistinguishably from anti-CD18 monoclonal antibodies 60.3 and IB4, In contrast, peptide (G)LYQAKRFKV(G) failed to reduce binding of I-125-fibrinogen to immobilized CD11b I domain, which was abolished by the fibrinogen-derived peptide KYG(190)WTVFQKRLDGSV(202), By Lineweaver-Burke analysis, peptide (G)LYQAKRFKV(G) inhibited factor X binding to CD11b/CD18 in a noncompetitive fashion, and intact factor X did not reduce monocyte-endothelial cell interaction, These data suggest that the factor X sequence (G)LYQAKRFKV(G) defines an ICAM-1-binding site on CD11b I domain physically distinct from and nonoverlapping with the fibrinogen interacting region(s). Engagement of this site induces a conformational change in the holoreceptor, which disrupts a distant factor X-binding site required for monocyte procoagulant activity, These observations demonstrate a dual regulatory role of CD11b I domain in ligand binding and provide a molecular basis for the recently reported anti-inflammatory properties of factor X homologous sequences in vivo.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, New Haven, CT 06536 USA	Yale University	Altieri, DC (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Pathol, BCMM 436B,295 Congress Ave, New Haven, CT 06536 USA.	Dario.Altieri@yale.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131, R01HL043773] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-54131, HL-43773] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ALTIERI DC, 1991, SCIENCE, V254, P1200, DOI 10.1126/science.1957171; ALTIERI DC, 1993, J BIOL CHEM, V268, P1847; ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ALTIERI DC, 1993, BLOOD, V81, P569; ARNAOUT MA, 1990, BLOOD, V75, P1037; CARLOS TM, 1994, BLOOD, V84, P2068; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Duperray A, 1997, J BIOL CHEM, V272, P435; GRANDALIANO G, 1994, J EXP MED, V179, P1737, DOI 10.1084/jem.179.5.1737; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LI R, 1995, J CELL BIOL, V129, P1143, DOI 10.1083/jcb.129.4.1143; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; ROZDZINSKI E, 1995, J CLIN INVEST, V95, P1078, DOI 10.1172/JCI117754; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHANKAR R, 1994, J BIOL CHEM, V269, P13936; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	25	25	25	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					744	748		10.1074/jbc.273.2.744	http://dx.doi.org/10.1074/jbc.273.2.744			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422726	hybrid			2022-12-25	WOS:000071411400015
J	Benzinger, GR; Kyle, JW; Blumenthal, KM; Hanck, DA				Benzinger, GR; Kyle, JW; Blumenthal, KM; Hanck, DA			A specific interaction between the cardiac sodium channel and site-3 toxin anthopleurin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-ANEMONE TOXIN; HIGH-AFFINITY BINDING; ALPHA-SCORPION TOXIN; AMINO-ACID-SEQUENCE; CATIONIC RESIDUES; PERIODIC PARALYSIS; EXCITABLE CELLS; MUTANT CYCLES; INACTIVATION; XANTHOGRAMMICA	The polypeptide neurotoxin anthopleurin B (ApB) isolated from the venom of the sea anemone Anthopleura xanthogrammica is one of a family of toxins that bind to the extracellular face of voltage-dependent sodium channels and retard channel inactivation, Because most regions of the sodium channel known to contribute to inactivation are located intracellularly or within the membrane bilayer, identification of the toxin/channel binding site is of obvious interest, Recently, mutation of a glutamic acid residue on the extracellular face of the fourth domain of the rat neuronal sodium channel (rBr2a) was shown to disrupt toxin/channel binding (Rogers, J. C., Qu, Y. S., Tanada, T. N., Scheuer, T., and Catterall, W. A. (1996) J. Biol. Chem. 271, 15950-15962), A negative charge at this position is highly conserved between mammalian sodium channel isoforms, We have constructed mutations of the corresponding residue (Asp-1612) in the rat cardiac channel isoform (rH1) and shown that the lowered affinity occurs primarily through an increase in the toxin/channel dissociation rate k(off). Further, we have used thermodynamic mutant cycle analysis to demonstrate a specific interaction between this anionic amino acid and Lys-37 of ApB (Delta Delta G = 1.5 kcal/mol), a residue that is conserved among many sea anemone toxins, Reversal of the charge at Asp-1612, as in the mutant D1612R, also affects channel inactivation independent of toxin (-14 mV shift in channel availability), Binding of the toxin to Asp-1612 may therefore contribute both to toxin/channel affinity and to transduction of the effects of the toxin on channel kinetics.	Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA; Univ Chicago, Dept Pharmacol & Physiol Sci, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University of Chicago; University of Chicago; University of Chicago; University System of Ohio; University of Cincinnati	Hanck, DA (corresponding author), Univ Chicago, Comm Neurobiol, MC6094,5841 S Maryland Ave, Chicago, IL 60637 USA.	d-hanck@uchicago.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL041543] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-RO1-41543, HL-PO1-20592] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07281] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benzinger GR, 1997, PFLUG ARCH EUR J PHY, V434, P742, DOI 10.1007/s004240050460; BERGMAN C, 1976, BIOCHIM BIOPHYS ACTA, V455, P173, DOI 10.1016/0005-2736(76)90162-0; CANNON SC, 1993, J PHYSIOL-LONDON, V466, P501; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1979, J GEN PHYSIOL, V74, P375, DOI 10.1085/jgp.74.3.375; DiasKadambi BL, 1996, J BIOL CHEM, V271, P23828, DOI 10.1074/jbc.271.39.23828; ELSHERIF N, 1992, CIRC RES, V70, P285, DOI 10.1161/01.RES.70.2.285; FRELIN C, 1984, MOL PHARMACOL, V26, P70; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GALLAGHER MJ, 1992, J BIOL CHEM, V267, P13958; GOLDIN AL, 1995, HDB RECEPTORS CHANNE, P73; HANCK DA, 1992, AM J PHYSIOL, V262, pH1197, DOI 10.1152/ajpheart.1992.262.4.H1197; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; KALLEN RG, 1990, NEURON, V4, P233, DOI 10.1016/0896-6273(90)90098-Z; Kelso GJ, 1996, BIOCHEMISTRY-US, V35, P14157, DOI 10.1021/bi961584d; KHERA PK, 1995, BIOCHEMISTRY-US, V34, P8533, DOI 10.1021/bi00027a003; KHERA PK, 1994, J BIOL CHEM, V269, P921; Khera PK, 1996, BIOCHEMISTRY-US, V35, P3503, DOI 10.1021/bi9528457; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; MONKS SA, 1995, STRUCTURE, V3, P791, DOI 10.1016/S0969-2126(01)00214-3; MOZHAYEVA GN, 1980, BIOCHIM BIOPHYS ACTA, V597, P587, DOI 10.1016/0005-2736(80)90230-8; NARAHASHI T, 1969, SCIENCE, V163, P680, DOI 10.1126/science.163.3868.680; NORTON RS, 1991, TOXICON, V29, P1051, DOI 10.1016/0041-0101(91)90205-6; NORTON TR, 1981, FED PROC, V40, P21; REIMER NS, 1985, J BIOL CHEM, V260, P8690; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; ROMEY G, 1976, P NATL ACAD SCI USA, V73, P4055, DOI 10.1073/pnas.73.11.4055; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; SCHULZ GE, 1979, PRINCIPLES PROTEIN S, P34; SCHWEITZ H, 1981, BIOCHEMISTRY-US, V20, P5245, DOI 10.1021/bi00521a023; SHEETS MF, 1995, J GEN PHYSIOL, V106, P617, DOI 10.1085/jgp.106.4.617; STRICHARTZ G, 1987, ANNU REV NEUROSCI, V10, P237; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; WARASHINA A, 1988, PFLUG ARCH EUR J PHY, V411, P88, DOI 10.1007/BF00581651; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WUNDERER G, 1978, EUR J BIOCHEM, V89, P11, DOI 10.1111/j.1432-1033.1978.tb20890.x; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8	44	88	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					80	84		10.1074/jbc.273.1.80	http://dx.doi.org/10.1074/jbc.273.1.80			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417050	hybrid			2022-12-25	WOS:000071295600016
J	Kim, HH; Tharayil, M; Rudd, CE				Kim, HH; Tharayil, M; Rudd, CE			Growth factor receptor-bound protein 2 SH2/SH3 domain binding to CD28 and its role in co-signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; SH3 DOMAINS; T-CELLS; TYROSINE KINASES; CROSS-LINKING; ACTIVATION; GRB2; ASSOCIATION; COSTIMULATION; PHOSPHORYLATION	The co-stimulatory antigen CD28 has been shown to bind to several intracellular proteins including phosphatidylinositol S-kinase, growth factor receptor-bound protein 2 (Grb2), and ITK, Paradoxically, Grb2 and phosphatidylinositol 3-kinase binding has been mapped to a similar pYMNM motif within the CD28 cytoplasmic tail, Given the importance of CD28 co-signaling to T cell function, questions exist regarding the mechanism by which Grb2 binds to CD28, and whether the interaction plays a role in co-stimulation. To biochemically characterize Grb2/CD28 binding, we initially utilized glutathione S-transferase-Grb2 fusion proteins carrying inactivating mutations within the SH2 and SH3 domains of Grb2, and assessed their ability to bind to CD28, In vitro binding experiments indicated that the Grb2 SH2 domain is critical for the association, while the SH3 domain plays an additional role in facilitating optimal binding, Enhanced binding via the SH3 domains was not observed when the C-terminal PXXP motif within CD28 was disrupted, thereby indicating that both SH2 and SH3 domains contribute to CD28 binding. Mutations that alter Grb2 binding were found to block the CD28-dependent interleukin-a production. Further, tyrosine phosphorylation of Vav and the costimulation-dependent activation of Jun N-terminal kinase was blocked in cells defective in CD28/Grb2 binding. These results provide evidence for an alternate CD28-mediated signaling process involving Grb2 binding to the co-receptor.	Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Rudd, CE (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.		Rudd, Christopher E/GOH-2021-2022; Rudd, Christopher E/ABF-7259-2021	Rudd, Christopher E/0000-0001-5295-9019; 	NATIONAL CANCER INSTITUTE [R01CA065704] Funding Source: NIH RePORTER; NCI NIH HHS [CA65704] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; CAI YC, 1995, IMMUNITY, V3, P417, DOI 10.1016/1074-7613(95)90171-X; Cefai D, 1996, INT IMMUNOL, V8, P1609, DOI 10.1093/intimm/8.10.1609; CHAN G, 1995, EUR J IMMUNOL, V25, P1999, DOI 10.1002/eji.1830250730; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; denHertog J, 1996, EMBO J, V15, P3016, DOI 10.1002/j.1460-2075.1996.tb00665.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; Gibson S, 1996, J BIOL CHEM, V271, P7079, DOI 10.1074/jbc.271.12.7079; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KIM HH, 1994, J BIOL CHEM, V269, P24747; KonKozlowski M, 1996, J BIOL CHEM, V271, P3856; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; MIKI H, 1994, J BIOL CHEM, V269, P5489; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PAI SY, 1994, EUR J IMMUNOL, V24, P2364, DOI 10.1002/eji.1830241016; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rudd CE, 1996, IMMUNITY, V4, P527, DOI 10.1016/S1074-7613(00)80479-3; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	99	104	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					296	301		10.1074/jbc.273.1.296	http://dx.doi.org/10.1074/jbc.273.1.296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417079	hybrid			2022-12-25	WOS:000071295600045
J	Michels, AA; Kanon, B; Konings, AWT; Ohtsuka, K; Bensaude, O; Kampinga, HH				Michels, AA; Kanon, B; Konings, AWT; Ohtsuka, K; Bensaude, O; Kampinga, HH			Hsp70 and Hsp40 chaperone activities in the cytoplasm and the nucleus of mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; INDUCIBLE 40-KDA PROTEIN; ATP-BINDING DOMAIN; MOLECULAR CHAPERONES; REACTION CYCLE; NUCLEOLAR LOCALIZATION; TOPOISOMERASE-I; DNAJ HOMOLOG; HELA-CELLS; STRESS	The existence and function of a Hsp40-Hsp70 chaperone machinery in mammalian cells in vivo was investigated, The rate of heat inactivation of firefly luciferase transiently expressed in hamster O23 fibroblasts was analyzed in cells co-transfected with the gene encoding the human Hsp40 (Ohtsuka, K. (1993) Biochem. Biophys. Res. Commun. 197, 235-240), the human inducible Hsp70 (Hunt, C., and Morimoto, R. I. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 6455-6459), or a combination of both, Whereas the expression of human Hsp70 alone in hamster cells was sufficient for the protection of firefly luciferase during heat shock, expression of the human Hsp40 alone was not, Rather, this led to a small but significant increase in the heat sensitivity of luciferase. The expression of the human Hsp40 only led to heat protection when the human Hsp70 was expressed as well. Under such conditions the rate of luciferase reactivation from the heat-inactivated state was increased, but the rate of inactivation during heat shock was not affected. Using constructs that direct firefly luciferase either to the cytoplasm or to the nucleus (Michels, A. A., Nguyen, V. -T., Konings, A. W. T., Kampinga, H. H., and Bensaude, O. (1995) Eur. J. Biochem. 234, 382-389), it was demonstrated that these chaperone functions are found in both compartments. Our data provide the first evidence on how the Hsp40/Hsp70 chaperone complex acts as heat protector in mammalian cells in vivo.	Univ Groningen, Fac Med, Dept Radiobiol, NL-9713 B2 Groningen, Netherlands; Ecole Normale Super, Ctr Rech Sci, Unite 1302, Paris 05, France; Aichi Canc Ctr, Res Inst, Expt Radiol Lab, Nagoya, Aichi 464, Japan	University of Groningen; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Aichi Cancer Center	Kampinga, HH (corresponding author), Univ Groningen, Fac Med, Dept Radiobiol, NL-9713 B2 Groningen, Netherlands.			Bensaude, Olivier/0000-0002-0259-6608; Kampinga, Harm/0000-0002-8966-8466; Michels, Annemieke/0000-0002-1735-1697				ANGELIDIS CE, 1991, EUR J BIOCHEM, V199, P35, DOI 10.1111/j.1432-1033.1991.tb16088.x; CALDERWOOD SK, 1983, BIOCHIM BIOPHYS ACTA, V734, P76, DOI 10.1016/0005-2736(83)90077-9; CIAVARRA RP, 1992, BIOCHEM BIOPH RES CO, V186, P166, DOI 10.1016/S0006-291X(05)80789-2; CIAVARRA RP, 1994, P NATL ACAD SCI USA, V91, P1751, DOI 10.1073/pnas.91.5.1751; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; Hahn GM, 1990, STRESS PROTEINS BIOL, P79; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1992, CELL STRUCT FUNCT, V17, P77, DOI 10.1247/csf.17.77; HATTORI H, 1993, J CELL SCI, V104, P629; HOHFELD J, 1995, CELL, V83, P589; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; KAMPINGA HH, 1993, J CELL SCI, V104, P11; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P96; LEPOCK JR, 1990, BIOCHIM BIOPHYS ACTA, V1055, P19, DOI 10.1016/0167-4889(90)90086-S; Li G C, 1996, EXS, V77, P425; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1992, P NATL ACAD SCI USA, V89, P2036, DOI 10.1073/pnas.89.6.2036; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; OHTSUKA K, 1990, BIOCHEM BIOPH RES CO, V166, P642, DOI 10.1016/0006-291X(90)90857-J; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; PINTO M, 1991, J BIOL CHEM, V266, P13941; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; STEGE GJJ, 1994, INT J HYPERTHER, V10, P659, DOI 10.3109/02656739409022446; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; ZACHAYUS JL, 1996, J CELL BIOCHEM, V60, P1; ZIEMIENOWICZ A, 1995, J BIOL CHEM, V270, P15479, DOI 10.1074/jbc.270.26.15479; [No title captured]	43	143	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33283	33289		10.1074/jbc.272.52.33283	http://dx.doi.org/10.1074/jbc.272.52.33283			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407119	hybrid			2022-12-25	WOS:000071182900080
J	Nevalainen, MT; Valve, EM; Ahonen, T; Yagi, A; Paranko, J; Harkonen, PL				Nevalainen, MT; Valve, EM; Ahonen, T; Yagi, A; Paranko, J; Harkonen, PL			Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture	FASEB JOURNAL			English	Review						autocrine/paracrine; androgen; insulin; prostate; PRL	MESSENGER-RIBONUCLEIC-ACID; METHYL-N-NITROSOUREA; LATERAL PROSTATE; GENE-EXPRESSION; GROWTH-HORMONE; PRL STORAGE; CELL-DEATH; DEVELOPMENTAL ESTROGENIZATION; RECEPTOR EXPRESSION; SECRETORY GRANULES	Peptide hormones and growth factors are involved in the regulation of prostatic cell proliferation, differentiation, and programmed cell death, which functions are primarily controlled by androgen, In carcinogenesis, prostatic cancer cells often lose androgen dependence and become largely dependent on local growth factors, The prostatic cancer cells able to respond to factors other than androgen by proliferation and inhibition of apoptosis are possibly able to survive, We demonstrate that prostatic epithelium expresses prolactin mRNA and protein in a characteristic manner, By using in situ hybridization, an overall distribution of prolactin mRNA was demonstrated in the epithelium of rat dorsal and lateral prostate, whereas a very specific localization of prolactin protein to single cells was observed by immunohistochemistry in the same tissues, In these cells, immunoelectron microscopy showed that prolactin was primarily localized to the secretory granules, These data demonstrate a selective regulation of prostatic prolactin at least at the level of transcript processing/translation and/or protein accumulation and secretion, In addition, the expression of prolactin protein in rat dorsal and lateral prostate was found to be androgen dependent in vivo in castrated and in castrated, testosterone-treated rats, as well as in vitro in organ cultures, Our results support the concept of an autocrine/paracrine loop of prolactin action in prostate where it could mediate some of androgen actions, Also, locally synthesized prolactin might belong to the factors that take over androgen regulation of prostatic cancer cells during the development of androgen-independent growth.	Univ Turku, Inst Biomed, Dept Anat, FIN-20520 Turku, Finland; Univ Turku, Med Res Lab, FIN-20520 Turku, Finland; Univ Turku, Inst Biol, Physiol Anim Lab, FIN-20014 Turku, Finland	University of Turku; University of Turku; University of Turku	Harkonen, PL (corresponding author), Univ Turku, Inst Biomed, Dept Anat, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Abrahamsson PA, 1996, PROSTATE, P3; APRIKIAN AG, 1993, CANCER, V71, P3952, DOI 10.1002/1097-0142(19930615)71:12<3952::AID-CNCR2820711226>3.0.CO;2-X; ARRANDALE JM, 1994, MOL ENDOCRINOL, V8, P1083, DOI 10.1210/me.8.8.1083; BONKHOFF H, 1993, VIRCHOWS ARCH A, V423, P291, DOI 10.1007/BF01606893; BOSLAND MC, 1990, CANCER RES, V50, P691; BUJAN L, 1993, HUM REPROD, V8, P74, DOI 10.1093/oxfordjournals.humrep.a137878; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; COSTELLO LC, 1994, PROSTATE, V24, P162, DOI 10.1002/pros.2990240311; Culig Z, 1996, PROSTATE, V28, P392, DOI 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Cunha GR, 1996, PROSTATE, P22; Denmeade SR, 1996, PROSTATE, V28, P251; DEVITO WJ, 1992, ENDOCRINOLOGY, V131, P2154, DOI 10.1210/en.131.5.2154; DIMATTIA GE, 1990, J BIOL CHEM, V265, P16412; DUNNING W. F., 1963, NATL CANCER INST MONOGR, V12, P351; EMANUELE NV, 1992, MOL ENDOCRINOL, V6, P35, DOI 10.1210/me.6.1.35; Farnsworth WE, 1996, PROSTATE, V28, P17; FIELDS K, 1993, LAB INVEST, V68, P354; GELLERSEN B, 1989, MOL CELL ENDOCRINOL, V64, P127, DOI 10.1016/0303-7207(89)90073-7; GELLERSEN B, 1995, MOL ENDOCRINOL, V9, P887, DOI 10.1210/me.9.7.887; GELLERSEN B, 1992, ENDOCRINOLOGY, V131, P1017, DOI 10.1210/en.131.3.1017; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 1996, ENDOCR REV, V17, P385, DOI 10.1210/er.17.4.385; Gothard LQ, 1996, MOL ENDOCRINOL, V10, P185, DOI 10.1210/me.10.2.185; GRECO TL, 1993, ENDOCR REV, V14, P59, DOI 10.1210/er.14.1.59; GUBBINS EJ, 1980, J BIOL CHEM, V255, P8655; GUYETTE WA, 1979, CELL, V17, P1013, DOI 10.1016/0092-8674(79)90340-4; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HIRAOKA Y, 1991, MOL CELL ENDOCRINOL, V75, P71; HO TWC, 1991, ENDOCRINOLOGY, V129, P184, DOI 10.1210/endo-129-1-184; HORSEMAN ND, 1994, ENDOCR REV, V15, P627, DOI 10.1210/er.15.5.627; IKONEN T, 1994, ENDOCRINOLOGY, V135, P1359, DOI 10.1210/en.135.4.1359; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; JESIK CJ, 1982, PROSTATE, V3, P81, DOI 10.1002/pros.2990030111; JOHANSSON R, 1975, THESIS U TURKU TURKU; JONES R, 1983, J ENDOCRINOL, V96, P407, DOI 10.1677/joe.0.0960407; KAIPIA A, 1992, ENDOCRINOLOGY, V131, P2703, DOI 10.1210/en.131.6.2703; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KEENAN EJ, 1981, ENDOCRINOLOGY, V109, P170, DOI 10.1210/endo-109-1-170; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; KLEIN G, 1990, BIOESSAYS, V12, P347, DOI 10.1002/bies.950120708; KURTZ A, 1993, BIOL REPROD, V48, P1095, DOI 10.1095/biolreprod48.5.1095; MANDAL A, 1991, INT J ANDROL, V14, P159, DOI 10.1111/j.1365-2605.1991.tb01077.x; MARTIKAINEN P, 1987, ANAT REC, V218, P166, DOI 10.1002/ar.1092180212; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P1268, DOI 10.1210/endo-127-3-1268; MARTIKAINEN PM, 1997, PROLACTIN DEATH ANTA; MASTRO RM, 1995, ENDOCRINOLOGY, V136, P69, DOI 10.1210/en.136.1.69; MAURER RA, 1981, J BIOL CHEM, V256, P524; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Nevalainen MT, 1997, J CLIN INVEST, V99, P618, DOI 10.1172/JCI119204; Nevalainen MT, 1996, ENDOCRINOLOGY, V137, P3078, DOI 10.1210/en.137.7.3078; NEVALAINEN MT, 1991, ENDOCRINOLOGY, V129, P612, DOI 10.1210/endo-129-2-612; NEVALAINEN MT, 1993, CANCER RES, V53, P5199; NOWAK RA, 1993, J CLIN ENDOCR METAB, V76, P1308, DOI 10.1210/jc.76.5.1308; OETTING WS, 1986, J BIOL CHEM, V261, P1649; Peehl DM, 1996, PROSTATE, P74; PELLEGRINI I, 1988, ENDOCRINOLOGY, V122, P2667, DOI 10.1210/endo-122-6-2667; PELLEGRINI I, 1992, MOL ENDOCRINOL, V6, P1023, DOI 10.1210/me.6.7.1023; PELLEGRINI I, 1990, ENDOCRINOLOGY, V126, P1087; Perucho M, 1996, NAT MED, V2, P630, DOI 10.1038/nm0696-630; POWERS CA, 1990, ENDOCRINOLOGY, V127, P1916, DOI 10.1210/endo-127-4-1916; PRICE D, 1963, NATL CANCER I MONOGR, V12, P351; PRINS GS, 1995, ENDOCRINOLOGY, V136, P1303, DOI 10.1210/en.136.3.1303; PRINS GS, 1992, ENDOCRINOLOGY, V130, P2401, DOI 10.1210/en.130.4.2401; PYLKKANEN L, 1992, THESIS U TURKU TURKU; RAMBOURG A, 1992, ANAT RECORD, V232, P169, DOI 10.1002/ar.1092320202; Reinikainen P, 1996, ENDOCRINOLOGY, V137, P4351, DOI 10.1210/en.137.10.4351; RUI H, 1987, MOL CELL ENDOCRINOL, V52, P91, DOI 10.1016/0303-7207(87)90101-8; RUI H, 1987, THESIS U OSLO OSLO; SABHARWAL P, 1992, P NATL ACAD SCI USA, V89, P7713, DOI 10.1073/pnas.89.16.7713; SantAgnese P.A., 1992, HUM PATHOL, V23, P287, DOI 10.1016/0046-8177(92)90110-o; SANTTI R, 1994, PROSTATE, V24, P67, DOI 10.1002/pros.2990240204; SANTTI R, 1990, INT J ANDROL, V13, P77, DOI 10.1111/j.1365-2605.1990.tb00963.x; SCHACHT MJ, 1992, PROSTATE, V20, P51, DOI 10.1002/pros.2990200107; SCHACHTER BS, 1984, ENDOCRINOLOGY, V114, P1947, DOI 10.1210/endo-114-5-1947; Schleicher RL, 1996, PROSTATE, V28, P32, DOI 10.1002/(SICI)1097-0045(199601)28:1<32::AID-PROS5>3.0.CO;2-Q; SCOMMEGNA A, 1994, FERTIL STERIL, V61, P331; SINHA YN, 1992, TRENDS ENDOCRIN MET, V3, P100, DOI 10.1016/1043-2760(92)90021-R; SINHA YN, 1995, ENDOCR REV, V16, P354, DOI 10.1210/er.16.3.354; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Sun ZY, 1996, MOL ENDOCRINOL, V10, P265, DOI 10.1210/me.10.3.265; THOMAS JA, 1975, J ENDOCRINOL, V65, P149, DOI 10.1677/joe.0.0650149; TIMME TL, 1994, ENDOCRINOLOGY, V134, P1039, DOI 10.1210/en.134.3.1039; TORNER L, 1995, ENDOCRINOLOGY, V136, P5454, DOI 10.1210/en.136.12.5454; TOUGARD C, 1980, AM J ANAT, V158, P471, DOI 10.1002/aja.1001580409; TRICHE TJ, 1971, LAB INVEST, V25, P596; TROWELL OA, 1959, EXP CELL RES, V16, P118, DOI 10.1016/0014-4827(59)90201-0; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Wallis M., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P295; WALVOORD DJ, 1976, INVEST UROL, V14, P60; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; Webber M M, 1981, Prog Clin Biol Res, V75B, P63; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; ZELLER R, 1991, CURRENT PROTOCOLS MO, pCH14; Zhau HYE, 1996, P NATL ACAD SCI USA, V93, P15152, DOI 10.1073/pnas.93.26.15152	103	68	71	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	1997	11	14					1297	1307		10.1096/fasebj.11.14.9409549	http://dx.doi.org/10.1096/fasebj.11.14.9409549			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409549				2022-12-25	WOS:000071144100011
J	Boehmer, PE				Boehmer, PE			The herpes simplex virus type-1 single-strand DNA-binding protein, ICP8, increases the processivity of the UL9 protein DNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI REP PROTEIN; ESCHERICHIA-COLI; POLYMERASE-ALPHA; CALF THYMUS; DUPLEX DNA; ORIGIN; REPLICATION; PRIMASE; ANTIGEN; ENZYME	Herpes simplex virus type-1 UL9 protein is a sequence-specific DNA-binding protein that recognizes elements in the viral origins of DNA replication and possesses DNA helicase activity, It forms an essential complex with its cognate single-strand DNA-binding protein, ICPS, The DNA helicase activity of the UL9 protein is greatly stimulated as a consequence of this interaction, A complex of these two proteins is thought to be responsible for unwinding the viral origins of DNA replication, The aim of this study was to identify the mechanism by which ICPS stimulates the translocation of the UL9 protein along DNA, The data show that the association of the UL9 protein with DNA substrate is slow and that its dissociation from the DNA substrate is fast, suggesting that it is nonprocessive. ICP8 caused maximal stimulation of DNA unwinding activity at equimolar UL9 protein concentrations, indicating that the active species is a complex that contains UL9 protein and ICP8 in I:1 ratio. ICP8 prevented dissociation of UL9 protein from the DNA substrate, suggesting that it increases its processivity, ICPS specifically stimulated the DNA-dependent ATPase activity of the UL9 protein with DNA cofactors that allow translocation of UL9 protein and those with secondary structure, These data suggest that UL9 protein and ICP8 form a specific complex that translocates along DNA. Within this complex, ICP8 tethers the UL9 protein to the DNA substrate, thereby preventing its dissociation, and participates directly in the assimilation and stabilization of the unwound DNA strand, thus facilitating translocation of the complex through regions of duplex DNA.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Boehmer, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA.			Boehmer, Paul/0000-0003-4479-0529	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038335] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 38335] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; BISWAS EE, 1993, BIOCHEMISTRY-US, V32, P13393, DOI 10.1021/bi00212a003; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1994, J BIOL CHEM, V269, P29329; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; BOROWIEC JA, 1996, DNA REPLICATION EUKA, P545; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; CHIOU HC, 1985, VIROLOGY, V145, P213, DOI 10.1016/0042-6822(85)90155-2; CRUTE JJ, 1991, J BIOL CHEM, V266, P4484; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DODSON MS, 1993, J BIOL CHEM, V268, P1213; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; ELIAS P, 1988, P NATL ACAD SCI USA, V85, P2959, DOI 10.1073/pnas.85.9.2959; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P1128, DOI 10.1093/nar/22.7.1128; GUSTAFSSON CM, 1995, J BIOL CHEM, V270, P19028, DOI 10.1074/jbc.270.32.19028; HUBSCHER U, 1996, DNA REPLICATION EUKA, P525; Kornberg A., 1992, DNA REPLICATION; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LITTLER E, 1983, J GEN VIROL, V64, P983, DOI 10.1099/0022-1317-64-5-983; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Makhov AM, 1996, J MOL BIOL, V258, P789, DOI 10.1006/jmbi.1996.0287; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; MCGEOCH DJ, 1988, J VIROL, V62, P444, DOI 10.1128/JVI.62.2.444-453.1988; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; RUYECHAN WT, 1983, J VIROL, V46, P661, DOI 10.1128/JVI.46.2.661-666.1983; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; THOMMES P, 1992, J BIOL CHEM, V267, P6063; VAUGHAN PJ, 1984, J GEN VIROL, V65, P2033, DOI 10.1099/0022-1317-65-11-2033; VILLANI G, 1994, J BIOL CHEM, V269, P21676; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; WU CA, 1988, J VIROL, V62, P435, DOI 10.1128/JVI.62.2.435-443.1988; YANCEYWRONA JE, 1992, EUR J BIOCHEM, V207, P479, DOI 10.1111/j.1432-1033.1992.tb17074.x; YARRANTON GT, 1979, P NATL ACAD SCI USA, V76, P1658, DOI 10.1073/pnas.76.4.1658; ZHANG SS, 1992, FEBS LETT, V312, P143, DOI 10.1016/0014-5793(92)80922-4	44	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2676	2683		10.1074/jbc.273.5.2676	http://dx.doi.org/10.1074/jbc.273.5.2676			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446572	hybrid			2022-12-25	WOS:000071736600027
J	Takamura, T; Kato, I; Kimura, N; Nakazawa, T; Yonekura, H; Takasawa, S; Okamoto, H				Takamura, T; Kato, I; Kimura, N; Nakazawa, T; Yonekura, H; Takasawa, S; Okamoto, H			Transgenic mice overexpressing type 2 nitric-oxide synthase in pancreatic beta cells develop insulin-dependent diabetes without insulitis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; DNA STRAND BREAKS; POLY(ADP-RIBOSE) SYNTHETASE; PROINSULIN SYNTHESIS; ISLET CELLS; NICK TRANSLATION; STREPTOZOTOCIN; INHIBITION; SECRETION; TOXICITY	We generated transgenic mice carrying the mouse type 2 nitric oxide synthase (NOS2) cDNA under the control of the insulin promoter. Western and immunohistochemical analyses revealed that NOS2 was expressed abundantly in transgenic islets but not in control islets. When islets were isolated and cultured, high levels of nitrite were released from the transgenic islets, In transgenic mice, the beta cell mass was markedly reduced without the infiltration of macrophages or lymphocytes, and extensive DNA strand breaks were detected in the islets by in situ nick translation, All the transgenic mice developed hypoinsulinemic diabetes by 4 weeks of age, and treatment with an inhibitor of NOS2, aminoguanidine (200 mg/kg body weight every 12 h), prevented or delayed the development of diabetes. The present study shows that the production of nitric oxide by beta cell NOS2 plays an essential role in the beta cell degeneration.	Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, Sendai, Miyagi 98077, Japan; Tohoku Univ, Sch Med, Dept Pathol, Aoba Ku, Sendai, Miyagi 98077, Japan	Tohoku University; Tohoku University	Okamoto, H (corresponding author), Tohoku Univ, Sch Med, Dept Biochem, Aoba Ku, 2-1 Seiryo Machi, Sendai, Miyagi 98077, Japan.							AKABANE A, 1995, BIOCHEM BIOPH RES CO, V215, P524, DOI 10.1006/bbrc.1995.2496; BOWMAN M, 1994, DIABETES, V43, pA235; CORBETT JA, 1992, DIABETES, V41, P552, DOI 10.2337/diabetes.41.4.552; CORBETT JA, 1992, DIABETES, V41, P897, DOI 10.2337/diabetes.41.8.897; DELANEY CA, 1993, FEBS LETT, V333, P291, DOI 10.1016/0014-5793(93)80673-I; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; FAJANS S, 1990, ELLENBERG RIFKINS DI, P346; Faust A, 1996, LESSONS ANIMAL DIABE, P47; FEHSEL K, 1993, DIABETES, V42, P496, DOI 10.2337/diabetes.42.3.496; FOULIS AK, 1987, J PATHOL, V152, P141, DOI 10.1002/path.1711520302; GEPTS W, 1985, DIABETIC PANCREAS, P337; GREEN IC, 1994, BIOCHEM SOC T, V22, P30, DOI 10.1042/bst0220030; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HELLER B, 1995, J BIOL CHEM, V270, P11176, DOI 10.1074/jbc.270.19.11176; HOLSTAD M, 1993, AUTOIMMUNITY, V15, P211; KALLMANN B, 1992, LIFE SCI, V51, P671, DOI 10.1016/0024-3205(92)90240-P; KATO I, 1994, J BIOL CHEM, V269, P21223; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MONCADA S, 1991, PHARMACOL REV, V43, P109; NOSE K, 1983, BIOCHEM BIOPH RES CO, V111, P383, DOI 10.1016/0006-291X(83)90317-0; OKAMOTO H, 1981, MOL CELL BIOCHEM, V37, P43, DOI 10.1007/BF02355886; OKAMOTO H, 1995, BIOCHIMIE, V77, P356, DOI 10.1016/0300-9084(96)88146-6; Okamoto H., 1996, LESSONS ANIMAL DIABE, P97; Okamoto H., 2008, MOL BIOL ISLETS LANG, P209; PENDINO KJ, 1995, AM J RESP CELL MOL, V13, P125, DOI 10.1165/ajrcmb.13.2.7542894; Rabinovitch A, 1996, ENDOCRINOLOGY, V137, P2093, DOI 10.1210/en.137.5.2093; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; SHIBATA S, 1995, PANCREAS, V10, P354, DOI 10.1097/00006676-199505000-00006; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; UCHIGATA Y, 1982, J BIOL CHEM, V257, P6084; UCHIGATA Y, 1983, DIABETES, V32, P316, DOI 10.2337/diabetes.32.4.316; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0; YONEMURA Y, 1988, INT J PANCREATOL, V3, P73	36	112	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2493	2496		10.1074/jbc.273.5.2493	http://dx.doi.org/10.1074/jbc.273.5.2493			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446547	hybrid			2022-12-25	WOS:000071736600002
J	Alvarez, M; Zeelen, JP; Mainfroid, V; Rentier-Delrue, F; Martial, JA; Wyns, L; Wierenga, RK; Maes, D				Alvarez, M; Zeelen, JP; Mainfroid, V; Rentier-Delrue, F; Martial, JA; Wyns, L; Wierenga, RK; Maes, D			Triose-phosphate isomerase (TIM) of the psychrophilic bacterium Vibrio marinus - Kinetic and structural properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMAL TRIOSEPHOSPHATE ISOMERASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BARREL PROTEINS; T4 LYSOZYME; RESOLUTION; GENES; LOOP; PURIFICATION; REPLACEMENT	The purification and characterization of triose-phosphate isomerase from the psychrophilic bacterium Vibrio marinus (vTIM) is described. Crystal structures of the vTIM-sulfate complex and the vTIM-2-phosphoglycolate complex (at a 2.7-Angstrom resolution) are also presented, The optimal growth temperature of Vibrio marinus is 15 degrees C. Stability studies show that vTIM is an unstable protein with a half-life of only 10 min at 25 degrees C. The vTIM sequence is most closely related to the sequence of Escherichia coli TIM (eTIM) (66% identity), and several unique structural features described for eTIM are also seen in vTIM, but eTIM is considerably more stable. The T-d values of vTIM and eTIM, determined by calorimetric studies, are 41 and 54 degrees C, respectively. Amino acid sequence comparison reveals that vTIM has an alanine in loop 8 (at position 238), whereas all other TIM sequences known to date have a serine. The vTIM mutant A238S was produced and characterized, Compared with wild type, the catalytic efficiency of the A238S mutant is somewhat reduced, and its stability is considerably increased.	European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Liege, Lab Biol Mol & Genie Genet, B-4000 Liege, Belgium; Free Univ Brussels VIB, Ultrastruct Unit, B-1640 Rhode St Genese, Belgium	European Molecular Biology Laboratory (EMBL); University of Liege; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Maes, D (corresponding author), European Mol Biol Lab, Meyerhofstr 1,Postfach 102209, D-69012 Heidelberg, Germany.	dommaes@vub.ac.be		Maes, Dominique/0000-0002-9179-3186				ABAGYAN RA, 1977, ICM VERSION 2 6; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BLABER M, 1993, BIOCHEMISTRY-US, V32, P11363, DOI 10.1021/bi00093a013; BORCHERT TV, 1993, STRUCTURE, V1, P205, DOI 10.1016/0969-2126(93)90021-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, XPLOR SYSTEM XRYA CR; CONOLLY ML, 1985, J AM CHEM SOC, V107, P1118; DELBONI LF, 1995, PROTEIN SCI, V4, P2594, DOI 10.1002/pro.5560041217; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GORAJ K, 1990, PROTEIN ENG, V3, P259, DOI 10.1093/protein/3.4.259; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LHOIR C, 1990, GENE, V89, P47, DOI 10.1016/0378-1119(90)90204-5; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MANDE SC, 1994, PROTEIN SCI, V3, P810, DOI 10.1002/pro.5560030510; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MISSET O, 1984, EUR J BIOCHEM, V144, P475, DOI 10.1111/j.1432-1033.1984.tb08490.x; MORITA RY, 1975, BACTERIOL REV, V39, P144, DOI 10.1128/MMBR.39.2.144-167.1975; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neria E, 1997, CHEM PHYS LETT, V267, P23, DOI 10.1016/S0009-2614(97)00068-7; NOBLE MEM, 1993, PROTEINS, V16, P311, DOI 10.1002/prot.340160402; NOBLE MEM, 1993, ACTA CRYSTALLOGR D, V49, P403, DOI 10.1107/S0907444993002628; OTWINOWSKI Z, 1993, DENZO OSCILLATION DA; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; RENTIERDELRUE F, 1993, J MOL BIOL, V229, P85, DOI 10.1006/jmbi.1993.1010; Schliebs W, 1996, PROTEIN SCI, V5, P229; SERRANO L, 1992, J MOL BIOL, V227, P544, DOI 10.1016/0022-2836(92)90906-Z; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA T, 1994, PROTEIN SCI, V3, P419; Thanki N, 1997, PROTEIN ENG, V10, P159, DOI 10.1093/protein/10.2.159; URFER R, 1992, PROTEIN SCI, V1, P31; Velanker SS, 1997, STRUCTURE, V5, P751, DOI 10.1016/S0969-2126(97)00230-X; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WIERENGA RK, 1991, J MOL BIOL, V220, P995, DOI 10.1016/0022-2836(91)90368-G; WIERENGA RK, 1991, PROTEINS, V10, P33, DOI 10.1002/prot.340100105; WOLFENDE.R, 1969, NATURE, V223, P704, DOI 10.1038/223704a0; ZEELEN JP, 1994, ACTA CRYSTALLOGR D, V50, P443, DOI 10.1107/S0907444994001277; 1994, ACTA CRYSTALLOGR S D, V50, P760	42	131	137	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2199	2206		10.1074/jbc.273.4.2199	http://dx.doi.org/10.1074/jbc.273.4.2199			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442062	hybrid, Green Submitted			2022-12-25	WOS:000071595200051
J	Bonny, C; Nicod, P; Waeber, G				Bonny, C; Nicod, P; Waeber, G			IB1, a JIP-1-related nuclear protein present in insulin-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; DNA-BINDING DOMAIN; GLUCOSE-TRANSPORTER; TRANSCRIPTIONAL REGULATION; DIABETIC HYPERGLYCEMIA; GLUT2 EXPRESSION; ENHANCER BINDING; GENE-EXPRESSION; TRANSGENIC MICE; REPORTER GENE	JIP-1 is a cytoplasmic inhibitor of the c-Jun aminoterminal kinase activated pathway recently cloned from a mouse brain cDNA library. We report herein the expression cloning of a rat cDNA encoding a JIP-1-related nuclear protein from a pancreatic beta-cell cDNA library that we named IB1 for Islet-Brain 1. IB1 was isolated by its ability to bind to GTII, a cis-regulatory element of the GLUTS promoter, The IB1 cDNA encodes a 714-amino acid protein, which differs from JIP-1 by the insertion of 47 amino acids in the carboxyl-terminal part of the protein. The remaining 667 amino acids are 97% identical to JIP-1. The 47-amino acid insertion contains a truncated phosphotyrosine interaction domain and a putative helix-loop-helix motif. Recombinant IB1 (amino acids 1-714 and 280-714) was shown to bind in vitro to GTII. Functionally IB1 transactivated the GLUTS gene, IB1 was localized within the cytoplasm and the nucleus of insulin-secreting cells or COS-7 cells transfected with an expression vector encoding IB1, Using a heterologous GAL4 system, we localized an activation domain of IB1 within the first 280 amino acids of the protein, These data demonstrate that IB1 is a DNA-binding protein related to JIP-1, which is highly expressed in pancreatic beta-cells where it functions as a transactivator of the GLUTS gene.	Univ Lausanne Hosp, Dept Internal Med B, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Bonny, C (corresponding author), CHU Vaudois, Dept Internal Med B, CH-1011 Lausanne, Switzerland.	gwaeber@chuv.hospvd.ch		Waeber, Gerard/0000-0003-4193-788X				ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BONNY C, 1995, MOL ENDOCRINOL, V9, P1413, DOI 10.1210/me.9.10.1413; BONNY C, 1997, INT END SOC M JUN 11; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JOHNSON JH, 1990, SCIENCE, V250, P546, DOI 10.1126/science.2237405; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LELOUP C, 1994, BRAIN RES, V638, P221, DOI 10.1016/0006-8993(94)90653-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OHNEDA M, 1993, DIABETES, V42, P1065, DOI 10.2337/diabetes.42.7.1065; ORCI L, 1990, J CLIN INVEST, V86, P1615, DOI 10.1172/JCI114883; ORCI L, 1989, SCIENCE, V245, P295, DOI 10.1126/science.2665080; ORCI L, 1990, P NATL ACAD SCI USA, V87, P9953, DOI 10.1073/pnas.87.24.9953; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rencurel F, 1997, BIOCHEM J, V322, P441, DOI 10.1042/bj3220441; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7239; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; TAKAKI R, 1986, IN VITRO CELL DEV B, V22, P120; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; THORENS B, 1990, P NATL ACAD SCI USA, V87, P6492, DOI 10.1073/pnas.87.17.6492; THORENS B, 1992, J CLIN INVEST, V90, P77, DOI 10.1172/JCI115858; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; WAEBER G, 1995, MOL CELL ENDOCRINOL, V114, P205, DOI 10.1016/0303-7207(95)96801-N; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184	39	130	149	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1843	1846		10.1074/jbc.273.4.1843	http://dx.doi.org/10.1074/jbc.273.4.1843			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442013	hybrid			2022-12-25	WOS:000071595200002
J	Dahlen, JR; Jean, F; Thomas, G; Foster, DC; Kisiel, W				Dahlen, JR; Jean, F; Thomas, G; Foster, DC; Kisiel, W			Inhibition of soluble recombinant furin by human proteinase inhibitor 8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOKINE RESPONSE MODIFIER; REACTIVE-BOND LOOP; TARGET PROTEINASES; SUBSTRATE REACTION; MESSENGER-RNA; SLOW-BINDING; GRANZYME-B; SERPIN; ENZYME; ALPHA-1-ANTITRYPSIN	Furin is a ubiquitous prototypical mammalian kexin/ subtilisin-like endoproteinase that is involved in the proteolytic processing of a variety of proteins in the exocytic and endocytic pathways, with cleavage occurring at the C terminus of the minimal consensus furin recognition sequence Arg-Xaa-Xaa-Arg. In this study, human proteinase inhibitor 8 (PI8), a widely expressed 45-kDa ovalbumin-type serpin that contains two sequences homologous to the minimal sequence for recognition by furin in its reactive site loop, was tested for its ability to inhibit a recombinant soluble form of human furin. PI8 formed an SDS-stable complex with furin and inhibited its amidolytic activity via a two-step mechanism with a k(assoc) of 6.5 x 10(5) M-1 S-1 and an overall K-i of 53.8 pm. Thus, PI8 inhibits furin in a rapid, tight binding manner that is characteristic of physiological serpin-proteinase interactions. PI8 is not only the first human ovalbumin-type serpin to demonstrate inhibitory activity toward furin, but it is also the first significant inhibitor of furin identified that is not a serpin reactive site loop mutant, either naturally occurring or engineered.	Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA; Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA; Zymogenet Inc, Seattle, WA 98102 USA	University of New Mexico; Oregon Health & Science University; Zymogenet Inc.	Kisiel, W (corresponding author), Univ New Mexico, Sch Med, Dept Pathol, Albuquerque, NM 87131 USA.	wkisiel@salud.unm.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035246] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL35246] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON ED, 1993, J BIOL CHEM, V268, P24887; BELIN D, 1989, EMBO J, V8, P3287, DOI 10.1002/j.1460-2075.1989.tb08489.x; BJORK I, 1992, J BIOL CHEM, V267, P19047; BJORK I, 1993, BIOCHEMISTRY-US, V32, P6501; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CHA S, 1975, BIOCHEM PHARMACOL, V24, P2177, DOI 10.1016/0006-2952(75)90050-7; COHEN AB, 1978, BIOCHEMISTRY-US, V17, P392, DOI 10.1021/bi00596a002; Dahlen JR, 1997, BIOCHEMISTRY-US, V36, P14874, DOI 10.1021/bi970977p; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P663; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; KorpulaMastalerz R, 1996, ACTA BIOCHIM POL, V43, P419; KWIATKOWSKI DJ, 1988, J CELL BIOL, V106, P375, DOI 10.1083/jcb.106.2.375; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LODERMANN H, 1984, J MOL BIOL, V177, P531; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MORRISON JF, 1982, TRENDS BIOCHEM SCI, V7, P102, DOI 10.1016/0968-0004(82)90157-8; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; QUAN LT, 1995, J BIOL CHEM, V270, P10377, DOI 10.1074/jbc.270.18.10377; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schick C, 1997, J BIOL CHEM, V272, P1849, DOI 10.1074/jbc.272.3.1849; Scott FL, 1996, J BIOL CHEM, V271, P1605, DOI 10.1074/jbc.271.3.1605; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; SKIVER K, 1991, J BIOL CHEM, V266, P9216; SPRECHER CA, 1995, J BIOL CHEM, V270, P29854; SUMINAMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P51, DOI 10.1016/S0006-291X(05)81380-4; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; TIAN WX, 1982, BIOCHEMISTRY-US, V21, P1028, DOI 10.1021/bi00534a031; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; YE RD, 1989, J BIOL CHEM, V264, P5495	37	73	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1851	1854		10.1074/jbc.273.4.1851	http://dx.doi.org/10.1074/jbc.273.4.1851			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442015	hybrid			2022-12-25	WOS:000071595200004
J	Gavin, IM; Usachenko, SI; Bavykin, SG				Gavin, IM; Usachenko, SI; Bavykin, SG			Nucleosome structural transition during chromatin unfolding is caused by conformational changes in nucleosomal DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENT MATING LOCI; YEAST HISTONE H4; CORE PARTICLE; PRIMARY ORGANIZATION; IONIC-STRENGTH; SACCHAROMYCES-CEREVISIAE; N-TERMINI; TRANSCRIPTION; REPRESSION; DOMAIN	We have recently reported that certain core histone-DNA contacts are altered in nucleosomes during chromatin unfolding (Usachenko, S. I., Gavin I. M., and Bavykin, S. G. (1996) J. Biol. Chem. 271, 3831-3836), In this work, we demonstrate that these alterations are caused by a conformational change in the nucleosomal DNA, Using zero-length protein-DNA cross linking, we have mapped histone-DNA contacts in isolated core particles at ionic conditions affecting DNA stiffness, which may change the nucleosomal DNA conformation, We found that the alterations in histone-DNA contacts induced by an increase in DNA stiffness in isolated core particles are identical to those observed in nucleosomes during chromatin unfolding. The change in the pattern of micrococcal nuclease digestion of linker histone-depleted chromatin at ionic conditions affecting chromatin compaction also suggests that the stretching of the linker DNA may alter the nucleosomal DNA conformation, resulting in a structural transition in the nucleosome which may play a role in rendering the nucleosome competent for transcription and/or replication.	VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Bavykin, SG (corresponding author), Argonne Natl Lab, Ctr Mechanist Biol & Biotechnol, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	sbavykin@everest.bim.anl.gov						ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AFINSEN CB, 1971, ENZYMES, V4, P177; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAVYKIN SG, 1985, NUCLEIC ACIDS RES, V13, P3439, DOI 10.1093/nar/13.10.3439; BAVYKIN SG, 1990, J MOL BIOL, V212, P495, DOI 10.1016/0022-2836(90)90328-J; BazettJones DP, 1996, NUCLEIC ACIDS RES, V24, P321, DOI 10.1093/nar/24.2.321; BEDNAR J, 1995, J CELL BIOL, V131, P1365, DOI 10.1083/jcb.131.6.1365; BELYAVSKY AV, 1980, J MOL BIOL, V139, P519, DOI 10.1016/0022-2836(80)90144-8; BURTON K, 1967, METHODS ENZYMOLOGY A, V12, P222; CHUNG DG, 1985, BIOCHEMISTRY-US, V24, P8028, DOI 10.1021/bi00348a029; CLARK DJ, 1990, J MOL BIOL, V211, P883, DOI 10.1016/0022-2836(90)90081-V; CUATRECA.P, 1967, J BIOL CHEM, V242, P1541; Czarnota GJ, 1996, J BIOL CHEM, V271, P3677; DAVIES N, 1991, BIOCHIM BIOPHYS ACTA, V1129, P57, DOI 10.1016/0167-4781(91)90212-5; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; EBRALIDSE KK, 1988, NATURE, V331, P365, DOI 10.1038/331365a0; EBRALIDSE KK, 1986, FEBS LETT, V194, P69, DOI 10.1016/0014-5793(86)80053-9; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Felsenfeld G, 1996, P NATL ACAD SCI USA, V93, P9384, DOI 10.1073/pnas.93.18.9384; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; GARCIARAMIREZ M, 1992, J BIOL CHEM, V267, P19587; GOULET I, 1988, J MOL BIOL, V200, P253, DOI 10.1016/0022-2836(88)90238-0; GRUSS C, 1992, BIOESSAYS, V14, P1, DOI 10.1002/bies.950140102; GUSCHIN DY, 1991, MOL BIOL, V25, P1400; HAGERMAN PJ, 1988, ANNU REV BIOPHYS BIO, V17, P265; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HIRAI M, 1988, BIOCHEMISTRY-US, V27, P7924, DOI 10.1021/bi00420a051; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KRUDE T, 1995, CURR BIOL, V5, P1232, DOI 10.1016/S0960-9822(95)00245-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; Lenfant F, 1996, EMBO J, V15, P3974, DOI 10.1002/j.1460-2075.1996.tb00771.x; LIBERTINI LJ, 1982, BIOCHEMISTRY-US, V21, P3327, DOI 10.1021/bi00257a013; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; LOHR D, 1979, P NATL ACAD SCI USA, V76, P6326, DOI 10.1073/pnas.76.12.6326; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MANIATIS T, 1975, BIOCHEMISTRY-US, V14, P3787, DOI 10.1021/bi00688a010; MANNING GS, 1989, J BIOMOL STRUCT DYN, V6, P877, DOI 10.1080/07391102.1989.10506519; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARKY NL, 1991, BIOPOLYMERS, V31, P1543, DOI 10.1002/bip.360311310; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MEGEE PC, 1995, GENE DEV, V9, P1716, DOI 10.1101/gad.9.14.1716; MIRZABEKOV AD, 1989, METHOD ENZYMOL, V170, P386; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; PRIOR CP, 1983, CELL, V34, P1033, DOI 10.1016/0092-8674(83)90561-5; PRUNELL A, 1979, SCIENCE, V204, P855, DOI 10.1126/science.441739; Pruss D, 1997, METHODS, V12, P36, DOI 10.1006/meth.1997.0445; RICHMOND TJ, 1993, COLD SPRING HARB SYM, V58, P265, DOI 10.1101/SQB.1993.058.01.031; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; RUIZCARRILLO A, 1979, P NATL ACAD SCI USA, V76, P3284, DOI 10.1073/pnas.76.7.3284; SCHWARZ PM, 1994, J BIOL CHEM, V269, P16284; SHICK VV, 1980, J MOL BIOL, V139, P491, DOI 10.1016/0022-2836(80)90143-6; SIBBET GJ, 1983, EUR J BIOCHEM, V133, P393, DOI 10.1111/j.1432-1033.1983.tb07475.x; STRUCK MM, 1992, J MOL BIOL, V224, P253, DOI 10.1016/0022-2836(92)90588-B; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMPSON JS, 1994, NATURE, V369, P245, DOI 10.1038/369245a0; TRAVERS AA, 1994, CURR BIOL, V4, P659, DOI 10.1016/S0960-9822(00)00148-2; UBERBACHER EC, 1989, J BIOMOL STRUCT DYN, V7, P1; USACHENKO SI, 1994, P NATL ACAD SCI USA, V91, P6845, DOI 10.1073/pnas.91.15.6845; Usachenko SI, 1996, J BIOL CHEM, V271, P3831; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WEISCHET WO, 1979, NUCLEIC ACIDS RES, V6, P1843, DOI 10.1093/nar/6.5.1843; WIDOM J, 1989, ANNU REV BIOPHYS BIO, V18, P365, DOI 10.1146/annurev.biophys.18.1.365; WU HM, 1979, BIOCHEMISTRY-US, V18, P3960, DOI 10.1021/bi00585a018; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735; YAO J, 1991, BIOCHEMISTRY-US, V30, P8408, DOI 10.1021/bi00098a019; ZIVANOVIC Y, 1990, J MOL BIOL, V214, P479, DOI 10.1016/0022-2836(90)90195-R; ZLATANOVA J, 1992, J CELL SCI, V103, P889	78	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2429	2434		10.1074/jbc.273.4.2429	http://dx.doi.org/10.1074/jbc.273.4.2429			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442093	hybrid			2022-12-25	WOS:000071595200082
J	Chaal, BK; Mould, RM; Barbrook, AC; Gray, JC; Howe, CJ				Chaal, BK; Mould, RM; Barbrook, AC; Gray, JC; Howe, CJ			Characterization of a cDNA encoding the thylakoidal processing peptidase from Arabidopsis thaliana - Implications for the origin and catalytic mechanism of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMEN PROTEIN PLASTOCYANIN; COLI LEADER PEPTIDASE; REACTION SPECIFICITIES; CHLOROPLASTS; TRANSPORT; SEQUENCE; TRANSLOCATION; PRECURSORS; MATURATION; BIOGENESIS	We have identified and sequenced a cDNA containing a complete open reading frame for a putative 340-amino acid precursor of the thylakoidal processing peptidase from Arabidopsis thaliana, The predicted amino acid sequence of the protein includes regions highly conserved among Type I leader peptidases and indicates that the enzyme uses a serine-lysine catalytic dyad mechanism. Phylogenetic analysis indicated a common ancestry of the enzyme with those from oxygenic photosynthetic prokaryotes, suggesting that the cDNA encoded the chloroplast enzyme. The catalytic domain was overexpressed in Escherichia coli, generating a product capable of cleaving the thylakoid-transfer domain from a chloroplast protein. Antibodies to the overexpressed polypeptide cross-reacted with a 30-kDa thylakoid membrane protein.	Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1QW, England; Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England	University of Cambridge; University of Cambridge; University of Cambridge	Howe, CJ (corresponding author), Univ Cambridge, Dept Biochem, Tennis Court Rd, Cambridge CB2 1QW, England.	c.j.howe@bioc.cam.ac.uk		Barbrook, Adrian/0000-0002-6209-7413				Barbrook AC, 1996, FEBS LETT, V398, P198, DOI 10.1016/S0014-5793(96)01239-2; BASSHAM DC, 1991, J BIOL CHEM, V266, P23606; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BLACK MT, 1993, J BACTERIOL, V175, P4957, DOI 10.1128/JB.175.16.4957-4961.1993; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; GRAY JC, 1995, TRENDS CELL BIOL, V5, P243, DOI 10.1016/S0962-8924(00)89018-2; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; HALPIN C, 1989, EMBO J, V8, P3917, DOI 10.1002/j.1460-2075.1989.tb08572.x; Howe CJ, 1996, BIOCHEM SOC T, V24, P750, DOI 10.1042/bst0240750; HUSON D, 1994, SPLITSTREE VERSION 1; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1987, J BIOL CHEM, V262, P16386; KIRWIN PM, 1988, J BIOL CHEM, V263, P18128; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOULD RM, 1998, CELL BIOL LAB HDB, V2, P286; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PACKER JCL, 1995, PLANT MOL BIOL, V27, P199, DOI 10.1007/BF00019191; Paetzel M, 1997, TRENDS BIOCHEM SCI, V22, P28, DOI 10.1016/S0968-0004(96)10065-7; Sambrook J., 2002, MOL CLONING LAB MANU; SHACKLETON JB, 1991, J BIOL CHEM, V266, P12152; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; SMEEKENS S, 1985, NATURE, V317, P456, DOI 10.1038/317456a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSCHANTZ WR, 1993, J BIOL CHEM, V268, P27349; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WALLACE TP, 1990, FEBS LETT, V272, P141, DOI 10.1016/0014-5793(90)80468-X; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	30	43	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					689	692		10.1074/jbc.273.2.689	http://dx.doi.org/10.1074/jbc.273.2.689			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422718	hybrid			2022-12-25	WOS:000071411400007
J	Anthonsen, MW; Ronnstrand, L; Wernstedt, C; Degerman, E; Holm, C				Anthonsen, MW; Ronnstrand, L; Wernstedt, C; Degerman, E; Holm, C			Identification of novel phosphorylation sites in hormone-sensitive lipase that are phosphorylated in response to isoproterenol and govern activation properties in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CARDIAC TROPONIN-I; ADIPOSE-TISSUE; RAT ADIPOCYTES; CAMP-PHOSPHODIESTERASE; SERINE RESIDUES; INSULIN; CELLS; EXPRESSION; LIPOLYSIS	Hormone-sensitive lipase (HSL) is the rate-limiting enzyme in lipolysis, Stimulation of rat adipocytes with isoproterenol results in phosphorylation of HSL and a 50-fold increase in the rate of lipolysis, In this study, we used site-directed mutagenesis and two-dimensional phosphopeptide mapping to show that phosphorylation sites other than the previously identified Ser-563 are phosphorylated in HSL in response to isoproterenol stimulation of P-32-labeled rat adipocytes, Phosphorylation of HSL in adipocytes in response to isoproterenol and in vitro phosphorylation of HSL containing Ser --> Ala mutations in residues 563 and 565 (S563A,S565A) with protein kinase A (PKA), followed by tryptic phosphopeptide mapping resulted in two tryptic phosphopeptides, These tryptic phosphopeptides co-migrated with the phosphopeptides released by the same treatment of F(654)HPRRSSQGVLHMPLYSSPIVK(675) phosphorylated with PKA, Analysis of the phosphorylation site mutants, S659A, S660A, and S659A,S660A disclosed that mutagenesis of both Ser-659 and Ser-660 was necessary to abolish the activation of HSL toward a triolein substrate after phosphorylation with PKA. Mutation of Ser-563 to alanine did not cause significant change of activation compared with wild-type HSL, Hence, our results demonstrate that in addition to the previously identified Ser-563, two other PKA phosphorylation sites, Ser-659 and Ser-660, are present in HSL and, furthermore, that Ser-659 and Ser-660 are the major activity controlling sites in vitro.	Univ Lund, Sect Mol Signaling, Dept Cell & Mol Biol, S-22100 Lund, Sweden; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Lund University; Ludwig Institute for Cancer Research	Holm, C (corresponding author), Univ Lund, Sect Mol Signaling, Dept Cell & Mol Biol, S-22100 Lund, Sweden.		Ronnstrand, Lars/A-2429-2011	Ronnstrand, Lars/0000-0003-1275-5809				AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; Belfrage P., 1984, P365; Contreras JA, 1996, J BIOL CHEM, V271, P31426, DOI 10.1074/jbc.271.49.31426; COOK KG, 1982, EUR J BIOCHEM, V125, P245, DOI 10.1111/j.1432-1033.1982.tb06675.x; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; EGAN JJ, 1992, P NATL ACAD SCI USA, V89, P8537, DOI 10.1073/pnas.89.18.8537; GARTON AJ, 1988, FEBS LETT, V229, P68, DOI 10.1016/0014-5793(88)80799-3; GARTON AJ, 1990, EUR J BIOCHEM, V191, P245, DOI 10.1111/j.1432-1033.1990.tb19116.x; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HELLER RA, 1972, BIOCHIM BIOPHYS ACTA, V270, P65, DOI 10.1016/0005-2760(72)90178-6; HIRSCH AH, 1984, J LIPID RES, V25, P665; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; Holm C, 1997, METHOD ENZYMOL, V286, P45; HOLM C, 1991, FEBS LETT, V285, P139, DOI 10.1016/0014-5793(91)80744-N; HOLM C, 1994, FEBS LETT, V344, P234, DOI 10.1016/0014-5793(94)00403-X; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; Horton MR, 1991, DIRECTED MUTAGENESIS, P217; KHOO JC, 1974, J CLIN INVEST, V53, P1124, DOI 10.1172/JCI107650; KHOO JC, 1974, J LIPID RES, V15, P602; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MITTMANN K, 1990, FEBS LETT, V273, P41, DOI 10.1016/0014-5793(90)81046-Q; Osterlund T, 1996, BIOCHEM J, V319, P411, DOI 10.1042/bj3190411; QUIRK PG, 1995, FEBS LETT, V370, P175, DOI 10.1016/0014-5793(95)00812-N; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; RASCON A, 1994, J BIOL CHEM, V269, P11962; RICHARDS JH, 1991, DIRECTED MUTAGENESIS, P199; RODBELL M, 1964, J BIOL CHEM, V239, P375; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; STRALFORS P, 1983, J BIOL CHEM, V258, P5146; STRALFORS P, 1984, P NATL ACAD SCI-BIOL, V81, P3317, DOI 10.1073/pnas.81.11.3317; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; TORNQVIST H, 1978, J LIPID RES, V19, P654; Zhang R, 1995, J BIOL CHEM, V270, P30773, DOI 10.1074/jbc.270.51.30773	34	349	362	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					215	221		10.1074/jbc.273.1.215	http://dx.doi.org/10.1074/jbc.273.1.215			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417067	hybrid			2022-12-25	WOS:000071295600033
J	Rock, MT; Brooks, WH; Roszman, TL				Rock, MT; Brooks, WH; Roszman, TL			Calcium-dependent signaling pathways in T cells - Potential role of calpain, protein tyrosine phosphatase 1B, and p130(Cas) in integrin-mediated signaling events	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; EXTRACELLULAR-MATRIX; ENDOPLASMIC-RETICULUM; HUMAN-PLATELETS; ADHESION; PHOSPHORYLATION; BINDING; TRANSDUCTION; SYSTEM; SRC	Engagement of beta 1 integrin receptors initiates an increase in intracellular calcium concentrations in T cells, potentially affecting calcium-sensitive signaling pathways. The calcium-activated cysteine protease, calpain, regulates a variety of cell functions by calcium-dependent limited proteolysis. To investigate the function of calpain in T cells, we sought to determine the role of this protease in calcium-dependent signaling events, Subsequent to elevations in intracellular calcium concentrations induced by ionomycin or adherence to fibronectin, calpain activity translocated to the cytoskeletal/membrane fraction of T cells. In addition, stimulation of T cells with these agents initiated the proteolytic cleavage of protein tyrosine phosphatase 1B by calpain. Enzymatic cleavage of protein tyrosine phosphatase 1B occurs near the endoplasmic reticulum-targeting sequence and results in the generation of an enzymatically active form of the phosphatase. Furthermore, we show that both the native and the cleaved forms of protein tyrosine phosphatase 1B interact with p130(Cas) in T cells, This interaction may serve to relocate protein tyrosine phosphatase 1B to sites of focal contact resulting in potential interactions with substrates previously inaccessible to the endoplasmic reticulum-associated phosphatase. Thus, we describe a novel calcium-dependent signaling pathway in T cells that may mediate signals generated by beta 1 integrin adherence to the extracellular matrix.	Univ Kentucky, Med Ctr, Dept Immunol Microbiol, Lexington, KY 40536 USA	University of Kentucky	Roszman, TL (corresponding author), Univ Kentucky, Med Ctr, Dept Immunol Microbiol, MN 414, Lexington, KY 40536 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047679, K05MH001069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017423] Funding Source: NIH RePORTER; NIMH NIH HHS [MH47679, KO5 MH01069] Funding Source: Medline; NINDS NIH HHS [NS17423] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bandyopadhyay D, 1997, J BIOL CHEM, V272, P1639, DOI 10.1074/jbc.272.3.1639; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DESHPANDE RV, 1993, NEUROCHEM RES, V18, P767, DOI 10.1007/BF00966771; DONNADIEU E, 1994, CURR BIOL, V4, P584, DOI 10.1016/S0960-9822(00)00130-5; ELLIOTT LH, 1995, METHODS NEUROSCIENCE, V24; FAULL RJ, 1994, J EXP MED, V179, P1307, DOI 10.1084/jem.179.4.1307; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1995, THROMB HAEMOSTASIS, V73, P987; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; HARTFIELD PJ, 1993, BIOCHEM BIOPH RES CO, V196, P1183, DOI 10.1006/bbrc.1993.2376; HEDMAN H, 1992, J IMMUNOL, V149, P2295; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Inomata M, 1996, ARCH BIOCHEM BIOPHYS, V328, P129, DOI 10.1006/abbi.1996.0152; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; LOW MG, 1986, BIOCHEM J, V237, P139, DOI 10.1042/bj2370139; MELLGREN RL, 1987, FASEB J, V1, P110, DOI 10.1096/fasebj.1.2.2886390; MELLONI E, 1992, BIOCHIMIE, V74, P217, DOI 10.1016/0300-9084(92)90120-4; MURACHI T, 1989, BIOCHEM INT, V18, P263; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; ODA A, 1993, J BIOL CHEM, V268, P12603; PATCH LA, 1995, J CELL SCI, V108, P1371; Petruzzelli L, 1996, J BIOL CHEM, V271, P7796, DOI 10.1074/jbc.271.13.7796; PONTREMOLI S, 1985, BIOCHIM BIOPHYS ACTA, V831, P335, DOI 10.1016/0167-4838(85)90116-5; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Retta SF, 1996, EXP CELL RES, V229, P307, DOI 10.1006/excr.1996.0376; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SHIMIZU Y, 1991, FASEB J, V5, P2292, DOI 10.1096/fasebj.5.9.1860621; SHIMIZU Y, 1990, NATURE, V345, P250, DOI 10.1038/345250a0; SJAASTAD MD, 1994, P NATL ACAD SCI USA, V91, P8214, DOI 10.1073/pnas.91.17.8214; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; SORIMACHI H, 1994, FEBS LETT, V343, P1, DOI 10.1016/0014-5793(94)80595-4; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TURNER CE, 1989, J BIOL CHEM, V264, P11938; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weismann M, 1997, J IMMUNOL, V158, P1618; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6	51	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33377	33383		10.1074/jbc.272.52.33377	http://dx.doi.org/10.1074/jbc.272.52.33377			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407132	hybrid			2022-12-25	WOS:000071182900093
J	Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ				Mao, WG; Irby, R; Coppola, D; Fu, L; Wloch, M; Turner, J; Yu, H; Garcia, R; Jove, R; Yeatman, TJ			Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential	ONCOGENE			English	Article						EGFR; Src; colon cancer	EPIDERMAL-GROWTH-FACTOR; HUMAN COLORECTAL CARCINOMAS; HUMAN BREAST-CANCER; NUDE-MICE; PP60C-SRC ACTIVITY; IN-VIVO; FAMILY KINASES; TRANSFORMATION; LINES; EXPRESSION	Recent data suggest that signal transduction may have a critical role in the development and regulation of the metastatic phenotype. Here, we investigated the role of c-Src activation in the process of human colon cancer metastasis to the Liver, Our data, derived from two different sets of human colon cancer cell line metastatic variants, suggest that not only do highly-metastatic cells display constitutively elevated c-Src protein kinase activity when compared to poorly metastatic cells, but also that receptor tyrosine kinases participate in the ligand-activation of c-Src above basal levels. Specifically, the epidermal growth factor receptor (EGFR), p185HER2/Neu and the hepatocyte growth factor receptor (c-Met) appear to be Linked to the process because they preferentially activate c-Src in highly-metastatic cells, EGFR was found to associate with c-Src in colon cancer cells and specific inhibitors of the EGFR resulted in a reduction of c-Src activity to basal levels. In addition, c-Src transfectants displayed partially-activated EGFRs, suggesting a feedback role for c-Src in the regulation of the EGFR. p185HER2/Neu was also identified in immunocomplexes of c-Src following Ligand activation of the EGFR, but only in highly-metastatic cells, Collectively, these observations suggest a paradigm whereby c-Src interacts with multiple cell-surface growth factors in a catalytic fashion for the development of tumor cells with metastatic potential.	Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Pathol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Med Microbiol & Immunol, Tampa, FL 33612 USA; Univ S Florida, H Lee Moffitt Canc Ctr, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Yeatman, TJ (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Dept Surg, Tampa, FL 33612 USA.			YU, Hua/0000-0003-0931-1000				ANTCZAK M, 1990, J VIROL, V64, P1451, DOI 10.1128/JVI.64.4.1451-1458.1990; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunton VG, 1997, ONCOGENE, V14, P283, DOI 10.1038/sj.onc.1200827; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; CHAKRABARTY S, 1995, CLIN EXP METASTAS, V13, P191, DOI 10.1007/BF00132207; COFFEY RJ, 1987, CANCER RES, V47, P4590; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; GARCIA R, 1991, ONCOGENE, V6, P1983; GREENBERG AH, 1989, INVAS METAST, V9, P360; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; JESSUP JM, 1989, CANCER RES, V49, P6906; JESSUP JM, 1988, CANCER RES, V48, P1689; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAMPS MP, 1986, CELL, V45, P105, DOI 10.1016/0092-8674(86)90542-8; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mahvi DM, 1996, HUM GENE THER, V7, P1535, DOI 10.1089/hum.1996.7.13-1535; Mayer K, 1996, ANTICANCER RES, V16, P1733; MORIKAWA K, 1988, CANCER RES, V48, P1943; MORIKAWA K, 1988, CANCER RES, V48, P6863; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, ADV CANCER RES, V64, P111, DOI 10.1016/S0065-230X(08)60836-2; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PENA SV, 1995, GASTROENTEROLOGY, V108, P117, DOI 10.1016/0016-5085(95)90015-2; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RADINSKY R, 1993, CANCER METAST REV, V12, P345, DOI 10.1007/BF00665962; Rewcastle GW, 1996, J MED CHEM, V39, P1823, DOI 10.1021/jm9508651; Shah V, 1994, In Vivo, V8, P321; TALAMONTI MA, 1991, J CLIN INVEST, V91, P53; TATSUKA PM, 1996, MOL CARCINOG, V15, P300; TERMUHLEN PM, 1993, J SURG RES, V54, P54; WANG P, 1991, BRIT J CANCER, V64, P531, DOI 10.1038/bjc.1991.344; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WEERNINK PAO, 1994, FEBS LETT, V352, P296, DOI 10.1016/0014-5793(94)00977-5; WILSON LK, 1989, MOL CELL BIOL, V9, P1536, DOI 10.1128/MCB.9.4.1536; WITTY JP, 1994, CANCER RES, V54, P4805; YEATMAN TJ, 1993, SEMIN SURG ONCOL, V9, P256; Yeatman TJ, 1996, CLIN EXP METASTAS, V14, P246; ZIRVI KA, 1993, CANCER LETT, V72, P39, DOI 10.1016/0304-3835(93)90008-W	53	171	184	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3083	3090		10.1038/sj.onc.1201496	http://dx.doi.org/10.1038/sj.onc.1201496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444956				2022-12-25	WOS:000070968000008
J	Cha, SS; Kim, JS; Cho, HS; Shin, NK; Jeong, W; Shin, HC; Kim, YJ; Hahn, JH; Oh, BH				Cha, SS; Kim, JS; Cho, HS; Shin, NK; Jeong, W; Shin, HC; Kim, YJ; Hahn, JH; Oh, BH			High resolution crystal structure of a human tumor necrosis factor-alpha mutant with low systemic toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUTATIONAL ANALYSIS; TNF RECEPTOR; MONOCLONAL-ANTIBODIES; 1.9-A RESOLUTION; CELL-LINES; BINDING; LYMPHOTOXIN; IDENTIFICATION; DERIVATIVES; REFINEMENT	A human tumor necrosis factor-alpha (TNF-alpha) mutant (M3S) with low systemic toxicity in vivo was designed, and its structures in two different crystal packings were determined crystallographically at 1.8 and 2.15-Angstrom resolution, respectively, to explain altered biological activities of the mutant, M3S contains four changes: a hydrophilic substitution of L29S,two hydrophobic substitutions of S52I and Y56F, and a deletion of the N-terminal seven amino acids that is disordered in the structure of wild type TNF-alpha. Compared with wild-type TNF-alpha, it exhibits 11- and 71-fold lower binding affinities for the human TNF-R55 and TNF-R75 receptors, respectively, and in vitro cytotoxic effect and in vivo systemic toxicity of M3S are 20 and 10 times lower, respectively, However, in a transplanted solid tumor mouse model, M3S suppresses tumor growth more efficiently than wild-type TNF-alpha, M3S is highly resistant to proteolysis by trypsin, and it exhibits increased thermal stability and a prolonged half-life in vivo, The L29S mutation causes substantial restructuring of the loop containing residues 29-36 into a rigid segment as a consequence of induced formation of intra-and intersubunit interactions, explaining the altered receptor binding affinity and thermal stability, A mass spectrometric analysis identified major proteolytic cleavage sites located on this loop, and thus the increased resistance of M3S to the proteolysis is consistent with the increased rigidity of the loop, The S52I and Y56F mutations do not induce a noticeable conformational change, The side chain of Phe(56) projects into a hydrophobic cavity, while Ile(52) is exposed to the bulk solvent, Ile(52) should be involved in hydrophobic interactions with the receptors, since a mutant containing the same mutations as in M3S except for the L29S mutation exhibits an increased receptor binding affinity. The low systemic toxicity of M3S appears to be the effect of the reduced and selective binding affinities for the TNF receptors, and the superior tumor-suppression of M3S appears to be the effect of its weak but longer antitumoral activity in vivo compared with wild-type TNF-alpha, It is also expected that the 1.8-Angstrom resolution structure will serve as an accurate model for explaining the structure-function relationship of wild-type TNF-alpha and many TNF-alpha mutants reported previously and for the design of new TNF-alpha mutants.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Sch Environm Engn, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Ctr Biofunct Mol, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Chem, Pohang 790784, Kyungbuk, South Korea; Hankyo Inst Technol, Prot Engn Lab, Yusung Gu, Taejon 305390, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, San 31, Pohang 790784, Kyungbuk, South Korea.		HAHN, JONGHOON/F-5384-2013; Oh, Byung-Ha/C-2061-2011	Cha, Sun-Shin/0000-0002-0913-8706				AGGARWAL BB, 1985, NATURE, V318, P665, DOI 10.1038/318665a0; BABARA JAJ, 1994, EMBO J, V13, P843; Baldwin RL, 1996, P NATL ACAD SCI USA, V93, P1021, DOI 10.1073/pnas.93.3.1021; BALDWIN RL, 1988, J IMMUNOL, V141, P2352; BALDWIN RL, 1995, J IMMUNOL, V154, P790; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CHANG MP, 1990, INFECT IMMUN, V58, P2644, DOI 10.1128/IAI.58.8.2644-2650.1990; CREASEY AA, 1987, CANCER RES, V47, P145; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GEIGERT J, 1987, DEV BIOL STAND, V69, P129; HAUSER GJ, 1990, CANCER RES, V50, P3503; ITOH N, 1993, J BIOL CHEM, V268, P10932; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Jeong W, 1997, BIOTECHNOL LETT, V19, P579, DOI 10.1023/A:1018305907918; KAGAN BL, 1992, SCIENCE, V255, P1427, DOI 10.1126/science.1371890; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; LOETSCHER H, 1993, J BIOL CHEM, V268, P26350; MARQUART M, 1980, J MOL BIOL, V141, P369, DOI 10.1016/0022-2836(80)90252-1; MASEGI T, 1993, BIOTECHNOL LETT, V15, P1107, DOI 10.1007/BF00131198; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAKAMURA S, 1991, INT J CANCER, V48, P744, DOI 10.1002/ijc.2910480519; NARHI LO, 1989, J PROTEIN CHEM, V8, P669, DOI 10.1007/BF01025607; RIECHMANN L, 1988, NATURE, V332, P323, DOI 10.1038/332323a0; RUFF MR, 1980, J IMMUNOL, V125, P1671; SCHALABY MR, 1990, J EXP MED, V172, P1517; SCHUCHMANN M, 1995, EUR J IMMUNOL, V25, P2183, DOI 10.1002/eji.1830250810; Seong J, 1997, ANTI-CANCER DRUG, V8, P80, DOI 10.1097/00001813-199701000-00011; SHIN NK, 1994, P BPERC INT S, V94, P43; SIDHU RS, 1989, ANTICANCER RES, V9, P1569; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Taniyama M, 1997, P NATL ACAD SCI USA, V94, P3324, DOI 10.1073/pnas.94.7.3324; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TSUJIMOTO M, 1987, J BIOCHEM-TOKYO, V101, P919, DOI 10.1093/oxfordjournals.jbchem.a121960; VANDERPOLL T, 1992, BLOOD, V79, P693; VANOSTADE X, 1994, PROTEIN ENG, V7, P5, DOI 10.1093/protein/7.1.5; VANOSTADE X, 1993, NATURE, V361, P266; VANOSTADE X, 1994, EUR J BIOCHEM, V220, P771; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VANZEE KJ, 1994, J EXP MED, V179, P1185, DOI 10.1084/jem.179.4.1185; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; YAMAMOTO R, 1989, PROTEIN ENG, V2, P553, DOI 10.1093/protein/2.7.553; ZHANG XM, 1992, J BIOL CHEM, V267, P24069	51	40	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2153	2160		10.1074/jbc.273.4.2153	http://dx.doi.org/10.1074/jbc.273.4.2153			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442056	hybrid			2022-12-25	WOS:000071595200045
J	Wang, YB; Huang, SA; Sah, VP; Ross, J; Brown, JH; Han, JH; Chien, KR				Wang, YB; Huang, SA; Sah, VP; Ross, J; Brown, JH; Han, JH; Chien, KR			Cardiac muscle cell hypertrophy and apoptosis induced by distinct members of the p38 mitogen-activated protein kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; MAP KINASE; HEAT-SHOCK; ADRENERGIC STIMULATION; INDUCIBLE EXPRESSION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; STRESS; GENE; PATHWAYS	p38 mitogen-activated protein (MAP) kinase activities were significantly increased in mouse hearts after chronic transverse aortic constriction, coincident with the onset of ventricular hypertrophy. Infection of cardiomyocytes with adenoviral vectors expressing up-stream activators for the p38 kinases, activated mutants of MAP kinase kinase 3b(E) (MKK3bE) and MAP kinase kinase 6b(E) (MKK6bE), elicited characteristic hypertrophic responses, including an increase in cell size, enhanced sarcomeric organization, and elevated atrial natriuretic factor expression. Overexpression of the activated MKK3bE in cardiomyocytes also led to an increase in apoptosis. The hypertrophic response was enhanced by co-infection of an adenoviral vector expressing wild type p38 beta, and was suppressed by the p38 beta dominant negative mutant. In contrast, the MKK3bE-induced cell death was increased by co-infection of an adenovirus expressing wild type p38 alpha, and was suppressed by the dominant negative p38 alpha mutant. This provides the first evidence in any cell system for divergent physiological functions for different members of the p38 MAP kinase family. The direct involvement of p38 pathways in cardiac hypertrophy and apoptosis suggests a significant role for p38 signaling in the pathophysiology of heart failure.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Research Institute	Chien, KR (corresponding author), Univ Calif San Diego, Dept Med, Mail Box 0613-C,9500 Gilman Dr, La Jolla, CA 92093 USA.	kckien@ucsd.edu	Han, J/G-4671-2010	Wang, Yibin/0000-0003-0852-0767	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028143, R37HL028143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL28143] Funding Source: Medline; NIAID NIH HHS [AI 41637] Funding Source: Medline; NIGMS NIH HHS [GM51417] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Barunwald E, 1996, HEART DIS TXB CARDIO, P1626; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Bogoyevitch MA, 1996, CIRC RES, V79, P162, DOI 10.1161/01.RES.79.2.162; CHEN J, 1997, IN PRESS CIRCULATI S; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Christensen G, 1997, AM J PHYSIOL-HEART C, V272, pH2513, DOI 10.1152/ajpheart.1997.272.6.H2513; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; GROSSMAN W, 1980, AM J MED, V69, P576, DOI 10.1016/0002-9343(80)90471-4; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1993, J BIOL CHEM, V268, P25009; HOUT J, 1997, CIRC RES, V80, P383; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; IWAKI K, 1990, J BIOL CHEM, V265, P13809; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; KNOWLTON KU, 1991, J BIOL CHEM, V266, P7759; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEMBO G, 1995, ANN NY ACAD SCI, V752, P115, DOI 10.1111/j.1749-6632.1995.tb17414.x; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MacLellan WR, 1997, CIRC RES, V81, P137, DOI 10.1161/01.RES.81.2.137; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Post GR, 1996, J BIOL CHEM, V271, P8452, DOI 10.1074/jbc.271.14.8452; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; ROCKMAN HA, 1994, P NATL ACAD SCI USA, V91, P2694, DOI 10.1073/pnas.91.7.2694; ROCKMAN HA, 1991, P NATL ACAD SCI USA, V88, P8277, DOI 10.1073/pnas.88.18.8277; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sheng ZL, 1997, J BIOL CHEM, V272, P5783, DOI 10.1074/jbc.272.9.5783; SIMPSON PC, 1989, ANNU REV PHYSIOL, V51, P189, DOI 10.1146/annurev.ph.51.030189.001201; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Villarreal FJ, 1996, J MOL CELL CARDIOL, V28, P735, DOI 10.1006/jmcc.1996.0068; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang Y, 1996, P NATL ACAD SCI USA, V93, P3932, DOI 10.1073/pnas.93.9.3932; Wollert KC, 1996, J BIOL CHEM, V271, P9535, DOI 10.1074/jbc.271.16.9535; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	53	686	713	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2161	2168		10.1074/jbc.273.4.2161	http://dx.doi.org/10.1074/jbc.273.4.2161			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442057	hybrid			2022-12-25	WOS:000071595200046
J	Zheng, CH; Xing, Z; Bian, ZC; Guo, CM; Akbay, A; Warner, L; Guan, JL				Zheng, CH; Xing, Z; Bian, ZC; Guo, CM; Akbay, A; Warner, L; Guan, JL			Differential regulation of Pyk2 and focal adhesion kinase (FAK) - The C-terminal domain of FAK confers response to cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL-TRANSDUCTION; V-SRC; PHOSPHORYLATION; ACTIVATION; INTEGRIN; IDENTIFICATION; PP125(FAK); PAXILLIN; CRK	Pyk2 is a recently described cytoplasmic tyrosine kinase that is related to focal adhesion kinase (FAK) and can be activated by a variety of stimuli that elevate intracellular calcium, in this report, we showed that Pyk2 and FAK tyrosine phosphorylation are regulated differentially by integrin-mediated cell adhesion and soluble factors both in rat aortic smooth muscle cells, which express endogenous Pyk2 and FAK, and in transfected Chinese hamster ovary cells, We also found that Pyk2 is diffusely present throughout the cytoplasm, while FAT( is localized in focal contacts as expected, suggesting that the different localization may account for their differential regulation, By analyzing a chimeric protein contain N-terminal and kinase domains of Pyk2 and C-terminal domain of FAK, we provided evidence that the distinctive C-terminal domains of Pyk2 and FAR were responsible for their differential regulation by integrins and soluble stimuli as well as their subcellular localization, Finally, we correlated FAR, Pyk2, and the chimeric protein binding to talin, but not paxillin, with their regulation by integrins and focal contact localization, These results demonstrate that the distinctive C-terminal domain of Pyk2 and FAK confer their differential regulation by different subcellular localization and association with the cytoskeletal protein talin.	Cornell Univ, Coll Vet Med, Dept Pathol, Canc Biol Labs, Ithaca, NY 14853 USA	Cornell University	Guan, JL (corresponding author), Cornell Univ, Coll Vet Med, Dept Pathol, Canc Biol Labs, Ithaca, NY 14853 USA.		Xing, Zheng/G-8366-2011; Xing, Zheng/O-3137-2015	Xing, Zheng/0000-0002-7288-0268; Xing, Zheng/0000-0002-7288-0268	NCI NIH HHS [T32CA09682] Funding Source: Medline; NIGMS NIH HHS [R01GM52890] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052890] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; DEVOR BB, 1993, BIOCHEM BIOPH RES CO, V190, P1084, DOI 10.1006/bbrc.1993.1160; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; Guan JL, 1997, MATRIX BIOL, V16, P195, DOI 10.1016/S0945-053X(97)90008-1; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1997, BIOCHEM J, V324, P141, DOI 10.1042/bj3240141; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TURNER CE, 1994, J CELL SCI, V107, P1583; VUORI K, 1993, J BIOL CHEM, V268, P21459; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993	33	123	129	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2384	2389		10.1074/jbc.273.4.2384	http://dx.doi.org/10.1074/jbc.273.4.2384			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442086	hybrid			2022-12-25	WOS:000071595200075
J	Bald, D; Amano, T; Muneyuki, E; Pitard, B; Rigaud, JL; Kruip, J; Hisabori, T; Yoshida, M; Shibata, M				Bald, D; Amano, T; Muneyuki, E; Pitard, B; Rigaud, JL; Kruip, J; Hisabori, T; Yoshida, M; Shibata, M			ATP synthesis by F0F1-ATP synthase independent of noncatalytic nucleotide binding sites and insensitive to azide inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; BACILLUS PS3; OXIDATIVE-PHOSPHORYLATION; THERMOPHILIC BACTERIUM; BACTERIORHODOPSIN; MECHANISM; LIPOSOMES; STIMULATION; ACTIVATION	ATP hydrolyzing activity of a mutant alpha(3) beta(3) gamma subcomplex of F0F1-ATP synthase (Delta NC) from the thermophilic Bacillus PS3, which lacked noncatalytic nucleotide binding sites, was inactivated completely soon after starting the reaction (Matsui, T., Muneyuki, E., Honda, M., Allison, W. S., Dou, C., and Yoshida, M. (1997) J. Biol. Chem. 272, 8215-8221), This inactivation is caused by rapid accumulation of the "MgADP inhibited form" which, in the case of wild-type enzyme, would be relieved by ATP binding to noncatalytic sites. We reconstituted F0F1-ATP synthase into liposomes together with bacteriorhodopsin and measured illumination-driven ATP synthesis. Remarkably, Delta NC F0F1-ATP synthase catalyzed continuous turnover of ATP synthesis while it could not promote ATP-driven proton translocation. ATP synthesis by Delta NC F0F1-ATP synthase, as well as wild-type enzyme, proceeded even in the presence of azide, an inhibitor of ATP hydrolysis that stabilizes the MgADP inhibited form. The time course of ATP synthesis by Delta NC F0F1-ATP synthase was linear, and gradual acceleration to the maximal rate, which was observed for the wild-type enzyme, was not seen. Thus, ATP synthesis can proceed without nucleotide binding to noncatalytic sites even though the rate is sub-maximal. These results indicate that the MgADP inhibited form is not produced in ATP synthesis reaction, and in this regard, ATP synthesis may not be a simple reversal of ATP hydrolysis.	Tokyo Inst Technol, Resources Utilizat Res Lab, Yokohama, Kanagawa 226, Japan; CEA, LCR, F-75231 Paris, France; Inst Curie, Sect Rech, UMR 168, F-75231 Paris, France	Tokyo Institute of Technology; CEA; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie	Yoshida, M (corresponding author), Tokyo Inst Technol, Resources Utilizat Res Lab, R-1,4259 Nagatsuta, Yokohama, Kanagawa 226, Japan.	myoshida@res.titech.ac.jp	Pitard, Bruno F/K-9270-2015; Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CHOATE GL, 1979, J BIOL CHEM, V254, P286; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FELDMAN RI, 1983, J BIOL CHEM, V258, P2178; FITIN AF, 1979, BIOCHEM BIOPH RES CO, V86, P434, DOI 10.1016/0006-291X(79)90884-2; HYNDMAN DJ, 1994, J BIOL CHEM, V269, P28871; JAULT JM, 1993, J BIOL CHEM, V268, P1558; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MILGROM YM, 1991, J BIOL CHEM, V266, P11551; MONTICELLO RA, 1992, J BACTERIOL, V174, P3370, DOI 10.1128/jb.174.10.3370-3376.1992; MUNEYUKI E, 1993, BIOCHIM BIOPHYS ACTA, V1144, P62, DOI 10.1016/0005-2728(93)90031-A; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; PAIK SR, 1994, BIOCHEMISTRY-US, V33, P126, DOI 10.1021/bi00167a016; PEREZ JA, 1990, BIOCHEMISTRY-US, V29, P10503, DOI 10.1021/bi00498a013; Pitard B, 1996, EUR J BIOCHEM, V235, P779, DOI 10.1111/j.1432-1033.1996.t01-1-00779.x; Pitard B, 1996, EUR J BIOCHEM, V235, P769, DOI 10.1111/j.1432-1033.1996.00769.x; RICHARD P, 1995, J BIOL CHEM, V270, P21571, DOI 10.1074/jbc.270.37.21571; ROSING J, 1977, J BIOL CHEM, V252, P2478; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONE N, 1975, J BIOL CHEM, V250, P7917; SYROESHKIN AV, 1995, FEBS LETT, V366, P29, DOI 10.1016/0014-5793(95)00487-T; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1995, J BIOL CHEM, V270, P21045, DOI 10.1074/jbc.270.36.21045; WEI JM, 1988, BIOCHIM BIOPHYS ACTA, V934, P72, DOI 10.1016/0005-2728(88)90121-1; YOSHIDA M, 1975, BIOCHEM BIOPH RES CO, V67, P1295, DOI 10.1016/0006-291X(75)90167-9	33	57	57	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					865	870		10.1074/jbc.273.2.865	http://dx.doi.org/10.1074/jbc.273.2.865			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422743	hybrid			2022-12-25	WOS:000071411400032
J	Debailleul, V; Laine, A; Huet, G; Mathon, P; d'Hooghe, MC; Aubert, JP; Porchet, N				Debailleul, V; Laine, A; Huet, G; Mathon, P; d'Hooghe, MC; Aubert, JP; Porchet, N			Human mucin genes MUC2, MUC3, MUC4, MUC5AC, MUC5B, and MUC6 express stable and extremely large mRNAs and exhibit a variable length polymorphism - An improved method to analyze large mRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; HUMAN GASTRIC MUCIN; MOLECULAR-CLONING; MESSENGER-RNA; INTESTINAL MUCIN; TRACHEOBRONCHIAL MUCIN; CELL-LINES; CHROMOSOMAL LOCALIZATION; APOLIPOPROTEIN B-100; SECRETING CELLS	Of the nine mucin genes that have been characterized, only MUC1 and MUC7 have been fully sequenced, and their transcripts can be detected as distinct bands of predicted size by Northern blot analysis. In contrast, the RNA patterns observed for each of the other MUC genes have usually shown a very high degree of polydispersity. This polydispersity has been believed to be one of the typical features of the mucin mRNAs, but until now, its origin has remained unexplained, In the work described in the present paper, we investigated two possible kinds of explanation for this phenomenon: namely that the extensive polydispersity results from a biological mechanism or that it is artifactual in origin. The data obtained, as a result of improving the purification and blotting methods, allowed us to show that in all of the tissues analyzed, each of the genes, MUC2-6, expresses mRNAs that are stable and are of an unusually large size to be found in eukaryotes (14-24 kilobases), Moreover, allelic variations in length of these mucin transcripts were observed, We demonstrate that these variations are directly related to the variable number of tandem repeat polymorphisms seen at the DNA level.	INSERM, U377, Lab Gerard Biserte, F-59045 Lille, France; INSERM, U124, F-59045 Lille, France; Ctr Hosp Reg & Univ Lille, Hop Huriez, Lab Biochim & Biol Mol, F-59037 Lille, France; Univ Lille 2, Fac Med, F-59037 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille	Porchet, N (corresponding author), INSERM, U377, Lab Gerard Biserte, Pl Verdun, F-59045 Lille, France.	jpa@lille.inserm.fr						AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; Baeckstrom D, 1996, GLYCOCONJUGATE J, V13, P833, DOI 10.1007/BF00702347; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; Bobek LA, 1996, GENOMICS, V31, P277, DOI 10.1006/geno.1996.0049; BOBEK LA, 1993, J BIOL CHEM, V268, P20563; BRESALIER RS, 1991, J CLIN INVEST, V87, P1037, DOI 10.1172/JCI115063; Buisine MP, 1996, GASTROENTEROLOGY, V110, P84, DOI 10.1053/gast.1996.v110.pm8536891; Carvalho F, 1997, GLYCOCONJUGATE J, V14, P107, DOI 10.1023/A:1018573201347; CHAMBERLAIN JS, 1988, SCIENCE, V239, P1416, DOI 10.1126/science.3347839; CHEN SH, 1986, J BIOL CHEM, V261, P2918; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; CREPIN M, 1990, BIORHEOLOGY, V27, P471; DANI C, 1984, P NATL ACAD SCI-BIOL, V81, P7046, DOI 10.1073/pnas.81.22.7046; DEKKER J, 1989, J BIOL CHEM, V264, P10431; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; Desseyn JL, 1997, J BIOL CHEM, V272, P3168, DOI 10.1074/jbc.272.6.3168; DUFOSSE J, 1993, BIOCHEM J, V293, P329, DOI 10.1042/bj2930329; DUPERAT VG, 1995, BIOCHEM J, V305, P211, DOI 10.1042/bj3050211; ECKHARDT AE, 1991, J BIOL CHEM, V266, P9678; FOYT HL, 1991, J BIOL CHEM, V266, P7300; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GENDLER SJ, 1987, P NATL ACAD SCI USA, V84, P6060, DOI 10.1073/pnas.84.17.6060; GUM JR, 1990, BIOCHEM BIOPH RES CO, V171, P407, DOI 10.1016/0006-291X(90)91408-K; GUM JR, 1989, J BIOL CHEM, V264, P6480; GUM JR, 1991, J BIOL CHEM, V266, P22733; GUM JR, 1994, J BIOL CHEM, V269, P2440; HO SB, 1993, CANCER RES, V53, P641; HO SB, 1995, CANCER RES, V55, P2681; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; JANY BH, 1991, J CLIN INVEST, V87, P77, DOI 10.1172/JCI115004; JEANPIERRE M, 1987, NUCLEIC ACIDS RES, V15, P9611, DOI 10.1093/nar/15.22.9611; Kitamura H, 1996, EUR J CANCER, V32A, P1788, DOI 10.1016/0959-8049(96)00168-2; KLOMP LWJ, 1995, BIOCHEM J, V308, P831, DOI 10.1042/bj3080831; LAINE RO, 1994, J BIOL CHEM, V269, P9693; LAW SW, 1986, P NATL ACAD SCI USA, V83, P8142, DOI 10.1073/pnas.83.21.8142; LESUFFLEUR T, 1991, J CELL BIOL, V115, P1409, DOI 10.1083/jcb.115.5.1409; LESUFFLEUR T, 1995, J BIOL CHEM, V270, P13665, DOI 10.1074/jbc.270.23.13665; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; LESUFFLEUR T, 1993, J CELL SCI, V106, P771; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; MEERZAMAN D, 1994, J BIOL CHEM, V269, P12932; MONIAUX N, 1996, 4 INT WORKSH CARC AS, P128; Nguyen PL, 1996, TUMOR BIOL, V17, P176, DOI 10.1159/000217980; NUNES DP, 1995, BIOCHEM J, V310, P41, DOI 10.1042/bj3100041; OGATA S, 1992, CANCER RES, V52, P5971; OHMORI H, 1994, J BIOL CHEM, V269, P17833; PASLEAU F, 1993, ONCOGENE, V8, P849; PELTZ S W, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P99; Pigny P, 1996, GENOMICS, V38, P340, DOI 10.1006/geno.1996.0637; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shankar V, 1997, AM J RESP CELL MOL, V16, P232, DOI 10.1165/ajrcmb.16.3.9070607; SHANKAR V, 1992, BIOCHEM BIOPH RES CO, V189, P958, DOI 10.1016/0006-291X(92)92297-B; SORIMACHI H, 1988, J BIOL CHEM, V263, P17678; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TAN KO, 1993, J BIOL CHEM, V268, P22900; TORIBARA NW, 1991, J CLIN INVEST, V88, P1005, DOI 10.1172/JCI115360; TORIBARA NW, 1993, J BIOL CHEM, V268, P5879; TURNER BS, 1995, BIOCHEM J, V308, P89, DOI 10.1042/bj3080089; TYTGAT KMAJ, 1995, BIOCHEM J, V309, P221, DOI 10.1042/bj3090221; VanKlinken BJW, 1995, BIOCHEM SOC T, V23, P814, DOI 10.1042/bst0230814; ZALESNA G, 1989, BIOCHEM INT, V18, P775; Zhang JQ, 1996, EUR J BIOCHEM, V239, P835, DOI 10.1111/j.1432-1033.1996.0835u.x	69	99	102	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					881	890		10.1074/jbc.273.2.881	http://dx.doi.org/10.1074/jbc.273.2.881			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422745	hybrid			2022-12-25	WOS:000071411400034
J	Dowbenko, D; Spencer, S; Quan, C; Lasky, LA				Dowbenko, D; Spencer, S; Quan, C; Lasky, LA			Identification of a novel polyproline recognition site in the cytoskeletal associated protein, proline serine threonine phosphatase interacting protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; WW DOMAIN; SH3 DOMAINS; PTP-PEST; RICH; PEPTIDE; DYSTROPHIN; MODULES; BIND; GENE	Protein-protein interactions are often mediated by the recognition of proline-rich domains by SH3 or WW modules, Previously, we demonstrated that the PEST type protein-tyrosine phosphatase, PTP HSCF (hematopoietic stem cell fraction), bound to a novel cytoskeletal associated protein, proline serine threonine phosphatase interacting protein (PST PIP), via an interaction between the proline-rich COOH terminus of the PTP and a site within the putative coiled-coil domain of PST PIP, Here we describe a more detailed analysis of this interaction, Earlier data suggested that the NH2, terminus of PST PIP was important for binding to the phosphatase, and deletion of the NH2-terminal 50 amino acids of the PST PIP resulted in an apparently misfolded protein that was incapable of binding PTP HSCF. To examine the region involved with binding to PTP HSCF, alanine-scanning mutants were produced at intervals throughout PST PIP., This analysis demonstrated that a tryptophan at position 232 was essential for binding in vitro., Transfection experiments demonstrated that the Trp(232) mutant protein was capable of association with the cortical cytoskeleton but was not bound to PTP HSCF in vivo., Alanine scanning of a peptide derived from the COOH-terminal proline-rich domain of PTP HSCF revealed that a subset of prolines, as well as other residues, was required for efficient binding to PST PIP, and introduction of alanines at some of these positions in the protein resulted in decreased binding to PST PIP in vitro and in vivo, Analysis of in vivo tyrosine phosphorylation of the Trp(232) mutant of PST PIP in the presence of v-Src revealed that this protein was phosphorylated more efficiently than the wild-type molecule, Thus, the interaction between PTP HSCF and PST PLP is mediated by a novel site in the cytoskeletal associated protein which interacts with residues within the proline-rich COOH terminus of the phosphatase.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioorgan Chem, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Lasky, LA (corresponding author), Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA.	lal@gene.com						ADCOCK MR, 1993, NATURE, V363, P83; ANDRE B, 1994, BIOCHEM BIOPH RES CO, V205, P1201, DOI 10.1006/bbrc.1994.2793; Bedford MT, 1997, EMBO J, V16, P2376, DOI 10.1093/emboj/16.9.2376; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Cheng J, 1996, BLOOD, V88, P1156, DOI 10.1182/blood.V88.4.1156.bloodjournal8841156; COHEN C, 1994, SCIENCE, V263, P488, DOI 10.1126/science.8290957; Einbond A, 1996, FEBS LETT, V384, P1, DOI 10.1016/0014-5793(96)00263-3; FANKHAUSER C, 1995, CELL, V82, P435, DOI 10.1016/0092-8674(95)90432-8; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Gamier L, 1996, NATURE, V381, P744, DOI 10.1038/381744a0; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kim YW, 1996, ONCOGENE, V13, P2275; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pirozzi G, 1997, J BIOL CHEM, V272, P14611, DOI 10.1074/jbc.272.23.14611; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Spencer S, 1997, J CELL BIOL, V138, P845, DOI 10.1083/jcb.138.4.845; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; Wittekind M, 1997, J MOL BIOL, V267, P933, DOI 10.1006/jmbi.1996.0886; YANG Q, 1993, J BIOL CHEM, V268, P6622	34	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					989	996		10.1074/jbc.273.2.989	http://dx.doi.org/10.1074/jbc.273.2.989			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422760	hybrid			2022-12-25	WOS:000071411400049
J	Gramolini, AO; Burton, EA; Tinsley, JM; Ferns, MJ; Cartaud, A; Cartaud, J; Davies, KE; Lunde, JA; Jasmin, BJ				Gramolini, AO; Burton, EA; Tinsley, JM; Ferns, MJ; Cartaud, A; Cartaud, J; Davies, KE; Lunde, JA; Jasmin, BJ			Muscle and neural isoforms of agrin increase utrophin expression in cultured myotubes via a transcriptional regulatory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; RECEPTOR EPSILON-SUBUNIT; MDX MOUSE MUSCLE; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; GENE-EXPRESSION; ACETYLCHOLINE-RECEPTORS; SYNAPTIC EXPRESSION; MESSENGER-RNA; MUTANT MICE	Duchenne muscular dystrophy is a prevalent X-linked neuromuscular disease for which there is currently no cure, Recently, it was demonstrated in a transgenic mouse model that utrophin could functionally compensate for the lack of dystrophin and alleviate the muscle pathology (Tinsley, J. M., Potter, A. C., Phelps, S. R., Fisher, R., Trickett, J. I., and Davies, K. E. (1996) Nature 384, 349-353). In this context, it thus becomes essential to determine the cellular and molecular mechanisms presiding over utrophin expression in attempts to overexpress the endogenous gene product throughout skeletal muscle fibers. In a recent study, we showed that the nerve exerts a profound influence on utrophin gene expression and postulated that nerve-derived trophic factors mediate the local transcriptional activation of the utrophin gene within nuclei located in the postsynaptic sarcoplasm (Gramolini, A, O., Dennis, C, L., Tinsley, J, M,, Robertson, G. S., Davies, K. E, Cartaud, J., and Jasmin, B. J. (1997) J. Biol. Chem. 272, 8117-8120). In the present study, we have therefore focused on the effect of agrin on utrophin expression in cultured C2 myotubes. In response to Torpedo-, muscle-, or nerve-derived agrin, we observed a significant 2-fold increase in utrophin mRNAs. By contrast, CGRP treatment failed to affect expression of utrophin transcripts. Western blotting experiments also revealed that the increase in utrophin mRNAs was accompanied by an increase in the levels of utrophin. To determine whether these changes were caused by parallel increases in the transcriptional activity of the utrophin gene, we transfected muscle cells with a 1.3-kilobase pair utrophin promoter-reporter (nlsLacZ) gene construct and treated them with agrin for 24-48 h. Under these conditions, both muscle- and nerve-derived agrin increased the activity of beta-galactosidase, indicating that agrin treatment led, directly or indirectly, to the transcriptional activation of the utrophin gene. Furthermore, this increase in transcriptional activity in response to agrin resulted from a greater number of myonuclei expressing the 1.3 kilobase pair utrophin promoter-nlsLacZ construct. Deletion of 800 base pairs 5' from this fragment decreased the basal levels of nlsLacZ expression and abolished the sensitivity of the utrophin promoter to exogenously applied agrin. In addition, site-directed mutagenesis of an N-box motif contained within this 800-base pair fragment demonstrated its essential contribution in this regulatory mechanism. Finally, direct gene transfer studies performed in vivo further revealed the importance of this DNA element for the synapse-specific expression of the utrophin gene along multinucleated muscle fibers. These data show that both muscle and neural isoforms of agrin can regulate expression of the utrophin gene and further indicate that agrin is not only involved in the mechanisms leading to the formation of clusters containing presynthesized synaptic molecules but that it can also participate in the local regulation of genes encoding synaptic proteins. Together, these observations are therefore relevant for our basic understanding of the events involved in the assembly and maintenance of the postsynaptic membrane domain of the neuromuscular junction and for the potential use of utrophin as a therapeutic strategy to counteract the effects of Duchenne muscular dystrophy.	Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Oxford, Dept Biochem, Genet Unit, Oxford OX1 3QU, England; Montreal Gen Hosp, Res Inst, Ctr Res Neurosci, Montreal, PQ H3G 1A4, Canada; Univ Denis Diderot, Inst Jacques Monod, F-75251 Paris 05, France	University of Ottawa; University of Oxford; McGill University; UDICE-French Research Universities; Universite Paris Cite	Jasmin, BJ (corresponding author), Univ Ottawa, Fac Med, Dept Cellular & Mol Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	bjasmin@danis.med.uottawa.ca	Burton, Edward/AAO-9677-2021; Burton, Edward/ABB-1324-2021	Burton, Edward/0000-0002-8072-4636; Ferns, Michael/0000-0002-1545-3024				ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BBLAE DJ, 1996, BRAIN PATHOL, V6, P37; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; Cartaud A, 1996, J CELL SCI, V109, P1837; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; Denzer AJ, 1997, J CELL BIOL, V137, P671, DOI 10.1083/jcb.137.3.671; DENZER AJ, 1995, J CELL BIOL, V131, P1547, DOI 10.1083/jcb.131.6.1547; DUCLERT A, 1990, P NATL ACAD SCI USA, V87, P1391, DOI 10.1073/pnas.87.4.1391; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; DUCLERT A, 1995, PHYSIOL REV, V75, P339, DOI 10.1152/physrev.1995.75.2.339; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; FARDEAU M, 1990, CR ACAD SCI III-VIE, V311, P197; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; Gautam M, 1996, CELL, V85, P525, DOI 10.1016/S0092-8674(00)81253-2; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; Gramolini A. O., 1996, Society for Neuroscience Abstracts, V22, P535; Gramolini AO, 1997, J BIOL CHEM, V272, P8117, DOI 10.1074/jbc.272.13.8117; Gramolini AO, 1997, BIOESSAYS, V19, P747, DOI 10.1002/bies.950190903; GUNDERSEN K, 1993, J CELL BIOL, V123, P1535, DOI 10.1083/jcb.123.6.1535; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; HOFFMAN EP, 1987, NATURE, V330, P754, DOI 10.1038/330754a0; JASMIN BJ, 1995, FEBS LETT, V374, P393, DOI 10.1016/0014-5793(95)01131-W; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Jones G, 1996, P NATL ACAD SCI USA, V93, P5985, DOI 10.1073/pnas.93.12.5985; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOIKE S, 1995, P NATL ACAD SCI USA, V92, P10624, DOI 10.1073/pnas.92.23.10624; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; Martin PT, 1996, DEV BIOL, V174, P125, DOI 10.1006/dbio.1996.0057; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; MIZUNO Y, 1993, J BIOCHEM-TOKYO, V114, P936, DOI 10.1093/oxfordjournals.jbchem.a124281; Nguyen T M, 1991, J Cell Biol, V115, P1695, DOI 10.1083/jcb.115.6.1695; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; PONS F, 1994, J NEUROL SCI, V122, P162, DOI 10.1016/0022-510X(94)90295-X; Rimer M., 1996, Society for Neuroscience Abstracts, V22, P1689; SadouletPuccio HM, 1996, BRAIN PATHOL, V6, P25, DOI 10.1111/j.1750-3639.1996.tb00780.x; SPRINGER TA, 1995, CURRENT PROTOCOLS MO; TAKEMITSU M, 1991, BIOCHEM BIOPH RES CO, V180, P1179, DOI 10.1016/S0006-291X(05)81320-8; TINSLEY JM, 1992, NATURE, V360, P591, DOI 10.1038/360591a0; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; ZHAO J, 1993, J NEUROL SCI, V114, P104, DOI 10.1016/0022-510X(93)90056-5	54	81	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					736	743		10.1074/jbc.273.2.736	http://dx.doi.org/10.1074/jbc.273.2.736			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422725	hybrid			2022-12-25	WOS:000071411400014
J	Quijano, VJ; Sheffield, LG				Quijano, VJ; Sheffield, LG			Prolactin decreases epidermal growth factor receptor kinase activity via a phosphorylation-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; MAP KINASE; EGF RECEPTOR; BREAST-CANCER; NB2 LYMPHOMA; AFFINITY; BINDING; MITOGEN	Previously, we have shown that prolactin inhibits epidermal growth factor (EGF)-induced mitogenesis in mouse mammary epithelial cells without altering the response to other growth promoting agents. This effect has been associated with reduced EGF induced EGF receptor (EGFR) tyrosine phosphorylation, Grb-2 association, and Ras activation. Our current hypothesis is that prolactin induces an alteration in EGFR kinase activity via a phosphorylation-dependent mechanism. To test this hypothesis, we treated normal murine mammary gland cells with or without 100 ng/ml prolactin. EGFR isolated by wheat germ agglutinin affinity chromatography from nontreated cells exhibited substantial ligand-induced phosphorylation, and EGFR isolated from prolactin-treated cells displayed minimal EGF-induced EGFR phosphorylation, as well as decreased kinase activity toward exogenous substrates. The observed decrease in ligand-induced EGFR phosphorylation could not be attributed to either differential amounts of EG;FR, decreased EGF binding affinity, or the presence of a phosphotyrosine phosphatase or ATPase. EGFR isolated from prolactin treated cells exhibited increased phosphorylation on threonine. Removal of this phosphorylation with alkaline phosphatase restored EGFR kinase activity to levels observed in nontreated cells. Therefore, these results suggest that prolactin antagonizes EGF signaling by increasing EGFR threonine phosphorylation and decreasing EGF-induced EGFR tyrosine phosphorylation.	Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sheffield, LG (corresponding author), Univ Wisconsin, Endocrinol Reprod Physiol Program, Madison, WI 53706 USA.				NICHD NIH HHS [HD 31532] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD031532] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARKEY RJ, 1988, BIOCHEM BIOPH RES CO, V156, P776, DOI 10.1016/S0006-291X(88)80911-2; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BOONSTRA J, 1985, J CELL PHYSIOL, V123, P347, DOI 10.1002/jcp.1041230309; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BORELLINI F, 1989, ENVIRON HEALTH PERSP, V80, P85, DOI 10.2307/3430734; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCKLEY AR, 1988, P NATL ACAD SCI USA, V85, P8649, DOI 10.1073/pnas.85.22.8649; CAREY GB, 1995, ARCH BIOCHEM BIOPHYS, V316, P179, DOI 10.1006/abbi.1995.1026; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; DOPPLER W, 1991, MOL ENDOCRINOL, V5, P1624, DOI 10.1210/mend-5-11-1624; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FEARN JC, 1985, CELL, V40, P991, DOI 10.1016/0092-8674(85)90359-9; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; FENTON SE, 1994, EXP CELL RES, V210, P102, DOI 10.1006/excr.1994.1015; Ferrag F, 1996, MOL ENDOCRINOL, V10, P451, DOI 10.1210/me.10.4.451; GLADHAUG IP, 1992, DIGEST DIS SCI, V37, P233, DOI 10.1007/BF01308177; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P13050; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; IMAGAWA W, 1994, PHYSL REPROD; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MORRISON P, 1993, J BIOL CHEM, V268, P15536; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; RAJKUMAR T, 1994, BREAST CANCER RES TR, V29, P3, DOI 10.1007/BF00666177; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SAKAI S, 1978, MOL CELL ENDOCRINOL, V12, P285, DOI 10.1016/0303-7207(78)90087-4; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SOLER C, 1994, J BIOL CHEM, V269, P12320; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALKER F, 1991, J BIOL CHEM, V266, P2746; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	46	26	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1200	1207		10.1074/jbc.273.2.1200	http://dx.doi.org/10.1074/jbc.273.2.1200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422787	hybrid			2022-12-25	WOS:000071411400076
J	Zimmerman, CM; Kariapper, MST; Mathews, LS				Zimmerman, CM; Kariapper, MST; Mathews, LS			Smad proteins physically interact with calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAD PROTEINS; BETA; RECEPTORS; DOMAINS	The Smad family of intracellular proteins mediates signals generated by activin and other transforming growth factor beta-related proteins via specific heteromeric complexes of transmembrane receptor serine kinases (1, 2). xSmad2 has been implicated as an activin signal mediator that may participate in transcriptional regulation (3, 4). We have employed an interaction cloning strategy to identify xSmad2-binding proteins and found that calmodulin directly associated with Smads. xSmad2, generated either by in vitro translation or by overexpression in COS cells, specifically bound to calmodulin-agarose; the association was calcium-dependent and required xSmad2 N-terminal residues, In the same assay, xSmad1 and hSmads 2, 3, and 4 also bound to calmodulin agarose. Furthermore, a calmodulin antagonist, W13, increased expression of the activin-inducible transcriptional reporter, 3TP-Lux, whereas overexpression of calmodulin suppressed this reporter, These observations demonstrate that Smad proteins interact with calmodulin in a calcium dependent way through conserved N-terminal amino acids and suggest a role for calmodulin in regulating Smad function.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Mathews, LS (corresponding author), Univ Michigan, Dept Biol Chem, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050416, T32GM008353] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-50416, T32 GM-08353] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BAUDIER J, 1995, BIOCHEMISTRY-US, V34, P7834, DOI 10.1021/bi00024a007; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; MARGOLIS B, 1995, DNA CLONING PRACTICA, P1; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; Onions J, 1997, J BIOL CHEM, V272, P23930, DOI 10.1074/jbc.272.38.23930; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	20	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					677	680		10.1074/jbc.273.2.677	http://dx.doi.org/10.1074/jbc.273.2.677			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422715	hybrid			2022-12-25	WOS:000071411400004
J	Banfic, H; Tang, XW; Batty, IH; Downes, CP; Chen, CS; Rittenhouse, SE				Banfic, H; Tang, XW; Batty, IH; Downes, CP; Chen, CS; Rittenhouse, SE			A novel integrin-activated pathway forms PKB/Akt-stimulatory phosphatidylinositol 3,4-bisphosphate via phosphatidylinositol 3-phosphate in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; BETA-GAMMA-SUBUNIT; THROMBIN; 3-KINASE; LIGAND; 3,4,5-TRISPHOSPHATE; RECEPTOR; BINDING	The aggregation of human platelets is an important physiological hemostatic event contingent upon receptor-dependent activation of the surface integrin alpha(IIb)beta(3) and subsequent binding of fabrinogen. Aggregating platelets form phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P-2), which has been reported to stimulate in vitro the activity of the proto-oncogenic protein kinase PKB/Akt, as has phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3. It has been assumed that PtdIns(3,4)P-2 is synthesized by either 5-phosphatase-catalyzed hydrolysis of PtdIns(3,4,5)P-3 produced by phosphoinositide 3-kinase (PI3K) or phosphorylation by PI3K. of PtdIns4P. We investigated the route(s) by which PtdIns(3,4)P, is formed after directly activating alpha(IIb)beta(3) with anti-ligand-induced binding site Fab fragment and report that aggregation does not lead to the generation of PtdIns(3,4,5)P-3, but to transient formation of PtdIns3P and generation of PMIns(3,4)P-2, the latter primarily by PMIns3P 4-kinase. Both this novel pathway and the activation of PKB/Akt are inhibited by the PI3K inhibitor, wort-mannin, and the calpain inhibitor, calpeptin, constituting the first evidence that PMIns(3,4)P-2 can stimulate PKB/Akt in vivo in the absence of PtdIns(3,4,5)P-3, Integrin-activated generation of the second messenger PMIns(3,4)P-2 thus depends upon a route distinct from that known to be utilized initially by growth factors. This pathway is of potential general relevance to the function of integrins.	Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland; Univ Kentucky, Div Med Chem & Pharmaceut, Lexington, KY 40536 USA	Jefferson University; Jefferson University; University of Dundee; University of Kentucky	Rittenhouse, SE (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Philadelphia, PA 19107 USA.			tang, xiuwen/0000-0002-6601-1234	NHLBI NIH HHS [HL 38622] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038622] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; CARTER AN, 1994, BIOCHEM J, V301, P415, DOI 10.1042/bj3010415; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; GOU DM, 1994, J CHEM SOC CHEM COMM, P2125, DOI 10.1039/c39940002125; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; Montsarrat N, 1997, FEBS LETT, V404, P23, DOI 10.1016/S0014-5793(97)00079-3; Norris FA, 1997, J BIOL CHEM, V272, P10987; Rittenhouse SE, 1996, BLOOD, V88, P4401, DOI 10.1182/blood.V88.12.4401.bloodjournal88124401; SORISKY A, 1992, BIOCHEM J, V286, P581, DOI 10.1042/bj2860581; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; SULTAN C, 1991, J BIOL CHEM, V266, P23554; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; vanderKaay J, 1997, J BIOL CHEM, V272, P5477, DOI 10.1074/jbc.272.9.5477; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; YAMAMOTO K, 1990, J BIOL CHEM, V265, P22086; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265; ZHANG J, 1992, J BIOL CHEM, V267, P4686	27	109	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					13	16		10.1074/jbc.273.1.13	http://dx.doi.org/10.1074/jbc.273.1.13			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417038	hybrid			2022-12-25	WOS:000071295600004
J	Kim, H; Lee, H; Yun, Y				Kim, H; Lee, H; Yun, Y			X-gene product of hepatitis B virus induces apoptosis in liver cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; NF-KAPPA-B; HBX PROTEIN; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; DNA-BINDING; TRANSCRIPTION; ANTIGEN; E1A; INDUCTION	Hepatitis B virus is a causative agent of hepatocellular carcinoma, and in the course of tumorigenesis, the X-gene product (HBx) is known to play important roles. Here, we investigated the transforming potential of HBx by conventional focus formation assay in NIH3T3 cells. Cells were cotransfected with the HBx expression plasmid along with other oncogenes including Ha-ras, v-src, v-myc, v-fos, and Ela. Unexpectedly, the introduction of HBx completely abrogated the focus-forming ability of all five tested oncogenes, In addition, the cotransfection of Bcl-2, an apoptosis inhibitor, reversed the HBx-mediated inhibition of focus formation, suggesting that the observed repression of focus formation by HBx is through the induction of apoptosis. Next, to test unequivocally whether HBx induces apoptosis in liver cells, we established stable Chang liver cell lines expressing HBx under the control of a tetracycline inducible promoter. Induction of HBx in these cells in the presence of 1% calf serum resulted in typical apoptosis phenomena such as DNA fragmentation, nuclear condensation, and fragmentation, Based on these results, we propose that HBx sensitizes liver cells to apoptosis upon hepatitis B virus infection, contributing to the development of hepatitis and the subsequent generation of hepatocellular carcinoma.	Mogam Biotechnol Res Inst, Signal Transduct Lab, Yonginsi 449910, Kyunggido, South Korea		Yun, Y (corresponding author), Mogam Biotechnol Res Inst, Signal Transduct Lab, 341 Pojungri, Yonginsi 449910, Kyunggido, South Korea.			Lee, Hyunsook/0000-0002-2251-5019				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; BORZILLO GV, 1992, ONCOGENE, V7, P869; BURSCH W, 1994, BIOCHEM CELL BIOL, V72, P669, DOI 10.1139/o94-088; Capovilla A, 1997, BIOCHEM BIOPH RES CO, V232, P255, DOI 10.1006/bbrc.1997.6269; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FROMM L, 1994, MOL CELL BIOL, V14, P6743, DOI 10.1128/MCB.14.10.6743; Galle PR, 1997, J HEPATOL, V27, P405, DOI 10.1016/S0168-8278(97)80189-4; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MILLER AD, 1985, J VIROL, V55, P521, DOI 10.1128/JVI.55.3.521-526.1985; MORIARTY AM, 1985, SCIENCE, V227, P429, DOI 10.1126/science.2981434; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PATEL T, 1995, HEPATOLOGY, V21, P1725, DOI 10.1002/hep.1840210635; PUISIEUX A, 1995, P NATL ACAD SCI USA, V92, P1342, DOI 10.1073/pnas.92.5.1342; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; WANG XW, 1995, CANCER RES, V55, P6012; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887; ZHU H, 1995, J VIROL, V69, P7960, DOI 10.1128/JVI.69.12.7960-7970.1995; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	45	175	188	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					381	385		10.1074/jbc.273.1.381	http://dx.doi.org/10.1074/jbc.273.1.381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417092	hybrid			2022-12-25	WOS:000071295600058
J	Klein, M; Martinoia, E; Weissenbock, G				Klein, M; Martinoia, E; Weissenbock, G			Directly energized uptake of beta-estradiol 17-(beta-D-glucuronide) in plant vacuoles is strongly stimulated by glutathione conjugates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE-ASSOCIATED PROTEIN; RYE PRIMARY LEAVES; SECALE-CEREALE; MESOPHYLL PROTOPLASTS; PARTIAL-PURIFICATION; MEMBRANE-VESICLES; EXPORT PUMP; TRANSPORT; GENE; ACCUMULATION	A directly energized vacuolar pump for glutathione (GS) conjugates has been described for several plant species, Since glucuronate conjugates also occur in plants, we addressed the question whether plant vacuoles take up the abiotic glucuronate conjugate estradiol 17-(beta-glucuronide) (E(2)17G) via a GS conjugate pump, which in some cases has been reported to accept various organic anions as substrate, or via a distinct glucuronate transporter, Uptake studies into vacuoles from rye and barley were performed with E(2)17G and metolachlor-GS (MOC-GS), a substrate of the GS conjugate ATPase, to compare glucuronate conjugate transport into vacuoles containing endogenous flavone glucuronides with those lacking specific glucuronate conjugates, respectively, Our results indicate that E(2)17G and MOC-GS are taken up into vacuoles of both plants via a directly energized mechanism since transport was (i) strictly ATP-dependent; (ii) inhibited by vanadate but not by bafilomycin Al, azide, verapamil, nor by dissipation of the vacuolar Delta pH or Delta Psi; (iii) E(2)17G uptake into rye vacuoles was partially driven by other nucleotides in the following order of efficiency: ATP > GTP > UTP congruent to CTP, whereas the non-hydrolyzable ATP analogue 5'-adenylyl-beta,gamma-imidodiphosphate, ADP, or PP; did not energize uptake, E(2)17G transport into rye vacuoles was saturable (K-m approximate to 0.2 mM), The rye-specific luteolin glucuronides decreased uptake rates of E(2)17G and MOC-GS into rye and barley vacuoles to comparable degrees with the mono-and diglucuronidated derivatives (40-60% inhibition) being more effective than the triglucuronide, Inhibition of E(2)17G uptake by luteolin 7-O-diglucuronide was competitive (K-i = 120 mu M) Taurocholate had no effect on E(2)17G transport, and uptake of MOC-GS was not inhibited by E(2)17G, Although GS conjugates and oxidized GS decreased MOC-GS transport, E(2)17G uptake into rye and barley vacuoles was stimulated up to 7-fold in a concentration-dependent manner by these substances, with dinitrobenzene-GS being most effective, The stimulation of the GS conjugates was not due to detergent or redox effects and was specific for the E(2)17G pump, GS conjugate stimulation of glucuronate uptake was unique for plants as E(2)17G uptake into yeast microsomal vesicles was not affected, By comparison with a Delta YCF1 yeast mutant, defective in vacuolar transport of GS conjugates mediated by YCF1, it was shown that E(2)17G was taken up into yeast vesicles via a YCF1-independent directly energized pump, These results indicate that E(2)17G as a glucuronate conjugate is transported across the vacuolar membranes of plants and yeast by a carrier distinct from the GS conjugate ATPase.	Univ Cologne, Inst Bot, Lehrstuhl 1, D-50931 Cologne, Germany; Univ Neuchatel, Inst Bot, Lab Physiol Vegetales, CH-2007 Neuchatel, Switzerland	University of Cologne; University of Neuchatel	Weissenbock, G (corresponding author), Univ Cologne, Inst Bot, Lehrstuhl 1, Gyrhofstr 15, D-50931 Cologne, Germany.	agweiss@novell.biolan.uni-koeln.de	Martinoia, Enrico/AAH-8712-2021					AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; ANHALT S, 1992, PLANTA, V187, P83, DOI 10.1007/BF00201627; ANHALT S, 1994, THESIS U KOLN; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Buchler M, 1996, J BIOL CHEM, V271, P15091; BURCHELL B, 1995, LIFE SCI, V57, P1819, DOI 10.1016/0024-3205(95)02073-R; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ELFERINK RPJO, 1994, PHARMACOL THERAPEUT, V64, P77, DOI 10.1016/0163-7258(94)90034-5; FUERST EP, 1986, WEED SCI, V34, P354, DOI 10.1017/S0043174500066972; Harborne J. B., 1988, FLAVONOIDS; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; Hinder B, 1996, J BIOL CHEM, V271, P27233, DOI 10.1074/jbc.271.44.27233; HORIO M, 1988, P NATL ACAD SCI USA, V85, P3580, DOI 10.1073/pnas.85.10.3580; HORTENSTEINER S, 1993, J BIOL CHEM, V268, P18446; KAISER G, 1984, PLANTA, V161, P562, DOI 10.1007/BF00407090; KAMIMOTO Y, 1989, J BIOL CHEM, V264, P11693; Keppler D, 1997, FASEB J, V11, P15, DOI 10.1096/fasebj.11.1.9034161; Klein M, 1996, J BIOL CHEM, V271, P29666, DOI 10.1074/jbc.271.47.29666; Kreuz K, 1996, PLANT PHYSIOL, V111, P349, DOI 10.1104/pp.111.2.349; Lautier D, 1996, BIOCHEM PHARMACOL, V52, P967, DOI 10.1016/0006-2952(96)00450-9; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; LI ZS, 1995, PLANT PHYSIOL, V107, P1257, DOI 10.1104/pp.107.4.1257; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Madon J, 1997, FEBS LETT, V406, P75, DOI 10.1016/S0014-5793(97)00245-7; MARRS KA, 1995, NATURE, V375, P397, DOI 10.1038/375397a0; MARTINOIA E, 1993, NATURE, V364, P247, DOI 10.1038/364247a0; MARTINOIA E, 1992, BOT ACTA, V105, P232, DOI 10.1111/j.1438-8677.1992.tb00293.x; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; REA PA, 1993, ANNU REV PLANT PHYS, V44, P157, DOI 10.1146/annurev.pp.44.060193.001105; RENTSCH D, 1991, PLANTA, V184, P532, DOI 10.1007/BF00197903; SCHULZ M, 1985, PHYTOCHEMISTRY, V24, P343, DOI 10.1016/S0031-9422(00)83549-9; SCHULZ M, 1986, Z NATURFORSCH C, V41, P22; SCHULZ M, 1987, PHYTOCHEMISTRY, V26, P933, DOI 10.1016/S0031-9422(00)82320-1; STRACK D, 1982, Z PFLANZENPHYSIOL, V108, P131, DOI 10.1016/S0044-328X(82)80064-0; Strack D., 1997, PLANT BIOCH, P387, DOI DOI 10.1016/B978-012214674-9/50011-4; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Tommasini R, 1996, P NATL ACAD SCI USA, V93, P6743, DOI 10.1073/pnas.93.13.6743; TOMMASINI R, 1993, Z NATURFORSCH C, V48, P867; Vore M, 1996, AM J PHYSIOL-GASTR L, V271, pG791, DOI 10.1152/ajpgi.1996.271.5.G791; Zhang K, 1996, BIOCHEM PHARMACOL, V52, P1631, DOI 10.1016/S0006-2952(96)00570-9	42	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					262	270		10.1074/jbc.273.1.262	http://dx.doi.org/10.1074/jbc.273.1.262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417074	hybrid			2022-12-25	WOS:000071295600040
J	Lu, Y; Xiong, XM; Helm, A; Kimani, K; Bragin, A; Skach, WR				Lu, Y; Xiong, XM; Helm, A; Kimani, K; Bragin, A; Skach, WR			Co- and posttranslational translocation mechanisms direct cystic fibrosis transmembrane conductance regulator N terminus transmembrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; SIGNAL RECOGNITION PROTEIN; NICOTINIC ACETYLCHOLINE-RECEPTOR; SYNTHESIZING SECRETORY PROTEIN; POSITIVELY CHARGED RESIDUES; HUMAN P-GLYCOPROTEIN; MICROSOMAL-MEMBRANES; SPANNING REGIONS; CHLORIDE CHANNEL; ALPHA-SUBUNIT	Transmembrane topology of most eukaryotic polytopic proteins is established cotranslationally at the endo plasmic reticulum membrane through the action of alternating signal and stop transfer sequences. Here we demonstrate that the cystic fibrosis transmembrane conductance regulator (CFTR) achieves its N terminus topology through a variation of this mechanism that involves both co-and posttranslational translocation events. Using a series of defined chimeric and truncated proteins expressed in a reticulocyte lysate system, we have identified two topogenic determinants encoded within the first (TM1) and second (TM2) membrane-spanning segments of CFTR. Each sequence independently (i) directed endoplasmic reticulum targeting, (ii) translocated appropriate flanking residues, and (iii) achieved its proper membrane-spanning orientation. Signal sequence activity of TM1, however, was inefficient due to the presence of two charged residues, Glu(92) and Lys(95), located within its hydrophobic core, As a result, TM1 was able to direct correct topology for less than half of nascent CFTR chains. In contrast to TM1, TM2 signal sequence activity was both efficient and specific. Even in the absence of a functional TM1 signal sequence, TM2 was able to direct CFTR N terminus topology through a ribosome dependent posttranslational mechanism. Mutating charged residues Glu(92) and Lys(95) to alanine improved TM1 signal sequence activity as well as the ability of TM1 to independently direct CFTR N terminus topology, Thus, a single functional signal sequence in either the first or second TM segment was sufficient for directing proper CFTR topology. These results identify two distinct and redundant translocation pathways for CFTR N terminus transmembrane assembly and support a model in which TM2 functions to ensure correct topology of CFTR chains that fail to translocate via TM1. This novel arrangement of topogenic information provides an alternative to conventional cotranslational pathways of polytopic protein biogenesis.	Univ Penn, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Skach, WR (corresponding author), Univ Penn, Dept Mol & Cellular Engn, Philadelphia, PA 19104 USA.				NCI NIH HHS [CA01614] Funding Source: Medline; NIDDK NIH HHS [DK51818] Funding Source: Medline; NIGMS NIH HHS [GM53457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K11CA001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053457] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1994, J BIOL CHEM, V269, P14865; AKIYAMA Y, 1990, J BACTERIOL, V172, P2888, DOI 10.1128/jb.172.6.2888-2893.1990; ANDERSON DJ, 1982, J CELL BIOL, V93, P501, DOI 10.1083/jcb.93.2.501; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Borel AC, 1996, BIOCHEMISTRY-US, V35, P10587, DOI 10.1021/bi960950q; Borel AC, 1996, CELL, V85, P379, DOI 10.1016/S0092-8674(00)81116-2; BRAELL WA, 1982, CELL, V28, P23, DOI 10.1016/0092-8674(82)90371-3; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CHAVEZ RA, 1992, J CELL BIOL, V116, P385, DOI 10.1083/jcb.116.2.385; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CONNOLLY T, 1991, SCIENCE, V252, P1171, DOI 10.1126/science.252.5009.1171; COSSON P, 1991, NATURE, V351, P414, DOI 10.1038/351414a0; CUTLER DF, 1986, J CELL BIOL, V102, P902, DOI 10.1083/jcb.102.3.902; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1993, CELL, V75, P615; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HO NS, 1989, GENE, V77, P51; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; LINGAPPA VR, 1978, P NATL ACAD SCI USA, V75, P2338, DOI 10.1073/pnas.75.5.2338; LINGAPPA VR, 1977, P NATL ACAD SCI USA, V74, P2432, DOI 10.1073/pnas.74.6.2432; LIPP J, 1989, J CELL BIOL, V109, P2013, DOI 10.1083/jcb.109.5.2013; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; MUECKLER M, 1986, CELL, V44, P629, DOI 10.1016/0092-8674(86)90272-2; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; PAPAZIAN DM, 1995, NEURON, V14, P1293, DOI 10.1016/0896-6273(95)90276-7; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; PEROZO E, 1994, BIOPHYS J, V66, P345, DOI 10.1016/S0006-3495(94)80783-0; PIND S, 1994, J BIOL CHEM, V269, P12784; Rapoport TA, 1996, CURR OPIN CELL BIOL, V8, P499, DOI 10.1016/S0955-0674(96)80027-5; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; ROTHMAN JE, 1977, NATURE, V269, P775, DOI 10.1038/269775a0; ROTHMAN RE, 1988, J BIOL CHEM, V263, P10470; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SKACH WR, 1994, CANCER RES, V54, P3202; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, MECH INTRACELLULAR T, P19; SZCZESNASKORUPA E, 1988, P NATL ACAD SCI USA, V85, P738, DOI 10.1073/pnas.85.3.738; SZCZESNASKORUPA E, 1989, J CELL BIOL, V108, P1237, DOI 10.1083/jcb.108.4.1237; TAM LY, 1994, J BIOL CHEM, V269, P32542; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WALTER P, 1981, J CELL BIOL, V91, P551, DOI 10.1083/jcb.91.2.551; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; WILLIAMS MA, 1986, MOL CELL BIOL, V6, P4317, DOI 10.1128/MCB.6.12.4317; Xiong XM, 1997, J CLIN INVEST, V100, P1079, DOI 10.1172/JCI119618; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742; Zhang JT, 1996, MOL BIOL CELL, V7, P471, DOI 10.1091/mbc.7.3.471	69	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					568	576		10.1074/jbc.273.1.568	http://dx.doi.org/10.1074/jbc.273.1.568			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417117	hybrid			2022-12-25	WOS:000071295600083
J	Massillon, D; Chen, W; Barzilai, N; Prus-Wertheimer, D; Hawkins, M; Liu, R; Taub, R; Rossetti, L				Massillon, D; Chen, W; Barzilai, N; Prus-Wertheimer, D; Hawkins, M; Liu, R; Taub, R; Rossetti, L			Carbon flux via the pentose phosphate pathway regulates the hepatic expression of the glucose-6-phosphatase and phosphoenolpyruvate carboxykinase genes in conscious rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STORAGE-DISEASE TYPE-1A; ACID-SYNTHASE GENE; DIABETIC RATS; LIVER GLUCOSE-6-PHOSPHATASE; MICROSOMAL GLUCOSE-6-PHOSPHATASE; GLUCOSE-PRODUCTION; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; FRUCTOSE 2,6-BISPHOSPHATE; ENZYME-DEFICIENT	Hepatic gene expression of P-enolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (Glc-6-Pase) is regulated in response to changes in the availability of substrates, in particular glucose (Glc; Massillon, D., Barzilai, N., Chen, W., Hu, M., and Rossetti, L., (1996) J. Biol. Chem. 271, 9871-9874). We investigated the mechanism(s) in conscious rats. Hyperglycemia per se caused a rapid and marked increase in Glc-6-Pase mRNA abun dance and protein levels. By contrast, hyperglycemia decreased the abundance of PEPCK mRNA, Importantly, inhibition of glucokinase activity by glucosamine infusion blunted both the stimulation of Glc-6-Pase and the inhibition of PEPCK gene expression by Glc, suggesting that an intrahepatic signal (metabolite) generated by the metabolism of glucose at or beyond Glc-6-P was responsible for the regulatory effect of Glc. The effect of Glc on the L-type pyruvate kinase gene is mediated by xylulose-5-P (Doiron, B., Cuif, M., Chen, R., and Kahn, A. (1996) J. Biol. Chem. 271, 5321-5324). Thus, we next investigated whether an isolated increase in the hepatic concentration of this metabolite can also reproduce the effects of Glc on Glc-6-Pase and PEPCK gene expression in vivo. Xylitol, which is directly converted to xylulose-5-P in the liver, was infused to raise the hepatic concentration of xylulose-5-P by similar to 3-fold. Xylitol infusion did not alter the levels of Glc-6-P and of fructose-2,6-biphosphate. However, it replicated the effects of hyperglycemia on Glc-6-Pase and PEPCK gene expression and resulted in a 75% increase in the in vivo flu through Glc-6-Pase (total glucose output).	Yeshiva Univ Albert Einstein Coll Med, Ctr Diabet Res & Training, Bronx, NY 10461 USA; Univ Penn, Sch Med, Ctr Human Genet, Philadelphia, PA 19104 USA	Yeshiva University; Albert Einstein College of Medicine; University of Pennsylvania	Rossetti, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Endocrinol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020541, R37DK048321, R29DK045024, P60DK020541, R01DK045024, R01DK048321] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 45024, DK 20541, DK 48321] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; Argaud D, 1997, J BIOL CHEM, V272, P12854, DOI 10.1074/jbc.272.19.12854; ARION WJ, 1980, J BIOL CHEM, V255, P396; BALKAN B, 1994, DIABETES, V43, P1173, DOI 10.2337/diabetes.43.10.1173; BARZILAI N, 1995, BIOCHEM J, V310, P819, DOI 10.1042/bj3100819; Barzilai N, 1996, DIABETES, V45, P1329, DOI 10.2337/diabetes.45.10.1329; BARZILAI N, 1993, J BIOL CHEM, V268, P25019; BURCHELL A, 1985, DIABETOLOGIA, V28, P852, DOI 10.1007/BF00291077; CASAZZA JP, 1986, ANAL BIOCHEM, V159, P243, DOI 10.1016/0003-2697(86)90338-6; CASAZZA JP, 1986, J BIOL CHEM, V261, P690; COUNTAWAY JL, 1988, J BIOL CHEM, V263, P2673; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; Foufelle F, 1996, ADV ENZYME REGUL, V36, P199, DOI 10.1016/0065-2571(95)00010-0; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; GLINSMANN WH, 1969, AM J PHYSIOL, V216, P698, DOI 10.1152/ajplegacy.1969.216.4.698; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; LEI KJ, 1995, J BIOL CHEM, V270, P11882, DOI 10.1074/jbc.270.20.11882; LEI KJ, 1993, SCIENCE, V262, P580, DOI 10.1126/science.8211187; Liu YQ, 1996, J BIOL CHEM, V271, P8824, DOI 10.1074/jbc.271.15.8824; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; ROSSETTI L, 1987, J CLIN INVEST, V79, P1510, DOI 10.1172/JCI112981; SACCA L, 1978, J CLIN ENDOCR METAB, V47, P1160, DOI 10.1210/jcem-47-5-1160; Schmoll D, 1996, FEBS LETT, V383, P63, DOI 10.1016/0014-5793(96)00224-4; SHELLY LL, 1993, J BIOL CHEM, V268, P21482; SHULMAN GI, 1978, J CLIN INVEST, V62, P487, DOI 10.1172/JCI109150; SHULMAN GI, 1980, J CLIN INVEST, V65, P496, DOI 10.1172/JCI109693; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; VANDEWERVE G, 1989, J BIOL CHEM, V264, P6033; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; VANSCHAFTINGEN E, 1995, BIOCHEM J, V308, P23, DOI 10.1042/bj3080023; VAULONT S, 1986, J BIOL CHEM, V261, P7621	49	74	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					228	234		10.1074/jbc.273.1.228	http://dx.doi.org/10.1074/jbc.273.1.228			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417069	hybrid			2022-12-25	WOS:000071295600035
J	Moscatello, DK; Holgado-Madruga, M; Emlet, DR; Montgomery, RB; Wong, AJ				Moscatello, DK; Holgado-Madruga, M; Emlet, DR; Montgomery, RB; Wong, AJ			Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFERS ENHANCED TUMORIGENICITY; EGFR GENE AMPLIFICATION; HUMAN GLIOBLASTOMA; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASES; CELLS; PROTEIN; PHOSPHORYLATION; TRANSFORMATION; EXPRESSION	The most frequently found alteration of the epidermal growth factor receptor (EGFR) in human tumors is a deletion of exons 2-7. This receptor, termed EGFRvIII, can transform NIH 3T3 cells, and the frequent expression of this variant implies that it confers a selective advantage upon tumor cells in vivo. Although EGFRvIII is a constitutively activated tyrosine kinase, there is no increase in Ras GTP levels and low levels of mitogen-activated protein kinase activity in NIH 3T3 cells expressing this variant. We investigated whether phosphatidylinositol (PI) 3-kinase was an effector in transformation by the EGFRvIII. High levels of PI 3-kinase activity were constitutively present in EGFRVIII-transformed cells and were dependent upon the kinase activity of the receptor. While mitogen-activated protein kinase activity was quickly down-regulated to basal levels after 12 h of continuous EGFR activation, there was a 3-fold increase in PI 3-kinase activity in cells expressing normal EGFR and an 8-fold increase in cells expressing EGFRvIII after 48 h. This increased activity may reflect enhanced binding to EGFRvIII and the presence of novel PI 3-kinase isoforms. Treatment with the PI 3-kinase inhibitors wortmannin and LY294002 blocked both anchorage-independent growth and growth in low serum media and also resulted in morphological reversion of EGFRvIII-transformed cells. These results support an essential role for PI 3-kinase in transformation by this EGFR variant.	Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Seattle Vet Adm Med Ctr, Div Oncol, Seattle, WA 98108 USA	Jefferson University; Jefferson University	Wong, AJ (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA069495, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034514] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09678, CA 69495] Funding Source: Medline; NINDS NIH HHS [NS34514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; Han YC, 1996, CANCER RES, V56, P3859; HARRIS AL, 1992, NATL CANC I MONOGR, V11, P181; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Moscatello DK, 1996, ONCOGENE, V13, P85; Nagane M, 1996, CANCER RES, V56, P5079; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; Panaretou C, 1997, J BIOL CHEM, V272, P2477; Parrizas M, 1997, J BIOL CHEM, V272, P154; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHWECHHEIMER K, 1995, INT J CANCER, V62, P145, DOI 10.1002/ijc.2910620206; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WICKSTRAND CJ, 1995, CANCER RES, V51, P3140; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; Yao R, 1996, ONCOGENE, V13, P343	41	258	276	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					200	206		10.1074/jbc.273.1.200	http://dx.doi.org/10.1074/jbc.273.1.200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417065	hybrid			2022-12-25	WOS:000071295600031
J	Savino, G; Briat, JF; Lobreaux, S				Savino, G; Briat, JF; Lobreaux, S			Inhibition of the iron-induced ZmFer1 maize ferritin gene expression by antioxidants and serine/threonine phosphatase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPZ PROTEIN PHOSPHATASES; MAP KINASE CASCADE; MESSENGER-RNA; OXIDATIVE STRESS; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; OKADAIC ACID; YEAST-CELLS; SIGNAL-TRANSDUCTION; NITRIC-OXIDE	Two pathways have been implicated in the regulation of maize ferritin synthesis in response to iron. One of them involves the plant hormone abscisic acid (ABA) and controls the expression of ZmFer2 gene(s). Another pathway, ABA-independent, has been characterized in a de-rooted maize plantlet system and involves an oxidative step, The ZmFer1 maize ferritin gene is not regulated by ABA, and it is shown in this paper that the corresponding mRNA accumulates in de-rooted maize plantlets and EMS (Black Mexican Sweet) maize cell suspension cultures in response to iron via the oxidative pathway described previously. To investigate ZmFer1 gene regulation further, the EMS cell system has been used to develop a transient expression assay using a ZmFer1-beta-glucuronidase fusion, Both iron induction and antioxidant inhibition of ZmFer1 gene expression were observed in this system. Using Northern blot analysis and transient expression experiments, it was shown that both okadaic acid and calyculin A, two serine/threonine phosphatase inhibitors, specifically inhibit ZmFer1 gene expression, These data indicate that an okadaic acid-sensitive protein phosphatase activity is involved in the regulation of the ZmFer1 ferritin gene in maize cells, and this activity is required for iron-induced expression of this gene.	INRA, ENSA, Lab Biochim & Physiol Mol Plantes, CNRS,Unite Rech 2133, F-34060 Montpellier 1, France	INRAE; Institut Agro; Montpellier SupAgro; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lobreaux, S (corresponding author), INRA, ENSA, Lab Biochim & Physiol Mol Plantes, CNRS,Unite Rech 2133, 2 Pl Viala, F-34060 Montpellier 1, France.							Bertauche N, 1996, EUR J BIOCHEM, V241, P193, DOI 10.1111/j.1432-1033.1996.0193t.x; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; CAUSSE M, 1994, MAIZE GENET COOP NEW, V68, P42; Chandok MR, 1996, MOL GEN GENET, V251, P599, DOI 10.1007/BF02173650; Christensen AH, 1996, TRANSGENIC RES, V5, P213, DOI 10.1007/BF01969712; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRICHTON RR, 1971, BIOCHIM BIOPHYS ACTA, V229, P75, DOI 10.1016/0005-2795(71)90320-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIX DJ, 1993, J MOL BIOL, V231, P230, DOI 10.1006/jmbi.1993.1278; DOMINOV JA, 1992, PLANT CELL, V4, P451, DOI 10.1105/tpc.4.4.451; DRYSDALE JW, 1975, BIOCHIM BIOPHYS ACTA, V383, P97, DOI 10.1016/0005-2787(75)90250-6; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; Gaymard F, 1996, BIOCHEM J, V318, P67, DOI 10.1042/bj3180067; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; HALLIWELL B, 1988, ATLAS SCI BIOCH, P48; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P87; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HUBER JLA, 1992, BIOCHEM J, V283, P877, DOI 10.1042/bj2830877; Jonak C, 1996, P NATL ACAD SCI USA, V93, P11274, DOI 10.1073/pnas.93.20.11274; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KIMATA Y, 1994, PLANT PHYSIOL, V104, P263, DOI 10.1104/pp.104.1.263; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; LAULHERE JP, 1988, J BIOL CHEM, V263, P10289; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LESCURE AM, 1990, BIOCHEM J, V272, P147, DOI 10.1042/bj2720147; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; LI WW, 1994, PLANT PHYSIOL, V106, P963, DOI 10.1104/pp.106.3.963; LOBREAUX S, 1993, EMBO J, V12, P651, DOI 10.1002/j.1460-2075.1993.tb05698.x; LOBREAUX S, 1995, PLANT J, V8, P443, DOI 10.1046/j.1365-313X.1995.08030443.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; LOBREAUX S, 1992, BIOCHEM J, V288, P931, DOI 10.1042/bj2880931; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; MACKINTOSH C, 1991, BIOCHEM J, V273, P733, DOI 10.1042/bj2730733; MACKINTOSH C, 1989, BIOCHEM J, V262, P335, DOI 10.1042/bj2620335; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; Mendoza I, 1996, J BIOL CHEM, V271, P23061, DOI 10.1074/jbc.271.38.23061; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; POSAS F, 1995, J BIOL CHEM, V270, P13036, DOI 10.1074/jbc.270.22.13036; POSAS F, 1993, FEBS LETT, V318, P282, DOI 10.1016/0014-5793(93)80529-4; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; RAZAFIMAHATRATRA P, 1991, NUCLEIC ACIDS RES, V19, P1491, DOI 10.1093/nar/19.7.1491; Rosen K., 1990, FOCUS, V12, P23; ROTHENBERGER S, 1990, NUCLEIC ACIDS RES, V18, P1175, DOI 10.1093/nar/18.5.1175; RUNDLE SJ, 1993, PLANT PHYSIOL, V103, P1165, DOI 10.1104/pp.103.4.1165; SADHU C, 1988, BIOTECHNIQUES, V6, P20; Sambrook J., 2002, MOL CLONING LAB MANU; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIEGL G, 1990, FEBS LETT, V270, P198, DOI 10.1016/0014-5793(90)81267-R; Smith RD, 1996, ANNU REV PLANT PHYS, V47, P101, DOI 10.1146/annurev.arplant.47.1.101; SPENCE MJ, 1991, PLANT MOL BIOL, V17, P499, DOI 10.1007/BF00040644; SUTY L, 1993, PLANT SCI, V90, P11, DOI 10.1016/0168-9452(93)90151-O; THEIL G, 1994, PLANT J, V5, P523; THOMSON AJ, 1992, J INORG BIOCHEM, V47, P197, DOI 10.1016/0162-0134(92)84065-U; Vansuyt G, 1997, FEBS LETT, V410, P195, DOI 10.1016/S0014-5793(97)00587-5; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; VILE GF, 1993, J BIOL CHEM, V268, P14678; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; WOLNIAK SM, 1992, J CELL SCI, V102, P691; ZHANG K, 1992, PLANT CELL PHYSIOL, V33, P677; ZIMMERMANN S, 1994, PLANT J, V6, P707, DOI 10.1046/j.1365-313X.1994.6050707.x	75	42	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33319	33326		10.1074/jbc.272.52.33319	http://dx.doi.org/10.1074/jbc.272.52.33319			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407124	hybrid			2022-12-25	WOS:000071182900085
J	Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP				Gaozza, E; Baker, SJ; Vora, RK; Reddy, EP			AATYK: A novel tyrosine kinase induced during growth arrest and apoptosis of myeloid cells	ONCOGENE			English	Article						AATYK; apoptosis; differentiation; SH3 binding motifs; tyrosine kinase; myeloid cells	GRANULOCYTIC DIFFERENTIATION; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; CONSERVED FEATURES; SIGNALING PROTEINS; LINE; EXPRESSION; DEATH; GENE; INTERLEUKIN-3	Apoptosis, or programmed cell death, is a process where developmental or environmental stimuli activate a genetic program to implement a series of events that culminate in cell death, To study the nature of genes that are induced during the apoptotic death of myeloid precursor cells. we utilized the 32Dc13 cell line, which is derived from normal mouse bone marrow, is non-tumorigenic and diploid, These cells are strictly dependent on IL-3 for growth and apoptose when deprived of IL-3, However, when these cells are transferred to medium containing G-CSF, the cell number increases 3-5-fold and after 12 days the entire population is differentiated into granulocytes followed by apoptotic death, In our search for genes that are induced during apoptosis and/or terminal differentiation of 32Dc13 cells, we identified a novel gene termed AATYK (Apoptosis Associated Tyrosine Kinase), whose expression is dramatically upregulated during IL-3 deprivation as well as G-CSF-induced terminal differentiation. In this report, we describe the sequence of the cDNA clone, derived from the mRNA transcript of this gene, These studies show that this gene encodes a protein with a tyrosine kinase domain at the N-terminal end and a proline-rich domain at the C-terminal end, We also report that the expression of this gene is blocked in v-abl or bcr-abl transformed myeloid cells which are unable to apoptose when grown in the absence of IL-3, However, AATYK expression is induced in 32D cells transformed by the v-abl gene when these cells are incubated in the presence of DMSO, which induces growth arrest and apoptotic death of the cells, On the other hand, DMSO fails to induce apoptosis or AATYK expression in 32D cells transformed by the bcr-abl oncogene, suggesting that AATYK expression may be a necessary pre-requisite for the induction of growth arrest and/or apoptosis of myeloid precursor cells.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER; NCI NIH HHS [CA68239] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Chivers PT, 1996, EMBO J, V15, P2659, DOI 10.1002/j.1460-2075.1996.tb00626.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COTTER TG, 1994, IMMUNOL REV, V142, P93, DOI 10.1111/j.1600-065X.1994.tb00884.x; GORDON N, 1995, BRAIN DEV-JPN, V17, P73, DOI 10.1016/0387-7604(94)00109-B; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HOFFMAN B, 1994, ONCOGENE, V9, P1807; Ishino M, 1995, ONCOGENE, V11, P2331; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KREIDER BL, 1990, MOL CELL BIOL, V131, P227; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANEUVILLE P, 1991, ONCOGENE, V6, P275; Lung CC, 1996, TRENDS GENET, V12, P389, DOI 10.1016/S0168-9525(96)90093-1; METTUS RV, 1994, ONCOGENE, V9, P3077; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OGAWA M, 1993, BLOOD, V81, P2844; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; RANE SG, 1994, ONCOGENE, V9, P2415; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROVERA G, 1987, ONCOGENE, V1, P29; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Sieff C A, 1994, Curr Opin Hematol, V1, P310; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; VALTIERI M, 1987, J IMMUNOL, V138, P3829; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0; Yuan JY, 1996, J CELL BIOCHEM, V60, P4, DOI 10.1002/(SICI)1097-4644(19960101)60:1<4::AID-JCB2>3.0.CO;2-1; Zhu JY, 1996, BLOOD, V87, P4368, DOI 10.1182/blood.V87.10.4368.bloodjournal87104368	41	61	62	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3127	3135		10.1038/sj.onc.1201575	http://dx.doi.org/10.1038/sj.onc.1201575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444961				2022-12-25	WOS:000070968000013
J	Bultmann, H; Santas, AJ; Peters, DMP				Bultmann, H; Santas, AJ; Peters, DMP			Fibronectin fibrillogenesis involves the heparin II binding domain of fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN FIBROBLAST-CULTURES; STAPHYLOCOCCUS-AUREUS; EXTRACELLULAR-MATRIX; CELLULAR-FIBRONECTIN; RECEPTOR; LOCALIZATION; SITE; FIBRILS; ANTIBODIES; ADHESION	Fibronectin matrix assembly is thought to involve binding interactions between the amino-terminal I1-5 repeats and the first type III repeat (III1). Here we report that a third site, located within the III12-14 repeats of the carboxyl-terminal heparin II domain of fibronectin, is also involved in fibrillogenesis. Heparin II fragments inhibited fibril formation and binding of I-125-labeled fibronectin and/or 70-kDa fragments to the cell surface, deoxycholate-insoluble matrix, and adsorbed 160-kDa cell adhesion fragments of fibronectin. The inhibitory effects of heparin II fragments were as large or up to 20 times larger than those of a 44-kDa fibronectin fragment containing the III1 repeat. Under physiological conditions, amino-terminal fragments of fibronectin containing the I1-5 repeats interacted preferentially with proteolytically derived heparin II fragments and a recombinant III12-14 peptide both in solution and in solid phase, indicating that matrix assembly may involve direct interactions between I1-5 and III12-14 repeats. Interactions between the I1-5 repeats and 160-kDa fragments containing the III12-14 and III1 repeats could be inhibited by greater than or equal to 90% by either an anti-III13-14 monoclonal antibody (mAb) (IST-S) or an anti-III1 mAb (9D2), suggesting that cooperative interactions between III12-14 and III1 repeats may also promote binding of the I1-5 repeats. Neither mAb IST-2 nor mAb 9D2, alone or in combination, inhibited binding of I-125-labeled 70-kDa fragments to cycloheximide treated cells plated on the 160-kDa substrate, suggesting that additional I1-5 binding sites, independent of the III1 and III12-14 repeats, may be involved in fibrillogenesis.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Peters, DMP (corresponding author), Univ Wisconsin, Dept Pathol, Rm 6590 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Santas, Amy/F-5532-2013	Santas, Amy/0000-0001-8342-9969	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047221] Funding Source: NIH RePORTER; NEI NIH HHS [EY0850] Funding Source: Medline; NIGMS NIH HHS [GM47221] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARKALOW FJB, 1991, J BIOL CHEM, V266, P7812; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; CHERNOUSOV MA, 1991, J BIOL CHEM, V266, P10851; DUFOUR S, 1991, EXP CELL RES, V193, P331, DOI 10.1016/0014-4827(91)90104-3; DZAMBA BJ, 1991, J CELL SCI, V100, P605; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ERICKSON HP, 1994, P NATL ACAD SCI USA, V91, P10114, DOI 10.1073/pnas.91.21.10114; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HOEKING DC, 1996, J CELL BIOL, V133, P431; HOMANDBERG GA, 1986, BIOCHEMISTRY-US, V25, P6917, DOI 10.1021/bi00370a027; Hynes R. O., 1989, FIBRONECTINS; Ingham KC, 1997, J BIOL CHEM, V272, P1718, DOI 10.1074/jbc.272.3.1718; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MORLA A, 1992, J CELL BIOL, V118, P421, DOI 10.1083/jcb.118.2.421; MOSHER DF, 1993, CURR OPIN STRUC BIOL, V3, P214, DOI 10.1016/S0959-440X(05)80155-1; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Mosher DF, 1989, FIBRONECTIN; Peters D. M. P., 1994, EXTRACELLULAR MATRIX, P315; Peters DM, 1996, INVEST OPHTH VIS SCI, V37, P2047; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; PETERS DMP, 1990, J CELL BIOL, V111, P249, DOI 10.1083/jcb.111.1.249; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; Sambrook J., 2002, MOL CLONING LAB MANU; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; SOTTILE J, 1991, J BIOL CHEM, V266, P12840; UGAROVA TP, 1995, BIOCHEMISTRY-US, V34, P4457, DOI 10.1021/bi00013a039; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1	45	84	87	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2601	2609		10.1074/jbc.273.5.2601	http://dx.doi.org/10.1074/jbc.273.5.2601			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446562	hybrid			2022-12-25	WOS:000071736600017
J	Kone, BC; Higham, SC				Kone, BC; Higham, SC			A novel N-terminal splice variant of the rat H+-K+-ATPase alpha 2 subunit - Cloning, functional expression, and renal adaptive response to chronic hypokalemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE POTASSIUM ABSORPTION; MESSENGER-RNA EXPRESSION; DISTAL COLON; ADENOSINE-TRIPHOSPHATASE; GASTRIC H,K-ATPASE; MOLECULAR-CLONING; BINDING PROTEINS; GENE; SEQUENCES; CDNA	The H+-K+-ATPase of renal collecting duct mediates K+ conservation during chronic hypokalemia, K+ deprivation promotes H+-K+-ATPase alpha 2 (HK alpha 2) gene expression in the medullary collecting duct, the principal site of active K+ reabsorption, suggesting that this isozyme contributes to renal K+ reclamation, We report here that alternative transcriptional initiation and mRNA splicing give rise to distinct N-terminal variants of the HK alpha 2 subunit, Sequence analysis and in vitro translation revealed that HK alpha 2a corresponds to the known HK alpha 2 cDNA (Crowson, M. S., and Shull, G. E. (1992) J. Biol. Chem. 267, 13740-13748), whereas HK alpha 2b represents a novel variant truncated by 108 amino acids at its N terminus, HK alpha 2b mRNA contains a complex 5'-untranslated region with eight upstream open reading frames, features implicated in translational regulation of other genes, Heterologous expression of HK alpha 2b with and without the gastric H+-K+-ATPase beta subunit in HEK 293 cells indicated that this variant encodes a KC uptake mechanism that is relatively Sch 28080-resistant, partially sensitive to ouabain, and appears to require coexpression with the gastric H+-K+-ATPase beta subunit for optimal functional activity, Northern analysis demonstrated that both subtypes (HK alpha 2b > HK alpha 2a) are expressed abundantly in distal colon and modestly in proximal colon and kidney, Moreover, the abundance of the two mRNAs increases coordinately among the renal zones, but not in colon, with chronic K+ deprivation. These results demonstrate the potential for complex control of HK alpha 2 gene expression by transcriptional and posttranscriptional mechanisms not recognized in other members of the Na+-K+-ATPase/H+-K+-ATPase family.	Univ Texas, Sch Med, Dept Internal Med, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Physiol, Houston, TX 77030 USA	University of Texas System; University of Texas System; University of Texas System; University of Texas System	Kone, BC (corresponding author), Univ Texas, Sch Med, Dept Internal Med, 6431 Fannin,MSB 4-148, Houston, TX 77030 USA.	bkone@heart.med.uth.tmc.edu			NIDDK NIH HHS [1R01 DK50745, 1R29 DK47981] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050745, R29DK047981] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahn KY, 1996, AM J PHYSIOL-RENAL, V271, pF314, DOI 10.1152/ajprenal.1996.271.2.F314; AHN KY, 1996, AM J PHYSIOL, V270, pF577; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; BuffinMeyer B, 1997, AM J PHYSIOL-RENAL, V272, pF124, DOI 10.1152/ajprenal.1997.272.1.F124; Codina J, 1996, J BIOL CHEM, V271, P29759, DOI 10.1074/jbc.271.47.29759; COSTA RH, 1988, P NATL ACAD SCI USA, V85, P3840, DOI 10.1073/pnas.85.11.3840; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; CROWSON MS, 1992, J BIOL CHEM, V267, P13740; DALY SE, 1994, J BIOL CHEM, V269, P23944; DELCASTILLO JR, 1991, AM J PHYSIOL, V261, pG1005, DOI 10.1152/ajpgi.1991.261.6.G1005; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; FELDMAN GM, 1997, AM J PHYSIOL, V272, pF59; FOSTER ES, 1986, AM J PHYSIOL, V251, pG619, DOI 10.1152/ajpgi.1986.251.5.G619; GRISHIN AV, 1994, FEBS LETT, V349, P144, DOI 10.1016/0014-5793(94)00655-5; GRISHIN AV, 1996, AM J PHYSIOL, V271, pC992; Jaisser F, 1996, AM J PHYSIOL-CELL PH, V270, pC679, DOI 10.1152/ajpcell.1996.270.2.C679; Kone BC, 1996, MINER ELECTROL METAB, V22, P349; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kuwahara M, 1996, AM J PHYSIOL-RENAL, V270, pF116, DOI 10.1152/ajprenal.1996.270.1.F116; LEE JS, 1995, J CLIN INVEST, V96, P2002, DOI 10.1172/JCI118247; Maeda M, 1996, J EXP BIOL, V199, P513; Marsy S, 1996, PFLUG ARCH EUR J PHY, V432, P494, DOI 10.1007/s004240050161; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MODYANOV NN, 1995, AM J PHYSIOL-CELL PH, V269, pC992, DOI 10.1152/ajpcell.1995.269.4.C992; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURAOKA A, 1984, GASTROENTEROLOGY, V106, P145; NEWMAN PR, 1990, DNA CELL BIOL, V9, P749, DOI 10.1089/dna.1990.9.749; OKUSA MD, 1992, AM J PHYSIOL, V262, pF488, DOI 10.1152/ajprenal.1992.262.3.F488; RATHJEN PD, 1990, CELL, V62, P1105, DOI 10.1016/0092-8674(90)90387-T; REESE MG, 1996, P PAC S BIOC KON HI; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SHAMRAJ OI, 1994, P NATL ACAD SCI USA, V91, P12952, DOI 10.1073/pnas.91.26.12952; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sverdlov VE, 1996, GENOMICS, V32, P317, DOI 10.1006/geno.1996.0125; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WALL SM, 1996, AM J PHYSIOL, V270, pR1037; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WINGO CS, 1989, J CLIN INVEST, V84, P361, DOI 10.1172/JCI114165; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; YOUNESIBRAHIM M, 1995, AM J PHYSIOL-RENAL, V268, pF1141, DOI 10.1152/ajprenal.1995.268.6.F1141; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111; [No title captured]	53	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2543	2552		10.1074/jbc.273.5.2543	http://dx.doi.org/10.1074/jbc.273.5.2543			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446555	hybrid			2022-12-25	WOS:000071736600010
J	Peter, H; Burkovski, A; Kramer, R				Peter, H; Burkovski, A; Kramer, R			Osmo-sensing by N- and C-terminal extensions of the glycine betaine uptake system BetP of Corynebacterium glutamicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL-ANESTHETIC TETRACAINE; ESCHERICHIA-COLI; TRANSPORT-SYSTEM; SALMONELLA-TYPHIMURIUM; HYPEROSMOTIC SHIFT; GENE; OSMOREGULATION; EXPRESSION; CELLS; PROU	The major uptake carrier for the compatible solute glycine betaine in Corynebacterium glutamicum is the secondary transport system BetP. It is effectively regulated by the external osmolality both on the level of expression and of activity. BetP carries highly charged domains both at the N and at the C terminus. We investigated the role of these extensions in the regulatory response to hyperosmotic stress. Mutants of the betP gene coding for proteins with truncated N- and C-terminal extensions were expressed in the C. glutamicum betP deletion strain DHP1 and were functionally characterized with respect to regulation of activity. The optimum of activation at 1.3 osmol/kg in wild type was shifted in the recombinant strains to about 2.6 osmol/kg in mutants with deletions in the N-terminal part. Deletions in the C-terminal domain resulted in a complete loss of regulation, The altered response to changes in osmolality led to severe consequences in the cellular adaption to hyperosmotic stress. Whereas in the wild type, the steady state level of glycine betaine accumulation is maintained by activity regulation of the BetP system itself, in the mutant with BetP proteins carrying truncations in the C-terminal domain, the observed steady state betaine accumulation was found to be due to a kinetic balance of unregulated glycine betaine uptake by the modifed BetP and efflux via the mechanosensitive efflux channel for compatible solutes at the same time.	Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Helmholtz Association; Research Center Julich	Kramer, R (corresponding author), Univ Cologne, Inst Biochem, Zulpicher Str 47, D-50674 Cologne, Germany.	r.kramer@uni-koeln.de		Burkovski, Andreas/0000-0003-1896-4521				ABE S, 1967, J GEN APPL MICROBIOL, V13, P279, DOI 10.2323/jgam.13.279; BOTTNER M, 1993, BIOPHYS J, V65, P2041, DOI 10.1016/S0006-3495(93)81254-2; CAIRNEY J, 1985, J BACTERIOL, V164, P1218, DOI 10.1128/JB.164.3.1218-1223.1985; CAIRNEY J, 1985, J BACTERIOL, V164, P1224, DOI 10.1128/JB.164.3.1224-1232.1985; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; EIKMANNS BJ, 1994, MICROBIOL-SGM, V140, P1817, DOI 10.1099/13500872-140-8-1817; FARWICK M, 1995, J BACTERIOL, V177, P4690, DOI 10.1128/jb.177.16.4690-4695.1995; Glaasker E, 1996, J BIOL CHEM, V271, P10060, DOI 10.1074/jbc.271.17.10060; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GROTHE S, 1986, J BACTERIOL, V166, P253, DOI 10.1128/jb.166.1.253-259.1986; HORNBY AP, 1981, BIOCHIM BIOPHYS ACTA, V647, P285, DOI 10.1016/0005-2736(81)90256-X; Kappes RM, 1996, J BACTERIOL, V178, P5071, DOI 10.1128/jb.178.17.5071-5079.1996; KEMPF B, 1995, J BIOL CHEM, V270, P16701, DOI 10.1074/jbc.270.28.16701; LAMARK T, 1991, MOL MICROBIOL, V5, P1049, DOI 10.1111/j.1365-2958.1991.tb01877.x; LAMBERT C, 1995, APPL ENVIRON MICROB, V61, P4334, DOI 10.1128/AEM.61.12.4334-4342.1995; LANDFALD B, 1986, J BACTERIOL, V165, P849, DOI 10.1128/jb.165.3.849-855.1986; LIEBL W, 1989, FEMS MICROBIOL LETT, V65, P299, DOI 10.1016/0378-1097(89)90234-6; LIN YM, 1995, J BACTERIOL, V177, P6874, DOI 10.1128/jb.177.23.6874-6880.1995; LUCHT JM, 1994, FEMS MICROBIOL REV, V14, P3, DOI 10.1016/0168-6445(94)90008-6; Maniatis T., 1982, MOL CLONING LAB MANU; MILNER JL, 1988, J BIOL CHEM, V263, P14900; Peter H, 1997, ARCH MICROBIOL, V168, P143, DOI 10.1007/s002030050480; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; Ruffert S, 1997, EUR J BIOCHEM, V247, P572, DOI 10.1111/j.1432-1033.1997.00572.x; SHIMOOKA T, 1992, BIOCHIM BIOPHYS ACTA, V1104, P261, DOI 10.1016/0005-2736(92)90039-O; SUGIURA A, 1994, MOL MICROBIOL, V14, P929, DOI 10.1111/j.1365-2958.1994.tb01328.x; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANTZEY PH, 1982, SCIENCE, V217, P1214; ZIMMANN P, 1995, J BIOL CHEM, V270, P28282	32	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2567	2574		10.1074/jbc.273.5.2567	http://dx.doi.org/10.1074/jbc.273.5.2567			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446558	hybrid			2022-12-25	WOS:000071736600013
J	Daniel, JL; Dangelmaier, C; Jin, JG; Ashby, B; Smith, JB; Kunapuli, SP				Daniel, JL; Dangelmaier, C; Jin, JG; Ashby, B; Smith, JB; Kunapuli, SP			Molecular basis for ADP-induced platelet activation I. Evidence for three distinct ADP receptors on human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FURA-2-LOADED HUMAN-PLATELETS; ADENYLATE-CYCLASE; INOSITOL 1,4,5-TRISPHOSPHATE; NUCLEOTIDE-BINDING; PHOSPHOLIPASE-C; CALCIUM; PURINOCEPTORS; METABOLISM; CELLS; AGGREGATION	Acting through cell surface receptors, ADP activates platelets resulting in shape change, aggregation, thromboxane A(2) production, and release of granule contents, ADP also causes a number of intracellular events including inhibition of adenylyl cyclase, mobilization of calcium from intracellular stores, and rapid calcium influx in platelets, However, the receptors that transduce these events remain unidentified and their molecular mechanisms of action have not been elucidated. The receptor responsible for the actions of ADP On platelets has been designated the P2T receptor, In this study we have used ARL 66096, a potent antagonist of ADP-induced platelet aggregation, and a P2X ionotropic receptor agonist, alpha,beta-methylene adenosine 5'-triphosphate, to distinguish the ADP-induced intracellular events, ARL 66096 blocked ADP-induced inhibition of adenylyl cyclase, but did not affect ADP-mediated intracellular calcium increases or shape change, Both ADP and 2-methylthio-ADP caused a 3-fold increase in the level of inositol 1,4,5-trisphosphate over control levels which peaked in a similar fashion to the Ca2+ transient. The increase in inositol 1,3,4-trisphosphate was of similar magnitude to that of inositol 1,4,5-trisphosphate. alpha,beta-Methylene adenosine 5'-triphosphate did not cause an increase in either of the inositol trisphosphates. These results clearly demonstrate the presence of two distinct platelet ADP receptors in addition to the P2X receptor: one coupled to adenylyl cyclase and the other coupled to mobilization of calcium from intracellular stores through inositol trisphosphates.	Temple Univ, Dept Physiol, Sch Med, Philadelphia, PA 19150 USA; Temple Univ, Dept Pharmacol, Sch Med, Philadelphia, PA 19150 USA; Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19150 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Daniel, JL (corresponding author), Temple Univ, Dept Physiol, Sch Med, 3420 Broad St, Philadelphia, PA 19150 USA.	kunapuli@sgi1.fels.temple.edu			NHLBI NIH HHS [R01-HL48114] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048114] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akbar GK, 1996, J RECEPT SIGNAL TR R, V16, P209, DOI 10.3109/10799899609039949; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; COLMAN RW, 1992, NEWS PHYSIOL SCI, V7, P274; CUSACK NJ, 1982, BRIT J PHARMACOL, V76, P221, DOI 10.1111/j.1476-5381.1982.tb09210.x; DANIEL JL, 1987, BIOCHEM J, V246, P109, DOI 10.1042/bj2460109; DANIEL JL, 1986, FEBS LETT, V206, P299, DOI 10.1016/0014-5793(86)81000-6; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; FREDHOLM BB, 1997, TRENDS PHARMACOL SCI, V18, P43; GAARDER A., 1961, NATURE, V192, P531, DOI 10.1038/192531a0; Gachet C, 1997, THROMB HAEMOSTASIS, V78, P271; GACHET C, 1992, EUR J BIOCHEM, V207, P259, DOI 10.1111/j.1432-1033.1992.tb17046.x; GRECO NJ, 1995, BBA-BIOMEMBRANES, V1236, P142, DOI 10.1016/0005-2736(95)00038-5; HALLAM TJ, 1985, J PHYSIOL-LONDON, V368, P131, DOI 10.1113/jphysiol.1985.sp015850; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; HELLEM ARVID JOHN, 1960, SCAND JOUR CLIN AND LAB INVEST, V12, P1; HOLMSEN H, 1979, ANNU REV MED, V30, P119, DOI 10.1146/annurev.me.30.020179.001003; HOLMSEN H, 1970, BRIT J HAEMATOL, V19, P643, DOI 10.1111/j.1365-2141.1970.tb01648.x; HOURANI SMO, 1994, TRENDS PHARMACOL SCI, V15, P103, DOI 10.1016/0165-6147(94)90045-0; HUMPHRIES RG, 1994, BRIT J PHARMACOL, V113, P1057, DOI 10.1111/j.1476-5381.1994.tb17100.x; JANNSENS R, 1996, BIOCHEM BIOPH RES CO, V221, P588; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Leon C, 1997, FEBS LETT, V403, P26, DOI 10.1016/S0014-5793(97)00022-7; MACFARLANE DE, 1975, BLOOD, V46, P309; MacKenzie AB, 1996, J BIOL CHEM, V271, P2879, DOI 10.1074/jbc.271.6.2879; Mao GF, 1996, PROSTAGLANDINS, V52, P175, DOI 10.1016/S0090-6980(96)00095-0; MILLS DCB, 1968, J PHYSIOL-LONDON, V195, P715, DOI 10.1113/jphysiol.1968.sp008484; MILLS DCB, 1972, ANN NY ACAD SCI, V201, P391, DOI 10.1111/j.1749-6632.1972.tb16312.x; MILLS DCB, 1992, ARTERIOSCLER THROMB, V12, P430, DOI 10.1161/01.ATV.12.4.430; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; MURGO AJ, 1994, BLOOD, V83, P1258; NURDEN P, 1995, J CLIN INVEST, V95, P1612, DOI 10.1172/JCI117835; OLBRICH C, 1989, CELL SIGNAL, V1, P483, DOI 10.1016/0898-6568(89)90033-8; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; RAHA S, 1993, BIOCHEM J, V292, P643, DOI 10.1042/bj2920643; SAGE SO, 1986, BIOCHEM BIOPH RES CO, V136, P1124, DOI 10.1016/0006-291X(86)90450-X; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Savi P, 1997, BRIT J HAEMATOL, V97, P185, DOI 10.1046/j.1365-2141.1997.d01-2132.x; Schachter JB, 1996, BRIT J PHARMACOL, V118, P167, DOI 10.1111/j.1476-5381.1996.tb15381.x; SHI XP, 1995, THROMB RES, V77, P235, DOI 10.1016/0049-3848(95)91611-N; VICKERS JD, 1990, EUR J BIOCHEM, V193, P521, DOI 10.1111/j.1432-1033.1990.tb19367.x; VICKERS JD, 1993, EUR J BIOCHEM, V216, P231, DOI 10.1111/j.1432-1033.1993.tb18137.x; VITTET D, 1992, EXP HEMATOL, V20, P1129	42	340	346	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2024	2029		10.1074/jbc.273.4.2024	http://dx.doi.org/10.1074/jbc.273.4.2024			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442039	hybrid			2022-12-25	WOS:000071595200028
J	Thurmond, DC; Goodridge, AG				Thurmond, DC; Goodridge, AG			Characterization of thyroid hormone response elements in the gene for chicken malic enzyme - Factors that influence triiodothyronine responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; DNA-BINDING DOMAIN; CO-REPRESSOR; TRANSCRIPTIONAL ACTIVATION; EMBRYO HEPATOCYTES; NUCLEAR RECEPTORS; DIRECT REPEATS; X RECEPTOR; HETERODIMERS; EXPRESSION	Transcription of the gene for malic enzyme in chick embryo hepatocytes is stimulated about 30-fold by triiodothyronine (T3), T3 responsiveness is mediated by seven direct repeat hexamers that resemble T3 response elements (T3REs); these elements are located far upstream in the 5'-flanking DNA (Hodnett, D. W., Fantozzzi, D. A., Thurmond, D. C., Klautky, S. A., MacPhee, K. G., Estrem, S. T., Xu, G., and Goodridge, A. G. (1996) Arch. Biochem. Biophys. 334, 309-324). In transiently transfected hepatocytes, single copies of six of these elements conferred varying degrees of T3 responsiveness to linked reporter genes, In gel electrophoretic mobility shift analyses, the T3REs bound retinoid X receptor (RXR)-T3 receptor (TR) heterodimers and non-RXR/TR factors present in nuclear extracts prepared from hepatocyte, Binding of the non-RXR/TR factors was specific to individual T3REs and was unaffected by antibodies to TR or RXR. Mutagenesis of binding sites for proteins specific for T3REs 2-5 altered binding of the proteins and T3 responsiveness, These factors appear to bind to and alter function of T3REs without binding directly to TR, differentiating their actions from other TR cofactors; they were tentatively characterized as co-repressors, inhibitors, and activators of T3RE function. Together with RXR and TR, they modulate T3 responsiveness of the gene for chicken malic enzyme.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Goodridge, AG (corresponding author), Ohio State Univ, Coll Biol Sci, 484 W 12th Ave, Columbus, OH 43210 USA.	goodridge.4@osu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021594, P30DK025295] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 25295, DK 21594] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold R, 1996, NUCLEIC ACIDS RES, V24, P2640, DOI 10.1093/nar/24.14.2640; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BAILLIE RA, 1993, J NUTR BIOCHEM, V4, P431, DOI 10.1016/0955-2863(93)90074-7; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BOGAZZI F, 1994, J BIOL CHEM, V269, P11683; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CONNOR H, 1995, J BIOL CHEM, V270, P15066, DOI 10.1074/jbc.270.25.15066; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DESAIYAJNIK V, 1993, MOL CELL BIOL, V13, P5057, DOI 10.1128/MCB.13.8.5057; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORMAN BM, 1992, MOL ENDOCRINOL, V6, P429, DOI 10.1210/me.6.3.429; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GOODRIDGE AG, 1968, BIOCHEM J, V108, P663, DOI 10.1042/bj1080663; GOODRIDGE AG, 1976, J BIOL CHEM, V251, P3027; HALLENBECK PL, 1992, P NATL ACAD SCI USA, V89, P5572, DOI 10.1073/pnas.89.12.5572; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Harbers M, 1996, NUCLEIC ACIDS RES, V24, P2252, DOI 10.1093/nar/24.12.2252; Hodnett DW, 1996, ARCH BIOCHEM BIOPHYS, V334, P309, DOI 10.1006/abbi.1996.0460; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Judelson C, 1996, J BIOL CHEM, V271, P10800, DOI 10.1074/jbc.271.18.10800; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEIDIG F, 1992, J BIOL CHEM, V267, P913; LENG XH, 1994, J BIOL CHEM, V269, P31436; LIU HC, 1994, MOL ENDOCRINOL, V8, P1021, DOI 10.1210/me.8.8.1021; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MADER S, 1993, EMBO J, V12, P5029, DOI 10.1002/j.1460-2075.1993.tb06196.x; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NORMAN MF, 1989, J BIOL CHEM, V264, P12063; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; PIEDRAFITA FJ, 1995, MOL ENDOCRINOL, V9, P563, DOI 10.1210/me.9.5.563; Rangan VS, 1996, J BIOL CHEM, V271, P2307, DOI 10.1074/jbc.271.4.2307; ROSEN ED, 1992, J BIOL CHEM, V267, P22010; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1989, ANNU REV PHYSIOL, V51, P623, DOI 10.1146/annurev.ph.51.030189.003203; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Tong GX, 1996, MOL CELL BIOL, V16, P1909; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YEN PM, 1992, J BIOL CHEM, V267, P23248	51	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1613	1622		10.1074/jbc.273.3.1613	http://dx.doi.org/10.1074/jbc.273.3.1613			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430703	hybrid			2022-12-25	WOS:000071411500050
J	Harper, JF; Hong, BM; Hwang, ID; Guo, HQ; Stoddard, R; Huang, JF; Palmgren, MG; Sze, H				Harper, JF; Hong, BM; Hwang, ID; Guo, HQ; Stoddard, R; Huang, JF; Palmgren, MG; Sze, H			A novel calmodulin-regulated Ca2+-ATPase (ACA2) from Arabidopsis with an N-terminal autoinhibitory domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; CA2+ PUMP; ENDOPLASMIC-RETICULUM; GENOMIC SEQUENCE; PROTEIN-KINASE; YEAST; BINDING; FAMILY	To study transporters involved in regulating intracellular Ca2+, we isolated a full-length cDNA encoding a Ca2+-ATPase from a model plant, Arabidopsis, and named it ACA2 (Arabidopsis Ca2+-ATPase, isoform 2). ACA2p is most similar to a "plasma membrane-type" Ca2+-ATPase, but is smaller (110 kDa), contains a unique N-terminal domain, and is missing a long C-terminal calmodulin-binding regulatory domain. In addition, ACA2p is localized to an endomembrane system and not the plasma membrane, as shown by aqueous-two phase fractionation of microsomal membranes. ACA2p was expressed in yeast as both a full-length protein (ACA2-1p) and an N-terminal truncation mutant (ACA2-2p; Delta residues 2-80). Only the truncation mutant restored the growth on Ca2+-depleted medium of a yeast mutant defective in both endogenous Ca2+ pumps, PMR1 and PMC1, Although basal Ca2+-ATPase activity of the full-length protein was low, it was stimulated 5-fold by calmodulin (50% activation around 30 nM). In contrast, the truncated pump was fully active and insensitive to calmodulin, A calmodulin binding sequence was identified within the first 36 residues of the N-terminal domain, as shown by calmodulin gel overlays on fusion proteins, Thus, ACA2 encodes a novel calmodulin-regulated Ca2+-ATPase distinguished by a unique N-terminal regulatory domain and a non-plasma membrane localization.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Maryland, Dept Plant Biol, College Pk, MD 20742 USA; Univ Copenhagen, Inst Mol Biol, DK-1353 Copenhagen K, Denmark	Scripps Research Institute; University System of Maryland; University of Maryland College Park; University of Copenhagen	Harper, JF (corresponding author), Scripps Res Inst, Dept Cell Biol, BCC283,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Harper@Scripps.edu	Palmgren, Michael/A-9808-2013	Palmgren, Michael/0000-0002-9982-6114				Askerlund P, 1996, PLANT PHYSIOL, V110, P913, DOI 10.1104/pp.110.3.913; ASKERLUND P, 1992, PLANT PHYSIOL, V100, P1670, DOI 10.1104/pp.100.4.1670; BAGINSKI ES, 1967, CLIN CHIM ACTA, V15, P155, DOI 10.1016/0009-8981(67)90340-3; BECKER DM, 1991, METHOD ENZYMOL, V194, P186; BOOTMAN MD, 1995, CELL, V83, P675, DOI 10.1016/0092-8674(95)90179-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Dainese P, 1997, EUR J BIOCHEM, V244, P31, DOI 10.1111/j.1432-1033.1997.00031.x; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; EVANS DE, 1994, PHYSIOL PLANTARUM, V90, P420, DOI 10.1111/j.1399-3054.1994.tb00408.x; FAGEN MJ, 1994, J MOL EVOL, V38, P57; Gill DL, 1996, BIOSCIENCE REP, V16, P139, DOI 10.1007/BF01206203; GILROY S, 1994, BIOESSAYS, V16, P677, DOI 10.1002/bies.950160914; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARPER JF, 1990, J BIOL CHEM, V265, P13601; HARPER JF, 1994, MOL GEN GENET, V244, P572, DOI 10.1007/BF00282747; HARPER JF, 1994, BIOCHEMISTRY-US, V33, P7267, DOI 10.1021/bi00189a031; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; Hirschi KD, 1996, P NATL ACAD SCI USA, V93, P8782, DOI 10.1073/pnas.93.16.8782; Huang JF, 1996, BIOCHEMISTRY-US, V35, P13222, DOI 10.1021/bi960498a; HUANG LQ, 1993, P NATL ACAD SCI USA, V90, P10066, DOI 10.1073/pnas.90.21.10066; Hwang I, 1997, PLANT PHYSIOL, V113, P535, DOI 10.1104/pp.113.2.535; ISHII T, 1995, EMBO J, V14, P58, DOI 10.1002/j.1460-2075.1995.tb06975.x; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Liang F, 1997, P NATL ACAD SCI USA, V94, P8579, DOI 10.1073/pnas.94.16.8579; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MALMSTROM S, 1997, FEBS LETT, V400, P624; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Quintero FJ, 1996, PLANT CELL, V8, P529, DOI 10.1105/tpc.8.3.529; RASICALDOGNO F, 1995, PLANT PHYSIOL, V108, P105, DOI 10.1104/pp.108.1.105; Rose MD., 1990, METHODS YEAST GENETI; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sambook J, 1989, MOL CLONING LAB MANU; Schaller GE, 1995, METHOD CELL BIOL, V50, P129, DOI 10.1016/S0091-679X(08)61027-4; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Sorin A, 1997, J BIOL CHEM, V272, P9895; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341	52	126	143	2	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1099	1106		10.1074/jbc.273.2.1099	http://dx.doi.org/10.1074/jbc.273.2.1099			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422775	hybrid			2022-12-25	WOS:000071411400064
J	Tijerina, P; Sayre, MH				Tijerina, P; Sayre, MH			Debilitating mutation in transcription factor IIE with differential effects on gene expression in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; INITIATION COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; BASAL TRANSCRIPTION; PROMOTER CLEARANCE; HEAT-SHOCK; IMMEDIATELY UPSTREAM; IN-VIVO; DNA; TFIIH	The influence of transcription factor (TF) IIE on mRNA synthesis in vivo was examined in a temperature-sensitive yeast mutant, A missense mutation in the con served zinc finger domain severely weakened TFIIE's transcription activity without appreciably affecting its quaternary structure, chromatographic properties, or cellular abundance, The mutation conferred recessive slow-growth and heat-sensitive phenotypes in yeast, but quantitative effects on promoter utilization by RNA polymerase II ranged from strongly negative to somewhat positive. Heat-induced activation of the HSP26, HSP104, and SSA4 genes was attenuated in the mutant, indicating dependence on TFIIE for maximal rates of de novo synthesis, Constitutive HSP expression in mutant cells was elevated, exposing a negative (likely indirect) influence by TFIIE in the absence of heat stress, Our results corroborate and extend recent findings of differential dependence on TFIIE activity for yeast promoters, but reveal an important counterpoint to the notion that dependence is tied to TATA element structure (Sakurai, H., Ohishi, T., and Fukasawa, T. (1997) J. Biol. Chem. 272, 15936-15942), We also provide empirical evidence for conservation of structure-activity relationships in TFIIE's zinc finger domain, and establish a direct link between TFIIE's biochemical activity in reconstituted transcription and its function in cellular mRNA synthesis.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA	Johns Hopkins University	Sayre, MH (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA.	msayre@welchlink.welch.jhu.edu			NCI NIH HHS [CA09110] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOORSTEIN WR, 1990, J BIOL CHEM, V265, P18912; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; COLLART MA, 1993, CURRENT PROTOCOLS MO, V2; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DUJON B, 1994, NATURE, V369, P371, DOI 10.1038/369371a0; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1997, P NATL ACAD SCI USA, V94, P9006, DOI 10.1073/pnas.94.17.9006; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GUZDER SN, 1994, NATURE, V367, P91, DOI 10.1038/367091a0; HALLADAY JT, 1995, MOL CELL BIOL, V15, P4890; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; Jiang Y, 1996, MOL CELL BIOL, V16, P1614; Kaiser C., 1994, METHODS YEAST GENETI; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Kuldell NH, 1997, MOL CELL BIOL, V17, P5288, DOI 10.1128/MCB.17.9.5288; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Leuther KK, 1996, CELL, V85, P773, DOI 10.1016/S0092-8674(00)81242-8; Li BY, 1996, MOL CELL BIOL, V16, P5433; Lin SJ, 1996, MOL CELL BIOL, V16, P6303; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MAXON ME, 1994, P NATL ACAD SCI USA, V91, P9529, DOI 10.1073/pnas.91.20.9529; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; OHKUMA Y, 1995, MOL CELL BIOL, V15, P4856; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PETERSON MG, 1991, NATURE, V354, P369; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; QIU HF, 1993, GENE DEV, V7, P2161, DOI 10.1101/gad.7.11.2161; RASMUSSEN EB, 1995, J MOL BIOL, V252, P522, DOI 10.1006/jmbi.1995.0517; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sakurai H, 1997, J BIOL CHEM, V272, P15936, DOI 10.1074/jbc.272.25.15936; Sakurai H, 1996, P NATL ACAD SCI USA, V93, P9488, DOI 10.1073/pnas.93.18.9488; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; Shi XM, 1997, MOL CELL BIOL, V17, P1160, DOI 10.1128/MCB.17.3.1160; SIKORSKI RS, 1989, GENETICS, V122, P19; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUSEK RE, 1990, MOL CELL BIOL, V10, P6362, DOI 10.1128/MCB.10.12.6362; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Valay JG, 1996, CR ACAD SCI III-VIE, V319, P183; Wang X, 1997, P NATL ACAD SCI USA, V94, P433, DOI 10.1073/pnas.94.2.433	53	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1107	1113		10.1074/jbc.273.2.1107	http://dx.doi.org/10.1074/jbc.273.2.1107			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422776	hybrid			2022-12-25	WOS:000071411400065
J	Yet, SF; McA'Nulty, MM; Folta, SC; Yen, HW; Yoshizumi, M; Hsieh, CM; Layne, MD; Chin, MT; Wang, H; Perrella, MA; Jain, MK; Lee, ME				Yet, SF; McA'Nulty, MM; Folta, SC; Yen, HW; Yoshizumi, M; Hsieh, CM; Layne, MD; Chin, MT; Wang, H; Perrella, MA; Jain, MK; Lee, ME			Human EZF, a Kruppel-like zinc finger protein, is expressed in vascular endothelial cells and contains transcriptional activation and repression domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; BOX-BINDING PROTEIN; TUMOR GENE-PRODUCT; FACTOR EKLF; FUNCTIONAL DOMAINS; BETA-THALASSEMIA; DNA; PROMOTER; SEQUENCE; CLONING	Members of the erythroid Kruppel-like factor (EKLF) multigene family contain three C-terminal zinc fingers, and they are typically expressed in a limited number of tissues. EKLF, the founding member, transactivates the beta-globin promoter by binding to the CACCC motif, EKLF is essential for expression of the beta-globin gene as demonstrated by gene deletion experiments in mice. Using a DNA probe from the zinc finger region of EKLF, we cloned a cDNA encoding a member of this family from a human vascular endothelial cell cDNA library, Sequence analysis indicated that our clone, hEZF is the human homologue of the recently reported mouse EZF and GKLF. hEZF is a single-copy gene that maps to chromosome 9q31. By gel mobility shift analysis, purified recombinant hEZF protein bound specifically to a probe containing the CACCC core sequence. In co-transfection experiments, we found that sense but not antisense hEZF decreased the activity of a reporter plasmid containing the CACCC sequence upstream of the thymidine kinase promoter by B-fold. In contrast, EKLF increased the activity of the reporter plasmid by 3-fold., By fusing hEZF to the DNA-binding domain of GAL4, we mapped a repression domain in hEZF to amino acids 181-388., We also found that amino acids 91-117 of hEZF confer an activation function on the GAL4 DNA-binding domain.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Lee, ME (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.		Yet, Shaw-Fang/O-8583-2019; Yet, Shaw-Fang/B-1067-2010	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL03194] Funding Source: Medline; NIGMS NIH HHS [GM53249] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5927; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BERG JM, 1990, J BIOL CHEM, V265, P6513; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LEE ME, 1991, J BIOL CHEM, V266, P16188; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MECHANT JL, 1996, MOL CELL BIOL, V16, P6644; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Ostling J, 1996, MOL CELL BIOL, V16, P753; PERKINS AC, 1995, NATURE, V375, P318; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SOGAWA K, 1993, NUCLEIC ACIDS RES, V21, P1527, DOI 10.1093/nar/21.7.1527; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	42	157	175	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1026	1031		10.1074/jbc.273.2.1026	http://dx.doi.org/10.1074/jbc.273.2.1026			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422764	hybrid			2022-12-25	WOS:000071411400053
J	Chang, BB; Persengiev, SP; de Diego, JG; Sacristan, MP; Zanca, DM; Kilpatrick, DL				Chang, BB; Persengiev, SP; de Diego, JG; Sacristan, MP; Zanca, DM; Kilpatrick, DL			Proximal promoter sequences mediate cell-specific and elevated expression of the favorable prognosis marker TrkA in human neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; FACTOR-INDUCED DIFFERENTIATION; N-MYC; GENE-EXPRESSION; FACTOR RECEPTOR; PROTO-ONCOGENE; SCHWANN-CELLS; TRANSCRIPTION; AMPLIFICATION; LINES	The nerve growth factor receptor, TrkA, has a critical role in the survival, differentiation, and function of neurons in the peripheral and central nervous systems, Recent studies have demonstrated a strong correlation between abundant expression of TrkA and a favorable prognosis of the pediatric tumor, neuroblastoma. This correlation suggests that TrkA may actively promote growth arrest and differentiation of neuroblastoma tumor cells and may be an important therapeutic target in the treatment of this disease, In the present study, we have examined the mechanistic basis for TrkA gene expression in human neuroblastoma cells, Northern blotting and nuclear run-on analyses demonstrated that transcription is a primary determinant of both cell-specific and variable expression of the TrkA gene in neuroblastoma cell lines that express it to different degrees, Cell-specific and variable transcription in neuroblastoma cells was recapitulated by transient transfection of TrkA promoter-luciferase reporter constructs, and regulatory sequences mediating these processes were localized to a 138-base pair region lying just upstream of the transcription initiation region, This neuroblastoma regulatory region formed multiple DNA-protein complexes in gel shift assays that were highly enriched in neuroblastoma cells exhibiting abundant TrkA expression, Thus, TrkA-positive neuroblastoma cells are distinguished by differential expression of putative transcription factors that ultimately may serve as targets for up-regulating TrkA expression in tumors with poor prognosis.	Univ Massachusetts, Med Ctr, Dept Physiol, Shrewsbury, MA 01545 USA; Univ Salamanca, Inst Microbiol Bioquim, Salamanca 37007, Spain	University of Massachusetts System; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Kilpatrick, DL (corresponding author), Univ Massachusetts, Med Ctr, Dept Physiol, Worcester Fdn Campus,222 Maple Ave, Shrewsbury, MA 01545 USA.		Sacristán, María P/A-9587-2016; Sacristan, Maria/Y-4923-2019	Sacristán, María P/0000-0003-2314-8430; Sacristan, Maria/0000-0003-2314-8430	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036468] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK36468] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ambros IM, 1996, NEW ENGL J MED, V334, P1505, DOI 10.1056/NEJM199606063342304; ANDERSSON G, 1994, CELL GROWTH DIFFER, V5, P27; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BIEDLER JL, 1973, CANCER RES, V33, P2643; BORRELLO MG, 1993, INT J CANCER, V54, P540, DOI 10.1002/ijc.2910540404; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brodeur GM, 1996, NEW ENGL J MED, V334, P1537, DOI 10.1056/NEJM199606063342311; BRODEUR GM, 1995, EUR J CANCER, V31A, P505, DOI 10.1016/0959-8049(95)00040-P; BRODEUR GM, 1995, METABOLIC MOL BASES, V1, P697; Chagnovich D, 1996, J BIOL CHEM, V271, P33580, DOI 10.1074/jbc.271.52.33580; CHEN J, 1990, CELL GROWTH DIFFER, V1, P79; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COOPER MJ, 1990, CELL GROWTH DIFFER, V1, P149; DiRocco G, 1997, MOL CELL BIOL, V17, P1244, DOI 10.1128/MCB.17.3.1244; DONOVAN MJ, 1993, AM J PATHOL, V143, P1560; GALCHEVAGARGOVA Z, 1993, MOL ENDOCRINOL, V7, P979, DOI 10.1210/me.7.8.979; Greco A, 1996, ONCOGENE, V13, P2463; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARTMAN DS, 1994, J NEUROCHEM, V63, P1261; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; ISRAEL MA, 1993, CANCER, V71, P3310, DOI 10.1002/1097-0142(19930515)71:10+<3310::AID-CNCR2820711728>3.0.CO;2-G; IWATA H, 1994, JPN J CANCER RES, V85, P32, DOI 10.1111/j.1349-7006.1994.tb02883.x; Jiang JG, 1997, ONCOGENE, V14, P3039, DOI 10.1038/sj.onc.1201152; KILPATRICK DL, 1990, MOL CELL BIOL, V10, P3717, DOI 10.1128/MCB.10.7.3717; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOGNER P, 1993, CANCER RES, V53, P2044; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; MATTHAY KTK, 1995, CA-CANCER J CLIN, V45, P179, DOI 10.3322/canjclin.45.3.179; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAKAGAWARA A, 1995, CANCER RES, V55, P1792; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Oettgen P, 1996, MOL CELL BIOL, V16, P5091; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; Persengiev SP, 1996, MOL ENDOCRINOL, V10, P742, DOI 10.1210/me.10.6.742; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; POLUHA W, 1995, ONCOGENE, V10, P185; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REYNOLDS CP, 1986, J NATL CANCER I, V76, P375; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; ROSS RA, 1983, J NATL CANCER I, V71, P741; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; Stram DO, 1996, J CLIN ONCOL, V14, P2417, DOI 10.1200/JCO.1996.14.9.2417; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; SUZUKI T, 1993, J NATL CANCER I, V85, P377, DOI 10.1093/jnci/85.5.377; TRIEZENBERG SJ, 1992, CURRENT PROTOCOLS MO; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	62	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					39	44		10.1074/jbc.273.1.39	http://dx.doi.org/10.1074/jbc.273.1.39			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417044	hybrid			2022-12-25	WOS:000071295600010
J	Florkiewicz, RZ; Anchin, J; Baird, A				Florkiewicz, RZ; Anchin, J; Baird, A			The inhibition of fibroblast growth factor-2 export by cardenolides implies a novel function for the catalytic subunit of Na+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; CAT CARDIAC-MUSCLE; ENDOPLASMIC-RETICULUM; EXTRACELLULAR-MATRIX; PROTEIN TRANSLOCATION; ANGIOGENIC PROTEIN; SIGNAL SEQUENCE; ELEVATED LEVELS; SODIUM-PUMP; CELLS	Basic fibroblast growth factor (FGF-S) is one of a select group of proteins that can exit cells through an alternate, endoplasmic reticulum/Golgi apparatus independent exocytic pathway, This alternate pathway has been termed protein export, In an attempt to better understand this process, we have identified a family of related compounds, "cardenolides," that inhibit FGF-2 export, The cardenolides inhibit FGF-2 export in a time and concentration dependent fashion, Inhibition of FGF-S export is specific in that the cardenolides have no effect on conventional protein secretion as measured by their inability to block release of the secreted protein human chorionic gonadotropin-alpha. Because cardenolides are known to inhibit ion transport activity mediated by Na+,K+-ATPase, we investigated whether there are functional interactions between FGF-S and their only known molecular target: the alpha-subunit of Na+,K+-ATPase. Export of FGF-2 from COS-l cells is selectively inhibited when co-transfected with expression vectors encoding the alpha-subunit and FGF-2. Moreover, antibodies to the alpha-subunit specifically co-immunoprecipitate FGF-2 along with the alpha-subunit while conversely, antibodies to FGF-2 specifically co-immunoprecipitate the alpha-subunit along with FGF-2. Finally, the ion transporting activities of the Na+,K+-ATPase can be uncoupled from protein export, Varying the external concentration of K+ has little effect on export of FGF-2. Taken together, these data: 1) identify a novel activity for cardenolides; 2) suggest a previously unknown role for the alpha-subunit of Na+, K+-ATPase in FGF-2 export; and 3) raise the possibility that the alpha-subunit itself may be an integral component of this alternate exocytic pathway mediating translocation of cytosolic FGF-2 to the cell surface.	PRIZM Pharmaceut, San Diego, CA 92121 USA		Florkiewicz, RZ (corresponding author), 11035 Roselle St, San Diego, CA 92121 USA.	rzflork@prizmpharm.com		Baird, Andrew/0000-0003-0027-9905	NIDDK NIH HHS [DK11811] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAIRD A, 1997, PEPTIDE GROWTH FACTO, P369; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; FALCONER IR, 1983, CHEMOTHERAPY, V29, P368, DOI 10.1159/000238221; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; FUJINO M, 1995, JPN J PHARMACOL, V67, P125, DOI 10.1254/jjp.67.125; FUJINO S, 1989, EXPERIENTIA, V45, P466, DOI 10.1007/BF01952032; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; HAMADA H, 1987, CANCER RES, V47, P2860; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; ISHII T, 1994, P NATL ACAD SCI USA, V91, P6103, DOI 10.1073/pnas.91.13.6103; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; KLEYMAN TR, 1987, J BIOL CHEM, V261, P2839; LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; MANABE T, 1993, J CELL PHYSIOL, V157, P445, DOI 10.1002/jcp.1041570303; MANIN M, 1995, BIOL REPROD, V52, P50, DOI 10.1095/biolreprod52.1.50; MAUNSBACH J, 1991, SODIUM PUMP STRUCTUR, P159; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; Mukhopadhyay D, 1996, BIOCHEM BIOPH RES CO, V229, P733, DOI 10.1006/bbrc.1996.1873; NGUYEN M, 1993, J NATL CANCER I, V85, P241, DOI 10.1093/jnci/85.3.241; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; NORBY JG, 1991, SOC GEN PHY, V46, P173; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; REPKE KRH, 1995, ANTI-CANCER DRUG DES, V10, P177; ROGELJ S, 1989, J CELL BIOL, V109, P823, DOI 10.1083/jcb.109.2.823; ROSE AM, 1994, CLIN CHEM, V40, P1674; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; SHAIKH IM, 1991, J BIOL CHEM, V266, P13672; SIDERS WM, 1995, J BIOL CHEM, V270, P16258, DOI 10.1074/jbc.270.27.16258; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; SOUTTER AD, 1993, CANCER RES, V53, P5297; STENKVIST B, 1979, LANCET, V1, P563; STENKVIST B, 1980, ANAL QUANT CYTOL, V2, P49; TARANTINI F, 1995, MOL BIOL CELL, V6, P350; ULLRICH KJ, 1979, ANNU REV PHYSIOL, V41, P181, DOI 10.1146/annurev.ph.41.030179.001145; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	56	126	129	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					544	551		10.1074/jbc.273.1.544	http://dx.doi.org/10.1074/jbc.273.1.544			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417114	hybrid			2022-12-25	WOS:000071295600080
J	Kolbinger, F; Streiff, MB; Katopodis, AG				Kolbinger, F; Streiff, MB; Katopodis, AG			Cloning of a human UDP-galactose : 2-acetamido-2-deoxy-D-glucose 3 beta-galactosyltransferase catalyzing the formation of type 1 chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE ANTIGENS; EXPRESSION; CDNA; LACTO; GLYCOSYLTRANSFERASES; BIOSYNTHESIS; CELLS; IDENTIFICATION; DETERMINANTS; SEQUENCES	Biochemical evidence suggests that the galactosyltransferase activity synthesizing type 1 carbohydrate chains is separate from the well characterized enzyme that is responsible for the synthesis of type 2 chains, This was recently confirmed by the cloning, from melanoma cells, of an enzyme capable of synthesizing type I chains, which was shown to have no homology to other galactosyltransferases. We report here the molecular cloning and functional expression of a second human beta 3-galactosyltransferase distinct from the melanoma enzyme. The new beta 3-galactosyltransferase has homology to the melanoma enzyme in the putative catalytic domain, but has longer cytoplasmic and stem regions and a carboxyl-terminal extension, Northern blots showed that the new gene is present primarily in brain and heart, When transfected into mammalian cells, this gene directs the synthesis of type 1 chains as determined by a monoclonal antibody specific for sialyl Lewis(a), A soluble version of the cloned enzyme was expressed in insect cells and purified, The soluble enzyme readily catalyzes the transfer of galactose to GlcNAc to form Gal(beta 1-3)GlcNAc. It also has a minor but distinct transfer activity toward Gal, LacNAc, and lactose, but is inactive toward GalNAc.	Novartis Pharma AG, Transplantat Preclin Res, CH-4002 Basel, Switzerland	Novartis	Katopodis, AG (corresponding author), Novartis Pharma AG, Transplantat Preclin Res, S386-645, CH-4002 Basel, Switzerland.	andreas.atopodis@pharma.novartis.com						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILLY P, 1988, EUR J BIOCHEM, V173, P417, DOI 10.1111/j.1432-1033.1988.tb14015.x; BERG EL, 1991, J BIOL CHEM, V266, P14869; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; BROCKHAUSEN I, 1995, GLYCOPROTEINS A, V29, P201; BROWN DG, 1993, HISTOCHEM J, V25, P452, DOI 10.1007/BF00157810; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DESPOSITO M, 1994, NUCLEIC ACIDS RES, V22, P4806, DOI 10.1093/nar/22.22.4806; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DINTER A, 1995, ADV EXP MED BIOL, V376, P53; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Geremia RA, 1997, GLYCOBIOLOGY, V7, pR5; HAEUWFIEVRE S, 1993, EUR J BIOCHEM, V215, P361, DOI 10.1111/j.1432-1033.1993.tb18042.x; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; HUANG X, 1995, GENOMICS, V14, P18; JOZIASSE DH, 1989, J BIOL CHEM, V264, P14290; JOZIASSE DH, 1987, FEBS LETT, V221, P139, DOI 10.1016/0014-5793(87)80368-X; KANNAGI R, 1985, J BIOL CHEM, V260, P6410; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KORNFELD R, 1978, BIOCHEMISTRY-US, V17, P1415, DOI 10.1021/bi00601a009; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEGAULT DJ, 1995, J BIOL CHEM, V270, P20987, DOI 10.1074/jbc.270.36.20987; LOWE JB, 1991, BIOCHEM SOC T, V19, P649, DOI 10.1042/bst0190649; MESSER M, 1991, BIOCHIM BIOPHYS ACTA, V1077, P79, DOI 10.1016/0167-4838(91)90528-8; MIZUOCHI T, 1982, J BIOL CHEM, V257, P13300; NISHI T, 1985, J BIOCHEM-TOKYO, V97, P153, DOI 10.1093/oxfordjournals.jbchem.a135039; Oriol R., 1995, BLOOD CEL B, P37; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; SASAKI K, 1994, Patent No. 0618759; Seko A, 1996, CANCER RES, V56, P3468; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHEARES BT, 1982, J BIOL CHEM, V257, P599; SHEARES BT, 1983, J BIOL CHEM, V258, P9893; SHERWOOD AL, 1992, J CELL BIOCHEM, V50, P165, DOI 10.1002/jcb.240500207; SHUR B D, 1991, Glycobiology, V1, P563, DOI 10.1093/glycob/1.6.563; STELLNER K, 1974, J BIOL CHEM, V249, P1022; Xu XH, 1996, J BIOL CHEM, V271, P8818, DOI 10.1074/jbc.271.15.8818; Yang W, 1996, EUR J CELL BIOL, V71, P53	43	52	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					433	440		10.1074/jbc.273.1.433	http://dx.doi.org/10.1074/jbc.273.1.433			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417100	hybrid			2022-12-25	WOS:000071295600066
J	LeBoeuf, RD; Ban, EMH; Green, MM; Stone, AS; Propst, SM; Blalock, JE; Tauber, JD				LeBoeuf, RD; Ban, EMH; Green, MM; Stone, AS; Propst, SM; Blalock, JE; Tauber, JD			Molecular cloning, sequence analysis, expression, and tissue distribution of suppressin, a novel suppressor of cell cycle entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASES; MESSENGER-RNAS; IDENTIFICATION; PROLIFERATION; PURIFICATION; INHIBITOR; PITUITARY; PATHWAYS; SITES	Suppressin (SPN) is an inhibitor of cell proliferation that was originally identified and purified to homogeneity from bovine pituitaries (LeBoeuf, R. D., Burns, J. N., Best, R. L., and Blalock, J. E. (1990) J. Biol. Chem. 265, 158-165). In this report we have cloned the full-length cDNA encoding rat SPN and have identified the tissue distribution of SPN expression. The cDNA of SPN is 1882 nucleotides with a 1488-base coding region and 55 and 339 nucleotides of 5'- and 3'-untranslated sequences, respectively. Northern gel analysis of rat pituitary mRNA showed a single hybridizing species at similar to 2 kilobases. Sequence analyses showed that the nucleotide and deduced amino acid sequences of SPN are novel and unrelated to any known vertebrate inhibitors of proliferation. However, the deduced amino acid sequence of SPN contains two domains that have extensive sequence identity with a recently cloned transcription activator in Drosophila, deformed epidermal autoregulatory factor-1 (DEAF-1, see Gross, C. T., and McGinnis, W. (1996) EMBO J. 15, 1961-1970) suggesting that SPN represents a vertebrate cognate of deformed epidermal autoregulatory factor-1. Reverse transcriptase-polymerase chain reaction and immunohistochemical analyses showed that the SPN mRNA and the SPN protein are expressed in every tissue examined including testis, spleen, skeletal muscle, liver, kidney, heart, and brain suggesting that SPN may be involved in the control of proliferation in a variety of cell types.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	LeBoeuf, RD (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, BHSB 850, Birmingham, AL 35294 USA.			Blalock, J. Edwin/0000-0001-5303-8123	NCI NIH HHS [CA 54290] Funding Source: Medline; NIAID NIH HHS [P30 AI27767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA054290] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAN EM, 1993, ENDOCRINOLOGY, V133, P241, DOI 10.1210/en.133.1.241; BAN EMH, 1995, IMMUNOL RES, V13, P1; CARR DJJ, 1990, J NEUROIMMUNOL, V30, P179, DOI 10.1016/0165-5728(90)90102-S; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1984, J BIOL CHEM, V259, P7835; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P92; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; FEINSTEIN PG, 1995, GENETICS, V140, P573; GLASS DB, 1986, J BIOL CHEM, V261, P2987; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; KADEREIT S, 1993, J BIOL CHEM, V268, P24432; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBOEUF RD, 1991, NETH J MED, V39, P295; LEBOEUF RD, 1990, J BIOL CHEM, V265, P158; LEBOEUF RD, 1990, ANN NY ACAD SCI, V594, P393; LEBOEUF RD, 1990, PROG NEUROENDOCRINIM, V3, P176; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MATTAJ IW, 1989, CELL, V57, P1, DOI 10.1016/0092-8674(89)90164-5; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NOTHWEHR SF, 1990, BIOESSAYS, V12, P479, DOI 10.1002/bies.950121005; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; POPOV KM, 1993, J BIOL CHEM, V268, P26602; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	33	29	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					361	368		10.1074/jbc.273.1.361	http://dx.doi.org/10.1074/jbc.273.1.361			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417089	hybrid			2022-12-25	WOS:000071295600055
J	Mithieux, G; Daniele, N; Payrastre, B; Zitoun, C				Mithieux, G; Daniele, N; Payrastre, B; Zitoun, C			Liver microsomal glucose-6-phosphatase is competitively inhibited by the lipid products of phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEMBRANE-BOUND ENZYMES; PHOSPHATASE-ACTIVITY; PHOSPHOLIPASES-C; RAT ADIPOCYTES; MESSENGER-RNA; DIABETIC RATS; INSULIN; ACTIVATION; 3,4,5-TRISPHOSPHATE	We have studied the effect of various phospholipids on the activity of glucose-6-phosphatase (Glc6Pase) in untreated and detergent-treated rat liver microsomes. Glc6Pase is inhibited in the presence of phosphoinositides in a dose-dependent manner within a range of concentration 0.5-10 mu M. The order of efficiency in untreated microsomes is: phosphatidylinositol (PI) 3,4,5P(3) > PI3,4P(2) = PI4,5P(2) > PI3P = PI4P > PI. In contrast, Glc6Pase is not inhibited in the presence of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine, diacylglycerol, and inositol 1,4,5-trisphosphate at concentrations up to 100 mu M The mechanism of Glc6Pase inhibition by PI4,5P(2), PI3,4P(2), and PI3,4,5P(3) is competitive in both untreated and detergent-treated microsomes. In untreated microsomes, the K-i for PI3,4,5P(3) (1.7 +/- 0.3 mu M, mean +/- S.D. n = 3) is significantly lower (p < 0.01) than that for PI3,4P(2) (5.0 +/- 0.8 mu M) and for PI4,5P(2) (4.7 +/- 0.7 mu M). In detergent-treated microsomes, Glc6Pase is less sensitive to the inhibition and there is no difference anymore among the K-i values for the three compounds: 8.3 +/- 0.8, 11.1 +/- 0.5 and 8.9 +/- 0.4 mu M for PI3,4,5P(3), PI3,4P(2), and PI4,5P(2), respectively. This inhibition phenomenon might be of special importance with regards to the insulin's inhibition of hepatic glucose production.	Fac Med RTH Laennec, INSERM, U449, F-69372 Lyon 08, France; Hop Purpan, Unit 326, F-31059 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse	Mithieux, G (corresponding author), Fac Med RTH Laennec, INSERM, U449, Rue Guillaume Paradin, F-69372 Lyon 08, France.		Danièle, Nathalie/J-7432-2013	Daniele, Nathalie/0000-0002-7985-2788; , Bernard/0000-0002-8693-0190; Gilles, Mithieux/0000-0003-3579-8529				Baginski ES, 1974, METH ENZYMOL; BODE AM, 1992, J BIOL CHEM, V267, P2860; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHRIST B, 1986, BIOCHEM J, V238, P185, DOI 10.1042/bj2380185; CRAIN RC, 1981, BIOCHEMISTRY-US, V20, P5320, DOI 10.1021/bi00521a035; DYATLOVITSKAYA EV, 1979, EUR J BIOCHEM, V99, P605, DOI 10.1111/j.1432-1033.1979.tb13293.x; FOLLI F, 1993, J CLIN INVEST, V92, P1787, DOI 10.1172/JCI116768; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; HABER BA, 1995, J CLIN INVEST, V95, P832, DOI 10.1172/JCI117733; JORGENSON RA, 1980, J BIOL CHEM, V255, P5907; KELLY KL, 1992, J BIOL CHEM, V267, P3423; KELLY KL, 1993, J BIOL CHEM, V268, P4391; LEMARCHANDBRUSTEL Y, 1995, ENDOCRINOLOGY, V136, P3564, DOI 10.1210/en.136.8.3564; Minassian C, 1996, MOL CELL BIOCHEM, V155, P37, DOI 10.1007/BF00714331; MINASSIAN C, 1994, J BIOL CHEM, V269, P16585; MINASSIAN C, 1995, J NUTR, V125, P2727; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 1996, EUR J BIOCHEM, V235, P799, DOI 10.1111/j.1432-1033.1996.00799.x; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Nave BT, 1996, BIOCHEM J, V318, P55, DOI 10.1042/bj3180055; NORDLIE RC, 1981, J BIOL CHEM, V256, P4768; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P53; OKADA T, 1994, J BIOL CHEM, V269, P3568; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; SAWAKI K, 1983, J BIOCHEM-TOKYO, V93, P525, DOI 10.1093/oxfordjournals.jbchem.a134207; SAWAKI K, 1983, J BIOCHEM-TOKYO, V93, P537, DOI 10.1093/oxfordjournals.jbchem.a134208; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; SNOKE RE, 1972, BIOCHIM BIOPHYS ACTA, V258, P188, DOI 10.1016/0005-2744(72)90978-3; STEPHENS L, 1993, J BIOL CHEM, V268, P17162; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Yang J, 1996, BIOCHEM J, V313, P125, DOI 10.1042/bj3130125; ZAKIM D, 1970, J BIOL CHEM, V245, P4953	38	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					17	19		10.1074/jbc.273.1.17	http://dx.doi.org/10.1074/jbc.273.1.17			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417039	hybrid			2022-12-25	WOS:000071295600005
J	Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A				Olson, MF; Sterpetti, P; Nagata, K; Toksoz, D; Hall, A			Distinct roles for DH and PH domains in the Lbc oncogene	ONCOGENE			English	Article						oncogene; Rho; Dbl; Pleckstrin-homology; exchange factor; actin	PLECKSTRIN HOMOLOGY DOMAIN; NUCLEOTIDE EXCHANGE FACTORS; STRUCTURAL SIMILARITIES; G(BETA-GAMMA) SUBUNITS; EXPRESSION CLONING; PLASMA-MEMBRANE; PROTEIN-RHO; DBL FAMILY; BINDING; TRANSDUCTION	Members of the Dbl-homology (DH) family of proteins promote guanine nucleotide exchange on Rho GTPases, Lbc, which specifically acts on Rho but not Rac or Cdc42, was isolated as a transforming oncogene and is composed of a DH and a Pleckstrin-homology (PH) domain, We show here that the Lbc DH domain alone is capable of stimulating new DNA synthesis in quiescent fibroblasts and Rho-dependent actin stress fiber assembly. However, the PH domain is required for subcellular localization of Lbc along actin stress fibers and for efficient transformation of NIH3T3 cells, The results show that, in contrast to other Dbl-homology proteins, the PH domain of Lbc is dispensable for activation of Rho in vivo, The PH domain-dependent subcellular localization of Lbc may, however, be important for growth factor activation of endogenous Lbc and for oncogenic transformation.	UCL, CRC, SIGNAL TRANSDUCT & ONCOGENE GRP, LONDON WC1E 6BT, ENGLAND; UCL, MRC, MOL CELL BIOL LAB, LONDON WC1E 6BT, ENGLAND; UCL, DEPT BIOCHEM, LONDON WC1E 6BT, ENGLAND; TUFTS UNIV, SCH MED, DEPT PHYSIOL, BOSTON, MA 02111 USA	University of London; University College London; University of London; University College London; University of London; University College London; Tufts University			Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; 				Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, CURR BIOL, V6, P1628, DOI 10.1016/S0960-9822(02)70786-0; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; Sambrook J., 2002, MOL CLONING LAB MANU; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Wang DS, 1996, BIOCHEM BIOPH RES CO, V225, P420, DOI 10.1006/bbrc.1996.1189; WANG YL, 1987, J CELL BIOL, V105, P2811, DOI 10.1083/jcb.105.6.2811; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAMAMOTO M, 1993, J BIOL CHEM, V268, P21509; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	58	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2827	2831		10.1038/sj.onc.1201594	http://dx.doi.org/10.1038/sj.onc.1201594			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419973				2022-12-25	WOS:A1997YJ80300008
J	Zhao, M; Schlame, M; Rua, D; Greenberg, ML				Zhao, M; Schlame, M; Rua, D; Greenberg, ML			Cardiolipin synthase is associated with a large complex in yeast mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; NUCLEAR-MAGNETIC-RESONANCE; CYTOCHROME-C-OXIDASE; ACYL-CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; RADIATION INACTIVATION; HEART-MITOCHONDRIA; MUTANT DEFICIENT; REDUCTASE; MEMBRANE	The phospholipid cardiolipin (CL) is ubiquitous in eucaryotes and is unique in structure, subcellular localization, and potential function, Previous studies have shown that CL is associated with major respiratory complexes in the mitochondrial membrane. To determine whether CL biosynthesis requires the presence of intact respiratory complexes, we measured activity of CL synthase, which catalyzes the synthesis of CL from cytidine diphosphate diacylglycerol and phosphatidylglycerol, in Saccharomyces cerevisiae strains with genetic defects in the oxidative phosphorylation system, Assembly mutants of cytochrome oxidase had significantly reduced CL synthase activity, while assembly mutants of respiratory complex III and the F0F1-ATPase were less inhibited, To obtain further information on the activity of CL synthase, we purified the enzyme and compared the size of the catalytic protein with the functional molecular mass, The enzyme was solubilized by Triton X-100 hom KSCN-extracted mitochondrial membranes of S. cerevisiae, The functional molecular mass of Triton-solubilized CL synthase, determined by radiation inactivation, was 150-240 kDa, indicating that the functional enzyme was a large complex, After partial purification, the enzyme eluted from a Superose 12 gel filtration column with an apparent molecular mass of 70 kDa, CL synthase was further purified by hydroxylapatite and cytidine diphosphate diacylglycerol affinity chromatographies, Mono Q anion exchange FPLC, and preparative gel electrophoresis. These steps led to identification of a 28-kDa protein, which had catalytic activity when eluted from an SDS-polyacrylamide gel, This 28-kDa protein also reacted with an antiserum that inactivated the enzyme, We conclude that yeast CL synthase is a 28-kDa protein, which forms an oligomeric complex whose biogenesis and/or activity is influenced by the assembly of cytochrome oxidase.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Greenberg, ML (corresponding author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037723] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37723] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEAUREGARD G, 1984, ANAL BIOCHEM, V140, P403, DOI 10.1016/0003-2697(84)90185-4; BEYER K, 1985, BIOCHEMISTRY-US, V24, P3821, DOI 10.1021/bi00336a001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1985, BIOCHIM BIOPHYS ACTA, V822, P1, DOI 10.1016/0304-4157(85)90002-4; EBLE KS, 1990, J BIOL CHEM, V265, P19434; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; FRY M, 1981, J BIOL CHEM, V256, P1874; GREENBERG ML, 1988, MOL CELL BIOL, V8, P4773, DOI 10.1128/MCB.8.11.4773; HAYERHARTL M, 1992, EUR J BIOCHEM, V209, P423, DOI 10.1111/j.1432-1033.1992.tb17305.x; HIRSCHBERG CB, 1972, P NATL ACAD SCI USA, V69, P506; Hostetler K. Y., 1982, PHOSPHOLIPIDS, V4, P215; HOSTETLER KY, 1972, BIOCHIM BIOPHYS ACTA, V260, P380, DOI 10.1016/0005-2760(72)90052-5; HOSTETLER KY, 1975, BIOCHIM BIOPHYS ACTA, V380, P382, DOI 10.1016/0005-2760(75)90106-X; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; KADENBACH B, 1982, FEBS LETT, V139, P109, DOI 10.1016/0014-5793(82)80498-5; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KEMPNER ES, 1979, ANAL BIOCHEM, V92, P2, DOI 10.1016/0003-2697(79)90617-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSON TJ, 1976, BIOCHEMISTRY-US, V15, P974, DOI 10.1021/bi00650a005; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OHTSUKA T, 1993, J BIOL CHEM, V268, P22914; OHTSUKA T, 1993, J BIOL CHEM, V268, P22908; PLUSCHKE G, 1978, J BIOL CHEM, V253, P5048; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; SCHLAME M, 1993, J BIOL CHEM, V268, P74; SCHLAME M, 1993, EUR J BIOCHEM, V212, P727, DOI 10.1111/j.1432-1033.1993.tb17711.x; SCHLAME M, 1991, J BIOL CHEM, V266, P22398; SCHLAME M, 1992, METHOD ENZYMOL, V209, P330; SCHLAME M, 1990, BIOCHEM J, V272, P589, DOI 10.1042/bj2720589; SCHLAME M, 1995, LIPIDS, V30, P633, DOI 10.1007/BF02537000; SPERKAGOTTLIEB CDM, 1988, BIOCHIM BIOPHYS ACTA, V946, P227, DOI 10.1016/0005-2736(88)90397-5; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TAMAI KT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P214, DOI 10.1016/0005-2760(90)90192-Z; WEISS H, 1990, TRENDS BIOCHEM SCI, V15, P178, DOI 10.1016/0968-0004(90)90155-5	36	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2402	2408		10.1074/jbc.273.4.2402	http://dx.doi.org/10.1074/jbc.273.4.2402			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442089	hybrid			2022-12-25	WOS:000071595200078
J	Shapiro, PS; Ahn, NG				Shapiro, PS; Ahn, NG			Feedback regulation of Raf-1 and mitogen-activated protein kinase (MAP) kinase kinases 1 and 2 by MAP kinase phosphatase-1 (MKP-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; PHOSPHORYLATION SITES; TYROSINE PHOSPHORYLATION; C-ELEGANS; IN-VIVO; V-RAF; CELLS; PATHWAY	Inactivation of growth factor-regulated mitogen-activated protein (MAP) kinases (ERK1 and ERK2) has been proposed to occur in part through dephosphorylation by the dual specificity MAP kinase phosphatase-1 (MKP-1), an immediate early gene that is induced by mitogenic signaling. In this study, we examined the effect of MKP-1 on signaling components upstream of ERK1 and ERK2. Coexpression of MKK1 or MKK2 with MKP-1 resulted in 7-10-fold activation of mitogen-activated protein kinase kinase (MKK), which required the presence of regulatory serine phosphorylation sites, Endogenous MKK1 and MKK2 were also activated upon MKP-1 expression. Raf-1, a direct regulator of MKK1 and MKK2, was activated under these conditions, and a synergistic activation of MKK was observed upon coexpression of Raf-1 and MKP-1. This effect did not appear to involve synthesis of autocrine growth factors or the inhibition of basal extracellular signal-regulated kinase (ERK) activity but was inhibited by a dominant negative Ras mutant, indicating that MKP-1 enhances Ras-dependent activation of Raf-1 in a cell autonomous manner. This study demonstrates positive feedback regulation of Raf-1 and MMK by the MKP-1 immediate early gene and a potential mechanism for activating Raf-1/MKK signaling pathways alternative to those involving ERK.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder	Shapiro, PS (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.				NIGMS NIH HHS [F32 GM18151, R01 GM48521] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018151, R01GM048521] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Degols G, 1996, MOL CELL BIOL, V16, P2870; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Farrar MA, 1996, NATURE, V383, P178, DOI 10.1038/383178a0; Franklin CC, 1995, ONCOGENE, V11, P2365; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HAINER S, 1994, MOL CELL BIOL, V14, P6696; Holt KH, 1996, MOL CELL BIOL, V16, P577; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JACOBY T, 1997, J BIOL CHEM, V272, P11749; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lenormand P, 1996, J BIOL CHEM, V271, P15762, DOI 10.1074/jbc.271.26.15762; LEWIS TL, 1998, IN PRESS ADV CANC RE, V74; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Mansour SJ, 1996, CELL GROWTH DIFFER, V7, P243; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; SEGER R, 1992, J BIOL CHEM, V267, P14373; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	64	60	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1788	1793		10.1074/jbc.273.3.1788	http://dx.doi.org/10.1074/jbc.273.3.1788			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430728	hybrid			2022-12-25	WOS:000071411500075
J	Taylor, PR; Nash, JT; Theodoridis, E; Bygrave, AE; Walport, MJ; Botto, M				Taylor, PR; Nash, JT; Theodoridis, E; Bygrave, AE; Walport, MJ; Botto, M			A targeted disruption of the murine complement factor B gene resulting in loss of expression of three genes in close proximity, factor B, C2, and D17H6S45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLOBIN LOCUS; BLOOD MONOCYTES; TRANSGENIC MICE; STEM-CELLS; PROTEINS; REGION; BIOSYNTHESIS; TERMINATION; COMPONENTS; ELEMENTS	Factor B is a serine protease, essential for the function of the alternative pathway of complement activation, To study further the importance of the alternative pathway of complement activation in vivo and to help elucidate any additional functions of factor B or its activation fragments we developed, by homologous recombination in embryonic stem cells, mice with a disrupted factor B gene. Factor B-deficient mice produced no detectable factor B mRNA or protein and had no detectable factor B enzymatic activity or alternative pathway function in their serum, Further studies revealed that the two adjacent genes, complement component C2 and D17H6S45, had been down regulated as a result of the disruption, The down-regulation of C2 gene expression was sufficient to cause a complete loss of classical pathway function as determined by the failure of sera from the deficient mice to opsonize antibody-sensitized sheep erythrocytes and by impairment of immune complex processing in vivo, The resulting mouse is deficient in both factor B and C2, and hence the alternative and classical pathways of complement activation, and adds to the repertoire of models for studying the in vivo role of complement in the immune system.	Hammersmith Hosp, Imperial Coll, Sch Med, Div Med,Rheumatol Sect, London W12 0NN, England	Imperial College London	Botto, M (corresponding author), Hammersmith Hosp, Imperial Coll, Sch Med, Div Med,Rheumatol Sect, Du Cane Rd, London W12 0NN, England.			Taylor, Philip/0000-0003-0163-1421; Walport, Mark/0000-0001-7220-5273				ALPER CA, 1980, CLIN IMMUNOL IMMUNOP, V16, P84, DOI 10.1016/0090-1229(80)90169-5; Altman PL, 1961, BLOOD OTHER BODY FLU, P9; AMBRUS JL, 1990, J IMMUNOL, V144, P1549; ANDREWS BS, 1978, J IMMUNOL METHODS, V22, P273, DOI 10.1016/0022-1759(78)90035-2; ASHFIELD R, 1994, EMBO J, V13, P5656, DOI 10.1002/j.1460-2075.1994.tb06904.x; ASHFIELD R, 1991, EMBO J, V10, P4197, DOI 10.1002/j.1460-2075.1991.tb04998.x; BOTTO M, 1996, MOL IMMUNOL S1, V33, P71; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P886; BROACH JR, 1982, CELL, V29, P227, DOI 10.1016/0092-8674(82)90107-6; CHAPLIN DD, 1983, P NATL ACAD SCI-BIOL, V80, P6947, DOI 10.1073/pnas.80.22.6947; Clark AJ, 1997, NUCLEIC ACIDS RES, V25, P1009, DOI 10.1093/nar/25.5.1009; COLE FS, 1982, IMMUNOLOGY, V46, P429; DAVIES KA, 1993, J IMMUNOL, V151, P3866; DENSEN P, 1996, MOL IMMUNOL, V33, P68; FARRIES TC, 1991, IMMUNOL TODAY, V12, P295, DOI 10.1016/0167-5699(91)90002-B; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOTZE O, 1979, J EXP MED, V149, P372, DOI 10.1084/jem.149.2.372; Guy LG, 1996, EMBO J, V15, P3713, DOI 10.1002/j.1460-2075.1996.tb00741.x; HALL RE, 1982, J EXP MED, V156, P834, DOI 10.1084/jem.156.3.834; KATZ Y, 1988, J EXP MED, V167, P1, DOI 10.1084/jem.167.1.1; LEIJH PCJ, 1982, J IMMUNOL, V129, P332; LIU K, 1995, P NATL ACAD SCI USA, V92, P7724, DOI 10.1073/pnas.92.17.7724; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720; MOREIRA A, 1995, EMBO J, V14, P3809, DOI 10.1002/j.1460-2075.1995.tb00050.x; MORRIS KM, 1982, J CLIN INVEST, V70, P906, DOI 10.1172/JCI110687; NONAKA M, 1989, MOL CELL BIOCHEM, V89, P1; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAOLUCCI ES, 1983, IMMUNOGENETICS, V17, P67, DOI 10.1007/BF00364290; PETERS MG, 1988, J EXP MED, V168, P1225, DOI 10.1084/jem.168.4.1225; PRAZ F, 1986, J EXP MED, V163, P1349, DOI 10.1084/jem.163.5.1349; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; Sambrook J., 2002, MOL CLONING LAB MANU; SPEISER PW, 1989, DNA-J MOLEC CELL BIO, V8, P745, DOI 10.1089/dna.1989.8.745; STAKNIS D, 1995, NUCLEIC ACIDS RES, V23, P4081, DOI 10.1093/nar/23.20.4081; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; STRAUSS ML, 1988, SCIENCE, V240, P201; STRUNK RC, 1988, J CLIN INVEST, V81, P1419, DOI 10.1172/JCI113472; SULLIVAN KE, 1994, EUR J IMMUNOL, V24, P393, DOI 10.1002/eji.1830240219; SUROWY CS, 1990, GENE, V90, P299, DOI 10.1016/0378-1119(90)90194-V; Taylor PR, 1997, MAMM GENOME, V8, P796, DOI 10.1007/s003359900579; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WHALEY K, 1980, J EXP MED, V151, P501, DOI 10.1084/jem.151.3.501; WU LC, 1987, CELL, V48, P331, DOI 10.1016/0092-8674(87)90436-3; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4	49	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1699	1704		10.1074/jbc.273.3.1699	http://dx.doi.org/10.1074/jbc.273.3.1699			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430715	hybrid			2022-12-25	WOS:000071411500062
J	Biade, S; Sobol, RW; Wilson, SH; Matsumoto, Y				Biade, S; Sobol, RW; Wilson, SH; Matsumoto, Y			Impairment of proliferating cell nuclear antigen-dependent apurinic/apyrimidinic site repair on linear DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; POLYMERASE-BETA; V(D)J RECOMBINATION; ESCHERICHIA-COLI; PCNA; COMPLEMENTATION; REQUIREMENT; RESIDUES; INVITRO; PROTEIN	Repair of apurinic/apyrimidinic (AP) sites by mammalian cell extracts was compared using circular and linear DNA substrates. Extracts prepared from DNA polymerase beta (pol beta)-proficient mouse fibroblasts repaired AP sites on both circular and linear DNA. However, extracts from the isogenic pol beta-knockout cells repaired AP sites on circular DNA but not efficiently on linear DNA. The circularity-dependent repair by the pol beta-knockout cell extract was completely inhibited by antiproliferating cell nuclear antigen (PCNA) antibody but fully restored by addition of purified PCNA. Pretreatment of the linear DNA with AP endonuclease did not improve repair, indicating that impairment of AP site repair on linear DNA by pol beta-knockout cell extracts is not due to inefficiency of damage incision but rather to deficiency at the subsequent steps. These results indicate that AP sites can be repaired on circular DNA by the PCNA-dependent pathway in addition to the pol beta-dependent pathway and that the PCNA-dependent repair mechanism is poorly functional on linear DNA in vitro.	Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; NIEHS, Res Triangle Pk, NC 27709 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Matsumoto, Y (corresponding author), Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	y_matsumoto@fccc.edu	Wilson, Samuel H/E-6644-2019; Sobol, Robert W./E-4125-2013	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563; Matsumoto, Yoshihiro/0000-0001-6580-7188	NCI NIH HHS [CA63154, CA 06927] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063154, R29CA063154] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Calsou P, 1996, J BIOL CHEM, V271, P27601, DOI 10.1074/jbc.271.44.27601; CHENGKEAT T, 1987, NUCLEIC ACIDS RES, V22, P9299; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Frosina G, 1996, J BIOL CHEM, V271, P9573, DOI 10.1074/jbc.271.16.9573; HANSSON J, 1990, NUCLEIC ACIDS RES, V18, P35, DOI 10.1093/nar/18.1.35; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lindahl T, 1995, J CELL SCI, P73; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PODUST LM, 1994, NUCLEIC ACIDS RES, V22, P2970, DOI 10.1093/nar/22.15.2970; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WALLACE SS, 1994, INT J RADIAT BIOL, V66, P579, DOI 10.1080/09553009414551661; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Yao N, 1996, GENES CELLS, V1, P101, DOI 10.1046/j.1365-2443.1996.07007.x	27	176	177	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					898	902		10.1074/jbc.273.2.898	http://dx.doi.org/10.1074/jbc.273.2.898			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422747	hybrid			2022-12-25	WOS:000071411400036
J	Chen, J; Kubalak, SW; Minamisawa, S; Price, RL; Becker, KD; Hickey, R; Ross, J; Chien, KR				Chen, J; Kubalak, SW; Minamisawa, S; Price, RL; Becker, KD; Hickey, R; Ross, J; Chien, KR			Selective requirement of myosin light chain 2v in embryonic heart function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CONTRACTION; SKELETAL-MUSCLE; GENE-EXPRESSION; MICE; SPECIFICATION; PATTERNS; DEFECTS; CELLS	Two major myosin light chain 2 isoforms are coexpressed in the early stages of murine cardiogenesis, a cardiac ventricular isoform and a cardiac atrial isoform, each of which is tightly regulated in a muscle cell-type-specific manner during embryogenesis (Chien, K. R., Zhu, H., Knowlton, K. U., Miller-Hance, W., van Bilsen, M., O'Brien, T. X., and Evans, S. M. (1993) Annu. Rev. Physiol. 55, 77-95). We have disrupted myosin light chain 2v gene in mice and monitored in vivo cardiac function in living myosin light chain 2v -/- embryos, The mutant embryos die at approximately embryonic day 12.5. In mutant ventricles, the myosin light chain 2a protein level is increased and reaches levels comparable to the myosin light chain 2v in the ventricles of wild type littermates and is appropriately incorporated into the thick filaments of mutant embryonic hearts, However despite the substitution of myosin light chain 2a, ultrastructural analysis revealed defects in sarcomeric assembly and an embryonic form of dilated cardiomyopathy characterized by a significantly reduced left ventricular ejection fraction in mutant embryos compared with wild type littermates, We conclude that myosin light chain 2v may have a unique function in the maintenance of cardiac contractility and ventricular chamber morphogenesis during mammalian cardiogenesis and that a chamber-specific combinatorial code for sarcomeric assembly may exist that ultimately requires myosin light chain 2v in ventricular muscle cells.	Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Ctr Mol Genet, La Jolla, CA 92093 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA; Univ S Carolina, Sch Med, Dept Dev Biol & Anat, Columbia, SC 29208 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Medical University of South Carolina; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Chien, KR (corresponding author), Univ Calif San Diego, Sch Med, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	kchien@ucsd.edu	Chen, Ju/E-5579-2011	Minamisawa, Susumu/0000-0003-4728-2116				DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DYSON E, 1995, P NATL ACAD SCI USA, V92, P7386, DOI 10.1073/pnas.92.16.7386; Fishman MC, 1997, DEVELOPMENT, V124, P2099; Gotshall KR, 1997, P NATL ACAD SCI USA, V94, P4710, DOI 10.1073/pnas.94.9.4710; Gruber PJ, 1996, J CLIN INVEST, V98, P1332, DOI 10.1172/JCI118920; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; IWAKI K, 1990, J BIOL CHEM, V265, P13809; KABALAK SW, 1996, METHODS MOL GENET, V8, P470; KATOH T, 1989, J CELL BIOL, V109, P1549, DOI 10.1083/jcb.109.4.1549; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; LOWEY S, 1995, BIOPHYS J, V68, pS120; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Palermo J, 1996, CIRC RES, V78, P504, DOI 10.1161/01.RES.78.3.504; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Price RL, 1996, ANAT REC, V245, P83; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Ross RS, 1996, DEVELOPMENT, V122, P1799; Sheng ZL, 1996, DEVELOPMENT, V122, P419; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SWEENEY HL, 1993, AM J PHYSIOL, V264, pC1085, DOI 10.1152/ajpcell.1993.264.5.C1085; Tanaka N, 1997, AM J PHYSIOL-HEART C, V273, pH1368, DOI 10.1152/ajpheart.1997.273.3.H1368; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523	29	144	153	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1252	1256		10.1074/jbc.273.2.1252	http://dx.doi.org/10.1074/jbc.273.2.1252			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422794	hybrid			2022-12-25	WOS:000071411400083
J	Lin, SH; Henzel, WJ; Nayak, S; Dennis, D				Lin, SH; Henzel, WJ; Nayak, S; Dennis, D			Photoaffinity labeling by 4-thiodideoxyuridine triphosphate of the HIV-1 reverse transcriptase active site during synthesis - Sequence of the unique labeled hexapeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DNA-POLYMERASE-BETA; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; TEMPLATE-PRIMER; BINDING DOMAIN; DNTP ANALOG; MECHANISM; IDENTIFICATION; SENSITIVITY	The active site of HIV-I reverse transcriptase (HIV-1 RT) was investigated by photoaffinity labeling based on catalytic competence, A stable ternary elongation complex was assembled containing enzyme, DNA template (RT20), DNA primer molecule (P12), and the necessary dNTPs (one of which was alpha-P-32-labeled) needed for primer elongation. The photoaffinity probe 4-thiodide-oxyuridine triphosphate was incorporated uniquely at the 3' terminus of the P-32-labeled DNA product, Upon photolysis, the p66 subunit of a HIV-1 RT heterodimer (p66/p51) was uniquely cross-linked to the DNA product and subsequently digested by either trypsin or endoproteinase Lys-C. The labeled HIV-1 RT peptide was separated, purified, and finally subjected to Edman microsequencing. A unique radioactive hexapeptide (V(276)RQLCK(281)) was identified and sequenced, Our photoaffinity labeling results were positioned on the HIV-1 RT DNA Fab complex x-ray crystallography structure and compared with the suggested aspartic triad active site.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Genentech Inc, San Francisco, CA 94080 USA	University of Delaware; Roche Holding; Genentech	Dennis, D (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.	ddennis@udel.edu		Henzel, William/0000-0003-2940-3797				BASU A, 1989, J BIOL CHEM, V264, P8746; BASU A, 1992, BIOCHEMISTRY-US, V31, P616, DOI 10.1021/bi00117a045; BOYER PL, 1992, J VIROL, V66, P1031, DOI 10.1128/JVI.66.2.1031-1039.1992; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; CHENG N, 1993, BIOCHEMISTRY-US, V32, P7630, DOI 10.1021/bi00081a005; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; Hsiou Y, 1996, STRUCTURE, V4, P853, DOI 10.1016/S0969-2126(96)00091-3; HUBER HE, 1990, J BIOL CHEM, V265, P10565; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JAJU M, 1995, J BIOL CHEM, V270, P9740, DOI 10.1074/jbc.270.17.9740; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; KATI WM, 1992, J BIOL CHEM, V267, P25988; KEDAR PS, 1990, BIOCHEMISTRY-US, V29, P3603, DOI 10.1021/bi00467a003; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MITCHELL LLW, 1992, BIOCHEMISTRY-US, V31, P7707, DOI 10.1021/bi00148a035; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; REARDON JE, 1990, J BIOL CHEM, V265, P20302; RODGERS DW, 1995, P NATL ACAD SCI USA, V90, P6320; RUTH JL, 1981, MOL PHARMACOL, V20, P415; SHENG NJ, 1993, BIOCHEMISTRY-US, V32, P4938, DOI 10.1021/bi00069a031; SOBOL RW, 1993, BIOCHEMISTRY-US, V30, P10623; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445	31	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					997	1002		10.1074/jbc.273.2.997	http://dx.doi.org/10.1074/jbc.273.2.997			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422761	hybrid			2022-12-25	WOS:000071411400050
J	Rouy, D; Duverger, N; Lin, SD; Emmanuel, F; Houdebine, LM; Denefle, P; Viglietta, C; Gong, E; Rubin, EM; Hughes, SD				Rouy, D; Duverger, N; Lin, SD; Emmanuel, F; Houdebine, LM; Denefle, P; Viglietta, C; Gong, E; Rubin, EM; Hughes, SD			Apolipoprotein(a) yeast artificial chromosome transgenic rabbits - Lipoprotein(a) assembly with human and rabbit apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); MICE; GENE; MUTAGENESIS; SITE	The in vivo analysis of lipoprotein(a) (Lp(a)), an independent atherosclerosis risk factor in humans, has been limited in part by its restricted distribution among mammals, Although transgenic mice have been created containing Lp(a), the relatively small size of the mouse has precluded some studies. To examine the properties of this molecule in a significantly larger mammal, we have used a 270-kilobase yeast artificial chromosome clone containing the human apolipoprotein(a) (apo(a)) gene and a 90-kilobase P1 phagemid clone containing the human apolipoprotein B (apoB) gene to create transgenic rabbits that express either or both transgenes, Expression of both transgenes was tissue specific and localized predominantly to the liver, Average apolipoprotein plasma levels in the rabbits were 2.5 mg/dl for apo(a) and 17.6 mg/dl for human apoB. In contrast to observations in apo(a) transgenic mice, we found that apo(a) plasma levels in the rabbits were stable throughout sexual maturity, Also, apo(a) formed a covalent association with the endogenous rabbit apoB albeit with a lower efficiency than its association with human apoB, The analysis of Lp(a) transgenic rabbits has provided new insights into apo(a) expression and Lp(a) assembly, In addition, these transgenic rabbits potential will provide an improved experimental model for the in vivo analysis of Lp(a) and its role in promoting atherosclerosis and restenosis.	Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Human Genome, Div Life Sci, Berkeley, CA 94720 USA; Ctr Rech Vitry Alfortville, Rhone Poulenc Rorer Gencell, Atherosclerosis Dept, F-94403 Vitry Sur Seine, France; INRA, F-78352 Jouy En Josas, France	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Sanofi-Aventis; Sanofi France; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Rubin, EM (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Ctr Human Genome, Div Life Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	emrubin@lbl.gov			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018574] Funding Source: NIH RePORTER; NHLBI NIH HHS [PPG HL18574] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CALLOW MJ, 1995, J BIOL CHEM, V270, P23914, DOI 10.1074/jbc.270.41.23914; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHIESA G, 1992, J BIOL CHEM, V267, P24369; COUTO LB, 1989, NUCLEIC ACIDS RES, V17, P8010, DOI 10.1093/nar/17.19.8010; Duverger N, 1996, ARTERIOSCL THROM VAS, V16, P1424, DOI 10.1161/01.ATV.16.12.1424; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gabel BR, 1996, ARTERIOSCL THROM VAS, V16, P1559, DOI 10.1161/01.ATV.16.12.1559; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Hughes SD, 1996, HUM GENE THER, V7, P39, DOI 10.1089/hum.1996.7.1-39; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; MAHER VMG, 1995, CURR OPIN LIPIDOL, V6, P229, DOI 10.1097/00041433-199508000-00007; MCCORMICK SPA, 1995, P NATL ACAD SCI USA, V92, P10147, DOI 10.1073/pnas.92.22.10147; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIEU VN, 1995, BIOCHEM J, V309, P899, DOI 10.1042/bj3090899; TRIEU VN, 1995, J BIOL CHEM, V270, P15471, DOI 10.1074/jbc.270.26.15471; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631	21	41	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1247	1251		10.1074/jbc.273.2.1247	http://dx.doi.org/10.1074/jbc.273.2.1247			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422793	hybrid			2022-12-25	WOS:000071411400082
J	Schneider, R; Wray, V; Nimtz, M; Lehmann, WD; Kirch, U; Antolovic, R; Schoner, W				Schneider, R; Wray, V; Nimtz, M; Lehmann, WD; Kirch, U; Antolovic, R; Schoner, W			Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIGITALIS-LIKE FACTORS; HUMAN PLASMA; PIG URINE; IDENTIFICATION; COMPOUND; HYPOTHALAMUS	In the search for endogenous cardiac glycosides, two different inhibitors of the sodium pump have been isolated from bovine adrenals, Inhibitor A with a molecular mass of 600 Da and a UV maximum at 250 nm was purified from 16 kg of bovine adrenals, The pure substance (<1 ng) inhibited the sodium pump of human red blood cells with an affinity similar to that of ouabain, yet it cross-reacted with antibodies against the bufadienolide proscillaridin A but not against the cardenolide ouabain, Inhibitor A was slightly more hydrophilic than ouabain on RP-C-18 high pressure liquid chromatography, Hence, it showed properties similar to the proscillaridin A immunoreactivity (Sich, B., Kirch, U., Tepel, M., Zideck, W., and Schoner, W. (1996) Hypertension 27, 1073-1078) that increased in humans with systolic blood pressure and pulse pressure. Inhibitor B of the sodium pump with a molecular mass of 584 Da was purified 10(6)-fold from 20 kg of bovine adrenals, It cross-reacted with antibodies against ouabain but not with antibodies against proscillaridin A and inhibited the sodium pump of human and rat red blood cells with the same affinity as ouabain, All other properties, such as the retention time in a C-18-reversed phase chromatography, molecular mass determination by electrospray mass spectrometry and fragmentation pattern, and UV and H-1 NMR spectroscopic data, were identical to ouabain. Hence, sodium pump inhibitor B from bovine adrenals is the cardenolide ouabain.	Univ Giessen, Fachbereich Vet Med, Inst Biochem & Endokrinol, D-35392 Giessen, Germany; Gesell Biotechnol Forsch GmbH, D-38124 Braunschweig, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Justus Liebig University Giessen; Gesellschaft fur Biotechnologische Forschung mbH; Helmholtz Association; German Cancer Research Center (DKFZ)	Schoner, W (corresponding author), Univ Giessen, Fachbereich Vet Med, Inst Biochem & Endokrinol, Frankfurter Str 100, D-35392 Giessen, Germany.							BAGROV AY, 1997, IN PRESS AM J HYPERT; DEWARDENER HE, 1985, PHYSIOL REV, V65, P658, DOI 10.1152/physrev.1985.65.3.658; FERRANDI M, 1992, AM J PHYSIOL, V263, pF739, DOI 10.1152/ajprenal.1992.263.4.F739; FIESER LF, 1961, STEROIDE, P801; GOTO A, 1992, PHARMACOL REV, V44, P377; GOTO A, 1990, BIOCHEM BIOPH RES CO, V173, P1093, DOI 10.1016/S0006-291X(05)80898-8; Haddy Francis J., 1995, P1055; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; Hamlyn John M., 1995, P1069; HAUPERT GT, 1994, SODIUM PUMP, P732; Hilton PJ, 1996, LANCET, V348, P303, DOI 10.1016/S0140-6736(96)02257-X; HINSON JP, 1995, J ENDOCRINOL, V146, P369, DOI 10.1677/joe.0.1460369; KITANO S, 1993, THER RES, V14, P201; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LICHTSTEIN D, 1993, EUR J BIOCHEM, V216, P261, DOI 10.1111/j.1432-1033.1993.tb18141.x; LUDENS JH, 1992, HYPERTENSION, V19, P721, DOI 10.1161/01.HYP.19.6.721; PERRIN A, 1997, MOL CELL ENDOCRINOL, V126, P1; PFANDER H, 1980, CHIMIA, V34, P179; REPKE KRH, 1995, ANGEW CHEM INT EDIT, V34, P282, DOI 10.1002/anie.199502821; SCHNEIDER R, 1997, IN PRESS AM J HYPERT; Schoner W, 1993, Prog Drug Res, V41, P249; Sich B, 1996, HYPERTENSION, V27, P1073, DOI 10.1161/01.HYP.27.5.1073; TAMURA M, 1994, J BIOL CHEM, V269, P11972; TAMURA M, 1993, EUR J BIOCHEM, V211, P317, DOI 10.1111/j.1432-1033.1993.tb19901.x; TAMURA M, 1988, BIOCHEMISTRY-US, V27, P4244, DOI 10.1021/bi00412a007; TAMURA M, 1993, BIOCHIM BIOPHYS ACTA, V1157, P15, DOI 10.1016/0304-4165(93)90073-H; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; WENZEL M, 1990, PHYSIOL BOHEMOSLOV, V39, P79; ZHAO N, 1995, BIOCHEMISTRY-US, V34, P9893, DOI 10.1021/bi00031a010	30	133	138	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					784	792		10.1074/jbc.273.2.784	http://dx.doi.org/10.1074/jbc.273.2.784			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422732	hybrid			2022-12-25	WOS:000071411400021
J	Thiele, C; Huttner, WB				Thiele, C; Huttner, WB			The disulfide-bonded loop of chromogranins, which is essential for sorting to secretory granules, mediates homodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B SECRETOGRANIN-I; TRANS-GOLGI NETWORK; BOVINE CHROMOGRANIN; PROTEIN; AGGREGATION; PATHWAY; CELLS; GENE; PROOPIOMELANOCORTIN; SEQUENCE	Chromogranins A and B, two widespread neuroendocrine secretory proteins, contain a homologous N-terminal disulfide-bonded loop that is required for sorting to secretory granules. Here we have investigated the role of this loop in the oligomerization of chromogranin A. Reduction of the disulfide bond or the addition of an excess of an N-terminal chromogranin A fragment containing the loop (CgA(1-60)) resulted in the dissociation into monomers of the chromogranin A dimer found at pH 7.4 and 6.4 and of the chromogranin tetramer found at pH 5.4. The addition of an excess of a synthetic peptide corresponding to the conserved C-terminal domain of chromogranin A (CgA(406-431)) had no effect on the chromogranin dimers at pH 7.4 and 6.4 and resulted in the dissociation of the chromogranin A tetramers at pH 5.4 into dimers. Fluorescence energy transfer experiments using fluorescently labeled CgA(1-60) showed that the N-terminal disulfide-bonded loop has a high affinity for homodimerization (K-D = 20 nM at pH 6.4), which was sufficient to mediate dimerization of full-length chromogranin A. Association and dissociation of loop-mediated chromogranin A dimerization approached completion within a few seconds. Our results imply that chromogranin A homodimerizes shortly after synthesis in the endoplasmic reticulum and that the loop-mediated homodimeric state is an essential prerequisite for its sorting, in the trans-Golgi network to secretory granules.	Heidelberg Univ, Dept Neurobiol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Huttner, WB (corresponding author), Heidelberg Univ, Dept Neurobiol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany.		Huttner, Wieland B./P-4080-2018					ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; Bartlett S F, 1974, Methods Enzymol, V31, P379; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BENEDUM UM, 1987, EMBO J, V6, P1203, DOI 10.1002/j.1460-2075.1987.tb02355.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1994, FEBS LETT, V351, P225, DOI 10.1016/0014-5793(94)00865-5; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; COOL DR, 1995, J BIOL CHEM, V270, P8723, DOI 10.1074/jbc.270.15.8723; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; IACANGELO AL, 1991, MOL ENDOCRINOL, V5, P1651, DOI 10.1210/mend-5-11-1651; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; POHL TM, 1990, FEBS LETT, V262, P219, DOI 10.1016/0014-5793(90)80194-N; SETTLEMAN J, 1985, J BIOL CHEM, V260, P1641; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; SMITH MH, 1970, HDB BIOCH, pC3; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TAM WWH, 1993, EUR J CELL BIOL, V62, P294; Thiele C, 1997, CURR BIOL, V7, pR496, DOI 10.1016/S0960-9822(06)00247-8; TOOZE J, 1989, J CELL BIOL, V109, P35, DOI 10.1083/jcb.109.1.35; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1993, MECHANISMS INTRACELL, P157; Ullman E F, 1981, Methods Enzymol, V74 Pt C, P28; Urbe S, 1997, BIOCHEM J, V321, P65, DOI 10.1042/bj3210065; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; YOO SH, 1990, J BIOL CHEM, V265, P14414	36	69	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1223	1231		10.1074/jbc.273.2.1223	http://dx.doi.org/10.1074/jbc.273.2.1223			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422790	hybrid			2022-12-25	WOS:000071411400079
J	Wojtaszek, PA; Heasley, LE; Siriwardana, G; Berl, T				Wojtaszek, PA; Heasley, LE; Siriwardana, G; Berl, T			Dominant-negative c-Jun NH2-terminal kinase 2 sensitizes renal inner medullary collecting duct cells to hypertonicity-induced lethality independent of organic osmolyte transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; ALDOSE REDUCTASE GENE; TRANSCRIPTION FACTOR; PROTEIN-KINASES; OSMOTIC-STRESS; MAP KINASE; EXPRESSION; ACTIVATION; PHOSPHORYLATION; TONICITY	The c-Jun NH2-terminal protein kinases (JNKs), as well as the extracellular signal-regulated protein kinases (ERKs) and p38 mitogen-activated protein kinase, are activated in renal cells in response to extracellular hypertonicity, To determine whether activation of JNKs by hypertonicity is isoform-specific, renal inner medullary collecting duct cells were stably transfected with cDNA's encoding hemagglutinin (HA)-tagged JNK1 and JNK2 isoforms, and the expressed kinases were immunoprecipitated with an anti-HA. antibody, Whereas both recombinant kinases were equivalently expressed, only immunoprecipitates from the HA-JNK2 cells displayed hypertonicity-inducible JNK activity, Furthermore, expression of dominant-negative JNK2 (HA-JNK2-APF) in stable clones inhibited hypertonicity-induced JNK activation by 40-70%, whereas expression of dominant-negative JNK1 (HA-JNK1-APF) had no significant inhibitory effect, Independent HA-JNK2-APF (but not HA-JNK1-APF) clones displayed greatly reduced viability relative to neomycin controls after 16 h of exposure to 600 mosM/kg hypertonic medium with percent survival of 20.5 +/- 2.7 and 31.5 +/- 7.3 for two independent HA-JNK2-APF clones compared with 80.1 +/- 1.0 for neomycin controls (p < 0.001, n = 5, mean +/- S.E.). However, neither JNK mutant blocked either regulatory volume increase or hypertonicity-induced enhancement of uptake of inositol, an organic osmolyte putatively involved in long term adaptation to hypertonicity, These results define JNK2 as the primary hypertonicity-activated JNK isoform in IMCD-3 cells and demonstrate its central importance in cellular survival in a hypertonic environment by a mechanism independent of acute regulatory volume increase as well as regulation of organic osmolyte uptake.	Univ Colorado, Sch Med, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Berl, T (corresponding author), Univ Colorado, Sch Med, Dept Med, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM048826] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19928] Funding Source: Medline; NIGMS NIH HHS [GM-48826] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; BERL T, 1997, AM J PHYSIOL, V272, pF304; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Butterfield L, 1997, J BIOL CHEM, V272, P10110; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Ferraris JD, 1996, J BIOL CHEM, V271, P18318, DOI 10.1074/jbc.271.31.18318; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANDLER JS, 1993, AM J PHYSIOL, V265, pC1449, DOI 10.1152/ajpcell.1993.265.6.C1449; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kojima R, 1996, J BIOL CHEM, V271, P12327, DOI 10.1074/jbc.271.21.12327; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; KYRIAKIS J, 1995, J BIOL CHEM, V271, P24313; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TERADA Y, 1994, J BIOL CHEM, V269, P31296; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; VEIS JH, 1991, AM J PHYSIOL, V260, pF619, DOI 10.1152/ajprenal.1991.260.5.F619; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20	27	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					800	804		10.1074/jbc.273.2.800	http://dx.doi.org/10.1074/jbc.273.2.800			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422734	hybrid			2022-12-25	WOS:000071411400023
J	Gilpin, BJ; Loechel, F; Mattei, MG; Engvall, E; Albrechtsen, R; Wewer, UM				Gilpin, BJ; Loechel, F; Mattei, MG; Engvall, E; Albrechtsen, R; Wewer, UM			A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM-EGG FUSION; DISINTEGRIN-LIKE; METALLOPROTEASE; GENE; LAMININ; FAMILY; PROTEIN; DOMAINS; CELL; HYBRIDIZATION	The ADAM (A Disintegrin And Metalloprotease) family of cell-surface proteins may have an important role in cellular interactions and in modulating cellular responses, In this report we describe a novel, secreted form of human ADAM 12 (meltrin alpha), designated ADAM 12-S (S for short), and a larger, membrane-bound form designated ADAM 12-L (L for long form). These two forms arise by alternative splicing of a single gene located on chromosome 10q26. Northern blotting demonstrated that mRNAs of both forms are abundant in human term placenta and are also present in some tumor cell lines. The ADAM 12-L transcript can also be detected in normal human adult skeletal, cardiac, and smooth muscle. Human A204 embryonal rhabdomyosarcoma cells that do not differentiate into muscle cells and do not express any form of ADAM 12 were stably transfected with an ADAM 12-S minigene encoding the disintegrin domain, the cysteine-rich domain, and the unique 34 amino acid carboxyl terminus. Nude mouse tumors derived from these transfected cells contained ectopic muscle cells of apparent mouse origin as shown by species-specific markers. These results may have potential applications in the development of muscle-directed gene and cell therapies.	Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark; Fac Med Timone, F-13385 Marseille, France; Burnham Inst, La Jolla, CA 92037 USA	University of Copenhagen; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Sanford Burnham Prebys Medical Discovery Institute	Wewer, UM (corresponding author), Univ Copenhagen, Inst Mol Pathol, Frederik V Vej 11, DK-2100 Copenhagen, Denmark.		; Gilpin, Brent/E-3463-2013	Albrechtsen, Reidar/0000-0003-4180-1827; Gilpin, Brent/0000-0002-8109-2271				Alfandari D, 1997, DEV BIOL, V182, P314, DOI 10.1006/dbio.1996.8458; ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bigler D, 1997, TRENDS CELL BIOL, V7, P220, DOI 10.1016/S0962-8924(97)01058-1; Bischoff R., 1994, MYOLOGY, VVolume 1, P97; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BUONANNO A, 1992, NUCLEIC ACIDS RES, V20, P539, DOI 10.1093/nar/20.3.539; Burkin HR, 1997, GENOMICS, V40, P190, DOI 10.1006/geno.1996.4531; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Cho CH, 1996, GENOMICS, V34, P413, DOI 10.1006/geno.1996.0305; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Fambrough D, 1996, P NATL ACAD SCI USA, V93, P13233, DOI 10.1073/pnas.93.23.13233; FOX JW, 1996, ZINC METALLOPROTEINA, P47; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; Huovila APJ, 1996, CURR OPIN CELL BIOL, V8, P692, DOI 10.1016/S0955-0674(96)80111-6; Jury JA, 1997, BIOCHEM J, V321, P577, DOI 10.1042/bj3210577; KATAGIRI T, 1995, CYTOGENET CELL GENET, V68, P39, DOI 10.1159/000133884; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEMIEUX N, 1992, CYTOGENET CELL GENET, V59, P311, DOI 10.1159/000133277; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; OTT MO, 1991, DEVELOPMENT, V111, P1097; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PERRY ACF, 1995, BIOCHEM J, V312, P239, DOI 10.1042/bj3120239; PERRY ACF, 1995, BIOCHEM J, V307, P843, DOI 10.1042/bj3070843; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shilling FM, 1997, DEV BIOL, V186, P155, DOI 10.1006/dbio.1997.8586; Vachon PH, 1996, J CELL BIOL, V134, P1483, DOI 10.1083/jcb.134.6.1483; Vidaeus CM, 1997, MOL REPROD DEV, V46, P363; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; WEWER UM, 1994, LAB INVEST, V71, P719; Wewer UM, 1997, AM J PATHOL, V151, P621; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yoshiyama K, 1997, GENOMICS, V41, P56, DOI 10.1006/geno.1997.4607	50	264	284	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					157	166		10.1074/jbc.273.1.157	http://dx.doi.org/10.1074/jbc.273.1.157			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417060	hybrid			2022-12-25	WOS:000071295600026
J	Hilliard, JJ; Simon, LD; Van Melderen, L; Maurizi, MR				Hilliard, JJ; Simon, LD; Van Melderen, L; Maurizi, MR			PinA inhibits ATP hydrolysis and energy-dependent protein degradation by Lon protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUBSTRATES ACTIVATE; LA; PURIFICATION; PROTEOLYSIS; PEPTIDES; BINDING; GENE	The bacteriophage T4 PinA protein inhibited degradation of [H-3]alpha-methyl casein by purified Lon protease from Escherichia coli, but inhibition was noncompetitive with respect to casein, PinA did not inhibit cleavage of the fluorogenic peptide, N-glutaryl-alanylalanylphenylalanyl-3-methoxynaphthylamide and, moreover, did not block the ability of protein substrates, such as casein, to activate cleavage of fluorogenic peptides by Lon, Thus, PinA does not block the proteolytic active site or the allosteric protein-binding site on Lon, Inhibition of basal ATPase activity was variable (50-90%), whereas inhibition of protein-activated ATPase activity was usually 80-95%, Inhibition was noncompetitive with respect to ATP, PinA did not block activation of peptide cleavage by nonhydrolyzable analogs of ATP, These data suggest that PinA does not bind at the ATPase active site of Lon and does not interfere with nucleotide binding to the enzyme, PinA inhibited cleavage of the 72-amino acid protein, CcdA, degradation of which requires ATP hydrolysis, but did not inhibit cleavage of the carboxyl-terminal 41-amino acid fragment of CcdA, degradation of which does not require ATP hydrolysis, PinA thus appears to interact at a novel regulatory or enzymatic site involved in the coupling between ATP hydrolysis and proteolysis, possibly blocking the protein unfolding or remodeling step essential for degradation of high molecular weight protein substrates by Lon.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08855 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rutgers State University New Brunswick	Maurizi, MR (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Rm 1B07, Bethesda, MD 20892 USA.			Van Melderen, Laurence/0000-0002-7778-1736				ANASTASI A, 1983, BIOCHEM J, V211, P129, DOI 10.1042/bj2110129; CHUNG CH, 1983, J BIOL CHEM, V258, P1032; FISCHER H, 1993, J BIOL CHEM, V268, P22502; GOLDBERG AL, 1994, METHOD ENZYMOL, V244, P350; GOLDBERG AL, 1985, J BIOL CHEM, V260, P2029; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Hilliard JJ, 1998, J BIOL CHEM, V273, P518, DOI 10.1074/jbc.273.1.518; MAURIZI MR, 1987, J BIOL CHEM, V262, P2696; MENON AS, 1987, J BIOL CHEM, V262, P14929; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; SHACTER E, 1984, ANAL BIOCHEM, V138, P416, DOI 10.1016/0003-2697(84)90831-5; SKORUPSKI K, 1988, J BACTERIOL, V170, P3016, DOI 10.1128/jb.170.7.3016-3024.1988; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; UEHARA Y, 1978, J BIOCHEM-TOKYO, V84, P1195, DOI 10.1093/oxfordjournals.jbchem.a132236; VanMelderen L, 1996, J BIOL CHEM, V271, P27730, DOI 10.1074/jbc.271.44.27730; WAXMAN L, 1985, J BIOL CHEM, V260, P2022; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218	20	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					524	527		10.1074/jbc.273.1.524	http://dx.doi.org/10.1074/jbc.273.1.524			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417111	hybrid			2022-12-25	WOS:000071295600077
J	Cupers, P; ter Haar, E; Boll, W; Kirchhausen, T				Cupers, P; ter Haar, E; Boll, W; Kirchhausen, T			Parallel dimers and anti-parallel tetramers formed by epidermal growth factor receptor pathway substrate clone 15 (EPS15)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; ACTIN CYTOSKELETON; COATED PITS; CLATHRIN; PROTEIN; DOMAIN; ORGANIZATION; VESICLES; LOCATION; AP-2	The recently discovered localization of epidermal growth factor receptor pathway substrate clone 15 (Eps15) to plasma membrane clathrin-coated pits and its constitutive association with the endocytic clathrin adaptor protein complex, AP-2, strongly suggest that Eps15 has an important role in the pathway of clathrin-dependent endocytic traffic. We report here that Eps15 forms dimers and tetramers of distinct shape, The Eps15 dimer is an elongated molecule, 32 nm in length. There is a globular "head" at one end of the molecule and an extended "stalk" of 25 nm which is kinked at about 17 nm away from the head. In the Eps15 dimer, two sub-units are arranged parallel to each other, so that the head corresponds to two side by side copies of the N-terminal region I, which contains the three Eps15 homology domains, The proximal part of the stalk is the coiled-coil central region II containing 20 heptad repeats. The kink is at the boundary between region II and the C-terminal region III, which contains the AP-2 binding site, 15 aspartic-proline-phenylalanine repeats, and proline-rich Src homology domain ligand sites. The Eps15 tetramer has a "dumbbell" shape, similar to 31 nm in length; it is formed by the anti-parallel association of two Eps15 dimers, Formation of these Eps15 tetramers appears to require contacts between regions I of one dimer and regions III of a second apposing dimer. The extended shapes of the Eps15 dimers and tetramers suggest how Eps15 oligomers are located in the clathrin coat. We discuss the implications for accessibility to partners and for proposed functions of Eps15.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36548] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; CROWTHER RA, 1981, J CELL BIOL, V91, P790, DOI 10.1083/jcb.91.3.790; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FOWLER WE, 1979, J MOL BIOL, V134, P241, DOI 10.1016/0022-2836(79)90034-2; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; Iannolo G, 1997, CANCER RES, V57, P240; KIRCHHAUSEN T, 1983, P NATL ACAD SCI-BIOL, V80, P2481, DOI 10.1073/pnas.80.9.2481; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; Robinson MS, 1996, MOL BIOL CELL, V7, P977; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; Tang HY, 1996, MOL CELL BIOL, V16, P4897; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; TYLER JM, 1980, J ULTRA MOL STRUCT R, V71, P95, DOI 10.1016/S0022-5320(80)90098-2; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; Wendland B, 1996, J CELL BIOL, V135, P1485, DOI 10.1083/jcb.135.6.1485; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530	26	59	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33430	33434		10.1074/jbc.272.52.33430	http://dx.doi.org/10.1074/jbc.272.52.33430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407139	hybrid			2022-12-25	WOS:000071182900100
J	Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ				Darby, TG; Meissner, J; Ruhlmann, A; Mueller, WH; Scheibe, RJ			Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1	ONCOGENE			English	Article						cross-talk; Fli-1; hormone nuclear receptors; repression; erythroleukemia	HUMAN GLUCOCORTICOID RECEPTOR; PROVIRAL INTEGRATION SITE; ONCOGENE FAMILY MEMBER; MURINE LEUKEMIA-VIRUS; ETS GENE FAMILY; A-I GENE; THYROID-HORMONE; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-DIFFERENTIATION	The Fli-1 protein is a member of the ets proto-oncogene family, whose overexpression is a consequence of Friend murine leukemia virus (F-MuLV) integration in Friend erythroleukemic cells. We present evidence that Fli-1 and the retinoic acid receptor (RAR alpha) can reciprocally repress one another's transcriptional activation. Overexpression of Fli-1 inhibits the retinoic acid-induced activation of genes carrying a functional retinoic acid response element (RARE), Conversely, RAR alpha is able to repress Fli-1-mediated transcriptional activation. Transfection analysis of RAR alpha and Fli-1 mutants in cultured cells demonstrate that the DNA binding domain of RAR alpha and the N-terminal region of Fli-1 are required for repression, Gel retardation analysis demonstrates that RAR alpha cannot bind to the Fli-1 binding site in the E74 promoter and the expression of Fli-1 does not affect RAR alpha binding to DIVA, Furthermore, the data suggest an indirect interaction between Fli-1 and RAR alpha mediated by a 'bridging' factor(s) present in nuclear extracts from RM10 erythroleukemia cells, Fli-1 also interferes with the action of receptors for thyroid or glucocorticoid hormone in several hematopoietic cell lines, The RA-induced differentiation and decrease of cell proliferation was blocked in myeloblastic leukemia HL-60 cells overexpressing the N-terminal region of Fli-1 at physiological concentrations of RA. These data suggest that accumulation of Fli-1 can oppose the transcriptional activity of hormone receptors in hematopoietic cells.	Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany; Hannover Med Sch, Zentrum Biochem, Inst Physiol, D-30623 Hannover, Germany; Max Delbruck Zentrum, Berlin, Germany; Hannover Med Sch, Inst Mol Biol, D-30623 Hannover, Germany	Hannover Medical School; Hannover Medical School; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Hannover Medical School	Scheibe, RJ (corresponding author), Hannover Med Sch, Zentrum Biochem, Dept Clin Chem, D-30623 Hannover, Germany.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Blomhoff R., 1994, VITAMIN A HLTH DIS; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CELADA A, 1992, J IMMUNOL, V148, P1102; CHAMBON P, 1991, FAMILY RETINOIC ACID; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DARROW AL, 1990, MOL CELL BIOL, V10, P5883, DOI 10.1128/MCB.10.11.5883; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DELGADO MD, 1994, ONCOGENE, V9, P1723; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DETHE H, 1991, RETINOIC ACID RECEPT; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUTHIER JM, 1993, EMBO J, V12, P5089, DOI 10.1002/j.1460-2075.1993.tb06203.x; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GLASS CK, 1991, REGULATION GNEE TRAN; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAGMAN J, 1994, CURR OPIN IMMUNOL, V6, P222, DOI 10.1016/0952-7915(94)90095-7; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HOFFMANN B, 1990, MOL ENDOCRINOL, V4, P1727, DOI 10.1210/mend-4-11-1727; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HROMAS R, 1993, BLOOD, V82, P2998; HROMAS R, 1993, BIOCHIM BIOPHYS ACTA, V1172, P155, DOI 10.1016/0167-4781(93)90283-J; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; Kastner P, 1994, ROLE NUCL RETINOIC A; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KLEMSZ MJ, 1993, J BIOL CHEM, V268, P5769; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEIDEN JM, 1994, CURR OPIN IMMUNOL, V6, P231, DOI 10.1016/0952-7915(94)90096-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LESSNICK SL, 1995, ONCOGENE, V10, P423; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; LINNEY E, 1992, CURR TOP DEV BIOL, V27, P309, DOI 10.1016/S0070-2153(08)60538-4; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MANGELSDORF DJ, 1994, RETINOID RECEPTORS R; MAO XH, 1994, J BIOL CHEM, V269, P18216; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAGAYA T, 1993, J BIOL CHEM, V268, P15766; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PFAHL M, 1991, MOL MECH RETINOIC AC; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RAO VN, 1993, ONCOGENE, V8, P2167; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHROEDER C, 1992, ONCOGENE, V7, P217; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1990, ONCOGENE, V5, P1761; SHYAM E, 1990, CANCER RES, V50, P5013; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SPORN MB, 1994, RETINOIDS; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Watson DK, 1997, ONCOGENE, V14, P213, DOI 10.1038/sj.onc.1200839; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG LQ, 1993, ONCOGENE, V8, P1621; ZHANG LQ, 1995, MOL CELL BIOL, V15, P6961	88	31	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3067	3082		10.1038/sj.onc.1201503	http://dx.doi.org/10.1038/sj.onc.1201503			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444955				2022-12-25	WOS:000070968000007
J	Curtis, DJ; Robb, L; Strasser, A; Begley, CG				Curtis, DJ; Robb, L; Strasser, A; Begley, CG			The CD2-scl transgene alters the phenotype and frequency of T-lymphomas in N-ras transgenic or p53 deficient mice	ONCOGENE			English	Article						scl; tal-1; p53; ras; lymphomagenesis	ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; PEDIATRIC-ONCOLOGY-GROUP; SCL GENE-PRODUCT; WILD-TYPE P53; CELL LEUKEMIA; ERYTHROID-DIFFERENTIATION; THYMOCYTE DEVELOPMENT; POINT MUTATIONS; TAL1	Abnormal expression of SCL (TAL-1/TCL5) occurs in the majority of paediatric cases of acute T-cell lymphoblastic leukemia (T-ALL), Unexpectedly however, transgenic mice carrying scl coupled to the human T-cell specific CD2 enhancer (CD2-scl) did not spontaneously develop T-cell lymphomas despite high levels of scl expression in their thymocytes, Analogous to other transgenic models of lymphomagenesis, it is likely that additional genetic abnormalities are required to cooperate with scl to trigger lymphomagenesis, Two possible candidates are the p53 and N-ras genes which are mutated in some cases of T-ALL, particularly in relapsed disease, Therefore, we examined lymphomagenesis in the progeny of CD2-scl mice crossed with N-ras transgenic mice or p53 deficient, Surprisingly, the frequency of lymphomas in the p53 nullizygous or N-ras transgenic mice was not enhanced by expression of the scl transgene, In fact, expression of scl in both genetic backgrounds paradoxically reduced the frequency of thymic lymphomas and, at least in the p53 nullizygous mice, shifted the pattern of organ involvement to the peripheral lymphoid organs, In contrast, CD2-scl transgene expression accelerated lymphomagenesis in p53 heterozygous mice, These data suggest that the collaborative effects of scl with N-ras or p53 vary according to the developmental stage of the T-cell.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC, AUSTRALIA; ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LAB, MELBOURNE, VIC, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital			Strasser, Andreas/C-7581-2013; Curtis, David/H-4996-2014	Strasser, Andreas/0000-0002-5020-4891; Curtis, David/0000-0001-9497-0996	NCI NIH HHS [CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1992, CANCER SURV, V15, P119; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BASH RO, 1995, BLOOD, V86, P666, DOI 10.1182/blood.V86.2.666.bloodjournal862666; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BORN W, 1988, J IMMUNOL, V140, P3228; BOS JL, 1989, CANCER RES, V49, P4682; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; Condorelli GL, 1996, CANCER RES, V56, P5113; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DICCIANNI MB, 1994, BLOOD, V84, P3105; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELWOOD NJ, 1993, ONCOGENE, V8, P3093; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HARRIS AW, 1988, CURR TOP MICROBIOL, V141, P82; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; LANIER LL, 1986, J IMMUNOL, V137, P2501; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; LUBBERT M, 1990, BLOOD, V75, P1163; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PURDIE CA, 1994, ONCOGENE, V9, P603; REYNOLDS PJ, 1990, MOL CELL BIOL, V10, P4266, DOI 10.1128/MCB.10.8.4266; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; WADA M, 1993, BLOOD, V82, P3163; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	45	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	1997	15	24					2975	2983		10.1038/sj.onc.1201467	http://dx.doi.org/10.1038/sj.onc.1201467			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416841				2022-12-25	WOS:A1997YK37700010
J	Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ				Beham, A; Marin, MC; Fernandez, A; Herrmann, J; Brisbay, S; Tari, AM; LopezBerestein, G; Lozano, G; Sarkiss, M; McDonnell, TJ			Bcl-2 inhibits p53 nuclear import following DNA damage	ONCOGENE			English	Article						apoptosis; bcl-2; nuclear import; p53; prostate cancer	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; P53-MEDIATED APOPTOSIS; CARCINOMA-CELLS; LYMPHOID-CELLS; CYCLE ARREST; G(1) ARREST; IN-VIVO; PROTEIN	Bcl-2 is an integral membrane oncoprotein that localizes to membranes of the mitochondria, endoplasmic reticulum, and nuclear envelope, Bcl-2 is a member of a family of cell death regulators and functions to inhibit apoptosis, Using confocal microscopy and immunoblotting we show that the ability of bcl-2 to suppress cell death following genotoxic damage can be a consequence of inhibiting nuclear import of induced wild-type p53 protein, Our data suggests that the ability of bcl-2 to modulate trafficking events is not cell type specific, These data support a 'gatekeeper' mechanism for cell death suppression by bcl-2.	UNIV TEXAS,MD ANDERSON CANCER CTR,DIV MOL PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT IMMUNOBIOL & DRUG CARRIERS,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Marin, Maria C/G-1040-2010; Sarkiss, Mona/AAX-1346-2020; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X	NCI NIH HHS [CA09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSON JLA, 1995, MOL CELL BIOL, V15, P6953; CAELLES C, 1994, NATURE, V370, P174; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DEJONG D, 1994, CANCER RES, V54, P256; ELKIND NB, 1995, ONCOGENE, V11, P841; FRITSCHE M, 1993, ONCOGENE, V8, P307; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Jordan J, 1997, J NEUROSCI, V17, P1397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAM D, 1994, P NATL ACAD SCI USA, V9, P6569; LIN YP, 1995, MOL CELL BIOL, V15, P6045; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARIN MC, 1994, ONCOGENE, V9, P3107; Marin MC, 1996, ONCOGENE, V12, P2259; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; McDonnell TJ, 1997, J UROLOGY, V157, P569, DOI 10.1016/S0022-5347(01)65204-2; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NAGASAWA H, 1995, CANCER RES, V55, P1842; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sheikh MS, 1996, CELL GROWTH DIFFER, V7, P1599; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; Wang YS, 1996, ONCOGENE, V12, P2731; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533	43	80	83	1	11	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2767	2772		10.1038/sj.onc.1201464	http://dx.doi.org/10.1038/sj.onc.1201464			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419967				2022-12-25	WOS:A1997YJ80300002
J	Brushaber, KR; O'Toole, GA; Escalante-Semerena, JC				Brushaber, KR; O'Toole, GA; Escalante-Semerena, JC			CobD, a novel enzyme with L-threonine-O-3-phosphate decarboxylase activity, is responsible for the synthesis of (R)-1-amino-2-propanol O-2-phosphate, a proposed new intermediate in cobalamin biosynthesis in Salmonella typhimurium LT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSG GENE ENCODES; MULTIFUNCTIONAL PROTEIN; HYDROGENOBYRINIC ACID; NUCLEOTIDE LOOP; COENZYME B-12; PURIFICATION; VITAMIN-B12; TRANSDUCTION; RESISTANCE; INSERTION	The cobD gene of Salmonella typhimurium LT2 has been cloned, sequenced, and overexpressed, The overexpressed protein had a molecular mass of similar to 40 kDa, in agreement with the mass predicted by the deduced amino acid sequence (40.8 kDa), Computer analysis of the deduced amino acid sequence of CobD identified a consensus pyridoxal phosphate-binding motif, The role of CobD in cobalamin biosynthesis in this bacterium has been established. CobD was shown to decarboxylate L-threonine O-3-phosphate to yield (R)-1-amino-2-propanol O-2-phosphate. We propose that the latter is a substrate in the reaction catalyzed by the CbiB enzyme proposed to be responsible for the conversion of adenosylcobyric acid to adenosylcobinamide and that the product of the reaction is adenosylcobinamide phosphate, not adenosylcobinamide as previously thought, The implications of these findings are discussed in light of the demonstrated kinase activity of the CobU enzyme (O'Toole, G. A., and Escalante-Semerena, J. C. (1995) J. Biol. Chem. 270, 23560-23569) responsible for the conversion of adenosylcobinamide to adenosylcobinamide phosphate, These findings shed light on the strategy used by this bacterium for the assimilation of exogenous unphosphorylated cobinamide from its environment. To our knowledge, CobD is the first enzyme reported to have L-threonine-O-3-phosphate decarboxylase activity, and computer analysis of its amino acid sequence suggests that it may be a member of a new class of pyridoxal phosphate-dependent decarboxylases.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Escalante-Semerena, JC (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.	jcescala@facstaff.wisc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040313, R01GM040313, T32GM008349] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM040313, GM08349, GM40313] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; BLANCHE F, 1993, ANGEW CHEM INT EDIT, V32, P1651, DOI 10.1002/anie.199316511; BLANCHE F, 1995, ANGEW CHEM INT EDIT, V34, P383, DOI 10.1002/anie.199503831; BLANCHE F, 1990, ANGEW CHEM INT EDIT, V29, P884, DOI 10.1002/anie.199008841; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOYLAN SA, 1981, J BIOL CHEM, V256, P1809; CHAN RK, 1972, VIROLOGY, V50, P883, DOI 10.1016/0042-6822(72)90442-4; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; ELLIOTT T, 1988, MOL GEN GENET, V213, P332, DOI 10.1007/BF00339599; ESCALANTESEMERENA JC, 1987, J BACTERIOL, V169, P2251, DOI 10.1128/jb.169.5.2251-2258.1987; Fazzio TG, 1996, J BACTERIOL, V178, P6952, DOI 10.1128/jb.178.23.6952-6959.1996; FORD SH, 1976, ARCH BIOCHEM BIOPHYS, V175, P121, DOI 10.1016/0003-9861(76)90490-2; FORD SH, 1976, BIOCHEM BIOPH RES CO, V72, P1077, DOI 10.1016/S0006-291X(76)80242-2; FORD SH, 1977, BIOCHIM BIOPHYS ACTA, V500, P217, DOI 10.1016/0304-4165(77)90062-9; GALLAGHER SR, 1996, CURRENT PROTOCOLS MO, V2; GOLDMAN BS, 1993, J BACTERIOL, V175, P1457, DOI 10.1128/JB.175.5.1457-1466.1993; GRABAU C, 1992, J BACTERIOL, V174, P2138, DOI 10.1128/JB.174.7.2138-2144.1992; HUFF E, 1959, J BIOL CHEM, V234, P1060; JETER RM, 1984, J BACTERIOL, V159, P206, DOI 10.1128/JB.159.1.206-213.1984; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KELLEY JJ, 1984, J BIOL CHEM, V259, P2124; KRASNA AI, 1957, J BIOL CHEM, V225, P745; KUNITZ M, 1952, J GEN PHYSIOL, V35, P423, DOI 10.1085/jgp.35.3.423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NEUBERGER A, 1960, BIOCHIM BIOPHYS ACTA, V41, P164, DOI 10.1016/0006-3002(60)90388-7; OTOOLE GA, 1994, J BIOL CHEM, V269, P26503; OTOOLE GA, 1993, J BACTERIOL, V175, P3317, DOI 10.1128/jb.175.11.3317-3326.1993; OTOOLE GA, 1995, J BIOL CHEM, V270, P23560, DOI 10.1074/jbc.270.40.23560; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; REMY E, 1996, 4 EUR S VIT B12 B12, P46; Rondon MR, 1997, PROG NUCLEIC ACID RE, V56, P347, DOI 10.1016/S0079-6603(08)61010-7; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SCHMIEGER H, 1973, MOL GEN GENET, V120, P181, DOI 10.1007/BF00267246; SCHMIEGER H, 1971, MOL GEN GENET, V110, P378, DOI 10.1007/BF00438281; SCOTT AI, 1993, ANGEW CHEM INT EDIT, V32, P1223, DOI 10.1002/anie.199312233; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; SPENCER JB, 1993, FEBS LETT, V335, P57, DOI 10.1016/0014-5793(93)80438-Z; TABOR S, 1990, CURRENT PROTOCOLS MO, V2; TAYLOR RT, 1973, ENZYMES, V9, P121; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WARREN MJ, 1994, BIOCHEM J, V302, P837, DOI 10.1042/bj3020837	44	40	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2684	2691		10.1074/jbc.273.5.2684	http://dx.doi.org/10.1074/jbc.273.5.2684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446573	hybrid			2022-12-25	WOS:000071736600028
J	Marians, KJ; Hiasa, H; Kim, DR; McHenry, CS				Marians, KJ; Hiasa, H; Kim, DR; McHenry, CS			Role of the core DNA polymerase III subunits at the replication fork - alpha is the only subunit required for processive replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COORDINATED LEADING-STRAND; ONE HOLOENZYME PARTICLE; OKAZAKI FRAGMENT SIZE; ESCHERICHIA-COLI; EPSILON-SUBUNIT; SLIDING CLAMPS; THETA-SUBUNIT; BETA-SUBUNIT; PHI-X174-TYPE PRIMOSOME; SALMONELLA-TYPHIMURIUM	The DNA polymerase III holoenzyme is composed of 10 subunits. The core of the polymerase contains the catalytic polymerase subunit, alpha, the proofreading 3' --> 5' exonuclease, epsilon, and a subunit of unknown function, theta. The availability of the holoenzyme subunits in purified form has allowed us to investigate their roles at the replication fork. We show here that of the three subunits in the core polymerase, only alpha is required to form processive replication forks that move at high rates and that exhibit coupled leading-and lagging-strand synthesis in vitro. Taken together with previous data this suggests that the primary determinant of replication fork processivity is the interaction between another holoenzyme subunit, tau, and the replication fork helicase, DnaB.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem Biophys & Genet, Denver, CO 80262 USA	Memorial Sloan Kettering Cancer Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Marians, KJ (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.				NIGMS NIH HHS [GM36255, GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R01GM036255, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1975, DNA SYNTHESIS ITS RE, P241; BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; CARTER JR, 1993, NUCLEIC ACIDS RES, V21, P3281, DOI 10.1093/nar/21.14.3281; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; DEGUEN GE, 1974, J BACTERIOL, V117, P477; FAY PJ, 1981, J BIOL CHEM, V256, P976; FAY PJ, 1982, J BIOL CHEM, V257, P5692; GEFTER ML, 1971, P NATL ACAD SCI USA, V68, P3150, DOI 10.1073/pnas.68.12.3150; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P16371; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kogoma T, 1996, CELL, V85, P625, DOI 10.1016/S0092-8674(00)81229-5; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LANCY ED, 1989, J BACTERIOL, V171, P5572, DOI 10.1128/jb.171.10.5572-5580.1989; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LIFSICS MR, 1992, J BACTERIOL, V174, P6965, DOI 10.1128/JB.174.21.6965-6973.1992; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI H, 1988, J BIOL CHEM, V263, P6570; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MODEL P, 1974, J MOL BIOL, V83, P231, DOI 10.1016/0022-2836(74)90389-1; MOK M, 1987, J BIOL CHEM, V262, P16644; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; STUKENBERG PT, 1995, J BIOL CHEM, V270, P13384, DOI 10.1074/jbc.270.22.13384; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WELCH MM, 1982, J BACTERIOL, V152, P351; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P16558; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4064; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4; ZECHNER EL, 1992, J BIOL CHEM, V267, P4054; ZECHNER EL, 1992, J BIOL CHEM, V267, P4045	58	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2452	2457		10.1074/jbc.273.4.2452	http://dx.doi.org/10.1074/jbc.273.4.2452			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442096	hybrid			2022-12-25	WOS:000071595200085
J	Spicer, AP; McDonald, JA				Spicer, AP; McDonald, JA			Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; SYNTHESIZE HYALURONAN; POLYSACCHARIDE BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; OLIGODENDROGLIOMA CELLS; CHITIN OLIGOSACCHARIDES; RECEPTOR RHAMM; ACID CAPSULE; DG42 GENE; XENOPUS	The three mammalian hyaluronan synthase (HAS) genes and the related Xenopus laevis gene, DG42, belong to a larger evolutionarily conserved vertebrate HAS gene family, We have characterized additional vertebrate HAS genes from chicken (chas2 and chas3) and Xenopus (xhas2, xhas3, and a unique Xenopus HAS-related sequence, xHAS-rs), Genomic structure analyses demonstrated that all vertebrate HAS genes share at least one exon-intron boundary, suggesting that they evolved from a common ancestral gene. Furthermore, the Has2 and Has3 genes are identical in structure, suggesting that they arose by a gene duplication event early in vertebrate evolution, Significantly, similarities in the genomic structures of the mouse Has1 and Xenopus DG42 genes strongly suggest that they are orthologues, Northern analyses revealed a similar temporal expression pattern of HAS genes in developing mouse and Xenopus embryos. Expression of mouse Has2, Has3, and Xenopus Has1 (DG42) led to hyaluronan biosynthesis in transfected mammalian cells. However, only mouse Has2 and Has3 expressing cells formed significant hyaluronan-dependent pericellular coats in culture, implying both functional similarities and differences among vertebrate HAS enzymes, We propose that vertebrate hyaluronan biosynthesis is regulated by a comparatively ancient gene family that has arisen by sequential gene duplication and divergence.	Mayo Clin Scottsdale, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix	Spicer, AP (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, Rowe Program Genet, Tupper Hall MS1A, Davis, CA 95616 USA.				NHLBI NIH HHS [1 F32 HL09311-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arrecubieta C, 1996, J EXP MED, V184, P449, DOI 10.1084/jem.184.2.449; Aruga J, 1996, J BIOL CHEM, V271, P1043, DOI 10.1074/jbc.271.2.1043; BROWN NP, 1995, J MOL BIOL, V249, P342, DOI 10.1006/jmbi.1995.0301; BULAWA CE, 1992, MOL CELL BIOL, V12, P1764, DOI 10.1128/MCB.12.4.1764; CHENG S, 1994, NATURE, V369, P684, DOI 10.1038/369684a0; CHENG S, 1994, P NATL ACAD SCI USA, V91, P5695, DOI 10.1073/pnas.91.12.5695; CLARRIS BJ, 1968, EXP CELL RES, V49, P181, DOI 10.1016/0014-4827(68)90530-2; COLLINSEMERSON JM, 1990, NUCLEIC ACIDS RES, V18, P6690, DOI 10.1093/nar/18.22.6690; CRATER DL, 1995, J BIOL CHEM, V270, P18452, DOI 10.1074/jbc.270.31.18452; DEANGELIS PL, 1994, BIOCHEMISTRY-US, V33, P9033, DOI 10.1021/bi00197a001; DEANGELIS PL, 1993, J BIOL CHEM, V268, P19181; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; DILLARD JP, 1995, J EXP MED, V181, P973, DOI 10.1084/jem.181.3.973; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; GOTTFERT M, 1993, FEMS MICROBIOL LETT, V104, P39, DOI 10.1016/0378-1097(93)90503-T; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Itano N, 1996, BIOCHEM BIOPH RES CO, V222, P816, DOI 10.1006/bbrc.1996.0827; Kass EH, 1944, J EXP MED, V79, P319, DOI 10.1084/jem.79.3.319; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; NAGAHASHI S, 1995, J BIOL CHEM, V270, P13961, DOI 10.1074/jbc.270.23.13961; NG KF, 1989, J BIOL CHEM, V264, P11776; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1986, ARTICULAR CARTILAGE, P81; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; RUDDLE FH, 1994, DEVELOPMENT, P155; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schultze M, 1996, CURR OPIN GENET DEV, V6, P631, DOI 10.1016/S0959-437X(96)80094-3; SEMINO CE, 1995, P NATL ACAD SCI USA, V92, P3498, DOI 10.1073/pnas.92.8.3498; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Spicer AP, 1997, GENOMICS, V41, P493, DOI 10.1006/geno.1997.4696; Spicer AP, 1996, J BIOL CHEM, V271, P23400, DOI 10.1074/jbc.271.38.23400; Spicer AP, 1997, J BIOL CHEM, V272, P8957; SURDEJ P, 1994, ANNU REV GENET, V28, P263; Varki A, 1996, P NATL ACAD SCI USA, V93, P4523, DOI 10.1073/pnas.93.10.4523; WAGNER GP, 1993, EXPERIENTIA, V49, P317, DOI 10.1007/BF01923410; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WESSELS MR, 1991, P NATL ACAD SCI USA, V88, P8317, DOI 10.1073/pnas.88.19.8317; WESSELS MR, 1994, INFECT IMMUN, V62, P433, DOI 10.1128/IAI.62.2.433-441.1994; WILKINSON M, 1991, NUCLEIC ACIDS RES, V19, P679, DOI 10.1093/nar/19.3.679; [No title captured]	53	265	287	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1923	1932		10.1074/jbc.273.4.1923	http://dx.doi.org/10.1074/jbc.273.4.1923			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442026	hybrid			2022-12-25	WOS:000071595200015
J	Tojo, H; Ichida, T; Okamoto, M				Tojo, H; Ichida, T; Okamoto, M			Purification and characterization of a catalytic domain of rat intestinal phospholipase B/lipase associated with brush border membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR ACETYLHYDROLASE; SUBSTRATE-SPECIFICITY; GUINEA-PIG; PANCREATIC LIPASE; MECHANISM; SPLEEN; A(2); LYSOPHOSPHOLIPASE; IDENTIFICATION; SIMILARITY	A brush border membrane-associated phospholipase B/lipase was solubilized from the distal two-thirds of rat small intestine by autolysis during storage at -35 degrees C over 1 month, and then the enzyme was purified to homogeneity and characterized enzymatically and structurally, The purified enzyme exhibited broad substrate specificity including esterase, phospholipase A(2), lysophospholipase, and lipase activities. SDS-gel electrophoretic and reverse-phase high performance liquid chromatographic analyses demonstrated that a single enzyme catalyzes these activities. It preferred hydrolysis at the sn-2 position of diacylphospholipid and diacylglycerol without strict stereoselectivity, whereas it apparently exhibited no positional specificity toward triacylglycerol. Diisopropyl fluorophosphate, an irreversible inhibitor of serine esterases and lipases, inhibited purified enzyme, When the position of enzyme on SDS-gel electrophoresis under the non-reducing conditions was determined by assaying the activity eluted from sliced gels, brush border membrane-associated enzyme corresponded to a similar to 150-kDa protein; autolysis gave a 35-kDa product, in agreement with the results of immunoblot analysis, The purified 35-kDa enzyme consisted of a 14-kDa peptide and a glycosylated 21-kDa peptide. Their NH2-terminal amino acid sequences were determined and found in the second repeat of 161-kDa phospholipase B/lipase with 4-fold tandem repeats of similar to 38 kDa each, which we cloned and sequenced in the accompanying paper (Takemori, H., Zolotaryov, F,, Ting, L., Urbain, T,, Komatsubara, T., Hatano, O., Okamoto, M,, and Tojo, H. (1998) J. Biol. Chem. 273, 2222-2231). These results indicate that the purified enzyme is the catalytic domain derived from the second repeat of brush border membrane-associated phospholipase B/lipase.	Osaka Univ, Sch Med, Dept Mol Physiol Chem, Suita, Osaka 565, Japan	Osaka University	Tojo, H (corresponding author), Osaka Univ, Sch Med, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	htojo@mr-mbio.med.osaka-u.ac.jp						ALPERS DH, 1994, PHYSL GASTROINTESTIN, V2, P1723; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOLL W, 1993, J BIOL CHEM, V268, P12901; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHO HS, 1993, J BIOL CHEM, V268, P9238; Cohen J.A., 1967, METHODS ENZYMOLOGY, P686; CREER MH, 1985, LIPIDS, V20, P922, DOI 10.1007/BF02534778; CYGLER M, 1994, J AM CHEM SOC, V116, P3180, DOI 10.1021/ja00087a002; FIELD RB, 1983, J BIOL CHEM, V258, P4563; FISHER AB, 1992, BIOCHEM J, V288, P407, DOI 10.1042/bj2880407; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GIDEZ LI, 1968, J LIPID RES, V9, P794; GROSS RW, 1992, TRENDS CARDIOVAS MED, V2, P115, DOI 10.1016/1050-1738(92)90016-L; HATTORI M, 1994, J BIOL CHEM, V269, P23150; HAUSER H, 1980, BIOCHIM BIOPHYS ACTA, V602, P567, DOI 10.1016/0005-2736(80)90335-1; HIDE WA, 1992, J LIPID RES, V33, P167; HILTON S, 1991, J BIOL CHEM, V266, P997; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; INADA M, 1991, EUR J BIOCHEM, V197, P323, DOI 10.1111/j.1432-1033.1991.tb15914.x; JENSEN GL, 1981, ANAL BIOCHEM, V113, P246, DOI 10.1016/0003-2697(81)90073-7; KUUSI T, 1979, MED BIOL, V57, P192; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDS WEM, 1963, J BIOL CHEM, V238, P898; MATTSON FH, 1966, J LIPID RES, V7, P536; PARKIN SM, 1982, BIOCHEM J, V207, P485, DOI 10.1042/bj2070485; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; Pinkus L M, 1981, Methods Enzymol, V77, P154; PLUCKTHUN A, 1982, BIOCHEMISTRY-US, V21, P1743; Sato T, 1997, J BIOL CHEM, V272, P2192; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SHARP JD, 1994, J BIOL CHEM, V269, P23250; SHIAU YF, 1987, PHYSL GASTROINTESTIN, P1527; SLOTBOOM AJ, 1970, CHEM PHYS LIPIDS, V4, P15, DOI 10.1016/0009-3084(70)90059-9; SOLDATOVA L, 1993, FEBS LETT, V320, P145, DOI 10.1016/0014-5793(93)80080-E; Takemori H, 1998, J BIOL CHEM, V273, P2222, DOI 10.1074/jbc.273.4.2222; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; THIRSTRUP K, 1994, BIOCHEMISTRY-US, V33, P2748, DOI 10.1021/bi00176a002; TIM TS, 1997, J BIOL CHEM, V272, P2542; TJOELKER LW, 1995, J BIOL CHEM, V270, P25481, DOI 10.1074/jbc.270.43.25481; TOJO H, 1991, METHOD ENZYMOL, V197, P390; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOJO H, 1993, J LIPID RES, V34, P837; UPTON C, 1995, TRENDS BIOCHEM SCI, V20, P178, DOI 10.1016/S0968-0004(00)89002-7; VAHOUNY GV, 1964, ARCH BIOCHEM BIOPHYS, V107, P7, DOI 10.1016/0003-9861(64)90262-0; VASKOVSKY VE, 1975, J CHROMATOGR, V114, P129, DOI 10.1016/S0021-9673(00)85249-8; Wacker H, 1997, BIOCHEMISTRY-US, V36, P3336, DOI 10.1021/bi962398a; WithersMartinez C, 1996, STRUCTURE, V4, P1363, DOI 10.1016/S0969-2126(96)00143-8	53	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2214	2221		10.1074/jbc.273.4.2214	http://dx.doi.org/10.1074/jbc.273.4.2214			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442064	hybrid			2022-12-25	WOS:000071595200053
J	Yans, LZ; Adams, ME				Yans, LZ; Adams, ME			Lycotoxins, antimicrobial peptides from venom of the wolf spider Lycosa carolinensis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTESTINAL HOST-DEFENSE; PHOSPHOLIPID-BILAYERS; CHANNEL FORMATION; ALPHA-LATROTOXIN; CALCIUM CHANNELS; OMEGA-AGATOXINS; XENOPUS SKIN; PANETH CELLS; FROG-SKIN; MAGAININS	Two peptide toxins with antimicrobial activity, lycotoxins I and II, were identified from venom of the wolf spider Lycosa carolinensis (Araneae: Lycosidae) by virtue of their abilities to reduce ion and voltage gradients across membranes, Both peptides were purified to homogeneity by reversed-phase liquid chromatography and determined to have the following primary structures by Edman microsequencing: IWLTALKFLGKHAA-KHLAKQQLSKL-NH2 for lycotoxin I and KIKWFKTMK-SIAKFIAKEQMKKHLGGE-OH for lycotoxin II, The predicted secondary structures of the lycotoxins display amphipathic alpha-helix character typical of antimicrobial pore-forming peptides, Antimicrobial assays showed that both lycotoxins potently inhibit the growth of bacteria (Escherichia coli) and yeast (Candida glabrata) at micromolar concentrations, To verify its hypothesized pore-forming activity, lycotoxin I was synthesized and shown to promote efflux of Ca2+ from synaptosomes, to cause hemolysis of erythrocytes, and to dissipate voltage gradients across muscle membrane, The lycotoxins may play a dual role in spider-prey interaction, functioning both in the prey capture strategy as well as to protect the spider from potentially infectious organisms arising from prey ingestion, Spider venoms may represent a potentially new source of novel antimicrobial agents with important medical implications.	Univ Calif Riverside, Dept Entomol, Environm Toxicol Program, Riverside, CA 92521 USA; Univ Calif Riverside, Environm Toxicol Grad Program, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Adams, ME (corresponding author), Univ Calif Riverside, Dept Entomol, Environm Toxicol Program, 5419 Boyce Hall, Riverside, CA 92521 USA.	adams@ucrac1.ucr.edu						ADAMS ME, 1989, J COMP PHYSIOL A, V164, P333, DOI 10.1007/BF00612993; ADAMS ME, 1990, J BIOL CHEM, V265, P861; ADAMS ME, 1993, MOL PHARMACOL, V44, P681; ADAMS ME, 1994, TRENDS NEUROSCI S, V19, P1; AGAWA Y, 1991, J BIOL CHEM, V266, P20218; AMICHE M, 1993, BIOCHEM BIOPH RES CO, V191, P983, DOI 10.1006/bbrc.1993.1314; Barbaro KC, 1996, J PROTEIN CHEM, V15, P337, DOI 10.1007/BF01886859; BEVINS CL, 1994, CIBA F SYMP, V186, P250; BINDOKAS VP, 1991, J NEUROPHYSIOL, V66, P590, DOI 10.1152/jn.1991.66.2.590; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1974, INFECT IMMUN, V10, P136, DOI 10.1128/IAI.10.1.136-145.1974; BOMAN HG, 1994, CIBA F S ANTIMICROBI, V186; CHEN HC, 1988, FEBS LETT, V236, P462, DOI 10.1016/0014-5793(88)80077-2; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CRUCIANI RA, 1991, P NATL ACAD SCI USA, V88, P3792, DOI 10.1073/pnas.88.9.3792; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; CRUZ JS, 1994, BRAZ J MED BIOL RES, V27, P2653; DALY JW, 1992, P NATL ACAD SCI USA, V89, P10960, DOI 10.1073/pnas.89.22.10960; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; FUTRELL JM, 1992, AM J MED SCI, V304, P261, DOI 10.1097/00000441-199210000-00008; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; GILL SS, 1987, INFECT IMMUN, V55, P1300, DOI 10.1128/IAI.55.5.1300-1308.1987; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; JACOB L, 1994, CIBA F SYMP, V186, P197; JACOB L, 1994, CIBA F SYMP, V186, P216; JONES DE, 1993, FEBS LETT, V315, P187, DOI 10.1016/0014-5793(93)81160-2; JONES DE, 1992, J BIOL CHEM, V267, P23216; KAWAI N, 1995, HDB NEUROTOXICOLOGY, P67; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Lockey TD, 1996, EUR J BIOCHEM, V236, P263, DOI 10.1111/j.1432-1033.1996.00263.x; MALOY WL, 1995, BIOPOLYMERS, V37, P105, DOI 10.1002/bip.360370206; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MATSUZAKI K, 1994, BIOCHEMISTRY-US, V33, P3342, DOI 10.1021/bi00177a027; MATSUZAKI K, 1995, BIOCHEMISTRY-US, V34, P6521, DOI 10.1021/bi00019a033; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MOORE KS, 1991, J BIOL CHEM, V266, P19851; NICHOLSON GM, 1994, PFLUG ARCH EUR J PHY, V428, P400, DOI 10.1007/BF00724524; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; RAO AG, 1995, MOL PLANT MICROBE IN, V8, P6, DOI 10.1094/MPMI-8-0006; REILLY DS, 1994, DEV BIOL, V162, P123, DOI 10.1006/dbio.1994.1072; REILLY DS, 1994, J HISTOCHEM CYTOCHEM, V42, P697, DOI 10.1177/42.6.8189032; RIBEIRO LA, 1990, TOXICON, V28, P715, DOI 10.1016/0041-0101(90)90260-E; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUSTER FL, 1992, ANTIMICROB AGENTS CH, V36, P1263, DOI 10.1128/AAC.36.6.1263; SELSTED ME, 1992, J CELL BIOL, V118, P929, DOI 10.1083/jcb.118.4.929; TAGLIALATELA M, 1990, MOL PHARMACOL, V38, P393; TAMBOURGI DV, 1995, J IMMUNOL, V155, P4459; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449	49	148	168	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2059	2066		10.1074/jbc.273.4.2059	http://dx.doi.org/10.1074/jbc.273.4.2059			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442044	hybrid			2022-12-25	WOS:000071595200033
J	Bandyopadhyay, D; Mandal, M; Adam, L; Mendelsohn, J; Kumar, R				Bandyopadhyay, D; Mandal, M; Adam, L; Mendelsohn, J; Kumar, R			Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK-REPAIR; LIGAND-INDUCED ACTIVATION; NF-KAPPA-B; MONOCLONAL-ANTIBODIES; EGF RECEPTOR; CATALYTIC SUBUNIT; CARCINOMA CELLS; GENE-PRODUCT; DAUDI CELLS; A431 CELLS	Binding of extracellular ligands to epidermal growth factor receptors (EGFR) activate signal transduction pathways associated with cell proliferation, and these events are inhibited by monoclonal antibodies against EGFR, Since efficient DNA repair in actively growing cells may require growth factor signaling, it was of interest to explore any linkage between EGFR-mediated signaling and DNA dependent protein kinase (DNA-PK), an enzyme believed to be involved in repairing double strand breaks and V(D)J recombination. We report that anti-EGFR monoclonal antibodies (mAbs), and not EGFR ligands, trigger a specific early physical interaction between EGFR and a 350-kDa catalytic subunit of DNA or its regulatory heterodimeric complex Ku70/80, in a variety of cell types, both in vivo and in vitro. Inhibition of EGFR signaling by anti-EGFR mAb was accompanied by a reduction in the levels of the DNA-PK and its activity in the nuclear fraction, Confocal imaging revealed that a substantial amount of DNA-PK was co-localized with EGFR in anti-EGFR mAb-treated cells, Anti-EGFR mAb-induced physical interaction between EGFR and DNA-PK or Ku70/80 was dependent on the presence of EGFR, but not on the levels of EGFR, The EGFR associated with DNA-PK or Ku70/80 retains its intrinsic kinase activity. Our findings demonstrate the existence of a novel cellular pathway in mammalian cells that involves physical interactions between EGFR and DNA-PK or Ku70/80 in response to inhibition of EGFR signaling, Our present observations suggest a possible role of EGFR signaling in maintenance of the nuclear levels of DNA-PK, and interference in EGFR signaling may possibly result in the impairment of DNA repair activity in the nuclei in anti EGFR mAb-treated cells.	Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Dept Clin Invest, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Cell Growth Regulat Sect, Dept Clin Invest, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@notes.mdacc.tmc.edu	Mandal, Mahitosh/GMW-6195-2022	Mandal, Mahitosh/0000-0003-3861-3323	NCI NIH HHS [CA65746] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA065746, R01CA065746] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ATLAS I, 1992, CANCER RES, V52, P3335; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHAN CW, 1996, J BIOL CHEM, V271, P8936; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; FAN Z, 1993, J BIOL CHEM, V268, P21073; GILL GN, 1984, J BIOL CHEM, V259, P7755; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; KORUTLA L, 1995, CARCINOGENESIS, V16, P1741, DOI 10.1093/carcin/16.8.1741; KORUTLA L, 1994, BBA-MOL CELL RES, V1224, P597, DOI 10.1016/0167-4889(94)90299-2; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; KUMAR R, 1994, J BIOL CHEM, V269, P25437; KUMAR R, 1992, P NATL ACAD SCI USA, V89, P6599, DOI 10.1073/pnas.89.14.6599; KUMAR R, 1991, MOL CELL BIOL, V11, P979, DOI 10.1128/MCB.11.2.979; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Mandal M, 1997, J BIOL CHEM, V272, P14183, DOI 10.1074/jbc.272.22.14183; Mandal M, 1996, J BIOL CHEM, V271, P30354, DOI 10.1074/jbc.271.48.30354; Mandal M, 1997, CARCINOGENESIS, V18, P229, DOI 10.1093/carcin/18.1.229; MARTIN TE, 1987, J CELL BIOL, V105, P2069, DOI 10.1083/jcb.105.5.2069; Mendelsohn J, 1990, Semin Cancer Biol, V1, P339; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; Morrison P, 1996, BIOCHEMISTRY-US, V35, P14618, DOI 10.1021/bi961630+; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; REEVES WH, 1997, ANTIBODIES, V3, P33; REIDEL H, 1988, P NATL ACAD SCI USA, V5, P1477; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	41	188	202	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1568	1573		10.1074/jbc.273.3.1568	http://dx.doi.org/10.1074/jbc.273.3.1568			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430697	hybrid			2022-12-25	WOS:000071411500044
J	Cegielska, A; Gietzen, KF; Rivers, A; Virshup, DM				Cegielska, A; Gietzen, KF; Rivers, A; Virshup, DM			Autoinhibition of casein kinase I epsilon (CHI epsilon) is relieved by protein phosphatases and limited proteolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							40 DNA-REPLICATION; KAPPA-B-ALPHA; SCHIZOSACCHAROMYCES-POMBE; MOLECULAR-CLONING; BUDDING YEAST; PHOSPHORYLATION; EXPRESSION; ISOFORMS; BINDING; GENES	Casein kinase I epsilon (CKI epsilon) is a member of the CKI gene family, members of which are involved in the control of SV40 DNA replication, DNA repair, and cell metabolism, The mechanisms that regulate CKI epsilon activity and substrate specificity are not well understood, We report that CKI epsilon, which contains a highly phosphorylated 123-amino acid carboxyl-terminal extension not present in CKI alpha, is substantially less active than CKI alpha in phosphorylating a number of substrates including SV40 large T antigen and is unable to inhibit the initiation of SV40 DNA replication. Two mechanisms for the activation of CKI epsilon have been identified, First, limited tryptic digestion of CKI epsilon produces a protease-resistant amino-terminal 39-kDa core kinase with several-fold enhanced activity, Second, phosphatase treatment of CKI epsilon activates CKI epsilon 5-20-fold toward T antigen, Similar treatment of a truncated form of CKI epsilon produced only a 2-fold activation, Notably, this activation was transient; reautophosphorylation led to a rapid down-regulation of the kinase within 5 min, Phosphatase treatment also activated CKI epsilon toward the novel substrates I kappa B alpha and Ets-1. These mechanisms may serve to regulate CKI epsilon and related forms of CKI in the cell, perhaps in response to DNA damage.	Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Div Hematol Oncol, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Div Mol Biol & Genet, 15 North 2030 East,Room 2100, Salt Lake City, UT 84112 USA.	David.Virshup@genetics.utah.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [3P30 CA42014, CA71074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA042014, R01CA071074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOSTINIS P, 1992, FEBS LETT, V305, P121, DOI 10.1016/0014-5793(92)80877-J; AGOSTINIS P, 1989, FEBS LETT, V259, P75, DOI 10.1016/0014-5793(89)81498-X; BAZENET CE, 1990, J BIOL CHEM, V265, P7369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CARMEL G, 1994, J BIOL CHEM, V269, P7304; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; CEGIELSKA A, 1994, J VIROL, V68, P269, DOI 10.1128/JVI.68.1.269-275.1994; CEGIELSKA A, 1993, MOL CELL BIOL, V13, P1202, DOI 10.1128/MCB.13.2.1202; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; FLOTOW H, 1991, J BIOL CHEM, V266, P3724; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; GRAVES PR, 1993, J BIOL CHEM, V268, P6394; HARLOW E, 1988, ANTIBODIES LABORATOR, P406; HO U, 1997, P NATL ACAD SCI USA, V94, P581; HOEKSTRA MF, 1994, MOL BIOL CELL, V5, P877, DOI 10.1091/mbc.5.8.877; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; Lin RT, 1996, MOL CELL BIOL, V16, P1401; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; MILNE DM, 1992, ONCOGENE, V7, P1361; ROBERTS JM, 1988, SCIENCE, V241, P1486, DOI 10.1126/science.2843984; RUIMING X, 1995, EMBO J, V14, P1015; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VANCURA A, 1994, J BIOL CHEM, V269, P19271; VIRSHUP DM, 1989, EMBO J, V8, P3891, DOI 10.1002/j.1460-2075.1989.tb08568.x; Virshup DM, 1993, ADV PROTEIN PHOSPHAT, V7, P271; WANG PC, 1992, MOL BIOL CELL, V3, P275, DOI 10.1091/mbc.3.3.275; Wang XM, 1996, MOL CELL BIOL, V16, P5375; ZHAI LM, 1995, J BIOL CHEM, V270, P12717, DOI 10.1074/jbc.270.21.12717; ZHAI LM, 1992, BIOCHEM BIOPH RES CO, V189, P944, DOI 10.1016/0006-291X(92)92295-9	39	142	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1357	1364		10.1074/jbc.273.3.1357	http://dx.doi.org/10.1074/jbc.273.3.1357			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430669	hybrid			2022-12-25	WOS:000071411500016
J	Currie, RA				Currie, RA			NF-Y is associated with the histone acetyltransferases GCN5 and P/CAF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT-BINDING-FACTOR; DNA-BINDING; FACTOR CBF; YEAST; TRANSCRIPTION; PROTEIN; ACTIVATION; COMPLEX; SUBUNIT; PURIFICATION	The ubiquitous transcription factor, NF-Y, plays a pivotal role in the cell cycle regulation of the mammalian cyclin A, cdc25C, and cdc2 genes, in the S-phase activation of the ribonucleotide reductase R2 gene, in addition to its critical role as a key proximal promoter factor in the transcriptional regulation of the albumin, collagen, lipoprotein lipase, major histocompatibility complex class II, and a variety of other eukaryotic and viral genes, In this report, the NF-Y complex has been shown to possess histone acetyltransferase activity through physical association with the related histone acetyltransferase enzymes, human GCN5 and P/CAF in vivo, The assembled NF-YA:B:C complex, and the NF-YB:YC, NF-YB:YC (DNA binding-subunit interaction domain), and NF YC:YB (DNA binding-subunit interaction domain) heterodimers were sufficient to support stable interaction with human GCN5 in vitro, suggesting that these histone acetyltransferases interact with a unique surface in the ancient YB:YC histone-fold motif. Deletion of either N- or C-terminal regions in human GCN5 disrupted interaction with NF-Y in vitro, In addition, human GCN5 was observed to activate NF-Y in transient transfections in vivo using a natural alpha 2(I) collagen promoter, These results suggest that these associated histone acetyltransferases may serve to modulate NF-Y transactivation potential by aiding disruption of local chromatin structure thereby facilitating NF-Y access to its CCAAT box DNA binding sites.	Picower Inst Med Res, Gene Regulat Lab, Manhasset, NY 11030 USA	Northwell Health	Currie, RA (corresponding author), Picower Inst Med Res, Gene Regulat Lab, Manhasset, NY 11030 USA.		Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI037686] Funding Source: NIH RePORTER; NIAID NIH HHS [AI37686] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARENTS G, 1991, P NATL ACAD SCI USA, V88, P10148, DOI 10.1073/pnas.88.22.10148; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, MOL CELL BIOL, V16, P593; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Harlow E., 1988, ANTIBODIES LABORATOR, P511; HAYNES SR, 1992, NUCLEIC ACIDS RES, V20, P2603, DOI 10.1093/nar/20.10.2603; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INOSTROZA JA, 1992, CELL, V70, P477; Kuo MH, 1996, NATURE, V383, P269, DOI 10.1038/383269a0; LEGER H, 1995, MOL CELL BIOL, V15, P3738; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MIZZEN CA, 1996, CELL, V87, P555; Nakshatri H, 1996, J BIOL CHEM, V271, P28784, DOI 10.1074/jbc.271.46.28784; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; Sambrook J., 2002, MOL CLONING LAB MANU; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; vanHolde K, 1996, P NATL ACAD SCI USA, V93, P10548, DOI 10.1073/pnas.93.20.10548; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	42	132	139	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1430	1434		10.1074/jbc.273.3.1430	http://dx.doi.org/10.1074/jbc.273.3.1430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430679	hybrid			2022-12-25	WOS:000071411500026
J	Kuwata, H; Nakatani, Y; Murakami, M; Kudo, I				Kuwata, H; Nakatani, Y; Murakami, M; Kudo, I			Cytosolic phospholipase A(2) is required for cytokine-induced expression of type IIA secretory phospholipase A(2) that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E-2 generation in rat 3Y1 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; ACTIVATED PROTEIN-KINASE; MAST-CELLS; NUCLEAR-ENVELOPE; MESANGIAL CELLS; D-2 GENERATION; H SYNTHASE-1; 14-KDA PHOSPHOLIPASE-A(2); ENDOPEROXIDE SYNTHASE-1; P388D(1) MACROPHAGES	Activation of rat fibroblastic 3Y1 cells with interleukin-1 beta (IL-1 beta) and tumor necrosis factor alpha (TNF alpha) induced delayed prostaglandin (PG) E-2 generation over 6-48 h, which occurred in parallel with de novo induction of type IIA secretory phospholipase A(2) (sPLA(2)) and cyclooxygenase (COX)-2, without accompanied by changes in the constitutive expression of type IV cytosolic PLA(2) (cPLA(2)) and COX-1, Types V and IIC sPLA(2)s were barely detectable in these cells, Studies using an anti-type IIA sPLA(2) antibody, sPLA(2) inhibitors, and a type IIA sPLA(2)-specific antisense oligonucleotide revealed that IL-1 beta/TNF alpha-induced delayed PGE(2) generation by these cells was largely dependent on inducible type IIA sPLA(2), which was functionally linked to inducible COX-2, Delayed PGE(2) generation was also suppressed markedly by the cPLA(2) inhibitor arachidonoyl trifluoromethyl ketone (AACOCF(3)), which attenuated induction of type IIA sPLA(2), but not COX-2, expression, AACOCF(3) inhibited the initial phase of cytokine-stimulated arachidonic acid release, and supplementing AACOCF(3)-treated cells with exogenous arachidonic acid partially restored type IIA sPLA(2) expression, These results suggest that certain metabolites produced by the cPLA(2)-dependent pathway are crucial for the subsequent induction of type IIA sPLA(2) expression and attendant delayed PGE(2) generation, Some lipoxygenase-derived products might be involved in this event, since IL-1 beta/TNF alpha-induced type IIA sPLA(2) induction and PGE(2) generation were reduced markedly by lipoxygenase, but not COX, inhibitors, In contrast, Ca2+ ionophore-stimulated immediate PGE(2) generation was regulated predominantly by the constitutive enzymes cPLA(2) and COX-1, even when type IIA sPLA(2) and COX-2 were maximally induced after IL-1 beta/TNF alpha treatment, revealing functional segregation of the constitutive and inducible PG biosynthetic enzymes.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 142, Japan	Showa University	Kudo, I (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 142, Japan.		Kuwata, Hiro/N-2023-2019	Kuwata, Hiro/0000-0002-5023-1777				Ashraf MDM, 1996, BIOCHEM BIOPH RES CO, V229, P726, DOI 10.1006/bbrc.1996.1872; Balboa MA, 1996, J BIOL CHEM, V271, P32381, DOI 10.1074/jbc.271.50.32381; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; Chapdelaine Joan M., 1995, Arthritis and Rheumatism, V38, pS293; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CUPILLARD L, 1997, J BIOL CHEM, V272, P15145; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DEWITT DL, 1993, ARCH BIOCHEM BIOPHYS, V306, P94, DOI 10.1006/abbi.1993.1485; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; FUTAKI N, 1993, GEN PHARMACOL, V24, P105, DOI 10.1016/0306-3623(93)90018-S; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; HANDLER JA, 1990, J BIOL CHEM, V265, P3669; HARA S, 1995, BBA-LIPID LIPID MET, V1257, P11, DOI 10.1016/0005-2760(95)00011-Z; HIDI R, 1993, J IMMUNOL, V151, P5613; HOECK WG, 1993, P NATL ACAD SCI USA, V90, P4475, DOI 10.1073/pnas.90.10.4475; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Li Q, 1997, J BIOL CHEM, V272, P2404, DOI 10.1074/jbc.272.4.2404; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Marshall LA, 1997, J BIOL CHEM, V272, P759, DOI 10.1074/jbc.272.2.759; Matsumoto H, 1997, BIOCHEM BIOPH RES CO, V230, P110, DOI 10.1006/bbrc.1996.5894; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; MURAKAMI M, 1991, FEBS LETT, V294, P247, DOI 10.1016/0014-5793(91)81440-J; MURAKAMI M, 1992, BIOCHIM BIOPHYS ACTA, V1124, P17, DOI 10.1016/0005-2760(92)90120-K; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1995, J IMMUNOL, V155, P4445; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; MURAKAMI M, 1993, J BIOL CHEM, V268, P839; MURAKAMI M, 1994, J BIOL CHEM, V269, P22269; MURAKAMI M, 1995, J BIOL CHEM, V270, P3239, DOI 10.1074/jbc.270.7.3239; MURAKAMI M, 1990, FEBS LETT, V268, P113, DOI 10.1016/0014-5793(90)80986-S; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; MURAKAMI M, 1989, BIOCHIM BIOPHYS ACTA, V1043, P34; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; NAKANO T, 1990, J BIOL CHEM, V265, P12745; OHASHI K, 1992, J BIOL CHEM, V267, P789; Penrose JF, 1996, J BIOL CHEM, V271, P11356, DOI 10.1074/jbc.271.19.11356; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; Rao GN, 1996, J BIOL CHEM, V271, P27760, DOI 10.1074/jbc.271.44.27760; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V180, P46, DOI 10.1016/S0006-291X(05)81252-5; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; SUGA H, 1993, EUR J BIOCHEM, V218, P807, DOI 10.1111/j.1432-1033.1993.tb18435.x; TANAKA K, 1993, INFLAMMATION, V17, P107, DOI 10.1007/BF00916098; TANAKA K, 1992, J ANTIBIOT, V45, P1071, DOI 10.7164/antibiotics.45.1071; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; Wissing D, 1997, P NATL ACAD SCI USA, V94, P5073, DOI 10.1073/pnas.94.10.5073; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	76	175	180	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1733	1740		10.1074/jbc.273.3.1733	http://dx.doi.org/10.1074/jbc.273.3.1733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430720	hybrid			2022-12-25	WOS:000071411500067
J	Sepuri, NBV; Schulke, N; Pain, D				Sepuri, NBV; Schulke, N; Pain, D			GTP hydrolysis is essential for protein import into the mitochondrial matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFIED PRECURSOR PROTEIN; ENERGIZED INNER MEMBRANE; NUCLEOSIDE TRIPHOSPHATES; INTERMEMBRANE SPACE; DYNAMIC INTERACTION; OUTER-MEMBRANE; TRANSLOCATION; HSP70; ATP; REQUIREMENT	Protein import into the innermost compartment of mitochondria (the matrix) requires a membrane potential (Delta Psi) across the inner membrane, as well as ATP-dependent interactions with chaperones in the matrix and cytosol, The role of nucleoside triphosphates other than ATP during import into the matrix, however, remains to be determined, Import of urea-denatured precursors does not require cytosolic chaperones, We have there fore used a purified and urea-denatured preprotein in our import assays to bypass the requirement of external ATP, Using this modified system, we demonstrate that GTP stimulates protein import into the matrix; the stimulatory effect is directly mediated by GTP hydrolysis and does not result from conversion of GTP to ATP, Both external GTP and matrix ATP are necessary; neither one can substitute for the other if efficient import is to be achieved, These results suggest a "push-pull" mechanism of import, which may be common to other posttranslational translocation pathways.	Univ Penn, Sch Med, Dept Physiol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pain, D (corresponding author), Univ Penn, Sch Med, Dept Physiol, D403 Richards Bldg,3700 Hamilton Walk, Philadelphia, PA 19104 USA.		Sepuri, Naresh/AAF-2704-2020					BECKER K, 1992, J BIOL CHEM, V267, P5637; BERTHOLD J, 1995, CELL, V81, P1085, DOI 10.1016/S0092-8674(05)80013-3; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHEN WJ, 1987, CELL, V49, P651, DOI 10.1016/0092-8674(87)90541-1; CYR DM, 1993, J BIOL CHEM, V268, P23751; DESHAIES RJ, 1988, NATURE, V332, P800, DOI 10.1038/332800a0; EILERS M, 1987, EMBO J, V6, P1073, DOI 10.1002/j.1460-2075.1987.tb04860.x; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; GASSER SM, 1982, J BIOL CHEM, V257, P3034; Glick B, 1991, Trends Cell Biol, V1, P99, DOI 10.1016/0962-8924(91)90037-A; GLICK BS, 1995, CELL, V80, P11, DOI 10.1016/0092-8674(95)90444-1; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HAYASHI SI, 1967, J BIOL CHEM, V242, P1030; HORST M, 1995, EMBO J, V14, P2293, DOI 10.1002/j.1460-2075.1995.tb07223.x; HWANG ST, 1991, J BIOL CHEM, V266, P21083; HWANG ST, 1989, P NATL ACAD SCI USA, V86, P8432, DOI 10.1073/pnas.86.21.8432; JASCUR T, 1992, J BIOL CHEM, V267, P13636; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; MARTIN J, 1991, J BIOL CHEM, V266, P18051; Mihara K, 1996, TRENDS CELL BIOL, V6, P104, DOI 10.1016/0962-8924(96)81000-2; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; MURAKAMI H, 1993, P NATL ACAD SCI USA, V90, P3358, DOI 10.1073/pnas.90.8.3358; NEUPERT W, 1990, CELL, V63, P447, DOI 10.1016/0092-8674(90)90437-J; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; Pfanner N, 1997, CURR BIOL, V7, pR100, DOI 10.1016/S0960-9822(06)00048-0; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; PFANNER N, 1986, FEBS LETT, V209, P152, DOI 10.1016/0014-5793(86)81101-2; PFANNER N, 1992, CELL, V68, P999, DOI 10.1016/0092-8674(92)90069-O; RASSOW J, 1991, FEBS LETT, V293, P85, DOI 10.1016/0014-5793(91)81157-4; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SCHNELL DJ, 1995, CELL, V83, P521, DOI 10.1016/0092-8674(95)90090-X; Schulke N, 1997, P NATL ACAD SCI USA, V94, P7314, DOI 10.1073/pnas.94.14.7314; SHEFFIELD WP, 1990, J BIOL CHEM, V265, P11069; SIMON SM, 1992, P NATL ACAD SCI USA, V89, P3770, DOI 10.1073/pnas.89.9.3770; STUART RA, 1994, EUR J BIOCHEM, V220, P9, DOI 10.1111/j.1432-1033.1994.tb18593.x; UNGERMANN C, 1994, SCIENCE, V266, P1250, DOI 10.1126/science.7973708; Ungermann C, 1996, EMBO J, V15, P735, DOI 10.1002/j.1460-2075.1996.tb00409.x; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511	48	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1420	1424		10.1074/jbc.273.3.1420	http://dx.doi.org/10.1074/jbc.273.3.1420			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430677	hybrid			2022-12-25	WOS:000071411500024
J	Zhang, XL; Hartz, PA; Philip, E; Racusen, LC; Majerus, PW				Zhang, XL; Hartz, PA; Philip, E; Racusen, LC; Majerus, PW			Cell lines from kidney proximal tubules of a patient with Lowe syndromelack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; OCULOCEREBRORENAL SYNDROME; HUMAN-PLATELETS; PHOSPHOINOSITIDE 3-KINASE; ENDOCYTIC PATHWAY; LYSOSOMES; 3,4,5-TRISPHOSPHATE; COMPLEX; SURFACE; FORMS	The protein product of the gene that when mutated is responsible for Lowe syndrome, or oculocerebrorenal syndrome (OCRL), is an inositol polyphosphate 5-phosphatase. It has a marked preference for phosphatidylinositol 4,5-bisphosphate although it hydrolyzes all four of the known inositol polyphosphate 5-phosphatase substrates: inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate, and phosphatidylinositol 3,4,5-trisphosphate. The enzyme activity of this protein is determined by a region of 672 out of a total of 970 amino acids that is homologous to inositol polyphosphate 5-phosphatase II. Cell lines from kidney proximal tubules of a patient with Lowe syndrome and a normal individual were used to study the function of OCRL. The cells from the Lowe syndrome patient lack OCRL protein. OCRL is the major phosphatidylinositol 4,5-bisphosphate 5-phosphatase in these cells. As a result, these cells accumulate phosphatidylinositol 4,5-bisphosphate even though at least four other inositol polyphosphate 5-phosphatase isozymes are present in these cells. OCRL is associated with lysosomal membranes in control proximal tubule cell lines suggesting that OCRL may function in lysosomal membrane trafficking by regulating the specific pool of phosphatidylinositol 4,5-bisphosphate that is associated with lysosomes.	Washington Univ, Sch Med, Div Hematol Oncol, Dept Internal Med, St Louis, MO 63110 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA	Washington University (WUSTL); Johns Hopkins University	Majerus, PW (corresponding author), Washington Univ, Sch Med, Div Hematol Oncol, Dept Internal Med, 660 S Euclid Ave,Box 8125, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016634, R01HL016634, T32HL007088] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL3289, HL 07088, HL 16634] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKASAKI K, 1994, J BIOCHEM, V116, P670; AKASAKI K, 1993, J BIOCHEM-TOKYO, V114, P598, DOI 10.1093/oxfordjournals.jbchem.a124223; AMES BN, 1960, J BIOL CHEM, V235, P769; ATTEE O, 1992, NATURE, V358, P239; Auethavekiat V, 1997, J BIOL CHEM, V272, P1786, DOI 10.1074/jbc.272.3.1786; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BECK KA, 1991, J BIOL CHEM, V266, P4442; Charnas LR, 1995, METABOLIC MOL BASES, P3705; CONNOLLY TM, 1985, J BIOL CHEM, V260, P7868; CUNNINGHAM TW, 1990, J BIOL CHEM, V265, P21676; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; DECOURCY K, 1991, EXP CELL RES, V192, P52, DOI 10.1016/0014-4827(91)90156-O; DeSmedt F, 1996, J BIOL CHEM, V271, P10419, DOI 10.1074/jbc.271.17.10419; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; HARDING CV, 1991, CELL, V64, P393, DOI 10.1016/0092-8674(91)90647-H; JACKSON SP, 1995, EMBO J, V14, P4490, DOI 10.1002/j.1460-2075.1995.tb00128.x; JAHRAUS A, 1994, J CELL SCI, V107, P145; JEFFERSON AB, 1995, J BIOL CHEM, V270, P9370, DOI 10.1074/jbc.270.16.9370; Jefferson AB, 1997, J BIOL CHEM, V272, P5983, DOI 10.1074/jbc.272.9.5983; Kavanaugh WM, 1996, CURR BIOL, V6, P438, DOI 10.1016/S0960-9822(02)00511-0; LEAHEY AM, 1993, HUM MOL GENET, V2, P461, DOI 10.1093/hmg/2.4.461; Lin T, 1997, AM J HUM GENET, V60, P1384, DOI 10.1086/515471; LOWE CU, 1952, AMA AM J DIS CHILD, V83, P164, DOI 10.1001/archpedi.1952.02040060030004; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MATZARIS M, 1994, J BIOL CHEM, V269, P3397; Mitchell CA, 1996, BIOCHEM SOC T, V24, P994, DOI 10.1042/bst0240994; NORRIS FA, 1994, J BIOL CHEM, V269, P8716; OLIVOSGLANDER IM, 1995, AM J HUM GENET, V57, P817; Osborne MA, 1996, J BIOL CHEM, V271, P29271, DOI 10.1074/jbc.271.46.29271; RACUSEN LC, 1995, J AM SOC NEPHROL, V6, P707; Reaves BJ, 1996, J CELL SCI, V109, P749; SPEED CJ, 1995, EUR J BIOCHEM, V234, P216, DOI 10.1111/j.1432-1033.1995.216_c.x; SUCHY SF, 1995, HUM MOL GENET, V4, P2245, DOI 10.1093/hmg/4.12.2245; Traub LM, 1996, J CELL BIOL, V135, P1801, DOI 10.1083/jcb.135.6.1801; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	38	125	128	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1574	1582		10.1074/jbc.273.3.1574	http://dx.doi.org/10.1074/jbc.273.3.1574			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430698	hybrid			2022-12-25	WOS:000071411500045
J	Arcaro, A				Arcaro, A			The small GTP-binding protein Rac promotes the dissociation of gelsolin from actin filaments in neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH OXIDASE; PHOSPHATIDYLINOSITOL TRISPHOSPHATE; ACTIVATED NEUTROPHILS; ADP-RIBOSYLATION; F-ACTIN; POLYMORPHONUCLEAR LEUKOCYTES; PERMEABILIZED NEUTROPHILS; RABBIT NEUTROPHILS; CHEMOTACTIC FACTOR; PLASMA-MEMBRANE	Gelsolin is an actin filament-capping protein that has been shown to play a key role in cell migration. Here we have studied the involvement of phosphoinositide 3-kinase (PI 3-kinase) and GTP-binding proteins (G-proteins) in the regulation of gelsolin-actin interactions in neutrophils. Inhibition of PI 3-kinase activity in vivo by wortmannin did not affect the dissociation of actin-gel-solin (1:1) complexes induced by neutrophil stimulation with N-formyl-Met-Leu-Phe. Guanosine 5'-[gamma-thio]triphosphate (GTP gamma S) indirectly promoted the dissociation of actin gelsolin complexes in a cell-free system using neutrophil cytosol, and this effect was blocked by the GDP dissociation inhibitor for Rho (Rho-GDI). The GTP gamma S-loaded (i) alpha(2) and the beta(1) gamma(2) subunits of heterotrimeric G-proteins (G(i) alpha(2) and G beta(1) gamma(2)) also triggered actin-gelsolin dissociation in a Rho-GDI-sensitive manner. GTP-loaded activated Rac, but not activated Rho, induced the dissociation of cytosolic actin-gelsolin complexes. The guanine nucleotide exchange on Rac was increased by addition of GTP gamma S-loaded G(i) alpha(2) or G beta(1) gamma(2) to neutrophil cytosol. These findings suggest that activation of Rac by G-protein-coupled receptors in neutrophils triggers uncapping of actin filaments, independently of PI 3-kinase.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland	University of Fribourg	Arcaro, A (corresponding author), UCL, Ludwig Inst Canc Res, 91 Riding House St, London W1P 8BT, England.	arcaro@ludwig.ucl.ac.uk	Arcaro, Alexandre/G-1711-2010	Arcaro, Alexandre/0000-0001-9107-2947				ABO A, 1994, BIOCHEM J, V298, P585, DOI 10.1042/bj2980585; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BENGTSSON T, 1988, J BIOL CHEM, V263, P17385; BRENNER SL, 1983, J BIOL CHEM, V258, P5013; Brill S, 1996, MOL CELL BIOL, V16, P4869; BRYAN J, 1985, J CELL BIOL, V101, P1236, DOI 10.1083/jcb.101.4.1236; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CARSON M, 1986, J CELL BIOL, V103, P2707, DOI 10.1083/jcb.103.6.2707; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHAPONNIER C, 1987, J EXP MED, V165, P97, DOI 10.1084/jem.165.1.97; CHUANG TH, 1993, J BIOL CHEM, V268, P26206; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DINUBILE MJ, 1988, METHOD ENZYMOL, V12, P246; DOBOS GJ, 1992, J IMMUNOL, V149, P609; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EBERLE M, 1990, J BIOL CHEM, V265, P16725; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; HOWARD T, 1990, J CELL BIOL, V110, P1983, DOI 10.1083/jcb.110.6.1983; HOWARD TH, 1984, J CELL BIOL, V98, P1265, DOI 10.1083/jcb.98.4.1265; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; JANMEY PA, 1987, J BIOL CHEM, V262, P12228; JANMEY PA, 1989, J BIOL CHEM, V264, P4825; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JANMEY PA, 1985, BIOCHEMISTRY-US, V24, P3714, DOI 10.1021/bi00335a046; KERNEN P, 1991, J CLIN INVEST, V87, P2012, DOI 10.1172/JCI115230; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KOCH G, 1994, BIOCHEM J, V299, P775, DOI 10.1042/bj2990775; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KURTH MC, 1984, J BIOL CHEM, V259, P7473; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; LEE E, 1994, METHOD ENZYMOL, V237, P140; LIND SE, 1987, J CELL BIOL, V105, P833, DOI 10.1083/jcb.105.2.833; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MUMBY SM, 1994, METHOD ENZYMOL, V237, P254; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBES CD, 1995, J CELL SCI, V108, P225; NOLAN RD, 1991, BIOCHEM BIOPH RES CO, V174, P524, DOI 10.1016/0006-291X(91)91448-L; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PARDEE JD, 1982, METHOD ENZYMOL, V85, P164; PHILIPS MR, 1995, J BIOL CHEM, V270, P11514, DOI 10.1074/jbc.270.19.11514; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUINN MT, 1993, J BIOL CHEM, V268, P20983; REDMOND T, 1994, J BIOL CHEM, V269, P21657; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SANDERS MC, 1990, J CELL BIOL, V110, P359, DOI 10.1083/jcb.110.2.359; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TARDIF M, 1995, J BIOL CHEM, V270, P28075; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; VanAelst L, 1996, EMBO J, V15, P3778, DOI 10.1002/j.1460-2075.1996.tb00751.x; VOLPI M, 1983, BIOCHEM BIOPH RES CO, V112, P957, DOI 10.1016/0006-291X(83)91711-4; WHITE JR, 1983, J BIOL CHEM, V258, P4041; WYMANN M, 1994, BIOCHEM J, V298, P517, DOI 10.1042/bj2980517; WYMANN MP, 1990, J BIOL CHEM, V265, P619; WYMANN MP, 1987, BIOCHEM BIOPH RES CO, V147, P361, DOI 10.1016/S0006-291X(87)80130-4; Zigmond SH, 1997, J CELL BIOL, V138, P363, DOI 10.1083/jcb.138.2.363	74	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					805	813		10.1074/jbc.273.2.805	http://dx.doi.org/10.1074/jbc.273.2.805			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422735	hybrid			2022-12-25	WOS:000071411400024
J	Huang, SG; Lin, QS; Klingenberg, M				Huang, SG; Lin, QS; Klingenberg, M			Slow-phase kinetics of nucleotide binding to the uncoupling protein from brown adipose tissue mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; FAT MITOCHONDRIA; MECHANISM; DISSOCIATION; COMPLEXES; ANALOGS; MYOSIN; SITE; RCC1; RAN	The kinetics of nucleotide binding to the uncoupling protein (UCP) from brown adipose tissue mitochondria were studied with a filter binding method, Fast and dow phases of binding were observed, corresponding to the two-stage binding model based on equilibrium binding studies (Huang, S. G., and Klingenberg, M. (1996) Biochemistry 35, 7846-7854) (Reaction 1). [GRAPHICS] REACTION 1 Although this method determines total binding, only the slow phase can be resolved. The fast unresolved phase represents the formation of the initial loose UCP-nucleotide complex (UN; K-d approximate to 2 mu M), whereas the slow phase reflects the tight binding (U*N) associated with a conformational change induced by the bound nucleotide, Best fits of the binding data yielded, for the slow phase, k(+1) values of 3.0 x 10(-3) s(-1) for GTP, 4.8 x 10(-3) s(-1) for ATP, 0.13 s(-1) for GDP, and >0.7 s(-1) for ADP and dissociation rate constants (k(-1)) of 0.10 x 10(-3) s(-1) for GTP, 0.58 x 10(-3) s(-1) for ATP, 8.8 x 10(-3) s(-1) for GDP, and >0.3 s(-1) for ADP at pH 6.7 and 4 degrees C, The rates were fairly pH-and temperature-dependent. The distribution constant K-c' (=k(+1)/k(-1)) between the tight and loose complexes ranged between 2 and 30, suggesting formation of 71-97% of the tight complex at equilibrium. The K-c' decreases with increasing pH, indicating a progressively less tight complex population. Anions (SO42-) form a loose complex with UCP, thus affecting the initial association step, but not the subsequent transition step. While the kinetic constants were verified by dilution and chase experiments as well as in mass action plots, they were further corroborated with data obtained by fluorescence competition measurements. Taken to together, our results show that nucleotide binding to UCP occurs via a two-stage mechanism in which the initial loose complex rearranges slowly into a tight complex.	Univ Munich, Inst Phys Biochem, D-80336 Munich, Germany; Chinese Acad Sci, Shanghai Inst Biochem, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	University of Munich; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Huang, SG (corresponding author), Univ Munich, Inst Phys Biochem, Schillerstr 44, D-80336 Munich, Germany.	Sghuang@pbm.med.uni-muenchen.de						BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BIRDSALL B, 1980, BIOCHEMISTRY-US, V19, P3723, DOI 10.1021/bi00557a013; ECCLESTON JF, 1987, SPECTROPHOTOMETRY SP, P137; HEATON GM, 1978, EUR J BIOCHEM, V82, P515, DOI 10.1111/j.1432-1033.1978.tb12045.x; HIMMSHAGEN J, 1976, ANNU REV PHYSIOL, V38, P315, DOI 10.1146/annurev.ph.38.030176.001531; HUANG SG, 1995, EUR J BIOCHEM, V229, P718, DOI 10.1111/j.1432-1033.1995.tb20519.x; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1996, BIOCHEMISTRY-US, V35, P7846, DOI 10.1021/bi960244p; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; KINOSIAN HJ, 1993, J BIOL CHEM, V268, P8683; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1986, METHOD ENZYMOL, V126, P498; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; LIN CS, 1982, BIOCHEMISTRY-US, V21, P2950, DOI 10.1021/bi00541a023; LIN CS, 1980, FEBS LETT, V113, P299, DOI 10.1016/0014-5793(80)80613-2; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACFARLANE DE, 1983, J CLIN INVEST, V71, P420, DOI 10.1172/JCI110786; NICHOLLS DG, 1976, EUR J BIOCHEM, V62, P223, DOI 10.1111/j.1432-1033.1976.tb10151.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; SMITH RE, 1969, PHYSIOL REV, V49, P330, DOI 10.1152/physrev.1969.49.2.330; WAGNER A, 1995, BIOCHEMISTRY-US, V34, P12535, DOI 10.1021/bi00039a007	24	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					859	864		10.1074/jbc.273.2.859	http://dx.doi.org/10.1074/jbc.273.2.859			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422742	hybrid			2022-12-25	WOS:000071411400031
J	McNeil, SE; Hobson, SA; Nipper, V; Rodland, KD				McNeil, SE; Hobson, SA; Nipper, V; Rodland, KD			Functional calcium-sensing receptors in rat fibroblasts are required for activation of SRC kinase and mitogen-activated protein kinase in response to extracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; INDUCED KERATINOCYTE DIFFERENTIATION; NEONATAL SEVERE HYPERPARATHYROIDISM; BOVINE PARATHYROID CELLS; SERUM-FREE MEDIUM; TYROSINE KINASE; CA2+-SENSING RECEPTOR; MOLECULAR-CLONING; INTRACELLULAR CALCIUM; COUPLED RECEPTORS	Changes in the concentration of extracellular calcium can affect the balance between proliferation and differentiation in several cell types, including keratinocytes, breast epithelial cells, and fibroblasts, This report demonstrates that elevation of extracellular calcium stimulates proliferation-associated signaling pathways in rat fibroblasts and implicates calcium-sensing receptors (CaR) as mediators of this response, Rat-1 fibroblasts express CaR mRNA and protein and respond to known agonists of the CaR with increased IP3 production and release of intracellular calcium, Agonists of the CaR can stimulate increased c-SRC kinase activity and increased extracellular signal-regulated kinase 1/mitogen-activated protein kinase activity, Both of the increases in SRC activity and mitogen-activated protein kinase activation are blocked in the presence of a nonfunctional mutant of the CaR, R796W, Proliferation of wild-type Rat-1 cells is sensitive to changes in extracellular calcium, but expression of the nonfunctional CaR mutant or inhibition of the calcium-dependent increase in SRC kinase activity block the proliferative response to calcium. These results provide evidence of a novel signal transduction pathway modulating the response of fibroblasts to extracellular calcium and imply that calcium-sensing receptors may play a role in regulating cell growth in response to extracellular calcium, in addition to their well known function in systemic calcium homeostasis.	Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA	Oregon Health & Science University	Rodland, KD (corresponding author), Oregon Hlth Sci Univ, Dept Cell & Dev Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.		Rodland, Karin/R-6186-2019	McNeil, Scott/0000-0002-7575-5198	NCI NIH HHS [CA-60738] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060738] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bikle DD, 1996, J CLIN INVEST, V97, P1085, DOI 10.1172/JCI118501; BLACK BL, 1989, FASEB J, V3, P2653, DOI 10.1096/fasebj.3.14.2512193; BROWN EM, 1995, J NUTR, V125, pS1965, DOI 10.1093/jn/125.suppl_7.1965S; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Emanuel RL, 1996, MOL ENDOCRINOL, V10, P555, DOI 10.1210/me.10.5.555; FILVAROFF E, 1994, J BIOL CHEM, V269, P21735; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; GODWIN AK, 1995, ENDOCRINOLOGY, V136, P4640, DOI 10.1210/en.136.10.4640; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HUANG SX, 1995, BIOCHEM J, V310, P881, DOI 10.1042/bj3100881; LI PM, 1993, ONCOGENE, V8, P1731; MEDEMA JP, 1995, ONCOGENE, V11, P757; MOSES HL, 1985, CANCER CELL, V3, P65; MULDOON LL, 1989, J BIOL CHEM, V264, P8529; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; OCHIENG J, 1991, J CELL BIOCHEM, V46, P250, DOI 10.1002/jcb.240460308; POLLAK MR, 1994, J CLIN INVEST, V93, P1108, DOI 10.1172/JCI117062; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RODLAND KD, 1993, MOL ENDOCRINOL, V7, P787, DOI 10.1210/me.7.6.787; Rodland KD, 1997, MOL ENDOCRINOL, V11, P281, DOI 10.1210/me.11.3.281; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHAO YH, 1993, MOL CELL BIOL, V13, P7507, DOI 10.1128/MCB.13.12.7507; ZHAO YH, 1992, P NATL ACAD SCI USA, V89, P8298, DOI 10.1073/pnas.89.17.8298	37	184	188	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1114	1120		10.1074/jbc.273.2.1114	http://dx.doi.org/10.1074/jbc.273.2.1114			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422777	hybrid			2022-12-25	WOS:000071411400066
J	Boss, O; Samec, S; Kuhne, F; Bijlenga, P; Assimacopoulos-Jeannet, F; Seydoux, J; Giacobino, JP; Muzzin, P				Boss, O; Samec, S; Kuhne, F; Bijlenga, P; Assimacopoulos-Jeannet, F; Seydoux, J; Giacobino, JP; Muzzin, P			Uncoupling protein-3 expression in rodent skeletal muscle is modulated by food intake but not by changes in environmental temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN-ADIPOSE-TISSUE; THERMOGENIC CAPACITY; RAT	A new member of the uncoupling protein (UCP) family called UCP3 has recently been cloned and shown to be highly expressed in skeletal muscle of rodents and humans, In the present study, UCP3 was overexpressed in C2C12 myoblasts where it acts as an uncoupling protein, Changes in UCP3 mRNA expression were examined in rodent muscles,under conditions known to modulate thermogenesis in brown adipose tissue, In skeletal muscle, UCP3 expression did not change in response to 48 h of cold exposure (6 degrees C), whereas it was decreased by 81% or increased 5.6-fold by 1 week of 50% food restriction or fasting, respectively. It was also decreased by 36% in soleus muscle of obese (fa/fa) as compared with lean Zucker rats, The unexpected rise of UCP3 mRNA level induced by fasting did not change in vitro muscle basal heat production rate but decreased by 31% the capacity to produce heat in response to the uncoupler carbonyl-cyanide p-trifluoromethoxyphenylhydrazone. This decrease may reflect underlying uncoupling by UCP3. Upregulation of UCP3 mRNA after a 24-h fast was still observed in mice exposed at thermoneutrality, These results show that the increase in UCP3 expression induced by fasting is associated with the maintenance of thermogenesis measured in muscle in vitro and is not modulated by environmental temperature. The notion that UCP3 expression is modulated by food intake is of importance to better understand the pathophysiology of obesity in humans.	Univ Geneva, Fac Med, Dept Biochem Med, CH-1211 Geneva 4, Switzerland; Univ Geneva, Fac Med, Dept Physiol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Boss, O (corresponding author), Univ Geneva, Fac Med, Dept Biochem Med, 1 Michel Servet, CH-1211 Geneva 4, Switzerland.		Bijlenga, Philippe/S-1049-2016	Bijlenga, Philippe/0000-0002-3586-2757				ASTRUP A, 1986, AM J PHYSIOL, V250, pE226, DOI 10.1152/ajpendo.1986.250.2.E226; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; CHINET A, 1977, J PHYSIOL-LONDON, V265, P43, DOI 10.1113/jphysiol.1977.sp011704; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FARKAS DL, 1989, BIOPHYS J, V56, P1053, DOI 10.1016/S0006-3495(89)82754-7; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; GUEZENNEC CY, 1988, EUR J APPL PHYSIOL O, V57, P114, DOI 10.1007/BF00691249; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; OHNO T, 1990, JPN J PHYSIOL, V40, P463, DOI 10.2170/jjphysiol.40.463; ROTHWELL NJ, 1982, BIOSCIENCE REP, V2, P543, DOI 10.1007/BF01314214; Simonsen L, 1993, INT J OBES S, V17, P47; THURLBY PL, 1986, CAN J PHYSIOL PHARM, V64, P1111, DOI 10.1139/y86-189; TRAYHURN P, 1988, AM J PHYSIOL, V254, pR11, DOI 10.1152/ajpregu.1988.254.1.R11; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740	18	262	268	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					5	8		10.1074/jbc.273.1.5	http://dx.doi.org/10.1074/jbc.273.1.5			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417036	hybrid			2022-12-25	WOS:000071295600002
J	MacLeod, KJ; Vasilyeva, E; Baleja, JD; Forgac, M				MacLeod, KJ; Vasilyeva, E; Baleja, JD; Forgac, M			Mutational analysis of the nucleotide binding sites of the yeast vacuolar proton-translocating ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE (H+)-ATPASE; ESCHERICHIA-COLI F1-ATPASE; H+-ATPASE; CATALYTIC SUBUNIT; ADENOSINE-TRIPHOSPHATASE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL-CHANGES; CDNA SEQUENCE; BETA-SUBUNIT; V-ATPASES	To further define the structure of the nucleotide binding sites on the vacuolar proton-translocating ATPase (V-ATPase), the role of aromatic residues at the catalytic sites was probed using site-directed mutagenesis of the VMA1 gene that encodes the A subunit in yeast, Substitutions were made at three positions (Phe(452), Tyr(532), and Phe(538)) that correspond to residues observed in the crystal structure of the homologous beta subunit of the bovine mitochondrial F-ATPase to be in proximity to the adenine ring of bound ATP. Although conservative substitutions at these positions had relatively little effect on V-ATPase activity, replacement with nonaromatic residues (such as alanine or serine) caused either a complete loss of activity (F452A) or a decrease in the affinity for ATP (Y532S and F538A). The F452A mutation also appeared to reduce stability of the V-ATPase complex. These results suggest that aromatic or hydrophobic res residues at these positions are essential to maintain activity and/or high affinity binding to the catalytic sites of the V-ATPase. Site-directed mutations were also made at residues (Phe(479) and Arg(483)) that are postulated to be contributed by the A subunit to the noncatalytic nucleotide binding sites. Generally, substitutions at these positions led to decreases in activity ranging from 30 to 70% relative to wild type as well as modest decreases in K-m for ATP, Interestingly, the R483E and R483Q mutants showed a time dependent increase in ATPase activity following addition of ATP, suggesting that events at the noncatalytic sites may modulate the catalytic activity of the enzyme.	Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University; Tufts University	Forgac, M (corresponding author), Tufts Univ, Sch Med, Dept Cellular & Mol Physiol, 136 Harrison Ave, Boston, MA 02111 USA.				NIGMS NIH HHS [GM 34478, R01 GM034478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034478, R37GM034478] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ANRAKU Y, 1992, J BIOENERG BIOMEMBR, V24, P395, DOI 10.1007/BF00762532; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1992, J BIOENERG BIOMEMBR, V24, P361, DOI 10.1007/BF00762529; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; BRUNGER AT, 1987, X PLOR SYSTEM XRAY C; Capaldi RA, 1996, J BIOENERG BIOMEMBR, V28, P397, DOI 10.1007/BF02113980; CHATTERJEE D, 1992, P NATL ACAD SCI USA, V89, P6257, DOI 10.1073/pnas.89.14.6257; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; FENG Y, 1992, J BIOL CHEM, V267, P5817; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fillingame RH, 1997, J EXP BIOL, V200, P217; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GLUCK SL, 1992, J BIOENERG BIOMEMBR, V24, P351, DOI 10.1007/BF00762528; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; IWAMOTO A, 1993, J BIOL CHEM, V268, P3156; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; KANE PM, 1989, J BIOL CHEM, V264, P19236; KANE PM, 1992, J BIOL CHEM, V267, P447; KANE PM, 1992, J BIOENERG BIOMEMBR, V24, P383, DOI 10.1007/BF00762531; KIBAK H, 1992, J BIOENERG BIOMEMBR, V24, P415, DOI 10.1007/BF00762534; KIBAK H, 1993, J BIOL CHEM, V268, P23325; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu JZ, 1996, BIOCHEMISTRY-US, V35, P10938, DOI 10.1021/bi9608065; Liu Q, 1996, J BIOL CHEM, V271, P2018, DOI 10.1074/jbc.271.4.2018; Liu Q, 1997, J BIOL CHEM, V272, P11750, DOI 10.1074/jbc.272.18.11750; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; OMOTE H, 1992, J BIOL CHEM, V267, P20571; PEDERSEN PL, 1996, BIOENERG BIOMEMBR, V28, P389; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SENIOR AE, 1992, J BIOL CHEM, V267, P21471; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SZE H, 1992, J BIOENERG BIOMEMBR, V24, P371, DOI 10.1007/BF00762530; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; WEBER J, 1992, J BIOL CHEM, V267, P1712; WEBER J, 1993, J BIOL CHEM, V268, P20126; WISHART DS, 1994, COMPUT APPL BIOSCI, V10, P121; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	58	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					150	156		10.1074/jbc.273.1.150	http://dx.doi.org/10.1074/jbc.273.1.150			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417059	hybrid			2022-12-25	WOS:000071295600025
J	Pooga, M; Hallbrink, M; Zorko, M; Langel, U				Pooga, M; Hallbrink, M; Zorko, M; Langel, U			Cell penetration by transportan	FASEB JOURNAL			English	Article						peptide synthesis; Bowes' melanoma cells; endocytosis; GTPase activity	CHIMERIC PEPTIDE; ANTENNAPEDIA HOMEODOMAIN; CEREBROSPINAL-FLUID; GALANIN RECEPTOR; G-PROTEINS; 3RD HELIX; MASTOPARAN; MEMBRANES; BINDING; PERMEABILITY	Transportan is a 27 amino acid-long peptide containing 12 functional amino acids from the amino terminus of the neuropeptide galanin and mastoparan in the carboxyl terminus, connected via a lysine. Transportan is a cell-penetrating peptide as judged by indirect immunofluorescence using N-epsilon 13-biotinyl-transportan. The internalization of biotinyl-transportan is energy independent and takes place efficiently at 37 degrees, 4 degrees, and 0 degrees C, Cellular uptake of transportan is probably not mediated by endocytosis, since it cannot be blocked by treating the cells with phenylarsine oxide or hyperosmolar sucrose solution and is nonsaturable, The kinetics of internalization was studied with the aid of the I-125-labeled peptide. At 37 degrees C, the maximal intracellular concentration is reached in about 20 min, The internalized transportan is protected from trypsin. The cell-penetrating ability of transportan is not restricted by cell type, but seems to be a general feature of this peptide, In Bowes' melanoma cells, transportan first localizes in the outer membrane and cytoplasmatic membrane structures, This is followed by a redistribution into the nuclear membrane and uptake into the nuclei where transportan concentrates in distinct substructures, probably the nucleoli.	Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden; Estonian Bioctr, EE-2400 Tartu, Estonia; Univ Ljubljana, Fac Med, Inst Biochem, Ljubljana 1000, Slovenia	Stockholm University; Estonian Biocentre; University of Ljubljana	Langel, U (corresponding author), Univ Stockholm, Arrhenius Lab, Dept Neurochem & Neurotoxicol, S-10691 Stockholm, Sweden.	ulo@neurochem.su.se	Pooga, Margus/A-8575-2011	Pooga, Margus/0000-0003-4532-4087; Langel, Ulo/0000-0001-6107-0844				AHREN B, 1986, BIOCHEM BIOPH RES CO, V140, P1059, DOI 10.1016/0006-291X(86)90742-4; BEDECS K, 1995, NEUROPEPTIDES, V29, P137, DOI 10.1016/0143-4179(95)90015-2; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; Consolo S, 1997, BRAIN RES, V756, P174, DOI 10.1016/S0006-8993(97)00146-7; DANILENKO M, 1993, BIOCHEM BIOPH RES CO, V196, P1296, DOI 10.1006/bbrc.1993.2393; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; FROST SC, 1985, J BIOL CHEM, V260, P2646; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; ILLINGER D, 1994, J CELL BIOL, V125, P783, DOI 10.1083/jcb.125.4.783; Jureus A., 1996, ACTA CHIM SLOV, V43, P51, DOI DOI 10.1007/S008940100045; Kask K, 1996, EMBO J, V15, P236, DOI 10.1002/j.1460-2075.1996.tb00354.x; KASK K, 1995, REGUL PEPTIDES, V59, P341, DOI 10.1016/0167-0115(95)00089-T; LAND T, 1991, INT J PEPT PROT RES, V38, P267; LAND T, 1991, METHODS NEUROSCIENCE, V5, P225; LANGEL U, 1992, INT J PEPT PROT RES, V39, P516; Langel U, 1996, REGUL PEPTIDES, V62, P47, DOI 10.1016/0167-0115(96)00002-X; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P8450, DOI 10.1021/bi960342a; MCKENZIE FR, 1992, SIGNAL TRANSDUCTION, P31; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; Ostenson CG, 1997, ENDOCRINOLOGY, V138, P3308, DOI 10.1210/en.138.8.3308; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SODERQVIST H, 1994, EUR J CELL BIOL, V64, P183; STOJAN J, 1997, IN PRESS J CHEM INF; TAM JP, 1986, J AM CHEM SOC, V108, P5242, DOI 10.1021/ja00277a031; TANIMURA A, 1991, BIOCHEM BIOPH RES CO, V177, P802, DOI 10.1016/0006-291X(91)91860-F; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815	32	519	596	3	85	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	1998	12	1					67	77		10.1096/fasebj.12.1.67	http://dx.doi.org/10.1096/fasebj.12.1.67			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438412				2022-12-25	WOS:000071523800008
J	Lykidis, A; Jackson, PD; Rock, CO; Jackowski, S				Lykidis, A; Jackson, PD; Rock, CO; Jackowski, S			The role of CDP-diacylglycerol synthetase and phosphatidylinositol synthase activity levels in the regulation of cellular phosphatidylinositol content	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PITUITARY PLASMA-MEMBRANE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; ESCHERICHIA-COLI; PHOSPHATIDATE PHOSPHOHYDROLASE; PHOSPHATIDYLCHOLINE SYNTHESIS; DIGLYCERIDE SYNTHETASE; ENDOPLASMIC-RETICULUM	The regulation of phosphatidylinositol synthesis was examined by cloning and expressing in COS-7 cells the human cDNAs encoding the two enzymes in the biosynthetic pathway, Human CDP-diacylglycerol synthetase (cds1) and phosphatidylinositol synthase (pis1) clones were identified in the human expressed sequence-tagged (EST) data base, and full-length cDNAs were obtained by library screening, The cds1 cDNA did not possess a recognizable mitochondrial import signal, and the activity of the expressed Cds1 protein was stimulated by nucleoside triphosphates in vitro, indicating that cds1 did not encode the mitochondrial-specific isozyme, There were two mRNA species (3.9 and 5.6 kilobases) detected on Northern blots hybridized with the cds1 probe that were expressed at distinctly different levels in various human tissues, Consistent with the presence of the two mRNAs, a cDNA predicted to encode a second human CDP-diacylglycerol synthetase (cds2) was also uncovered in the EST data base, In contrast to the two cds mRNAs, a single, 2.1-kilobase pis1 mRNA was uniformly expressed in all human tissues examined, Expression of the pis1 gene led to the overproduction of both phosphatidylinositol synthase and phosphatidylinositol:inositol exchange reactions, indicating that the Pis1 polypeptide catalyzed both of these activities, Phosphatase treatment of cell extracts abolished the CMP-independent phosphatidylinositol:inositol exchange reaction, and exchange activity was completely restored by the addition of CMP, Overexpression of cds1 or pis1 alone or in combination did not enhance the rate of phosphatidylinositol biosynthesis, Also, overexpression did not result in a significant proportional increase in the cellular levels of CDP-diacylglycerol or phosphatidylinositol, These data illustrate that the levels of Cds1 and Pis1 protein expression are not critical determinants of cellular PtdIns content and argue against a determining role for the activity of either of these enzymes in the regulation of PtdIns biosynthesis.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Jackowski, S (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM 45737, GM 34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R01GM045737, R37GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANTONSSON BE, 1994, BIOCHEM J, V297, P517, DOI 10.1042/bj2970517; BALLAS LM, 1981, BIOCHIM BIOPHYS ACTA, V665, P586, DOI 10.1016/0005-2760(81)90274-5; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BERRY G, 1986, J NEUROCHEM, V46, P1073, DOI 10.1111/j.1471-4159.1986.tb00620.x; BLEASDALE JE, 1981, BIOCHIM BIOPHYS ACTA, V664, P428, DOI 10.1016/0005-2760(81)90065-5; BRINDLEY DN, 1984, PROG LIPID RES, V23, P115, DOI 10.1016/0163-7827(84)90001-8; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; CUBITT AB, 1989, BIOCHEM J, V257, P639, DOI 10.1042/bj2570639; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Dillon DA, 1997, J BIOL CHEM, V272, P10361; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gilmore AP, 1996, NATURE, V381, P531, DOI 10.1038/381531a0; Goto K, 1996, J LIPID MEDIAT CELL, V14, P251, DOI 10.1016/0929-7855(96)00533-0; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Heacock AM, 1996, J NEUROCHEM, V67, P2200; Hodgkin MN, 1996, BIOCHEM SOC T, V24, P991, DOI 10.1042/bst0240991; HOKIN LE, 1985, ANNU REV BIOCHEM, V54, P205, DOI 10.1146/annurev.biochem.54.1.205; ICHO T, 1985, J BIOL CHEM, V260, P2078; IMAI A, 1987, J BIOL CHEM, V262, P6457; IMAI A, 1987, NATURE, V325, P726, DOI 10.1038/325726a0; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Jiang YW, 1996, J BIOL CHEM, V271, P29529, DOI 10.1074/jbc.271.47.29529; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; KATES M, 1975, TECHNIQUES LIPIDOLOG, P355; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KLEZOVITCH O, 1993, FEBS LETT, V320, P256, DOI 10.1016/0014-5793(93)80598-O; LITEPLO RG, 1980, BIOCHIM BIOPHYS ACTA, V619, P660, DOI 10.1016/0005-2760(80)90115-0; MCPHEE F, 1991, BIOCHEM J, V275, P187, DOI 10.1042/bj2750187; MOK AYP, 1993, BIOCHEM CELL BIOL, V71, P183, DOI 10.1139/o93-029; MOK AYP, 1992, FEBS LETT, V312, P236, DOI 10.1016/0014-5793(92)80942-A; MONACO ME, 1994, BIOCHEM J, V304, P301, DOI 10.1042/bj3040301; Nakashima A, 1997, J BIOL CHEM, V272, P9567; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NOH DY, 1995, BBA-REV CANCER, V1242, P99, DOI 10.1016/0304-419X(95)00006-0; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; RAETZ CRH, 1972, J BIOL CHEM, V247, P2245; Saito S, 1997, J BIOL CHEM, V272, P9503; SANTIAGO OM, 1993, BIOCHEM J, V290, P179, DOI 10.1042/bj2900179; SCHLAME M, 1993, J BIOL CHEM, V268, P74; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SPARROW CP, 1985, J BIOL CHEM, V260, P2084; TAKENAWA T, 1980, ARCH BIOCHEM BIOPHYS, V202, P601, DOI 10.1016/0003-9861(80)90467-1; Tanaka S, 1996, FEBS LETT, V393, P89, DOI 10.1016/0014-5793(96)00858-7; VAZIRI C, 1993, BIOCHEM J, V294, P793, DOI 10.1042/bj2940793; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Weeks R, 1997, DNA CELL BIOL, V16, P281, DOI 10.1089/dna.1997.16.281; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; Xu FY, 1997, BIOCHEM BIOPH RES CO, V232, P261, DOI 10.1006/bbrc.1997.6270	55	92	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33402	33409		10.1074/jbc.272.52.33402	http://dx.doi.org/10.1074/jbc.272.52.33402			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407135	hybrid			2022-12-25	WOS:000071182900096
J	Mor, O; Read, M; Fried, M				Mor, O; Read, M; Fried, M			p53 in polyoma virus transformed REF52 cells	ONCOGENE			English	Article						p53; polyoma virus; cell cycle; DNA damage; p21; MDM2	WILD-TYPE P53; P53-DEPENDENT G(1) ARREST; DNA-DAMAGE RESPONSE; GROWTH ARREST; HUMAN FIBROBLASTS; T-ANTIGEN; PROTEIN; EXPRESSION; ONCOGENES; IDENTIFICATION	While cellular transformation by small DNA tumour viruses usually involves targeting the product of the p53 tumour suppressor gene by a virally encoded protein, none of the three polyoma virus (Py) specified T antigens have been observed to interact with p53, We show that primary mouse embryo fibroblasts and REF52 cells, which resemble primary cells in requiring co-operating oncogenes for transformation, cannot be transformed by the Py oncogene, middle T-antigen (PyMT), alone, These cells can be transformed by the complete Py early region, which encodes the Py large, middle and small T-antigens, We find that PyMT can transform rodent cells lacking a functional p53 protein (p53 null mouse embryo fibroblasts and DN-REF52 cells which contain a dominant negative p53), In Py transformed REF52 cells (Py-REF52) there is no significant accumulation of p53 protein, as opposed to SV40 transformed REF52 cells (SV-REF52) in which the amount of steady state p53 protein is elevated, However accumulation of p53 is observed following exposure of Py-REF52 cells to u.v. Treatment of Py-REF52 cells with X-rays results in a rapid increase in the levels of the p53-induced proteins p21/WAF1 and MDM2. In untransformed REF52 cells, S-irradiation causes p53 activation, which results in induction of both G1/S and G2/M blocks, In SV-REF52 and DN-REF52 cells, p53 abrogation results in the absence of both the G1/S and G2/M blocks, Only the absence of a G1/S block is observed in Py-REF52 cells exposed to S-irradiation, Together these results indicate that in contrast to most other DNA tumour viruses, Py does not appear to interefere with the DNA damage induced transactivation activities of the p53 protein but absence of a functional p53 protein can mediate transformation by the PyMT oncogene in the absence of other co-operating oncogenes, Possible modes of transformation by Py are discussed.	Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, London WC2A 3PX, England	Cancer Research UK	Fried, M (corresponding author), Imperial Canc Res Fund, Eukaryot Gene Org & Express Lab, POB 123, London WC2A 3PX, England.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CUZIN F, 1984, BIOCHIM BIOPHYS ACTA, V781, P193, DOI 10.1016/0167-4781(84)90084-8; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dilworth S M, 1990, Semin Cancer Biol, V1, P407; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORD M, 1985, P NATL ACAD SCI USA, V82, P3370, DOI 10.1073/pnas.82.10.3370; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HICKS GG, 1991, MOL CELL BIOL, V11, P1344, DOI 10.1128/MCB.11.3.1344; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Lu X, 1996, ONCOGENE, V13, P413; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Maniatis T., 1982, MOL CLONING LAB MANU; MICHIELI P, 1994, CANCER RES, V54, P3691; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, EXP CELL RES, V215, P386, DOI 10.1006/excr.1994.1356; STEWART N, 1995, ONCOGENE, V10, P109; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	42	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3113	3119		10.1038/sj.onc.1201549	http://dx.doi.org/10.1038/sj.onc.1201549			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444959				2022-12-25	WOS:000070968000011
J	Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ				Wang, XT; Gorospe, M; Huang, Y; Holbrook, NJ			p27(Kip1) overexpression causes apoptotic death of mammalian cells	ONCOGENE			English	Article						apoptosis; cdk inhibitor; cell growth; Bcl-2	DEPENDENT KINASE INHIBITOR; ANTICANCER AGENTS; CARCINOMA CELLS; CDK INHIBITORS; MICE LACKING; CYCLE ARREST; G(1) ARREST; GROWTH; P21; DIFFERENTIATION	p27(Kip1), a member of the Cip/Kip family of cyclin-dependent kinase (cdk) inhibitors, has been Implicated in mediating G1 arrest in response to a variety of growth inhibitory signals, Its importance in regulating cell growth is emphasized by the fact that mice lacking p27(Kip1) are abnormally large and display hyperplasia of multiple tissues, However, these mice retain the ability to undergo G1 arrest in response to growth inhibitory signals, suggesting that p27(Kip1) may serve other functions important for controlling tissue growth, In the present study, we utilized an adenoviral vector-based expression system to examine the consequences of p27(Kip1) overexpression in the human carcinoma cell lines A549, HeLa and RKO, in human melanoma SK-MEL-110 cells, in human lung fibroblasts IMR90 and in the rat fibroblast line Rat1, We demonstrate that overexpression of p27(Kip1) leads to apoptotic cell death in all cell types, and further show that ectopic expression of Bcl-2 can protect HeLa cells from apoptosis mediated by p27(Kip1) overexpression, To our knowledge, this is the first study demonstrating that p27(Kip1) can induce apoptosis, Our findings provide new insight into the possible functions of this growth regulatory protein, and support the potential utility of gene therapeutic approaches aimed at elevating p27(Kip1) expression for treatment of human cancers.	NIA,GENE EXPRESS & AGING SECT,BIOL CHEM LAB,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)								Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Gorospe M, 1996, MOL CELL BIOL, V16, P762; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; ROBERTS JM, 1994, COLD SPRING HARB SYM, V59, P31, DOI 10.1101/SQB.1994.059.01.006; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wu XP, 1996, ONCOGENE, V12, P1397; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052	31	193	212	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2991	2997		10.1038/sj.onc.1201450	http://dx.doi.org/10.1038/sj.onc.1201450			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416843				2022-12-25	WOS:A1997YK37700012
J	Armstead, VE; Minchenko, AG; Campbell, B; Lefer, AM				Armstead, VE; Minchenko, AG; Campbell, B; Lefer, AM			P-selectin is up-regulated in vital organs during murine traumatic shock	FASEB JOURNAL			English	Article						adhesion molecules; endothelium; RNase protection assay; splanchnic organs; immunohistochemistry; NF-kappa B	NF-KAPPA-B; ENDOTHELIAL-CELL-ADHESION; GRANULE MEMBRANE-PROTEIN; TUMOR-NECROSIS-FACTOR; LOWER TORSO ISCHEMIA; NEUTROPHIL ADHERENCE; REPERFUSION INJURY; LUNG INJURY; ACTIVATION; EXPRESSION	Murine traumatic shock is associated with increased adherence of neutrophils to the vascular endothelium resulting in neutrophil infiltration and tissue damage. We examined the effects of trauma on the expression of the adhesion molecule P-selectin in several vital organs (i.e., heart, lungs, liver, kidneys, and small intestine) 2 h after induction of Noble-Collip drum trauma in anesthetized rats. Total RNA was extracted from these organs and P-selectin mRNA was quantified by RNase protection assays. P-selectin mRNA was significantly increased over control nontraumatized, anesthetized rats in all vital organs (P<0.05 or less), with the largest increase occurring in the lung (P<0.01). Immunohistochemical analysis showed increased expression of P-selectin protein in postcapillary venules of all vital organs after trauma. To further investigate the possible mechanisms of increased P-selectin mRNA transcription promoter activity during trauma, we quantified binding of proteins from nuclear extracts to the KB site ((-218)GGGGGTGACCC(-207)) Of the P-selectin gene by electrophoretic mobility shift assay, We confirmed the results of NF-kappa B binding by demonstrating increases in p50 and p52, as well as decreases in I kappa B in cytoplasmic and nuclear extracts from the lungs of trauma rats by Western blotting. Increased activity of the transcription factor, nuclear factor kappa B (NF-kappa B), occurred in all vital organs of the trauma rats compared to sham-operated controls. Our findings suggest that severe trauma results in up-regulation of P-selectin at the transcriptional level, which is partly controlled by an NF-kappa B-responsive element in the region of the P-selectin promoter. This increased activation of NF-kappa B binding may contribute to the widespread increases in P-selectin expression observed in several vital organs 2 h after trauma, which in turn may play a key role in the pathogenesis of traumatic shock.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Lefer, AM (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.		Minchenko, Oleksandr/AAV-5742-2020	Minchenko, Oleksandr/0000-0002-7093-5173	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045434] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45434] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstead VE, 1997, AM J PHYSIOL-HEART C, V273, pH740, DOI 10.1152/ajpheart.1997.273.2.H740; BAUE AE, 1992, ARCH SURG-CHICAGO, V127, P1451; BECKSTEAD JH, 1986, BLOOD, V67, P285; BOLDT J, 1995, CHEST, V107, P787, DOI 10.1378/chest.107.3.787; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1993, LAB INVEST, V68, P499; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; Gibbs SAL, 1996, SURGERY, V119, P652, DOI 10.1016/S0039-6060(96)80189-9; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HILL J, 1993, J APPL PHYSIOL, V74, P659, DOI 10.1152/jappl.1993.74.2.659; Johnson DR, 1996, J BIOL CHEM, V271, P16317, DOI 10.1074/jbc.271.27.16317; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LEFER AM, 1987, AM J PHYSIOL, V252, pR193, DOI 10.1152/ajpregu.1987.252.2.R193; LEFER AM, 1993, ANNU REV PHARMACOL, V33, P71, DOI 10.1146/annurev.pa.33.040193.000443; LORANT DE, 1991, J CELL BIOL, V115, P223, DOI 10.1083/jcb.115.1.223; Noble RL, 1942, Q J EXP PHYSIOL CMS, V31, P187, DOI 10.1113/expphysiol.1942.sp000856; PAN JL, 1995, J BIOL CHEM, V270, P23077, DOI 10.1074/jbc.270.39.23077; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; Rong YQ, 1996, J NEUROCHEM, V67, P662; SANDERS WE, 1992, BLOOD, V80, P795; Scalia R, 1996, SHOCK, V6, P177, DOI 10.1097/00024382-199609000-00004; Shono T, 1996, MOL CELL BIOL, V16, P4231; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIMMONS RK, 1996, J TRAUMA INJURY INF, V41, P653; SKURK C, 1995, SHOCK, V3, P13; SKURK C, 1994, AM J PHYSIOL-HEART C, V267, pH2124, DOI 10.1152/ajpheart.1994.267.6.H2124; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; SUGAMA Y, 1992, J CELL BIOL, V119, P935, DOI 10.1083/jcb.119.4.935; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; WELBOURN R, 1991, J APPL PHYSIOL, V70, P2645, DOI 10.1152/jappl.1991.70.6.2645; WELBOURN R, 1992, CIRC RES, V71, P82, DOI 10.1161/01.RES.71.1.82; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501	41	25	29	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1271	1279		10.1096/fasebj.11.14.9409546	http://dx.doi.org/10.1096/fasebj.11.14.9409546			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409546				2022-12-25	WOS:000071144100008
J	D'Souza, S; Garcia-Cabado, A; Yu, F; Teter, K; Lukacs, G; Skorecki, K; Moore, HP; Orlowski, J; Grinstein, S				D'Souza, S; Garcia-Cabado, A; Yu, F; Teter, K; Lukacs, G; Skorecki, K; Moore, HP; Orlowski, J; Grinstein, S			The epithelial sodium-hydrogen antiporter Na+/H+ exchanger 3 accumulates and is functional in recycling endosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED TRANSCYTOSIS; BREFELDIN-A; MEMBRANE-TRANSPORT; ENDOCYTIC PATHWAY; GROWTH-FACTOR; CELL-SURFACE; H+ EXCHANGE; MDCK CELLS; K562 CELLS; PROTEIN	Na+/H+ exchangers (NHEs) mediate electroneutral exchange of Na+ for H+ and thereby play a central role in pH regulation and Na+ homeostasis. NHE3, the predominant epithelial isoform, is found in apical membranes of renal and intestinal epithelial cells, where it contributes to NaCl (re)absorption. NHE activity has been detected in endomembrane vesicles of epithelial cells, but the precise compartment involved and its functional role have not been defined. Many aspects of the targeting machinery that defines the compartmentation and polarity of epithelia are also functional in nonepithelial cells. We therefore compared the targeting of NHE1, the basolateral isoform, with that of NHE3 in Chinese hamster ovary cells. To circumvent the confounding effects of endogenous exchangers, epitope-tagged constructs of NHE1 and NHE3 were stably expressed in antiport-deficient (AP-1) cells. While NHE1 was found almost exclusively in the surface membrane, NHE3 was also found intracellularly, accumulating in a juxtanuclear compartment. Confocal microscopy showed this compartment to be distinct from the Golgi, trans-Golgi network, and lysosomes. Instead, NHE3 colocalized with transferrin receptors and with cellubrevin, markers of recycling endosomes. The activity of NHE3 in endomembranes was assessed by targeting pH-sensitive probes to the recycling endosomes using a chimeric cellubrevin construct with an accessible extracellular epitope. Fluorescence ratio imaging indicated that cellubrevin resides intracellularly in an acidic compartment. In AP-1 cells, endosomal acidification was unaffected by omission of Na+ but was dissipated entirely by concanamycin, a blocker of H+-ATPases. In contrast, the cellubrevin compartment was more acidic in NHE3 transfectants, and the acidification was only partially reduced by concanamycin. Moreover, removal of extracellular Na+ resulted in a significant alkalization of the endocytic compartment. These results indicate that NHE3 is present and active in recycling endosomes. By recruiting NHE3 to the plasma membrane, modulation of vesicular traffic could contribute to the regulation of Na+ reabsorption across epithelia.	Hosp Sick Children, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Resp Res, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1X8, Canada; McGill Univ, Dept Physiol, Montreal, PQ H36 1Y6, Canada; Univ Calif Berkeley, Dept Cell Biol, Berkeley, CA 94720 USA; Technion Israel Inst Technol, Bruce Rappaport Med Sch, IL-31096 Haifa, Israel	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; McGill University; University of California System; University of California Berkeley; Technion Israel Institute of Technology	Grinstein, S (corresponding author), Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickids.on.ca		Yu, Frank/0000-0001-9306-1731; Lukacs, Gergely/0000-0003-0900-0675; Teter, Ken/0000-0003-4176-9361; Orlowski, John/0000-0001-7371-175X				APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; BIEMESDERFER D, 1995, J AM SOC NEPHROL, V6, P372; BROWN D, 1993, J CELL SCI, P49; CAIN CC, 1989, P NATL ACAD SCI USA, V86, P544, DOI 10.1073/pnas.86.2.544; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; COURTOISCOUNTRY N, 1996, MOL BIOL CELL, V7, P80; DAMKE H, 1992, BIOCHEM BIOPH RES CO, V185, P719, DOI 10.1016/0006-291X(92)91685-J; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; FRANKI N, 1995, AM J PHYSIOL-CELL PH, V269, pC797, DOI 10.1152/ajpcell.1995.269.3.C797; FUCHS R, 1989, P NATL ACAD SCI USA, V86, P539, DOI 10.1073/pnas.86.2.539; GARCIACABADO AG, 1996, J BIOL CHEM, V271, P3590; GOSS GG, 1994, J BIOL CHEM, V269, P8741; GRINSTEIN S, 1993, EMBO J, V12, P5209, DOI 10.1002/j.1460-2075.1993.tb06216.x; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; HENSLEY CB, 1989, AM J PHYSIOL, V257, pC637, DOI 10.1152/ajpcell.1989.257.4.C637; HILDEN SA, 1990, AM J PHYSIOL, V258, pF1311; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; KNIGHT A, 1995, MOL BIOL CELL, V6, P597, DOI 10.1091/mbc.6.5.597; MA YH, 1994, J BIOL CHEM, V269, P30734; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NOEL J, 1995, AM J PHYSIOL-CELL PH, V268, pC283, DOI 10.1152/ajpcell.1995.268.2.C283; Odorizzi G, 1996, J CELL BIOL, V135, P139, DOI 10.1083/jcb.135.1.139; Orlowski J, 1996, J BIOL CHEM, V271, P19922, DOI 10.1074/jbc.271.33.19922; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; POUYSSEGUR J, 1984, P NATL ACAD SCI-BIOL, V81, P4833, DOI 10.1073/pnas.81.15.4833; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SABOLIC I, 1990, AM J PHYSIOL, V258, pF1245, DOI 10.1152/ajprenal.1990.258.5.F1245; SCHONHORN JE, 1994, MOL CELL BIOCHEM, V135, P159, DOI 10.1007/BF00926519; Shapiro J, 1997, J HISTOCHEM CYTOCHEM, V45, P3, DOI 10.1177/002215549704500102; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; SOLEIMANI M, 1995, J INVEST MED, V43, P419; TETER K, 1996, MOL BIOL CELL, V7, P327; THATTE HS, 1994, J CELL PHYSIOL, V160, P345, DOI 10.1002/jcp.1041600216; VANDYKE RW, 1995, AM J PHYSIOL-CELL PH, V269, pC943, DOI 10.1152/ajpcell.1995.269.4.C943; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WAN JS, 1992, J BIOL CHEM, V267, P13446; Wilson JM, 1997, J CELL BIOL, V136, P319, DOI 10.1083/jcb.136.2.319; WOOD SA, 1992, J CELL BIOL, V119, P273, DOI 10.1083/jcb.119.2.273; Yoshimori T, 1996, J CELL BIOL, V133, P247, DOI 10.1083/jcb.133.2.247; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1; Zhang X, 1996, J AM SOC NEPHROL, V7, pA1281; Zhang YB, 1996, AM J PHYSIOL-RENAL, V270, pF1004, DOI 10.1152/ajprenal.1996.270.6.F1004	50	191	191	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2035	2043		10.1074/jbc.273.4.2035	http://dx.doi.org/10.1074/jbc.273.4.2035			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442041	hybrid			2022-12-25	WOS:000071595200030
J	Kisselev, AF; Akopian, TN; Goldberg, AL				Kisselev, AF; Akopian, TN; Goldberg, AL			Range of sizes of peptide products generated during degradation of different proteins by archaeal proteasomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							20S PROTEASOME; THERMOPLASMA-ACIDOPHILUM; ANTIGENIC PEPTIDES; COMPLEX; INHIBITORS; SUBUNITS; PA28	The 20 S proteasome processively degrades cell proteins to peptides, Information on the sizes and nature of these products is essential for understanding the proteasome's degradative mechanism, the subsequent steps in protein turnover, and major histocompatibility complex class I antigen presentation, Using proteasomes from Thermoplasma acidophilum and four unfolded polypeptides as substrates (insulin-like growth factor, lactalbumin, casein, and alkaline phosphatase, whose lengths range from 71 to 471 residues), we demonstrate that the number of cuts made in a polypeptide and the time needed to degrade it increase with length, The average size of peptides generated from these four polypeptides was 8 +/- 1 residues, but ranged from 6 to 10 residues, depending on the protein, as determined by two new independent methods. However, the individual peptide products ranged in length from approximately 3 to 30 residues, as demonstrated by mass spectrometry and size-exclusion chromatography. The sizes of individual peptides fit a lognormal distribution, No length was predominant, and more than half were shorter than 10 residues, Peptide abundance decreased with increasing length, and less than 10% exceeded 20 residues, These findings indicate that: 1) the proteasome does not generate peptides according to the "molecular ruler" hypothesis, and 2) other peptidases must function after the proteasome to complete the turnover of cell proteins to amino acids.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.							Akopian TN, 1997, J BIOL CHEM, V272, P1791, DOI 10.1074/jbc.272.3.1791; Baumeister W, 1997, CURR OPIN STRUC BIOL, V7, P273, DOI 10.1016/S0959-440X(97)80036-X; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DICK LR, 1994, J IMMUNOL, V152, P3884; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; Ehring B, 1996, EUR J BIOCHEM, V235, P404, DOI 10.1111/j.1432-1033.1996.00404.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; GORNICK L, 1993, CARTOON GUIDE STAT; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Niedermann G, 1996, P NATL ACAD SCI USA, V93, P8572, DOI 10.1073/pnas.93.16.8572; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SILVESTRE MPC, 1994, J AGR FOOD CHEM, V42, P2778, DOI 10.1021/jf00048a024; Stock D, 1995, COLD SPRING HARB SYM, V60, P525, DOI 10.1101/SQB.1995.060.01.056; Stuart DI, 1997, NATURE, V386, P437, DOI 10.1038/386437a0; TAMURA T, 1995, CURR BIOL, V5, P766, DOI 10.1016/S0960-9822(95)00153-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199; WENZEL T, 1994, FEBS LETT, V349, P205, DOI 10.1016/0014-5793(94)00665-2	28	162	166	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1982	1989		10.1074/jbc.273.4.1982	http://dx.doi.org/10.1074/jbc.273.4.1982			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442034	hybrid			2022-12-25	WOS:000071595200023
J	Miralles, F; Ron, D; Baiget, M; Felez, J; Munoz-Canoves, P				Miralles, F; Ron, D; Baiget, M; Felez, J; Munoz-Canoves, P			Differential regulation of urokinase-type plasminogen activator expression by basic fibroblast growth factor and serum in myogenesis - Requirement of a common mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE GROWTH; SIGNAL-TRANSDUCTION; LYSOPHOSPHATIDIC ACID; CELL-PROLIFERATION; MYOBLAST FUSION; GENE-EXPRESSION; RECEPTORS; FAMILY; COMMITMENT; ONCOGENES	The broad spectrum protease urokinase-type plasminogen activator (uPA) has been implicated in muscle regeneration in vivo as well as in myogenic proliferation and differentiation in vitro. These processes are known to be modulated by basic fibroblast growth factor (FGF-P) and serum. We therefore investigated the mechanism(s) underlying the regulation of uPA expression by these two stimuli in proliferating and differentiating myoblasts. The expression of uPA mRNA and the activity of the uPA gene product were induced by FGF-2 and serum in proliferating myoblasts. uPA induction occurred at the level of transcription and required the uPA-PEA3/AP1 enhancer element, since deletion of this site in the full promoter abrogated induction by FGF-S and serum. Using L6E9 skeletal myoblasts, devoid of endogenous FGF receptors, which have been engineered to express either FGF receptor-1 (FGFR1) or FGF receptor-4 (FGFR4), we have demonstrated that both receptors, known to be expressed in skeletal muscle cell precursors, were able to mediate uPA induction by FGF-2, whereas serum stimulation was FGF receptor-independent. The induction of uPA by FGF-2 and serum in FGFR1- and in FGFR4-expressing myoblasts required the mitogen-activated protein kinase pathway, since treatment of cells with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinase-2 kinase, PD98059, blocked uPA promoter induction. Although FGF-S and serum induced uPA in proliferating myoblasts, their actions on cell-cell contact-induced differentiating myoblasts differed dramatically. FGF-S, but not serum, repressed uPA expression in differentiation-committed myoblasts, and these effects were also shown to occur at the level of uPA transcription. Altogether, these results indicate a dual regulation of the uPA gene by FGF-P and serum, which ensures uPA expression throughout the whole myogenic process in different myoblastic lineages. The effects of FGF-2 and serum on uPA expression may contribute to the proteolytic activity required during myoblast migration and fusion, as well as in muscle regeneration.	Inst Recerca Oncol, Dept Receptors Cellulars, Barcelona 08907, Spain; Hosp Sant Pau, Unitat Genet Mol, Barcelona, Spain; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Hospital of Santa Creu i Sant Pau; Technion Israel Institute of Technology	Munoz-Canoves, P (corresponding author), Inst Recerca Oncol, Dept Receptors Cellulars, Km 2-7, Barcelona 08907, Spain.	pmunoz@iro.es	Munoz-Canoves, Pura/B-3889-2015	Miralles, Francesc/0000-0003-3069-2725				ANDERSON JE, 1991, DEV BIOL, V147, P96, DOI 10.1016/S0012-1606(05)80010-7; BARLOVATZMEIMON G, 1990, NATO ADV SCI I A-LIF, V191, P229; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; CAMPBELL JS, 1995, P NATL ACAD SCI USA, V92, P870, DOI 10.1073/pnas.92.3.870; Carmeliet P, 1996, FIBRINOLYSIS, V10, P195, DOI 10.1016/S0268-9499(96)80017-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GAGOS JA, 1996, J ELL BIOL, V134, P837; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GUERIN CW, 1995, DEV DYNAM, V202, P91, DOI 10.1002/aja.1002020109; Guthridge M, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008871; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HUGHES SM, 1990, NATURE, V345, P350, DOI 10.1038/345350a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOSEPHSILVERSTEIN J, 1989, J CELL BIOL, V108, P2459, DOI 10.1083/jcb.108.6.2459; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KUDLA AJ, 1995, MOL CELL BIOL, V15, P3238; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIU Y, 1995, J BIOL CHEM, V270, p83P77; MunozCanoves P, 1997, THROMB HAEMOSTASIS, V77, P526; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; SAKSELA O, 1985, BIOCHIM BIOPHYS ACTA, V823, P35, DOI 10.1016/0304-419X(85)90014-9; SHAOUL E, 1995, ONCOGENE, V10, P1553; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; STARK KL, 1991, DEVELOPMENT, V113, P641; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TEMPLETON TJ, 1992, DEV BIOL, V154, P169, DOI 10.1016/0012-1606(92)90057-N; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yoshida S, 1996, J CELL BIOL, V132, P181, DOI 10.1083/jcb.132.1.181	43	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2052	2058		10.1074/jbc.273.4.2052	http://dx.doi.org/10.1074/jbc.273.4.2052			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442043	hybrid			2022-12-25	WOS:000071595200032
J	Nishimura, R; Kato, Y; Chen, D; Harris, SE; Mundy, GR; Yoneda, T				Nishimura, R; Kato, Y; Chen, D; Harris, SE; Mundy, GR; Yoneda, T			Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell fine C2C12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; BONE; PATHWAY; FAMILY; REGULATORS; DROSOPHILA; RECEPTORS; SIGNALS; GENES	Since the bone morphogenetic proteins (BRSPs) are members of the transforming growth factor-beta (TGF-beta) superfamily that induce the differentiation of-mesenchymal precursor cells into the osteogenic cells, we identified the relevant signaling molecules responsible for mediating BMP-2 effects on mesenchymal precursor cells. BMP-2 induces osteoblastic differentiation of the pluripotent mesenchymal cell line C2C12 by increasing alkaline phosphatase activity and osteocalcin production. As recent studies have demonstrated that cytoplasmic Smad proteins are involved in TGF-beta superfamily signaling, we plan to isolate the relevant Smad family members involved in osteoblastic differentiation. me identified human Smad5, which is highly homologous to Smad1. BMP-2 caused serine phosphorylation of Smad5 as well as Smad1. In contrast, TGF-beta failed to cause serine phosphorylation of Smad1 and Smad5. We found Smad5 is directly activated by BMP type Ia or Ib receptors through physical association with these receptors. Following phosphorylation, Smad5 bound to DPC4, another Smad family member, and the complex was translocated to the nucleus. Overexpression of point-mutated Smad5: (G419S) or a C-terminal deletion mutant DPC4 (DPC4 Delta C) blocked the induction of alkaline phosphatase activity osteocalcin production, and Smad5-DPC4 signaling cascades upon BMP-2 treatment in C2C12 cells. These data suggest that activation of Smad5 and subsequent Smad5-DPC4 complex formation are key steps in the BMP signaling pathway, which mediates BMP-2-induced osteoblastic differentiation of the C2C12 mesenchymal cells.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol & Bone Metab, San Antonio, TX 78284 USA; Osaka Univ, Fac Dent, Dept Biochem, Osaka 5650871, Japan	University of Texas System; University of Texas Health San Antonio; Osaka University	Yoneda, T (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Endocrinol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.			Nishimura, Riko/0000-0001-7279-8363	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045229] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK45229-05] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1996, P NATL ACAD SCI USA, V93, P12992, DOI 10.1073/pnas.93.23.12992; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARRIS SE, 1994, J BONE MINER RES, V9, P389; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; KINGSLEY DM, 1994, TRENDS GENET, V10, P16, DOI 10.1016/0168-9525(94)90014-0; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; LAGMA G, 1996, NATURE, V383, P832; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; RAFTERY LA, 1995, GENETICS, V139, P241; REDDI AH, 1994, CURR OPIN GENET DEV, V4, P737, DOI 10.1016/0959-437X(94)90141-O; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WU R, 1996, MOL CELL BIOL, V17, P2521; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	32	268	287	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1872	1879		10.1074/jbc.273.4.1872	http://dx.doi.org/10.1074/jbc.273.4.1872			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442019	hybrid			2022-12-25	WOS:000071595200008
J	Efthymiadis, A; Briggs, LJ; Jans, DA				Efthymiadis, A; Briggs, LJ; Jans, DA			The HIV-1 Tat nuclear localization sequence confers novel nuclear import properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOLAR-TARGETING SIGNAL; GTP-BINDING PROTEIN; SV40 T-ANTIGEN; I REX; IDENTIFICATION; TRANSPORT; DISTINCT; RAN; RNA; PHOSPHORYLATION	The different classes of conventional nuclear localization sequences (NLSs) resemble one another in that NLS-dependent nuclear protein import is energy-dependent and mediated by the cytosolic NLS-binding importin/ karyopherin subunits and monomeric GTP-binding protein Ran/TC4. Based on analysis of the nuclear import kinetics mediated by the NLS of the human immunodeficiency virus accessory protein Tat using in vivo and in vitro nuclear transport assays and confocal laser scanning microscopy, we report a novel nuclear import pathway. We demonstrate that the Tat-NLS, not recognized by importin 58/97 subunits as shown using an enzyme-linked immunosorbent assay-based binding assay, is sufficient to target the 476-kDa heterologous beta-galactosidase protein to the nucleus in ATP-dependent but cytosolic factor-independent fashion. Excess SV40 large tumor antigen (T-ag) NLS-containing peptide had no significant effect on the nuclear import kinetics implying that the Tat-NLS was able to confer nuclear accumulation through a pathway distinct from conventional NLS-dependent pathways. Nucleoplasmic accumulation of the Tat-NLS-beta-galactosidase fusion protein, in contrast to that of a T-ag-NLS-containing fusion protein, also occurred in the absence of an intact nuclear envelope, implying that the Tat-NLS conferred binding to nuclear components. This is in stark contrast to known NLSs such as those of T-ag which confer nuclear entry rather than retention. Significantly, the ability to accumulate in the nucleus in the absence of an intact nuclear envelope was blocked in the absence of ATP, as well as by nonhydrolyzable ATP and GTP analogs, demonstrating that ATP is required to effect release from a complex with insoluble cytoplasmic components. Taken together, the results demonstrate that, dependent on ATP for release from cytoplasmic retention, the Tat-NLS is able to confer nuclear entry and binding to nuclear components. These unique properties indicate that Tat accumulates in the nucleus through a novel import pathway.	Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signalling Lab, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Jans, DA (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Nucl Signalling Lab, POB 334, Canberra, ACT 2601, Australia.	dnj224@leonard.anu.edu.au	Briggs, Lyndall J/A-7549-2011					Akhlynina TV, 1997, J BIOL CHEM, V272, P20328, DOI 10.1074/jbc.272.33.20328; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; CHIN DJ, 1991, J VIROL, V65, P1758, DOI 10.1128/JVI.65.4.1758-1764.1991; COCHRANE AW, 1990, J VIROL, V64, P881, DOI 10.1128/JVI.64.2.881-885.1990; DANG CV, 1989, J BIOL CHEM, V264, P18019; Efthymiadis A, 1997, J BIOL CHEM, V272, P22134, DOI 10.1074/jbc.272.35.22134; FENRICK R, 1989, J VIROL, V63, P5006, DOI 10.1128/JVI.63.12.5006-5012.1989; Fridell RA, 1997, J CELL SCI, V110, P1325; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HOFER L, 1991, J VIROL, V65, P3379, DOI 10.1128/JVI.65.6.3379-3383.1991; Hubner S, 1997, J BIOL CHEM, V272, P17191, DOI 10.1074/jbc.272.27.17191; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; JANS DA, 1991, J CELL BIOL, V115, P1203, DOI 10.1083/jcb.115.5.1203; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Luciw P., 1996, VIROLOGY; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P4318, DOI 10.1073/pnas.92.10.4318; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; NOSAKA T, 1989, P NATL ACAD SCI USA, V86, P9798, DOI 10.1073/pnas.86.24.9798; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; RANKI A, 1994, ARCH VIROL, V139, P365, DOI 10.1007/BF01310798; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; RUBEN S, 1989, J VIROL, V63, P1; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SUBRAMANIAN T, 1990, VIROLOGY, V176, P178, DOI 10.1016/0042-6822(90)90242-J; Sweet DJ, 1996, J CELL BIOL, V133, P971, DOI 10.1083/jcb.133.5.971; TAKEI Y, 1994, J BIOCHEM-TOKYO, V115, P578, DOI 10.1093/oxfordjournals.jbchem.a124378; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191	42	151	171	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1623	1628		10.1074/jbc.273.3.1623	http://dx.doi.org/10.1074/jbc.273.3.1623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430704	hybrid			2022-12-25	WOS:000071411500051
J	Hung, IH; Casareno, RLB; Labesse, G; Mathews, FS; Gitlin, JD				Hung, IH; Casareno, RLB; Labesse, G; Mathews, FS; Gitlin, JD			HAH1 is a copper-binding protein with distinct amino acid residues mediating copper homeostasis and antioxidant defense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; AMYOTROPHIC-LATERAL-SCLEROSIS; MENKES DISEASE; CANDIDATE GENE; TRANSPORTING ATPASE; YEAST; ENCODES; DISMUTASE; OXIDASE; CELLS	HAH1 is a 68-amino acid protein originally identified as a human homologue of Atx1p, a multi-copy suppressor of oxidative injury in sod1 Delta yeast, Molecular modeling of HAH1 predicts a protein structure of two alpha-helices overlaying a four-stranded antiparallel beta-sheet with a potential metal binding site involving two conserved cysteine residues. Consistent with this model, in vitro studies with recombinant HAH1 directly demonstrated binding of Cu(I), and site-directed mutagenesis identified these cysteine residues as copper ligands. Expression of wild type and mutant HAH1 in atx1 Delta yeast revealed the essential role of these cysteine residues in copper trafficking to the secretory compartment in vivo, as expression of a Cys-12/Cys-15 double mutant abrogated copper incorporation into the multicopper oxidase Fet3p. In contrast, mutation of the highly conserved lysine residues in the carboxyl terminus of HAH1 had no effect on copper trafficking to the secretory pathway but eliminated the antioxidant function of HAH1 in sod1 Delta yeast, Taken together, these data support the concept of a unique copper coordination environment in HAH1 that permits this protein to function as an intracellular copper chaperone mediating distinct biological processes in eucaryotic cells.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Gitlin, JD (corresponding author), Washington Univ, St Louis Childrens Hosp, Sch Med, Edward Mallinckrodt Dept Pediat, 1 Childrens Pl, St Louis, MO 63110 USA.	gitlin@kidsa1.wustl.edu		Labesse, Gilles/0000-0002-6861-3300	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K08HD058219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044464, R01DK044464] Funding Source: NIH RePORTER; NICHD NIH HHS [K08 HD058219] Funding Source: Medline; NIDDK NIH HHS [DK44464] Funding Source: Medline; NIGMS NIH HHS [GM20530] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; BRYANT SH, 1993, PROTEINS, V16, P92, DOI 10.1002/prot.340160110; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Dierick HA, 1997, HUM MOL GENET, V6, P409, DOI 10.1093/hmg/6.3.409; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Hottinger AF, 1997, EUR J NEUROSCI, V9, P1548, DOI 10.1111/j.1460-9568.1997.tb01511.x; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; MORBY AP, 1995, MOL MICROBIOL, V17, P25, DOI 10.1111/j.1365-2958.1995.mmi_17010025.x; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TUFFERY P, 1995, J MOL GRAPHICS, V13, P67, DOI 10.1016/0263-7855(94)00011-G; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YANG XL, 1997, BIOCHEM J, V326, P987; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	122	128	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1749	1754		10.1074/jbc.273.3.1749	http://dx.doi.org/10.1074/jbc.273.3.1749			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430722	hybrid			2022-12-25	WOS:000071411500069
J	Schildbach, JF; Robinson, CR; Sauer, RT				Schildbach, JF; Robinson, CR; Sauer, RT			Biophysical characterization of the TraY protein of Escherichia coli F factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA HELICASE-I; INTEGRATION HOST FACTOR; PLASMID ORIGIN; GENE-PRODUCT; CRYSTAL-STRUCTURE; MET REPRESSOR; ARC REPRESSOR; ORIT; SEQUENCE; BINDING	The TraY protein is required for efficient bacterial conjugation by Escherichia coli F factor. TraY has two functional roles: participating in the "relaxosome," a protein-DNA complex that nicks one strand of the F factor plasmid, and up-regulating transcription from the traYI promoter. The traY gene was cloned, and the TraY protein was expressed, purified, and characterized, TraY has a mixed alpha-helix and beta-sheet secondary structure as judged by its circular dichroism spectrum, is monomeric, and undergoes reversible urea denaturation with Delta G(u), = 6 kcal/mol at 25 degrees C., The kinetics of protein unfolding and refolding, as measured by changes in fluorescence, are complex, suggesting the presence of intermediates or of heterogeneity in the folding reaction, TraY has been classified as a member of the ribbon-helix-helix family of transcription factors but is unusual in appearing to have tandem repeats of the beta alpha alpha motif in the same polypeptide chain, The data presented here show that folding and assembly of the functional (beta alpha alpha)(2), unit occurs as an intramolecular reaction and not by cross-folding between different polypeptide chains.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Schildbach, JF (corresponding author), Johns Hopkins Univ, Dept Biol, 144 Mudd Hall,3400 N Charles St, Baltimore, MD 21218 USA.			Sauer, Robert/0000-0002-1719-5399; Schildbach, Joel/0000-0002-3038-9745	NIAID NIH HHS [AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMMAN E, 1983, GENE, V25, P167; [Anonymous], 1996, ESCHERICHIA COLI SAL; BONVIN AMJJ, 1994, J MOL BIOL, V236, P328, DOI 10.1006/jmbi.1994.1138; BOWIE JU, 1990, J MOL BIOL, V211, P5, DOI 10.1016/0022-2836(90)90004-6; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; BURGERING MJM, 1994, BIOCHEMISTRY-US, V33, P15036, DOI 10.1021/bi00254a012; Cohn E. J., 1943, PROTEINS AMINO ACIDS; DOERING D, 1992, THESIS MIT; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; HOWARD MT, 1995, J BIOL CHEM, V270, P28381; INAMOTO S, 1988, J BACTERIOL, V170, P2749, DOI 10.1128/jb.170.6.2749-2757.1988; LAHUE EE, 1990, J BACTERIOL, V172, P1385, DOI 10.1128/jb.172.3.1385-1391.1990; Laue T, 1992, ULTRACENTRIFUGATION, P90; LUO Y, 1994, MOL MICROBIOL, V11, P459, DOI 10.1111/j.1365-2958.1994.tb00327.x; Maneewannakul K, 1996, MOL MICROBIOL, V22, P197, DOI 10.1046/j.1365-2958.1996.00087.x; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1995, J BIOL CHEM, V270, P28374; NELSON WC, 1993, J BACTERIOL, V175, P2221, DOI 10.1128/JB.175.8.2221-2228.1993; Nelson WC, 1996, MOL MICROBIOL, V20, P1179, DOI 10.1111/j.1365-2958.1996.tb02638.x; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; REYGERS U, 1991, EMBO J, V10, P2689, DOI 10.1002/j.1460-2075.1991.tb07812.x; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROBERTSON CA, 1988, J BIOL CHEM, V263, P3554; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHERMAN JA, 1994, J BIOL CHEM, V269, P26220; Silverman PM, 1996, J BACTERIOL, V178, P5787, DOI 10.1128/jb.178.19.5787-5789.1996; SINGER M, 1989, MICROBIOL REV, V53, P1; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMPSON R, 1984, EMBO J, V3, P1175, DOI 10.1002/j.1460-2075.1984.tb01947.x; WILLETTS NS, 1972, J BACTERIOL, V112, P773, DOI 10.1128/JB.112.2.773-778.1972	34	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1329	1333		10.1074/jbc.273.3.1329	http://dx.doi.org/10.1074/jbc.273.3.1329			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430665	hybrid			2022-12-25	WOS:000071411500012
J	Hannan, RD; Hempel, WM; Cavanaugh, A; Arino, T; Dimitrov, SI; Moss, T; Rothblum, L				Hannan, RD; Hempel, WM; Cavanaugh, A; Arino, T; Dimitrov, SI; Moss, T; Rothblum, L			Affinity purification of mammalian RNA polymerase I - Identification of an associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR UBF; RAT RIBOSOMAL DNA; FACTOR-TIF-IA; CASEIN KINASE; LARGEST SUBUNIT; LYMPHOSARCOMA-P1798 CELLS; SACCHAROMYCES-CEREVISIAE; 2ND-LARGEST SUBUNIT; HORMONAL-REGULATION; RDNA TRANSCRIPTION	Overlapping cDNA clones encoding the two largest subunits of rat RNA polymerase I, designated A194 and A127, were isolated from a Reuber hepatoma cDNA library. Analyses of the deduced amino acid Sequences revealed that A194 and A127 are the homologues of yeast A190 and A135 and have homology to the beta' and beta subunits of Escherichia coli RNA polymerase I. Antibodies raised against the recombinant A194 and A127 proteins recognized single proteins of approximately 190 and 120 kDa on Western blots of total cellular proteins of mammalian origin. N1S1 cell lines expressing recombinant His tagged A194 and FLAG-tagged A127 proteins were isolated, These proteins were incorporated into functional RNA polymerase I complexes, and active enzyme, containing FLAG-tagged A127, could be immunopurified to approximately 80% homogeneity in a single chromatographic step over an anti-FLAG affinity column, Immunoprecipitation of A194 from P-32 metabolically labeled cells with anti-A194 antiserum demonstrated that this subunit is a phosphoprotein. Incubation of the FLAG affinity-purified RNA polymerase I complex with [gamma-P-32]ATP resulted in autophosphorylation of the A194 subunit of RPI, indicating the presence of associated kinase(s). One of these kinases was demonstrated to be CK2, a serine/threonine protein kinase implicated in the regulation of cell growth and proliferation.	Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Univ Laval, Hotel Dieu, Canc Res Ctr, Quebec City, PQ G1R 2J6, Canada	Laval University	Rothblum, L (corresponding author), Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA.	LROTHBLUM@GEISINGER.edu	dimitrov, stefan/M-7697-2013	dimitrov, stefan/0000-0002-1326-3630; Moss, Thomas (Tom)/0000-0003-2047-4783; Hannan, Ross/0000-0002-2166-4493	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047638] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47638] Funding Source: Medline; NIGMS NIH HHS [GM48991] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; AGOSTINIS P, 1992, J BIOL CHEM, V267, P9732; ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BELENGUER P, 1989, NUCLEIC ACIDS RES, V17, P6625; BELL GI, 1976, NATURE, V261, P429, DOI 10.1038/261429a0; BREANT B, 1983, EUR J BIOCHEM, V130, P247; BUHLER JM, 1976, FEBS LETT, V71, P37, DOI 10.1016/0014-5793(76)80893-9; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; CASSIDY BG, 1986, MOL CELL BIOL, V7, P2396; CAVANAUGH AH, 1983, J BIOL CHEM, V258, P9768; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Cho H, 1997, J BIOL CHEM, V272, P11495; COCHET C, 1982, BIOCHEM PHARMACOL, V31, P1357, DOI 10.1016/0006-2952(82)90028-4; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7934, DOI 10.1073/pnas.82.23.7934; Cornelissen A W, 1988, Oxf Surv Eukaryot Genes, V5, P91; COULTER DE, 1985, J BIOL CHEM, V260, P3190; DAHMUS ME, 1981, J BIOL CHEM, V256, P1239; DATTA PK, 1995, J BIOL CHEM, V270, P8637, DOI 10.1074/jbc.270.15.8637; DUCEMAN BW, 1981, J BIOL CHEM, V256, P755; ENGELKE DR, 1983, J BIOL CHEM, V258, P1921; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GHOSH SK, 1997, ONCOGENE, V14, P589; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; GOKAL PK, 1990, J BIOL CHEM, V265, P16234; GOLDBERG MI, 1977, BIOCHEMISTRY-US, V16, P1655, DOI 10.1021/bi00627a021; GRACHEV MA, 1982, FEBS LETT, V137, P89, DOI 10.1016/0014-5793(82)80321-9; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GRUMMT I, 1987, CELL NUCLEUS, V5, P373; Hanada K, 1996, EMBO J, V15, P2217, DOI 10.1002/j.1460-2075.1996.tb00575.x; HANNAN RD, 1995, J BIOL CHEM, V270, P8290, DOI 10.1074/jbc.270.14.8290; Hannan RD, 1996, J BIOL CHEM, V271, P3213, DOI 10.1074/jbc.271.6.3213; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; Hempel WM, 1996, MOL CELL BIOL, V16, P557; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JACOB ST, 1995, BIOCHEM J, V306, P617, DOI 10.1042/bj3060617; JAMES P, 1991, J BIOL CHEM, V266, P5616; KELLY S, 1990, J BIOL CHEM, V265, P7787; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MATSUI T, 1976, EUR J BIOCHEM, V71, P351, DOI 10.1111/j.1432-1033.1976.tb11121.x; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MEMET S, 1988, J BIOL CHEM, V263, P2830; MOSS T, 1995, PROG NUCLEIC ACID RE, V50, P25, DOI 10.1016/S0079-6603(08)60810-7; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; Niu Huifeng, 1995, Gene Expression, V4, P111; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PADMANABHA R, 1987, J BIOL CHEM, V262, P1829; PADMANABHA R, 1990, MOL CELL BIOL, V10, P4089, DOI 10.1128/MCB.10.8.4089; PAULE MR, 1984, NUCLEIC ACIDS RES, V12, P8161, DOI 10.1093/nar/12.21.8161; PAULE MR, 1994, TRANSCRIPTION MECHAN, P83; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; RIVA M, 1987, J BIOL CHEM, V262, P14377; ROSE KM, 1981, P NATL ACAD SCI-BIOL, V78, P2833, DOI 10.1073/pnas.78.5.2833; ROTHBLUM LI, 1982, NUCLEIC ACIDS RES, V10, P7345, DOI 10.1093/nar/10.22.7345; RUET A, 1980, J BIOL CHEM, V255, P6450; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SCHAPP G, 1994, EMBO J, V13, P190; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SCHWARTZ LB, 1974, J BIOL CHEM, V249, P5898; SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; SOMMERCORN J, 1987, P NATL ACAD SCI USA, V84, P821; SONG CZ, 1994, J BIOL CHEM, V269, P26976; SUZUKI N, 1987, J BIOL CHEM, V262, P4696; SUZUKI N, 1992, J STEROID BIOCHEM, V42, P305, DOI 10.1016/0960-0760(92)90133-4; SWEETSER D, 1987, P NATL ACAD SCI USA, V84, P1192, DOI 10.1073/pnas.84.5.1192; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; TOWER J, 1987, CELL, V50, P873, DOI 10.1016/0092-8674(87)90514-9; TREICH I, 1991, J BIOL CHEM, V266, P21971; WEIL PA, 1979, J BIOL CHEM, V254, P6163; XIE WQ, 1991, BIOTECHNIQUES, V11, P342; YANO R, 1991, MOL CELL BIOL, V11, P754, DOI 10.1128/MCB.11.2.754; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	82	59	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1257	1267		10.1074/jbc.273.2.1257	http://dx.doi.org/10.1074/jbc.273.2.1257			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422795	hybrid			2022-12-25	WOS:000071411400084
J	Laurent, O; Bruckert, F; Adessi, C; Satre, M				Laurent, O; Bruckert, F; Adessi, C; Satre, M			In vitro reconstituted Dictyostelium discoideum early endosome fusion is regulated by Rab7 but proceeds in the absence of ATP-Mg2+ from the bulk solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; GTP-BINDING PROTEINS; CELL-FREE SYSTEM; MEMBRANE-FUSION; VESICLES; DOCKING; IDENTIFICATION; GLYCOPROTEINS; COMPARTMENTS; PINOCYTOSIS	We characterized the in vitro fusion of endosomal compartments from Dictyostelium discoideum, Fusion activity was restricted to early compartments, was dependent on cytosolic proteins, and was activated by GTP and guanosine 5'-O(3-thio)triphosphate (GTP gamma S). This stimulation suggests the involvement of a small G protein, which we propose to be Rab7 on the basis of the strong inhibitory effect of anti-Rab7 antibodies. It is noteworthy that in the presence of GTP gamma S, the concentration of ATP-Mg2+ could be reduced to less than 1 nM without loss of fusion activity, Under these conditions, competing residual ATP with adenosine 5'-O-(3-thio)triphosphate-Mg2+ also failed to inhibit endosome fusion, The presence of an ATP-depleting system alone blocked fusion probably because endogenous GTP was removed by coupling through NDP kinase, Moreover, whether ATP was present or not, GTP gamma S-activated fusion was equally sensitive to anti-Rab7 antibodies or N-ethylmaleimide and was restricted to early compartments, These results show that soluble ATP-Mg2+ is not needed for endosome fusion, Since homotypic fusion of endosomes in D. discoideum has been shown to depend on the ATPase N-ethylmaleimide-sensitive factor (Lenhard, J. M., Mayorga, L., and Stahl, P. D. (1992) J. Biol. Chem. 267, 1896-1903), the nucleotide exchange on the N-ethylmaleimide sensitive factor must take place before GTP gamma S activation in this system.	CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim & Biophys Syst Integres, CNRS,UMR 314, F-38054 Grenoble 9, France; CEA Grenoble, Dept Biol Mol & Struct, Lab Chim Prot, F-38054 Grenoble, France	CEA; Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); CEA	Bruckert, F (corresponding author), CEA Grenoble, Dept Biol Mol & Struct, Lab Biochim & Biophys Syst Integres, CNRS,UMR 314, 17 Rue Martyrs, F-38054 Grenoble 9, France.	bruckert@tour.ceng.cea.fr						ADESSI C, 1995, J CELL SCI, V108, P3331; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AUBRY L, 1993, J CELL SCI, V105, P861; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; Barbieri MA, 1996, ARCH BIOCHEM BIOPHYS, V326, P64, DOI 10.1006/abbi.1996.0047; BUCZYNSKI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P296, DOI 10.1016/0167-4838(90)90288-Q; Buczynski G, 1997, MOL BIOL CELL, V8, P1343, DOI 10.1091/mbc.8.7.1343; BUSH J, 1995, GUIDEBOOK SMALL GTPA; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Hacker U, 1997, J CELL SCI, V110, P105; Harlow E., 1988, ANTIBODIES LAB MANUA; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; Johannes L, 1996, J CELL SCI, V109, P2875; KLEIN G, 1986, BIOCHEM BIOPH RES CO, V138, P1146, DOI 10.1016/S0006-291X(86)80402-8; KORNFELD S, 1989, ANN REV CELL BIOL, V5, P482; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NOLTA KV, 1994, J BIOL CHEM, V269, P2225; NOLTA KV, 1994, BBA-MOL CELL RES, V1224, P237, DOI 10.1016/0167-4889(94)90196-1; OHALLORAN TJ, 1992, J CELL BIOL, V118, P1371, DOI 10.1083/jcb.118.6.1371; PADH H, 1993, J BIOL CHEM, V268, P6742; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Rothman JE, 1996, PROTEIN SCI, V5, P185; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SPIRO DJ, 1995, J BIOL CHEM, V270, P13693, DOI 10.1074/jbc.270.23.13693; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TEMESVARI L, 1994, J BIOL CHEM, V269, P25719; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; YAMAGUCHI Y, 1993, AM J PHYSIOL, V264, pG880, DOI 10.1152/ajpgi.1993.264.5.G880; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	43	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					793	799		10.1074/jbc.273.2.793	http://dx.doi.org/10.1074/jbc.273.2.793			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422733	hybrid			2022-12-25	WOS:000071411400022
J	Raabe, T; Bukrinsky, M; Currie, RA				Raabe, T; Bukrinsky, M; Currie, RA			Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B; FACTOR BIOSYNTHESIS; PRIMARY MACROPHAGES; MESSENGER-RNA; ENDOTOXIN; GENE; MECHANISMS; ACTIVATION; ENHANCERS; PROMOTER	The synthesis of tumor necrosis factor-alpha has been suggested to be regulated at both the transcriptional and translational levels in response to stimulation by bacterial lipopolysaccharide, although the relative contribution of these two mechanisms has not been quantitatively evaluated. Here, using the murine monocytic cell line RAW 264.7 as a model system, we show that steady-state TNF-alpha! mRNA levels increase similar to 77-fold following treatment with lipopolysaccharide for 2 h and to a maximum of 164-fold after 8 h as measured by an RNase protection assay. The TNF-alpha gene transcription rate increases similar to 5-fold following exposure to lipopolysaccharide for 2 h as measured by a nuclear run-on assay. TNF-alpha mRNA stability did not change in the presence of lipopolysaccharide. A ribosomal sedimentation assay and an RNA transfection assay revealed that the translation rate of endogenous as well as transiently trans fected TNF-alpha mRNAs increases only similar to 2-3-fold after stimulation with lipopolysaccharide for 2 h. Taken together, these results suggest that the large increase in the level of secreted TNF-alpha protein in RAW 264.7 cells is due primarily to activation of TNF-alpha gene transcription.	Picower Inst Med Res, Lab Gene Regulat, Manhasset, NY 11030 USA; Picower Inst Med Res, Lab Mol Pathogenesis Human Immunodeficiency Virus, Manhasset, NY 11030 USA	Northwell Health; Northwell Health	Raabe, T (corresponding author), Ohio State Univ, Dept Hematol & Oncol, Columbus, OH 43210 USA.		Raabe, Tobias D/V-5606-2018; Currie, Richard/N-6074-2017	Currie, Richard/0000-0002-6528-3326	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047272, R29DK047272] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-38245] Funding Source: Medline; NIDDK NIH HHS [DK-47272] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAILEY SA, 1993, BIOCHEMISTRY-US, V32, P5881, DOI 10.1021/bi00073a022; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BEUTLER B, 1991, J CLIN INVEST, V87, P1336, DOI 10.1172/JCI115137; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DROUET C, 1991, J IMMUNOL, V147, P1694; Espel E, 1996, EUR J IMMUNOL, V26, P2417, DOI 10.1002/eji.1830261023; FREUDENBERG MA, 1986, INFECT IMMUN, V51, P891, DOI 10.1128/IAI.51.3.891-895.1986; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDFELD AE, 1990, P NATL ACAD SCI USA, V87, P9769, DOI 10.1073/pnas.87.24.9769; HAMBLETON J, 1995, J EXP MED, V182, P47; HAN J, 1991, J IMMUNOL, V146, P1843; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; JEFFERIES HBJ, 1994, J BIOL CHEM, V269, P4367; JONGENEEL CV, 1992, TUMOR NECROSIS FACTO; MICHALEK SM, 1980, J INFECT DIS, V141, P55, DOI 10.1093/infdis/141.1.55; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUCHMANN M, 1995, EUR J IMMUNOL, V25, P2183, DOI 10.1002/eji.1830250810; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; ZHENG S, 1993, J BIOL CHEM, V268, P17233	24	157	161	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					974	980		10.1074/jbc.273.2.974	http://dx.doi.org/10.1074/jbc.273.2.974			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422758	hybrid			2022-12-25	WOS:000071411400047
J	Wang, JS; Dong, XW; Myung, KJ; Hendrickson, EA; Reeves, WH				Wang, JS; Dong, XW; Myung, KJ; Hendrickson, EA; Reeves, WH			Identification of two domains of the p70 Ku protein mediating dimerization with p80 and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; ANTIGEN; KINASE; GENE; TRANSCRIPTION; SUBUNIT; PRODUCT; REPAIR; CDNA	The Ku autoantigen is a heterodimer of 70 (p70) and similar to 80 kDa (p80) subunits that is the DNA-binding component of the DNA-dependent protein kinase (DNA-PK) complex involved in DNA repair and V(D)J recombination. Binding to DNA ends is critical to the function of DNA-PK, but how Ku interacts with DNA is not completely understood. To define the role of p70 and p80 and their dimerization in DNA binding, heterodimers were assembled by co-expressing the subunits using recombinant baculoviruses, Two p70 dimerization sites, amino acids 1-115 and 430-482, respectively, mere identified, Binding of p70 to linear double-stranded DNA could be demonstrated by an immunoprecipitation assay, and required the C-terminal portion (amino acids 430-609), but not interaction with p80, The p70 mutants 1-600, 1-542, 1-115, and 430-600 did not bind DNA efficiently, However, DNA binding of 1-600, 1-542, and 1-115, but not 430-600, was restored by dimerization with p80, indicating that p70 has two DNA binding sites, each partially overlapping one of the dimerization sites, The C-terminal domain can bind DNA by itself, but the N-terminal domain requires dimerization with p80, These observations could be relevant to the multiple functional activities of Ku and explain controversies regarding the role of dimerization in DNA binding.	Univ N Carolina, Div Rheumatol & Immunol, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr,Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Brown University	Reeves, WH (corresponding author), Univ N Carolina, Div Rheumatol & Immunol, Lineberger Comprehens Canc Ctr, Thurston Arthrit Res Ctr,Dept Med, 3330 Thurston Bldg,CB 7280, Chapel Hill, NC 27599 USA.				NIAID NIH HHS [R01-AI35763] Funding Source: Medline; NIAMS NIH HHS [T32-AR7416, R01-AR40391] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040391, T32AR007416] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLAWAY GP, 1989, BIOCHEM BIOPH RES CO, V167, P747; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; Danska JS, 1996, MOL CELL BIOL, V16, P5507; DAVIDSON HW, 1989, J CELL BIOL, V109, P85, DOI 10.1083/jcb.109.1.85; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; GRIFFIN W, 1996, NATURE, V380, P265; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; Han ZY, 1996, J BIOL CHEM, V271, P14098, DOI 10.1074/jbc.271.24.14098; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; KUHN A, 1993, NUCLEIC ACIDS RES, V21, P2057, DOI 10.1093/nar/21.9.2057; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; MIMORI T, 1986, J BIOL CHEM, V261, P375; ONO M, 1994, NUCLEIC ACIDS RES, V22, P3918, DOI 10.1093/nar/22.19.3918; REEVES WH, 1989, J BIOL CHEM, V264, P5047; REEVES WH, 1997, ANTIBODIES, P3; Romero F, 1996, MOL CELL BIOL, V16, P37; SCHWYZER M, 1980, J BIOL CHEM, V255, P5627; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; Wang JS, 1997, ARTHRITIS RHEUM-US, V40, P1344, DOI 10.1002/1529-0131(199707)40:7<1344::AID-ART20>3.0.CO;2-V; WANG JS, 1994, J CELL SCI, V107, P3223; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7; Wu XT, 1996, MOL CELL BIOL, V16, P5186	26	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					842	848		10.1074/jbc.273.2.842	http://dx.doi.org/10.1074/jbc.273.2.842			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422740	Green Published, hybrid			2022-12-25	WOS:000071411400029
J	Zhang, P; Sun, YB; Hsu, H; Zhang, LF; Zhang, YN; Lee, MYWT				Zhang, P; Sun, YB; Hsu, H; Zhang, LF; Zhang, YN; Lee, MYWT			The interdomain connector loop of human PCNA is involved in a direct interaction with human polymerase delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; NUCLEOTIDE EXCISION-REPAIR; INHIBITS DNA-REPLICATION; CATALYTIC SUBUNIT; MOLECULAR-CLONING; SCHIZOSACCHAROMYCES-POMBE; AUXILIARY PROTEIN; ESCHERICHIA-COLI; CALF THYMUS; EXPRESSION	Proliferating cell nuclear antigen (PCNA) is required for processive DNA synthesis catalyzed by DNA polymerase delta (pol delta) and polymerase epsilon. We have shown that the epitope of a human PCNA inhibitory monoclonal antibody (74B1), which inhibits the PCNA stimulation of DNA synthesis catalyzed by pol delta, maps to residues 121-135, which overlap the interdomain connector loop of PCNA (residues 119-133). We have mutagenized residues 122-133 of human PCNA. The mutant proteins were expressed in Escherichia coli and purified to near-homogeneity, The interactions of the mutants with antibody 74B1 were examined; mutation of Gly-127 abolished the recognition by antibody 74B1 in a Western blot analysis, confirming the epitope assignment of 74B1, Mutations of Val-123, Leu-126, Gly-127, and Ile-128 affected the ability of PCNA to stimulate DNA synthesis by pol delta in several different assays. These mutations affected the interactions between PCNA and pol delta as determined by enzyme-linked immunosorbent assays, These mutants were also affected in their abilities to form a ternary complex with a DNA template-primer, as determined by electrophoretic mobility gel shift assays, The findings show that the interdomain connector loop region is involved in binding of pol delta, This same region is involved in the binding of p21, and our findings support the view that the mechanism of inhibition of DNA synthesis by p21 is due to a competition for PCNA binding to pol delta.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA	University of Miami; University of Miami	Lee, MYWT (corresponding author), New York Med Coll, Dept Biochem & Mol Biol, Valhalla, NY 10595 USA.				NIGMS NIH HHS [GM 31973] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031973] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BURGERS PMJ, 1995, MOL CELL BIOL, V15, P4420; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gibbs E, 1997, J BIOL CHEM, V272, P2373; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HUGHES DA, 1992, MOL GEN GENET, V231, P401, DOI 10.1007/BF00292709; JIANG YQ, 1995, ARCH BIOCHEM BIOPHYS, V320, P297, DOI 10.1016/0003-9861(95)90013-6; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LEE SH, 1991, J BIOL CHEM, V266, P594; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; MacNeill SA, 1996, EMBO J, V15, P4613, DOI 10.1002/j.1460-2075.1996.tb00839.x; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; NG L, 1993, J BIOL CHEM, V268, P13571; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Roos G, 1996, EXP CELL RES, V226, P208, DOI 10.1006/excr.1996.0220; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Sun YB, 1997, J BIOL CHEM, V272, P13013, DOI 10.1074/jbc.272.20.13013; TAN CK, 1986, J BIOL CHEM, V261, P2310; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Warbrick E, 1997, ONCOGENE, V14, P2313, DOI 10.1038/sj.onc.1201072; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P13748; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002; ZHANG P, 1995, J BIOL CHEM, V270, P7993, DOI 10.1074/jbc.270.14.7993; ZHANG SJ, 1995, J BIOL CHEM, V270, P7988, DOI 10.1074/jbc.270.14.7988; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484	40	62	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					713	719		10.1074/jbc.273.2.713	http://dx.doi.org/10.1074/jbc.273.2.713			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422722	hybrid			2022-12-25	WOS:000071411400011
J	Christophe, OD; Lenting, PJ; Kolkman, JA; Brownlee, GG; Mertens, K				Christophe, OD; Lenting, PJ; Kolkman, JA; Brownlee, GG; Mertens, K			Blood coagulation factor IX residues Glu(78) and Arg(94) provide a link between both epidermal growth factor-like domains that is crucial in the interaction with factor VIII light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; AFFINITY CALCIUM-BINDING; FACTOR-X ACTIVATION; FACTOR-LIKE MODULES; VONWILLEBRAND-FACTOR; HEMOPHILIA-B; SITE; SEQUENCE; ENZYME; MUTATIONS	Recently, we established that mutations at calcium-binding sites within the first epidermal growth factor (EGF)-like domain of activated factor IX affect its interaction with factor VIIIa (Lenting, P. J,, Christophe, O, D,, ter Maat, H,, Rees, D, J, G,, and Mertens, K, (1996) J, Biol, Chem. 271, 25332-25337), In the present study, we have investigated the functional role of residue Glu(78) which is not involved in calcium binding, Glu(78) is, also located in the first EGF like domain and, when mutated to Lys, is associated with severe hemophilia B. Because Glu(78) is conserved in related vitamin K-dependent proteins, it is difficult to understand how a mutation at this position is associated with factor M-specific function, In this study, we addressed the hypothesis that Glu(78) exerts its biological activity by interacting with another residue, One candidate was found to be the second EGF-like domain residue, Arg(94), which is also associated with severe hemophilia B when mutated, We constructed a series of mutants that included mutations at position 78 alone (Glu(78) to Lys/Glu(78) to Asp) or at both positions 78 and 94 (Glu(78) to Lys and Arg(94) to Asp), The functional parameters of immunopurified and activated mutants were compared with normal activated factor IX. Mutants were indistinguishable from normal factor Ma in cleaving the synthetic substrate CH3SO2-Leu-Gly-Arg-p-nitroanilide or activating factor X in the absence of factor VIIIa, In contrast, in the presence of factor VIIIa, factor Ma Glu(78) to Asp and factor Ma Glu(78) to Lys/Arg(94) to Asp were stimulated to the same extent as normal factor Ma, whereas factor Ma Glu(78) to Lys was markedly less stimulated (140-fold versus 2,000-fold), This suggests that residues 78 and 94 should carry an opposite charge for a normal interaction of factor Ma to factor VIIIa, This hypothesis was confirmed in inhibition studies employing synthetic peptides comprising the factor Ma-binding motifs of factor VIII heavy (Ser(558)-Gln(565)) Or light chain (Glu(1811)-Lys(1818)) and in direct binding studies, We propose that residues 78 and 94 link both EGF-like domains and thereby maintain the integrity of the factor VIII light chain binding site.	Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Plasma Protein Technol, NL-1066 CX Amsterdam, Netherlands; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Mertens, K (corresponding author), Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Dept Plasma Protein Technol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Lenting, Peter/F-8269-2013; Lenting, Peter/AAH-5663-2019; christophe, olivier/W-4268-2017	Lenting, Peter/0000-0002-7937-3429; Lenting, Peter/0000-0002-7937-3429; christophe, olivier/0000-0002-9080-6336				ANSON DS, 1984, EMBO J, V3, P1053, DOI 10.1002/j.1460-2075.1984.tb01926.x; ASTERMARK J, 1992, J BIOL CHEM, V267, P3249; ASTERMARK J, 1991, J BIOL CHEM, V266, P2438; BAJAJ SP, 1985, J BIOL CHEM, V260, P1574; BECKMANN RJ, 1985, NUCLEIC ACIDS RES, V13, P5233, DOI 10.1093/nar/13.14.5233; BOTTEMA CDK, 1991, AM J HUM GENET, V49, P820; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CHANG JY, 1995, THROMB HAEMOSTASIS, V73, P1202; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; DONATH MJSH, 1995, J BIOL CHEM, V270, P3648, DOI 10.1074/jbc.270.8.3648; EVANS JP, 1989, BLOOD, V74, P207; FAY PJ, 1994, J BIOL CHEM, V269, P20522; FUNG MR, 1985, P NATL ACAD SCI USA, V82, P3591, DOI 10.1073/pnas.82.11.3591; Giannelli F, 1996, NUCLEIC ACIDS RES, V24, P103, DOI 10.1093/nar/24.1.103; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; KATAYAMA K, 1979, P NATL ACAD SCI USA, V76, P4990, DOI 10.1073/pnas.76.10.4990; KURACHI K, 1982, P NATL ACAD SCI-BIOL, V79, P6461, DOI 10.1073/pnas.79.21.6461; Lenting PJ, 1996, J BIOL CHEM, V271, P25332, DOI 10.1074/jbc.271.41.25332; LENTING PJ, 1995, J BIOL CHEM, V270, P14884, DOI 10.1074/jbc.270.25.14884; Lenting PJ, 1996, J BIOL CHEM, V271, P1935, DOI 10.1074/jbc.271.4.1935; LENTING PJ, 1994, J BIOL CHEM, V269, P7150; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LIN SW, 1990, J BIOL CHEM, V265, P144; MADISON EL, 1990, J BIOL CHEM, V265, P21423; MANN KG, 1990, BLOOD, V76, P1; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MEDVED LV, 1994, BIOCHEMISTRY-US, V33, P478, DOI 10.1021/bi00168a012; MERTENS K, 1990, THROMB HAEMOSTASIS, V64, P138; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1084, DOI 10.1177/22.12.1084; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; REES DJG, 1988, EMBO J, V7, P2053, DOI 10.1002/j.1460-2075.1988.tb03045.x; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; STEL HV, 1984, BLOOD, V63, P1408; STENFLO J, 1991, BLOOD, V78, P1637; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WU SM, 1990, GENE, V86, P275, DOI 10.1016/0378-1119(90)90290-8; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	42	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					222	227		10.1074/jbc.273.1.222	http://dx.doi.org/10.1074/jbc.273.1.222			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417068	hybrid			2022-12-25	WOS:000071295600034
J	Han, SJ; Choi, KY; Brey, PT; Lee, WJ				Han, SJ; Choi, KY; Brey, PT; Lee, WJ			Molecular cloning and characterization of a Drosophila p38 mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; GENE-EXPRESSION; C-JUN; PHOSPHORYLATION; TYROSINE; STRESS; CELLS; YEAST; TRANSFORMATION; MORPHOGENESIS	A mitogen-activated protein kinase (MAPK) has been cloned and sequenced from a Drosophila neoplasmic l(2)mbn cell line. The cDNA sequence analysis showed that this Drosophila kinase is a homologue of mammalian p38 MAPK and the yeast HOG1 gene and thus was referred to as Dp38. A distinguishing feature of all MAPKs is the conserved sequence TGY in the activation domain. Dp38 was rapidly tyrosine 186-phosphorylated in response to osmotic stress, heat shock, serum starvation, and H2O2 in Drosophila l(2)mbn and Schneider cell lines. However, unlike mammalian p38 MAPK, the addition of lipopolysaccharide (LPS) did not significantly affect the phosphorylation of Dp38 in the LPS-responsive l(2)mbn cell line. Following osmotic stress, tyrosine 186-phosphorylated forms of Dp38 MAPK were detected exclusively in nuclear regions of Schneider cells. Yeast complementation studies demonstrated that the Saccharomyces cerevisiae HOG1 mutant strain JBY10 (hog1-Delta 1) was functionally complemented by Dp38 cDNA in hyperosmolar medium, These findings demonstrate that similar osmotic stress-responsive signal transduction pathways are conserved in yeast, Drosophila, and mammalian cells, whereas LPS signal transduction pathways appear to be different.	Yonsei Univ, Coll Med, Med Res Ctr, Immunol Lab, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; Inst Pasteur, Lab Biochim & Biol Mol Insectes, F-75724 Paris 15, France	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Lee, WJ (corresponding author), Yonsei Univ, Coll Med, Med Res Ctr, Immunol Lab, CPO Box 8044, Seoul, South Korea.	wjlee1@yumc.yonsei.ac.kr	Han, Sung-Jun/B-9547-2012					ARGOS P, 1990, METHOD ENZYMOL, V182, P751; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Engstrom Ylva, 1998, P211; Gateff E., 1998, Molecular mechanisms of immune responses in insects., P189; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; PETERSEN UM, 1995, EMBO J, V14, P3146, DOI 10.1002/j.1460-2075.1995.tb07317.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, GENE DEV, V11, P1717, DOI 10.1101/gad.11.13.1717; RIO DC, 1985, MOL CELL BIOL, V5, P1833, DOI 10.1128/MCB.5.8.1833; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Sherman F., 1986, METHODS YEAST GENETI; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tryselius Y, 1997, INSECT MOL BIOL, V6, P173, DOI 10.1111/j.1365-2583.1997.tb00085.x; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531	41	85	90	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					369	374		10.1074/jbc.273.1.369	http://dx.doi.org/10.1074/jbc.273.1.369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417090	hybrid			2022-12-25	WOS:000071295600056
J	Shinohara, ML; Loros, JJ; Dunlap, JC				Shinohara, ML; Loros, JJ; Dunlap, JC			Glyceraldehyde-3-phosphate dehydrogenase is regulated on a daily basis by the circadian clock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA-GLYCOSYLASE; CELL-CYCLE REGULATION; NEUROSPORA-CRASSA; ASPERGILLUS-NIDULANS; SEQUENCE-ANALYSIS; CONTROLLED GENES; RAT-LIVER; RNA; CLONING; EXPRESSION	Circadian clocks function to govern a wide range of rhythmic activities in organisms, An integral part of rhythmicity is the daily control of target genes by the clock, Here we describe the sequence and analysis of a novel clock-controlled gene, ccg-7, showing similarity to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic enzyme widely used as a constitutive control in a variety of systems, That ccg-7 encodes GAPDH was confirmed by demonstrating that in vitro synthesized CCG-7 possesses GAPDH activity. Rhythms in both ccg-7 mRNA accumulation and CCG-7 (GAPDH) activity are observed in a clock wild-type strain where the peak in GAPDH activity lags several hours behind the peak in ccg-7 mRNA accumulation in the late night, Together with our previous observation that ccg-7 mRNA is not developmentally regulated, we show that ccg-7 is not induced by environmental stresses such as glucose or nitrogen deprivation (which also trigger development), heat shock, or osmotic stress, Thus, the finding that GAPDH is clock-regulated points to a specific role for the circadian clock in controlling aspects of general metabolism and provides evidence for circadian regulation of a gene found in most living organisms.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Dunlap, JC (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.	jay.c.dunlap@dartmouth.edu	Loros, Jennifer/B-6293-2014; Dunlap, Jay/L-6232-2013	Dunlap, Jay/0000-0003-1577-0457; Shinohara, Mari/0000-0002-6808-9844	NIMH NIH HHS [MH01186, MH44651] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K05MH001186, R01MH044651] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALEXANDER MC, 1988, P NATL ACAD SCI USA, V85, P5092, DOI 10.1073/pnas.85.14.5092; ALLEN RW, 1987, J BIOL CHEM, V262, P649; Amelunxen R E, 1975, Methods Enzymol, V41, P268; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BAXI MD, 1995, BIOCHEMISTRY-US, V34, P9700, DOI 10.1021/bi00030a007; BellPedersen D, 1996, P NATL ACAD SCI USA, V93, P13096, DOI 10.1073/pnas.93.23.13096; BellPedersen D, 1996, MOL CELL BIOL, V16, P513; BELLPEDERSEN D, 1992, GENE DEV, V6, P2382, DOI 10.1101/gad.6.12a.2382; Bernard M, 1997, P NATL ACAD SCI USA, V94, P304, DOI 10.1073/pnas.94.1.304; Burke JR, 1996, NAT MED, V2, P347, DOI 10.1038/nm0396-347; CHOI GH, 1990, NUCLEIC ACIDS RES, V18, P5566, DOI 10.1093/nar/18.18.5566; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; EDELMANN SE, 1994, EXP MYCOL, V18, P70, DOI 10.1006/emyc.1994.1007; EDMUNDS LN, 1983, AM J ANAT, V168, P389, DOI 10.1002/aja.1001680404; EHRENMAN K, 1986, P NATL ACAD SCI USA, V83, P5875, DOI 10.1073/pnas.83.16.5875; FAGAN TF, 1996, SOC RES BIOL RHYTHMS, P75; Foulkes NS, 1996, NATURE, V381, P83, DOI 10.1038/381083a0; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; HOCHBERG ML, 1974, J BACTERIOL, V120, P1164, DOI 10.1128/JB.120.3.1164-1175.1974; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JUNGEHULSING U, 1994, CURR GENET, V25, P101, DOI 10.1007/BF00309533; KAPOOR M, 1995, J BACTERIOL, V177, P212, DOI 10.1128/jb.177.1.212-221.1995; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; Kay S A, 1993, Semin Cell Biol, V4, P81, DOI 10.1006/scel.1993.1010; Laxalt AM, 1996, PLANT MOL BIOL, V30, P961, DOI 10.1007/BF00020807; LINDGREN KM, 1994, THESIS DARTMOUTH MED; Liu Y, 1997, CELL, V89, P477, DOI 10.1016/S0092-8674(00)80228-7; LOROS JJ, 1989, SCIENCE, V243, P385, DOI 10.1126/science.2563175; LOROS JJ, 1991, MOL CELL BIOL, V11, P558, DOI 10.1128/MCB.11.1.558; MANSUR NR, 1993, NUCLEIC ACIDS RES, V21, P993, DOI 10.1093/nar/21.4.993; MARTINEZ P, 1989, J MOL BIOL, V208, P551, DOI 10.1016/0022-2836(89)90147-2; MCNALLY MT, 1988, CURR GENET, V14, P545, DOI 10.1007/BF00434079; MCNULTY SE, 1995, BIOCHEM BIOPH RES CO, V212, P165, DOI 10.1006/bbrc.1995.1951; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NESS GC, 1991, FEBS LETT, V288, P21, DOI 10.1016/0014-5793(91)80993-D; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; PUNT PJ, 1990, GENE, V93, P101, DOI 10.1016/0378-1119(90)90142-E; PUNT PJ, 1988, GENE, V69, P49, DOI 10.1016/0378-1119(88)90377-0; QUAIL EA, 1995, FEBS LETT, V359, P126, DOI 10.1016/0014-5793(95)00023-3; Ricci M, 1991, FUNGAL GENET NEWSLET, V38, P87; RIDDER R, 1992, CURR GENET, V21, P207, DOI 10.1007/BF00336843; RONAI Z, 1993, INT J BIOCHEM, V25, P1073, DOI 10.1016/0020-711X(93)90123-V; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SAHNI M, 1997, FUNGAL GENET NEWSL, V44, P47; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; SOKOLOVSKY VY, 1992, J GEN MICROBIOL, V138, P2045, DOI 10.1099/00221287-138-10-2045; SUGAHARA T, 1995, FEBS LETT, V368, P92, DOI 10.1016/0014-5793(95)00607-B; TEMPLETON MD, 1992, GENE, V122, P225, DOI 10.1016/0378-1119(92)90055-T; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANWERT SL, 1992, CURR GENET, V22, P29, DOI 10.1007/BF00351738	54	67	69	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					446	452		10.1074/jbc.273.1.446	http://dx.doi.org/10.1074/jbc.273.1.446			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417102	hybrid			2022-12-25	WOS:000071295600068
J	Bezombes, C; Maestre, N; Laurent, G; Levade, T; Bettaieb, A; Jaffrezou, JP				Bezombes, C; Maestre, N; Laurent, G; Levade, T; Bettaieb, A; Jaffrezou, JP			Restoration of TNF-alpha-induced ceramide generation and apoptosis in resistant human leukemia KG1a cells by the p-glycoprotein blocker PSC833	FASEB JOURNAL			English	Article						TNF-alpha; sphingomyelin asymmetry; sphingomyelinase; ceramide	TUMOR-NECROSIS-FACTOR; PLASMA-MEMBRANE; MULTIDRUG-RESISTANCE; INDUCED CYTOTOXICITY; SPHINGOMYELIN CYCLE; IONIZING-RADIATION; DNA FRAGMENTATION; DEATH; PHOSPHATIDYLCHOLINE; RECEPTOR	Tumor necrosis factor (TNF-alpha) is a cytokine with antitumor activity against several cellular models, TNF-alpha-induced apoptosis seems to be mediated by a signaling pathway termed 'sphingomyelin-ceramide' pathway, which consists of the hydrolysis of sphingomyelin and the production of its breakdown product ceramide, Our study shows that KG1a cells, which are inherently resistant to TNF-alpha and do not produce ceramide upon cytokine stimulation, can be sensitized by the use of the P-glycoprotein inhibitor PSC833, Coincubation with 1 mu M of this cyclosporin derivative restored the apoptotic potential of 10 ng/ml TNF-alpha, This effect was associated with the restoration of ceramide generation (315%) and activation of neutral, but not acid sphingomyelinase activity (143%), Furthermore, we demonstrate that treatment of KG1a cells with 1 mu M PSC833 led to a threefold increase in inner plasma membrane sphingomyelin content and basal neutral sphingomyelinase activity, These results support the hypothesis whereby resistance to TNF-alpha-mediated apoptosis of certain leukemic cells is linked to the disposability of the sphingomyelin pool, These data also suggest a role for P-glycoprotein in sphingomyelin transverse plasma membrane asymmetry.	Ctr Claudius Regaud, INSERM, CJF 9503, F-31052 Toulouse, France; CHU Purpan, Serv Hematol, F-31059 Toulouse, France; CHU Rangueil, INSERM 466, Lab Biochim Med, F-31403 Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Jaffrezou, JP (corresponding author), Ctr Claudius Regaud, INSERM, CJF 9503, 20 Rue Pont St Pierre, F-31052 Toulouse, France.	jaffrezou@regaud-tlse.fnclcc.fr	Levade, Thierry/O-8948-2014; Bezombes, christine/X-8479-2019; Bezombes, Christine/G-2743-2017; Bezombes, Christine/AAC-1724-2020	Bezombes, christine/0000-0003-4079-4872; 				Andrieu N, 1996, EUR J BIOCHEM, V236, P738, DOI 10.1111/j.1432-1033.1996.00738.x; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; BAILLY JD, 1995, LEUKEMIA, V9, P799; Banker DE, 1997, BLOOD, V89, P243, DOI 10.1182/blood.V89.1.243.243_243_255; Bettaieb A, 1996, BLOOD, V88, P1465, DOI 10.1182/blood.V88.4.1465.bloodjournal8841465; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; CHEN M, 1995, CANCER RES, V55, P991; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DEVAUX PF, 1994, CHEM PHYS LIPIDS, V73, P107, DOI 10.1016/0009-3084(94)90177-5; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FILIPSKI J, 1990, EMBO J, V9, P1319, DOI 10.1002/j.1460-2075.1990.tb08241.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORD JM, 1990, PHARMACOL REV, V42, P155; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HIGUCHI M, 1994, J IMMUNOL, V152, P4017; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; KIM MY, 1991, J BIOL CHEM, V266, P484; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LEVADE T, 1986, J CLIN CHEM CLIN BIO, V24, P205; LINARDIC CM, 1994, J BIOL CHEM, V269, P23530; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MCCONKEY DJ, 1991, J IMMUNOL, V146, P1072; MERRILL AH, 1990, BIOCHIM BIOPHYS ACTA, V1044, P113; MUNKER R, 1987, BLOOD, V70, P1730; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PAYRASTRE B, 1988, BIOCHIM BIOPHYS ACTA, V939, P355, DOI 10.1016/0005-2736(88)90081-8; QuilletMary A, 1996, LEUKEMIA, V10, P417; RECORD M, 1985, BIOCHIM BIOPHYS ACTA, V819, P1, DOI 10.1016/0005-2736(85)90188-9; RECORD M, 1984, BIOCHIM BIOPHYS ACTA, V778, P449, DOI 10.1016/0005-2736(84)90393-6; RECORD M, 1982, BIOCHIM BIOPHYS ACTA, V699, P57; RIBBES G, 1985, FEBS LETT, V191, P195, DOI 10.1016/0014-5793(85)80007-7; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STOFFEL W, 1980, H-S Z PHYSIOL CHEM, V361, P755, DOI 10.1515/bchm2.1980.361.1.755; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TERCE F, 1988, J BIOL CHEM, V263, P3142; TWENTYMAN PR, 1991, EUR J CANCER, V27, P1639, DOI 10.1016/0277-5379(91)90435-G; VALLARI S, 1990, ARCH BIOCHEM BIOPHYS, V71, P538; van Helvoort A, 1997, J CELL SCI, V110, P75; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Weisburg JH, 1996, J EXP MED, V183, P2699, DOI 10.1084/jem.183.6.2699; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	58	121	124	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					101	109		10.1096/fasebj.12.1.101	http://dx.doi.org/10.1096/fasebj.12.1.101			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438415				2022-12-25	WOS:000071523800011
J	Konieczny, I; Helinski, DR				Konieczny, I; Helinski, DR			Helicase delivery and activation by DnaA and TrfA proteins during the initiation of replication of the broad host range plasmid RK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; GENE-PRODUCT; NUCLEOPROTEIN STRUCTURES; ENZYMATIC REPLICATION; PHYSICAL-PROPERTIES; ENCODED PROTEINS; ORIGIN; COMPLEX; INVITRO; PURIFICATION	Specific binding of the plasmid-encoded protein, TrfA, and the Escherichia coli DnaA protein to the origin region (oriV) is required for the initiation of replication of the broad host range plasmid RK2, It has been shown that the DnaA protein which binds to DnaA boxes upstream of the TrfA-binding sites (iterons) cannot by itself form an open complex, but it enhances the formation of the open complex by TrfA (Konieczny, I., Doran, K. S., Helinski, D. R., Blasina, A. (1997) J. Biol. Chem. 272, 20173), In this study an in vitro replication system is reconstituted from purified TrfA protein and E. coli proteins, With this system, a specific interaction between the DnaA and DnaB proteins is required for delivery of the helicase to the RK2 origin region, Although the DnaA protein directs the DnaB-DnaC complex to the plasmid replication origin, it cannot by itself activate the helicase, Both DnaA and TrfA proteins are required for DnaB-induced template unwinding, We propose that specific changes in the nucleoprotein structure mediated by TrfA result in a repositioning of the DnaB helicase within the open origin region and an activation of the DnaB protein for template unwinding.	Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA; Univ Gdansk, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of California System; University of California San Diego; Fahrenheit Universities; University of Gdansk	Helinski, DR (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Biol, La Jolla, CA 92093 USA.			Konieczny, Igor/0000-0002-1588-5601	NIAID NIH HHS [AI 07194] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI007194] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALFANO C, 1989, J BIOL CHEM, V264, P10709; ALFANO C, 1989, J BIOL CHEM, V264, P10699; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5247; BAKER TA, 1986, CELL, V45, P53, DOI 10.1016/0092-8674(86)90537-4; BAKER TA, 1987, J BIOL CHEM, V262, P6877; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GAYLO PJ, 1987, J BACTERIOL, V169, P4703, DOI 10.1128/jb.169.10.4703-4709.1987; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HWANG DS, 1988, J BIOL CHEM, V263, P10625; INGMER H, 1992, MOL GEN GENET, V232, P431, DOI 10.1007/BF00266248; Kaguni JM, 1997, MOL CELLS, V7, P145; KAGUNI JM, 1984, CELL, V38, P138; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; KOBORI JA, 1982, J BIOL CHEM, V257, P13763; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; MALLORY JB, 1990, J BIOL CHEM, V265, P13297; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MATSUI M, 1985, J MOL BIOL, V184, P529, DOI 10.1016/0022-2836(85)90299-2; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; MUKHOPADHYAY G, 1993, EMBO J, V12, P4547, DOI 10.1002/j.1460-2075.1993.tb06143.x; OGAWA T, 1985, P NATL ACAD SCI USA, V82, P3562, DOI 10.1073/pnas.82.11.3562; PANSEGRAU W, 1994, J MOL BIOL, V239, P623, DOI 10.1006/jmbi.1994.1404; PERRI S, 1993, J BIOL CHEM, V268, P3662; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; Ratnakar PVAL, 1996, P NATL ACAD SCI USA, V93, P5522, DOI 10.1073/pnas.93.11.5522; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SCHNOS M, 1988, CELL, V52, P385, DOI 10.1016/S0092-8674(88)80031-X; SHAH DS, 1995, J MOL BIOL, V254, P608, DOI 10.1006/jmbi.1995.0642; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; THOMAS CM, 1981, MOL GEN GENET, V181, P1, DOI 10.1007/BF00338996; THOMAS CM, 1980, J BACTERIOL, V141, P213, DOI 10.1128/JB.141.1.213-222.1980; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; TOOUKDARIAN AE, 1996, J BIOL CHEM, V271, P7072; VANDERENDE A, 1985, P NATL ACAD SCI USA, V82, P3954; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WOELKER B, 1993, NUCLEIC ACIDS RES, V21, P5025, DOI 10.1093/nar/21.22.5025; YUNG BYM, 1990, J BIOL CHEM, V265, P1282; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	51	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33312	33318		10.1074/jbc.272.52.33312	http://dx.doi.org/10.1074/jbc.272.52.33312			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407123	hybrid			2022-12-25	WOS:000071182900084
J	Cupers, P; Jadhav, AP; Kirchhausen, T				Cupers, P; Jadhav, AP; Kirchhausen, T			Assembly of clathrin coats disrupts the association between Eps15 and AP-2 adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; VESICLES; PROTEIN; COMPLEXES; DOMAIN; PITS	Eps15 is a phosphorylation substrate of the epidermal growth factor receptor kinase, In vivo, it is largely found in complex with AP-2, the plasma membrane clathrin adaptor protein complex. Although AP-2 is uniformly distributed across the surface of clathrin-coated pits and vesicles, Eps15 is preferentially found in the rims of endocytic clathrin-coated pits (1), This observation suggests that Eps15 may disengage from AP-2 during coat formation. Here we use two new anti-Eps15 antibodies to show that, contrary to our own earlier suggestion, coated vesicles isolated from brain do not contain detectable amounts of Eps15. Furthermore, when AP-2 complexes that are saturated with Eps15 are used for in vitro assembly of clathrin-AP-2 coats, normal structures are formed that contain the expected amounts of clathrin and AP-2, but the amount of Eps15 present is dramatically lower than that of AP-2. We propose that during coated pit formation, addition of clathrin to the growing edge at the rim of the pit releases Eps15 from AP-2.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Kirchhausen, T (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 200 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM36548] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036548] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECK KA, 1991, J BIOL CHEM, V266, P4437; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Clairmont KB, 1997, CELL MOL LIFE SCI, V53, P611, DOI 10.1007/s000180050080; CUPTERS P, 1998, IN PRESS J BIOL CHEM, V273; DIFIORE P, 1997, TRENDS BIOCHEM SCI, V263, P411; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Iannolo G, 1997, CANCER RES, V57, P240; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; KIRCHHAUSEN T, 1993, CURR OPIN STRUC BIOL, V3, P182, DOI 10.1016/S0959-440X(05)80150-2; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; vanDelft S, 1997, J CELL BIOL, V136, P811, DOI 10.1083/jcb.136.4.811; VANDEURS B, 1984, EMBO J, V3, P1959, DOI 10.1002/j.1460-2075.1984.tb02076.x	22	49	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1847	1850		10.1074/jbc.273.4.1847	http://dx.doi.org/10.1074/jbc.273.4.1847			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442014	hybrid			2022-12-25	WOS:000071595200003
J	Ray, RB; Meyer, K; Steele, R; Shrivastava, A; Aggarwal, BB; Ray, R				Ray, RB; Meyer, K; Steele, R; Shrivastava, A; Aggarwal, BB; Ray, R			Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY(ADP-RIBOSE) POLYMERASE; IMMUNE-RESPONSES; B VIRUS; REPLICATION; CLEAVAGE; INVITRO; GENOME; DEATH; ALPHA; KILL	Hepatitis C virus (HCV) putative core protein has displayed many intriguing biological properties, Since tumor necrosis factor (TNF) plays an important role in controlling viral infection, in this study the effect of the core protein was investigated on the TNF-alpha induced apoptosis of human breast carcinoma cells (MCF7). RCV core protein when expressed inhibited TNF-alpha-induced apoptotic cell death unlike the control MCF7 cells, as determined by cell viability and DNA fragmentation analysis. Additionally, HCV core protein blocked the TNF-induced proteolytic cleavage of the death substrate poly(ADP-ribose) polymerase from its native 116-kDa protein to the characteristic 85-kDa polypeptide, Results from this study suggest that the HCV core protein plays a role in the inhibition of TNF-alpha-mediated cell death. Thus, the ability of core protein to inhibit the TNF-mediated apoptotic signaling pathway may provide a selective advantage for HCV replication, allowing for evasion of host antiviral defense mechanisms.	St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, St Louis, MO 63110 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Med Oncol, Cytokine Res Lab, Houston, TX 77030 USA	Saint Louis University; University of Texas System; UTMD Anderson Cancer Center	Ray, R (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Infect Dis & Immunol, 3635 Vista Ave,FDT-8N, St Louis, MO 63110 USA.		Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [CA52799] Funding Source: Medline; NIAID NIH HHS [AI-45250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052799, R01CA052799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045250] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL BB, 1992, TUMOR NECROSIS FACTO; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.immunol.13.1.29; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; Dimitrov T, 1997, J VIROL, V71, P2830, DOI 10.1128/JVI.71.4.2830-2837.1997; FANG JWS, 1994, HEPATOLOGY, V20, P251; Geissler M, 1997, J IMMUNOL, V158, P1231; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Guilhot S, 1996, AM J PATHOL, V148, P801; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hu SM, 1997, J BIOL CHEM, V272, P9621; Jin YD, 1997, J CLIN IMMUNOL, V17, P140, DOI 10.1023/A:1027326415164; Kakumu S, 1997, CLIN EXP IMMUNOL, V108, P138, DOI 10.1046/j.1365-2249.1997.d01-987.x; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LAGGING LM, 1995, J VIROL, V69, P5859, DOI 10.1128/JVI.69.9.5859-5863.1995; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; MAJOR ME, 1995, J VIROL, V69, P5798, DOI 10.1128/JVI.69.9.5798-5805.1995; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; MESTAN J, 1986, NATURE, V323, P816, DOI 10.1038/323816a0; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Rao L, 1997, CURR OPIN GENET DEV, V7, P52, DOI 10.1016/S0959-437X(97)80109-8; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Rudin CM, 1997, ANNU REV MED, V48, P267; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; Shimizu I, 1997, J GASTROENTEROL, V32, P47, DOI 10.1007/BF01213296; Shisler J, 1997, J VIROL, V71, P8299, DOI 10.1128/JVI.71.11.8299-8306.1997; SMITH GK, 1992, CANCER RES, V52, P4895; Srinivas RV, 1996, VIRUS RES, V45, P87, DOI 10.1016/S0168-1702(96)01361-5; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Totpal K, 1996, J INTERF CYTOK RES, V16, P259, DOI 10.1089/jir.1996.16.259; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	49	199	208	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2256	2259		10.1074/jbc.273.4.2256	http://dx.doi.org/10.1074/jbc.273.4.2256			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442069	hybrid			2022-12-25	WOS:000071595200058
J	Aurisicchio, L; Di Lauro, R; Zannini, M				Aurisicchio, L; Di Lauro, R; Zannini, M			Identification of the thyroid transcription factor-1 as a target for rat MST2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CELL-SURFACE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MESSENGER-RNAS; FACTOR-I; PHOSPHORYLATION; STE20; PROMOTER; YEAST	Thyroid transcription factor-1 (TTF-1) is a homeodomain-containing transcription factor that is required for thyroid-specific expression of the thyroglobulin and thyroperoxidase genes as well as for lung-specific expression of the surfactant protein A, B, and C and the CC10 and the HNF-3 alpha genes, TTF-1 is a phosphoprotein, and the phosphorylation of TTF-1 has been studied already. However, the kinase(s) that could be responsible for this phosphorylation have not been known, In this paper we report the identification by in-gel kinase assay of a 56-kDa serine/threonine kinase that is able to phosphorylate TTF-1 in thyroid cells. The cloning of this kinase revealed that we had identified the rat homolog of the human MST2 kinase, The pathway in which human MST2 functions is not known; however, it does not appear to involve either mitogen-activated protein kinases such as Erk1 and Erk2 nor the stress-activated protein kinases such as JNK and p38, We show that the activity responsible for TTF-1 phosphorylation is constitutive in thyroid cells, Furthermore, we demonstrate that TTF-1 is phosphorylated in vivo by rMST2 at the same residues that had been identified previously as the major phosphorylation sites. Thus, TTF-1 represents the first identified target of this class of protein kinases.	Staz Zool Anton Dohrn, I-80121 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli; University of Naples Federico II	Zannini, M (corresponding author), Staz Zool Anton Dohrn, Villa Comunale, I-80121 Naples, Italy.	stella@alpha.szn.it	Di Lauro, Roberto/A-2746-2012; Zannini, Mariastella/I-1735-2012	Di Lauro, Roberto/0000-0001-9493-3036; Aurisicchio, Luigi/0000-0003-3110-4534	Telethon [E.0406] Funding Source: Medline	Telethon(Fondazione Telethon)		ADAMS SL, 1977, P NATL ACAD SCI USA, V74, P3399, DOI 10.1073/pnas.74.8.3399; Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CANO E, 1995, J CELL SCI, V108, P3599; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HATZ P, 1994, J BIOL CHEM, V269, P16802; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Peterson RS, 1997, CELL GROWTH DIFFER, V8, P69; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Zannini M, 1996, J BIOL CHEM, V271, P2249, DOI 10.1074/jbc.271.4.2249	35	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1477	1482		10.1074/jbc.273.3.1477	http://dx.doi.org/10.1074/jbc.273.3.1477			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430685	hybrid			2022-12-25	WOS:000071411500032
J	Colombo, MI; Gelberman, SC; Whiteheart, SW; Stahl, PD				Colombo, MI; Gelberman, SC; Whiteheart, SW; Stahl, PD			N-Ethylmaleimide-sensitive factor-dependent alpha-SNAP release, an early event in the docking/fusion process, is not regulated by Rab GTPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; ATTACHMENT PROTEINS SNAPS; FUSION PROTEIN; MEMBRANE-FUSION; VESICULAR TRANSPORT; VESICLE FUSION; ENDOSOME FUSION; GOLGI MEMBRANES; IN-VITRO; NSF	The N-ethylmaleimide-sensitive factor (NSF) is required for multiple intracellular vesicle transport events, In vitro biochemical studies have demonstrated that NSF, soluble NSF attachment proteins (SNAPs), and SNAP receptors form a 20 S particle, This complex is disassembled by the ATPase activity of NSF, We have studied particle disassembly in a membrane environment by examining the binding of recombinant SNAPs and NSF to endosomal membranes, We present evidence that alpha-SNAP is released from the membranes in a temperature-and time-dependent manner and that this release is mediated by the ATPase activity of NSF, Our results indicate that NSF mutants in the first ATP binding domain completely abrogate alpha-SNAP release, whereas no inhibitory effect is observed with a mutant in the second ATP binding domain, Interestingly, neither beta-SNAP nor gamma-SNAP are released by the ATPase activity of NSF, indicating that these proteins are retained on the membranes by interactions that differ from those that retain alpha-SNAP, Although the small Rab GTPases are known to play a role in SNARE complex assembly, our results indicate that these GTPases do not regulate the NSF-dependent release of alpha-SNAP.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Kentucky, Coll Med, Chandler Med Ctr, Dept Biochem, Lexington, KY 40536 USA	Washington University (WUSTL); University of Kentucky	Colombo, MI (corresponding author), Univ Nacl Cuyo, CONICET, Fac Ciencias Med, Inst Histol & Embriol, Mendoza, Argentina.		Stahl, Philip/D-6315-2012	Whiteheart, Sidney/0000-0001-5577-0473				Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; COLOMBO MI, 1992, METHOD ENZYMOL, V219, P32; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; Hicke L, 1997, MOL BIOL CELL, V8, P13, DOI 10.1091/mbc.8.1.13; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; Johannes L, 1996, J CELL SCI, V109, P2875; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; MORGAN A, 1996, NATURE, V382, P686; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALLANCK L, 1995, J BIOL CHEM, V270, P18742, DOI 10.1074/jbc.270.32.18742; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; SOLLNER T, 1995, FEBS LETT, V369, P80, DOI 10.1016/0014-5793(95)00594-Y; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEEL G, 1996, EMBO J, V1, P745; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUMIDA M, 1994, J BIOL CHEM, V269, P20636; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; Tagaya M, 1996, J BIOL CHEM, V271, P466, DOI 10.1074/jbc.271.1.466; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	54	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1334	1338		10.1074/jbc.273.3.1334	http://dx.doi.org/10.1074/jbc.273.3.1334			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430666	hybrid			2022-12-25	WOS:000071411500013
J	Zeng, CB; Aleshin, AE; Chen, GJ; Honzatko, RB; Fromm, HJ				Zeng, CB; Aleshin, AE; Chen, GJ; Honzatko, RB; Fromm, HJ			The roles of glycine residues in the ATP binding site of human brain hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HALVES; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; PURIFICATION; CONFORMATION; SPECIFICITY; INHIBITION; MECHANISM; SEQUENCE	Mutants of hexokinase I (Arg(539) --> Lys, Thr(661) --> Ala, Thr(661) --> Val, Gly(534) --> Ala, Gly(679) --> Ala, and Gly(862) --> Ala), located putatively in the vicinity of the ATP binding pocket, were constructed, purified to homogeneity, and studied by circular dichroism (CD) spectroscopy, fluorescence spectroscopy, and initial velocity kinetics, The wild-type and mutant enzymes have similar secondary structures on the basis of CD spectroscopy, The mutation Gly(679) --> Ala had little effect on the kinetic properties of the enzyme, Compared with the wild type enzyme, however, the Gly(534) --> Ala mutant exhibited a 4000-fold decrease in k(cat) and the Gly(862) --> Ala mutant showed an 11-fold increase in K-m for ATP. Glucose 6-phosphate inhibition of the three glycine mutants is comparable to that of the wild-type enzyme, Inorganic phosphate is, however, less effective in relieving glucose 6-phosphate inhibition of the Gly(862) --> Ala mutant, relative to the wild-type enzyme and entirely ineffective in relieving inhibition of the Gly(534) --> Ala mutant. Although the fluorescence emission spectra showed some difference for the Gly(862) --> Ala mutant relative to that of the wild-type enzyme, indicating an environmental alteration around tryptophan residues, no change was observed for the Gly(534) --> Ala and Gly(679) --> Ala mutants, Gly(862) --> Ala and Gly(534) --> Ala are the first instances of single residue mutations in hexokinase I that affect the binding affinity of ATP and abolish phosphate-induced relief of glucose 6-phosphate inhibition, respectively.	Iowa State Univ Sci & Technol, Dept Biochem & Biophys, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem & Biophys, 1210 Mol Biol Bldg, Ames, IA 50011 USA.	hjfromm@iastate.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS010546, R01NS010546] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 10546] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; ARORA KK, 1991, J BIOL CHEM, V266, P5359; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BORK P, 1992, P NATL ACAD SCI USA, V89, P7290, DOI 10.1073/pnas.89.16.7290; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BOSSEMEYER D, 1994, TRENDS BIOCHEM SCI, V19, P201, DOI 10.1016/0968-0004(94)90022-1; BOSSEMEYER D, 1993, NATURE, V363, P590, DOI 10.1038/363590a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; FERRARI RICHARD A., 1959, ARCH BIOCHEM AND BIOPHYS, V80, P372, DOI 10.1016/0003-9861(59)90264-4; FROMM HJ, 1981, REGULATION CARBOHYDR, P45; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARRISON RW, 1985, THESIS YALE U NEW HA; HOLROYDE MJ, 1976, FEBS LETT, V62, P215, DOI 10.1016/0014-5793(76)80056-7; KANG C, 1994, J BIOL CHEM, V269, P24046; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; LIU F, 1991, BIOCHEM BIOPH RES CO, V177, P305, DOI 10.1016/0006-291X(91)91983-J; LOWRY OH, 1964, J BIOL CHEM, V239, P31; MANNING TA, 1984, BIOCHEM BIOPH RES CO, V118, P90, DOI 10.1016/0006-291X(84)91071-4; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Poland BW, 1996, J MOL BIOL, V264, P1013, DOI 10.1006/jmbi.1996.0693; Rapoport S, 1968, Essays Biochem, V4, P69; ROSE IA, 1974, ARCH BIOCHEM BIOPHYS, V164, P729, DOI 10.1016/0003-9861(74)90086-1; RUDOLPH FB, 1971, J BIOL CHEM, V246, P6611; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P1; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; URETA T, 1975, ISOZYMES, V3, P575; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zeng CB, 1996, BIOCHEMISTRY-US, V35, P13157, DOI 10.1021/bi960750e; ZENG CB, 1995, J BIOL CHEM, V270, P10509, DOI 10.1074/jbc.270.18.10509	33	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					700	704		10.1074/jbc.273.2.700	http://dx.doi.org/10.1074/jbc.273.2.700			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422720	hybrid			2022-12-25	WOS:000071411400009
J	Feldman, DA; Weinhold, PA				Feldman, DA; Weinhold, PA			Cytidylyltransferase-binding protein is identical to transcytosis-associated protein (TAP/p115) and enhances the lipid activation of cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; CHOLINE-PHOSPHATE CYTIDYLYLTRANSFERASE; CHINESE-HAMSTER OVARY; FATTY-ACIDS PROMOTE; RAT-LIVER; ENDOPLASMIC-RETICULUM; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; SACCHAROMYCES-CEREVISIAE; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; FEEDBACK-REGULATION	We previously identified a protein from rat liver that binds CTP:phosphocholine cytidylyltransferase (CT). We have now purified this protein (cytidylyltransferase-binding protein (CTBP)) from rat liver, The purification involved precipitation at pH 5 and extraction of the precipitate with buffer, followed by sequential chromatography on DEAE Sepharose and butyl-agarose. Final purification was accomplished by either preparative electrophoresis or hydroxylapatite chromatography, Amino acid sequences from six peptides derived from pure CTBP matched sequences in transcytosis-associated protein (TAP) with 98% identity, Thus, CTBP was positively identified to be TAP, Purified CTBP increased the activity of purified CT measured with phosphatidylcholine (PC)/oleic acid, In the absence of PC/oleic acid, CTBP did not stimulate CT activity. Dilution of CT to reduce the Triton X-100 concentration produced a loss of CT activity, The lost activity was recovered by the addition of CTBP plus PC/oleic acid to the assay, but not by the addition of either PC/oleic acid or CTBP alone. Removal of CTBP from purified preparations by immunoprecipitation with CTBP antibodies eliminated the activation of CT, Both CT and CTBP were shown to bind to PC/oleic acid liposomes, The formation of complexes between CT and CTBP in the absence of PC/oleic acid liposomes could not be demonstrated, These results suggest that CTBP functions to modify the interaction of CT with PC/oleic acid liposomes, resulting in an increase in the catalytic activity perhaps by the formation of a ternary complex between CT, CTBP, and lipid. Overall, these results suggest that CTBP (TAP) may function to coordinate the biosynthesis of phosphatidylcholine with vesicle transport.	Vet Adm Med Ctr, Ann Arbor, MI 48105 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Michigan System; University of Michigan	Weinhold, PA (corresponding author), Vet Adm Med Ctr, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.							BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; DEMORENO MR, 1985, ANAL BIOCHEM, V151, P466, DOI 10.1016/0003-2697(85)90206-4; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; FELDMAN DA, 1993, J BIOL CHEM, V268, P3127; FELDMAN DA, 1985, BIOCHIM BIOPHYS ACTA, V833, P429, DOI 10.1016/0005-2760(85)90100-6; HATCH GM, 1992, J BIOL CHEM, V267, P15751; HIGGINS JA, 1987, J LIPID RES, V28, P268; Houweling M, 1996, EUR J CELL BIOL, V69, P55; JAMIL H, 1990, J BIOL CHEM, V265, P4332; JAMIL H, 1990, BIOCHEM J, V270, P749, DOI 10.1042/bj2700749; JAMIL H, 1993, BIOCHEM J, V291, P418; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KENT C, 1990, PROG LIPID RES, V29, P87, DOI 10.1016/0163-7827(90)90010-I; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1993, PROTEIN EXPRES PURIF, V4, P1, DOI 10.1006/prep.1993.1001; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PELECH SL, 1983, J BIOL CHEM, V258, P6782; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; SKINNER HB, 1995, P NATL ACAD SCI USA, V92, P112, DOI 10.1073/pnas.92.1.112; SLEIGHT R, 1983, J BIOL CHEM, V258, P836; SLOMIANY A, 1992, EXP CELL RES, V201, P321, DOI 10.1016/0014-4827(92)90280-L; TERCE F, 1991, BIOCHIM BIOPHYS ACTA, V1084, P69, DOI 10.1016/0005-2760(91)90057-O; UTAL AK, 1991, J BIOL CHEM, V266, P24084; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE JE, 1988, J BIOL CHEM, V263, P5898; WANG YL, 1993, J BIOL CHEM, V268, P5512; WANG YL, 1993, J BIOL CHEM, V268, P5899; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; WATKINS JD, 1991, J BIOL CHEM, V266, P21113; WATKINS JD, 1992, J BIOL CHEM, V267, P5686; WATKINS JD, 1990, J BIOL CHEM, V265, P2190; WEINHOLD PA, 1992, METHOD ENZYMOL, V209, P248; WEINHOLD PA, 1994, BBA-LIPID LIPID MET, V1210, P335, DOI 10.1016/0005-2760(94)90238-0; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; WEINHOLD PA, 1991, J BIOL CHEM, V266, P6093; WEINHOLD PA, 1995, ARCH BIOCHEM BIOPHYS, V318, P147, DOI 10.1006/abbi.1995.1215	41	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					102	109		10.1074/jbc.273.1.102	http://dx.doi.org/10.1074/jbc.273.1.102			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417053	hybrid			2022-12-25	WOS:000071295600019
J	Godavarti, R; Sasisekharan, R				Godavarti, R; Sasisekharan, R			Heparinase I from Flavobacterium heparinum - Role of positive charge in enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; SITE-DIRECTED MUTAGENESIS; SUBSTRATE-SPECIFICITY; CHEMICAL MODIFICATION; HISTIDINE RESIDUE; LYASES; CATALYSIS; BINDING; GLYCOSAMINOGLYCANS; IDENTIFICATION	Heparinases are bacterial enzymes that are powerful tools to study the physiological roles of heparin-like complex polysaccharides, In addition, heparinases have significant therapeutic applications, We had proposed earlier that cysteine 135 and histidine 203 together form the catalytic domain in heparinase I, We had also identified a heparin binding domain in heparinase I containing two positively charged clusters HB-1 and HB-2 in a primary heparin binding site and other positively charged residues in the vicinity of cysteine 135, In this study, through systematic site-directed mutagenesis studies, we show that the alteration of the positive charge of the HB I region has a pronounced effect on heparinase I activity. More specifically, site-directed mutagenesis of K199A (contained in HB-1) results in a 15-fold reduction in catalytic activity, whereas a K198A mutation (also in HB-1) results in only a 2- to 3-fold reduction in heparinase I activity, A K132A mutation, in close proximity to cysteine 135, also resulted in reduced (8-fold) activity, Heparin affinity chromatography experiments indicated moderately lowered binding affinities for the K132A, K198A, and the K199A mutant enzymes, The above results, taken together with our previous observations, lead us to propose that the positively charged heparin binding domain provides the necessary microenvironment for the catalytic domain of heparinase I, The dominant effect of lysine 199 suggests an additional, more direct, role in catalysis for this residue.	MIT, Div Toxicol, Whitaker Coll Hlth Sci & Technol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Sasisekharan, R (corresponding author), MIT, Div Toxicol, Whitaker Coll Hlth Sci & Technol, 77 Massachusetts Ave,E18-568, Cambridge, MA 02139 USA.				NIGMS NIH HHS [GM 31318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031318, R01GM031318] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNSTEIN H, 1988, METHOD ENZYMOL, V137, P515; Binari RC, 1997, DEVELOPMENT, V124, P2623; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARDIN AD, 1991, METHOD ENZYMOL, V203, P556; DESAI UR, 1993, ARCH BIOCHEM BIOPHYS, V306, P461, DOI 10.1006/abbi.1993.1538; DIPERSIO LP, 1991, J BIOL CHEM, V266, P4033; ERNST S, 1995, CRIT REV BIOCHEM MOL, V30, P387, DOI 10.3109/10409239509083490; Ernst S, 1996, BIOCHEM J, V315, P589, DOI 10.1042/bj3150589; GACESA P, 1987, FEBS LETT, V212, P199, DOI 10.1016/0014-5793(87)81344-3; Godavarti R, 1996, BIOCHEM BIOPH RES CO, V225, P751, DOI 10.1006/bbrc.1996.1246; Godavarti R, 1996, BIOCHEMISTRY-US, V35, P6846, DOI 10.1021/bi960356g; HATA A, 1993, J BIOL CHEM, V268, P8447; Higuchi R., 1990, PCR PROTOCOLS GUIDE; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LEWIS SD, 1981, BIOCHEMISTRY-US, V20, P48, DOI 10.1021/bi00504a009; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LINHARDT RJ, 1990, BIOCHEMISTRY-US, V29, P2611, DOI 10.1021/bi00462a026; LOHSE DL, 1992, J BIOL CHEM, V267, P24347; SANANTONIO JD, 1993, BIOCHEMISTRY-US, V32, P4746, DOI 10.1021/bi00069a008; SASISEKHARAN R, 1994, P NATL ACAD SCI USA, V91, P1524, DOI 10.1073/pnas.91.4.1524; Sasisekharan R, 1996, J BIOL CHEM, V271, P3124, DOI 10.1074/jbc.271.6.3124; SASISEKHARAN R, 1995, BIOCHEMISTRY-US, V34, P14441, DOI 10.1021/bi00044a022; SASISEKHARAN R, 1993, P NATL ACAD SCI USA, V90, P3660, DOI 10.1073/pnas.90.8.3660; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TEJIDOR L, 1993, THROMB HAEMOSTASIS, V69, P866; WU HF, 1995, ARCH BIOCHEM BIOPHYS, V317, P85, DOI 10.1006/abbi.1995.1139; YANG VC, 1985, J BIOL CHEM, V260, P1849; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012	29	28	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					248	255		10.1074/jbc.273.1.248	http://dx.doi.org/10.1074/jbc.273.1.248			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417072	hybrid			2022-12-25	WOS:000071295600038
J	Mari, BP; Anderson, IC; Mari, SE; Ning, YY; Lutz, Y; Kobzik, L; Shipp, MA				Mari, BP; Anderson, IC; Mari, SE; Ning, YY; Lutz, Y; Kobzik, L; Shipp, MA			Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE STROMELYSIN-3; BREAST-CARCINOMA; MATRIX METALLOPROTEINASES; STRUCTURAL DETERMINANTS; GENE-EXPRESSION; CELL CARCINOMA; NUDE-MICE; ACTIVATION; CANCER; PROGRESSION	Stromelysin-3 (STR-3) is a recently characterized matrix metalloproteinase (MIMP) with a unique pattern of expression and substrate specificity, Unlike other MMPs, STR-3 is consistently and dramatically overexpressed by multiple epithelial malignancies, including carcinomas of the breast, lung, colon, head and neck, and skin. Recent studies suggest that STR-3 promotes the local establishment of epithelial malignancies, contributing to tumor cell survival and implantation in host tissues; however, STR-3's mechanism of action remains undefined, STR-3 is a stromal cell product, prompting speculation that infiltrating stromal cells secrete STR-3 in response to tumor-derived factors, To explore this possibility, we developed a tumor/"stroma" coculture assay in which non-small cell lung cancer (NSCLC) cell lines were grown on confluent monolayers of normal pulmonary fibroblasts, In these tumor/stroma cocultures, NSCLCs stimulate normal pulmonary fibroblasts to secrete STR-8 and release extracellular basic fibroblast growth factor, Thereafter, STR-3 is processed at a unique internal sequence via a basic fibroblast growth factor-and MMP-dependent mechanism to a previously unidentified 35-kDa protein that lacks enzymatic activity. 35-kDa STR-3 is the most abundant STR-3 protein in tumor/stroma cocultures and is only detected when normal pulmonary fibroblasts are cultured with malignant bronchial epithelial cells, Therefore, the tumor-specific processing of STR-3 to the 35 kDa protein is likely to be an important regulatory mechanism.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Univ Strasbourg 1, IGBMC, CNRS, INSERM U184, F-67404 Strasbourg, France	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Shipp, MA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.		Mari, Bernard P/F-8960-2013; Mari, Bernard/Q-5832-2019; Mari, Bernard P/D-7445-2015; Mari, Bernard P/GVS-3100-2022	Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182; Mari, Bernard P/0000-0002-0422-9182				ANDERSON IC, 1995, CANCER RES, V55, P4120; ANGLARD P, 1995, J BIOL CHEM, V270, P20337, DOI 10.1074/jbc.270.35.20337; Atkinson SJ, 1995, J BIOL CHEM, V270, P30479, DOI 10.1074/jbc.270.51.30479; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BASSET P, 1994, CANCER-AM CANCER SOC, V74, P1045, DOI 10.1002/1097-0142(19940801)74:3+<1045::AID-CNCR2820741511>3.0.CO;2-7; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BIKFALVI A, 1995, EUR J CANCER, V31A, P1101, DOI 10.1016/0959-8049(95)00169-J; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V9, P541; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; Bolon I, 1996, LAB INVEST, V75, P1; COLTRINI D, 1995, CANCER RES, V55, P4729; CRAWFORD HC, 1994, INVAS METAST, V14, P234; DAVIES B, 1993, CANCER RES, V53, P2087; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GANJU RK, 1994, J CLIN INVEST, V94, P1784, DOI 10.1172/JCI117526; GEBHARD W, 1986, PROTEINASE INHIBITOR, P375; GILL GN, 1984, J BIOL CHEM, V259, P7755; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LEFEBVRE O, 1992, J CELL BIOL, V119, P997, DOI 10.1083/jcb.119.4.997; LEFEBVRE O, 1995, DEVELOPMENT, V121, P947; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; MARET A, 1995, CANCER RES, V55, P5075; MARI B, 1994, J BIOL CHEM, V269, P8517; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MAST AE, 1991, J BIOL CHEM, V266, P15810; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; Miyake H, 1996, CANCER RES, V56, P2440; MULLER D, 1993, CANCER RES, V53, P165; MURPHY G, 1993, J BIOL CHEM, V268, P15435; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NOEL A, 1995, J BIOL CHEM, V270, P22866, DOI 10.1074/jbc.270.39.22866; Noel AC, 1996, J CLIN INVEST, V97, P1924, DOI 10.1172/JCI118624; PATTERTON D, 1995, DEV BIOL, V167, P252, DOI 10.1006/dbio.1995.1021; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; PEI DQ, 1994, J BIOL CHEM, V269, P25849; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROUYER N, 1994, INVAS METAST, V14, P269; Sang QXA, 1996, J PROTEIN CHEM, V15, P137, DOI 10.1007/BF01887395; SANTAVICCA M, 1995, INT J CANCER, V64, P336, DOI 10.1002/ijc.2910640510; Santavicca M, 1996, BIOCHEM J, V315, P953, DOI 10.1042/bj3150953; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; TAKAHASHI JA, 1991, FEBS LETT, V288, P65, DOI 10.1016/0014-5793(91)81004-R; TARABOLETTI G, 1995, J NATL CANCER I, V87, P293, DOI 10.1093/jnci/87.4.293; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; WANG X, 1994, CANCER RES, V54, P4726; WOLF C, 1992, J INVEST DERMATOL, V99, P870, DOI 10.1111/1523-1747.ep12614846; WOLF C, 1993, P NATL ACAD SCI USA, V90, P1843, DOI 10.1073/pnas.90.5.1843	54	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					618	626		10.1074/jbc.273.1.618	http://dx.doi.org/10.1074/jbc.273.1.618			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417124	hybrid			2022-12-25	WOS:000071295600090
J	Salgado, J; Kroes, SJ; Berg, A; Moratal, JM; Canters, GW				Salgado, J; Kroes, SJ; Berg, A; Moratal, JM; Canters, GW			The dynamic properties of the M121H azurin metal site as studied by NMR of the paramagnetic Cu(II) and Co(II) metalloderivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALCALIGENES-DENITRIFICANS AZURIN; PSEUDOMONAS-AERUGINOSA AZURIN; NUCLEAR-MAGNETIC-RESONANCE; COPPER SITE; COBALT(II) DERIVATIVES; CRYSTAL-STRUCTURE; H-1-NMR; MUTANT; BLUE; SPECTROSCOPY	The M121H azurin mutant in solution presents various species in equilibrium that can be detected and studied by H-1 NMR of the Cu(II) and Co(II) paramagnetic metalloderivatives. In both cases up to three species are observed in slow exchange, the proportions of which are different for the two metalloderivatives. Above pH 5 the major species displays a tetrahedral coordination in which the His(121) can be observed as a coordinated residue, Its metal site corresponds to a new type of site that is defined as a type 1.5 site. The second and third species resemble the wild type (type 1) azurin and, above pH 4.5, they are present only at a low concentration. At low pH a protonation process increases the proportion of both type 1 species at the expense of the type 1.5 species. This process, characterized by a pK(a) = 4.3, is assigned to the protonation of His(121). At high pH the NMR spectrum of the Co(II)-M121H azurin experiences an additional transition, which is not observed in the case of the Cu(II) protein. The dynamic properties of the M121H metal site appear to be related to changes in the coordination geometry and the strength of the axial interaction between the N-delta 1 (His(121)) and the metal.	Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Univ Valencia, Dept Inorgan Chem, E-46100 Burjassot, Valencia, Spain	Leiden University; Leiden University - Excl LUMC; University of Valencia	Moratal, JM (corresponding author), Leiden Univ, Leiden Inst Chem, POB 9502, NL-2300 RA Leiden, Netherlands.		Salgado, Jesús/A-7759-2013	Salgado, Jesús/0000-0002-8537-1550; Berg, Axel/0000-0001-5196-5791				BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BARRICK D, 1995, CURR OPIN BIOTECH, V6, P411, DOI 10.1016/0958-1669(95)80070-0; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BERTINI I, 1993, CHEM REV, V93, P2833, DOI 10.1021/cr00024a009; BERTINI I, 1986, NMR PARAMAGNETIC MOL; BROWNER MF, 1994, NAT STRUCT BIOL, V1, P327, DOI 10.1038/nsb0594-327; CANTERS GW, 1993, FEBS LETT, V325, P39, DOI 10.1016/0014-5793(93)81410-2; CHEN ZG, 1994, J AM CHEM SOC, V116, P8772, DOI 10.1021/ja00098a040; COVINGTON AK, 1968, ANAL CHEM, V40, P700, DOI 10.1021/ac60260a013; DANIELSEN E, 1997, IN PRESS EUR J BIOCH; DENBLAAUWEN T, 1993, J AM CHEM SOC, V115, P1121, DOI 10.1021/ja00056a042; DIBILIO AJ, 1992, INORG CHIM ACTA, V198, P145, DOI 10.1016/S0020-1693(00)92355-7; GROENEVELD CM, 1988, J MOL BIOL, V200, P189, DOI 10.1016/0022-2836(88)90343-9; HELLINGA HW, 1996, DESIGN METALLOPROTEI, P369; HIGAKI JN, 1990, BIOCHEMISTRY-US, V29, P8582, DOI 10.1021/bi00489a012; HOITINK CWG, 1992, J BIOL CHEM, V267, P13836; HOITINK CWG, 1993, THESIS U LEIDEN; INUBUSHI T, 1983, J MAGN RESON, V51, P128, DOI 10.1016/0022-2364(83)90109-9; Kalverda AP, 1996, BIOCHEMISTRY-US, V35, P3085, DOI 10.1021/bi9518508; KARLSSON BG, 1991, PROTEIN ENG, V4, P343, DOI 10.1093/protein/4.3.343; Kroes SJ, 1996, J BIOL INORG CHEM, V1, P551, DOI 10.1007/s007750050091; Kroes SJ, 1996, EUR J BIOCHEM, V240, P342, DOI 10.1111/j.1432-1033.1996.0342h.x; LOMMEN A, 1990, J BIOL CHEM, V265, P2768; LU Y, 1993, J AM CHEM SOC, V115, P5907, DOI 10.1021/ja00067a003; MATTHEWS DJ, 1995, CURR OPIN BIOTECH, V6, P419, DOI 10.1016/0958-1669(95)80071-9; MCMILLIN DR, 1974, P NATL ACAD SCI USA, V71, P4760, DOI 10.1073/pnas.71.12.4760; MIZOGUCHI TJ, 1992, J AM CHEM SOC, V114, P10076, DOI 10.1021/ja00051a059; MORATAL JM, 1995, EUR J BIOCHEM, V228, P653, DOI 10.1111/j.1432-1033.1995.tb20305.x; MORATAL JM, 1993, INORG CHEM, V32, P3587, DOI 10.1021/ic00069a006; NAR H, 1992, EUR J BIOCHEM, V205, P1123, DOI 10.1111/j.1432-1033.1992.tb16881.x; PICCIOLI M, 1995, INORG CHEM, V34, P737, DOI 10.1021/ic00107a027; Pinto AL, 1997, P NATL ACAD SCI USA, V94, P5562, DOI 10.1073/pnas.94.11.5562; REGAN L, 1993, ANNU REV BIOPH BIOM, V22, P257, DOI 10.1146/annurev.bb.22.060193.001353; ROBINSON RA, 1969, J RES NBS A PHYS CH, VA 73, P299, DOI 10.6028/jres.073A.025; SALGADO J, 1995, EUR J BIOCHEM, V231, P358, DOI 10.1111/j.1432-1033.1995.tb20708.x; Salgado J, 1996, BIOCHEMISTRY-US, V35, P1810, DOI 10.1021/bi951748a; SOLOMON EI, 1993, SCIENCE, V259, P1575, DOI 10.1126/science.8384374; STEWART JD, 1994, J AM CHEM SOC, V116, P415, DOI 10.1021/ja00080a065; VILA AJ, 1994, FEBS LETT, V355, P15, DOI 10.1016/0014-5793(94)01141-9	39	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					177	185		10.1074/jbc.273.1.177	http://dx.doi.org/10.1074/jbc.273.1.177			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417062	Green Published, hybrid			2022-12-25	WOS:000071295600028
J	Yagisawa, H; Sakuma, K; Paterson, HF; Cheung, R; Allen, V; Hirata, H; Watanabe, Y; Hirata, M; Williams, RL; Katan, M				Yagisawa, H; Sakuma, K; Paterson, HF; Cheung, R; Allen, V; Hirata, H; Watanabe, Y; Hirata, M; Williams, RL; Katan, M			Replacements of single basic amino acids in the pleckstrin homology domain of phospholipase C-delta 1 alter the ligand binding, phospholipase activity, and interaction with the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOLAYER SURFACE PRESSURE; BRUTONS TYROSINE KINASE; HIGH-AFFINITY; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; MACROMOLECULAR INTERACTIONS; INOSITOL PHOSPHATES; BILAYER-MEMBRANES; ENZYME-ACTIVITY; HL-60 CELLS; PH DOMAINS	The pleckstrin homology (PH) domain of phosphatidylinositol-specific phospholipase C-delta 1 (PLC-delta 1) binds to both D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P-s) and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,B)P-2) with high affinities. We have previously identified a region rich in basic amino acids within the PH domain critical for ligand binding (Yagisawa, H., Hirata, M., Kanematsu, T., Watanabe, Y., Ozaki, S., Sakuma, H., Tanaka, H., Yabuta, N., Kamata, H., Hirata, H., and Nojima, H. (1994) J. Biol. Chem. 269, 20179-20188; Hirata, M., Kanematsu, T., Sakuma, K., Koga, T., Watanabe, Y., Ozaki, S., and Yagisawa, H. (1994) Biochem. Biophys. Res. Commun. 205, 1563-1571). To investigate the role of these basic residues, we have performed site-directed mutagenesis replacing each of the basic amino acid in the N-terminal 60 residues of PLC-delta 1 (Lys(24), Lys(30), Lys(32), Arg(37), Arg(38), Arg(40), Lys(43), Lys(49), Arg(56), Lys(57), and Arg(60)) with a neutral or an acidic amino acid. The effects of these mutations on the PH domain ligand binding properties and their consequence for substrate hydrolysis and membrane interactions of PLC-delta 1 were analyzed using several assay systems. Analysis of [H-3]-Ins(1,4,5)P-3 binding, measurement of the binding affinities, and measurements of phospholipase activity using PtdIns-(4,5)P-2-containing phospholipid vesicles, demonstrated that residues Lys(30), Lys(32), Arg(37), Ar-38, Arg(40), and Lys(57) were required for these PLC-delta 1 functions; in comparison, other mutations resulted in a moderate reduction. A subset of selected mutations was further analyzed for the enzyme activity toward substrate present in cellular membranes of permeabilized cells and for interaction with the plasma membrane after microinjection. These experiments demonstrated that mutations affecting ligand binding and PtdIns(4,5)P-3 hydrolysis in phospholipid vesicles also resulted in reduction in the hydrolysis of cellular polyphosphoinositides and loss of membrane attachment. All residues (with the exception of the K43E substitution) found to be critical for the analyzed PLC-delta 1 functions are present at the surface of the PH domain shown to contain the Ins(1,4,5)P-3 binding pocket.	Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima Sci Garden City, Hyogo 67812, Japan; Inst Canc Res, Chester Beatty Labs, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; Ehime Univ, Fac Engn, Dept Appl Chem, Matsuyama, Ehime 790, Japan; Kyushu Univ, Fac Dent, Dept Biochem, Fukuoka 812, Japan; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Hyogo; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Ehime University; Kyushu University; MRC Laboratory Molecular Biology	Yagisawa, H (corresponding author), Himeji Inst Technol, Fac Sci, Dept Life Sci, Harima Sci Garden City, Hyogo 67812, Japan.			Williams, Roger/0000-0001-7754-4207				BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bromann PA, 1997, J BIOL CHEM, V272, P16240, DOI 10.1074/jbc.272.26.16240; BUNCE CM, 1993, BIOCHEM J, V289, P667, DOI 10.1042/bj2890667; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COCKCROFT S, 1994, METHOD ENZYMOL, V238, P154; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CULLEN DC, 1987, BIOSENSORS, V3, P211; Cunningham E, 1996, P NATL ACAD SCI USA, V93, P6589, DOI 10.1073/pnas.93.13.6589; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRECH M, 1995, BIOCHEM SOC T, V23, P616, DOI 10.1042/bst0230616; Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474; Fukuda M, 1996, J BIOL CHEM, V271, P18838, DOI 10.1074/jbc.271.31.18838; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HENRY RA, 1995, AM J PHYSIOL-CELL PH, V269, pC349, DOI 10.1152/ajpcell.1995.269.2.C349; HIRATA M, 1990, BIOCHEM BIOPH RES CO, V168, P379, DOI 10.1016/0006-291X(90)91719-9; HIRATA M, 1994, BIOCHEM BIOPH RES CO, V205, P1563, DOI 10.1006/bbrc.1994.2845; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; KONISHI H, 1994, BIOCHEM BIOPH RES CO, V205, P1770, DOI 10.1006/bbrc.1994.2874; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; O'Shannessy D J, 1994, Curr Opin Biotechnol, V5, P65, DOI 10.1016/S0958-1669(05)80072-2; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; OZAKI S, 1992, CARBOHYD RES, V234, P189, DOI 10.1016/0008-6215(92)85048-5; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SARASTE M, 1995, CURR OPIN STRUC BIOL, V5, P403, DOI 10.1016/0959-440X(95)80104-9; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; Takeuchi H, 1996, BIOCHEM J, V318, P561, DOI 10.1042/bj3180561; TAKEUCHI H, 1997, IN PRESS BIOCH BIOPH; WATANABE Y, 1991, BIOORG MED CHEM LETT, V1, P399, DOI 10.1016/S0960-894X(00)80264-4; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAGISAWA H, 1991, J HYPERTENS, V9, P997, DOI 10.1097/00004872-199111000-00004; YEUNG D, 1995, TRAC-TREND ANAL CHEM, V14, P49, DOI 10.1016/0165-9936(95)91472-5	60	120	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					417	424		10.1074/jbc.273.1.417	http://dx.doi.org/10.1074/jbc.273.1.417			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417098	hybrid			2022-12-25	WOS:000071295600064
J	Pankhaniya, R; Jabrane-Ferrat, N; Gaufo, GO; Sreedharan, SP; Dazin, P; Kaye, J; Goetzl, EJ				Pankhaniya, R; Jabrane-Ferrat, N; Gaufo, GO; Sreedharan, SP; Dazin, P; Kaye, J; Goetzl, EJ			Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes	FASEB JOURNAL			English	Article						neuropeptide; immunology; T lymphocyte; receptor; apoptosis	MODEL BASEMENT-MEMBRANE; T-CELLS; POLYPEPTIDE VIP; IMMUNE-SYSTEMS; EXPRESSION; NEUROPEPTIDES; CHEMOTAXIS; SELECTION; NEUROIMMUNOMODULATION; LYMPHOCYTES	The prominence of vasoactive intestinal peptide (VIP) in rodent thymic neurons suggested that this potent mediator of T cell functions may alter developmental responses of thymocytes to T cell receptor (TCR) -dependent stimulation, CD4(+)8(+) DPK cells derived from a thymic lymphoma of a TCR transgenic mouse respond to pigeon cytochrome C (PCC) antigen in association with distinct I-E MHC II haplotypes on antigen-presenting cells (APCs) by differentiating into CD4(+)8(-) T cells, The specific recognition of VIP by two types of homologous C-protein-coupled receptors (VIPR1 and VIPR2) on DPK cells was attributable predominantly to VIPR1 before and to VIPR2 after exposure to APCs and PCC, as assessed by quantification of the respective mRNAs, PCC-evoked differentiation of DPK cells was enhanced significantly by 1 to 100 nM VIP after 3 to 4 days, The effects of VIP analogs with VIPR type selectivity implied that VIP enhancement of differentiation of DPK cells was mediated principally by VIPR2, Differential reduction in the expression of each type of VIPR by transfection of DPK cells with plasmids encoding the respective antisense mRNAs confirmed the central role of VIPR2 in VIP-enhanced conversion to CD4(+)8(-) T cells. The suppression of DPK cell differentiation by inhibitors of adenylyl cyclase and protein kinase A suggested a transductional role for VIP-elicited increases in [cAMP](i). That the changes in frequency of CD4(+)8(+) and CD4(+)8(-) DPK cells reflected principally differentiation was supported by the lack of consistent differences between the two subsets in the effects of VIP and VIPR2 agonist on cell number, viability, apoptosis, and proliferation, VIP may be one endogenous mediator that explains the unique thymic microenvironment for topographically specific development of T cells.	Univ Calif San Francisco, Dept Med & Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Scripps Res Inst, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Scripps Research Institute	Goetzl, EJ (corresponding author), Univ Calif San Francisco, Dept Med & Microbiol, Room UB8B,Box 0711,533 Parnassus, San Francisco, CA 94143 USA.		Jabrane-Ferrat, Nabila/K-1224-2014; Gaufo, Gary/D-3928-2011	Jabrane-Ferrat, Nabila/0000-0003-4809-7836; Gaufo, Gary/0000-0003-3695-3500; Kaye, Jonathan/0000-0002-1634-9069	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029912, R37AI029912, U01AI034570] Funding Source: NIH RePORTER; NIAID NIH HHS [AI29912, AI34570] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187, DOI 10.1164/ajrccm/144.5.1187; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; BOIRIVANT M, 1994, GASTROENTEROLOGY, V106, P576, DOI 10.1016/0016-5085(94)90688-2; FINK T, 1988, NEUROSCI LETT, V90, P39, DOI 10.1016/0304-3940(88)90783-5; Fujieda S, 1996, J CLIN INVEST, V98, P1527, DOI 10.1172/JCI118944; GANEA D, 1993, J NEUROIMMUNOL, V47, P147, DOI 10.1016/0165-5728(93)90025-T; GOETZL EJ, 1995, J IMMUNOL, V154, P1041; GOETZL EJ, 1992, FASEB J, V6, P2646, DOI 10.1096/fasebj.6.9.1612288; Grossman Z, 1996, P NATL ACAD SCI USA, V93, P14747, DOI 10.1073/pnas.93.25.14747; Groves T, 1997, J IMMUNOL, V158, P65; HASSNER A, 1993, J ALLERGY CLIN IMMUN, V92, P891, DOI 10.1016/0091-6749(93)90067-P; ICHIKAWA S, 1994, REGUL PEPTIDES, V54, P385, DOI 10.1016/0167-0115(94)90536-3; JOHNSTON JA, 1994, J IMMUNOL, V153, P1762; Kaltreider HB, 1997, AM J RESP CELL MOL, V16, P133, DOI 10.1165/ajrcmb.16.2.9032120; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; LITWIN DK, 1992, REGUL PEPTIDES, V40, P63, DOI 10.1016/0167-0115(92)90084-8; MCCONKEY DJ, 1990, J IMMUNOL, V145, P1227; MERRILL JE, 1995, FASEB J, V9, P611, DOI 10.1096/fasebj.9.8.7768352; Metwali A, 1996, J IMMUNOL, V157, P265; MOSIMANN BL, 1993, J ALLERGY CLIN IMMUN, V92, P95, DOI 10.1016/0091-6749(93)90043-F; OTTAWAY CA, 1991, GASTROENTEROL CLIN N, V20, P511; POIRIER G, 1994, IMMUNITY, V1, P385, DOI 10.1016/1074-7613(94)90069-8; SAID SI, 1994, CL ALLER IM, V4, P143; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; Shao H, 1997, J EXP MED, V185, P731, DOI 10.1084/jem.185.4.731; SMITH CH, 1993, J IMMUNOL, V151, P3274; STEAD RH, 1987, P NATL ACAD SCI USA, V84, P2975, DOI 10.1073/pnas.84.9.2975; SUN L, 1993, J NEUROIMMUNOL, V48, P59, DOI 10.1016/0165-5728(93)90059-8; VACCHIO MS, 1994, J EXP MED, V179, P1835, DOI 10.1084/jem.179.6.1835; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; Xia MH, 1996, J CLIN IMMUNOL, V16, P21, DOI 10.1007/BF01540969; Xia MH, 1996, J CELL BIOCHEM, V61, P452, DOI 10.1002/(SICI)1097-4644(19960601)61:3<452::AID-JCB12>3.3.CO;2-9; Xia MH, 1996, J IMMUNOL, V157, P1132; Xia MH, 1996, J IMMUNOL, V156, P160; YU YL, 1991, J CLIN LAB ANAL, V5, P262	35	32	32	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					119	127		10.1096/fasebj.12.1.119	http://dx.doi.org/10.1096/fasebj.12.1.119			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438417				2022-12-25	WOS:000071523800013
J	Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S				Cai, ZZ; Capoulade, C; MoyretLalle, C; AmorGueret, M; Feunteun, J; Larsen, AK; BressacdePaillerets, B; Chouaib, S			Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function	ONCOGENE			English	Article						cell death; p53; resistance; TNF	TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; FACTOR-ALPHA; C-MYC; ADRIAMYCIN-RESISTANT; SUPEROXIDE-DISMUTASE; FACTOR CYTOTOXICITY; HUMAN FIBROBLASTS; INDUCED APOPTOSIS; GENE-EXPRESSION	We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-alpha (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr, Use of single-strand conformation polymorphism (SSCP) analysis and DNA sequencing shows that MCF7 has a wild-type p53 gene, whereas both TNF-resistant sublines exhibit mutant p53, This includes a point mutation R280K in MCF7/R-A1 cells, and a point mutation at the splicing acceptor site on the upstream border of exon 5 resulting in a 21 pb deletion in MCF7/Adr cells, These mutations result in loss of p53 capacity to transactivate FASAY (functional assay in yeast), In contrast to what is observed for parental MCF7 cells, treatment of resistant sublines with TNF or gamma-irradiation fails neither to induce the expression of the p53-regulated gene products p21(waf1/CIP1) and MDM2, nor to arrest the cells in the G(1) phase of the cell cycle, Disruption of p53 wild-type function in MCF7 cells by transfection with human papillomavirus type-16 E6 gene, leads to abrogation of the cytotoxic, but not the cytostatic activity of TNF, Altogether, our results strongly suggest that wild-type p53 is involved in cytotoxic action of TNF, and point out that loss of p53 function contributes to resistance of tumor cell to TNF-induced killing.	INST GUSTAVE ROUSSY,INSERM,CJF 9411,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,UNITE MARQUEURS GENET CANC,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 147,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE; CTR LEON BERARD,INSERM,U453,F-69373 LYON,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard			Chouaib, Salem/F-7939-2016; Moyret-Lalle, Caroline/G-2742-2013; Feunteun, Jean/AAZ-1267-2020; Paillerets, Brigitte Bressac-de/D-8954-2018	Moyret-Lalle, Caroline/0000-0002-8359-2018; Paillerets, Brigitte Bressac-de/0000-0003-0245-8608; Feunteun, Jean/0000-0003-1212-9189				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1996, INT J CANCER, V68, P535, DOI 10.1002/(SICI)1097-0215(19961115)68:4<535::AID-IJC21>3.0.CO;2-2; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CAIGNARD A, 1997, IN PRESS ONCOLOGY RE, V4; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU SK, 1994, MOL CELL BIOL, V14, P2556; CHOUAIB S, 1992, B CANCER, V79, P935; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DARZYNKIEWICZ Z, 1984, CANCER RES, V44, P83; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FAN SJ, 1995, CANCER RES, V55, P1649; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Gallardo D, 1996, CANCER RES, V56, P4891; HARRISON DJ, 1995, J PATHOL, V175, P7, DOI 10.1002/path.1711750103; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KASTAN MB, 1991, CANCER RES, V51, P6304; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAZAR V, 1994, HUM MOL GENET, V3, P2257, DOI 10.1093/hmg/3.12.2257; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNOR PM, 1993, CANCER RES, V53, P4776; Ogretmen B, 1997, ONCOGENE, V14, P499, DOI 10.1038/sj.onc.1200855; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PAGLIACCI MC, 1993, LYMPHOKINE CYTOK RES, V12, P439; PUSZTAI L, 1993, BRIT J CANCER, V67, P290, DOI 10.1038/bjc.1993.55; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Shiohara M, 1996, J CELL PHYSIOL, V166, P568, DOI 10.1002/(SICI)1097-4652(199603)166:3<568::AID-JCP11>3.0.CO;2-3; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VANHAESEBROECK B, 1992, J IMMUNOL, V148, P2785; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WU H, 1993, GENE DEV, V7, P1126; Yang B, 1996, CLIN CANCER RES, V2, P1649; YIN D, 1995, NEUROSURGERY, V27, P762; ZYAD A, 1994, CANCER RES, V54, P825	63	82	83	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2817	2826		10.1038/sj.onc.1201445	http://dx.doi.org/10.1038/sj.onc.1201445			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419972				2022-12-25	WOS:A1997YJ80300007
J	Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P				Porfiri, E; Rubinfeld, B; Albert, I; Hovanes, K; Waterman, M; Polakis, P			Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin	ONCOGENE			English	Article						beta-catenin; LEF1; wnt-1; cancer	TUMOR-SUPPRESSOR PROTEIN; TRANSCRIPTION FACTOR LEF-1; APC GENE-PRODUCT; ALPHA-ENHANCER; SIGNAL-TRANSDUCTION; ACTIVATION DOMAIN; XENOPUS EMBRYOS; CELL-ADHESION; E-CADHERIN; IN-VIVO	Signal transduction by beta-catenin involves its posttranslational stabilization and import to the nucleus where it interacts with transcription factors, Recent implications for beta-catenin signaling in cancer prompted us to examine colon cancer cell lines for the expression of LEF-1, a transcription factor that binds to beta-catenin, The analysis of several cell lines revealed the expression of LEF1 mRNA and a constitutive association of the LEF-1 protein with beta-catenin, In contrast to the colon cells, PC12 and 293 cells did not contain a beta-catenin-LEF-1 complex, even though both proteins were detected in cell lysates, In these cells, the association of endogenous LEF1 and beta-catenin was induced by stimulation with the wnt-1 proto-oncogene. The complex formed following transient stimulation with wnt-1 and also persisted in cells stably expressing wnt-1. Ectopic overexpression of beta-catenin in 293 cells also induced the assembly of the beta-catenin-LEF-1 complex and activated gene transcription from a LEF-1-dependent promotor, Expression of mutant oncogenic forms of beta-catenin identified in cancer cells resulted in higher levels of transcriptional activity, The results suggest that a cancer pathway driven by wnt-1, or mutant forms of beta-catenin, may involve the formation of a persistent transcriptionally active complex of beta-catenin and LEF1.	ONYX PHARMACEUT,RICHMOND,CA 94806; UNIV CALIF IRVINE,DEPT MICROBIOL,IRVINE,CA 92697; UNIV CALIF IRVINE,DEPT MOL GENET,IRVINE,CA 92697	University of California System; University of California Irvine; University of California System; University of California Irvine				Rubinfeld, Bonnee/0000-0001-9861-6775				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Inomata M, 1996, CANCER RES, V56, P2213; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LOEB DM, 1993, J NEUROSCI, V13, P2919; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Pai LM, 1997, DEVELOPMENT, V124, P2255; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; Tao YS, 1996, J CELL BIOL, V134, P1271, DOI 10.1083/jcb.134.5.1271; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WATERMAN M L, 1990, New Biologist, V2, P621; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	37	129	131	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2833	2839		10.1038/sj.onc.1201462	http://dx.doi.org/10.1038/sj.onc.1201462			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419974				2022-12-25	WOS:A1997YJ80300009
J	Koschak, A; Bugianesi, RM; Mitterdorfer, J; Kaczorowski, GJ; Garcia, ML; Knaus, HG				Koschak, A; Bugianesi, RM; Mitterdorfer, J; Kaczorowski, GJ; Garcia, ML; Knaus, HG			Subunit composition of brain voltage-gated potassium channels determined by hongotoxin-1, a novel peptide derived from Centruroides limbatus venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROMULTIMERIC K+ CHANNELS; HIGH-CONDUCTANCE; SMOOTH-MUSCLE; RAT-BRAIN; PURIFICATION; LOCALIZATION; INHIBITORS; TERMINALS; BINDING	Five novel peptidyl inhibitors of Shaker type (K(v)1) K+ channels have been purified to homogeneity from venom of the scorpion Centruroides limbatus, The complete primary amino acid sequence of the major component, hongotoxin-1 (HgTX1), has been determined and confirmed after expression of the peptide in Escherichia coli, HgTX1 inhibits I-125-margatoxin binding to rat brain membranes as well as depolarization-induced Rb-86(+) flux through homotetrameric K(v)1.1, K(v)1.2, and K(v)1.3 channels stably transfected in HEK-293 cells, but it displays much lower affinity for K(v)1.6 channels, A HgTX1, double mutant (HgTX1-A19Y/Y37F) was constructed to allow high specific activity iodination of the peptide, HgTX1-A19Y/Y37F and monoiodinated HgTX1-A19Y/Y37F are equally potent in inhibiting I-125-margatoxin binding to rat brain membranes as HgTX1 (IC50 values similar to 0.3 pM), I-125-HgTX1-A19Y/Y37F binds with subpicomolar affinities to membranes derived from HEK-293 cells expressing homotetrameric K(v)1.1, K(v)1.2, and K(v)1.3 channels and to rat brain membranes (K-d values 0.1-0.25 phl, respectively) but with lower affinity to K(v)1.6 channels (K-d 9.6 PM), and it does not interact with either K(v)1.4 or K(v)1.5 channels, Several subpopulations of native K(v)1 subunit oligomers that contribute to the rat brain HgTX1 receptor have been deduced by immunoprecipitation experiments using antibodies specific for K(v)1 subunits, HgTX1, represents a novel and useful tool with which to investigate subclasses of voltage-gated K+ channels and K(v)1 subunit assembly in different tissues.	Univ Innsbruck, Inst Biochem Pharmacol, A-6020 Innsbruck, Austria; Merck Res Labs, Dept Membrane Biochem & Biophys, Rahway, NJ 07065 USA	University of Innsbruck; Merck & Company	Knaus, HG (corresponding author), Univ Innsbruck, Inst Biochem Pharmacol, Peter Mayr Str 1, A-6020 Innsbruck, Austria.	hans.g.knaus@uibk.ac.at						Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARBONE E, 1982, NATURE, V296, P90, DOI 10.1038/296090a0; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIACALVO M, 1993, J BIOL CHEM, V268, P18866; GARCIACALVO M, 1994, J BIOL CHEM, V269, P676; Helms LMH, 1997, BIOCHEMISTRY-US, V36, P3737, DOI 10.1021/bi962351p; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KNAUS HG, 1995, BIOCHEMISTRY-US, V34, P13627, DOI 10.1021/bi00041a043; Knaus HG, 1996, J NEUROSCI, V16, P955; KNAUS HG, 1994, J BIOL CHEM, V269, P3921; KNAUS HG, 1994, BIOCHEMISTRY-US, V33, P5819, DOI 10.1021/bi00185a021; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Koschak A, 1997, BIOCHEMISTRY-US, V36, P1943, DOI 10.1021/bi962074m; KOSCHAK A, 1997, BIOPHYS J, V71, pA32; RUSSELL SN, 1994, AM J PHYSIOL-CELL PH, V267, pC1729, DOI 10.1152/ajpcell.1994.267.6.C1729; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; SHENG M, 1993, NATURE, V365, P72, DOI 10.1038/365072a0; VAZQUEZ J, 1990, J BIOL CHEM, V265, P15564; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588	23	103	119	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2639	2644		10.1074/jbc.273.5.2639	http://dx.doi.org/10.1074/jbc.273.5.2639			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446567	hybrid			2022-12-25	WOS:000071736600022
J	Mazzucato, M; De Marco, L; Masotti, A; Pradella, P; Bahou, WF; Ruggeri, ZM				Mazzucato, M; De Marco, L; Masotti, A; Pradella, P; Bahou, WF; Ruggeri, ZM			Characterization of the initial alpha-thrombin interaction with glycoprotein Ib alpha in relation to platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; ACUTE CORONARY SYNDROMES; IX COMPLEX; SURFACE GLYCOPROTEINS; MOLECULAR-CLONING; PLASMA-MEMBRANE; ARTERY DISEASE; RECEPTOR; PROTEIN; DOMAIN	We have evaluated the properties of alpha-thrombin interaction with platelets within 1 min from exposure to the agonist, a time frame during which most induced activation responses are initiated and completed. Binding at 37 degrees C was rapidly reversible and completely blocked by a monoclonal antibody, LJ-Ib10, previously shown to be directed against the alpha-thrombin interaction site on glycoprotein (GP) Ib alpha. By 2-5 min, however, binding was no longer fully reversible and was only partially inhibited by: the anti-GP Ib alpha antibody. Results were similar at room temperature (22-25 degrees C), whereas the initial characteristics of alpha-thrombin interaction with platelets were preserved for at least 20 min at 4 degrees C. Equilibrium binding isotherms obtained at the latter temperature were compatible with a two-site model, but the component ascribed to GP IB alpha, completely inhibited by LJ-Ib10, had "moderate" affinity (k(d) on the order of 10(-8) M) and relatively high capacity, rather than "high" affinity (k(d) on the order of 10(-10) M) and low capacity as currently thought, The parameters of alpha-thrombin binding to intact GP Ib alpha on platelets at 4 degrees C corresponded closely to those measured with isolated GP Ib alpha fragments regardless of temperature. Blocking the alpha-thrombin-GP Ib alpha interaction caused partial inhibition of ATP release and prevented the association with platelets of measurable proteolytic activity. These results support the concept that GP Ib alpha contributes to the thrombogenic potential of alpha-thrombin.	Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, I-33081 Aviano, PN, Italy; SUNY Stony Brook, Dept Med, Stony Brook, NY 11794 USA; Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA	IRCCS Aviano (CRO); State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Scripps Research Institute; Scripps Research Institute	Ruggeri, ZM (corresponding author), Ctr Riferimento Oncol, Serv Immunotrasfus & Anal Clin, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	ruggeri@scripps.edu	Mazzucato, Mario/ABF-5472-2020	Mazzucato, Mario/0000-0001-8319-053X	NHLBI NIH HHS [HL-42846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042846, R37HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAHOU WF, 1993, J CLIN INVEST, V91, P1405, DOI 10.1172/JCI116344; BIENZ D, 1986, BLOOD, V68, P720; BLOMBACK M, 1974, THROMB RES, V5, P621, DOI 10.1016/0049-3848(74)90052-8; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; CARTY DJ, 1986, BLOOD, V67, P1738; CHESEBRO JH, 1992, NEW ENGL J MED, V327, P192, DOI 10.1056/NEJM199207163270310; COLLER BS, 1983, BLOOD, V61, P99; Connolly AJ, 1996, NATURE, V381, P516, DOI 10.1038/381516a0; DAVIDSON JF, 1988, J CLIN PATHOL, V41, P1322; DEMARCO L, 1990, J CLIN INVEST, V86, P25, DOI 10.1172/JCI114692; DEMARCO L, 1991, J BIOL CHEM, V266, P23776; DEMARCO L, 1994, J BIOL CHEM, V269, P6478; Dong JF, 1997, BLOOD, V89, P4355, DOI 10.1182/blood.V89.12.4355; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; GEAR ARL, 1982, BLOOD, V60, P1231; GEAR ARL, 1982, J LAB CLIN MED, V100, P866; GEORGE JN, 1986, J CLIN INVEST, V78, P340, DOI 10.1172/JCI112582; GEORGE JN, 1988, BLOOD, V71, P1253; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; GRONKE RS, 1987, J BIOL CHEM, V262, P3030; HANDA M, 1986, J BIOL CHEM, V261, P2579; HARMON JT, 1986, J BIOL CHEM, V261, P3224; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; Ishihara H, 1997, NATURE, V386, P502, DOI 10.1038/386502a0; KERMODE JC, 1989, BIOCHEM PHARMACOL, V38, P2053, DOI 10.1016/0006-2952(89)90057-9; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LEONG L, 1992, BIOCHEMISTRY-US, V31, P2567, DOI 10.1021/bi00124a017; Liu LB, 1997, J BIOL CHEM, V272, P1997, DOI 10.1074/jbc.272.3.1997; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; MARTIN BM, 1976, BIOCHEMISTRY-US, V15, P4886, DOI 10.1021/bi00667a021; MICHELSON AD, 1994, BLOOD, V83, P3562; MICHELSON AD, 1991, BLOOD, V77, P770; MICHELSON AD, 1987, BLOOD, V70, P1673; MOSHER DF, 1979, BLOOD, V53, P437; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P542; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OKUMURA T, 1978, J BIOL CHEM, V253, P3435; PHILLIPS DR, 1977, BIOCHEM BIOPH RES CO, V75, P940, DOI 10.1016/0006-291X(77)91473-5; RINDERKNECHT H, 1962, NATURE, V193, P167, DOI 10.1038/193167b0; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; TOLLEFSEN DM, 1974, J BIOL CHEM, V249, P2646; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WHITE GC, 1997, THROMB RES, V38, P641	54	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1880	1887		10.1074/jbc.273.4.1880	http://dx.doi.org/10.1074/jbc.273.4.1880			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442020	hybrid			2022-12-25	WOS:000071595200009
J	Osterwalder, T; Cinelli, P; Baici, A; Pennella, A; Krueger, SR; Schrimpf, SP; Meins, M; Sonderegger, P				Osterwalder, T; Cinelli, P; Baici, A; Pennella, A; Krueger, SR; Schrimpf, SP; Meins, M; Sonderegger, P			The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE-PROMOTING FACTOR; LONG-TERM POTENTIATION; SERPIN-LIKE PROTEIN; POLYACRYLAMIDE GELS; NERVOUS-SYSTEM; SYNAPSE ELIMINATION; DETECTING PROTEINS; NEURONAL CELLS; MESSENGER-RNA; SCHWANN-CELLS	Neuroserpin is an axonally secreted serine proteinase inhibitor that is expressed in neurons during embryogenesis and in the adult nervous system. To identify target proteinases, we used a eucaryotic expression system based on the mouse myeloma cell line J558L and vectors including a promoter from an Ig-kappa-variable region, an Ig-kappa enhancer, and the exon encoding the Ig-kappa constant region (C kappa) and produced recombinant neuroserpin as a wild-type protein or as a fusion protein with C kappa. We investigated the capability of recombinant neuroserpin to form SDS-stable complexes with, and to reduce the amidolytic activity of, a variety of serine proteinases in vitro. Consistent with its primary structure at the reactive site, neuroserpin exhibited inhibitory activity against trypsin-like proteinases. Although neuroserpin bound and inactivated plasminogen activators and plasmin, no interaction was observed with thrombin. A reactive site mutant of neuroserpin neither formed complexes with nor inhibited the amidolytic activity of any of the tested proteinases. Kinetic analysis of the inhibitory activity revealed neuroserpin to be a slow binding inhibitor of plasminogen activators and plasmin. Thus, we postulate that neuroserpin could represent a regulatory element of extracellular proteolytic events in the nervous system mediated by plasminogen activators or plasmin.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	University of Zurich; University of Zurich; University Zurich Hospital; Friedrich Miescher Institute for Biomedical Research	Sonderegger, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	pson@bioc.unizh.ch		Baici, Antonio/0000-0002-2980-0541; Cinelli, Paolo/0000-0002-0163-9055; Krueger, Stefan/0000-0001-8739-7052				AKIYAMA H, 1993, NEUROSCI LETT, V164, P233, DOI 10.1016/0304-3940(93)90899-V; BAIRD JL, 1995, J NEUROSCI, V15, P6605; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COOPERMAN BS, 1993, J BIOL CHEM, V268, P23616; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; DIHANICH M, 1991, NEURON, V6, P575, DOI 10.1016/0896-6273(91)90060-D; EATON DL, 1984, J BIOL CHEM, V259, P6241; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; Frey U, 1996, J NEUROSCI, V16, P2057; FRIEDMAN GC, 1995, J COMP NEUROL, V360, P658; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GLOOR S, 1986, CELL, V47, P687; Gschwend TP, 1997, MOL CELL NEUROSCI, V9, P207, DOI 10.1006/mcne.1997.0616; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GURWITZ D, 1988, P NATL ACAD SCI USA, V85, P3440, DOI 10.1073/pnas.85.10.3440; GUZDEK A, 1990, FEBS LETT, V272, P125, DOI 10.1016/0014-5793(90)80464-T; HANTAI D, 1989, P NATL ACAD SCI USA, V86, P362, DOI 10.1073/pnas.86.1.362; HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; ICHINOSE A, 1984, FEBS LETT, V175, P412, DOI 10.1016/0014-5793(84)80779-6; KALDERON N, 1979, P NATL ACAD SCI USA, V76, P5992, DOI 10.1073/pnas.76.11.5992; Krebber A, 1997, J IMMUNOL METHODS, V201, P35, DOI 10.1016/S0022-1759(96)00208-6; KRYSTOSEK A, 1984, J CELL BIOL, V98, P773, DOI 10.1083/jcb.98.2.773; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LIU Y, 1994, P NATL ACAD SCI USA, V91, P10300, DOI 10.1073/pnas.91.22.10300; LONGAS MO, 1980, BIOCHEM J, V189, P481, DOI 10.1042/bj1890481; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; MCGUIRE PG, 1990, NEURON, V4, P633, DOI 10.1016/0896-6273(90)90121-U; Monard D, 1993, Perspect Dev Neurobiol, V1, P165; MOONEN G, 1982, NATURE, V298, P753, DOI 10.1038/298753a0; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Nakaya N, 1996, MOL BRAIN RES, V42, P293, DOI 10.1016/S0169-328X(96)00133-7; NISHIBORI M, 1995, NEUROSCI LETT, V200, P125, DOI 10.1016/0304-3940(95)12095-L; Nishibori M, 1995, NEUROSCI RES, V24, P47, DOI 10.1016/0168-0102(95)00973-6; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OI VT, 1983, P NATL ACAD SCI-BIOL, V80, P825, DOI 10.1073/pnas.80.3.825; OMalley KM, 1997, J BIOL CHEM, V272, P5354, DOI 10.1074/jbc.272.8.5354; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; POHL G, 1984, BIOCHEMISTRY-US, V23, P3701, DOI 10.1021/bi00311a020; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; RADER C, 1993, EUR J BIOCHEM, V215, P133, DOI 10.1111/j.1432-1033.1993.tb18015.x; RAO JS, 1993, J NEUROSCI RES, V34, P340, DOI 10.1002/jnr.490340311; RUEGG MA, 1989, EMBO J, V8, P55, DOI 10.1002/j.1460-2075.1989.tb03348.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHAFFNER W, 1980, P NATL ACAD SCI-BIOL, V77, P2163, DOI 10.1073/pnas.77.4.2163; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; SEEDS NW, 1996, NEUROSCIENCE, V22; SHERMAN PM, 1992, J BIOL CHEM, V267, P7588; SONDEREGGER P, 1985, EMBO J, V4, P1395, DOI 10.1002/j.1460-2075.1985.tb03792.x; STOECKLI ET, 1989, EUR J BIOCHEM, V180, P249, DOI 10.1111/j.1432-1033.1989.tb14640.x; STONE SR, 1995, BIOCHEMISTRY-US, V34, P5164, DOI 10.1021/bi00015a030; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUNECKER A, 1991, EMBO J, V10, P3655, DOI 10.1002/j.1460-2075.1991.tb04932.x; TRAUNECKER A, 1991, TRENDS BIOTECHNOL, V9, P109, DOI 10.1016/0167-7799(91)90038-J; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1997, J NEUROSCI, V17, P543; vanMeijer M, 1996, J BIOL CHEM, V271, P7423, DOI 10.1074/jbc.271.13.7423; WALLEN P, 1983, EUR J BIOCHEM, V132, P681, DOI 10.1111/j.1432-1033.1983.tb07418.x; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Zoubine MN, 1996, DEV BIOL, V179, P447, DOI 10.1006/dbio.1996.0274	74	111	120	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2312	2321		10.1074/jbc.273.4.2312	http://dx.doi.org/10.1074/jbc.273.4.2312			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442076	hybrid, Green Accepted			2022-12-25	WOS:000071595200065
J	Imai, T; Chantry, D; Raport, CJ; Wood, CL; Nishimura, M; Godiska, R; Yoshie, O; Gray, PW				Imai, T; Chantry, D; Raport, CJ; Wood, CL; Nishimura, M; Godiska, R; Yoshie, O; Gray, PW			Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EOTAXIN RECEPTOR; EXPRESSION; RANTES; GENE; CELLS	Macrophage-derived chemokine (MDC) is a recently identified member of the CC chemokine family. MDC is not closely related to other chemokines, sharing most similarity with thymus- and activation-regulated chemokine (TARC), which contains 37% identical amino acids. Both chemokines are highly expressed in the thymus, with little expression seen in other tissues, in addition, the genes for MDC and TARC are encoded by human chromosome 16. To explore this relationship in greater detail, we have more precisely localized the MDC gene to chromosome 16q13, the same position reported for the TARC gene, We have also examined the interaction of MDC with CC chemokine receptor 4 (CCR4), recently shown to be a receptor for TARC. Using a fusion protein of MDC with secreted alkaline phosphatase, we observed high affinity binding of MDC-secreted alkaline phosphatase to CCR4-transfected L1.2 cells (K-d = 0.18 nM). MDC and TARC competed for binding to CCR4, while no binding competition was observed for six other chemokines (MCP-1, MCP-3, MCP-4, RANTES (regulated on activation normal T cell expressed and secreted), macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta). MDC was tested for calcium mobilization in L1.2 cells tranfected with seven different CC chemokine receptors. MDC induced a calcium flux in CCR4-transfected cells, but other receptors did not respond to MDC. TARC, which also induced calcium mobilization in CCR4 transfectants, was unable to desensitize the response to MDC. In contrast, MDC fully desensitized a subsequent response to TARC. Both MDC and TARC functioned as chemoattractants for CCR4 transfectants, confirming that MDC is also a functional ligand for CCR4, Since MDC and TARC are both expressed in the thymus, one role for these chemokines may be to attract CCR4-bearing thymocytes in the process of T cell education and differentiation.	Shionogi Inst Med Sci, Osaka 566, Japan; ICOS Corp, Bothell, WA 98021 USA	Shionogi & Company Limited; Icos Corporation	Gray, PW (corresponding author), Shionogi Inst Med Sci, 2-5-1 Mishima, Osaka 566, Japan.		Godiska, Ronald/V-7489-2017	Godiska, Ronald/0000-0003-0101-6365; Yoshie, Osamu/0000-0003-4353-5809				Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Chang MS, 1997, J BIOL CHEM, V272, P25229, DOI 10.1074/jbc.272.40.25229; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595; Hieshima K, 1997, J IMMUNOL, V159, P1140; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; Napolitano M, 1996, J IMMUNOL, V157, P2759; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Nomiyama H, 1997, GENOMICS, V40, P211, DOI 10.1006/geno.1996.4552; Pal R, 1997, SCIENCE, V278, P695, DOI 10.1126/science.278.5338.695; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Sambrook J., 2002, MOL CLONING LAB MANU; Samson M, 1996, EUR J IMMUNOL, V26, P3021, DOI 10.1002/eji.1830261230; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; VONBOEHMER H, 1997, CURR BIOL, V7, P308; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; YOSHIDA T, 1995, FEBS LETT, V360, P155, DOI 10.1016/0014-5793(95)00093-O	33	305	327	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1764	1768		10.1074/jbc.273.3.1764	http://dx.doi.org/10.1074/jbc.273.3.1764			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430724	hybrid			2022-12-25	WOS:000071411500071
J	Weaver, CD; Gundersen, V; Verdoorn, TA				Weaver, CD; Gundersen, V; Verdoorn, TA			A high affinity glutamate/aspartate transport system in pancreatic islets of Langerhans modulates glucose-stimulated insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS D-ASPARTATE; RAT-BRAIN; GLUTAMATE TRANSPORTER; GLUCAGON-SECRETION; AMPA SUBTYPE; RECEPTOR; IMMUNOCYTOCHEMISTRY; CYSTINE; CELLS; FIBROBLASTS	To examine the role of glutamatergic signaling in the function of pancreatic islets, we have characterized a high affinity glutamate/aspartate uptake system in this tissue, The islet [H-3]glutamate uptake activity was Na+ dependent, and it was blocked by L-trans-pyrrolidine-2,4-dicarboxylic acid, a blocker of neuronal and glial glutamate transporters, Islet glutamate transport activity exhibited a V-max of 8.48 +/- 1.47 fmol/min/islet (n = 4), which corresponds to 102.2 +/- 17.7 pmol/min/mg islet protein, The apparent K-m of islet glutamate transport activity depended on the glucose concentration used in the assay, In the presence of glucose concentrations that do not stimulate insulin secretion (2.8 mM), the apparent K-m was 34.7 +/- 7.8 mu M (n = 3), However, in high glucose (16.7 mM) the apparent K-m increased to 112.7 +/- 16.5 mu M (n = 3) with little or no change in V-max. Like most known plasma membrane glutamate transporters, islet glutamate transporters also transported D-aspartate, Anti-D-aspartate immunoreactivity showed that the islet glutamate/aspartate transport activity was localized to the non-beta cell islet mantle, In perifusion experiments with isolated islets in the absence of exogenous amino acids, L-trans-pyrrolidine-2,4-dicarboxylic acid in the presence of 8.3 mM glucose potentiated insulin secretion 23.3 +/- 2.3% (n = 3) compared with 8.3 mM glucose alone. This effect was abolished in the presence of the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, 6-cyano-7-nitroquinoxaline-2,3-dione. Furthermore, 6-cyano-7-nitroquinoxaline-2,3-dione alone inhibited glucose-stimulated insulin secretion in isolated islets by 15.9 +/- 5.9% (n = 3). Taken together these data suggest that a high affinity glutamate transport system exists in pancreatic islets and that this system contributes to a glutamatergic signaling pathway that can modulate glucose-inducible insulin secretion.	Bristol Myers Squibb Co, CNS Drug Discovery, Wallingford, CT 06492 USA; Univ Oslo, Inst Anat, N-0317 Oslo, Norway	Bristol-Myers Squibb; University of Oslo	Weaver, CD (corresponding author), Bristol Myers Squibb Co, CNS Drug Discovery, 5 Res Pkwy, Wallingford, CT 06492 USA.				NIDDK NIH HHS [P60-DK20593, R01DK51556] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BANNAI S, 1980, J BIOL CHEM, V255, P2372; BANNAI S, 1986, J BIOL CHEM, V261, P2256; BERTRAND G, 1993, EUR J PHARMACOL, V237, P45, DOI 10.1016/0014-2999(93)90091-U; BERTRAND G, 1992, BRIT J PHARMACOL, V106, P354, DOI 10.1111/j.1476-5381.1992.tb14340.x; BERTRAND G, 1995, AM J PHYSIOL-ENDOC M, V269, pE551, DOI 10.1152/ajpendo.1995.269.3.E551; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; BRUNSTEDT J, 1980, DIABETES METAB, V6, P87; DAVIES LP, 1976, J NEUROCHEM, V26, P1007, DOI 10.1111/j.1471-4159.1976.tb06485.x; GERBER JC, 1980, BRAIN RES BULL, V5, P341, DOI 10.1016/0361-9230(80)90055-6; GUNDERSEN V, 1993, NEUROSCIENCE, V57, P97, DOI 10.1016/0306-4522(93)90114-U; GUNDERSEN V, 1995, J NEUROSCI, V15, P4417; HEGRE OD, 1983, IN VITRO CELL DEV B, V19, P611; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANEKO T, 1987, J NEUROSCI, V7, P302; KLOCKNER U, 1994, J NEUROSCI, V14, P5759; MANFRAS BJ, 1994, BBA-BIOMEMBRANES, V1195, P185, DOI 10.1016/0005-2736(94)90026-4; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nicholson B, 1996, J BIOL CHEM, V271, P12159, DOI 10.1074/jbc.271.21.12159; Price CJ, 1996, MOL PHARMACOL, V50, P1665; Robinson M B, 1997, Adv Pharmacol, V37, P69; ROBINSON MB, 1991, BRAIN RES, V544, P196, DOI 10.1016/0006-8993(91)90054-Y; RORSMAN P, 1989, NATURE, V341, P233, DOI 10.1038/341233a0; RORSMAN P, 1991, BIOCHEM PHARMACOL, V41, P1783, DOI 10.1016/0006-2952(91)90116-M; SEHLIN J, 1972, HORMONES, V3, P156, DOI 10.1159/000178265; STORMMATHISEN J, 1983, NATURE, V301, P517, DOI 10.1038/301517a0; STORMMATHISEN J, 1990, J HISTOCHEM CYTOCHEM, V38, P1733, DOI 10.1177/38.12.1979340; TRIMBLE ER, 1981, AM J PHYSIOL, V240, pE422, DOI 10.1152/ajpendo.1981.240.4.E422; TRIMBLE ER, 1982, J CLIN INVEST, V69, P405, DOI 10.1172/JCI110464; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977	32	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1647	1653		10.1074/jbc.273.3.1647	http://dx.doi.org/10.1074/jbc.273.3.1647			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430708	hybrid			2022-12-25	WOS:000071411500055
J	Rossi, V; Bally, I; Thielens, NM; Esser, AF; Arlaud, GJ				Rossi, V; Bally, I; Thielens, NM; Esser, AF; Arlaud, GJ			Baculovirus-mediated expression of truncated modular fragments from the catalytic region of human complement serine protease C1s - Evidence for the involvement of both complement control protein modules in the recognition of the C4 protein substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1ST COMPONENT; MONOCLONAL-ANTIBODIES; PROTEOLYTIC CLEAVAGE; INSECT CELLS; ACTIVATION; PURIFICATION; SEQUENCE; C1BARS; CHAIN; SITE	C1s is the modular serine protease responsible for cleavage of C4 and C2, the protein substrates of the first component of complement, Its catalytic region (gamma-B) comprises two complement control protein (CCP) modules, a short activation peptide (ap), and a serine protease domain (SP), A baculovirus-mediated expression system was used to produce recombinant truncated fragments from this region, deleted either from the first CCP module (CCP2-ap-SP) or from both CCP modules (ap-SP), The aglycosylated fragment CCP2-ap-SPag was also expressed by using tunicamycin, The fragments were produced at yields of 0.6-3 mg/liter of culture, isolated, and characterized chemically and then tested functionally by comparison with intact C1s and its proteolytic gamma-B fragment, All recombinant fragments were expressed in a proenzyme form and cleaved by C (1) over bar r to generate active enzymes expressing esterolytic activity and reactivity toward C1 inhibitor comparable to those of intact C (1) over bar s. Likewise, the activated fragments gamma-B, CCP2-ap-SP, and ap-SP retained C (1) over bar s ability to cleave C2 in the fluid phase, In contrast, whereas fragment gamma-B cleaved C4 as efficiently as C (1) over bar s, the C4-cleaving activity of CCP2-ap-SP was greatly reduced (about 70-fold) and that of ap-SP was abolished, It is concluded that C4 cleavage involves substrate recognition sites located in both CCP modules of C (1) over bar s, whereas C2 cleavage is affected mainly by the serine protease domain, Evidence is also provided that the carbohydrate moiety linked to the second CCP module of C (1) over bar s has no significant effect on catalytic activity.	CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, F-38027 Grenoble 1, France; Univ Missouri, Sch Biol Sci, Kansas City, MO 64110 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Missouri System; University of Missouri Kansas City	Arlaud, GJ (corresponding author), CEA, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, 41 Ave Martyrs, F-38027 Grenoble 1, France.		Thielens, Nicole M/F-2512-2013; Rossi, Véronique/AAF-3412-2021	Thielens, Nicole M/0000-0002-7354-0302; Rossi, Véronique/0000-0002-6700-3578	NIAID NIH HHS [R01-AI 19478] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019478] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARLAUD GJ, 1993, METHOD ENZYMOL, V223, P61; ARLAUD GJ, 1987, IMMUNOL TODAY, V8, P106, DOI 10.1016/0167-5699(87)90860-7; ARLAUD GJ, 1980, BIOCHIM BIOPHYS ACTA, V616, P116, DOI 10.1016/0005-2744(80)90269-7; ARLAUD GJ, 1979, MOL IMMUNOL, V16, P445, DOI 10.1016/0161-5890(79)90069-5; BORK P, 1995, TRENDS BIOCH SCI S, V20, pC3; BUDZKO DB, 1970, IMMUNOCHEMISTRY, V7, P227, DOI 10.1016/0019-2791(70)90158-8; CARTER PE, 1983, BIOCHEM J, V215, P565, DOI 10.1042/bj2150565; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DAVIS AE, 1993, METHOD ENZYMOL, V223, P97; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; GAL P, 1989, COMPLEMENT INFLAMMAT, V6, P433; He SP, 1997, FEBS LETT, V405, P42, DOI 10.1016/S0014-5793(96)01529-3; ISENMAN DE, 1982, BIOCHEMISTRY-US, V21, P1109, DOI 10.1021/bi00535a001; KERR MA, 1987, BIOCHEM J, V171, P99; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Lacroix M, 1997, BIOCHEMISTRY-US, V36, P6270, DOI 10.1021/bi962719i; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; LUO C, 1992, BIOCHEMISTRY-US, V31, P4254, DOI 10.1021/bi00132a015; MACKINNON CM, 1987, EUR J BIOCHEM, V169, P547, DOI 10.1111/j.1432-1033.1987.tb13644.x; MATSUMOTO M, 1989, J IMMUNOL, V142, P2743; MATSUMOTO M, 1986, J IMMUNOL, V137, P2907; MULLEREBERHARD HJ, 1988, ANNU REV IMMUNOL, V5, P21; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P221; PERONA JJ, 1995, PROTEIN SCI, V4, P337; PETILLOT Y, 1995, FEBS LETT, V358, P323, DOI 10.1016/0014-5793(94)01429-5; REBOUL A, 1977, FEBS LETT, V79, P45, DOI 10.1016/0014-5793(77)80347-5; REID KBM, 1986, IMMUNOL TODAY, V7, P230, DOI 10.1016/0167-5699(86)90110-6; ROSSI V, 1995, BIOCHEMISTRY-US, V34, P7311, DOI 10.1021/bi00022a004; SCHREIBER RD, 1974, J EXP MED, V140, P1324, DOI 10.1084/jem.140.5.1324; SCHUMAKER VN, 1987, ANNU REV IMMUNOL, V5, P21, DOI 10.1146/annurev.iy.05.040187.000321; SPYCHER SE, 1986, EUR J BIOCHEM, V156, P49, DOI 10.1111/j.1432-1033.1986.tb09546.x; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; THIELENS NM, 1990, BIOCHEMISTRY-US, V29, P3570, DOI 10.1021/bi00466a021; THIELENS NM, 1982, FEBS LETT, V141, P19, DOI 10.1016/0014-5793(82)80006-9; THIELENS NM, 1990, J BIOL CHEM, V265, P14469; TOSI M, 1987, BIOCHEMISTRY-US, V26, P8516, DOI 10.1021/bi00400a004; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; Xu YY, 1997, J IMMUNOL, V158, P5958; YEH JC, 1993, BIOCHEMISTRY-US, V32, P11087, DOI 10.1021/bi00092a019; ZACCAI G, 1990, FEBS LETT, V269, P19, DOI 10.1016/0014-5793(90)81108-Z	42	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1232	1239		10.1074/jbc.273.2.1232	http://dx.doi.org/10.1074/jbc.273.2.1232			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422791	hybrid			2022-12-25	WOS:000071411400080
J	Willwand, K; Mumtsidu, E; Kuntz-Simon, G; Rommelaere, J				Willwand, K; Mumtsidu, E; Kuntz-Simon, G; Rommelaere, J			Initiation of DNA replication at palindromic telomeres is mediated by a duplex-to-hairpin transition induced by the minute virus of mice nonstructural protein NS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALEUTIAN DISEASE VIRUS; FORM DNA; 3'-TERMINAL HAIRPIN; SECONDARY STRUCTURE; VIRAL ORIGIN; PARVOVIRUS; INVITRO; GENOME; SEQUENCE; GENE	The linear single-stranded DNA genome of the minute virus of mice (MVM) is replicated via a double-stranded replicative form (RF) intermediate, Amplification of this RF is initiated by the folding-back of palindromic sequences serving as primers for strand-displacement synthesis and formation of dimeric RF DNA. Using an in vitro replication assay and a cloned MVM DNA template, we observed hairpin-primed DNA replication at both MVM DNA termini, with a bias toward right-end initiation. Initiation of DNA replication is favored by nuclear components of A9 cell extract and highly stimulated by the MVM nonstructural protein NS1. Hairpin-primed DNA replication is also observed in the presence of NS1 and the Klenow fragment of the Escherichia coli DNA polymerase I. Addition of ATP gamma S (adenosine 5'-O-(thio-triphosphate)) blocks the initiation of DNA replication but not the extension of pre-existing hairpin primers formed in the presence of NS1 only, The NS1-mediated unwinding of the right-end palindrome may account for the recently reported capacity of NS1 for driving dimer RF synthesis in vitro.	Deutsch Krebsforschungszentrum, Abt 0610, Dept Appl Tumor Virol, D-69009 Heidelberg, Germany; Format INSERM, U375, D-69009 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Willwand, K (corresponding author), Deutsch Krebsforschungszentrum, Abt 0610, Dept Appl Tumor Virol, Postfach 101949, D-69009 Heidelberg, Germany.	k.willwand@dkfz-heidelberg.de	Simon, Gaelle/ABI-1479-2020	Simon, Gaelle/0000-0003-1099-5075				ANTONIETTI JP, 1988, J VIROL, V62, P552, DOI 10.1128/JVI.62.2.552-557.1988; ASTELL CR, 1986, J VIROL, V57, P565; AVIZONIS DZ, 1995, BIOPOLYMERS, V35, P187, DOI 10.1002/bip.360350207; Baldauf AQ, 1997, J VIROL, V71, P971, DOI 10.1128/JVI.71.2.971-980.1997; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; Berns KI, 1996, FIELDS VIROLOGY, P2173; BOURGUIGNON GJ, 1976, J VIROL, V20, P290, DOI 10.1128/JVI.20.1.290-306.1976; BUTLER DK, 1995, MOL CELL BIOL, V15, P7117; CAVALIER.T, 1974, NATURE, V250, P467, DOI 10.1038/250467a0; Christensen J, 1997, J VIROL, V71, P1405, DOI 10.1128/JVI.71.2.1405-1416.1997; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Cossons N, 1996, VIROLOGY, V216, P258, DOI 10.1006/viro.1996.0058; Cossons N, 1996, VIROLOGY, V224, P320, DOI 10.1006/viro.1996.0535; COTMORE SF, 1989, J VIROL, V63, P3902, DOI 10.1128/JVI.63.9.3902-3911.1989; COTMORE SF, 1989, J VIROL, V63, P1002, DOI 10.1128/JVI.63.2.1002-1006.1989; COTMORE SF, 1994, EMBO J, V13, P4145, DOI 10.1002/j.1460-2075.1994.tb06732.x; COTMORE SF, 1995, SEMIN VIROL, V6, P271, DOI 10.1006/smvy.1995.0033; COTMORE SF, 1995, J VIROL, V69, P1652, DOI 10.1128/JVI.69.3.1652-1660.1995; COTMORE SF, 1993, J VIROL, V67, P1579, DOI 10.1128/JVI.67.3.1579-1589.1993; COTMORE SF, 1987, ADV VIRUS RES, V33, P91, DOI 10.1016/S0065-3527(08)60317-6; COTMORE SF, 1986, J VIROL, V58, P724, DOI 10.1128/JVI.58.3.724-732.1986; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DELANGE AM, 1987, J VIROL, V61, P1957, DOI 10.1128/JVI.61.6.1957-1963.1987; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1996, DNA REPLICATION EUKA, P45; DEZAMAROCZY M, 1984, GENE, V32, P439, DOI 10.1016/0378-1119(84)90019-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; GESHELIN P, 1974, J MOL BIOL, V88, P785, DOI 10.1016/0022-2836(74)90399-4; HAUSWIRTH WW, 1979, VIROLOGY, V93, P57, DOI 10.1016/0042-6822(79)90275-7; HEARING J, 1992, J VIROL, V66, P694, DOI 10.1128/JVI.66.2.694-705.1992; HOFMANN JFX, 1991, CELL, V64, P951, DOI 10.1016/0092-8674(91)90319-T; JAEGER JA, 1989, P NATL ACAD SCI USA, V86, P7706, DOI 10.1073/pnas.86.20.7706; JAEGER JA, 1990, METHOD ENZYMOL, V183, P281; KARRER KM, 1976, J MOL BIOL, V104, P421, DOI 10.1016/0022-2836(76)90280-1; Kelly T J, 1988, Adv Virus Res, V34, P1, DOI 10.1016/S0065-3527(08)60514-X; KORNBERG A, 1992, DNA REPLICATION, P275; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHNER RL, 1983, J BIOL CHEM, V258, P1185; LILLEY DMJ, 1985, NUCLEIC ACIDS RES, V13, P1443, DOI 10.1093/nar/13.5.1443; LOCHELT M, 1989, J GEN VIROL, V70, P1105, DOI 10.1099/0022-1317-70-5-1105; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; Moss B, 1983, MECHANISM DNA REPLIC, P449; MOYER RW, 1981, CELL, V27, P391, DOI 10.1016/0092-8674(81)90422-0; MULLER DE, 1983, J GEN VIROL, V64, P1043, DOI 10.1099/0022-1317-64-5-1043; MULLER UR, 1982, NATURE, V298, P582, DOI 10.1038/298582a0; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NUESCH JPF, 1995, VIROLOGY, V209, P122, DOI 10.1006/viro.1995.1236; NUESCH JPF, 1993, VIROLOGY, V196, P637, DOI 10.1006/viro.1993.1520; PRITCHARD AE, 1981, P NATL ACAD SCI-BIOL, V78, P7341, DOI 10.1073/pnas.78.12.7341; Pujol A, 1997, J VIROL, V71, P7393, DOI 10.1128/JVI.71.10.7393-7403.1997; Rasmussen C, 1996, VIROLOGY, V224, P235, DOI 10.1006/viro.1996.0525; SALAS M, 1996, DNA REPLICATION EUKA, P131; SCHEFFLE.IE, 1968, J MOL BIOL, V36, P291, DOI 10.1016/0022-2836(68)90156-3; SIEGL G, 1985, INTERVIROLOGY, V23, P61, DOI 10.1159/000149587; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; SPIRO C, 1995, J BIOL CHEM, V270, P27702, DOI 10.1074/jbc.270.46.27702; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STOW ND, 1990, VIROLOGY, V177, P570, DOI 10.1016/0042-6822(90)90522-S; TATTERSALL P, 1976, NATURE, V263, P106, DOI 10.1038/263106a0; TATTERSALL P, 1973, J VIROL, V12, P1446, DOI 10.1128/JVI.12.6.1446-1456.1973; TULLIS GE, 1988, J VIROL, V62, P2736, DOI 10.1128/JVI.62.8.2736-2744.1988; WILLWAND K, 1991, J VIROL, V65, P4629, DOI 10.1128/JVI.65.9.4629-4635.1991; WILLWAND K, 1990, J VIROL, V64, P1598, DOI 10.1128/JVI.64.4.1598-1605.1990; Willwand K, 1997, J GEN VIROL, V78, P2647, DOI 10.1099/0022-1317-78-10-2647; WILLWAND K, 1993, J VIROL, V67, P5660, DOI 10.1128/JVI.67.9.5660-5663.1993; WILSON GM, 1991, VIROLOGY, V185, P90, DOI 10.1016/0042-6822(91)90757-3; WILSON VG, 1991, J VIROL, V65, P5314, DOI 10.1128/JVI.65.10.5314-5322.1991; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; XODO LE, 1988, J BIOMOL STRUCT DYN, V6, P139, DOI 10.1080/07391102.1988.10506487; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	73	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1165	1174		10.1074/jbc.273.2.1165	http://dx.doi.org/10.1074/jbc.273.2.1165			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422783	hybrid			2022-12-25	WOS:000071411400072
J	Hernandez, M; Burillo, SL; Crespo, MS; Nieto, ML				Hernandez, M; Burillo, SL; Crespo, MS; Nieto, ML			Secretory phospholipase A(2) activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A(2) in the human astrocytoma cell line 1321N1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; MUSCARINIC RECEPTOR ACTIVATION; LYSOPHOSPHATIDIC ACID; SIGNAL-TRANSDUCTION; SEPTIC SHOCK; PHOSPHOINOSITIDE HYDROLYSIS; II PHOSPHOLIPASE-A2; MEMBRANE-RECEPTOR; MOLECULAR-CLONING; THROMBIN RECEPTOR	The biological effects of type IIA 14-kDa phospholipase A(2) (sPLA(2)) on 1321N1 astrocytoma cells were studied. sPLA(2) induced a release of [H-3]arachidonic acid ([H-3]AA) similar to that elicited by lysophosphatidic acid (LPA), a messenger acting via a G-protein-coupled receptor and a product of sPLA(2) on lipid microvesicles. In contrast, no release of [1-C-14]oleate could be detected in cells labeled with this fatty acid. As these findings pointed to a selective mechanism of [H-3]AA release, it was hypothesized that sPLA(2) could act by a signaling mechanism involving the activation of cytosolic PLA, (cPLA(2)), i.e. the type of PLA(2) involved in the release of [H-3]AA elicited by agonists. In keeping with this view, stimulation of 1321N1 cells with sPLA(2) elicited the decrease in electrophoretic mobility that is characteristic of the phosphorylation of cPLA(2), as well as activation of p42 mitogen-activated protein (MAP) kinase, c-Jun kinase, and p38 MAP kinase. Incubation with sPLA(2), of quiescent 1321N1 cells elicited a mitogenic response as judged from an increased incorporation of [H-3]thymidine. Attempts to correlate the effect of extracellular PLA(2) with the generation of LPA were negative, Incubation with pertussis toxin prior to the addition of either sPLA(2) or LPA only showed abrogation of the response to LPA, thus suggesting the involvement of pertussis-sensitive G(i)-proteins in the case of LPA(2) Treatments with inhibitors of the catalytic effect of sPLA(2) such as p-bromophenacyl bromide and dithiothreitol did not prevent the effect on cPLA(2) activation. In contrast, preincubation of 1321N1 cells with the antagonist of the sPLA(2) receptor p-aminophenyl-alpha-D-mannopyranoside-bovine serum albumin, blocked cPLA(2) activation with a EC50 similar to that described for the inhibition of binding of sPLA(2) to its receptor. Moreover, treatment of 1321N1 cells with the MAP kinase kinase inhibitor PD-98059 inhibited the activation of both cPLA(2) and p42 MAP kinase produced by sPLA(2). In summary, these data indicate the existence in astrocytoma cells of a signaling pathway triggered by engagement of a sPLA(2)-binding structure, that produces the release of [H-3]AA by activating the MAP kinase cascade and cPLA(2), and leads to a mitogenic response after longer periods of incubation.	Univ Valladolid, CSIC, Fac Med, Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Crespo, MS (corresponding author), Univ Valladolid, CSIC, Fac Med, Inst Mol Biol & Genet, E-47005 Valladolid, Spain.		hernández, marita/H-6122-2015; Nieto, Maria L/G-7492-2015	hernández, marita/0000-0002-3999-5653; Nieto, Maria L/0000-0001-6842-799X				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; ARITA H, 1991, J BIOL CHEM, V266, P19139; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARTOLI F, 1994, J BIOL CHEM, V269, P15625; Bayon Y, 1997, BIOCHEM J, V323, P281, DOI 10.1042/bj3230281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chilton F, 1996, J CLIN INVEST, V97, P2161, DOI 10.1172/JCI118654; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; FONTEH AN, 1994, J IMMUNOL, V152, P5438; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; GIJON MA, 1995, BIOCHEM J, V306, P167, DOI 10.1042/bj3060167; Grass DS, 1996, J CLIN INVEST, V97, P2233, DOI 10.1172/JCI118664; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Hack CE, 1997, IMMUNOL TODAY, V18, P111, DOI 10.1016/S0167-5699(97)01002-5; Hernandez M, 1997, BIOCHEM J, V328, P263, DOI 10.1042/bj3280263; Jacques C, 1997, J CLIN INVEST, V99, P1864, DOI 10.1172/JCI119353; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Kolko M, 1996, J BIOL CHEM, V271, P32722, DOI 10.1074/jbc.271.51.32722; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; LAMBEAU G, 1994, J BIOL CHEM, V269, P1575; LAMORTE VJ, 1993, J BIOL CHEM, V268, P19411; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; LISTER MD, 1989, J BIOL CHEM, V264, P8520; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MAYER RJ, 1993, FASEB J, V7, P339, DOI 10.1096/fasebj.7.2.8440410; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; MURAKAMI M, 1993, J IMMUNOL, V151, P5675; NAIR X, 1993, INFLAMMATION, V17, P205, DOI 10.1007/BF00916106; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; Nicolas JP, 1997, J BIOL CHEM, V272, P7173, DOI 10.1074/jbc.272.11.7173; NIETO M, 1994, MOL PHARMACOL, V46, P406; OKA S, 1991, J BIOL CHEM, V266, P9956; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PERNAS P, 1991, BIOCHEM BIOPH RES CO, V178, P1298, DOI 10.1016/0006-291X(91)91035-B; Post GR, 1996, MOL BIOL CELL, V7, P1679, DOI 10.1091/mbc.7.11.1679; PRUZANSKI W, 1986, J INVEST DERMATOL, V86, P380, DOI 10.1111/1523-1747.ep12285639; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Serhan CN, 1996, FASEB J, V10, P1147, DOI 10.1096/fasebj.10.10.8751717; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SMITH DB, 1994, CURRENT PROTOCOLS MO; STEPHENSON DT, 1994, BRAIN RES, V637, P97, DOI 10.1016/0006-8993(94)91221-1; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TOHKIN M, 1993, J BIOL CHEM, V268, P2865; TOKOMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TREJO J, 1991, J BIOL CHEM, V266, P7876; VADAS P, 1984, J LAB CLIN MED, V104, P873; VADAS P, 1993, AM J TROP MED HYG, V49, P455, DOI 10.4269/ajtmh.1993.49.455; VADAS P, 1993, CRIT CARE MED, V21, P1087, DOI 10.1097/00003246-199307000-00027; VADAS P, 1981, NATURE, V293, P583, DOI 10.1038/293583a0; VOLWERK JJ, 1974, BIOCHEMISTRY-US, V13, P1446, DOI 10.1021/bi00704a020; WIJKANDER J, 1995, J BIOL CHEM, V270, P26543, DOI 10.1074/jbc.270.44.26543	67	141	144	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					606	612		10.1074/jbc.273.1.606	http://dx.doi.org/10.1074/jbc.273.1.606			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417122	Green Published, hybrid			2022-12-25	WOS:000071295600088
J	Wu, CY; Keightley, SY; Leung-Hagesteijn, C; Radeva, G; Coppolino, M; Goicoechea, S; McDonald, JA; Dedhar, S				Wu, CY; Keightley, SY; Leung-Hagesteijn, C; Radeva, G; Coppolino, M; Goicoechea, S; McDonald, JA; Dedhar, S			Integrin-induced protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVASION SUPPRESSOR GENE; HAIRY-CELL LEUKEMIA; GROWTH FACTOR-BETA; TUMOR INVASION; MONOCLONAL-ANTIBODY; RECEPTOR; ADHESION; ALPHA-5-BETA-1; DOMAIN; IDENTIFICATION	Fibronectin (Fn) matrix plays important roles in many biological processes including morphogenesis and tumorigenesis. Recent studies have demonstrated a critical role of integrin cytoplasmic domains in regulating Fn matrix assembly, implying that intracellular integrin-binding proteins may be involved in controlling extracellular Fn matrix assembly, We report here that overexpression of integrin linked kinase (ILK), a newly identified serine/threonine kinase that binds to the integrin beta(1) cytoplasmic domain, dramatically stimulated Fn matrix assembly in epithelial cells. The integrin-linked kinase activity is involved in transducing signals leading to the up-regulation of Fn matrix assembly, as overexpression of a kinase-inactive ILK mutant failed to enhance the matrix assembly, Moreover, the increase in Fn matrix assembly induced by ILK overexpression was accompanied by a substantial reduction in the cellular E-cadherin. Finally, we show that ILK-overexpressing epithelial cells readily formed tumors in nude mice, despite forming an extensive Fn matrix, These results identify ILK as an important regulator of pericellular Fn matrix assembly, and suggest a novel critical role of this integrin-linked kinase in cell growth, cell survival, and tumorigenesis.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Toronto, Sunnybrook Hlth Sci Ctr, Canc Biol Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Mayo Clin Scottsdale, Samuel C Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Mayo Clinic; Mayo Clinic Phoenix	Wu, CY (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	cwu@bmg.bhs.uab.edu		Goicoechea, Silvia/0000-0003-1107-389X; Dedhar, Shoukat/0000-0003-4355-1657				AGUIRRE KM, 1994, J BIOL CHEM, V269, P27863; AKIYAMA SK, 1990, BIOCHIM BIOPHYS ACTA, V1031, P91, DOI 10.1016/0304-4157(90)90004-V; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; BURTHEM J, 1994, BLOOD, V83, P497; BURTHEM J, 1994, LEUKEMIA LYMPHOMA, V14, P19; CHAMMAS R, 1991, TUMOR BIOL, V12, P309, DOI 10.1159/000217732; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DARRIBERE T, 1992, DEV DYNAM, V194, P63, DOI 10.1002/aja.1001940108; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; DEDHAR S, 1990, BIOESSAYS, V12, P583, DOI 10.1002/bies.950121205; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1990, FIBRONECTINS; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; IGNOTZ RA, 1987, J BIOL CHEM, V262, P6443; JULIANO RL, 1993, SEMIN CANCER BIOL, V4, P277; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; LIMPER AH, 1991, J BIOL CHEM, V266, P9697; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; MAREEL M, 1994, MOL BIOL REP, V19, P45, DOI 10.1007/BF00987321; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Mosher DF, 1989, FIBRONECTIN; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; RUOSLAHTI E, 1994, KIDNEY INT, V45, pS17; Ruoslahti E, 1996, TUMOR BIOL, V17, P117, DOI 10.1159/000217975; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; RUOSLAHTI E, 1994, INVAS METAST, V14, P87; SAGA S, 1988, CANCER RES, V48, P5510; Saulnier R, 1996, EXP CELL RES, V222, P360, DOI 10.1006/excr.1996.0045; SCHREINER C, 1991, CANCER RES, V51, P1738; SCHREINER CL, 1989, J CELL BIOL, V109, P3157, DOI 10.1083/jcb.109.6.3157; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARZBAUER JE, 1991, J CELL BIOL, V113, P1463, DOI 10.1083/jcb.113.6.1463; Sechler JL, 1996, J CELL BIOL, V134, P573, DOI 10.1083/jcb.134.2.573; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VUORI K, 1993, J BIOL CHEM, V268, P21459; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wu CY, 1996, CELL ADHES COMMUN, V4, P149, DOI 10.3109/15419069609014219; WU CY, 1995, J CELL SCI, V108, P821; WU CY, 1993, J BIOL CHEM, V268, P21883; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YANG JT, 1993, DEVELOPMENT, V119, P1093; YOSHIDANORO C, 1984, DEV BIOL, V101, P19, DOI 10.1016/0012-1606(84)90112-X; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235; ZUK A, 1994, DEV DYNAM, V201, P378, DOI 10.1002/aja.1002010409	75	246	265	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					528	536		10.1074/jbc.273.1.528	http://dx.doi.org/10.1074/jbc.273.1.528			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417112	hybrid			2022-12-25	WOS:000071295600078
J	Yuziuk, JA; Bertoni, C; Beccari, T; Orlacchio, A; Wu, YY; Li, SC; Li, YT				Yuziuk, JA; Bertoni, C; Beccari, T; Orlacchio, A; Wu, YY; Li, SC; Li, YT			Specificity of mouse G(M2) activator protein and beta-N-acetylhexosaminidases A and B - Similarities and differences with their human counterparts in the catabolism of G(M2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAY-SACHS-DISEASE; SEQUENCE-ANALYSIS; HEXOSAMINIDASE-A; GANGLIOSIDE GM2; SUBSTRATE; HYDROLYSIS; SUBUNIT; CLONING; HEXA; IDENTIFICATION	Tay Sachs disease, an inborn lysosomal disease featuring a buildup of G(M2) in the brain, is caused by a deficiency of beta-hexosaminidase A (Hex A) or G(M2) activator. Of the two human lysosomal Hex isozymes, only Hex A, not Hex B, cleaves G(M2) in the presence of G(M2) activator. In contrast, mouse Hex B has been reported to be more active than Hex A in cleaving G(M2) (Burg, J., Banerjee, A., Conzelmann, E., and Sandhoff, K. (1983) Hoppe Seyler's Z. Physiol. Chem. 364, 821-829), In two independent studies, mice with the targeted disruption of the Hexa gene did not display the severe buildup of brain G(M2) or the concomitant abnormal behavioral manifestations seen in human Tay-Sachs patients. The results of these two studies were suggested to be attributed to the reported G(M2) degrading activity of mouse Hex B. To clarify the specificity of mouse Hex A and Hex B and to better understand the observed results of the mouse model of Tay-Sachs disease, we have purified mouse liver Hex A and Hex B and also prepared the recombinant mouse G(M2) activator, Contrary to the findings of Burg et al., we found that the specificities of mouse Hex A and Hex B toward the catabolism of G(M2) were not different from the corresponding human Hex isozymes. Mouse Hex A, but not Hex B, hydrolyzes G(M2) in the presence of G(M2) activator, whereas G(M2) is refractory to mouse Hex B with or without G(M2) activator. Importantly, we found that, in contrast to human G(M2) activator, mouse G(M2) activator could effectively stimulate the hydrolysis of G(A2) by mouse Hex A and to a much lesser extent also by Hex B. These results provide clear evidence on the existence of an alternative pathway for G(M2) catabolism in mice by converting G(M2) to G(A2) and subsequently to lactosylceramide. They also provide the explanation for the lack of excessive G(M2) accumulation in the Hexa gene-disrupted mice.	Tulane Univ, Sch Med, Dept Biochem SL 43, New Orleans, LA 70112 USA; Univ Perugia, Dipartimento Biol Cellulare & Mol, I-06126 Perugia, Italy	Tulane University; University of Perugia	Li, YT (corresponding author), Tulane Univ, Sch Med, Dept Biochem SL 43, 1430 Tulane Ave, New Orleans, LA 70112 USA.		Bertoni, Carmen/N-8901-2015		NINDS NIH HHS [NS 09626] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009626] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAPAT B, 1988, FEBS LETT, V237, P191, DOI 10.1016/0014-5793(88)80199-6; BAYLERAN J, 1987, AM J HUM GENET, V41, P532; BECCARI T, 1992, BIOCHEM J, V285, P593, DOI 10.1042/bj2850593; BECCARI T, 1988, BIOCHEM J, V252, P617, DOI 10.1042/bj2520617; BELLACHIOMA G, 1993, BIOCHEM J, V294, P227, DOI 10.1042/bj2940227; BURG J, 1983, H-S Z PHYSIOL CHEM, V364, P821, DOI 10.1515/bchm2.1983.364.2.821; COHENTANNOUDJI M, 1995, MAMM GENOME, V6, P844, DOI 10.1007/BF00292433; DEGASPERI R, 1989, BIOCHEM J, V260, P777, DOI 10.1042/bj2600777; FUCHS W, 1983, CLIN CHIM ACTA, V133, P253, DOI 10.1016/0009-8981(83)90269-3; FURST W, 1992, BIOCHIM BIOPHYS ACTA, V1126, P1, DOI 10.1016/0005-2760(92)90210-M; GEIGER B, 1976, BIOCHEMISTRY-US, V15, P3484, DOI 10.1021/bi00661a014; GRAVEL RA, 1995, METABOLIC MOL BASES, P2839; HARRIS G, 1954, CHEM IND-LONDON, P249; HASILIK A, 1980, J BIOL CHEM, V255, P4937; INUI K, 1984, CLIN GENET, V26, P318; KISHIMOTO Y, 1992, J LIPID RES, V33, P1255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI SC, 1995, J BIOL CHEM, V270, P24246, DOI 10.1074/jbc.270.41.24246; LI SC, 1981, J BIOL CHEM, V256, P6234; LI YT, 1973, J BIOL CHEM, V248, P7512; LI YT, 1984, LYSOSOM BIOL PATHOL, P99; Liu YJ, 1997, P NATL ACAD SCI USA, V94, P8138, DOI 10.1073/pnas.94.15.8138; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ODOWD BF, 1988, BIOCHEMISTRY-US, V27, P5216, DOI 10.1021/bi00414a041; PANEUF F, 1996, HUM MOL GENET, V5, P1; Pennybacker M, 1996, J BIOL CHEM, V271, P17377, DOI 10.1074/jbc.271.29.17377; POTIER M, 1979, ANAL BIOCHEM, V94, P287, DOI 10.1016/0003-2697(79)90362-2; ROBINSON D, 1968, BIOCHEM J, V107, P321, DOI 10.1042/bj1070321; SANDHOFF K, 1971, H-S Z PHYSIOL CHEM, V352, P1119, DOI 10.1515/bchm2.1971.352.2.1119; SANGO K, 1995, NAT GENET, V11, P170, DOI 10.1038/ng1095-170; SVENNERHOLM L, 1973, J BIOL CHEM, V248, P740; SVENNERHOLM L, 1972, METHODS CARBOHYD CHE, V6, P464; WENGER DA, 1972, ARCH BIOCHEM BIOPHYS, V153, P116, DOI 10.1016/0003-9861(72)90427-4; WU YY, 1994, J BIOL CHEM, V269, P16276; YAMANAKA S, 1994, GENOMICS, V21, P588, DOI 10.1006/geno.1994.1318; YAMANAKA S, 1994, P NATL ACAD SCI USA, V91, P9975, DOI 10.1073/pnas.91.21.9975; Yuziuk JA, 1996, BIOCHEM J, V315, P1041, DOI 10.1042/bj3151041; ZHOU B, 1989, J BIOL CHEM, V264, P12272	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					66	72		10.1074/jbc.273.1.66	http://dx.doi.org/10.1074/jbc.273.1.66			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417048	hybrid			2022-12-25	WOS:000071295600014
J	Reuven, NB; Zhou, ZH; Deutscher, MP				Reuven, NB; Zhou, ZH; Deutscher, MP			Functional overlap of tRNA nucleotidyltransferase, poly(A) polymerase I, and polynucleotide phosphorylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; ESCHERICHIA-COLI K-12; MESSENGER-RNA; IDENTIFICATION; GENE	Repair of the 3'-terminal-CCA sequence of tRNA generally requires the action of the enzyme tRNA nucleotidyltransferase. However, in Escherichia coli in the absence of this enzyme, a decreased level of tRNA end repair continues. To ascertain the enzymes responsible for this residual repair, mutant strains were constructed lacking tRNA nucleotidyltransferase and other enzymes potentially involved in the process, poly(A) polymerase I and polynucleotide phosphorylase (PNPase). Strains lacking tRNA nucleotidyltransferase and either one of the other enzymes displayed decreased growth rates and increased levels of defective tRNA compared with the single cca mutant. Triple mutants lacking all three enzymes grew very slowly, had even more defective tRNA, and were devoid of activity incorporating AMP into tRNA-C-C. Overexpression of poly(A) polymerase I, but not PNPase, partially compensated for the absence of tRNA nucleotidyltransferase. These data show that poly(A) polymerase I and PNPase participate in the end repair process and are required to maintain functional tRNA levels when tRNA nucleotidyltransferase is absent.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06030 USA	University of Miami; University of Connecticut	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.		Reuven, Nina/AAM-8711-2020	Reuven, Nina/0000-0003-1569-3818	NIGMS NIH HHS [GM16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER S, 1965, J MOL BIOL, V13, P629, DOI 10.1016/S0022-2836(65)80131-0; Cao GJ, 1996, P NATL ACAD SCI USA, V93, P11580, DOI 10.1073/pnas.93.21.11580; Coburn GA, 1996, J BIOL CHEM, V271, P15776, DOI 10.1074/jbc.271.26.15776; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CUDNY H, 1986, J BIOL CHEM, V261, P6450; DEUTSCHE.MP, 1974, J BACTERIOL, V118, P621, DOI 10.1128/JB.118.2.621-627.1974; Deutscher M. P., 1983, ENZYMES NUCLEIC ACID, V2, P159; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; DEUTSCHER MP, 1977, J MOL BIOL, V117, P1095, DOI 10.1016/S0022-2836(77)80015-6; FOURNIER MJ, 1985, MICROBIOL REV, V49, P379, DOI 10.1128/MMBR.49.4.379-397.1985; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; KALAPOS MP, 1994, BIOCHEM BIOPH RES CO, V198, P459, DOI 10.1006/bbrc.1994.1067; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; LITTAUER UZ, 1982, ENZYMES, P518; LIU JD, 1989, J BACTERIOL, V171, P1254, DOI 10.1128/jb.171.3.1254-1261.1989; MCGANN RG, 1980, EUR J BIOCHEM, V106, P321; MCMURRY LM, 1987, J BACTERIOL, V169, P1321, DOI 10.1128/jb.169.3.1321-1324.1987; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; REUVEN NB, 1993, P NATL ACAD SCI USA, V90, P4350, DOI 10.1073/pnas.90.10.4350; YANCEY SD, 1990, BIOCHIMIE, V72, P835, DOI 10.1016/0300-9084(90)90193-K; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	25	40	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33255	33259		10.1074/jbc.272.52.33255	http://dx.doi.org/10.1074/jbc.272.52.33255			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407115	hybrid			2022-12-25	WOS:000071182900076
J	Warmuth, M; Bergmann, M; Priess, A; Hauslmann, K; Emmerich, B; Hallek, M				Warmuth, M; Bergmann, M; Priess, A; Hauslmann, K; Emmerich, B; Hallek, M			The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; C-ABL; PHILADELPHIA-CHROMOSOME; MYELOID CELLS; HEMATOPOIETIC-CELLS; STRUCTURAL BASIS; ADAPTER PROTEIN; SH2 DOMAINS; ACTIVATION	bcr-abl, the oncogene causing chronic myeloid leukemia, encodes a fusion protein with constitutively active tyrosine kinase and transforming capacity in hematopoietic cells. Various intracellular signaling intermediates become activated and/or associate by/with Bcr-Abl, including the Src family kinase Hck. To elucidate some of the structural requirements and functional consequences of the association of Bcr-Abl with Hcb, their interaction was investigated in transiently transfected COS7 cells. Neither the complex formation of Hck kinase with Bcr-Abl nor the activation of Hck by Bcr-Abl was dependent on the Abl kinase activity. Both inactivating point mutations of Hck and dephosphorylation of Hck enhanced its complex formation with Bcr-Abl, indicating that their physical interaction was negatively regulated by Hck (auto)phosphorylation. Finally, experiments with a series of kinase negative Bcr-Abl mutants showed that Hck phosphorylated Bcr-Abl and induced the binding of Grb2 to Tyr(177) of Bcr-Abl. Taken together, our results suggest that Bcr-Abl preferentially binds inactive forms of Hck by an Abl kinase-independent mechanism. This physical interaction stimulates the Hck tyrosine kinase, which may then phosphorylate the Grb2-binding site in Bcr-Abl.	Univ Munich, Klinikum Innenstadt, D-80336 Munich, Germany	University of Munich	Hallek, M (corresponding author), Univ Munich, Klinikum Innenstadt, Ziemssenstr 1, D-80336 Munich, Germany.		Hallek, Michael/Y-3191-2019	Hallek, Michael/0000-0002-7425-4455				BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; DRUKER B, 1992, BLOOD, V79, P2215; Dunant NM, 1996, J VIROL, V70, P1323, DOI 10.1128/JVI.70.3.1323-1330.1996; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOTOH A, 1995, EXP HEMATOL, V23, P1153; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; Hallek M, 1996, BRIT J HAEMATOL, V94, P5, DOI 10.1046/j.1365-2141.1996.6102053.x; Heaney C, 1997, BLOOD, V89, P297, DOI 10.1182/blood.V89.1.297.297_297_306; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Jain SK, 1996, BLOOD, V88, P1542; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MARU Y, 1995, MOL CELL BIOL, V15, P835; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MOAREFI L, 1997, NATURE, V385, P650; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RAMAKRISHNAN L, 1989, BIOCHIM BIOPHYS ACTA, V989, P209, DOI 10.1016/0304-419X(89)90043-7; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 1996, ONCOGENE, V12, P839; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; Shuai K, 1996, ONCOGENE, V13, P247; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SKORSKI T, 1995, CANCER RES, V55, P2275; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Tauchi T, 1997, J BIOL CHEM, V272, P1389, DOI 10.1074/jbc.272.2.1389; TENHOEVE J, 1994, BLOOD, V84, P1731; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; Walkenhorst J, 1996, ONCOGENE, V12, P1513; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; WilsonRawls J, 1996, CANCER RES, V56, P3426; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	55	105	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33260	33270		10.1074/jbc.272.52.33260	http://dx.doi.org/10.1074/jbc.272.52.33260			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407116	hybrid			2022-12-25	WOS:000071182900077
J	Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A				Kishida, S; Koyama, S; Matsubara, K; Kishida, M; Matsuura, Y; Kikuchi, A			Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator	ONCOGENE			English	Article						RalGDS; Ras; Ral; Rap; posttranslational modification	GUANINE-NUCLEOTIDE EXCHANGE; H-RAS; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; POSTTRANSLATIONAL MODIFICATION; PROTEIN-KINASE; R-RAS; B-RAF; P21; TRANSFORMATION	Ral GDP dissociation stimulator (RalGDS), a putative effector protein of Ras, stimulated the GDP/GTP exchange reaction of the post-tanslationally lipid-modified but not the unmodified form of Ral in response to epidermal growth factor in COS cells, The RalGDS action on Ral was enhanced by an active form of Res but not a Ras mutant which was not post-translationally modified in the cells, The RalGDS activity was inhibited by acidic membrane phospholipids such as phosphatidylinositol and phosphatidylserine but not by phosphatidylcholine or phosphatidylethanolamines in vitro. The posttranslationally modified form but not unmodified form of Ras, Ral, and Rap were incorporated in liposomes consisting of these phospholipids. When Ral was incorporated alone in the liposomes, RalGDS did not stimulate the dissociation of GDP from Ral, When Rat was incorporated with the GTP-bound form of Ras in the liposomes, RalGDS stimulated the dissociation of GDP from Ral, while the GDP-bound form of Ras did not affect the RalGDS action, The Ras-dependent Ral activation through RalGDS required the Ras-binding domain of RalGDS, Rap, which shared the same effector loop as Ras, also stimulated the dissociation of GDP from Ral through RalGDS in the liposomes, although Rap did not enhance the RalGDS action in COS cells, Taken together with our previous observations that Ras recruits RalGDS to the membrane, these results indicate that the post-translational modifications of Ras and Ral are important for Ras-dependent Ral activation through RalGDS and that colocalization of Ras and Ral on the membrane is necessary for Ral activation in intact cells.	HIROSHIMA UNIV,SCH MED,DEPT BIOCHEM,MINAMI KU,HIROSHIMA 734,JAPAN; NATL INST INFECT DIS,DEPT VIROL 2,SHINJYUKU KU,TOKYO 162,JAPAN	Hiroshima University; National Institute of Infectious Diseases (NIID)				kishida, shosei/0000-0003-0405-851X				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BERGER G, 1994, BRIT J HAEMATOL, V88, P372, DOI 10.1111/j.1365-2141.1994.tb05033.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Gajewski TF, 1996, CELL, V87, P589, DOI 10.1016/S0092-8674(00)81377-X; GORMAN CM, 1985, HIGH EFFICIENCY GENE; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; Hinoi T, 1996, J BIOL CHEM, V271, P19710, DOI 10.1074/jbc.271.33.19710; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; KAWAMURA S, 1991, JPN J CANCER RES, V82, P758, DOI 10.1111/j.1349-7006.1991.tb02699.x; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LopezBarahona M, 1996, ONCOGENE, V12, P463; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MALY FE, 1994, J BIOL CHEM, V269, P18743; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McCormick F, 1996, NAT STRUCT BIOL, V3, P653, DOI 10.1038/nsb0896-653; Murai H, 1997, J BIOL CHEM, V272, P10483; Okada T, 1996, J BIOL CHEM, V271, P4671; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Summers MD, 1987, MANUAL METHODS BACUL; TSAI MH, 1990, SCIENCE, V250, P982, DOI 10.1126/science.2237442; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WITTINGHOFER A, 1995, FEBS LETT, V369, P52, DOI 10.1016/0014-5793(95)00667-X; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zheng Y, 1996, J BIOL CHEM, V271, P23815, DOI 10.1074/jbc.271.39.23815	43	61	62	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2899	2907		10.1038/sj.onc.1201473	http://dx.doi.org/10.1038/sj.onc.1201473			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416833				2022-12-25	WOS:A1997YK37700002
J	Ramamoorthy, S; Giovanetti, E; Qian, Y; Blakely, RD				Ramamoorthy, S; Giovanetti, E; Qian, Y; Blakely, RD			Phosphorylation and regulation of antidepressant-sensitive serotonin transporters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN NOREPINEPHRINE TRANSPORTER; PLACENTAL CHORIOCARCINOMA CELLS; NEUROTRANSMITTER TRANSPORTERS; DOPAMINE TRANSPORTER; DEPENDENT REGULATION; XENOPUS-OOCYTES; NITRIC-OXIDE; EXPRESSION; GENE	Antidepressant-sensitive serotonin (5-hydroxytryptamine, 5HT) transporters (SERTs) are responsible for efficient synaptic clearance of extracellular 5HT. Previously (Qian, Y., Galli, A., Ramamoorthy, S., Risso, S., DeFelice, L. J., and Blakely, R. D. (1997) J. Neurosci. 17, 45-47), we demonstrated that protein kinase (PKC)-linked pathways in transfected HEK-293 cells lead to the internalization of cell-surface human (h) SERT protein and a reduction in 5HT uptake capacity. In the present study, we report that PKC activators rapidly, and in a concentration-dependent manner, elevate the basal level of hSERT phosphorylation 5-6-fold. Similarly, protein phosphatase (PP1/PP2A) inhibitors down-regulate 5HT transport and significantly elevate hSERT P-32 incorporation, effects that are additive with those of PKC activators. Moreover, hSERT phosphorylation induced by beta-phorbol 12-myristate 13-acetate is abolished selectively by the PKC inhibitors staurosporine and bisindolymaleimide I, whereas hSERT phosphorylation induced by phosphatase inhibitors is insensitive to these agents at comparable concentrations. Protein kinase A and protein kinase G activators fail to acutely down-regulate 5HT uptake but significantly enhance hSERT phosphorylation. Basal hSERT and okadaic acid-induced phosphorylation were insensitive to chelation of intracellular calcium and Ca2+/calmodulin-dependent protein kinase inhibitors. Together these results reveal hSERT to be a phosphoprotein whose phosphorylation state is likely to be tightly controlled by multiple kinase and phosphatase pathways that may also influence the transporter's regulated trafficking.	Vanderbilt Univ, Sch Med, Dept Pharmacol, MRBII, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, MRBII, Rm 419, Nashville, TN 37232 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07390] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; ANDERSON GM, 1995, SOC NEUR ABSTR, V21; APPARSUNDARAM S, 1996, SOC NEUR ABSTR, V22; BALKOVETZ DF, 1989, J BIOL CHEM, V264, P2195; Barker Eric L., 1995, P321; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bradley CC, 1997, J NEUROCHEM, V69, P1356; BROWNSTEIN MJ, 1994, RECENT PROG HORM RES, V49, P27; Cook EH, 1997, MOL PSYCHIATR, V2, P247; COOL DR, 1991, J BIOL CHEM, V266, P15750; COREY JL, 1994, J BIOL CHEM, V269, P14759; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Fleckenstein AE, 1996, J PHARMACOL EXP THER, V279, P200; Fozzard J., 1989, PERIPHERAL ACTIONS 5; Fuller RW, 1996, ANN NY ACAD SCI, V794, P90, DOI 10.1111/j.1749-6632.1996.tb32512.x; FULLER RW, 1994, LIFE SCI, V55, P163, DOI 10.1016/0024-3205(94)00876-0; GUAN XM, 1988, BRAIN RES BULL, V21, P43, DOI 10.1016/0361-9230(88)90118-9; Heils A, 1996, J NEUROCHEM, V66, P2621; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Huff RA, 1997, J NEUROCHEM, V68, P225; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Krueger KM, 1997, J BIOL CHEM, V272, P5; LAUNAY JM, 1994, AM J PHYSIOL, V266, P526; LESCH KP, 1994, J NEURAL TRANSM-GEN, V95, P157, DOI 10.1007/BF01276434; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; MELIKIAN HE, 1994, J BIOL CHEM, V269, P12290; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; MILLER KJ, 1995, SOC NEUR ABSTR, V21; Montgomery Stuart A., 1995, P1043; MYERS CL, 1989, AM J PHYSIOL, V257, pL253, DOI 10.1152/ajplung.1989.257.4.L253; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OGLIVIE AD, 1996, LANCET, V347, P731; OSAWA I, 1994, NEUROSCI RES, V19, P287, DOI 10.1016/0168-0102(94)90041-8; POGUN S, 1994, BRAIN RES, V641, P83, DOI 10.1016/0006-8993(94)91818-X; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; QIAN Y, 1995, J NEUROSCI, V15, P1261; QIAN Y, 1995, SOC NEUR ABSTR, V21; QIAN Y, 1996, THESIS EMORY U; Quick MW, 1997, J NEUROSCI, V17, P2967; RAMAMOORTHY JD, 1995, J BIOL CHEM, V270, P17189, DOI 10.1074/jbc.270.29.17189; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RAMAMOORTHY S, 1993, J BIOL CHEM, V268, P21626; RAMAMOORTHY S, 1998, IN PRESS METHODS ENZ; Reith M E, 1988, NIDA Res Monogr, V88, P23; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RUDNICK G, 1992, BIOCHEMISTRY-US, V31, P6710, DOI 10.1021/bi00144a010; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; RUDNICK G, 1978, BIOCHEMISTRY-US, V17, P4739, DOI 10.1021/bi00615a021; Sakai N, 1997, J NEUROCHEM, V68, P2618; SATO K, 1995, J NEUROCHEM, V65, P1967; SHAFQAT S, 1993, MOL ENDOCRINOL, V7, P1517, DOI 10.1210/me.7.12.1517; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; STAHL SM, 1977, ARCH GEN PSYCHIAT, V34, P509; TATE CG, 1994, J BIOL CHEM, V269, P26303; UHL GR, 1992, TRENDS NEUROSCI, V15, P265, DOI 10.1016/0166-2236(92)90068-J; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Yura A, 1996, BRAIN RES, V738, P96, DOI 10.1016/0006-8993(96)00762-7	63	241	246	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2458	2466		10.1074/jbc.273.4.2458	http://dx.doi.org/10.1074/jbc.273.4.2458			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442097	hybrid			2022-12-25	WOS:000071595200086
J	Walker, D; Bichet, D; Campbell, KP; De Waard, M				Walker, D; Bichet, D; Campbell, KP; De Waard, M			A beta(4) isoform-specific interaction site in the carboxyl-terminal region of the voltage-dependent Ca2+ channel alpha(1A) subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CALCIUM-CHANNEL; FUNCTIONAL EXPRESSION; IDENTIFICATION; CLONING; BRAIN; ALPHA(1)-SUBUNIT; INACTIVATION; DIVERSITY; DOMAIN; MOTIF	The voltage-gated calcium channel beta subunit is a cytoplasmic protein that stimulates activity of the channel-forming subunit, alpha(1), in several ways. Complementary binding sites on alpha(1) and beta have been identified that are highly conserved among isoforms of the two subunits, but this interaction alone does not account for all of the functional effects of the beta subunit. We describe here the characterization in vitro of a second interaction, involving the carboxyl-terminal cytoplasmic domain of alpha(1A) and showing specificity for the beta(4) (and to a lesser extent beta(2a)) isoform. A deletion and chimera approach showed that the carboxyl-terminal region of beta(4), poorly conserved between beta isoforms, contains the interaction site and plays a role in the regulation of channel inactivation kinetics. This is the first demonstration of a molecular basis for the specificity of functional effects seen for different combinations of these two channel components.	Fac Med Nord, Inst Federat Jean Roche, INSERM U464, F-13916 Marseille 20, France; Univ Iowa, Coll Med, Howard Hughes Med Inst, Iowa City, IA 52242 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Howard Hughes Medical Institute; University of Iowa	De Waard, M (corresponding author), Fac Med Nord, Inst Federat Jean Roche, INSERM U464, Bd Pierre Dramard, F-13916 Marseille 20, France.	dewaard.m@jean-roche.univ-mrs.fr	De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Campbell, Kevin/0000-0003-2066-5889; Bichet, Delphine/0000-0002-9601-089X; Walker, Denise/0000-0003-1534-1679				Brice NL, 1997, EUR J NEUROSCI, V9, P749, DOI 10.1111/j.1460-9568.1997.tb01423.x; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CHIEN AJ, 1995, J BIOL CHEM, V270, P30036; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DeWaard M, 1996, FEBS LETT, V380, P272, DOI 10.1016/0014-5793(96)00007-5; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1994, NEURON, V13, P495, DOI 10.1016/0896-6273(94)90363-8; ELLINOR PT, 1993, NATURE, V363, P455, DOI 10.1038/363455a0; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; FLOCKERZI V, 1986, NATURE, V323, P66, DOI 10.1038/323066a0; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Hsueh YP, 1997, NEURON, V18, P803, DOI 10.1016/S0896-6273(00)80319-0; JAY SD, 1991, J BIOL CHEM, V266, P3287; Klockner U, 1997, AM J PHYSIOL-HEART C, V272, pH1372, DOI 10.1152/ajpheart.1997.272.3.H1372; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; Liu HY, 1996, J BIOL CHEM, V271, P13804, DOI 10.1074/jbc.271.23.13804; Ludwig A, 1997, J NEUROSCI, V17, P1339; Marubio LM, 1996, RECEPTOR CHANNEL, V4, P243; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLCESE R, 1994, NEURON, V13, P1433, DOI 10.1016/0896-6273(94)90428-6; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; Snutch T P, 1992, Curr Opin Neurobiol, V2, P247, DOI 10.1016/0959-4388(92)90111-W; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; SOONG TW, 1993, SCIENCE, V260, P1193; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; Tareilus E, 1997, P NATL ACAD SCI USA, V94, P1703, DOI 10.1073/pnas.94.5.1703; TOMLINSON WJ, 1993, NEUROPHARMACOLOGY, V32, P1117, DOI 10.1016/0028-3908(93)90006-O; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62	38	128	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2361	2367		10.1074/jbc.273.4.2361	http://dx.doi.org/10.1074/jbc.273.4.2361			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442082	hybrid			2022-12-25	WOS:000071595200071
J	Kisselev, P; Wessel, R; Pisch, S; Bornscheuer, U; Schmid, RD; Schwarz, D				Kisselev, P; Wessel, R; Pisch, S; Bornscheuer, U; Schmid, RD; Schwarz, D			Branched phosphatidylcholines stimulate activity of cytochrome P450SCC (CYP11A1) in phospholipid vesicles by enhancing cholesterol binding, membrane incorporation, and protein exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIDE-CHAIN CLEAVAGE; PURIFIED CYTOCHROME-P-450SCC; ADRENODOXIN BINDING; P-450SCC; CARDIOLIPIN; SITE; AGGREGATION; ACTIVATION; LIPOSOMES; ENZYME	Phosphatidylcholines (PCs) with branched fatty acyl chains substituted in the two positions of the main chains (branched PCs) have been shown to be potent activators of the side chain cleavage activity of cytochrome P450SCC (CYP11A1) (Schwarz, D.,, Kisselev, P.,, Wessel, R.,, Jueptner, O., and Schmid, R., D., (1996) J., Biol, Chem, 271, 12840-12846), The present study reports on the effect of a series of branched PC on cholesterol binding, membrane integration, and protein exchange in large unilamellar vesicles prepared by an extrusion technique, Enzyme kinetics using vesicles as well as optical titration using a micelle system with the detergent Tween 20 demonstrate that activation is correlated with the fraction of P450SCC in the high spin form, The potency of branched PCs both to activate the enzyme and to induce spin state changes increases with increasing lengths of both the branched and main fatty acyl chains, We found that the extent as well as the rate of integration of P450SCC into vesicle membranes studied by gel chromatography and stopped flow kinetics were increased by branched PC, Finally, it is demonstrated by measurement of the enzymatic activity in primary and secondary vesicles that branched PCs are potent in retaining a very rapid exchange of P450SCC between vesicles, in contrast to cardiolipin, that partially inhibits this exchange process, The data suggest that different properties of P450SCC in membrane systems including cholesterol binding, membrane integration, and protein exchange are affected by branched PCs and probably by other phospholipids, too, and therefore must be considered in an explanation of the observed high stimulation of activity.	Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; Charite Humboldt Univ Berlin, Inst Clin Pharmacol, D-10098 Berlin, Germany; Byelarussian Acad Sci, Inst Bioorgan Chem, Minsk 220141, BELARUS; Univ Stuttgart, Inst Tech Biochem, D-70569 Stuttgart, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Academy of Sciences of Belarus (NASB); Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus; University of Stuttgart	Schwarz, D (corresponding author), Max Delbruck Ctr Mol Med, Robert Roessle Str 10, D-13125 Berlin, Germany.	schwarz@orion.rz.mdc-berlin.de	Bornscheuer, Uwe T/C-4612-2012	Bornscheuer, Uwe T/0000-0003-0685-2696				CHASHCHIN VL, 1984, BIOCHIM BIOPHYS ACTA, V787, P27, DOI 10.1016/0167-4838(84)90104-3; DHARIWAL MS, 1991, BIOCHEMISTRY-US, V30, P4940, DOI 10.1021/bi00234a015; DHARIWAL MS, 1989, BIOCHEMISTRY-US, V28, P8397, DOI 10.1021/bi00447a019; FARKASH Y, 1986, ENDOCRINOLOGY, V118, P1353, DOI 10.1210/endo-118-4-1353; GRUNER SM, 1985, ANNU REV BIOPHYS BIO, V14, P211, DOI 10.1146/annurev.biophys.14.1.211; HALL PF, 1979, J BIOL CHEM, V254, P547; HANUKOGLU I, 1981, J BIOL CHEM, V256, P4329, DOI 10.1016/S0021-9258(19)69437-8; HUI SW, 1989, P NATL ACAD SCI USA, V86, P5825, DOI 10.1073/pnas.86.15.5825; KOWLURU RA, 1983, J BIOL CHEM, V258, P8053; LAMBETH JD, 1981, J BIOL CHEM, V256, P4757; LAMBETH JD, 1980, J BIOL CHEM, V255, P8282; LAMBETH JD, 1990, FRONTIERS BIOTRANSFO, V3, P58; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; Nussdorfer G G, 1986, Int Rev Cytol, V98, P1; OMURA T, 1964, J BIOL CHEM, V239, P2370; PEMBER SO, 1983, J BIOL CHEM, V258, P3198; RURUP J, 1994, CHEM PHYS LIPIDS, V72, P175, DOI 10.1016/0009-3084(94)90100-7; Schwarz D, 1997, BIOCHEMISTRY-US, V36, P14262, DOI 10.1021/bi9714262; Schwarz D, 1996, J BIOL CHEM, V271, P12840, DOI 10.1074/jbc.271.22.12840; SCHWARZ D, 1988, BIOMED BIOCHIM ACTA, V47, P609; SCHWARZ D, 1994, J STRUCT BIOL, V113, P207, DOI 10.1006/jsbi.1994.1055; SEYBERT DW, 1979, J BIOL CHEM, V254, P2088; TAKIKAWA O, 1978, ARCH BIOCHEM BIOPHYS, V190, P300, DOI 10.1016/0003-9861(78)90279-5; THOMAS PD, 1988, BIOCHEM J, V254, P155, DOI 10.1042/bj2540155; TUCKEY RC, 1982, J BIOL CHEM, V257, P2887; USANOV S A, 1987, Biokhimiya, V52, P110; WADA A, 1992, J BIOL CHEM, V267, P22877; YAMAKURA F, 1981, BIOCHIM BIOPHYS ACTA, V649, P343, DOI 10.1016/0005-2736(81)90424-7	29	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1380	1386		10.1074/jbc.273.3.1380	http://dx.doi.org/10.1074/jbc.273.3.1380			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430672	hybrid			2022-12-25	WOS:000071411500019
J	Pham, CTN; Thomas, DA; Mercer, JD; Ley, TJ				Pham, CTN; Thomas, DA; Mercer, JD; Ley, TJ			Production of fully active recombinant murine granzyme B in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPEPTIDYL PEPTIDASE-I; CELL-DEATH; SERINE PROTEASES; ICE/CED-3 PROTEASE; DNA FRAGMENTATION; RAPID INDUCTION; GENE-EXPRESSION; PICHIA-PASTORIS; TARGET-CELLS; APOPTOSIS	Granzyme B (GzmB) is a neutral serine protease found in cytotoxic lymphocytes; this enzyme is critically involved in delivering the rapid apoptotic signal to susceptible target cells. GzmB has been difficult to study and has not yet been produced in non-mammalian systems because of the complex processing events that are thought to be required for its activation. In this report, we have successfully produced fully active, soluble recombinant GzmB (rGzmB) in a yeast-based system by fusing GzmB cDNA in frame with yeast alpha-factor cDNA, using the yeast KEX2 signal peptidase to release the processed enzyme into the supernatant of yeast cultures, We expressed the proenzyme form of GzmB as well and determined that pro-GzmB is efficiently converted to its active form by the cysteine proteinase dipeptidyl peptidase I, The fully processed enzyme was able to hydrolyze the synthetic substrate N-t-butyloxycarbonyl-L-alanyl-L-alanyl-L-aspartyl (Boc-Ala-Ala-Asp) thiobenzyl ester with a k(cat) of 17 s(-1) and catalytic efficiency k(cat)/K-m of 181,237 M-1 s(-1); the recombinant enzyme is therefore at least twice as active as purified native GzmB, In addition, the recombinant enzyme hydrolyzes Boc-Ala-Ala-Met thiobenzyl ester with a K-cat of 3.2 s(-1) and a catalytic efficiency k(cat)/K-m of 65,306 M-1 s(-1). Purified rGzmB can also cleave the putative substrate caspase-3 into its signature p20/p10 forms, Unlike caspases, rGzmB is not sensitive to inhibition by several peptide-based inhibitors, including Ac-DEVD-CHO, Ac-YVAD-CMK, and ZIETD-FMK as well as Zn2+ (a known inhibitor of caspase-3). Structural studies of rGzmB may allow us to better understand the substrate specificity of this enzyme and to design better inhibitors.	Washington Univ, Sch Med, Dept Internal Med, Div Bone Marrow Transplantat & Stem Cell Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Ley, TJ (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Bone Marrow Transplantat & Stem Cell Biol, 660 S Euclid,Box 8007, St Louis, MO 63110 USA.				NCI NIH HHS [CA 49712] Funding Source: Medline; NHLBI NIH HHS [K08 HL03774] Funding Source: Medline; NIDDK NIH HHS [DK 49786] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049712] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049786] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CAPUTO A, 1993, J BIOL CHEM, V268, P17672; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Darmon AJ, 1996, J BIOL CHEM, V271, P21709, DOI 10.1074/jbc.271.36.21709; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DIKOV MM, 1994, J BIOL CHEM, V269, P25897; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; Graubert TA, 1996, BLOOD, V87, P1232, DOI 10.1182/blood.V87.4.1232.bloodjournal8741232; Graubert TA, 1997, J CLIN INVEST, V100, P904, DOI 10.1172/JCI119606; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; Kummer JA, 1996, J BIOL CHEM, V271, P9281, DOI 10.1074/jbc.271.16.9281; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MCGUIRE MJ, 1993, J BIOL CHEM, V268, P2458; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOFARBER K, 1995, YEAST, V11, P1331; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; Perry DK, 1997, J BIOL CHEM, V272, P18530, DOI 10.1074/jbc.272.30.18530; Pham C T, 1997, Semin Immunol, V9, P127, DOI 10.1006/smim.1997.0060; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; POE M, 1991, J BIOL CHEM, V266, P98; Quan LT, 1996, P NATL ACAD SCI USA, V93, P1972, DOI 10.1073/pnas.93.5.1972; ROMANOS M, 1995, CURR OPIN BIOTECH, V6, P527, DOI 10.1016/0958-1669(95)80087-5; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHRESTA S, 1995, P NATL ACAD SCI USA, V92, P5679, DOI 10.1073/pnas.92.12.5679; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907	40	49	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1629	1633		10.1074/jbc.273.3.1629	http://dx.doi.org/10.1074/jbc.273.3.1629			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430705	hybrid			2022-12-25	WOS:000071411500052
J	Schulte, S; Unger, C; Mo, JA; Wendler, O; Bauer, E; Frischholz, S; von der Mark, K; Kalden, JR; Holmdahl, R; Burkhardt, H				Schulte, S; Unger, C; Mo, JA; Wendler, O; Bauer, E; Frischholz, S; von der Mark, K; Kalden, JR; Holmdahl, R; Burkhardt, H			Arthritis-related B cell epitopes in collagen II are conformation-dependent and sterically privileged in accessible sites of cartilage collagen fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODIES; IMMUNE-COMPLEXES; SYNOVIAL-FLUID; LYMPHOCYTES-T; X COLLAGEN; MICE; IDENTIFICATION; BINDING; GENE	In collagen-induced arthritis, a murine autoimmune model for rheumatoid arthritis, immunization with native but not heat-denatured cartilage-specific collagen type II (CII) induces a B cell response that largely contributes to arthritogenicity. Previously, we have shown that monoclonal antibodies established from arthritis prone DBA/1 mice require the triple-helical conformation of their epitopes for antigen recognition. Here, we present a novel approach to characterize arthritis-related conformational epitopes by preparing a panel of 130 chimeric collagen X/CII molecules. The insertion of a series of CII cassettes into the triple-helical recombinant collagen X allowed for the first time the identification of five triple-helical immunodominant domains of 5-11 amino acid length, to which 75% of 36 monoclonal antibodies bound. A consensus motif, "R G hydrophobic," was found in all immunodominant epitopes. The antibodies were encoded by a certain combination of V-genes in germline configuration, indicating a role of the consensus motif in V-gene selection. The immunodominant domains are spread over the entire monomeric CII molecule with no apparent order; however, a highly organized arrangement became apparent when the CII molecules were displayed in the quarter-staggered assembly within a fibril. This discrete epitope organization most likely reflects structural constraints that restrict the exposure of CII epitopes on the surface of heterotypically assembled cartilage fibrils. Thus, our data suggest a preimmune B cell selection process that is biased by the accessibility of CII determinants in the intact cartilage tissue.	Univ Erlangen Nurnberg, Dept Internal Med 3, Inst Clin Immunol, D-91054 Erlangen, Germany; Univ Erlangen Nurnberg, Inst Expt Med, D-91054 Erlangen, Germany; Univ Lund, Dept Cell & Mol Biol, Sect Med Inflammat Res, S-22100 Lund, Sweden	University of Erlangen Nuremberg; University of Erlangen Nuremberg; Lund University	Burkhardt, H (corresponding author), Univ Erlangen Nurnberg, Dept Internal Med 3, Inst Clin Immunol, Krankenhausstr 12, D-91054 Erlangen, Germany.	harald-.burkhardt@med3.med.uni-erlangen.de	Holmdahl, Rikard/AAI-7682-2020	Wendler, Olaf/0000-0002-5443-4889				BACHMANN MF, 1995, EUR J IMMUNOL, V25, P3345; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BENTZ H, 1978, EUR J BIOCHEM, V92, P563, DOI 10.1111/j.1432-1033.1978.tb12778.x; Brand DD, 1996, J IMMUNOL, V157, P5178; BRUNSBERG U, 1994, EUR J IMMUNOL, V24, P1698, DOI 10.1002/eji.1830240736; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; BURKHARDT H, 1991, EUR J IMMUNOL, V21, P49, DOI 10.1002/eji.1830210109; CLAGUE RB, 1984, ARTHRITIS RHEUM, V27, P1370, DOI 10.1002/art.1780271207; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; EBLE JA, 1993, EMBO J, V12, P4795, DOI 10.1002/j.1460-2075.1993.tb06168.x; FIETZEK PP, 1975, MOL CELL BIOCHEM, V8, P141, DOI 10.1007/BF01792765; Fugger L, 1996, EUR J IMMUNOL, V26, P928, DOI 10.1002/eji.1830260431; Girkontaite I, 1996, MATRIX BIOL, V15, P231, DOI 10.1016/S0945-053X(96)90114-6; GLANVILLE RW, 1981, H-S Z PHYSIOL CHEM, V362, P943, DOI 10.1515/bchm2.1981.362.2.943; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HELFGOTT SM, 1984, CLIN IMMUNOL IMMUNOP, V31, P403, DOI 10.1016/0090-1229(84)90092-8; Hodge A, 1963, ASPECTS PROTEIN STRU, P289; HOLMDAHL R, 1988, LAB INVEST, V58, P53; HOLMDAHL R, 1991, AUTOIMMUNITY, V10, P27, DOI 10.3109/08916939108997144; HOLMDAHL R, 1987, IMMUNOLOGY, V61, P369; HOLMDAHL R, 1990, IMMUNOL REV, V118, P193, DOI 10.1111/j.1600-065X.1990.tb00817.x; HOLMDAHL R, 1986, ARTHRITIS RHEUM, V29, P400, DOI 10.1002/art.1780290314; HOLMDAHL R, 1990, SCAND J IMMUNOL, V31, P147, DOI 10.1111/j.1365-3083.1990.tb02754.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; JANSSON L, 1993, CLIN EXP IMMUNOL, V94, P459, DOI 10.1111/j.1365-2249.1993.tb08218.x; JASIN HE, 1985, ARTHRITIS RHEUM, V28, P241, DOI 10.1002/art.1780280302; KIRSCH T, 1991, EUR J BIOCHEM, V196, P575, DOI 10.1111/j.1432-1033.1991.tb15852.x; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LIN RH, 1991, J EXP MED, V173, P1433, DOI 10.1084/jem.173.6.1433; Malmstrom V, 1996, P NATL ACAD SCI USA, V93, P4480, DOI 10.1073/pnas.93.9.4480; MICHAELSSON E, 1994, J EXP MED, V180, P745, DOI 10.1084/jem.180.2.745; MILLER EJ, 1976, BIOCHEMISTRY-US, V15, P787, DOI 10.1021/bi00649a009; MO JA, 1993, EUR J IMMUNOL, V23, P2503, DOI 10.1002/eji.1830231019; Mo JA, 1996, J IMMUNOL, V157, P2440; MO JA, 1994, SCAND J IMMUNOL, V39, P122, DOI 10.1111/j.1365-3083.1994.tb03350.x; NORDLING C, 1991, IMMUNOLOGY, V72, P486; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; RONNELID J, 1994, ARTHRITIS RHEUM-US, V37, P1023, DOI 10.1002/art.1780370707; RUBIN AS, 1987, LAB INVEST, V57, P524; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P463; SIEGEL RC, 1976, J BIOL CHEM, V251, P5779; STASTNY P, 1978, NEW ENGL J MED, V298, P869, DOI 10.1056/NEJM197804202981602; TARKOWSKI A, 1989, ARTHRITIS RHEUM, V32, P1087, DOI 10.1002/anr.1780320906; TERATO K, 1992, J IMMUNOL, V148, P2103; TERATO K, 1985, J EXP MED, V162, P637, DOI 10.1084/jem.162.2.637; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VONDERMARK K, 1982, EUR J BIOCHEM, V124, P57; WOOLEY PH, 1981, J EXP MED, V154, P688, DOI 10.1084/jem.154.3.688; WORTHINGTON J, 1991, AUTOIMMUNITY, V10, P201, DOI 10.3109/08916939109001890; WU H, 1990, P NATL ACAD SCI USA, V87, P5888, DOI 10.1073/pnas.87.15.5888; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; WU JJ, 1992, J BIOL CHEM, V267, P23007	56	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1551	1561		10.1074/jbc.273.3.1551	http://dx.doi.org/10.1074/jbc.273.3.1551			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430695	hybrid			2022-12-25	WOS:000071411500042
J	Shih, S; Hwang, HY; Carter, D; Stenberg, P; Ullman, B				Shih, S; Hwang, HY; Carter, D; Stenberg, P; Ullman, B			Localization and targeting of the Leishmania donovani hypoxanthine-guanine phosphoribosyltransferase to the glycosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRYPANOSOMA-BRUCEI; ADENINE PHOSPHORIBOSYLTRANSFERASE; GENE; EXPRESSION; CLONING; METABOLISM; MEXICANA; COMPARTMENTATION; PROMASTIGOTES; DEHYDROGENASE	Hypoxanthine-guanine phosphoribosyltransferase (HGPRT) is a key enzyme in the purine salvage pathway of many protozoan parasites, The predicted amino acid sequences of certain HGPRT proteins from parasites of the Trypanosomatidae family reveal a COOH-terminal tripeptide signal that is consistent with the degenerate topogenic signal targeting proteins to the glycosome, a fuel metabolizing microbody unique to these parasites. To determine definitively the intracellular milieu of HGPRT in these pathogens, polyclonal antiserum to the purified recombinant HGPRT from Leishmania donovani was generated in rabbits, and confocal and immunoelectron microscopy were employed to establish that the L. donovani HGPRT is localized exclusively to the glycosome, No HGPRT protein was detected in Delta hgprt null mutants in which both alleles of the HGPRT locus had been replaced by a drug-resistance cassette, Transfectants of the Delta hgprt knockout strain in which a wildtype HGPRT was amplified on an expression plasmid contained augmented amounts of HGPRT, all of which was localized to the glycosome, Delta hgprt transfectants containing amplified copies of a mutated HGPRT construct in which the Ser-Lys-Val COOH-terminal targeting signal had been deleted expressed HGPRT throughout the parasite, including subcellular organelles such as the nucleus and flagellum, These data demonstrate that the L. donovani HGPRT is compartmentalized exclusively within the glycosome and that the COOH-terminal tripeptide of the protein is necessary to achieve targeting to this organelle.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pathol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Ullman, B (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.	ullmanb@ohsu.edu	; Carter, Darrick/N-3304-2016	Hwang, Ho-Yon/0000-0003-0204-8932; Carter, Darrick/0000-0001-5901-3402	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023682, R37AI023682] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23682] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen T, 1995, MOL BIOCHEM PARASIT, V74, P99, DOI 10.1016/0166-6851(95)02475-1; ALLEN T, 1989, MOL BIOCHEM PARASIT, V33, P273, DOI 10.1016/0166-6851(89)90089-3; ALLEN TE, 1994, MOL BIOCHEM PARASIT, V65, P233, DOI 10.1016/0166-6851(94)90075-2; ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; ALLEN TE, 1995, MOL BIOCHEM PARASIT, V73, P133, DOI 10.1016/0166-6851(94)00105-V; BERENS RL, 1995, BIOCH PARASITIC ORGA, pCH16; BLATTNER J, 1992, J CELL BIOL, V119, P1129, DOI 10.1083/jcb.119.5.1129; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; Campbell W.C., 1986, CHEMOTHERAPY PARASIT; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; GALLERANO RH, 1990, AM J TROP MED HYG, V43, P159, DOI 10.4269/ajtmh.1990.43.159; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GUTTERIDGE WE, 1982, FEMS MICROBIOL LETT, V13, P207, DOI 10.1111/j.1574-6968.1982.tb08257.x; HAMMOND DJ, 1985, J BIOL CHEM, V260, P5646; HANNAERT V, 1994, EUR J BIOCHEM, V225, P143, DOI 10.1111/j.1432-1033.1994.00143.x; HART DT, 1984, MOL BIOCHEM PARASIT, V13, P159, DOI 10.1016/0166-6851(84)90110-5; HASSAN HF, 1985, COMP BIOCHEM PHYS B, V81, P1037, DOI 10.1016/0305-0491(85)90110-5; Hwang HY, 1997, J BIOL CHEM, V272, P19488, DOI 10.1074/jbc.272.31.19488; Hwang HY, 1996, J BIOL CHEM, V271, P30840, DOI 10.1074/jbc.271.48.30840; IOVANNISCI DM, 1983, J PARASITOL, V69, P633, DOI 10.2307/3281131; Jiang Y, 1996, EXP PARASITOL, V82, P73, DOI 10.1006/expr.1996.0010; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFON SW, 1982, BIOCHEM PHARMACOL, V31, P231, DOI 10.1016/0006-2952(82)90216-7; MARR JJ, 1978, BIOCHIM BIOPHYS ACTA, V544, P360, DOI 10.1016/0304-4165(78)90104-6; MARR JJ, 1983, MOL BIOCHEM PARASIT, V7, P339, DOI 10.1016/0166-6851(83)90016-6; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; MOTTRAM JC, 1985, EXP PARASITOL, V59, P265, DOI 10.1016/0014-4894(85)90081-5; OPPERDOES FR, 1993, BIOCHIMIE, V75, P231, DOI 10.1016/0300-9084(93)90081-3; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PALELLA TD, 1989, METABOLIC BASIS INHE, P965; PIPER RC, 1995, J CELL BIOL, V128, P499, DOI 10.1083/jcb.128.4.499; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOMMER JM, 1992, MOL BIOL CELL, V3, P749, DOI 10.1091/mbc.3.7.749; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; ULLMAN B, 1984, PHARM RES-DORDR, P194, DOI 10.1023/A:1016365128531; WILSON K, 1991, J BIOL CHEM, V266, P1665	39	58	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1534	1541		10.1074/jbc.273.3.1534	http://dx.doi.org/10.1074/jbc.273.3.1534			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430693	hybrid			2022-12-25	WOS:000071411500040
J	Chen, KD; Chen, LY; Huang, HL; Lieu, CH; Chang, YN; Chang, MDT; Lai, YK				Chen, KD; Chen, LY; Huang, HL; Lieu, CH; Chang, YN; Chang, MDT; Lai, YK			Involvement of p38 mitogen-activated protein kinase signaling pathway in the rapid induction of the 78-kDa glucose-regulated protein in 9L rat brain tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; FACTOR-ALPHA GENE; C-JUN; MAMMALIAN-CELLS; NECROSIS-FACTOR; MAP KINASE; GRP78 PROMOTER; HEAT-SHOCK; TRANSCRIPTIONAL ACTIVATION; CYTOKINE BIOSYNTHESIS	We have previously shown that treatment with okadaic acid (OA) followed by heat shock (HS) (termed OA --> HS treatment) leads to rapid transactivation of the 78-kDa glucose-regulated protein gene (grp78) in 9L rat brain tumor cells, A cAMP-responsive element-like (CRE-like, TGACGTGA) promoter sequence and a protein kinase A signaling pathway are involved in this induction, and activation of both CRE binding protein (CREB) and activating transcription factor-2 (ATF-2) is required in the above process, Herein, we report that transactivation of grp78, as well as phosphorylation/activation of ATF-2, can be completely annihilated by SB203580, a highly specific inhibitor of p38 mitogen-activated protein kinase (p38(MAPK)). Activation of p38(MAPK) by OA --> HS is also substantiated by its own phosphorylation as well as the phosphorylation and activation of MAPK activating protein kinase-2 in cells subjected to this treatment, The involvement of p38(MAPK) in the activation of ATF-2, which leads to the transactivation of rat grp78, is confirmed by electrophoretic mobility shift assay using a probe containing the CRE-like sequence as well as by transient transfection assays with a plasmid containing a 710-base pair stretch of the grp78 promoter, Together with our previous studies, these results led us to conclude that phosphorylation/ activation of CREB upon OA --> HS treatment is mediated by cAMP-dependent protein kinase, whereas that of ATF-2 is mediated by p38(MAPK), The transcription factors may bind to each other to form heterodimers that in turn transactivate grp78 by binding to the CRE-like element, This suggests that distinct signaling pathways converge on CREB-ATF-2, where each subunit is individually activated by a specific class of protein kinases, This may allow modulation of grp78 transactivation by diverse external stimuli.	Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan	National Tsing Hua University	Lai, YK (corresponding author), Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan.	lslyk@life.nthu.edu.tw	Chen, Liuh-Yow/AAA-3963-2021	Chen, Liuh-Yow/0000-0002-9857-068X				ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P25; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; Chen KD, 1997, EUR J BIOCHEM, V248, P120, DOI 10.1111/j.1432-1033.1997.t01-1-00120.x; CHEN KD, 1996, J CELL BIOCHEM, V61, P25; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DAY AR, 1989, DNA-J MOLEC CELL BIO, V8, P301, DOI 10.1089/dna.1.1989.8.301; DECESARE D, 1995, ONCOGENE, V11, P365; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Guay J, 1997, J CELL SCI, V110, P357; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HOU MC, 1993, J CELL BIOCHEM, V51, P91, DOI 10.1002/jcb.240510116; Hsieh KP, 1996, J BIOL CHEM, V271, P2709, DOI 10.1074/jbc.271.5.2709; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; KASSIS S, 1993, AGENTS ACTIONS, V39, pC64, DOI 10.1007/BF01972722; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; KOONG AC, 1994, RADIAT RES, V138, pS60, DOI 10.2307/3578763; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI YK, 1993, J CELL BIOCHEM, V53, P161, DOI 10.1002/jcb.240530209; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE JC, 1993, ANN NY ACAD SCI, V696, P149; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU ES, 1992, J BIOL CHEM, V267, P7128; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Morley SJ, 1997, J BIOL CHEM, V272, P17887, DOI 10.1074/jbc.272.28.17887; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PROSTKO CR, 1991, J BIOL CHEM, V266, P19790; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RESENDEZ E, 1986, J CELL BIOL, V103, P2145, DOI 10.1083/jcb.103.6.2145; Richards JP, 1996, J BIOL CHEM, V271, P13716, DOI 10.1074/jbc.271.23.13716; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; Saklatvala J, 1996, J BIOL CHEM, V271, P6586, DOI 10.1074/jbc.271.12.6586; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; Shuman JD, 1997, J BIOL CHEM, V272, P12793, DOI 10.1074/jbc.272.19.12793; Tamai KT, 1997, RECENT PROG HORM RES, V52, P121; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WATOWICH SS, 1988, MOL CELL BIOL, V8, P393, DOI 10.1128/MCB.8.1.393; WEIZSAECKER M, 1981, J NEUROL, V224, P183, DOI 10.1007/BF00313280; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	73	39	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					749	755		10.1074/jbc.273.2.749	http://dx.doi.org/10.1074/jbc.273.2.749			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422727	hybrid			2022-12-25	WOS:000071411400016
J	Daaka, Y; Luttrell, LM; Ahn, S; Della Rocca, GJ; Ferguson, SSG; Caron, MG; Lefkowitz, RJ				Daaka, Y; Luttrell, LM; Ahn, S; Della Rocca, GJ; Ferguson, SSG; Caron, MG; Lefkowitz, RJ			Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; BETA-ARRESTIN; BETA(2)-ADRENERGIC RECEPTOR; ANGIOTENSIN-II; EGF RECEPTOR; INTERNALIZATION; DESENSITIZATION; PHOSPHORYLATION; SEQUESTRATION; PATHWAY	The classical paradigm for G protein-coupled receptor (GPCR) signal transduction involves the agonist dependent interaction of GPCRs with heterotrimeric G proteins at the plasma membrane and the subsequent generation, by membrane-localized effecters, of soluble second messengers or ion currents, Termination of GPCR signals follows G protein-coupled receptor kinase (GRK)- and beta-arrestin-mediated receptor uncoupling and internalization. Here we show that these paradigms are inadequate to account for GPCR-mediated, Ras-dependent activation of the mitogen-activated protein (MAP) kinases Erk1 and -2, In HEK293 cells expressing dominant suppressor mutants of beta-arrestin or dynamin, beta(2)-adrenergic receptor-mediated activation of MAP kinase is inhibited, The inhibitors of receptor internalization specifically blocked Raf-mediated activation of MEK. Plasma membrane-delimited steps in the GPCR-mediated activation of the MAP kinase pathway, such as tyrosine phosphorylation of Shc and Raf kinase activation by Pas, are unaffected by inhibitors of receptor internalization. Thus, GRKs and beta-arrestins, which uncouple GPCRs and target them for internalization, function as essential elements in the GPCR-mediated MAP kinase signaling cascade.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Lefkowitz, RJ (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA.		Lefkowitz, Robert/AAW-2649-2021; Della Rocca, Gregory/AAM-5281-2021	Luttrell, Louis/0000-0003-2805-6949	NHLBI NIH HHS [HL16037] Funding Source: Medline; NIGMS NIH HHS [T32GM-07171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARAK LS, 1994, J BIOL CHEM, V269, P2790; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRAHAM JM, 1992, CELL BIOL LABFAX; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hoffman JF, 1996, J BIOL CHEM, V271, P18394, DOI 10.1074/jbc.271.31.18394; INGLESE J, 1993, J BIOL CHEM, V268, P23735; Krueger KM, 1997, J BIOL CHEM, V272, P5; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; McClure SJ, 1996, MOL MEMBR BIOL, V13, P189, DOI 10.3109/09687689609160598; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Oppermann M, 1996, J BIOL CHEM, V271, P13266, DOI 10.1074/jbc.271.22.13266; PIPPIG S, 1995, MOL PHARMACOL, V47, P666; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANBIESEN T, 1997, ENDOCR REV, V272, P4637; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WALDO GL, 1983, J BIOL CHEM, V258, P3900; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302	29	452	462	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					685	688		10.1074/jbc.273.2.685	http://dx.doi.org/10.1074/jbc.273.2.685			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422717	hybrid			2022-12-25	WOS:000071411400006
J	Nicholson, MW; Barclay, AN; Singer, MS; Rosen, SD; van der Merwe, PA				Nicholson, MW; Barclay, AN; Singer, MS; Rosen, SD; van der Merwe, PA			Affinity and kinetic analysis of L-selectin (CD62L) binding to glycosylation-dependent cell-adhesion molecule-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIALYL-LEWIS-X; LYMPHOCYTE HOMING RECEPTOR; HIGH ENDOTHELIAL VENULES; P-SELECTIN; CARBOHYDRATE INTERACTIONS; GLYCOPROTEIN LIGAND-1; MONOCLONAL-ANTIBODIES; LEUKOCYTE ADHESION; RAT LYMPHOCYTES; MYELOID CELLS	The selectin family of cell adhesion molecules mediates the tethering and rolling of leukocytes on blood vessel endothelium. It has been postulated that the molecular basis of this highly dynamic adhesion is the low affinity and rapid kinetics of selectin interactions. However, affinity and kinetic analyses of monomeric selections binding their natural ligands have not previously been reported. Leukocyte selectin (L-selectin, CD62L) binds preferentially to O-linked carbohydrates present on a small number of mucin-like glycoproteins, such as glycosylation-dependent cell adhesion molecule-1 (Gly-CAM-1), expressed in high endothelial venules. Gly-CAM-1 is a soluble secreted protein which, following binding to CD62L, stimulates beta(2)-integrin-mediated adhesion of lymphocytes. Using surface plasmon resonance, we show that a soluble monomeric form of CD62L binds to purified immobilized GlyCAM-1 with a dissociation constant (K-d) of 108 mu M. CD62L dissociates from GlyCAM-1 with a very fast dissociation rate constant (greater than or equal to 10 s(-1)) which agrees well with the reported dissociation rate constant of CD62L-mediated leukocyte tethers. The calculated association rate constant is greater than or equal to 10(5) M-1 s(-1). At concentrations just above its mean serum level (similar to 1.5 mu g/ml or similar to 30 nM), GlyCAM-1 binds multivalently to immobilized CD62L. It follows that soluble GlyCAM-1 may cross-link CD62L when it binds to cells, suggesting a mechanism for signal transduction.	Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Immunol, San Francisco, CA 94143 USA	University of Oxford; University of California System; University of California San Francisco; University of California System; University of California San Francisco	van der Merwe, PA (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, S Parks Rd, Oxford OX1 3RE, England.		van der Merwe, P. Anton/F-8539-2011					Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; Barclay A. N., 1997, LEUCOCYTE ANTIGEN FA, V2nd; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BEBBINGTON C R, 1991, Methods (Orlando), V2, P136, DOI 10.1016/S1046-2023(05)80214-2; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BRANDLEY BK, 1993, GLYCOBIOLOGY, V3, P633, DOI 10.1093/glycob/3.6.633; BROWN MH, 1994, PROTEIN ENG, V7, P515, DOI 10.1093/protein/7.4.515; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CLARK SJ, 1988, J EXP MED, V167, P1861, DOI 10.1084/jem.167.6.1861; COOKE RM, 1994, BIOCHEMISTRY-US, V33, P10591, DOI 10.1021/bi00201a004; DAVIS SJ, 1993, BIOCHEM SOC T, V21, P952, DOI 10.1042/bst0210952; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4830, DOI 10.1021/bi00182a011; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; HENSLEY P, 1994, J BIOL CHEM, V269, P23949; HOKE D, 1995, CURR BIOL, V5, P670, DOI 10.1016/S0960-9822(95)00132-1; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; IMAI Y, 1992, GLYCOBIOLOGY, V2, P373, DOI 10.1093/glycob/2.4.373; IMAI Y, 1993, NATURE, V361, P555; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; JACOB GS, 1995, BIOCHEMISTRY-US, V34, P1210, DOI 10.1021/bi00004a014; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; KIKUTA A, 1994, BLOOD, V84, P3766, DOI 10.1182/blood.V84.11.3766.bloodjournal84113766; Koenig A, 1997, GLYCOBIOLOGY, V7, P79, DOI 10.1093/glycob/7.1.79; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NATH D, 1995, J BIOL CHEM, V270, P26184, DOI 10.1074/jbc.270.44.26184; NELSON RM, 1993, BLOOD, V82, P3253; NELSON RM, 1993, J CLIN INVEST, V91, P1157, DOI 10.1172/JCI116275; NICHOLSON MW, 1995, THESIS U OXFORD; PATEL TP, 1994, BIOCHEMISTRY-US, V33, P14815, DOI 10.1021/bi00253a021; Poppe L, 1997, J AM CHEM SOC, V119, P1727, DOI 10.1021/ja9610702; Puri KD, 1997, J IMMUNOL, V158, P405; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; Sanders WJ, 1996, BIOCHEMISTRY-US, V35, P14862, DOI 10.1021/bi9613640; SCUDDER PR, 1994, GLYCOBIOLOGY, V4, P929, DOI 10.1093/glycob/4.6.929; Seddon B, 1996, EUR J IMMUNOL, V26, P2702, DOI 10.1002/eji.1830261123; Simon JHM, 1997, J VIROL, V71, P1476, DOI 10.1128/JVI.71.2.1476-1484.1997; SIMON SI, 1995, J IMMUNOL, V155, P1502; Singer MS, 1996, J IMMUNOL METHODS, V196, P153, DOI 10.1016/0022-1759(96)00106-8; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; TAMATANI T, 1993, J IMMUNOL, V150, P1735; TAMATANI T, 1993, EUR J IMMUNOL, V23, P2181, DOI 10.1002/eji.1830230920; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VANDERMERWE PA, 1993, EMBO J, V12, P4945, DOI 10.1002/j.1460-2075.1993.tb06188.x; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; vanderMerwe PA, 1997, J EXP MED, V185, P393, DOI 10.1084/jem.185.3.393; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; WATANABE T, 1992, BIOCHIM BIOPHYS ACTA, V1131, P321, DOI 10.1016/0167-4781(92)90033-V; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221; WILLIAMS AF, 1991, NATURE, V352, P473, DOI 10.1038/352473a0; WILLIAMS AF, 1977, CELL, V12, P663, DOI 10.1016/0092-8674(77)90266-5; YOSHIDA T, 1994, EUR J BIOCHEM, V222, P703, DOI 10.1111/j.1432-1033.1994.tb18915.x	69	169	174	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					763	770		10.1074/jbc.273.2.763	http://dx.doi.org/10.1074/jbc.273.2.763			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422729	hybrid			2022-12-25	WOS:000071411400018
J	Butscher, WG; Powers, C; Olive, M; Vinson, C; Gardner, K				Butscher, WG; Powers, C; Olive, M; Vinson, C; Gardner, K			Coordinate transactivation of the interleukin-2 CD28 response element by c-Rel and ATF-1/CREB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; NF-KAPPA-B; ACCESSORY MOLECULE CD28; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; PROTEIN-KINASE; MULTIORGAN INFLAMMATION; SIGNAL-TRANSDUCTION; GENE-TRANSCRIPTION; LYMPHOCYTES-T	The interleukin-a CD28 response element (CD28RE) acts as a composite enhancer, in conjunction with a 3'-12-O-tetradecanoylphorbol-13-acetate response element (TRE)-like element, to confer CD28 receptor-dependent inducibility to the interleukin-2 promoter in T-cells, When inserted as a single copy upstream of a basal promoter, this composite enhancer, termed the CD28RE-TRE, is both highly active and CD28-inducible in transactivation assays, A multicomponent nuclear protein complex that binds the CD28RE-TRE was isolated by DNA affinity chromatography from nuclear extracts of mitogen- and CD28 receptor-costimulated hu. man T-cells. Immunological and biochemical analyses of this complex reveal the presence of c-Rel, ATF-1, and CREB2 as major DNA-binding components, Coexpression of c-Rel in combination with ATF-1, CREB2, or ATF-1/CREB2 leads to synergistic transactivation of a CD28RE-TRE reporter plasmid in quiescent Jurkat T-cells, Furthermore, CD28-dependent transactivation of the CD28RE-TRE is specifically inhibited by cAMP response element-binding protein (CREB) dominant-negative expression vectors, Moreover, mutant promoter constructs in which the internal 5'-CD28RE and 3'-TRE-like sequences have been topologically positioned 180 degrees out of phase with one another show loss of mitogen-and CD28-dependent inducibility. Finally, the addition of the CREB binding transcriptional coactivator p300 leads to a dramatic CREB-dependent increase in both mitogen-and CD28-mediated transactivation of the CD28RE-TRE. These findings demonstrate that full physiological responsiveness to CD28 receptor stimulation in T-cells is dependent on topologically linked sequences within the CD28RE-TRE composite enhancer and provide strong support of a direct role for the CREB family of transcription factors and p300/CREB-binding protein coactivator proteins in cytokine gene induction during T-cell activation.	NCI, Pathol Lab, NIH, Bethesda, MD 20892 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gardner, K (corresponding author), NCI, Pathol Lab, NIH, Bldg 10,Rm 2N212, Bethesda, MD 20892 USA.		Powers, Ciaran/E-3890-2011					AHN S, 1998, IN PRESS MOL CELL BI; ALLISON JP, 1994, CURR OPIN IMMUNOL, V6, P414, DOI 10.1016/0952-7915(94)90120-1; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; AVOTS A, 1995, IMMUNOBIOLOGY, V193, P254, DOI 10.1016/S0171-2985(11)80551-6; BARTIK MM, 1994, CELL IMMUNOL, V158, P116, DOI 10.1006/cimm.1994.1261; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; Civil A, 1996, J BIOL CHEM, V271, P8321, DOI 10.1074/jbc.271.14.8321; CIVIL A, 1995, RES IMMUNOL, V146, P158, DOI 10.1016/0923-2494(96)80250-1; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FARINA AR, 1993, J BIOL CHEM, V268, P26466; FRASER JD, 1992, J EXP MED, V175, P1131, DOI 10.1084/jem.175.4.1131; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GARDNER K, 1994, J BIOL CHEM, V269, P32963; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Ho HY, 1997, EUR J IMMUNOL, V27, P222, DOI 10.1002/eji.1830270133; Hsueh YP, 1997, J IMMUNOL, V158, P85; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JUNE CH, 1989, J AUTOIMMUN, V2, P55, DOI 10.1016/0896-8411(89)90117-0; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LIU F, 1993, J BIOL CHEM, V268, P6714; MASSON N, 1993, NUCLEIC ACIDS RES, V21, P4166, DOI 10.1093/nar/21.18.4166; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; PAPAVASSILIOU AG, 1994, ANTICANCER RES, V14, P1801; Powers C, 1996, J BIOL CHEM, V271, P30089, DOI 10.1074/jbc.271.47.30089; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, COLD SPRING HARB SYM, V53, P749, DOI 10.1101/SQB.1988.053.01.085; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.immunol.2.1.319; Snapper CM, 1996, J IMMUNOL, V156, P183; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; THOMPSON CB, 1989, P NATL ACAD SCI USA, V86, P1333, DOI 10.1073/pnas.86.4.1333; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773	65	79	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					552	560		10.1074/jbc.273.1.552	http://dx.doi.org/10.1074/jbc.273.1.552			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417115	hybrid			2022-12-25	WOS:000071295600081
J	Mason, PB; Lis, JT				Mason, PB; Lis, JT			Cooperative and competitive protein interactions at the Hsp70 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TATA-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVATION DOMAIN; HIGHLY CONSERVED DOMAIN; HEAT-SHOCK FACTOR; IN-VIVO; UPSTREAM ACTIVATOR; FACTOR-TFIIB; HSP26 GENE; DROSOPHILA	Drosophila heat shock factor (HSF) binds to specific sequence elements of heat shock genes and can activate their transcription 200-fold. Though HSF has an acidic activation domain, the mechanistic details of heat shock gene activation remain undefined. Here we report that HSF interacts directly with the general transcription factor TBP (TATA-box binding protein), and these two factors bind cooperatively to heat shock promoters. A third factor that binds heat shock promoters, GAGA factor, also interacts with HSF and further stabilizes HSF binding to heat shock elements (HSEs). The interaction of HSF and TBP is explored in some detail here and is shown to be mediated by residues in both the amino- and carboxyl terminal portions of HSF. This HSF/TBP interaction can be specifically disrupted by competition with the potent acidic transcriptional activator VP16. We further show that the acidic domain of the largest subunit of Drosophila RNA polymerase II (Pol II) associates with TBP in vitro and is specifically displaced from TBP upon addition of HSF. The region of TBP that mediates both HSF and Pol II acidic domain binding maps to the conserved carboxyl terminal repeats and depends on at least one of the TBP residues known to be contacted by VP16 and to be critical for transcription activation. We discuss these findings in the context of a model in which HSF triggers hsp70 transcription by freeing the hsp70 promoter-paused Pol II from the constraints on elongation caused by the affinity of Pol II for general transcription factors.	Cornell Univ, Dept Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Cornell University	Lis, JT (corresponding author), Cornell Univ, Dept Biochem Mol & Cell Biol, Ithaca, NY 14853 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025232, R37GM025232] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRADSHER JN, 1993, J BIOL CHEM, V268, P25587; CHATTERJEE S, 1995, NATURE, V374, P820, DOI 10.1038/374820a0; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; GLASER RL, 1990, MOL CELL BIOL, V10, P131, DOI 10.1128/MCB.10.1.131; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KLAGES N, 1995, NATURE, V374, P822, DOI 10.1038/374822a0; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; LEE M, 1995, MOL CELL BIOL, V15, P5461; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; Maniatis T., 1982, MOL CLONING LAB MANU; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; NAKAI A, 1995, MOL CELL BIOL, V15, P5268; NONET ML, 1989, GENETICS, V123, P715; OBRIEN T, 1995, GENE DEV, V9, P1098, DOI 10.1101/gad.9.9.1098; OBRIEN T, 1991, MOL CELL BIOL, V11, P5285, DOI 10.1128/MCB.11.10.5285; PAN GH, 1994, J BIOL CHEM, V269, P30101; PRICE DH, 1987, J BIOL CHEM, V262, P3244; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; Shen F, 1996, J BIOL CHEM, V271, P4827; SHOPLAND LS, 1995, GENE DEV, V9, P2756, DOI 10.1101/gad.9.22.2756; SPENCER CA, 1990, ONCOGENE, V5, P777; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wisniewski J, 1996, NUCLEIC ACIDS RES, V24, P367, DOI 10.1093/nar/24.2.367; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966; XIAO H, 1994, MOL CELL BIOL, V14, P7507, DOI 10.1128/MCB.14.11.7507; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIAO H, 1995, MOL CELL BIOL, V15, P5757	42	78	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33227	33233		10.1074/jbc.272.52.33227	http://dx.doi.org/10.1074/jbc.272.52.33227			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407112	hybrid			2022-12-25	WOS:000071182900073
J	del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC				del Peso, L; Hernandez-Alcoceba, R; Embade, N; Carnero, A; Esteve, P; Paje, C; Lacal, JC			Rho proteins induce metastatic properties in vivo	ONCOGENE			English	Article						Rho proteins; metastasis; dbl; ost; vav	GTP-BINDING PROTEIN; GUANINE-NUCLEOTIDE EXCHANGE; JNK/SAPK SIGNALING PATHWAY; TUMOR-CELL INVASION; ACTIN STRESS FIBERS; PHOSPHOLIPASE-D; RAS TRANSFORMATION; 3T3 CELLS; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION	Rho proteins have been implicated in the regulation of multiple signal transduction processes, Some of the members of this family, including the rho gene from Aplysia californica and the human genes (rhoA, rhoB and rac-1), are proto-oncogenes since when properly mutated they can induce cell transformation, and the generated rho-transformed cells are tumorigenic when inoculated into mice, In addition to their tumorigenic activity, there is evidence suggesting that Rho proteins mag contribute to the metastatic phenotype, However, all the experiments implicating Rho proteins or Rho-regulating proteins in the induction of metastatic potential are either indirect or have been performed in vitro. In this study, we investigated whether cells transformed by rho oncogenes do have metastatic potential in vivo. We present evidence that cells transformed by the Aplysia californica rho gene, when injected directly into the blood stream are able to efficiently colonize lungs and secondary organs, consistent with the acquisition of the metastatic potential, Moreover, tumors derived from subcutaneous injections of these rho-transformed cells are also able to metastasize in distant organs, a strong support to the hypothesis that Rho proteins play a role in the metastatic phenotype. Finally, cells transformed by the human oncogenes dbl, vav and ost, three well-known guanine exchange factors for members of the Rho family, or cells transformed by the activated human rac-1 or rhoA genes do also have metastatic potential when injected into the blood stream, These results demonstrate that signaling pathways regulated by Rho proteins play an important role in the acquisition of the metastatic phenotype in vivo.	CSIC, Inst Invest Biomed, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid, Spain.		del Peso, Luis/K-9391-2014; embade, Nieves/K-5190-2014; Lacal, Juan Carlos/AAL-2235-2020; IBIS, CANCER/P-3323-2015; Lacal, Juan Carlos/N-9064-2015	del Peso, Luis/0000-0003-4014-5688; embade, Nieves/0000-0001-9878-3290; Lacal, Juan Carlos/0000-0002-1908-2777; Carnero, Amancio/0000-0003-4357-3979				AEPFELBACHER M, 1994, P NATL ACAD SCI USA, V91, P4263, DOI 10.1073/pnas.91.10.4263; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1993, RAS SUPERFAMILY GTPA, P203; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, P NATL ACAD SCI USA, V90, P6523, DOI 10.1073/pnas.90.14.6523; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; DAVIES BR, 1993, ONCOGENE, V8, P999; Esteve P, 1995, ONCOGENE, V11, P2657; ESTEVE P, UNPUB; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hirai A, 1997, J BIOL CHEM, V272, P13; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JIMENEZ B, 1995, ONCOGENE, V10, P811; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LEEUWEN FN, 1995, ONCOGENE, V11, P2215; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Miele ME, 1996, MOL CARCINOGEN, V15, P284, DOI 10.1002/(SICI)1098-2744(199604)15:4<284::AID-MC6>3.0.CO;2-G; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PAI JK, 1994, ANTI-CANCER DRUG DES, V9, P363; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PERONA R, 1993, ONCOGENE, V8, P1285; PERONA R, 1997, GENE DEV, V15, P463; PERONA R, 1993, RAS SUPERFAMILY GTPA; PESO L, 1996, BIOCHEM J, V322, P519; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsuka M, 1996, MOL CARCINOGEN, V15, P300, DOI 10.1002/(SICI)1098-2744(199604)15:4<300::AID-MC7>3.0.CO;2-J; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WILLIGER BT, 1995, J BIOL CHEM, V270, P29656; ZHANG J, 1993, J BIOL CHEM, V268, P22251	61	154	159	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 18	1997	15	25					3047	3057						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444953				2022-12-25	WOS:000070968000005
J	Drane, P; Barel, M; Balbo, M; Frade, R				Drane, P; Barel, M; Balbo, M; Frade, R			Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53	ONCOGENE			English	Article						p53; antigen related	WILD-TYPE P53; DNA-BINDING FUNCTION; LARGE T-ANTIGEN; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODY; GROWTH SUPPRESSION; CELLULAR PROTEIN; TUMOR-ANTIGEN; IN-VITRO; KINASE-C	Immunological screening with the anti-p53 moAb, PAb1801 of a cDNA expression library, prepared from human B lymphoma cells, led us to identify a new human 205 kDa protein called RB18A for 'Recognized By PAb1801 moAntibody'. Immunoblotting or immunoprecipitation of fusion protein or in vitro translated protein, respectively, demonstrated that RB18A protein was recognized by several anti-p53 moAb reacting with the N or C-terminal domains of p53. Full length sequence of RB18B cDNA and computer analysis demonstrated that despite common antigenic determinants between RB18A and p53 proteins, nucleotide and deduced protein sequences did not reveal any significant homologies. RB18A mRNA was detected in all tissues tested except in kidney. In addition, RB18A protein shared identical functions with p53 protein: binding to DNA or to p53 and self-oligomerization. Furthermore, RB18A regulated p53 specific binding on his DNA consensus binding site. These functions were associated to the C-terminal domain of RB18A protein and more specifically to the PAb421 binding site present in this domain. The activation by RB18A of p53 binding on DNA was induced through an unstable interaction between both proteins. Altogether, our data demonstrated that RB18A protein shares antigenic and functional properties with p53 and regulated p53 functions.	Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.			BAREL, Monique/0000-0001-8171-7027				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAREL M, 1991, J IMMUNOL, V147, P1286; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DAUD AI, 1993, AM J PHYSIOL, V264, pH1693, DOI 10.1152/ajpheart.1993.264.5.H1693; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; Kim KK, 1996, J BIOL CHEM, V271, P29255, DOI 10.1074/jbc.271.46.29255; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEGROS Y, 1994, ONCOGENE, V9, P2071; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; Milne DM, 1996, ONCOGENE, V13, P205; MILNER J, 1987, ONCOGENE, V1, P453; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Simons A, 1997, ONCOGENE, V14, P145, DOI 10.1038/sj.onc.1200825; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG Q, 1994, MOL CELL BIOL, V14, P1929, DOI 10.1128/MCB.14.3.1929	63	48	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	1997	15	25					3013	3024		10.1038/sj.onc.1201492	http://dx.doi.org/10.1038/sj.onc.1201492			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL559	9444950				2022-12-25	WOS:000070968000002
J	Floreani, M; Skaper, SD; Facci, L; Lipartiti, M; Giusti, P				Floreani, M; Skaper, SD; Facci, L; Lipartiti, M; Giusti, P			Melatonin maintains glutathione homeostasis in kainic acid-exposed rat brain tissues	FASEB JOURNAL			English	Article						oxidative stress; neuroprotection; glutathione peroxidase; glutathione reductase; GSH; ROS	KAINATE-INDUCED EXCITOTOXICITY; INDUCED LIPID-PEROXIDATION; SIGNAL-TRANSDUCING SYSTEM; CEREBELLAR GRANULE CELLS; PRIMARY CULTURES; OXIDATIVE STRESS; NEURONS; DAMAGE; PROTECTION; MECHANISMS	Reduced glutathione (GSH) is a key component of the cellular defense cascade against injury caused by reactive oxygen species, Because kainic acid (KA) neurotoxicity is probably mediated at least in part by oxidative stress, we examined the influence of KA treatment on GSH content and GSH-related enzyme activities in adult rats, A single injection of KA (10 mg/kg i.p.) time-dependently decreased forebrain GSH (maximal reduction at 48 h). KA also markedly lowered GSH levels in amygdala and hippocampus, but not in the corpus striatum, which is resistant to KA injury, The pineal secretory product melatonin has been shown to exert neuroprotective effects against KA-induced excitotoxicity in rats, Melatonin (2.5 mp/kg i.p., administered four times) partially prevented all. decreases in GSH of KA-treated rats, These neuroprotective effects of melatonin may result from a sparing of glutathione reductase, which decreased in KA-treated but not in KA/melatonin-treated animals. Moreover, KA caused a rapid decrease in the GSH content of cultured cerebellar granule neurons but not astrocytes, These cell types both express functional KA receptors, but only the former are sensitive to reactive oxygen species-dependent KA injury, Melatonin counteracted the changes in GSH induced by KA in cultured cerebellar granule neurons, Our results suggest that melatonin prevents the neurotoxic effects of reactive oxygen species linked to KA receptor activation by maintaining cellular GSH homeostasis.	Univ Padua, Dept Pharmacol, I-35131 Padua, Italy	University of Padua	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol, Largo E Meneghetti 2, I-35131 Padua, Italy.			GIUSTi, Pietro/0000-0001-9352-4046				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; BAZAN NG, 1986, BASIC MECH EPILEPSIE, V44, P385; BONDY SC, 1993, BRAIN RES, V610, P229, DOI 10.1016/0006-8993(93)91405-H; CAGNOLI CM, 1995, J PINEAL RES, V18, P222, DOI 10.1111/j.1600-079X.1995.tb00163.x; CARLBERG I, 1975, J BIOL CHEM, V250, P5475; CHENG Y, 1994, NEUROCHEM RES, V19, P1557, DOI 10.1007/BF00969006; CHUANG JI, 1994, J PINEAL RES, V17, P11, DOI 10.1111/j.1600-079X.1994.tb00107.x; Cooper A.J.L., 1993, MOL GENETIC BASIS NE, P209; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; GIUSTI P, 1995, EXP NEUROL, V131, P39, DOI 10.1016/0014-4886(95)90005-5; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; Giusti P, 1996, J PINEAL RES, V20, P226, DOI 10.1111/j.1600-079X.1996.tb00263.x; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Huang J, 1996, BRAIN RES, V711, P184, DOI 10.1016/0006-8993(95)01376-8; JAIN A, 1991, P NATL ACAD SCI USA, V88, P1913, DOI 10.1073/pnas.88.5.1913; KATO K, 1991, J PHARMACOL EXP THER, V256, P402; LEBARS D, 1991, NUCL MED BIOL, V18, P357; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANEV H, 1994, NEUROREPORT, V5, P2661, DOI 10.1097/00001756-199412000-00064; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Maney H., 1995, Society for Neuroscience Abstracts, V21, P1518; Matuszak Z, 1997, FREE RADICAL BIO MED, V23, P367, DOI 10.1016/S0891-5849(96)00614-4; MCCASLIN PP, 1987, BRAIN RES, V417, P380, DOI 10.1016/0006-8993(87)90469-0; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Meister A., 1995, BIOTHIOLS HLTH DIS, P165; Melchiorri D, 1996, BIOCHEM PHARMACOL, V51, P1095, DOI 10.1016/0006-2952(96)00055-X; MELCHIORRI D, 1995, FASEB J, V9, P1205, DOI 10.1096/fasebj.9.12.7672513; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MILANI D, 1989, GLIA, V2, P161, DOI 10.1002/glia.440020305; NICOLETTI F, 1986, J NEUROSCI, V6, P1905; NORLUND JJ, 1977, J CLIN ENDOCR METAB, V45, P768; OLANOW CW, 1992, ANN NEUROL, V32, P52; OLNEY JW, 1974, BRAIN RES, V77, P507, DOI 10.1016/0006-8993(74)90640-4; PHILLIS JW, 1994, PROG NEUROBIOL, V42, P441, DOI 10.1016/0301-0082(94)90046-9; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; PIGEOLET E, 1991, FREE RADICAL BIO MED, V11, P191, DOI 10.1016/0891-5849(91)90171-X; PROHASKA JR, 1976, J NEUROCHEM, V27, P1379, DOI 10.1111/j.1471-4159.1976.tb02619.x; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; SAIJA A, 1994, GEN PHARMACOL-VASC S, V25, P97, DOI 10.1016/0306-3623(94)90016-7; SEWERYNEK E, 1995, J PINEAL RES, V19, P51, DOI 10.1111/j.1600-079X.1995.tb00170.x; Sewerynek E, 1996, HEPATO-GASTROENTEROL, V43, P898; SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17; SPERK G, 1994, PROG NEUROBIOL, V42, P1, DOI 10.1016/0301-0082(94)90019-1; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; Tan DX, 1993, ENDOCR J, V1, P57; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Uz Tolga, 1997, Croatian Medical Journal, V38, P205	52	88	90	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1309	1315		10.1096/fasebj.11.14.9409550	http://dx.doi.org/10.1096/fasebj.11.14.9409550			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409550				2022-12-25	WOS:000071144100012
J	Bergelson, S; Klingmuller, U; Socolovsky, M; Hsiao, JG; Lodish, HF				Bergelson, S; Klingmuller, U; Socolovsky, M; Hsiao, JG; Lodish, HF			Tyrosine residues within the intracellular domain of the erythropoietin receptor mediate activation of AP-1 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; SIGNAL-TRANSDUCTION; STAT5 ACTIVATION; CELL-LINE; PHOSPHORYLATION; GENE; PROLIFERATION; INTERACTS; BINDING; JAK2	Binding of erythropoietin (Epo) to the Epo receptor (EpoR) initiates a signaling cascade resulting in tyrosine phosphorylation of several proteins and induction of AP-1 transcription factor(s). While Epo is known to activate c-fos gene expression, the mechanism of AP-1 activation is unknown. Here we show that AP-1 activation by Epo requires tyrosine kinase activity and also de novo protein synthesis. Using a mutant EpoR containing no cytosolic tyrosine residues, and a set of eight mutants containing a single cytosolic tyrosine residue, we show that multiple EpoR tyrosines, thought to activate multiple intracellular signal transduction proteins, can mediate AP-1 activation. An EpoR containing only tyrosine 343 or tyrosine 464 supports a maximal level of AP-1 activation We also show that AP-1 activation does not require maximal STAT5 activation and may occur via a STAT5-independent signaling pathway.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.		Klingmüller, Ursula/G-8477-2013	Klingmüller, Ursula/0000-0001-9845-3099; Socolovsky, Merav/0000-0001-6747-7960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CURRAN T, 1993, ADV SEC MESS PHOSPH, V28, P271; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; GOBERT S, 1995, BLOOD, V86, P598, DOI 10.1182/blood.V86.2.598.bloodjournal862598; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; Klingmuller U, 1997, P NATL ACAD SCI USA, V94, P3016, DOI 10.1073/pnas.94.7.3016; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; NEUMANN D, 1993, J BIOL CHEM, V268, P13639; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; Rajotte D, 1996, BLOOD, V88, P2906, DOI 10.1182/blood.V88.8.2906.bloodjournal8882906; Shimizu R, 1996, BIOCHEM BIOPH RES CO, V222, P1, DOI 10.1006/bbrc.1996.0688; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; TSUDA H, 1994, EUR J HAEMATOL, V52, P73; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wang DM, 1996, MOL CELL BIOL, V16, P6141; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, NATURE, V377, P242, DOI 10.1038/377242a0; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; Yoshimura A, 1996, EMBO J, V15, P1055, DOI 10.1002/j.1460-2075.1996.tb00443.x	35	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2396	2401		10.1074/jbc.273.4.2396	http://dx.doi.org/10.1074/jbc.273.4.2396			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442088	hybrid			2022-12-25	WOS:000071595200077
J	Huang, XM; Crute, BE; Sun, CH; Tang, YY; Kelley, JJ; Lewis, AF; Hartman, KL; Laue, TM; Speck, NA; Bushweller, JH				Huang, XM; Crute, BE; Sun, CH; Tang, YY; Kelley, JJ; Lewis, AF; Hartman, KL; Laue, TM; Speck, NA; Bushweller, JH			Overexpression, purification, and biophysical characterization of the heterodimerization domain of the core-binding factor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; HETERONUCLEAR NMR-SPECTROSCOPY; ACUTE LYMPHOBLASTIC-LEUKEMIA; FETAL LIVER HEMATOPOIESIS; BACKBONE DYNAMICS; DNA-BINDING; AML1 GENE; ESCHERICHIA-COLI; RUNT DOMAIN; PROTEIN	Core-binding factors (CBF) are heteromeric transcription factors essential for several developmental processes, including hematopoiesis. CBFs contain a DNA-binding CBF alpha subunit and a non-DNA binding CBF beta subunit that increases the affinity of CBF alpha for DNA. We have developed a procedure for overexpressing and purifying full-length CBF beta as web as a truncated form containing the N-terminal 141 amino acids using a novel glutaredoxin fusion expression system. Substantial quantities of the CBF beta proteins can be produced in this manner allowing for their biophysical characterization. me show that the full-length and truncated forms of CBF beta bind to a CBF alpha.DNA complex with very similar affinities, Sedimentation equilibrium measurements show these proteins to be monomeric. Circular dichroism spectroscopy demonstrates that CBF beta is a mixed alpha/beta protein and NMR spectroscopy shows that the truncated and full-length proteins are structurally similar and suitable for structure determination by NMR spectroscopy.	Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Dartmouth Coll, Dept Chem, Hanover, NH 03755 USA; Univ New Hampshire, Dept Biochem, Durham, NH 03824 USA	Dartmouth College; Dartmouth College; University System Of New Hampshire; University of New Hampshire	Huang, XM (corresponding author), Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368; Bushweller, John/0000-0002-5386-1758	NCI NIH HHS [R01 CA75611, R01 CA/GM 58343] Funding Source: Medline; NIAID NIH HHS [K02 AI01481] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058343, R01CA075611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K02AI001481] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Billeter M, 1995, J BIOMOL NMR, V5, P1; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; Cantor C. R., 1980, BIOPHYSICAL CHEM, P563; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P7387, DOI 10.1021/bi00484a006; Crute BE, 1996, J BIOL CHEM, V271, P26251, DOI 10.1074/jbc.271.42.26251; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Golling G, 1996, MOL CELL BIOL, V16, P932; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GRASBERGER BL, 1993, J MOL BIOL, V230, P364, DOI 10.1006/jmbi.1993.1152; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; Kagoshima H, 1996, J BIOL CHEM, V271, P33074, DOI 10.1074/jbc.271.51.33074; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KHARAKOZ DP, 1989, BIOPHYS CHEM, V34, P115, DOI 10.1016/0301-4622(89)80049-3; LAUE TM, 1992, DS835 BECKM INSTR IN; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU PP, 1995, BLOOD, V85, P2289, DOI 10.1182/blood.V85.9.2289.bloodjournal8592289; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; POWERS R, 1992, BIOCHEMISTRY-US, V31, P9150, DOI 10.1021/bi00153a006; PRESS WH, 1986, NUMERICAL RECIPES AR, P683; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; SKLENAR V, 1987, J MAGN RESON, V73, P375, DOI 10.1016/0022-2364(87)90214-9; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; STAROVASNIK MA, 1992, BIOCHEMISTRY-US, V31, P9891, DOI 10.1021/bi00156a006; THORNELL A, 1991, J VIROL, V65, P42, DOI 10.1128/JVI.65.1.42-50.1991; VENABLE RM, 1988, BIOPOLYMERS, V27, P1001, DOI 10.1002/bip.360270609; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WILLIAMSON M P, 1990, Biopolymers, V29, P1423, DOI 10.1002/bip.360291009; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	53	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2480	2487		10.1074/jbc.273.4.2480	http://dx.doi.org/10.1074/jbc.273.4.2480			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442100	hybrid			2022-12-25	WOS:000071595200089
J	Khvotchev, M; Sudhof, TC				Khvotchev, M; Sudhof, TC			Developmentally regulated alternative splicing in a novel synaptojanin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL; BINDING; PROTEIN; YEAST	Phosphatidylinositol phosphates (PIPs) perform central functions in signal transduction and membrane traffic. Synaptojanin is a PIP 5-phosphatase that is expressed in a brain-specific and a ubiquitous splice variants and is thought to constitute the major PIP B-phosphatase in mammalian brain (Woscholski, R., Finan, P. M., Radley, E., Totty, N. F., Sterling, A. E., Hsuan, J. J., Waterfield, M. D., and Parker, P. J. (1997) J. Biol. Chem, 272, 9625-9628). me now describe synaptojanin 2, a novel isoform of synaptojanin that, similar to synaptojanin 1, contains an N-terminal SAC1-like sequence and a central 5-phosphatase domain but a distinct, unique C-terminal sequence. Transfection studies demonstrated that synaptojanin 2, like synaptojanin 1, is an active PIP phosphatase. An interesting feature of synaptojanin 1 is the presence of a long open reading frame in the 3' region of the brain mRNA that in non-brain tissues is joined to the coding region by alternative splicing, resulting in a shorter synaptojanin 1 form in brain and a longer form in peripheral tissues (Ramjaun, A. R., and McPherson, P. S. (1996) J. Biol. Chem 271, 24856-24861). Although it exhibits no homology to synaptojanin I in this region, synaptojanin 2 also contains an open reading frame in the 3' region that is subject to alternative splicing. Similar to synaptojanin 1, alternative splicing of synaptojanin 2 is tissue-specific and creates a shorter isoform expressed in brain and a longer form in peripheral tissues. The similar alternative splicing of two homologous proteins in a region of non-homology raises the possibility of evolutionary convergence and supports the significance of the variants. Analysis of mRNAs from three brain regions at different developmental stages revealed that alternative splicing of synaptojanin 2 is a developmentally late event, occurring only after the first postnatal week after the generation of neurons and initial synaptogenesis.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA.		Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER; NIMH NIH HHS [R01-MH52804] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; Hao WH, 1997, J BIOL CHEM, V272, P6393, DOI 10.1074/jbc.272.10.6393; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; Jefferson AB, 1996, BIOCHEMISTRY-US, V35, P7890, DOI 10.1021/bi9602627; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Majerus PW, 1996, GENE DEV, V10, P1051, DOI 10.1101/gad.10.9.1051; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NORRIS FA, 1995, J BIOL CHEM, V270, P214, DOI 10.1074/jbc.270.1.214; NOVICK P, 1989, GENETICS, V121, P659; Ramjaun AR, 1996, J BIOL CHEM, V271, P24856, DOI 10.1074/jbc.271.40.24856; Sambrook J., 2002, MOL CLONING LAB MANU; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; Woscholski R, 1995, J BIOL CHEM, V270, P31001, DOI 10.1074/jbc.270.52.31001; Woscholski R, 1997, J BIOL CHEM, V272, P9625	18	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2306	2311		10.1074/jbc.273.4.2306	http://dx.doi.org/10.1074/jbc.273.4.2306			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442075	hybrid			2022-12-25	WOS:000071595200064
J	Takemori, H; Zolotaryov, FN; Ting, L; Urbain, T; Komatsubara, T; Hatano, O; Okamoto, M; Tojo, H				Takemori, H; Zolotaryov, FN; Ting, L; Urbain, T; Komatsubara, T; Hatano, O; Okamoto, M; Tojo, H			Identification of functional domains of rat intestinal phospholipase B/lipase - Its cDNA cloning, expression, and tissue distribution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; LACTASE-PHLORHIZIN HYDROLASE; GUINEA-PIG; TEST MEAL; PROTEIN; BIOSYNTHESIS; ANCHOR; LYSOPHOSPHOLIPASE; GLYCOSIDASES; PURIFICATION	A cDNA encoding a rat intestinal Ca2+-independent phospholipase B/lipase (PLB/LIP) was cloned from an ileac mucosa cDNA library using a probe amplified by polymerase chain reaction based on the purified enzyme's sequence. PLB/LIP consists of an NH2-terminal signal peptide, four tandem repeats of about 350 amino acids each, and a hydrophobic domain near the COOH terminus. The enzyme purified previously was found to be derived from the second repeat part. To examine the function of each domain, the full-length PLB/LIP, individual repeats, and a protein lacking the COOH-terminal hydrophobic stretch were expressed in COS-7 cells. The results showed that the second repeat, but not the other repeats, had all the activities (phospholipase A(2), lysophospholipase, and lipase) found in the purified natural and expressed full-length enzymes, suggesting repeat 2 is a catalytic domain. The full-length enzyme was mainly present in membrane fractions and efficiently solubilized by treatment with 1% Triton X-100, but not with phosphatidylinositol-specific phospholipase C. Deletion of the COOH-terminal hydrophobic stretch caused the secretion of >90% of synthesized PLB/LIP into culture media. These results suggest the hydrophobic domain is not replaced by a glycosylphosphatidylinositol anchor but serves as a membrane anchor directly. A message of the full-length PLB/LIP was abundantly expressed in the ileum and also, in a smaller, but significant amount, in the esophagus and testis. Immunohistochemistry showed that PLB/LIP is localized in brush border membranes of the absorptive cells, Paneth cells, and acrosomes of spermatid, suggesting its roles related and unrelated to intestinal digestion.	Osaka Univ, Sch Med, Dept Mol Physiol Chem, Suita, Osaka 565, Japan; Nara Med Univ, Dept Anat, Shijo, Kashiwara 634, Japan	Osaka University; Nara Medical University	Tojo, H (corresponding author), Osaka Univ, Sch Med, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 565, Japan.	htojo@mr-mbio.med.osaka-u.ac.jp						BERGET SM, 1984, NATURE, V309, P179, DOI 10.1038/309179a0; BLACK SM, 1993, ENDOCRINOLOGY, V132, P539, DOI 10.1210/en.132.2.539; BOLL W, 1993, J BIOL CHEM, V268, P12901; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CARRIERE F, 1993, SCAND J GASTROENTERO, V28, P443, DOI 10.3109/00365529309098247; DIAGNE A, 1987, LIPIDS, V22, P33, DOI 10.1007/BF02534872; ELSBACH P, 1979, J BIOL CHEM, V254, P1000; GASSAMADIAGNE A, 1992, J BIOL CHEM, V267, P13418; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARWIG SSL, 1995, J CLIN INVEST, V95, P603, DOI 10.1172/JCI117704; HATANO O, 1994, DEVELOPMENT, V120, P2787; HOOPER NM, 1988, BIOCHEM J, V250, P865, DOI 10.1042/bj2500865; KELLER P, 1995, FEBS LETT, V368, P563, DOI 10.1016/0014-5793(95)00679-4; Kurabuchi S, 1997, CELL TISSUE RES, V288, P485, DOI 10.1007/s004410050834; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MINAMI T, 1993, BIOCHIM BIOPHYS ACTA, V1170, P125; NONAKA Y, 1995, EUR J BIOCHEM, V229, P249, DOI 10.1111/j.1432-1033.1995.tb20462.x; PALAZZOLO MJ, 1990, GENE, V88, P25, DOI 10.1016/0378-1119(90)90056-W; PIND S, 1991, BIOCHEM CELL BIOL, V69, P346, DOI 10.1139/o91-054; PIND S, 1989, LIPIDS, V24, P357, DOI 10.1007/BF02535141; RAPOPORT TA, 1991, FASEB J, V5, P2792, DOI 10.1096/fasebj.5.13.1916103; Rinderknecht H, 1986, EXOCRINE PANCREAS BI, P163; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; TABOR S, 1990, CURRENT PROTOCOLS S, V11; TATSUMI H, 1990, HISTOCHEMISTRY, V94, P135, DOI 10.1007/BF02440179; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; Tojo H, 1998, J BIOL CHEM, V273, P2214, DOI 10.1074/jbc.273.4.2214; TOJO H, 1988, J BIOL CHEM, V263, P5724; TOJO H, 1993, J LIPID RES, V34, P837; WACKER H, 1992, J BIOL CHEM, V267, P18744	33	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2222	2231		10.1074/jbc.273.4.2222	http://dx.doi.org/10.1074/jbc.273.4.2222			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442065	hybrid			2022-12-25	WOS:000071595200054
J	Erickson, JP; Wu, JJ; Goddard, JG; Tigyi, G; Kawanishi, K; Tomei, LD; Kiefer, MC				Erickson, JP; Wu, JJ; Goddard, JG; Tigyi, G; Kawanishi, K; Tomei, LD; Kiefer, MC			Edg-2/Vzg-1 couples to the yeast pheromone response pathway selectively in response to lysophosphatidic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; PROTEIN-TYROSINE PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; MAP KINASE; RAT-1 FIBROBLASTS; ALPHA-SUBUNIT; GROWTH-FACTOR; CELL-CYCLE; RECEPTOR; ACTIVATION	We have functionally expressed the human cDNA encoding the putative lysophosphatidic acid (LPA) receptor Edg-2 (Vzg-1) in Saccharomyces cerevisiae in an attempt to determine the agonist specificity of this G-protein-coupled receptor. LPA activated the pheromone response pathway in S. cerevisiae expressing Edg-2 in a time- and dose-dependent manner as determined by induction of a pheromone-responsive FUS1::lacZ reporter gene, LPA-mediated activation of the pheromone response pathway was dependent on mutational inactivation of the SST2 gene, the GTPase-activating protein for the yeast G(alpha) protein (the GPA1 gene product), This indicates that, in sst2 Delta yeast cells, Edg-2 can efficiently couple to the yeast heterotrimeric G-protein in response to LPA and activate the yeast mitogen-activated protein kinase pathway, The Edg-2 receptor showed a high degree of specificity for LPA; other lyso-glycerophospholipids, sphingosine 1-phosphate, and diacyl-glycerophospholipids did not activate FUS1::lacZ. LPA analogs including a cyclic phosphoester form and ether-linked forms of LPA activated FUS1::lacZ, although fatty acid chains of 6 and 10 carbons did not activate FUS1::lacZ, suggesting a role for the side chain in ligand binding or receptor activation, These results indicate that Edg-2 encodes a highly specific LPA receptor.	LXR Biotechnol Inc, Richmond, CA 94804 USA; Univ Tennessee, Dept Physiol & Biophys, Coll Med, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Erickson, JP (corresponding author), LXR Biotechnol Inc, 1401 Marina Way S, Richmond, CA 94804 USA.	jerickson@lxr.com						AHMED S, 1993, J BIOL CHEM, V268, P10709; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; BLUMER KJ, 1988, J BIOL CHEM, V263, P10836; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Casamassima A, 1997, J BIOL CHEM, V272, P9363; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; ELION EA, 1991, COLD SPRING HARB SYM, V56, P41; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; FREIDMAN P, 1997, J BIOL CHEM, V271, P953; Guo Z, 1996, P NATL ACAD SCI USA, V93, P14367, DOI 10.1073/pnas.93.25.14367; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1993, J BIOL CHEM, V268, P20717; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; JANLINK K, 1995, BIOCHEM J, V307, P609; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KING K, 1990, SCIENCE, V250, P121, DOI 10.1126/science.2171146; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Macrae AD, 1996, MOL BRAIN RES, V42, P245, DOI 10.1016/S0169-328X(96)00128-3; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; MOLLENAAR WH, 1997, CURR OPIN CELL BIOL, V9, P168; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; NEIMAN AM, 1993, TRENDS GENET, V9, P390, DOI 10.1016/0168-9525(93)90139-9; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; Price LA, 1996, MOL PHARMACOL, V50, P829; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; TIGYI G, 1994, P NATL ACAD SCI USA, V91, P1908, DOI 10.1073/pnas.91.5.1908; Umansky SR, 1997, CELL DEATH DIFFER, V4, P608, DOI 10.1038/sj.cdd.4400282; Yatomi Y, 1997, J BIOL CHEM, V272, P5291, DOI 10.1074/jbc.272.8.5291; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	44	111	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1506	1510		10.1074/jbc.273.3.1506	http://dx.doi.org/10.1074/jbc.273.3.1506			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430689	hybrid			2022-12-25	WOS:000071411500036
J	Greenwood, JA; Pallero, MA; Theibert, AB; Murphy-Ullrich, JE				Greenwood, JA; Pallero, MA; Theibert, AB; Murphy-Ullrich, JE			Thrombospondin signaling of focal adhesion disassembly requires activation of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTEGRIN-ASSOCIATED PROTEIN; CELL-SURFACE CALRETICULIN; HUMAN-MELANOMA CELLS; SWISS 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; VINCULIN DISTRIBUTION; EXTRACELLULAR-MATRIX; REGULATORY SUBUNIT; ENDOTHELIAL-CELLS	Thrombospondin is an extracellular matrix protein involved in modulating cell adhesion, Thrombospondin stimulates a rapid loss of focal adhesion plaques and reorganization of the actin cytoskeleton in cultured bovine aortic endothelial cells, The focal adhesion labilizing activity of thrombospondin is localized to the amino-terminal domain, specifically amino acids 17-35, Use of a synthetic peptide (hep I), containing amino acids 17-35 of thrombospondin, enables us to examine the signaling mechanisms specifically involved in thrombospondin-induced disassembly of focal adhesions, We tested the hypothesis that activation of phosphoinositide 3-kinase is a necessary step in the thrombospondin-induced signaling pathway regulating focal adhesion disassembly. Both wortmannin and LY294002, membrane permeable inhibitors of phosphoinositide 3-kinase activity, blocked hep I-induced disassembly of focal adhesions. Similarly, wortmannin inhibited hep I-mediated actin microfilament reorganization and the hep I-induced translocation of alpha-actinin from focal adhesion plaques. Hep I also stimulated phosphoinositide 3-kinase activity approximately 2-3-fold as measured in anti-phosphoinositide 3-kinase and anti-phosphotyrosine immunoprecipitates. Increased immunoreactivity for the 85-kDa regulatory subunit in anti-phosphotyrosine immunoprecipitates suggests that the p85/p110 form of phosphoinositide 3-kinase is involved in this pathway, In P-32(i)-labeled cells, hep I increased levels of phosphatidylinositol (3,4,5)-trisphosphate, the major product of phosphoinositide 3-kinase phosphorylation. These results suggest that thrombospondin signals the disassembly of focal adhesions and reorganization of the actin cytoskeleton by a pathway involving stimulation of phosphoinositide 3-kinase activity.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Greenwood, JA (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall G038, Birmingham, AL 35294 USA.	jeffrey@vh.path.uab.edu		Greenwood, Juliet/0000-0001-6438-964X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH050102] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07450] Funding Source: Medline; NICHD NIH HHS [P50HD32901] Funding Source: Medline; NIMH NIH HHS [R29 MH50102] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Antonetti DA, 1996, MOL CELL BIOL, V16, P2195; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Bachelot C, 1996, BBA-MOL CELL RES, V1311, P45, DOI 10.1016/0167-4889(95)00176-X; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; Chellaiah M, 1996, MOL BIOL CELL, V7, P743, DOI 10.1091/mbc.7.5.743; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GEIGER B, 1992, COLD SPRING HARB SYM, V57, P631, DOI 10.1101/SQB.1992.057.01.069; GILMORE AP, 1996, SCIENCE, V381, P531; GLASS WF, 1993, J CELL PHYSIOL, V157, P296; GOUT I, 1992, BIOCHEM J, V288, P395, DOI 10.1042/bj2880395; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HADARI YR, 1992, J BIOL CHEM, V267, P17483; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HERMAN B, 1986, J CELL PHYSIOL, V126, P115, DOI 10.1002/jcp.1041260116; HYNES RO, 1990, FIBRONECTINS, P200; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu PJ, 1997, J BIOL CHEM, V272, P466; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Molz L, 1996, J BIOL CHEM, V271, P13892, DOI 10.1074/jbc.271.23.13892; MurphyUllrich JE, 1996, J CELL SCI, V109, P2499; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1988, J BIOL CHEM, V263, P6400; MURPHYULLRICH JE, 1987, J CELL BIOL, V105, P1603, DOI 10.1083/jcb.105.4.1603; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; MURPHYULLRICH JE, 1995, TRENDS GLYCOSCI GLYC, V7, P89; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; NOBES CD, 1995, J CELL SCI, V108, P225; PAVALKO FM, 1995, EXP CELL RES, V217, P534, DOI 10.1006/excr.1995.1119; PONS S, 1995, MOL CELL BIOL, V15, P4453; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; ROBERTS DD, 1988, CANCER RES, V48, P6785; ROBERTS DD, 1987, J CELL BIOL, V104, P131, DOI 10.1083/jcb.104.1.131; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLIWA M, 1984, J CELL BIOL, V99, P1045, DOI 10.1083/jcb.99.3.1045; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; Shimizu Y, 1996, IMMUNOL TODAY, V17, P565, DOI 10.1016/S0167-5699(96)10061-X; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; SUN XJ, 1989, J BIOL CHEM, V264, P11288; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TIDBALL JG, 1993, J CELL BIOL, V123, P627, DOI 10.1083/jcb.123.3.627; TOKER A, 1994, J BIOL CHEM, V269, P32358; TURNER CE, 1989, J BIOL CHEM, V264, P11938; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Vanhaesebroeck B, 1996, CANCER SURV, V27, P249; Virbasius JV, 1996, J BIOL CHEM, V271, P13304, DOI 10.1074/jbc.271.23.13304; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; WOODS A, 1988, COLLAGEN REL RES, V8, P155; WOODS A, 1992, J CELL SCI, V101, P277; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	76	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1755	1763		10.1074/jbc.273.3.1755	http://dx.doi.org/10.1074/jbc.273.3.1755			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430723	hybrid			2022-12-25	WOS:000071411500070
J	Hehner, SP; Heinrich, M; Bork, PM; Vogt, M; Ratter, F; Lehmann, V; Schulze-Osthoff, K; Droge, W; Schmitz, ML				Hehner, SP; Heinrich, M; Bork, PM; Vogt, M; Ratter, F; Lehmann, V; Schulze-Osthoff, K; Droge, W; Schmitz, ML			Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TRANSCRIPTION FACTOR; SODIUM-SALICYLATE; ENDOTHELIAL-CELLS; PROTEASOME PATHWAY; POTENT INHIBITORS; INDUCED APOPTOSIS; GENE-EXPRESSION; MICE LACKING; PROTEIN	Extracts from certain Mexican Indian medicinal plants used in traditional indigenous medicine for the treatment of inflammations contain sequiterpene lactones (SLs), which specifically inhibit the transcription factor NF-kappa B (Bork, P. M., Schmitz, M. L., Kuhnt, M., Escher, C., and Heinrich, M. (1997) FEES Lett. 402, 85-90). Here we show that SLs prevented the activation of NF-kappa B by different stimuli such as phorbol esters, tumor necrosis factor-alpha, ligation of the T-cell receptor, and hydrogen peroxide in various cell types. Treatment of cells with SLs prevented the induced degradation of I kappa B-alpha and I kappa B-beta by all these stimuli, suggesting that they interfere with a rather common step in the activation of NF-kappa B. SLs did neither interfere with DNA binding activity of activated NF-kappa B nor with the activity of the protein tyrosine kinases p59(fyn) and p60(src). Micromolar amounts of SLs prevented the induced expression of the NF-kappa B target gene intracellular adhesion molecule 1. Inhibition of NF-kappa B by SLs resulted in an enhanced cell killing of murine fibroblast cells by tumor necrosis factor-alpha. SLs lacking an exomethylene group in conjugation with the lactone function displayed no inhibitory activity on NF-kappa B. The analysis of the cellular redox state by fluorescence-activated cell sorter showed that the SLs had no direct or indirect anti oxidant properties.	Deutsch Krebsforschungszentrum, Immunochem Abt, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Pharmaceut Biol, D-79104 Freiburg, Germany; Dept Internal Med 1, Med Clin, D-72076 Tubingen, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of Freiburg	Schmitz, ML (corresponding author), Deutsch Krebsforschungszentrum, Immunochem Abt, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	l.schmitz@dkfz-heidelberg.de	Schulze-Osthoff, Klaus/N-9025-2013; Schmitz, M. Lienhard/D-9328-2017; Heinrich, Michael/C-3727-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Schmitz, M. Lienhard/0000-0002-6984-7192; Heinrich, Michael/0000-0003-2611-6303				ALAM M, 1992, Indian Journal of Experimental Biology, V30, P38; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BEYAERT R, 1994, FEBS LETT, V340, P9, DOI 10.1016/0014-5793(94)80163-0; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Chen C H, 1994, Bioorg Med Chem, V2, P137, DOI 10.1016/S0968-0896(00)82008-8; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cobb RR, 1996, EUR J IMMUNOL, V26, P839, DOI 10.1002/eji.1830260417; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Hayashi K, 1996, J ANTIMICROB CHEMOTH, V37, P759, DOI 10.1093/jac/37.4.759; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hwang D, 1996, BIOCHEM BIOPH RES CO, V226, P810, DOI 10.1006/bbrc.1996.1433; IM WB, 1985, J BIOL CHEM, V260, P9452; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Lawrenson JG, 1996, J NEUROL SCI, V139, P117; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Limbourg FP, 1996, J BIOL CHEM, V271, P20392, DOI 10.1074/jbc.271.34.20392; Lipton SA, 1997, NAT MED, V3, P20, DOI 10.1038/nm0197-20; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PERRY NB, 1995, J NAT PRODUCTS, V58, P1131, DOI 10.1021/np50121a027; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; Schmitz ML, 1995, TOXICOL LETT, V82-3, P407, DOI 10.1016/0378-4274(95)03491-9; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115; SUMNER H, 1992, BIOCHEM PHARMACOL, V43, P2313, DOI 10.1016/0006-2952(92)90308-6; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; Weimann C, 1997, BOT ACTA, V110, P62, DOI 10.1111/j.1438-8677.1997.tb00612.x; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zumbansen M, 1997, J BIOL CHEM, V272, P10904	67	347	363	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1288	1297		10.1074/jbc.273.3.1288	http://dx.doi.org/10.1074/jbc.273.3.1288			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430659	hybrid			2022-12-25	WOS:000071411500006
J	Hosaka, M; Sudhof, TC				Hosaka, M; Sudhof, TC			Synapsins I and II are ATP-binding proteins with differential Ca2+ regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE PHOSPHOPROTEINS; PHOSPHORYLATION; KINASE; ACTIN; GENE; MICE; RAT	Synapsins I and II are abundant phosphoproteins that are localized to synaptic vesicles and have essential functions in regulating synaptic vesicle exocytosis, Synapsins contain a single evolutionarily conserved, large central domain, the C-domain, that accounts for the majority of their sequences, Unexpectedly, the crystal structure of the C-domain from synapsin I revealed that it is structurally closely related to several ATPases despite the absence of sequence similarities (Esser, L., Wang, C.-R., Hosaka, M., Smagula, C. S., Sudhof, T. C., and Deisenhofer, J. (1998) EMBO J., in press). We now show that the C-domains of both synapsin I and synapsin II constitute high affinity ATP-binding modules, The two C-domains exhibit similar ATP affinities but are differentially regulated; ATP binding to synapsin I is Ca2+-dependent whereas ATP binding to synapsin II, is Ca2+-independent, In synapsin I, the Ca2+ requirement for ATP binding is mediated by a single, evolutionarily conserved glutamate residue (Glu(373)) at a position where synapsin II contains a lysine residue, Exchange of Glu(373) for lysine converts synapsin I from a Ca2+-dependent protein into a Ca2+-independent ATP-binding protein, Our studies suggest that synapsins I and II function on synaptic vesicles as ATP-binding proteins that are differentially regulated by Ca2+.	Univ Texas, SW Med Sch, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Dept Mol Genet, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Sch, Howard Hughes Med Inst, Dallas, TX 75235 USA.	TSudho@mednet.swmed.edu		Hosaka, Masahiro/0000-0002-1422-1774				Artymiuk PJ, 1996, NAT STRUCT BIOL, V3, P128, DOI 10.1038/nsb0296-128; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; ESSER L, 1998, IN PRESS EMBO J; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HO MF, 1991, J BIOL CHEM, V266, P5600; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JOHNSON EM, 1972, J BIOL CHEM, V247, P5650; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Klagges BRE, 1996, J NEUROSCI, V16, P3154; Matsubara M, 1996, J BIOL CHEM, V271, P21108, DOI 10.1074/jbc.271.35.21108; Matsuda K, 1996, PROTEIN ENG, V9, P1083, DOI 10.1093/protein/9.12.1083; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; Ryan TA, 1996, J CELL BIOL, V134, P1219, DOI 10.1083/jcb.134.5.1219; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; STONE DK, 1984, J BIOL CHEM, V259, P2701; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1996, UEH MEM FDN S INT MO, P3; Tang JX, 1996, J BIOL CHEM, V271, P8556, DOI 10.1074/jbc.271.15.8556; ULLRICH B, 1995, NEUROPHARMACOLOGY, V34, P1371, DOI 10.1016/0028-3908(95)00132-P; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314	28	85	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1425	1429		10.1074/jbc.273.3.1425	http://dx.doi.org/10.1074/jbc.273.3.1425			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430678	hybrid			2022-12-25	WOS:000071411500025
J	Huang, XZ; Honkanen, RE				Huang, XZ; Honkanen, RE			Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-THREONINE PHOSPHATASES; RECESSIVE RETINITIS-PIGMENTOSA; CATALYTIC SUBUNIT; POTENT INHIBITOR; HEPATOMA-CELLS; CALCINEURIN-A; CDNA CLONE; SEQUENCE; TYPE-2A; DOMAIN	A novel serine/threonine protein phosphatase (PPase) designated PP7 was identified from cDNA produced from human retina RNA. PP7 has a molecular mass of similar to 75 kDa, and the deduced amino acid sequence of PP7 contains a phosphatase catalytic core domain that possesses all of the invariant motifs of the PP1, PP2A, PP2B, PP4, PP5, and PP6 gene family. However, PP7 has unique N- and C-terminal regions and shares <35% identity with the other known PPases. The unique C-terminal region of PP7 contains multiple Ca2+ binding sites (i.e. EF-hand motifs). This region of PP7 is similar to the Drosophila retinal degeneration C gene product (rdgC), and PP7 and rdgC share 42.1% identity. Unlike the other known PPases, the expression of PP7 is not ubiquitous; PP7 was only detected in retina and retinal-derived Y-79 retinoblastoma cells. Expression of recombinant human PP7 in baculovirus-infected SF21 insect cells produces an active soluble enzyme that is capable of utilizing phosphohistone and p-nitrophenyl phosphate as substrates. The activity of recombinant PP7 is dependent on Mg2+ and is activated by calcium (IC50 congruent to 250 mu M). PP7 is not affected by calmodulin and is insensitive to inhibition by okadaic acid, microcystin-LR, calyculin A, and cantharidin.	Univ S Alabama, Dept Biochem & Mol Biol, Coll Med, Mobile, AL 36688 USA	University of South Alabama	Honkanen, RE (corresponding author), Univ S Alabama, Dept Biochem & Mol Biol, Coll Med, MSB 2198, Mobile, AL 36688 USA.	Honkanen@sungcg.usouthal.edu			NATIONAL CANCER INSTITUTE [R01CA060750, R29CA060750] Funding Source: NIH RePORTER; NCI NIH HHS [CA60750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARINO J, 1988, P NATL ACAD SCI USA, V85, P4252, DOI 10.1073/pnas.85.12.4252; BARIK S, 1993, P NATL ACAD SCI USA, V90, P10633, DOI 10.1073/pnas.90.22.10633; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BARKER HM, 1994, BBA-MOL CELL RES, V1220, P212, DOI 10.1016/0167-4889(94)90138-4; BARTON GJ, 1994, EUR J BIOCHEM, V220, P225, DOI 10.1111/j.1432-1033.1994.tb18618.x; Bastians H, 1996, J CELL SCI, V109, P2865; BECKER W, 1994, J BIOL CHEM, V269, P22586; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BREWIS ND, 1992, BIOCHIM BIOPHYS ACTA, V1171, P231, DOI 10.1016/0167-4781(92)90129-N; BREWIS ND, 1993, EMBO J, V12, P987, DOI 10.1002/j.1460-2075.1993.tb05739.x; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; CHINKERS M, 1994, P NATL ACAD SCI USA, V91, P11075, DOI 10.1073/pnas.91.23.11075; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1991, METHOD ENZYMOL, V201, P389; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; CRITZ SD, 1995, NEUROPROTOCOLS, V6, P78; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; Ferreira PA, 1995, DEGENERATIVE DISEASES OF THE RETINA, P263; FOWLES C, 1989, BIOCHEMISTRY-US, V28, P9385, DOI 10.1021/bi00450a020; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GORDON SE, 1992, NEURON, V9, P739, DOI 10.1016/0896-6273(92)90036-D; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HONKANAN RE, 1994, TOXICON, V32, P339, DOI 10.1016/0041-0101(94)90086-8; HONKANEN RE, 1993, FEBS LETT, V330, P283, DOI 10.1016/0014-5793(93)80889-3; HONKANEN RE, 1990, J BIOL CHEM, V265, P19401; HONKANEN RE, 1991, MOL PHARMACOL, V40, P577; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; KINCAID RL, 1988, P NATL ACAD SCI USA, V85, P8983, DOI 10.1073/pnas.85.23.8983; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; KUNO T, 1989, BIOCHEM BIOPH RES CO, V165, P1352, DOI 10.1016/0006-291X(89)92752-6; MCLAUGHLIN ME, 1995, P NATL ACAD SCI USA, V92, P3249, DOI 10.1073/pnas.92.8.3249; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Minke B, 1995, DEGENERATIVE DISEASES OF THE RETINA, P227; MURAMATSU T, 1992, P NATL ACAD SCI USA, V89, P529, DOI 10.1073/pnas.89.2.529; Ohguro H, 1996, J BIOL CHEM, V271, P5215; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P415, DOI 10.1021/bi00428a001; PALCZEWSKI K, 1991, EXP EYE RES, V53, P101, DOI 10.1016/0014-4835(91)90151-4; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; SAADAT M, 1994, CANCER DETECT PREV, V18, P115; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; SHASTRY BS, 1994, AM J MED GENET, V52, P467, DOI 10.1002/ajmg.1320520413; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SILVA EFDE, 1991, BIOCHIM BIOPHYS ACTA, V1089, P269, DOI 10.1016/0167-4781(91)90023-F; SILVA OBDC, 1987, FEBS LETT, V226, P176; SOGAWA K, 1995, CANCER LETT, V89, P1; SONG Q, 1993, GENE, V129, P291, DOI 10.1016/0378-1119(93)90282-8; SOUIED EH, 1997, INVESTIG OPHTHLAMO S, V38, P796; Stark WS, 1995, DEGENERATIVE DISEASES OF THE RETINA, P217; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; WADZINSKI BE, 1990, J BIOL CHEM, V265, P21504; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; ZACK DJ, 1997, INVESTIG OPHTHALMO S, V38, P911; ZHUO S, 1993, J BIOL CHEM, V268, P17754	60	100	108	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1462	1468		10.1074/jbc.273.3.1462	http://dx.doi.org/10.1074/jbc.273.3.1462			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430683	hybrid			2022-12-25	WOS:000071411500030
J	Lin, YL; Shivji, MKK; Chen, C; Kolodner, R; Wood, RD; Dutta, A				Lin, YL; Shivji, MKK; Chen, C; Kolodner, R; Wood, RD; Dutta, A			The evolutionarily conserved zinc finger motif in the largest subunit of human replication protein a is required for DNA replication and mismatch repair but not for nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMIAN VIRUS-40 DNA; POLYMERASE-ALPHA-PRIMASE; BINDING-PROTEIN; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; CALF THYMUS; SV40 ORIGIN; DROSOPHILA-MELANOGASTER; CRITHIDIA-FASCICULATA	The largest subunit of the replication protein A (RPA) contains an evolutionarily conserved zinc finger motif that lies outside of the domains required for binding to single-stranded DNA or forming the RPA holocomplex. In previous studies, we showed that a point mutation in this motif (RPA(m)) cannot support SV40 DNA replication. We have now investigated the role of this motif in several steps of DNA replication and in two DNA repair pathways. RPA(m) associates with T antigen, assists the unwinding of double-stranded DNA at an origin of replication, stimulates DNA polymerases alpha and delta, and supports the formation of the initial short Okazaki fragments. However, the synthesis of a leading strand and later Okazaki fragments is impaired. In contrast, RPA(m) can function well during the incision step of nucleotide excision repair and in a full repair synthesis reaction, with either UV-damaged or cisplatin-adducted DNA. Two deletion mutants of the Rpa1 subunit (eliminating amino acids 1-278 or 222-411) were not functional in nucleotide excision repair. We report for the first time that wild type RPA is required for a mismatch repair reaction in vitro. Neither the deletion mutants nor RPA(m) can support this reaction. Therefore, the zinc finger of the largest subunit of RPA is required for a function that is essential for DNA replication and mismatch repair but not for nucleotide excision repair.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Dana Farber Canc Inst, Charles A Dana Div Human Canc Genet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Dutta, A (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	adutta@bustoff.bwh.harvard.edu	Dutta, Anindya/P-3203-2016; Chen, Clark C/C-8714-2013; Wood, Richard/M-6319-2018	Chen, Clark C/0000-0001-6258-9277; Wood, Richard/0000-0002-9495-6892; Dutta, Anindya/0000-0002-4319-0073	NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050006] Funding Source: NIH RePORTER; NCI NIH HHS [CA60499, R01 CA060499, R01 CA060499-05] Funding Source: Medline; NIGMS NIH HHS [GM 50006] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADACHI Y, 1992, J CELL BIOL, V119, P1, DOI 10.1083/jcb.119.1.1; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; ATRAZHEV A, 1992, EUR J BIOCHEM, V210, P855, DOI 10.1111/j.1432-1033.1992.tb17489.x; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; BULLOCK PA, 1989, P NATL ACAD SCI USA, V86, P3944, DOI 10.1073/pnas.86.11.3944; BULLOCK PA, 1991, MOL CELL BIOL, V11, P2350, DOI 10.1128/MCB.11.5.2350; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DEAN FB, 1987, P NATL ACAD SCI USA, V84, P16, DOI 10.1073/pnas.84.1.16; DENIS D, 1993, MOL CELL BIOL, V13, P2882, DOI 10.1128/MCB.13.5.2882; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; DUTTA A, 1995, CELL CYCLE MAT METHO, P175; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GOETZ GS, 1988, J BIOL CHEM, V263, P383; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; KENNY MK, 1990, J BIOL CHEM, V265, P769; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LANFORD RE, 1988, VIROLOGY, V167, P72, DOI 10.1016/0042-6822(88)90055-4; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; LI L, 1995, MOL CELL BIOL, V15, P5396; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; Longhese MP, 1996, NUCLEIC ACIDS RES, V24, P3533, DOI 10.1093/nar/24.18.3533; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Moggs JG, 1996, J BIOL CHEM, V271, P7177, DOI 10.1074/jbc.271.12.7177; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MUSTERNASSAL C, 1986, P NATL ACAD SCI USA, V83, P7618, DOI 10.1073/pnas.83.20.7618; NAKAGAWA M, 1991, NUCLEIC ACIDS RES, V19, P4292, DOI 10.1093/nar/19.15.4292; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Podust VN, 1997, J BIOL CHEM, V272, P6303, DOI 10.1074/jbc.272.10.6303; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; ROBERTS JD, 1993, METHODS MOL GENET, V2, P295; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHIVJI MKK, 1995, BIOCHEMISTRY-US, V34, P5011, DOI 10.1021/bi00015a012; SMITH J, 1995, MOL CELL BIOL, V15, P1632; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950	78	126	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1453	1461		10.1074/jbc.273.3.1453	http://dx.doi.org/10.1074/jbc.273.3.1453			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430682	hybrid			2022-12-25	WOS:000071411500029
J	Matsuya, M; Sasaki, H; Aoto, H; Mitaka, T; Nagura, K; Ohba, T; Ishino, M; Takahashi, S; Suzuki, R; Sasaki, T				Matsuya, M; Sasaki, H; Aoto, H; Mitaka, T; Nagura, K; Ohba, T; Ishino, M; Takahashi, S; Suzuki, R; Sasaki, T			Cell adhesion kinase beta forms a complex with a new member, Hic-5, of proteins localized at focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-SITU HYBRIDIZATION; TYROSINE KINASE; MOLECULAR-CLONING; LIM DOMAIN; PAXILLIN; PHOSPHORYLATION; BINDING; IDENTIFICATION; ACTIVATION; CYTOSKELETAL	Cell adhesion kinase beta (CAK beta/PYK2) is the second protein-tyrosine kinase of the focal adhesion kinase subfamily, We identified a cDNA that encodes a CAK beta-binding protein, This cDNA clone encodes the human homologue of Hic-5, the cDNA of which was cloned in 1994 as transforming growth factor beta 1- and hydrogen peroxide-inducible mRNA. We found that Hic-5 exclusively localized at focal adhesions in a rat fibroblast line, WFB., This localization of Hic-5 was confirmed in WFB cells expressing Myc-tagged Hic-5, The amino acid sequence of Hic-5 is highly similar to that of paxillin in the four LD motifs as well as in the four contiguous LIM domains. The Hic-5 N-terminal domain directly associated in vitro with the extreme C-terminal region (residue 801 to the end) of CAK beta., CAK beta was coimmunoprecipitated with Hic-5 from the WFB cell lysate, The coimmunoprecipitation of CAK beta with Hic-5 was markedly inhibited by the addition of the extreme C-terminal region of CAK beta., Coimmunoprecipitation of Hic-5 with CAK beta, which was shown in COS-7 cells doubly transfected with cDNA constructs of CAK beta and Myc-tagged Hic-5, was lost when the CAK beta amino acid residues 741-903 were deleted, Hic-5 was tyrosine-phosphorylated in Src-transformed 3Y1 cells and in cells treated with pervanadate. Hic-5 associated with CAK beta was selectively tyrosine-phosphorylated in WFB cells exposed to hypertonic osmotic stress, These results indicate that Hic-5 is a paxillin-related component of focal adhesions and binds to CAK beta, implying possible involvement of Hic-5 in the downstream signaling of CAK beta.	Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Biochem,Chuo Ku, Sapporo, Hokkaido 060, Japan; Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Pathol,Chuo Ku, Sapporo, Hokkaido 060, Japan	Sapporo Medical University; Sapporo Medical University	Sasaki, T (corresponding author), Sapporo Med Univ, Sch Med, Canc Res Inst, Dept Biochem,Chuo Ku, South-1,West-17, Sapporo, Hokkaido 060, Japan.		Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; DAWID IB, 1995, CR ACAD SCI III-VIE, V318, P295; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Inazawa J, 1996, HUM GENET, V98, P508, DOI 10.1007/s004390050249; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Ma EA, 1997, EUR J IMMUNOL, V27, P329, DOI 10.1002/eji.1830270147; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MICHALOPOULOS G, 1975, EXP CELL RES, V94, P70, DOI 10.1016/0014-4827(75)90532-7; Mitaka T, 1997, AM J PATHOL, V150, P267; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Sasaki Hiroko, 1995, Tumor Research, V30, P37; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Shibanuma M, 1997, MOL CELL BIOL, V17, P1224, DOI 10.1128/MCB.17.3.1224; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; TANAKA H, 1988, J CELL PHYSIOL, V136, P421, DOI 10.1002/jcp.1041360305; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; WENG ZG, 1993, J BIOL CHEM, V268, P14956; Wu RY, 1996, J BIOL CHEM, V271, P15934, DOI 10.1074/jbc.271.27.15934; YAGIHASHI A, 1988, CANCER RES, V48, P2798; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	49	116	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1003	1014		10.1074/jbc.273.2.1003	http://dx.doi.org/10.1074/jbc.273.2.1003			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422762	hybrid			2022-12-25	WOS:000071411400051
J	Wilks, A; Schmitt, MP				Wilks, A; Schmitt, MP			Expression and characterization of a heme oxygenase (Hmu O) from Corynebacterium diphtheriae - Iron acquisition requires oxidative cleavage of the heme macrocycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; YERSINIA-ENTEROCOLITICA; TRANSPORT-SYSTEM; TOXIN; PROTEIN; DTXR; HEMOGLOBIN; SEQUENCE; BINDING; BACTERIA	A full-length heme oxygenase gene from the pathogenic bacterium Corynebacterium diphtheriae has been subcloned and expressed in Escherichia coli. The enzyme is expressed at high levels as a soluble catalytically active protein that results in the accumulation of biliverdin within the E. coli cells. The purified heme oxygenase forms a 1:1 complex with heme (K-d, 2.5 +/- 1 mu M) and has hemeprotein spectra similar to those previously reported for the purified eukaryotic heme oxygenases. In the presence of an E. coli NADPH-dependent reductase isolated during the purification of Hmu O, the heme-Hmu O complex is catalytically turned over to yield biliverdin IX alpha and carbon monoxide, A number of redox partners were investigated for their ability to reconstitute Hmu O activity in vitro. Of these the most efficient appeared to be the recombinant NADH-dependent putidaredoxin/putidaredoxin reductase from Pseudomonas putida. As with the E. coli NADPH-dependent reductase the final products of the reaction were biliverdin IX alpha and carbon monoxide. This is the first bacterial heme oxygenase to be described to date. The close relationship between iron acquisition and pathogenesis suggests that the release of iron from heme by heme oxygenase may play a crucial role in the pathogenicity of C. diphtheriae.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; US FDA, Lab Bacterial Toxins, Div Bacterial Prod, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; US Food & Drug Administration (FDA)	Wilks, A (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	wilks@cgl.ucsf.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026743, R01DK030297] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK30297, P30 DK26743] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BLANTON KJ, 1990, J BACTERIOL, V172, P5225, DOI 10.1128/jb.172.9.5225-5235.1990; BOYD J, 1990, P NATL ACAD SCI USA, V87, P5968, DOI 10.1073/pnas.87.15.5968; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRAUN V, 1985, TRENDS BIOCHEM SCI, V10, P76; CHRISTIE AB, 1987, INFECT DIS EPIDEMIOL, V2, P1183; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; EFSTRATIOU A, 1993, LANCET, V341, P1592, DOI 10.1016/0140-6736(93)90727-X; ESCHENBRENNER M, 1994, BIOCHEM BIOPH RES CO, V198, P127, DOI 10.1006/bbrc.1994.1018; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazazzera BA, 1996, J BIOL CHEM, V271, P2762, DOI 10.1074/jbc.271.5.2762; Lee JH, 1997, INFECT IMMUN, V65, P4273, DOI 10.1128/IAI.65.10.4273-4280.1997; MILLS M, 1995, J BACTERIOL, V177, P3004, DOI 10.1128/jb.177.11.3004-3009.1995; OCARRA P, 1969, FEBS LETT, V5, P295; OTTO BR, 1992, CRIT REV MICROBIOL, V18, P217, DOI 10.3109/10408419209114559; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; Sambrook J., 2002, MOL CLONING LAB MANU; SCHACTER BA, 1972, J BIOL CHEM, V247, P3601; SCHMITT MP, 1991, INFECT IMMUN, V59, P1899, DOI 10.1128/IAI.59.6.1899-1904.1991; Schmitt MP, 1997, INFECT IMMUN, V65, P4634, DOI 10.1128/IAI.65.11.4634-4641.1997; SCHMITT MP, 1994, J BACTERIOL, V176, P1141, DOI 10.1128/JB.176.4.1141-1149.1994; Schmitt MP, 1997, J BACTERIOL, V179, P838, DOI 10.1128/jb.179.3.838-845.1997; STOEBNER JA, 1988, INFECT IMMUN, V56, P2891, DOI 10.1128/IAI.56.11.2891-2895.1988; STOJILJKOVIC I, 1994, MOL MICROBIOL, V13, P719, DOI 10.1111/j.1365-2958.1994.tb00465.x; STOJILJKOVIC I, 1992, EMBO J, V11, P4359, DOI 10.1002/j.1460-2075.1992.tb05535.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAO X, 1994, MOL MICROBIOL, V14, P191, DOI 10.1111/j.1365-2958.1994.tb01280.x; WEINBERG ED, 1978, MICROBIOL REV, V42, P45, DOI 10.1128/MMBR.42.1.45-66.1978; Wilks A, 1996, BIOCHEMISTRY-US, V35, P930, DOI 10.1021/bi952405f; WILKS A, 1995, BIOCHEMISTRY-US, V34, P4421, DOI 10.1021/bi00013a034; WILKS A, 1993, J BIOL CHEM, V268, P22357; YOSHIDA T, 1979, J BIOL CHEM, V254, P4487	35	178	181	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					837	841		10.1074/jbc.273.2.837	http://dx.doi.org/10.1074/jbc.273.2.837			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422739	hybrid			2022-12-25	WOS:000071411400028
J	Cong, M; Thompson, VF; Goll, DE; Antin, PB				Cong, M; Thompson, VF; Goll, DE; Antin, PB			The bovine calpastatin gene promoter and a new N-terminal region of the protein are targets for cAMP-dependent protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE CALPASTATIN; ACTIVATED NEUTRAL PROTEASE; M-CALPAIN; ENDOGENOUS INHIBITOR; MOLECULAR DIVERSITY; ESCHERICHIA-COLI; PIG CALPASTATIN; PURIFICATION; PROTEOLYSIS; EXPRESSION	To investigate the regulation of calpastatin gene expression, we isolated bovine heart calpastatin cDNAs and 5'-regions of the calpastatin gene. Analysis of 5'-cDNA sequence identified a new translation initiation site that is in frame and 204 nucleotides upstream of the previously designated start site, Conceptual translation from this upstream AUG produces a protein containing 68 additional N-terminal amino acids. This "XL" region contains three potential PKA phosphorylation sites but shares no homology with other regions of calpastatin or with any known protein, Immunoblot studies demonstrated that heart and liver contain a calpastatin protein of 145 kDa on SDS-polyacrylamide gel electrophoresis that comigrates with full-length bacterially expressed calpastatin and calpastatin produced by coupled in vitro transcription-translation from the upstream AUG, An antibody raised against the XL region recognized the 145 kDa band, demonstrating that the upstream AUG is utilized and that the 145-kDa band represents full-length calpastatin in vivo, Transient transfection assays demonstrated that sequence within 272 nucleotides upstream of transcription initiation of the calpastatin gene is sufficient to direct moderate level transcription. Promoter sequences further upstream act to inhibit or stimulate transcriptional activity. Exposure of transfected cells to dibutyryl cAMP resulted in a 7-20-fold increase in promoter activity for constructs containing at least 272 nucleotides of upstream promoter sequence. Deletion analysis indicates that at least one cAMP-responsive element resides within 102 nucleotides of transcription initiation.	Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA; Univ Arizona, Dept Anat & Cell Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona; University of Arizona	Antin, PB (corresponding author), Univ Arizona, Dept Nutr Sci, Tucson, AZ 85721 USA.	pba@u.arizona.edu		Antin, Parker/0000-0001-9066-7412				ADACHI Y, 1991, J BIOL CHEM, V266, P3968; Asada K, 1989, J Enzyme Inhib, V3, P49, DOI 10.3109/14756368909030363; BRUSTIS JJ, 1994, EUR J CELL BIOL, V64, P320; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DEJONGH KS, 1994, J NEUROCHEM, V63, P1558, DOI 10.1046/j.1471-4159.1994.63041558.x; DELMAS V, 1994, REV PHYSIOL BIOCH P, V124, P1, DOI 10.1007/BFb0031030; EDMUNDS T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P197, DOI 10.1016/0167-4838(91)90059-9; EMORI Y, 1987, P NATL ACAD SCI USA, V84, P3590, DOI 10.1073/pnas.84.11.3590; EMORI Y, 1988, J BIOL CHEM, V263, P2364; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABENER JF, 1995, VITAM HORM, V51, P1057; HATHAWAY DR, 1982, J BIOL CHEM, V257, P9072; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; ISHIDA S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P436; KAPPRELL HP, 1989, J BIOL CHEM, V264, P17888; KILLEFER J, 1994, J ANIM SCI, V72, P606, DOI 10.2527/1994.723606x; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRETCHMAR DH, 1990, J ANIM SCI, V68, P1760; LEE WJ, 1992, J BIOL CHEM, V267, P8437; LEPLEY RA, 1985, BIOCHIM BIOPHYS ACTA, V828, P95, DOI 10.1016/0167-4838(85)90014-7; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1988, J BIOL CHEM, V263, P10254; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLGREN RL, 1986, ARCH BIOCHEM BIOPHYS, V246, P233, DOI 10.1016/0003-9861(86)90468-6; MELLGREN RL, 1983, ARCH BIOCHEM BIOPHYS, V225, P779, DOI 10.1016/0003-9861(83)90089-9; OTSUKA Y, 1987, J BIOL CHEM, V262, P5839; PARR T, 1992, EUR J BIOCHEM, V208, P333, DOI 10.1111/j.1432-1033.1992.tb17191.x; PONTREMOLI S, 1992, BIOCHEM BIOPH RES CO, V187, P751, DOI 10.1016/0006-291X(92)91259-S; SALAMINO F, 1994, BIOCHEM BIOPH RES CO, V199, P1326, DOI 10.1006/bbrc.1994.1376; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SHANNON JD, 1985, INTRACELLULAR PROTEI, P257; SHEA TB, 1995, J NEUROCHEM, V65, P517; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1991, BIOMED BIOCHIM ACTA, V50, P517; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG SY, 1988, J ANIM SCI, V66, P2545	40	85	90	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					660	666		10.1074/jbc.273.1.660	http://dx.doi.org/10.1074/jbc.273.1.660			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417129	hybrid			2022-12-25	WOS:000071295600095
J	Di Matteo, G; Salerno, M; Guarguaglini, G; Di Fiore, B; Palitti, F; Lavia, P				Di Matteo, G; Salerno, M; Guarguaglini, G; Di Fiore, B; Palitti, F; Lavia, P			Interactions with single-stranded and double-stranded DNA-binding factors and alternative promoter conformation upon transcriptional activation of the Htf9-a/RanBP1 and Htf9-c genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOIC ACID RECEPTORS; RNA-POLYMERASE-II; HOUSEKEEPING PROMOTER; RESPONSE ELEMENT; CPG ISLAND; C-MYC; REGULATORY ELEMENT; CELL-CYCLE; PROTEIN; MOUSE	The murine Htf9-a/RanBP1 and Htf9-c genes are divergently transcribed from a shared TATA-less promoter. Transcription of both genes is initiated on complementary DNA strands and is controlled by cell cycle-dependent mechanisms, The bidirectional promoter harbors a genomic footprint flanking the major transcription start site of both genes, Transient promoter assays showed that the footprinted element is important for transcription of both genes. Protein-binding experiments and antibody assays indicated that members of the retinoid X receptor family interact with the double-stranded site, In addition, distinct factors interact with single DNA strands of the element, Double-stranded binding factors were highly expressed in liver cells, in which neither gene is transcribed, while single-stranded binding proteins were abundant in cycling cells, in which transcription of both genes is efficient, In vivo S1 analysis of the promoter depicted an S1-sensitive organization in cells in which transcription of both genes is active; SI sensitivity was not detected in conditions of transcriptional repression, Thus, the same element is a target for either retinoid X receptor factors, or for single-stranded binding proteins, and form distinct complexes in different cellular conditions depending on the DNA conformation in the binding site.	Univ Rome La Sapienza, CNR, Ctr Evolutionary Genet, Dept Genet & Mol Biol, I-00185 Rome, Italy; Univ Rome La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome	Lavia, P (corresponding author), Univ Rome La Sapienza, CNR, Ctr Evolutionary Genet, Dept Genet & Mol Biol, I-00185 Rome, Italy.		Lavia, Patrizia/J-5793-2019; Lavia, Patrizia/AAL-3982-2021	Lavia, Patrizia/0000-0003-3310-6701; SALERNO, Massimiliano/0000-0002-1093-5454; DI MATTEO, GIGLIOLA/0000-0001-8344-5635				ACKERMAN SL, 1993, P NATL ACAD SCI USA, V90, P11865, DOI 10.1073/pnas.90.24.11865; BAZAR L, 1995, J BIOL CHEM, V270, P8241, DOI 10.1074/jbc.270.14.8241; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BOUTERFA HL, 1995, DNA CELL BIOL, V14, P909, DOI 10.1089/dna.1995.14.909; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; Brunel F, 1996, NUCLEIC ACIDS RES, V24, P1608, DOI 10.1093/nar/24.9.1608; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen S, 1997, MOL ENDOCRINOL, V11, P3, DOI 10.1210/me.11.1.3; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DIMATTEO G, 1995, CELL GROWTH DIFFER, V6, P1213; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; Giffin W, 1995, DNA CELL BIOL, V14, P1025, DOI 10.1089/dna.1995.14.1025; Guarguaglini G, 1997, BIOCHEM J, V325, P277, DOI 10.1042/bj3250277; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HUDSON LG, 1990, CELL, V62, P1165, DOI 10.1016/0092-8674(90)90393-S; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAVIA P, 1987, EMBO J, V6, P2773, DOI 10.1002/j.1460-2075.1987.tb02572.x; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Michelotti GA, 1996, MOL CELL BIOL, V16, P2656, DOI 10.1128/mcb.16.6.2656; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; NAGATA T, 1994, GENE, V142, P183, DOI 10.1016/0378-1119(94)90259-3; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Rush MG, 1996, BIOESSAYS, V18, P103, DOI 10.1002/bies.950180206; Saito H, 1996, J BIOL CHEM, V271, P8911, DOI 10.1074/jbc.271.15.8911; SANTRA M, 1994, J BIOL CHEM, V269, P579; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; Schulman IG, 1997, GENE DEV, V11, P299, DOI 10.1101/gad.11.3.299; SHIMURA H, 1995, MOL ENDOCRINOL, V9, P527, DOI 10.1210/me.9.5.527; SOMMA MP, 1991, NUCLEIC ACIDS RES, V19, P2817, DOI 10.1093/nar/19.11.2817; SOMMA MP, 1991, NUCLEIC ACIDS RES, V19, P4451, DOI 10.1093/nar/19.16.4451; Soprano DR, 1996, ONCOGENE, V12, P577; STAPLETON G, 1993, NUCLEIC ACIDS RES, V21, P2465, DOI 10.1093/nar/21.10.2465; TOMONAGA, 1996, P NATL ACAD SCI US, V93, P5830; TYNDALL C, 1992, J MOL BIOL, V226, P289, DOI 10.1016/0022-2836(92)90945-G; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5814, DOI 10.1073/pnas.89.13.5814; Xu G, 1996, J BIOL CHEM, V271, P16008, DOI 10.1074/jbc.271.27.16008; YANG YZ, 1995, ENDOCRINOLOGY, V136, P2896, DOI 10.1210/en.136.7.2896; ZENZIEGREGORY B, 1993, MOL CELL BIOL, V13, P3841, DOI 10.1128/MCB.13.7.3841	47	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					495	505		10.1074/jbc.273.1.495	http://dx.doi.org/10.1074/jbc.273.1.495			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417108				2022-12-25	WOS:000071295600074
J	Lai, WS; Thompson, MJ; Blackshear, PJ				Lai, WS; Thompson, MJ; Blackshear, PJ			Characteristics of the intron involvement in the mitogen-induced expression of Zfp-36	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; FINGER TRANSCRIPTION FACTOR; RECEPTOR GENE-EXPRESSION; BOX-BINDING PROTEINS; DNA-BINDING; SYNERGISTIC ACTIVATION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; SV40 ENHANCER	Zfp-36, the gene encoding the putative zinc finger protein tristetraprolin (TTP), is rapidly induced in fibro blasts by a variety of growth factors. Recent gene knockout experiments have shown that TTP-deficient mice developed arthritis, cachexia, and autoimmunity, all apparently mediated by an excess of tumor necrosis factor cu, We recently showed that full serum inducibility of Zfp-36 requires elements in the promoter; in addition, removal of the single intron strikingly inhibited serum-induced TTP expression, We show here that replacement of the intron with unrelated sequences, or removal of 95% of the intron but retention of the splice sites, each resulted in the maintenance of approximately 45 and 19%, respectively, of full serum-induced expression. In addition, deletion of intron sequences base pairs 601-655 decreased the serum-induced expression of TTP by 65%. Sequence base pairs 618-626 bound specifically to the transcription factor Spl; mutation of this binding motif decreased TTP expression by 70%, suggesting that Spl binding to this motif contributes to serum induction of Zfp-36. We conclude that full serum-induced expression of Zfp-36 depends on the activation of conventional promoter elements as well as elements in the single intron, and that the presence per se of the intron in its natural location also contributes significantly to the regulated expression of this gene.	Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Sect Diabet & Metab,Div Endocrinol Metab & Nutr, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, MD-A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.		Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007012, K11DK002227] Funding Source: NIH RePORTER; NIDDK NIH HHS [K11-DK02227-02, T32-DK-07012] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P789, DOI 10.1101/SQB.1988.053.01.089; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALDWIN AS, 1987, MOL CELL BIOL, V7, P305, DOI 10.1128/MCB.7.1.305; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; BANERJI J, 1983, CELL, V33, P729, DOI 10.1016/0092-8674(83)90015-6; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; CALLIS J, 1987, GENE DEV, V1, P1183, DOI 10.1101/gad.1.10.1183; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DAngelo DD, 1996, J BIOL CHEM, V271, P19696, DOI 10.1074/jbc.271.33.19696; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GILLIES SD, 1983, CELL, V33, P717, DOI 10.1016/0092-8674(83)90014-4; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HAMANN L, 1994, MOL CELL BIOL, V14, P5786, DOI 10.1128/MCB.14.9.5786; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; LAI WS, 1995, J BIOL CHEM, V270, P25266, DOI 10.1074/jbc.270.42.25266; LAI WS, 1990, J BIOL CHEM, V265, P16556; LEMAIGRE FP, 1990, MOL CELL BIOL, V10, P1811, DOI 10.1128/MCB.10.4.1811; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Liska Deann J., 1992, Gene Expression, V2, P379; LOBACH DF, 1993, GENOMICS, V17, P194, DOI 10.1006/geno.1993.1301; MA QF, 1995, ONCOGENE, V10, P487; MADORE SJ, 1995, VIROLOGY, V206, P1150, DOI 10.1006/viro.1995.1041; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; POGULIS RJ, 1993, J BIOL CHEM, V268, P2493; ROTHENEDER H, 1991, NUCLEIC ACIDS RES, V19, P6805, DOI 10.1093/nar/19.24.6805; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; THOMPSON MJ, 1994, J BIOL CHEM, V269, P21127; Thompson MJ, 1996, GENE, V174, P225, DOI 10.1016/0378-1119(96)00084-4; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WAKABAYASHIITO N, 1994, J BIOL CHEM, V269, P29831; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794; Xie W.Q., 1991, BIOTECHNIQUES, V11, P326; YOST SE, 1993, MOL CELL BIOL, V13, P5439, DOI 10.1128/MCB.13.9.5439; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x	62	44	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					506	517		10.1074/jbc.273.1.506	http://dx.doi.org/10.1074/jbc.273.1.506			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417109	hybrid			2022-12-25	WOS:000071295600075
J	Larsson, PKA; Claesson, HE; Kennedy, BP				Larsson, PKA; Claesson, HE; Kennedy, BP			Multiple splice variants of the human calcium-independent phospholipase A(2) and their effect on enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANKYRIN-LIKE REPEATS; HUMAN-LYMPHOCYTES; ARACHIDONIC-ACID; CELL-DEATH; 5-LIPOXYGENASE; EXPRESSION; PROTEINS; PURIFICATION; GENE	Recently, the cloning of a novel Ca2+-independent phospholipase A(2) (iPLA(2)) from Chinese hamster ovary cells as well as from mouse and rat sources containing a C-terminal lipase motif and eight N-terminal ankyrin repeats has been described. In this report we describe the cloning of the human iPLA(2) cDNA and its expression in B-cells and show that the iPLA(2) gene undergoes extensive alternative splicing generating multiple isoforms that contribute to a novel mechanism to control iPLA(2) activity. The full-length cDNA clone encodes a 806-amino acid protein with a calculated molecular mass of 88 kDa, The protein contains a lipase motif, GXSXG, and ankyrin repeats, as described for the hamster and rodent forms of the enzyme but has an additional 54-amino acid proline rich insertion in the last of the eight ankyrin repeats (residues 395-449). Furthermore, at least three additional isoforms most likely due to alternative splicing were identified. One that is present as a partial cDNA in the expressed sequence tag data base is similar to iPLA(2) but terminates just after the lipase active site, and two other-isoforms contain only the iPLA(2) ankyrin repeat sequence (ankyrin-iPLA(2)-1 and -2), Ankyrin repeats are involved in protein-protein interactions and because the purified iPLA(2) enzyme exists as a multimeric complex of 270-350 kDa, the expression of just the ankyrin-iPLA(2) sequence suggested that these may also interact with the iPLA(2) oligomeric complexes and perhaps modulate PLA(2) activity. Transfection of the human iPLA(2) cDNA into COS cells resulted in a substantial increase in calcium-independent PLA(2) activity in cell lysate, No activity above background was observed following ankyrin-iPLA(2)-1 cDNA transfection. However, co-transfection of the ankyrin-iPLA(2)-1 and the iPLA(2) cDNAs resulted in a 2-fold reduction in activity compared with iPLA(2) alone, A similar co-transfection of ankyrin-iPLA(2)-1 cDNA with the cPLA(2) cDNA had no effect on PLA(2) activity, These results suggest that the ankyrin-iPLA(2) sequence can function as a negative regulator of iPLA(2) activity and that the alternative splicing of the iPLA(2) gene can have a direct effect on the attenuation of enzyme activity.	Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Dorval, PQ H9R 4P8, Canada	Karolinska Institutet; Merck & Company	Claesson, HE (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, Doktorsringen 9A3, S-17177 Stockholm, Sweden.			Forsell, Pontus/0000-0002-8384-1547; Claesson, Hans-Erik/0000-0002-1960-6542				ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; AVILACARINO J, 1987, INT J CANCER, V40, P691, DOI 10.1002/ijc.2910400521; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CHEN J, 1994, J BIOL CHEM, V269, P2365; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; FELTENMARK S, 1995, BRIT J HAEMATOL, V90, P585, DOI 10.1111/j.1365-2141.1995.tb05588.x; Gilbert JJ, 1996, J IMMUNOL, V156, P2054; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; HAZEN SL, 1991, BIOCHEM J, V280, P581, DOI 10.1042/bj2800581; HIRASHIMA Y, 1992, J NEUROCHEM, V59, P708, DOI 10.1111/j.1471-4159.1992.tb09426.x; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; JAKOBSSON PJ, 1995, EUR J BIOCHEM, V232, P37, DOI 10.1111/j.1432-1033.1995.tb20778.x; JAKOBSSON PJ, 1992, P NATL ACAD SCI USA, V89, P3521, DOI 10.1073/pnas.89.8.3521; JAKOBSSON PJ, 1991, BIOCHEM BIOPH RES CO, V178, P302, DOI 10.1016/0006-291X(91)91814-S; JAKOBSSON PJ, 1995, ADV PROSTAG THROMB L, V23, P293; Ma ZM, 1997, J BIOL CHEM, V272, P11118; OITVAI ZN, 1994, CELL, V79, P189; Portilla D, 1996, J BIOL CHEM, V271, P15451, DOI 10.1074/jbc.271.26.15451; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tew DG, 1996, ARTERIOSCL THROM VAS, V16, P591, DOI 10.1161/01.ATV.16.4.591; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7	34	165	172	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					207	214		10.1074/jbc.273.1.207	http://dx.doi.org/10.1074/jbc.273.1.207			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417066	hybrid			2022-12-25	WOS:000071295600032
J	Wong, M; Fish, EN				Wong, M; Fish, EN			RANTES and MIP-1 alpha activate stats in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; ANGIOTENSIN-II; CHEMOATTRACTANT PROTEIN-1; RHEUMATOID-ARTHRITIS; SIGNAL-TRANSDUCTION; CYTOKINE RECEPTORS; CHEMOKINE RANTES; HUMAN BASOPHIL; BETA-FAMILY; EXPRESSION	The chemokines RANTES (regulated on activation, normal T cell expressed and secreted) and MIP (macrophage inflammatory protein)-1 alpha have been implicated in regulating T cell functions. RANTES-induced T cell activation is apparently mediated via two distinct signal transduction cascades: one linked to recruitment of pertussis toxin-sensitive G proteins and the other linked to protein-tyrosine kinase activation. In this report, we identified that the transcription factors Stat1 and Stat3 (for signal transducers and activators of transcription) are rapidly activated in T cells in response to RANTES and MIP-1 alpha. Nuclear extracts from MOLT-4 and Jurkat T cells treated with RANTES or MIP-1 alpha contain tyrosine-phosphorylated Stat1:1 and Stat1:3 dimers that exhibit DNA-binding activity. We demonstrated that RANTES and MIP-1 alpha treatment of Jurkat cells resulted in transcriptional activation of a Stat-inducible gene, c-fos, with kinetics consistent with Stat activation by these chemokines. RANTES and MIP-1 alpha mediate their effects via shared chemokine receptors (CCRs): CCR1, CCR4, and CCR5. Our data revealed a concordance between chemokine-induced Stat activation and c-fos induction and CCR4 and CCR5 expression. These findings indicate that chemokine-mediated activation of G-protein-coupled receptors leads to signal transduction that invokes intracellular phosphorylation intermediates used by other cytokine receptors.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	Fish, EN (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, Rm 73,FitzGerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.							ALAM R, 1994, J IMMUNOL, V153, P3155; ALAM R, 1993, J IMMUNOL, V150, P3442; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BHAT GJ, 1995, J BIOL CHEM, V270, P19059, DOI 10.1074/jbc.270.32.19059; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; DAHINDEN CA, 1994, J EXP MED, V179, P751, DOI 10.1084/jem.179.2.751; DRISCOLL KE, 1994, EXP LUNG RES, V20, P473, DOI 10.3109/01902149409031733; Dubois PM, 1996, J IMMUNOL, V156, P1356; EILERS A, 1994, MOL CELL BIOL, V14, P1364, DOI 10.1128/MCB.14.2.1364; GHISLAIN J, 1994, J IMMUNOL, V153, P3655; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; HOSAKA S, 1994, CLIN EXP IMMUNOL, V97, P451; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; KAPP A, 1994, J INVEST DERMATOL, V102, P906, DOI 10.1111/1523-1747.ep12383399; KUNA P, 1995, J ALLERGY CLIN IMMUN, V95, P574, DOI 10.1016/S0091-6749(95)70320-9; LOCATI M, 1994, J BIOL CHEM, V269, P4746; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROBINSON E, 1995, CLIN EXP IMMUNOL, V101, P398; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SOZZANI S, 1994, J IMMUNOL, V152, P3615; SOZZANI S, 1993, J IMMUNOL, V150, P1544; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; Taub DD, 1996, J IMMUNOL, V156, P2095; UNUTMAZ D, 1994, J EXP MED, V180, P1159, DOI 10.1084/jem.180.3.1159; VADDI K, 1994, J LEUKOCYTE BIOL, V55, P756, DOI 10.1002/jlb.55.6.756; VADDI K, 1994, J IMMUNOL, V153, P4721; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEBER M, 1995, J IMMUNOL, V154, P4166; Wong M, 1997, J RHEUMATOL, V24, P1179	43	141	145	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					309	314		10.1074/jbc.273.1.309	http://dx.doi.org/10.1074/jbc.273.1.309			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417081	hybrid			2022-12-25	WOS:000071295600047
J	Ornatsky, OI; Andreucci, JJ; McDermott, JC				Ornatsky, OI; Andreucci, JJ; McDermott, JC			A dominant-negative form of transcription factor MEF2 inhibits myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING SPECIFICITY; HELIX-LOOP-HELIX; MUSCLE DEVELOPMENT; SKELETAL-MUSCLE; GENE MYF-5; FACTOR-II; MADS; FAMILY; MYOD; DROSOPHILA	A biological role for MEF2 (myocyte enhancer factor 2) activity during mammalian myogenesis has been inferred but not directly proven because of its role in the transcriptional activation of many muscle-specific genes. Therefore, our purpose was to determine whether MEF2 activity is absolutely required for mammalian myogenesis. Using a dominant-negative approach to address this question, we constructed a mutated MEF2A protein comprised of the amino-terminal DNA binding/dimerization domain of MEF2A without its trans-activation domain as a bacterial fusion protein (GST-131) or in a eukaryotic expression vector (pcDNA-131). GST-131 and the protein encoded by pcDNA-131 bind specifically to the MEF2 cis element and abrogate trans-activation of a MEF2-responsive luciferase reporter gene by wild type MEF2A, thus serving a role as trans-dominant inhibitors of MEF2 function. In congruence with their ability to interfere with wild type MEF2 function, microinjection of GST-131 or pcDNA-131 into L6E9 or C2C12 myoblasts inhibited myotube formation. Immunofluorescence analysis showed that the expression of myogenin, myosin heavy chain, and MEF2A were inhibited in the GST-131 or pcDNA-131-injected cells compared with GST or pcDNA-injected controls. We also document that this trans dominant MEF2 inhibitor impairs the myogenic conversion of C3H10T1/2 fibroblasts by MyoD. Thus, these data provide evidence that the trans-activation function of the MEF2 proteins during mammalian myogenesis is required for muscle-specific gene expression and differentiation.	York Univ, Fac Pure & Appl Sci, Dept Biol, Toronto, ON M3J 1PE, Canada; York Univ, Fac Pure & Appl Sci, Dept Kinesiol, Toronto, ON M3J 1PE, Canada	York University - Canada; York University - Canada	McDermott, JC (corresponding author), York Univ, Fac Pure & Appl Sci, Dept Biol, 841 Farquharson LSB,4700 Keele St, Toronto, ON M3J 1PE, Canada.							BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lee Y, 1997, MOL CELL BIOL, V17, P2745, DOI 10.1128/MCB.17.5.2745; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; NURRISH SJ, 1995, MOL CELL BIOL, V15, P4076; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; West AG, 1997, MOL CELL BIOL, V17, P2876, DOI 10.1128/MCB.17.5.2876; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	38	101	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33271	33278		10.1074/jbc.272.52.33271	http://dx.doi.org/10.1074/jbc.272.52.33271			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407117	hybrid			2022-12-25	WOS:000071182900078
J	Vostrov, AA; Quitschke, WW				Vostrov, AA; Quitschke, WW			The zinc finger protein CTCF binds to the APB beta domain of the amyloid beta-protein precursor promoter - Evidence for a role in transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; ALZHEIMERS-DISEASE; MESSENGER-RNA; DNA-BINDING; REGULATORY ELEMENTS; DOWNS-SYNDROME; EXPRESSION; REGION; INTERLEUKIN-1; INTERACTS	The promoter of the amyloid beta-protein precursor (APP) gene directs high levels of cell type-specific transcription with 94 base pairs 5' to the main transcriptional start site. An essential activator domain in this proximal APP promoter is a nuclear factor binding site designated as APB beta, The recognition domain for the APB beta binding factor is located between position -93 and -82 relative to the main transcriptional start site. The nuclear factor that binds to the APB beta site was partially purified by multiple steps of ion exchange and hydroxyapatite chromatography. Based on UV cross-linking results, a protein with an apparent molecular mass of 140 kDa was selected as the putative APB beta binding protein. After the final purification step consisting of preparative SDS-polyacrylamide gel electrophoresis, partial peptide sequences were obtained that completely matched the transcriptional factor CTCF, This protein is a known regulator of c-myc and lysozyme gene expression, and it binds to a variety of diverse DNA sequences. The binding of CTCF to the APB beta domain was further established by competition with CTCF binding oligonucleotides in mobility shift electrophoresis. The identity was also confirmed by the observation that the APB beta binding factor is recognized by antibodies against C- and N-terminal sequences of CTCF. In addition, oligonucleotide competition during in vitro transcription affirmed that CTCF acts as a transcriptional activator in the APP gene promoter.	SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Quitschke, WW (corresponding author), SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA.	wquitschke@mail.psychiatry.sunsyb.edu			NINDS NIH HHS [NS30994] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030994] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; Bourbonniere M, 1996, MOL BRAIN RES, V35, P304, DOI 10.1016/0169-328X(95)00208-A; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; CHERNAK JM, 1993, GENE, V133, P255, DOI 10.1016/0378-1119(93)90648-M; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; Dewji NN, 1996, MOL BRAIN RES, V35, P325, DOI 10.1016/0169-328X(95)00214-D; DONNELLY RJ, 1990, CELL MOL NEUROBIOL, V10, P485, DOI 10.1007/BF00712843; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HASSANAIN HH, 1993, ANAL BIOCHEM, V213, P162, DOI 10.1006/abio.1993.1400; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOFFMAN PW, 1995, NUCLEIC ACIDS RES, V23, P2229, DOI 10.1093/nar/23.12.2229; HOFFMAN PW, 1994, BIOCHEM BIOPH RES CO, V201, P610, DOI 10.1006/bbrc.1994.1745; IZUMI R, 1992, GENE, V112, P189, DOI 10.1016/0378-1119(92)90375-Y; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; KOHNE AC, 1993, J MOL BIOL, V232, P747, DOI 10.1006/jmbi.1993.1428; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; Kusiak JW, 1996, MOL CHEM NEUROPATHOL, V28, P153, DOI 10.1007/BF02815217; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; MANN DMA, 1990, ACTA NEUROPATHOL, V80, P318, DOI 10.1007/BF00294651; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; POLLWEIN P, 1993, BIOCHEM BIOPH RES CO, V190, P637, DOI 10.1006/bbrc.1993.1096; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; Quitschke Wolfgang W., 1995, P79, DOI 10.1016/B978-012286965-5/50007-8; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; Quitschke WW, 1996, J BIOL CHEM, V271, P22231, DOI 10.1074/jbc.271.36.22231; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P9539; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmechel D E, 1988, Alzheimer Dis Assoc Disord, V2, P96, DOI 10.1097/00002093-198802020-00002; TREJO J, 1994, J BIOL CHEM, V269, P21682; VIOLETTE SM, 1992, P NATL ACAD SCI USA, V89, P3805, DOI 10.1073/pnas.89.9.3805; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; Warren BS, 1996, J BIOL CHEM, V271, P11434, DOI 10.1074/jbc.271.19.11434; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WIRAK DO, 1991, EMBO J, V10, P289, DOI 10.1002/j.1460-2075.1991.tb07949.x; WU C, 1987, SCIENCE, V238, P1247, DOI 10.1126/science.3685975	49	150	156	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33353	33359		10.1074/jbc.272.52.33353	http://dx.doi.org/10.1074/jbc.272.52.33353			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407128	hybrid			2022-12-25	WOS:000071182900089
J	PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y				PinkasKramarski, R; Eilam, R; Alroy, I; Levkowitz, G; Lonai, P; Yarden, Y			Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation	ONCOGENE			English	Article						EGF family; signal transduction; tyrosine kinase; NDF/neuregulin; nervous system	EPIDERMAL GROWTH-FACTOR; EMBRYONAL CARCINOMA-CELLS; FACTOR HEREGULIN; NERVOUS-SYSTEM; NEUREGULIN RECEPTORS; CARDIAC DEVELOPMENT; CELLULAR-RESPONSE; NEU; SURVIVAL; ISOFORMS	Two receptor tyrosine kinases, ErB-3 and ErbB-4, mediate signaling by Neu differentiation factors (NDFs, also called neuregulins), while ErbB-1 and ErbB-2 serve as co-receptors, We show that the two NDF/neuregulin differ in spatial and temporal expression The kinase-defective receptor, ErbB-3, is expressed primarily in epithelial layers of various organs, in the peripheral nervous system, and in adult brain, whereas ErbB-4 is restricted to the developing central nervous system and to the embryonic heart, An example of alternating expression of the two receptors is provided by the developing cerebellum: During postnatal cerebellar development, ErbB-4 expression slightly decreases along with a decline in NDF transcription, whereas ErbB-3 expression commences after the peak of neurogenesis, To study functional differences, we established primary brain cultures and found that ErbB-3 was expressed only in oligodendrocytes, whereas ErbB-4 expression was shared by oligodendrocytes, astrocytes and neurons, Blocking the action of endogenous NDF in vitro, by using a soluble form of ErbB-4, accelerated neurite outgrowth in both primary cultures and in neuronal-type cultures of the P19 teratocarcinoma, suggesting an inhibitory effect of NDF on neural differentiation, Apparently, ErbB-3 is associated with proliferation of P19 cells, whereas ErbB-4 correlates with a differentiated phenotype, We conclude that the two NDF receptors play distinct, rather than redundant, developmental and physiological roles.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT MOL GENET,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; Pinkas-Kramarski, Ronit/0000-0002-1000-369X				ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BAIN G, 1993, MOL BRAIN RES, V17, P23, DOI 10.1016/0169-328X(93)90068-Z; BARDE YA, 1980, P NATL ACAD SCI-BIOL, V77, P1199, DOI 10.1073/pnas.77.2.1199; Baulida J, 1996, J BIOL CHEM, V271, P5251; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; BENBARUCH N, 1997, HORMONES GROWTH FACT; BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427; CANNOLL PD, 1996, NEURON, V17, P229; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CARRAWAY KL, 1995, CURR OPIN NEUROBIOL, V5, P606, DOI 10.1016/0959-4388(95)80065-4; CHEN MS, 1994, J COMP NEUROL, V349, P389, DOI 10.1002/cne.903490306; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; CORFAS G, 1995, NEURON, V14, P103, DOI 10.1016/0896-6273(95)90244-9; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Grinspan JB, 1996, J NEUROSCI, V16, P6107; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOGAN B, 1986, COLD SPRING HARBOR; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kramer R, 1996, P NATL ACAD SCI USA, V93, P4833, DOI 10.1073/pnas.93.10.4833; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI ADO, 1995, J NEUROSCI, V15, P1329; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MCBURNEY MW, 1993, INT J DEV BIOL, V37, P135; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; Perrimon N, 1997, CELL, V89, P13, DOI 10.1016/S0092-8674(00)80177-4; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1992, ONCOGENE, V7, P1273; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, ONCOGENE, V12, P345; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; Syroid DE, 1996, P NATL ACAD SCI USA, V93, P9229, DOI 10.1073/pnas.93.17.9229; Trachtenberg JT, 1996, NATURE, V379, P174, DOI 10.1038/379174a0; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZHU XJ, 1995, EMBO J, V14, P5842, DOI 10.1002/j.1460-2075.1995.tb00272.x	67	108	117	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2803	2815		10.1038/sj.onc.1201466	http://dx.doi.org/10.1038/sj.onc.1201466			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419971				2022-12-25	WOS:A1997YJ80300006
J	Joseph-Liauzun, E; Delmas, P; Shire, D; Ferrara, P				Joseph-Liauzun, E; Delmas, P; Shire, D; Ferrara, P			Topological analysis of the peripheral benzodiazepine receptor in yeast mitochondrial membranes supports a five-transmembrane structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; PROTEIN-STRUCTURE; BINDING; BACTERIORHODOPSIN; LOCALIZATION; EXPRESSION; CHANNEL	The peripheral benzodiazepine receptor, implicated in the transport of cholesterol from the outer to the inner mitochondrial membrane, is predicted by hydropathy analysis to feature five membrane-spanning domains, with the amino terminus within the mitochondrial periplasm and the carboxyl terminus in the external cytoplasm. We have tested these structural predictions directly by immunodetection of c-Myc-tagged peripheral benzodiazepine receptor on intact yeast mitochondria and by specific labeling in yeast membranes of cysteine residues introduced by site-directed mutagenesis. The combined results support the model originally proposed with some minor but important modifications. The theoretical model predicted relatively short cu-helical domains, only long enough to span a phospholipid monolayer, whereas the results presented here would support a model with extended alpha-helices sufficiently long to span an entire membrane bilayer, with concomitant shorter loop and tail regions.	Sanofi Rech, Dept Microbiol, Ctr Labege, F-31676 Labege, France; Sanofi Rech, Dept Prot Biochem, Ctr Labege, F-31676 Labege, France; Sanofi Rech, Dept Organ Chem, Ctr Labege, F-31676 Labege, France	Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France; Sanofi-Aventis; Sanofi France	Joseph-Liauzun, E (corresponding author), Sanofi Rech, Dept Microbiol, Ctr Labege, Labege Innopol BP 137, F-31676 Labege, France.	evelyne.liauzun@tls1.elfsanofi.fr						AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BERNASSAU JM, 1993, J MOL GRAPHICS, V11, P236, DOI 10.1016/0263-7855(93)80003-A; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; CEPURI V, 1990, J BIOL CHEM, V265, P12978; Dussossoy D, 1996, CYTOMETRY, V24, P39; FARGES R, 1993, FEBS LETT, V335, P305, DOI 10.1016/0014-5793(93)80407-L; FARGES R, 1994, MOL PHARMACOL, V46, P1160; GARNIER M, 1994, MOL PHARMACOL, V45, P201; Grigorieff N, 1996, J MOL BIOL, V259, P393, DOI 10.1006/jmbi.1996.0328; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jones PC, 1996, MOL MEMBR BIOL, V13, P53, DOI 10.3109/09687689609160575; JOSEPHLIAUZUN E, 1995, GENE, V155, P195, DOI 10.1016/0378-1119(94)00727-A; JosephLiauzun E, 1997, J BIOL CHEM, V272, P28102, DOI 10.1074/jbc.272.44.28102; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; PAPADOPOULOS V, 1991, J BIOL CHEM, V266, P3682; PAROLA AL, 1991, J BIOL CHEM, V266, P14082; RIOND J, 1991, EUR J PHARM-MOLEC PH, V208, P307, DOI 10.1016/0922-4106(91)90076-T; RIOND J, 1991, EUR J BIOCHEM, V195, P305, DOI 10.1111/j.1432-1033.1991.tb15707.x; SPRENGEL R, 1989, J BIOL CHEM, V264, P20415; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; TEUFEL M, 1993, EMBO J, V12, P3399, DOI 10.1002/j.1460-2075.1993.tb06014.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YAFFE MP, 1991, METHOD ENZYMOL, V194, P627; Yeliseev AA, 1997, P NATL ACAD SCI USA, V94, P5101, DOI 10.1073/pnas.94.10.5101; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	28	92	93	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2146	2152		10.1074/jbc.273.4.2146	http://dx.doi.org/10.1074/jbc.273.4.2146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442055	hybrid			2022-12-25	WOS:000071595200044
J	Leong, GM; Wang, KS; Marton, MJ; Blanco, JCG; Wang, IM; Rolfes, RJ; Ozato, K; Segars, JH				Leong, GM; Wang, KS; Marton, MJ; Blanco, JCG; Wang, IM; Rolfes, RJ; Ozato, K; Segars, JH			Interaction between the retinoid X receptor and transcription factor IIB is ligand-dependent in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; PROLIFERATOR-ACTIVATED RECEPTOR; TATA-BINDING PROTEIN; RNA-POLYMERASE-II; FACTOR-TFIIB; NUCLEAR RECEPTOR; BASAL TRANSCRIPTION; ACID RECEPTORS; RXR-ALPHA; PREINITIATION COMPLEX	The retinoid X receptor (RXR) influences gene activation through heterodimeric and homodimeric association with DNA and associates with TATA binding protein, TAF110, and cAMP response element-binding protein-binding protein; yet the molecular mechanisms responsible for gene activation by RXRs remain incompletely defined. Since the general transcription factor IIB (TFIIB) is a common target of sequence-specific transcriptional activators, we suspected that RXR might regulate target genes via an interaction with TFIIB. Coimmunoprecipitation, far Western analysis, and glutathione S-transferase binding studies indicated that murine RXR beta (mRXR beta) was capable of binding to human TFIIB in vitro. Functional analysis with a dual-hybrid yeast system and cotransfection assays revealed the interaction of mRXR beta with TFIIB to be ligand-dependent in vivo. Truncation experiments mapped the essential binding regions to the carboxyl region of mRXR beta (amino acids (aa) 254-389) and two regions in the carboxyl region of TFIIB (aa 178-201 and aa 238-271). Furthermore, the Delta 390-410 mRXR beta mutant bound to TFIIB in vitro but was not active in the dual-hybrid yeast system, suggesting that the extreme carboxyl region of RXR was required for in vivo interaction with TFIIB. These data indicate that interaction of mRXR beta with TFIIB is specific, direct, and ligand-dependent in vivo and suggest that gene activation by RXR involves TFIIB.	NICHHD, Unit Mol Mechanisms Reprod, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; NICHHD, Mol Genet Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Segars, JH (corresponding author), Uniformed Serv Univ Hlth Sci, OSD, Bldg A,Rm 3078,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Blanco, Jorge/AAW-3752-2020	Blanco, Jorge/0000-0002-6173-0213; Leong, Gary/0000-0001-5763-095X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000636] Funding Source: NIH RePORTER; NICHD NIH HHS [Z01-HD00636] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARBERIS A, 1993, P NATL ACAD SCI USA, V90, P5628, DOI 10.1073/pnas.90.12.5628; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Beato M, 1996, STEROIDS, V61, P240, DOI 10.1016/0039-128X(96)00030-X; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BLANCO JCG, 1995, P NATL ACAD SCI USA, V92, P1535, DOI 10.1073/pnas.92.5.1535; Blanco JCG, 1996, GENES CELLS, V1, P209, DOI 10.1046/j.1365-2443.1996.d01-229.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen JY, 1996, NATURE, V382, P819, DOI 10.1038/382819a0; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; COLGAN J, 1995, P NATL ACAD SCI USA, V92, P1955, DOI 10.1073/pnas.92.6.1955; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Fondell JD, 1996, MOL CELL BIOL, V16, P281; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HALL BL, 1993, P NATL ACAD SCI USA, V90, P6929, DOI 10.1073/pnas.90.15.6929; HARPER JW, 1993, CELL, V75, P805; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LEBLANC BP, 1995, GENE DEV, V9, P1811, DOI 10.1101/gad.9.15.1811; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MACDONALD PN, 1995, J BIOL CHEM, V270, P4748, DOI 10.1074/jbc.270.9.4748; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; Masuyama H, 1997, MOL ENDOCRINOL, V11, P218, DOI 10.1210/me.11.2.218; MEDIN JA, 1994, MOL CELL ENDOCRINOL, V105, P27, DOI 10.1016/0303-7207(94)90032-9; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; Nunez SB, 1997, MOL CELL ENDOCRINOL, V127, P27, DOI 10.1016/S0303-7207(96)03980-9; NUNEZ SB, 1995, RECENT PROG HORM RES, V50, P409; ONATE SA, 1995, SCIENCE, V270, P1354; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; QI JS, 1995, MOL CELL BIOL, V15, P1817; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SCHULMAN IG, 1995, P NATL ACAD SCI USA, V92, P8288, DOI 10.1073/pnas.92.18.8288; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; SONG C, 1994, P NATL ACAD SCI USA, V91, P10809, DOI 10.1073/pnas.91.23.10809; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; YAMASHITA S, 1993, SCIENCE, V261, P463, DOI 10.1126/science.8332911; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	89	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2296	2305		10.1074/jbc.273.4.2296	http://dx.doi.org/10.1074/jbc.273.4.2296			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442074	hybrid			2022-12-25	WOS:000071595200063
J	Li, YB; Zhu, H; Kuppusamy, P; Roubaud, V; Zweier, JL; Trush, MA				Li, YB; Zhu, H; Kuppusamy, P; Roubaud, V; Zweier, JL; Trush, MA			Validation of lucigenin (bis-N-methylacridinium) as a chemilumigenic probe for detecting superoxide anion radical production by enzymatic and cellular systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALVEOLAR MACROPHAGES; CHEMI-LUMINESCENCE; HEART-MITOCHONDRIA; GENERATION; DEHYDROGENASE; ACTIVATION; OXIDATION; CELLS	Lucigenin is most noted for its wide use as a chemiluminescent detector of superoxide anion radical (O-?((radical anion)))production by biological systems. However, its validity as a O-2((radical anion))-detecting probe has recently been questioned in view of its ability to undergo redox cycling in several in vitro enzymatic systems, which produce little or no O-2((radical anion)). Whether and to what extent lucigenin redox cycling occurs in systems that produce significant amounts of O-2((radical anion)) has not been carefully investigated. We examined and correlated three end points, including sensitive measurement of lucigenin-derived chemiluminescence (LDCL), O-2((radical anion)) consumption by oxygen polarography, and O-2((radical anion)) production by 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline-N-oxide spin trapping to characterize the potential of lucigenin to undergo redox cycling and as such to act as an additional source of O-2((radical anion)) in various enzymatic and cellular systems, Marked LDCL was elicited at lucigenin concentrations ranging from 1 to 5 mu M in all of the O-2((radical anion))-generating systems examined, including xanthine oxidase (XO)/xanthine, lipoamide dehydrogenase/NADH, isolated mitochondria, mitochondria in intact cells, and phagocytic NADPH oxidase. These concentrations of lucigenin were far below those that stimulated additional O-2 consumption or O-2((radical anion)) production in the above systems, Moreover, a significant linear correlation between LDCL and superoxide dismutase-inhibitable cytochrome c reduction was observed in the XO/xanthine and phagocytic NADPH oxidase systems. In contrast to the above O-2((radical anion))-generating systems, no LDCL was observed at non-redox cycling concentrations of lucigenin in the glucose oxidase/glucose and XO/NADH systems, which do not produce a significant amount of O-2((radical anion)). Thus, LDCL still appears to be a valid probe for detecting O-2((radical anion)) production by enzymatic and cellular sources.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Div Toxicol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Cardiol, Dept Med,Mol & Cellular Biophys Labs, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Electron Paramagnet Resonance Ctr, Baltimore, MD 21224 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Trush, MA (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Div Toxicol Sci, 615 N Wolfe St, Baltimore, MD 21205 USA.	mtrush@jhsph.edu			NIEHS NIH HHS [ES03760, ES03819, ES08078] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008078, P30ES003819, R01ES003760] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEN RC, 1986, METHOD ENZYMOL, V133, P449; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC, P4; ESTERLINE RL, 1989, BIOCHEM BIOPH RES CO, V159, P584, DOI 10.1016/0006-291X(89)90034-X; FAULKNER K, 1993, FREE RADICAL BIO MED, V15, P447, DOI 10.1016/0891-5849(93)90044-U; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GREENLEE L, 1962, BIOCHEMISTRY-US, V1, P779, DOI 10.1021/bi00911a008; GRINBLAT L, 1991, BIOCHEM INT, V23, P83; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; KENSLER TW, 1981, CANCER RES, V41, P216; LI YB, 1993, ARCH BIOCHEM BIOPHYS, V300, P346, DOI 10.1006/abbi.1993.1047; Li YB, 1996, MOL PHARMACOL, V49, P412; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V337, P115, DOI 10.1006/abbi.1997.9766; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; NOHL H, 1986, BIOCHEM BIOPH RES CO, V138, P533, DOI 10.1016/S0006-291X(86)80529-0; REMBISH SJ, 1994, RES COMMUN MOL PATH, V85, P115; REMBISH SJ, 1994, FREE RADICAL BIO MED, V17, P117, DOI 10.1016/0891-5849(94)90109-0; REMBISH SJ, 1994, THESIS JOHNS HOPKINS; REMBISH SJ, 1991, IN VITRO TOXICOL, P463; REMBISH SJ, 1992, TOXICOLOGIST, V12, P281; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Slater E., 1967, METHODS ENZYMOLOGY, P48; SOHAL RS, 1992, MUTAT RES, V275, P295, DOI 10.1016/0921-8734(92)90033-L; STORCH J, 1988, ANAL BIOCHEM, V169, P262, DOI 10.1016/0003-2697(88)90283-7; TRUSH MA, 1978, METHOD ENZYMOL, V57, P462; TRUSH MA, 1997, ACTA HAEMATOL S1, V98, P90; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0; TWERDOK LE, 1992, TOXICOL APPL PHARM, V112, P266, DOI 10.1016/0041-008X(92)90196-Y; VasquezVivar J, 1997, FEBS LETT, V403, P127, DOI 10.1016/S0014-5793(97)00036-7; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253	35	466	475	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2015	2023		10.1074/jbc.273.4.2015	http://dx.doi.org/10.1074/jbc.273.4.2015			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442038	hybrid			2022-12-25	WOS:000071595200027
J	Stein, E; Huynh-Do, U; Lane, AA; Cerretti, DP; Daniel, TO				Stein, E; Huynh-Do, U; Lane, AA; Cerretti, DP; Daniel, TO			Nck recruitment to Eph receptor, EphB1/ELK, couples ligand activation to c-Jun kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ADAPTER PROTEIN; AXON GUIDANCE; IN-VITRO; FAMILY; BINDING; ELF-1; SITE; IDENTIFICATION; PROMOTES	Eph family receptor tyrosine kinases signal axonal guidance, neuronal bundling, and angiogenesis; yet the signaling systems that couple these receptors to targeting and cell-cell assembly responses are incompletely defined. Functional links to regulators of cytoskeletal structure are anticipated based on receptor mediated cell-cell aggregation and migratory responses. We used two-hybrid interaction cloning to identify EphB1-interactive proteins. Six independent cDNAs encoding the SH2 domain of the adapter protein, Nck, were recovered in a screen of a murine embryonic library. We mapped the EphB1 subdomain that binds Nck and its Drosophila homologue, DOCK, to the juxtamembrane region. Within this subdomain, Tyr(594) was required for Nck binding, In P19 embryonal carcinoma cells, activation of EphB1 (ELH) by its ligand, ephrin-B1/Fc, recruited Nck to native receptor complexes and activated c-Jun kinase (JNK/SAPK), Transient overexpression of mutant EphB1 receptors (Y594F) blocked Nck recruitment to EphB1, attenuated downstream JNK activation, and blocked cell attachment responses, These findings identify Nck as an important intermediary linking EphB1 signaling to JNK.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Sch Med, Dept Med, Nashville, TN 37232 USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Daniel, TO (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pharmacol, MCN S3223,21St & Garland St, Nashville, TN 37232 USA.	tom.daniel@mcmail.vanderbilt.edu	Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692; Lane, Andrew/0000-0001-7380-0226	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038517, R01DK047078] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38517, DK47078] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1997, Cell, V90, P403; ATKI A, 1997, J BIOL CHEM, V272, P1429; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; Bohme B, 1996, J BIOL CHEM, V271, P24747, DOI 10.1074/jbc.271.40.24747; Brambilla R, 1995, MOL CELL NEUROSCI, V6, P487, DOI 10.1006/mcne.1995.0001; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; Choudhury GG, 1996, AM J PHYSIOL-RENAL, V270, pF295, DOI 10.1152/ajprenal.1996.270.2.F295; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Ellis C, 1996, ONCOGENE, V12, P1727; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JYERS M, 1992, EMBO J, V11, P1773; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; Martin M, 1997, IN VITRO CELL DEV-AN, V33, P261, DOI 10.1007/s11626-997-0045-y; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OOI J, 1995, ONCOGENE, V10, P1621; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Quilliam LA, 1996, J BIOL CHEM, V271, P28772, DOI 10.1074/jbc.271.46.28772; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; Rose MD., 1990, METHODS YEAST GENETI; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Schultz J, 1997, PROTEIN SCI, V6, P249; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Su YC, 1997, EMBO J, V16, P1279, DOI 10.1093/emboj/16.6.1279; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WESTWICK JK, 1995, METHOD ENZYMOL, V255, P342; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	47	139	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1303	1308		10.1074/jbc.273.3.1303	http://dx.doi.org/10.1074/jbc.273.3.1303			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430661	hybrid			2022-12-25	WOS:000071411500008
J	Chen, JH; Vijayakumar, S; Li, XQ; Al-Awqati, Q				Chen, JH; Vijayakumar, S; Li, XQ; Al-Awqati, Q			Kanadaptin is a protein that interacts with the kidney but not the erythroid form of band 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCALATED CELLS; EPITHELIAL-CELLS; LUMINAL MEMBRANE; TURTLE-BLADDER; IN-VITRO; POLARITY; PLASTICITY; EXCHANGER; INSERTION; SURFACE	Although epithelial membrane proteins are separately targeted to apical or basolateral domains, some are apically located in one cell type but are basolateral in others. More dramatically, the anion exchanger of a clonal cell line of intercalated cells derived from the kidney can be retargeted from the apical to basolateral domain. This Cl:HCO3 exchanger, kAE1, is an alternately spliced form of the erythroid anion exchanger (AE1, band 3), but unlike band 3 it does not bind ankyrin. Here we identify a new protein (kanadaptin) that binds to the cytoplasmic domain of kAE1 in vitro and in vivo but not to the erythroid AE1 or to ankyrin. No significant homologous proteins have been reported so far. Kanadaptin is widely expressed in epithelial (kidney, lung, and liver) and non-epithelial cells (brain and skeletal and cardiac muscle). In kidney, we found by immunocytochemistry that kanadaptin was only expressed in the collecting tubule. In the intercalated cells of this segment, it colocalized with k4E1 in cytoplasmic vesicles but not when the exchanger was in the basolateral membrane. These results raised the possibility that this protein is involved in the targeting of kAE1 vesicles to their final destination.	Columbia Univ Coll Phys & Surg, Dept Med & Physiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem, New York, NY 10032 USA	Columbia University; Columbia University	Al-Awqati, Q (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med & Physiol, 630 W 168th St, New York, NY 10032 USA.	qa1@columbia.edu	Al-Awqati, Qais/B-2465-2009; vijayakumar, soundarapandian/B-4539-2010	Al-Awqati, Qais/0000-0001-7141-1040	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039532, R01DK020999, R37DK020999] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39532, DK20999] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROSIUS FC, 1989, J BIOL CHEM, V264, P7784; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; CANNON C, 1985, NATURE, V314, P443, DOI 10.1038/314443a0; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DING Y, 1994, J BIOL CHEM, V269, P32201; DRENCKHAHN D, 1985, SCIENCE, V230, P1287, DOI 10.1126/science.2933809; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863; Kopito R R, 1990, Int Rev Cytol, V123, P177, DOI 10.1016/S0074-7696(08)60674-9; KUDRYCKI KE, 1989, J BIOL CHEM, V264, P8185; MICHAELY P, 1993, J BIOL CHEM, V268, P22703; MICHAELY P, 1995, J BIOL CHEM, V270, P22050, DOI 10.1074/jbc.270.37.22050; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; PATHAK RK, 1990, J CELL BIOL, V112, P863; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; SCHUSTER VL, 1993, ANNU REV PHYSIOL, V55, P267, DOI 10.1146/annurev.ph.55.030193.001411; SCHWARTZ GJ, 1985, NATURE, V318, P368, DOI 10.1038/318368a0; Takito J, 1996, J CLIN INVEST, V98, P2324, DOI 10.1172/JCI119044; VANADELSBERG J, 1994, CELL, V76, P1053, DOI 10.1016/0092-8674(94)90382-4; VANADELSBERG JS, 1993, J BIOL CHEM, V268, P11283; WANG CC, 1995, J BIOL CHEM, V270, P17892, DOI 10.1074/jbc.270.30.17892; ZURZOLO C, 1993, J CELL BIOL, V121, P1031, DOI 10.1083/jcb.121.5.1031	23	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1038	1043		10.1074/jbc.273.2.1038	http://dx.doi.org/10.1074/jbc.273.2.1038			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422766	hybrid			2022-12-25	WOS:000071411400055
J	Day, R; Lazure, C; Basak, A; Boudreault, A; Limperis, P; Dong, WJ; Lindberg, I				Day, R; Lazure, C; Basak, A; Boudreault, A; Limperis, P; Dong, WJ; Lindberg, I			Prodynorphin processing by proprotein convertase 2 - Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILISIN-LIKE PROTEASE; PROHORMONE CONVERTASE; GENE-EXPRESSION; MESSENGER-RNA; ENZYMATIC CHARACTERIZATION; ENDOPROTEASE FAMILY; PEPTIDE PRECURSORS; ANTERIOR-PITUITARY; CONSENSUS SEQUENCE; ARGININE RESIDUE	Endoproteolytic processing of the 26-kDa protein pre cursor prodynorphin (proDyn) at paired and single basic residues is most likely carried out by the proprotein convertases (PCs); however, the role of PCs at single basic residues is unclear, In previous studies we showed that limited proDyn processing by PC1/PC3 at both paired and single basic residues resulted in the formation of 8- and 10-kDa intermediates, Because PC2 is colocalized with proDyn, we examined the potential role of this convertase in cleaving proDyn. PC2 cleaved proDyn to produce dynorphin (Dyn) A 1-17, Dyn B 1-13, and alpha-neo-endorphin, without a previous requirement for PC1/PC3. PC2 also cleaved at single basic residues, resulting in the formation of the C-peptide and Dyn A 1-8., Only PC2, but not furin or PC1/PC3, could cleave the Arg-Pro bond to yield Dyn 1-8., Structure-activity studies with Dyn A 1-17 showed that a P-4, Arg residue is important for single basic cleavage by PC2 and that the P-1' Pro residue impedes processing. Conversion of Dyn A 1-17 or Dyn B 1-13 into leucine-enkephalin (Leu-Enk) by PC2 was never observed; however, Dyn AB 1-32 cleavage yielded small amounts of Leu-Enk, suggesting that Leu-Enk can be generated from the proDyn precursor only through a specific pathway. Finally, PC2 cleavages at single and paired basic residues were enhanced when carried out in the presence of carboxypeptidase (CP) E. Enhancement was blocked by GEMSA, a specific inhibitor of CPE activity, and could be duplicated by other carboxypeptidases, including CPD, CPB, or CPM. Our data suggest that carboxypeptidase activity enhances PC2 processing by the elimination of product inhibition caused by basic residue-extended peptides.	Univ Sherbrooke, Fac Med, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Clin Res Inst Montreal, Lab Neuropeptide Struct & Metab, Montreal, PQ H2W 1R7, Canada; Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada; Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	University of Sherbrooke; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; McGill University; Louisiana State University System	Day, R (corresponding author), Univ Sherbrooke, Fac Med, Dept Pharmacol, 3001 12ieme Ave N, Sherbrooke, PQ J1H 5N4, Canada.		Lindberg, Iris/Q-3825-2019		NATIONAL INSTITUTE ON DRUG ABUSE [R56DA005084, R01DA005084] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA005084, R56 DA005084] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BARR PJ, 1991, DNA CELL BIOL, V10, P319, DOI 10.1089/dna.1991.10.319; BASAK A, 1995, INT J PEPT PROT RES, V46, P228; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; BLOOMQUIST BT, 1991, MOL ENDOCRINOL, V5, P2014, DOI 10.1210/mend-5-12-2014; BOUDRESAULT A, 1993, PROTIEN SCI S1, V2, P97; BRESLIN MB, 1993, J BIOL CHEM, V268, P27084; Bruzzaniti A, 1996, BIOCHEM J, V314, P727, DOI 10.1042/bj3140727; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; COLLARD MW, 1990, MOL ENDOCRINOL, V4, P1488, DOI 10.1210/mend-4-10-1488; DAY R, 1991, P NATL ACAD SCI USA, V88, P1320, DOI 10.1073/pnas.88.4.1320; DAY R, 1993, NEUROSCI LETT, V149, P27, DOI 10.1016/0304-3940(93)90339-M; DAY R, 1989, ENDOCRINOLOGY, V124, P2392, DOI 10.1210/endo-124-5-2392; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DAY R, 1993, ENDOCRINOLOGY, V133, P2652, DOI 10.1210/en.133.6.2652; DAY R, 1994, REGUL PEPTIDES, V54, P77, DOI 10.1016/0167-0115(94)90397-2; DAY R, 1993, HDB EXPT PHARM OPIOI, V104, P449; DEVI L, 1991, FEBS LETT, V280, P189, DOI 10.1016/0014-5793(91)80290-J; DEVI L, 1991, J NEUROCHEM, V56, P320, DOI 10.1111/j.1471-4159.1991.tb02598.x; DONG W, 1997, J NEUROSCI, V17, P543; DUPUY A, 1994, FEBS LETT, V337, P60, DOI 10.1016/0014-5793(94)80630-6; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Keil B, 1992, SPECIFICITY PROTEOLY, P206; KHACHATURIAN H, 1985, TRENDS NEUROSCI, V8, P111, DOI 10.1016/0166-2236(85)90048-7; KHACHATURIAN H, 1986, ENDOCRINOLOGY, V119, P1409, DOI 10.1210/endo-119-3-1409; KIEFER MC, 1991, DNA CELL BIOL, V10, P757, DOI 10.1089/dna.1991.10.757; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LUSSON J, 1993, P NATL ACAD SCI USA, V90, P6691, DOI 10.1073/pnas.90.14.6691; Meerabux J, 1996, CANCER RES, V56, P448; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NAKAGAWA T, 1993, J BIOCHEM-TOKYO, V113, P132, DOI 10.1093/oxfordjournals.jbchem.a124015; NAKAYAMA K, 1992, J BIOL CHEM, V267, P16335; NAKAYAMA K, 1992, J BIOL CHEM, V267, P5897; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHAFER MKH, 1995, METH NEUROSCI, V23, P16; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1992, MOL ENDOCRINOL, V6, P1559, DOI 10.1210/me.6.10.1559; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SEIDAH NG, 1996, P NATL ACAD SCI USA, V93, P342; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SMEEKENS SP, 1992, P NATL ACAD SCI USA, V89, P8822, DOI 10.1073/pnas.89.18.8822; TEZAPSIDIS N, 1994, BIOCHEM J, V301, P607, DOI 10.1042/bj3010607; TRUJILLO KA, 1990, BRAIN RES, V518, P244, DOI 10.1016/0006-8993(90)90977-J; VANHOOF G, 1995, FASEB J, V9, P736, DOI 10.1096/fasebj.9.9.7601338; VIEAU D, 1995, ENDOCRINOLOGY, V136, P1187, DOI 10.1210/en.136.3.1187; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; ZHU XR, 1995, J CELL BIOL, V129, P1641, DOI 10.1083/jcb.129.6.1641	53	115	120	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					829	836		10.1074/jbc.273.2.829	http://dx.doi.org/10.1074/jbc.273.2.829			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422738	hybrid			2022-12-25	WOS:000071411400027
J	Bandyopadhyay, S; Starke, DW; Mieyal, JJ; Gronostajski, RM				Bandyopadhyay, S; Starke, DW; Mieyal, JJ; Gronostajski, RM			Thioltransferase (glutaredoxin) reactivates the DNA-binding activity of oxidation-inactivated nuclear factor I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN S-THIOLATION; REDOX REGULATION; TRANSCRIPTION FACTOR; CYSTEINE RESIDUE; N-ACETYLCYSTEINE; ESCHERICHIA-COLI; ACTIVITY INVITRO; REPAIR ENZYME; KAPPA-B; CELLS	The reversible oxidative inactivation of transcription factors has been proposed to be important in cellular responses to oxidant stress and in several signal transduction pathways, The nuclear factor I (NFI) family of transcription factors is sensitive to oxidative inactivation due to the presence of a conserved, oxidation-sensitive cysteine residue within the NFI DNA-binding domain. Here we show that restoration of the DNA-binding activity of oxidized NFI-C can be catalyzed in vitro by the cellular enzyme thioltransferase (glutaredoxin) coupled to GSH and GSSG reductase. To test whether GSH-dependent pathways play a role in the maintenance of NFI activity in vivo, we used buthionine sulfoximine, an agent that inhibits GSH synthesis, and N-acetylcysteine, an agent that can replenish intracellular GSH, Pretreatment of HeLa cells with buthionine sulfoximine greatly potentiated the inactivation of NFI by the oxidizing agent diamide, Inclusion of N-acetylcysteine in the culture medium during the recovery period following diamide treatment increased the extent of restoration of NFI activity, These results suggest that maintenance of the DNA-binding activity of NFI proteins during oxidant stress in vivo requires a GSH-dependent pathway, likely involving thioltransferase-catalyzed reduction of the oxidation sensitive cysteine residue on NFI.	Cleveland Clin Fdn, Dept Canc Biol NN1 14, Lerner Res Inst, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Gronostajski, RM (corresponding author), Cleveland Clin Fdn, Dept Canc Biol NN1 14, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gronosr@cesmtp.ccf.org		Gronostajski, Richard/0000-0003-4264-208X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034908] Funding Source: NIH RePORTER; NICHD NIH HHS [HD34908] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BANDYOPADHYAY S, 1994, J BIOL CHEM, V269, P29949; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P264, DOI 10.1006/abbi.1994.1166; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; CHANG M, 1993, BIOCHEMISTRY-US, V32, P4263, DOI 10.1021/bi00067a014; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gravina Mieyal S.A, 1995, BIOTHIOLS HLTH DIS, P305; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kulkarni S, 1996, CELL GROWTH DIFFER, V7, P501; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEEGWATER PAJ, 1985, EMBO J, V4, P1515, DOI 10.1002/j.1460-2075.1985.tb03811.x; LII CK, 1994, ARCH BIOCHEM BIOPHYS, V308, P231, DOI 10.1006/abbi.1994.1033; MANNERVIK B, 1989, COENZYMES COFACTORS, V3, P475; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCBRIDE AA, 1992, P NATL ACAD SCI USA, V89, P7531, DOI 10.1073/pnas.89.16.7531; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MERTENS K, 1991, J CHROMATOGR-BIOMED, V565, P149, DOI 10.1016/0378-4347(91)80379-Q; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; NOVAK A, 1992, J BIOL CHEM, V267, P12986; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; ROEDERER M, 1992, AIDS RES HUM RETROV, V8, P209, DOI 10.1089/aid.1992.8.209; ROKUTAN K, 1994, AM J PHYSIOL, V266, pG247, DOI 10.1152/ajpgi.1994.266.2.G247; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUPPEKOISTINEN I, 1994, ARCH BIOCHEM BIOPHYS, V315, P226, DOI 10.1006/abbi.1994.1494; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SHAW JP, 1986, J CELL PHYSIOL, V129, P193, DOI 10.1002/jcp.1041290210; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	50	123	127	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					392	397		10.1074/jbc.273.1.392	http://dx.doi.org/10.1074/jbc.273.1.392			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417094	hybrid			2022-12-25	WOS:000071295600060
J	Fernandez-Canon, JM; Penalva, MA				Fernandez-Canon, JM; Penalva, MA			Characterization of a fungal maleylacetoacetate isomerase gene and identification of its human homologue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; HEREDITARY TYROSINEMIA; ASPERGILLUS-NIDULANS; EXPRESSION; MODEL	We have previously used Aspergillus nidulans as a fungal model for human phenylalanine catabolism. This model was crucial for our characterization of the human gene involved in alcaptonuria, We use here an identical approach to characterize at the cDNA level the human gene for maleylacetoacetate isomerase (MAAI, EC 5.2.1.2), the only as yet unidentified structural gene of the phenylalanine catabolic pathway. We report here the first characterization of a gene encoding a MAAI enzyme from any organism, the A. nidulans maiA gene. maiA disruption prevents growth on phenylalanine (Phe) and phenylacetate and results in the absence of MAAI activity in vitro and Phe toxicity. The MaiA protein shows strong amino acid sequence identity to glutathione S-transferases and has MAAI activity when expressed in Escherichia coli. maiA is clustered with fahA and hmgA, the genes encoding the two other enzymes of the common part of the Phe/phenylacetate pathways, Based on the high amino acid sequence conservation existing between other homologous A. nidulans and human enzymes of this pathway, we used the MaiA sequence in data base searches to identify human expressed sequence tags encoding its putative homologues, Four such cDNAs were sequenced and shown to be encoded by the same gene, They encode a protein with 45% sequence identity to MaiA, which showed MAAI activity when expressed in E. coli, Human MAAI deficiency would presumably cause tyrosinemia that would be characterized by the absence of succinylacetone, the diagnostic compound resulting from fumarylacetoacetate hydrolase deficiency in humans and fungi. Culture supernatants of an A. nidulans strain disrupted for maiA are succinylacetone-negative but specifically contain cia and/or trans isomers of 2,4-dioxohept-2-enoic acid. We suggest that this compound(s) might be diagnostic for human MAAI deficiency.	CSIC, Ctr Invest Biol, Dept Mol Microbiol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Penalva, MA (corresponding author), CSIC, Ctr Invest Biol, Dept Mol Microbiol, Velazquez 144, E-28006 Madrid, Spain.	cibp173@fresno.csic.es	Fernández-Cañón, José Manuel/AAO-5607-2020; Fernandez-canon, Jose/ADI-4196-2022; Fernández-Cañón, José Manuel/AAO-6088-2020; Penalva, Miguel A/G-2295-2015	Fernández-Cañón, José Manuel/0000-0002-8092-2181; Penalva, Miguel A/0000-0002-3102-2806				BERGER R, 1988, PEDIATR RES, V23, P328; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLUTTERBUCK AJ, 1993, GENETIC MAPS LOCUS M, V3; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; EDWARDS SW, 1956, J BIOL CHEM, V220, P79; ESPESO EA, 1992, MOL MICROBIOL, V6, P1457, DOI 10.1111/j.1365-2958.1992.tb00866.x; FERNANDEZCANON JM, 1995, J BIOL CHEM, V270, P21199, DOI 10.1074/jbc.270.36.21199; FERNANDEZCANON JM, 1995, P NATL ACAD SCI USA, V92, P9132, DOI 10.1073/pnas.92.20.9132; FernandezCanon JM, 1996, NAT GENET, V14, P19, DOI 10.1038/ng0996-19; FernandezCanon JM, 1997, ANAL BIOCHEM, V245, P218, DOI 10.1006/abio.1996.9957; Garrod AE, 1908, LANCET, V2, P73; Garrod AE, 1902, LANCET, V2, P1616; Granadino B, 1997, GENOMICS, V43, P115, DOI 10.1006/geno.1997.4805; Jorquera R, 1997, BIOCHEM BIOPH RES CO, V232, P42, DOI 10.1006/bbrc.1997.6220; KNOX WE, 1955, J BIOL CHEM, V216, P489; KNOX WE, 1955, METHOD ENZYMOL, V2, P287, DOI 10.1016/S0076-6879(55)02202-7; LADU BN, 1958, J BIOL CHEM, V230, P251; LEE HE, 1989, BIOCHEM INT, V18, P91; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINDBLAD B, 1977, P NATL ACAD SCI USA, V74, P4641, DOI 10.1073/pnas.74.10.4641; MITCHELL GA, 1994, METABOLIC MOL BASIS, P1077; MORRISON WS, 1976, BIOCHEMISTRY-US, V15, P4228, DOI 10.1021/bi00664a015; Overturf K, 1996, NAT GENET, V12, P266, DOI 10.1038/ng0396-266; SCRIVER CR, 1994, ANNU REV GENET, V28, P141; SELTZER S, 1973, J BIOL CHEM, V248, P215; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9	26	137	165	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					329	337		10.1074/jbc.273.1.329	http://dx.doi.org/10.1074/jbc.273.1.329			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417084	hybrid, Green Published			2022-12-25	WOS:000071295600050
J	Ichikawa, S; Hatanaka, H; Yuuki, T; Iwamoto, N; Kojima, S; Nishiyama, C; Ogura, K; Okumura, Y; Inagaki, F				Ichikawa, S; Hatanaka, H; Yuuki, T; Iwamoto, N; Kojima, S; Nishiyama, C; Ogura, K; Okumura, Y; Inagaki, F			Solution structure of Der f 2, the major mite allergen for atopic diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL SOLUTION STRUCTURE; MAGNETIC-RESONANCE SPECTROSCOPY; DER-P-II; ESCHERICHIA-COLI; FACTOR-XIII; DERMATOPHAGOIDES-PTERONYSSINUS; LEPIDOGLYPHUS-DESTRUCTOR; HUMAN EPIDIDYMIS; PROTEIN; IGE	House dust mites cause heavy atopic diseases such as asthma and dermatitis. Among allergens from Dermatophagoides farinae, Der f 2 shows the highest positive rate for atopic patients, but its biological function in mites has been perfectly unknown, as well as the functions of its homologs in human and other animals. We have determined the tertiary structure of Der f 2 by multidimensional nuclear magnetic resonance spectroscopy. Der f 2 was found to be a single-domain protein of immunoglobulin fold, and its structure was the most similar to those of the two regulatory domains of transglutaminase, This fact, binding to the bacterial surface, and other small pieces of information hinted that Her f 2 is related to the innate antibacterial defense system in mites. The immunoglobulin E epitopes are also discussed on the basis of the tertiary structure.	Tokyo Metropolitan Inst Med Sci, Dept Mol Physiol, Bunkyo Ku, Tokyo 113, Japan; Japan Womens Univ, Fac Sci, Dept Biol & Mat Sci, Bunkyo Ku, Tokyo 112, Japan; Asahi Breweries Ltd, Biosci Res & Dev Lab, Ohta Ku, Tokyo 143, Japan; RIKEN, Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Lab Gene Technol & Safety, Ibaraki, Osaka 305, Japan	Tokyo Metropolitan Institute of Medical Science; Japan Womens University; RIKEN	Hatanaka, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Mol Physiol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 113, Japan.		Kojima, Soichi/N-7104-2015	Kojima, Soichi/0000-0002-5252-1612				Aabin B, 1996, INT ARCH ALLERGY IMM, V109, P50, DOI 10.1159/000237231; ATKINSON HAC, 1994, TOXICOLOGY, V91, P281, DOI 10.1016/0300-483X(94)90015-9; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BREITENEDER H, 1989, EMBO J, V8, P1935, DOI 10.1002/j.1460-2075.1989.tb03597.x; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Cavanagh J., 1996, PROTEIN NMR SPECTROS; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118, DOI 10.1159/000235101; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ICHINOSE A, 1986, BIOCHEMISTRY-US, V25, P6900, DOI 10.1021/bi00370a025; Iwamoto N, 1996, INT ARCH ALLERGY IMM, V109, P356, DOI 10.1159/000237263; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen LB, 1997, EUR J BIOCHEM, V243, P437, DOI 10.1111/j.1432-1033.1997.0437a.x; Meszaros M, 1996, INSECT BIOCHEM MOLEC, V26, P7, DOI 10.1016/0965-1748(95)00077-1; METZGER H, 1986, ANNU REV IMMUNOL, V4, P419, DOI 10.1146/annurev.iy.04.040186.002223; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P5117, DOI 10.1021/bi00137a005; METZLER WJ, 1992, BIOCHEMISTRY-US, V31, P8697, DOI 10.1021/bi00152a003; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62, DOI 10.1159/000236804; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159, DOI 10.1159/000236514; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; REDDY ESP, 1979, NATURE, V279, P725, DOI 10.1038/279725a0; REITER B, 1967, NATURE, V216, P328, DOI 10.1038/216328a0; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1111/j.1365-2222.1997.tb00667.x; STEWART GA, 1992, EXP APPL ACAROL, V16, P165, DOI 10.1007/BF01201499; STEWART GA, 1992, J ALLERGY CLIN IMMUN, V90, P141, DOI 10.1016/S0091-6749(06)80029-1; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TAKAHASHI K, 1990, INT ARCH ALLER A IMM, V91, P80, DOI 10.1159/000235094; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; VANHAGEHAMSTEN M, 1995, CLIN EXP ALLERGY, V25, P536, DOI 10.1111/j.1365-2222.1995.tb01091.x; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225, DOI 10.1016/0161-5890(91)90009-9; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; WISHART DS, 1994, J BIOMOL NMR, V4, P171; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233, DOI 10.1080/00021369.1991.10870757	45	94	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					356	360		10.1074/jbc.273.1.356	http://dx.doi.org/10.1074/jbc.273.1.356			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417088	hybrid			2022-12-25	WOS:000071295600054
J	Mo, CJ; Holland, TC				Mo, CJ; Holland, TC			Determination of the transmembrane topology of herpes simplex virus type 1 glycoprotein K (gK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE DNA-SEQUENCE; CAUSES CELL-FUSION; ENDOPLASMIC-RETICULUM; NUCLEOTIDE-SEQUENCE; INTRACELLULAR-TRANSPORT; EQUINE HERPESVIRUS-1; GOLGI-APPARATUS; SYN PHENOTYPE; GENE; PROTEIN	Herpes simplex virus type 1 glycoprotein K (gK) plays an essential role in viral replication and cell fusion. gK is a very hydrophobic membrane protein that contains a signal sequence and several hydrophobic regions, It has been shown that mutations inducing cell fusion map to two distinct domains of gK, suggesting that these domains are functionally important, To understand the transmembrane topology of gK and the localization of these functional domains, we constructed a set of gK deletion, insertion, and truncation mutants and expressed these by in vitro translation in the presence of microsomal membranes, The transmembrane topology of gK was determined by examination of the post-translational processing and protease sensitivity of the mutant proteins. Our data demonstrate that gK contains three transmembrane domains (amino acids 125-139, 226-239, and 311-325). Another hydrophobic domain (amino acids 241-265), which is relatively less hydrophobic and much longer compared with the transmembrane sequences, is located in the extracellular loop, The analysis showed that the domains containing syncytial mutations are both ectodomains. They may interact with each other to form a complex tertiary structure that is critical for the biological function of gK.	Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA	Wayne State University	Holland, TC (corresponding author), Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA.				NIAID NIH HHS [R01 AI22162, K04 AI00875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K04AI000875, R01AI022162] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AlBarazi HO, 1996, J VIROL, V70, P7198, DOI 10.1128/JVI.70.10.7198-7208.1996; Andersson AM, 1997, J VIROL, V71, P218, DOI 10.1128/JVI.71.1.218-225.1997; BAINES JD, 1991, J VIROL, V65, P6414, DOI 10.1128/JVI.65.12.6414-6424.1991; BAUMEISTER J, 1995, J VIROL, V69, P5560, DOI 10.1128/JVI.69.9.5560-5567.1995; BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; BOND VC, 1982, J GEN VIROL, V61, P245, DOI 10.1099/0022-1317-61-2-245; BOND VC, 1984, VIROLOGY, V132, P368, DOI 10.1016/0042-6822(84)90042-4; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN SM, 1973, J GEN VIROL, V18, P329, DOI 10.1099/0022-1317-18-3-329; BZIK DJ, 1984, VIROLOGY, V137, P185, DOI 10.1016/0042-6822(84)90022-9; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CREIGHTON TE, 1992, PROTEIN FOLDING; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEBROY C, 1990, GENE, V88, P275, DOI 10.1016/0378-1119(90)90043-Q; DEBROY C, 1985, VIROLOGY, V145, P36, DOI 10.1016/0042-6822(85)90199-0; DELUCA N, 1982, VIROLOGY, V122, P411, DOI 10.1016/0042-6822(82)90240-9; DOLTER KE, 1994, J VIROL, V68, P8277, DOI 10.1128/JVI.68.12.8277-8281.1994; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; HUTCHINSON L, 1995, J VIROL, V69, P5401, DOI 10.1128/JVI.69.9.5401-5413.1995; HUTCHINSON L, 1993, VIROLOGY, V196, P514, DOI 10.1006/viro.1993.1507; HUTCHINSON L, 1995, J VIROL, V69, P4556, DOI 10.1128/JVI.69.7.4556-4563.1995; JACOBSON JG, 1989, J VIROL, V63, P1839, DOI 10.1128/JVI.63.4.1839-1843.1989; Jayachandra S, 1997, J VIROL, V71, P5012, DOI 10.1128/JVI.71.7.5012-5024.1997; JOHNSON MA, 1995, ARCH VIROL, V140, P623, DOI 10.1007/BF01309954; Khadr A, 1996, GENE, V168, P189, DOI 10.1016/0378-1119(95)00776-8; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LITTLE SP, 1981, VIROLOGY, V112, P686, DOI 10.1016/0042-6822(81)90314-7; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; PERSON S, 1976, J VIROL, V17, P183, DOI 10.1128/JVI.17.1.183-190.1976; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; POGUEGEILE KL, 1987, VIROLOGY, V157, P67, DOI 10.1016/0042-6822(87)90314-X; RAMASWAMY R, 1992, VIROLOGY, V186, P579, DOI 10.1016/0042-6822(92)90024-J; READ GS, 1980, J VIROL, V35, P105, DOI 10.1128/JVI.35.1.105-113.1980; REN DL, 1994, VIROLOGY, V204, P242, DOI 10.1006/viro.1994.1528; ROOP C, 1993, J VIROL, V67, P2285, DOI 10.1128/JVI.67.4.2285-2297.1993; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SPEAR PG, 1993, MEMBRANE FUSION INDU, P201; SPEAR PG, 1985, HERPESVIRUSES, V3, P315; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; TERRYALLISON T, 1997, 22 INT HERP WORKSH A, P279; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VONSTRANDMANN EP, 1995, PROTEIN ENG, V8, P733; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529; ZHAO Y, 1992, J VIROL, V66, P5363, DOI 10.1128/JVI.66.9.5363-5372.1992	53	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33305	33311		10.1074/jbc.272.52.33305	http://dx.doi.org/10.1074/jbc.272.52.33305			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407122	hybrid			2022-12-25	WOS:000071182900083
J	Kay, RR				Kay, RR			The biosynthesis of differentiation-inducing factor, a chlorinated signal molecule regulating Dictyostelium development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STALK CELL-DIFFERENTIATION; SLIME-MOLD DICTYOSTELIUM; FATTY-ACID SYNTHASES; AFLATOXIN BIOSYNTHESIS; O-METHYLTRANSFERASES; ESCHERICHIA-COLI; DISCOIDEUM; MORPHOGEN; DIF; ENZYME	Differentiation-inducing factor (DIF)-1 is a chlorinated alkyl phenone released by developing Dictyostelium amoebae, which induces them to differentiate into stalk cells, A biosynthetic pathway for DIF-1 is proposed from labeling, inhibitor, and enzymological experiments, Cells incorporate Cl-36(-) into DIF-1 during development, showing that the chlorine atoms originate from chloride ions; peak incorporation is at the first finger stage, DIF-1 synthesis can be blocked by cerulenin, a polyketide synthase inhibitor, suggesting that it is made from a polyketide, This is most likely the C-12 polyketide (2,4,6-trihydroxyphenyl)-1-hexan-1-one (THPH). Feeding experiments confirm that living cells can convert THPH to DIF-1, Conversion requires both chlorination and methylation of THPH, and enzymatic activities able to do this exist in cell lysates, The chlorinating activity, assayed using Cl-36(-), is stimulated by H2O2 and requires both soluble and particulate components, It is specific for THPH and does not use this compound after O-methylation. The methyltransferase is soluble, uses S-adenosyl-L-methionine as a co-substrate, has a K-m for dichloro-THPH of about 1.1 mu M, and strongly prefers this substrate to close analogues, Both chlorinating and methyltransferase activities increase in development in parallel with DIF-1 production, and both are greatly reduced in a mutant strain that makes little DIF-1, It is proposed that DIF-1 is made by the initial assembly of a C-12 polyketide skeleton, which is then chlorinated and methylated.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Kay, RR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Kay, Robert R/0000-0001-9836-7967				BERKS M, 1990, DEVELOPMENT, V110, P977; BIRCH AJ, 1967, SCIENCE, V156, P202, DOI 10.1126/science.156.3772.202; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROOKMAN JJ, 1982, DEV BIOL, V91, P191, DOI 10.1016/0012-1606(82)90022-7; BROOKMAN JJ, 1987, DEVELOPMENT, V100, P119; Brown DW, 1996, P NATL ACAD SCI USA, V93, P14873, DOI 10.1073/pnas.93.25.14873; CHANCE K, 1976, J BACTERIOL, V128, P21, DOI 10.1128/JB.128.1.21-27.1976; CHEN YP, 1991, J BIOL CHEM, V266, P23909; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EARLY AE, 1988, DEVELOPMENT, V103, P519; GUITTON MC, 1988, CELL DIFFER DEV, V22, P203, DOI 10.1016/0045-6039(88)90012-7; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; INOKOSHI J, 1994, MOL GEN GENET, V244, P90, DOI 10.1007/BF00280191; INSALL R, 1990, EMBO J, V9, P3323, DOI 10.1002/j.1460-2075.1990.tb07532.x; INSALL R, 1992, EMBO J, V11, P2849, DOI 10.1002/j.1460-2075.1992.tb05352.x; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KAY RR, 1987, METHOD CELL BIOL, V28, P433; KAY RR, 1992, BIOCHEM J, V281, P155, DOI 10.1042/bj2810155; KAY RR, 1983, EUR J BIOCHEM, V136, P51, DOI 10.1111/j.1432-1033.1983.tb07703.x; KAY RR, 1989, DEVELOPMENT, V107, P81; KAY RR, 1983, NATURE, V303, P242, DOI 10.1038/303242a0; KAY RR, 1989, DEVELOPMENT, V105, P753; KHOURI HE, 1988, ARCH BIOCHEM BIOPHYS, V262, P592, DOI 10.1016/0003-9861(88)90410-9; KOPACHIK W, 1983, CELL, V33, P397, DOI 10.1016/0092-8674(83)90421-X; KREUZMAN AJ, 1988, J BIOL CHEM, V263, P15626; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; MADIGAN SJ, 1989, J BACTERIOL, V171, P1492, DOI 10.1128/jb.171.3.1492-1495.1989; Mahanti N, 1996, APPL ENVIRON MICROB, V62, P191, DOI 10.1128/AEM.62.1.191-195.1996; MARTIN JF, 1975, BIOCHIM BIOPHYS ACTA, V411, P186, DOI 10.1016/0304-4165(75)90298-6; MASENTO MS, 1988, BIOCHEM J, V256, P23, DOI 10.1042/bj2560023; MASENTO MS, 1987, THESIS U LONDON LOND; Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392; MORANDINI P, 1995, BIOCHEM J, V306, P735, DOI 10.1042/bj3060735; MORRIS DR, 1966, J BIOL CHEM, V241, P1763; MORRIS HR, 1988, BIOCHEM J, V249, P903, DOI 10.1042/bj2490903; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; NAYLER O, 1992, EUR J BIOCHEM, V208, P531, DOI 10.1111/j.1432-1033.1992.tb17217.x; Neidleman S.L., 1986, BIOHALOGENATION PRIN; OHagan D., 1991, POLYKETIDE METABOLIT; OHNO H, 1975, J BIOCHEM-TOKYO, V78, P1149, DOI 10.1093/oxfordjournals.jbchem.a131010; Omura S, 1981, Methods Enzymol, V72, P520; ROBERTS G, 1983, FEBS LETT, V159, P13, DOI 10.1016/0014-5793(83)80407-4; Schaap P, 1996, DIFFERENTIATION, V60, P1, DOI 10.1046/j.1432-0436.1996.6010001.x; Siggaard-Andersen Mads, 1993, Protein Sequences and Data Analysis, V5, P325; SIGGAARDANDERSEN M, 1994, P NATL ACAD SCI USA, V91, P11027, DOI 10.1073/pnas.91.23.11027; SOBOLEWSKI A, 1983, DIFFERENTIATION, V25, P93; TOWN CD, 1976, NATURE, V262, P717, DOI 10.1038/262717a0; TRAYNOR D, 1991, J BIOL CHEM, V266, P5291; VANWAARDE A, 1985, BIOCHIM BIOPHYS ACTA, V836, P27, DOI 10.1016/0005-2760(85)90216-4; WANG M, 1989, DEVELOPMENT, V105, P569; WATTS DJ, 1970, BIOCHEM J, V119, P171, DOI 10.1042/bj1190171; WEISS U, 1980, BIOSYNTHESIS AROMATI; WILLIAMS JG, 1987, CELL, V49, P185, DOI 10.1016/0092-8674(87)90559-9; YABE K, 1989, APPL ENVIRON MICROB, V55, P2172, DOI 10.1128/AEM.55.9.2172-2177.1989	54	53	57	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 30	1998	273	5					2669	2675		10.1074/jbc.273.5.2669	http://dx.doi.org/10.1074/jbc.273.5.2669			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YU621	9446571	hybrid			2022-12-25	WOS:000071736600026
J	Fagerstrom, S; Pahlman, S; Nanberg, E				Fagerstrom, S; Pahlman, S; Nanberg, E			Protein kinase C-dependent tyrosine phosphorylation of p130(cas) in differentiating neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN NEURO-BLASTOMA; NERVE GROWTH-FACTOR; 38 KDA PROTEIN; V-SRC; SIGNAL-TRANSDUCTION; SH3 DOMAINS; 3T3 CELLS; PTP-PEST; CONES	The cell signaling docking protein p130(cas) became tyrosine-phosphorylated in SH-SY5Y human neuroblastoma cells during induced differentiation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and serum or a combination of basic fibroblast growth factor (bFGF) and insulin-like growth factor-I (IGF-I). The differentiating cells develop a neuronal phenotype with neurites and growth cones and sustained activation of protein kinase C (PKC) and pp60(c-src). The TPA-induced p130(cas) phosphorylation increased within 5 min of stimulation and persisted for at least 4 days, whereas bFGF/IGF-I-induced p130(cas) phosphorylation was biphasic, However, the increase in tyrosine phosphorylation of p130(cas) was not restricted to differentiation inducing stimuli. The phosphorylation was blocked by the specific PKC inhibitor GF 109203X, and transient transfection with active PKC-epsilon induced p130(cas) tyrosine phosphorylation, pp60(c-src), known to directly phosphorylate p130(cas) in other cell systems, was not activated after stimulation with TPA or bFGF/IGF-I for up to 30 min, and the initial p130(cas) phosphorylation was resistant to the Src family kinase inhibitor herbimycin A. However, in long term stimulated cells, herbimycin A blocked the induced phosphorylation of p130(cas), Also, overexpression of src induced phosphorylation of p130(cas). p130(cas) protein and phosphorylated p130(cas) were present in growth cones isolated from differentiated SH-SY5Y cells. Inhibition of PKC activity in differentiating cells with GF 109203X leads to a rapid retraction of growth cone filopodia, and p130(cas) phosphorylation decreased transiently (within minutes), Growth cones isolated from these cells were virtually devoid of phosphorylated p130(cas). These data suggest a function for p130(cas) as a PKC downstream target in SH-SY5Y cells and possibly also in their growth cones.	Lund Univ, Hosp MAS, Dept Lab Med, Wallenberg Lab, S-20502 Malmo, Sweden; Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden	Lund University; Uppsala University; Uppsala University Hospital	Pahlman, S (corresponding author), Lund Univ, Hosp MAS, Dept Lab Med, Wallenberg Lab, S-20502 Malmo, Sweden.	Sven.Pahlman@medforsk.mas.lu.se						AIGNER L, 1995, J CELL BIOL, V128, P647, DOI 10.1083/jcb.128.4.647; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BIEDLER JL, 1973, CANCER RES, V33, P2643; BIEDLER JL, 1978, CANCER RES, V38, P3751; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnham MR, 1996, ONCOGENE, V12, P2467; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; GARTON AJ, 1994, EMBO J, V13, P3763, DOI 10.1002/j.1460-2075.1994.tb06687.x; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; GENOT EM, 1995, J BIOL CHEM, V270, P9833, DOI 10.1074/jbc.270.17.9833; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; HABIB T, 1994, J BIOL CHEM, V269, P25243; Harte MT, 1996, J BIOL CHEM, V271, P13649, DOI 10.1074/jbc.271.23.13649; HELMKE S, 1995, CELL MOTIL CYTOSKEL, V30, P194, DOI 10.1002/cm.970300304; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; Keegan K, 1993, Curr Opin Neurobiol, V3, P14, DOI 10.1016/0959-4388(93)90029-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; LAVENIUS E, 1994, GROWTH FACTORS, V10, P29, DOI 10.3109/08977199409019601; MARONEY AC, 1995, J NEUROCHEM, V64, P540; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MEYERSON G, 1993, FEBS LETT, V332, P27, DOI 10.1016/0014-5793(93)80475-A; MEYERSON G, 1992, J CELL SCI, V103, P233; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PAHLMAN S, 1981, INT J CANCER, V28, P583, DOI 10.1002/ijc.2910280509; PAHLMAN S, 1991, P NATL ACAD SCI USA, V88, P9994, DOI 10.1073/pnas.88.22.9994; PAHLMAN S, 1983, CELL DIFFER DEV, V12, P165, DOI 10.1016/0045-6039(83)90006-4; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; PARROW V, 1992, J CELL PHYSIOL, V152, P536, DOI 10.1002/jcp.1041520313; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; PURCHIO AF, 1985, SCIENCE, V229, P1393, DOI 10.1126/science.2994221; Ribon V, 1996, J BIOL CHEM, V271, P7375, DOI 10.1074/jbc.271.13.7375; RUUSALA AI, 1985, DEV BRAIN RES, V18, P27, DOI 10.1016/0165-3806(85)90247-0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; Vuori K, 1996, MOL CELL BIOL, V16, P2606; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	51	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2336	2343		10.1074/jbc.273.4.2336	http://dx.doi.org/10.1074/jbc.273.4.2336			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442079	hybrid			2022-12-25	WOS:000071595200068
J	Sheikh-Hamad, D; Di Mari, J; Suki, WN; Safirstein, R; Watts, BA; Rouse, D				Sheikh-Hamad, D; Di Mari, J; Suki, WN; Safirstein, R; Watts, BA; Rouse, D			p38 kinase activity is essential for osmotic induction of mRNAs for HSP70 and transporter for organic solute betaine in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; AMINO-TERMINAL KINASES; ALDOSE REDUCTASE GENE; RENAL MEDULLARY CELLS; TUMOR-NECROSIS-FACTOR; SIGNAL-TRANSDUCTION; HYPERTONIC STRESS; HEAT-SHOCK; EXPRESSION; CLONING	In renal cells, hypertonicity induces genes for heat shock proteins (HSP70, alpha B-crystallin), as well as enzymes and transporters directly involved in the metabolism and transport of protective organic osmolytes, While heat shock proteins are induced by many stresses including osmotic stress, the induction of the osmolytes genes appears to be specific to osmotic stress. These two adaptive mechanisms allow kidney cells to survive and function in the hypertonic environment that exists on routine basis in kidney medulla, In mammalian cells, hypertonicity induces three mitogen-activated protein kinase pathways: ERK (extracellular regulated kinase), JNK (Jun N-terminal kinase), and p38, ERK activation by osmotic stress is a consistent finding in many cells, but it is not essential for transcriptional. regulation of mRNA for transporter of organic osmolyte betaine, While the growth of yeast cells on NaCl-supplemented medium is dependent on HOG1 pathway, it is still unclear which pathway mediates the adaptation to osmotic stress in mammalian cells, Here, we show that inhibition of p38 kinase activity, using the specific inhibitor SB203580 (4-(fluorophenyl)-2-(4-methylsulfonylphenyl)-5-(4-pyridyl) imidazole), abolishes the hypertonicity-mediated induction of mRNAs for HSP70 and betaine transporter in Madin-Darby canine kidney cells, The inhibition is dose-dependent and correlates with the in situ activity of native p38 kinase, determined as MAPKAPK-2 activity in cell extracts, As reported previously, the activities of ERK-1 and -2 were not affected by SB203580, but surprisingly, inhibition of native p38 kinase activity correlates with up-regulation of native JNK-1 activity in osmotically stressed cells, p38 mRNA is induced by hypertonic stress and is attenuated with p38 kinase inhibition, We also find that thermal induction of HSP70 mRNA is not affected by p38 kinase inhibition, Such findings suggest that p38 kinase activity is essential for the induction of genes involved in the adaptation of mammalian cells to osmotic stress and that the increased activity of JNK-1 during p38 kinase inhibition is consistent with regulation of JNK-1 by p38 kinase in osmotically stressed cells, In addition, the transduction pathways mediating HSP70 mRNA induction by different stresses appear to be divergent; osmotic induction of HSP70 is p38 kinase-dependent, while thermal induction is not.	Baylor Coll Med, Dept Med, Div Renal, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Med, Div Renal, Galveston, TX 77555 USA	Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Sheikh-Hamad, D (corresponding author), Baylor Coll Med, Dept Med, Div Renal, 6550 Fannin St,Suite 1273, Houston, TX 77030 USA.	sheikh@bcm.tmc.edu						ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; Berl T, 1997, AM J PHYSIOL-RENAL, V272, pF305, DOI 10.1152/ajprenal.1997.272.3.F305; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN DM, 1991, AM J PHYSIOL, V261, pC594, DOI 10.1152/ajpcell.1991.261.4.C594; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DASGUPTA S, 1992, EXP EYE RES, V54, P461, DOI 10.1016/0014-4835(92)90058-Z; FERRARIS JD, 1994, P NATL ACAD SCI USA, V91, P10742, DOI 10.1073/pnas.91.22.10742; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; GROUDINE M, 1982, CELL, V30, P131, DOI 10.1016/0092-8674(82)90019-8; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; KWON HM, 1995, BIOCHEM BIOPH RES CO, V213, P975, DOI 10.1006/bbrc.1995.2224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINMI Y, 1996, BRAIN RES MOL BIOL R, V40, P64; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NAKANISHI T, 1990, AM J PHYSIOL, V258, pF1061, DOI 10.1152/ajprenal.1990.258.4.F1061; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; POMBO CM, 1994, J BIOL CHEM, V269, P26546; SHEIKHHAMAD D, 1994, AM J PHYSIOL, V267, pF28, DOI 10.1152/ajprenal.1994.267.1.F28; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; TAUB M, 1979, P NATL ACAD SCI USA, V76, P3338, DOI 10.1073/pnas.76.7.3338; UCHIDA S, 1989, AM J PHYSIOL, V256, pC614, DOI 10.1152/ajpcell.1989.256.3.C614; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Watts BA, 1996, J AM SOC NEPHROL, V7, pA0303; WHEATLEY DN, 1974, EXP CELL RES, V87, P219, DOI 10.1016/0014-4827(74)90474-1; WHEATLEY DN, 1974, J CELL SCI, V15, P221; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649; YAMAUCHI A, 1993, AM J PHYSIOL, V364, pF20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	45	161	162	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1832	1837		10.1074/jbc.273.3.1832	http://dx.doi.org/10.1074/jbc.273.3.1832			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430735	hybrid			2022-12-25	WOS:000071411500082
J	Bothner, B; Dong, XF; Bibbs, L; Johnson, JE; Siuzdak, G				Bothner, B; Dong, XF; Bibbs, L; Johnson, JE; Siuzdak, G			Evidence of viral capsid dynamics using limited proteolysis and mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ICOSAHEDRAL ANIMAL VIRUS; POSTTRANSLATIONAL MODIFICATIONS; MATURATION; POLIOVIRUS; PROTEINS; BINDING; DNA; RNA; VP1	Virus particles are stable yet exhibit highly dynamic character given the events that shape their life cycle. Isolated from their hosts, the nucleoprotein particles are macromolecules that can be crystallized and studied by x-ray diffraction. During assembly, maturation and entry, however, they are highly dynamic and display remarkable plasticity. These dynamic properties can only be inferred from the x-ray structure and must be studied by methods that are sensitive to mobility. We have used matrix-assisted laser desorption/ionization mass spectrometry combined with time resolved, limited proteolysis (Cohen, S. L., Ferre-D'Amare, A. R., Burley, S. K., and Chait, B. T. (1995) Protein Sci. 4, 1088-1099; Kriwacki, R. W., Wu, J., Tennant, T., Wright, P. E., and Siuzdak, G. (1997) J. Chromatogr. 777, 23-30; Kriwacki, R. W., Wu, J., Siuzdak, G., and Wright, P. E. (1996) J. Am. Chem. Sec. 118, 5320-5321) to examine the viral capsid of flock house virus. Employing less than 10 mu g of virus, time course digestion products were assigned to polypeptides of the subunit. Although surface regions in the three-dimensional structure were susceptible to cleavage on extended exposure to the protease, the first digestion products were invariably from parts of the subunit that are internal to the x-ray structure. Regions in the N- and C-terminal portions of the subunit, located within the shell in the x-ray structure, but implicated in RNA neutralization and RNA release and delivery, respectively, were the most susceptible to cleavage demonstrating transient exposure of these polypeptides to the viral surface.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Johnson, JE (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.			Siuzdak, Gary/0000-0002-4749-0014	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR007273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048870] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR07273-01] Funding Source: Medline; NIGMS NIH HHS [5 P01 GM48870-05] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHENG RH, 1994, STRUCTURE, V2, P271; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Despeyroux D, 1996, RAPID COMMUN MASS SP, V10, P937, DOI 10.1002/(SICI)1097-0231(19960610)10:8<937::AID-RCM598>3.0.CO;2-9; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; FRICKS CE, 1990, J VIROL, V64, P1934, DOI 10.1128/JVI.64.5.1934-1945.1990; GALLAGHER TM, 1988, J VIROL, V62, P3399, DOI 10.1128/JVI.62.9.3399-3406.1988; GORMAN JJ, 1992, TRAC-TREND ANAL CHEM, V11, P96, DOI 10.1016/0165-9936(92)85007-R; GORMAN JJ, 1990, BIOMED ENVIRON MASS, V19, P646, DOI 10.1002/bms.1200191104; Jonscher KR, 1997, J BIOL CHEM, V272, P1735, DOI 10.1074/jbc.272.3.1735; Jurinke C, 1996, GENET ANAL-BIOMOL E, V13, P67, DOI 10.1016/1050-3862(95)00151-4; Kriwacki RW, 1996, J AM CHEM SOC, V118, P5320, DOI 10.1021/ja960752m; Kriwacki RW, 1997, J CHROMATOGR A, V777, P23, DOI 10.1016/S0021-9673(97)00527-X; LI QH, 1994, J VIROL, V68, P3965, DOI 10.1128/JVI.68.6.3965-3970.1994; Munshi S, 1996, J MOL BIOL, V261, P1, DOI 10.1006/jmbi.1996.0437; NELSON RW, 1995, RAPID COMMUN MASS SP, V9, P1380, DOI 10.1002/rcm.1290091411; Siuzdak G, 1996, CHEM BIOL, V3, P45, DOI 10.1016/S1074-5521(96)90083-6; Winkler MA, 1996, J CHROMATOGR A, V744, P177, DOI 10.1016/0021-9673(96)00184-7; ZLOTNICK A, 1994, J BIOL CHEM, V269, P13680	18	151	153	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					673	676		10.1074/jbc.273.2.673	http://dx.doi.org/10.1074/jbc.273.2.673			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422714	hybrid			2022-12-25	WOS:000071411400003
J	Soga, S; Kozawa, T; Narumi, H; Akinaga, S; Irie, K; Matsumoto, K; Sharma, SV; Nakano, H; Mizukami, T; Hara, M				Soga, S; Kozawa, T; Narumi, H; Akinaga, S; Irie, K; Matsumoto, K; Sharma, SV; Nakano, H; Mizukami, T; Hara, M			Radicicol leads to selective depletion of Raf kinase and disrupts K-Ras-activated aberrant signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TRANSFORMED CELLS; COMPLEX; SRC; GAP; DIFFERENTIATION; PHOSPHORYLATION; DESTABILIZATION; ASSOCIATION; EXPRESSION	Activation of Ras leads to the constitutive activation of a downstream phosphorylation cascade comprised of Raf-1, mitogen-activated protein kinase (MAPK) kinase, and MAPK, We have developed a yeast-based assay in which the Saccharomyces cerevisiae mating pheromone-induced MAPK pathway relied on co-expression of K-Ras and Raf-1, Radicicol, an antifungal antibiotic, was found to inhibit the K-ras signaling pathway reconstituted in yeast, In K-ras-transformed, rat epithelial, and K-ras-activated, human pancreatic carcinoma cell lines, radicicol inhibited K Ras-induced hyperphosphorylation of Erk2, In addition, the level of Raf kinase was significantly decreased in radicicol-treated cells, whereas the levels of K-Ras and MAPK remained unchanged, These results suggest that radicicol disrupts the K-Ras-activated signaling pathway by selectively depleting Raf kinase and raises the possibility that pharmacological destabilization of Raf kinase could be a new and powerful approach for the treatment of K-ras-activated human cancers.	Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 194, Japan; Kyowa Hakko Kogyo Co Ltd, Pharmaceut Res Labs, Nagaizumi, Shizuoka 411, Japan; Nagoya Univ, Fac Sci, Dept Mol Biol, Chikusa Ku, Nagoya, Aichi 46401, Japan; Univ Tennessee, Ctr Hlth Sci, Dept Microbiol & Immunol, Memphis, TN 38163 USA	Kyowa Kirin Ltd; Kyowa Kirin Ltd; Nagoya University; University of Tennessee System; University of Tennessee Health Science Center	Hara, M (corresponding author), Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, 3-6-6 Asahimachi, Machida, Tokyo 194, Japan.	mhara@kyowa.co.jp						BOS JL, 1989, CANCER RES, V49, P4682; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DELMOTTE P, 1953, NATURE, V171, P344, DOI 10.1038/171344a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; EREDE B, 1993, CURR OPIN CELL BIOL, V5, P254; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HALL TJ, 1994, BIOCHEM BIOPH RES CO, V199, P1237, DOI 10.1006/bbrc.1994.1363; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITOH H, 1983, J BACTERIOL, V153, P163; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KWON HJ, 1995, J BIOCHEM-TOKYO, V118, P221, DOI 10.1093/oxfordjournals.jbchem.a124882; KWON HJ, 1992, CANCER RES, V52, P6926; KWON HJ, 1992, BIOSCI BIOTECH BIOCH, V56, P538; McCAPRA FRANK, 1964, TETRAHEDRON LETT, V15/16, P869; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIRRINGTON RN, 1964, TETRAHEDRON LETT, V7, P365; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; Monia BP, 1996, P NATL ACAD SCI USA, V93, P15481, DOI 10.1073/pnas.93.26.15481; MORAN M, 1991, MOL CELL BIOL, V11, P1553; OIKAWA T, 1993, EUR J PHARMACOL, V241, P221, DOI 10.1016/0014-2999(93)90206-W; PENDERGAST GC, 1995, ONCOGENE, V10, P2289; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHERMAN F, 1986, LAB COURSE MANUAL ME, P178; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TAMAOKI T, 1985, BIOCHEM BIOPH RES CO, V132, P126, DOI 10.1016/0006-291X(85)90997-0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; YAMADA H, 1986, BIOCHEM BIOPH RES CO, V140, P167, DOI 10.1016/0006-291X(86)91072-7; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; ZHAO JF, 1995, ONCOGENE, V11, P161	37	97	98	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					822	828		10.1074/jbc.273.2.822	http://dx.doi.org/10.1074/jbc.273.2.822			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422737	hybrid			2022-12-25	WOS:000071411400026
J	Winkler, GS; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Weeda, G				Winkler, GS; Vermeulen, W; Coin, F; Egly, JM; Hoeijmakers, JHJ; Weeda, G			Affinity purification of human DNA repair transcription factor TFIIH using epitope-tagged xeroderma pigmentosum B protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; NUCLEOTIDE-EXCISION-REPAIR; FACTOR BTF2; PROMOTER; COMPLEX; BTF2/TFIIH; KINASE; ATPASE; YEAST; COMPLEMENTATION	TFIIH is a high molecular weight complex with a remarkable dual function in nucleotide excision repair and initiation of RNA polymerase II transcription. Mutations in the largest subunits, the XPB and XPD helicases, are associated with three inherited disorders: xeroderma pigmentosum, Cockayne's syndrome, and trichothiodystrophy. To facilitate the purification and biochemical characterization of this intricate complex, we generated a cell line stably expressing tagged XPB, allowing the immunopurification of the XPB protein and associated factors. Addition of two tags, a N-terminal hexameric histidine stretch and a C-terminal hemagglutinin epitope, to this highly conserved protein did not interfere with its functioning in repair and transcription. The hemagglutinin epitope allowed efficient TFIIH immunopurification to homogeneity from a fractionated whole cell extract in essentially one step. We conclude that the predominant active form of TFIIH is composed of nine subunits and that there is one molecule of XPB per TFIIH complex. The affinity-purified complex exhibits all expected TFIIH activities: DNA-dependent ATPase, helicase, C-terminal domain kinase, and participation in in vitro and in vivo nucleotide excision repair and in vitro transcription. The affinity purification procedure described here is fast and simple, does not require extensive chromatographic procedures, and yields highly purified, active TFIIH.	Erasmus Univ, Ctr Med Genet, Dept Cell Biol, NL-3000 DR Rotterdam, Netherlands; Ctr Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Ctr Med Genet, Dept Cell Biol, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Vermeulen, Wim/W-8708-2019; Coin, Frédéric/F-5925-2013; Hoeijmakers, Jan/AAX-6972-2021	Vermeulen, Wim/0000-0003-3616-734X; Coin, Frédéric/0000-0002-5620-8519; Winkler, Sebastiaan/0000-0002-0476-162X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Adamczewski JP, 1996, EMBO J, V15, P1877, DOI 10.1002/j.1460-2075.1996.tb00538.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOOTSMA D, 1998, IN PRESS METABOLIC M; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLORES O, 1992, J BIOL CHEM, V267, P2786; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GERARD M, 1991, J BIOL CHEM, V266, P20940; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; Harlow E., 1988, ANTIBODIES LAB MANUA; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; HOLSTEGE FCP, 1995, EMBO J, V14, P810, DOI 10.1002/j.1460-2075.1995.tb07059.x; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MANLEY JL, 1983, METHOD ENZYMOL, V101, P568; Marinoni JC, 1997, EMBO J, V16, P1093, DOI 10.1093/emboj/16.5.1093; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; ROBINS P, 1991, EMBO J, V10, P3913, DOI 10.1002/j.1460-2075.1991.tb04961.x; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; STEFANINI M, 1993, AM J HUM GENET, V53, P817; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0; Weeda G, 1997, NUCLEIC ACIDS RES, V25, P2274, DOI 10.1093/nar/25.12.2274; WOOD RD, 1988, CELL, V53, P97, DOI 10.1016/0092-8674(88)90491-6; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	46	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1092	1098		10.1074/jbc.273.2.1092	http://dx.doi.org/10.1074/jbc.273.2.1092			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422774	hybrid, Green Published			2022-12-25	WOS:000071411400063
J	Mary, S; Gomeza, J; Prezeau, L; Bockaert, J; Pin, JP				Mary, S; Gomeza, J; Prezeau, L; Bockaert, J; Pin, JP			A cluster of basic residues in the carboxyl-terminal tail of the short metabotropic glutamate receptor 1 variants impairs their coupling to phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTOR; ALTERNATIVELY SPLICED FORMS; G-PROTEIN ACTIVATION; SIGNAL-TRANSDUCTION; HORMONE RECEPTOR; CALCIUM RELEASE; XENOPUS OOCYTES; DOMAIN; EXPRESSION; MGLUR1	Among phospholipase C-coupled metabotropic glutamate receptors (mGluRs), some have a surprisingly long carboxyl-terminal intracellular domain (mGluR1a, -5a, and -5b), and others have a short one (mGluR1a, -1c, and -1d). All mGluR1 sequences are identical up to 46 residues following the 7th transmembrane domain, followed by 313, 20, 11, and 26 specific residues in mGluR1a, mGluR1b, mGluR1c, and mGluR1d, respectively. Several functional differences have been described between the long isoforms (mGluR1a, -5a, and -5b) and the short ones (mGluR1b, -1c, and -1d). Compared with the long receptors, the short ones induce slower increases in intracellular Ca2+ are activated by higher concentration of agonists, and do not exhibit constitutive, agonist-independent activity, To identify the residues responsible for these functional properties, a series of truncated, chimeric, and mutated receptors were constructed We found that the deletion of the last 19 carboxyl-terminal residues in mGluR1c changed its properties into those of mGluR1a. Moreover, the exchange of the long carboxyl-terminal domain of mGluR5a with that of mGluR1c generated a chimeric receptor that possessed functional properties similar to those of mGluR1c. Mutagenesis of specific residues within the 19 carboxyl-terminal residues of mGluR1c revealed the importance of a cluster of 4 basic residues in defining the specific properties of this receptor. Since this cluster is part of the sequence common to all mGluR1 variants, we conclude that the long carboxyl-terminal domain of mGluR1a suppresses the inhibitory action of this sequence element.	CNRS, INSERM, Ctr Pharmacol Endocrinol, UPR 9023, F-34094 Montpellier 05, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Pin, JP (corresponding author), CNRS, INSERM, Ctr Pharmacol Endocrinol, UPR 9023, 141 Rue Cardonille, F-34094 Montpellier 05, France.		Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X				ABE T, 1992, J BIOL CHEM, V267, P13361; ATON B, 1984, EXP EYE RES, V38, P547, DOI 10.1016/0014-4835(84)90173-8; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; Flor PJ, 1996, J NEUROCHEM, V67, P58; FONG TM, 1992, MOL PHARMACOL, V41, P24; GABELLINI N, 1993, NEUROREPORT, V4, P531, DOI 10.1097/00001756-199305000-00017; GABELLINI N, 1994, NEUROCHEM INT, V24, P533, DOI 10.1016/0197-0186(94)90004-3; Gomeza J, 1996, MOL PHARMACOL, V50, P923; Gomeza J, 1996, J BIOL CHEM, V271, P2199, DOI 10.1074/jbc.271.4.2199; Groblewski T, 1997, J BIOL CHEM, V272, P1822, DOI 10.1074/jbc.272.3.1822; HAMPSON DR, 1994, NEUROSCIENCE, V60, P325, DOI 10.1016/0306-4522(94)90246-1; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; JOLY C, 1995, J NEUROSCI, V15, P3970; Kaupmann K, 1997, NATURE, V386, P239, DOI 10.1038/386239a0; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KUHN H, 1981, BIOCHEMISTRY-US, V20, P2410; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; Laurie DJ, 1996, EUR J PHARMACOL, V296, pR1, DOI 10.1016/0014-2999(95)00868-3; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LECHLEITER J, 1991, NATURE, V350, P505, DOI 10.1038/350505a0; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; Mary S, 1997, EUR J PHARMACOL, V335, P65, DOI 10.1016/S0014-2999(97)01155-2; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; MORRISON DF, 1991, J BIOL CHEM, V266, P20118; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; Pin Jean-Philippe, 1996, V39, P343; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1994, EMBO J, V13, P342, DOI 10.1002/j.1460-2075.1994.tb06267.x; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; Prezeau L, 1996, MOL PHARMACOL, V49, P422; REN Q, 1993, J BIOL CHEM, V268, P16483; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SIMONCINI L, 1993, BIOPHYS J, V64, pA84; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; TAKAHASHI K, 1993, J BIOL CHEM, V268, P19341; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011	49	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					425	432		10.1074/jbc.273.1.425	http://dx.doi.org/10.1074/jbc.273.1.425			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417099	hybrid			2022-12-25	WOS:000071295600065
J	Wolosker, H; Kline, D; Bian, Y; Blackshaw, S; Cameron, M; Fralich, TJ; Schnaar, RL; Snyder, SH				Wolosker, H; Kline, D; Bian, Y; Blackshaw, S; Cameron, M; Fralich, TJ; Schnaar, RL; Snyder, SH			Molecularly cloned mammalian glucosamine-6-phosphate deaminase localizes to transporting epithelium and lacks oscillin activity	FASEB JOURNAL			English	Article						metabolism; hexosamines; cloning; sialic acid; GNPDA	REPETITIVE CALCIUM TRANSIENTS; ESCHERICHIA-COLI; MOUSE EGG; SIALIC ACIDS; PROTEIN; SPERM; PURIFICATION; GLUCOSAMINE; CELLS	Glucosamine-6-phosphate deaminase (GNPDA) catalyzes the conversion of glucosamine-6-phosphate to fructose-6-phosphate, a reaction that under physiological conditions proceeds to the formation of fructose-6-phosphate. Though first identified in mammalian tissues in 1956, the enzyme has not previously been molecularly characterized in mammalian tissues, although a bacterial GNPDA has been cloned. Recently, a protein displaying similarity to bacterial GNPDA was purified and cloned from sperm extract. It was proposed that this protein was the factor, found in sperm extracts, that causes calcium oscillations in cells; thus, the protein was named 'oscillin.' We demonstrate that oscillin is the mammalian form of glucosamine 6-phosphate deaminase by showing that cloned oscillin has a robust GNPDA activity and can account for all such activity in mammalian tissues extracts. In situ hybridization and immunohistochemistry localize GNPDA selectively to tissues with high energy requirements such as the apical zone of transporting epithelia in the proximal convoluted tubules of the kidney and the small intestine; to neurons (but not glia) and especially to nerve terminals in the brain; and to motile sperm. Recombinant GNPDA and GNPDA purified to homogeneity from hamster sperm fail to elevate intracellular calcium when injected into mouse eggs over a wide range of concentrations under conditions in which sperm extracts elicit pronounced calcium oscillations. Thus, the calcium-releasing or oscillin activity of sperm extracts is due to a substance other than GNPDA. Since GNPDA is the sole enzyme linking hexosamine systems with glycolytic pathways, we propose that it provides a source of energy in the form of phosphosugar derived from the catabolism of hexosamines found in glycoproteins, glycolipids, and sialic acid-containing macromolecules. Evidence that GNPDA can regulate hexosamine stores comes from our observation that transfection of GNPDA into HEK-293 cells reduces cellular levels of sialic acid.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Kent State Univ, Dept Biol Sci, Kent, OH 44242 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Schnaar, Ronald L/S-8967-2016; Kline, Douglas/AAH-5955-2020	Schnaar, Ronald L/0000-0002-7701-5484; Kline, Douglas/0000-0003-2555-6729; Wolosker, Herman/0000-0001-5508-9194	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R15HD031683] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 31683] Funding Source: Medline; NIDA NIH HHS [DA00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		CALCAGNO M, 1984, BIOCHIM BIOPHYS ACTA, V787, P165, DOI 10.1016/0167-4838(84)90076-1; COMB DG, 1958, J BIOL CHEM, V232, P807; CORFIELD AP, 1985, BIOCHEM J, V226, P163, DOI 10.1042/bj2260163; DAVIS JS, 1967, ANAL BIOCHEM, V19, P72, DOI 10.1016/0003-2697(67)90135-2; ERIKSSON G, 1984, ARCH BIOCHEM BIOPHYS, V235, P692, DOI 10.1016/0003-9861(84)90245-5; HARLOW E, 1988, ANTIBODIES; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; Kay JE, 1996, BIOCHEM J, V314, P361, DOI 10.1042/bj3140361; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; KLINE D, 1992, J BIOL CHEM, V267, P17624; LELOIR LF, 1956, BIOCHIM BIOPHYS ACTA, V20, P30; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MEHLMANN LM, 1994, BIOL REPROD, V51, P1088, DOI 10.1095/biolreprod51.6.1088; Parrington J, 1996, NATURE, V379, P364, DOI 10.1038/379364a0; ROGERS MJ, 1988, GENE, V62, P197; ROME LH, 1986, BIOCHEM J, V268, P707; Sambrook J., 1989, MOL CLONING; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Sette C, 1997, DEVELOPMENT, V124, P2267; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stricker SA, 1997, DEV BIOL, V186, P185, DOI 10.1006/dbio.1997.8594; SUZUKI H, 1989, J BIOL CHEM, V264, P1368; SWANN K, 1990, DEVELOPMENT, V110, P1295; Swann K, 1996, Rev Reprod, V1, P33, DOI 10.1530/ror.0.0010033; WEIDANZ JA, 1995, BRIT J HAEMATOL, V91, P72, DOI 10.1111/j.1365-2141.1995.tb05247.x; Weidanz JA, 1996, BRIT J HAEMATOL, V95, P645, DOI 10.1046/j.1365-2141.1996.d01-1955.x; WU II, 1997, MOL REPROD DEV, V46, P176	27	110	112	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	1998	12	1					91	99		10.1096/fasebj.12.1.91	http://dx.doi.org/10.1096/fasebj.12.1.91			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YR723	9438414				2022-12-25	WOS:000071523800010
J	Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R				Antelman, D; Perry, S; Hollingsworth, R; Gregory, RJ; Driscoll, B; Fung, YK; Bookstein, R			Engineered mutants of pRB with improved growth suppression potential	ONCOGENE			English	Article						retinoblastoma; E2F; promoter repression	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; BLADDER-CARCINOMA CELLS; DNA-BINDING ACTIVITY; SUSCEPTIBILITY GENE; TUMOR-SUPPRESSOR; TERMINAL REGION; T-ANTIGEN; RB GENE; DEPENDENT KINASE	We have constructed a panel of substitution mutants which affect one or more of the putative cdk target sites of the RB protein. We have examined the activity of these mutants relative to wild-type RB by both a transcriptional repression assay and by measuring growth suppression in vitro. We find that some phosphorylation site mutants of pRB can repress E2 transcription more strongly than wild-type RB. These mutants are partially resistant to phosphorylation by cdks and can arrest tumor cells in G1 in vitro. Our results indicate a functional correlation between the ability to repress E2F-dependent transcription and the ability to suppress tumor cell growth in vitro. In addition, we describe two classes of RB mutants: N-terminal truncated p56(RB) and a novel mutant of RB containing multiple substitutions near its nuclear localization signal. Both classes of RB mutants have greater activity than the mild-type protein. Because RB is a key regulator of cell cycle progression, expression of a more potent, phosphorylation resistant RB may have utility in both RB(-/-) and RB(+/+) tumors as well as in hyperproliferative disorders.	PHARMACIA & UPJOHN INC,KALAMAZOO,MI 49001; GENZYME INC,FRAMINGHAM,MA; CHILDRENS HOSP LOS ANGELES,DIV OPTHAMOL,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT MICROBIOL,LOS ANGELES,CA 90033	Pfizer; Sanofi-Aventis; Children's Hospital Los Angeles; University of Southern California	Antelman, D (corresponding author), CANJI INC,3030 SCI PK RD,SAN DIEGO,CA 92121, USA.							AKIYAMA T, 1992, P NATL ACAD SCI USA, V89, P7900, DOI 10.1073/pnas.89.17.7900; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ARROYO M, 1992, NUCLEIC ACIDS RES, V20, P5947, DOI 10.1093/nar/20.22.5947; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GOODRICH DW, 1992, CANCER RES, V52, P1968; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1990, MOL CELL BIOL, V10, P6586, DOI 10.1128/MCB.10.12.6586; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HORTON LE, 1995, CELL GROWTH DIFFER, V6, P395; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1992, DNA CELL BIOL, V11, P539, DOI 10.1089/dna.1992.11.539; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; INOUE A, 1995, J BIOL CHEM, V270, P22571, DOI 10.1074/jbc.270.38.22571; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KITAGAWA M, 1995, ONCOGENE, V10, P229; KRATZKE RA, 1993, CELL GROWTH DIFFER, V4, P629; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MITTNACHT S, 1991, COLD SPRING HARB SYM, V56, P197; OOKAWA K, 1993, ONCOGENE, V8, P2175; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SUZUKITAKAHASHI I, 1995, ONCOGENE, V10, P1691; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WANG NP, 1993, ONCOGENE, V8, P279; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEN SF, 1994, J IMMUNOL METHODS, V169, P231, DOI 10.1016/0022-1759(94)90267-4; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; XU HJ, 1994, P NATL ACAD SCI USA, V91, P9837, DOI 10.1073/pnas.91.21.9837; Xu HJ, 1996, CANCER RES, V56, P2245; ZHU L, 1994, COLD SPRING HARB SYM, V59, P75, DOI 10.1101/SQB.1994.059.01.011; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	64	8	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2855	2866		10.1038/sj.onc.1201465	http://dx.doi.org/10.1038/sj.onc.1201465			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419977				2022-12-25	WOS:A1997YJ80300012
J	Sohal, RS				Sohal, RS			Mitochondria generate superoxide anion radicals and hydrogen peroxide	FASEB JOURNAL			English	Editorial Material							OXIDATIVE DAMAGE; DROSOPHILA-MELANOGASTER; HEART-MITOCHONDRIA; LIFE-SPAN; DISMUTASE; OVEREXPRESSION; RESTRICTION; CATALASE; RELEASE; MICE		So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA	Southern Methodist University	Sohal, RS (corresponding author), So Methodist Univ, Dept Biol Sci, Dallas, TX 75275 USA.							AGARWAL S, 1994, P NATL ACAD SCI USA, V91, P12332, DOI 10.1073/pnas.91.25.12332; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Forman HJ, 1997, FASEB J, V11, P374, DOI 10.1096/fasebj.11.5.9141504; GRISWOLD CM, 1993, GENETICS, V134, P781; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; MUSCARI C, 1990, BASIC RES CARDIOL, V85, P172, DOI 10.1007/BF01906970; NOHL H, 1978, EUR J BIOCHEM, V82, P563, DOI 10.1111/j.1432-1033.1978.tb12051.x; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465; SETO NOL, 1990, P NATL ACAD SCI USA, V87, P4270, DOI 10.1073/pnas.87.11.4270; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1995, J BIOL CHEM, V270, P15671, DOI 10.1074/jbc.270.26.15671; SOHAL RS, 1994, FREE RADICAL BIO MED, V16, P621, DOI 10.1016/0891-5849(94)90062-0; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; TURRENS JF, 1982, ARCH BIOCHEM BIOPHYS, V217, P411, DOI 10.1016/0003-9861(82)90519-7; TURRENS JF, 1985, ARCH BIOCHEM BIOPHYS, V237, P408, DOI 10.1016/0003-9861(85)90293-0	19	44	45	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	DEC	1997	11	14					1269	1270		10.1096/fasebj.11.14.9409545	http://dx.doi.org/10.1096/fasebj.11.14.9409545			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	YN210	9409545				2022-12-25	WOS:000071144100007
J	Mattu, TS; Pleass, RJ; Willis, AC; Kilian, M; Wormald, MR; Lellouch, AC; Rudd, PM; Woof, JM; Dwek, RA				Mattu, TS; Pleass, RJ; Willis, AC; Kilian, M; Wormald, MR; Lellouch, AC; Rudd, PM; Woof, JM; Dwek, RA			The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SECRETORY IMMUNOGLOBULIN-A; O-LINKED OLIGOSACCHARIDES; PERFORMANCE LIQUID-CHROMATOGRAPHY; OVINE SUBMAXILLARY MUCIN; HINGE REGION; HEAVY-CHAIN; RHEUMATOID-ARTHRITIS; COMPLEMENT ACTIVATION; MONOCLONAL-ANTIBODY	The human serum immunoglobulins IgG and IgA1 are produced in bone marrow and both interact with specific cellular receptors that mediate biological events. In contrast to IgA1, the glycosylation of IgG has been well characterized, and its interaction with various Fe receptors (Fc gamma Rs) has been well studied. In this paper, we have analyzed the glycosylation of IgA1 and IgA1 Fab and Fc as well as three recombinant IgA1 molecules, including two N-glycosylation mutants. Amino acid sequencing data of the IgA1 Fc O-glycosylated hinge region indicated that O-glycans are located at Thr(228), Ser(230), and Ser(232), while O-glycan sites at Thr(228), Thr(236) are partially occupied. Over 90% of the N-glycans in IgA1 were sialylated, in contrast to IgG, where <10% contain sialic acid. This paper contains the first report of Fab glycosylation in IgA1, and (in contrast to IgG: Fab, which contains only N-linked glycans) both N- and O-linked oligosaccharides were identified. Analysis of the N-glycans attached to recombinant IgA1 indicated that the C alpha 2 N-glycosylation site contained mostly biantennary glycans, while the tailpiece site, absent in IgG, contained mostly triantennary structures. Further analysis of these data suggested that processing at one Fc N-glycosylation site affects the other. Neutrophil Fc alpha R binding studies, using recombinant IgA1, indicated that neither the tailpiece region nor the N-glycans in the C alpha 2 domain contribute to IgA1-neutrophil Fc alpha R binding. This contrasts with IgG, where removal of the Fc N-glycans reduces binding to the Fc gamma R. The primary sequence and disulfide bond pattern of IgA1, together with the crystal structures of IgG1 Fc and mouse IgA Fab and the glycan sequencing data, were used to generate a molecular model of IgA1. As a consequence of both the primary sequence and S-S bond pattern, the N-glycans in IgA1 Fc are not confined within the inter-alpha-chain space. The accessibility of the C alpha 2 N-glycans provides an explanation for the increased sialylation and galactosylation of IgA1 Fc over that of IgG Fc N-glycans, which are confined in the space between the two C gamma 2 domains. This also suggests why in contrast to IgG Fc, the IgA1 N-glycans are not undergalactosylated in rheumatoid arthritis.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus, Denmark; CNRS, CERMAV, F-38041 Grenoble 9, France; Univ Oxford, Dept Biochem, MRC, Immunochem Unit, Oxford OX1 3QU, England	University of Oxford; University of Dundee; Aarhus University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Oxford	Mattu, TS (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, S Parks Rd, Oxford OX1 3QU, England.		Lellouch, Annemarie/E-9905-2014; Pleass, Richard/N-7831-2019; Pleass, Richard J/L-4148-2015; Wormald, Mark R/G-2785-2011	Pleass, Richard/0000-0001-7438-8296; Pleass, Richard J/0000-0001-7438-8296; Wormald, Mark R/0000-0002-4853-2773; Kilian, Mogens/0000-0002-5861-0472	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLEN AC, 1995, CLIN EXP IMMUNOL, V100, P470; ANDRE PM, 1990, J CLIN LAB ANAL, V4, P115, DOI 10.1002/jcla.1860040208; Atkin JD, 1996, J IMMUNOL, V157, P156; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER J, 1974, J BIOL CHEM, V249, P7260; BASTIAN A, 1992, BIOL CHEM H-S, V373, P1255, DOI 10.1515/bchm3.1992.373.2.1255; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BREWER JW, 1994, J BIOL CHEM, V269, P17338; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; CARRAYANNOPOULO.L, 1996, J EXP MED, V183, P1579; CARRAYANNOPOULO.L, 1994, P NATL ACAD SCI USA, V91, P8348; CHANG SC, 1995, THESIS U OXFORD; CHAPLIN MF, 1986, CARBOHYDRATE ANAL PR, P15; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; Chuang PD, 1997, J IMMUNOL, V158, P724; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DELACROIX DL, 1982, IMMUNOLOGY, V47, P383; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; ENDO T, 1995, MOL IMMUNOL, V32, P931, DOI 10.1016/0161-5890(95)00078-S; ENDO T, 1994, MOL IMMUNOL, V31, P1415, DOI 10.1016/0161-5890(94)90157-0; FALLGREENGEBAUER E, 1993, BIOL CHEM H-S, V374, P1023, DOI 10.1515/bchm3.1993.374.7-12.1023; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; FUJIYAMA Y, 1986, MOL IMMUNOL, V23, P147; FUKUDA M, 1986, J BIOL CHEM, V261, P2796; FURUKAWA K, 1990, INT IMMUNOL, V2, P105, DOI 10.1093/intimm/2.1.105; GERKEN TA, 1989, BIOCHEMISTRY-US, V28, P5536, DOI 10.1021/bi00439a030; GOOCHEE CF, 1991, BIO-TECHNOL, V9, P1347, DOI 10.1038/nbt1291-1347; Gooley AA, 1997, NATURE, V385, P557, DOI 10.1038/385557a0; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; HICKMAN S, 1977, J BIOL CHEM, V252, P4402; INFANTE AJ, 1979, J BIOL CHEM, V254, P9006; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P92; JARVIS GA, 1991, J IMMUNOL, V147, P1962; KEHRY MR, 1982, BIOCHEMISTRY-US, V21, P5415, DOI 10.1021/bi00265a006; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; KILLEEN N, 1987, EMBO J, V6, P4029, DOI 10.1002/j.1460-2075.1987.tb02747.x; KINOSHITA N, 1991, CANCER RES, V51, P5888; KRUGMANN S, 1997, J IMMUNOL, V159, P224; LEATHERBARROW RJ, 1985, MOL IMMUNOL, V22, P407, DOI 10.1016/0161-5890(85)90125-7; LIU YSV, 1979, J BIOL CHEM, V254, P2839; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; Lund J, 1996, J IMMUNOL, V157, P4963; MATSUDA H, 1990, MOL IMMUNOL, V27, P571, DOI 10.1016/0161-5890(90)90076-C; MATTU TS, 1996, THESIS U OXFORD; MELLIS SJ, 1983, J BIOL CHEM, V258, P1557; MESTECKY J, 1995, FASEB J, V9, pA74; MORTON HC, 1993, J IMMUNOL, V151, P4743; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; MURAMATSU T, 1993, GLYCOBIOLOGY, V3, P294; NIKOLOVA EB, 1994, SCAND J IMMUNOL, V39, P275, DOI 10.1111/j.1365-3083.1994.tb03371.x; PADLAN E, 1991, P NATL ACAD SCI USA, V80, P6632; Pao YL, 1996, BIOCHEM BIOPH RES CO, V219, P157, DOI 10.1006/bbrc.1996.0198; PAREKH RB, 1985, NATURE, V316, P452, DOI 10.1038/316452a0; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; PATEL TP, 1992, BIOCHEM J, V285, P839, DOI 10.1042/bj2850839; PIERCECRETEL A, 1981, EUR J BIOCHEM, V114, P169, DOI 10.1111/j.1432-1033.1981.tb06188.x; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PirieShepherd SR, 1997, J BIOL CHEM, V272, P7408, DOI 10.1074/jbc.272.11.7408; REINHOLDT J, 1990, INFECT IMMUN, V58, P1186, DOI 10.1128/IAI.58.5.1186-1194.1990; RUDD PM, 1994, IMMUNOLOGY, V83, P99; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; RUSSELL MW, 1989, EUR J IMMUNOL, V19, P2243, DOI 10.1002/eji.1830191210; RUSSELL MW, 1989, SCAND J IMMUNOL, V30, P175, DOI 10.1111/j.1365-3083.1989.tb01199.x; SAVVIDOU G, 1981, MOL IMMUNOL, V18, P793, DOI 10.1016/0161-5890(81)90001-8; SHOGREN R, 1989, BIOCHEMISTRY-US, V28, P5525, DOI 10.1021/bi00439a029; SKEA DL, 1988, MOL IMMUNOL, V25, P1, DOI 10.1016/0161-5890(88)90084-3; SUH S W, 1986, Proteins Structure Function and Genetics, V1, P74, DOI 10.1002/prot.340010112; TAKAHASHI N, 1982, P NATL ACAD SCI-BIOL, V79, P2850, DOI 10.1073/pnas.79.9.2850; TAKAYASU T, 1982, BIOCHEM BIOPH RES CO, V105, P1066, DOI 10.1016/0006-291X(82)91078-6; TAO MH, 1989, J IMMUNOL, V143, P2595; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; TORANO A, 1978, P NATL ACAD SCI USA, V75, P966, DOI 10.1073/pnas.75.2.966; TORANO A, 1977, P NATL ACAD SCI USA, V74, P2301, DOI 10.1073/pnas.74.6.2301; TSUCHIYA N, 1989, J RHEUMATOL, V16, P285; WALKER MR, 1989, BIOCHEM J, V259, P1356; WALLICK SC, 1988, J EXP MED, V168, P1099, DOI 10.1084/jem.168.3.1099; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; WORMALD MR, 1991, EUR J BIOCHEM, V198, P131, DOI 10.1111/j.1432-1033.1991.tb15995.x; WORMALD RW, 1997, BIOCHEMISTRY-US, V36, P1370; WRIGHT A, 1993, SPRINGER SEMIN IMMUN, V15, P259; YANG CY, 1979, H-S Z PHYSIOL CHEM, V360, P1919; Youings A, 1996, BIOCHEM J, V314, P621, DOI 10.1042/bj3140621; YOUNG NM, 1990, MOL IMMUNOL, V27, P1083, DOI 10.1016/0161-5890(90)90096-I; ZHANG W, 1994, IMMUNOLOGY, V81, P137; [No title captured]	92	320	353	1	37	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2260	2272		10.1074/jbc.273.4.2260	http://dx.doi.org/10.1074/jbc.273.4.2260			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442070	hybrid			2022-12-25	WOS:000071595200059
J	Mosior, M; Six, DA; Dennis, EA				Mosior, M; Six, DA; Dennis, EA			Group IV cytosolic phospholipase A(2) binds with high affinity and specificity to phosphatidylinositol 4,5-bisphosphate resulting in dramatic increases in activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLECKSTRIN HOMOLOGY DOMAIN; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; PH DOMAIN; INOSITOL TRISPHOSPHATE; ANIONIC PHOSPHOLIPIDS; BILAYER-MEMBRANES; PHORBOL ESTERS; CELL-LINE; CALCIUM	The group TV cytosolic phospholipase A(2) (cPLA(2)) exhibits a potent and specific increase in affinity for lipid surfaces containing phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P-2) at physiologically relevant concentrations. Specifically, the presence of 1 mol % PtdIns(4,5)P-2 in phosphatidylcholine vesicles results in a 20-fold increase in the binding affinity of cPLA(2). This increased affinity is accompanied by an increase in substrate hydrolysis of a similar magnitude. The binding studies and kinetic analysis indicate that PtdIns(4,5)P-2 binds to cPLA(2) in a 1:1 stoichiometry. The magnitude of the effect of PtdIns(4,5)P-2 is unique among anionic phospholipids and larger than that for other polyphosphate phosphatidylinositols. The effect of PtdIns(4,5)P-2 on the activity of cPLA(2) is at least an order of magnitude larger than the concomitant changes in the fraction of the enzyme associated with lipid membranes. Striking parallels between the interaction of cPLA(2) with PtdIns(4,5)P-2 and the interaction of the pleckstrin homology domain of phospholipase C delta(1) with PtdIns(4,5)(2) combined with sequence analysis of cPLA(2) lead us to propose the existence and location of a pleckstrin homology domain in cPLA(2). We further show that the very nature of the interaction of proteins such as cPLA(2) with multiple ligands incorporated into membranes follows a specific model which necessitates the use of an experimental methodology suitable for a membrane interface to allow for a meaningful analysis of the data.	Univ Calif San Diego, Revelle Coll, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Dennis, EA (corresponding author), Univ Calif San Diego, Revelle Coll, Dept Chem & Biochem, La Jolla, CA 92093 USA.	ead@ucud.edu	Six, David A/D-6523-2011; Dennis, Edward A./M-5554-2019	Six, David A/0000-0002-9013-1711; Dennis, Edward A./0000-0003-3738-3140	NIGMS NIH HHS [GM 51603, GM 07240, GM 20501] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alb JG, 1996, CURR OPIN CELL BIOL, V8, P534, DOI 10.1016/S0955-0674(96)80032-9; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P1974, DOI 10.1021/bi00381a029; BECKER GW, 1994, BIO-TECHNOL, V12, P69, DOI 10.1038/nbt0194-69; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BURKE JR, 1995, BIOCHEMISTRY-US, V34, P15165, DOI 10.1021/bi00046a024; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; CondeFrieboes K, 1996, J AM CHEM SOC, V118, P5519, DOI 10.1021/ja953553w; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; EPAND RM, 1990, BIOCHEM CELL BIOL, V68, P17, DOI 10.1139/o90-003; EPAND RM, 1988, BIOCHIM BIOPHYS ACTA, V945, P161, DOI 10.1016/0005-2736(88)90478-6; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; KRAMER RM, 1995, AGENT ACTION SUPPL, V46, P65; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Lomasney JW, 1996, J BIOL CHEM, V271, P25316, DOI 10.1074/jbc.271.41.25316; Mosior M, 1996, P NATL ACAD SCI USA, V93, P1907, DOI 10.1073/pnas.93.5.1907; Mosior M, 1996, BIOCHEMISTRY-US, V35, P1612, DOI 10.1021/bi952031q; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; Wang DS, 1996, J ORG CHEM, V61, P5905, DOI 10.1021/jo960602u; WOLF M, 1985, J BIOL CHEM, V260, P5718; ZHANG YY, 1991, METHOD ENZYMOL, V197, P456	50	154	159	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2184	2191		10.1074/jbc.273.4.2184	http://dx.doi.org/10.1074/jbc.273.4.2184			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442060	Green Published, hybrid			2022-12-25	WOS:000071595200049
J	Ting, NSY; Kao, PN; Chan, DW; Lintott, LG; Lees-Miller, SP				Ting, NSY; Kao, PN; Chan, DW; Lintott, LG; Lees-Miller, SP			DNA-dependent protein kinase interacts with antigen receptor response element binding proteins NF90 and NF45	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; CATALYTIC SUBUNIT; BETA-SUBUNIT; KU PROTEIN; COMPLEX-FORMATION; AUTOANTIGEN KU; TRANSCRIPTION; SEQUENCE; REPAIR; CELLS	The DNA-dependent protein kinase (DNA-PK) is composed of a large catalytic subunit of approximately 470 kDa (DNA-PKcs) and the DNA-binding protein, Ku. Absence of DNA-PK activity confers sensitivity to x-rays and defects in both DNA double-strand break repair and V(D)J recombination. However, the precise function of DNA-PK in DNA double-strand break repair is not known. Here me show, using electrophoretic mobility shift assays, that polypeptides in a fraction purified from human cells interact with DNA-PK and stabilize the formation of a complex containing DNA-PKcs-Ku and DNA. Five polypeptides in this fraction have been identified by amino-terminal sequence analysis and/or immunoblotting. These proteins are NF90 and NF45, which are the 90- and 45-kDa subunits of a protein known to bind specifically to the antigen receptor response element of the interleukin 2 promoter, and the alpha, beta, and gamma subunits of eukaryotic translation initiation factor eIF-2. We also show that NF90, NF45, and eIF-2 beta are substrates for DNA-PK in vitro. In addition, recombinant NF90 promotes formation of a complex between DNA-PKcs, Ru, and DNA, and antibodies to recombinant NF90 or recombinant NF45 immunoprecipitate DNA-PKcs in vitro. Together, our data suggest that NF90, in complex with NF45, interacts with DNA-PKcs and Ku on DNA and that NF90 and NF45 may be important for the function of DNA-PK.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; Stanford Univ, Dept Pulm Med, Stanford, CA 94305 USA	University of Calgary; Stanford University	Lees-Miller, SP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.			Lees-Miller, Susan/0000-0001-5809-2516; Lintott, Lauri/0000-0003-1119-590X				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 1996, CURR TOP MICROBIOL, V217, P91; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BOUBNOV NV, 1995, MOL CELL BIOL, V15, P5700; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chu G, 1996, CURR TOP MICROBIOL, V217, P113; CLARK SJ, 1989, BIOCHIM BIOPHYS ACTA, V1010, P377, DOI 10.1016/0167-4889(89)90065-7; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DUNCAN RF, 1987, MOL CELL BIOL, V7, P1293, DOI 10.1128/MCB.7.3.1293; FALZON M, 1993, J BIOL CHEM, V268, P10546; FLYNN A, 1993, BIOCHIM BIOPHYS ACTA, V1174, P117, DOI 10.1016/0167-4781(93)90105-M; FRIED LM, 1996, P NATL ACAD SCI USA, V93, P13835; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Harlow E., 1988, ANTIBODIES LABORATOR, P310; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; Jackson SP, 1996, CANCER SURV, V28, P261; KAO PN, 1994, J BIOL CHEM, V269, P20691; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KUHN A, 1995, GENE DEV, V9, P193, DOI 10.1101/gad.9.2.193; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Lobo MVT, 1997, HISTOCHEM J, V29, P453, DOI 10.1023/A:1026455421490; Maldonado E, 1996, NATURE, V381, P86, DOI 10.1038/381086a0; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Merrick WC., 1996, TRANSLATION CONTROL, P31; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; Romero F, 1996, MOL CELL BIOL, V16, P37; Satoh M, 1996, CLIN EXP IMMUNOL, V105, P460, DOI 10.1046/j.1365-2249.1996.d01-775.x; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; STUIVER MH, 1990, J EXP MED, V172, P1049, DOI 10.1084/jem.172.4.1049; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; WANG Y, 1995, MOL CELL BIOL, V15, P2157; Weaver DT, 1996, CRIT REV EUKAR GENE, V6, P345, DOI 10.1615/CritRevEukarGeneExpr.v6.i4.20; WETTENHALL REH, 1986, J BIOL CHEM, V261, P2444; Wu XT, 1996, MOL CELL BIOL, V16, P5186; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	49	108	113	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2136	2145		10.1074/jbc.273.4.2136	http://dx.doi.org/10.1074/jbc.273.4.2136			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442054	hybrid, Green Submitted			2022-12-25	WOS:000071595200043
J	Adams, TE; Hansen, JA; Starr, R; Nicola, NA; Hilton, DJ; Billestrup, N				Adams, TE; Hansen, JA; Starr, R; Nicola, NA; Hilton, DJ; Billestrup, N			Growth hormone preferentially induces the rapid, transient expression of SOCS-3, a novel inhibitor of cytokine receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAT5; JAK2; ACTIVATION	Four members (SOCS-1, SOCS-2, SOCS-3, and CIS) of a family of cytokine-inducible, negative regulators of cytokine receptor signaling have recently been identified, To address whether any of these genes are induced in response to growth hormone (GH), serum-starved 3T3-F442A fibroblasts were incubated with GH for various time points, and the expression of the SOCS gene family was analyzed by Northern blotting GH stimulated the rapid, transient induction of SOCS-3 mRNA, peaking 30 min after the initiation of GH exposure and declining to basal levels by 2 h., Expression of the other SOCS genes (SOCS-1, SOCS-2, CIS) was also up-regulated by GH, although to a lesser extent than SOCS-3 and with differing kinetics, SOCS-3 expression was also strongly induced in 3T3-F442A cells treated with leukemia-inhibitory factor (LIF), with weaker induction of SOCS-1 and CIS being observed, The preferential induction of SOCS-3 mRNA was also observed in hepatic RNA isolated from the livers of mice that had received a single supraphysiological dose of GH intraperitoneally, Co-transfection studies revealed that constitutive expression of SOCS-1 and SOCS-3, but not SOCS-2 or CIS, blocked GH-induced transactivation of the GH-responsive serine protease inhibitor 2.1 gene promoter.	Univ Melbourne, Ctr Anim Biotechnol, Parkville, Vic 3052, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; Hagedorn Res Inst, DK-2820 Gentofte, Denmark	University of Melbourne; Walter & Eliza Hall Institute; Novo Nordisk; Hagedorn Research Institute	Adams, TE (corresponding author), CSIRO, Div Mol Sci, 343 Royal Parade, Parkville, Vic 3052, Australia.		Nicola, Nicos/D-2989-2011; Adams, Timothy E/I-6231-2012; Hilton, Douglas J/C-7250-2013	Nicola, Nicos/0000-0003-1054-7889; Adams, Timothy E/0000-0003-3436-0066; Hilton, Douglas J/0000-0002-7698-2392; Arnsdorf, Johnny/0000-0002-2738-0811; Billestrup, Nils/0000-0002-4968-8067	NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA022556, R37CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKERS T, 1994, BIOTECHNIQUES, V16, P1074; CarterSu C, 1996, ANNU REV PHYSIOL, V58, P187, DOI 10.1146/annurev.ph.58.030196.001155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chow JC, 1996, ENDOCRINOLOGY, V137, P2880, DOI 10.1210/en.137.7.2880; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Hackett RH, 1997, J BIOL CHEM, V272, P11128; Hansen JA, 1997, J MOL ENDOCRINOL, V18, P213, DOI 10.1677/jme.0.0180213; Hansen LH, 1996, J BIOL CHEM, V271, P12669, DOI 10.1074/jbc.271.21.12669; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x	15	257	261	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1285	1287		10.1074/jbc.273.3.1285	http://dx.doi.org/10.1074/jbc.273.3.1285			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430658	hybrid			2022-12-25	WOS:000071411500005
J	Bowen, ME; Gettins, PGW				Bowen, ME; Gettins, PGW			Bait region involvement in the dimer-dimer interface of human alpha(2)-macroglobulin and in mediating gross conformational change - Evidence from cysteine variants that form interdimer disulfides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-2-MACROGLOBULIN; 3-DIMENSIONAL STRUCTURES; CROSS-LINKING; METHYLAMINE; CLEAVAGE; PROTEINASES; CHYMOTRYPSIN; LOCALIZATION; COMPLEX; TRYPSIN	We have characterized four human alpha(2)-macroglobulin (alpha(2)M) bait region variants (G679C, M690C, V700C, and T705C) to test the hypothesis that the bait regions are involved in the interface between noncovalently associated dimers, All four variants folded correctly as judged by many normal properties, However, the presence of a cysteine resulted in disulfide formation between otherwise noncovalently associated dimers in all four variants, The extent of disulfide cross-linking varied with the location of the cysteine and gave a mixture of species that probably contained two, one, or zero interdimer disulfides in the tetramer. This was reflected in heterogeneity of conformational change upon thiol ester cleavage by methylamine, with the presence of crosslinks correlating with blockage of conformational change, The stoichiometry of trypsin inhibition was less in all cases than for wild-type alpha(2)M The M690C variant also showed evidence of some species with an intramolecular disulfide between bait regions of monomers within the same dimer, Taken together, the results are consistent with a location of the four bait regions in contact with, or in very close proximity to, one another, This suggests that they form all or part of the "cavity body" seen in the low resolution x-ray structure of transformed alpha(2)M.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gettins, PGW (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, 1819-1853 W Polk St, Chicago, IL 60612 USA.			Bowen, Mark/0000-0002-9525-6986	NIGMS NIH HHS [GM54414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN GR, 1995, J BIOL CHEM, V270, P25133, DOI 10.1074/jbc.270.42.25133; ARAKAWA H, 1986, BIOCHEMISTRY-US, V25, P6785, DOI 10.1021/bi00370a009; BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BJORK I, 1984, BIOCHEM J, V217, P303; BJORK I, 1985, BIOCHEMISTRY-US, V24, P2653; BOEL E, 1990, BIOCHEMISTRY-US, V29, P4081, DOI 10.1021/bi00469a009; Bowen ME, 1997, ARCH BIOCHEM BIOPHYS, V337, P191, DOI 10.1006/abbi.1996.9760; DANGOTT LJ, 1982, BIOCHEM BIOPH RES CO, V107, P1243, DOI 10.1016/S0006-291X(82)80131-9; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GETTINS P, 1986, BIOCHEMISTRY-US, V25, P5011, DOI 10.1021/bi00366a007; GETTINS P, 1989, BIOCHEMISTRY-US, V28, P5613, DOI 10.1021/bi00439a041; GETTINS P, 1988, BIOCHEMISTRY-US, V27, P2905, DOI 10.1021/bi00408a036; GETTINS P, 1990, BIOCHEMISTRY-US, V29, P7747, DOI 10.1021/bi00485a025; GETTINS PGW, 1995, BIOCHEMISTRY-US, V34, P12233, DOI 10.1021/bi00038a018; GETTINS PGW, 1995, J BIOL CHEM, V270, P14160, DOI 10.1074/jbc.270.23.14160; JENSEN PEH, 1986, J BIOL CHEM, V261, P5863; Kolodziej SJ, 1996, J STRUCT BIOL, V116, P366, DOI 10.1006/jsbi.1996.0054; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LJ, 1985, BIOCHEMISTRY-US, V24, P1585, DOI 10.1021/bi00328a002; LARSSON LJ, 1989, BIOCHEMISTRY-US, V28, P7636, DOI 10.1021/bi00445a020; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; ROCHE PA, 1989, BIOCHEMISTRY-US, V28, P7629, DOI 10.1021/bi00445a019; ROCHE PA, 1988, BIOCHEMISTRY-US, V27, P759, DOI 10.1021/bi00402a040; SCHROETER JP, 1992, J STRUCT BIOL, V109, P235, DOI 10.1016/1047-8477(92)90036-A; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1981, FEBS LETT, V127, P167, DOI 10.1016/0014-5793(81)80197-4; STOOPS JK, 1994, ANN NY ACAD SCI, V737, P212, DOI 10.1111/j.1749-6632.1994.tb44314.x; STRICKLAND DK, 1984, BIOCHEMISTRY-US, V23, P3115, DOI 10.1021/bi00309a002; STRICKLAND DK, 1991, BIOCHEMISTRY-US, V30, P2797, DOI 10.1021/bi00225a009	29	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1825	1831		10.1074/jbc.273.3.1825	http://dx.doi.org/10.1074/jbc.273.3.1825			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430734	hybrid			2022-12-25	WOS:000071411500081
J	Kim, J; Lin, JJ; Xu, RH; Kung, HF				Kim, J; Lin, JJ; Xu, RH; Kung, HF			Mesoderm induction by heterodimeric AP-1 (c-Jun and c-Fos) and its involvement in mesoderm formation through the embryonic fibroblast growth factor Xbra autocatalytic loop during the early development of Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; NULL MUTATION; REQUIRES FGF; EXPRESSION; ACTIVIN; ACTIVATION; DORSAL; SPECIFICATION; GASTRULATION; SIGNALS	We have previously demonstrated the involvement of AP-1/Jun in fibroblast growth factor (FGF) signaling by loss-of-function assay (Dong, Z., Xu, R.-H., Kim, J., Zhan, S.-N., Ma, W.-Y., Colburn, N. H., and Kung, H. (1996) J. Biol, Chem. 271, 9942-9946), Further investigations by gain-of-function are reported in this study, AP-1 transactivation activity was increased by the treatment of animal cap explants with FGF, Ectopic overexpression of two components of AP-1 (c-jun and c-fos together, but not alone) produced posteriorized embryos and induced mesoderm formation in animal cap explants, indicating that both AP-1 heterodimers are required for mesoderm induction, Since Ras/AP-1 functions downstream of FGF signaling, we then tested the involvement of Ras/AP-1 in mesoderm maintenance mediated by embryonic FGF/ Xbra using dominant-negative mutants, Mesoderm maintenance mediated by embryonic FGF/Xbra was blocked by dominant-negative mutants of Ras/AP-1, and AP-1 enhanced the expression of Xbra, Further studies demonstrated the inhibition of Ras/AP-1-mediated mesoderm formation by dominant-negative mutants of the FGF receptor and Xbra, These results indicate that Ras/ AP-1 and FGF/Xbra signals are involved in the mesoderm maintenance machinery and mesoderm formation through the synergistic action of the diversified signal pathways derived from the FGF/Xbra autocatalytic loop.	NCI, Lab Biochem Physiol, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA; Sci Applicat Int Corp, Intramural Res & Support Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Science Applications International Corporation (SAIC)	Kung, HF (corresponding author), NCI, Lab Biochem Physiol, Div Basic Sci, Frederick Canc Res & Dev Ctr,NIH, Frederick, MD 21702 USA.	Kungh@mail.ncifcrf.gov	Xu, Ren-He/AAK-7392-2021; Xu, Ren-He/M-3125-2016					AMAYA E, 1993, DEVELOPMENT, V118, P477; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Conlon FL, 1996, DEVELOPMENT, V122, P2427; CORNELL RA, 1994, DEVELOPMENT, V120, P453; CORNELL RA, 1995, DEVELOPMENT, V121, P2429; Cox WG, 1995, DEVELOPMENT, V121, P4349; CUNLIFFE V, 1992, NATURE, V358, P427, DOI 10.1038/358427a0; CURRAN T, 1987, ONCOGENE, V2, P79; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GRAVES LM, 1994, P NATL ACAD SCI USA, V91, P1662, DOI 10.1073/pnas.91.5.1662; HARLAND R, 1988, DEVELOPMENT CAMB, V102, P341; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KIMELMAN D, 1992, DEVELOPMENT, V114, P261; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P444; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; Pownall ME, 1996, DEVELOPMENT, V122, P3881; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; SLACK JMW, 1989, DEVELOPMENT, V105, P147; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1993, EMBO J, V12, P4463, DOI 10.1002/j.1460-2075.1993.tb06135.x; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; Taira M, 1997, P NATL ACAD SCI USA, V94, P895, DOI 10.1073/pnas.94.3.895; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WHITMAN M, 1989, SCIENCE, V244, P803, DOI 10.1126/science.2658054; Xu RH, 1996, P NATL ACAD SCI USA, V93, P834, DOI 10.1073/pnas.93.2.834; XU RH, 1995, BIOCHEM BIOPH RES CO, V212, P212, DOI 10.1006/bbrc.1995.1958; Xu RH, 1997, J NEUROSCI, V17, P6892	45	20	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1542	1550		10.1074/jbc.273.3.1542	http://dx.doi.org/10.1074/jbc.273.3.1542			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430694	hybrid			2022-12-25	WOS:000071411500041
J	Lai, TS; Slaughter, TF; Peoples, KA; Hettasch, JM; Greenberg, CS				Lai, TS; Slaughter, TF; Peoples, KA; Hettasch, JM; Greenberg, CS			Regulation of human tissue transglutaminase function by magnesium-nucleotide complexes - Identification of distinct binding sites for Mg-GTP and Mg-ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG LIVER TRANSGLUTAMINASE; CROSS-LINKING ENZYMES; CELL-LINE; PROTEIN; TRANSFECTION; DOMAIN; GAP	Tissue transglutaminase (tTG) catalyzes a Ca2+- dependent transglutaminase (TGase) activity that stabilizes tissues and a GTP hydrolysis activity that regulates cell receptor signaling, The purpose of this study was to examine the true substrates for nucleotide hydrolysis and the effects of these substrates on modulating the dual enzymatic activities of tTG. We found that Mg-GTP and Mg-ATP are the true substrates of the hydrolysis reaction, tTG hydrolyzed Mg-GTP and Mg-ATP at similar rates and interacted with Mg-ATP (K-m = 39 +/- 10 mu M) at a 3-fold greater steady-state affinity than with Mg-GTP (K-m = 130 +/- 35 mu M). In addition, Mg-ATP inhibited GTP hydrolysis (IC50 = 24 mu M), whereas 1 mm Mg-GTP reduced ATP hydrolysis by only 20%, Furthermore, the TGase activity of tTG was inhibited by Mg-GTP, Mg-GDP, and Mg-GMP, with IC50 values of 9, 9, and 400 mu M, respectively, whereas the Mg-adenine nucleotides were ineffective, Kinetic analysis of the hydrolysis reaction demonstrates the presence of separate binding sites far Mg-GTP and Mg-ATP. Finally, we found that Mg-GTP protected tTG from proteolytic degradation by trypsin, whereas Mg-ATP was ineffective, In conclusion, we report that Mg-GTP and Mg-ATP can bind to distinct sites and serve as substrates for nucleotide hydrolysis. Fur- thermore, binding of Mg-GTP causes a conformational change and the inhibition of TGase activity, whereas Mg-ATP is ineffective, The implication of these findings in regulating the intracellular and extracellular function of tTG is discussed.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Greenberg, CS (corresponding author), Duke Univ, Med Ctr, Dept Med, POB 2603, Durham, NC 27710 USA.	green032@mc.duke.edu		, Thung-Shen/0000-0002-8791-9698	NHLBI NIH HHS [HL 03205, HL 28391, HL 38245] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038245, K08HL003205, P60HL028391] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Baek KJ, 1996, BIOCHEMISTRY-US, V35, P2651, DOI 10.1021/bi9522965; BERGAMINI CM, 1988, FEBS LETT, V239, P255, DOI 10.1016/0014-5793(88)80928-1; BERGAMINI CM, 1993, BIOCHEM J, V291, P37, DOI 10.1042/bj2910037; BERS DM, 1994, METHOD CELL BIOL, V40, P4; BIRCKBICHLER PJ, 1985, HYBRIDOMA, V4, P179, DOI 10.1089/hyb.1985.4.179; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRD JC, 1987, J BIOL CHEM, V262, P11699; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; Chowdhury ZA, 1997, EXP CELL RES, V231, P38, DOI 10.1006/excr.1996.3448; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; EISENTHAL R, 1993, ENZYME ASSAYS, P277; FESUS L, 1995, J CELL BIOCHEM, P151; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GENTILE V, 1991, J BIOL CHEM, V266, P478; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; JOHNSON TS, 1994, ONCOGENE, V9, P2935; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KORNER G, 1989, BIOCHEM J, V262, P633, DOI 10.1042/bj2620633; Lai TS, 1997, J BIOL CHEM, V272, P16295, DOI 10.1074/jbc.272.26.16295; Lai TS, 1996, J BIOL CHEM, V271, P31191, DOI 10.1074/jbc.271.49.31191; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; MIRAGLIA CC, 1985, ANAL BIOCHEM, V144, P165, DOI 10.1016/0003-2697(85)90099-5; Morrison J F, 1979, Methods Enzymol, V63, P257; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; O'Sullivan W J, 1979, Methods Enzymol, V63, P294; PATERSON CR, 1983, ESSENTIALS HUMAN BIO, P237; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SINGH US, 1995, BIOCHEMISTRY-US, V34, P15863, DOI 10.1021/bi00048a032; SLAUGHTER TF, 1992, ANAL BIOCHEM, V205, P166, DOI 10.1016/0003-2697(92)90594-W; TAKEUCHI Y, 1992, FEBS LETT, V307, P177, DOI 10.1016/0014-5793(92)80762-6; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361	38	102	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1776	1781		10.1074/jbc.273.3.1776	http://dx.doi.org/10.1074/jbc.273.3.1776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430726	hybrid			2022-12-25	WOS:000071411500073
J	Al-Shami, A; Mahanna, W; Naccache, PH				Al-Shami, A; Mahanna, W; Naccache, PH			Granulocyte-macrophage colony-stimulating factor-activated signaling pathways in human neutrophils - Selective activation of Jak2, Stat3, and Stat5B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR GM-CSF; PROTEIN-TYROSINE KINASE; PHOSPHATIDIC-ACID; PHOSPHOLIPASE-D; BETA(C) CHAIN; DNA-BINDING; RECEPTOR; PHOSPHORYLATION; INTERLEUKIN-3; INVOLVEMENT	Granulocyte-macrophage colony stimulating factor (GM-CSF) regulates many of the biological functions of human neutrophils, This includes the stimulation of protein synthesis and the tyrosine phosphorylation of various proteins among which is JAK2. The present study was aimed at characterizing in detail the pattern of activation by GM-CSF of the JAK/STAT pathway in human neutrophils. The results obtained show that the stimulation of human neutrophils by GM-CSF specifically led to tyrosine phosphorylation of JAK2 and had no effect on JAK1, JAK3, or TYK2, Furthermore, GM-CSF induced the tyrosine phosphorylation of STAT3 and STAT5 but not of STAT1, STAT2, STAT4, or STAT6. Tyrosine phosphorylation of STAT3 was transient reaching its maximum at 15 min. STAT5 presented a different pattern of tyrosine phosphorylation. The anti-STAT5 antibodies identified two proteins at 94 and 92 kDa. The 94-kDa STAT5 was constitutively tyrosine phosphorylated and showed no change upon GM-CSF stimulation. On the other hand, the 92-kDa STAT5 was tyrosine phosphorylated within 1 min of GM-CSF treatment and this was maintained for at least 30 min. By the use of specific antibodies, it was determined that only STAT5B, and not STAT5A, was tyrosine phosphorylated in GM-CSF-treated neutrophils. Furthermore, GM-CSF treatment induced an increase in the ability of STAT3 and STAT5B, but not STAT5A, to bind DNA probes. The specificity of the pattern of activation of the JAK/STAT pathway suggests that it may be directly linked to the modulation of the functions of mature nondividing, human neutrophils by GM-CSF.	CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, St Foy, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med, St Foy, PQ G1V 4G2, Canada; NIAID, Immunogenet Lab, NIH, Bethesda, MD 20852 USA	Laval University; Laval University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Naccache, PH (corresponding author), CHUL, Ctr Rech, Ctr Rech Rhumatol & Immunol, 2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.	paul.naccache@crchul.ulaval.ca	Al-Shami, Amin/D-3889-2009					AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; ATKINSON YH, 1988, IMMUNOLOGY, V64, P519; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; CLARK SC, 1988, INT J CELL CLONING, V6, P365, DOI 10.1002/stem.5530060602; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DANDREA R, 1994, BLOOD, V83, P2802, DOI 10.1182/blood.V83.10.2802.2802; DIPERSIO JF, 1988, J IMMUNOL, V140, P4315; DORSCH M, 1994, BIOCHEM BIOPH RES CO, V200, P562, DOI 10.1006/bbrc.1994.1485; GASSON JC, 1984, SCIENCE, V226, P1339, DOI 10.1126/science.6390681; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; Ihle JN, 1996, PHILOS T R SOC B, V351, P159, DOI 10.1098/rstb.1996.0012; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; LI Y, 1995, J IMMUNOL, V155, P2165; LINNEKIN D, 1995, J BIOL CHEM, V270, P4950, DOI 10.1074/jbc.270.9.4950; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; MCCOLL SR, 1991, BLOOD, V78, P1842; Meinke A, 1996, MOL CELL BIOL, V16, P6937; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NACCACHE PH, 1991, CELL SIGNAL, V3, P635, DOI 10.1016/0898-6568(91)90040-2; NACCACHE PH, 1988, J IMMUNOL, V140, P3541; Nagata Y, 1996, BIOCHEM BIOPH RES CO, V221, P785, DOI 10.1006/bbrc.1996.0674; NATHAN CF, 1989, BLOOD, V73, P301; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RAPOPORT AP, 1992, BLOOD REV, V6, P43, DOI 10.1016/0268-960X(92)90007-D; Rosen RL, 1996, BLOOD, V88, P1206, DOI 10.1182/blood.V88.4.1206.bloodjournal8841206; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; THOMPSON NT, 1995, BIOCHEM SOC T, V23, pS196, DOI 10.1042/bst023196s; WIESBART RH, 1985, NATURE, V314, P361; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WOJCHOWSKI DM, 1993, STEM CELLS, V11, P381, DOI 10.1002/stem.5530110505; YUO A, 1993, BIOCHIM BIOPHYS ACTA, V1156, P197, DOI 10.1016/0304-4165(93)90136-V; Zhang DX, 1996, J BIOL CHEM, V271, P9503, DOI 10.1074/jbc.271.16.9503; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814	42	98	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1058	1063		10.1074/jbc.273.2.1058	http://dx.doi.org/10.1074/jbc.273.2.1058			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422769	hybrid			2022-12-25	WOS:000071411400058
J	Schulz, S; Wedel, BJ; Matthews, A; Garbers, DL				Schulz, S; Wedel, BJ; Matthews, A; Garbers, DL			The cloning and expression of a new guanylyl cyclase orphan receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATRIURETIC-PEPTIDE RECEPTOR; OLFACTORY SENSORY NEURONS; A RECEPTOR; RETINA; DOMAIN; LOCALIZATION; ACTIVATION; SIGNAL; KIDNEY; FORM	A novel membrane form of guanylyl cyclase (GC-G) has been identified through the isolation of a full-length cDNA clone; it is predicted to contain an extracellular ligand binding domain, a single transmembrane segment, and intracellular protein kinase-like and cyclase catalytic domains, That GC-G represents a guanylyl cyclase was confirmed by both transient expression in COS-7 cells and stable expression in H293 cells, Endogenous cyclic GRIP concentrations of transfected or stable cells, however, were much higher than control cells, suggesting an inability of the cells to effectively regulate GC-G cyclase activity, Of six Cys residues found within the extracellular domain of guanylyl cyclase-il (GC-A) the receptor for atrial natriuretic peptide, five are conserved within GC G. Ligands for the other cyclase receptors, nevertheless, failed to stimulate GC-G expressed in transient or stable cells, suggesting that the unknown ligands possess a structure different from the natriuretic peptides or heat-stable enterotoxins. I-125-ANP also failed to bind to H293 cells overexpressing GC-G, Based on Northern hybridization, mRNA for GC-G was predominantly expressed in lung, intestine, and skeletal muscle, Using the candidate gene approach to potentially define function, the gene for GC-G was mapped to the distal region of mouse chromosome 19 (syntenic with human chromosome 10q), but no human genetic defect has been ascribed to the GC-G locus, The finding of a new membrane form of guanylyl cyclase in peripheral tissues suggests the existence of another family or subfamily of ligands that signal through elevations of cGMP.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wedel, BJ (corresponding author), Thomas Jefferson Univ, Dept Med, Div Clin Pharmacol, 1100 Walnut St, Philadelphia, PA 19107 USA.	bwedel@mednet.swmed.edu						CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; DOMINO SE, 1991, METHOD ENZYMOL, V195, P345; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; FULLER F, 1988, J BIOL CHEM, V263, P9395; FURUYA M, 1993, BIOCHEM BIOPH RES CO, V193, P248, DOI 10.1006/bbrc.1993.1616; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; ITAKURA M, 1994, J BIOL CHEM, V269, P8314; JULIFS DM, 1997, P NATL ACAD SCI USA, V94, P3388; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Kojima M, 1995, BIOCHEM BIOPH RES CO, V217, P993, DOI 10.1006/bbrc.1995.2868; KOLLER KJ, 1991, SCIENCE, V252, P120, DOI 10.1126/science.1672777; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; LOWE DG, 1989, EMBO J, V8, P1377, DOI 10.1002/j.1460-2075.1989.tb03518.x; LOWE DG, 1995, P NATL ACAD SCI USA, V92, P5535, DOI 10.1073/pnas.92.12.5535; McNicoll N, 1996, BIOCHEMISTRY-US, V35, P12950, DOI 10.1021/bi960818q; NAKAMURA M, 1994, MOL PHARM, V42, P982; PORTER JG, 1992, AM J PHYSIOL, V263, pC1001, DOI 10.1152/ajpcell.1992.263.5.C1001; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SAHEKI T, 1991, J BIOL CHEM, V266, P11122; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Schulz S, 1997, J CLIN INVEST, V100, P1590, DOI 10.1172/JCI119683; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; SHYJAN AW, 1992, NEURON, V9, P727, DOI 10.1016/0896-6273(92)90035-C; STULTS JT, 1994, BIOCHEMISTRY-US, V33, P11372, DOI 10.1021/bi00203a036; Wong SKF, 1995, J BIOL CHEM, V270, P30818, DOI 10.1074/jbc.270.51.30818; YAMAGUCHI M, 1990, J BIOL CHEM, V265, P20414; Yang RB, 1996, GENOMICS, V31, P367, DOI 10.1006/geno.1996.0060; YANG RB, 1995, P NATL ACAD SCI USA, V92, P602, DOI 10.1073/pnas.92.2.602; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; YUEN PST, 1990, BIOCHEMISTRY-US, V29, P10872, DOI 10.1021/bi00501a002	36	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1032	1037		10.1074/jbc.273.2.1032	http://dx.doi.org/10.1074/jbc.273.2.1032			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422765	hybrid			2022-12-25	WOS:000071411400054
J	Chen, DR; Bachellier, S; Lilley, DMJ				Chen, DR; Bachellier, S; Lilley, DMJ			Activation of the leu-500 promoter by a reversed polarity tetA gene - Response to global plasmid supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TOPOISOMERASE-I; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; GYRASE GENES; TRANSCRIPTION; MUTANTS; TRANSLATION; RESISTANCE; MUTATIONS; TOPA	The leu-500 promoter is inactivated by a mutation in the -10 region but can be activated in topA Escherichia coli and Salmonella strains, We have found that the tetA gene plays a vital role in the topic-dependent activation of a plasmid-borne leu-500 promoter, In previous studies, the leu-500 promoter and tetA gene have been arranged divergently. In this study we have reversed the polarity of the tetA gene, thus locating the leu-500 promoter at the 3' end of tetA, Despite being formally located in the downstream region of tetA, the leu-500 promoter is equally well activated in a topA strain in this environment, even though it is 1.6 kilobase pairs away from the promoter of the reversed tetA gene. Activation of the leu-500 promoter depends on transcription and translation of tetA but is largely insensitive to the function of other transcription units on the plasmid. These results require a change in viewpoint of the role of tetA, from local to global supercoiling, We conclude that transcription of the tetA gene is the main generator of transcription-induced supercoiling that activates the leu-500 promoter. Unbalanced relaxation of this supercoiling leads to a net increase in the negative linking difference of the plasmid globally, and there is a linear correlation between the change in global plasmid topology and the activation of the leu-500 promoter. Thus the leu-500 promoter appears to respond to the negative supercoiling of the plasmid overall.	Univ Dundee, Dept Biochem, Canc Res Campaign, Nucle Acid Struct Res Grp, Dundee DD1 4HN, Scotland	University of Dundee	Lilley, DMJ (corresponding author), Univ Dundee, Dept Biochem, Canc Res Campaign, Nucle Acid Struct Res Grp, Dundee DD1 4HN, Scotland.		Bachellier-Bassi, Sophie/AAB-7981-2020	Bachellier-Bassi, Sophie/0000-0003-3970-4825				BOWATER RP, 1994, BIOCHEMISTRY-US, V33, P9266, DOI 10.1021/bi00197a030; CHEN DR, 1992, P NATL ACAD SCI USA, V89, P8784, DOI 10.1073/pnas.89.18.8784; CHEN DR, 1993, BIOCHEMISTRY-US, V32, P13162, DOI 10.1021/bi00211a027; CHEN DR, 1994, J BACTERIOL, V176, P3757, DOI 10.1128/JB.176.12.3757-3764.1994; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; DUBNAU E, 1972, MOL GEN GENET, V117, P91, DOI 10.1007/BF00267607; GARTENBERG MR, 1993, P NATL ACAD SCI USA, V90, P10514, DOI 10.1073/pnas.90.22.10514; GEMMILL RM, 1984, J BACTERIOL, V158, P948, DOI 10.1128/JB.158.3.948-953.1984; LILLEY DMJ, 1991, MOL MICROBIOL, V5, P779, DOI 10.1111/j.1365-2958.1991.tb00749.x; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOCKSHON D, 1983, NUCLEIC ACIDS RES, V11, P2999, DOI 10.1093/nar/11.10.2999; LODGE JK, 1989, J BACTERIOL, V171, P2181, DOI 10.1128/jb.171.4.2181-2187.1989; LYNCH AS, 1993, J BACTERIOL, V175, P1645, DOI 10.1128/JB.175.6.1645-1655.1993; MA D, 1994, J BIOL CHEM, V269, P15362; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; MCCLELLAN JA, 1990, P NATL ACAD SCI USA, V87, P8373, DOI 10.1073/pnas.87.21.8373; Mojica FJM, 1996, MOL MICROBIOL, V22, P919, DOI 10.1046/j.1365-2958.1996.01541.x; MUKAI FH, 1963, P NATL ACAD SCI USA, V50, P140, DOI 10.1073/pnas.50.1.140; PRUSS GJ, 1985, J BACTERIOL, V164, P947, DOI 10.1128/JB.164.2.947-949.1985; PRUSS GJ, 1986, P NATL ACAD SCI USA, V83, P8952, DOI 10.1073/pnas.83.23.8952; PRUSS GJ, 1982, CELL, V31, P35, DOI 10.1016/0092-8674(82)90402-0; RICHARDSON SMH, 1988, EMBO J, V7, P1863, DOI 10.1002/j.1460-2075.1988.tb03019.x; RICHARDSON SMH, 1984, EMBO J, V3, P1745, DOI 10.1002/j.1460-2075.1984.tb02041.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH GR, 1981, CELL, V24, P599, DOI 10.1016/0092-8674(81)90085-4; Spirito F, 1996, J BACTERIOL, V178, P7129, DOI 10.1128/jb.178.24.7129-7137.1996; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0	29	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					653	659		10.1074/jbc.273.1.653	http://dx.doi.org/10.1074/jbc.273.1.653			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417128	hybrid			2022-12-25	WOS:000071295600094
J	Fletcher, JE; Lindorfer, MA; DeFilippo, JM; Yasuda, H; Guilmard, M; Garrison, JC				Fletcher, JE; Lindorfer, MA; DeFilippo, JM; Yasuda, H; Guilmard, M; Garrison, JC			The G protein beta(5) subunit interacts selectively with the G(q) alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACULOVIRUS EXPRESSION SYSTEM; BINDING REGULATORY PROTEINS; HETEROTRIMERIC G-PROTEINS; RHODOPSIN TRANSDUCIN INTERACTIONS; RAT SYMPATHETIC NEURONS; TRIMERIC G-PROTEINS; GAMMA-SUBUNITS; PHOSPHOLIPASE-C; SF9 CELLS; COUPLED RECEPTORS	The diversity in the heterotrimeric G protein alpha, beta, and gamma subunits may allow selective protein-protein interactions and provide specificity for signaling pathways. We examined the ability of five a subunits (alpha(i1), alpha(i2), alpha(o), alpha(s), and alpha(q),) to associate with three beta subunits (beta(1), beta(2), and beta(5)) dimerized to a gamma(2) subunit containing an amino-terminal hexahistidine-FLAG affinity tag (gamma(2HF)). Sf9 insect cells were used to overexpress the recombinant proteins. The hexahistidine-FLAG sequence does not hinder the function of the beta(1) gamma(2HF) dimer as it can be specifically eluted from an alpha(i1)-agarose column with GDP and AlF4-, and purified beta(1) gamma(2HF) dimer stimulates type II adenylyl cyclase. The beta(1) gamma(2HF) and beta(2) gamma(2HF) dimers immobilized on an anti-FLAG affinity column bound all five alpha subunits tested, whereas the beta(5) gamma(2HF) dimer bound only alpha(q). The ability of other alpha subunits to compete with the alpha(q) subunit for binding to the beta(5) gamma(2HF) dimer was tested. Addition of increasing amounts of purified, recombinant alpha(i1) to the alpha(q) in a Sf9 cell extract did not decrease the amount of alpha(q) bound to the beta(5) gamma(2HF) column. When G proteins in an extract of brain membranes were activated with GDP and AlF4- and deactivated in the presence of equal amounts of the beta(1) gamma(2HF) or beta(5) gamma(2HF) dimers, only alpha(q) bound to the beta(5) gamma(2HF) dimer. The alpha(q) beta(5) gamma(2HF) interaction on the column was functional as GDP, and AlF4- specifically eluted cu, from the column. These results indicate that although the beta(1) and beta(2) subunits interact with alpha subunits from the alpha(i), alpha(s), and alpha(q) families, the structurally divergent beta(5) subunit only interacts with alpha(q).	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Garrison, JC (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Box 448, Charlottesville, VA 22908 USA.				NATIONAL CANCER INSTITUTE [P01CA040042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019952] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA-40042] Funding Source: Medline; NIDDK NIH HHS [R01-DK-19952] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BLOOM H, 1987, ELECTROPHORESIS, V8, P93; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CAULFIELD MP, 1994, J PHYSIOL-LONDON, V477, P415, DOI 10.1113/jphysiol.1994.sp020203; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; Coso OA, 1996, J BIOL CHEM, V271, P3963; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dippel E, 1996, P NATL ACAD SCI USA, V93, P1391, DOI 10.1073/pnas.93.4.1391; Figler RA, 1996, MOL PHARMACOL, V50, P1587; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GRABER SG, 1992, J BIOL CHEM, V267, P1271; GRABER SG, 1992, J BIOL CHEM, V267, P13123; GRABER SG, 1996, METH NEUROSCI, V29, P207; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HILLE B, 1994, TRENDS NEUROSCI, V17, P531, DOI 10.1016/0166-2236(94)90157-0; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; JONES S, 1995, NEURON, V14, P399, DOI 10.1016/0896-6273(95)90295-3; KALKBRENNER F, 1995, EMBO J, V14, P4728, DOI 10.1002/j.1460-2075.1995.tb00154.x; KISSELEV O, 1995, J BIOL CHEM, V270, P25356, DOI 10.1074/jbc.270.43.25356; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lindorfer MA, 1996, J BIOL CHEM, V271, P18582, DOI 10.1074/jbc.271.31.18582; MacrezLepretre N, 1997, J BIOL CHEM, V272, P10095; MAURICE DH, 1993, BIOCHEM J, V290, P765, DOI 10.1042/bj2900765; MENDE U, 1995, J BIOL CHEM, V270, P15892, DOI 10.1074/jbc.270.26.15892; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PANG IH, 1990, J BIOL CHEM, V265, P18707; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; Peng YW, 1997, P NATL ACAD SCI USA, V94, P1995, DOI 10.1073/pnas.94.5.1995; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; Popova JS, 1997, J BIOL CHEM, V272, P6760, DOI 10.1074/jbc.272.10.6760; Robeva AS, 1996, BIOCHEM PHARMACOL, V51, P545, DOI 10.1016/0006-2952(95)02235-X; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAYLOR JM, 1994, J BIOL CHEM, V269, P27618; UEDA N, 1994, J BIOL CHEM, V269, P4388; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Watson AJ, 1996, J BIOL CHEM, V271, P28154, DOI 10.1074/jbc.271.45.28154; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; YAMAUCHI J, 1995, BIOCHEM BIOPH RES CO, V214, P694, DOI 10.1006/bbrc.1995.2341; Yan K, 1996, J BIOL CHEM, V271, P7141, DOI 10.1074/jbc.271.12.7141; Yasuda H, 1996, J BIOL CHEM, V271, P18588, DOI 10.1074/jbc.271.31.18588; YAU KW, 1994, INVEST OPHTH VIS SCI, V35, P9; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	64	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					636	644		10.1074/jbc.273.1.636	http://dx.doi.org/10.1074/jbc.273.1.636			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417126	hybrid			2022-12-25	WOS:000071295600092
J	Langley, E; Kemppainen, JA; Wilson, EM				Langley, E; Kemppainen, JA; Wilson, EM			Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; RETINOIC ACID RECEPTORS; HUMAN ESTROGEN-RECEPTOR; VITAMIN-D-RECEPTOR; GLUCOCORTICOID RECEPTOR; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTOR; HOMODIMER FORMATION	Structural alignment of the human androgen receptor dimer was investigated by introducing steroid binding domain mutations that cause partial or complete androgen insensitivity into fusion proteins containing the full-length androgen receptor or the steroid binding domain, Most of the mutants had unchanged apparent equilibrium androgen binding affinity and increased dissociation rates of [H-3]methyltrienolone and required increased dihydrotestosterone concentrations for transcriptional activation, In a 2-hybrid protein interaction assay in mammalian cells, the steroid binding domain interacts with an NH2-terminal-DNA binding domain fragment and with the full-length androgen receptor at physiological androgen concentrations in a dose-dependent manner, However, mutations at Val-889 and Arg-752 disrupt the NH2/carboxyl-terminal interaction when introduced into the steroid binding domain fragment but not when present in the full-length androgen receptor, The N-C bimolecular interaction reduces the dissociation rate of bound androgen and slows the degradation rate of the carboxyl-terminal steroid binding domain fragment, The results suggest that steroid binding domain residues Val-889 and Arg-752 are critical to the NH2-/carboxyl-terminal interaction and that an intermolecular N-C interaction occurs during receptor dimerization that results in an antiparallel arrangement of androgen receptor monomers.	Univ N Carolina, Labs Reprod Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Wilson, EM (corresponding author), Univ N Carolina, Labs Reprod Biol, CB 7500,Rm 374 Med Sci Res Bldg, Chapel Hill, NC 27599 USA.			Langley, Elizabeth/0000-0001-6180-8036	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016910, P30HD018968, U54HD035041, R37HD016910] Funding Source: NIH RePORTER; NICHD NIH HHS [HD16910, P30-HD18968, IU54-HD35041] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brandt ME, 1997, J BIOL CHEM, V272, P4843, DOI 10.1074/jbc.272.8.4843; BROWN TR, 1992, 74 ANN M END SOC SAN; DAHLMANWRIGHT K, 1991, J BIOL CHEM, V266, P3107; DAHLMANWRIGHT K, 1990, J BIOL CHEM, V265, P14030; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DEBELLIS A, 1994, J CLIN ENDOCR METAB, V78, P513, DOI 10.1210/jc.78.3.513; DEMARZO AM, 1991, P NATL ACAD SCI USA, V88, P72, DOI 10.1073/pnas.88.1.72; DROUIN J, 1992, MOL ENDOCRINOL, V6, P1299, DOI 10.1210/me.6.8.1299; ERIKSSON P, 1990, J BIOL CHEM, V265, P3535; ERIKSSON P, 1991, J STRUCT BIOL, V107, P48, DOI 10.1016/1047-8477(91)90030-Z; EVANS BAJ, 1992, J ENDOCRINOL S, V135; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; KELCE WR, 1995, NATURE, V375, P581, DOI 10.1038/375581a0; KEMPPAINEN JA, 1992, J BIOL CHEM, V267, P968; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; MCPHAUL MJ, 1991, J CLIN INVEST, V87, P1413, DOI 10.1172/JCI115147; NAGAYA T, 1993, J BIOL CHEM, V268, P24278; NISHIKAWA J, 1995, NUCLEIC ACIDS RES, V23, P606, DOI 10.1093/nar/23.4.606; Perlmann T, 1996, MOL ENDOCRINOL, V10, P958, DOI 10.1210/me.10.8.958; QI JS, 1995, MOL CELL BIOL, V15, P1817; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RODRIGUEZ R, 1990, MOL ENDOCRINOL, V4, P1782, DOI 10.1210/mend-4-12-1782; SABBAH M, 1989, J BIOL CHEM, V264, P2397; SALOMONSSON M, 1994, J STEROID BIOCHEM, V48, P447, DOI 10.1016/0960-0760(94)90192-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; TAN JA, 1988, MOL ENDOCRINOL, V2, P1276, DOI 10.1210/mend-2-12-1276; THOLE HH, 1994, J STEROID BIOCHEM, V48, P463, DOI 10.1016/0960-0760(94)90194-5; TOWERS TL, 1993, P NATL ACAD SCI USA, V90, P6310, DOI 10.1073/pnas.90.13.6310; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WONG CI, 1993, J BIOL CHEM, V268, P19004; WRANGE O, 1989, J BIOL CHEM, V264, P5253; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YARBROUGH WG, 1990, J BIOL CHEM, V265, P8893; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZHUANG Y, 1995, MOL ENDOCRINOL, V9, P457, DOI 10.1210/me.9.4.457	47	202	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					92	101		10.1074/jbc.273.1.92	http://dx.doi.org/10.1074/jbc.273.1.92			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417052	hybrid, Green Published			2022-12-25	WOS:000071295600018
J	Menendez, M; Rivas, G; Diaz, JF; Andreu, JM				Menendez, M; Rivas, G; Diaz, JF; Andreu, JM			Control of the structural stability of the tubulin dimer by one high affinity bound magnesium ion at nucleotide N-site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF BRAIN TUBULIN; DIFFERENTIAL SCANNING CALORIMETRY; INDUCED SELF-ASSOCIATION; CIRCULAR-DICHROISM; DOUBLE RINGS; PROTEIN DENATURATION; GUANINE-NUCLEOTIDES; BINDING-SITES; GDP-TUBULIN; MICROTUBULES	Tubulin liganded with GTP at the N-site in the alpha-subunit and with GDP at the E-site in the beta-subunit (GDP-tubulin) reversibly binds one high affinity Mg2+ cation (K-b = 1.1 x 10(7) M-1), whereas tubulin liganded with GTP at both subunits (GTP-tubulin) binds one more high affinity Mg2+. The two cation binding loci are identified as nucleotide sites N and E, respectively. Mg2+ at the N-site controls the stability and structure of the alpha beta-tubulin dimer. Mg2+ dissociation is followed by the slow release of bound nucleotide and functional inactivation. Mg2+ bound to the N-site significantly increases the thermal stability of the GDP-tubulin dimer (by 10 degrees C and similar to 50 kcal mol(-1) of experimental enthalpy change). However, the thermal stability of Mg2+-liganded GDP- and GTP-tubulin is the same. Mg2+ binding to the N-site is linked to the alpha beta-dimer formation. The binding of Mg2+, the alpha-subunit communicates a marked enhancement of fluorescence to a colchicine analogue bound to the beta-subunit. Colchicine, in turn, thermally stabilizes Mg2+-depleted tubulin. The tubulin properties described would be simply explained if the N-site and the colchicine site are at the alpha-beta dimerization interface. It follows that the E-site would be at the beta-end of the tubulin dimer, consistent with the known functional role of the E nucleotide gamma-phosphate and coordinated cation controlling microtubule stability.	Consejo Super Invest Cient, Ctr Invest Biol, Madrid 28006, Spain; Consejo Super Invest Cient, Inst Quim Fis, Madrid 28006, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC)	Andreu, JM (corresponding author), Consejo Super Invest Cient, Ctr Invest Biol, Velazquez 144, Madrid 28006, Spain.		Díaz, J. Fernando/U-3532-2017; Menendez, Margarita/M-1795-2014; Díaz, J. Fernando/M-6853-2019; Rivas, German/AAG-7458-2022; Rivas, German/AFL-7528-2022	Díaz, J. Fernando/0000-0003-2743-3319; Menendez, Margarita/0000-0002-3267-4443; Díaz, J. Fernando/0000-0003-2743-3319; Rivas, German/0000-0003-3450-7478; Rivas, German/0000-0003-3450-7478; Andreu, Jose M/0000-0001-8064-6933				ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P6465, DOI 10.1021/bi00268a023; ANDREU JM, 1984, BIOCHEMISTRY-US, V23, P1742, DOI 10.1021/bi00303a025; ANDREU JM, 1992, J MOL BIOL, V226, P169, DOI 10.1016/0022-2836(92)90132-4; ARRIAGA P, 1992, BIOCHEMISTRY-US, V31, P6603, DOI 10.1021/bi00143a034; BARBIER P, 1998, IN PRESS BIOCHEMISTR; Bartfai T, 1979, Adv Cyclic Nucleotide Res, V10, P219; BRANDTS JF, 1990, BIOCHEMISTRY-US, V29, P6927, DOI 10.1021/bi00481a024; BUTTLAIRE DH, 1980, J BIOL CHEM, V255, P2164; Carlier MF, 1991, CURR OPIN CELL BIOL, V3, P12, DOI 10.1016/0955-0674(91)90160-Z; CARLIER MF, 1991, J BIOL CHEM, V266, P12361; Carlier MF, 1997, BIOPHYS J, V73, P418, DOI 10.1016/S0006-3495(97)78081-0; CHATELIER RC, 1987, BIOPOLYMERS, V26, P507, DOI 10.1002/bip.360260405; CORREIA JJ, 1988, J BIOL CHEM, V263, P10681; CORREIA JJ, 1987, J BIOL CHEM, V262, P17278; COURTNEY RC, 1953, J AM CHEM SOC, V75, P4814, DOI 10.1021/ja01115a057; CROOM HB, 1985, BIOCHEMISTRY-US, V24, P768, DOI 10.1021/bi00324a035; DAPEREDA JM, 1996, BIOCHEMISTRY-US, V35, P14203; DAWSON RMC, 1986, DATA BIOCH RES, P404; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P2747, DOI 10.1021/bi00062a003; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4567, DOI 10.1021/bi00692a002; FRIGON RP, 1975, BIOCHEMISTRY-US, V14, P4559, DOI 10.1021/bi00692a001; GREENWALD ISIDOR, 1940, JOUR BIOL CHEM, V135, P65; GROVER S, 1994, EUR J BIOCHEM, V222, P163, DOI 10.1111/j.1432-1033.1994.tb18854.x; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; HYMAN AA, 1996, CELL, V84, P410; JEMIOLO DK, 1982, J BIOL CHEM, V257, P8148; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KIRCHNER K, 1985, EMBO J, V4, P2397, DOI 10.1002/j.1460-2075.1985.tb03945.x; KLOTZ IM, 1985, Q REV BIOPHYS, V18, P227, DOI 10.1017/S0033583500000354; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; LEE JC, 1975, BIOCHEMISTRY-US, V14, P5183, DOI 10.1021/bi00694a025; LEE JC, 1977, BIOCHEMISTRY-US, V16, P1754, DOI 10.1021/bi00627a037; LEE JC, 1973, J BIOL CHEM, V248, P7253; MEJILLANO MR, 1991, ARCH BIOCHEM BIOPHYS, V291, P356, DOI 10.1016/0003-9861(91)90146-A; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MENENDEZ M, 1989, J BIOL CHEM, V264, P16367; Menendez M, 1995, EUR J BIOCHEM, V234, P887, DOI 10.1111/j.1432-1033.1995.887_a.x; Minton A.P., 1994, MODERN ANAL ULTRACEN, P81; MOZOVILLARIAS A, 1991, EUR BIOPHYS J, V19, P295, DOI 10.1007/BF00183318; OSEI AA, 1990, FEBS LETT, V276, P85, DOI 10.1016/0014-5793(90)80513-I; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; PERCZEL A, 1992, PROTEINS, V13, P57, DOI 10.1002/prot.340130106; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RIVAS G, 1992, BIOCHEMISTRY-US, V31, P11707, DOI 10.1021/bi00162a006; RIVAS GA, 1991, EUR BIOPHYS J BIOPHY, V20, P287, DOI 10.1007/BF00450564; SACKETT DL, 1991, BIOCHEMISTRY-US, V30, P3511, DOI 10.1021/bi00228a023; SANCHEZRUIZ JM, 1992, BIOPHYS J, V61, P921, DOI 10.1016/S0006-3495(92)81899-4; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P885, DOI 10.1021/bi00170a006; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P394; SHRAKE A, 1990, J BIOL CHEM, V265, P5055; SHRAKE A, 1992, BIOPOLYMERS, V32, P925, DOI 10.1002/bip.360320804; Sillen L.G., 1971, STABILITY CONSTANTS; SPIEGELMAN BM, 1977, CELL, V12, P587, DOI 10.1016/0092-8674(77)90259-8; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Tabor H, 1943, J BIOL CHEM, V148, P627; van Holde K. E., 1986, PHYSICAL BIOCH, P110; WARD LD, 1994, BIOCHEMISTRY-US, V33, P11900, DOI 10.1021/bi00205a028; WEISENBERG RC, 1968, BIOCHEMISTRY-US, V7, P4466, DOI 10.1021/bi00852a043; Wyman J, 1990, BINDING LINKAGE FUNC; YANG JT, 1986, METHOD ENZYMOL, V130, P208	67	61	66	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					167	176		10.1074/jbc.273.1.167	http://dx.doi.org/10.1074/jbc.273.1.167			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417061	hybrid, Green Published			2022-12-25	WOS:000071295600027
J	Nakahara, H; Mueller, SC; Nomizu, M; Yamada, Y; Yeh, YY; Chen, WT				Nakahara, H; Mueller, SC; Nomizu, M; Yamada, Y; Yeh, YY; Chen, WT			Activation of beta 1 integrin signaling stimulates tyrosine phosphorylation of p190(RhoGAP) and membrane-protrusive activities at invadopodia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CELL-ADHESION; TRANSFORMED-CELLS; IN-VITRO; PROTEINS; PEPTIDES; INVASION; KINASE; SITES; P190	The ligation of available alpha 6 beta 1 integrin in adherent LOX melanoma cells by laminin G peptides and integrin stimulatory antibodies induced cell invasiveness, independent of adhesion activity of integrins that were prebound to extracellular matrix (Nakahara, H, Nomizu, M., Akiyama, S. K,, Yamada, Y., Yeh, Y., and Chen, W,-T, (1996) J. Biol. Chem. 271, 27221-27224). Here, we show that this induced invasion involves an increase in tyrosine phosphorylation of a 190-kDa GTPase-activating protein for Rho family members (p190(RhoGAP); p190) and membrane-protrusive activities at invadopodia, This tyrosine phosphorylation does not occur when the adherent cells are treated with non-activating antibody against pi integrin, control laminin peptides, or tyrosine kinase inhibitors genistein and herbimycin A, Although p190 and F-actin co-distribute in all cell cortex extensions, tyrosine-phosphorylated proteins including p190 appear to associate with F-actin specifically in invadopodia. In addition, the localized matrix degradation and membrane-protrusive activities were blocked by treatment of LOX cells with tyrosine kinase inhibitors as well as microinjection of antibodies directed against p190 but not by non-perturbing antibodies or control buffers, We suggest that activation of the alpha 6 beta 1 integrin signaling regulates the tyrosine phosphorylation state of p190 which in turn connects downstream signaling pathways through Rho family GTPases to actin cytoskeleton in invadopodia, thus promoting membrane-protrusive and degradative activities necessary for cell invasion.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, TRB E415,3970 Reservoir Rd NW, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Cell Biol, Washington, DC 20007 USA; NIDR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Georgetown University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Chen, WT (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, TRB E415,3970 Reservoir Rd NW, Washington, DC 20007 USA.	chenw@gunet.georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA039077, R01CA061273] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033711] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-39077, CA-61273] Funding Source: Medline; NHLBI NIH HHS [HL-33711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; Burbelo PD, 1995, J BIOL CHEM, V270, P30919, DOI 10.1074/jbc.270.52.30919; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; Chen Wen-Tien, 1994, Journal of Tissue Culture Methods, V16, P177, DOI 10.1007/BF01540646; Chen WT, 1996, ENZYME PROTEIN, V49, P59, DOI 10.1159/000468616; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; CHEN WT, 1985, NATURE, V316, P156, DOI 10.1038/316156a0; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Coopman PJ, 1996, MOL BIOL CELL, V7, P1789, DOI 10.1091/mbc.7.11.1789; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONSKY WL, 1994, CANCER RES, V54, P5702; MONSKY WL, 1993, CANCER RES, V53, P3159; MUELLER SC, 1991, J CELL SCI, V99, P213; MUELLER SC, 1992, J CELL BIOL, V119, P1309, DOI 10.1083/jcb.119.5.1309; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; PATCH LA, 1995, J CELL SCI, V108, P1371; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; SCHALLER MD, 1995, J CELL BIOL, V130, P1181, DOI 10.1083/jcb.130.5.1181; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259	32	156	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					9	12		10.1074/jbc.273.1.9	http://dx.doi.org/10.1074/jbc.273.1.9			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417037	hybrid			2022-12-25	WOS:000071295600003
J	Park, H; Park, SS; Jin, EH; Song, JS; Ryu, SE; Yu, MH; Hong, HJ				Park, H; Park, SS; Jin, EH; Song, JS; Ryu, SE; Yu, MH; Hong, HJ			Identification of functionally important residues of human thrombopoietin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MPL LIGAND; CYTOKINE RECEPTOR SUPERFAMILY; HUMAN GROWTH-HORMONE; EXTRACELLULAR DOMAIN; CLONING; MEGAKARYOCYTOPOIESIS; DIMERIZATION; STIMULATION; EXPRESSION; ACTIVATION	Thrombopoietin (TPO) is a megakaryocyte growth and differentiation factor, It consists of a characteristic two domain structure, The amino terminal domain of TPO has a sequence homology with erythropoietin and is required for the binding and activation of its receptor c-Mpl. To determine the functionally important regions interacting with its receptor, a series of site directed mutants of TPO were constructed based on a three-dimensional model of the amino-terminal domain, Two strategies of mutagenesis were employed: 1) nonnative N-linked glycosylation scan of 12 residues predicted to be on the surface, and 2) alanine replacement scan of mostly charged 44 amino acid residues, Each TPO mutein was transiently expressed in COS7 cells, and the specific bioactivity of the TPO protein secreted into the culture medium was measured using a recombinant BaF3 cell line expressing human c-Mpl. Four alanine substitutions at Arg(10), Pro(42), Glu(50), and Lys(138) nearly or completely abolished the activity, whereas the mutation at Arg(14) Slightly decreased the activity, suggesting that these residues are functionally important in interacting with its receptor, These residues mapped to helix A, loop AB, and helix D, Sequence comparison between human TPO and other mammalian TPO showed that the identified residues are completely conserved among the species, However, unlike the recent report on the mutational analysis of TPO, alanine substitutions at Lys(52), Lys(59), Arg(136), and Arg(140) did not affect the TPO activity significantly in our system, The identified receptor binding regions of TPO are analogous to those of human growth hormone and erythropoietin, Based on the similarity of these three cytokines, we propose that Lys(138) Of helix D and Pro(42) and Glu(50) of loop AB may constitute one binding region, whereas Arg(10) and Lys(14) Of helix A may constitute the other binding region to dimerize the receptors.	KIST, Korea Res Inst Biosci & Biotechnol, Antibody Engn Res Unit, Protein Engn Res Grp, Taejon 305600, South Korea	Korea Institute of Science & Technology (KIST); Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Hong, HJ (corresponding author), KIST, Korea Res Inst Biosci & Biotechnol, Antibody Engn Res Unit, Protein Engn Res Grp, POB 115, Taejon 305600, South Korea.							ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; BARTLEY TD, 1994, CELL, V77, P1117, DOI 10.1016/0092-8674(94)90450-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Caravella JA, 1996, PROTEINS, V24, P394, DOI 10.1002/(SICI)1097-0134(199603)24:3<394::AID-PROT13>3.0.CO;2-H; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GURNEY AL, 1995, BLOOD, V85, P981, DOI 10.1182/blood.V85.4.981.bloodjournal854981; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OGAMI K, 1995, GENE, V158, P309, DOI 10.1016/0378-1119(95)00125-P; PAN JL, 1993, J BIOL CHEM, V268, P22600; PARK H, 1997, IN PRESS MOL CELLS; Pearce KH, 1997, J BIOL CHEM, V272, P20595, DOI 10.1074/jbc.272.33.20595; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	23	26	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					256	261		10.1074/jbc.273.1.256	http://dx.doi.org/10.1074/jbc.273.1.256			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417073	hybrid			2022-12-25	WOS:000071295600039
J	Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS				Spady, DK; Cuthbert, JA; Willard, MN; Meidell, RS			Overexpression of cholesterol 7 alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene - LDL transport and plasma LDL concentrations are reduced	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; HERITABLE HYPERLIPIDEMIC RABBITS; BILE-ACID BIOSYNTHESIS; ILEAL-BYPASS-SURGERY; FEEDBACK-REGULATION; APOLIPOPROTEIN-B; MESSENGER-RNA; CHOLESTYRAMINE; METABOLISM; HAMSTER	This study was undertaken to determine the effect of transient overexpression of hepatic cholesterol 7 alpha-hydroxylase on low density lipoprotein (LDL) cholesterol transport in mice lacking LDL receptors (LDL receptor(-/-)). Primary overexpression of hepatic 7 alpha-hydroxylase in LDL receptor(-/-) mice was accompanied by a dose-dependent decrease in the rate of LDL cholesterol appearance in plasma (whole body LDL cholesterol transport) and a corresponding reduction in circulating LDL cholesterol levels. The increase in hepatic 7 alpha-hydroxylase activity necessary to achieve a 50% reduction in plasma LDL cholesterol concentrations was similar to 10-fold, In comparison, cholestyramine increased hepatic 7 alpha-hydroxylase activity similar to 3 fold and reduced plasma LDL cholesterol concentrations by 17%, This study demonstrates that augmentation of hepatic 7 alpha-hydroxylase expression is an effective strategy for lowering plasma LDL concentrations even in animals with a genetic absence of LDL receptors.	Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Spady, DK (corresponding author), Univ Texas, SW Med Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	spady@utsw.swmed.edu			NHLBI NIH HHS [HL-47551, HL-1766, HL-38049] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038049, R01HL047551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CHAO YS, 1982, J BIOL CHEM, V257, P3623; CHIANG JYL, 1991, METHOD ENZYMOL, V206, P483; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELSSON H, 1967, EUR J BIOCHEM, V2, P44, DOI 10.1111/j.1432-1033.1967.tb00103.x; DESILVA HV, 1994, J LIPID RES, V35, P1297; Gaw A, 1996, ARTERIOSCL THROM VAS, V16, P236, DOI 10.1161/01.ATV.16.2.236; GLASS CK, 1983, J BIOL CHEM, V258, P7161; Goldstein J, 1995, FAMILIAL HYPERCHOLES, P1981; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Hofmann A F, 1972, Surg Annu, V4, P305; HOLMQUIST L, 1978, ANAL BIOCHEM, V88, P457, DOI 10.1016/0003-2697(78)90444-X; HORNICK CA, 1983, P NATL ACAD SCI-BIOL, V80, P6096, DOI 10.1073/pnas.80.19.6096; HORTON JD, 1994, J CLIN INVEST, V93, P2084, DOI 10.1172/JCI117203; HUFF MW, 1985, J LIPID RES, V26, P1175; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JOHNSON FL, 1983, J CLIN INVEST, V72, P221, DOI 10.1172/JCI110961; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P5693, DOI 10.1073/pnas.79.18.5693; KOVANEN PT, 1981, P NATL ACAD SCI-BIOL, V78, P1194, DOI 10.1073/pnas.78.2.1194; Kozarsky KF, 1996, NAT GENET, V13, P54, DOI 10.1038/ng0596-54; KOZARSKY KF, 1994, J BIOL CHEM, V269, P13695; LI J, 1995, J CLIN INVEST, V95, P768, DOI 10.1172/JCI117725; LILLIENAU J, 1993, GASTROENTEROLOGY, V104, P38, DOI 10.1016/0016-5085(93)90833-X; MOL MJTM, 1991, BIOCHEM J, V278, P651, DOI 10.1042/bj2780651; OSONO Y, 1995, J CLIN INVEST, V95, P1124, DOI 10.1172/JCI117760; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; PROBSTFIELD JL, 1991, EUR J CLIN PHARMACOL, V40, pS69, DOI 10.1007/BF01409413; REIHNER E, 1990, J LIPID RES, V31, P2219; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SHEFFER S, 1970, J LIPID RES, V11, P404; SHEPHERD J, 1980, NEW ENGL J MED, V302, P1219, DOI 10.1056/NEJM198005293022202; SPADY DK, 1983, J LIPID RES, V24, P303; SPADY DK, 1987, J LIPID RES, V28, P32; Spady DK, 1996, J BIOL CHEM, V271, P18623, DOI 10.1074/jbc.271.31.18623; SPADY DK, 1992, J BIOL CHEM, V267, P5584; SPADY DK, 1995, J CLIN INVEST, V96, P700, DOI 10.1172/JCI118113; STALENHOEF AFH, 1984, J LIPID RES, V25, P1350; SUCKLING KE, 1991, ATHEROSCLEROSIS, V89, P183, DOI 10.1016/0021-9150(91)90059-C; Torchia EC, 1996, BIOCHEM BIOPH RES CO, V225, P128, DOI 10.1006/bbrc.1996.1141; UCHIDA K, 1984, J LIPID RES, V25, P236; VLAHCEVIC ZR, 1992, SEMIN LIVER DIS, V12, P403, DOI 10.1055/s-2008-1040410; WILLARD JE, 1994, CIRCULATION, V89, P2190, DOI 10.1161/01.CIR.89.5.2190; WONG MH, 1994, J BIOL CHEM, V269, P1340; Xu G, 1996, HEPATOLOGY, V24, P882	47	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					126	132		10.1074/jbc.273.1.126	http://dx.doi.org/10.1074/jbc.273.1.126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417056	hybrid			2022-12-25	WOS:000071295600022
J	Thomas, JW; Ellis, B; Boerner, RJ; Knight, WB; White, GC; Schaller, MD				Thomas, JW; Ellis, B; Boerner, RJ; Knight, WB; White, GC; Schaller, MD			SH2- and SH3-mediated interactions between focal adhesion kinase and Src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; PROLINE-RICH PEPTIDES; C-SRC; HIGH-AFFINITY; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; CELL-ADHESION; DOMAIN; BINDING; PHOSPHORYLATION	Intramolecular SH2 and SH3 interactions mediate enzymatic repression of the Src kinases. One mechanism of activation is disruption of these interactions by the formation of higher affinity SH2 and SH3 interactions with specific Ligands. We show that a consensus Src SH3-binding site residing upstream of the Src SH2-binding site in FAK can function as a ligand for the Src SH3 domain. Surface plasmon resonance experiments indicate that a FAK: peptide containing both the Src SH2 and SH3-binding sites exhibits increased affinity for Src, Furthermore, the presence of both sites in vitro more potently activates c-Src. A FAK mutant (FAK(Pro-2)) with substitutions destroying the SH3-binding site shows reduced binding to Src in vivo, This mutation also reduces Src-dependent tyrosine phosphorylation on the mutant itself and downstream substrates, such as paxillin, These observations suggest that an SH3-mediated interaction between Src-like kinases and FAK may be important for complex formation and downstream signaling in vivo.	Univ N Carolina, Dept Anat & Cell Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Glaxo Wellcome Inc, Dept Biochem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Bioanalyt Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Dept Mol Sci, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Schaller, MD (corresponding author), Univ N Carolina, Dept Anat & Cell Biol, 534 Taylor Hall CB 7090, Chapel Hill, NC 27599 USA.	crispy4@med.unc.edu			NATIONAL CANCER INSTITUTE [F32CA074490] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NCI NIH HHS [1F32CA74490] Funding Source: Medline; NHLBI NIH HHS [HL45100] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; BOERNER RJ, 1995, BIOCHEMISTRY-US, V34, P15351, DOI 10.1021/bi00046a044; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1996, J CELL SCI, V109, P1787; Chook YM, 1996, J BIOL CHEM, V271, P30472, DOI 10.1074/jbc.271.48.30472; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; CousinsWasti RC, 1996, BIOCHEMISTRY-US, V35, P16746, DOI 10.1021/bi9620868; Couture C, 1996, J BIOL CHEM, V271, P24880, DOI 10.1074/jbc.271.40.24880; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; EDISON AM, 1995, J BIOL CHEM, V270, P27112, DOI 10.1074/jbc.270.45.27112; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; ELLIS B, 1994, J CELL BIOCH B S, V18, P276; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUAPPONE AC, 1997, IN PRESS MOL CELL BI; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; LIM WA, 1994, PROTEIN SCI, V3, P1261, DOI 10.1002/pro.5560030812; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LIU XQ, 1993, ONCOGENE, V8, P1119; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; Matsuda M, 1996, J BIOL CHEM, V271, P14468, DOI 10.1074/jbc.271.24.14468; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; OKADA M, 1993, J BIOL CHEM, V268, P18070; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PAYNE G, 1993, P NATL ACAD SCI USA, V90, P4902, DOI 10.1073/pnas.90.11.4902; Pisabarro MT, 1996, BIOCHEMISTRY-US, V35, P10634, DOI 10.1021/bi960203t; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; XU RX, 1995, BIOCHEMISTRY-US, V34, P2107, DOI 10.1021/bi00007a003; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	65	209	211	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					577	583		10.1074/jbc.273.1.577	http://dx.doi.org/10.1074/jbc.273.1.577			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417118	Green Published, hybrid			2022-12-25	WOS:000071295600084
J	Zhu, X; Jiang, MS; Birnbaumer, L				Zhu, X; Jiang, MS; Birnbaumer, L			Receptor-activated Ca2+ influx via human Trp3 stably expressed in human embryonic kidney (HEK)293 cells - Evidence for a non-capacitative Ca2+ entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACRIMAL ACINAR-CELLS; CALCIUM-ENTRY; DROSOPHILA TRP; MAST-CELLS; CATION CHANNELS; RAT HEPATOCYTES; DEPLETION; STORES; PROTEIN; MECHANISMS	Ca2+ release from its internal stores as a result of activation of phospholipase C is accompanied by Ca2+ influx from the extracellular space. Ca2+ influx channels may be formed of proteins homologous to Drosophila Trp. At least six non-allelic Trp genes are present in the mouse genome. Full-length human, bovine, mouse, and rat cDNAs for Trp1, 3, 4, 6 have been cloned. Expression of these genes in various mammalian cells has provided evidence that Trp proteins form plasma membrane Ca2+-permeant channels that can be activated by an agonist that activates phospholipase C, by inositol 1,4,5-trisphosphate, and/or store depletion. We have stably expressed human Trp3 (hTrp3) in human embryonic kidney (HEK)293 cells. Measurement of intracellular Ca2+ concentrations in Fura2-loaded cells showed that cell lines expressing hTrp3 have significantly higher basal and agonist-stimulated influxes of Ca2+, Mn2+ Ba2+, and Sr2+ than control cells. The increase in Ca2+ entry attributable to the expression of hTrp3 obtained upon store depletion by thapsigargin was much lower than that obtained by stimulation with agonists acting via a G(q)-coupled receptor. Addition of agonists to thapsigargin-treated Trp3 cells resulted in a further increase in the entry of divalent cations. The increased cation entry in Trp3 cells was blocked by high concentrations of SKF 96365, verapamil, La3+, Ni2+, and Gd3+. The Trp3-mediated Ca2+ influx activated by agonists was inhibited by a phospholipase C inhibitor, U73122. We propose that expression of hTrp3 in these cells forms a nonselective cation channel that opens after the activation of phospholipase C but not after store depletion. In addition, a subpopulation of the expressed hTrp3 may form heteromultimeric channels with endogenous proteins that are sensitive to store depletion.	Ohio State Univ, Dept Pharmacol, Columbus, OH 43210 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Univ Calif Los Angeles, Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Mol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90095 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Zhu, X (corresponding author), Ohio State Univ, Dept Pharmacol, 206 Rightmire Hal,1060 Carmack Rd, Columbus, OH 43210 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054235] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45198] Funding Source: Medline; NIGMS NIH HHS [GM54235] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1994, MOL CELL ENDOCRINOL, V98, P119, DOI 10.1016/0303-7207(94)90129-5; BERRIDGE MJ, 1994, BIOCHEM J, V312, P1; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BRENT LH, 1993, J CELL PHYSIOL, V155, P520, DOI 10.1002/jcp.1041550310; CHOW SC, 1993, BIOCHEM J, V293, P395, DOI 10.1042/bj2930395; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; DONG YJ, 1995, AM J PHYSIOL-CELL PH, V269, pC1332, DOI 10.1152/ajpcell.1995.269.5.C1332; FASOLATO C, 1993, P NATL ACAD SCI USA, V90, P3068, DOI 10.1073/pnas.90.7.3068; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Funayama M, 1996, MOL BRAIN RES, V43, P259, DOI 10.1016/S0169-328X(96)00208-2; Gillo B, 1996, P NATL ACAD SCI USA, V93, P14146, DOI 10.1073/pnas.93.24.14146; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; Innamorati G, 1996, MOL PHARMACOL, V50, P467; KASS GEN, 1990, J BIOL CHEM, V265, P17486; KASS GEN, 1994, BBA-MOL CELL RES, V1223, P226, DOI 10.1016/0167-4889(94)90230-5; KWAN CY, 1990, J BIOL CHEM, V265, P678; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MATTHEWS G, 1989, J PHYSIOL-LONDON, V418, P105, DOI 10.1113/jphysiol.1989.sp017830; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MOCHIZUKIODA N, 1994, J BIOL CHEM, V269, P9651; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; MONTERO M, 1994, J BIOL CHEM, V269, P29451; MOZHAYEVA GN, 1991, J MEMBRANE BIOL, V124, P113, DOI 10.1007/BF01870456; Obukhov AG, 1996, EMBO J, V15, P5833, DOI 10.1002/j.1460-2075.1996.tb00970.x; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Sadeghi HM, 1997, J RECEPT SIGNAL TR R, V17, P433, DOI 10.3109/10799899709036619; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON AK, 1991, J BIOL CHEM, V266, P23856; VACA L, 1993, AM J PHYSIOL, V264, pH1319, DOI 10.1152/ajpheart.1993.264.4.H1319; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC920, DOI 10.1152/ajpcell.1994.267.4.C920; VACA L, 1995, AM J PHYSIOL-CELL PH, V269, pC733, DOI 10.1152/ajpcell.1995.269.3.C733; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vannier B, 1996, BIOCHEMISTRY-US, V35, P1358, DOI 10.1021/bi952290f; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; XU X, 1994, J BIOL CHEM, V269, P12645; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	56	299	313	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					133	142		10.1074/jbc.273.1.133	http://dx.doi.org/10.1074/jbc.273.1.133			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417057	hybrid			2022-12-25	WOS:000071295600023
J	Bost, F; McKay, R; Dean, N; Mercola, D				Bost, F; McKay, R; Dean, N; Mercola, D			The JUN kinase stress-activated protein kinase pathway is required for epidermal growth factor stimulation of growth of human A549 lung carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASES; C-ALPHA EXPRESSION; JNK ACTIVATION; RAS TRANSFORMATION; SIGNALING CASCADE; MESSENGER-RNA; PHOSPHORYLATION; INHIBITION; INDUCTION; CANCER	Epidermal growth factor (EGF) plays a major role in non-small cell lung cancer cell autocrine growth and has been reported to activate the JUN kinase/stress-activated protein kinase (JNK/SAPK) pathway in model cells, Activation of JNK/SAPK leads to the phosphorylation of c-JUN protooncogene on serines 63 and 73, This mechanism is required for and cooperates in the transformation of rat embryo fibroblasts by Ha-RAS, However, the function of JNK/SAPK in human tumor growth is unknown. We have tested several lung carcinoma cell lines, All exhibited UV-C-inducible JNK/SAPK activity; two exhibited constitutive activity in low serum, and two (M103 and A549) exhibited EGF-inducible JNK/SAPK activity, In A549 cells, EGF induced a rapid and prolonged (up to 24 h) activation of the JNB/SAPK pathway that correlated with a 150-190% growth stimulation. Stably transfected clones of A549 cells expressing c-JUN(S63A,S73A), a transdominant inhibitor of c-JUN, completely blocked the EGF-stimulated proliferation effect but did not alter the basal proliferation rate, Consistent with these results JNK antisense oligonucleotides targeted to JNK1 and JNK2 entirely eliminated the EGF-stimulated JNK/SAPK activity and blocked EGF-stimulated growth but not basal growth, In contrast, specific inhibition of the RAF/ERK pathway by PD98059 (MER1 inhibitor) completely blocked ERK activation by EGF and basal cell growth but not EGF-stimulated growth, thereby dissociating the growth-promoting roles of each pathway. Our observations indicate, for the first time, that JNK/SAPK may be a preferential effector pathway for the growth properties of EGF in A549 cells.	Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA; ISIS Pharmaceut, Dept Mol Pharmacol, Carlsbad, CA 92008 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	Isis Pharmaceuticals Inc; University of California System; University of California San Diego	Mercola, D (corresponding author), Sidney Kimmel Canc Ctr, San Diego, CA 92121 USA.	danmercola@usa.net	BOST, Frederic/AAN-4691-2020; mercola, dan/L-4182-2013	BOST, Frederic/0000-0003-4509-4701; mercola, dan/0000-0002-0281-9840	NCI NIH HHS [CA63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adamson ED, 1997, CURR TOP DEV BIOL, V35, P71, DOI 10.1016/S0070-2153(08)60257-4; Adler V, 1996, CARCINOGENESIS, V17, P2073, DOI 10.1093/carcin/17.9.2073; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARTEAGA CL, 1996, LUNG CANC PRINCIPLES, P99; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Dean N, 1996, CANCER RES, V56, P3499; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DERIJARD B, 1994, CELL, V76, P1; DOTZLAW H, 1990, CANCER RES, V50, P4204; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FALETTE NS, 1994, BREAST CANCER RES TR, V30, P275, DOI 10.1007/BF00665968; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAEDER M, 1988, CANCER RES, V48, P1132; HASHIMOTO K, 1994, J BIOL CHEM, V269, P20060; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KARIN M, 1995, J BIOL CHEM, V270, P14683; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MONAGHAN P, 1990, INT J CANCER, V46, P935, DOI 10.1002/ijc.2910460531; Monia BP, 1996, NAT MED, V2, P668, DOI 10.1038/nm0696-668; NAGANE M, 1996, CANCER RES, V56, P5077; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; POTAPOVA O, 1996, CANCER RES, V56, P2800; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RABIASZ GJ, 1992, BRIT J CANCER, V66, P254, DOI 10.1038/bjc.1992.253; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; REISS M, 1991, CANCER RES, V51, P6254; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; RUSCH V, 1993, CANCER RES, V53, P2379; Rusch V, 1997, CLIN CANCER RES, V3, P515; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SEIMIYA S, 1997, J BIOL CHEM, V272, P4631; SHERR CJ, 1994, GWUMC DEPT, P17; SHERWIN SA, 1981, CANCER RES, V41, P3538; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SMITH MR, 1990, MOL CELL BIOL, V10, P3828, DOI 10.1128/MCB.10.7.3828; STILES CD, 1983, CELL, V33, P653, DOI 10.1016/0092-8674(83)90008-9; Szabo E, 1996, CANCER RES, V56, P305; TATEISHI M, 1990, CANCER RES, V50, P7077; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VEALE D, 1989, CANCER RES, V49, P1313; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WU JX, 1990, ONCOGENE, V5, P989	76	148	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33422	33429		10.1074/jbc.272.52.33422	http://dx.doi.org/10.1074/jbc.272.52.33422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407138	hybrid			2022-12-25	WOS:000071182900099
J	Ye, XS; Fincher, RR; Tang, A; McNeal, KK; Gygax, SE; Wexler, AN; Ryan, KB; James, SW; Osmani, SA				Ye, XS; Fincher, RR; Tang, A; McNeal, KK; Gygax, SE; Wexler, AN; Ryan, KB; James, SW; Osmani, SA			Proteolysis and tyrosine phosphorylation of p34(cdc2)/cyclin B - The role of MCM2 and initiation of DNA replication to allow tyrosine phosphorylation of p34(cdc2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; SISTER-CHROMATID SEPARATION; MATURATION-PROMOTING FACTOR; NIMA PROTEIN-KINASE; ASPERGILLUS-NIDULANS; FISSION YEAST; S-PHASE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; NUCLEAR-LOCALIZATION	Previously, it has been shown that Aspergillus cells lacking the function of nimQ and the anaphase-promoting complex (APC) component bimE(APC1) enter mitosis without replicating DNA, Here nimQ is shown to encode an MCM2 homologue, Although mutation of nimQ(MCM2) inhibits initiation of DNA replication, a few cells do enter mitosis, Cells arrested at G(1)/S by lack of nimQ(MCM2) contain p34(cdc2)/cyclin B, but p34(cdc2) remains tyrosine dephosphorylated, even after DNA damage, However, arrest of DNA replication using hydroxyurea followed by inactivation of nimQ(MCM2) and bimE(APC1) does not abrogate the S phase arrest checkpoint over mitosis, nimQ(MCM2), likely via initiation of DNA replication, is therefore required to trigger tyrosine phosphorylation of p34(cdc2) during the G(1) to S transition, which may occur by inactivation of nimT(cdc25), Cells lacking both nimQ(MCM2) and bimE(APC1) are deficient in the S phase arrest checkpoint over mitosis because they lack both tyrosine phosphorylation of p34(cdc2) and the function of bimE(APC1), Initiation of DNA replication, which requires nimQ(MCM2), is apparently critical to switch mitotic regulation from the APC to include tyrosine phosphorylation of p34(cdc2), at G(1)/S. We also show that cells arrested at G(1)/S due to lack of nimQ(MCM2) continue to replicate spindle pole bodies in the absence of DNA replication and can undergo anaphase in the absence of APC function.	Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA; Gettysburg Coll, Dept Biochem, Gettysburg, PA 17325 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Gettysburg College	Osmani, SA (corresponding author), Penn State Univ, Coll Med, Weis Ctr Res, Henry Hood Res Program, Danville, PA 17822 USA.		Osmani, Stephen A./AAS-3904-2021		NIGMS NIH HHS [GM42564] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042564] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BALLANCE DJ, 1983, BIOCHEM BIOPH RES CO, V112, P284, DOI 10.1016/0006-291X(83)91828-4; BERGEN LG, 1984, J BACTERIOL, V159, P114, DOI 10.1128/JB.159.1.114-119.1984; BERGEN LG, 1983, J BACTERIOL, V156, P155, DOI 10.1128/JB.156.1.155-160.1983; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; BRODY H, 1991, NUCLEIC ACIDS RES, V19, P3105, DOI 10.1093/nar/19.11.3105; Chong JPJ, 1996, TRENDS BIOCHEM SCI, V21, P102, DOI 10.1016/0968-0004(96)10013-X; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Coue M, 1996, EMBO J, V15, P1085, DOI 10.1002/j.1460-2075.1996.tb00446.x; DALTON S, 1995, P NATL ACAD SCI USA, V92, P2514, DOI 10.1073/pnas.92.7.2514; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURSO G, 1995, J CELL SCI, V108, P3109; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GEMS D, 1991, GENE, V98, P61, DOI 10.1016/0378-1119(91)90104-J; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; Grallert B, 1996, GENE DEV, V10, P2644, DOI 10.1101/gad.10.20.2644; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; Heichman KA, 1996, CELL, V85, P39, DOI 10.1016/S0092-8674(00)81080-6; Hendrickson M, 1996, P NATL ACAD SCI USA, V93, P12223, DOI 10.1073/pnas.93.22.12223; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFMANN JFX, 1994, EMBO J, V13, P425, DOI 10.1002/j.1460-2075.1994.tb06277.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JAMES SW, 1995, J CELL SCI, V108, P3485; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kearsey SE, 1996, BIOESSAYS, V18, P183, DOI 10.1002/bies.950180305; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KIMURA H, 1994, EMBO J, V13, P4311, DOI 10.1002/j.1460-2075.1994.tb06751.x; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Krude T, 1996, J CELL SCI, V109, P309; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LI JJ, 1993, CELL, V74, P223, DOI 10.1016/0092-8674(93)90413-K; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; Maiorano D, 1996, EMBO J, V15, P861, DOI 10.1002/j.1460-2075.1996.tb00421.x; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MIYAKE S, 1993, MOL BIOL CELL, V4, P1003, DOI 10.1091/mbc.4.10.1003; MORRIS NR, 1975, GENET RES, V26, P237, DOI 10.1017/S0016672300016049; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OAKLEY BR, 1990, CELL, V61, P1289, DOI 10.1016/0092-8674(90)90693-9; OAKLEY BR, 1983, J CELL BIOL, V96, P1155, DOI 10.1083/jcb.96.4.1155; OAKLEY BR, 1993, CELL CYCLE PRACTICAL, P127; OAKLEY CE, 1989, NATURE, V338, P662, DOI 10.1038/338662a0; OCONNELL MJ, 1992, EMBO J, V11, P2139, DOI 10.1002/j.1460-2075.1992.tb05273.x; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OKISHIO H, 1996, J CELL SCI, V109, P319; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI AH, 1994, J CELL SCI, V107, P1519; OSMANI SA, 1988, CELL, V52, P241, DOI 10.1016/0092-8674(88)90513-2; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Romanowski P, 1996, TRENDS CELL BIOL, V6, P184, DOI 10.1016/0962-8924(96)10015-5; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; SAKA Y, 1993, CELL, V74, P383, DOI 10.1016/0092-8674(93)90428-S; Sambrook J., 2002, MOL CLONING LAB MANU; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; SU TT, 1995, CELL, V81, P825, DOI 10.1016/0092-8674(95)90000-4; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; TIMBERLAKE WE, 1985, EXP MYCOL, V9, P351, DOI 10.1016/0147-5975(85)90008-8; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; TREISMAN JE, 1995, GENE DEV, V9, P1709, DOI 10.1101/gad.9.14.1709; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; YAN H, 1993, GENE DEV, V7, P2149, DOI 10.1101/gad.7.11.2149; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x; YE XS, 1997, EMBO J, V15, P101; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	88	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33384	33393		10.1074/jbc.272.52.33384	http://dx.doi.org/10.1074/jbc.272.52.33384			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407133	Green Submitted, hybrid			2022-12-25	WOS:000071182900094
J	Huguet, C; Crepieux, P; Laudet, V				Huguet, C; Crepieux, P; Laudet, V			Rel/NF-kappa B transcription factors and I kappa B inhibitors: Evolution from a unique common ancestor	ONCOGENE			English	Article						ankyrin repeat protein; rel homology domain; NF-AT; molecular phylogeny	CANDIDATE PROTOONCOGENE BCL-3; CHICKEN SPLEEN-CELLS; DNA-BINDING SUBUNIT; C-REL; PROTO-ONCOGENE; GENE FAMILY; V-REL; FUNCTIONAL-CHARACTERIZATION; SIGNAL-TRANSDUCTION; PRECURSOR P105	From the sequences of Rel/NF-kappa B and I kappa B proteins, we constructed an alignment of their Rel Homology Domain (RHD) and ankyrin repeat domain, Using this alignment, we performed tree reconstruction with both distance matrix and parsimony analysis and estimated the branching robustness using bootstrap resampling methods, We defined four subfamilies of Rel/NF-kappa B transcription factors: (i) cRel, RelA, ReLB, Dorsal and Dif; (ii) NF-kappa B1 and NF-kappa B2; (iii) Relish and (iv) NF-AT factors, the most divergent members, Subfamilies I and II are clustered together whereas Relish diverged earlier than other Rel/NF-kappa B proteins, Three subfamilies of I kappa B inhibitors were also defined: (i) NF-kappa B1 and NF-kappa B2; (ii) close to subfamily I, the short I kappa B proteins I kappa B alpha. I kappa B beta and Bcl-3; (iii) Relish that diverged earlier than other I kappa B inhibitors, Our definition of groups and subfamilies fits to structural and functional features of the Rel/NF-kappa B and I kappa B proteins, We also showed that ankyrin repeats of NF-kappa B1, NF-kappa B2 and Relish are short I kappa B-specific ankyrin motifs. These proteins defining a link between Rel/NF-kappa B and I kappa B families, we propose that all these factors evolved from a common ancestral RHD-ankyrin structure within a unique superfamily, explaining the specificities of interaction between the different Rel/NF-kappa B dimers and the various I kappa B inhibitors.	INST BIOL LILLE,IFR3,UMR319,LAB MECANISMES DEV & CANCERISAT,F-59021 LILLE,FRANCE; INST BIOL LILLE,IFR3,LAB REGULAT PROC INVAS ANGIOGENESE & APOPTOSE,EP560,F-59021 LILLE,FRANCE				Crepieux, Pascale/X-3217-2019					ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ATCHLEY WR, 1995, P NATL ACAD SCI USA, V92, P10217, DOI 10.1073/pnas.92.22.10217; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BIRKENMEIER CS, 1993, J BIOL CHEM, V268, P9533; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BROWNELL E, 1989, ONCOGENE, V4, P935; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DUBREUIL RR, 1994, P NATL ACAD SCI USA, V91, P10285, DOI 10.1073/pnas.91.22.10285; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 1996, ONCOGENE, V13, P1367; GRUMONT RJ, 1989, ONCOGENE RES, V4, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; Heron E, 1995, GENOMICS, V30, P493, DOI 10.1006/geno.1995.1270; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLIS DM, 1992, J HERED, V83, P189, DOI 10.1093/oxfordjournals.jhered.a111190; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Huguet C, 1994, Cell Death Differ, V1, P71; IKEDA T, 1993, GENE, V133, P237, DOI 10.1016/0378-1119(93)90645-J; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; ITO CY, 1995, GENOMICS, V29, P490, DOI 10.1006/geno.1995.9977; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KAO KR, 1991, P NATL ACAD SCI USA, V88, P2697, DOI 10.1073/pnas.88.7.2697; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KUMAR S., 1993, MEGA MOL EVOLUTIONAR; LAMBERT S, 1990, P NATL ACAD SCI USA, V87, P1730, DOI 10.1073/pnas.87.5.1730; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MULLER CW, 1996, NATURE STRUCTURE BIO, V3, P244; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; PHILIPPE H, 1993, NUCLEIC ACIDS RES, V21, P5264, DOI 10.1093/nar/21.22.5264; RUBEN SM, 1992, MOL CELL BIOL, V12, P444, DOI 10.1128/MCB.12.2.444; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Suyang H, 1996, MOL CELL BIOL, V16, P5444; SUZUKI K, 1995, NUCLEIC ACIDS RES, V23, P4664, DOI 10.1093/nar/23.22.4664; SWOFFORD DL, 1991, PHYLOGENETICAL ANAL; TANNAHILL D, 1995, INT J DEV BIOL, V39, P549; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WASSERMAN SA, 1993, MOL BIOL CELL, V4, P767, DOI 10.1091/mbc.4.8.767; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	81	47	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 11	1997	15	24					2965	2974		10.1038/sj.onc.1201471	http://dx.doi.org/10.1038/sj.onc.1201471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YK377	9416840				2022-12-25	WOS:A1997YK37700009
J	Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z				Bayewitch, ML; Avidor-Reiss, T; Levy, R; Pfeuffer, T; Nevo, I; Simonds, WF; Vogel, Z			Differential modulation of adenylyl cyclases I and II by various G(beta) subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; CELLS; EXPRESSION; BRAIN; RESPONSIVENESS; PURIFICATION; ACTIVATION; DIVERSITY; CLONING	The accepted dogma concerning the regulation of adenylyl cyclase (AC) activity by G(beta gamma) dimers states that the various isoforms of AC respond differently to the presence of free G(beta gamma) It has been demonstrated that AC I activity is inhibited and AC II activity is stimulated by G(beta gamma) subunits, This result does not address the possible G differences in modulation that may exist among the different G(beta gamma) heterodimers, Six isoforms of G(beta) and 12 isoforms of G(gamma) have been cloned to date, We have established a cell transfection system in which G(beta) and G(gamma) cDNAs were cotransfected with either AC isoform I or II and the activity of these isoforms was determined, We found that while AC I activity was inhibited by both G(beta 1/gamma 2) and G(beta 5/gamma 2) combinations, AC II responded differentially and was stimulated by G(beta 1/gamma 2). This finding demonstrates differential modulatory activity by different combinations of G(beta gamma) on the same AC isoform and demonstrates another level of complexity within the AC signaling system.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Univ Dusseldorf, Dept Physiol Chem 2, D-40225 Dusseldorf, Germany; NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA	Weizmann Institute of Science; Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Vogel, Z (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.	bnvogel@weizmann.weizmann.ac.il	Avidor-Reiss, Tomer/AAK-6153-2020	Avidor-Reiss, Tomer/0000-0003-0918-526X	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006265] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-06265] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bayewitch M, 1996, J BIOL CHEM, V271, P9902, DOI 10.1074/jbc.271.17.9902; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Choi EJ, 1993, CURR OPIN CELL BIOL, V5, P269, DOI 10.1016/0955-0674(93)90115-7; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Droste M, 1996, FEBS LETT, V391, P209, DOI 10.1016/0014-5793(96)00735-1; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GARRITSEN A, 1994, J BIOL CHEM, V269, P24418; GARRITSEN A, 1993, P NATL ACAD SCI USA, V90, P7706, DOI 10.1073/pnas.90.16.7706; Gudermann T, 1996, ANNU REV PHARMACOL, V36, P429; HELPER JR, 1992, TRENDS BIOCHEM SCI, V17, P383; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KLUXEN FW, 1993, ANAL BIOCHEM, V208, P352, DOI 10.1006/abio.1993.1060; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM K, 1989, BIOTECHNIQUES, V7, P576; LOPEZILASACA M, 1997, NATURE, V275, P394; PFEUFFER E, 1991, METHOD ENZYMOL, V195, P83; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; UEDA N, 1994, J BIOL CHEM, V269, P4388; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Yoshimura M, 1996, MOL PHARMACOL, V50, P43; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; Zhang SY, 1996, J BIOL CHEM, V271, P33575, DOI 10.1074/jbc.271.52.33575	33	74	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2273	2276		10.1074/jbc.273.4.2273	http://dx.doi.org/10.1074/jbc.273.4.2273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442071	hybrid			2022-12-25	WOS:000071595200060
J	Cha, HH; Cram, EJ; Wang, EC; Huang, AJ; Kasler, HG; Firestone, GL				Cha, HH; Cram, EJ; Wang, EC; Huang, AJ; Kasler, HG; Firestone, GL			Glucocorticoids stimulate p21 gene expression by targeting multiple transcriptional elements within a steroid responsive region of the p21(waf1/cip1) promoter in rat hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; HUMAN BREAST-CARCINOMA; BINDING-PROTEIN-ALPHA; P53-INDEPENDENT PATHWAY; RETINOBLASTOMA PROTEIN; HORMONE RECEPTORS; CDK INHIBITORS; CANCER-CELLS; G(1) ARREST; GROWTH	Glucocorticoids can induce a G(1) arrest in the cell cycle progression of BDS1 rat hepatoma cells. In these cells, dexamethasone, a synthetic glucocorticoid, stimulated a rapid:and selective increase in expression of the p21 cyclin-dependent kinase (CDR) inhibitor mRNA and protein and virtually abolished CDK2 phosphorylation of the retinoblastoma protein. Expression of the p27 CDK inhibitor, and other G(1)-acting cell cycle proteins, remained unaffected, Dexamethasone stimulated p21 promoter activity in a p53-independent manner that required functional glucocorticoid receptors. Transforming growth factor-beta, which also induced a G, cell cycle arrest of the hepatoma cells, failed to elicit this response, Analysis of 5' deletions of the p21 promoter uncovered a glucocorticoid responsive region between nucleotides -1481 and -1184, which does not contain a canonical glucocorticoid response element but which can confer dexamethasone responsiveness to a heterologous promoter. Fine mapping of this region uncovered three distinct 50-60-base pair transcriptional elements that likely function as targets of glucocorticoid receptor signaling. Finally, ectopic expression of p21 had no effect oh hepatoma cell growth in the absence of glucocorticoids but facilitated the ability of dexamethasone to inhibit cell proliferation. Thus, our results have established a direct transcriptional link between glucocorticoid receptor signaling and the regulated promoter activity of a CDK inhibitor gene that is involved in the cell cycle arrest of hepatoma cells.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Firestone, GL (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 591 LSA, Berkeley, CA 94720 USA.							AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; Alpan RS, 1996, CELL GROWTH DIFFER, V7, P893; APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; CASTELLANO TJ, 1978, ENDOCRINOLOGY, V102, P1107, DOI 10.1210/endo-102-4-1107; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; COOK PW, 1988, J BIOL CHEM, V263, P19296; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDIERY WS, 1993, CELL, V75, P817; ELDIERY WS, 1994, CANCER RES, V54, P1169; ELDIERY WS, 1995, CANCER RES, V55, P2910; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FIRESTONE GL, 1995, HORMONES AGING, P325; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Fredersdorf S, 1996, AM J PATHOL, V148, P825; Fuse T, 1996, BIOCHEM BIOPH RES CO, V225, P759, DOI 10.1006/bbrc.1996.1247; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1996, MOL CELL BIOL, V16, P6654; GOYA L, 1991, CANCER LETT, V58, P211, DOI 10.1016/0304-3835(91)90103-O; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; HARPER JW, 1993, CELL, V75, P805; HENDERSON IC, 1974, ENDOCRINOLOGY, V94, P1637, DOI 10.1210/endo-94-6-1637; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HUANG DP, 1984, CANCER RES, V44, P2976; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Koike T, 1996, DIFFERENTIATION, V61, P35, DOI 10.1046/j.1432-0436.1996.6110035.x; Li XS, 1996, CANCER RES, V56, P5055; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; MACLEOD KF, 1995, GENE DEV, V9, P985; Maelandsmo GM, 1996, AM J PATHOL, V149, P1813; Maiyar AC, 1997, MOL ENDOCRINOL, V11, P312, DOI 10.1210/me.11.3.312; McEwan IJ, 1997, BIOESSAYS, V19, P153, DOI 10.1002/bies.950190210; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; PAJOVIC S, 1994, J BIOL CHEM, V269, P2215; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; QIN XQ, 1995, MOL CELL BIOL, V15, P742; Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577; Ramos RA, 1996, MOL CELL BIOL, V16, P5288; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SANCHEZ I, 1993, CELL GROWTH DIFFER, V4, P215; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Taub R, 1996, FASEB J, V10, P413, DOI 10.1096/fasebj.10.4.8647340; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; WAHLI W, 1991, FASEB J, V5, P2243, DOI 10.1096/fasebj.5.9.1860615; WALDMAN T, 1995, CANCER RES, V55, P5187; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	80	98	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1998	2007		10.1074/jbc.273.4.1998	http://dx.doi.org/10.1074/jbc.273.4.1998			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442036	hybrid			2022-12-25	WOS:000071595200025
J	Ishida, A; Kameshita, I; Fujisawa, H				Ishida, A; Kameshita, I; Fujisawa, H			A novel protein phosphatase that dephosphorylates and regulates Ca2+/calmodulin-dependent protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; 3 DISTINCT FORMS; CA-2+-INDEPENDENT ACTIVITY; AUTOPHOSPHORYLATION SITES; MUTANT MICE; SYNAPSIN-I; CAM KINASE; CALMODULIN; ACTIVATION; GENERATION	A synthetic peptide corresponding to the autophosphorylation site of Ca2+/calmodulin-dependent protein kinase II (CaMKII) (residues 281-289) was conjugated to paramagnetic particles, and phosphorylated by a constitutively active CaMKII fragment. Using this phosphopeptide conjugate as a substrate, a calyculin A-insensitive, Mn2+-dependent, and poly-L-lysine-stimulated protein phosphatase activity was detected in the crude extract of rat brain. The protein phosphatase (designated as CaMKII phosphatase) (CaMKIIPase) was purified to near homogeneity from rat brain, CaMKIIPase showed apparent molecular weights of 54,000 and 65,000, on SDS-polyacrylamide gel electrophoresis and gel-filtration analysis, respectively. It was not inhibited by 100 nnr calyculin A or 10 mu M okadaic acid. Mn2+, but not Mg2+, was absolutely required for activity. CaMKIIPase was potently activated by polycations. Autophosphorylated CaMKII was dephosphorylated by CaMKIIPase, whereas phosphorylase kinase, mixed histones, myelin basic protein, and alpha-casein (which had been phosphorylated by cAMP-dependent protein kinase) and phosphorylase a (phosphorylated by phosphorylase kinase) were not sig nificantly dephosphorylated. No other proteins than CaMKII in rat brain extract which had been phosphorylated by CaMKII were dephosphorylated. The stimulated Ca2+-independent activity of autophosphorylated CaMKII was reversed by the action of CaMKIIPase. Thus, CaMKIIPase appears to be a specialized protein phosphatase for the regulation of CaMKII.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan	Asahikawa Medical College	Ishida, A (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 078, Japan.							BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Cohen P T, 1996, Adv Pharmacol, V36, P67; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; FUJISAWA H, 1990, BIOESSAYS, V12, P27, DOI 10.1002/bies.950120106; FUKUNAGA K, 1993, J BIOL CHEM, V268, P133; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; IKEDA A, 1991, J BIOL CHEM, V266, P11582; ISHIDA A, 1994, J BIOCHEM-TOKYO, V115, P1075, DOI 10.1093/oxfordjournals.jbchem.a124460; Ishida A, 1997, ANAL BIOCHEM, V254, P152, DOI 10.1006/abio.1997.2426; Ishida A, 1996, BBA-MOL CELL RES, V1311, P211, DOI 10.1016/0167-4889(95)00197-2; ISHIDA A, 1995, J BIOL CHEM, V270, P2163, DOI 10.1074/jbc.270.5.2163; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kameshita I, 1997, ANAL BIOCHEM, V245, P149, DOI 10.1006/abio.1996.9945; KATOH T, 1991, J BIOL CHEM, V266, P3039; KWIATKOWSKI AP, 1988, J BIOL CHEM, V263, P6484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOU LL, 1989, J NEUROSCI, V9, P2020; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; OKUNO S, 1990, BIOCHIM BIOPHYS ACTA, V1038, P204, DOI 10.1016/0167-4838(90)90206-U; PATO MD, 1983, J BIOL CHEM, V258, P7055; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SAITOH Y, 1987, J NEUROCHEM, V49, P1286, DOI 10.1111/j.1471-4159.1987.tb10022.x; SAMBROOK J, 1989, MOL CLONING LABORATO, pE37; SCHWORER CM, 1988, J BIOL CHEM, V263, P13486; SCHWORER CM, 1986, J BIOL CHEM, V261, P8581; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Soderling TR, 1996, BBA-PROTEIN STRUCT M, V1297, P131, DOI 10.1016/S0167-4838(96)00105-7; Strack S, 1997, J NEUROCHEM, V68, P2119; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; USUI H, 1988, J BIOL CHEM, V263, P3752; WANG YX, 1995, J BIOL CHEM, V270, P25607, DOI 10.1074/jbc.270.43.25607; YAMAUCHI T, 1980, FEBS LETT, V116, P141, DOI 10.1016/0014-5793(80)80628-4; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YAMAUCHI T, 1981, BIOCHEM BIOPH RES CO, V100, P807, DOI 10.1016/S0006-291X(81)80246-X	45	90	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					1904	1910		10.1074/jbc.273.4.1904	http://dx.doi.org/10.1074/jbc.273.4.1904			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442023	hybrid			2022-12-25	WOS:000071595200012
J	Luczak, JA; Redick, SD; Schwarzbauer, JE				Luczak, JA; Redick, SD; Schwarzbauer, JE			A single cysteine, cys-64, is essential for assembly of tenascin-C hexabrachions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX PROTEIN; HUMAN FIBRINOGEN; CRYSTAL-STRUCTURE; CELL ATTACHMENT; DISULFIDE BONDS; COILED-COIL; FIBRONECTIN; SECRETION; BINDING; LOCALIZATION	Tenascin-C is a large, multimeric extracellular matrix protein that is found in a variety of tissues and can have profound effects on cell adhesion, It is secreted from cells as a hexamer of six identical chains called a hexabrachion, Disulfide bonding among tenascin subunits mediates intracellular assembly into hexamers, The amino-terminal assembly domain consists of heptad repeats and at least six cysteine residues (Cys-64, -111, -113, -140, -146, -147) that could be involved in multimerization, We have now determined the requirements for these cysteine residues during hexamer assembly, Our results show that only Cys-64 is required to form the hexameric structure. Mutation of Cys-64 to glycine resulted in release of trimer intermediates, which probably form via the heptad repeats, but no hexamers were secreted, In contrast, individual or pairs of mutations of each of the other cysteines had no effect on tenascin hexamer formation, and inclusion of any other cysteine mutations along with C64G; did not further disrupt the multimer pattern, However, when all six cysteines were mutated, monomers were the major extracellular form. Together, these results show that trimers are an intermediate of tenascin-C assembly and that Cys-64 is essential for formation of hexabrachions.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	Princeton University; University of North Carolina; University of North Carolina Chapel Hill	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarzbauer@molbio.princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593				AUKHIL I, 1993, J BIOL CHEM, V268, P2542; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BRISTOW J, 1993, J CELL BIOL, V122, P265, DOI 10.1083/jcb.122.1.265; BUDZYNSKI AZ, 1986, CRC CR REV ONCOL-HEM, V6, P97, DOI 10.1016/S1040-8428(86)80019-1; Carnemolla B, 1996, J BIOL CHEM, V271, P8157, DOI 10.1074/jbc.271.14.8157; CHIQUETEHRISMANN R, 1991, CELL REGUL, V2, P927, DOI 10.1091/mbc.2.11.927; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Crossin KL, 1996, J CELL BIOCHEM, V61, P592; Deryugina EI, 1996, J CELL SCI, V109, P643; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; FUSS B, 1993, J CELL BIOL, V120, P1237, DOI 10.1083/jcb.120.5.1237; GULCHER JR, 1989, P NATL ACAD SCI USA, V86, P1588, DOI 10.1073/pnas.86.5.1588; Hagios C, 1996, J CELL BIOL, V134, P1499, DOI 10.1083/jcb.134.6.1499; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HUANG SM, 1993, BIOCHEM BIOPH RES CO, V190, P488, DOI 10.1006/bbrc.1993.1074; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MATSUMOTO K, 1994, J CELL BIOL, V125, P483, DOI 10.1083/jcb.125.2.483; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; PESHEVA P, 1989, J CELL BIOL, V109, P1765, DOI 10.1083/jcb.109.4.1765; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; REDICK SD, 1995, J CELL SCI, V108, P1761; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SIRI A, 1991, NUCLEIC ACIDS RES, V19, P525, DOI 10.1093/nar/19.3.525; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; WELLER A, 1991, J CELL BIOL, V112, P355, DOI 10.1083/jcb.112.2.355; Xu WF, 1996, J BIOL CHEM, V271, P27948, DOI 10.1074/jbc.271.44.27948; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; ZHANG JZ, 1994, J BIOL CHEM, V269, P652; ZHANG JZ, 1993, J BIOL CHEM, V268, P11278; Zhang JZ, 1996, J BIOL CHEM, V271, P30083, DOI 10.1074/jbc.271.47.30083; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 23	1998	273	4					2073	2077		10.1074/jbc.273.4.2073	http://dx.doi.org/10.1074/jbc.273.4.2073			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YT367	9442046	Green Published, hybrid			2022-12-25	WOS:000071595200035
J	Chen, YR; Wang, WF; Kong, ANT; Tan, TH				Chen, YR; Wang, WF; Kong, ANT; Tan, TH			Molecular mechanisms of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; RADIATION-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; JNK ACTIVATION; PHENETHYL ISOTHIOCYANATE; GAMMA-RADIATION; B-CELLS; IN-VIVO; STRESS	Isothiocyanates have strong chemopreventive properties against many carcinogen-induced cancers in experimental animal models. Here, we report that phenylmethyl isocyacyanate (PMITC) and phenylethyl isothiocyanate (PEITC) induced sustained c-Jun N-terminal kinase (JNK) activation in a dose-dependent manner. The sustained JNK activation caused by isothiocyanates was associated with apoptosis induction in various cell types, An inhibitor of the caspase/interleukin-1 beta-converting enzyme blocked isothiocyanate-induced apoptosis without inhibiting the JNK activation, which suggests that JNK activation by isothiocyanates is an event that is independent or upstream of the activation of caspase/interleukin-1 beta-converting enzyme proteases. PEITC-induced apoptosis was suppressed by interfering with the JNK pathway with a dominant-negative mutant of JNK1 or MEKK1 (JNK1(APF) and MEKK1(KR), respectively), implying that the JNK pathway is required for apoptotic signaling. Isothiocyanate-induced JNK activation was blocked by the antioxidants 2-mercaptoethanol and N-acetyl-L-cysteine, suggesting that the death signaling was triggered by oxidative stress. Overexpression of Bcl-2 suppressed PEITC-induced JNK activation. In addition, Bcl-2 and Bcl-x(L) suppressed PEITC-induced apoptosis, but failed to protect cells from death induced by overexpression of activated JNK1. These results suggest that Bcl-2 and Bcl-x(L) are upstream of JNK. Taken together, our results indicate (i) that JNK mediates PMITC- and PEITC-induced apoptosis and (ii) that PMITC and PEITC may have chemotherapeutic functions besides their chemopreventive functions.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Univ Illinois, Coll Pharm, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60612 USA	Baylor College of Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Tan, TH (corresponding author), Baylor Coll Med, Dept Microbiol & Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Tan, Tse-Hua/E-3983-2010; Kong, Ah-Ng Tony/AAX-2828-2020; Tan, Tse-Hua/ABD-7080-2021; Chen, Yi-Rong/E-3991-2010	Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002	NIAID NIH HHS [R01-AI38649] Funding Source: Medline; NIGMS NIH HHS [R29-GM49172, R01-GM49875] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875, R29GM049172] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berberich I, 1996, EMBO J, V15, P92, DOI 10.1002/j.1460-2075.1996.tb00337.x; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUO Z, 1993, CARCINOGENESIS, V14, P1167, DOI 10.1093/carcin/14.6.1167; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HECHT SS, 1995, J CELL BIOCHEM, P195; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Li YS, 1996, MOL CELL BIOL, V16, P5947; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYASHITA T, 1995, CELL, V80, P293; MORSE MA, 1993, CANCER LETT, V72, P103, DOI 10.1016/0304-3835(93)90018-5; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Na SQ, 1996, J BIOL CHEM, V271, P11209, DOI 10.1074/jbc.271.19.11209; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Park DS, 1996, J BIOL CHEM, V271, P21898, DOI 10.1074/jbc.271.36.21898; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH TJ, 1990, CANCER RES, V50, P6817; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STONER GD, 1991, CANCER RES, V51, P2063; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TALALAY P, 1993, ADV ENZYME REGUL, V28, P273; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; WATTENBERG LW, 1987, CARCINOGENESIS, V8, P1971, DOI 10.1093/carcin/8.12.1971; WATTENBERG LW, 1981, CANCER RES, V41, P2991; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAN MH, 1994, NATURE, V372, P798; Yu R, 1996, CANCER LETT, V107, P73, DOI 10.1016/0304-3835(96)04345-5; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	58	235	244	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1769	1775		10.1074/jbc.273.3.1769	http://dx.doi.org/10.1074/jbc.273.3.1769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430725	hybrid			2022-12-25	WOS:000071411500072
J	Murthy, A; Gonzalez-Agosti, C; Cordero, E; Pinney, D; Candia, C; Solomon, F; Gusella, J; Ramesh, V				Murthy, A; Gonzalez-Agosti, C; Cordero, E; Pinney, D; Candia, C; Solomon, F; Gusella, J; Ramesh, V			NHE-RF, a regulatory cofactor for Na+-H+ exchange, is a common interactor for merlin and ERM (MERM) proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR; MEMBRANE ASSOCIATION; RADIXIN; EZRIN; MOESIN; NEUROFIBROMATOSIS-2; FAMILY; PURIFICATION; LOCALIZATION; GENE	We have identified the human homologue of a regulatory cofactor of Na+-H+ exchanger (NHE-RF) as a novel interactor for merlin, the neurofibromatosis 2 tumor suppressor protein, NHE-RF mediates protein kinase A regulation of Na+-H+ exchanger NHE3 to which it is thought to bind via one of its two PDZ domains. The carboxyl-terminal region of NHE-RF, downstream of the PDZ domains, interacts with the amino-terminal protein 4.1 domain-containing segment of merlin in yeast two-hybrid assays. This interaction also occurs in affinity binding assays with full-length NHE-RF expressed in COS-7 cells. NHE-RF binds to the related ERM proteins, moesin and radixin. We have localized human NHE-RF to actin-rich structures such as membrane ruffles, microvilli, and filopodia in HeLa and COS-7 cells, where it co-localizes with merlin and moesin, These findings suggest that hNHE-RF and its binding partners may participate in a larger complex (one component of which might be a Na+-H+ exchanger) that could be crucial for the actin filament assembly activated by the ERM proteins and for the tumor suppressor function of merlin.	Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA; MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Ramesh, V (corresponding author), Massachusetts Gen Hosp, Mol Neurogenet Unit, Bldg 149,13th St, Charlestown, MA 02129 USA.				NIDCD NIH HHS [NIDCD 03354] Funding Source: Medline; NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R03DC003354] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BIRGBAUER E, 1991, THESIS MIT CAMBRIDGE; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; GRINSTEIN S, 1993, EMBO J, V12, P209; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARGUINDEY S, 1995, CRIT REV ONCOGENE, P1; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; MAGENDANTZ M, 1995, J BIOL CHEM, V270, P25324, DOI 10.1074/jbc.270.43.25324; Martin M, 1997, MOL BIOL CELL, V8, P1543, DOI 10.1091/mbc.8.8.1543; Orlowski J, 1997, J BIOL CHEM, V272, P22373, DOI 10.1074/jbc.272.36.22373; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vexler ZS, 1996, J BIOL CHEM, V271, P22281, DOI 10.1074/jbc.271.37.22281; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903; WINCKLER B, 1994, J CELL SCI, V107, P2523; XU L, 1998, IN PRESS EXP CELL RE; Yun CHC, 1997, P NATL ACAD SCI USA, V94, P3010, DOI 10.1073/pnas.94.7.3010; YUN CHC, 1995, AM J PHYSIOL-GASTR L, V269, pG1, DOI 10.1152/ajpgi.1995.269.1.G1	33	210	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 16	1998	273	3					1273	1276		10.1074/jbc.273.3.1273	http://dx.doi.org/10.1074/jbc.273.3.1273			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ670	9430655	hybrid			2022-12-25	WOS:000071411500002
J	Ellis, LM; Staley, CA; Liu, WB; Fleming, RYD; Parikh, NU; Bucana, CD; Gallick, GE				Ellis, LM; Staley, CA; Liu, WB; Fleming, RYD; Parikh, NU; Bucana, CD; Gallick, GE			Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PP60C-SRC PROTEIN-KINASE; PERMEABILITY FACTOR; TUMOR ANGIOGENESIS; HYPOXIC INDUCTION; GENE-MUTATIONS; HUMAN PLACENTA; RAS ONCOGENES; CANCER; PROLIFERATION; TUMORIGENESIS	Vascular endothelial growth factor (VEGF) is implicated in the angiogenesis of human colon cancer. Recent evidence suggests that factors that regulate VEGF expression may partially depend on c-src-mediated signal transduction pathways. The tyrosine kinase activity of Src is activated in most colon tumors and cell lines, We established stable subclones of the human colon adenocarcinoma cell line HT29 in which Src expression and activity are decreased specifically as a result of a transfected antisense expression vector. This study determined whether VEGF expression is decreased in these cell lines and whether the smaller size and reduced growth rate of antisense vector-transfected cell lines in vivo might result, in part, from reduced vascularization of tumors. Northern blot analysis of these cell lines revealed that VEGF mRNA expression was decreased in proportion to the decrease in Src kinase activity. Under hypoxic conditions, cells with decreased Src activity had a <2-fold increase in VEGF expression, whereas parental cells had a >50-fold increase. VEGF protein in the supernatants of cells was also reduced in antisense transfectants compared with that from parental cells, In nude mice, subcutaneous tumors from antisense transfectants showed a significant reduction in vascularity. These results suggest that Src activity regulates the expression of VEGF in colon tumor cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Cell Biol, Houston, TX 77030 USA; Emory Univ, Sch Med, Dept Surg Oncol, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Emory University	Gallick, GE (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,POB 108, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [T32CA009599, U19CA053617, R01CA065527, U01CA053617] Funding Source: NIH RePORTER; NCI NIH HHS [CA65527, T-32 CA09599, CA53617] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONY FW, 1994, PLACENTA, V15, P557, DOI 10.1016/S0143-4004(05)80424-2; BAKER SJ, 1990, CANCER RES, V50, P7717; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BROWN LF, 1993, AM J PATHOL, V143, P1255; BROWN LF, 1993, CANCER RES, V53, P4727; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; DVORAK HF, 1979, JNCI-J NATL CANCER I, V62, P1459; Ellis LM, 1996, SURGERY, V120, P871, DOI 10.1016/S0039-6060(96)80097-3; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Fogh J., 1975, HUMAN TUMOR CELLS IN, VVolume 1, P115, DOI [10.1007/978-1-4757-1647-4_5, DOI 10.1007/978-1-4757-1647-4_5]; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; Gleadle JM, 1997, BLOOD, V89, P503, DOI 10.1182/blood.V89.2.503; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; HSU S, 1995, J CELL PHYSIOL, V165, P239, DOI 10.1002/jcp.1041650204; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Koura AN, 1996, CANCER RES, V56, P3891; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Mattern J, 1996, BRIT J CANCER, V73, P931, DOI 10.1038/bjc.1996.166; MATTERN J, 1995, INT J ONCOL, V6, P1059; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAK J, 1995, CANCER RES, V55, P4575; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Takahashi Y, 1997, ARCH SURG-CHICAGO, V132, P541; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Toi M, 1995, CLIN CANCER RES, V1, P961; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857	38	176	202	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					1052	1057		10.1074/jbc.273.2.1052	http://dx.doi.org/10.1074/jbc.273.2.1052			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422768	hybrid			2022-12-25	WOS:000071411400057
J	Soldatov, NM; Oz, M; O'Brien, KA; Abernethy, DR; Morad, M				Soldatov, NM; Oz, M; O'Brien, KA; Abernethy, DR; Morad, M			Molecular determinants of L-type Ca2+ channel inactivation - Segment exchange analysis of the carboxyl-terminal cytoplasmic motif encoded by exons 40-42 of the human alpha(1C) subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT INACTIVATION; CA2+-SENSITIVE INACTIVATION; CALCIUM-CHANNEL; DIVERSITY	Recently we have described a splice variant of the L-type Ca2+ channel (alpha(1C,86)) in which 80 amino acids (1572-1651) of the conventional alpha(1C,77) were substituted by another 81 amino acids due to alternative splicing of exons 40-42, Ba2+ current (I-Ba) through alpha(1C,86) exhibited faster inactivation kinetics, was strongly voltage-dependent, and had no Ca2+-dependent inactivation. An oligonucleotide-directed segment substitution and expression of the mutated channels in Xenopus oocytes were used to study the molecular determinants for gating of the channel within the 80-amino acid domain. Replacement of segments 1572-1598 or 1595-1652 of the "slow" alpha(1C,77) channel with the respective segments of the "fast" alpha(1C,86) gave rise to rapidly inactivating alpha(1C,86)-like channel isoforms, We found that replacement of either motifs (1572)IKTEG(1576) or (1600)LLDQV(1604) of alpha(1C,77) with the respective sequences of alpha(1C,86) caused strong but partial acceleration of I-Ba inactivation. Replacement of both sequences produced an alpha(1C,86)-like fast channel which had no Ca2+-dependent inactivation. These results support the hypothesis that motifs 1572-1576 and 1600-1604 of alpha(1C,77) contribute cooperatively to inactivation kinetics of alpha(1C) and are critical for Ca2+-dependent inactivation of the channel.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University	Soldatov, NM (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, 3900 Reservoir Rd NW, Washington, DC 20007 USA.		Oz, Murat/E-2148-2012		NHLBI NIH HHS [HL16152] Funding Source: Medline; NIA NIH HHS [AG08226] Funding Source: Medline; NIGMS NIH HHS [GM08386] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016152] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008226] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; CATTERALL WA, 1991, SCIENCE, V253, P1499, DOI 10.1126/science.1654596; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; HILLE B, 1992, IONIC CHANNELS EXCIT, P1; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; NAKAYAMA S, 1992, J MOL EVOL, V34, P416, DOI 10.1007/BF00162998; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; SOLDATOV NM, 1994, GENOMICS, V22, P77, DOI 10.1006/geno.1994.1347; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zong XG, 1996, FEBS LETT, V378, P121, DOI 10.1016/0014-5793(95)01434-9	19	87	87	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 9	1998	273	2					957	963		10.1074/jbc.273.2.957	http://dx.doi.org/10.1074/jbc.273.2.957			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YQ669	9422756	hybrid			2022-12-25	WOS:000071411400045
J	Blackman, SC; Dawson, G; Antonakis, K; Le Breton, GC				Blackman, SC; Dawson, G; Antonakis, K; Le Breton, GC			The identification and characterization of oligodendrocyte thromboxane A(2) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ASTROCYTOMA-CELLS; HUMAN-PLATELETS; 13-AZAPROSTANOIC ACID; POLYACRYLAMIDE GELS; IONOPHORE IONOMYCIN; PHOSPHOLIPASE-C; H-2 RECEPTORS; RAT-BRAIN; G-PROTEIN; PROSTAGLANDIN	The presence of functional thromboxane A(2) receptors in neonatal rat oligodendrocytes and human oligodendroglioma cells was investigated using immunocytochemistry, ligand affinity chromatography, radioligand binding analysis, immunoblot analysis, and calcium mobilization studies. Immunocytochemical studies revealed the presence of receptor protein on both oligodendrocytes and human oligodendroglioma cells, Ligand affinity chromatography allowed for the purification of a protein with an electrophoretic mobility (55 kDa) indistinguishable from human platelet thromboxane A(2) receptors. This affinity purified protein was immunoreactive against a polyclonal anti-thromboxane A(2) receptor antibody. Intact human oligodendroglioma cells specifically bound [H-3]SQ29,548 with a K-D of 4 nM and were found to have approximately 3500 binding sites per cell. Human oligodendroglioma cells also demonstrated calcium mobilization in response to receptor activation with U46619. These results demonstrate the presence of a functional thromboxane A(2) receptor in oligodendrocytes and are consistent with previous observations indicating a high density of thromboxane A(2) receptors in myelinated brain and spinal cord fiber tracts.	Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Chicago, Sch Med, Dept Biochem, Chicago, IL 60637 USA; Inst Rech Sci Canc, F-94801 Villejuif, France	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago	Le Breton, GC (corresponding author), Univ Illinois, Dept Pharmacol, 835 S Wolcott Ave,MC 868, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL-24530] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bazan N G, 1980, Adv Neurol, V28, P197; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; BORG C, 1994, J BIOL CHEM, V269, P6109; BOTTENSTEIN JE, 1986, P NATL ACAD SCI USA, V83, P1955, DOI 10.1073/pnas.83.6.1955; BRACE LD, 1985, AM J PHYSIOL, V249, pH1, DOI 10.1152/ajpheart.1985.249.1.H1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRASS LF, 1987, J CLIN INVEST, V79, P1269, DOI 10.1172/JCI112947; Bresnahan BA, 1996, KIDNEY INT, V49, P1207, DOI 10.1038/ki.1996.174; CHIERCHIA S, 1987, FASEB J, V46, P81; DANIEL EE, 1991, AM REV RESPIR DIS, V143, pS3, DOI 10.1164/ajrccm/143.3_Pt_2.S3; Dubois-Dalcq Monique, 1992, P81; Giulian D, 1996, NEUROCHEM INT, V29, P65, DOI 10.1016/0197-0186(95)00140-9; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; HANASAKI K, 1990, BIOCHEM PHARMACOL, V40, P2535, DOI 10.1016/0006-2952(90)90096-4; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; HEDBERG A, 1988, J PHARMACOL EXP THER, V245, P786; HEDBERG A, 1989, AM J PHYSIOL, V256, pE256, DOI 10.1152/ajpendo.1989.256.2.E256; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HORN PT, 1984, J CARDIOVASC PHARM, V6, P609, DOI 10.1097/00005344-198407000-00009; Hsu KS, 1996, AM J PHYSIOL-CELL PH, V271, pC1269, DOI 10.1152/ajpcell.1996.271.4.C1269; KIM SO, 1992, BIOCHEM PHARMACOL, V43, P313; KNEZEVIC I, 1993, J BIOL CHEM, V268, P26011; KNEZEVIC I, 1992, J PHARMACOL EXP THER, V260, P947; KOUDSTAAL PJ, 1993, STROKE, V24, P219, DOI 10.1161/01.STR.24.2.219; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBRETON GC, 1979, P NATL ACAD SCI USA, V76, P4097; LUMLEY P, 1989, BRIT J PHARMACOL, V97, P783, DOI 10.1111/j.1476-5381.1989.tb12017.x; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY S, 1990, GLIA, V3, P205, DOI 10.1002/glia.440030307; NAKAHATA N, 1995, RES COMMUN MOL PATH, V87, P243; NAKAHATA N, 1992, BRAIN RES, V583, P100, DOI 10.1016/S0006-8993(10)80013-7; NAKAHATA N, 1989, EUR J PHARMACOL, V162, P407, DOI 10.1016/0014-2999(89)90331-2; OATES JA, 1988, NEW ENGL J MED, V319, P761, DOI 10.1056/NEJM198809223191206; OGLETREE ML, 1987, FED PROC, V46, P133; OWEN NE, 1981, AM J PHYSIOL, V241, pH613, DOI 10.1152/ajpheart.1981.241.4.H613; PATSCHEKE H, 1986, CLIN PHARMACOL THER, V39, P145, DOI 10.1038/clpt.1986.25; PEARCE B, 1989, J NEUROCHEM, V52, P971, DOI 10.1111/j.1471-4159.1989.tb02549.x; PETRONI A, 1994, DEV BRAIN RES, V78, P169, DOI 10.1016/0165-3806(94)90023-X; POST GR, 1992, MOL CHEM NEUROPATHOL, V16, P303, DOI 10.1007/BF03159976; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SMITH KJ, 1988, J NEUROL SCI, V83, P37, DOI 10.1016/0022-510X(88)90018-4; SMITH KJ, 1994, BRAIN, V117, P1351, DOI 10.1093/brain/117.6.1351; SZUCHET S, 1980, BRAIN RES, V200, P151, DOI 10.1016/0006-8993(80)91101-4; TAKANO S, 1992, RES COMMUN CHEM PATH, V76, P155; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARTANIAN T, 1986, SCIENCE, V234, P1395, DOI 10.1126/science.2431483; VARTANIAN T, 1988, P NATL ACAD SCI USA, V85, P939, DOI 10.1073/pnas.85.3.939	51	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					475	483		10.1074/jbc.273.1.475	http://dx.doi.org/10.1074/jbc.273.1.475			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417106	hybrid			2022-12-25	WOS:000071295600072
J	Choi, SG; Yi, Y; Kim, YS; Kato, M; Chang, J; Chung, HW; Hahm, KB; Yang, HK; Rhee, HH; Bang, YJ; Kim, SJ				Choi, SG; Yi, Y; Kim, YS; Kato, M; Chang, J; Chung, HW; Hahm, KB; Yang, HK; Rhee, HH; Bang, YJ; Kim, SJ			A novel ets-related transcription factor, ERT/ESX/ESE-1, regulates expression of the transforming growth factor-beta type II receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; MICROSATELLITE INSTABILITY; MOLECULAR-CLONING; DOMAIN PROTEIN; CANCER CELLS; GENE; FAMILY; PROMOTER; MEMBER; ELEMENTS	A 2.5-kilobase cDNA clone that encodes a 371-amino acid novel transcription factor was isolated from a human placenta cDNA library using a yeast one-hybrid system, The novel ets-related transcription factor (ERT) showed a homology with the ETS DNA-binding domain, Using constructs of the transforming growth factor-beta (TGF-beta) type II receptor (RII) promoter linked to the luciferase gene, we have demonstrated that ERT activates transcription of the TGF-beta RII gene through the 5'-TTTCCTGTTTCC-3' response element spanning nucleotides +13 to +24 and multiple additional ETS binding sites between -1816 and -82 of the TGF-beta RII promoter, A specific interaction between ERT and the ETS binding sites was also demonstrated using an electrophoretic mobility shift assay, Deletion mapping of ERT protein suggests that the transactivation domain resides in the amino terminus while the DNA-binding domain is localized to the carboxyl-terminal region, Our results suggest that ERT might be a major transcription factor involved in the transcriptional regulation of the TGF-beta RII gene.	NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Canc Res Ctr, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, NIH, Bldg 41,Rm B1106, Bethesda, MD 20892 USA.		Yang, Han-Kwang/J-2767-2012; Bang, Yung Jue/J-2759-2012	Bang, Yung Jue/0000-0001-6000-4597				BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; GITLIN SD, 1991, J VIROL, V65, P5513, DOI 10.1128/JVI.65.10.5513-5523.1991; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KADIN M, 1994, P NATL ACAD SCI USA, V9, P6002; Kim David H., 1996, Journal of Biomedical Science, V3, P143, DOI 10.1007/BF02253095; Kim DH, 1997, J BIOL CHEM, V272, P688; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Markowitz Sanford D., 1996, Cytokine and Growth Factor Reviews, V7, P93, DOI 10.1016/1359-6101(96)00001-9; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MYEROFF LL, 1995, CANCER RES, V55, P5545; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SUN LZ, 1994, J BIOL CHEM, V269, P26449; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	33	105	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					110	117		10.1074/jbc.273.1.110	http://dx.doi.org/10.1074/jbc.273.1.110			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417054	hybrid			2022-12-25	WOS:000071295600020
J	Sun, TX; Liang, JJN				Sun, TX; Liang, JJN			Intermolecular exchange and stabilization of recombinant human alpha A- and alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY STRUCTURE; LENS CRYSTALLINS; CIRCULAR-DICHROISM; EXPRESSION; DIFFERENTIATION; CONFORMATION; AGGREGATION; SUBUNITS; CHAIN	Lens alpha-crystallin subunits alpha A and alpha B are differentially expressed and have a 3-to-1 ratio in most mammalian lenses by intermolecular exchange. The biological significance of this composition and the mechanism of exchange are not clear. Preparations of human recombinant alpha A- and alpha B-crystallins provide a good system in which to study this phenomenon. Both recombinant alpha A- and alpha B-crystallins are folded and aggregated to the size of the native cu-crystallin. During incubation together, they undergo an intermolecular exchange as shown by native isoelectric focusing. Circular dichroism measurements indicate that the protein with a 3-to-1 ratio of alpha A- and alpha B-crystallins has the same secondary structure but somewhat different tertiary structures after exchange: the near-UV CD increases after exchange. The resulting hybrid aggregate is more stable than the individual homogeneous aggregates: at 62 degrees C, alpha B-crystallin is more susceptible to aggregation and displays a greater light scattering than alpha A-crystallin. This heat-induced aggregation of alpha B-crystallin, however, was suppressed by intermolecular exchange with alpha A-crystallin, These phenomena are also observed by fast performance liquid chromatography gel filtration patterns. The protein structure of alpha B-crystallin is stabilized by intermolecular exchange with alpha A-crystallin.	Brigham & Womens Hosp, Ctr Ophthalm Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Liang, JJN (corresponding author), Brigham & Womens Hosp, Ctr Ophthalm Res, 221 Longwood Ave, Boston, MA 02115 USA.				NEI NIH HHS [EY 05803] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andley UP, 1996, J BIOL CHEM, V271, P31973, DOI 10.1074/jbc.271.50.31973; AUGUSTEYN RC, 1987, FEBS LETT, V222, P1, DOI 10.1016/0014-5793(87)80180-1; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRAHMA SK, 1987, CURR EYE RES, V6, P1291, DOI 10.3109/02713688708997554; CARVER JA, 1994, EXP EYE RES, V59, P231, DOI 10.1006/exer.1994.1101; CHIESA R, 1989, CURR EYE RES, V8, P151, DOI 10.3109/02713688908995186; Das BK, 1997, BIOCHEM BIOPH RES CO, V236, P370, DOI 10.1006/bbrc.1997.6950; Das BK, 1997, CURR EYE RES, V16, P303, DOI 10.1076/ceyr.16.4.303.10691; DEJONG WW, 1975, FEBS LETT, V58, P310, DOI 10.1016/0014-5793(75)80286-9; DELCOUR J, 1974, BIOCHEM BIOPH RES CO, V57, P134, DOI 10.1016/S0006-291X(74)80367-0; HORWITZ J, 1993, INVEST OPHTH VIS SCI, V34, P10; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P1044; Kahn P C, 1979, Methods Enzymol, V61, P339; KRAMPS JA, 1977, FEBS LETT, V74, P82, DOI 10.1016/0014-5793(77)80757-6; LIANG J, 1989, INVEST OPHTH VIS SCI, V30, P2065; LIANG JN, 1982, BIOCHEMISTRY-US, V21, P1847, DOI 10.1021/bi00537a022; LIANG JN, 1991, EXP EYE RES, V53, P61, DOI 10.1016/0014-4835(91)90145-5; LIANG JN, 1988, EXP EYE RES, V47, P17, DOI 10.1016/0014-4835(88)90020-6; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; MAITI M, 1988, FEBS LETT, V236, P109, DOI 10.1016/0014-5793(88)80295-3; MERCK KB, 1992, BIOCHIM BIOPHYS ACTA, V1130, P267, DOI 10.1016/0167-4781(92)90439-7; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; Robinson ML, 1996, INVEST OPHTH VIS SCI, V37, P2276; SIEZEN RJ, 1980, EUR J BIOCHEM, V111, P435, DOI 10.1111/j.1432-1033.1980.tb04958.x; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; STRICKLA.EH, 1969, BIOCHEMISTRY-US, V8, P3205, DOI 10.1021/bi00836a012; Sun TX, 1997, J BIOL CHEM, V272, P6220, DOI 10.1074/jbc.272.10.6220; TAKEMOTO L, 1994, CURR EYE RES, V13, P35, DOI 10.3109/02713689409042396; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; WALSH MT, 1991, J BIOL CHEM, V266, P20079; WANG KY, 1994, J BIOL CHEM, V269, P13601	31	107	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 2	1998	273	1					286	290		10.1074/jbc.273.1.286	http://dx.doi.org/10.1074/jbc.273.1.286			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YP612	9417077	hybrid			2022-12-25	WOS:000071295600043
J	Komatsu, M; Carraway, CAC; Fregien, NL; Carraway, KL				Komatsu, M; Carraway, CAC; Fregien, NL; Carraway, KL			Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY ADENOCARCINOMA CELLS; SURFACE GLYCOPROTEIN COMPLEX; TUMOR ASCITES-CELLS; MOLECULAR-CLONING; EPISIALIN MUC1; ADHESION; EXPRESSION; MAT-B1	Sialomucin complex (SMC) is a large, heterodimeric glycoprotein complex composed of mucin (ASGP-1) and transmembrane (ASGP-2) subunits and expressed abundantly on the cell surface of ascites 13762 rat mammary adenocarcinoma cells. We have isolated recombinant cDNAs containing different numbers of ASGP-1 mucin repeats, which can be expressed as protein products with variable lengths. To study the anti adhesive effect of SMC, these cDNAs were transfected into human cancer cell lines. Using a tetracycline-responsive, inducible expression system, we demonstrated that the overexpression of SMC induces morphology changes, cell detachment, and cell-cell dissociation of transfected A375 human melanoma cells in culture. The transition between the adherent and suspension states of the cells is fully reversible and dependent on the SMC expression level. The anti-adhesion effect of SMC was further analyzed kinetically by measuring the cell adhesion of transfected A375 melanoma and MCF-7 breast cancer cell lines to fibronectin, laminin, and collagen IV, demonstrating that SMC disrupts integrin-mediated cell adhesion to extracellular matrix proteins. The degree of this anti-adhesion effect was dependent on the number of mucin repeats in the SMC molecule as well as the level of cell surface expression.	Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R 124, Miami, FL 33101 USA.			Komatsu, Masanobu/0000-0001-7548-137X	NATIONAL CANCER INSTITUTE [P30CA014395, R01CA052498] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498, CA 14395] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; BECKER JW, 1989, P NATL ACAD SCI USA, V86, P1088, DOI 10.1073/pnas.86.3.1088; CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1992, J CELL SCI, V103, P299; CODINGTON JF, 1983, BIOMEMBRANE, V11, P207; CYSTER JG, 1991, EMBO J, V10, P893, DOI 10.1002/j.1460-2075.1991.tb08022.x; FONTENOT JD, 1993, CANCER RES, V53, P5386; GENDLER SJ, 1995, ANNU REV PHYSIOL, V57, P607, DOI 10.1146/annurev.ph.57.030195.003135; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gui GPH, 1997, BRIT J CANCER, V75, P623, DOI 10.1038/bjc.1997.113; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; HULL SR, 1984, J BIOL CHEM, V259, P4866; JENTOFT N, 1990, TRENDS BIOCHEM SCI, V15, P291, DOI 10.1016/0968-0004(90)90014-3; KEMPERMAN H, 1994, J CELL BIOL, V127, P2071, DOI 10.1083/jcb.127.6.2071; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; MANJUNATH N, 1993, J IMMUNOL, V151, P1528; MORIARTY J, 1990, CANCER RES, V50, P6800; NICOLSON G L, 1991, Current Opinion in Oncology, V3, P75, DOI 10.1097/00001622-199102000-00012; NICOLSON GL, 1988, BIOCHIM BIOPHYS ACTA, V948, P175, DOI 10.1016/0304-419X(88)90010-8; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SHERBLOM AP, 1986, CANCER RES, V46, P4543; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Sommers CL, 1996, J MAMMARY GLAND BIOL, V1, P219, DOI 10.1007/BF02013645; STECK PA, 1983, EXP CELL RES, V147, P255, DOI 10.1016/0014-4827(83)90208-2; VALDIZAN MC, 1992, J CELL PHYSIOL, V151, P451, DOI 10.1002/jcp.1041510304; VANKLINKEN BJW, 1995, AM J PHYSIOL-GASTR L, V269, pG613, DOI 10.1152/ajpgi.1995.269.5.G613; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WU K, 1994, J BIOL CHEM, V269, P11950; WU K, 1994, ONCOGENE, V9, P3139	33	138	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33245	33254		10.1074/jbc.272.52.33245	http://dx.doi.org/10.1074/jbc.272.52.33245			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407114	hybrid			2022-12-25	WOS:000071182900075
J	Staffa, A; Acheson, NH; Cochrane, A				Staffa, A; Acheson, NH; Cochrane, A			Novel exonic elements that modulate splicing of the human fibronectin EDA exon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; IMMUNODEFICIENCY-VIRUS TYPE-1; SITE SELECTION; GENE; ENHANCER; INTRON; SEQUENCE; INHIBITION; BINDING; IDENTIFICATION	Three exons in the fibronectin primary transcript are alternatively spliced in a tissue-and developmental stage-specific manner. One of these exons, EDA, has been shown previously by others to contain two splicing regulatory elements between 155 and 180 nucleotides downstream of the 3'-splice site: an exon splicing enhancer and a negative element. By transient expression of a chimeric beta-globin/fibronectin EDA intron in COS-7 cells, we have identified two additional exonic splicing regulatory elements. RNA generated by a construct containing the first 120 nucleotides of the fibronectin EDA exon was spliced with an efficiency of approximately 50%. Deletion of most of the fibronectin EDA exon sequences resulted in a 20-fold increase in the amount of spliced RNA, indicative of an exon splicing silencer. Deletion and mutagenesis studies suggest that the fibronectin exon splicing silencer is associated with a conserved RNA secondary structure, In addition, sequences between nucleotides 93 and 118 of the EDA exon contain a non-purine-rich splicing enhancer as demonstrated by its ability to function in a heterologous context.	Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada	University of Toronto; McGill University	Cochrane, A (corresponding author), Univ Toronto, Dept Med Genet & Microbiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							AMENDT BA, 1994, MOL CELL BIOL, V14, P3960, DOI 10.1128/MCB.14.6.3960; AMENDT BA, 1995, J VIROL, V69, P5068, DOI 10.1128/JVI.69.8.5068-5076.1995; AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; CAPUTI M, 1994, NUCLEIC ACIDS RES, V22, P1018, DOI 10.1093/nar/22.6.1018; Carlo T, 1996, RNA, V2, P342; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DIRKSEN WP, 1995, J BIOL CHEM, V270, P5346, DOI 10.1074/jbc.270.10.5346; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FU XD, 1995, RNA, V1, P663; GOODING C, 1994, EMBO J, V13, P3861, DOI 10.1002/j.1460-2075.1994.tb06697.x; HELFMAN DM, 1990, GENE DEV, V4, P98, DOI 10.1101/gad.4.1.98; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HORN DA, 1993, FEBS LETT, V324, P123, DOI 10.1016/0014-5793(93)81376-B; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; Hynes RO, 1990, FIBRONECTINS; Kornblihtt AR, 1996, FASEB J, V10, P248, DOI 10.1096/fasebj.10.2.8641558; LAVIGUEUR A, 1993, GENE DEV, V7, P2405, DOI 10.1101/gad.7.12a.2405; LOU H, 1995, MOL CELL BIOL, V15, P7135; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; MARDON HJ, 1987, NUCLEIC ACIDS RES, V15, P7725, DOI 10.1093/nar/15.19.7725; MCNALLY MT, 1991, VIROLOGY, V185, P99, DOI 10.1016/0042-6822(91)90758-4; NEMEROFF ME, 1992, MOL CELL BIOL, V12, P962, DOI 10.1128/MCB.12.3.962; PAOLELLA G, 1988, NUCLEIC ACIDS RES, V16, P3545, DOI 10.1093/nar/16.8.3545; PINTEL DJ, 1995, SEMIN VIROL, V6, P283, DOI 10.1006/smvy.1995.0034; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; Ryan KJ, 1996, MOL CELL BIOL, V16, P4014; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SHEN J, 1994, MOL CELL BIOL, V14, P7385, DOI 10.1128/MCB.14.11.7385; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOMASEKHAR MB, 1985, NUCLEIC ACIDS RES, V13, P5591, DOI 10.1093/nar/13.15.5591; STAFFA A, 1994, J VIROL, V68, P3071, DOI 10.1128/JVI.68.5.3071-3079.1994; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TAKESHIMA Y, 1995, J CLIN INVEST, V95, P515, DOI 10.1172/JCI117693; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; VANOERS CCM, 1994, MOL CELL BIOL, V14, P951, DOI 10.1128/MCB.14.2.951; VIBEPEDERSEN K, 1984, EMBO J, V3, P2511, DOI 10.1002/j.1460-2075.1984.tb02165.x; WANG Z, 1995, RNA, V1, P21; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; XU R, 1993, MOL CELL BIOL, V13, P3360; YEAKLEY JM, 1993, MOL CELL BIOL, V13, P5999, DOI 10.1128/MCB.13.10.5999; Zheng ZM, 1996, J VIROL, V70, P4691, DOI 10.1128/JVI.70.7.4691-4699.1996	50	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 26	1997	272	52					33394	33401		10.1074/jbc.272.52.33394	http://dx.doi.org/10.1074/jbc.272.52.33394			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	YN575	9407134	hybrid			2022-12-25	WOS:000071182900095
